<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="acel70168" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Aging Cell</journal-id><journal-id journal-id-type="iso-abbrev">Aging Cell</journal-id><journal-id journal-id-type="pmc-domain-id">2481</journal-id><journal-id journal-id-type="pmc-domain">acel</journal-id><journal-id journal-id-type="publisher-id">ACEL</journal-id><journal-title-group><journal-title>Aging Cell</journal-title></journal-title-group><issn pub-type="ppub">1474-9718</issn><issn pub-type="epub">1474-9726</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12507418</article-id><article-id pub-id-type="pmcid-ver">PMC12507418.1</article-id><article-id pub-id-type="pmcaid">12507418</article-id><article-id pub-id-type="pmcaiid">12507418</article-id><article-id pub-id-type="pmid">40729555</article-id><article-id pub-id-type="doi">10.1111/acel.70168</article-id><article-id pub-id-type="publisher-id">ACEL70168</article-id><article-id pub-id-type="other">ACE-25-0297-RAr</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Proteomic Signatures of Epigenetic Age in African Green Monkey Cerebrospinal Fluid and Plasma</article-title></title-group><contrib-group><contrib id="acel70168-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Elsworth</surname><given-names initials="JD">John D.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0323-0886</contrib-id><xref rid="acel70168-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>jelsworth@virscio.com</email></address></contrib><contrib id="acel70168-cr-0002" contrib-type="author"><name name-style="western"><surname>Neutzner</surname><given-names initials="A">Albert</given-names></name><xref rid="acel70168-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="acel70168-cr-0003" contrib-type="author"><name name-style="western"><surname>Roux</surname><given-names initials="J">Julien</given-names></name><xref rid="acel70168-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="acel70168-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="acel70168-cr-0004" contrib-type="author"><name name-style="western"><surname>Gordevicius</surname><given-names initials="J">Juozas</given-names></name><xref rid="acel70168-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="acel70168-cr-0005" contrib-type="author"><name name-style="western"><surname>Milciute</surname><given-names initials="M">Milda</given-names></name><xref rid="acel70168-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="acel70168-cr-0006" contrib-type="author"><name name-style="western"><surname>Dzikiti</surname><given-names initials="L">Loveness</given-names></name><xref rid="acel70168-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="acel70168-cr-0007" contrib-type="author"><name name-style="western"><surname>Wakeman</surname><given-names initials="DR">Dustin R.</given-names></name><xref rid="acel70168-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="acel70168-cr-0008" contrib-type="author"><name name-style="western"><surname>Danielsson</surname><given-names initials="B">Brooke</given-names></name><xref rid="acel70168-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="acel70168-cr-0009" contrib-type="author"><name name-style="western"><surname>Agca</surname><given-names initials="C">Cavit</given-names></name><xref rid="acel70168-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="acel70168-cr-0010" contrib-type="author"><name name-style="western"><surname>Lawrence</surname><given-names initials="MS">Matthew S.</given-names></name><xref rid="acel70168-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="acel70168-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>Virscio Inc</institution>
<city>New Haven</city>
<named-content content-type="country-part">Connecticut</named-content>
<country country="US">USA</country>
</aff><aff id="acel70168-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Biomedicine</named-content>
<institution>University of Basel</institution>
<city>Basel</city>
<country country="CH">Switzerland</country>
</aff><aff id="acel70168-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Swiss Institute of Bioinformatics</institution>
<city>Basel</city>
<country country="CH">Switzerland</country>
</aff><aff id="acel70168-aff-0004">
<label>
<sup>4</sup>
</label>
<institution>Epigenetic Clock Development Foundation</institution>
<city>Torrance</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
John D. Elsworth (<email>jelsworth@virscio.com</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>24</volume><issue seq="20">10</issue><issue-id pub-id-type="pmc-issue-id">498575</issue-id><issue-id pub-id-type="doi">10.1111/acel.v24.10</issue-id><elocation-id>e70168</elocation-id><history><date date-type="rev-recd"><day>24</day><month>6</month><year>2025</year></date><date date-type="received"><day>28</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>03</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 Virscio Inc. The Epigenetic Clock Development Foundation and The Author(s). <italic toggle="yes">Aging Cell</italic> published by Anatomical Society and John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ACEL-24-e70168.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ACEL-24-e70168.pdf"/><abstract><title>ABSTRACT</title><p>Strategies to slow the aging process or mitigate its consequences on health rely on the validation of minimally&#8208;invasive biomarkers of aging that can be used to track aging and test the effectiveness of antiaging interventions. Study of aging in a nonhuman primate species offers a robust translational approach to achieving these aims, avoiding wide differences in genetics and environmental exposures that confound human aging studies. As epigenetic age appears to predict biological aging, biomarkers linked to epigenetic aging should be especially valuable in identifying individual differences in aging progression and documenting the impact of antiaging strategies. Proteins are the final effectors in most signaling pathways, indicating that alteration in levels of circulating proteins potentially offers an informative and valuable quantitative index of aging. Accordingly, a proteomic analysis was conducted on matching CSF and plasma samples collected from a large group of African green monkeys, with epigenetic ages ranging from young to old as determined by differential methylation of blood DNA. In addition to analyzing the data with linear statistical models, a gradient boosting machine learning technique was employed to identify not only individual CSF and plasma proteins that correlated with aging progression but also groups of proteins that could be used as predictors of global aging and of specialized aspects of aging such as inflammation. Overall, this study identified new CSF and plasma protein targets for understanding aging biology, together with identifying biomarkers to track changes in the rate of biological aging in a translationally relevant nonhuman primate model.</p></abstract><abstract abstract-type="graphical"><p>Epigenetic age together with plasma and CSF proteomes were quantified in a large number of African green monkeys. This study identified new accessible protein biomarkers (&#8220;clocks&#8221;) for understanding aging biology and to track changes in the rate of biological aging in a translationally relevant nonhuman primate model.<boxed-text position="anchor" content-type="graphic" id="acel70168-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ACEL-24-e70168-g004.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="acel70168-kwd-0001">aging</kwd><kwd id="acel70168-kwd-0002">blood</kwd><kwd id="acel70168-kwd-0003">CSF</kwd><kwd id="acel70168-kwd-0004">epigenetics</kwd><kwd id="acel70168-kwd-0005">nonhuman primate</kwd><kwd id="acel70168-kwd-0006">proteomics</kwd><kwd id="acel70168-kwd-0007">vervet monkey</kwd></kwd-group><counts><fig-count count="7"/><table-count count="0"/><page-count count="14"/><word-count count="9400"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:08.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="acel70168-ntgp-0001"><fn fn-type="funding" id="acel70168-note-0001"><p>
<bold>Funding:</bold> The authors received no specific funding for this work.</p></fn></fn-group></notes></front><body id="acel70168-body-0001"><sec id="acel70168-sec-0001"><label>1</label><title>Introduction</title><p>Advancing age is the major risk factor and predictor for numerous prevalent diseases (Kennedy et&#160;al.&#160;<xref rid="acel70168-bib-0030" ref-type="bibr">2014</xref>). With a global aging population, there is an urgent need both to gain a deeper understanding of the aging process and to develop reliable methods to test antiaging strategies. Progress in understanding and testing is necessary for improved treatment of age&#8208;associated disease and effective interventions to increase healthspan (Campisi et&#160;al.&#160;<xref rid="acel70168-bib-0009" ref-type="bibr">2019</xref>).</p><p>There are differences among individuals between their chronological age&#8212;the time since birth&#8212;and biological age, defined as an individual's age established by the level of age&#8208;dependent biological changes, such as accumulation of molecular and cellular damage (Moqri et&#160;al.&#160;<xref rid="acel70168-bib-0041" ref-type="bibr">2023</xref>). The aging process has been characterized by multiple interconnected cellular and molecular hallmarks (Lopez&#8208;Otin et&#160;al.&#160;<xref rid="acel70168-bib-0036" ref-type="bibr">2023</xref>). Consequently, a major challenge in aging research is the development of biomarkers that could accurately track the biological age of an individual and discriminate, at an early stage, different health trajectories (Aging Biomarker Consortium&#160;<xref rid="acel70168-bib-0002" ref-type="bibr">2023</xref>; Galkin et&#160;al.&#160;<xref rid="acel70168-bib-0018" ref-type="bibr">2020</xref>). Success in this approach would further our understanding of the aging process and facilitate the design of strategies that prevent, delay, or reduce the severity of age&#8208;related diseases, inform clinical trial interpretation, and enable more accurate epidemiology and effective public health policy.</p><p>Alterations in protein levels in easily accessible tissues, such as blood, have long been known to be reliable indicators of certain disorders, such as cardiovascular disease (Ellis&#160;<xref rid="acel70168-bib-0017" ref-type="bibr">1991</xref>) and to alter during normal aging (Bruunsgaard et&#160;al.&#160;<xref rid="acel70168-bib-0008" ref-type="bibr">2000</xref>). With the ability to quantify the abundance of over a thousand proteins, recent proteomics studies in humans have identified many proteins whose abundance increases or decreases in the blood with age (Argentieri et&#160;al.&#160;<xref rid="acel70168-bib-0004" ref-type="bibr">2024</xref>; Coenen et&#160;al.&#160;<xref rid="acel70168-bib-0012" ref-type="bibr">2023</xref>; Goeminne et&#160;al.&#160;<xref rid="acel70168-bib-0019" ref-type="bibr">2025</xref>; Johnson et&#160;al.&#160;<xref rid="acel70168-bib-0029" ref-type="bibr">2020</xref>; Kuo et&#160;al.&#160;<xref rid="acel70168-bib-0033" ref-type="bibr">2024</xref>; Oh et&#160;al.&#160;<xref rid="acel70168-bib-0042" ref-type="bibr">2023</xref>; Sathyan et&#160;al.&#160;<xref rid="acel70168-bib-0047" ref-type="bibr">2020</xref>). Validation of proteins that best reflect the aging process is hampered by variation in health, genetics, lifestyle, and environmental and pharmacological exposures across human individuals, although some studies have been conducted using large well&#8208;phenotyped cohorts (e.g., UK Biobank database). In addition, methodological differences are present across studies, impacting the panels of assayed proteins and their quantification. Nevertheless, because proteins are the final effectors of most biochemical processes, probing the proteome for signatures of aging holds great promise for understanding the aging process, defining enhanced aging biomarkers, and identifying targets for antiaging interventions.</p><p>Humans share great similarity in lifespan, genomics, biochemistry, and pharmacological response to therapeutics with nonhuman primates (NHPs) (Phillips et&#160;al.&#160;<xref rid="acel70168-bib-0043" ref-type="bibr">2014</xref>). Consequently, studies conducted in NHPs are highly translationally relevant and can be more tightly controlled than studies on humans. Identification of validated NHP aging biomarkers would allow their application as endpoints in future NHP studies of aging biology and antiaging interventions. The current study reports changes in the proteome across the lifespan of African green monkeys (<italic toggle="yes">
<styled-content style="fixed-case" toggle="no">Chlorocebus aethiops</styled-content> sabaeus</italic>) using a proxy of biological age as the independent variable. Quantification and analysis of proteins in matched plasma and CSF samples enabled a novel comparison of changes in the peripheral and central compartments.</p><p>The St Kitts origin African green monkey is one of the most studied nonhuman Old World primates, with extensive genomic and systems characterization, constrained environmental and genetic variability, low infectious disease burden, and a long history of use in biomedical research supporting preclinical drug development (Jasinska et&#160;al.&#160;<xref rid="acel70168-bib-0027" ref-type="bibr">2013</xref>, <xref rid="acel70168-bib-0028" ref-type="bibr">2017</xref>). The animals sampled in the present study were housed at the St Kitts Biomedical Research Foundation (SKBRF), a facility in St Kitts, an island in the West Indies, and are derived from a small founder population introduced from West Africa about 350&#8201;years ago. Some of the African green monkeys at the facility originate from the wild population on the island, and the birthdate of such animals is unknown, so we used an epigenetic &#8220;clock&#8221; (Horvath and Raj&#160;<xref rid="acel70168-bib-0023" ref-type="bibr">2018</xref>) based on changes in CpG DNA methylation at discrete sites in the genome as a proxy for biological age. Epigenetic clocks have been used to identify differences in biological aging that skew individuals of a given chronological age from their expected epigenetic age (Horvath and Raj&#160;<xref rid="acel70168-bib-0023" ref-type="bibr">2018</xref>; Wang et&#160;al.&#160;<xref rid="acel70168-bib-0053" ref-type="bibr">2022</xref>). Accelerated epigenetic aging has been associated with many diseases and even predicts all&#8208;cause mortality risk, independent of chronological age, lifestyle habits, and morbidity (Colicino et&#160;al.&#160;<xref rid="acel70168-bib-0013" ref-type="bibr">2020</xref>). Using a large group of male and female African green monkeys, we identified proteins in their plasma and CSF significantly associated with epigenetic age. These novel biomarkers in African green monkeys should prove useful in studies of biological aging mechanisms and anti&#8208;aging interventions.</p></sec><sec sec-type="methods" id="acel70168-sec-0002"><label>2</label><title>Methods</title><sec id="acel70168-sec-0003"><label>2.1</label><title>Animals</title><p>African green (&#8220;vervet&#8221;) monkeys (<italic toggle="yes">
<styled-content style="fixed-case" toggle="no">Chlorocebus aethiops</styled-content> sabaeus</italic>) were housed at SKBRF, an organization accredited by AAALAC International, and were either born at the facility or were sourced from the abundant free&#8208;ranging population located on the island of St. Kitts. The lifespan of African green monkeys is typically 20&#8211;30&#8201;years old in a protected and enriched environment such as the outdoor social group enclosures of SKBRF. Blood and cisternal CSF samples were drawn from the animals while sedated by an intramuscular injection of ketamine (8&#8201;mg/kg) and xylazine (1.6&#8201;mg/kg).</p></sec><sec id="acel70168-sec-0004"><label>2.2</label><title>Epigenetic Blood Clock</title><p>Venous blood samples were collected from 96 male and female African green monkeys with known chronological ages ranging between from 3&#8201;months to 17&#8201;years old. Samples (0.5&#8201;mL) were gently mixed in K<sub>2</sub>EDTA tubes to prevent coagulation and 0.1&#8201;mL aliquots transferred to screw&#8208;cap microtubes (Sarstedt, item 72.730.005) and stored in a &#8722;80&#176;C freezer. DNA was extracted from a single aliquot from each monkey using a spin&#8208;column protocol &#8220;DNeasy Blood &amp; Tissue&#8221; kit (Qiagen, item 69506). Final eluates were further purified by the &#8220;DNA Clean and Concentrator&#8208;5&#8221; kit (Zymo Research, item D4014). A microvolume spectrophotometer (NanoDrop One, Thermo Fisher Scientific) determined the concentration (&#8805;&#8201;15&#8201;ng/&#956;L) and purity (mean&#8201;&#177;&#8201;S.D., 260/280&#8201;=&#8201;1.86&#8201;&#177;&#8201;0.04, 260/230&#8201;=&#8201;2.30&#8201;&#177;&#8201;0.11) of isolated DNA and the final extract (~50&#8201;&#956;L) was stored in &#8220;Safe&#8208;Lock&#8221; microtubes tubes (Eppendorf, item 0030123603) within a &#8722;80&#176;C freezer. A portion (30&#8201;&#956;L) of each extract was transferred to a 96&#8208;well plate, which was sealed and shipped in a liquid nitrogen vapor shipper to Virscio laboratories (New Haven, CT) and stored in a &#8722;80&#176;C freezer until delivery on dry ice to the Epigenetic Clock Development Foundation (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://clockfoundation.org" ext-link-type="uri">clockfoundation.org</ext-link>) for analysis of DNA methylation sites.</p></sec><sec id="acel70168-sec-0005"><label>2.3</label><title>
<styled-content style="fixed-case" toggle="no">DNA</styled-content> Methylation Profiling</title><p>The isolated DNA underwent bisulfite conversion using the Zymo EZ DNA methylation kit (Zymo, Irvine, CA, USA). A minimum of 150&#8201;ng of total bisulfite&#8208;converted DNA was processed using the Horvath 320&#8201;k methylation assay (Epigenetic Clock Development Foundation, Los Angeles, CA, USA). DNA methylation was measured using the custom Illumina chip &#8220;HorvathMammalMethylChip40&#8221;. Raw data were normalized using the Sensible Step&#8208;wise Analysis of Methylation data (SeSAMe) R package (Zhou et&#160;al.&#160;<xref rid="acel70168-bib-0056" ref-type="bibr">2018</xref>), resulting in a methylation estimate (beta value) corresponding to each array probe for every individual in the dataset and a detection <italic toggle="yes">p</italic> value corresponding to the confidence in the normalized beta value. Beta values from SeSAMe were derived from the ratio of the fluorescence intensity of a methylated probe for a specific CpG to the total overall probe intensity (the sum of the signal from both the methylated and unmethylated probes plus a constant) (Du et&#160;al.&#160;<xref rid="acel70168-bib-0015" ref-type="bibr">2010</xref>). Beta values range from zero to one, with a value of zero indicating that no copies of the gene were methylated. To identify technical outliers after SeSAMe normalization, an unsupervised hierarchical clustering analysis based on the inter&#8208;array correlation was used. Data were filtered by detection <italic toggle="yes">p</italic> value as calculated in SeSAMe (Zhou et&#160;al.&#160;<xref rid="acel70168-bib-0056" ref-type="bibr">2018</xref>).</p></sec><sec id="acel70168-sec-0006"><label>2.4</label><title>Statistics: Epigenetic Age Determination</title><p>To construct the reliable and accurate epigenetic clock, DNA methylation data from the Virscio African green monkey blood clock was integrated with data from a blood clock developed using the African green monkey colony at the Vervet Research Colony (VRC, Wake Forest). This latter colony was originally established 4 decades ago with 57 founder monkeys imported from St Kitts (Jasinska et&#160;al.&#160;<xref rid="acel70168-bib-0026" ref-type="bibr">2022</xref>). Additional internal datasets from Virscio's African green monkey blood samples were also included, resulting in a combined dataset of 336 samples. These samples were processed as previously described, with unreliable probes filtered out if detection <italic toggle="yes">p</italic> values exceeded 0.05 in more than 90% of the samples. To construct an epigenetic clock, the dataset was split into training (70%) and validation (30%) subsets. The preProcess function from the R package caret was used to remove variables with zero or near&#8208;zero variance, while also centering and scaling the beta value matrix. A 10&#8208;fold cross&#8208;validation procedure was employed to train an age predictor using the glmnet method, which implements elastic net regularization. The algorithm tested 10 different lambda values to identify the optimal parameter that minimized the root mean squared error. The resulting clock was validated on the independent validation dataset and subsequently used for determining the epigenetic age of animals of unknown chronological age used in the proteomic study reported here.</p></sec><sec id="acel70168-sec-0007"><label>2.5</label><title>Sample Collection for Proteomic Analysis</title><p>Samples of venous blood and cisternal CSF were collected from 25 male and 74 female African green monkeys of unknown chronological age, estimated to range between 4 and 25&#8201;years old based on physical characteristics and behavior (Wakeman et&#160;al.&#160;<xref rid="acel70168-bib-0052" ref-type="bibr">2022</xref>). Animals were food fasted overnight before collections that took place between 9&#8201;am and 1&#8201;pm; specifically occurring between 9 and 10&#8201;am for 12%, between 10 and 11&#8201;am for 66%, between 11&#8201;am and noon for 19%, and between noon and 1&#8201;pm for 3%. Each CSF sample was divided among cryotubes and quickly stored within a &#8722;80&#176;C freezer. Each blood sample was added to a lithium heparin vacutainer tube, gently mixed, stored on ice, and within 1&#8201;h for the majority and 2&#8201;h for all samples, centrifuged for 10&#8201;min at 1300 &#215; g at 4&#176;C to separate plasma, which was removed and quickly stored in cryotubes within a &#8722;80&#176;C freezer. Plasma and CSF samples were shipped in a liquid nitrogen vapor shipper to Virscio laboratories (New Haven, CT) and stored in a &#8722;80&#176;C freezer until delivery on dry ice to Olink Proteomics (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://olink.com" ext-link-type="uri">https://olink.com</ext-link>) for analysis on the &#8220;Olink Explore 1536&#8221; platform, a multiplex proximity ligation immunoassay allowing the detection and quantification of 1463 unique proteins in each sample. The time between sample freezing at SKBRF and first thawing of samples immediately before analysis at Olink was between 7 and 14&#8201;months. The collection and storage conditions used are in accordance with data from Olink regarding optimal sample processing for proteomics (Shen et&#160;al.&#160;<xref rid="acel70168-bib-0048" ref-type="bibr">2018</xref>). Sequence similarity of the assayed human proteins to their African green monkey orthologs was verified and was overall very high (Figure&#160;<xref rid="acel70168-supitem-0001" ref-type="supplementary-material">S1</xref>). Subsequently, after establishing the epigenetic blood clock for the African green monkey (described above), most of the animals (21 male and 60 female) used for the Olink proteomic analyses were resampled to collect another blood sample for extraction of DNA, as described above, for determination of epigenetic ages, which was used as the independent variable in the proteomic analyses.</p></sec><sec id="acel70168-sec-0008"><label>2.6</label><title>Statistics: Protein Data Analyses</title><p>The dependent variable for the Olink protein assay is a normalized protein expression (NPX) value, which is an arbitrary relative quantification unit on a log2 scale, based on the number of cycles needed for the fluorescent signal to surpass a threshold line in the qPCR analysis for each protein (cycle threshold, Ct). A high NPX value corresponds to a high protein concentration, and because NPX is on a log2 scale, a 1 unit NPX increase represents a doubling of protein concentration. The Olink quality control consists of four internal controls that are spiked into every sample and are designed to monitor the three main steps of the Olink protocol: immunoreaction, extension, and amplification/detection. A principal component analysis was performed on the NPX values in CSF or plasma samples together and separately (R package stats, v4.4.1). A scatterplot of the first two principal components was examined to identify outlier samples; no sample was eliminated from data analyses.</p><p>The initial analyses to detect age&#8208;dependent protein NPX values used an analysis of variance (ANOVA) with the Benjamini&#8211;Hochberg method to correct for multiple comparisons (Lualdi and Fasano&#160;<xref rid="acel70168-bib-0039" ref-type="bibr">2019</xref>). Proteins that passed an adjusted <italic toggle="yes">p</italic> value threshold of 0.05 were then used in post hoc testing of pairwise differences in abundance among 3 predefined epigenetic age groups. The chosen age bins were chosen to reflect developmental timelines for this species and to balance sample sizes within each bin (Figure&#160;<xref rid="acel70168-supitem-0001" ref-type="supplementary-material">S2A</xref>). Four years of age marks the approximate onset of sexual maturity, so the 4&#8211;11&#8201;years group corresponds to young adults (Y), with the 12&#8211;19&#8201;years group representing middle&#8208;age (M), with animals &#8805;&#8201;19&#8201;years being referred to as aged (A). In addition, a linear regression analysis was performed (epigenetic age vs. NPX value) for each protein that exhibited significant changes across the 3 age bins to determine the strength of the association between individual protein abundance and age in CSF and in plasma.</p><p>Subsequently, the limma R/Bioconductor package (3.60.6) was used to identify differential expression of proteins according to age after loess normalizing of NPX values (Ritchie et&#160;al.&#160;<xref rid="acel70168-bib-0045" ref-type="bibr">2015</xref>). Later on, machine learning techniques including gradient boosting (R package XGBoost v1.7.8.1) and k&#8208;means clustering (R package stats v4.4.1) were used (Bock&#160;<xref rid="acel70168-bib-0007" ref-type="bibr">2008</xref>; Chen and Guestrin&#160;<xref rid="acel70168-bib-0011" ref-type="bibr">2016</xref>). It was anticipated that these algorithms would reveal more complex relationships in the data than ANOVA and would help in analyzing, interpreting, and visualizing the proteomic data.</p></sec><sec id="acel70168-sec-0009"><label>2.7</label><title>Statistics: Summary</title><p>The main goals of the study were (1) to identify novel proteins in plasma and CSF that change in abundance during epigenetic aging, (2) to discern how accurately a small subset of specific CSF or plasma proteins could predict epigenetic age (&#8220;protein clocks&#8221;), and (3) to identify specific cellular pathways affected by epigenetic aging, using Ingenuity Pathway Analysis (Kramer et&#160;al.&#160;<xref rid="acel70168-bib-0032" ref-type="bibr">2014</xref>).</p></sec></sec><sec sec-type="results" id="acel70168-sec-0010"><label>3</label><title>Results</title><sec id="acel70168-sec-0011"><label>3.1</label><title>African Green Monkey Blood Clock</title><p>Based on DNA methylation patterns, an epigenetic clock was constructed using DNA extracted from the blood of St Kitts African green monkeys having a known birth date. The final model was optimized with a lambda value of 0.98, which minimized the root mean squared error (RMSE) during the 10&#8208;fold cross&#8208;validation process. This lambda value was used in the final epigenetic clock model, which was validated on the independent validation dataset. The resulting model was able to predict epigenetic age with high confidence (correlation coefficient (<italic toggle="yes">r</italic>) 0.97, coefficient of determination (<italic toggle="yes">R</italic>
<sup>2</sup>) 0.93, and a mean absolute error (MAE) of 1.2&#8201;years). This clock was then used to derive the epigenetic age of each monkey in the proteomic study of aging (Figure&#160;<xref rid="acel70168-fig-0001" ref-type="fig">1</xref>). The median epigenetic clock age of animals in the study was 18&#8201;&#177;&#8201;4.4&#8201;years.</p><fig position="float" fig-type="FIGURE" id="acel70168-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Establishing an African green monkey epigenetic blood clock. DNA methylation analysis was conducted on blood samples from 336 animals of known chronological age; 70% were used for model construction and remaining 100 samples were used for the shown validation. The 100 animals comprised both female and males with mean age: 6.5&#8201;&#177;&#8201;6.7&#8201;years; 64 females with mean age: 7.5&#8201;&#177;&#8201;7.3&#8201;years; 35 males with mean age: 4.5&#8201;&#177;&#8201;2.4&#8201;years. The figure shows a linear regression of chronological versus epigenetic age with annotation of the coefficient of determination (<italic toggle="yes">R</italic>
<sup>2</sup>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="ACEL-24-e70168-g005.jpg"/></fig></sec><sec id="acel70168-sec-0012"><label>3.2</label><title>Initial Analysis of Proteomic Data</title><p>The levels of 1463 CSF and plasma proteins were determined in 81 animals and expressed as NPX values (Figure&#160;<xref rid="acel70168-supitem-0001" ref-type="supplementary-material">S2B</xref>). We performed principal component analysis (PCA) based on loess normalized CSF and plasma protein levels (Figure&#160;<xref rid="acel70168-fig-0002" ref-type="fig">2A</xref>) and observed a clear separation between plasma and CSF samples on the first principal component, explaining 87.8% of the observed variance (Figure&#160;<xref rid="acel70168-supitem-0001" ref-type="supplementary-material">S3</xref>). When performing PCA on CSF (Figure&#160;<xref rid="acel70168-fig-0002" ref-type="fig">2B</xref>) or plasma (Figure&#160;<xref rid="acel70168-fig-0002" ref-type="fig">2C</xref>) samples separately, no obvious clustering of samples was detected, neither based on sex nor epigenetic age.</p><fig position="float" fig-type="FIGURE" id="acel70168-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Cluster analysis and determination of differentially expressed proteins. Principal component analyses for unsupervised sample clustering were performed based on top 150 (A) CSF and plasma, (B) CSF, (C) plasma loess normalized NPX values, showing distribution based on either sex (upper panel of A, B, C) or epigenetic years (lower panels of A, B, C). In 2A&#8211;C, CSF samples are depicted as circles and plasma as triangles. Using limma with epigenetic age as continuous variable, differences in (D) CSF and (E) plasma protein levels between young and aged animals were analyzed.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="ACEL-24-e70168-g007.jpg"/></fig><p>We used an ANOVA with post hoc testing to identify proteins that exhibited progressive significant changes across 3 predefined age groups (i.e., Y &gt; M &gt; A or Y &lt; M &lt; A; Table&#160;<xref rid="acel70168-supitem-0002" ref-type="supplementary-material">S1A</xref>). In addition to the two proteins displaying such a pattern in CSF, there were 47 additional CSF proteins and 100 plasma proteins that had significant changes in protein abundance across 2 of 3 age group combinations (e.g., Y &lt; M, Y &lt; A, and Y &#8814; M); eight of these proteins were in both CSF and plasma (ACVRL1, COL1A1, CST1, EDA2R, FGFR2, KLK6, OXT, and TNFRSF19). The 10 CSF and 10 plasma proteins that demonstrated the highest degrees of significance are in Table&#160;<xref rid="acel70168-supitem-0002" ref-type="supplementary-material">S1B</xref>. In addition, to examine to what extent age contributed to the variance in abundance for individual proteins in Table&#160;<xref rid="acel70168-supitem-0002" ref-type="supplementary-material">S1</xref>, linear regression analyses were performed, with statistical results shown in those tables. A two&#8208;way analysis of variance (ANOVA) model using age and sex as independent variables was run to assess which proteins exhibited male&#8211;female differences in the levels of age&#8208;dependent proteins or a sex*age interaction. This indicated that there was a significant main effect of sex for no proteins in CSF and 44 plasma proteins and a sex*age interaction for no proteins in CSF and 2 plasma (GNE and PPCDC) proteins; however, none of these proteins were among those identified by later analyses as relevant for age prediction.</p></sec><sec id="acel70168-sec-0013"><label>3.3</label><title>Unbiased Determination of Age&#8208;Related Changes in <styled-content style="fixed-case" toggle="no">CSF</styled-content> and Plasma Proteins</title><p>Using limma with a model including age as a continuous variable, we identified 188 CSF and 99 plasma proteins significantly associated with age (FDR&#8201;&lt;&#8201;0.05; Figure&#160;<xref rid="acel70168-fig-0002" ref-type="fig">2D,E</xref>). However, the size of age&#8208;dependent changes was low (CSF: mean logFC&#8201;=&#8201;0.025&#8201;&#177;&#8201;0.07; Plasma: mean logFC&#8201;=&#8201;0.007&#8201;&#177;&#8201;0.06). To establish an alternative unbiased epigenetic age cutoff between young and aged animals, we performed k&#8208;means clustering to partition sets of proteins into statistically separate clusters based on their correlation to epigenetic age. A preliminary examination of the distribution of correlations among the proteins revealed, as expected, that relatively few proteins (correlation greater than: number of proteins; &#177;0.4: 93; &#177;0.5: 15; &#177;0.6: 2) exhibited a strong correlation with age (Figure&#160;<xref rid="acel70168-supitem-0001" ref-type="supplementary-material">S4A</xref>). Cluster analysis based on proteins with an epigenetic age&#8208;correlation coefficient of &gt;&#177;0.4 to &#177;0.6 grouped animals into two clusters with significantly different mean ages. The mean age of animals contained in the cluster of older animals was around 19&#8201;years (&#177;0.4/&#177;0.5: 18.8&#8201;&#177;&#8201;1.9&#8201;years; &#177;0.6: 18.75&#8201;&#177;&#8201;2.1&#8201;years), while the mean age of animals grouped into the cluster of younger animals varied between 9.2&#8201;&#177;&#8201;5.6 and 13.4&#8201;&#177;&#8201;7&#8201;years (Figure&#160;<xref rid="acel70168-supitem-0001" ref-type="supplementary-material">S4B</xref>).</p><p>Next, we performed PCA analysis using 93 proteins with a Spearman coefficient of &gt; &#177;0.4. Confirming k&#8208;means clustering, PCA resulted in a clear separation of animals into young (5&#8211;10&#8201;years) and aged animals (&gt;&#8201;16&#8201;years) with intermediate aged animals (11&#8211;15&#8201;years) located between these two clusters (Figure&#160;<xref rid="acel70168-supitem-0001" ref-type="supplementary-material">S4C</xref>). We then explored whether epigenetic age can be inferred from the levels of age&#8208;correlating proteins. For this, we fitted a linear model for each of the 93 best age&#8208;correlated proteins (Spearman &gt; &#177;0.4) on a training set generated by a 70:30 split (training:holdout&#8212;Figure&#160;<xref rid="acel70168-supitem-0001" ref-type="supplementary-material">S5</xref>) and predicted the epigenetic age of the holdout samples by averaging the predicted ages across the 93 proteins used. As shown in Figure&#160;<xref rid="acel70168-supitem-0001" ref-type="supplementary-material">S4D</xref>, calculation of epigenetic age for samples in the holdout data set did not yield accurate age prediction. While the age of older animals was underestimated, the age of younger animals was overestimated. We confirmed this through the analysis of residuals showing non&#8208;normal distribution (Anderson&#8208;Darling test: A&#8201;=&#8201;0.76; <italic toggle="yes">p</italic> value&#8201;=&#8201;0.04) indicative of insufficient modeling accuracy.</p></sec><sec id="acel70168-sec-0014"><label>3.4</label><title>Identification of Age&#8208;Predictive Proteins Through <styled-content style="fixed-case" toggle="no">XGBoost</styled-content> Analysis</title><p>To improve epigenetic age prediction, we used XGBoost regularizing gradient boosting to infer epigenetic age from plasma and CSF protein levels. For this, we randomly split the sample data from the 81 animals into a training (57 animals) and hold&#8208;out test set (24 animals) while preserving age distribution (Figure&#160;<xref rid="acel70168-supitem-0001" ref-type="supplementary-material">S5</xref>). Following hyperparameter tuning, we generated XGBoost models based on plasma and/or CSF protein levels (Figure&#160;<xref rid="acel70168-fig-0003" ref-type="fig">3A</xref>). We found that hyperparameter tuned models trained on levels of all proteins (both in CSF and plasma) were able to predict epigenetic age from hold&#8208;out data with a mean error of 3.3&#8201;years and an <italic toggle="yes">R</italic>
<sup>2</sup>&#8201;=&#8201;0.68. Models trained only on CSF or only on plasma protein levels were slightly less predictive with a mean error of 3.7&#8201;years (<italic toggle="yes">R</italic>
<sup>2</sup>&#8201;=&#8201;0.32) and 3.0&#8201;years (<italic toggle="yes">R</italic>
<sup>2</sup>&#8201;=&#8201;0.76), respectively. Analysis of residuals confirmed a reduction of the age underestimation for older animals and age overestimation for younger animals (Figure&#160;<xref rid="acel70168-fig-0003" ref-type="fig">3B</xref>).</p><fig position="float" fig-type="FIGURE" id="acel70168-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>XGBoost modeling to predict epigenetic age from CSF and plasma NPX values. (A) A dataset of 1472 CSF and 1472 NPX plasma levels from 81 animals was randomly split 70:30 into a training and test dataset, respectively (see Figure&#160;<xref rid="acel70168-supitem-0001" ref-type="supplementary-material">S5</xref>). Hyperparameter&#8208;optimized XGBoost models for regressing epigenetic age from CSF and/or plasma protein features were trained on the training dataset and epigenetic age of animals in the test dataset was predicted. Shown are linear models of epigenetic versus predicted age of animals in the test dataset with the respective coefficient of determination (<italic toggle="yes">R</italic>
<sup>2</sup>) and (B) Anderson&#8208;Darling testing of residuals for normality as measure of model robustness. Annotation: MPE is the mean prediction error in years, A is the Anderson&#8208;Darling statistics and its <italic toggle="yes">p</italic> value, with <italic toggle="yes">p</italic>&#8201;&gt;&#8201;0.05 signifying normal distribution of residuals.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="ACEL-24-e70168-g006.jpg"/></fig><p>In a next step, we aimed at minimizing the feature space for XGBoost model training, while retaining predictive power, in order to identify a reduced set of proteins for epigenetic age prediction. For this, we selected 50 high&#8208;gain protein features (CSF&#8201;+&#8201;plasma, CSF, plasma) that contributed to the predictive power of the above&#8208;described XGBoost models (Figure&#160;<xref rid="acel70168-supitem-0001" ref-type="supplementary-material">S6</xref>). Using hyperparameter tuning (Figure&#160;<xref rid="acel70168-supitem-0001" ref-type="supplementary-material">S7</xref>), we trained additional XGBoost models on decreasing numbers of features and evaluated their performance by repeatedly predicting epigenetic age and determining <italic toggle="yes">R</italic>
<sup>2</sup> of the resulting predicted vs. epigenetic age linear model (Figure&#160;<xref rid="acel70168-fig-0004" ref-type="fig">4</xref>). Interestingly, we found that models trained on only 10 plasma protein features had predictive power comparable to models trained on complete feature sets (<italic toggle="yes">R</italic>
<sup>2</sup> for linear fit of predicted vs. known epigenetic age: Top 10 plasma&#8212;<italic toggle="yes">R</italic>
<sup>2</sup>: 0.72). Similarly, 10 protein features were sufficient to generate XGBoost models with high predictive power for CSF (<italic toggle="yes">R</italic>
<sup>2</sup>: 0.52) and for CSF&#8201;+&#8201;plasma (<italic toggle="yes">R</italic>
<sup>2</sup>: 0.46). As shown in Figure&#160;<xref rid="acel70168-fig-0004" ref-type="fig">4</xref>, XGBoost models based on 10 highest&#8208;gain CSF and/or plasma features and above established hyperparameters predicted epigenetic age with &#177;2.5 (plasma), &#177;2.7 (CSF), and &#177;3.0 (CSF&#8201;+&#8201;plasma) years with normal residual distribution. Thus, limiting the feature space did not negatively impact model performance.</p><fig position="float" fig-type="FIGURE" id="acel70168-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Determination of minimally effective XGBoost feature space. (A) Between 10 and 50 CSF and/or plasma protein features identified as high gain in XGBoost models trained on complete datasets of 1472 CSF and/or plasma protein features (compare to Figure&#160;<xref rid="acel70168-fig-0003" ref-type="fig">3</xref>) were used for XGBoost model hyperparameter optimization. Based on the best performing hyperparameter set (compare to Figure&#160;<xref rid="acel70168-supitem-0001" ref-type="supplementary-material">S7</xref>), XGBoost models were trained on the 70:30 training dataset (Figure&#160;<xref rid="acel70168-supitem-0001" ref-type="supplementary-material">S5</xref>) and used to regress epigenetic age of the test data set with the boxplot. Plots are annotated with the R<sup>2</sup> of the resulting linear regressions, the mean prediction error (MPE) in years, and the Anderson&#8208;Darling test for residual distribution analysis (A and p).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="ACEL-24-e70168-g001.jpg"/></fig></sec><sec id="acel70168-sec-0015"><label>3.5</label><title>Comparing Age&#8208;Correlating Proteins With <styled-content style="fixed-case" toggle="no">XGBoost</styled-content> Protein Feature Set</title><p>As XGBoost models outperformed linear model&#8208;based age prediction, we analyzed the overlap between XGBoost high gain features with proteins showing the highest age&#8208;correlated CSF and/or plasma levels based on Spearman coefficients. Interestingly, among the smallest set (<italic toggle="yes">n</italic>&#8201;=&#8201;10) of CSF and plasma protein features used for XGBoost modeling, several correlated with epigenetic age and had a Spearman coefficient &gt;&#8201;&#177;0.5 (Figure&#160;<xref rid="acel70168-fig-0005" ref-type="fig">5A</xref>&#8212;CSF: CA14, EDA2R, and PAEP; plasma: ACVRL1, COL1A1, EDA2R, FABP4, and IL7R). Furthermore, out of 15 CSF or plasma protein features correlating with age (Spearman coefficient &gt;&#8201;&#177;0.5), 5 did not contribute with high gain to XGBoost models; however, 5 age&#8208;correlating CSF protein features (CA14, CHI3L1, CPB1, EDA2R, and PAEP) and 5 plasma protein features (ACVRL1, COL1A1, EDA2R, FABP4, and IL7R) had predictive value during XGBoost modeling (Figure&#160;<xref rid="acel70168-fig-0005" ref-type="fig">5B</xref>). The smallest set (<italic toggle="yes">n</italic>&#8201;=&#8201;10) of high gain XGBoost protein features contained some with Spearman correlation &lt; &#177;0.5 in CSF (CD69, COL1A1, GDF15, LAIR1, PIGR, SERPINA12 and SH2B3) and in plasma (ADM, CALCA, COL9A1, HMOX1, and PRELP). As 10 high gain features were sufficient for generating well&#8208;performing XGBoost models, we used these 10 protein features to perform k&#8208;means clustering (Figure&#160;<xref rid="acel70168-fig-0005" ref-type="fig">5C</xref>). Using silhouette plots, we first determined 2 as the optimal number of clusters. Plotting the principal component dimensions 1 and 2 illustrated a clear separation of both 2 clusters. Interestingly, cluster separation seemed most prominent when clustering was performed based on the 10 highest gain plasma features. Mean epigenetic age was 12.5&#8201;&#177;&#8201;5.4, 11.8&#8201;&#177;&#8201;5.5, and 7.4&#8201;&#177;&#8201;2.4&#8201;years for animals in cluster 1, and 18.5&#8201;&#177;&#8201;2.6, 18.2&#8201;&#177;&#8201;2.7, and 17.4&#8201;&#177;&#8201;3.6&#8201;years for animals in cluster 2 when considering the highest gain CSF&#8201;+&#8201;plasma, CSF, or plasma XGBoost features, respectively. Based on these clustering results, we categorized animals into 2 age groups (&lt;=10 and &gt;&#8201;10) for differential protein level analysis using limma. We found 74 plasma and 93 CSF proteins to have significantly different levels between young (&#8804;&#8201;10&#8201;years) and aged (&gt;&#8201;10&#8201;years) animals (Figure&#160;<xref rid="acel70168-fig-0006" ref-type="fig">6A,B</xref>). Table&#160;<xref rid="acel70168-supitem-0002" ref-type="supplementary-material">S3</xref> lists the most relevant epigenetic age&#8208;related proteins in CSF and plasma identified by ANOVA and XGBoost together with notation of their biological function and any previous associations with age.</p><fig position="float" fig-type="FIGURE" id="acel70168-fig-0005" orientation="portrait"><label>FIGURE 5</label><caption><p>Comparing proteins with age&#8208;correlated levels and XGBoost high gain protein features. (A) A compilation of CSF and/or plasma proteins with a Spearman correlation between NPX value and epigenetic age &gt;&#177;0.5 or the top 10 to top 50 protein features from XGBoost models trained on CSF and plasma, only CSF, or only plasma protein features. (B) The Venn diagrams highlight the overlap between age&#8208;correlating CSF and plasma proteins (Spearman &gt; &#177;0.5) and the top 50 proteins contributing to XGBoost modeling. (C) Samples from 81 animals were clustered using k&#8208;means using 10 CSF and/or plasma protein features selected based on their high XGBoost gain value. Shown are silhouette plots (left panel) to establish the number of clusters for the k&#8208;means algorithm, a PCA plot of the k&#8208;means result (middle panel) and the epigenetic age of the animals sorted into the respective cluster (right panel).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-11" orientation="portrait" xlink:href="ACEL-24-e70168-g002.jpg"/></fig><fig position="float" fig-type="FIGURE" id="acel70168-fig-0006" orientation="portrait"><label>FIGURE 6</label><caption><p>Proteins with age&#8208;related expression pattern are involved in immune&#8208;response pathways. To identify CSF (A) or plasma proteins (B) related to aging, differences in NPX protein values were modeled using limma between animals with an epigenetic age up to 10&#8201;years, and animals aged 11 and older. Highlighted in red are proteins with adjusted <italic toggle="yes">p</italic> value &lt;&#8201;0.05, labeled are the top 20 (10 up/10 down) CSF and plasma proteins with age&#8208;dependent differences in NPX value and highest <italic toggle="yes">p</italic> value after Benjamini&#8211;Hochberg adjustment for multiple testing. Using Ingenuity Pathway Analysis, the connection of age&#8208;regulated CSF and plasma proteins to diseases (C) and regulatory pathways (D) was analyzed. Color&#8208;coding of disease, function, and pathway names highlights involvement of CSF (blue), plasma (brown), or plasma and CSF proteins (magenta).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-13" orientation="portrait" xlink:href="ACEL-24-e70168-g003.jpg"/></fig><p>Using Ingenuity Pathway Analysis (Kramer et&#160;al.&#160;<xref rid="acel70168-bib-0032" ref-type="bibr">2014</xref>) on age&#8208;regulated CSF and plasma proteins, we evaluated whether specific diseases, functions, or molecular pathways were affected by aging. Overall, aging affected 49 disease processes (Figure&#160;<xref rid="acel70168-fig-0006" ref-type="fig">6C</xref>&#8212;CSF: 18; plasma: 31), as well as 21 molecular pathways (Figure&#160;<xref rid="acel70168-fig-0006" ref-type="fig">6D</xref>&#8212;CSF: 12; plasma: 9) with IPA activation <italic toggle="yes">z</italic>&#8208;scores between &#177;2.2 (Tables&#160;<xref rid="acel70168-supitem-0002" ref-type="supplementary-material">S4</xref> and <xref rid="acel70168-supitem-0002" ref-type="supplementary-material">S5</xref>).</p></sec></sec><sec sec-type="discussion" id="acel70168-sec-0016"><label>4</label><title>Discussion</title><p>The present study was successful in demonstrating a highly significant statistical relationship between chronological age of St Kitts African green monkeys and their epigenetic age, as determined by an analysis of discrete methylation sites in DNA extraction from each blood sample. The Mean Absolute Error is 1.2&#8201;years (<italic toggle="yes">r</italic>&#8201;=&#8201;0.97) which compares favorably with MAE 1.6 (<italic toggle="yes">r</italic>&#8201;=&#8201;0.95) obtained for rhesus monkey (Horvath et&#160;al.&#160;<xref rid="acel70168-bib-0024" ref-type="bibr">2021</xref>), the only other Old World monkey to have a species&#8208;specific epigenetic blood clock. The availability of this bioinformatics tool allows estimation of the epigenetic age of African green monkeys. Previous evidence has demonstrated that epigenetic clocks capture aspects of biological aging and that their rate of change can alter over time in response to relatively short&#8208;term experimental or environmental perturbations (Lu et&#160;al.&#160;<xref rid="acel70168-bib-0038" ref-type="bibr">2020</xref>; Stubbs et&#160;al.&#160;<xref rid="acel70168-bib-0050" ref-type="bibr">2017</xref>). Unlike chronological age, epigenetic age is derived by bioinformatics and necessarily associated with a degree of error; however, an advantage of using epigenetic age rather than chronological age in the current study is that the proteins associated with epigenetic age should provide insights into biological aging, which is more relevant than chronological age in understanding aging mechanisms and identifying antiaging intervention strategies.</p><p>Several studies have examined the relationship between human aging and changes in blood plasma or serum (Argentieri et&#160;al.&#160;<xref rid="acel70168-bib-0004" ref-type="bibr">2024</xref>; Coenen et&#160;al.&#160;<xref rid="acel70168-bib-0012" ref-type="bibr">2023</xref>; Johnson et&#160;al.&#160;<xref rid="acel70168-bib-0029" ref-type="bibr">2020</xref>; Kuo et&#160;al.&#160;<xref rid="acel70168-bib-0033" ref-type="bibr">2024</xref>; Sathyan et&#160;al.&#160;<xref rid="acel70168-bib-0047" ref-type="bibr">2020</xref>) or CSF (Baird et&#160;al.&#160;<xref rid="acel70168-bib-0006" ref-type="bibr">2012</xref>; Zhang et&#160;al.&#160;<xref rid="acel70168-bib-0055" ref-type="bibr">2005</xref>) proteomes. While each of these revealed proteins that alter in abundance in association with age, it is notable that there is a lack of consistency among the studies in the specific proteins identified, doubtless due to factors such as the diversity in subject genetics, lifestyle, and environmental exposures, in addition to differences in the proteomic platform employed and the method of quantification. A key advantage to the use of St Kitts origin African green monkeys for proteomic studies is their high level of homozygosity due to the geographic isolation of the population that propagated from only a few founder members originally introduced to the island (Jasinska et&#160;al.&#160;<xref rid="acel70168-bib-0027" ref-type="bibr">2013</xref>). Furthermore, the animals in this study would have experienced a more uniform array of environmental factors than subjects recruited for the human studies, with high technical consistency in specimen collection and analysis. There have been very few previous reports on the impact of age on the plasma or CSF proteome in nonhuman primates (Liu et&#160;al.&#160;<xref rid="acel70168-bib-0035" ref-type="bibr">2024</xref>; Varma et&#160;al.&#160;<xref rid="acel70168-bib-0051" ref-type="bibr">2024</xref>) and none that compared these 2 proteomes in the same subjects across the lifespan of the species.</p><p>ANOVA recognized proteins that exhibited a change in abundance across age groups and for which age alone accounted for a high degree of their variability. Notably, several of these age&#8208;related identified proteins in CSF, such as members of the tumor necrosis factor (TNF) receptor superfamily, have critical roles in regulating immune responses, inflammation, and cell survival (Aggarwal&#160;<xref rid="acel70168-bib-0001" ref-type="bibr">2003</xref>; Hunter and Jones&#160;<xref rid="acel70168-bib-0025" ref-type="bibr">2015</xref>). Interestingly, while strong links between aging and levels of EDA2R in blood have been previously noted (Harris et&#160;al.&#160;<xref rid="acel70168-bib-0021" ref-type="bibr">2020</xref>; Maggio et&#160;al.&#160;<xref rid="acel70168-bib-0040" ref-type="bibr">2006</xref>), the present finding of an association between these proteins in CSF and aging has not been reported before. No proteins were defined by ANOVA as being significantly altered across each age bin in both CSF and plasma together.</p><p>An ANOVA is unable to discern patterns of association between factors in a large dataset such as that generated by Olink. We were specifically interested in deriving a small subset of proteins in CSF, plasma, or both fluids that would reliably predict age and to compare the estimated accuracy of such a protein clock with our epigenetic clock. As the study population contained animals of a wide range of ages, statistical grouping of animals into young and aged based on differential protein abundances was not straightforward. Initial PCA and k&#8208;means clustering based on the entirety of measured proteins did not result in the clear separation of animals into two or more age groups. This is likely due to the large number of age&#8208;independent proteins confounding clustering into discernible age groups. Therefore, we focused on sub&#8208;groups of proteins with increasingly stronger associations with age. Using this approach, we identified a Spearman correlation coefficient cut&#8208;off of &#177;0.4 that only took proteins with a strong age&#8208;dependent component into account for clustering. While this allowed the grouping of animals meaningfully into young (&#8804;&#8201;10&#8201;years) and aged (&gt;&#8201;10&#8201;years), we reasoned that a simple Spearman cut&#8208;off might miss proteins contributing to aging with a less clear level&#8208;age relationship.</p><p>An alternative strategy utilizing XGBoost regularizing gradient boosting was better adapted to the Olink dataset, as reviewed by (Salehi et&#160;al.&#160;<xref rid="acel70168-bib-0046" ref-type="bibr">2022</xref>). Importantly, and in contrast to other machine learning approaches such as neural networks, XGBoost allows not only extraction of features that contribute to the predictive model but also reports their relative importance. An initial model trained on all proteins in either CSF or plasma predicted epigenetic age with a mean error of 3.7 and 3.0&#8201;years, respectively, associated with highly significant linear regressions. Encouraged by this finding, we explored whether improved predictive power could be achieved with a reduced set of proteins for epigenetic age regression. Remarkably, we found that XGBoost models based on 10 highest gain CSF or plasma features predicted epigenetic age with mean errors of &#177;2.7 and &#177;2.5&#8201;years, respectively, with normal residual distribution. K&#8208;means clustering analysis was then based on these top 10 proteins in CSF or in plasma, which yielded 2 distinct clusters approximately representing ages equal to or less than 10&#8201;years and over 10&#8201;years of age. This observation has an interesting parallel with a recent human study, which revealed nonlinear patterns in molecular markers of aging, with substantial dysregulation occurring at two major periods occurring at approximately 44&#8201;years and 60&#8201;years of chronological age (Shen et&#160;al.&#160;<xref rid="acel70168-bib-0049" ref-type="bibr">2024</xref>).</p><p>Age&#8208;related proteins found in the present study comprised some that had previously been linked with chronological progression and also disclosed several that had not previously been associated with aging in human studies. Those latter proteins could either represent nonhuman primate&#8208;specific aging proteins or those that were obscured by confounding factors in human&#8208;based studies. A comparison of the best blood protein predictors of human chronological age in the large recent study by Argentieri et&#160;al.&#160;(<xref rid="acel70168-bib-0004" ref-type="bibr">2024</xref>) with the optimized protein predictors of epigenetic age in the current nonhuman primate study (Figure&#160;<xref rid="acel70168-supitem-0001" ref-type="supplementary-material">S8</xref>) revealed many targets in common, whose relationships to aging mechanisms now deserve further attention. The statistical relationship between the level of individual proteins and epigenetic aging is noteworthy. For example, linear regression analyses revealed that over 40% of the variance in CSF EDA2R levels and CSF CHI3L1 levels was explained by epigenetic aging. In addition, Spearman rank correlation of 0.6 or greater existed for CSF EDA2R and PAEP. Not unexpectedly, the 2 statistical approaches (ANOVA, machine learning algorithms) deployed here revealed some overlap of the most strongly age&#8208;associated proteins, but the machine learning models were able to discern relationships between age&#8208;dependent proteins and derive a protein clock based on as low as 10 protein features that accurately predicted epigenetic age. Consequently, future studies utilizing African green monkeys could quantify alterations in aging trajectory using both the epigenetic clock and the protein clock.</p><p>Two general details of the identified CSF proteins linked with aging in the current study deserve further comment. Firstly, some of the proteins in CSF that were associated with aging do not have a well&#8208;defined role in the CNS (e.g., PAEP and REG1A) and this observation warrants further investigation of the possible function of such proteins in brain biochemistry. However, another observation, a tendency for CSF protein levels to increase with age, may at least in part explain the first point noted above. Proteins detected in the CSF are produced either by brain cells, the choroid plexus, or derived from the plasma by leaking through either the blood&#8211;brain barrier or the blood&#8208;CSF barrier. It is now appreciated that the blood&#8211;brain barrier functions less effectively in aged subjects (Yang et&#160;al.&#160;<xref rid="acel70168-bib-0054" ref-type="bibr">2020</xref>), essentially allowing higher molecular weight proteins to cross into the CNS more easily in older compared with younger subjects, with evidence for dysregulation of the blood&#8211;brain barrier becoming further exacerbated in certain neurodegenerative disorders (Knox et&#160;al.&#160;<xref rid="acel70168-bib-0031" ref-type="bibr">2022</xref>). Secondly, a reduction in CSF turnover occurs during aging, which has a significant concentrating effect on CSF proteins and has been suggested as the major determinant in causing CSF protein concentrations to increase during aging (Chen et&#160;al.&#160;<xref rid="acel70168-bib-0010" ref-type="bibr">2012</xref>). Consequently, the presence of a protein in CSF cannot be linked with certainty to its origin in CNS, and a change in concentration of a protein in CSF during aging cannot be assumed to be associated with altered CNS production of the protein. Despite such uncertainties surrounding the reason for detecting certain levels of protein in CSF, inclusion of them in a protein clock as a biomarker of aging is still a valid strategy.</p><p>Using a blood epigenetic clock, the current study identified age&#8208;related proteins circulating in body fluids that can be repeatedly and readily obtained, which is an advantage as these types of samples will have most utility in future longitudinal studies of aging in African green monkeys (and other species). While epigenetic clocks based on a specific tissue predict aging in that tissue somewhat better than blood clocks or universal clocks, the ability of blood epigenetic clocks to accurately predict age in different tissues indicates strong conservation of epigenetic aging mechanisms in different tissues (Hannum et&#160;al.&#160;<xref rid="acel70168-bib-0020" ref-type="bibr">2013</xref>; Richardson et&#160;al.&#160;<xref rid="acel70168-bib-0044" ref-type="bibr">2025</xref>). In addition, the ability of clocks generated in one species to accurately predict age in other species (Jasinska et&#160;al.&#160;<xref rid="acel70168-bib-0026" ref-type="bibr">2022</xref>; Lu et&#160;al.&#160;<xref rid="acel70168-bib-0037" ref-type="bibr">2023</xref>) supports the relevance to other primate species, including humans, of the presently derived African green monkey blood epigenetic clock and associated proteomic data. Subsets of proteins currently identified in plasma and CSF accurately track epigenetic age in African green monkeys, but it should be noted that recent human studies have modeled plasma proteomic data to detect organ&#8208;specific aging and organ&#8208;specific disease (Goeminne et&#160;al. <xref rid="acel70168-bib-0019" ref-type="bibr">2025</xref>). Thus, there is opportunity for future studies in African green monkeys to tune epigenetic and proteomic models to be more responsive to changes in specific tissues and organs either by constructing tissue&#8208;specific clocks or pan&#8208; or universal clocks with validation by biomarker evaluation at the tissue level.</p><p>Analysis of the biochemical processes that are linked with the age&#8208;associated proteins indicated that pathways activated in older compared to younger animals involves immunological processes as well as pathways related to tissue homeostasis and wound healing. These observations are consistent with a higher need for tissue repair and a general pro&#8208;inflammatory environment in aged animals. Interestingly, such a pro&#8208;inflammatory response was not only seen in plasma, but also in CSF of aged animals. Chronic low&#8208;grade inflammation (&#8220;inflammaging&#8221;) is a hallmark of aging, is linked to the pathogenesis of many age&#8208;related diseases, and is characterized by chronic activation of the innate immune system (Dugan et&#160;al.&#160;<xref rid="acel70168-bib-0016" ref-type="bibr">2023</xref>). The relevance of inflammaging to the progression of aging is supported by studies in long&#8208;lived mice (Arranz et&#160;al.&#160;<xref rid="acel70168-bib-0005" ref-type="bibr">2010</xref>) and centenarians (Arai et&#160;al.&#160;<xref rid="acel70168-bib-0003" ref-type="bibr">2015</xref>), who exhibit relatively low levels of systemic inflammation. Although a small subset of proteins statistically linked with aging in the present study can together form an impressively accurate protein clock to predict epigenetic and biological aging, it does not quite match the strength of correlation between age and DNA methylation in the African green monkey. However, much more is known of the function of the individual proteins in a protein clock than is understood about the influence that methylation exerts on the separate CpG sites that comprise the DNA clock. This offers the prospect of tailoring a protein clock to a particular physiological function in addition to a version responsive to the more global effects of aging. For example, a subset of CSF or plasma proteins involved in inflammation that have a high statistical link with aging could be combined to form a protein inflammaging clock. In addition, because of the evidence for inflammation being an important component of Alzheimer disease (Heneka et&#160;al.&#160;<xref rid="acel70168-bib-0022" ref-type="bibr">2024</xref>), changes in the plasma or CSF proteomic markers could be a valuable approach to tracking progression or amelioration of the pathology in African green monkey models, such as in induced (Wakeman et&#160;al.&#160;<xref rid="acel70168-bib-0052" ref-type="bibr">2022</xref>) or age&#8208;related (Corey et&#160;al.&#160;<xref rid="acel70168-bib-0014" ref-type="bibr">2023</xref>; Latimer et&#160;al.&#160;<xref rid="acel70168-bib-0034" ref-type="bibr">2019</xref>; Varma et&#160;al.&#160;<xref rid="acel70168-bib-0051" ref-type="bibr">2024</xref>) models of Alzheimer's disease. Varma et&#160;al.&#160;(<xref rid="acel70168-bib-0051" ref-type="bibr">2024</xref>) used circumscribed proteomic platforms to explore the relationship between changes in plasma and CSF proteins as a function of aging, sex, cognitive decline, and levels of the putative Alzheimer's disease biomarkers in African green monkeys. By reporting associations between these multiple endpoints, including changes in proteins related to immune&#8208;related inflammation, metabolism, and cellular processes, this study strongly supports the use of African green monkeys in age&#8208;related studies.</p><p>Collectively, this study demonstrates that large&#8208;scale plasma and CSF proteomics coupled with machine learning can be leveraged to measure and track aging in nonhuman primates by minimally invasive means. The derivation of accurate CSF and plasma protein clocks for the African green monkey will enable longitudinal evaluation of changes in a small subset of proteins to be a reliable indicator of epigenetic age and biological age in the African green monkey and should also be of relevance to tracking biological age&#8208;related changes in other species of Old World monkeys and humans. The availability of these tools in addition to the blood epigenetic clock for the African green monkey should enable the testing of novel antiaging interventions and their translation to humans to extend healthspan. The blood and CSF clocks constructed here could be further informed by additional analyses of CSF and plasma from animals at the very young and old ranges of the population demographic. Future studies in African green monkeys will further validate the accuracy of protein clocks in predicting epigenetic age and delineate the relationship between these indices of aging in this species with telomere shortening, senescent cell accumulation, and behavioral hallmarks of aging, such as muscle strength, motor coordination, and cognitive performance.</p></sec><sec id="acel70168-sec-0017"><title>Author Contributions</title><p>J.D.E., D.R.W., and M.S.L. conceived the study; J.D.E. and D.R.W. collected the data; A.N., J.R., J.G., M.M., and L.D. analyzed the data; J.D.E. and A.N. wrote the manuscript; J.R., M.M., M.S.L., D.R.W., B.D., and C.A. revised the manuscript.</p></sec><sec sec-type="COI-statement" id="acel70168-sec-0019"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="acel70168-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
Figures&#160;S1&#8211;S8.
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ACEL-24-e70168-s002.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="acel70168-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>
Tables S1&#8211;S5.
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ACEL-24-e70168-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="acel70168-sec-0018"><title>Acknowledgements</title><p>We thank Dr. Russ Addis and Dr. Tamas Horvath for their valuable contributions toward the initial concept and planning of the study. The authors also acknowledge the excellent assistance from the veterinary and animal care teams at the St. Kitts Biomedical Research Foundation.</p></ack><sec sec-type="data-availability" id="acel70168-sec-0021"><title>Data Availability Statement</title><p>All data that support the findings of this study are available from the authors upon request.</p></sec><ref-list content-type="cited-references" id="acel70168-bibl-0001"><title>References</title><ref id="acel70168-bib-0001"><mixed-citation publication-type="journal" id="acel70168-cit-0001"><string-name name-style="western"><surname>Aggarwal</surname>, <given-names>B. B.</given-names></string-name><year>2003</year>. &#8220;<article-title>Signalling Pathways of the TNF Superfamily: A Double&#8208;Edged Sword</article-title>.&#8221; <source>Nature Reviews. Immunology</source><volume>3</volume>, no. <issue>9</issue>: <fpage>745</fpage>&#8211;<lpage>756</lpage>. <pub-id pub-id-type="doi">10.1038/nri1184</pub-id>.</mixed-citation></ref><ref id="acel70168-bib-0002"><mixed-citation publication-type="journal" id="acel70168-cit-0002"><collab collab-type="authors">Aging Biomarker Consortium</collab>
. <year>2023</year>. &#8220;<article-title>Biomarkers of Aging</article-title>.&#8221; <source>Science China. Life Sciences</source><volume>66</volume>, no. <issue>5</issue>: <fpage>893</fpage>&#8211;<lpage>1066</lpage>. <pub-id pub-id-type="doi">10.1007/s11427-023-2305-0</pub-id>.<pub-id pub-id-type="pmid">37076725</pub-id><pub-id pub-id-type="pmcid">PMC10115486</pub-id></mixed-citation></ref><ref id="acel70168-bib-0003"><mixed-citation publication-type="journal" id="acel70168-cit-0003"><string-name name-style="western"><surname>Arai</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><given-names>C. M.</given-names><surname>Martin&#8208;Ruiz</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Takayama</surname></string-name>, et&#160;al. <year>2015</year>. &#8220;<article-title>Inflammation, but Not Telomere Length, Predicts Successful Ageing at Extreme Old Age: A Longitudinal Study of Semi&#8208;Supercentenarians</article-title>.&#8221; <source>eBioMedicine</source><volume>2</volume>, no. <issue>10</issue>: <fpage>1549</fpage>&#8211;<lpage>1558</lpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2015.07.029</pub-id>.<pub-id pub-id-type="pmid">26629551</pub-id><pub-id pub-id-type="pmcid">PMC4634197</pub-id></mixed-citation></ref><ref id="acel70168-bib-0004"><mixed-citation publication-type="journal" id="acel70168-cit-0004"><string-name name-style="western"><surname>Argentieri</surname>, <given-names>M. A.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Xiao</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Bennett</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Proteomic Aging Clock Predicts Mortality and Risk of Common Age&#8208;Related Diseases in Diverse Populations</article-title>.&#8221; <source>Nature Medicine</source><volume>30</volume>, no. <issue>9</issue>: <fpage>2450</fpage>&#8211;<lpage>2460</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-024-03164-7</pub-id>.</mixed-citation></ref><ref id="acel70168-bib-0005"><mixed-citation publication-type="journal" id="acel70168-cit-0005"><string-name name-style="western"><surname>Arranz</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Lord</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>De la Fuente</surname></string-name>. <year>2010</year>. &#8220;<article-title>Preserved Ex&#160;Vivo Inflammatory Status and Cytokine Responses in Naturally Long&#8208;Lived Mice</article-title>.&#8221; <source>Age (Dordrecht, Netherlands)</source><volume>32</volume>, no. <issue>4</issue>: <fpage>451</fpage>&#8211;<lpage>466</lpage>. <pub-id pub-id-type="doi">10.1007/s11357-010-9151-y</pub-id>.<pub-id pub-id-type="pmid">20508994</pub-id><pub-id pub-id-type="pmcid">PMC2980596</pub-id></mixed-citation></ref><ref id="acel70168-bib-0006"><mixed-citation publication-type="journal" id="acel70168-cit-0006"><string-name name-style="western"><surname>Baird</surname>, <given-names>G. S.</given-names></string-name>, <string-name name-style="western"><given-names>S. K.</given-names><surname>Nelson</surname></string-name>, <string-name name-style="western"><given-names>T. R.</given-names><surname>Keeney</surname></string-name>, et&#160;al. <year>2012</year>. &#8220;<article-title>Age&#8208;Dependent Changes in the Cerebrospinal Fluid Proteome by Slow Off&#8208;Rate Modified Aptamer Array</article-title>.&#8221; <source>American Journal of Pathology</source><volume>180</volume>, no. <issue>2</issue>: <fpage>446</fpage>&#8211;<lpage>456</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2011.10.024</pub-id>.<pub-id pub-id-type="pmid">22122984</pub-id><pub-id pub-id-type="pmcid">PMC3349859</pub-id></mixed-citation></ref><ref id="acel70168-bib-0007"><mixed-citation publication-type="journal" id="acel70168-cit-0007"><string-name name-style="western"><surname>Bock</surname>, <given-names>H.</given-names></string-name><year>2008</year>. &#8220;<article-title>Origins and Extensions of the k&#8208;Means Algorithm in Cluster Analysis</article-title>.&#8221; <source>Electronic Journal for History of Probability and Statistics</source><volume>4</volume>: <fpage>1</fpage>&#8211;<lpage>18</lpage>.</mixed-citation></ref><ref id="acel70168-bib-0008"><mixed-citation publication-type="journal" id="acel70168-cit-0008"><string-name name-style="western"><surname>Bruunsgaard</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><given-names>A. N.</given-names><surname>Pedersen</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Schroll</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Skinhoj</surname></string-name>, and <string-name name-style="western"><given-names>B. K.</given-names><surname>Pedersen</surname></string-name>. <year>2000</year>. &#8220;<article-title>TNF&#8208;Alpha, Leptin, and Lymphocyte Function in Human Aging</article-title>.&#8221; <source>Life Sciences</source><volume>67</volume>, no. <issue>22</issue>: <fpage>2721</fpage>&#8211;<lpage>2731</lpage>. <pub-id pub-id-type="doi">10.1016/s0024-3205(00)00851-1</pub-id>.<pub-id pub-id-type="pmid">11105988</pub-id></mixed-citation></ref><ref id="acel70168-bib-0009"><mixed-citation publication-type="journal" id="acel70168-cit-0009"><string-name name-style="western"><surname>Campisi</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Kapahi</surname></string-name>, <string-name name-style="western"><given-names>G. J.</given-names><surname>Lithgow</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Melov</surname></string-name>, <string-name name-style="western"><given-names>J. C.</given-names><surname>Newman</surname></string-name>, and <string-name name-style="western"><given-names>E.</given-names><surname>Verdin</surname></string-name>. <year>2019</year>. &#8220;<article-title>From Discoveries in Ageing Research to Therapeutics for Healthy Ageing</article-title>.&#8221; <source>Nature</source><volume>571</volume>, no. <issue>7764</issue>: <fpage>183</fpage>&#8211;<lpage>192</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-019-1365-2</pub-id>.<pub-id pub-id-type="pmid">31292558</pub-id><pub-id pub-id-type="pmcid">PMC7205183</pub-id></mixed-citation></ref><ref id="acel70168-bib-0010"><mixed-citation publication-type="journal" id="acel70168-cit-0010"><string-name name-style="western"><surname>Chen</surname>, <given-names>C. P.</given-names></string-name>, <string-name name-style="western"><given-names>R. L.</given-names><surname>Chen</surname></string-name>, and <string-name name-style="western"><given-names>J. E.</given-names><surname>Preston</surname></string-name>. <year>2012</year>. &#8220;<article-title>The Influence of Ageing in the Cerebrospinal Fluid Concentrations of Proteins That Are Derived From the Choroid Plexus, Brain, and Plasma</article-title>.&#8221; <source>Experimental Gerontology</source><volume>47</volume>, no. <issue>4</issue>: <fpage>323</fpage>&#8211;<lpage>328</lpage>. <pub-id pub-id-type="doi">10.1016/j.exger.2012.01.008</pub-id>.<pub-id pub-id-type="pmid">22532968</pub-id></mixed-citation></ref><ref id="acel70168-bib-0011"><mixed-citation publication-type="miscellaneous" id="acel70168-cit-0011"><string-name name-style="western"><surname>Chen</surname>, <given-names>T.</given-names></string-name>, and <string-name name-style="western"><given-names>C.</given-names><surname>Guestrin</surname></string-name>. <year>2016</year>. <article-title>&#8220;XGBoost: A Scalable Tree Boosting System. Paper Presented at the KDD'16: Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, San Francisco, CA.&#8221;</article-title></mixed-citation></ref><ref id="acel70168-bib-0012"><mixed-citation publication-type="journal" id="acel70168-cit-0012"><string-name name-style="western"><surname>Coenen</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Lehallier</surname></string-name>, <string-name name-style="western"><given-names>H. E.</given-names><surname>de Vries</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Middeldorp</surname></string-name>. <year>2023</year>. &#8220;<article-title>Markers of Aging: Unsupervised Integrated Analyses of the Human Plasma Proteome</article-title>.&#8221; <source>Frontiers in Aging</source><volume>4</volume>: <elocation-id>1112109</elocation-id>. <pub-id pub-id-type="doi">10.3389/fragi.2023.1112109</pub-id>.<pub-id pub-id-type="pmid">36911498</pub-id><pub-id pub-id-type="pmcid">PMC9992741</pub-id></mixed-citation></ref><ref id="acel70168-bib-0013"><mixed-citation publication-type="journal" id="acel70168-cit-0013"><string-name name-style="western"><surname>Colicino</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Marioni</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Ward&#8208;Caviness</surname></string-name>, et&#160;al. <year>2020</year>. &#8220;<article-title>Blood DNA Methylation Sites Predict Death Risk in a Longitudinal Study of 12, 300 Individuals</article-title>.&#8221; <source>Aging (Albany NY)</source><volume>12</volume>, no. <issue>14</issue>: <fpage>14092</fpage>&#8211;<lpage>14124</lpage>. <pub-id pub-id-type="doi">10.18632/aging.103408</pub-id>.<pub-id pub-id-type="pmid">32697766</pub-id><pub-id pub-id-type="pmcid">PMC7425458</pub-id></mixed-citation></ref><ref id="acel70168-bib-0014"><mixed-citation publication-type="journal" id="acel70168-cit-0014"><string-name name-style="western"><surname>Corey</surname>, <given-names>T. M.</given-names></string-name>, <string-name name-style="western"><given-names>O.</given-names><surname>Illanes</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Lawrence</surname></string-name>, <string-name name-style="western"><given-names>S. E.</given-names><surname>Perez</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Liddie</surname></string-name>, and <string-name name-style="western"><given-names>J. J.</given-names><surname>Callanan</surname></string-name>. <year>2023</year>. &#8220;<article-title>Naturally Occurring Histological Findings and Alzheimer's&#8208;Like Pathology in the Brain of Aging African Green Monkeys (<styled-content style="fixed-case" toggle="no">
<italic toggle="no">Chlorocebus sabaeus</italic>
</styled-content>)</article-title>.&#8221; <source>Journal of Comparative Neurology</source><volume>531</volume>, no. <issue>13</issue>: <fpage>1276</fpage>&#8211;<lpage>1298</lpage>. <pub-id pub-id-type="doi">10.1002/cne.25494</pub-id>.<pub-id pub-id-type="pmid">37279778</pub-id></mixed-citation></ref><ref id="acel70168-bib-0015"><mixed-citation publication-type="journal" id="acel70168-cit-0015"><string-name name-style="western"><surname>Du</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>C. C.</given-names><surname>Huang</surname></string-name>, et&#160;al. <year>2010</year>. &#8220;<article-title>Comparison of Beta&#8208;Value and M&#8208;Value Methods for Quantifying Methylation Levels by Microarray Analysis</article-title>.&#8221; <source>BMC Bioinformatics</source><volume>11</volume>: <elocation-id>587</elocation-id>. <pub-id pub-id-type="doi">10.1186/1471-2105-11-587</pub-id>.<pub-id pub-id-type="pmid">21118553</pub-id><pub-id pub-id-type="pmcid">PMC3012676</pub-id></mixed-citation></ref><ref id="acel70168-bib-0016"><mixed-citation publication-type="journal" id="acel70168-cit-0016"><string-name name-style="western"><surname>Dugan</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Conway</surname></string-name>, and <string-name name-style="western"><given-names>N. A.</given-names><surname>Duggal</surname></string-name>. <year>2023</year>. &#8220;<article-title>Inflammaging as a Target for Healthy Ageing</article-title>.&#8221; <source>Age and Ageing</source><volume>52</volume>, no. <issue>2</issue>: <elocation-id>afac328</elocation-id>. <pub-id pub-id-type="doi">10.1093/ageing/afac328</pub-id>.<pub-id pub-id-type="pmid">36735849</pub-id></mixed-citation></ref><ref id="acel70168-bib-0017"><mixed-citation publication-type="journal" id="acel70168-cit-0017"><string-name name-style="western"><surname>Ellis</surname>, <given-names>A. K.</given-names></string-name><year>1991</year>. &#8220;<article-title>Serum Protein Measurements and the Diagnosis of Acute Myocardial Infarction</article-title>.&#8221; <source>Circulation</source><volume>83</volume>, no. <issue>3</issue>: <fpage>1107</fpage>&#8211;<lpage>1109</lpage>. <pub-id pub-id-type="doi">10.1161/01.cir.83.3.1107</pub-id>.<pub-id pub-id-type="pmid">1999018</pub-id></mixed-citation></ref><ref id="acel70168-bib-0018"><mixed-citation publication-type="journal" id="acel70168-cit-0018"><string-name name-style="western"><surname>Galkin</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Mamoshina</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Aliper</surname></string-name>, <string-name name-style="western"><given-names>J. P.</given-names><surname>de Magalhaes</surname></string-name>, <string-name name-style="western"><given-names>V. N.</given-names><surname>Gladyshev</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Zhavoronkov</surname></string-name>. <year>2020</year>. &#8220;<article-title>Biohorology and Biomarkers of Aging: Current State&#8208;Of&#8208;The&#8208;Art, Challenges and Opportunities</article-title>.&#8221; <source>Ageing Research Reviews</source><volume>60</volume>: <elocation-id>101050</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.arr.2020.101050</pub-id>.<pub-id pub-id-type="pmid">32272169</pub-id></mixed-citation></ref><ref id="acel70168-bib-0019"><mixed-citation publication-type="journal" id="acel70168-cit-0019"><string-name name-style="western"><surname>Goeminne</surname>, <given-names>L. J. E.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Vladimirova</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Eames</surname></string-name>, et&#160;al. <year>2025</year>. &#8220;<article-title>Plasma Protein&#8208;Based Organ&#8208;Specific Aging and Mortality Models Unveil Diseases as Accelerated Aging of Organismal Systems</article-title>.&#8221; <source>Cell Metabolism</source><volume>37</volume>, no. <issue>1</issue>: <fpage>205</fpage>&#8211;<lpage>222</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2024.10.005</pub-id>.<pub-id pub-id-type="pmid">39488213</pub-id></mixed-citation></ref><ref id="acel70168-bib-0020"><mixed-citation publication-type="journal" id="acel70168-cit-0020"><string-name name-style="western"><surname>Hannum</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Guinney</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Zhao</surname></string-name>, et&#160;al. <year>2013</year>. &#8220;<article-title>Genome&#8208;Wide Methylation Profiles Reveal Quantitative Views of Human Aging Rates</article-title>.&#8221; <source>Molecular Cell</source><volume>49</volume>, no. <issue>2</issue>: <fpage>359</fpage>&#8211;<lpage>367</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2012.10.016</pub-id>.<pub-id pub-id-type="pmid">23177740</pub-id><pub-id pub-id-type="pmcid">PMC3780611</pub-id></mixed-citation></ref><ref id="acel70168-bib-0021"><mixed-citation publication-type="journal" id="acel70168-cit-0021"><string-name name-style="western"><surname>Harris</surname>, <given-names>S. E.</given-names></string-name>, <string-name name-style="western"><given-names>S. R.</given-names><surname>Cox</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Bell</surname></string-name>, et&#160;al. <year>2020</year>. &#8220;<article-title>Neurology&#8208;Related Protein Biomarkers Are Associated With Cognitive Ability and Brain Volume in Older Age</article-title>.&#8221; <source>Nature Communications</source><volume>11</volume>, no. <issue>1</issue>: <fpage>800</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-019-14161-7</pub-id>.</mixed-citation></ref><ref id="acel70168-bib-0022"><mixed-citation publication-type="journal" id="acel70168-cit-0022"><string-name name-style="western"><surname>Heneka</surname>, <given-names>M. T.</given-names></string-name>, <string-name name-style="western"><given-names>W. M.</given-names><surname>van der Flier</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Jessen</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Neuroinflammation in Alzheimer Disease</article-title>.&#8221; <source>Nature Reviews Immunology</source><volume>25</volume>: <fpage>321</fpage>&#8211;<lpage>352</lpage>. <pub-id pub-id-type="doi">10.1038/s41577-024-01104-7</pub-id>.</mixed-citation></ref><ref id="acel70168-bib-0023"><mixed-citation publication-type="journal" id="acel70168-cit-0023"><string-name name-style="western"><surname>Horvath</surname>, <given-names>S.</given-names></string-name>, and <string-name name-style="western"><given-names>K.</given-names><surname>Raj</surname></string-name>. <year>2018</year>. &#8220;<article-title>DNA Methylation&#8208;Based Biomarkers and the Epigenetic Clock Theory of Ageing</article-title>.&#8221; <source>Nature Reviews. Genetics</source><volume>19</volume>, no. <issue>6</issue>: <fpage>371</fpage>&#8211;<lpage>384</lpage>. <pub-id pub-id-type="doi">10.1038/s41576-018-0004-3</pub-id>.</mixed-citation></ref><ref id="acel70168-bib-0024"><mixed-citation publication-type="journal" id="acel70168-cit-0024"><string-name name-style="western"><surname>Horvath</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Zoller</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Haghani</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>Epigenetic Clock and Methylation Studies in the Rhesus Macaque</article-title>.&#8221; <source>Geroscience</source><volume>43</volume>, no. <issue>5</issue>: <fpage>2441</fpage>&#8211;<lpage>2453</lpage>. <pub-id pub-id-type="doi">10.1007/s11357-021-00429-8</pub-id>.<pub-id pub-id-type="pmid">34487267</pub-id><pub-id pub-id-type="pmcid">PMC8599607</pub-id></mixed-citation></ref><ref id="acel70168-bib-0025"><mixed-citation publication-type="journal" id="acel70168-cit-0025"><string-name name-style="western"><surname>Hunter</surname>, <given-names>C. A.</given-names></string-name>, and <string-name name-style="western"><given-names>S. A.</given-names><surname>Jones</surname></string-name>. <year>2015</year>. &#8220;<article-title>IL&#8208;6 as a Keystone Cytokine in Health and Disease</article-title>.&#8221; <source>Nature Immunology</source><volume>16</volume>, no. <issue>5</issue>: <fpage>448</fpage>&#8211;<lpage>457</lpage>. <pub-id pub-id-type="doi">10.1038/ni.3153</pub-id>.<pub-id pub-id-type="pmid">25898198</pub-id></mixed-citation></ref><ref id="acel70168-bib-0026"><mixed-citation publication-type="journal" id="acel70168-cit-0026"><string-name name-style="western"><surname>Jasinska</surname>, <given-names>A. J.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Haghani</surname></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Zoller</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>Epigenetic Clock and Methylation Studies in Vervet Monkeys</article-title>.&#8221; <source>Geroscience</source><volume>44</volume>, no. <issue>2</issue>: <fpage>699</fpage>&#8211;<lpage>717</lpage>. <pub-id pub-id-type="doi">10.1007/s11357-021-00466-3</pub-id>.<pub-id pub-id-type="pmid">34591235</pub-id><pub-id pub-id-type="pmcid">PMC9135907</pub-id></mixed-citation></ref><ref id="acel70168-bib-0027"><mixed-citation publication-type="journal" id="acel70168-cit-0027"><string-name name-style="western"><surname>Jasinska</surname>, <given-names>A. J.</given-names></string-name>, <string-name name-style="western"><given-names>C. A.</given-names><surname>Schmitt</surname></string-name>, <string-name name-style="western"><given-names>S. K.</given-names><surname>Service</surname></string-name>, et&#160;al. <year>2013</year>. &#8220;<article-title>Systems Biology of the Vervet Monkey</article-title>.&#8221; <source>ILAR Journal</source><volume>54</volume>, no. <issue>2</issue>: <fpage>122</fpage>&#8211;<lpage>143</lpage>. <pub-id pub-id-type="doi">10.1093/ilar/ilt049</pub-id>.<pub-id pub-id-type="pmid">24174437</pub-id><pub-id pub-id-type="pmcid">PMC3814400</pub-id></mixed-citation></ref><ref id="acel70168-bib-0028"><mixed-citation publication-type="journal" id="acel70168-cit-0028"><string-name name-style="western"><surname>Jasinska</surname>, <given-names>A. J.</given-names></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Zelaya</surname></string-name>, <string-name name-style="western"><given-names>S. K.</given-names><surname>Service</surname></string-name>, et&#160;al. <year>2017</year>. &#8220;<article-title>Genetic Variation and Gene Expression Across Multiple Tissues and Developmental Stages in a Nonhuman Primate</article-title>.&#8221; <source>Nature Genetics</source><volume>49</volume>, no. <issue>12</issue>: <fpage>1714</fpage>&#8211;<lpage>1721</lpage>. <pub-id pub-id-type="doi">10.1038/ng.3959</pub-id>.<pub-id pub-id-type="pmid">29083405</pub-id><pub-id pub-id-type="pmcid">PMC5714271</pub-id></mixed-citation></ref><ref id="acel70168-bib-0029"><mixed-citation publication-type="journal" id="acel70168-cit-0029"><string-name name-style="western"><surname>Johnson</surname>, <given-names>A. A.</given-names></string-name>, <string-name name-style="western"><given-names>M. N.</given-names><surname>Shokhirev</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Wyss&#8208;Coray</surname></string-name>, and <string-name name-style="western"><given-names>B.</given-names><surname>Lehallier</surname></string-name>. <year>2020</year>. &#8220;<article-title>Systematic Review and Analysis of Human Proteomics Aging Studies Unveils a Novel Proteomic Aging Clock and Identifies Key Processes That Change With Age</article-title>.&#8221; <source>Ageing Research Reviews</source><volume>60</volume>: <elocation-id>101070</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.arr.2020.101070</pub-id>.<pub-id pub-id-type="pmid">32311500</pub-id></mixed-citation></ref><ref id="acel70168-bib-0030"><mixed-citation publication-type="journal" id="acel70168-cit-0030"><string-name name-style="western"><surname>Kennedy</surname>, <given-names>B. K.</given-names></string-name>, <string-name name-style="western"><given-names>S. L.</given-names><surname>Berger</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Brunet</surname></string-name>, et&#160;al. <year>2014</year>. &#8220;<article-title>Geroscience: Linking Aging to Chronic Disease</article-title>.&#8221; <source>Cell</source><volume>159</volume>, no. <issue>4</issue>: <fpage>709</fpage>&#8211;<lpage>713</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2014.10.039</pub-id>.<pub-id pub-id-type="pmid">25417146</pub-id><pub-id pub-id-type="pmcid">PMC4852871</pub-id></mixed-citation></ref><ref id="acel70168-bib-0031"><mixed-citation publication-type="journal" id="acel70168-cit-0031"><string-name name-style="western"><surname>Knox</surname>, <given-names>E. G.</given-names></string-name>, <string-name name-style="western"><given-names>M. R.</given-names><surname>Aburto</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Clarke</surname></string-name>, <string-name name-style="western"><given-names>J. F.</given-names><surname>Cryan</surname></string-name>, and <string-name name-style="western"><given-names>C. M.</given-names><surname>O'Driscoll</surname></string-name>. <year>2022</year>. &#8220;<article-title>The Blood&#8208;Brain Barrier in Aging and Neurodegeneration</article-title>.&#8221; <source>Molecular Psychiatry</source><volume>27</volume>, no. <issue>6</issue>: <fpage>2659</fpage>&#8211;<lpage>2673</lpage>. <pub-id pub-id-type="doi">10.1038/s41380-022-01511-z</pub-id>.<pub-id pub-id-type="pmid">35361905</pub-id><pub-id pub-id-type="pmcid">PMC9156404</pub-id></mixed-citation></ref><ref id="acel70168-bib-0032"><mixed-citation publication-type="journal" id="acel70168-cit-0032"><string-name name-style="western"><surname>Kramer</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Green</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Pollard</surname><suffix>Jr.</suffix></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Tugendreich</surname></string-name>. <year>2014</year>. &#8220;<article-title>Causal Analysis Approaches in Ingenuity Pathway Analysis</article-title>.&#8221; <source>Bioinformatics</source><volume>30</volume>, no. <issue>4</issue>: <fpage>523</fpage>&#8211;<lpage>530</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btt703</pub-id>.<pub-id pub-id-type="pmid">24336805</pub-id><pub-id pub-id-type="pmcid">PMC3928520</pub-id></mixed-citation></ref><ref id="acel70168-bib-0033"><mixed-citation publication-type="journal" id="acel70168-cit-0033"><string-name name-style="western"><surname>Kuo</surname>, <given-names>C. L.</given-names></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Liu</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Proteomic Aging Clock (PAC) Predicts Age&#8208;Related Outcomes in Middle&#8208;Aged and Older Adults</article-title>.&#8221; <source>Aging Cell</source><volume>23</volume>: <elocation-id>e14195</elocation-id>. <pub-id pub-id-type="doi">10.1111/acel.14195</pub-id>.<pub-id pub-id-type="pmid">38747160</pub-id><pub-id pub-id-type="pmcid">PMC11320350</pub-id></mixed-citation></ref><ref id="acel70168-bib-0034"><mixed-citation publication-type="journal" id="acel70168-cit-0034"><string-name name-style="western"><surname>Latimer</surname>, <given-names>C. S.</given-names></string-name>, <string-name name-style="western"><given-names>C. A.</given-names><surname>Shively</surname></string-name>, <string-name name-style="western"><given-names>C. D.</given-names><surname>Keene</surname></string-name>, et&#160;al. <year>2019</year>. &#8220;<article-title>A Nonhuman Primate Model of Early Alzheimer's Disease Pathologic Change: Implications for Disease Pathogenesis</article-title>.&#8221; <source>Alzheimer's &amp; Dementia</source><volume>15</volume>, no. <issue>1</issue>: <fpage>93</fpage>&#8211;<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1016/j.jalz.2018.06.3057</pub-id>.</mixed-citation></ref><ref id="acel70168-bib-0035"><mixed-citation publication-type="journal" id="acel70168-cit-0035"><string-name name-style="western"><surname>Liu</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Lu</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Yang</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Analysis of the Aging&#8208;Related Biomarker in a Nonhuman Primate Model Using Multilayer Omics</article-title>.&#8221; <source>BMC Genomics</source><volume>25</volume>, no. <issue>1</issue>: <fpage>639</fpage>. <pub-id pub-id-type="doi">10.1186/s12864-024-10556-z</pub-id>.<pub-id pub-id-type="pmid">38926642</pub-id><pub-id pub-id-type="pmcid">PMC11209966</pub-id></mixed-citation></ref><ref id="acel70168-bib-0036"><mixed-citation publication-type="journal" id="acel70168-cit-0036"><string-name name-style="western"><surname>Lopez&#8208;Otin</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Blasco</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Partridge</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Serrano</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Kroemer</surname></string-name>. <year>2023</year>. &#8220;<article-title>Hallmarks of Aging: An Expanding Universe</article-title>.&#8221; <source>Cell</source><volume>186</volume>, no. <issue>2</issue>: <fpage>243</fpage>&#8211;<lpage>278</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2022.11.001</pub-id>.<pub-id pub-id-type="pmid">36599349</pub-id></mixed-citation></ref><ref id="acel70168-bib-0037"><mixed-citation publication-type="journal" id="acel70168-cit-0037"><string-name name-style="western"><surname>Lu</surname>, <given-names>A. T.</given-names></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Fei</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Haghani</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>Universal DNA Methylation Age Across Mammalian Tissues</article-title>.&#8221; <source>Nature Aging</source><volume>3</volume>: <fpage>1144</fpage>&#8211;<lpage>1166</lpage>. <pub-id pub-id-type="doi">10.1038/s43587-023-00462-6</pub-id>.<pub-id pub-id-type="pmid">37563227</pub-id><pub-id pub-id-type="pmcid">PMC10501909</pub-id></mixed-citation></ref><ref id="acel70168-bib-0038"><mixed-citation publication-type="journal" id="acel70168-cit-0038"><string-name name-style="western"><surname>Lu</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Brommer</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Tian</surname></string-name>, et&#160;al. <year>2020</year>. &#8220;<article-title>Reprogramming to Recover Youthful Epigenetic Information and Restore Vision</article-title>.&#8221; <source>Nature</source><volume>588</volume>, no. <issue>7836</issue>: <fpage>124</fpage>&#8211;<lpage>129</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2975-4</pub-id>.<pub-id pub-id-type="pmid">33268865</pub-id><pub-id pub-id-type="pmcid">PMC7752134</pub-id></mixed-citation></ref><ref id="acel70168-bib-0039"><mixed-citation publication-type="journal" id="acel70168-cit-0039"><string-name name-style="western"><surname>Lualdi</surname>, <given-names>M.</given-names></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Fasano</surname></string-name>. <year>2019</year>. &#8220;<article-title>Statistical Analysis of Proteomics Data: A Review on Feature Selection</article-title>.&#8221; <source>Journal of Proteomics</source><volume>198</volume>: <fpage>18</fpage>&#8211;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/j.jprot.2018.12.004</pub-id>.<pub-id pub-id-type="pmid">30529743</pub-id></mixed-citation></ref><ref id="acel70168-bib-0040"><mixed-citation publication-type="journal" id="acel70168-cit-0040"><string-name name-style="western"><surname>Maggio</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Guralnik</surname></string-name>, <string-name name-style="western"><given-names>D. L.</given-names><surname>Longo</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Ferrucci</surname></string-name>. <year>2006</year>. &#8220;<article-title>Interleukin&#8208;6 in Aging and Chronic Disease: A Magnificent Pathway</article-title>.&#8221; <source>Journals of Gerontology. Series A, Biological Sciences and Medical Sciences</source><volume>61</volume>, no. <issue>6</issue>: <fpage>575</fpage>&#8211;<lpage>584</lpage>. <pub-id pub-id-type="doi">10.1093/gerona/61.6.575</pub-id>.<pub-id pub-id-type="pmid">16799139</pub-id><pub-id pub-id-type="pmcid">PMC2645627</pub-id></mixed-citation></ref><ref id="acel70168-bib-0041"><mixed-citation publication-type="journal" id="acel70168-cit-0041"><string-name name-style="western"><surname>Moqri</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Herzog</surname></string-name>, <string-name name-style="western"><given-names>J. R.</given-names><surname>Poganik</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>Biomarkers of Aging for the Identification and Evaluation of Longevity Interventions</article-title>.&#8221; <source>Cell</source><volume>186</volume>, no. <issue>18</issue>: <fpage>3758</fpage>&#8211;<lpage>3775</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2023.08.003</pub-id>.<pub-id pub-id-type="pmid">37657418</pub-id><pub-id pub-id-type="pmcid">PMC11088934</pub-id></mixed-citation></ref><ref id="acel70168-bib-0042"><mixed-citation publication-type="journal" id="acel70168-cit-0042"><string-name name-style="western"><surname>Oh</surname>, <given-names>H. S.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Rutledge</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Nachun</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>Organ Aging Signatures in the Plasma Proteome Track Health and Disease</article-title>.&#8221; <source>Nature</source><volume>624</volume>, no. <issue>7990</issue>: <fpage>164</fpage>&#8211;<lpage>172</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-023-06802-1</pub-id>.<pub-id pub-id-type="pmid">38057571</pub-id><pub-id pub-id-type="pmcid">PMC10700136</pub-id></mixed-citation></ref><ref id="acel70168-bib-0043"><mixed-citation publication-type="journal" id="acel70168-cit-0043"><string-name name-style="western"><surname>Phillips</surname>, <given-names>K. A.</given-names></string-name>, <string-name name-style="western"><given-names>K. L.</given-names><surname>Bales</surname></string-name>, <string-name name-style="western"><given-names>J. P.</given-names><surname>Capitanio</surname></string-name>, et&#160;al. <year>2014</year>. &#8220;<article-title>Why Primate Models Matter</article-title>.&#8221; <source>American Journal of Primatology</source><volume>76</volume>, no. <issue>9</issue>: <fpage>801</fpage>&#8211;<lpage>827</lpage>. <pub-id pub-id-type="doi">10.1002/ajp.22281</pub-id>.<pub-id pub-id-type="pmid">24723482</pub-id><pub-id pub-id-type="pmcid">PMC4145602</pub-id></mixed-citation></ref><ref id="acel70168-bib-0044"><mixed-citation publication-type="journal" id="acel70168-cit-0044"><string-name name-style="western"><surname>Richardson</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Brandt</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Jain</surname></string-name>, et&#160;al. <year>2025</year>. &#8220;<article-title>Characterization of DNA Methylation Clock Algorithms Applied to Diverse Tissue Types</article-title>.&#8221; <source>Aging (Albany NY)</source><volume>17</volume>, no. <issue>1</issue>: <fpage>67</fpage>&#8211;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.18632/aging.206182</pub-id>.<pub-id pub-id-type="pmid">39754638</pub-id><pub-id pub-id-type="pmcid">PMC11810061</pub-id></mixed-citation></ref><ref id="acel70168-bib-0045"><mixed-citation publication-type="journal" id="acel70168-cit-0045"><string-name name-style="western"><surname>Ritchie</surname>, <given-names>M. E.</given-names></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Phipson</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Wu</surname></string-name>, et&#160;al. <year>2015</year>. &#8220;<article-title>Limma Powers Differential Expression Analyses for RNA&#8208;Sequencing and Microarray Studies</article-title>.&#8221; <source>Nucleic Acids Research</source><volume>43</volume>, no. <issue>7</issue>: <elocation-id>e47</elocation-id>. <pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id>.<pub-id pub-id-type="pmid">25605792</pub-id><pub-id pub-id-type="pmcid">PMC4402510</pub-id></mixed-citation></ref><ref id="acel70168-bib-0046"><mixed-citation publication-type="journal" id="acel70168-cit-0046"><string-name name-style="western"><surname>Salehi</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>P. J.</given-names><surname>Coates</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>Reiterative Modeling of Combined Transcriptomic and Proteomic Features Refines and Improves the Prediction of Early Recurrence in Squamous Cell Carcinoma of Head and Neck</article-title>.&#8221; <source>Computers in Biology and Medicine</source><volume>149</volume>: <elocation-id>105991</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.compbiomed.2022.105991</pub-id>.<pub-id pub-id-type="pmid">36007290</pub-id></mixed-citation></ref><ref id="acel70168-bib-0047"><mixed-citation publication-type="journal" id="acel70168-cit-0047"><string-name name-style="western"><surname>Sathyan</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Ayers</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Gao</surname></string-name>, et&#160;al. <year>2020</year>. &#8220;<article-title>Plasma Proteomic Profile of Age, Health Span, and All&#8208;Cause Mortality in Older Adults</article-title>.&#8221; <source>Aging Cell</source><volume>19</volume>, no. <issue>11</issue>: <elocation-id>e13250</elocation-id>. <pub-id pub-id-type="doi">10.1111/acel.13250</pub-id>.<pub-id pub-id-type="pmid">33089916</pub-id><pub-id pub-id-type="pmcid">PMC7681045</pub-id></mixed-citation></ref><ref id="acel70168-bib-0048"><mixed-citation publication-type="journal" id="acel70168-cit-0048"><string-name name-style="western"><surname>Shen</surname>, <given-names>Q.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Bjorkesten</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Galli</surname></string-name>, et&#160;al. <year>2018</year>. &#8220;<article-title>Strong Impact on Plasma Protein Profiles by Precentrifugation Delay but Not by Repeated Freeze&#8208;Thaw Cycles, as Analyzed Using Multiplex Proximity Extension Assays</article-title>.&#8221; <source>Clinical Chemistry and Laboratory Medicine</source><volume>56</volume>, no. <issue>4</issue>: <fpage>582</fpage>&#8211;<lpage>594</lpage>. <pub-id pub-id-type="doi">10.1515/cclm-2017-0648</pub-id>.<pub-id pub-id-type="pmid">29040064</pub-id></mixed-citation></ref><ref id="acel70168-bib-0049"><mixed-citation publication-type="journal" id="acel70168-cit-0049"><string-name name-style="western"><surname>Shen</surname>, <given-names>X.</given-names></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Zhou</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Nonlinear Dynamics of Multi&#8208;Omics Profiles During Human Aging</article-title>.&#8221; <source>Nature Aging</source><volume>4</volume>: <fpage>1619</fpage>&#8211;<lpage>1634</lpage>. <pub-id pub-id-type="doi">10.1038/s43587-024-00692-2</pub-id>.<pub-id pub-id-type="pmid">39143318</pub-id><pub-id pub-id-type="pmcid">PMC11564093</pub-id></mixed-citation></ref><ref id="acel70168-bib-0050"><mixed-citation publication-type="journal" id="acel70168-cit-0050"><string-name name-style="western"><surname>Stubbs</surname>, <given-names>T. M.</given-names></string-name>, <string-name name-style="western"><given-names>M. J.</given-names><surname>Bonder</surname></string-name>, <string-name name-style="western"><given-names>A. K.</given-names><surname>Stark</surname></string-name>, et&#160;al. <year>2017</year>. &#8220;<article-title>Multi&#8208;Tissue DNA Methylation Age Predictor in Mouse</article-title>.&#8221; <source>Genome Biology</source><volume>18</volume>, no. <issue>1</issue>: <fpage>68</fpage>. <pub-id pub-id-type="doi">10.1186/s13059-017-1203-5</pub-id>.<pub-id pub-id-type="pmid">28399939</pub-id><pub-id pub-id-type="pmcid">PMC5389178</pub-id></mixed-citation></ref><ref id="acel70168-bib-0051"><mixed-citation publication-type="journal" id="acel70168-cit-0051"><string-name name-style="western"><surname>Varma</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Luo</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Bostrom</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Plasma and CSF Biomarkers of Aging and Cognitive Decline in Caribbean Vervets</article-title>.&#8221; <source>Alzheimer's &amp; Dementia</source><volume>20</volume>, no. <issue>8</issue>: <fpage>5460</fpage>&#8211;<lpage>5480</lpage>. <pub-id pub-id-type="doi">10.1002/alz.14038</pub-id>.</mixed-citation></ref><ref id="acel70168-bib-0052"><mixed-citation publication-type="journal" id="acel70168-cit-0052"><string-name name-style="western"><surname>Wakeman</surname>, <given-names>D. R.</given-names></string-name>, <string-name name-style="western"><given-names>M. R.</given-names><surname>Weed</surname></string-name>, <string-name name-style="western"><given-names>S. E.</given-names><surname>Perez</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>Intrathecal Amyloid&#8208;Beta Oligomer Administration Increases Tau Phosphorylation in the Medial Temporal Lobe in the African Green Monkey: A Nonhuman Primate Model of Alzheimer's Disease</article-title>.&#8221; <source>Neuropathology and Applied Neurobiology</source><volume>48</volume>, no. <issue>4</issue>: <elocation-id>e12800</elocation-id>. <pub-id pub-id-type="doi">10.1111/nan.12800</pub-id>.<pub-id pub-id-type="pmid">35156715</pub-id><pub-id pub-id-type="pmcid">PMC10902791</pub-id></mixed-citation></ref><ref id="acel70168-bib-0053"><mixed-citation publication-type="journal" id="acel70168-cit-0053"><string-name name-style="western"><surname>Wang</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Hu</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>Epigenetic Regulation of Aging: Implications for Interventions of Aging and Diseases</article-title>.&#8221; <source>Signal Transduction and Targeted Therapy</source><volume>7</volume>, no. <issue>1</issue>: <fpage>374</fpage>. <pub-id pub-id-type="doi">10.1038/s41392-022-01211-8</pub-id>.<pub-id pub-id-type="pmid">36336680</pub-id><pub-id pub-id-type="pmcid">PMC9637765</pub-id></mixed-citation></ref><ref id="acel70168-bib-0054"><mixed-citation publication-type="journal" id="acel70168-cit-0054"><string-name name-style="western"><surname>Yang</surname>, <given-names>A. C.</given-names></string-name>, <string-name name-style="western"><given-names>M. Y.</given-names><surname>Stevens</surname></string-name>, <string-name name-style="western"><given-names>M. B.</given-names><surname>Chen</surname></string-name>, et&#160;al. <year>2020</year>. &#8220;<article-title>Physiological Blood&#8208;Brain Transport Is Impaired With Age by a Shift in Transcytosis</article-title>.&#8221; <source>Nature</source><volume>583</volume>, no. <issue>7816</issue>: <fpage>425</fpage>&#8211;<lpage>430</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2453-z</pub-id>.<pub-id pub-id-type="pmid">32612231</pub-id><pub-id pub-id-type="pmcid">PMC8331074</pub-id></mixed-citation></ref><ref id="acel70168-bib-0055"><mixed-citation publication-type="journal" id="acel70168-cit-0055"><string-name name-style="western"><surname>Zhang</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><given-names>D. R.</given-names><surname>Goodlett</surname></string-name>, <string-name name-style="western"><given-names>E. R.</given-names><surname>Peskind</surname></string-name>, et&#160;al. <year>2005</year>. &#8220;<article-title>Quantitative Proteomic Analysis of Age&#8208;Related Changes in Human Cerebrospinal Fluid</article-title>.&#8221; <source>Neurobiology of Aging</source><volume>26</volume>, no. <issue>2</issue>: <fpage>207</fpage>&#8211;<lpage>227</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2004.03.012</pub-id>.<pub-id pub-id-type="pmid">15582749</pub-id></mixed-citation></ref><ref id="acel70168-bib-0056"><mixed-citation publication-type="journal" id="acel70168-cit-0056"><string-name name-style="western"><surname>Zhou</surname>, <given-names>W.</given-names></string-name>, <string-name name-style="western"><given-names>T. J.</given-names><surname>Triche</surname><suffix>Jr.</suffix></string-name>, <string-name name-style="western"><given-names>P. W.</given-names><surname>Laird</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Shen</surname></string-name>. <year>2018</year>. &#8220;<article-title>SeSAMe: Reducing Artifactual Detection of DNA Methylation by Infinium BeadChips in Genomic Deletions</article-title>.&#8221; <source>Nucleic Acids Research</source><volume>46</volume>, no. <issue>20</issue>: <elocation-id>e123</elocation-id>. <pub-id pub-id-type="doi">10.1093/nar/gky691</pub-id>.<pub-id pub-id-type="pmid">30085201</pub-id><pub-id pub-id-type="pmcid">PMC6237738</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="alz70706" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement</journal-id><journal-id journal-id-type="pmc-domain-id">4549</journal-id><journal-id journal-id-type="pmc-domain">alzdem</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Alzheimer's &amp; Dementia</journal-title></journal-title-group><issn pub-type="ppub">1552-5260</issn><issn pub-type="epub">1552-5279</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12504065</article-id><article-id pub-id-type="pmcid-ver">PMC12504065.1</article-id><article-id pub-id-type="pmcaid">12504065</article-id><article-id pub-id-type="pmcaiid">12504065</article-id><article-id pub-id-type="doi">10.1002/alz.70706</article-id><article-id pub-id-type="publisher-id">ALZ70706</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Association of dietary sodium intake with late&#8208;life cognitive decline and postmortem neuropathology in community&#8208;dwelling older adults</article-title><alt-title alt-title-type="left-running-head">TONG <sc>et&#160;al</sc>.</alt-title></title-group><contrib-group><contrib id="alz70706-cr-0001" contrib-type="author"><name name-style="western"><surname>Tong</surname><given-names initials="H">Han</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9821-5928</contrib-id><xref rid="alz70706-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70706-cr-0002" contrib-type="author"><name name-style="western"><surname>Capuano</surname><given-names initials="AW">Ana W.</given-names></name><xref rid="alz70706-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70706-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70706-cr-0003" contrib-type="author"><name name-style="western"><surname>Agarwal</surname><given-names initials="P">Puja</given-names></name><xref rid="alz70706-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70706-cr-0004" contrib-type="author"><name name-style="western"><surname>Mehta</surname><given-names initials="RI">Rupal I.</given-names></name><xref rid="alz70706-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70706-cr-0005" contrib-type="author"><name name-style="western"><surname>Sood</surname><given-names initials="A">Ajay</given-names></name><xref rid="alz70706-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70706-cr-0006" contrib-type="author"><name name-style="western"><surname>Bennett</surname><given-names initials="DA">David A.</given-names></name><xref rid="alz70706-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70706-cr-0007" contrib-type="author" corresp="yes"><name name-style="western"><surname>Arvanitakis</surname><given-names initials="Z">Zoe</given-names></name><xref rid="alz70706-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>zoe_arvanitakis@rush.edu</email></address></contrib></contrib-group><aff id="alz70706-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Rush Alzheimer's Disease Center</named-content>
<institution>Rush University Medical Center</institution>
<city>Chicago</city>
<named-content content-type="country-part">Illinois</named-content>
<country country="US">USA</country>
</aff><aff id="alz70706-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>University of Chicago</institution>
<city>Chicago</city>
<named-content content-type="country-part">Illinois</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Zoe Arvanitakis, MD, MS, Rush Alzheimer's Disease Center, Rush University Medical Center, 1750&#8201;W.&#160;Harrison&#8201;Street,&#8201;Suite&#8201;1000,&#8201;Chicago,&#8201;IL&#8201;60612,&#8201;USA.<break/> Email: <email>zoe_arvanitakis@rush.edu</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>21</volume><issue seq="400">10</issue><issue-id pub-id-type="pmc-issue-id">497699</issue-id><issue-id pub-id-type="doi">10.1002/alz.v21.10</issue-id><elocation-id>e70706</elocation-id><history><date date-type="rev-recd"><day>20</day><month>8</month><year>2025</year></date><date date-type="received"><day>16</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>21</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Alzheimer's &amp; Dementia</italic> published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ALZ-21-e70706.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ALZ-21-e70706.pdf"/><abstract><title>Abstract</title><sec id="alz70706-sec-0010"><title>INTRODUCTION</title><p>Studies link sodium intake to cognition, but most were cross&#8208;sectional, and associations with neuropathology remain unclear.</p></sec><sec id="alz70706-sec-0020"><title>METHODS</title><p>1520 community&#8208;dwelling adults (mean age 80.7 years) had annual evaluations (mean follow&#8208;up 7.6 years), including 19 neuropsychological tests and a food frequency questionnaires (FFQ). Postmortem neuropathologies were documented in 717 deceased participants. Associations of dietary sodium intake estimated from the FFQ with cognitive decline and neuropathology were examined using adjusted regression models.</p></sec><sec id="alz70706-sec-0030"><title>RESULTS</title><p>Compared to the middle sodium intake quintile (median 2264&#160;mg/day), the lowest quintile (1764&#160;mg/day), but not the highest (2800&#160;mg/day), was associated with faster decline in global cognition, particularly episodic memory and semantic memory. Among the deceased, the lowest quintile was associated with higher immunohistochemistry&#8208;based tau tangle density, but not with amyloid burden or infarcts.</p></sec><sec id="alz70706-sec-0040"><title>DISCUSSION</title><p>Low dietary sodium intake is associated with faster cognitive decline and more neuropathology, specifically tangles. Dietary sodium likely plays a role in brain health.</p></sec><sec id="alz70706-sec-0050"><title>Highlights</title><p>
<list list-type="bullet" id="alz70706-list-0001"><list-item><p>The relation of dietary sodium to brain health is not well understood.</p></list-item><list-item><p>In this community&#8208;based study, FFQs were used to estimate dietary sodium intake.</p></list-item><list-item><p>Longitudinal neurocognitive and postmortem neuropathology evaluations were conducted.</p></list-item><list-item><p>Among 1520 older adults without known dementia followed annually for 7.6 years, low sodium intake was associated with faster decline in global cognition.</p></list-item><list-item><p>Among a subset who died and came to autopsy, low sodium intake was associated with higher tangle density, but not with amyloid burden or infarcts.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="alz70706-kwd-0001">Alzheimer's disease</kwd><kwd id="alz70706-kwd-0002">arteriolosclerosis</kwd><kwd id="alz70706-kwd-0003">cerebrovascular disease</kwd><kwd id="alz70706-kwd-0004">cognitive decline</kwd><kwd id="alz70706-kwd-0005">dietary sodium</kwd><kwd id="alz70706-kwd-0006">neurodegenerative</kwd><kwd id="alz70706-kwd-0007">neuropathology</kwd><kwd id="alz70706-kwd-0008">tau</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>National Institute on Aging</institution><institution-id institution-id-type="doi">10.13039/100000049</institution-id></institution-wrap></funding-source><award-id>P30AG010161</award-id><award-id>P30AG072975</award-id><award-id>R01AG017917</award-id><award-id>RF1AG059621</award-id><award-id>R01AG074549</award-id></award-group></funding-group><counts><fig-count count="0"/><table-count count="6"/><page-count count="12"/><word-count count="8055"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:07.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="alz70706-cite-0001"><string-name name-style="western"><surname>Tong</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Capuano</surname><given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>Agarwal</surname><given-names>P</given-names></string-name>, et&#160;al. <article-title>Association of dietary sodium intake with late&#8208;life cognitive decline and postmortem neuropathology in community&#8208;dwelling older adults</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>21</volume>:<elocation-id>e70706</elocation-id>. <pub-id pub-id-type="doi">10.1002/alz.70706</pub-id><pub-id pub-id-type="pmid">41058017</pub-id></mixed-citation>
</p></notes></front><body><sec id="alz70706-sec-0060"><label>1</label><title>BACKGROUND</title><p>Dementia is one of the most prominent and debilitating chronic conditions of aging, with no known cure, making its prevention a top public health priority.<xref rid="alz70706-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="alz70706-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> One important strategy that has been proposed to prevent dementia involves dietary interventions.<xref rid="alz70706-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="alz70706-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> In particular, some studies have found that greater adherence to a healthy diet is associated with slower late&#8208;life cognitive decline and a lower burden of postmortem Alzheimer's disease (AD) neuropathology, a major contributor to dementia.<xref rid="alz70706-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="alz70706-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="alz70706-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Although various healthy diets share common features, they may differ in key components, such as sodium intake. Some diets emphasize limiting sodium to 2300&#160;mg/day or less,<xref rid="alz70706-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> while others do not impose such restrictions.<xref rid="alz70706-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="alz70706-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> This raises the question of whether sodium intake is associated with cognitive health.</p><p>High sodium intake is well established as a risk factor for hypertension,<xref rid="alz70706-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> which in turn is a known contributor to dementia.<xref rid="alz70706-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Given this link, several studies have examined the relationship between sodium levels and cognitive function, but the findings remain mixed.<xref rid="alz70706-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Some research suggests that lower sodium intake is associated with better cognition,<xref rid="alz70706-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="alz70706-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="alz70706-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="alz70706-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> while other studies found no significant relationship.<xref rid="alz70706-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="alz70706-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="alz70706-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="alz70706-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> One study even reported that lower sodium intake was linked to poorer cognitive performance.<xref rid="alz70706-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> These inconsistencies may stem from differences in the demographic and clinical characteristics of study populations, as well as differences in study design and the relatively small sample sizes in most prior studies. Furthermore, little is known about brain mechanisms underlying the potential link between sodium intake and cognition. A 4&#8208;week dietary intervention study found that, in cognitively normal middle&#8208;aged adults, a Mediterranean&#8208;like low sodium (approximately 1300&#160;mg/day for 2000 calories) diet improved cerebrospinal fluid biomarkers for AD and cerebral perfusion, whereas a Western&#8208;like high&#8208;sodium (approximately 3200&#160;mg/day for 2000 calories) diet had the opposite effects.<xref rid="alz70706-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> However, whether these findings extend to older adults or have lasting effects remains unclear. Moreover, we are not aware of any previous study that examined the association of sodium intake with postmortem neuropathologic changes.</p><p>The goal of this study was to investigate the association between baseline daily dietary sodium intake, as assessed by validated food frequency questionnaire (FFQ) data, and longitudinally measured cognitive function (global cognition and five individual cognitive domains) in 1520 participants of the community&#8208;based, clinical&#8208;pathologic Rush Memory and Aging Project (MAP). Furthermore, in a subset of 717 participants who were deceased and autopsied, we sought to examine the association of mean sodium intake from baseline through follow&#8208;up with postmortem neurodegenerative neuropathologies (including amyloid, tau tangles, transactive response DNA binding protein 43 kDa [TDP&#8208;43], and Lewy bodies) and cerebrovascular neuropathologies (brain infarcts, atherosclerosis, arteriolosclerosis, and cerebral amyloid angiopathy, i.e., cerebral amyloid angiopathy [CAA]). We hypothesized that dietary sodium intake was associated with cognitive decline and neuropathology, without specifying the direction of these associations due to mixed findings on cognition and scarce prior data on neuropathology.</p></sec><sec id="alz70706-sec-0070"><label>2</label><title>METHODS</title><sec id="alz70706-sec-0080"><label>2.1</label><title>Study population</title><p>All participants of this study were from the MAP, a longitudinal, community&#8208;based, clinical&#8208;pathologic cohort study of cognitive aging.<xref rid="alz70706-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> MAP received Institutional Review Board approval from Rush University Medical Center and began enrolling older adults without known dementia from retirement communities across the Chicago metropolitan area since 1997. Participants signed an informed consent to undergo annual clinical evaluations including dietary assessment (started in 2004) and neuropsychological testing, and a subset signed an anatomical gift act to donate their brain at the time of death.<xref rid="alz70706-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>
</p><p>For this study, we included only participants who had at least one complete dietary assessment, with the first complete dietary assessment serving as the analytical baseline. We also required the included participants to have no dementia diagnosis at the analytical baseline and to have neuropsychological testing data available at both the analytical baseline and at least one follow&#8208;up visit. Of a total of 2425 MAP participants enrolled in the parent study, at the time of analysis, 1520 older adults met the inclusion criteria. The age at the analytical baseline ranged from 57.9 to 98.7 years, with a mean of 80.7 years. Of these, 855 died, and 744 underwent an autopsy (87% autopsy rate). Of those who were autopsied, 717 had neuropathologic data available.</p><boxed-text position="float" content-type="box" orientation="portrait"><sec id="alz70706-sec-0090"><title>RESEARCH IN CONTEXT</title><p>
<list list-type="order" id="alz70706-list-0002"><list-item><p>
<bold>Systematic review</bold>: Using PubMed, we reviewed the literature which showed an association of dietary sodium intake with late&#8208;life cognitive decline. Although no human study has examined associations of sodium intake with postmortem neuropathologies, one study has identified association of sodium intake with cerebrospinal fluid markers of AD pathology in middle&#8208;aged adults.</p></list-item><list-item><p>
<bold>Interpretation</bold>: Our study found that low baseline sodium intake was associated with faster late&#8208;life cognitive decline, suggesting adequate sodium intake may be important for maintaining brain health. Among the deceased participants, low sodium intake was associated with a higher density of neurofibrillary tangles, but not with A&#946; accumulation. These findings suggest that low sodium intake might contribute to hyperphosphorylated tau accumulation and cognitive impairment through unidentified mechanisms.</p></list-item><list-item><p>
<bold>Future directions</bold>: Future studies should further explore how age and other demographic, lifestyle, and clinical factors may affect the association of sodium with cognitive decline, as well as examine underlying mechanisms linking sodium with neuropathology.</p></list-item></list>
</p></sec></boxed-text></sec><sec id="alz70706-sec-0100"><label>2.2</label><title>Neuropsychological testing</title><p>At each study visit, participants completed 21 neuropsychological tests. Nineteen of these tests were grouped to form composite measures of global cognition and five cognitive domains: episodic memory (seven tests), working memory (four tests), semantic memory (four tests), perceptual speed (two tests), and visuospatial abilities (two tests).<xref rid="alz70706-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> Raw scores of individual tests were converted to <italic toggle="yes">z</italic>&#8208;scores, using the baseline mean and standard deviation from the entire cohort. These <italic toggle="yes">z</italic>&#8208;scores of individual tests were then averaged to calculate composite scores for global cognition or individual cognitive domains. Detailed information about individual tests has been published elsewhere.<xref rid="alz70706-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="alz70706-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>
</p></sec><sec id="alz70706-sec-0110"><label>2.3</label><title>Dietary assessment</title><p>Dietary sodium intakes were estimated using a modified Harvard semi&#8208;quantitative FFQ that was validated for use in older Chicago community residents.<xref rid="alz70706-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> The FFQ determines the typical frequency of intake of more than 137 food items and dietary supplements over the past 12 months. The reported frequency of food consumption was multiplied by the nutrient content of natural portion sizes (e.g., one apple) or sex&#8208;specific mean portion sizes from the oldest men and women in national surveys. The nutrient content of each food was based on United States Department of Agriculture (USDA) food composition tables and supplementary nutrient databases (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://fdc.nal.usda.gov/" ext-link-type="uri">https://fdc.nal.usda.gov/</ext-link>). Daily nutrient intakes for each participant were computed by summing over the frequency&#8208;based nutrient content of all the food items. All nutrients, including sodium intake, were calorie&#8208;adjusted using the residual regression method within sex.<xref rid="alz70706-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>
</p><p>Sodium intake was computed as milligrams per day and assessed in quintiles. We designated the middle quintile as the reference group, considering that both low and high sodium intakes could adversely affect cognition. Additionally, the dietary guidelines for Americans 2020&#8211;2025 (available at DietaryGuidelines.gov) recommend limiting sodium intake to no more than 2300&#160;mg/day, which is very similar to the median intake of our middle quintile (2264&#160;mg/day). According to What We Eat in America (WWEIA), the National Health and Nutrition Examination Survey (NHANES) August 2021&#8211;August 2023 (available at ars.usda.gov/nea/bhnrc/fsrg), adults aged 71 years and older consumed an average of 3139&#160;mg/day for men and 2472&#160;mg/day for women.</p><p>The Mediterranean dietary approaches to stop hypertension (DASH) intervention for neurodegenerative delay (MIND) diet score assesses adherence to a dietary pattern designed to support brain health. This diet is modeled after the Mediterranean and DASH diets, with modifications informed by research on nutrition and dementia.<xref rid="alz70706-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> To calculate the MIND diet score,<xref rid="alz70706-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> food items from the FFQ are classified into 10 brain&#8208;healthy and five unhealthy food groups. Each group is scored from 0 to 1 (including increments of 0.5) based on the frequency of consumption of the associated food items. The total MIND diet score ranges from 0 to 15, with higher scores reflecting greater adherence to the brain&#8208;healthy MIND diet.</p></sec><sec id="alz70706-sec-0120"><label>2.4</label><title>Clinical evaluations</title><p>At enrollment (study baseline) and at each annual visit, participants underwent a comprehensive clinical evaluation. Mild cognitive impairment (MCI) and dementia were identified, as previously reported.<xref rid="alz70706-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="alz70706-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> Self&#8208;reported demographics (including date of birth, sex, and years of education) were collected at enrollment. In addition, the following data collected at the time of the first dietary assessment (analytical baseline) were included in this study: body mass index (BMI); mean systolic and diastolic blood pressures (calculated as the average of two seated and one standing measurements); hours of weekly physical activity (total hours spent in five categories: walking for exercise, gardening or yard work, calisthenics or general exercise, bicycling, and swimming or water exercises); hours of cognitive activity; history of hypertension; use of antihypertensive or diuretic medications; and history of diabetes, stroke, heart attack, and smoking. Apolipoprotein E (<italic toggle="yes">APOE</italic>) &#949;4 allele data were also available.</p></sec><sec id="alz70706-sec-0130"><label>2.5</label><title>Brain autopsy and neuropathologic assessment</title><p>Brain autopsies were performed following a standardized procedure as described in detail elsewhere.<xref rid="alz70706-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> Briefly, the brain was removed, and the cerebral hemispheres were cut into 1&#8208;cm coronal slabs. Slabs from one hemisphere were frozen to &#8722;80&#176;C.&#160;Slabs not designated for freezing were fixed in 4% paraformaldehyde for 3 to 21 days before the macroscopic examination for infarcts and the dissection of diagnostic blocks. The blocks were paraffin&#8208;embedded, cut into 6&#8208;&#181;m sections, and mounted on microscope slides. Neuropathologic diagnoses were made by board&#8208;certified neuropathologists blinded to clinical data.</p><p>For assessing AD neuropathologic change (ADNC), a modified Bielschowsky silver stain was used to visualize neuritic plaques and neurofibrillary tangles. The counts of these two neuropathologic markers within an area of 1 mm<sup>2</sup> from sections of midfrontal, superior temporal, inferior parietal, and entorhinal cortices were summarized as one continuous, standardized measure, global ADNC score. In addition, quantitative measures of amyloid burden and neurofibrillary tangle density were obtained using immunohistochemistry with antibodies to amyloid beta (A&#946;) and phosphorylated tau.<xref rid="alz70706-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> Given the non&#8208;normal distribution of these measures, the raw data were square&#8208;root&#8208;transformed for further analyses.</p><p>Levels of ADNC in each deceased and brain autopsied participant were also categorized semi&#8208;quantitatively (low, intermediate, and high) using the 2012 National institute on Aging&#8208;Alzheimer's Association guidelines for the neuropathologic assessment of AD.<xref rid="alz70706-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>
</p><p>The presence of Stage 2 or 3 limbic&#8208;predominant age&#8208;related TDP&#8208;43 encephalopathy neuropathologic change (LATE&#8208;NC) was evaluated by identifying TDP&#8208;43 cytoplasmic inclusions in neurons and glia using immunohistochemistry in eight brain regions, employing an&#160;anti&#8208;phospho&#8208;TDP&#8208;43&#160;(pS409/410) monoclonal antibody&#160;(TAR5P&#8208;1D3, Ascenion; 1:100).<xref rid="alz70706-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="alz70706-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>
</p><p>The presence of Lewy bodies was assessed by immunohistochemistry with an anti&#8208;alpha&#8208;synuclein monoclonal antibody (LB509, Zymed; 1:50), using the avidin&#8208;biotin method with alkaline phosphatase as the color developer. The following seven regions were examined for Lewy bodies: substantia nigra, entorhinal cortex, anterior cingulate cortex, midfrontal cortex, superior or middle temporal cortex, inferior parietal cortex, and amygdala.<xref rid="alz70706-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>
</p><p>Cerebrovascular disease and gross infarcts were identified on macroscopic examination and classified by number, location (cortical, subcortical), and volume (in square millimeters). Each gross infarct was then dissected and confirmed on microscopic examination, and classified by age (acute, subacute, and chronic). Microinfarcts were identified under the microscope in blocks of nine brain regions that were stained with H&amp;E, and their location and age were also recorded.<xref rid="alz70706-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> Only chronic gross infarcts and chronic microinfarcts were considered in this study.</p><p>Cerebral vessel pathology was also examined systematically.<xref rid="alz70706-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> Atherosclerosis severity was graded using a semi&#8208;quantitative scale from 0 (no atherosclerosis) to 6 (severe atherosclerosis) following visual inspection of vessels in the circle of Willis. Similarly, arteriolosclerosis severity was graded using a scale from 0 (no arteriolosclerosis) to 7 (complete small vessel occlusion) during histologic examination of the anterior basal ganglia. Last, CAA severity was graded in several neocortical brain regions, based on the degree of immunohistochemical labeling with anti&#8208;A&#946;.<xref rid="alz70706-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref> For all cerebral vessel pathologies, final scoring was summarized on an ordinal four&#8208;point scale &#8211; none (0), mild (1), moderate (2), or severe (3).</p></sec><sec id="alz70706-sec-0140"><label>2.6</label><title>Statistical approach</title><p>Initial analyses included a graphical examination of the variables and their correlations. Dietary sodium intake was categorized into quintiles, which allowed for a balanced comparison across different levels of sodium intake, helping to identify potential dose&#8208;response relationships with cognitive decline while reducing the influence of extreme values. The associations of baseline calorie&#8208;adjusted dietary sodium intake among participants without dementia, with longitudinally assessed cognitive function, were performed using a series of linear mixed&#8208;effects models. All models were adjusted for age, sex, education, MIND diet score, and the interaction of each of these variables with time. Further analyses added terms for other potential confounders/mediators to the basic model, including BMI, systolic and diastolic blood pressures, hours of weekly physical activity, cognitive activity, total calorie intake, history of hypertension, antihypertensive/diuretic use, history of diabetes, history of stroke, history of heart attack,&#160;history of smoking, serum sodium level, and the presence of the <italic toggle="yes">APOE</italic> &#949;4 allele.</p><p>In a subset of deceased and autopsied participants who had neuropathologic data available, we examined the associations of mean dietary sodium intake (over all the years with FFQ data) with postmortem neuropathologic measures. Linear regression was used for quantitative ADNC variables: silver stain&#8208;based global ADNC score and immunohistochemistry&#8208;based amyloid burden and tau tangle density.</p><p>Logistic regression was used to examine the relation of sodium intake with the presence of neurodegenerative pathology (intermediate to high levels of ADNC, Stage 2 and 3 LATE&#8208;NC, and Lewy bodies), cerebrovascular pathology, including the presence (vs. absence) of infarcts (any chronic infarcts, gross chronic infarcts, chronic microinfarcts, chronic cortical infarcts, and chronic subcortical infarcts), and the severity (two&#8208;levels: none or mild vs. moderate or severe) of cerebral blood vessel pathology (atherosclerosis, arteriolosclerosis, and CAA).</p><p>All models were adjusted for age, sex, education, and MIND diet score, with or without additional covariates as mentioned earlier. Analyses were conducted using SAS/STAT software, version 9.4 of the SAS system for Linux (SAS Institute). A two&#8208;tailed hypothesis was assumed.</p></sec></sec><sec id="alz70706-sec-0150"><label>3</label><title>RESULTS</title><sec id="alz70706-sec-0160"><label>3.1</label><title>Sample characteristics</title><p>The characteristics of the 1520 participants included in this study are presented in Table&#160;<xref rid="alz70706-tbl-0001" ref-type="table">1</xref>, organized into sodium intake quintile groups based on estimated calorie&#8208;adjusted daily intake levels at the first dietary assessment available. The analytical sample was primarily White (93%) and female (75%), with an average age of 80.7 years (&#177;&#160;7.2) at the time of first dietary assessment (analytical baseline). The mean follow&#8208;up duration was 7.6 years. Characteristics of the participants were similar among the five sodium intake groups (quintiles), except that the highest quintile group had a lower proportion of females and a higher prevalence of diabetes diagnoses compared to the other quintile groups (Table&#160;<xref rid="alz70706-tbl-0001" ref-type="table">1</xref>).</p><table-wrap position="float" id="alz70706-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Participant characteristics by daily dietary sodium intake quintiles.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Quintile group</th><th align="left" rowspan="1" colspan="1">Q1</th><th align="left" rowspan="1" colspan="1">Q2</th><th align="left" rowspan="1" colspan="1">Q3</th><th align="left" rowspan="1" colspan="1">Q4</th><th align="left" rowspan="1" colspan="1">Q5</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sample size</td><td align="left" rowspan="1" colspan="1">304</td><td align="left" rowspan="1" colspan="1">304</td><td align="left" rowspan="1" colspan="1">304</td><td align="left" rowspan="1" colspan="1">304</td><td align="left" rowspan="1" colspan="1">304</td></tr><tr><td align="left" rowspan="1" colspan="1">Sodium intake, mg/day, median (interquartile range)</td><td align="left" rowspan="1" colspan="1">1764 (1609 to 1861)</td><td align="left" rowspan="1" colspan="1">2064 (2006 to 2116)</td><td align="left" rowspan="1" colspan="1">2264 (2209 to 2320)</td><td align="left" rowspan="1" colspan="1">2490 (2424 to 2560)</td><td align="left" rowspan="1" colspan="1">2800 (2709 to 2997)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Demographics</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age, years</td><td align="left" rowspan="1" colspan="1">80.0 &#177; 7.4</td><td align="left" rowspan="1" colspan="1">80.5 &#177; 7.3</td><td align="left" rowspan="1" colspan="1">80.0 &#177; 7.4</td><td align="left" rowspan="1" colspan="1">81.2 &#177; 6.8</td><td align="left" rowspan="1" colspan="1">81.6 &#177; 7.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Female sex, %<xref rid="alz70706-tbl1-note-0002" ref-type="table-fn">
<sup>*</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">88.2</td><td align="left" rowspan="1" colspan="1">81.6</td><td align="left" rowspan="1" colspan="1">75.3</td><td align="left" rowspan="1" colspan="1">70.1</td><td align="left" rowspan="1" colspan="1">60.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Education, years</td><td align="left" rowspan="1" colspan="1">14.9 &#177; 3.1</td><td align="left" rowspan="1" colspan="1">15.1 &#177; 2.8</td><td align="left" rowspan="1" colspan="1">15.6 &#177; 3.1</td><td align="left" rowspan="1" colspan="1">15.7 &#177; 3.3</td><td align="left" rowspan="1" colspan="1">15.7 &#177; 3.0</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Dietary assessment</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Total energy, kcal/d</td><td align="left" rowspan="1" colspan="1">1660 &#177; 757</td><td align="left" rowspan="1" colspan="1">1758 &#177; 556</td><td align="left" rowspan="1" colspan="1">1775 &#177; 474</td><td align="left" rowspan="1" colspan="1">1779 &#177; 448</td><td align="left" rowspan="1" colspan="1">1682 &#177; 428</td></tr><tr><td align="left" rowspan="1" colspan="1">MIND diet score</td><td align="left" rowspan="1" colspan="1">7.1 &#177; 1.7</td><td align="left" rowspan="1" colspan="1">7.6 &#177; 1.7</td><td align="left" rowspan="1" colspan="1">7.7 &#177; 1.7</td><td align="left" rowspan="1" colspan="1">7.6 &#177; 1.8</td><td align="left" rowspan="1" colspan="1">7.7 &#177; 1.8</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Lifestyle factors</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Physical activity, hours/week</td><td align="left" rowspan="1" colspan="1">3.3 &#177; 3.7</td><td align="left" rowspan="1" colspan="1">3.4 &#177; 3.3</td><td align="left" rowspan="1" colspan="1">3.7 &#177; 4.2</td><td align="left" rowspan="1" colspan="1">4.0 &#177; 4.0</td><td align="left" rowspan="1" colspan="1">3.5 &#177; 3.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Cognitive activity</td><td align="left" rowspan="1" colspan="1">3.2 &#177; 0.7</td><td align="left" rowspan="1" colspan="1">3.2 &#177; 0.6</td><td align="left" rowspan="1" colspan="1">3.3 &#177; 0.6</td><td align="left" rowspan="1" colspan="1">3.2 &#177; 0.6</td><td align="left" rowspan="1" colspan="1">3.2 &#177; 0.6</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Physical exam</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index, kg/m<sup>2</sup>
</td><td align="left" rowspan="1" colspan="1">27.5 &#177; 5.5</td><td align="left" rowspan="1" colspan="1">27.4 &#177; 5.1</td><td align="left" rowspan="1" colspan="1">27.4 &#177; 5.1</td><td align="left" rowspan="1" colspan="1">27.6 &#177; 4.7</td><td align="left" rowspan="1" colspan="1">27.8 &#177; 4.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure, mmHg</td><td align="left" rowspan="1" colspan="1">134 &#177; 20</td><td align="left" rowspan="1" colspan="1">133 &#177; 19</td><td align="left" rowspan="1" colspan="1">132 &#177; 18</td><td align="left" rowspan="1" colspan="1">134 &#177; 17</td><td align="left" rowspan="1" colspan="1">132 &#177; 19</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure, mmHg</td><td align="left" rowspan="1" colspan="1">75 &#177; 12</td><td align="left" rowspan="1" colspan="1">75 &#177; 11</td><td align="left" rowspan="1" colspan="1">75 &#177; 12</td><td align="left" rowspan="1" colspan="1">75 &#177; 12</td><td align="left" rowspan="1" colspan="1">75 &#177; 11</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Medical conditions</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension, %</td><td align="left" rowspan="1" colspan="1">58.2</td><td align="left" rowspan="1" colspan="1">55.9</td><td align="left" rowspan="1" colspan="1">52.6</td><td align="left" rowspan="1" colspan="1">57.9</td><td align="left" rowspan="1" colspan="1">55.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Antihypertensive use, %</td><td align="left" rowspan="1" colspan="1">70.7</td><td align="left" rowspan="1" colspan="1">70.7</td><td align="left" rowspan="1" colspan="1">64.5</td><td align="left" rowspan="1" colspan="1">69.4</td><td align="left" rowspan="1" colspan="1">74.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes, %<xref rid="alz70706-tbl1-note-0002" ref-type="table-fn">
<sup>*</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">12.8</td><td align="left" rowspan="1" colspan="1">10.9</td><td align="left" rowspan="1" colspan="1">10.5</td><td align="left" rowspan="1" colspan="1">14.1</td><td align="left" rowspan="1" colspan="1">19.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Stroke, %</td><td align="left" rowspan="1" colspan="1">10.6</td><td align="left" rowspan="1" colspan="1">11.6</td><td align="left" rowspan="1" colspan="1">10.0</td><td align="left" rowspan="1" colspan="1">8.0</td><td align="left" rowspan="1" colspan="1">9.7</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Laboratory testing</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> &#949;4, %</td><td align="left" rowspan="1" colspan="1">22.9</td><td align="left" rowspan="1" colspan="1">25.9</td><td align="left" rowspan="1" colspan="1">23.6</td><td align="left" rowspan="1" colspan="1">19.7</td><td align="left" rowspan="1" colspan="1">17.5</td></tr></tbody></table><table-wrap-foot><fn id="alz70706-tbl1-note-0001"><p>
<italic toggle="yes">Note</italic>: Data are presented as mean &#177; SD unless otherwise specified. Q1&#8208;Q5 refers to first&#8208;fifth quintiles.</p></fn><fn id="alz70706-tbl1-note-0002"><label>*</label><p>
<italic toggle="yes">p</italic> &lt; 0.05 in chi&#8208;squared test. <italic toggle="yes">n</italic> = 1520.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="alz70706-sec-0170"><label>3.2</label><title>Associations of dietary sodium intake with cognitive decline</title><p>We first examined the associations of dietary sodium intake with global cognitive function using linear mixed models adjusted for age, sex, education, the MIND diet score, and the interaction of each variable with time (Table&#160;<xref rid="alz70706-tbl-0002" ref-type="table">2</xref>). A total of 11,502 observations of cognition data from 1520 participants were included. A detailed frequency distribution of the number of cognitive assessments is provided in the Supporting Information (Table <xref rid="alz70706-supinfo-0001" ref-type="">S1</xref> and Figure <xref rid="alz70706-supinfo-0001" ref-type="">S1</xref>). As noted in the &#8220;Methods&#8221; section, we used the middle quintile of sodium intake as the reference because it approximates the recommended limit of 2300&#160;mg/day and accounts for the potential non&#8208;linear relationship between sodium intake and cognition. We did not find any associations between higher sodium intake quintiles (Q4 and Q5) and either the level of global cognition or the rate of its decline. In contrast, the two lowest quintiles (Q1 and Q2) of sodium intake were both associated with lower baseline levels of global cognition. In addition, the lowest quintile (Q1) of sodium intake was also associated with a faster rate of global cognitive decline. These associations remained significant after additionally adjusting for total energy intake, physical activity, cognitive activity, BMI, systolic blood pressure, diastolic blood pressure, antihypertensive use, diabetes, and stroke (data not shown). However, Q1 was no longer associated with global cognitive decline after additionally adjusting for <italic toggle="yes">APOE</italic> &#949;4 (estimate&#160;=&#160;&#8722;0.015, SE&#160;=&#160;0.010, <italic toggle="yes">p</italic>&#160;=&#160;0.087). To examine whether the association differed by <italic toggle="yes">APOE</italic> &#949;4 status, we conducted stratified analyses. <italic toggle="yes">APOE</italic> &#949;4 genotype data were available for 1194 participants (78.6% of the full sample). Among participants without any <italic toggle="yes">APOE</italic> &#949;4 allele (<italic toggle="yes">n</italic>&#160;=&#160;929; 7856 observations), sodium intake in the lowest quintile was not associated with global cognitive decline (estimate&#160;=&#160;&#8722;0.012, SE&#160;=&#160;0.010, <italic toggle="yes">p</italic>&#160;=&#160;0.236). Similarly, among participants with one or two <italic toggle="yes">APOE</italic> &#949;4 alleles (<italic toggle="yes">n</italic>&#160;=&#160;265; 2185 observations), no significant association was observed (estimate&#160;=&#160;&#8722;0.028, SE&#160;=&#160;0.023, <italic toggle="yes">p</italic>&#160;=&#160;0.238).</p><table-wrap position="float" id="alz70706-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Associations of dietary sodium intake with cognitive decline.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" colspan="6" style="border-bottom:solid 1px #000000" rowspan="1">Estimate (SE, <italic toggle="yes">p</italic> value)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Predictor</th><th align="left" rowspan="1" colspan="1">Global cognition</th><th align="left" rowspan="1" colspan="1">Episodic memory</th><th align="left" rowspan="1" colspan="1">Working memory</th><th align="left" rowspan="1" colspan="1">Semantic memory</th><th align="left" rowspan="1" colspan="1">Perceptual speed</th><th align="left" rowspan="1" colspan="1">Visuospatial ability</th></tr></thead><tbody><tr><td colspan="3" align="left" rowspan="1">
<bold>Sodium intake</bold>
</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Q1</td><td align="char" rowspan="1" colspan="1">&#8722;0.112 (0.039, 0.004)</td><td align="char" rowspan="1" colspan="1">
<bold>&#8722;0.137 (0.051, 0.008)</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>&#8722;0.116 (0.056, 0.036)</bold>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.084 (0.045, 0.065)</td><td align="char" rowspan="1" colspan="1">&#8722;0.069 (0.055, 0.211)</td><td align="char" rowspan="1" colspan="1">
<bold>&#8722;0.173 (0.053, 0.001)</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Q2</td><td align="char" rowspan="1" colspan="1">
<bold>&#8722;0.081 (0.039, 0.037)</bold>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.086 (0.051, 0.091)</td><td align="char" rowspan="1" colspan="1">&#8722;0.093 (0.055, 0.093)</td><td align="char" rowspan="1" colspan="1">&#8722;0.029 (0.045, 0.524)</td><td align="char" rowspan="1" colspan="1">&#8722;0.056 (0.054, 0.301)</td><td align="char" rowspan="1" colspan="1">&#8722;0.095 (0.053, 0.071)</td></tr><tr><td align="left" rowspan="1" colspan="1">Q3</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">Ref</td></tr><tr><td align="left" rowspan="1" colspan="1">Q4</td><td align="char" rowspan="1" colspan="1">&#8722;0.025 (0.039, 0.512)</td><td align="char" rowspan="1" colspan="1">&#8722;0.022 (0.051, 0.668)</td><td align="char" rowspan="1" colspan="1">&#8722;0.083 (0.055, 0.130)</td><td align="char" rowspan="1" colspan="1">0.004 (0.045, 0.931)</td><td align="char" rowspan="1" colspan="1">0.002 (0.055, 0.965)</td><td align="char" rowspan="1" colspan="1">&#8722;0.003 (0.053, 0.954)</td></tr><tr><td align="left" rowspan="1" colspan="1">Q5</td><td align="char" rowspan="1" colspan="1">&#8722;0.019 (0.039, 0.622)</td><td align="char" rowspan="1" colspan="1">0.013 (0.052, 0.799)</td><td align="char" rowspan="1" colspan="1">&#8722;0.106 (0.056, 0.057)</td><td align="char" rowspan="1" colspan="1">&#8722;0.003 (0.046, 0.944)</td><td align="char" rowspan="1" colspan="1">&#8722;0.011 (0.055, 0.840)</td><td align="char" rowspan="1" colspan="1">0.021 (0.054, 0.693)</td></tr><tr><td colspan="4" align="left" rowspan="1">
<bold>Interactions of sodium intake with time</bold>
</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Q1*Time</td><td align="char" rowspan="1" colspan="1">
<bold>&#8722;0.022 (0.009, 0.012)</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>&#8722;0.027 (0.011, 0.011)</bold>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.011 (0.008, 0.157)</td><td align="char" rowspan="1" colspan="1">
<bold>&#8722;0.025 (0.010, 0.010)</bold>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.015 (0.008, 0.073)</td><td align="char" rowspan="1" colspan="1">&#8722;0.008 (0.008, 0.336)</td></tr><tr><td align="left" rowspan="1" colspan="1">Q2*Time</td><td align="char" rowspan="1" colspan="1">&#8722;0.014 (0.009, 0.114)</td><td align="char" rowspan="1" colspan="1">&#8722;0.018 (0.011, 0.092)</td><td align="char" rowspan="1" colspan="1">&#8722;0.006 (0.008, 0.452)</td><td align="char" rowspan="1" colspan="1">
<bold>&#8722;0.026 (0.010, 0.007)</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>&#8722;0.018 (0.008, 0.032)</bold>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.008 (0.008, 0.319)</td></tr><tr><td align="left" rowspan="1" colspan="1">Q3*Time</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">Ref</td></tr><tr><td align="left" rowspan="1" colspan="1">Q4*Time</td><td align="char" rowspan="1" colspan="1">&#8722;0.006 (0.009, 0.486)</td><td align="char" rowspan="1" colspan="1">&#8722;0.009 (0.011, 0.399)</td><td align="char" rowspan="1" colspan="1">0.004 (0.008, 0.665)</td><td align="char" rowspan="1" colspan="1">&#8722;0.012 (0.010, 0.222)</td><td align="char" rowspan="1" colspan="1">&#8722;0.001 (0.008, 0.917)</td><td align="char" rowspan="1" colspan="1">0.001 (0.008, 0.909)</td></tr><tr><td align="left" rowspan="1" colspan="1">Q5*Time</td><td align="char" rowspan="1" colspan="1">&#8722;0.006 (0.009, 0.493)</td><td align="char" rowspan="1" colspan="1">&#8722;0.007 (0.011, 0.509)</td><td align="char" rowspan="1" colspan="1">&#8722;0.001 (0.009, 0.902)</td><td align="char" rowspan="1" colspan="1">0.000 (0.010, 0.996)</td><td align="char" rowspan="1" colspan="1">&#8722;0.005 (0.009, 0.561)</td><td align="char" rowspan="1" colspan="1">&#8722;0.008 (0.008, 0.339)</td></tr></tbody></table><table-wrap-foot><fn id="alz70706-tbl2-note-0001"><p>
<italic toggle="yes">Note</italic>: Six linear mixed models were adjusted for age, sex, education, MIND diet score, and their interactions with time. Data in bold denote statistical significance. Q1&#8211;Q5 represent quintile groups of estimated daily dietary sodium intake from food sources, adjusted for total energy intake. A total of 11,502 observations of cognition data from 1520 participants were included.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>Because the relation of sodium intake to cognition may differ by age, we conducted additional analyses stratified by the median age (81.5 years): Among the older age group (age &#8805; 81.5 years; <italic toggle="yes">n</italic>&#160;=&#160;760, 5020 observations), the lowest quintile of sodium intake was associated with faster decline in global cognition (estimate&#160;=&#160;&#8722;0.035, SE&#160;=&#160;0.014, <italic toggle="yes">p</italic>&#160;=&#160;0.013). Among the younger age group (age&#160;&lt;&#160;81.5 years; <italic toggle="yes">n</italic>&#160;=&#160;760, 6482 observations), the lowest quintile of sodium intake was not associated with decline in global cognition (estimate&#160;=&#160;&#8722;0.010, SE&#160;=&#160;0.011, <italic toggle="yes">p</italic>&#160;=&#160;0.361). No other associations between sodium intake and global cognitive decline were observed in either age group.</p><p>Given that the highest sodium intake quintile group had a lower proportion of females compared to the other groups, we conducted additional stratified analyses by sex. Among females (<italic toggle="yes">n</italic>&#160;=&#160;1141; 8787 observations), the lowest quintile of sodium intake was associated with a faster rate of global cognitive decline (estimate&#160;= &#8722;0.023, SE&#160;=&#160;0.010, <italic toggle="yes">p</italic>&#160;=&#160;0.026). This association was not statistically significant in males (<italic toggle="yes">n</italic>&#160;=&#160;379; 2715 observations; estimate&#160;=&#160;&#8722;0.036, SE&#160;=&#160;0.020, <italic toggle="yes">p</italic>&#160;=&#160;0.078). Similar to the full sample analysis, we did not observe significant associations between high sodium intake and cognitive decline in either sex.</p><p>Given that sodium intake was estimated via food frequency questionnaire and may be influenced by early cognitive changes, we conducted a sensitivity analysis excluding participants who developed MCI or dementia within 2 years of baseline. This analysis included 8059 observations from 977 participants, representing 64% of the full sample (<italic toggle="yes">n</italic>&#160;=&#160;1520). We found no association between the lowest quintile of sodium intake and decline in global cognition (estimate&#160;=&#160;&#8722;0.010, SE&#160;=&#160;0.009, <italic toggle="yes">p</italic>&#160;=&#160;0.268) or any other associations between sodium intake and global cognitive decline.</p><p>Next, we conducted secondary analyses using similarly adjusted linear mixed models to examine the associations of sodium intake and cognitive function within each of the five separate domains: episodic memory, working memory, semantic memory, perceptual speed, and visuospatial abilities (Table&#160;<xref rid="alz70706-tbl-0002" ref-type="table">2</xref>). We found that the lowest quintile of sodium (Q1) intake was associated with lower baseline level of episodic memory, working memory, and visuospatial ability. Also, Q1 was associated with a faster rate of cognitive decline in episodic memory and semantic memory. Further, Q2 was associated with a faster rate of decline in semantic memory and perceptual speed. There was no other association between sodium intake and the level or rate of decline in individual cognitive domains.</p></sec><sec id="alz70706-sec-0180"><label>3.3</label><title>Associations of dietary sodium intake with neurodegenerative pathologies</title><p>In a subset of 717 deceased and autopsied participants, we examined the associations of mean dietary sodium intake with neurodegenerative diseases. We first examined associations of sodium intake with ADNC burden (assessed with silver stain&#8208;based global ADNC score and immunohistochemistry&#8208;based amyloid burden and tau tangle density) using separate linear regression models adjusted for age at death, sex, education, and MIND diet score (Table&#160;<xref rid="alz70706-tbl-0003" ref-type="table">3</xref>). Although none of the quintile groups of sodium intake were associated with global ADNC score or amyloid burden, the lowest quintile (Q1) of sodium intake was associated with a higher tau tangle density. This association remained significant after additionally adjusting for total energy intake, physical activity, cognitive activity, BMI, systolic blood pressure, diastolic blood pressure, antihypertensive use, diabetes, stroke, and <italic toggle="yes">APOE</italic> &#949;4. We did not find any association between high&#8208;sodium&#8208;intake quintiles (Q4 and Q5) and tau tangle density.</p><table-wrap position="float" id="alz70706-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Associations of dietary sodium intake with quantitative ADNC burden.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" colspan="3" style="border-bottom:solid 1px #000000" rowspan="1">Estimate (SE, p&#8208;value)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Predictor</th><th align="left" rowspan="1" colspan="1">Global ADNC Score</th><th align="left" rowspan="1" colspan="1">Amyloid Burden</th><th align="left" rowspan="1" colspan="1">Tau Tangle Density</th></tr></thead><tbody><tr><td colspan="3" align="left" rowspan="1">
<bold>Sodium intake</bold>
</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Q1</td><td align="char" rowspan="1" colspan="1">0.145 (0.087, 0.095)</td><td align="char" rowspan="1" colspan="1">0.100 (0.090, 0.265)</td><td align="char" rowspan="1" colspan="1">
<bold>0.279 (0.109, 0.010)</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Q2</td><td align="char" rowspan="1" colspan="1">0.054 (0.085, 0.529)</td><td align="char" rowspan="1" colspan="1">0.125 (0.088, 0.157)</td><td align="char" rowspan="1" colspan="1">0.180 (0.106, 0.091)</td></tr><tr><td align="left" rowspan="1" colspan="1">Q3</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">Ref</td></tr><tr><td align="left" rowspan="1" colspan="1">Q4</td><td align="char" rowspan="1" colspan="1">0.022 (0.086, 0.802)</td><td align="char" rowspan="1" colspan="1">0.035 (0.088, 0.696)</td><td align="char" rowspan="1" colspan="1">0.029 (0.107, 0.785)</td></tr><tr><td align="left" rowspan="1" colspan="1">Q5</td><td align="char" rowspan="1" colspan="1">&#8722;0.133 (0.091, 0.147)</td><td align="char" rowspan="1" colspan="1">&#8722;0.063 (0.094, 0.500)</td><td align="char" rowspan="1" colspan="1">&#8722;0.165 (0.113, 0.145)</td></tr></tbody></table><table-wrap-foot><fn id="alz70706-tbl3-note-0001"><p>
<italic toggle="yes">Note</italic>: Three linear regression models were adjusted for age, sex, education, and MIND diet score. Q1&#8211;Q5 represent quintile groups of estimated daily dietary sodium intake from food sources, adjusted for total energy intake. <italic toggle="yes">n</italic> = 717.</p></fn><fn id="alz70706-tbl3-note-0002"><p>Abbreviation: ADNC, Alzheimer's disease neuropathologic change.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>Next, we examined the associations of sodium intake with the presence of ADNC, TDP&#8208;43, and Lewy bodies using logistic regressions (Table&#160;<xref rid="alz70706-tbl-0004" ref-type="table">4</xref>). We did not find any significant associations.</p><table-wrap position="float" id="alz70706-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>Association of dietary sodium intake with presence of ADNC (intermediate to high levels), LATE&#8208;NC (Stage 2 or 3), and Lewy body pathology.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" colspan="3" style="border-bottom:solid 1px #000000" rowspan="1">OR, Estimate (SE, p&#8208;value)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Predictor</th><th align="left" rowspan="1" colspan="1">ADNC</th><th align="left" rowspan="1" colspan="1">LATE&#8208;NC</th><th align="left" rowspan="1" colspan="1">Lewy bodies</th></tr></thead><tbody><tr><td colspan="4" align="left" rowspan="1">
<bold>Sodium intake</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Q1</td><td align="left" rowspan="1" colspan="1">1.589, 0.463 (0.256, 0.070)</td><td align="left" rowspan="1" colspan="1">1.463, 0.380 (0.251, 0.130)</td><td align="left" rowspan="1" colspan="1">0.769, &#8722;0.263 (0.275, 0.340)</td></tr><tr><td align="left" rowspan="1" colspan="1">Q2</td><td align="left" rowspan="1" colspan="1">1.158, 0.147 (0.244, 0.548)</td><td align="left" rowspan="1" colspan="1">1.415, 0.347 (0.245, 0.157)</td><td align="left" rowspan="1" colspan="1">0.784, &#8722;0.244 (0.269, 0.363)</td></tr><tr><td align="left" rowspan="1" colspan="1">Q3</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">Ref</td></tr><tr><td align="left" rowspan="1" colspan="1">Q4</td><td align="left" rowspan="1" colspan="1">1.160, 0.149 (0.246, 0.546)</td><td align="left" rowspan="1" colspan="1">1.003, 0.003 (0.252, 0.991)</td><td align="left" rowspan="1" colspan="1">0.832, &#8722;0.185 (0.265, 0.486)</td></tr><tr><td align="left" rowspan="1" colspan="1">Q5</td><td align="left" rowspan="1" colspan="1">0.964, &#8722;0.037 (0.256, 0.886)</td><td align="left" rowspan="1" colspan="1">1.092, 0.088 (0.266, 0.742)</td><td align="left" rowspan="1" colspan="1">0.992, &#8722;0.008 (0.272, 0.976)</td></tr></tbody></table><table-wrap-foot><fn id="alz70706-tbl4-note-0001"><p>
<italic toggle="yes">Note</italic>: Three logistic regression models were adjusted for age, sex, education, and MIND diet score. Q1&#8211;Q5 represent quintile groups of estimated daily dietary sodium intake from food sources, adjusted for total energy intake. <italic toggle="yes">n</italic> = 717.</p></fn><fn id="alz70706-tbl4-note-0002"><p>Abbreviations: ADNC, Alzheimer's disease neuropathologic change; LATE&#8208;NC, limbic&#8208;predominant age&#8208;related TDP&#8208;43 encephalopathy neuropathologic change.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="alz70706-sec-0190"><label>3.4</label><title>Association of dietary sodium intake with cerebrovascular pathologies</title><p>We studied the associations of sodium intake with the presence of chronic brain infarcts using separate logistic regression models (Table&#160;<xref rid="alz70706-tbl-0005" ref-type="table">5</xref>). We did not find any association of sodium intake with the presence of any chronic brain infarcts, including with the presence of gross infarcts, microinfarcts, cortical infarcts, or subcortical infarcts.</p><table-wrap position="float" id="alz70706-tbl-0005" content-type="TABLE" orientation="portrait"><label>TABLE 5</label><caption><p>Association of dietary sodium intake with presence of brain infarcts.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" colspan="5" style="border-bottom:solid 1px #000000" rowspan="1">OR, estimate (SE, <italic toggle="yes">p</italic> value)</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Size of infarct</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Location of infarct</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Predictor</th><th align="left" rowspan="1" colspan="1">Any infarct</th><th align="left" rowspan="1" colspan="1">Gross infarcts</th><th align="left" rowspan="1" colspan="1">Micro&#8208;infarcts</th><th align="left" rowspan="1" colspan="1">Cortical infarcts</th><th align="left" rowspan="1" colspan="1">Subcortical infarcts</th></tr></thead><tbody><tr><td colspan="6" align="left" rowspan="1">
<bold>Sodium intake</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Q1</td><td align="left" rowspan="1" colspan="1">0.996, &#8722;0.004 (0.241, 0.988)</td><td align="left" rowspan="1" colspan="1">1.011, 0.011 (0.246, 0.963)</td><td align="left" rowspan="1" colspan="1">0.950, &#8722;0.051 (0.253, 0.839)</td><td align="left" rowspan="1" colspan="1">0.757, &#8722;0.279 (0.254, 0.272)</td><td align="left" rowspan="1" colspan="1">0.802, &#8722;0.220 (0.252, 0.382)</td></tr><tr><td align="left" rowspan="1" colspan="1">Q2</td><td align="left" rowspan="1" colspan="1">1.122, 0.115 (0.237, 0.626)</td><td align="left" rowspan="1" colspan="1">0.938, &#8722;0.064 (0.242,0.791)</td><td align="left" rowspan="1" colspan="1">1.202, 0.184 (0.243, 0.450)</td><td align="left" rowspan="1" colspan="1">0.986, &#8722;0.014 (0.243, 0.953)</td><td align="left" rowspan="1" colspan="1">0.887, &#8722;0.120 (0.244, 0.624)</td></tr><tr><td align="left" rowspan="1" colspan="1">Q3</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">Ref</td></tr><tr><td align="left" rowspan="1" colspan="1">Q4</td><td align="left" rowspan="1" colspan="1">1.101, 0.097 (0.239, 0.687)</td><td align="left" rowspan="1" colspan="1">0.989, &#8722;0.011 (0.244, 0.963)</td><td align="left" rowspan="1" colspan="1">1.139, 0.130 (0.247, 0.598)</td><td align="left" rowspan="1" colspan="1">0.983, &#8722;0.018 (0.245, 0.943)</td><td align="left" rowspan="1" colspan="1">0.911, &#8722;0.093 (0.249, 0.709)</td></tr><tr><td align="left" rowspan="1" colspan="1">Q5</td><td align="left" rowspan="1" colspan="1">1.051, 0.049 (0.251, 0.845)</td><td align="left" rowspan="1" colspan="1">1.088, 0.084 (0.256, 0.743)</td><td align="left" rowspan="1" colspan="1">1.164, 0.152 (0.259, 0.559)</td><td align="left" rowspan="1" colspan="1">1.120, 0.114 (0.255, 0.656)</td><td align="left" rowspan="1" colspan="1">0.991, &#8722;0.009 (0.260, 0.972)</td></tr></tbody></table><table-wrap-foot><fn id="alz70706-tbl5-note-0001"><p>
<italic toggle="yes">Note</italic>: Three logistic regression models were adjusted for age, sex, education, and MIND diet score.Q1&#8211;Q5 represent quintile groups of estimated daily dietary sodium intake from food sources, adjusted for total energy intake. <italic toggle="yes">n</italic> = 717. Analyses evaluated for outcomes of chronic infarcts only.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>Last, we examined the associations of sodium intake with the presence of moderate to severe cerebral vessel pathologies (Table&#160;<xref rid="alz70706-tbl-0006" ref-type="table">6</xref>). We found that both first and fourth quintiles of sodium intake (Q1 and Q4) were associated with higher odds of presence of moderate to severe arteriolosclerosis. These associations remained significant after additionally adjusting for other covariates (data not shown). We did not find an association of second and fifth quintile of sodium intake (Q2 and Q5) with moderate to severe arteriolosclerosis. Additionally, we did not find any association of sodium intake with the presence of moderate to severe atherosclerosis or CAA.</p><table-wrap position="float" id="alz70706-tbl-0006" content-type="TABLE" orientation="portrait"><label>TABLE 6</label><caption><p>Association of dietary sodium intake with presence of moderate to severe cerebral vessel pathologies.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" colspan="3" style="border-bottom:solid 1px #000000" rowspan="1">OR, Estimate (SE, <italic toggle="yes">p</italic>&#8208;value)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Predictor</th><th align="left" rowspan="1" colspan="1">Atherosclerosis</th><th align="left" rowspan="1" colspan="1">Arteriolosclerosis</th><th align="left" rowspan="1" colspan="1">CAA</th></tr></thead><tbody><tr><td colspan="4" align="left" rowspan="1">
<bold>Sodium intake</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Q1</td><td align="char" rowspan="1" colspan="1">1.152, 0.141 (0.266, 0.595)</td><td align="char" rowspan="1" colspan="1">
<bold>1.895, 0.639 (0.271, 0.018)</bold>
</td><td align="char" rowspan="1" colspan="1">1.125, 0.117 (0.247, 0.635)</td></tr><tr><td align="left" rowspan="1" colspan="1">Q2</td><td align="char" rowspan="1" colspan="1">0.797, &#8722;0.226 (0.269, 0.399)</td><td align="char" rowspan="1" colspan="1">1.431, 0.358 (0.268, 0.182)</td><td align="char" rowspan="1" colspan="1">1.389, 0.329 (0.240, 0.171)</td></tr><tr><td align="left" rowspan="1" colspan="1">Q3</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">Ref</td></tr><tr><td align="left" rowspan="1" colspan="1">Q4</td><td align="char" rowspan="1" colspan="1">0.939, &#8722;0.063 (0.267, 0.813)</td><td align="char" rowspan="1" colspan="1">
<bold>1.948, 0.667 (0.270, 0.014)</bold>
</td><td align="char" rowspan="1" colspan="1">0.798, &#8722;0.226 (0.249, 0.365)</td></tr><tr><td align="left" rowspan="1" colspan="1">Q5</td><td align="char" rowspan="1" colspan="1">0.750, &#8722;0.288 (0.293, 0.325)</td><td align="char" rowspan="1" colspan="1">1.446, 0.369 (0.292, 0.207)</td><td align="char" rowspan="1" colspan="1">0.980, &#8722;0.021 (0.258, 0.936)</td></tr></tbody></table><table-wrap-foot><fn id="alz70706-tbl6-note-0001"><p>
<italic toggle="yes">Note</italic>: Three logistic regression models were adjusted for age, sex, education, and MIND diet score. Q1&#8211;Q5 represent quintile groups of estimated daily dietary sodium intake from food sources, adjusted for total energy intake. Data in bold denotes statistical significance. <italic toggle="yes">n</italic> = 717.</p></fn><fn id="alz70706-tbl6-note-0002"><p>Abbreviation: CAA, cerebral amyloid angiopathy.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec></sec><sec id="alz70706-sec-0200"><label>4</label><title>DISCUSSION</title><p>In this study of dietary sodium intake and late&#8208;life cognition in 1520 community&#8208;dwelling older adults, we found that, compared to the middle quintile of sodium intake (&#8764;2300&#160;mg/day), the lowest quintile was associated with a faster decline in global cognition. In analyses with separate cognitive domains, the lowest quintile of sodium intake was associated with declines in episodic memory and semantic memory, while the second quintile was linked to declines in semantic memory and perceptual speed. In a subset of 717 deceased participants, the lowest quintile of sodium intake was associated with a higher burden of tau tangle density. But there was no association with ADNC, amyloid, TDP&#8208;43, or Lewy bodies. For cerebrovascular outcomes, both the lowest and fourth highest quintiles of sodium intake were associated with increased odds of moderate to severe brain arteriolosclerosis. No associations were observed between sodium intake and other cerebrovascular pathologies including infarcts or other vessel pathologies. Taken together, these findings suggest that compared to the recommended sodium intake of 2300&#160;mg/ day, lower dietary sodium intake of 1800&#160;mg/day is associated with faster late&#8208;life cognitive decline and higher tau tangle density, whereas both low and high sodium intake are associated with arteriolosclerosis.</p><p>Most previous studies on the association of dietary sodium intake with global cognition were cross&#8208;sectional and yielded mixed results.<xref rid="alz70706-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Some found that higher sodium intake was associated with cognitive impairment,<xref rid="alz70706-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="alz70706-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> while others found no significant relationship.<xref rid="alz70706-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="alz70706-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="alz70706-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> One cross&#8208;sectional study of 925 older adults (mean age 74.5 years, 60% female) found that lower dietary sodium was associated with poor cognition, and higher dietary sodium was associated with better cognition.<xref rid="alz70706-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> Only a few studies examined the longitudinal association between dietary sodium intake and global cognitive decline in community&#8208;dwelling older adults. One study of 1262 older adults (mean baseline age 74.2 years, 51% female) found sodium intake measured by FFQ was independently associated with greater global cognitive decline over a 3&#8208;year period in sedentary but not physically active older adults.<xref rid="alz70706-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> Another study estimated sodium intake using FFQ in 1194 participants (mean baseline age 74.2 years, 54% female) and found no association with cognitive decline over 6.9 years.<xref rid="alz70706-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> A recent study estimating sodium intake through urinary sodium excretion in 2041 Chinese older adults (mean baseline age 68.5 years, 52% female) found that higher sodium intake was linked to faster cognitive decline over an average follow&#8208;up of 11.4 years.<xref rid="alz70706-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> However, given the relatively young mean baseline age, it may not fully reflect the association between sodium intake and cognitive decline in more advanced old age. These mixed findings across study designs may stem from the reliance of most studies on a single screening test of global cognition, such as the Mini&#8208;Mental State Examination (MMSE), which may lack sensitivity to detect subtle changes.<xref rid="alz70706-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> In our study, using a comprehensive battery of neuropsychological tests and statistically robust linear mixed models, we found that low sodium intake (Q1 and Q2) was associated with a lower baseline level of global cognition, in line with findings from the cross&#8208;sectional study of 925 older adults (mean age 74.5 years, 60% female).<xref rid="alz70706-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> Further, we showed that the lowest quintile of sodium intake (Q1) was associated with a faster subsequent decline in global cognition, an arguably more clinically relevant outcome, even after accounting for lifestyle and clinical factors. This may be driven by domain&#8208;specific effects, with possible cumulative contributions from modest, non&#8208;significant declines in others. Adjustment for <italic toggle="yes">APOE</italic> &#949;4 attenuated the association, suggesting genetic confounding or reduced power from a smaller sample. Stratified analyses by <italic toggle="yes">APOE</italic> &#949;4 showed no association in either group, likely reflecting limited power. The results of stratified analyses by age and by sex suggest that the observed association between low sodium intake and faster global cognitive decline may be driven by participants aged 81.5 years and older and by females. The sensitivity analysis excluding participants who developed MCI or dementia within 2 years showed no association, suggesting early cognitive changes may drive the main analysis findings, though limited power could also play a role. We did not find an association of high sodium intake with the level or decline of global cognition. This can be because the highest quintile of sodium intake was not particularly high. It is also possible that participants experiencing early stages of cognitive decline might have altered eating habits, leading to lower sodium intake.<xref rid="alz70706-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>
</p><p>Most studies on sodium intake and cognitive domains were cross&#8208;sectional with a small sample size and reported null findings.<xref rid="alz70706-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> One exception, the previously mentioned cross&#8208;sectional study of 925 older adults (mean age 74.5 years, 60% female), found that lower sodium intake was associated with poorer performance on the Trail Making Test Part B, a measure of executive function, but only among individuals aged 80 and older.<xref rid="alz70706-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> Consistent with these findings, in our sample of 1520 older adults with a mean age of 81 years, we observed that the lowest quintile of sodium intake was associated with lower levels of working memory, a component of executive function, and visuospatial abilities. Additionally, we found that lower sodium was also associated with a lower level of episodic memory and a faster decline in episodic memory, the earliest affected domain in both normal aging and AD.<xref rid="alz70706-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> We further found that low sodium intake was associated with faster decline in semantic memory and perceptual speed. Associations remained after adjusting for <italic toggle="yes">APOE</italic> &#949;4. Although our findings suggest that low sodium intake may adversely affect multiple cognitive domains in older adults, results from other populations have differed. For example, in a randomized controlled trial of 160 sedentary men and women (mean age 65.4 years, 46% female) with cognitive impairment but no dementia and risks factors for cardiovascular diseases, researchers found that reduced sodium intake through the DASH diet was associated with better executive function after 6 months.<xref rid="alz70706-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> These contrasting findings underscore the need for future research to explore how age, cardiovascular risk, and other lifestyle and clinical factors (e.g., depression, and others) may modify the relationship between sodium intake and cognitive trajectories in older adults.</p><p>Previous evidence linking sodium intake to neurodegenerative neuropathologies is limited and mostly based on non&#8208;human data. A 2019 study reported that dietary salt induced hyperphosphorylation of tau followed by cognitive dysfunction in mice.<xref rid="alz70706-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> Similarly, another study found that elevated salt intake in mice induced tau hyperphosphorylation and synaptic loss during aging.<xref rid="alz70706-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref> A recent study showed both increased hippocampal amyloid and phosphorylated tau with cognitive impairment in mice fed a high&#8208;salt diet.<xref rid="alz70706-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref> However, the relevance of these findings to humans remains uncertain, as the high&#8208;salt diets used greatly exceed human salt consumption.<xref rid="alz70706-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref>, <xref rid="alz70706-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref> The only relevant human study published found that a Mediterranean&#8208;like low&#8208;sodium diet improved cerebrospinal fluid biomarkers for AD and cerebral perfusion, whereas a Western&#8208;like high&#8208;sodium diet had the opposite effects in cognitively normal middle&#8208;aged adults.<xref rid="alz70706-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> In our study, we examined the association of sodium intake with multiple neuropathologies and including across both neurodegenerative and cerebrovascular pathologies. We found that individuals in the lowest quintile of sodium intake had a higher density of hyperphosphorylated tau. However, no association was observed between sodium intake and amyloid burden, the presence of intermediate to high levels of ADNC, and other neurodegenerative neuropathologies (e.g., LATE&#8208;NC, Lewy bodies). These findings suggest that while dietary sodium intake in older adults might not be directly linked to classical ADNC, low sodium intake might contribute to hyperphosphorylated tau accumulation and cognitive impairment through alternative mechanisms, such as oxidative stress.<xref rid="alz70706-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref>
</p><p>We also examined the association of sodium intake with multiple cerebrovascular neuropathologies. We found that both high and low sodium intake were associated with increased odds of moderate to severe arteriolosclerosis. This suggests a potential U&#8208;shaped relationship. Both extremes may harm vascular brain health.<xref rid="alz70706-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> High sodium intake may exacerbate hypertension and endothelial dysfunction,<xref rid="alz70706-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref> while chronic low sodium intake could activate compensatory mechanisms such as renin&#8208;angiotensin system and sympathetic nervous system leading to vascular remodeling.<xref rid="alz70706-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref>, <xref rid="alz70706-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref> We found no association between the highest quintile (Q5) of sodium intake and increased odds of moderate or severe arteriolosclerosis. While this may reflect the presence of protective factors such as genetic predispositions or medication use, it is also possible that selection bias contributed to this finding, as individuals with poorer health may have been less likely to participate.</p><p>This study has several limitations that should be noted when interpreting the findings. First, we considered only sodium from foods reported on the questionnaire, excluding salt added during cooking or at the table. Second, we estimated sodium intake using a self&#8208;reported FFQ, which may be subject to recall bias and inaccuracies related to cognitive impairment, although the participants were without baseline dementia and the FFQ validated.<xref rid="alz70706-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> Third, the lowest and the highest sodium intake quintiles were not substantially different from the middle quintile, which may have limited statistical power to detect associations. Fourth, selection bias is possible given the advanced baseline age, as individuals in poorer health or with higher sodium intake may have died earlier and contributed less data, leading to underestimation of associations.&#160;Finally, because the participants were predominantly White and highly educated older adults, our findings may not be generalizable to more diverse or younger populations. Despite these limitations, this study has important strengths. First, we used an extensive battery of neuropsychological tests to assess global cognition and five specific cognitive domains, providing a nuanced and robust evaluation of cognitive function. Second, the annual follow&#8208;up assessments conducted over an average of 7.6 years generated high&#8208;density longitudinal data, allowing us to rigorously model the trajectory of late&#8208;life cognitive decline. Third, the systematic and comprehensive neuropathologic evaluation enhanced our ability to examine the association between sodium intake and common dementia&#8208;related pathologies.</p><p>In conclusion, our findings reveal a complex relationship between sodium intake and brain health in late life, suggesting that maintaining a balanced sodium intake may be important for preserving cognitive function and limiting neuropathologic burden.</p></sec><sec sec-type="COI-statement" id="alz70706-sec-0220"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors have no conflicts of interest to declare. Author disclosures are available in the <xref rid="alz70706-supinfo-0001" ref-type="">supporting information</xref>.</p></sec><sec id="alz70706-sec-0250"><title>CONSENT STATEMENT</title><p>The Rush MAP was approved by the Institutional Review Board of Rush University Medical Center. All participants signed an informed consent before enrollment, and a subset of participants signed an anatomical gift act to donate their brain tissues for research at the time of death.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="alz70706-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="alz70706-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70706-s002.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70706-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70706-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="alz70706-sec-0210"><title>ACKNOWLEDGMENTS</title><p>The authors are grateful to all participants of the Rush MAP for their altruism and commitment to this ongoing study since 1997. The authors thank all Rush Alzheimer's Disease Center staff and faculty, in particular Traci Colvin for study coordination, Ryan Johnson for laboratory management, John Gibbons for data management, and Woojeong Bang for statistical programming. This work was funded by the National Institute on Aging grants P30AG010161, P30AG072975, R01AG017917, RF1AG059621, and R01AG074549.</p></ack><sec sec-type="data-availability" id="alz70706-sec-0240"><title>DATA AVAILABILITY STATEMENT</title><p>All data supporting the conclusions of this article can be requested for research purposes via Rush Alzheimer's Disease Center Research Resource Sharing Hub at radc.rush.edu.</p></sec><ref-list id="alz70706-bibl-0001"><title>REFERENCES</title><ref id="alz70706-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="alz70706-cite-0002"><collab collab-type="authors">GBD 2019 Dementia Forecasting Collaborators</collab>
. <article-title>Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019</article-title>. <source>Lancet Public Health</source>. <year>2022</year>;<volume>7</volume>(<issue>2</issue>):<fpage>e105</fpage>&#8208;<lpage>e125</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2468-2667(21)00249-8</pub-id><pub-id pub-id-type="pmid">34998485</pub-id><pub-id pub-id-type="pmcid">PMC8810394</pub-id></mixed-citation></ref><ref id="alz70706-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="alz70706-cite-0003"><collab collab-type="authors">GBD 2019 Collaborators</collab>
. <article-title>Global mortality from dementia: application of a new method and results from the Global Burden of Disease Study 2019</article-title>. <source>Alzheimers Dement (N Y)</source>. <year>2021</year>;<volume>7</volume>(<issue>1</issue>):<elocation-id>e12200</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/trc2.12200</pub-id><pub-id pub-id-type="pmid">34337138</pub-id><pub-id pub-id-type="pmcid">PMC8315276</pub-id></mixed-citation></ref><ref id="alz70706-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="alz70706-cite-0004"><string-name name-style="western"><surname>Livingston</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Huntley</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sommerlad</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Dementia prevention, intervention, and care: 2020 report of the Lancet Commission</article-title>. <source>Lancet</source>. <year>2020</year>;<volume>396</volume>(<issue>10248</issue>):<fpage>413</fpage>&#8208;<lpage>446</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(20)30367-6</pub-id><pub-id pub-id-type="pmid">32738937</pub-id><pub-id pub-id-type="pmcid">PMC7392084</pub-id></mixed-citation></ref><ref id="alz70706-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="alz70706-cite-0005"><string-name name-style="western"><surname>Livingston</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Huntley</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>KY</given-names></string-name>, et&#160;al. <article-title>Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission</article-title>. <source>Lancet</source>. <year>2024</year>;<volume>404</volume>(<issue>10452</issue>):<fpage>572</fpage>&#8208;<lpage>628</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(24)01296-0</pub-id><pub-id pub-id-type="pmid">39096926</pub-id></mixed-citation></ref><ref id="alz70706-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="alz70706-cite-0006"><string-name name-style="western"><surname>Chen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Dhana</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Association of the Mediterranean dietary approaches to stop hypertension intervention for neurodegenerative delay (MIND) diet with the risk of dementia</article-title>. <source>JAMA Psychiatry</source>. <year>2023</year>;<volume>80</volume>(<issue>6</issue>):<fpage>630</fpage>&#8208;<lpage>638</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2023.0800</pub-id><pub-id pub-id-type="pmid">37133875</pub-id><pub-id pub-id-type="pmcid">PMC10157510</pub-id></mixed-citation></ref><ref id="alz70706-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="alz70706-cite-0007"><string-name name-style="western"><surname>Agarwal</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Leurgans</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Agrawal</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Association of Mediterranean&#8208;DASH intervention for neurodegenerative delay and mediterranean diets with Alzheimer disease pathology</article-title>. <source>Neurology</source>. <year>2023</year>;<volume>100</volume>(<issue>22</issue>):<fpage>e2259</fpage>&#8208;<lpage>e2268</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000207176</pub-id><pub-id pub-id-type="pmid">36889921</pub-id><pub-id pub-id-type="pmcid">PMC10259273</pub-id></mixed-citation></ref><ref id="alz70706-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="alz70706-cite-0008"><string-name name-style="western"><surname>Shannon</surname><given-names>OM</given-names></string-name>, <string-name name-style="western"><surname>Ranson</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Gregory</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Mediterranean diet adherence is associated with lower dementia risk, independent of genetic predisposition: findings from the UK Biobank prospective cohort study</article-title>. <source>BMC Med</source>. <year>2023</year>;<volume>21</volume>(<issue>1</issue>):<fpage>81</fpage>&#8208;<lpage>83</lpage>. doi:<pub-id pub-id-type="doi">10.1186/s12916-023-02772-3</pub-id><pub-id pub-id-type="pmid">36915130</pub-id><pub-id pub-id-type="pmcid">PMC10012551</pub-id></mixed-citation></ref><ref id="alz70706-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="alz70706-cite-0009"><string-name name-style="western"><surname>Sacks</surname><given-names>FM</given-names></string-name>, <string-name name-style="western"><surname>Svetkey</surname><given-names>LP</given-names></string-name>, <string-name name-style="western"><surname>Vollmer</surname><given-names>WM</given-names></string-name>, et&#160;al. <article-title>Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. DASH&#8208;sodium collaborative research group</article-title>. <source>N Engl J Med</source>. <year>2001</year>;<volume>344</volume>(<issue>1</issue>):<fpage>3</fpage>&#8208;<lpage>10</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJM200101043440101</pub-id><pub-id pub-id-type="pmid">11136953</pub-id></mixed-citation></ref><ref id="alz70706-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="alz70706-cite-0010"><string-name name-style="western"><surname>Morris</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Tangney</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sacks</surname><given-names>FM</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Aggarwal</surname><given-names>NT</given-names></string-name>. <article-title>MIND diet associated with reduced incidence of Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2015</year>;<volume>11</volume>(<issue>9</issue>):<fpage>1007</fpage>&#8208;<lpage>1014</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jalz.2014.11.009</pub-id><pub-id pub-id-type="pmid">25681666</pub-id><pub-id pub-id-type="pmcid">PMC4532650</pub-id></mixed-citation></ref><ref id="alz70706-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="alz70706-cite-0011"><string-name name-style="western"><surname>Filippini</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Malavolti</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Whelton</surname><given-names>PK</given-names></string-name>, <string-name name-style="western"><surname>Vinceti</surname><given-names>M</given-names></string-name>. <article-title>Sodium intake and risk of hypertension: a systematic review and dose&#8208;response meta&#8208;analysis of observational cohort studies</article-title>. <source>Curr Hypertens Rep</source>. <year>2022</year>;<volume>24</volume>(<issue>5</issue>):<fpage>133</fpage>&#8208;<lpage>144</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11906-022-01182-9</pub-id><pub-id pub-id-type="pmid">35246796</pub-id></mixed-citation></ref><ref id="alz70706-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="alz70706-cite-0012"><string-name name-style="western"><surname>Ou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>X</given-names></string-name>, et&#160;al. <article-title>Blood pressure and risks of cognitive impairment and dementia: a systematic review and meta&#8208;analysis of 209 prospective studies</article-title>. <source>Hypertension</source>. <year>2020</year>;<volume>76</volume>(<issue>1</issue>):<fpage>217</fpage>&#8208;<lpage>225</lpage>. doi:<pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.120.14993</pub-id><pub-id pub-id-type="pmid">32450739</pub-id></mixed-citation></ref><ref id="alz70706-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="alz70706-cite-0013"><string-name name-style="western"><surname>Mohan</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Yap</surname><given-names>KH</given-names></string-name>, <string-name name-style="western"><surname>Reidpath</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Link between dietary sodium intake, cognitive function, and dementia risk in middle&#8208;aged and older adults: a systematic review</article-title>. <source>J Alzheimers Dis</source>. <year>2020</year>;<volume>76</volume>(<issue>4</issue>):<fpage>1347</fpage>&#8208;<lpage>1373</lpage>. doi:<pub-id pub-id-type="doi">10.3233/JAD-191339</pub-id><pub-id pub-id-type="pmid">32675410</pub-id><pub-id pub-id-type="pmcid">PMC7504986</pub-id></mixed-citation></ref><ref id="alz70706-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="alz70706-cite-0014"><string-name name-style="western"><surname>Blumenthal</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Mabe</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Lifestyle and neurocognition in older adults with cognitive impairments: a randomized trial</article-title>. <source>Neurology</source>. <year>2019</year>;<volume>92</volume>(<issue>3</issue>):<fpage>e212</fpage>&#8208;<lpage>e223</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000006784</pub-id><pub-id pub-id-type="pmid">30568005</pub-id><pub-id pub-id-type="pmcid">PMC6340382</pub-id></mixed-citation></ref><ref id="alz70706-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="alz70706-cite-0015"><string-name name-style="western"><surname>Fiocco</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Shatenstein</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Ferland</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>Sodium intake and physical activity impact cognitive maintenance in older adults: the NuAge Study</article-title>. <source>Neurobiol Aging</source>. <year>2012</year>;<volume>33</volume>(<issue>4</issue>):<fpage>829</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2011.07.004</pub-id>. e21&#8208;829.e28.<pub-id pub-id-type="pmid">21855174</pub-id></mixed-citation></ref><ref id="alz70706-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="alz70706-cite-0016"><string-name name-style="western"><surname>Afsar</surname><given-names>B</given-names></string-name>. <article-title>The relationship between cognitive function, depressive behaviour and sleep quality with 24&#8208;h urinary sodium excretion in patients with essential hypertension</article-title>. <source>High Blood Press Cardiovasc Prev</source>. <year>2013</year>;<volume>20</volume>(<issue>1</issue>):<fpage>19</fpage>&#8208;<lpage>24</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40292-013-0002-7</pub-id><pub-id pub-id-type="pmid">23529378</pub-id></mixed-citation></ref><ref id="alz70706-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="alz70706-cite-0017"><string-name name-style="western"><surname>Salerno&#8208;Kennedy</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Cashman</surname><given-names>KD</given-names></string-name>. <article-title>The relationship between nutrient intake and cognitive performance in people at risk of dementia</article-title>. <source>Ir J Med Sci</source>. <year>2007</year>;<volume>176</volume>(<issue>3</issue>):<fpage>193</fpage>&#8208;<lpage>198</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11845-007-0036-8</pub-id><pub-id pub-id-type="pmid">17464526</pub-id></mixed-citation></ref><ref id="alz70706-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="alz70706-cite-0018"><string-name name-style="western"><surname>Brownbill</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Ilich</surname><given-names>JZ</given-names></string-name>. <article-title>Cognitive function in relation with bone mass and nutrition: cross&#8208;sectional association in postmenopausal women</article-title>. <source>BMC Womens Health</source>. <year>2004</year>;<volume>4</volume>(<issue>1</issue>):<fpage>2</fpage>&#8208;<lpage>2</lpage>. doi:<pub-id pub-id-type="doi">10.1186/1472-6874-4-2</pub-id><pub-id pub-id-type="pmid">15163349</pub-id><pub-id pub-id-type="pmcid">PMC434519</pub-id></mixed-citation></ref><ref id="alz70706-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="alz70706-cite-0019"><string-name name-style="western"><surname>Hwang</surname><given-names>SY</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>J</given-names></string-name>. <article-title>An examination of the association of cognitive functioning, adherence to sodium restriction and Na/K ratios in Korean heart failure patients</article-title>. <source>J Clin Nurs</source>. <year>2016</year>;<volume>25</volume>(<issue>11&#8208;12</issue>):<fpage>1766</fpage>&#8208;<lpage>1776</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jocn.13198</pub-id><pub-id pub-id-type="pmid">27139174</pub-id></mixed-citation></ref><ref id="alz70706-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="alz70706-cite-0020"><string-name name-style="western"><surname>Bojar</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Wierzbinska&#8208;Stepniak</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Witczak</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Raczkiewicz</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Owoc</surname><given-names>A</given-names></string-name>. <article-title>Are cognitive functions in post&#8208;menopausal women related with the contents of macro&#8208; and micro&#8208;components in the diet?</article-title>. <source>Ann Agric Environ Med</source>. <year>2015</year>;<volume>22</volume>(<issue>1</issue>):<fpage>178</fpage>&#8208;<lpage>184</lpage>. doi:<pub-id pub-id-type="doi">10.5604/12321966.1141391</pub-id><pub-id pub-id-type="pmid">25780851</pub-id></mixed-citation></ref><ref id="alz70706-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="alz70706-cite-0021"><string-name name-style="western"><surname>Nowak</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Fried</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Jovanovich</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Dietary sodium/potassium intake does not affect cognitive function or brain imaging indices</article-title>. <source>Am J Nephrol</source>. <year>2018</year>;<volume>47</volume>(<issue>1</issue>):<fpage>57</fpage>&#8208;<lpage>65</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000486580</pub-id><pub-id pub-id-type="pmid">29393090</pub-id><pub-id pub-id-type="pmcid">PMC5815363</pub-id></mixed-citation></ref><ref id="alz70706-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="alz70706-cite-0022"><string-name name-style="western"><surname>Rush</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Kritz&#8208;Silverstein</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Laughlin</surname><given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Fung</surname><given-names>TT</given-names></string-name>, <string-name name-style="western"><surname>Barrett&#8208;Connor</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>McEvoy</surname><given-names>LK</given-names></string-name>. <article-title>Association between dietary sodium intake and cognitive function in older adults</article-title>. <source>J Nutr Health Aging</source>. <year>2017</year>;<volume>21</volume>(<issue>3</issue>):<fpage>276</fpage>&#8208;<lpage>283</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12603-016-0766-2</pub-id><pub-id pub-id-type="pmid">28244567</pub-id><pub-id pub-id-type="pmcid">PMC5334786</pub-id></mixed-citation></ref><ref id="alz70706-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="alz70706-cite-0023"><string-name name-style="western"><surname>Hoscheidt</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sanderlin</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Baker</surname><given-names>LD</given-names></string-name>, et&#160;al. <article-title>Mediterranean and Western diet effects on Alzheimer's disease biomarkers, cerebral perfusion, and cognition in mid&#8208;life: a randomized trial</article-title>. <source>Alzheimers Dement</source>. <year>2022</year>;<volume>18</volume>(<issue>3</issue>):<fpage>457</fpage>&#8208;<lpage>468</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.12421</pub-id><pub-id pub-id-type="pmid">34310044</pub-id><pub-id pub-id-type="pmcid">PMC9207984</pub-id></mixed-citation></ref><ref id="alz70706-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="alz70706-cite-0024"><string-name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Buchman</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Boyle</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Barnes</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></string-name>. <article-title>Religious orders study and rush memory and aging project</article-title>. <source>J Alzheimers Dis</source>. <year>2018</year>;<volume>64</volume>(<issue>s1</issue>):<fpage>S161</fpage>&#8208;<lpage>S189</lpage>. doi:<pub-id pub-id-type="doi">10.3233/JAD-179939</pub-id><pub-id pub-id-type="pmid">29865057</pub-id><pub-id pub-id-type="pmcid">PMC6380522</pub-id></mixed-citation></ref><ref id="alz70706-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="alz70706-cite-0025"><string-name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Arvanitakis</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname><given-names>RS</given-names></string-name>. <article-title>Overview and findings from the religious orders study</article-title>. <source>Curr Alzheimer Res</source>. <year>2012</year>;<volume>9</volume>(<issue>6</issue>):<fpage>628</fpage>&#8208;<lpage>645</lpage>. doi:<pub-id pub-id-type="doi">10.2174/156720512801322573</pub-id><pub-id pub-id-type="pmid">22471860</pub-id><pub-id pub-id-type="pmcid">PMC3409291</pub-id></mixed-citation></ref><ref id="alz70706-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="alz70706-cite-0026"><string-name name-style="western"><surname>Wilson</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Barnes</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Krueger</surname><given-names>KR</given-names></string-name>, <string-name name-style="western"><surname>Hoganson</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Bienias</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></string-name>. <article-title>Early and late life cognitive activity and cognitive systems in old age</article-title>. <source>J Int Neuropsychol Soc</source>. <year>2005</year>;<volume>11</volume>(<issue>4</issue>):<fpage>400</fpage>&#8208;<lpage>407</lpage>.<pub-id pub-id-type="pmid">16209420</pub-id></mixed-citation></ref><ref id="alz70706-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="alz70706-cite-0027"><string-name name-style="western"><surname>Wilson</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Barnes</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>D</given-names></string-name>. <article-title>Assessment of lifetime participation in cognitively stimulating activities</article-title>. <source>J Clin Exp Neuropsychol</source>. <year>2003</year>;<volume>25</volume>(<issue>5</issue>):<fpage>634</fpage>&#8208;<lpage>642</lpage>. doi:<pub-id pub-id-type="doi">10.1076/jcen.25.5.634.14572</pub-id><pub-id pub-id-type="pmid">12815501</pub-id></mixed-citation></ref><ref id="alz70706-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="alz70706-cite-0028"><string-name name-style="western"><surname>Morris</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Tangney</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Bienias</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Evans</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname><given-names>RS</given-names></string-name>. <article-title>Validity and reproducibility of a food frequency questionnaire by cognition in an older biracial sample</article-title>. <source>Am J Epidemiol</source>. <year>2003</year>;<volume>158</volume>(<issue>12</issue>):<fpage>1213</fpage>&#8208;<lpage>1217</lpage>. doi:<pub-id pub-id-type="doi">10.1093/aje/kwg290</pub-id><pub-id pub-id-type="pmid">14652307</pub-id></mixed-citation></ref><ref id="alz70706-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="alz70706-cite-0029"><string-name name-style="western"><surname>Willett</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Stampfer</surname><given-names>MJ</given-names></string-name>. <article-title>Total energy intake: implications for epidemiologic analyses</article-title>. <source>Am J Epidemiol</source>. <year>1986</year>;<volume>124</volume>(<issue>1</issue>):<fpage>17</fpage>&#8208;<lpage>27</lpage>. doi:<pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a114366</pub-id><pub-id pub-id-type="pmid">3521261</pub-id></mixed-citation></ref><ref id="alz70706-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="alz70706-cite-0030"><string-name name-style="western"><surname>Barnes</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Dhana</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, et&#160;al. <article-title>Trial of the MIND diet for prevention of cognitive decline in older persons</article-title>. <source>N Engl J Med</source>. <year>2023</year>;<volume>389</volume>(<issue>7</issue>):<fpage>602</fpage>&#8208;<lpage>611</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2302368</pub-id><pub-id pub-id-type="pmid">37466280</pub-id><pub-id pub-id-type="pmcid">PMC10513737</pub-id></mixed-citation></ref><ref id="alz70706-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="alz70706-cite-0031"><string-name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Bienias</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Evans</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname><given-names>RS</given-names></string-name>. <article-title>Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions</article-title>. <source>Neurology</source>. <year>2005</year>;<volume>64</volume>(<issue>5</issue>):<fpage>834</fpage>&#8208;<lpage>841</lpage>. doi:<pub-id pub-id-type="doi">10.1212/01.WNL.0000152982.47274.9E</pub-id><pub-id pub-id-type="pmid">15753419</pub-id></mixed-citation></ref><ref id="alz70706-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="alz70706-cite-0032"><string-name name-style="western"><surname>Arvanitakis</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname><given-names>RS</given-names></string-name>, et&#160;al. <article-title>Diabetes is related to cerebral infarction but not to AD pathology in older persons</article-title>. <source>Neurology</source>. <year>2006</year>;<volume>67</volume>(<issue>11</issue>):<fpage>1960</fpage>&#8208;<lpage>1965</lpage>. doi:<pub-id pub-id-type="doi">10.1212/01.wnl.0000247053.45483.4e</pub-id><pub-id pub-id-type="pmid">17159101</pub-id></mixed-citation></ref><ref id="alz70706-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="alz70706-cite-0033"><string-name name-style="western"><surname>Hyman</surname><given-names>BT</given-names></string-name>, <string-name name-style="western"><surname>Phelps</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Beach</surname><given-names>TG</given-names></string-name>, et&#160;al. <article-title>National institute on aging&#8208;Alzheimer's association guidelines for the neuropathologic assessment of Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2012</year>;<volume>8</volume>(<issue>1</issue>):<fpage>1</fpage>&#8208;<lpage>13</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jalz.2011.10.007</pub-id><pub-id pub-id-type="pmid">22265587</pub-id><pub-id pub-id-type="pmcid">PMC3266529</pub-id></mixed-citation></ref><ref id="alz70706-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="alz70706-cite-0034"><string-name name-style="western"><surname>Nag</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Boyle</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Leurgans</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></string-name>. <article-title>TDP&#8208;43 pathology in anterior temporal pole cortex in aging and Alzheimer's disease</article-title>. <source>Acta Neuropathol Commun</source>. <year>2018</year>;<volume>6</volume>(<issue>1</issue>):<fpage>33</fpage>&#8208;<lpage>33</lpage>. doi:<pub-id pub-id-type="doi">10.1186/s40478-018-0531-3</pub-id><pub-id pub-id-type="pmid">29716643</pub-id><pub-id pub-id-type="pmcid">PMC5928580</pub-id></mixed-citation></ref><ref id="alz70706-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="alz70706-cite-0035"><string-name name-style="western"><surname>Nelson</surname><given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>Dickson</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Trojanowski</surname><given-names>JQ</given-names></string-name>, et&#160;al. <article-title>Limbic&#8208;predominant age&#8208;related TDP&#8208;43 encephalopathy (LATE): consensus working group report</article-title>. <source>Brain</source>. <year>2019</year>;<volume>142</volume>(<issue>6</issue>):<fpage>1503</fpage>&#8208;<lpage>1527</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awz099</pub-id><pub-id pub-id-type="pmid">31039256</pub-id><pub-id pub-id-type="pmcid">PMC6536849</pub-id></mixed-citation></ref><ref id="alz70706-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="alz70706-cite-0036"><string-name name-style="western"><surname>Nag</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Barnes</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>Association of lewy bodies with age&#8208;related clinical characteristics in black and white decedents</article-title>. <source>Neurology</source>. <year>2021</year>;<volume>97</volume>(<issue>8</issue>):<fpage>e825</fpage>&#8208;<lpage>e835</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000012324</pub-id><pub-id pub-id-type="pmid">34088871</pub-id><pub-id pub-id-type="pmcid">PMC8397586</pub-id></mixed-citation></ref><ref id="alz70706-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="alz70706-cite-0037"><string-name name-style="western"><surname>Arvanitakis</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Leurgans</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Barnes</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></string-name>. <article-title>Microinfarct pathology, dementia, and cognitive systems</article-title>. <source>Stroke</source>. <year>2011</year>;<volume>42</volume>(<issue>3</issue>):<fpage>722</fpage>&#8208;<lpage>727</lpage>. doi:<pub-id pub-id-type="doi">10.1161/STROKEAHA.110.595082</pub-id><pub-id pub-id-type="pmid">21212395</pub-id><pub-id pub-id-type="pmcid">PMC3042494</pub-id></mixed-citation></ref><ref id="alz70706-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="alz70706-cite-0038"><string-name name-style="western"><surname>Arvanitakis</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Capuano</surname><given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>Leurgans</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></string-name>. <article-title>Relation of cerebral vessel disease to Alzheimer's disease dementia and cognitive function in elderly people: a cross&#8208;sectional study</article-title>. <source>Lancet Neurol</source>. <year>2016</year>;<volume>15</volume>(<issue>9</issue>):<fpage>934</fpage>&#8208;<lpage>943</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422(16)30029-1</pub-id><pub-id pub-id-type="pmid">27312738</pub-id><pub-id pub-id-type="pmcid">PMC4969105</pub-id></mixed-citation></ref><ref id="alz70706-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="alz70706-cite-0039"><string-name name-style="western"><surname>Arvanitakis</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Capuano</surname><given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, et&#160;al. <article-title>Brain insulin signaling and cerebrovascular disease in human postmortem brain</article-title>. <source>Acta Neuropathol Commun</source>. <year>2021</year>;<volume>9</volume>(<issue>1</issue>):<fpage>71</fpage>&#8208;<lpage>79</lpage>. doi:<pub-id pub-id-type="doi">10.1186/s40478-021-01176-9</pub-id><pub-id pub-id-type="pmid">33858515</pub-id><pub-id pub-id-type="pmcid">PMC8048276</pub-id></mixed-citation></ref><ref id="alz70706-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="alz70706-cite-0040"><string-name name-style="western"><surname>Fiocco</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Shatenstein</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Ferland</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>Sodium intake and physical activity impact cognitive maintenance in older adults: the NuAge Study</article-title>. <source>Neurobiol Aging</source>. <year>2012</year>;<volume>33</volume>(<issue>4</issue>):<fpage>829</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2011.07.004</pub-id>. e21&#8208;829.e28.<pub-id pub-id-type="pmid">21855174</pub-id></mixed-citation></ref><ref id="alz70706-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="alz70706-cite-0041"><string-name name-style="western"><surname>Liu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Xing</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>F</given-names></string-name>, et&#160;al. <article-title>Excessive dietary salt intake exacerbates cognitive impairment progression and increases dementia risk in older adults</article-title>. <source>J Am Med Dir Assoc</source>. <year>2023</year>;<volume>24</volume>(<issue>1</issue>):<fpage>125</fpage>&#8208;<lpage>129</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jamda.2022.10.001</pub-id><pub-id pub-id-type="pmid">36351463</pub-id></mixed-citation></ref><ref id="alz70706-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="alz70706-cite-0042"><string-name name-style="western"><surname>Tombaugh</surname><given-names>TN</given-names></string-name>, <string-name name-style="western"><surname>McIntyre</surname><given-names>NJ</given-names></string-name>. <article-title>The mini&#8208;mental state examination: a comprehensive review</article-title>. <source>J Am Geriatr Soc</source>. <year>1992</year>;<volume>40</volume>(<issue>9</issue>):<fpage>922</fpage>&#8208;<lpage>935</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1532-5415.1992.tb01992.x</pub-id><pub-id pub-id-type="pmid">1512391</pub-id></mixed-citation></ref><ref id="alz70706-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="alz70706-cite-0043"><string-name name-style="western"><surname>Kimura</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sugimoto</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Niida</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Toba</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sakurai</surname><given-names>T</given-names></string-name>. <article-title>Association between appetite and sarcopenia in patients with mild cognitive impairment and early&#8208;stage Alzheimer's Disease: a case&#8208;control study</article-title>. <source>Front Nutr</source>. <year>2018</year>;<volume>5</volume>:<fpage>128</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fnut.2018.00128</pub-id><pub-id pub-id-type="pmid">30619874</pub-id><pub-id pub-id-type="pmcid">PMC6305366</pub-id></mixed-citation></ref><ref id="alz70706-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="alz70706-cite-0044"><string-name name-style="western"><surname>Tromp</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Dufour</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lithfous</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pebayle</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Despres</surname><given-names>O</given-names></string-name>. <article-title>Episodic memory in normal aging and Alzheimer disease: insights from imaging and behavioral studies</article-title>. <source>Ageing Res Rev</source>. <year>2015</year>;<volume>24</volume>(<issue>Pt B</issue>):<fpage>232</fpage>&#8208;<lpage>262</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.arr.2015.08.006</pub-id><pub-id pub-id-type="pmid">26318058</pub-id></mixed-citation></ref><ref id="alz70706-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="alz70706-cite-0045"><string-name name-style="western"><surname>Blumenthal</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Mabe</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Lifestyle and neurocognition in older adults with cognitive impairments: a randomized trial</article-title>. <source>Neurology</source>. <year>2019</year>;<volume>92</volume>(<issue>3</issue>):<fpage>e212</fpage>&#8208;<lpage>e223</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000006784</pub-id><pub-id pub-id-type="pmid">30568005</pub-id><pub-id pub-id-type="pmcid">PMC6340382</pub-id></mixed-citation></ref><ref id="alz70706-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="alz70706-cite-0046"><string-name name-style="western"><surname>Faraco</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Hochrainer</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Segarra</surname><given-names>SG</given-names></string-name>, et&#160;al. <article-title>Dietary salt promotes cognitive impairment through tau phosphorylation</article-title>. <source>Nature</source>. <year>2019</year>;<volume>574</volume>(<issue>7780</issue>):<fpage>686</fpage>&#8208;<lpage>690</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41586-019-1688-z</pub-id><pub-id pub-id-type="pmid">31645758</pub-id><pub-id pub-id-type="pmcid">PMC7380655</pub-id></mixed-citation></ref><ref id="alz70706-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="alz70706-cite-0047"><string-name name-style="western"><surname>Yuan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wen</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Dietary salt disrupts tricarboxylic acid cycle and induces tau hyperphosphorylation and synapse dysfunction during aging</article-title>. <source>Aging Dis</source>. <year>2022</year>;<volume>13</volume>(<issue>5</issue>):<fpage>1532</fpage>&#8208;<lpage>1545</lpage>. doi:<pub-id pub-id-type="doi">10.14336/AD.2022.0220</pub-id><pub-id pub-id-type="pmid">36186135</pub-id><pub-id pub-id-type="pmcid">PMC9466974</pub-id></mixed-citation></ref><ref id="alz70706-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="alz70706-cite-0048"><string-name name-style="western"><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>High salt diet induces cognitive impairment and is linked to the activation of IGF1R/mTOR/p70S6K signaling</article-title>. <source>Metab Brain Dis</source>. <year>2024</year>;<volume>39</volume>(<issue>5</issue>):<fpage>803</fpage>&#8208;<lpage>819</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11011-024-01358-z</pub-id><pub-id pub-id-type="pmid">38771412</pub-id></mixed-citation></ref><ref id="alz70706-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="alz70706-cite-0049"><string-name name-style="western"><surname>Powles</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fahimi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Micha</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24&#160;h urinary sodium excretion and dietary surveys worldwide</article-title>. <source>BMJ Open</source>. <year>2013</year>;<volume>3</volume>(<issue>12</issue>):<fpage>e003733</fpage>&#8208;<lpage>e003733</lpage>. doi:<pub-id pub-id-type="doi">10.1136/bmjopen-2013-003733</pub-id><pub-id pub-id-type="pmcid">PMC3884590</pub-id><pub-id pub-id-type="pmid">24366578</pub-id></mixed-citation></ref><ref id="alz70706-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="alz70706-cite-0050"><string-name name-style="western"><surname>Fibbi</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Marroncini</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Anceschi</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Naldi</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Peri</surname><given-names>A</given-names></string-name>. <article-title>Hyponatremia and oxidative stress</article-title>. <source>Antioxidants (Basel)</source>. <year>2021</year>;<volume>10</volume>(<issue>11</issue>):<fpage>1768</fpage>. doi:<pub-id pub-id-type="doi">10.3390/antiox10111768</pub-id><pub-id pub-id-type="pmid">34829639</pub-id><pub-id pub-id-type="pmcid">PMC8614907</pub-id></mixed-citation></ref><ref id="alz70706-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="alz70706-cite-0051"><string-name name-style="western"><surname>Mente</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>O'Donnell</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rangarajan</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies</article-title>. <source>Lancet</source>. <year>2016</year>;<volume>388</volume>(<issue>10043</issue>):<fpage>465</fpage>&#8208;<lpage>475</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(16)30467-6</pub-id><pub-id pub-id-type="pmid">27216139</pub-id></mixed-citation></ref><ref id="alz70706-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="alz70706-cite-0052"><string-name name-style="western"><surname>Patik</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Lennon</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Farquhar</surname><given-names>WB</given-names></string-name>, <string-name name-style="western"><surname>Edwards</surname><given-names>DG</given-names></string-name>. <article-title>Mechanisms of dietary sodium&#8208;induced impairments in endothelial function and potential countermeasures</article-title>. <source>Nutrients</source>. <year>2021</year>;<volume>13</volume>(<issue>1</issue>):<fpage>270</fpage>. doi:<pub-id pub-id-type="doi">10.3390/nu13010270</pub-id><pub-id pub-id-type="pmid">33477837</pub-id><pub-id pub-id-type="pmcid">PMC7832854</pub-id></mixed-citation></ref><ref id="alz70706-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="alz70706-cite-0053"><string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zou</surname><given-names>X</given-names></string-name>, et&#160;al. <article-title>Long&#8208;term low salt diet increases blood pressure by activation of the renin&#8208;angiotensin and sympathetic nervous systems</article-title>. <source>Clin Exp Hypertens</source>. <year>2019</year>;<volume>41</volume>(<issue>8</issue>):<fpage>739</fpage>&#8208;<lpage>746</lpage>. doi:<pub-id pub-id-type="doi">10.1080/10641963.2018.1545850</pub-id><pub-id pub-id-type="pmid">30451012</pub-id><pub-id pub-id-type="pmcid">PMC6525650</pub-id></mixed-citation></ref><ref id="alz70706-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="alz70706-cite-0054"><string-name name-style="western"><surname>Braam</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Cupples</surname><given-names>WA</given-names></string-name>, <string-name name-style="western"><surname>Hamza</surname><given-names>SM</given-names></string-name>. <article-title>Understanding the two faces of low&#8208;salt intake</article-title>. <source>Curr Hypertens Rep</source>. <year>2017</year>;<volume>19</volume>(<issue>6</issue>):<fpage>49</fpage>. doi:<pub-id pub-id-type="doi">10.1007/s11906-017-0744-z</pub-id><pub-id pub-id-type="pmid">28501983</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">1524</journal-id><journal-id journal-id-type="pmc-domain">frontpharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12504481</article-id><article-id pub-id-type="pmcid-ver">PMC12504481.1</article-id><article-id pub-id-type="pmcaid">12504481</article-id><article-id pub-id-type="pmcaiid">12504481</article-id><article-id pub-id-type="doi">10.3389/fphar.2025.1605214</article-id><article-id pub-id-type="publisher-id">1605214</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Pharmacological mechanisms and therapeutic prospects of plant metabolites from traditional Chinese medicine in regulating programmed cell death in Alzheimer&#8217;s disease</article-title><alt-title alt-title-type="left-running-head">Pan et al.</alt-title><alt-title alt-title-type="right-running-head"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.3389/fphar.2025.1605214" ext-link-type="uri">10.3389/fphar.2025.1605214</ext-link></alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Pan</surname><given-names initials="P">Pengyu</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3022496/overview"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Zhao</surname><given-names initials="T">Tengyu</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="J">Jian</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2658654/overview"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="Y">Yuhan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="X">Xinyue</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Li</surname><given-names initials="Q">Quan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhou</surname><given-names initials="Y">Yanyan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>School of Basic Medicine, Heilongjiang University of Chinese Medicine</institution>, <addr-line>Harbin</addr-line>, <country>China</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Key Laboratory of Basic Theory Research on Traditional Chinese Medicine</institution>, <addr-line>Harbin</addr-line>, <addr-line>Heilongjiang</addr-line>, <country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1889241/overview" ext-link-type="uri">Ashish Mehta</ext-link>, Garvan Institute of Medical Research, Australia</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/762944/overview" ext-link-type="uri">Zhenyan Song</ext-link>, Hunan University of Chinese Medicine, China</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2939427/overview" ext-link-type="uri">Prabhash Nath Tripathi</ext-link>, University of Arkansas for Medical Sciences, United States</p></fn><corresp id="c001">*Correspondence: Quan Li, <email>liquan_hljucm@163.com</email>; Yanyan Zhou, <email>13339319259@163.com</email></corresp><fn fn-type="equal" id="fn001"><label>
<sup>&#8224;</sup>
</label><p>These authors have contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>24</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">480654</issue-id><elocation-id>1605214</elocation-id><history><date date-type="received"><day>03</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>03</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Pan, Zhao, Zhang, Zhou, Zhang, Li and Zhou.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Pan, Zhao, Zhang, Zhou, Zhang, Li and Zhou</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fphar-16-1605214.pdf"/><abstract><p>Alzheimer&#8217;s disease (AD) is a progressive neurodegenerative disorder marked by cognitive decline and neuronal loss. Multiple forms of programmed cell death (PCD)&#8212;including apoptosis, pyroptosis, ferroptosis, cuproptosis, and disulfidoptosis&#8212;contribute to its pathogenesis, regulated by protein families such as caspases, RIPKs, gasdermins, and ATGs. Plant metabolites widely distributed across medicinal plants and enriched in botanical drugs used in traditional Chinese medicine (TCM), such as alkaloids, flavonoids, saponins, and polysaccharides, have attracted increasing attention for their potential regulatory effects on these PCD pathways. These metabolites are not unique to TCM, but their prevalence in TCM prescriptions provides a valuable framework for pharmacological investigation. Their biological activities are often determined by structural features&#8212;for example, the isoquinoline scaffold of berberine enhances membrane permeability, facilitating neuroprotective actions. Despite substantial research, comprehensive summaries remain limited. This review systematically integrates progress from the past 2&#160;decades on how plant metabolites, particularly those enriched in TCM botanical drugs, regulate PCD in AD, with the aim of clarifying pharmacological mechanisms and highlighting prospects for drug discovery and clinical translation.</p></abstract><kwd-group><kwd>Alzheimer&#8217;s disease</kwd><kwd>traditional Chinese medicine</kwd><kwd>programmed cell death</kwd><kwd>plant metabolites</kwd><kwd>neuroprotection</kwd><kwd>ferroptosis</kwd><kwd>Apoptosis</kwd></kwd-group><funding-group><award-group><funding-source id="cn001"><institution-wrap><institution>National Natural Science Foundation of China
</institution><institution-id institution-id-type="doi">10.13039/501100001809</institution-id></institution-wrap></funding-source><award-id award-type="contract" rid="cn001">81774197</award-id></award-group><award-group><funding-source id="cn002"><institution-wrap><institution>Natural Science Foundation of Heilongjiang Province
</institution><institution-id institution-id-type="doi">10.13039/501100005046</institution-id></institution-wrap></funding-source><award-id award-type="contract" rid="cn002">LH 2022H070</award-id></award-group></funding-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by the National Natural Science Foundation of China (81774197), and the Natural Science Foundation of Heilongjiang Province (LH 2022H070).</funding-statement></funding-group><counts><page-count count="24"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Ethnopharmacology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>1 Introduction</title><p>Alzheimer&#8217;s disease (AD) is a neurodegenerative disease with insidious onset, characterized by progressive cognitive decline and neuronal loss. Epidemiological data show that the incidence of AD is positively correlated with age. Currently, Currently, over 50 million people worldwide are affected, and approximately one-tenth of individuals older than 65 years develop the disease (<xref rid="B85" ref-type="bibr">Luo et al., 2023</xref>; <xref rid="B53" ref-type="bibr">Hou et al., 2019</xref>). AD has become one of the most expensive, deadly and burdensome diseases and a major challenge for global public health. Although existing drugs such as acetylcholinesterase inhibitors can temporarily relieve symptoms, they cannot reverse the disease process and have significant side effects. Therefore, it is essential to explore novel multi-target therapeutic strategies (<xref rid="B116" ref-type="bibr">Sharma et al., 2024</xref>).</p><p>Cell death can be broadly classified into two types: accidental cell death (ACD) and programmed cell death (PCD). ACD occurs when external insults overwhelm the cell&#8217;s repair capacity, leading to necrosis. In contrast, PCD is a regulated process critical for removing damaged cells, promoting tissue renewal, supporting organismal development, defending against pathogens, and maintaining homeostasis. Depending on the context, PCD can be induced, inhibited, or modulated. Over the past five&#160;decades, several distinct PCD pathways have been identified, including apoptosis, necroptosis, autophagy, pyroptosis, ferroptosis, cuproptosis, and disulfidoptosis (<xref rid="B36" ref-type="bibr">Fricker et al., 2018</xref>).</p><p>In recent years, research on plant metabolites used in traditional Chinese medicine (TCM) has revealed their potential therapeutic advantages in AD (<xref rid="B122" ref-type="bibr">Siddiqui et al., 2024a</xref>; <xref rid="B123" ref-type="bibr">Siddiqui et al., 2024b</xref>). These metabolites exert multi-target and multi-pathway regulatory effects, enabling more precise therapeutic strategies. For example, alkaloids can modulate apoptosis, ferroptosis, and autophagy in neuronal cells; saponins can regulate apoptosis, pyroptosis, and ferroptosis; and flavonoids influence apoptosis, pyroptosis, autophagy, and ferroptosis simultaneously. Notably, these pathways exhibit extensive crosstalk, with autophagy serving as a central hub. However, the exact roles of plant metabolites in regulating PCD and the underlying molecular mechanisms remain incompletely understood. Importantly, this review emphasize that the pharmacological effects of these metabolites are grounded in structure&#8211;activity relationships (SAR). All effects are supported by experimental data at defined doses rather than general claims of efficacy. For instance, salidroside demonstrates optimal effects at 40&#160;&#956;M in HT22 cells and 50&#160;mg/kg day in A&#946;1&#8211;42-induced AD mice, whereas berberine shows protective effects at 30&#8211;60&#160;&#956;M in ferroptosis models. Incorporating representative dose ranges ensures scientific rigor and prevents overstating the uniqueness of TCM-derived metabolites.</p><p>In this review, we aim to elucidate the mechanisms by which plant metabolites associated with TCM regulate PCD in AD. These insights may not only reveal novel therapeutic targets for AD prevention and treatment but also provide a foundation for future experimental and clinical studies (<xref rid="F1" ref-type="fig">Figure 1</xref>).</p><fig position="float" id="F1" orientation="portrait"><label>FIGURE 1</label><caption><p>The relationship between PCD and AD.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-16-1605214-g001.jpg"><alt-text content-type="machine-generated">Diagram depicting Alzheimer's Disease (AD) with sections representing cell death types: apoptosis, necroptosis, pyroptosis, ferroptosis, and autophagy. Each type lists related compounds like berberine, ginsenoside, sinomenine, quercetin, and curcumin. Center has "AD" with "A&#946;" and "Tau" linked to inflammation.</alt-text></graphic></fig></sec><sec id="s2"><title>2 Forms of PCD</title><p>PCD is a form of cell death in multicellular organisms regulated by a variety of signaling pathways, which plays a key role (<xref rid="B182" ref-type="bibr">Zhang L. et al., 2024</xref>) in body development, tissue remodeling, and disease prevention and control. Under normal physiological conditions, PCD plays an indispensable role as an important protective mechanism to maintain cell homeostasis (<xref rid="B168" ref-type="bibr">Yang K. et al., 2022</xref>). Under pathological conditions, abnormal PCD levels, whether insufficient or excessive, may lead to serious consequencessuch as neurodegenerative diseases, autoimmune diseases and cancer (<xref rid="B8" ref-type="bibr">Bello et al., 2018</xref>; <xref rid="B177" ref-type="bibr">Zhang Q. et al., 2022</xref>). Each PCD mode has its own unique morphological characteristics, biochemical pathways and regulatory mechanisms.</p><sec id="s2-1"><title>2.1 Apoptosis</title><p>Apoptosis is a form of PCD in multicellular organisms. The process can be divided into two main stages: the formation of apoptotic bodies and their subsequent recognition, phagocytosis and degradation by neighboring cells. The signal transduction mechanism of apoptosis mainly includes the triggeringof endogenous and exogenous pathways (<xref rid="B31" ref-type="bibr">Elliott and Ravichandran, 2010</xref>; <xref rid="B41" ref-type="bibr">Galluzzi et al., 2018</xref>). When DNA damage, hypoxia and metabolic stress occur, the endogenous pathway of apoptosis, also known as mitochondrial pathway, will be triggered by the decrease of mitochondrial membrane potential and the increase of membrane permeability (<xref rid="B97" ref-type="bibr">Nossing and Ryan, 2023</xref>). Bcl-2 family members, including anti-apoptotic proteins such as Bcl-2 and Bcl-xl, pro-apoptotic proteins such as Bax and Bak, and BH3-only proteins such as Bad and Bid, are key mediators in regulating mitochondrial membrane permeability (<xref rid="B24" ref-type="bibr">Czabotar et al., 2014</xref>). Under the action of various pro-apoptotic signals, pro-apoptotic proteins such as Bax and Bak are no longer inhibited, and extend to the mitochondrial outer membrane and promote mitochondrial outer membrane permeability (MOMP), leading to the increase of mitochondrial membrane permeability (<xref rid="B153" ref-type="bibr">Wei et al., 2001</xref>; <xref rid="B130" ref-type="bibr">Tait and Green, 2010</xref>; <xref rid="B12" ref-type="bibr">Bock and Tait, 2020</xref>). Cytochrome C (Cytc) is transferred from the mitochondria to the cytoplasm and binds to apoptosis protease-activating factor-1 (Apaf-1) to form a multimercomplex to activate Pro-Caspase 9, which then activates downstream apoptotic effector proteins to lead to apoptosis (<xref rid="B16" ref-type="bibr">Cain et al., 2002</xref>). When the extracellular environment is disturbed, death receptors on the membrane surface receive the death signal transmitted by extracellular ligands and activate the extrinsic apoptotic pathway (<xref rid="B136" ref-type="bibr">Tenev et al., 2011</xref>). There are at least eight apoptosis-related death receptor protein family members on the surface of mammalian cells, among which Fas (APO-1/CD95), TNFR1, TRAILR1 (DR4) and TRAILR2 (DR5) are the most common (<xref rid="B127" ref-type="bibr">Suliman et al., 2001</xref>; <xref rid="B103" ref-type="bibr">Peter and Krammer, 1998</xref>; <xref rid="B3" ref-type="bibr">Ashkenazi and Dixit, 1998</xref>). The cytoplasmic portion of these receptors contains the Death Domain (DD), which is used to recruit key molecules (<xref rid="B47" ref-type="bibr">Han Y. H. et al., 2023</xref>). After binding to their ligands, the receptors form death-inducing signaling complex (DISC) to initiate the extrinsic apoptotic pathway (<xref rid="B173" ref-type="bibr">Yang et al., 2024</xref>). Fas and TNFR1 are typical representatives. Upon binding to FasL and TNF, respectively, it triggers trimerization of intracellular receptors and exposure of death domains to recruit adaptor proteins FADD and TRADD (<xref rid="B89" ref-type="bibr">Macewan, 2002</xref>; <xref rid="B44" ref-type="bibr">Guicciardi and Gores, 2009</xref>). FADD recruits and activates the precursor Caspase-8, which converts to the apoptosis-initiating protein Caspase-8. Subsequently, the activated Caspase-8 activates the apoptotic effector protein Caspase-3, leading to PCD (<xref rid="B29" ref-type="bibr">Dickens et al., 2012</xref>). In contrast, TRADD activates TNFR-related factor TRAF-2 upon binding to RIP1. TRAF-2 interacts with TRAF-1 to recruit cIAPs to form a complex that inhibits Caspase-8 activity and its release to prevent apoptosis and promote survival (<xref rid="B56" ref-type="bibr">Hsu et al., 1996a</xref>; <xref rid="B57" ref-type="bibr">Hsu et al., 1996b</xref>). In addition, the endogenous and exogenous pathways of apoptosis are not completely independent, but can interact together to regulate the apoptotic process under specific conditions. For example, activated Caspase-8 can cleave Bid to produce t-Bid, which is transported to mitochondria to promote the release of Cytc and ultimately induce apoptosis (<xref rid="B176" ref-type="bibr">Zhang et al., 2021</xref>; <xref rid="B102" ref-type="bibr">Perez and White, 2000</xref>) (<xref rid="F2" ref-type="fig">Figure 2a</xref>).</p><fig position="float" id="F2" orientation="portrait"><label>FIGURE 2</label><caption><p>Mechanisms of various PCD. Mechanism diagram of PCD in different forms. <bold>(a)</bold> Apoptosis: The endogenous and exogenous apoptosis pathways and their cross-regulation. In the endogenous pathway, ligand binding to a cell surface receptor recruits FADD to form DISC, activating Caspase-8 and cleaving Caspase-3/7. In the exogenous pathway, pro-apoptotic proteins (Bax, Bak) trigger Cytc release from mitochondria, forming apoptosome with Apaf-1, activating Caspase-9 and cleaving Caspase-3/7. Cross-pathway regulation occurs when Caspase-8 cleaves Bid into tBid, enhancing mitochondrial signaling. <bold>(b) </bold>Necroptosis: Taking the binding of TNF-&#945; to TNFR1 as an example, activation of TNFR1 recruits TRADD, RIPK1, and cIAP1/2 to form complex <bold>(I)</bold>. If caspase-8 is inhibited, complex I dissociates, RIPK1 combines with RIPK3 to form the necrosome (complex IIb), and phosphorylation of RIPK1, RIPK3, and MLKL disrupts membrane integrity, triggering necroptosis. <bold>(c)</bold> Pyroptosis: Pathogen-associated molecular patterns (PAMPs) are recognized by pattern recognition receptors (PRRs), which recruit the adaptor protein ASC. This activates Caspase-1 (classical pathway) or Caspase-4/5/11 (non-classical pathway). The activated Caspases cleave Gasdermin D (GSDMD), forming pores in the cell membrane. These pores disrupt osmotic balance, causing pyroptosis and releasing inflammatory mediators. <bold>(d)</bold> Ferroptosis: The inhibition of System Xc<sup>&#8722;</sup> reduces cystine uptake, depletes intracellular cysteine, and blocks glutathione (GSH) synthesis, preventing lipid peroxide reduction and causing peroxide accumulation. Increased intracellular free Fe<sup>2+</sup> generates ROS <italic toggle="yes">via</italic> the Fenton reaction, promoting lipid peroxidation. The FSP1-CoQ10 antioxidant axis, independent of the GPX4 pathway, eliminates lipid radicals; its dysfunction triggers ferroptosis. <bold>(e)</bold> Cuproptosis: Cu<sup>2+</sup> accumulates excessively in cells dependent on mitochondrial respiration, it binds to lipoylated DLAT, inducing abnormal oligomerization of DLAT. This increase in insoluble DLAT levels can result in cytotoxicity and subsequently lead to cell death. Conversely, FDX1 facilitates the reduction of Cu<sup>2+</sup> to the more toxic Cu<sup>+</sup>, which inhibits Fe-S cluster protein synthesis and ultimately induces apoptosis. <bold>(f)</bold> Autophagy: Loss of mitochondrial membrane potential (&#916;&#936;m) causes PINK1 accumulation on the outer membrane of damaged mitochondria, activating Parkin <italic toggle="yes">via</italic> ubiquitin phosphorylation and recruiting it to the mitochondrial surface. Autophagy occurs through two main pathways: the ubiquitin-dependent pathway, where autophagy receptors like OPTN and NDP52 bind LC3, and the direct labeling pathway, where receptors like BNIP3, NIX, and FUNDC1 directly interact with LC3.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-16-1605214-g002.jpg"><alt-text content-type="machine-generated">Illustration depicting various cellular pathways involved in cell death mechanisms. Panel (a) shows extrinsic and intrinsic apoptosis pathways. Panel (b) illustrates necroptosis via TNF signaling. Panel (c) describes pyroptosis triggered by different stimuli, including bacteria and chemotherapy drugs. Panel (d) depicts ferroptosis, emphasizing lipid peroxidation and iron metabolism. Panel (e) Overview of pathways related to Cuproptosis. Panel (f) shows the autophagy pathway in mitochondrial degradation, focusing on autophagosome formation and lysosomal fusion. Each panel highlights specific proteins, enzymes, and cellular components involved in these processes.</alt-text></graphic></fig></sec><sec id="s2-2"><title>2.2 Necroptosis</title><p>Necroptosis is a form of PCD between apoptosis and necrosis. Since the concept of PCD was proposed in the 20th century, apoptosis has been regarded as the main form of PCD, and it is generally believed that it is closely related to the activation of Caspase family (<xref rid="B43" ref-type="bibr">Grootjans et al., 2017</xref>). However, with the development of research, scientists have found that death receptor-induced cell death still occurs even when Caspase family is inhibited. This mode of death shows typical necrosis-like morphological features such as cell swelling and deformation, cell membrane rupture. This suggests that Caspase activation is not the only mechanism that determines cell fate during PCD and that there are other possible cell death pathways (<xref rid="B154" ref-type="bibr">Weinlich et al., 2017</xref>; <xref rid="B40" ref-type="bibr">Galluzzi et al., 2017</xref>). This novel mode of cell death, necroptosis, was first reported by Degterev et al., in 2005 (<xref rid="B27" ref-type="bibr">Degterev et al., 2005</xref>). The activation of necroptosis is an active and dependent process of intracellular signal transduction, and its regulatory mechanism is similar to that of apoptosis. Among them, TNF-&#945; is the most important upstream signaling molecule of necroptosis, and its receptor TNFR1 can recruit a variety of proteins, including TRADD, RIPK1, CIAP1, CIAP2 and LUBAC, which together form a signaling complex named &#8220;complex &#8544;&#8221; (<xref rid="B2" ref-type="bibr">Annibaldi and Meier, 2018</xref>). In most cases, CIAP and LUBAC in complex I promote the ubiquitination of RIPK1 through K63 linkage and linear ubiquitin chains, which further recruit TAK and IKK complexes to activate NF-&#954;B and MAPK signaling pathways, thereby promoting the production of inflammatory factors and maintaining cell survival (<xref rid="B2" ref-type="bibr">Annibaldi and Meier, 2018</xref>). In addition, the K63-linked ubiquitin chain on RIPK1 is hydrolyzed under the action of two deubiquitinating enzymes, CYLD and A20, thereby promoting the formation of complex II (<xref rid="B104" ref-type="bibr">Priem et al., 2020</xref>; <xref rid="B82" ref-type="bibr">Lork et al., 2017</xref>; <xref rid="B18" ref-type="bibr">Chen, 2012</xref>). The dissociated RIPK1 forms complex &#8545;b together with FADD and Caspase-8. When Caspase-8 activity is inhibited, RIPK1 further recruits and phosphorylates RIPK3 to form a RIPK1-RIPK3 necrosome (<xref rid="B73" ref-type="bibr">Li et al., 2012</xref>; <xref rid="B22" ref-type="bibr">Cho et al., 2009</xref>). RIPK1 and RIPK3 activate MLKL through autophosphorylation and cross-phosphorylation <italic toggle="yes">via</italic> homotypic interaction in the RHIM domain. Subsequently, RIPK3 catalyzes the phosphorylation of MLKL at Thr357 and Ser358 in its pseudokinase domain. After MLKL phosphorylation, its conformation changes, exposing the four-helix bundle (4HB) domain, which promotes MLKL oligomerization (<xref rid="B95" ref-type="bibr">Murphy et al., 2013</xref>). Oligomerization of MLKL migrates to the plasma membrane, where it forms a permeable pore, destroying the integrity of the membrane, and eventually causing programmed necrosis (<xref rid="B20" ref-type="bibr">Chen et al., 2014</xref>; <xref rid="B145" ref-type="bibr">Wang et al., 2014</xref>; <xref rid="B65" ref-type="bibr">Kaczmarek et al., 2013</xref>). In addition to TNF, other stimulating factors such as Fas, DR3, DR4, DR5 and DR6 can also trigger this process (<xref rid="B10" ref-type="bibr">Bi et al., 2017</xref>; <xref rid="B126" ref-type="bibr">Strilic et al., 2016</xref>) (<xref rid="F2" ref-type="fig">Figure 2b</xref>).</p></sec><sec id="s2-3"><title>2.3 Pyroptosis</title><p>Pyroptosis, also known as inflammatory necrosis of cells, is characterized by the continuous expansion of cells until cell membrane rupture, resulting in the release of cell contents and triggering an intense inflammatory response. Pyroptosis is an important part of the body&#8217;s innate immune response and plays a key role in the pathological process of immune system and nervous system diseases. The process is usually induced and executed by members of the Gasdermin (GSDM) protein family. The GSDM family of proteins contains six members, Five of them are Gasdermin A (GSDMA), Gasdermin B (GSDMB), Gasdermin C (GSDMC), Gasdermin D (GSDMD) and Gasdermin E (GSDME) -- each plays a unique rolein pore formation and pyroptosis-induced cell death (<xref rid="B169" ref-type="bibr">Yang F. et al., 2022</xref>). The GSDM-mediated pyroptosis pathway can proceed in either an inflammasome-dependent or an inflammasome-independent manner. The canonical inflammasome pathway is mediated by Caspase-1, while the non-canonical inflammasome pathway is mediated by Caspase-11 (mouse) and Caspase-4/5 (human), respectively. Both pathways eventually lead to the cleavage of GSDMD to generate its N-terminal and C-terminal fragments, of which the N-terminal fragment (GSDMD-N, or pore-forming domain PFD) is further oligomerized to form holes in the cell membrane (<xref rid="B138" ref-type="bibr">Toldo and Abbate, 2024</xref>). In the classical inflammasome pathway, GSDMD cleavage activates Pro-IL-1&#946; and Pro-IL-18 to form mature inflammatory factors IL-1&#946; and IL-18, which are released to the outside of the cell, followed by pyroptosis and lytic death of the cell (<xref rid="B110" ref-type="bibr">Rathinam and Fitzgerald, 2016</xref>; <xref rid="B14" ref-type="bibr">Broz and Dixit, 2016</xref>). In the non-canonical pathway, when stimulated by Gram-negative bacteria and their lipopolysaccharide (LPS), Caspase-4, Caspase-5 and Caspase-11 can directly bind to and be activated by LPS to cleave GSDMD protein. The N-terminus of GSDMD protein can not only mediate cell membrane lysis and pyroptosis, but also activate NLRP3 inflammasome to activate Caspase-1, and finally produce and release IL-1&#946; (<xref rid="B46" ref-type="bibr">Hagar et al., 2013</xref>; <xref rid="B119" ref-type="bibr">Shi et al., 2014</xref>). In addition to the above two modes of pyroptosis, Caspase-3/8-mediated pathway and GSDM protein-related induction pathway can also trigger pyroptosis (<xref rid="B138" ref-type="bibr">Toldo and Abbate, 2024</xref>). Specifically, Caspase-3 can be activated by a variety of stimulants such as drugs and viruses, and specifically cleave GSDME protein to mediate the pyroptosis process (<xref rid="B81" ref-type="bibr">Liu et al., 2022</xref>). However, the mechanism of caspase-8-mediated pyroptosis is more complex: first, after the tumor necrosis factor (TNF) -mediated death receptor signaling is activated, GSDMC can be cleaved by Caspase-8, and then apoptosis converts to pyroptosis in GSDMc-expressing cells (<xref rid="B106" ref-type="bibr">Qin et al., 2025</xref>). Second, when YopJ, a <italic toggle="yes">Yersinia</italic> effector protein, inhibited the activity of TGF-&#946;-activated kinase-1 (TAK1) or IKK kinase, it activated the RIPK1-Caspase-8 pathway, leading to the cleavage of GSDMD and accelerated the occurrence of pyroptosis (<xref rid="B98" ref-type="bibr">Orning et al., 2018</xref>; <xref rid="B114" ref-type="bibr">Sarhan et al., 2018</xref>). Studies have shown that GSDM mediated pyroptosis plays an important role in pathological processes such as neuroinflammation and mental diseases. As a defense mechanism, pyroptosis not only helps to remove pathogens and restore the stability of the intracellular environment, but also enhances the recognition and clearance efficiency of phagocytes such as neutrophils by encapsulating toxic substances. However, if the regulation is not balanced, it may lead to excessive tissue inflammation, which is closely related to a variety of nervous system diseases such as AD and Parkinson&#8217;s disease (<xref rid="B178" ref-type="bibr">Zhang S. et al., 2022</xref>) (<xref rid="F2" ref-type="fig">Figure 2c</xref>).</p></sec><sec id="s2-4"><title>2.4 Ferroptosis</title><p>Ferroptosis is a non-apoptotic cell death mode dependent on iron, which was first proposed by Dixon et al., in 2012 (<xref rid="B30" ref-type="bibr">Dixon et al., 2012</xref>). As an essential trace element for cells to maintain their morphology and function, iron plays an important role in oxygen transport, ATP synthesis, and DNA biosynthesis. Under normal physiological conditions, divalent iron (Fe<sup>2+</sup>) from food is transported to intestinal epithelial cells for absorption through divalent metal transporter 1 (DMT1). The absorbed Fe<sup>2+</sup> is oxidized to Fe<sup>3+</sup> in the intestinal mucosal epithelial cells, which is bound to transferrin (TF) and transported to the cells (<xref rid="B99" ref-type="bibr">Outten and Theil, 2009</xref>). The transferrin receptor (TFR1) on the cell surface recognizes and binds to a complex carrying trivalent iron (Tf-Fe<sup>3+</sup>) (<xref rid="B35" ref-type="bibr">Frazer and Anderson, 2014</xref>). It endocytoses into the cell interior. Once inside the cell, prostate transmembrane epithelial 3 antigen (STEAP3) reduces Fe<sup>3+</sup> to Fe<sup>2+</sup>. Some Fe<sup>2+</sup> is stored in the available LIP, while excess Fe<sup>2+</sup> is stored in ferritin (<xref rid="B13" ref-type="bibr">Bogdan et al., 2016</xref>). Ferritin is an important iron storage protein, which can dynamically regulate the oxidation of ferrous ions (Fe<sup>2+</sup>) to ferric iron (Fe<sup>3+</sup>) for intracellular enzymatic reactions or storage. When the Fe<sup>2+</sup> stored in the LIP binds to nuclear receptor coactivator 4 (NCOA4), it will trigger ferroautophagy and form autolysosome, leading to the degradation of ferritin and the release of large amounts of Fe<sup>2+</sup> to complete the iron metabolism process (<xref rid="B51" ref-type="bibr">Hou et al., 2016</xref>). However, excessive iron uptake, decreased iron storage, or blocked iron removal due to a variety of factors may lead to intracellular Fe<sup>2+</sup> overload. Excess Fe<sup>2+</sup> undergoes the Fenton reaction with hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) to generate strongly oxidizing hydroxyl radicals (&#183;OH). These free radicals can directly attack polyunsaturated fatty acids (such as arachidonic acid AA and adrenal acid AdA) in the cell membrane, trigger lipid peroxidation, accelerate the occurrence of lipid peroxidation, produce a large number of reactive oxygen species (ROS), and then promote ferroptosis (<xref rid="B21" ref-type="bibr">Chen et al., 2023</xref>). Lipid peroxidation triggered by iron metabolism disorder is a key mechanism leading to cell damage and ferroptosis. In addition, the imbalance of the antioxidant system of amino acids can also trigger the accumulation of lipid peroxides, which in turn promotes the occurrence of ferroptosis. A variety of antioxidant pathways have been evolved to resist oxidative stress damage, including cystine glutamate antitransporter receptor (system XC<sup>&#8722;</sup>) pathway, glutathione peroxidase 4 (GPX4) pathway, inhibitor of ferroptosis protein 1-Coenzyme Q10 (FSP1-CoQ10) pathway and P53 pathway (<xref rid="B189" ref-type="bibr">Zheng and Conrad, 2020</xref>; <xref rid="B9" ref-type="bibr">Bersuker et al., 2019</xref>). System XC<sup>&#8722;</sup> is an important amino acid transport system, which consists of a heterodimer of solute transport family 7A11 (SLC7A11) and SLC3A2 subunits. The main function of this system is to transport cystine, the precursor of the major intracellular antioxidant glutathione (GSH), into the cell. During ferroptosis, GSH reduces lipid peroxides to normal lipids through GPX4 to prevent their accumulation, thereby inhibiting the occurrence of ferroptosis. When system XC<sup>&#8722;</sup> is inhibited or its function is reduced, the intracellular cystine uptake is reduced, resulting in decreased GSH synthesis, which in turn reduces the antioxidant capacity of cells, increases the accumulation of lipid peroxides, and ultimately promotes ferroptosis (<xref rid="B62" ref-type="bibr">Jiang et al., 2015</xref>). P53 can inhibit the uptake of cystine by system XC- by down-regulating the expression of cystine, affect the activity of GPX4, reduce the antioxidant capacity of cells, and accelerate the occurrence (<xref rid="B159" ref-type="bibr">Xie et al., 2017</xref>) of ferroptosis. Coenzyme Q10 (CoQ10), as an important lipid-soluble antioxidant <italic toggle="yes">in vivo</italic>, can effectively capture free radicals generated during lipid peroxidation and inhibit the accumulation of lipid peroxides. In addition, CoQ10 is able to regenerate other antioxidants such as &#945;-tocopherol (vitamin E), thereby indirectly inhibiting lipid peroxidation. Ferroptosis inhibitor protein 1 (FSP1) is a key protein in the regulation of ferroptosis. It catalyzes the REDOX cycle of CoQ10 to generate ubiquinol, which further reduces the accumulation of lipid peroxides and prevents the occurrenceof ferroptosis (<xref rid="B9" ref-type="bibr">Bersuker et al., 2019</xref>; <xref rid="B69" ref-type="bibr">Kuang et al., 2020</xref>) (<xref rid="F2" ref-type="fig">Figure 2d</xref>).</p></sec><sec id="s2-5"><title>2.5 Cuproptosis</title><p>Copper is an indispensable trace element in the physiological processes of all types of cells in the human body. It is widely involved in mitochondrial respiration, antioxidant reactions, biosynthesis of biological compounds, and energy metabolism. Therefore, the uptake, distribution and metabolism of copper are strictly regulated (<xref rid="B133" ref-type="bibr">Tang et al., 2022</xref>; <xref rid="B92" ref-type="bibr">Maung et al., 2021</xref>). The imbalance of copper homeostasis in the body will trigger a form of cell death caused by excessive copper, namely, Cuproptosis (<xref rid="B140" ref-type="bibr">Tsvetkov et al., 2022</xref>). The basic metabolic process of copper relies on three key copper transporters: SLC31A1 is responsible for copper uptake, while ATP7A and ATP7B are responsible for copper efflux. Prostate six-transmembrane epidermal antigen (STEAP), a metalloreductase located on the surface of small intestinal epithelial cells, reduces Cu<sup>2+</sup> to Cu<sup>+</sup> and subsequently enters the cell through the high-affinity transmembrane transporter copper transporter 1 (CTR1). Once inside the cell, Cu<sup>+</sup> binds to copper chaperones through the cytoplasmic, mitochondrial and Golgi pathways, and is targeted for delivery to different copper proteins (<xref rid="B39" ref-type="bibr">Galler et al., 2020</xref>). For example, in the cytoplasm, superoxide dismutase copper chaperones (CCS) activate superoxide dismutase 1 (SOD1), which plays an important antioxidant role by regulating the distribution of SOD1 in the cell, ensuring the balance of ROS in the body, and preventing oxidative damage caused by copper overload (<xref rid="B152" ref-type="bibr">Wang et al., 2024</xref>). In mitochondria, Cytc oxidase copper chaperone 17 (Cox17) mediates the transport of copper from the cytoplasm to the mitochondria and participates in the respiratory chain and REDOX pathway. In addition, most of the Cu<sup>+</sup> entering hepatocytes is transported to the trans-Golgi network (TGN) through the antioxidant protein 1 (ATOX1), and copper is excreted by the major transporter ATP7A/B. Together, they maintain the body&#8217;s copper homeostasis (<xref rid="B25" ref-type="bibr">Da et al., 2022</xref>). When copper homeostasis is disrupted for various reasons, the intracellular copper concentration increases. Copper ionophores such as elesclomol (ES) and disulfiram (DSF) can directly bind to extracellular Cu<sup>2+</sup> and actively enter the cell, where they are targeted and enriched inmitochondria through the mitochondrial membrane (<xref rid="B140" ref-type="bibr">Tsvetkov et al., 2022</xref>; <xref rid="B87" ref-type="bibr">Lutsenko et al., 2010</xref>). On the one hand, Cu<sup>2+</sup> is reduced to more toxic Cu<sup>+</sup> under the action of ferredoxin 1 (FDX1), which inhibits the synthesis of Fe-S Cluster proteins related to mitochondrial respiration and triggers a proteotoxic stress response that eventually leads to cell death (<xref rid="B139" ref-type="bibr">Tsvetkov et al., 2019</xref>). On the other hand, FDX1, as an upstream regulator of protein lipoacylation, participates in the tricarboxylic acid cycle and binds to lipoacylated mitochondrial proteins (such as DLAT), causing protein oligomerization and producing ROS to induce oxidative stress. These abnormal processes together eventually lead to cuproptosis of cells (<xref rid="B129" ref-type="bibr">Sun et al., 2023</xref>). Therefore, the accumulation of intracellular copper exceeding the limit is the direct cause of cuproptosis. Cu death can be induced by directly delivering Cu<sup>2+</sup> into cells using copper ionophore, over-expressing the copper transporter SLC31A1/CTR1, or down-regulating the expression of ATP7A/B protein to increase the intracellular Cu+ concentration (<xref rid="B161" ref-type="bibr">Xie J. et al., 2023</xref>) (<xref rid="F2" ref-type="fig">Figure 2e</xref>).</p></sec><sec id="s2-6"><title>2.6 Autophagy</title><p>Autophagy is a process of engulfing damaged or aged organelles and proteins, encapsulating them into vesicles to form autolysosomes for degradation, and ultimately achieving cell self-renewal. This process can be divided into two types: selective and non-selective (<xref rid="B42" ref-type="bibr">Gatica et al., 2018</xref>; <xref rid="B96" ref-type="bibr">Nakatogawa, 2020</xref>). In view of the important role of selective autophagy in maintaining body homeostasis and its ability to target the removal of damaged mitochondria, mitophagy, as an important branch of selective autophagy, has become a hot research field (<xref rid="B143" ref-type="bibr">Vargas et al., 2023</xref>). In mammals, the regulatory pathways of mitophagy can be classified into two categories (<xref rid="B66" ref-type="bibr">Khaminets et al., 2016</xref>): Ubiquitin-dependent and independent.</p><p>PINK1/Parkin signaling, which is dependent on extensive ubiquitylation of mitochondrial surface proteins, is the classical pathway to mediate mitophagy. Pten-induced kinase 1 (PINK1) plays a key role in this process (<xref rid="B50" ref-type="bibr">Harper et al., 2018</xref>). Under normal physiological conditions, PINK1 is transported to the inner mitochondrial membrane through the mitochondrial outer membrane translocase complex (TOM) and is rapidly degraded to maintain mitochondrial quality control (<xref rid="B6" ref-type="bibr">Bausewein et al., 2020</xref>; <xref rid="B113" ref-type="bibr">Ruth et al., 2014</xref>; <xref rid="B115" ref-type="bibr">Sekine et al., 2019</xref>). When Mitochondrial damage results in loss of Mitochondrial Membrane Potential (MMP), PINK1 is unable to enter the inner Membrane and accumulates steadily on the Outer Mitochondrial Membrane (OMM). It undergoes rapid autophosphorylation and undergoes a series of modifications on Parkin, such as binding to Ser 65 phosphorylated ubiquitin (pSer 65-Ub) to activate E3 ubiquitin ligase activity. In addition, PINK1 interacts with microtubule-associated protein 1A/1B light chain 3 (LC3) to initiate autophagosome formation and fusion with lysosomes, ultimately promoting the degradationof damaged mitochondria (<xref rid="B68" ref-type="bibr">Koyano et al., 2014</xref>; <xref rid="B109" ref-type="bibr">Rasool et al., 2018</xref>).</p><p>In addition to participating in ubiquitin-dependent mitophagy, some mitochondrial proteins also act as mitophagy receptors, directly mediating the targeted binding and degradation process of dysfunctional mitochondria to autophagosomes (<xref rid="B100" ref-type="bibr">Palikaras et al., 2018</xref>). For example, autophagy receptor proteins such as BNIP3, NIX/BNIP3L, FUNDC1 and AMBRA1 interact with LC3 and GABARAP through their LIR domains to efficiently mediate mitochondrial clearance (<xref rid="B42" ref-type="bibr">Gatica et al., 2018</xref>; <xref rid="B91" ref-type="bibr">Marinkovic et al., 2021</xref>; <xref rid="B49" ref-type="bibr">Hanna et al., 2012</xref>) (<xref rid="F2" ref-type="fig">Figure 2f</xref>) (<xref rid="T1" ref-type="table">Table 1</xref>).</p><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>The biological differences of PCD patterns.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th colspan="2" align="center" rowspan="1">Characteristics</th><th align="center" rowspan="1" colspan="1">Apoptosis</th><th align="center" rowspan="1" colspan="1">Necroptosis</th><th align="center" rowspan="1" colspan="1">Autophagy</th><th align="center" rowspan="1" colspan="1">Pyroptosis</th><th align="center" rowspan="1" colspan="1">Ferroptosis</th><th align="center" rowspan="1" colspan="1">Cuproptosis</th></tr></thead><tbody valign="top"><tr><td colspan="2" align="center" rowspan="1">Biochemical characteristics</td><td align="left" rowspan="1" colspan="1">The caspase-mediated activation of oligonucleosomal DNA fragmentation</td><td align="left" rowspan="1" colspan="1">The ATP level was observed to decrease, while the activation of RIP1, RIP3, and MLK was noted</td><td align="left" rowspan="1" colspan="1">LC3 lipidation, formation of autophagosomes, increased autophagic flux, and Enhanced lysosomal activity were observed</td><td align="left" rowspan="1" colspan="1">Dependent or independent activation of Caspase-1, cleavage of GSDMD, and subsequent release of inflammatory factors</td><td align="left" rowspan="1" colspan="1">The process involves the reduction of GSH inhibition of GPX4, iron accumulation and lipid peroxidation.</td><td align="center" rowspan="1" colspan="1">Abnormal oligomerization of DLAT and inhibition of the level of Fe-S cluster proteins</td></tr><tr><td colspan="2" align="center" rowspan="1">Morphological characteristics</td><td align="left" rowspan="1" colspan="1">Cell shrinkage, preservation of membrane integrity, nuclear condensation and DNA fragmentation within the nucleus</td><td align="left" rowspan="1" colspan="1">Organelles exhibit swelling, cell membranes undergo rupture, and both cytoplasm and nuclei display disintegration</td><td align="left" rowspan="1" colspan="1">The cell membrane structure remains intact, while the cytoplasm exhibits vacuolation</td><td align="left" rowspan="1" colspan="1">Cell membrane disruption, cellular swelling and expansion with vesicle-like protrusions, preservation of nuclear integrity, and DNA fragmentation</td><td align="left" rowspan="1" colspan="1">The mitochondria become smaller, the density of the cell membrane increases, and the cristae of the mitochondria decrease</td><td align="center" rowspan="1" colspan="1">Mitochondrial contraction, cell membrane rupture Endoplasmic reticulum damage, and chromatin rupture</td></tr><tr><td rowspan="2" align="center" colspan="1">Core regulatory genes</td><td align="center" rowspan="1" colspan="1">Positive</td><td align="center" rowspan="1" colspan="1">Bax, Bak, Caspase, P53</td><td align="center" rowspan="1" colspan="1">RIPK1, RIPK3, MLKL</td><td align="center" rowspan="1" colspan="1">LC3, Beclin-1, ATG5, ATG7</td><td align="center" rowspan="1" colspan="1">Caspase-1, Capase-11, GSDMD</td><td align="center" rowspan="1" colspan="1">TFR1, ACSL4, P53</td><td align="center" rowspan="1" colspan="1">FDX1, LIAS, DLAT</td></tr><tr><td align="center" rowspan="1" colspan="1">Negatie</td><td align="center" rowspan="1" colspan="1">Bcl-2, Bcl-xL</td><td align="center" rowspan="1" colspan="1">Caspase-8, FADD, A20</td><td align="center" rowspan="1" colspan="1">mTOR, AKT</td><td align="center" rowspan="1" colspan="1">GPX4</td><td align="center" rowspan="1" colspan="1">GPS4, SLC7A11, FSP1-CoQ10</td><td align="center" rowspan="1" colspan="1">SLC31Al, CTR1, ATP7, ATP8</td></tr><tr><td colspan="2" align="center" rowspan="1">Immune characteristics</td><td align="center" rowspan="1" colspan="1">Anti-Inflammatory</td><td align="center" rowspan="1" colspan="1">Pro-Inflammatory</td><td align="center" rowspan="1" colspan="1">Anti-Inflammatory</td><td align="center" rowspan="1" colspan="1">Pro-Inflammatory</td><td align="center" rowspan="1" colspan="1">Pro-Inflammatory</td><td align="center" rowspan="1" colspan="1">Pro-Inflammatory</td></tr></tbody></table></table-wrap></sec></sec><sec id="s3"><title>3 Pathological association and interaction mechanism between different forms of PCD and AD</title><p>A core pathological feature of AD includes the cleavage of amyloid precursor protein (APP) by &#946;-secretase and &#947;-secretase, resulting in the formation of neurotoxic &#946;-amyloid oligomers (A&#946; oligomers). A&#946; is A polypeptide containing 39 to 43 amino acids, which is produced by the proteolytic action of APP by &#946;-secretase and &#947;-secretase (<xref rid="B64" ref-type="bibr">Jucker and Walker, 2023</xref>). A&#946; can be divided into monomers, oligomers, fibrils and amyloid fibers. Studies have shown that A&#946; monomer itself does not directly affect neuronal function, but its hydrolysis and formation of soluble oligomers is the key factor in the development of AD (<xref rid="B64" ref-type="bibr">Jucker and Walker, 2023</xref>). In addition, Tau protein is a microtubule-associated protein encoded by a single gene, which is mainly distributed in hippocampal neurons. Its main physiological function is to promote the polymerization of microtubule-associated proteins in neurons and maintain the stability of microtubule structure, thereby ensuring the realization of normal physiological functions of neurons. Under normal physiological conditions, Tau protein has fewer phosphorylation sites. However, under pathological conditions, Tau protein is hyperphosphorylated and aggregated to form neurofibrillary tangles (NFTs), which in turn blocks nerve signal transmission and neurotransmitter transport, leading to the occurrence of AD (<xref rid="B93" ref-type="bibr">Mueller et al., 2021</xref>). The cascade reaction caused by A&#946; deposition and Tau protein hyperphosphorylation promotes the formation of neurofibrillary tangles (NFTS) in the brain, which further aggravates the development of AD. It is noteworthy that different types of PCD pathways can participate in and aggravate this cascade reaction.</p><sec id="s3-1"><title>3.1 The mechanism of apoptosis and AD</title><p>A&#946; can bind to Fas and TNF-&#945; receptors on the cell membrane of neurons and activate the endogenous apoptosis signaling pathway. For example, after binding to Fas receptor, A&#946; induces the expression and release of Fas ligand (FasL), forming Fas-fasl complex and activating caspase-8 to initiate apoptosis. Studies have shown that in AD model mice, the expression of Fas receptor in hippocampal neurons is upregulated, which is positively correlated with the degree of A&#946; deposition. Meanwhile, administration of FasL antagonist can reduce neuronal apoptosis and improve cognitive function. In addition, A&#946; deposition directly acts on mitochondria, increasing membrane permeability and releasing pro-apoptotic factors such as Cytc. Cytc binds to Apaf-1 and activates caspase-9 to initiate the mitochondria-mediated apoptotic pathway (<xref rid="B70" ref-type="bibr">Kumari et al., 2023</xref>). At the same time, A&#946; deposition can also induce the production of A large number of ROS, which triggers oxidative stress. It attacks DNA, proteins and lipids, causing oxidative damage. It further activates the apoptotic signaling pathway in the cell, which eventually leads to apoptosis. Tau binds to Thr212/Thr231/Ser262 and other sites, which will dissociate from microtubules and lead to hyperphosphorylation. With the release of Cytc, Tau binds to Apaf-1 to form apoptotic bodies and activate the cascade of Caspase-9/3 (<xref rid="B1" ref-type="bibr">Alonso et al., 2010</xref>). In addition, phosphorylated Tau protein decreased the activity of PI3K/Akt pathway, increased the expression of pro-apoptotic factor Bax, and decreased the expression of anti-apoptotic factor Bcl-2 by competitively inhibiting the regulation of &#946;-catenin by GSK-3&#946; (<xref rid="B141" ref-type="bibr">Ulamek-Koziol et al., 2020</xref>). Notably, Caspase-3 can cleave Asp421 site of Tau protein to generate truncated Tau protein, which further aggravates the apoptotic process (<xref rid="B1" ref-type="bibr">Alonso et al., 2010</xref>).</p></sec><sec id="s3-2"><title>3.2 Mechanisms of necroptosis and AD</title><p>In neurodegenerative diseases, necroptosis is mediated by A series of signaling pathways. Firstly, necroptosis can lead to the loss and damage of neurons, which further aggravates the deposition of A&#946; and the formation of neurofibrillary tangles. Secondly, necroptosis can release inflammatory factors, such as IL-1&#946; and TNF-&#945;, activate microglia and astrocytes, trigger neuroinflammatory responses, and further damage the function and survival of neurons. Among them, the RIPK1/RIPK3/MLKL signaling axis is the key regulatory pathway. In the brain of AD patients, A&#946; binds to the receptor on the cell membrane, activates the downstream RIPK1, and then phosphorylates RIPK3, leading to the phosphorylation and oligomerization of MLKL. Finally, A&#946; inserts into the cell membrane to form holes, causing the release of cell contents and inducing the occurrence of cell necroptosis. In addition, cell necroptosis can also affect the intracellular REDOX balance, increase the production of ROS, and lead to oxidative stress damage, thereby promoting the aggregation of A&#946; and neurotoxicity. Other studies have shown that p-MLKL, a necrotizing marker of apoptosis, co-localizes with Tau pathology in AD models. Inhibition of RIPK1 or MLKL can significantly reduce Tau aggregation and improve cognitive function (<xref rid="B4" ref-type="bibr">Balusu and De Strooper, 2024</xref>).</p></sec><sec id="s3-3"><title>3.3 Mechanisms of pyroptosis and AD</title><p>A&#946; and neuronal pyroptosis is A two-way regulation mechanism, which depends on NLRP family proteins in cultured neurons in cortical regions. When NLRP3 inflammasome activity is inhibited, A&#946; deposition is significantly reduced. Dempsey et al. found that the use of NLRP3 inhibitor MCC950 can effectively inhibit the expression of NLRP3 and its downstream Caspase-1, thereby inhibiting pyroptosis and reducing A&#946; accumulation (<xref rid="B28" ref-type="bibr">Dempsey et al., 2017</xref>). In addition to inhibiting NLRP3, pyroptosis can also be inhibited by inhibiting other inflammasomes such as NLRP1, NLRC4 and AIM2, which in turn reduces A&#946; deposition (<xref rid="B131" ref-type="bibr">Tan et al., 2014</xref>). During the progression of AD, pyroptosis of microglia promotes the formation of ASC-A&#946; complexes, not only exacerbating the accumulation of A&#946; but also leading to the assembly of NLRP3 inflammasomes, activation of caspase-1, maturation of IL-1&#946;, and cleavage of GSDMD, and further promoting pyroptosis of adjacent microglia. Tau protein showed similar to amyloid A&#946; activation mechanism of NLRP3 inflammatory corpuscle. Specifically, phagocytosis of Tau by microglia disrupts lysosomal stability, leading to the release of cathepsin B and its binding to the NLRP3 inflammasome, thereby participating in its activation. This process induces the secretion of interleukin-1&#946; (IL-1&#946;) in an ASC-dependent manner (<xref rid="B125" ref-type="bibr">Stancu et al., 2019</xref>). When NLRP3 or ASC is deficient, Tau phosphorylation is significantly inhibited, and key kinases that induce Tau phosphorylation, such as CaMKII-&#945; and GSK-3&#946;, are significantly downregulated, while PP2A, a phosphatase that promotes Tau dephosphorylation, is significantly upregulated. This suggests that NLRP3 inflammasome can promote the pathological process of Tau by regulating the phosphorylation level of tau protein (<xref rid="B146" ref-type="bibr">Wang et al., 2020</xref>).</p></sec><sec id="s3-4"><title>3.4 Mechanisms of ferroptosis and AD</title><p>In the ferroptosis pathway, the 5&#8242;untranslated region of APP mrna contains an Iron Response Element (IRE) that is regulated by intracellular iron levels. The expression of APP can be regulated by post-transcriptional Iron Regulatory Protein (IRP). When intracellular iron overload occurs, iron ions bind to IRP and promote its dissociation from IRE, thereby increasing the translation efficiency of APP, leading to the increase of APP protein level and finally the production of excess A&#946; (<xref rid="B7" ref-type="bibr">Belaidi et al., 2018</xref>). As an important proprotein convertase, Furin protease can convert a variety of precursor proteins into mature proteins. The presence of iron ions can reduce the transcription and translation level of Furin, inhibit the activity of &#945;-secretase and activate &#946;-secretase, thus playing a key role in the processing of APP (<xref rid="B45" ref-type="bibr">Guillemot et al., 2013</xref>). Studies have shown that A&#946; can promote ferroptosis by activating signaling pathways such as mGLIUS and STIM proteins, and regulating the expression of ferroptosis-related genes such as FTH1 and SAT1. The interaction between ferroptosis and Tau protein also shows the characteristics of bidirectional regulation. The imbalance of iron metabolism activates glycogen synthase kinase-3&#946; (GSK-3&#946;), promotes abnormal phosphorylation of Tau protein, inhibits the ubiquitin-proteasome system, and hinders the degradation of Tau protein, thereby accelerating its pathological aggregation (<xref rid="B148" ref-type="bibr">Wang et al., 2022a</xref>). In addition, ferroptosis-inducing agents further aggravate the toxic effects of Tau by inhibiting System Xc- and GPX4 (<xref rid="B149" ref-type="bibr">Wang et al., 2022b</xref>).</p></sec><sec id="s3-5"><title>3.5 Mechanism of cuproptosis and AD</title><p>Cuproptosis is a novel form of cell death, which is associated with the abnormal accumulation of intracellular copper ions. Studies have shown that copper content is significantly increasedin peripheral blood and brain tissue of AD patients (<xref rid="B191" ref-type="bibr">Zhou et al., 2022</xref>). Excessive copper ions can bind to lipoic acid esterified proteins in mitochondria, leading to mitochondrial dysfunction and the loss of iron-sulfur cluster proteins, which in turn induces proteotoxic stress and further promotes the deposition and aggregation of A&#946;. A&#946; deposition is not only one of the pathological features of AD, but also may affect the occurrence of cuproptosis through A variety of mechanisms. On the one hand, A&#946; deposition can lead to increased levels of oxidative stress in cells, and oxidative stress is one of the important factors inducing the death of copper. On the other hand, A&#946; deposition may interfere with the distribution and metabolism of intracellular copper, increase the accumulation of copper ions in cells, and thus promote the occurrence of cuproptosis. Studies have shown that A&#946; peptide and APP bind to copper through specific amino acid residues (such as histidine His13, His14, His6 and tyrosine Tyr10), and reduce Cu<sup>2+</sup> to Cu<sup>+</sup> through CTR1. This process generates ROS, which in turn leads to oxidative damage of A&#946; peptide, intracellular proteins and lipids. And aggravate neurotoxicity (<xref rid="B94" ref-type="bibr">Multha et al., 1996</xref>). Knockout of CTR1 can significantly reduce the accumulation of copper in the brain, thereby alleviating A&#946;42-induced neurodegeneration and enhancing the resistance to oxidative damage. Inhibition of CTR1 can effectively regulate the accumulation of copper in the brain and improve A&#946;-induced neurotoxicity (<xref rid="B71" ref-type="bibr">Lang et al., 2013</xref>).</p></sec><sec id="s3-6"><title>3.6 Mechanisms of autophagy and AD</title><p>In recent years, autophagy has become A hot spot in AD research. In AD, autophagy participates in the clearance of A&#946; and promotes the degradation of p-tau, which is of greatsignificance for the improvement of AD (<xref rid="B155" ref-type="bibr">Weller and Budson, 2018</xref>). Specifically, the autophagy-lysosome pathway plays an important role in the metabolism of A&#946;, and intracellular A&#946; is mainly degraded by lysosomal metabolism. Under normal circumstances, A&#946; produced by autophagosomes is transported to lysosomes and degraded by A variety of hydrolases. Therefore, the amount of A&#946; in neuronal lysosomes is very small. However, under pathological conditions, the content of A&#946; in lysosomes increases significantly due to the blockage of this pathway, and the excessive deposition of A&#946; and APP will lead to autophagy dysfunction, and the clearance of A&#946; by autophagy will fall into A decompensated stage. With the continuous exploration of the pathogenesis of AD, it has been found that inducing autophagy in the early stage of AD can switch a large number of APP-rich metabolic substrates to the autophagy-lysosome system metabolic pathway, accelerate the clearance of misfolded proteins and damaged organelles, and thus improve AD (<xref rid="B156" ref-type="bibr">Whyte et al., 2017</xref>). Autophagy is also one of the key mechanisms to clear phosphorylated tau protein from neurons. Studies have shown that the damage of autophagy-lysosome system can lead to the formation of tau oligomers and insoluble aggregates. Autophagy dysfunction is closely related to the excessive accumulation of p-tau in the brain, which can be significantly alleviated by inducing autophagy (<xref rid="B183" ref-type="bibr">Zhang J. et al., 2024</xref>; <xref rid="B124" ref-type="bibr">Silva et al., 2019</xref>). Studies have found that activation of AMPK-mTOR pathway can enhance the autophagy pathway to reduce the content of tau protein, thereby improving the cognitive impairmentof AD mice (<xref rid="B90" ref-type="bibr">Malampati et al., 2020</xref>). In addition, some studies have suggested that activating the Nrf2/Keap1/NQO-1 pathway can increase autophagy flux and promote the clearance of P-tau, thus playing a therapeutic rolein AD (<xref rid="B88" ref-type="bibr">Ma et al., 2024</xref>).</p></sec></sec><sec id="s4"><title>4 Mechanisms of interaction between different PCDS</title><p>Multiple modes of PCD and their combination play important roles in the development and progression of AD. As a key node in the turnover of old and new cells, autophagy plays a central role in the regulation of AD by crosstalk with a variety of PCD pathways. Autophagy is a form of PCD that involves the encapsulation of intracellular proteins or organelles into autophagic vesicles, which fuse with lysosomes to achieve the degradation of their contents and the recycling of autophagic substrates, and ultimately trigger cell self-digestion (<xref rid="B34" ref-type="bibr">Fleming et al., 2022</xref>). In addition, autophagy can interact with various forms of PCD such as apoptosis, necroptosis, pyroptosis, ferroptosis, and cuproptosis in AD.</p><sec id="s4-1"><title>4.1 Autophagy-apoptosis-necroptosis</title><p>Autophagy has been confirmed as an important physiological protective mechanism in cells. In the early stage of disease, the body actively activates autophagy pathway to prevent cell apoptosis. However, with the progression of the disease, when autophagy function is impaired, it may lead to a significant increase in neuronal apoptosis. In recent years, more and more studies have shown that the excitability and toxicity of glutamate play a key role in neurodegenerative diseases. It has been reported that the activation of autophagy is closely related to the level of glutamate. For example, in a cell model of glutamate-induced AD, glutamate stimulation significantly upregulated the expression of autophagy-related proteins Beclin-1 and LC3-II, decreased the Bax/Bcl-2 ratio and P62 protein level, and restored mitochondrial membrane potential. These results indicate that the increased level of autophagy can effectively inhibit the expression of apoptosis-related proteins and reduce the deposition of &#946;-amyloid (A&#946;), Tau protein phosphorylation and the formation of neurofibrillary tangles (NFTs), which provides A new theoretical basis (<xref rid="B162" ref-type="bibr">Xie D. et al., 2023</xref>). In addition, IKK&#946;-activating enzyme has been shown to inhibit the occurrence of necroptosis by enhancing autophagy activity in A&#946;-induced neuroblastoma cell model. Specifically, when autophagy-related proteins were silenced, the expression of necrotizing effectors in cells was significantly increased, further exacerbating the necrotizing process. These results indicated that autophagy could effectively inhibit RIPK-mediated necroptosis in A&#946;-induced neuroblastoma cells. Further studies have found that IKK&#946; is an upstream signaling molecule of autophagy, and its activation can significantly improve necroptosis caused by impaired autophagy and reduce A&#946; deposition, which has potential value for the treatment of AD (<xref rid="B150" ref-type="bibr">Wang W. et al., 2022</xref>).</p></sec><sec id="s4-2"><title>4.2 Autophagy-necroptosis-ferroptosis</title><p>Previous studies have found that necroptosis in rats with A&#946;-induced AD can increase the expression of SLC7A11, the key factor of ferroptosis, and decrease the level of TFR, leading to the decrease of RIPK1 and RIPK3 expression, and thus improve the pathological process of AD mediated by necroptosis. Further studies have found that necrospot-1, an inhibitor of necroptosis, has no effect on ferroptosis, but A&#946; induced necroptosis is inhibited by ferrostatin, indicating that ferroptosis pathway may act as an upstream signal of necroptosis to regulate A&#946; neurotoxicity in AD (<xref rid="B132" ref-type="bibr">Tang et al., 2021</xref>).</p></sec><sec id="s4-3"><title>4.3 Autophagy-ferroptosis - cuproptosis</title><p>Autophagy plays a key role in the regulation of ferroptosis. Excess iron interacts with ferritin and binds to NCOA4 to induce selective autophagy and release more free iron. At the same time, P62 can lead to abnormal expression of ferritin autophagy, resulting in large iron accumulation and iron overload (<xref rid="B108" ref-type="bibr">Quiles and Mancias, 2019</xref>). At the same time, there is crosstalk between mitophagy and ferroptosis in the process of AD. By establishing A&#160;cell model of A&#946;-induced AD damage, we found that there was a crosstalk between CD36/PINK/Parkin-mediated mitophagy and ferroptosis. This ferroptosis pathway could be exacerbated by mitophagy inhibitors. These results indicate that CD36/PINK/Parkin-mediated mitophagy plays an important role in regulating ferroptosis and inhibiting the deposition of A&#946; in AD (<xref rid="B74" ref-type="bibr">Li et al., 2022</xref>). Therefore, dysregulation of the autophagy system may directly lead to the abnormal accumulation of iron in the brain of AD, which in turn triggers ferroptosis. Notably, SLC7A11, a key inhibitor of ferroptosis, is also closely related to cuproptosis. Studies have found that when the expression level of SLC7A11 is upregulated, it can promote the synthesis of glutathione from cysteine, which in turn chelates copper ions, reduce the level of intracellular copper ions, and inhibit the occurrence of cuproptosis (<xref rid="B184" ref-type="bibr">Zhang P. et al., 2024</xref>). Although there are few reports on the crosstalk relationship among autophagy, ferroptosis and cuproptosis in AD, using SLC7A11 as a cross point to link autophagy, ferroptosis and cuproptosis can provide clues for future research on the pathogenesis of AD (<xref rid="F3" ref-type="fig">Figure 3</xref>).</p><fig position="float" id="F3" orientation="portrait"><label>FIGURE 3</label><caption><p>The interaction mechanism between different forms of PCD.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-16-1605214-g003.jpg"><alt-text content-type="machine-generated">Flowchart depicting cellular processes and signaling pathways linking mitophagy and iron metabolism to Alzheimer's disease (AD) improvement. Key elements include Beclin-1, LC3II, RIPK, P62, SLC7A11, and GSDMD, with processes like apoptosis, necroptosis, and pyroptosis highlighted. Components like GLU, MMP, IKK&#946;, ATG4, ATG5, CD36, PINK1, Parkin, NLRP3, NCOA4, GSH, Cu, and iron somatostatin are shown interacting, all pointing to AD improvement.</alt-text></graphic></fig></sec></sec><sec id="s5"><title>5 Plant metabolites of traditional Chinese medicine regulate the pathways of PCD in AD cells</title><p>This review summarizes recent advances in PCD in AD. Subsequently, we summarized and analyzed the experimental studies, recent reviews and network pharmacological analysis literature on the use of plant metabolites of traditional Chinese medicine in the treatment of AD in the past decade. In this review, we summarized the efficacy and mechanisms of plant metabolites of traditional Chinese medicine in regulating PCD (<xref rid="F4" ref-type="fig">Figure 4</xref>) (<xref rid="T2" ref-type="table">Tables 2</xref>&#8211;<xref rid="T6" ref-type="table">6</xref>).</p><fig position="float" id="F4" orientation="portrait"><label>FIGURE 4</label><caption><p>The chemical structure of natural active components.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-16-1605214-g004.jpg"><alt-text content-type="machine-generated">Chemical structures with corresponding names: Berberine, Huperzine A, Matrine, Astragaloside, Sinomenine, Baicalin, Salidroside, Ginsenoside-Rg2, Icariin, Lycium barbarum polysaccharide, Astragalin polysaccharide. Below each name are detailed boxes with pathways and effects visualized, connected to a brain icon representing neural implications.</alt-text></graphic></fig><table-wrap position="float" id="T2" orientation="portrait"><label>TABLE 2</label><caption><p>Regulation of apoptosis by active components of traditional Chinese medicine.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">Target of action</th><th align="center" rowspan="1" colspan="1">Experimental subjects</th><th align="center" rowspan="1" colspan="1">Possible mechanisms</th><th align="center" rowspan="1" colspan="1">Natural plant molecules</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td rowspan="16" align="center" colspan="1">Apoptosis</td><td align="center" rowspan="1" colspan="1">HT22 cells</td><td align="center" rowspan="1" colspan="1">&#8593;MOMP<break/>&#8595;ROS, P65, Cytc, Caspase-3, Caspase-9</td><td align="center" rowspan="1" colspan="1">Berberine</td><td align="center" rowspan="1" colspan="1">
<xref rid="B184" ref-type="bibr">Zhang et al. (2024c)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">N2a cells</td><td align="center" rowspan="1" colspan="1">&#8593;Bcl-2<break/>&#8595;ROS, Caspase-3, c-jun, Bax, P53</td><td align="center" rowspan="1" colspan="1">Huperzine A</td><td align="center" rowspan="1" colspan="1">
<xref rid="B151" ref-type="bibr">Wang et al. (2023)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">A&#946;-included astrocyte</td><td align="center" rowspan="1" colspan="1">&#8595;NF-&#954;B, P65</td><td align="center" rowspan="1" colspan="1">Huperzine A</td><td align="center" rowspan="1" colspan="1">
<xref rid="B134" ref-type="bibr">Tao et al. (2013)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">APP/PS1 mice</td><td align="center" rowspan="1" colspan="1">&#8593;Bcl-2, PC12, &#8595;Bax</td><td align="center" rowspan="1" colspan="1">Matrine</td><td align="center" rowspan="1" colspan="1">
<xref rid="B164" ref-type="bibr">Yan et al. (2007)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Lipopolysaccharide -induced macrophages</td><td align="center" rowspan="1" colspan="1">&#8595;Bax, Caspase-3</td><td align="center" rowspan="1" colspan="1">Sinomenine</td><td align="center" rowspan="1" colspan="1">
<xref rid="B83" ref-type="bibr">Lu et al. (2023)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">PC-12 cells</td><td align="center" rowspan="1" colspan="1">&#8593;Nrf2/Ho-1 Pathway, PC12, Bcl-2<break/>&#8595;Bax, MDA, ROS</td><td align="center" rowspan="1" colspan="1">Lycium barbarum polysaccharides</td><td align="center" rowspan="1" colspan="1">
<xref rid="B5" ref-type="bibr">Bao et al. (2024)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">APP/PS1 mice</td><td align="center" rowspan="1" colspan="1">&#8593;Nrf2, GSH-PH, SOD &#8595;Keap1, MDA</td><td align="center" rowspan="1" colspan="1">Astragalus polysaccharides</td><td align="center" rowspan="1" colspan="1">
<xref rid="B188" ref-type="bibr">Zhao et al. (2024)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">
<italic toggle="yes">Drosophila melanogaster</italic>
</td><td align="center" rowspan="1" colspan="1">&#8593;JAK/STAT Pathway<break/>&#8595;Cytc, Caspase-3, Caspase-9</td><td align="center" rowspan="1" colspan="1">Astragalus polysaccharides</td><td align="center" rowspan="1" colspan="1">
<xref rid="B105" ref-type="bibr">Qin et al. (2020)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">ICR mice</td><td align="center" rowspan="1" colspan="1">&#8593;Bcl-2 &#8595;Bax, Caspase-3, Caspase-9</td><td align="center" rowspan="1" colspan="1">Ginsenoside</td><td align="center" rowspan="1" colspan="1">(<xref rid="B147" ref-type="bibr">Wang et al., 2021</xref>), (<xref rid="B86" ref-type="bibr">Luong et al., 2021</xref>)</td></tr><tr><td align="center" rowspan="1" colspan="1">HT22 cells</td><td align="center" rowspan="1" colspan="1">&#8593;MAPK Pathway, Bcl-2<break/>&#8595;Bax, AIF, P38</td><td align="center" rowspan="1" colspan="1">Ginsenoside</td><td align="center" rowspan="1" colspan="1">
<xref rid="B52" ref-type="bibr">Hou et al. (2017)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">A&#946;-included mice</td><td align="center" rowspan="1" colspan="1">&#8593;PI3K/AKT Pathway, Bcl-2<break/>&#8595;Bax, Caspases</td><td align="center" rowspan="1" colspan="1">Ginsenoside</td><td align="center" rowspan="1" colspan="1">
<xref rid="B33" ref-type="bibr">Fernandez-Moriano et al. (2017)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">hydrobromide-Induced mice</td><td align="center" rowspan="1" colspan="1">&#8593;Nrf2 &#8595;Keap1</td><td align="center" rowspan="1" colspan="1">Ginsenoside</td><td align="center" rowspan="1" colspan="1">
<xref rid="B67" ref-type="bibr">Kim et al. (2019)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">A&#946;-included mice</td><td align="center" rowspan="1" colspan="1">&#8593;BDNF/TRKB/CREB, BDNF, TrkB, P-CREB &#8595;TUNEL</td><td align="center" rowspan="1" colspan="1">Icarin</td><td align="center" rowspan="1" colspan="1">
<xref rid="B135" ref-type="bibr">Tao et al. (2021)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">APP/PS1 mice</td><td align="center" rowspan="1" colspan="1">&#8593;Wnt/&#946;-catenin, Wnt-3a</td><td align="center" rowspan="1" colspan="1">Icarin</td><td align="center" rowspan="1" colspan="1">
<xref rid="B174" ref-type="bibr">Zeng et al. (2022)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">PC-12 cells</td><td align="center" rowspan="1" colspan="1">&#8593;ERK/AKT Pathway, PC12<break/>&#8595;Capase3, Caspase7</td><td align="center" rowspan="1" colspan="1">Salidroside</td><td align="center" rowspan="1" colspan="1">
<xref rid="B58" ref-type="bibr">Hu et al. (2024a)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">A&#946;-included mice</td><td align="center" rowspan="1" colspan="1">&#8593;Nrf2/Ho-1 Pathway, Bcl-2<break/>&#8595;Capase3, Bax, LDH</td><td align="center" rowspan="1" colspan="1">Salidroside</td><td align="center" rowspan="1" colspan="1">
<xref rid="B79" ref-type="bibr">Liao et al. (2019)</xref>
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T3" orientation="portrait"><label>TABLE 3</label><caption><p>Regulation of Pyroptosis by active components of traditional Chinese medicine.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">Target of action</th><th align="center" rowspan="1" colspan="1">Experimental subjects</th><th align="center" rowspan="1" colspan="1">Possible mechanisms</th><th align="center" rowspan="1" colspan="1">Natural plant molecules</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td rowspan="4" align="center" colspan="1">Pyroptosis</td><td align="center" rowspan="1" colspan="1">Lipopolysaccharide -induced macrophages</td><td align="center" rowspan="1" colspan="1">&#8593;ARG-1, Microglia (M2)<break/>&#8595;iNOS, Microglia (M1)</td><td align="center" rowspan="1" colspan="1">Sinomenine</td><td align="center" rowspan="1" colspan="1">
<xref rid="B83" ref-type="bibr">Lu et al. (2023)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">A&#946;O-included mice</td><td align="center" rowspan="1" colspan="1">&#8593;PPAR gamma<break/>&#8595;IL-1&#946;, IL-18, GSK-3&#946;, Caspase-1</td><td align="center" rowspan="1" colspan="1">Astragaloside</td><td align="center" rowspan="1" colspan="1">
<xref rid="B118" ref-type="bibr">Shen et al. (2023)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">MPTP-included mice</td><td align="center" rowspan="1" colspan="1">&#8595;NLRP3, IL-1&#946;, Caspase-1</td><td align="center" rowspan="1" colspan="1">Senegenin</td><td align="center" rowspan="1" colspan="1">
<xref rid="B137" ref-type="bibr">Tian et al. (2022)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">A&#946;-included mice<break/>D-galactose-included<break/>Mice and PC12 cells</td><td align="center" rowspan="1" colspan="1">&#8595;NLRP3, Caspase-1</td><td align="center" rowspan="1" colspan="1">Salidroside</td><td align="center" rowspan="1" colspan="1">
<xref rid="B160" ref-type="bibr">Xie et al. (2020)</xref>
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T4" orientation="portrait"><label>TABLE 4</label><caption><p>Regulation of Autophagy by active components of traditional Chinese medicine.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">Target of action</th><th align="center" rowspan="1" colspan="1">Experimental subjects</th><th align="center" rowspan="1" colspan="1">Possible mechanisms</th><th align="center" rowspan="1" colspan="1">Natural plant molecules</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td rowspan="6" align="center" colspan="1">Autophagy</td><td align="center" rowspan="1" colspan="1">APP/PS1 mice</td><td align="center" rowspan="1" colspan="1">&#8593;Pink1/Parkin Pathway, LC3&#8545; &#8595;P62</td><td align="center" rowspan="1" colspan="1">Berberine</td><td align="center" rowspan="1" colspan="1">
<xref rid="B180" ref-type="bibr">Zhang et al. (2023a)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Neonatal mice</td><td align="center" rowspan="1" colspan="1">&#8593;AMPK/mTOR/ULK1 Pathway, ULK1</td><td align="center" rowspan="1" colspan="1">Matrine</td><td align="center" rowspan="1" colspan="1">
<xref rid="B158" ref-type="bibr">Xie et al. (2016)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">MPTP-included mice</td><td align="center" rowspan="1" colspan="1">&#8593;Beclin-1, LC3&#8545;/LC3&#8544;<break/>&#8595;PI3K/AKT/mTOR Pathway, P62</td><td align="center" rowspan="1" colspan="1">Sinomenine</td><td align="center" rowspan="1" colspan="1">
<xref rid="B55" ref-type="bibr">Hou et al. (2024)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">LPS-induced mice</td><td align="center" rowspan="1" colspan="1">&#8593;Pink1/Parkin Pathway, LC3&#8545;/LC3&#8544;, Beclin-1</td><td align="center" rowspan="1" colspan="1">Lycium barbarum polysaccharides</td><td align="center" rowspan="1" colspan="1">
<xref rid="B138" ref-type="bibr">Toldo and Abbate (2024)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">PC12 cells</td><td align="center" rowspan="1" colspan="1">&#8593;PI3K/AKT, Beclin-1</td><td align="center" rowspan="1" colspan="1">Senegenin</td><td align="center" rowspan="1" colspan="1">(<xref rid="B165" ref-type="bibr">Yan et al., 2024</xref>), (<xref rid="B181" ref-type="bibr">Zhang et al., 2023b</xref>)</td></tr><tr><td align="center" rowspan="1" colspan="1">HT22 cells</td><td align="center" rowspan="1" colspan="1">&#8593;LC3&#8545;/LC3&#8544;, Pink1/Parkin Pathway</td><td align="center" rowspan="1" colspan="1">Senegenin</td><td align="center" rowspan="1" colspan="1">
<xref rid="B11" ref-type="bibr">Bieri et al. (2018)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">D-galactose-included<break/>PC12 cells</td><td align="center" rowspan="1" colspan="1">&#8595; PC12 &#8593;LC3&#8545;/LC3&#8544;</td><td align="center" rowspan="1" colspan="1">Icarin</td><td align="center" rowspan="1" colspan="1">
<xref rid="B157" ref-type="bibr">Xiao et al. (2022)</xref>
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T5" orientation="portrait"><label>TABLE 5</label><caption><p>Regulation of Ferroptosis by active components of traditional Chinese medicine.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">Target of action</th><th align="center" rowspan="1" colspan="1">Experimental subjects</th><th align="center" rowspan="1" colspan="1">Possible mechanisms</th><th align="center" rowspan="1" colspan="1">Natural plant molecules</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td rowspan="5" align="center" colspan="1">Ferroptosis</td><td align="center" rowspan="1" colspan="1">3 &#215; Tg-AD mice</td><td align="center" rowspan="1" colspan="1">&#8593;GPX4, FPN1, SLC7A11<break/>&#8595;MDA, ACSL4, ROS</td><td align="center" rowspan="1" colspan="1">Berberine</td><td align="center" rowspan="1" colspan="1">
<xref rid="B150" ref-type="bibr">Wang et al. (2022c)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">D-gal-induced PC-12 cells</td><td align="center" rowspan="1" colspan="1">&#8593;SLC7A11, GPX4<break/>&#8595;ASK1-MKK7-JNK Pathway</td><td align="center" rowspan="1" colspan="1">Ginsenoside</td><td align="center" rowspan="1" colspan="1">
<xref rid="B23" ref-type="bibr">Cui et al. (2021)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">PC-12</td><td align="center" rowspan="1" colspan="1">&#8593;ACSL4, GPX4</td><td align="center" rowspan="1" colspan="1">Senegenin</td><td align="center" rowspan="1" colspan="1">
<xref rid="B77" ref-type="bibr">Li et al. (2023c)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">A&#946;-included mice</td><td align="center" rowspan="1" colspan="1">&#8593;Nrf2/Ho-1, Nrf2/GPX4 Pathway, SLC7A11, GPX4</td><td align="center" rowspan="1" colspan="1">Salidroside</td><td align="center" rowspan="1" colspan="1">(<xref rid="B15" ref-type="bibr">Cai et al., 2021</xref>), (<xref rid="B120" ref-type="bibr">Shuangmei, 2021</xref>)</td></tr><tr><td align="center" rowspan="1" colspan="1">APP/PS1 mice</td><td align="center" rowspan="1" colspan="1">&#8593;DMD2, SLC7A11</td><td align="center" rowspan="1" colspan="1">Icarin</td><td align="center" rowspan="1" colspan="1">
<xref rid="B80" ref-type="bibr">Liu et al. (2018)</xref>
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T6" orientation="portrait"><label>TABLE 6</label><caption><p>Regulation of cuproptosis by active components of traditional Chinese medicine.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">Target of action</th><th align="center" rowspan="1" colspan="1">Experimental subjects</th><th align="center" rowspan="1" colspan="1">Possible mechanisms</th><th align="center" rowspan="1" colspan="1">Natural plant molecules</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td rowspan="3" align="center" colspan="1">Cuproptosis</td><td align="center" rowspan="1" colspan="1">APP/PS1 mice</td><td align="center" rowspan="1" colspan="1">&#8595;P-tau,ROS,GSK-3&#946;</td><td align="center" rowspan="1" colspan="1">Curcumin</td><td align="center" rowspan="1" colspan="1">
<xref rid="B78" ref-type="bibr">Li et al. (2025)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">HT22 cells</td><td align="center" rowspan="1" colspan="1">&#8595;P-tau,ROS</td><td align="center" rowspan="1" colspan="1">Quercetin</td><td align="center" rowspan="1" colspan="1">
<xref rid="B166" ref-type="bibr">Yang et al. (2013)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Tg mice</td><td align="center" rowspan="1" colspan="1">&#8595;P-tau,ROS</td><td align="center" rowspan="1" colspan="1">Epigallocatechin gallate</td><td align="center" rowspan="1" colspan="1">
<xref rid="B117" ref-type="bibr">Shen et al. (2018)</xref>
</td></tr></tbody></table></table-wrap><sec id="s5-1"><title>5.1 Alkaloids (primarily regulate apoptosis and autophagy via &#8220;Nrf2/AMPK/mTOR&#8221;)</title><sec id="s5-1-1"><title>5.1.1 Berberine</title><p>Berberine is a plant metabolites commonly found in rhizome of <italic toggle="yes">Coptis chinensis Franch [</italic>Ranunculaceae<italic toggle="yes">]</italic> and <italic toggle="yes">Scutellaria baicalensis Georgi [</italic>Lamiaceae<italic toggle="yes">]</italic>, Berberine&#8217;s isoquinoline structure enables it to penetrate cell membranes, interact with multiple targets, and exert antioxidant and anti-inflammatory effects. It can also have beneficial effects on neurovascular degeneration by protecting blood vessels. Numerous studies have shown that berberine can reduce A&#946; deposition and the formation of NFTs in A phosphorylated way of Tau protein. It has the ability to cross the blood-brain barrier, reduce inflammation, reduce oxidative damage, protect neurons, and reduce neurotoxicity in the brain. A recent study reported that berberine not only improved cognitive impairment in AD mice, reduced neuronal damage, A&#946; deposition, and Tau hyperphosphorylation, but also increased the expression levels of SOD, GSH, GPX4, FPN1, and SLC7A11, and reduced MDA, ACSL4, and ROS levels by regulating Nrf2 transcription levels. It can effectively reduce the abnormal accumulation of iron in the brain of mice, and finally reduce the deposition of A&#946; (<xref rid="B75" ref-type="bibr">Li et al., 2023a</xref>). A recent study involving the protective effects of &#946;-amyloid-induced neurotoxicity in HT22 cells found that berberine could inhibit apoptosis and intracellular ROS levels, increase mitochondrial membrane potential, and reduce the rates of p-p65/p65, Cytc and Caspase-9/3 cleavage, This may be related to the presence of an electrophilic nitrogen-containing heterocycle and aromatic ring in berberine, which allows it to bind with key intracellular proteins, regulate the cell cycle, and promote cell survival. Thus, berberine inhibited the mitochondrial pathway of cell apoptosis and effectively reduced A&#946; deposition (<xref rid="B180" ref-type="bibr">Zhang R. L. et al., 2023</xref>). In addition, berberine was found to improve cognitive function in AD mice by inducing autophagy and reducing the pathological accumulation of A&#946; and Tau through activating the PINK/Parkin signaling pathway. At the same time, berberine has strong lipophilicity, which can promote the removal of damaged mitochondria and reduce oxidative stress and inflammation, thereby protecting neurons from injury. This finding provides an important theoretical basis for the application of berberine in the treatment of AD (<xref rid="B151" ref-type="bibr">Wang et al., 2023</xref>).</p></sec><sec id="s5-1-2"><title>5.1.2 Huperzine A</title><p>Huperzine A is a highly effective, specific and reversible cholinesterase inhibitor, which is extracted and isolated from <italic toggle="yes">Huperzia serrata (Thunb.) Trevis [</italic>Lycopodiaceae<italic toggle="yes">]</italic>. Due to the presence of a pyridine ring in its structure, it is able to form hydrogen bonds with the acidic amino acids in the active site of acetylcholinesterase, enabling it to bind tightly to the enzyme&#8217;s active site. This interaction inhibits the hydrolysis of acetylcholine, thereby slowing its degradation in the synaptic cleft. As a result, acetylcholine&#8217;s activation of its receptors is enhanced, improving the efficiency of neurotransmission and ultimately contributing to the improvement of cognitive function (<xref rid="B37" ref-type="bibr">Friedli and Inestrosa, 2021</xref>). Huperzine A has been shown to attenuate neuronal apoptosis by reducing ROS generation and Caspase-3 activity in A&#946;25-35 and crissorine induced apoptosis models. This may be due to the strong electron-donating effect of the aromatic ring in its molecule, which can react with free radicals through hydrogen atom donation, thereby reducing the damage caused by free radicals to cells. Huperzine A, due to its aromatic ring structure and nitrogen-containing heterocycle, interacts with specific receptors on the cell membrane, regulating intracellular signaling pathways. It upregulates the anti-apoptotic protein Bcl-2 and downregulates the expression levels of pro-apoptotic factors c-jun, Bax, and P53, further reducing the occurrence of cell apoptosis (<xref rid="B134" ref-type="bibr">Tao et al., 2013</xref>). Other studies have shown that huperzine A may promote the transformation of APP to non-amyloid pathway by activating MAPK signaling pathway, increase the production of soluble APP, and reduce the accumulation of &#946;-amyloid peptide (A&#946;), thus playing a neuroprotective role (<xref rid="B164" ref-type="bibr">Yan et al., 2007</xref>). In addition, huperzine A can also prevent D-galactose induced neurovascular injury and blood-brain barrier dysfunction by preventing nuclear translocation of NF-&#954;B, thus effectively preventing neuronal apoptosis (<xref rid="B158" ref-type="bibr">Xie et al., 2016</xref>). These findings demonstrate the extensive neuroprotective effects of huperzine A across various forms of PCD. This neuroprotection is achieved through its molecular structure, which enables it to interact with different cellular targets and signaling pathways, providing a solid theoretical foundation for its application in AD treatment.</p></sec><sec id="s5-1-3"><title>5.1.3 Matrine</title><p>Matrine is an alkaloid extracted from <italic toggle="yes">Sophora flavescens Aiton [</italic>Fabaceae<italic toggle="yes">]</italic>, which has a variety of pharmacological effects such as anti-apoptosis, anti-oxidation and immune regulation, and is widely used in the treatment of neurodegenerative and cardiovascular diseases. Previous studies have shown that oxidative stress and apoptosis are two key factors in the pathogenesis of AD, and they are both involved in its pathological process. Specifically, the formation of A&#946; and senile plaques can activate oxygen free radicals, leading to A decrease in the activity of antioxidant enzymes such as superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px), thereby reducing the ability to remove malondialdehyde (MDA) and free radicals, initiating neuronal apoptosis, and inhibiting the expression of the anti-apoptotic factor Bcl-2. At the same time, it activates the expression of pro-apoptotic factor Bax, which eventually leads to neuronal dysfunction. The <italic toggle="yes">in vitro</italic> model of PC12 cells induced by A&#946;25-35 showed that the viability of PC12 cells was significantly decreased, and the levels of oxidative stress and apoptosis were increased, suggesting that the occurrence of AD may be closely related to oxidative stress and apoptosis caused by A&#946; deposition. Further studies have shown that the indole ring and nitrogen-containing heterocycle in matrine confer significant lipophilicity, enabling it to traverse cell membranes and interact with specific intracellular receptors and enzymes. The electron-donating properties of the aromatic ring and nitrogen heterocycle allow matrine to donate hydrogen atoms, thereby effectively scavenging peroxides and free radicals within the body. This could effectively inhibit oxidative stress and apoptosis, thereby reducing the damage to PC12 cells induced by A&#946;25-35, suggesting its potential value in the treatment of AD (<xref rid="B175" ref-type="bibr">Zhang et al., 2020</xref>). In addition, matrine can enhance mitophagy by activating AMPK/mTOR/ULK1 signaling pathway, thereby reducing neuronal apoptosis and inflammatory response and improving nerve injuryin rats (<xref rid="B72" ref-type="bibr">Li Aaqi, 2024</xref>). In addition, matrine can inhibit pyroptosis and reduce the release (<xref rid="B83" ref-type="bibr">Lu et al., 2023</xref>) of inflammatory factors in the central nervous system by inhibiting the expression of GSDMD protein.</p></sec><sec id="s5-1-4"><title>5.1.4 Sinomenine</title><p>Sinomenine is an isoquinoline alkaloid extracted from the roots and stems of <italic toggle="yes">Sinomenium acutum (Thunb.) Rehder and E.H.Wilson [</italic>Menispermaceae<italic toggle="yes">]</italic>, and its derivatives have been extensively studied as bioactive agents. Existing studies have shown that sinomenine exerts broad pharmacological effects, including anti-tumor, anti-inflammatory, neuroprotective, and immunosuppressive properties, through the aromatic and nitrogen-containing heterocyclic structures in its molecule. These effects are mediated by its influence on signaling pathways such as PI3K/Akt/mTOR, NF-&#954;B, MAPK, and JAK/STAT. For this reason, sinomenine also plays an important role in cardio-cerebrovascular protection and organ protection through NF-&#954;B, Nrf2, MAPK and PI3K/Akt/mTOR signaling pathways (<xref rid="B55" ref-type="bibr">Hou et al., 2024</xref>). Specifically, sinomenine could inhibit the expression of iNOS, increase the level of ARG-1, and promote the polarization of macrophages from M1 to M2, thereby reducing neuroinflammation. At the same time, sinomenine could increase the expression of type II collagen and aggrecan, reduce the level of ROS and MDA, increase the activity of SOD, enhance the antioxidant capacity of the body, and inhibit cell apoptosisby down-regulating the expression of Bax, Caspase-3, MMP-2/9 and iNOS (<xref rid="B54" ref-type="bibr">Hou et al., 2022</xref>). In addition, sinomenine can inhibit the PI3K/Akt/mTOR pathway, upregulate the ratio of Beclin1 and LC3-II/LC3-I and downregulate the expression of P62, promote the autophagy of dopaminergic neurons to improve the activity of neurons, and exert its potential pharmacological effects (<xref rid="B5" ref-type="bibr">Bao et al., 2024</xref>).</p></sec></sec><sec id="s5-2"><title>5.2 Polysaccharides (primarily regulate apoptosis, autophagy and ferroptosis via &#8220;Nrf2/Pink1/GPX4&#8221;)</title><sec id="s5-2-1"><title>5.2.1 Lycium barbarum polysaccharide</title><p>Lycium barbarum polysaccharide is a water-soluble polysaccharide extracted from <italic toggle="yes">Lycium chinense Mill [</italic>Solanaceae<italic toggle="yes">]</italic>,which is considered to be the commonly metabolite in <italic toggle="yes">L. chinense Mill [</italic>Solanaceae<italic toggle="yes">]</italic>. Lycium barbarum polysaccharide are composed of various monosaccharide units, such as glucose, mannose, arabinose, and galactose, which are linked by specific glycosidic bonds to form polysaccharide chains with a defined spatial conformation. This intricate structure endows the polysaccharides with a range of biological activities, including antioxidant, anti-apoptotic, autophagy-inducing, and neuroprotective effects. Specifically, Lycium barbarum polysaccharide contain multiple hydrogen bond donors and electron-donating groups that can interact with free radicals, thereby exhibiting strong antioxidant activity. This enables them to effectively scavenge free radicals and concurrently inhibit various forms of PCD. Previous studies have shown that LBP can effectively inhibit oxidative stress in the hippocampus and significantly improve scopolamine-induced cognitive and memory impairment by reducing the ratio of Bax/Bcl-2 (<xref rid="B186" ref-type="bibr">Zhao et al., 2017</xref>). Current studies have shown that LBP exhibits protective effects against neurotoxicity by up-regulating Nrf2/HO-1 signaling, and the enhancement of Nrf2/HO-1 signaling helps to inhibit HO<sub>2</sub>-induced<sub>2</sub> PC12 cell damage while ameliorating oxidative stress and ameliorating apoptosis (<xref rid="B17" ref-type="bibr">Cao et al., 2017</xref>). In addition, LBP also showed a significant neuroprotective effect on glutamate-induced apoptosis. Further studies showed that LBP played a protective role against neurotoxicity by up-regulating the Nrf2/HO-1 signaling pathway, which helped to improve oxidative stress and cell apoptosis (<xref rid="B63" ref-type="bibr">Jiang et al., 2023</xref>). By (<xref rid="B190" ref-type="bibr">Zhenghao et al., 2024</xref>) activating SLC7A11/GPX4 signaling pathway, LBP also enhanced GPX4 activity, reduced ferroptosis induced by lipid peroxidation, and reduced A&#946; deposition. In the brain tissue of AD patients, the disorder of mitophagy leads to mitochondrial morphology, structure and function abnormalities, which in turn leads to cell damage and neuronal death (<xref rid="B188" ref-type="bibr">Zhao et al., 2024</xref>). Furtherstudies have shown that with the disorder of autophagy function in vivo, excessive &#946;-amyloid (A&#946;) protein is observed in the brain of AD patients, suggesting that the disorder of mitophagy may be closely related to the pathogenesis and progression of AD (<xref rid="B142" ref-type="bibr">Um et al., 2024</xref>). In a study on the effect of &#946;1-42 on the activity of SH-SY5Y cells, it was found that the protein expressions of Pink1, Parkin, LC3-II/LC3-I and Beclin-1 were significantly increased, while P62 protein expression was decreased after intervention with LBP. These results suggest that LBP may reduce the damage of SH-SY5Y cells induced by A&#946; 1&#8211;42 and maintain the metabolic balance by regulating mitophagy through its unique sugar chain structure, which has potential important significance for the prevention of AD (<xref rid="B106" ref-type="bibr">Qin et al., 2025</xref>).</p></sec><sec id="s5-2-2"><title>5.2.2 Astragalus polysaccharide</title><p>Astragalus membranaceus is the dried root of the leguminous plant <italic toggle="yes">Astragalus mongholicus Bunge [</italic>Fabaceae<italic toggle="yes">]</italic>,which has the functions of tonifying qi, rising Yang, solidifying surface, antiperspirating, and reducing swelling. Astragalus polysaccharide a representative metabolite present in <italic toggle="yes">stragalus mongholicus Bunge [</italic>Fabaceae<italic toggle="yes">]</italic>. As one of the common metabolites, Astragalus polysaccharide has shown a variety of biological effects in the central nervous system, such as anti-inflammatory, anti-oxidation, immunomodulation and neuroprotection. Studies have shown that astragalus polysaccharides can activate the Nrf2 signaling pathway through its unique sugar chain structure, promoting its translocation to the nucleus and inhibiting its expression in the cytoplasm. This process restoring the expression levels of Keap1, SOD, GSH-Px and MDA, and significantly reducing cell apoptosis and A&#946; deposition. It can also significantly improve the cognitive ability of APP/PS1 mice (<xref rid="B105" ref-type="bibr">Qin et al., 2020</xref>). In a study on metabolic stress in AD, Astragalus polysaccharide not only significantly reversed the abnormal body weight and insulin level, but also improved the overall metabolic status. It also reduced the number of activated microglia and astrocytes around amyloid plaques, thereby reducing neuroinflammation. Notably, Astragalus polysaccharidedid not directly reduce A&#946; deposition, but rather improved the behavioral performanceof AD mice by counteracting metabolic stress and ameliorating metabolic stress-induced neuroinflammation (<xref rid="B60" ref-type="bibr">Huang et al., 2017</xref>). In addition, aging is an important factor that increases the risk of neurodegenerative diseases such as AD. In an anti-aging experiment in <italic toggle="yes">Drosophila</italic>, it was found that the &#946;-1,3-glucan in astragalus polysaccharides can bind to important Toll-like receptors in the immune system, which significantly alleviate intestinal homeostasis imbalance, improve sleep disorders, and protect neurons by rescuing aging-induced JAK/STAT, Toll and IMD pathways, downregulating the expression of Cyt C and Caspase-3/9, and reducing apoptosis. It can also delay the onset of AD phenotype in A&#946;42-induced AD flies (<xref rid="B76" ref-type="bibr">Li et al., 2023b</xref>).</p></sec></sec><sec id="s5-3"><title>5.3 Saponins (primarily regulate apoptosis, pyroptosis and autophagy via &#8220;STAT/PI3K//Pink1&#8221;)</title><sec id="s5-3-1"><title>5.3.1 Astragaloside</title><p>Saponins can promote the growth and development of human immune organs through a variety of signaling pathways, regulate the activity of immune cells, and increase the secretion of immune-related cytokines and specific antibodies. The potential pharmacological effects of saponins on the central nervous system have been a research hotspot (<xref rid="B118" ref-type="bibr">Shen et al., 2023</xref>). <italic toggle="yes">Astragalus mongholicus Bunge [</italic>Fabaceae<italic toggle="yes">]</italic> is a commonly used traditional Chinese medicine for the treatment of AD. Astragalosides, among the mainly metabolites of astragalus membranaceus, have various biological functions such as regulating immunity, anti-oxidation, anti-apoptosis and inhibiting neurotoxins. Astragaloside, include astragaloside &#8544;, astragaloside &#8545;, astragaloside &#8546; and astragaloside &#8547;, among these, Astragaloside IV demonstrates the most optimal biological activity due to the synergistic effect of its extended sugar chain structure and the triterpene aglycone portion (<xref rid="B26" ref-type="bibr">Dai et al., 2020</xref>). Although this metabolite is frequently studied in the context of TCM, it is also present in other medicinal plants beyond TCM use, highlighting its broader pharmacological significance. Studies have shown that astragaloside &#8547;, as A selective natural PPAR&#947; agonist, inhibits BACE1 activity by activating and upregulating the expression of PPAR&#947;, thereby enhancing the phagocytosis of A&#946; and reducing the release of cytokines, ultimately reducing the level of A&#946; in APP/PS1 mouse model (<xref rid="B118" ref-type="bibr">Shen et al., 2023</xref>). In addition, Wang et al. found that astragaloside &#8547; can effectively block A&#946;o-induced neuronal pyroptosis and has A high binding affinity with pyroptosis-related protein Caspase-1, further revealing the specific mechanism of astragaloside &#8547; in pyroptosis and its potential application value in the prevention and treatment of AD (<xref rid="B147" ref-type="bibr">Wang et al., 2021</xref>).</p></sec><sec id="s5-3-2"><title>5.3.2 Ginsenoside</title><p>
<italic toggle="yes">Panax ginseng C.A.Mey [</italic>Araliaceae<italic toggle="yes">]</italic>. belongs to the family Araliaceae and comprises a group of plants with significant medicinal properties. As a common tonic traditional Chinese medicine, ginseng has a variety of pharmacological effects such as anti-fatigue, anti-virus and anti-oxidation. Ginsenoside, the main metabolites in ginseng, has been shown to have significant neuroprotective effects in animal and cell model studies (<xref rid="B86" ref-type="bibr">Luong et al., 2021</xref>). Ginsenosides can be divided into three groups according to differences in their chemical skeletons (aglycones) and sugar chain attachment sites:protopanaxtriol type (PPT; They include ginsenosides Rg1, Re, Rg2, Rh1, and Rf), protoginsenosides (PPD; Including ginsenoside Rb1, Rb2, Rd, Rg3, and Rh2) and oleanolic acid derivative forms (e.g., ginsenoside Ro) (<xref rid="B52" ref-type="bibr">Hou et al., 2017</xref>). After deglycosylation, protopanaxadiol-type ginsenosides Rd and Rb1 exhibit increased lipophilicity, enabling them to directly insert into cellular and mitochondrial membranes, thereby altering membrane lipid fluidity and lipid raft architecture. These changes can further influence the localization and conformation of membrane-associated proteins, such as members of the Bcl-2 family, TLR4, and TNFR, ultimately facilitating the regulation of key signaling pathways involved in apoptosis, autophagy, and inflammation. Caspase family is involved in the pathological process of neuronal apoptosis in AD. Studies have shown that ginsenoside Rd, Rb1 and Rg1 can effectively alleviate neuronal apoptosisinduced by hydrogen peroxide and &#946;-amyloid protein (A&#946;) by down-regulating the protein levels of Caspase-3 and Caspase-9 and increasing the ratio of Bcl-2/Bax (<xref rid="B52" ref-type="bibr">Hou et al., 2017</xref>; <xref rid="B33" ref-type="bibr">Fernandez-Moriano et al., 2017</xref>). In addition, ginsenoside Rb2, with reduced total sugar residues and decreased molecular polarity, exhibits enhanced lipophilicity, which enables it to more readily interact with cellular and mitochondrial membranes. This structural property facilitates its modulation of intracellular signaling cascades. Specifically, Rb2 has been shown to alleviate glutamate-induced neurotoxicity by suppressing the activation of p38 and preventing the translocation of Apoptosis Inducing Factor (AIF) within the mitogen-activated protein kinase (MAPK) signaling pathway. Through these mechanisms, Rb2 not only reduces neuronal apoptosis but also preserves mitochondrial integrity, thereby highlighting the critical role of its structural features in conferring neuroprotective effects.In addition, ginsenoside Rb2 can upregulate the expression of anti-apoptotic gene Bcl-2, reduce the level of pro-apoptotic gene Bax, and inhibit the apoptosis of cells mediated by AIF, so as to play a neuroprotective role and achieve the effectof treating AD. (<xref rid="B67" ref-type="bibr">Kim et al., 2019</xref>) CUI et al. showed that ginsenoside Rg2 can activate the PI3K/Akt signaling pathway in the hippocampus of AD rats induced by A&#946;25-35, significantly increase the ratio of Bcl-2 to Bax in the hippocampus, and reduce the expression level of Caspase, thereby effectively improving the learning and memory ability of AD rats (<xref rid="B23" ref-type="bibr">Cui et al., 2021</xref>). In addition to its intervention effect on apoptosis, more and more studies have pointed out that the accumulation of autophagosomes in hippocampus and cortical axons leads to the block of autophagic flow and the failure of autophagosomes to properly fuse with the lysosomes around the cell body in the early stages of AD. Therefore, enhancing autophagy is considered to be a promising therapeutic strategy to deal with the toxicity of misfolded proteins. The protopanaxadiol-type metabolite ginsenoside CK, characterized by its low number of sugar moieties and high lipophilicity, can readily embed into membrane structures and induce oxidative modification of Keap1, thereby releasing Nrf2. This activation of the Nrf2/Keap1 signaling pathway upregulates antioxidant enzymes, enhances the cellular capacity to eliminate reactive oxygen species (ROS), and confers antioxidant and cytoprotective effects, ultimately improving memory function in AD mouse models (<xref rid="B167" ref-type="bibr">Yang et al., 2019</xref>). In addition, ginsenoside CK can also inhibit the ASK1-MKK7-JNK signaling pathway, reduce the expression of ferroptosis marker Ptgs2, and upregulate key proteins such as SLC7A11 and GPX4 to reduce the accumulation of unstable iron in the brain, thereby inhibiting ferroptosis, which helps to prevent and improve the occurrence and development of AD (<xref rid="B165" ref-type="bibr">Yan et al., 2024</xref>).</p></sec><sec id="s5-3-3"><title>5.3.3 Senegenin</title><p>Senegenin is the common bioactive components of <italic toggle="yes">Polygala tenuifolia Willd [</italic>Polygalaceae<italic toggle="yes">],</italic>which belong to the structure of pentocyclic triterpene saponins. The chemical properties of most senugenin are unstable, and it is easy to hydrolyze into senugenin, senugenin, polygallic acid, polygalactosenoside and various sugar groups under external conditions (<xref rid="B181" ref-type="bibr">Zhang L. et al., 2023</xref>). Because of its significant anti-aging and antioxidant pharmacological effects, Senegenin play a key role in the prevention and treatment of AD and related mechanisms. Studies have shown that Senegenin may interfere with pyroptosis, autophagy and ferroptosis through a variety of mechanisms, thereby effectively preventing and treating AD. With the development of AD, A&#946;1-42 activates the PI3K/Akt signaling pathway in neuronal cells, leading to A significant decrease in autophagy function and the expression of Beclin-1, affecting the formation of autophagosomes, and further aggravating neuronal cell damage. At the same time, insufficient autophagy flux in the brain further leads to mitochondrial damage and A&#946; protein deposition, which ultimately impairs cognitive function (<xref rid="B111" ref-type="bibr">Ren et al., 2022</xref>; <xref rid="B11" ref-type="bibr">Bieri et al., 2018</xref>). As an important component of autophagosome, LC3-II is closely related to autophagic flux (<xref rid="B144" ref-type="bibr">Wan et al., 2023</xref>). Senegenin predominantly possesses an oleanane/oleanolic-type triterpenoid aglycone skeleton, characterized by a hydrophobic plane that facilitates interaction with membrane phospholipids, lipid rafts, and cholesterol-rich microdomains. Deglycosylation and deacylation increase lipophilicity and enhance blood&#8211;brain barrier permeability; upregulate the expression of PINK1 and Parkin in neurons, promote the localization of Parkin in mitochondria, activate autophagy, and ultimately reduce the secretion of A&#946; (<xref rid="B137" ref-type="bibr">Tian et al., 2022</xref>). In addition, according to its structure senegenin can inhibit pyroptosis and delay the progression of AD. Studies have shown that senegenin can cross the blood-brain barrier and upregulate the expression of SHP-2, thereby inhibiting the activation of NLRP3 and reducing the release of IL-1&#946; (<xref rid="B101" ref-type="bibr">Pellegrini et al., 2019</xref>). Fan.et al.further confirmed that senegenin significantly reduced the expression and activation of pyroptosis factors NLRP3, Pro-caspase-1, Caspase-1, Pro-IL-1&#946; and IL-1&#946;, effectively inhibited pyroptosis and improved the symptoms of AD (<xref rid="B32" ref-type="bibr">Fan et al., 2017</xref>). The study found that exist in the brain iron deposition in patients with AD and iron balance the typical pathological features (<xref rid="B48" ref-type="bibr">Hannn Q. et al., 2023</xref>). A number of studies have shown that senegenin as the principal metabolites of <italic toggle="yes">P. tenuifolia Willd</italic>, polygalasaponins possess multiple glycosidic chains and galloyl substituents that confer substantial antioxidant capacity. Upon hydrolysis, the resulting aglycones or secondary metabolites more readily penetrate the nucleus and mitochondria, where they modulate oxidative stress. Through these actions, senegenin effectively suppress ferroptotic signaling cascades in neurons and thereby exert neuroprotective effects against AD. Importantly, these activities are closely associated with their structural features, as the balance between glycosylation, acyl substitution and aglycone exposure determines lipophilicity and the magnitude of their antioxidant and anti-ferroptotic effects (<xref rid="B77" ref-type="bibr">LI C. et al., 2023</xref>; <xref rid="B187" ref-type="bibr">Zhao et al., 2023</xref>). Experimental studies have shown that senegenin can inhibit the ferroptosis pathway in PC12 cells, significantly upregulate the expression of ferroptosis related proteins SLC7A11 and GPX4 in the brain of AD mice, prevent the occurrence of ferroptosis, correct the abnormal iron metabolism, and play A neuroprotective role in AD mice (<xref rid="B179" ref-type="bibr">Zhang H. et al., 2022</xref>).</p></sec></sec><sec id="s5-4"><title>5.4 Flavonoid (primarily regulate apoptosis and ferroptosis via &#8220;Nrf2/Ho-1/GPX4&#8221;)</title><sec id="s5-4-1"><title>5.4.1 Icariin</title><p>
<italic toggle="yes">Epimedium brevicornu Maxim [</italic>Berberidaceae<italic toggle="yes">]</italic> is a perennial herb of Epimedium genus in Berberidaceae, which has the functions of toning liver and kidney, strengthening muscles and bones, eliminating wind and dampness, and invigorating essence and qi. Studies have shown that the extracts of <italic toggle="yes">E. brevicornu Maxim</italic> contain more than 260 metabolites, among which the main metabolites icariin has been shown to have significant antioxidant, anti-inflammatory and immunomodulatory effects (<xref rid="B135" ref-type="bibr">Tao et al., 2021</xref>). Recent studies have further revealed the potential of icariin in the treatment of central nervous system diseases, such as AD, Parkinson&#8217;s disease and ischemic stroke, and its mechanism involves multi-target and multi-pathway neuroprotective effects (<xref rid="B174" ref-type="bibr">Zeng et al., 2022</xref>). Specifically, icariin exhibits amphiphilic properties due to the balance between its methoxy group and glycosidic moieties, whereby the methoxy substitution (-OCH3)enhances lipophilicity while the glycosidic chains increase hydrophilicity. This amphiphilic nature enables icariin to embed into the mitochondrial membrane, thereby maintaining its structural integrity and stabilizing the mitochondrial membrane potential (&#916;&#968;m). In addition, icariin upregulates the BDNF/TrkB/CREB signaling pathway, promoting the expression of brain-derived neurotrophic factor (BDNF) and its receptor tropomyosin receptor kinase B (TrkB), as well as enhancing the levels of phosphorylated cAMP response element-binding protein (p-CREB). Through these mechanisms, icariin effectively reverses A&#946;25&#8211;35-induced neuronal apoptosis, reduces the number of TUNEL-positive cells, and prevents the activation of the apoptotic signaling cascade (<xref rid="B80" ref-type="bibr">Liu et al., 2018</xref>). Icariin can effectively inhibit cell apoptosisin AD by restoring the inhibited Wnt/&#946;-catenin signaling pathway, up-regulating the expression of Wnt-3a and promoting the phosphorylation of GSK-3&#946; at Ser-9 (<xref rid="B157" ref-type="bibr">Xiao et al., 2022</xref>). In a study on the effect of icariin on the neurobehavioral ability of AD mice and its mechanism, it was found that ferroptosis was activated in AD model mice. Further studies have demonstrated that the hydroxyl groups at the C-5 and C-4&#8242; positions of icariin confer antioxidant capacity, functioning as hydrogen donors to scavenge free radicals, thereby inhibiting mitochondrial lipid peroxidation and iron-driven lipid peroxidation chain reactions to attenuate ferroptosis, ultimately ameliorating cognitive deficits and behavioral abnormalities in mice. In addition, recent evidence has identified MDM2 as a potential key molecular target of icariin, through which it upregulates the expression of SLC7A11 and suppresses neuronal ferroptosis, thereby providing a plausible mechanistic basis for the prevention and treatment of Alzheimer&#8217;s disease. (<xref rid="B171" ref-type="bibr">Yang Y. et al., 2023</xref>). In addition, icariin can significantly improve neurological dysfunction, effectively prevent D-galactose (D-gal) -induced cell damage and apoptosis, and block the opening of mitochondrial permeability transition pore (mPTP) to improve mitochondrial dysfunction and inhibit excessive mitophagy (<xref rid="B58" ref-type="bibr">Hu S. S. et al., 2024</xref>).</p></sec><sec id="s5-4-2"><title>5.4.2 Salidroside</title><p>Salidroside is a metabolite extracted from the root and stem of the medicinal plant <italic toggle="yes">Rhodiola rosea L [</italic>Crassulaceae<italic toggle="yes">]</italic> It has a variety of pharmacological effects such as anti-fatigue, anti-aging, immune regulation and free radical scavenging. Salidroside possesses a p-hydroxyphenylethanol aglycone as its core skeleton, in which the phenolic hydroxyl group (&#8211;OH) functions as a hydrogen atom/electron donor to directly scavenge reactive oxygen species (ROS) and free radicals, thereby inhibiting lipid peroxidation. Moreover, the synergistic contribution of its phenolic hydroxyl group (electron-donating) and glycosidic moiety (&#8211;Glc) endows salidroside with amphiphilic properties, enabling it to exert pharmacological effects not only in aqueous environments (e.g.,.cytosol, plasma) but also in membrane-associated environments (e.g., cellular membranes, mitochondrial membranes, lipid rafts). This amphiphilicity facilitates both antioxidant defense and modulation of redox-sensitive signaling pathways, underscoring the critical structure&#8211;activity relationship (SAR) underlying its neuroprotective and cytoprotective activities. Xie et al. reported that salidroside exhibits significant potential in attenuating oxidative stress and inflammatory injury in neuronal cells, which is largely attributable to its p-hydroxyphenylethanol aglycone. The phenolic hydroxyl group (&#8211;OH) within this scaffold serves as a hydrogen atom/electron donor, directly scavenging ROS and free radicals and thereby suppressing lipid peroxidation, while the attached glucose moiety improves hydrophilicity and bioavailability, enabling systemic distribution. Through these structural features, salidroside enhances intestinal mucosal integrity and reduces circulating granulocyte&#8211;macrophage colony-stimulating factor levels, thereby modulating peripheral circulation (<xref rid="B160" ref-type="bibr">Xie et al., 2020</xref>). Preliminary studies further demonstrated that salidroside attenuates apoptosis in PC12 cells by inhibiting caspase-3/7 activity and activating ERK1/2 and Akt signaling pathways (<xref rid="B79" ref-type="bibr">Liao et al., 2019</xref>). Consistently, salidroside reduces lactate dehydrogenase (LDH) release, lowers malondialdehyde (MDA) and ROS levels, elevates superoxide dismutase (SOD) activity, and stabilizes mitochondrial membrane permeability. Cai et al. investigated its potential in slowing the progression of AD and revealed that the antioxidant capacity conferred by its phenolic hydroxyl groups contributes to the suppression of NLRP3 inflammasome activation and the release of downstream proinflammatory cytokines (<xref rid="B15" ref-type="bibr">Cai et al., 2021</xref>). This inhibition of pyroptosis alleviates D-galactose-induced memory deficits and hippocampal neuronal injury by directly targeting the NLRP3/caspase-1 signaling pathway. Moreover, the amphiphilic nature derived from the synergy between the phenolic hydroxyl group and glycosidic moiety allows salidroside to restore primary neuronal morphology, enhance cell viability, decrease LDH release, increase the Bcl-2/Bax ratio, reduce caspase-3 expression, and activate the Nrf2/HO-1 signaling pathway, thereby mitigating neuronal apoptosis (<xref rid="B120" ref-type="bibr">Shuangmei, 2021</xref>). Yang provided compelling evidence that the same structural features also underlie its ability to activate the Nrf2/HO-1 pathway, thereby inhibiting ferroptosis in AD model mice and HT22 cells (<xref rid="B170" ref-type="bibr">Yang S. et al., 2022</xref>). Subsequent studies further confirmed that salidroside modulates the Nrf2/GPX4 axis, upregulating SLC7A11 and GPX4 expression, which effectively suppresses neuronal ferroptosis (<xref rid="B172" ref-type="bibr">Yang S. et al., 2023</xref>). Collectively, these findings underscore that the pharmacological activities of salidroside&#8212;including anti-apoptotic, anti-pyroptotic, and anti-ferroptotic effects&#8212;are intimately linked to its structural characteristics, providing a mechanistic basis for its neuroprotective role in AD.</p></sec></sec></sec><sec sec-type="conclusion" id="s6"><title>6 Conclusion</title><p>Traditional Chinese medicine natural products come from a wide range of sources. Although these medicinal ingredients are also found in fruits and vegetables, their content is particularly abundant in a variety of plants and herbs. Thousands of years ago, various countries around the world had recognized the therapeutic effects of these natural products through medical practice, including the use of plants and animals in pharmacological and dietary therapies. In recent years, with the continuous deepening of research and the continuous advancement of technology, countries such as China, Korean, Japan, and India, among others, have paid particular attention to traditional Chinese herbal medicines and their shared metabolites, many of which are enriched in TCM, Kampo, and Ayurveda traditions, thus serving as valuable resources for new drug development in a global ethnopharmacological context&#8221;. In Korean medicine, the unique Ginsenoside Rg3 of red ginseng and curcumin in Indian Ayurvedic medicine play significant roles in promoting autophagy, clearing A&#946;, inhibiting tau phosphorylation, and reducing neuroinflammation and apoptosis. For the use of compound decoction, the ginsenosides and astragalosides in the Buzhongyiqi Decoction (China/Korea) can significantly reduce the expression level of A&#946;42 in the cerebral cortex. The standardized extract of Ginkgo biloba (China/EU) can inhibit the phosphorylation of tau protein. The Icariin, 2,3,5,4&#8242;-tetrahydroxyldiphenylethylene-2-O-glucoside (TGSH) and Senegenin in the Bushentiansui Decoction (China) can inhibit cell apoptosis and restore memory. Whether derived from traditional Chinese medicine, Korean medicine, or other global traditional medical systems, traditional Chinese herbal medicine and its metabolites are valuable resources for combating Alzheimer&#8217;s disease. Although these have complex and multifaceted regulatory mechanisms for various forms of PCD, their potential as therapeutic agents for AD remains indisputable.</p><p>Previous studies have clearly indicated that both senile plaques formed by excessive deposition of A&#946; and NFTs formed by excessive phosphorylation of Tau protein are closely associated with PCD. Although a large number of experiments have supported this view, most studies have mainly focused on regulating apoptosis and autophagy. In contrast, there are relatively few studies on targeted regulation of other forms of PCD, such as pyroptosis, necroptosis, ferroptosis, cuproptosis, <italic toggle="yes">etc.</italic>, and the crosstalk relationships among various forms of PCD. Therefore, based on this, this paper clarifies the bidirectional pathological relationships between various forms of PCD and AD, and explains the crosstalk relationships among various forms of PCD with autophagy as the core. In addition, this study further clarifies that a certain traditional Chinese medicine natural product has the ability to multi-target and multi-dimensionally regulate various forms of PCD and their related signaling pathways in AD, thereby improving AD, indicating its potential for treating and preventing AD. For example, berberine listed in this paper can improve AD by inhibiting apoptosis, autophagy, and ferroptosis, and salidroside can improve AD by inhibiting apoptosis, pyroptosis, and ferroptosis.</p><p>Through research, it has been demonstrated that the efficacy of traditional Chinese medicine natural products in modulating PCD is closely associated with drug concentration. Specifically, berberine suppresses ferroptosis in HT22 cells at 30&#8211;60&#160;&#956;M and exhibits optimal anti-apoptotic activity in PC12 cells at 50&#8211;200&#160;&#956;M (<xref rid="B59" ref-type="bibr">Hu F. et al., 2024</xref>; <xref rid="B107" ref-type="bibr">Huang et al., 2022</xref>); salidroside shows the strongest effects at 40&#160;&#956;M in HT22 cells and 50&#160;mg/kgd in A&#946;1&#8211;42-induced mice; ginsenosides such as Rg1 and Rd are most effective at 5&#8211;10&#160;&#956;M, whereas Rb1 demonstrates maximal anti-apoptotic protection at 10&#160;nmol/L compared with weaker effects at both 0.1&#160;nmol/L and 1&#160;&#956;M (<xref rid="B84" ref-type="bibr">Luo, 2024</xref>). It is noteworthy that in certain experimental studies, it has been observed that specific traditional Chinese medicine natural products exhibit optimal efficacy at high doses. For instance, in the context of enhancing cell apoptosis, the Bcl-2/Bax ratio was found to be the highest in the high-dose group of tenuigenin (<xref rid="B166" ref-type="bibr">Yang et al., 2013</xref>). In addition, the effectiveness of traditional Chinese medicine natural products is not only dose-dependent but may also be influenced by the duration of use. Therefore, during application, it is crucial to avoid excessive dosages or prolonged usage to mitigate the risk of adverse reactions and toxic side effects. Moreover, cuproptosis represents a relatively novel form of PCD. Consequently, the mechanisms by which Plant metabolites regulate PCD remain incompletely understood, and effective therapeutic agents targeting this pathway are scarce. According to current research, cuproptosis is closely associated with elevated ROS levels. Experimental evidence demonstrates that curcumin, quercetin, and epigallocatechin gallate (EGCG) suppress cuproptosis <italic toggle="yes">via</italic> antioxidant pathways (<xref rid="B78" ref-type="bibr">Li et al., 2025</xref>; <xref rid="B117" ref-type="bibr">Shen et al., 2018</xref>; <xref rid="B128" ref-type="bibr">Sun et al., 2017</xref>; <xref rid="B112" ref-type="bibr">Rezai-Zadeh et al., 2008</xref>). Thus, we hypothesize that TCM-derived natural metabolites with antioxidant properties and the capacity to inhibit ROS expression may possess potential for inhibiting cuproptosis in cells, thereby contributing to the prevention and treatment of AD.</p><p>In conclusion, despite the intricate and multifaceted regulatory mechanisms of traditional Chinese medicine natural products on various forms of PCD, their efficacy as therapeutic agents for AD remains compelling. To ensure scientific rigor, we have summarized the minimum effective concentrations (MECs), representative dose ranges, and optimal concentrations of the major metabolites discussed in this review in a supplementary table, rather than repeating them in each section. This provides a unified methodological basis for all efficacy claims, highlighting that these pharmacological activities are strictly dependent on structure&#8211;activity relationships (SAR) and experimentally defined doses (<xref rid="T7" ref-type="table">Table 7</xref>). By targeting pathways such as apoptosis, autophagy, necroptosis, ferroptosis, and cuproptosis, they can mitigate amyloid-&#946; deposition, reduce neurotoxicity, protect neurons from damage, and thereby alleviate the pathological hallmarks of AD. These findings have been corroborated through animal and cellular experiments. Currently, the mechanistic investigations linking AD to PCD modes like apoptosis, autophagy, and ferroptosis are relatively comprehensive, and the regulatory effects of TCM natural products on these three canonical forms of PCD have been extensively explored. However, the investigation into emerging novel PCD mechanisms, such as cuproptosis, panoptosis, and disulfidoptosis, remains limited. The connections between these mechanisms and AD, as well as the modulatory effects of natural products from traditional Chinese medicine on them, warrant further exploration. Another issue is the different parts of the same traditional Chinese medicine, or the different components of the same traditional Chinese medicine. Comparative studies are needed to determine which type of traditional Chinese medicine is more effective, such as astragalus polysaccharides and astragalus saponins, among different components of the same herb. In the future, we will focus on elucidating the specific role of cuproptosis in the pathogenesis of AD and how natural products from traditional Chinese medicine regulate cuproptosis to prevent and treat this condition. Additionally, in addition to cell programmed death, Alzheimer&#8217;s disease is associated with aging, family inheritance, neuroinflammation, vascular factors and even excessive exposure to environmental pollutants and unhealthy lifestyle. We will continue to explore more natural products of Traditional Chinese medicine with potential therapeutic effects, and adopt emerging experimental tools such as single-cell omics tools, <italic toggle="yes">in vivo</italic> biosensor technology, gene editing and microfluidic chip technology to provide more effective options for the prevention and treatment of Alzheimer&#8217;s disease with TCM natural products and explore deeper potential effects. By integrating molecular docking and network pharmacology approaches, we aim to enhance treatment efficacy and improve the quality of life for patients with AD.</p><table-wrap position="float" id="T7" orientation="portrait"><label>TABLE 7</label><caption><p>Representative plant metabolites regulating PCD in AD: pharmacological parameters and mechanisms.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">Metabolite</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">In vitro</italic> models &amp; mechanisms</th><th align="center" rowspan="1" colspan="1">Effective concentration range</th><th align="center" rowspan="1" colspan="1">Optimal concentration</th><th align="center" rowspan="1" colspan="1">Optimal <italic toggle="yes">in vivo</italic> dosage</th><th align="center" rowspan="1" colspan="1">Duration</th><th align="center" rowspan="1" colspan="1">Key pathways and proteins</th><th align="center" rowspan="1" colspan="1">Reference</th></tr></thead><tbody valign="top"><tr><td align="center" rowspan="1" colspan="1">Berberine</td><td align="center" rowspan="1" colspan="1">HT22 (erastin-induced ferroptosis)<break/>PC12/N2a (A&#946;, apoptosis)</td><td align="center" rowspan="1" colspan="1">30&#8211;200&#160;&#956;M</td><td align="center" rowspan="1" colspan="1">60&#160;&#956;M (ferroptosis)<break/>50&#8211;200&#160;&#956;M (apoptosis)</td><td align="center" rowspan="1" colspan="1">30&#8211;50&#160;mg/kg&#183;d (AD mice)</td><td align="center" rowspan="1" colspan="1">2&#8211;4 weeks</td><td align="center" rowspan="1" colspan="1">Nrf2&#8211;HO-1/GPX4, AMPK, Bcl-2/Bax, caspase-3</td><td align="center" rowspan="1" colspan="1">
<xref rid="B107" ref-type="bibr">Huang et al. (2022)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Sinomenine</td><td align="center" rowspan="1" colspan="1">PC12 (H<sub>2</sub>O<sub>2</sub> oxidative stress, apoptosis)</td><td align="center" rowspan="1" colspan="1">0.1&#8211;5&#160;&#956;M</td><td align="center" rowspan="1" colspan="1">1&#8211;2&#160;&#956;M</td><td align="center" rowspan="1" colspan="1">30&#8211;90&#160;mg/kg&#183;d (AD mice)</td><td align="center" rowspan="1" colspan="1">1&#8211;3 weeks</td><td align="center" rowspan="1" colspan="1">Nrf2,NF-&#954;B, MAPK, caspase-3</td><td align="center" rowspan="1" colspan="1">
<xref rid="B121" ref-type="bibr">Shukla and Sharma (2011)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Matrine</td><td align="center" rowspan="1" colspan="1">PC12 (A&#946;25&#8211;35 apoptosis)<break/>N2a (oxidative stress)</td><td align="center" rowspan="1" colspan="1">10&#8211;50&#160;&#956;M</td><td align="center" rowspan="1" colspan="1">20&#8211;30&#160;&#956;M</td><td align="center" rowspan="1" colspan="1">10&#8211;40&#160;mg/kg&#183;d (AD mice)</td><td align="center" rowspan="1" colspan="1">2&#8211;6 weeks</td><td align="center" rowspan="1" colspan="1">ROS,Bcl-2/Bax, caspase-3, PI3K/Akt</td><td align="center" rowspan="1" colspan="1">
<xref rid="B61" ref-type="bibr">Jiang and Wang (2020)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Astragalosides (AS-IV)</td><td align="center" rowspan="1" colspan="1">SH-SY5Y (6-OHDA-induced apoptosis)</td><td align="center" rowspan="1" colspan="1">50&#8211;200&#160;&#956;M</td><td align="center" rowspan="1" colspan="1">100&#160;&#956;M</td><td align="center" rowspan="1" colspan="1">20&#8211;80&#160;mg/kg&#183;d (AD mice)</td><td align="center" rowspan="1" colspan="1">3&#8211;6 weeks</td><td align="center" rowspan="1" colspan="1">JAK2/STAT3<break/>NF-&#954;B, Nrf2/HO-1</td><td align="center" rowspan="1" colspan="1">
<xref rid="B163" ref-type="bibr">Xu et al. (2021)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Tenuigenin (Senegenin)</td><td align="center" rowspan="1" colspan="1">PC12 (apoptosis, autophagy)</td><td align="center" rowspan="1" colspan="1">5&#8211;50&#160;&#956;M</td><td align="center" rowspan="1" colspan="1">50&#160;&#956;M</td><td align="center" rowspan="1" colspan="1">30&#8211;60&#160;mg/kg&#183;d (AD mice)</td><td align="center" rowspan="1" colspan="1">4&#8211;8 weeks</td><td align="center" rowspan="1" colspan="1">Bcl-2/Bax<break/>PINK1/Parkin, caspase-3</td><td align="center" rowspan="1" colspan="1">
<xref rid="B19" ref-type="bibr">Chen et al. (2010)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Astragalus polysaccharides (APS)</td><td align="center" rowspan="1" colspan="1">PC12/HT22 oxidative stress model (H<sub>2</sub>O<sub>2</sub>-induced)</td><td align="center" rowspan="1" colspan="1">100&#8211;1000&#160;&#956;g/mL</td><td align="center" rowspan="1" colspan="1">250&#8211;500&#160;&#956;g/mL</td><td align="center" rowspan="1" colspan="1">200&#160;mg/kg&#183;d (AD mice); 500&#160;mg/kg&#183;d (AD mice)</td><td align="center" rowspan="1" colspan="1">200&#160;mg/kg&#183;d (2 months)<break/>500&#160;mg/kg&#183;d (7 weeks)</td><td align="center" rowspan="1" colspan="1">Nrf2/Keap1, SOD, GSH-Px, MDA, JAK/STAT, Toll/IMD, PI3K/Akt/mTOR</td><td align="center" rowspan="1" colspan="1">
<xref rid="B60" ref-type="bibr">Huang et al. (2017)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Lycium barbarum polysaccharides (LBP)</td><td align="center" rowspan="1" colspan="1">SH-SY5Y (A&#946; toxicity, apoptosis)</td><td align="center" rowspan="1" colspan="1">100&#8211;400&#160;&#956;g/mL</td><td align="center" rowspan="1" colspan="1">200&#8211;400&#160;&#956;g/mL</td><td align="center" rowspan="1" colspan="1">10&#8211;40&#160;mg/kg&#183;d (AD mice)</td><td align="center" rowspan="1" colspan="1">3&#8211;8 weeks</td><td align="center" rowspan="1" colspan="1">PI3K/Akt, Bcl-2, Bax, caspase-3, mitophagy</td><td align="center" rowspan="1" colspan="1">
<xref rid="B185" ref-type="bibr">Zhao et al. (2016)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Icariin</td><td align="center" rowspan="1" colspan="1">SH-SY5Y, PC12 (A&#946;-induced apoptosis)</td><td align="center" rowspan="1" colspan="1">5&#8211;20&#160;&#956;M</td><td align="center" rowspan="1" colspan="1">10&#160;&#956;M</td><td align="center" rowspan="1" colspan="1">30&#8211;60&#160;mg/kg&#183;d (AD mice)</td><td align="center" rowspan="1" colspan="1">3&#8211;6 weeks</td><td align="center" rowspan="1" colspan="1">BDNF/TrkB/CREB, caspase-3, LC3-II</td><td align="center" rowspan="1" colspan="1">
<xref rid="B38" ref-type="bibr">Fu et al. (2018)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Salidroside</td><td align="center" rowspan="1" colspan="1">HT22 (oxidative stress, ferroptosis)<break/>PC12 (apoptosis, pyroptosis)</td><td align="center" rowspan="1" colspan="1">20&#8211;80&#160;&#956;M</td><td align="center" rowspan="1" colspan="1">40&#160;&#956;M</td><td align="center" rowspan="1" colspan="1">50&#160;mg/kg&#183;d (AD mice)</td><td align="center" rowspan="1" colspan="1">2&#8211;4 weeks</td><td align="center" rowspan="1" colspan="1">Nrf2/HO-1, GPX4, NLRP3/caspase-1, Bcl-2/Bax</td><td align="center" rowspan="1" colspan="1">
<xref rid="B170" ref-type="bibr">Yang et al. (2022c)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Huperzine A</td><td align="center" rowspan="1" colspan="1">Neurons (AChE inhibition, apoptosis regulation)</td><td align="center" rowspan="1" colspan="1">nM level effective</td><td align="center" rowspan="1" colspan="1">0.1&#8211;1&#160;&#956;M</td><td align="center" rowspan="1" colspan="1">0.2&#8211;0.4&#160;mg/day (humans)<break/>0.2&#8211;0.7&#160;mg/kg (mice)</td><td align="center" rowspan="1" colspan="1">weeks&#8211;months</td><td align="center" rowspan="1" colspan="1">AChE inhibition, Bcl-2, Bax, caspase-3</td><td align="center" rowspan="1" colspan="1">
<xref rid="B166" ref-type="bibr">Yang et al. (2013)</xref>
</td></tr></tbody></table></table-wrap></sec></body><back><sec sec-type="author-contributions" id="s7"><title>Author contributions</title><p>PP: Writing &#8211; review and editing, Writing &#8211; original draft. TZ: Software, Writing &#8211; review and editing. JZ: Investigation, Writing &#8211; review and editing. YuZ: Data curation, Writing &#8211; review and editing. XZ: Writing &#8211; review and editing, Supervision. QL: Writing &#8211; review and editing, Funding acquisition. YaZ: Writing &#8211; review and editing, Funding acquisition.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s10"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p><p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alonso</surname><given-names>A. D.</given-names></name><name name-style="western"><surname>Di Clerico</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Corbo</surname><given-names>C. P.</given-names></name><name name-style="western"><surname>Alaniz</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Grundke-Iqbal</surname><given-names>I.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegeneration</article-title>. <source>J. Biol. Chem.</source><volume>285</volume> (<issue>40</issue>), <fpage>30851</fpage>&#8211;<lpage>30860</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M110.110957</pub-id><pub-id pub-id-type="pmid">20663882</pub-id><pub-id pub-id-type="pmcid">PMC2945578</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Annibaldi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Meier</surname><given-names>P.</given-names></name></person-group> (<year>2018</year>). <article-title>Checkpoints in TNF-induced cell death: implications in inflammation and cancer</article-title>. <source>Trends Mol. Med.</source><volume>24</volume> (<issue>1</issue>), <fpage>49</fpage>&#8211;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmed.2017.11.002</pub-id><pub-id pub-id-type="pmid">29217118</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashkenazi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dixit</surname><given-names>V. M.</given-names></name></person-group> (<year>1998</year>). <article-title>Death receptors: signaling and modulation</article-title>. <source>Science</source><volume>281</volume> (<issue>5381</issue>), <fpage>1305</fpage>&#8211;<lpage>1308</lpage>. <pub-id pub-id-type="doi">10.1126/science.281.5381.1305</pub-id><pub-id pub-id-type="pmid">9721089</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balusu</surname><given-names>S.</given-names></name><name name-style="western"><surname>De Strooper</surname><given-names>B.</given-names></name></person-group> (<year>2024</year>). <article-title>The necroptosis cell death pathway drives neurodegeneration in Alzheimer&#8217;s disease</article-title>. <source>Acta Neuropathol.</source><volume>147</volume> (<issue>1</issue>), <fpage>96</fpage>. <pub-id pub-id-type="doi">10.1007/s00401-024-02747-5</pub-id><pub-id pub-id-type="pmid">38852117</pub-id><pub-id pub-id-type="pmcid">PMC11162975</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bao</surname><given-names>X.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name></person-group> (<year>2024</year>). <article-title>Sinomenine exerts a neuroprotective effect on PD mouse model through inhibiting PI3K/AKT/mTOR pathway to enhance autophagy</article-title>. <source>Int. J. Neurosci.</source><volume>134</volume> (<issue>3</issue>), <fpage>301</fpage>&#8211;<lpage>309</lpage>. <pub-id pub-id-type="doi">10.1080/00207454.2022.2100780</pub-id><pub-id pub-id-type="pmid">35815397</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bausewein</surname><given-names>T.</given-names></name><name name-style="western"><surname>Naveed</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nussberger</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>The structure of the TOM core complex in the mitochondrial outer membrane</article-title>. <source>Biol. Chem.</source><volume>401</volume> (<issue>6-7</issue>), <fpage>687</fpage>&#8211;<lpage>697</lpage>. <pub-id pub-id-type="doi">10.1515/hsz-2020-0104</pub-id><pub-id pub-id-type="pmid">32142473</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belaidi</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Gunn</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>B. X.</given-names></name><name name-style="western"><surname>Ayton</surname><given-names>S.</given-names></name><name name-style="western"><surname>Appukuttan</surname><given-names>A. T.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>B. R.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Marked age-related changes in brain iron homeostasis in amyloid protein precursor Knockout mice</article-title>. <source>Neurotherapeutics</source><volume>15</volume> (<issue>4</issue>), <fpage>1055</fpage>&#8211;<lpage>1062</lpage>. <pub-id pub-id-type="doi">10.1007/s13311-018-0656-x</pub-id><pub-id pub-id-type="pmid">30112699</pub-id><pub-id pub-id-type="pmcid">PMC6277293</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bello</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zambron</surname><given-names>B. K.</given-names></name><name name-style="western"><surname>El&#237;as-Rodr&#237;guez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gajate</surname><given-names>C.</given-names></name><name name-style="western"><surname>Robina</surname><given-names>I.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Induction of cell killing and autophagy by amphiphilic pyrrolidine derivatives on human pancreatic cancer cells</article-title>. <source>Eur. J. Med. Chem.</source><volume>150</volume>, <fpage>457</fpage>&#8211;<lpage>478</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2018.02.086</pub-id><pub-id pub-id-type="pmid">29547833</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bersuker</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hendricks</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Magtanong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ford</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>P. H.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis</article-title>. <source>Nature</source><volume>575</volume> (<issue>7784</issue>), <fpage>688</fpage>&#8211;<lpage>692</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-019-1705-2</pub-id><pub-id pub-id-type="pmid">31634900</pub-id><pub-id pub-id-type="pmcid">PMC6883167</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bittner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Knoll</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ehrenschwender</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Death receptor 3 mediates necroptotic cell death</article-title>. <source>Cell Mol. Life Sci.</source><volume>74</volume> (<issue>3</issue>), <fpage>543</fpage>&#8211;<lpage>554</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-016-2355-2</pub-id><pub-id pub-id-type="pmid">27592300</pub-id><pub-id pub-id-type="pmcid">PMC11107694</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bieri</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lucin</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>O'Brien</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Villeda</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Wyss-Coray</surname><given-names>T.</given-names></name></person-group> (<year>2018</year>). <article-title>Proteolytic cleavage of Beclin 1 exacerbates neurodegeneration</article-title>. <source>Mol. Neurodegener.</source><volume>13</volume> (<issue>1</issue>), <fpage>68</fpage>. <pub-id pub-id-type="doi">10.1186/s13024-018-0302-4</pub-id><pub-id pub-id-type="pmid">30594228</pub-id><pub-id pub-id-type="pmcid">PMC6310967</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bock</surname><given-names>F. J.</given-names></name><name name-style="western"><surname>Tait</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Mitochondria as multifaceted regulators of cell death</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source><volume>21</volume> (<issue>2</issue>), <fpage>85</fpage>&#8211;<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1038/s41580-019-0173-8</pub-id><pub-id pub-id-type="pmid">31636403</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bogdan</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Miyazawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tsuji</surname><given-names>Y.</given-names></name></person-group> (<year>2016</year>). <article-title>Regulators of iron homeostasis: new players in metabolism, cell death, and disease</article-title>. <source>Trends Biochem. Sci.</source><volume>41</volume> (<issue>3</issue>), <fpage>274</fpage>&#8211;<lpage>286</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2015.11.012</pub-id><pub-id pub-id-type="pmid">26725301</pub-id><pub-id pub-id-type="pmcid">PMC4783254</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Broz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dixit</surname><given-names>V. M.</given-names></name></person-group> (<year>2016</year>). <article-title>Inflammasomes: mechanism of assembly, regulation and signalling</article-title>. <source>Nat. Rev. Immunol.</source><volume>16</volume> (<issue>7</issue>), <fpage>407</fpage>&#8211;<lpage>420</lpage>. <pub-id pub-id-type="doi">10.1038/nri.2016.58</pub-id><pub-id pub-id-type="pmid">27291964</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Salidroside ameliorates Alzheimer's disease by targeting NLRP3 inflammasome-mediated pyroptosis</article-title>. <source>Front. Aging Neurosci.</source><volume>13</volume>, <fpage>809433</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2021.809433</pub-id><pub-id pub-id-type="pmid">35126093</pub-id><pub-id pub-id-type="pmcid">PMC8814655</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cain</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bratton</surname><given-names>S. B.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>G. M.</given-names></name></person-group> (<year>2002</year>). <article-title>The Apaf-1 apoptosome: a large caspase-activating complex</article-title>. <source>Biochimie</source><volume>84</volume> (<issue>2-3</issue>), <fpage>203</fpage>&#8211;<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1016/s0300-9084(02)01376-7</pub-id><pub-id pub-id-type="pmid">12022951</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Du</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hei</surname><given-names>Q.</given-names></name></person-group> (<year>2017</year>). <article-title>
<italic toggle="yes">Lycium barbarum</italic> polysaccharide protects against neurotoxicity via the Nrf2-HO-1 pathway</article-title>. <source>Exp. Ther. Med.</source><volume>14</volume> (<issue>5</issue>), <fpage>4919</fpage>&#8211;<lpage>4927</lpage>. <pub-id pub-id-type="doi">10.3892/etm.2017.5127</pub-id><pub-id pub-id-type="pmid">29201196</pub-id><pub-id pub-id-type="pmcid">PMC5704330</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z. J.</given-names></name></person-group> (<year>2012</year>). <article-title>Ubiquitination in signaling to and activation of IKK</article-title>. <source>Immunol. Rev.</source><volume>246</volume> (<issue>1</issue>), <fpage>95</fpage>&#8211;<lpage>106</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-065X.2012.01108.x</pub-id><pub-id pub-id-type="pmid">22435549</pub-id><pub-id pub-id-type="pmcid">PMC3549672</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y. J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X. B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z. X.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>L. L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W. Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name></person-group> (<year>2010</year>). <article-title>Tenuigenin protects cultured hippocampal neurons against methylglyoxal-induced neurotoxicity</article-title>. <source>Eur. J. Pharmacol.</source><volume>645</volume> (<issue>1-3</issue>), <fpage>1</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2010.06.034</pub-id><pub-id pub-id-type="pmid">20609361</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>D.</given-names></name><name name-style="western"><surname>He</surname><given-names>W. T.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death</article-title>. <source>Cell Res.</source><volume>24</volume> (<issue>1</issue>), <fpage>105</fpage>&#8211;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1038/cr.2013.171</pub-id><pub-id pub-id-type="pmid">24366341</pub-id><pub-id pub-id-type="pmcid">PMC3879712</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Z. M.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>D. S.</given-names></name></person-group> (<year>2023</year>). <article-title>The interaction between ferroptosis and inflammatory signaling pathways</article-title>. <source>Cell Death Dis.</source><volume>14</volume> (<issue>3</issue>), <fpage>205</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-023-05716-0</pub-id><pub-id pub-id-type="pmid">36944609</pub-id><pub-id pub-id-type="pmcid">PMC10030804</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>Y. S.</given-names></name><name name-style="western"><surname>Challa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Moquin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Genga</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ray</surname><given-names>T. D.</given-names></name><name name-style="western"><surname>Guildford</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation</article-title>. <source>Cell</source><volume>137</volume> (<issue>6</issue>), <fpage>1112</fpage>&#8211;<lpage>1123</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2009.05.037</pub-id><pub-id pub-id-type="pmid">19524513</pub-id><pub-id pub-id-type="pmcid">PMC2727676</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y.</given-names></name></person-group> (<year>2021</year>). <article-title>Protective effects of ginsenoside Rg2 against memory impairment and neuronal death induced by A&#946;25-35 in rats</article-title>. <source>J. Ethnopharmacol.</source><volume>266</volume>, <fpage>113466</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2020.113466</pub-id><pub-id pub-id-type="pmid">33049344</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Czabotar</surname><given-names>P. E.</given-names></name><name name-style="western"><surname>Lessene</surname><given-names>G.</given-names></name><name name-style="western"><surname>Strasser</surname><given-names>A.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>J. M.</given-names></name></person-group> (<year>2014</year>). <article-title>Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source><volume>15</volume> (<issue>1</issue>), <fpage>49</fpage>&#8211;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1038/nrm3722</pub-id><pub-id pub-id-type="pmid">24355989</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Da</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>De Luca</surname><given-names>A.</given-names></name><name name-style="western"><surname>Squitti</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rongioletti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Machado</surname><given-names>C. M. L.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Copper in tumors and the use of copper-based compounds in cancer treatment</article-title>. <source>J. Inorg. Biochem.</source><volume>226</volume>, <fpage>111634</fpage>. <pub-id pub-id-type="doi">10.1016/j.jinorgbio.2021.111634</pub-id><pub-id pub-id-type="pmid">34740035</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Quality markers for Astragali Radix and its products based on process analysis</article-title>. <source>Front. Pharmacol.</source><volume>11</volume>, <fpage>554777</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.554777</pub-id><pub-id pub-id-type="pmid">33390938</pub-id><pub-id pub-id-type="pmcid">PMC7775524</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Degterev</surname><given-names>A.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Boyce</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jagtap</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mizushima</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury</article-title>. <source>Nat. Chem. Biol.</source><volume>1</volume> (<issue>2</issue>), <fpage>112</fpage>&#8211;<lpage>119</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio711</pub-id><pub-id pub-id-type="pmid">16408008</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dempsey</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rubio</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Bryson</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Finucane</surname><given-names>O.</given-names></name><name name-style="western"><surname>Larkin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>E. L.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-beta and cognitive function in APP/PS1 mice</article-title>. <source>Brain Behav. Immun.</source><volume>61</volume>, <fpage>306</fpage>&#8211;<lpage>316</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2016.12.014</pub-id><pub-id pub-id-type="pmid">28003153</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dickens</surname><given-names>L. S.</given-names></name><name name-style="western"><surname>Powley</surname><given-names>I. R.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>MacFarlane</surname><given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>The &#8216;complexities' of life and death: death receptor signalling platforms</article-title>. <source>Exp. Cell Res.</source><volume>318</volume> (<issue>11</issue>), <fpage>1269</fpage>&#8211;<lpage>1277</lpage>. <pub-id pub-id-type="doi">10.1016/j.yexcr.2012.04.005</pub-id><pub-id pub-id-type="pmid">22542855</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dixon</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Lemberg</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Lamprecht</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Skouta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zaitsev</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Gleason</surname><given-names>C. E.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Ferroptosis: an iron-dependent form of nonapoptotic cell death</article-title>. <source>Cell</source><volume>149</volume> (<issue>5</issue>), <fpage>1060</fpage>&#8211;<lpage>1072</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2012.03.042</pub-id><pub-id pub-id-type="pmid">22632970</pub-id><pub-id pub-id-type="pmcid">PMC3367386</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elliott</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Ravichandran</surname><given-names>K. S.</given-names></name></person-group> (<year>2010</year>). <article-title>Clearance of apoptotic cells: implications in health and disease</article-title>. <source>J. Cell Biol.</source><volume>189</volume> (<issue>7</issue>), <fpage>1059</fpage>&#8211;<lpage>1070</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.201004096</pub-id><pub-id pub-id-type="pmid">20584912</pub-id><pub-id pub-id-type="pmcid">PMC2894449</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name></person-group> (<year>2017</year>). <article-title>Tenuigenin protects dopaminergic neurons from inflammation via suppressing NLRP3 inflammasome activation in microglia</article-title>. <source>J. Neuroinflammation</source><volume>14</volume> (<issue>1</issue>), <fpage>256</fpage>. <pub-id pub-id-type="doi">10.1186/s12974-017-1036-x</pub-id><pub-id pub-id-type="pmid">29262843</pub-id><pub-id pub-id-type="pmcid">PMC5738892</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fernandez-Moriano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gonzalez-Burgos</surname><given-names>E.</given-names></name><name name-style="western"><surname>Iglesias</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lozano</surname><given-names>R.</given-names></name><name name-style="western"><surname>G&#243;mez-Serranillos</surname><given-names>M. P.</given-names></name></person-group> (<year>2017</year>). <article-title>Evaluation of the adaptogenic potential exerted by ginsenosides Rb1 and Rg1 against oxidative stress-mediated neurotoxicity in an <italic toggle="yes">in vitro</italic> neuronal model</article-title>. <source>PLoS One</source><volume>12</volume> (<issue>8</issue>), <fpage>e0182933</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0182933</pub-id><pub-id pub-id-type="pmid">28813475</pub-id><pub-id pub-id-type="pmcid">PMC5558939</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fleming</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bourdenx</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fujimaki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Karabiyik</surname><given-names>C.</given-names></name><name name-style="western"><surname>Krause</surname><given-names>G. J.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>The different autophagy degradation pathways and neurodegeneration</article-title>. <source>Neuron</source><volume>110</volume> (<issue>6</issue>), <fpage>935</fpage>&#8211;<lpage>966</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2022.01.017</pub-id><pub-id pub-id-type="pmid">35134347</pub-id><pub-id pub-id-type="pmcid">PMC8930707</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frazer</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>G. J.</given-names></name></person-group> (<year>2014</year>). <article-title>The regulation of iron transport</article-title>. <source>Biofactors</source><volume>40</volume> (<issue>2</issue>), <fpage>206</fpage>&#8211;<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1002/biof.1148</pub-id><pub-id pub-id-type="pmid">24132807</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fricker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tolkovsky</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Borutaite</surname><given-names>V.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>G. C.</given-names></name></person-group> (<year>2018</year>). <article-title>Neuronal cell death</article-title>. <source>Physiol. Rev.</source><volume>98</volume> (<issue>2</issue>), <fpage>813</fpage>&#8211;<lpage>880</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00011.2017</pub-id><pub-id pub-id-type="pmid">29488822</pub-id><pub-id pub-id-type="pmcid">PMC5966715</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedli</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Inestrosa</surname><given-names>N. C.</given-names></name></person-group> (<year>2021</year>). <article-title>Huperzine A and its neuroprotective molecular signaling in Alzheimer's disease</article-title>. <source>Molecules</source><volume>26</volume> (<issue>21</issue>), <fpage>6531</fpage>. <pub-id pub-id-type="doi">10.3390/molecules26216531</pub-id><pub-id pub-id-type="pmid">34770940</pub-id><pub-id pub-id-type="pmcid">PMC8587556</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>). <article-title>Stimulatory effect of icariin on the proliferation of neural stem cells from rat hippocampus</article-title>. <source>BMC Complement. Altern. Med.</source><volume>18</volume> (<issue>1</issue>), <fpage>34</fpage>. <pub-id pub-id-type="doi">10.1186/s12906-018-2095-y</pub-id><pub-id pub-id-type="pmid">29378551</pub-id><pub-id pub-id-type="pmcid">PMC5789743</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galler</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lebrun</surname><given-names>V.</given-names></name><name name-style="western"><surname>Raibaut</surname><given-names>L.</given-names></name><name name-style="western"><surname>Faller</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wezynfeld</surname><given-names>N. E.</given-names></name></person-group> (<year>2020</year>). <article-title>How trimerization of CTR1 N-terminal model peptides tunes Cu-binding and redox-chemistry</article-title>. <source>Chem. Commun. (Camb)</source><volume>56</volume> (<issue>81</issue>), <fpage>12194</fpage>&#8211;<lpage>12197</lpage>. <pub-id pub-id-type="doi">10.1039/d0cc04693k</pub-id><pub-id pub-id-type="pmid">32914794</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galluzzi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kepp</surname><given-names>O.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>F. K.</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name></person-group> (<year>2017</year>). <article-title>Necroptosis: mechanisms and relevance to disease</article-title>. <source>Annu. Rev. Pathol.</source><volume>12</volume>, <fpage>103</fpage>&#8211;<lpage>130</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-pathol-052016-100247</pub-id><pub-id pub-id-type="pmid">27959630</pub-id><pub-id pub-id-type="pmcid">PMC5786374</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galluzzi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vitale</surname><given-names>I.</given-names></name><name name-style="western"><surname>Aaronson</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Abrams</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Adam</surname><given-names>D.</given-names></name><name name-style="western"><surname>Agostinis</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on cell death 2018</article-title>. <source>Cell Death Differ.</source><volume>25</volume> (<issue>3</issue>), <fpage>486</fpage>&#8211;<lpage>541</lpage>. <pub-id pub-id-type="doi">10.1038/s41418-017-0012-4</pub-id><pub-id pub-id-type="pmid">29362479</pub-id><pub-id pub-id-type="pmcid">PMC5864239</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gatica</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lahiri</surname><given-names>V.</given-names></name><name name-style="western"><surname>Klionsky</surname><given-names>D. J.</given-names></name></person-group> (<year>2018</year>). <article-title>Cargo recognition and degradation by selective autophagy</article-title>. <source>Nat. Cell Biol.</source><volume>20</volume> (<issue>3</issue>), <fpage>233</fpage>&#8211;<lpage>242</lpage>. <pub-id pub-id-type="doi">10.1038/s41556-018-0037-z</pub-id><pub-id pub-id-type="pmid">29476151</pub-id><pub-id pub-id-type="pmcid">PMC6028034</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grootjans</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vanden</surname><given-names>B. T.</given-names></name><name name-style="western"><surname>Vandenabeele</surname><given-names>P.</given-names></name></person-group> (<year>2017</year>). <article-title>Initiation and execution mechanisms of necroptosis: an overview</article-title>. <source>Cell Death Differ.</source><volume>24</volume> (<issue>7</issue>), <fpage>1184</fpage>&#8211;<lpage>1195</lpage>. <pub-id pub-id-type="doi">10.1038/cdd.2017.65</pub-id><pub-id pub-id-type="pmid">28498367</pub-id><pub-id pub-id-type="pmcid">PMC5520172</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guicciardi</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Gores</surname><given-names>G. J.</given-names></name></person-group> (<year>2009</year>). <article-title>Life and death by death receptors</article-title>. <source>FASEB J.</source><volume>23</volume> (<issue>6</issue>), <fpage>1625</fpage>&#8211;<lpage>1637</lpage>. <pub-id pub-id-type="doi">10.1096/fj.08-111005</pub-id><pub-id pub-id-type="pmid">19141537</pub-id><pub-id pub-id-type="pmcid">PMC2698650</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guillemot</surname><given-names>J.</given-names></name><name name-style="western"><surname>Canuel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Essalmani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Prat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Seidah</surname><given-names>N. G.</given-names></name></person-group> (<year>2013</year>). <article-title>Implication of the proprotein convertases in iron homeostasis: proprotein convertase 7 sheds human transferrin receptor 1 and furin activates hepcidin</article-title>. <source>Hepatology</source><volume>57</volume> (<issue>6</issue>), <fpage>2514</fpage>&#8211;<lpage>2524</lpage>. <pub-id pub-id-type="doi">10.1002/hep.26297</pub-id><pub-id pub-id-type="pmid">23390091</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hagar</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Aachoui</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ernst</surname><given-names>R. K.</given-names></name><name name-style="western"><surname>Miao</surname><given-names>E. A.</given-names></name></person-group> (<year>2013</year>). <article-title>Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock</article-title>. <source>Science</source><volume>341</volume> (<issue>6151</issue>), <fpage>1250</fpage>&#8211;<lpage>1253</lpage>. <pub-id pub-id-type="doi">10.1126/science.1240988</pub-id><pub-id pub-id-type="pmid">24031018</pub-id><pub-id pub-id-type="pmcid">PMC3931427</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>Y. H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H. N.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>T.</given-names></name></person-group> (<year>2023a</year>). <article-title>Regulation of anoikis by extrinsic death receptor pathways</article-title>. <source>Cell Commun. Signal</source><volume>21</volume> (<issue>1</issue>), <fpage>227</fpage>. <pub-id pub-id-type="doi">10.1186/s12964-023-01247-5</pub-id><pub-id pub-id-type="pmid">37667281</pub-id><pub-id pub-id-type="pmcid">PMC10478316</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>K.</given-names></name></person-group> (<year>2023b</year>). <article-title>Research progress of ferroptosis in Alzheimer disease: a review</article-title>. <source>Med. Baltim.</source><volume>102</volume> (<issue>36</issue>), <fpage>e35142</fpage>. <pub-id pub-id-type="doi">10.1097/MD.0000000000035142</pub-id><pub-id pub-id-type="pmid">37682127</pub-id><pub-id pub-id-type="pmcid">PMC10489260</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanna</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Quinsay</surname><given-names>M. N.</given-names></name><name name-style="western"><surname>Orogo</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Giang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rikka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gustafsson</surname><given-names>&#197;. B.</given-names></name></person-group> (<year>2012</year>). <article-title>Microtubule-associated protein 1 light chain 3 (LC3) interacts with Bnip3 protein to selectively remove endoplasmic reticulum and mitochondria via autophagy</article-title>. <source>J. Biol. Chem.</source><volume>287</volume> (<issue>23</issue>), <fpage>19094</fpage>&#8211;<lpage>19104</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M111.322933</pub-id><pub-id pub-id-type="pmid">22505714</pub-id><pub-id pub-id-type="pmcid">PMC3365942</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harper</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Ordureau</surname><given-names>A.</given-names></name><name name-style="western"><surname>Heo</surname><given-names>J. M.</given-names></name></person-group> (<year>2018</year>). <article-title>Building and decoding ubiquitin chains for mitophagy</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source><volume>19</volume> (<issue>2</issue>), <fpage>93</fpage>&#8211;<lpage>108</lpage>. <pub-id pub-id-type="doi">10.1038/nrm.2017.129</pub-id><pub-id pub-id-type="pmid">29358684</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Song</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lotze</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Zeh</surname><given-names>H. J.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Autophagy promotes ferroptosis by degradation of ferritin</article-title>. <source>Autophagy</source><volume>12</volume> (<issue>8</issue>), <fpage>1425</fpage>&#8211;<lpage>1428</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.2016.1187366</pub-id><pub-id pub-id-type="pmid">27245739</pub-id><pub-id pub-id-type="pmcid">PMC4968231</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sung</surname><given-names>C.</given-names></name></person-group> (<year>2017</year>). <article-title>Ginsenoside Rd as a potential neuroprotective agent prevents trimethyltin injury</article-title>. <source>Biomed. Rep.</source><volume>6</volume> (<issue>4</issue>), <fpage>435</fpage>&#8211;<lpage>440</lpage>. <pub-id pub-id-type="doi">10.3892/br.2017.864</pub-id><pub-id pub-id-type="pmid">28413642</pub-id><pub-id pub-id-type="pmcid">PMC5374896</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Babbar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hasselbalch</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Croteau</surname><given-names>D. L.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Ageing as a risk factor for neurodegenerative disease</article-title>. <source>Nat. Rev. Neurol.</source><volume>15</volume> (<issue>10</issue>), <fpage>565</fpage>&#8211;<lpage>581</lpage>. <pub-id pub-id-type="doi">10.1038/s41582-019-0244-7</pub-id><pub-id pub-id-type="pmid">31501588</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Effect of regulating macrophage polarization phenotype on intervertebral disc degeneration</article-title>. <source>Immun. Inflamm. Dis.</source><volume>10</volume> (<issue>11</issue>), <fpage>e714</fpage>. <pub-id pub-id-type="doi">10.1002/iid3.714</pub-id><pub-id pub-id-type="pmid">36301028</pub-id><pub-id pub-id-type="pmcid">PMC9609449</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Bioactivities and mechanisms of action of sinomenine and its derivatives: a comprehensive review</article-title>. <source>Molecules</source><volume>29</volume> (<issue>2</issue>), <fpage>540</fpage>. <pub-id pub-id-type="doi">10.3390/molecules29020540</pub-id><pub-id pub-id-type="pmid">38276618</pub-id><pub-id pub-id-type="pmcid">PMC10818773</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shu</surname><given-names>H. B.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Goeddel</surname><given-names>D. V.</given-names></name></person-group> (<year>1996a</year>). <article-title>TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways</article-title>. <source>Cell</source><volume>84</volume> (<issue>2</issue>), <fpage>299</fpage>&#8211;<lpage>308</lpage>. <pub-id pub-id-type="doi">10.1016/s0092-8674(00)80984-8</pub-id><pub-id pub-id-type="pmid">8565075</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shu</surname><given-names>H. B.</given-names></name><name name-style="western"><surname>Baichwal</surname><given-names>V.</given-names></name><name name-style="western"><surname>Goeddel</surname><given-names>D. V.</given-names></name></person-group> (<year>1996b</year>). <article-title>TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex</article-title>. <source>Immunity</source><volume>4</volume> (<issue>4</issue>), <fpage>387</fpage>&#8211;<lpage>396</lpage>. <pub-id pub-id-type="doi">10.1016/s1074-7613(00)80252-6</pub-id><pub-id pub-id-type="pmid">8612133</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name></person-group> (<year>2022</year>). <article-title>Berberine inhibits erastin-induced ferroptosis of mouse hippocampal neuronal cells possibly by activating the Nrf2-HO-1/GPX4 pathway</article-title>. <source>J. South. Med. Univ.</source><volume>42</volume> (<issue>6</issue>), <fpage>937</fpage>&#8211;<lpage>943</lpage>. <pub-id pub-id-type="doi">10.12122/j.issn.1673-4254.2022.06.19</pub-id><pub-id pub-id-type="pmid">35790446</pub-id><pub-id pub-id-type="pmcid">PMC9257364</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T. Y.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>F. X.</given-names></name><name name-style="western"><surname>Yue</surname><given-names>B. W.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2024a</year>). <article-title>Icariin ameliorates D-galactose-induced cell injury in neuron-like PC12 cells by inhibiting MPTP opening</article-title>. <source>Curr. Med. Sci.</source><volume>44</volume> (<issue>4</issue>), <fpage>748</fpage>&#8211;<lpage>758</lpage>. <pub-id pub-id-type="doi">10.1007/s11596-024-2892-0</pub-id><pub-id pub-id-type="pmid">38900385</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2024b</year>). <article-title>Berberine inhibits excessive autophagy and protects myocardium against ischemia/reperfusion injury via the RhoE/AMPK pathway</article-title>. <source>Int. J. Mol. Med.</source><volume>53</volume> (<issue>5</issue>), <fpage>49</fpage>. <pub-id pub-id-type="doi">10.3892/ijmm.2024.5373</pub-id><pub-id pub-id-type="pmid">38577949</pub-id><pub-id pub-id-type="pmcid">PMC10999226</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y. C.</given-names></name><name name-style="western"><surname>Tsay</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>C. W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H. K.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Astragalus membranaceus-polysaccharides ameliorates obesity, hepatic steatosis, neuroinflammation and cognition impairment without affecting amyloid deposition in metabolically stressed APPswe/PS1dE9 mice</article-title>. <source>Int. J. Mol. Sci.</source><volume>18</volume> (<issue>12</issue>), <fpage>2746</fpage>. <pub-id pub-id-type="doi">10.3390/ijms18122746</pub-id><pub-id pub-id-type="pmid">29258283</pub-id><pub-id pub-id-type="pmcid">PMC5751345</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name></person-group> (<year>2020</year>). <article-title>Matrine protects PC12 cells from lipopolysaccharide-evoked inflammatory injury via upregulation of miR-9</article-title>. <source>Pharm. Biol.</source><volume>58</volume> (<issue>1</issue>), <fpage>314</fpage>&#8211;<lpage>320</lpage>. <pub-id pub-id-type="doi">10.1080/13880209.2020.1719165</pub-id><pub-id pub-id-type="pmid">32297823</pub-id><pub-id pub-id-type="pmcid">PMC7178860</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kon</surname><given-names>N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Su</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hibshoosh</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Ferroptosis as a p53-mediated activity during tumour suppression</article-title>. <source>Nature</source><volume>520</volume> (<issue>7545</issue>), <fpage>57</fpage>&#8211;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1038/nature14344</pub-id><pub-id pub-id-type="pmid">25799988</pub-id><pub-id pub-id-type="pmcid">PMC4455927</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mu</surname><given-names>Y.</given-names></name></person-group> (<year>2023</year>). <article-title>Lycium barbarum polysaccharide-glycoprotein ameliorates ionizing radiation-induced epithelial injury by regulating oxidative stress and ferroptosis via the Nrf2 pathway</article-title>. <source>Free Radic. Biol. Med.</source><volume>204</volume>, <fpage>84</fpage>&#8211;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2023.04.020</pub-id><pub-id pub-id-type="pmid">37119863</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jucker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>L. C.</given-names></name></person-group> (<year>2023</year>). <article-title>Alzheimer&#8217;s disease: from immunotherapy to immunoprevention</article-title>. <source>Cell</source><volume>186</volume> (<issue>20</issue>), <fpage>4260</fpage>&#8211;<lpage>4270</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2023.08.021</pub-id><pub-id pub-id-type="pmid">37729908</pub-id><pub-id pub-id-type="pmcid">PMC10578497</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaczmarek</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vandenabeele</surname><given-names>P.</given-names></name><name name-style="western"><surname>Krysko</surname><given-names>D. V.</given-names></name></person-group> (<year>2013</year>). <article-title>Necroptosis: the release of damage-associated molecular patterns and its physiological relevance</article-title>. <source>Immunity</source><volume>38</volume> (<issue>2</issue>), <fpage>209</fpage>&#8211;<lpage>223</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2013.02.003</pub-id><pub-id pub-id-type="pmid">23438821</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khaminets</surname><given-names>A.</given-names></name><name name-style="western"><surname>Behl</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dikic</surname><given-names>I.</given-names></name></person-group> (<year>2016</year>). <article-title>Ubiquitin-dependent and independent signals in selective autophagy</article-title>. <source>Trends Cell Biol.</source><volume>26</volume> (<issue>1</issue>), <fpage>6</fpage>&#8211;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/j.tcb.2015.08.010</pub-id><pub-id pub-id-type="pmid">26437584</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>D. H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D. W.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>B. H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>G. S.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Ginsenoside Rb2 suppresses the glutamate-mediated oxidative stress and neuronal cell death in HT22 cells</article-title>. <source>J. Ginseng Res.</source><volume>43</volume> (<issue>2</issue>), <fpage>326</fpage>&#8211;<lpage>334</lpage>. <pub-id pub-id-type="doi">10.1016/j.jgr.2018.12.002</pub-id><pub-id pub-id-type="pmid">30976171</pub-id><pub-id pub-id-type="pmcid">PMC6437470</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koyano</surname><given-names>F.</given-names></name><name name-style="western"><surname>Okatsu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kosako</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tamura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Go</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Ubiquitin is phosphorylated by PINK1 to activate parkin</article-title>. <source>Nature</source><volume>510</volume> (<issue>7503</issue>), <fpage>162</fpage>&#8211;<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1038/nature13392</pub-id><pub-id pub-id-type="pmid">24784582</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Oxidative damage and antioxidant defense in ferroptosis</article-title>. <source>Front. Cell Dev. Biol.</source><volume>8</volume>, <fpage>586578</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2020.586578</pub-id><pub-id pub-id-type="pmid">33043019</pub-id><pub-id pub-id-type="pmcid">PMC7527737</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dhapola</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>D. H.</given-names></name></person-group> (<year>2023</year>). <article-title>Apoptosis in Alzheimer&#8217;s disease: insight into the signaling pathways and therapeutic avenues</article-title>. <source>Apoptosis</source><volume>28</volume> (<issue>7-8</issue>), <fpage>943</fpage>&#8211;<lpage>957</lpage>. <pub-id pub-id-type="doi">10.1007/s10495-023-01848-y</pub-id><pub-id pub-id-type="pmid">37186274</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Inhibition of human high-affinity copper importer Ctr1 orthologous in the nervous system of <italic toggle="yes">Drosophila ameliorates</italic> A&#946;42-induced Alzheimer&#8217;s disease-like symptoms</article-title>. <source>Neurobiol. Aging</source><volume>34</volume> (<issue>11</issue>), <fpage>2604</fpage>&#8211;<lpage>2612</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2013.05.029</pub-id><pub-id pub-id-type="pmid">23827522</pub-id><pub-id pub-id-type="pmcid">PMC3770863</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li Aaqi</surname><given-names>Z. G. J. H.</given-names></name></person-group> (<year>2024</year>). <article-title>Effect of matrine on sevoflurane-induced mitochondrial autophagy in neonatal rats by regulating the AMPK/mTOR/ULK1 signaling pathway</article-title>. <source>Hebei Med. Journa</source><volume>46</volume> (<issue>17</issue>), <fpage>2565</fpage>&#8211;<lpage>2569</lpage>. <pub-id pub-id-type="doi">10.3969/i.issn.1002-7386.2024.17.001</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mcquade</surname><given-names>T.</given-names></name><name name-style="western"><surname>Siemer</surname><given-names>A. B.</given-names></name><name name-style="western"><surname>Napetschnig</surname><given-names>J.</given-names></name><name name-style="western"><surname>Moriwaki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>Y. S.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis</article-title>. <source>Cell</source><volume>150</volume> (<issue>2</issue>), <fpage>339</fpage>&#8211;<lpage>350</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2012.06.019</pub-id><pub-id pub-id-type="pmid">22817896</pub-id><pub-id pub-id-type="pmcid">PMC3664196</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>&#946;-amyloid protein induces mitophagy-dependent ferroptosis through the CD36/PINK/PARKIN pathway leading to blood-brain barrier destruction in Alzheimer's disease</article-title>. <source>Cell Biosci.</source><volume>12</volume> (<issue>1</issue>), <fpage>69</fpage>. <pub-id pub-id-type="doi">10.1186/s13578-022-00807-5</pub-id><pub-id pub-id-type="pmid">35619150</pub-id><pub-id pub-id-type="pmcid">PMC9134700</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2023a</year>). <article-title>Berberine ameliorates iron levels and ferroptosis in the brain of 3 &#215; Tg-AD mice</article-title>. <source>Phytomedicine</source><volume>118</volume>, <fpage>154962</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2023.154962</pub-id><pub-id pub-id-type="pmid">37506403</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2023b</year>). <article-title>Regulation and mechanism of Astragalus polysaccharide on ameliorating aging in <italic toggle="yes">Drosophila melanogaster</italic>
</article-title>. <source>Int. J. Biol. Macromol.</source><volume>234</volume>, <fpage>123632</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2023.123632</pub-id><pub-id pub-id-type="pmid">36801290</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>G.</given-names></name></person-group> (<year>2023c</year>). <article-title>Tenuifolin in the prevention of Alzheimer&#8217;s disease-like phenotypes: investigation of the mechanisms from the perspectives of calpain system, ferroptosis, and apoptosis</article-title>. <source>Phytother. Res.</source><volume>37</volume> (<issue>10</issue>), <fpage>4621</fpage>&#8211;<lpage>4638</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.7930</pub-id><pub-id pub-id-type="pmid">37364988</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Kan</surname><given-names>Y. K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name></person-group> (<year>2025</year>). <article-title>Cuproptosis and copper as potential mechanisms and intervention targets in Alzheimer&#8217;s disease</article-title>. <source>Biomed. Pharmacother.</source><volume>183</volume>, <fpage>117814</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2025.117814</pub-id><pub-id pub-id-type="pmid">39809124</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>Z. L.</given-names></name><name name-style="western"><surname>Su</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y. F.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Y. J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Salidroside protects PC-12 cells against amyloid beta-induced apoptosis by activation of the ERK1/2 and AKT signaling pathways</article-title>. <source>Int. J. Mol. Med.</source><volume>43</volume> (<issue>4</issue>), <fpage>1769</fpage>&#8211;<lpage>1777</lpage>. <pub-id pub-id-type="doi">10.3892/ijmm.2019.4088</pub-id><pub-id pub-id-type="pmid">30720058</pub-id><pub-id pub-id-type="pmcid">PMC6414153</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Q.</given-names></name></person-group> (<year>2018</year>). <article-title>Icariside II, a phosphodiesterase-5 inhibitor, attenuates beta-amyloid-induced cognitive deficits via BDNF/TrkB/CREB signaling</article-title>. <source>Cell Physiol. Biochem.</source><volume>49</volume> (<issue>3</issue>), <fpage>985</fpage>. <pub-id pub-id-type="doi">10.1159/000493232</pub-id><pub-id pub-id-type="pmid">30196289</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Apoptin induces pyroptosis of colorectal cancer cells via the GSDME-dependent pathway</article-title>. <source>Int. J. Biol. Sci.</source><volume>18</volume> (<issue>2</issue>), <fpage>717</fpage>&#8211;<lpage>730</lpage>. <pub-id pub-id-type="doi">10.7150/ijbs.64350</pub-id><pub-id pub-id-type="pmid">35002520</pub-id><pub-id pub-id-type="pmcid">PMC8741846</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lork</surname><given-names>M.</given-names></name><name name-style="western"><surname>Verhelst</surname><given-names>K.</given-names></name><name name-style="western"><surname>Beyaert</surname><given-names>R.</given-names></name></person-group> (<year>2017</year>). <article-title>CYLD, A20 and OTULIN deubiquitinases in NF-&#954;B signaling and cell death: so similar, yet so different</article-title>. <source>Cell Death Differ.</source><volume>24</volume> (<issue>7</issue>), <fpage>1172</fpage>&#8211;<lpage>1183</lpage>. <pub-id pub-id-type="doi">10.1038/cdd.2017.46</pub-id><pub-id pub-id-type="pmid">28362430</pub-id><pub-id pub-id-type="pmcid">PMC5520167</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Inhibition of gasdermin D (GSDMD) as a promising therapeutic approach for atopic dermatitis</article-title>. <source>Int. Immunopharmacol.</source><volume>124</volume> (<issue>Pt B</issue>), <fpage>110958</fpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2023.110958</pub-id><pub-id pub-id-type="pmid">37741129</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>X.</given-names></name></person-group> (<year>2024</year>). <source>Identification of potential therapeutic targets and molecularmechanisms of 20(R)-ginsenoside Rg3 against AD[D]</source>. <publisher-name>Kunming City, China: Kunming Medical University</publisher-name>.</mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Thomassen</surname><given-names>J. Q.</given-names></name><name name-style="western"><surname>Bellenguez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Grenier-Boley</surname><given-names>B.</given-names></name><name name-style="western"><surname>de Rojas</surname><given-names>I.</given-names></name><name name-style="western"><surname>Castillo</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Genetic associations between modifiable risk factors and Alzheimer disease</article-title>. <source>JAMA Netw. Open</source><volume>6</volume> (<issue>5</issue>), <fpage>e2313734</fpage>. <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.13734</pub-id><pub-id pub-id-type="pmid">37195665</pub-id><pub-id pub-id-type="pmcid">PMC10193187</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luong</surname><given-names>H. D.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>N. H.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>C. T.</given-names></name></person-group> (<year>2021</year>). <article-title>Pharmacological properties of ginsenosides in inflammation-derived cancers</article-title>. <source>Mol. Cell Biochem.</source><volume>476</volume> (<issue>9</issue>), <fpage>3329</fpage>&#8211;<lpage>3340</lpage>. <pub-id pub-id-type="doi">10.1007/s11010-021-04162-w</pub-id><pub-id pub-id-type="pmid">33900512</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lutsenko</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bhattacharjee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hubbard</surname><given-names>A. L.</given-names></name></person-group> (<year>2010</year>). <article-title>Copper handling machinery of the brain</article-title>. <source>Metallomics</source><volume>2</volume> (<issue>9</issue>), <fpage>596</fpage>&#8211;<lpage>608</lpage>. <pub-id pub-id-type="doi">10.1039/c0mt00006j</pub-id><pub-id pub-id-type="pmid">21072351</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>R. Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>R.-X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Therapeutic effect of nicotinamide mononucleotide on Alzheimer&#8217;s disease through activating autophagy and anti-oxidative stress</article-title>. <source>Biomed. Pharmacother.</source><volume>178</volume>, <fpage>117199</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2024.117199</pub-id><pub-id pub-id-type="pmid">39053426</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macewan</surname><given-names>D. J.</given-names></name></person-group> (<year>2002</year>). <article-title>TNF ligands and receptors--a matter of life and death</article-title>. <source>Br. J. Pharmacol.</source><volume>135</volume> (<issue>4</issue>), <fpage>855</fpage>&#8211;<lpage>875</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjp.0704549</pub-id><pub-id pub-id-type="pmid">11861313</pub-id><pub-id pub-id-type="pmcid">PMC1573213</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malampati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>J. X.</given-names></name><name name-style="western"><surname>Chun-Kit</surname><given-names>T. B.</given-names></name><name name-style="western"><surname>Nalluri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C. B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Targeting aggrephagy for the treatment of Alzheimer's disease</article-title>. <source>Cells</source><volume>9</volume> (<issue>2</issue>), <fpage>311</fpage>. <pub-id pub-id-type="doi">10.3390/cells9020311</pub-id><pub-id pub-id-type="pmid">32012902</pub-id><pub-id pub-id-type="pmcid">PMC7072705</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marinkovic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sprung</surname><given-names>M.</given-names></name><name name-style="western"><surname>Novak</surname><given-names>I.</given-names></name></person-group> (<year>2021</year>). <article-title>Dimerization of mitophagy receptor BNIP3L/NIX is essential for recruitment of autophagic machinery</article-title>. <source>Autophagy</source><volume>17</volume> (<issue>5</issue>), <fpage>1232</fpage>&#8211;<lpage>1243</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.2020.1755120</pub-id><pub-id pub-id-type="pmid">32286918</pub-id><pub-id pub-id-type="pmcid">PMC8143235</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maung</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Olea-Flores</surname><given-names>M.</given-names></name><name name-style="western"><surname>Elkhadragy</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schachtschneider</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Navarro-Tito</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>The molecular and cellular basis of copper dysregulation and its relationship with human pathologies</article-title>. <source>FASEB J.</source><volume>35</volume> (<issue>9</issue>), <fpage>e21810</fpage>. <pub-id pub-id-type="doi">10.1096/fj.202100273RR</pub-id><pub-id pub-id-type="pmid">34390520</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mueller</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Combs</surname><given-names>B.</given-names></name><name name-style="western"><surname>Alhadidy</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Brady</surname><given-names>S. T.</given-names></name><name name-style="western"><surname>Morfini</surname><given-names>G. A.</given-names></name><name name-style="western"><surname>Kanaan</surname><given-names>N. M.</given-names></name></person-group> (<year>2021</year>). <article-title>Tau: a signaling hub protein</article-title>. <source>Front. Mol. Neurosci.</source><volume>14</volume>, <fpage>647054</fpage>. <pub-id pub-id-type="doi">10.3389/fnmol.2021.647054</pub-id><pub-id pub-id-type="pmid">33815057</pub-id><pub-id pub-id-type="pmcid">PMC8017207</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Multhaup</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schlicksupp</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hesse</surname><given-names>L.</given-names></name><name name-style="western"><surname>Beher</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ruppert</surname><given-names>T.</given-names></name><name name-style="western"><surname>Masters</surname><given-names>C. L.</given-names></name><etal/></person-group> (<year>1996</year>). <article-title>The amyloid precursor protein of Alzheimer&#8217;s disease in the reduction of copper(II) to copper(I)</article-title>. <source>Science</source><volume>271</volume> (<issue>5254</issue>), <fpage>1406</fpage>&#8211;<lpage>1409</lpage>. <pub-id pub-id-type="doi">10.1126/science.271.5254.1406</pub-id><pub-id pub-id-type="pmid">8596911</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Czabotar</surname><given-names>P. E.</given-names></name><name name-style="western"><surname>Hildebrand</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Lucet</surname><given-names>I. S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Alvarez-Diaz</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism</article-title>. <source>Immunity</source><volume>39</volume> (<issue>3</issue>), <fpage>443</fpage>&#8211;<lpage>453</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2013.06.018</pub-id><pub-id pub-id-type="pmid">24012422</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakatogawa</surname><given-names>H.</given-names></name></person-group> (<year>2020</year>). <article-title>Mechanisms governing autophagosome biogenesis</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source><volume>21</volume> (<issue>8</issue>), <fpage>439</fpage>&#8211;<lpage>458</lpage>. <pub-id pub-id-type="doi">10.1038/s41580-020-0241-0</pub-id><pub-id pub-id-type="pmid">32372019</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nossing</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>K. M.</given-names></name></person-group> (<year>2023</year>). <article-title>50 years on and still very much alive: &#8216;Apoptosis&#8217;: a basic biological phenomenon with wide-ranging implications in tissue kinetics</article-title>. <source>Br. J. Cancer</source><volume>128</volume> (<issue>3</issue>), <fpage>426</fpage>&#8211;<lpage>431</lpage>. <pub-id pub-id-type="doi">10.1038/s41416-022-02020-0</pub-id><pub-id pub-id-type="pmid">36369364</pub-id><pub-id pub-id-type="pmcid">PMC9938139</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orning</surname><given-names>P.</given-names></name><name name-style="western"><surname>Weng</surname><given-names>D.</given-names></name><name name-style="western"><surname>Starheim</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ratner</surname><given-names>D.</given-names></name><name name-style="western"><surname>Best</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Pathogen blockade of TAK1 triggers caspase-8-dependent cleavage of gasdermin D and cell death</article-title>. <source>Science</source><volume>362</volume> (<issue>6418</issue>), <fpage>1064</fpage>&#8211;<lpage>1069</lpage>. <pub-id pub-id-type="doi">10.1126/science.aau2818</pub-id><pub-id pub-id-type="pmid">30361383</pub-id><pub-id pub-id-type="pmcid">PMC6522129</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Outten</surname><given-names>F. W.</given-names></name><name name-style="western"><surname>Theil</surname><given-names>E. C.</given-names></name></person-group> (<year>2009</year>). <article-title>Iron-based redox switches in biology</article-title>. <source>Antioxid. Redox Signal</source><volume>11</volume> (<issue>5</issue>), <fpage>1029</fpage>&#8211;<lpage>1046</lpage>. <pub-id pub-id-type="doi">10.1089/ars.2008.2296</pub-id><pub-id pub-id-type="pmid">19021503</pub-id><pub-id pub-id-type="pmcid">PMC2842161</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palikaras</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lionaki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tavernarakis</surname><given-names>N.</given-names></name></person-group> (<year>2018</year>). <article-title>Mechanisms of mitophagy in cellular homeostasis, physiology and pathology</article-title>. <source>Nat. Cell Biol.</source><volume>20</volume> (<issue>9</issue>), <fpage>1013</fpage>&#8211;<lpage>1022</lpage>. <pub-id pub-id-type="doi">10.1038/s41556-018-0176-2</pub-id><pub-id pub-id-type="pmid">30154567</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pellegrini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fornai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Antonioli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Blandizzi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Calderone</surname><given-names>V.</given-names></name></person-group> (<year>2019</year>). <article-title>Phytochemicals as novel therapeutic strategies for NLRP3 inflammasome-related neurological, metabolic, and inflammatory diseases</article-title>. <source>Int. J. Mol. Sci.</source><volume>20</volume> (<issue>12</issue>), <fpage>2876</fpage>. <pub-id pub-id-type="doi">10.3390/ijms20122876</pub-id><pub-id pub-id-type="pmid">31200447</pub-id><pub-id pub-id-type="pmcid">PMC6627634</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perez</surname><given-names>D.</given-names></name><name name-style="western"><surname>White</surname><given-names>E.</given-names></name></person-group> (<year>2000</year>). <article-title>TNF-alpha signals apoptosis through a bid-dependent conformational change in Bax that is inhibited by E1B 19K</article-title>. <source>Mol. Cell</source><volume>6</volume> (<issue>1</issue>), <fpage>53</fpage>&#8211;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/s1097-2765(00)00007-1</pub-id><pub-id pub-id-type="pmid">10949027</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peter</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Krammer</surname><given-names>P. H.</given-names></name></person-group> (<year>1998</year>). <article-title>Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis</article-title>. <source>Curr. Opin. Immunol.</source><volume>10</volume> (<issue>5</issue>), <fpage>545</fpage>&#8211;<lpage>551</lpage>. <pub-id pub-id-type="doi">10.1016/s0952-7915(98)80222-7</pub-id><pub-id pub-id-type="pmid">9794832</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Priem</surname><given-names>D.</given-names></name><name name-style="western"><surname>van</surname><given-names>L. O. O. G.</given-names></name><name name-style="western"><surname>Bertrand</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>A20 and cell death-driven inflammation</article-title>. <source>Trends Immunol.</source><volume>41</volume> (<issue>5</issue>), <fpage>421</fpage>&#8211;<lpage>435</lpage>. <pub-id pub-id-type="doi">10.1016/j.it.2020.03.001</pub-id><pub-id pub-id-type="pmid">32241683</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H. T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Astragalus polysaccharide alleviates cognitive impairment and beta-amyloid accumulation in APP/PS1 mice via Nrf2 pathway</article-title>. <source>Biochem. Biophys. Res. Commun.</source><volume>531</volume> (<issue>3</issue>), <fpage>431</fpage>&#8211;<lpage>437</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2020.07.122</pub-id><pub-id pub-id-type="pmid">32800555</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Siwei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Minfang</surname><given-names>G.</given-names></name></person-group> (<year>2025</year>). <article-title>Lycium barbarum polysaccharide intervenes in SH-SY5Y cell injury induced by beta-amyloid protein 1-42: protective effect of mitochondrial autophagy</article-title>. <source>Chin. J. Tissue Eng. Res</source>. <pub-id pub-id-type="doi">10.12307/2025.545</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quiles</surname><given-names>D. R. M.</given-names></name><name name-style="western"><surname>Mancias</surname><given-names>J. D.</given-names></name></person-group> (<year>2019</year>). <article-title>NCOA4-Mediated ferritinophagy: a potential link to neurodegeneration</article-title>. <source>Front. Neurosci.</source><volume>13</volume>, <fpage>238</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2019.00238</pub-id><pub-id pub-id-type="pmid">30930742</pub-id><pub-id pub-id-type="pmcid">PMC6427834</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rasool</surname><given-names>S.</given-names></name><name name-style="western"><surname>Soya</surname><given-names>N.</given-names></name><name name-style="western"><surname>Truong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Croteau</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lukacs</surname><given-names>G. L.</given-names></name><name name-style="western"><surname>Trempe</surname><given-names>J. F.</given-names></name></person-group> (<year>2018</year>). <article-title>PINK1 autophosphorylation is required for ubiquitin recognition</article-title>. <source>EMBO Rep.</source><volume>19</volume> (<issue>4</issue>), <fpage>e44981</fpage>. <pub-id pub-id-type="doi">10.15252/embr.201744981</pub-id><pub-id pub-id-type="pmid">29475881</pub-id><pub-id pub-id-type="pmcid">PMC5891426</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rathinam</surname><given-names>V. A.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>K. A.</given-names></name></person-group> (<year>2016</year>). <article-title>Inflammasome complexes: emerging mechanisms and effector functions</article-title>. <source>Cell</source><volume>165</volume> (<issue>4</issue>), <fpage>792</fpage>&#8211;<lpage>800</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2016.03.046</pub-id><pub-id pub-id-type="pmid">27153493</pub-id><pub-id pub-id-type="pmcid">PMC5503689</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name></person-group> (<year>2022</year>). <article-title>Senegenin inhibits a&#946;<sub>1-42</sub>-induced PC12 cells apoptosis and oxidative stress via activation of the PI3K/Akt signaling pathway</article-title>. <source>Neuropsychiatr. Dis. Treat.</source><volume>18</volume>, <fpage>513</fpage>&#8211;<lpage>524</lpage>. <pub-id pub-id-type="doi">10.2147/NDT.S346238</pub-id><pub-id pub-id-type="pmid">35280979</pub-id><pub-id pub-id-type="pmcid">PMC8904946</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rezai-Zadeh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Arendash</surname><given-names>G. W.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Runfeldt</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice</article-title>. <source>Brain Res.</source><volume>1214</volume>, <fpage>177</fpage>&#8211;<lpage>187</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2008.02.107</pub-id><pub-id pub-id-type="pmid">18457818</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruth</surname><given-names>E.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>L. A. A. J.</given-names></name><name name-style="western"><surname>Burman</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>W. Y.</given-names></name><name name-style="western"><surname>Pallanck</surname><given-names>L. J.</given-names></name></person-group> (<year>2014</year>). <article-title>PINK1-Parkin pathway activity is regulated by degradation of PINK1 in the mitochondrial matrix</article-title>. <source>PLoS Genet.</source><volume>10</volume>, <fpage>e1004279</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pgen.1004279</pub-id><pub-id pub-id-type="pmid">24874806</pub-id><pub-id pub-id-type="pmcid">PMC4038460</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarhan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B. C.</given-names></name><name name-style="western"><surname>Muendlein</surname><given-names>H. I.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nilson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>A. Y.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Caspase-8 induces cleavage of gasdermin D to elicit pyroptosis during Yersinia infection</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>115</volume> (<issue>46</issue>), <fpage>E10888-E10897</fpage>&#8211;<lpage>E10897</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1809548115</pub-id><pub-id pub-id-type="pmid">30381458</pub-id><pub-id pub-id-type="pmcid">PMC6243247</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sekine</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sideris</surname><given-names>D. P.</given-names></name><name name-style="western"><surname>Bunker</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Youle</surname><given-names>R. J.</given-names></name></person-group> (<year>2019</year>). <article-title>Reciprocal roles of Tom7 and OMA1 during mitochondrial import and activation of PINK1</article-title>. <source>Mol. Cell</source><volume>73</volume> (<issue>5</issue>), <fpage>1028</fpage>&#8211;<lpage>1043</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2019.01.002</pub-id><pub-id pub-id-type="pmid">30733118</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>P.</given-names></name><name name-style="western"><surname>Giri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tripathi</surname><given-names>P. N.</given-names></name></person-group> (<year>2024</year>). <article-title>Emerging trends: neurofilament biomarkers in precision neurology</article-title>. <source>Neurochem. Res.</source><volume>49</volume> (<issue>12</issue>), <fpage>3208</fpage>&#8211;<lpage>3225</lpage>. <pub-id pub-id-type="doi">10.1007/s11064-024-04244-3</pub-id><pub-id pub-id-type="pmid">39347854</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>X. Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ting</surname><given-names>O. Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Quercetin inhibits okadaic acid-induced tau protein hyperphosphorylation through the Ca2+-calpain-p25-CDK5 pathway in HT22 cells</article-title>. <source>Int. J. Mol. Med.</source><volume>41</volume> (<issue>2</issue>), <fpage>1138</fpage>&#8211;<lpage>1146</lpage>. <pub-id pub-id-type="doi">10.3892/ijmm.2017.3281</pub-id><pub-id pub-id-type="pmid">29207020</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Potential immunoregulatory mechanism of plant saponins: a review</article-title>. <source>Molecules</source><volume>29</volume> (<issue>1</issue>), <fpage>113</fpage>. <pub-id pub-id-type="doi">10.3390/molecules29010113</pub-id><pub-id pub-id-type="pmid">38202696</pub-id><pub-id pub-id-type="pmcid">PMC10780299</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Inflammatory caspases are innate immune receptors for intracellular LPS</article-title>. <source>Nature</source><volume>514</volume> (<issue>7521</issue>), <fpage>187</fpage>&#8211;<lpage>192</lpage>. <pub-id pub-id-type="doi">10.1038/nature13683</pub-id><pub-id pub-id-type="pmid">25119034</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shuangmei</surname><given-names>Z. W. Z. A.</given-names></name></person-group> (<year>2021</year>). <article-title>Attenuation of A&#946;25-35-induced neurotoxicity by salidroside through activation of Nrf2/HO-1 pathway</article-title>. <source>Chin. Archives Traditional Chin. Med.</source><volume>39</volume> (<issue>1</issue>), <fpage>101</fpage>&#8211;<lpage>106</lpage>. <pub-id pub-id-type="doi">10.13193/j.issn.1673-7717.2021.01.027</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shukla</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S. K.</given-names></name></person-group> (<year>2011</year>). <article-title>Sinomenine inhibits microglial activation by A&#946; and confers neuroprotection</article-title>. <source>J. Neuroinflammation</source><volume>8</volume>, <fpage>117</fpage>. <pub-id pub-id-type="doi">10.1186/1742-2094-8-117</pub-id><pub-id pub-id-type="pmid">21917137</pub-id><pub-id pub-id-type="pmcid">PMC3182919</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siddiqui</surname><given-names>N.</given-names></name><name name-style="western"><surname>Saifi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chaudhary</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tripathi</surname><given-names>P. N.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></name></person-group> (<year>2024a</year>). <article-title>Multifaceted neuroprotective role of Punicalagin: a review</article-title>. <source>Neurochem. Res.</source><volume>49</volume> (<issue>6</issue>), <fpage>1427</fpage>&#8211;<lpage>1436</lpage>. <pub-id pub-id-type="doi">10.1007/s11064-023-04081-w</pub-id><pub-id pub-id-type="pmid">38085406</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siddiqui</surname><given-names>N.</given-names></name><name name-style="western"><surname>Talib</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tripathi</surname><given-names>P. N.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></name></person-group> (<year>2024b</year>). <article-title>Therapeutic potential of baicalein against neurodegenerative diseases: an updated review</article-title>. <source>Health Sci. Rev.</source><volume>11</volume>, <fpage>100172</fpage>. <pub-id pub-id-type="doi">10.1016/j.hsr.2024.100172</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sampaio-Marques</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>P.</given-names></name><name name-style="western"><surname>Neves-Carvalho</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dioli</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Dysregulation of autophagy and stress granule-related proteins in stress-driven Tau pathology</article-title>. <source>Cell Death Differ.</source><volume>26</volume> (<issue>8</issue>), <fpage>1411</fpage>&#8211;<lpage>1427</lpage>. <pub-id pub-id-type="doi">10.1038/s41418-018-0217-1</pub-id><pub-id pub-id-type="pmid">30442948</pub-id><pub-id pub-id-type="pmcid">PMC6748085</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stancu</surname><given-names>I. C.</given-names></name><name name-style="western"><surname>Cremers</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vanrusselt</surname><given-names>H.</given-names></name><name name-style="western"><surname>Couturier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vanoosthuyse</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kessels</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Aggregated Tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology <italic toggle="yes">in vivo</italic>
</article-title>. <source>Acta Neuropathol.</source><volume>137</volume> (<issue>4</issue>), <fpage>599</fpage>&#8211;<lpage>617</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-018-01957-y</pub-id><pub-id pub-id-type="pmid">30721409</pub-id><pub-id pub-id-type="pmcid">PMC6426830</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strilic</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Albarran-Juarez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wachsmuth</surname><given-names>L.</given-names></name><name name-style="western"><surname>Han</surname><given-names>K.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>U. C.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis</article-title>. <source>Nature</source><volume>536</volume> (<issue>7615</issue>), <fpage>215</fpage>&#8211;<lpage>218</lpage>. <pub-id pub-id-type="doi">10.1038/nature19076</pub-id><pub-id pub-id-type="pmid">27487218</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suliman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Datta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>R. K.</given-names></name></person-group> (<year>2001</year>). <article-title>Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways</article-title>. <source>Oncogene</source><volume>20</volume> (<issue>17</issue>), <fpage>2122</fpage>&#8211;<lpage>2133</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1204282</pub-id><pub-id pub-id-type="pmid">11360196</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Teng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group> (<year>2017</year>). <article-title>Curcumin decreases hyperphosphorylation of tau by down-regulating Caveolin-1/GSK-3&#946; in N2a/APP695swe cells and APP/PS1 double transgenic Alzheimer&#8217;s disease mice</article-title>. <source>Am. J. Chin. Med.</source><volume>45</volume> (<issue>8</issue>), <fpage>1667</fpage>&#8211;<lpage>1682</lpage>. <pub-id pub-id-type="doi">10.1142/S0192415X17500902</pub-id><pub-id pub-id-type="pmid">29132216</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Lactylation of METTL16 promotes cuproptosis via m(6)A-modification on FDX1 mRNA in gastric cancer</article-title>. <source>Nat. Commun.</source><volume>14</volume> (<issue>1</issue>), <fpage>6523</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-023-42025-8</pub-id><pub-id pub-id-type="pmid">37863889</pub-id><pub-id pub-id-type="pmcid">PMC10589265</pub-id></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tait</surname><given-names>S. W.</given-names></name><name name-style="western"><surname>Green</surname><given-names>D. R.</given-names></name></person-group> (<year>2010</year>). <article-title>Mitochondria and cell death: outer membrane permeabilization and beyond</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source><volume>11</volume> (<issue>9</issue>), <fpage>621</fpage>&#8211;<lpage>632</lpage>. <pub-id pub-id-type="doi">10.1038/nrm2952</pub-id><pub-id pub-id-type="pmid">20683470</pub-id></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X. C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H. F.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>C. D.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Amyloid-beta induces NLRP1-dependent neuronal pyroptosis in models of Alzheimer&#8217;s disease</article-title>. <source>Cell Death Dis.</source><volume>5</volume> (<issue>8</issue>), <fpage>e1382</fpage>. <pub-id pub-id-type="doi">10.1038/cddis.2014.348</pub-id><pub-id pub-id-type="pmid">25144717</pub-id><pub-id pub-id-type="pmcid">PMC4454321</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name></person-group> (<year>2021</year>). <article-title>Ferroptosis: molecular mechanisms and health implications</article-title>. <source>Cell Res.</source><volume>31</volume> (<issue>2</issue>), <fpage>107</fpage>&#8211;<lpage>125</lpage>. <pub-id pub-id-type="doi">10.1038/s41422-020-00441-1</pub-id><pub-id pub-id-type="pmid">33268902</pub-id><pub-id pub-id-type="pmcid">PMC8026611</pub-id></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name></person-group> (<year>2022</year>). <article-title>Cuproptosis: a copper-triggered modality of mitochondrial cell death</article-title>. <source>Cell Res.</source><volume>32</volume> (<issue>5</issue>), <fpage>417</fpage>&#8211;<lpage>418</lpage>. <pub-id pub-id-type="doi">10.1038/s41422-022-00653-7</pub-id><pub-id pub-id-type="pmid">35354936</pub-id><pub-id pub-id-type="pmcid">PMC9061796</pub-id></mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Quantitative proteomic analysis reveals the neuroprotective effects of huperzine A for amyloid beta treated neuroblastoma N2a cells</article-title>. <source>Proteomics</source><volume>13</volume> (<issue>8</issue>), <fpage>1314</fpage>&#8211;<lpage>1324</lpage>. <pub-id pub-id-type="doi">10.1002/pmic.201200437</pub-id><pub-id pub-id-type="pmid">23424162</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tao</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>The antitumor effects of icaritin against breast cancer is related to estrogen receptors</article-title>. <source>Curr. Mol. Med.</source><volume>21</volume> (<issue>1</issue>), <fpage>73</fpage>&#8211;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.2174/1566524020666200530212440</pub-id><pub-id pub-id-type="pmid">32472997</pub-id></mixed-citation></ref><ref id="B136"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tenev</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bianchi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Darding</surname><given-names>M.</given-names></name><name name-style="western"><surname>Broemer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Langlais</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wallberg</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs</article-title>. <source>Mol. Cell</source><volume>43</volume> (<issue>3</issue>), <fpage>432</fpage>&#8211;<lpage>448</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2011.06.006</pub-id><pub-id pub-id-type="pmid">21737329</pub-id></mixed-citation></ref><ref id="B137"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name></person-group> (<year>2022</year>). <article-title>Senegenin alleviates A&#946;<sub>1-42</sub> induced cell damage through triggering mitophagy</article-title>. <source>J. Ethnopharmacol.</source><volume>295</volume>, <fpage>115409</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2022.115409</pub-id><pub-id pub-id-type="pmid">35640739</pub-id></mixed-citation></ref><ref id="B138"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toldo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abbate</surname><given-names>A.</given-names></name></person-group> (<year>2024</year>). <article-title>The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases</article-title>. <source>Nat. Rev. Cardiol.</source><volume>21</volume> (<issue>4</issue>), <fpage>219</fpage>&#8211;<lpage>237</lpage>. <pub-id pub-id-type="doi">10.1038/s41569-023-00946-3</pub-id><pub-id pub-id-type="pmid">37923829</pub-id><pub-id pub-id-type="pmcid">PMC11550901</pub-id></mixed-citation></ref><ref id="B139"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsvetkov</surname><given-names>P.</given-names></name><name name-style="western"><surname>Detappe</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Keys</surname><given-names>H. R.</given-names></name><name name-style="western"><surname>Brune</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ying</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Mitochondrial metabolism promotes adaptation to proteotoxic stress</article-title>. <source>Nat. Chem. Biol.</source><volume>15</volume> (<issue>7</issue>), <fpage>681</fpage>&#8211;<lpage>689</lpage>. <pub-id pub-id-type="doi">10.1038/s41589-019-0291-9</pub-id><pub-id pub-id-type="pmid">31133756</pub-id><pub-id pub-id-type="pmcid">PMC8183600</pub-id></mixed-citation></ref><ref id="B140"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsvetkov</surname><given-names>P.</given-names></name><name name-style="western"><surname>Coy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Petrova</surname><given-names>B.</given-names></name><name name-style="western"><surname>Dreishpoon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abdusamad</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Copper induces cell death by targeting lipoylated TCA cycle proteins</article-title>. <source>Science</source><volume>375</volume> (<issue>6586</issue>), <fpage>1254</fpage>&#8211;<lpage>1261</lpage>. <pub-id pub-id-type="doi">10.1126/science.abf0529</pub-id><pub-id pub-id-type="pmid">35298263</pub-id><pub-id pub-id-type="pmcid">PMC9273333</pub-id></mixed-citation></ref><ref id="B141"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ulamek-Koziol</surname><given-names>M.</given-names></name><name name-style="western"><surname>Czuczwar</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Januszewski</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pluta</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Proteomic and genomic changes in tau protein, which are associated with Alzheimer&#8217;s disease after ischemia-reperfusion brain injury</article-title>. <source>Int. J. Mol. Sci.</source><volume>21</volume> (<issue>3</issue>), <fpage>892</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21030892</pub-id><pub-id pub-id-type="pmid">32019137</pub-id><pub-id pub-id-type="pmcid">PMC7037789</pub-id></mixed-citation></ref><ref id="B142"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Um</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Nathan</surname><given-names>A. B. P.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y. Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D. Y.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Selective induction of Rab9-dependent alternative mitophagy using a synthetic derivative of isoquinoline alleviates mitochondrial dysfunction and cognitive deficits in Alzheimer&#8217;s disease models</article-title>. <source>Theranostics</source><volume>14</volume> (<issue>1</issue>), <fpage>56</fpage>&#8211;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.7150/thno.88718</pub-id><pub-id pub-id-type="pmid">38164158</pub-id><pub-id pub-id-type="pmcid">PMC10750208</pub-id></mixed-citation></ref><ref id="B143"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vargas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hamasaki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kawabata</surname><given-names>T.</given-names></name><name name-style="western"><surname>Youle</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Yoshimori</surname><given-names>T.</given-names></name></person-group> (<year>2023</year>). <article-title>The mechanisms and roles of selective autophagy in mammals</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source><volume>24</volume> (<issue>3</issue>), <fpage>167</fpage>&#8211;<lpage>185</lpage>. <pub-id pub-id-type="doi">10.1038/s41580-022-00542-2</pub-id><pub-id pub-id-type="pmid">36302887</pub-id></mixed-citation></ref><ref id="B144"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>STING directly recruits WIPI2 for autophagosome formation during STING-induced autophagy</article-title>. <source>EMBO J.</source><volume>42</volume> (<issue>8</issue>), <fpage>e112387</fpage>. <pub-id pub-id-type="doi">10.15252/embj.2022112387</pub-id><pub-id pub-id-type="pmid">36872914</pub-id><pub-id pub-id-type="pmcid">PMC10106988</pub-id></mixed-citation></ref><ref id="B145"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Su</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rizo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L. F.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3</article-title>. <source>Mol. Cell</source><volume>54</volume> (<issue>1</issue>), <fpage>133</fpage>&#8211;<lpage>146</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2014.03.003</pub-id><pub-id pub-id-type="pmid">24703947</pub-id></mixed-citation></ref><ref id="B146"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>&#945;-synuclein promotes progression of Parkinson&#8217;s disease by upregulating autophagy signaling pathway to activate NLRP3 inflammasome</article-title>. <source>Exp. Ther. Med.</source><volume>19</volume> (<issue>2</issue>), <fpage>931</fpage>&#8211;<lpage>938</lpage>. <pub-id pub-id-type="doi">10.3892/etm.2019.8297</pub-id><pub-id pub-id-type="pmid">32010254</pub-id><pub-id pub-id-type="pmcid">PMC6966172</pub-id></mixed-citation></ref><ref id="B147"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>G.</given-names></name></person-group> (<year>2021</year>). <article-title>Depichering the effects of astragaloside IV on AD-like phenotypes: a systematic and experimental investigation</article-title>. <source>Oxid. Med. Cell Longev.</source><volume>2021</volume>, <fpage>1020614</fpage>. <pub-id pub-id-type="doi">10.1155/2021/1020614</pub-id><pub-id pub-id-type="pmid">34616501</pub-id><pub-id pub-id-type="pmcid">PMC8487832</pub-id></mixed-citation></ref><ref id="B148"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mei</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2022a</year>). <article-title>Ferroptosis promotes microtubule-associated protein tau aggregation via GSK-3&#946; activation and proteasome inhibition</article-title>. <source>Mol. Neurobiol.</source><volume>59</volume> (<issue>3</issue>), <fpage>1486</fpage>&#8211;<lpage>1501</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-022-02731-8</pub-id><pub-id pub-id-type="pmid">34997541</pub-id></mixed-citation></ref><ref id="B149"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>N.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name></person-group> (<year>2022b</year>). <article-title>Molecular mechanisms of ferroptosis and its role in prostate cancer therapy</article-title>. <source>Crit. Rev. Oncol. Hematol.</source><volume>176</volume>, <fpage>103732</fpage>. <pub-id pub-id-type="doi">10.1016/j.critrevonc.2022.103732</pub-id><pub-id pub-id-type="pmid">35697233</pub-id></mixed-citation></ref><ref id="B150"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name></person-group> (<year>2022c</year>). <article-title>IKK&#946; alleviates neuron injury in Alzheimer&#8217;s disease via regulating autophagy and RIPK1-mediated necroptosis</article-title>. <source>Mol. Neurobiol.</source><volume>59</volume> (<issue>4</issue>), <fpage>2407</fpage>&#8211;<lpage>2423</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-021-02652-y</pub-id><pub-id pub-id-type="pmid">35083662</pub-id></mixed-citation></ref><ref id="B151"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name></person-group> (<year>2023</year>). <article-title>Berberine rescues D-ribose-induced Alzheimer&#8217;s pathology via promoting mitophagy</article-title>. <source>Int. J. Mol. Sci.</source><volume>24</volume> (<issue>6</issue>), <fpage>5896</fpage>. <pub-id pub-id-type="doi">10.3390/ijms24065896</pub-id><pub-id pub-id-type="pmid">36982968</pub-id><pub-id pub-id-type="pmcid">PMC10055824</pub-id></mixed-citation></ref><ref id="B152"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pei</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group> (<year>2024</year>). <article-title>Copper in colorectal cancer: from copper-related mechanisms to clinical cancer therapies</article-title>. <source>Clin. Transl. Med.</source><volume>14</volume> (<issue>6</issue>), <fpage>e1724</fpage>. <pub-id pub-id-type="doi">10.1002/ctm2.1724</pub-id><pub-id pub-id-type="pmid">38804588</pub-id><pub-id pub-id-type="pmcid">PMC11131360</pub-id></mixed-citation></ref><ref id="B153"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Zong</surname><given-names>W. X.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>E. H.</given-names></name><name name-style="western"><surname>Lindsten</surname><given-names>T.</given-names></name><name name-style="western"><surname>Panoutsakopoulou</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>A. J.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death</article-title>. <source>Science</source><volume>292</volume> (<issue>5517</issue>), <fpage>727</fpage>&#8211;<lpage>730</lpage>. <pub-id pub-id-type="doi">10.1126/science.1059108</pub-id><pub-id pub-id-type="pmid">11326099</pub-id><pub-id pub-id-type="pmcid">PMC3049805</pub-id></mixed-citation></ref><ref id="B154"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weinlich</surname><given-names>R.</given-names></name><name name-style="western"><surname>Oberst</surname><given-names>A.</given-names></name><name name-style="western"><surname>Beere</surname><given-names>H. M.</given-names></name><name name-style="western"><surname>Green</surname><given-names>D. R.</given-names></name></person-group> (<year>2017</year>). <article-title>Necroptosis in development, inflammation and disease</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source><volume>18</volume> (<issue>2</issue>), <fpage>127</fpage>&#8211;<lpage>136</lpage>. <pub-id pub-id-type="doi">10.1038/nrm.2016.149</pub-id><pub-id pub-id-type="pmid">27999438</pub-id></mixed-citation></ref><ref id="B155"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weller</surname><given-names>J.</given-names></name><name name-style="western"><surname>Budson</surname><given-names>A.</given-names></name></person-group> (<year>2018</year>). <article-title>Current understanding of Alzheimer&#8217;s disease diagnosis and treatment</article-title>. <source>F1000Res</source><volume>7</volume>, <fpage>F1000 Faculty Rev-1161</fpage>. <pub-id pub-id-type="doi">10.12688/f1000research.14506.1</pub-id><pub-id pub-id-type="pmid">30135715</pub-id><pub-id pub-id-type="pmcid">PMC6073093</pub-id></mixed-citation></ref><ref id="B156"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whyte</surname><given-names>L. S.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Hemsley</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Hopwood</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Sargeant</surname><given-names>T. J.</given-names></name></person-group> (<year>2017</year>). <article-title>Endo-lysosomal and autophagic dysfunction: a driving factor in Alzheimer&#8217;s disease?</article-title><source>J. Neurochem.</source><volume>140</volume> (<issue>5</issue>), <fpage>703</fpage>&#8211;<lpage>717</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.13935</pub-id><pub-id pub-id-type="pmid">28027395</pub-id></mixed-citation></ref><ref id="B157"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>H. H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R. H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H. B.</given-names></name><name name-style="western"><surname>Song</surname><given-names>H. P.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Icarisid II rescues cognitive dysfunction via activation of Wnt/&#946;-catenin signaling pathway promoting hippocampal neurogenesis in APP/PS1 transgenic mice</article-title>. <source>Phytother. Res.</source><volume>36</volume> (<issue>5</issue>), <fpage>2095</fpage>&#8211;<lpage>2108</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.7430</pub-id><pub-id pub-id-type="pmid">35230733</pub-id></mixed-citation></ref><ref id="B158"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Effect of Huperzine A on A&#946;-induced p65 of astrocyte <italic toggle="yes">in vitro</italic>
</article-title>. <source>Biosci. Biotechnol. Biochem.</source><volume>80</volume> (<issue>12</issue>), <fpage>2334</fpage>&#8211;<lpage>2337</lpage>. <pub-id pub-id-type="doi">10.1080/09168451.2016.1222265</pub-id><pub-id pub-id-type="pmid">27554967</pub-id></mixed-citation></ref><ref id="B159"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>The tumor suppressor p53 limits ferroptosis by blocking DPP4 activity</article-title>. <source>Cell Rep.</source><volume>20</volume> (<issue>7</issue>), <fpage>1692</fpage>&#8211;<lpage>1704</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2017.07.055</pub-id><pub-id pub-id-type="pmid">28813679</pub-id></mixed-citation></ref><ref id="B160"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Salidroside attenuates cognitive dysfunction in senescence-accelerated mouse prone 8 (SAMP8) mice and modulates inflammation of the gut-brain axis</article-title>. <source>Front. Pharmacol.</source><volume>11</volume>, <fpage>568423</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.568423</pub-id><pub-id pub-id-type="pmid">33362539</pub-id><pub-id pub-id-type="pmcid">PMC7759146</pub-id></mixed-citation></ref><ref id="B161"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.</given-names></name></person-group> (<year>2023a</year>). <article-title>Cuproptosis: mechanisms and links with cancers</article-title>. <source>Mol. Cancer</source><volume>22</volume> (<issue>1</issue>), <fpage>46</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-023-01732-y</pub-id><pub-id pub-id-type="pmid">36882769</pub-id><pub-id pub-id-type="pmcid">PMC9990368</pub-id></mixed-citation></ref><ref id="B162"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>D.</given-names></name><name name-style="western"><surname>Song</surname><given-names>C.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2023b</year>). <article-title>Moschus ameliorates glutamate-induced cellular damage by regulating autophagy and apoptosis pathway</article-title>. <source>Sci. Rep.</source><volume>13</volume> (<issue>1</issue>), <fpage>18586</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-023-45878-7</pub-id><pub-id pub-id-type="pmid">37903904</pub-id><pub-id pub-id-type="pmcid">PMC10616123</pub-id></mixed-citation></ref><ref id="B163"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name></person-group> (<year>2021</year>). <article-title>Astragaloside IV protects 6-hydroxydopamine-induced SH-SY5Y cell model of Parkinson&#8217;s disease via activating the JAK2/STAT3 pathway</article-title>. <source>Front. Neurosci.</source><volume>15</volume>, <fpage>631501</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2021.631501</pub-id><pub-id pub-id-type="pmid">33833662</pub-id><pub-id pub-id-type="pmcid">PMC8021720</pub-id></mixed-citation></ref><ref id="B164"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H. Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X. C.</given-names></name></person-group> (<year>2007</year>). <article-title>Involvement of M1-muscarinic acetylcholine receptors, protein kinase C and mitogen-activated protein kinase in the effect of huperzine A on secretory amyloid precursor protein-alpha</article-title>. <source>Neuroreport</source><volume>18</volume> (<issue>7</issue>), <fpage>689</fpage>&#8211;<lpage>692</lpage>. <pub-id pub-id-type="doi">10.1097/WNR.0b013e3280c1e28c</pub-id><pub-id pub-id-type="pmid">17426600</pub-id></mixed-citation></ref><ref id="B165"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>G.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Ginsenoside compound K alleviates brain aging by inhibiting ferroptosis through modulation of the ASK1-MKK7-JNK signaling pathway</article-title>. <source>Phytomedicine</source><volume>135</volume>, <fpage>156239</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2024.156239</pub-id><pub-id pub-id-type="pmid">39547099</pub-id></mixed-citation></ref><ref id="B166"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X. Z.</given-names></name><name name-style="western"><surname>Q</surname><given-names>C.</given-names></name><name name-style="western"><surname>Q</surname><given-names>C.</given-names></name></person-group> (<year>2013</year>). <article-title>Protection of tenuigenin against apoptosis of PC12 cells induced by amyloid beta-protein fragment 1-40</article-title>. <source>Chin. J. Pharmacol. Toxic</source>. <volume>27</volume>, <fpage>379</fpage>&#8211;<lpage>384</lpage>. <pub-id pub-id-type="doi">10.3867/j.issn.1000-3002.2013.03.013</pub-id></mixed-citation></ref><ref id="B167"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xiu</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Ginsenoside compound K regulates amyloid beta via the nrf2/Keap1 signaling pathway in mice with scopolamine hydrobromide-induced memory impairments</article-title>. <source>J. Mol. Neurosci.</source><volume>67</volume> (<issue>1</issue>), <fpage>62</fpage>&#8211;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1007/s12031-018-1210-3</pub-id><pub-id pub-id-type="pmid">30535776</pub-id></mixed-citation></ref><ref id="B168"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>A.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2022a</year>). <article-title>The mechanism of ferroptosis regulating oxidative stress in ischemic stroke and the regulation mechanism of natural pharmacological active components</article-title>. <source>Biomed. Pharmacother.</source><volume>154</volume>, <fpage>113611</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2022.113611</pub-id><pub-id pub-id-type="pmid">36081288</pub-id></mixed-citation></ref><ref id="B169"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bettadapura</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Smeltzer</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name></person-group> (<year>2022b</year>). <article-title>Pyroptosis and pyroptosis-inducing cancer drugs</article-title>. <source>Acta Pharmacol. Sin.</source><volume>43</volume> (<issue>10</issue>), <fpage>2462</fpage>&#8211;<lpage>2473</lpage>. <pub-id pub-id-type="doi">10.1038/s41401-022-00887-6</pub-id><pub-id pub-id-type="pmid">35288674</pub-id><pub-id pub-id-type="pmcid">PMC9525650</pub-id></mixed-citation></ref><ref id="B170"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Pei</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2022c</year>). <article-title>Salidroside attenuates neuronal ferroptosis by activating the Nrf2/HO1 signaling pathway in A&#946;<sub>1-42</sub>-induced Alzheimer&#8217;s disease mice and glutamate-injured HT22 cells</article-title>. <source>Chin. Med.</source><volume>17</volume> (<issue>1</issue>), <fpage>82</fpage>. <pub-id pub-id-type="doi">10.1186/s13020-022-00634-3</pub-id><pub-id pub-id-type="pmid">35787281</pub-id><pub-id pub-id-type="pmcid">PMC9254541</pub-id></mixed-citation></ref><ref id="B171"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Pei</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2023a</year>). <article-title>Icariin improves cognitive impairment by inhibiting ferroptosis of nerve cells</article-title>. <source>Aging (Albany NY)</source><volume>15</volume> (<issue>20</issue>), <fpage>11546</fpage>&#8211;<lpage>11553</lpage>. <pub-id pub-id-type="doi">10.18632/aging.205144</pub-id><pub-id pub-id-type="pmid">37889523</pub-id><pub-id pub-id-type="pmcid">PMC10637794</pub-id></mixed-citation></ref><ref id="B172"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pei</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2023b</year>). <article-title>Salidroside alleviates cognitive impairment by inhibiting ferroptosis via activation of the Nrf2/GPX4 axis in SAMP8 mice</article-title>. <source>Phytomedicine</source><volume>114</volume>, <fpage>154762</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2023.154762</pub-id><pub-id pub-id-type="pmid">36965372</pub-id></mixed-citation></ref><ref id="B173"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>C. Y.</given-names></name><name name-style="western"><surname>Lien</surname><given-names>C. I.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>Y. C.</given-names></name><name name-style="western"><surname>Tu</surname><given-names>Y. F.</given-names></name><name name-style="western"><surname>Kulczyk</surname><given-names>A. W.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y. C.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Deciphering DED assembly mechanisms in FADD-procaspase-8-cFLIP complexes regulating apoptosis</article-title>. <source>Nat. Commun.</source><volume>15</volume> (<issue>1</issue>), <fpage>3791</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-024-47990-2</pub-id><pub-id pub-id-type="pmid">38710704</pub-id><pub-id pub-id-type="pmcid">PMC11074299</pub-id></mixed-citation></ref><ref id="B174"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Icariin and its metabolites as potential protective phytochemicals against cardiovascular disease: from effects to molecular mechanisms</article-title>. <source>Biomed. Pharmacother.</source><volume>147</volume>, <fpage>112642</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2022.112642</pub-id><pub-id pub-id-type="pmid">35078094</pub-id></mixed-citation></ref><ref id="B175"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>C.</given-names></name></person-group> (<year>2020</year>). <article-title>Matrine: a promising natural product with various pharmacological activities</article-title>. <source>Front. Pharmacol.</source><volume>11</volume>, <fpage>588</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.00588</pub-id><pub-id pub-id-type="pmid">32477114</pub-id><pub-id pub-id-type="pmcid">PMC7232545</pub-id></mixed-citation></ref><ref id="B176"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sun-Waterhouse</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Anti-inflammatory and antioxidant effects of Chaetoglobosin Vb in LPS-induced RAW264.7 cells: achieved via the MAPK and NF-&#954;B signaling pathways</article-title>. <source>Food Chem. Toxicol.</source><volume>147</volume>, <fpage>111915</fpage>. <pub-id pub-id-type="doi">10.1016/j.fct.2020.111915</pub-id><pub-id pub-id-type="pmid">33285210</pub-id></mixed-citation></ref><ref id="B177"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name></person-group> (<year>2022a</year>). <article-title>Cell death mechanisms in cerebral ischemia-reperfusion injury</article-title>. <source>Neurochem. Res.</source><volume>47</volume> (<issue>12</issue>), <fpage>3525</fpage>&#8211;<lpage>3542</lpage>. <pub-id pub-id-type="doi">10.1007/s11064-022-03697-8</pub-id><pub-id pub-id-type="pmid">35976487</pub-id></mixed-citation></ref><ref id="B178"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L. S.</given-names></name></person-group> (<year>2022b</year>). <article-title>Role of pyroptosis in inflammatory bowel disease (IBD): from gasdermins to DAMPs</article-title>. <source>Front. Pharmacol.</source><volume>13</volume>, <fpage>833588</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2022.833588</pub-id><pub-id pub-id-type="pmid">35677444</pub-id><pub-id pub-id-type="pmcid">PMC9168461</pub-id></mixed-citation></ref><ref id="B179"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2022c</year>). <article-title>Senegenin rescues PC12 cells with oxidative damage through inhibition of ferroptosis</article-title>. <source>Mol. Neurobiol.</source><volume>59</volume> (<issue>11</issue>), <fpage>6983</fpage>&#8211;<lpage>6992</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-022-03014-y</pub-id><pub-id pub-id-type="pmid">36068400</pub-id></mixed-citation></ref><ref id="B180"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>B. X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G. Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y. Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q. H.</given-names></name></person-group> (<year>2023a</year>). <article-title>Protective effects of berberine against beta-amyloid-induced neurotoxicity in HT22 cells via the Nrf2/HO-1 pathway</article-title>. <source>Bioorg Chem.</source><volume>133</volume>, <fpage>106210</fpage>. <pub-id pub-id-type="doi">10.1016/j.bioorg.2022.106210</pub-id><pub-id pub-id-type="pmid">36724611</pub-id></mixed-citation></ref><ref id="B181"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yong</surname><given-names>Y. Y.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Law</surname><given-names>B. Y. K.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>M. L.</given-names></name><etal/></person-group> (<year>2023b</year>). <article-title>Therapeutic potential of Polygala saponins in neurological diseases</article-title>. <source>Phytomedicine</source><volume>108</volume>, <fpage>154483</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2022.154483</pub-id><pub-id pub-id-type="pmid">36260972</pub-id></mixed-citation></ref><ref id="B182"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name></person-group> (<year>2024a</year>). <article-title>Crosstalk among mitophagy, pyroptosis, ferroptosis, and necroptosis in central nervous system injuries</article-title>. <source>Neural Regen. Res.</source><volume>19</volume> (<issue>8</issue>), <fpage>1660</fpage>&#8211;<lpage>1670</lpage>. <pub-id pub-id-type="doi">10.4103/1673-5374.389361</pub-id><pub-id pub-id-type="pmid">38103229</pub-id><pub-id pub-id-type="pmcid">PMC10960298</pub-id></mixed-citation></ref><ref id="B183"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name></person-group> (<year>2024b</year>). <article-title>Recent advances in Alzheimer&#8217;s disease: mechanisms, clinical trials and new drug development strategies</article-title>. <source>Signal Transduct. Target Ther.</source><volume>9</volume> (<issue>1</issue>), <fpage>211</fpage>. <pub-id pub-id-type="doi">10.1038/s41392-024-01911-3</pub-id><pub-id pub-id-type="pmid">39174535</pub-id><pub-id pub-id-type="pmcid">PMC11344989</pub-id></mixed-citation></ref><ref id="B184"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jing</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2024c</year>). <article-title>Inhibiting the compensatory elevation of xCT collaborates with disulfiram/copper-induced GSH consumption for cascade ferroptosis and cuproptosis</article-title>. <source>Redox Biol.</source><volume>69</volume>, <fpage>103007</fpage>. <pub-id pub-id-type="doi">10.1016/j.redox.2023.103007</pub-id><pub-id pub-id-type="pmid">38150993</pub-id><pub-id pub-id-type="pmcid">PMC10788306</pub-id></mixed-citation></ref><ref id="B185"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>N.</given-names></name></person-group> (<year>2016</year>). <article-title>Lycium barbarum polysaccharides protect against trimethyltin chloride-induced apoptosis via Sonic hedgehog and PI3K/Akt signaling pathways in mouse Neuro-2a cells</article-title>. <source>Oxid. Med. Cell Longev.</source><volume>2016</volume>, <fpage>9826726</fpage>. <pub-id pub-id-type="doi">10.1155/2016/9826726</pub-id><pub-id pub-id-type="pmid">27143997</pub-id><pub-id pub-id-type="pmcid">PMC4838808</pub-id></mixed-citation></ref><ref id="B186"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X. Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y. P.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>P. S.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Neuroprotective effects of Lycium barbarum polysaccharide on focal cerebral ischemic injury in mice</article-title>. <source>Neurochem. Res.</source><volume>42</volume> (<issue>10</issue>), <fpage>2798</fpage>&#8211;<lpage>2813</lpage>. <pub-id pub-id-type="doi">10.1007/s11064-017-2293-x</pub-id><pub-id pub-id-type="pmid">28508173</pub-id></mixed-citation></ref><ref id="B187"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Mechanisms of ferroptosis in Alzheimer&#8217;s disease and therapeutic effects of natural plant products: a review</article-title>. <source>Biomed. Pharmacother.</source><volume>164</volume>, <fpage>114312</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2023.114312</pub-id><pub-id pub-id-type="pmid">37210894</pub-id></mixed-citation></ref><ref id="B188"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>D.</given-names></name><name name-style="western"><surname>Long</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Altered synaptic currents, mitophagy, mitochondrial dynamics in Alzheimer&#8217;s disease models and therapeutic potential of Dengzhan Shengmai capsules intervention</article-title>. <source>J. Pharm. Anal.</source><volume>14</volume> (<issue>3</issue>), <fpage>348</fpage>&#8211;<lpage>370</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpha.2023.10.006</pub-id><pub-id pub-id-type="pmid">38618251</pub-id><pub-id pub-id-type="pmcid">PMC11010627</pub-id></mixed-citation></ref><ref id="B189"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Conrad</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>The metabolic underpinnings of ferroptosis</article-title>. <source>Cell Metab.</source><volume>32</volume> (<issue>6</issue>), <fpage>920</fpage>&#8211;<lpage>937</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2020.10.011</pub-id><pub-id pub-id-type="pmid">33217331</pub-id></mixed-citation></ref><ref id="B190"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhenghao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yaping</surname><given-names>M.</given-names></name><name name-style="western"><surname>Changsheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Min</surname><given-names>B.</given-names></name></person-group> (<year>2024</year>). <article-title>Lycium barbarum polysaccharide inhibits iron death through SLC7A11/GPX4 pathway to reduce cerebral ischemia - reperfusion injury in mice</article-title>. <source>Chin. J. Neuroanat.</source><volume>40</volume> (<issue>5</issue>), <fpage>607</fpage>&#8211;<lpage>612</lpage>. <pub-id pub-id-type="doi">10.16557/j.cnki.1000-7547.2024.05.011</pub-id></mixed-citation></ref><ref id="B191"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Simultaneous visualization and quantification of copper (II) ions in Alzheimer&#8217;s disease by a near-infrared fluorescence probe</article-title>. <source>Biosens. Bioelectron.</source><volume>198</volume>, <fpage>113858</fpage>. <pub-id pub-id-type="doi">10.1016/j.bios.2021.113858</pub-id><pub-id pub-id-type="pmid">34871835</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="dad270195" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement (Amst)</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement (Amst)</journal-id><journal-id journal-id-type="pmc-domain-id">3002</journal-id><journal-id journal-id-type="pmc-domain">dadm</journal-id><journal-id journal-id-type="publisher-id">DAD2</journal-id><journal-title-group><journal-title>Alzheimer's &amp; Dementia : Diagnosis, Assessment &amp; Disease Monitoring</journal-title></journal-title-group><issn pub-type="epub">2352-8729</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12505190</article-id><article-id pub-id-type="pmcid-ver">PMC12505190.1</article-id><article-id pub-id-type="pmcaid">12505190</article-id><article-id pub-id-type="pmcaiid">12505190</article-id><article-id pub-id-type="doi">10.1002/dad2.70195</article-id><article-id pub-id-type="publisher-id">DAD270195</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Speech and language features as indicators of neuropsychiatric symptoms in a memory clinic population</article-title><alt-title alt-title-type="left-running-head">ALEXOPOULOU <sc>et al</sc>.</alt-title></title-group><contrib-group><contrib id="dad270195-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Alexopoulou</surname><given-names initials="ZS">Zampeta&#8208;Sofia</given-names></name><xref rid="dad270195-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>Sofia.ALEXOPOULOU@univ-cotedazur.fr</email></address></contrib><contrib id="dad270195-cr-0002" contrib-type="author"><name name-style="western"><surname>Mallick</surname><given-names initials="E">Elisa</given-names></name><xref rid="dad270195-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="dad270195-cr-0003" contrib-type="author"><name name-style="western"><surname>Tr&#246;ger</surname><given-names initials="J">Johannes</given-names></name><xref rid="dad270195-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="dad270195-cr-0004" contrib-type="author"><name name-style="western"><surname>ter Huurne</surname><given-names initials="D">Daphne</given-names></name><xref rid="dad270195-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="dad270195-cr-0005" contrib-type="author"><name name-style="western"><surname>Possemis</surname><given-names initials="N">Nina</given-names></name><xref rid="dad270195-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="dad270195-cr-0006" contrib-type="author"><name name-style="western"><surname>Manera</surname><given-names initials="V">Valeria</given-names></name><xref rid="dad270195-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="dad270195-cr-0007" contrib-type="author"><name name-style="western"><surname>Ramakers</surname><given-names initials="I">Inez</given-names></name><xref rid="dad270195-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="dad270195-cr-0008" contrib-type="author"><name name-style="western"><surname>K&#246;nig</surname><given-names initials="A">Alexandra</given-names></name><xref rid="dad270195-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="dad270195-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="dad270195-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib></contrib-group><aff id="dad270195-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">CoBTeK (Cognition&#8208;Behaviour&#8208;Technology) Research Lab</named-content>
<institution>Universit&#233; C&#244;te d'Azur</institution>
<city>Nice</city>
<country country="FR">France</country>
</aff><aff id="dad270195-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>ki:elements GmbH</institution>
<city>Saarbr&#252;cken</city>
<country country="DE">Germany</country>
</aff><aff id="dad270195-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Psychiatry and Psychology</named-content>
<institution>Maastricht University Medical Centre+ (MUMC+)</institution>
<city>Maastricht</city>
<country country="NL">the Netherlands</country>
</aff><aff id="dad270195-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Alzheimer Center Limburg</named-content>
<named-content content-type="organisation-division">Department of Psychiatry &amp; Neuropsychology</named-content>
<named-content content-type="organisation-division">Mental Health and Neuroscience Research Institute</named-content>
<institution>Maastricht University</institution>
<city>Maastricht</city>
<country country="NL">the Netherlands</country>
</aff><aff id="dad270195-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Clinique G&#233;riatrique du Cerveau et du Mouvement, Centre M&#233;moire de Ressources et de Recherche</named-content>
<institution>Universit&#233; C&#244;te d'Azur</institution>
<institution>Centre Hospitalier et Universitaire</institution>
<city>Nice</city>
<country country="FR">France</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Zampeta&#8208;Sofia Alexopoulou, Memory Clinic and Research Centre, Institut Claude Pompidou, 10 rue Moli&#232;re, 06100 Nice, France.<break/> Email: <email>Sofia.ALEXOPOULOU@univ-cotedazur.fr</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><season>Oct-Dec</season><year>2025</year></pub-date><volume>17</volume><issue seq="50">4</issue><issue-id pub-id-type="pmc-issue-id">497563</issue-id><issue-id pub-id-type="doi">10.1002/dad2.v17.4</issue-id><elocation-id>e70195</elocation-id><history><date date-type="rev-recd"><day>28</day><month>8</month><year>2025</year></date><date date-type="received"><day>14</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>11</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Alzheimer's &amp; Dementia: Diagnosis, Assessment &amp; Disease Monitoring</italic> published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="DAD2-17-e70195.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:DAD2-17-e70195.pdf"/><abstract><title>Abstract</title><sec id="dad270195-sec-0010"><title>INTRODUCTION</title><p>Neuropsychiatric symptoms (NPSs) are early hallmarks of neurocognitive disorders (NCDs). Speech alterations might indicate both cognitive and behavioral changes in NCDs, aiding in diagnosis and disease monitoring. This study examined associations between automatically extracted speech/language features and NPS severity.</p></sec><sec id="dad270195-sec-0020"><title>METHODS</title><p>A total of <italic toggle="yes">N</italic>&#160;=&#160;37 subjective cognitive decline and <italic toggle="yes">N</italic>&#160;=&#160;20 mild cognitive impairment participants from the BioBank Alzheimer Centre Limburg study were recorded performing a low&#8208;constraint free&#8208;speech task. NPSs were assessed using the Geriatric Depression Scale and the Neuropsychiatric Inventory. Acoustic and linguistic features were automatically extracted. Correlation analysis was performed (adjusted for age, sex, and Mini&#8208;Mental State Examination) between the features and clinical scales.</p></sec><sec id="dad270195-sec-0030"><title>RESULTS</title><p>Features correlated significantly with NPSs. Indicatively, depression correlated with local jitter (<italic toggle="yes">r&#160;</italic>=&#160;0.38, <italic toggle="yes">p&#160;</italic>&lt;&#160;0.001) and agitation with the sum of pause duration (<italic toggle="yes">r&#160;</italic>=&#160;0.32, <italic toggle="yes">p&#160;</italic>&lt;&#160;0.027).</p></sec><sec id="dad270195-sec-0040"><title>DISCUSSION</title><p>Speech analysis offers a promising tool for evaluating NPSs in NCDs.</p></sec><sec id="dad270195-sec-0050"><title>Highlights</title><p>
<list list-type="bullet" id="dad270195-list-0001"><list-item><p>We found links between neuropsychiatric symptom (NPS) severity and speech markers in memory clinic patients.</p></list-item><list-item><p>Temporal markers positively correlated with the presence and severity of agitation.</p></list-item><list-item><p>Depression was positively correlated with voice instabilities.</p></list-item><list-item><p>Anxiety was negatively associated with metrics of lexical diversity.</p></list-item><list-item><p>Speech analysis provides an objective tool to assess NPSs in subjective cognitive decline and mild cognitive impairment patients.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dad270195-kwd-0001">agitation</kwd><kwd id="dad270195-kwd-0002">anxiety</kwd><kwd id="dad270195-kwd-0003">apathy</kwd><kwd id="dad270195-kwd-0004">depression</kwd><kwd id="dad270195-kwd-0005">digital biomarkers</kwd><kwd id="dad270195-kwd-0006">mild cognitive impairment</kwd><kwd id="dad270195-kwd-0007">neurocognitive disorders</kwd><kwd id="dad270195-kwd-0008">neuropsychiatric symptoms</kwd><kwd id="dad270195-kwd-0009">speech analysis</kwd><kwd id="dad270195-kwd-0010">speech biomarkers</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>EIT Health</institution><institution-id institution-id-type="doi">10.13039/100014419</institution-id></institution-wrap></funding-source><award-id>19249</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>HORIZON EUROPE Marie Sklodowska&#8208;Curie Actions</institution><institution-id institution-id-type="doi">10.13039/100018694</institution-id></institution-wrap></funding-source><award-id>101071485</award-id></award-group></funding-group><counts><fig-count count="2"/><table-count count="1"/><page-count count="8"/><word-count count="5487"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October-December 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:08.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="dad270195-cite-0001"><string-name name-style="western"><surname>Alexopoulou</surname><given-names>Z&#8208;S</given-names></string-name>, <string-name name-style="western"><surname>Mallick</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Tr&#246;ger</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Speech and language features as indicators of neuropsychiatric symptoms in a memory clinic population</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>17</volume>:<elocation-id>e70195</elocation-id>. <pub-id pub-id-type="doi">10.1002/dad2.70195</pub-id></mixed-citation>
</p></notes></front><body><sec id="dad270195-sec-0060"><label>1</label><title>BACKGROUND</title><p>Neuropsychiatric symptoms (NPSs), defined as behavioral non&#8208;cognitive disturbances, can manifest before measurable cognitive impairment in neurocognitive disorders (NCDs) and persist throughout the disease course.<xref rid="dad270195-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="dad270195-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Present in 35% to 85% of individuals with mild cognitive impairment (MCI),<xref rid="dad270195-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> they are key prognostic factors for dementia progression, linked to higher MCI incidence<xref rid="dad270195-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="dad270195-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> and to disease&#8208;specific cerebrospinal fluid amyloid and tau&#160;biomarkers.<xref rid="dad270195-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="dad270195-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Agitation, anxiety, and apathy are among the NPSs most strongly associated with incident MCI,<xref rid="dad270195-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> while depression was identified at the Lancet Commission's latest report&#160;as one of the 14 modifiable dementia risk factors.<xref rid="dad270195-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> More importantly, the review by The Real&#8208;World Outcomes Across the Alzheimer's Disease Spectrum for Better Care: Multi&#8208;Modal Data Access Platform (ROADMAP) initiative emphasized that behavioral and psychiatric outcomes (including emotions of anxiety, depression, apathy, verbal/physical aggression, and irritation) were consistently prioritized and deemed meaningful by patients, caregivers, and professionals directly impacted by Alzheimer's disease (AD) across all stages.<xref rid="dad270195-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Consequently, NPSs are crucial focus areas for disease prognosis and prevention. Early NPS understanding and management can enhance diagnosis, indicate a high risk of dementia progression, and mitigate negative impacts on patients and caregivers.</p><p>Despite the importance of NPSs in early&#8208;stage NCD detection, research and clinical practice face challenges due to a lack of objective and sensitive measures for these symptoms. NPSs are frequently misdiagnosed, underdiagnosed, and inadequately treated.<xref rid="dad270195-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="dad270195-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Current gold&#8208;standard questionnaires and interview protocols heavily rely on subjective reports, making them susceptible to biases from patients&#8217; or caregivers&#8217; recalls, cognition, culture&#8208;related boundaries, and societal stigma.<xref rid="dad270195-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="dad270195-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> These tools often summarize traits rather than emotional states; they are time consuming and not cost effective in routine clinical use.<xref rid="dad270195-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
</p><p>Limitations are evident in widely used questionnaires. The Geriatric Depression Scale (GDS) incorporates three validated items for assessing apathy within the depression ratings, potentially overestimating the overlap between syndromes and underestimating the true prevalence of apathy.<xref rid="dad270195-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> The Neuropsychiatric Inventory (NPI), though well established in clinical practice and trials,<xref rid="dad270195-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> was initially developed for dementia patients<xref rid="dad270195-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> and relies on retrospective caregiver reports. This increases its vulnerability to recall and interpretation biases because it relies on the caregiver's cultural background, education, and overall mental/physical state (i.e., fatigue, stress, denial).<xref rid="dad270195-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Although new tools like the Mild Behavioral Impairment Checklist attempt to improve NPS screening,<xref rid="dad270195-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> they still may lack objectivity in administration. Collectively these limitations underscore the necessity for complementary, observer&#8208;independent methods to assess NPSs in early NCDs.</p><p>Current technological advancements in automatic speech recognition and language processing enable an unbiased evaluation of behavioral symptoms, including emotional and psychiatric states. Speech is a promising assessment modality due to its high sensitivity to the subtle disruptions caused by neurocognitive and psychiatric disorders.<xref rid="dad270195-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> Changes in speech and language features are evident in neuropsychiatric conditions. Depression severity affects prosodic, articulatory, and frequency characteristics, including voice quality, loudness/pitch, and vowel sounds.<xref rid="dad270195-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="dad270195-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> Similarly, apathy, a significant dementia risk factor,<xref rid="dad270195-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> correlates with temporal and prosodic aspects, such as less and slower speech and altered F0 range (perceived pitch).<xref rid="dad270195-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> Anxiety in MCI has also been linked to voice quality features and increased muscle tension.<xref rid="dad270195-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="dad270195-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> Therefore, subtle speech alterations could act as indicators of behavioral changes, supporting an early differential diagnosis and patient monitoring.</p><p>Given the current lack of sufficiently objective and sensitive measures of NPSs in NCDs, exploring the added value of novel assessment markers is crucial. Patients with subjective cognitive decline (SCD) or MCI are particularly suitable, as the initial neurodegenerative damage may subtly affect emotion regulation and behavior. Identifying indicators of NPSs in these patients could support the continuous monitoring of disease progression. Therefore, the objective of this study was to examine associations between automatically extracted speech and language markers and the presence and severity of NPSs in SCD/MCI patients. We hypothesized that the severity of specific NPSs would relate to distinct speech/language indicators.</p></sec><sec id="dad270195-sec-0070"><label>2</label><title>METHODS</title><sec id="dad270195-sec-0080"><label>2.1</label><title>Participants</title><p>Data were retrospectively obtained from participants enrolled in the Deep Speech Analysis for Cognitive Assessment in Clinical Trials (DeepSpA) longitudinal observational study, taking place at the memory clinic of Maastricht University Medical Center+. Baseline data were used from a total of <italic toggle="yes">N&#160;=&#160;</italic>57 participants, <italic toggle="yes">N&#160;=&#160;</italic>37 diagnosed with SCD, and <italic toggle="yes">N&#160;=&#160;</italic>20 diagnosed with MCI. Diagnosis was based on an extensive evaluation by experts, integrating the anamnesis, neuropsychological assessment (including domains of memory, attention/concentration, executive functioning, language, and orientation), an interview with an informal caregiver, magnetic resonance imaging/computed tomography (MRI/CT) findings, blood tests, and&#8212;when clinically indicated&#8212;lumbar puncture. For the diagnosis of MCI, Diagnostic and Statistical Manual of Mental Disorders Fifth Edition criteria were applied for mild NCD.<xref rid="dad270195-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> Participants presenting subjective cognitive complaints but no objective impairment on neuropsychological testing and no salient structural abnormalities on MRI/CT were categorized as having SCD.</p><boxed-text position="float" content-type="box" orientation="portrait"><sec id="dad270195-sec-0090"><title>RESEARCH IN CONTEXT</title><p>
<list list-type="order" id="dad270195-list-0002"><list-item><p>
<bold>Systematic review</bold>: We reviewed the literature using conventional sources, including PubMed, Scopus and Google Scholar. Few studies have investigated the association between the severity of neuropsychiatric symptoms (NPSs) and speech and language markers in patients with mild cognitive impairment (MCI) or subjective cognitive decline (SCD). Relevant research is cited.</p></list-item><list-item><p>
<bold>Interpretation</bold>: Our findings suggest that the presence and severity of NPSs in SCD/MCI are linked to distinct alterations in free&#8208;speech patterns, objectively captured by both acoustic and linguistic markers. Depression and anxiety severity are characterized by limited lexical diversity, whereas agitation is associated with temporal and frequency acoustic measures.</p></list-item><list-item><p>
<bold>Future directions</bold>: We propose the use of automated speech analysis for the characterization of NPSs in early&#8208;stage cognitive impairment. The presence and severity of NPSs are crucial factors of dementia progression and, therefore, the development of unbiased and time&#8208;efficient assessments is necessary to advance differential diagnosis and patient monitoring.</p></list-item></list>
</p></sec></boxed-text><p>Participants were included if they had a Mini&#8208;Mental State Examination (MMSE) score of &#8805; 20 and a global Clinical Dementia Rating score of &#8804; 1. Exclusion criteria included non&#8208;degenerative neurological conditions, lack of a reliable informant, or clinical judgment deeming a 1 year follow&#8208;up assessment unfeasible. Importantly, a recent history of severe psychiatric disorders, such as current major depressive disorder (within 12 months), schizophrenia, bipolar disorder, or psychotic problems (not otherwise specified) was also an exclusion criterion.</p><p>The study adhered to the Ethical Principles for Medical Research Involving Human Subjects, as outlined in the Declaration of Helsinki and the European General Data Protection Regulation. The local Medical Ethical Committee approved the study (MEC 15&#8208;4&#8208;100) at METC azM/UM. Prior to participating in any study&#8208;related activities, all participants provided informed consent.</p></sec><sec id="dad270195-sec-0100"><label>2.2</label><title>Clinical assessment</title><p>During their baseline visit, patients underwent an extensive neuropsychological assessment alongside standard clinical assessments. NPS presence and severity were assessed using the GDS&#8208;15 (total score) and the NPI (total score and subitems). GDS assesses the presence of depression in the older population, consisting of 15 questions (yes/no): 10 reveal the presence of depression if answered positively, and 5 when answered negatively.<xref rid="dad270195-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> Total scores range between 0 and 4 (normal), 5 and 8 (mild depression), 9 and 11 (moderate depression), and 12 and 15 (severe depression).</p><p>NPI is a caregiver&#8208;based questionnaire evaluating the presence of psychopathology in patients with AD and other dementias.<xref rid="dad270195-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> It screens for the presence (yes/no), frequency, severity, and caregiver distress related to 12 NPSs. For each behavioral domain, four scores are assessed: frequency, severity, total score (frequency &#215; severity [F*S]), and caregiver distress. The overall NPI score is the sum of the 12 domain scores, excluding caregiver distress. For our analysis, we focused on the NPI subitems of agitation, depression, apathy, and anxiety NPSs, which strongly predict incident MCI and dementia.</p></sec><sec id="dad270195-sec-0110"><label>2.3</label><title>Speech protocol and processing</title><p>During the baseline neuropsychological assessment, participants also recorded a predefined free&#8208;speech task, describing for 1 to 2 minutes a previous vacation. Free and spontaneous speech tasks can evoke emotional responses (or their absence) by prompting individuals to recount potentially emotionally arousing events. Alterations in affective states are anticipated to affect speech, which vocal exercises or highly constrained tasks do not efficiently capture.<xref rid="dad270195-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> Responses were recorded and collected using the proprietary mobile application of ki:elements (Mili).<xref rid="dad270195-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>
</p><p>Audio features were extracted directly and automatically from the transcripts and speech signal using Python scripts from the ki:elements proprietary speech processing library &#8220;Sigma.&#8221; The pipeline involves automatic speech recognition to transcribe speech and extract both linguistic and acoustic features (see Figure&#160;<xref rid="dad270195-fig-0001" ref-type="fig">1</xref>).</p><fig position="float" fig-type="FIGURE" id="dad270195-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Schematic diagram of the speech data (pre)processing and detection pipeline. ASR, automatic speech recognition.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="DAD2-17-e70195-g002.jpg"/></fig><p>Linguistic features reflect what is said. This is captured through the use of selective words and grammar, including adjective or verb rates, indexes of lexical richness (e.g., Brunet's index), or the number of semantic clusters. Acoustic features encompass a range of characteristics such as temporal measures (e.g., pause length, speaking rate), frequency (e.g., F1&#8211;F3 formants and perceived pitch), energy (e.g., voice instability, loudness), and spectral features (e.g., frequency distribution, voice quality). An overview of the extracted linguistic and acoustic features is provided in Table <xref rid="dad270195-supinfo-0001" ref-type="">S1</xref> and Table <xref rid="dad270195-supinfo-0001" ref-type="">S2</xref> in supporting information.<xref rid="dad270195-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>
</p></sec><sec id="dad270195-sec-0120"><label>2.4</label><title>Statistical analysis</title><p>Statistical analysis was computed in R version 4.2.3 (2023.03.15)<xref rid="dad270195-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> and Python version 3.10.13. Due to the limited sample size, non&#8208;parametric tests were used. Group differences were assessed using the Kruskal&#8211;Wallis <italic toggle="yes">H</italic> and Pearson chi&#8208;squared (&#967;<sup>2</sup>) test. For each speech feature, a linear regression model was fitted (sklearn package<xref rid="dad270195-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>), to remove the variance explained by age, sex, and MMSE. The model's residuals were used to compute Spearman rank correlations with the GDS total score and the NPI subitems of depression, apathy, anxiety, and agitation. Per NPI subitem, the measures of symptom presence, frequency, severity, and F*S were used to compute correlations. Spearman &#961; was used as a correlation metric, considering results as significant using a threshold of <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05. Due to the small sample size, the correlation analysis was performed across all participants, regardless of group classification (i.e., SCD or MCI). The features were clustered in separate groups as shown in Table <xref rid="dad270195-supinfo-0001" ref-type="">S1</xref> and Table <xref rid="dad270195-supinfo-0001" ref-type="">S2</xref>. Multiple&#8208;comparison corrections were applied separately per category using the Benjamini&#8211;Hochberg (BH) procedure.</p></sec></sec><sec id="dad270195-sec-0130"><label>3</label><title>RESULTS</title><sec id="dad270195-sec-0140"><label>3.1</label><title>Demographics and group differences</title><p>A total of 57 participants were included in the analysis. Based on the NPI presence subitem, overall 14% presented agitation, 28% depression, 7% anxiety, and 24.5% apathy. Demographic and clinical characteristics are presented in Table&#160;<xref rid="dad270195-tbl-0001" ref-type="table">1</xref>. Education was categorized into low, mid, and high according to the Dutch Verhage education classification.<xref rid="dad270195-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> As expected, the groups did not present severe NPSs as assessed by the GDS and NPI. Comparing groups based on clinical diagnosis, the MCI group scored significantly higher only on the NPI total score and the NPI Apathy F*S subitem.</p><table-wrap position="float" id="dad270195-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Demographic and clinical characteristics of the data set used.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">SCD (<italic toggle="yes">N</italic>&#160;= 37)</th><th align="left" rowspan="1" colspan="1">MCI (<italic toggle="yes">N</italic>&#160;= 20)</th><th align="left" rowspan="1" colspan="1">Group differences</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="left" rowspan="1" colspan="1">60.70 (9.99)</td><td align="left" rowspan="1" colspan="1">69.45 (8.39)</td><td align="left" rowspan="1" colspan="1">
<bold>H(1)&#160;= 8.97, <italic toggle="yes">p</italic>&#160;= 0.003</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex (%, females)</td><td align="left" rowspan="1" colspan="1">37.83</td><td align="left" rowspan="1" colspan="1">30.0</td><td align="left" rowspan="1" colspan="1">&#967;<sup>2</sup>(1)&#160;= 0.09, <italic toggle="yes">p</italic>&#160;= 0.763</td></tr><tr><td align="left" rowspan="1" colspan="1">Education (%, low, mid, high)&#160;</td><td align="left" rowspan="1" colspan="1">27/32.4/40.5</td><td align="left" rowspan="1" colspan="1">30/40/30</td><td align="left" rowspan="1" colspan="1">&#967;<sup>2</sup>(2)&#160;= 0.64, <italic toggle="yes">p</italic>&#160;= 0.724</td></tr><tr><td align="left" rowspan="1" colspan="1">MMSE</td><td align="left" rowspan="1" colspan="1">28.78 (1.23)</td><td align="left" rowspan="1" colspan="1">27.40 (1.27)</td><td align="left" rowspan="1" colspan="1">
<bold>H(1)&#160;= 13.77, <italic toggle="yes">p</italic>&#160;&lt; 0.001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">CDR Global</td><td align="left" rowspan="1" colspan="1">0.31 (0.25)</td><td align="left" rowspan="1" colspan="1">0.50 (0.17)</td><td align="left" rowspan="1" colspan="1">
<bold>&#967;<sup>2</sup>(2)&#160;= 11.83, <italic toggle="yes">p</italic>&#160;= 0.002</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">CDR Total</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>&#967;<sup>2</sup>(2)&#160;= 8.23, <italic toggle="yes">p</italic>&#160;= 0.016</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>&#160;= 14</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>&#160;= 1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">0.5</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>&#160;= 23</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>&#160;= 17</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>&#160;= 0</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>&#160;= 1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Missing</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>&#160;= 0</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>&#160;= 1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">NPI Total</td><td align="left" rowspan="1" colspan="1">6.95 (10.20)</td><td align="left" rowspan="1" colspan="1">14.74 (13.00)</td><td align="left" rowspan="1" colspan="1">
<bold>H(1)&#160;= 5.92, <italic toggle="yes">p</italic>&#160;= 0.015</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">NPI agitation F*S</td><td align="left" rowspan="1" colspan="1">0.41 (1.61)</td><td align="left" rowspan="1" colspan="1">0.74 (2.02)</td><td align="left" rowspan="1" colspan="1">H(1)&#160;= 0.33, <italic toggle="yes">p</italic>&#160;= 0.567</td></tr><tr><td align="left" rowspan="1" colspan="1">NPI anxiety F*S</td><td align="left" rowspan="1" colspan="1">0.49 (2.18)</td><td align="left" rowspan="1" colspan="1">0.79 (2.80)</td><td align="left" rowspan="1" colspan="1">H(1)&#160;= 0.46, <italic toggle="yes">p</italic>&#160;= 0.498</td></tr><tr><td align="left" rowspan="1" colspan="1">NPI depression F*S</td><td align="left" rowspan="1" colspan="1">0.70 (1.51)</td><td align="left" rowspan="1" colspan="1">1.63 (3.00)</td><td align="left" rowspan="1" colspan="1">H(1)&#160;= 2.28, <italic toggle="yes">p</italic>&#160;= 0.131</td></tr><tr><td align="left" rowspan="1" colspan="1">NPI apathy F*S</td><td align="left" rowspan="1" colspan="1">0.57 (1.77)</td><td align="left" rowspan="1" colspan="1">2.58 (3.72)</td><td align="left" rowspan="1" colspan="1">
<bold>H(1)&#160;= 9.05, <italic toggle="yes">p</italic>&#160;= 0.003</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">GDS Total</td><td align="left" rowspan="1" colspan="1">2.95 (2.33)</td><td align="left" rowspan="1" colspan="1">3.85 (3.65)</td><td align="left" rowspan="1" colspan="1">H(1)&#160;= 0.22, <italic toggle="yes">p</italic>&#160;= 0.641</td></tr></tbody></table><table-wrap-foot><fn id="dad270195-tbl1-note-0001"><p>
<italic toggle="yes">Note</italic>: Data are presented as mean (standard deviation) unless otherwise specified. Significant group differences are marked in bold.</p></fn><fn id="dad270195-tbl1-note-0002"><p>Abbreviations: CDR, Clinical Dementia Rating scale; GDS, Geriatric Depression Scale; MCI, mild cognitive impairment; MMSE, Mini&#8208;Mental State Examination; NPI F*S, Neuropsychiatric Inventory Frequency &#215; Severity score; SCD, subjective cognitive decline.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="dad270195-sec-0150"><label>3.2</label><title>Correlations between acoustic and linguistic markers and clinical measures of NPSs</title><p>After regressing out the variance from age, sex, and MMSE from the extracted features, we identified significant correlations between the adjusted residuals and the presence (yes/no), severity (1/2/3 for mild/moderate/severe), frequency (1/2/3/4 for rarely up to very often), and F*S of NPS. These were assessed by the NPI subitems for depression, apathy, anxiety, and agitation. We also found significant associations with the GDS total score. Significant correlations between features and the GDS total score, as well as the NPI F*S scores of NPS, are displayed in Figure&#160;<xref rid="dad270195-fig-0002" ref-type="fig">2</xref>. Detailed significant and non&#8208;significant results can be found in Table <xref rid="dad270195-supinfo-0001" ref-type="">S3</xref> in supporting information. Additionally, Figure <xref rid="dad270195-supinfo-0001" ref-type="">S1</xref> in supporting information illustrates the significant correlations with the NPI scores of presence, severity, and frequency separately.</p><fig position="float" fig-type="FIGURE" id="dad270195-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Spearman rank correlations controlled for age, sex, and MMSE, between acoustic and linguistic features and clinical scales of NPS. Only significant correlations are reported. Linguistic feature names are marked with red and acoustic with purple. The strength and direction of correlations are reflected by the value, the color and intensity of the squares (positive correlations in blue; negative correlations in red). F*S, NPI Frequency &#215; Severity Score; GDS, Geriatric Depression Scale total score; MMSE, Mini&#8208;Mental State Examination; NPI, Neuropsychiatric Inventory; NPS, neuropsychiatric symptom.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="DAD2-17-e70195-g001.jpg"/></fig><p>Indicatively, the NPI agitation positively correlated with acoustic temporal markers of overall duration, utterance duration, and the number of pauses, while negatively correlating with pitch&#8208;related acoustic markers. NPI depression and anxiety negatively correlated with the Honore statistic, a metric of lexical richness which takes into account the number of unique words, the total vocabulary, and the total amount of words in the text.<xref rid="dad270195-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> The higher the values of the Honore statistic, the greater the lexical diversity. NPI depression also positively correlated with acoustic measures of jitter and shimmer. Further, NPI anxiety positively correlated with the Brunet index, another marker of lexical diversity that is not affected by the length of text. It is calculated as Brunet index&#160;=&#160;<italic toggle="yes">N</italic>^V^(&#8722;0.165) where V is the total vocabulary used and <italic toggle="yes">N</italic> is the total number of words in the text.<xref rid="dad270195-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> Lexical richness is higher with lower Brunet index values. Finally, NPI apathy presented significant correlations with only two acoustic features (frequency and spectral characteristics).</p><p>Most significant correlations between the features and the clinical scales did not survive the BH correction. However, the association between the F*S of depression and two acoustic markers, the &#8220;standard deviation of h1&#8208;h2 harmonic difference&#8221; (<italic toggle="yes">r&#160;</italic>=&#160;&#8722;0.4, <italic toggle="yes">p&#160;</italic>&lt;&#160;0.001) and &#8220;local absolute jitter&#8221; (<italic toggle="yes">r&#160;</italic>=&#160;0.38, <italic toggle="yes">p&#160;</italic>&lt;&#160;0.001), did remain significant. The positive associations between the F*S of agitation and several temporal measures (overall duration, sum of pause durations, and sum/sd of utterance duration) also remained significant (see Table <xref rid="dad270195-supinfo-0001" ref-type="">S3</xref>).</p><p>Finally, we have incorporated in the <xref rid="dad270195-supinfo-0001" ref-type="">Supplementary Materials</xref> in supporting information a representative case study of a participant with prominent agitation symptoms (see Table <xref rid="dad270195-supinfo-0001" ref-type="">S4</xref> in supporting information and description). The aim is to showcase both the technical computation and the clinical translation of our speech&#8208;based markers.</p></sec></sec><sec id="dad270195-sec-0160"><label>4</label><title>DISCUSSION</title><p>In this exploratory study, we focused on identifying associations between automatically extracted acoustic and linguistic features and NPSs in a memory clinic population. There was an absence of severe NPSs in the cohort as assessed by two gold&#8208;standard scales (GDS, NPI), as severe psychiatric disorders were excluded from the original study design. Encouragingly, even with this limited clinical spectrum and the limited statistical power of our analysis due to the modest sample size, we identified significant associations between agitation, anxiety, apathy, and depression and distinct acoustic and certain linguistic markers. Our findings suggest that alterations in free&#8208;speech patterns, objectively captured by automatic speech analysis, may reflect underlying minor or mild NPSs in patients with NCDs.</p><p>Agitation was the NPI item most strongly correlated with several features. While usually present in moderate to severe stages of NCDs, in our cohort, it was effectively captured by acoustic markers. Agitation, characterized by a higher state of arousal compared to depression or apathy, presented positive associations, even after BH correction, with several temporal metrics of verbal output, such as the overall speech and utterance duration and duration/number of pauses. Although agitation in NCDs can manifest with a wide range of physical behaviors, it is also linked with verbal non&#8208;aggressive behaviors such as increased sentence and question repetition or ceaseless talking.<xref rid="dad270195-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> These clinical verbal manifestations likely explain the positive correlations with the identified features. Notably, although agitated individuals seemed to produce longer utterances, this did not correspond to an increased lexical richness or diversity. We found no associations with linguistic markers, but a positive correlation with frequency and length of pauses. This pattern aligns with agitation as a state of higher arousal but potentially diminished cognitive control over the output content.</p><p>Agitation significantly correlated with other key acoustic features, presenting negative associations with mean pitch and a series of pitch&#8208;related features. Agitation in dementia is frequently presented in terms of shouting and is often associated with feelings of anger and anxiety, which acoustically have long been linked to elevated pitch.<xref rid="dad270195-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> However, in our cohort, we observed the opposite pattern, which could indicate a different underlying mechanism. Agitation is a particularly difficult NPS to assess within NCDs. It encompasses a wide spectrum of symptoms and can co&#8208;occur with aggression, but not all agitated behaviors necessarily involve aggressive manifestations. Theoretical models explain verbal agitation in dementia in terms of discomfort caused by several factors, including fatigue or depression,<xref rid="dad270195-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> which acoustically are not necessarily linked to increased tension and pitch. Further, while anger is a component of agitation, early research has differentiated the expression of &#8220;hot&#8221; versus milder forms of agitation/irritation, known as &#8220;cold&#8221; anger.<xref rid="dad270195-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> Compared to hot anger, cold anger is characterized by lower arousal levels and acoustically can be marked with more subtle vocal signals, including lower pitch and standard speech rate.<xref rid="dad270195-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>
</p><p>We also found significant associations between depression severity and linguistic markers. Depression showed an inverse relationship with the Honore statistic, a metric of lexical diversity. Clinically, it has been documented for more than a century that patients at lower arousal states, like depression, present distinct speech patterns, including a more hesitant and effortful speech production,<xref rid="dad270195-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> likely reflecting the use of a more limited vocabulary. Similar diminished lexical richness in depressed patients compared to healthy individuals was also found in a recent study by Menne et&#160;al.<xref rid="dad270195-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> We also identified a positive association with pronoun rate, consistent with literature reporting that depressed patients tend to use more first&#8208;person pronouns (i.e., I, me, mine, myself).<xref rid="dad270195-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>, <xref rid="dad270195-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> This reflects an increased self&#8208;awareness and ruminative state that is often a key clinical presentation, even in late&#8208;life depression. Although in our analysis we did not specifically focus on first&#8208;person pronouns, the overall positive correlation with the &#8220;pronoun rate&#8221; feature could reflect the aforementioned mechanism.</p><p>Consistent with the literature, we found positive correlations between source and frequency acoustic features and depression severity. Specifically, jitter and shimmer are widely recognized voice quality measures for non&#8208;invasive and quantitative evaluation of vocal fold physiology. Jitter captures the cycle&#8208;to&#8208;cycle variations in glottal period duration, which can be an indicator of voice instability, while shimmer measures amplitude fluctuations.<xref rid="dad270195-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> These reflect micro&#8208;perturbations in vocal fold vibration and therefore can be a measure of voice loudness or intensity. In depression and psychomotor retardation, both jitter and shimmer appear to be consistently affected and increase, indicating neurophysiological changes in muscle tension, laryngeal control, and the vocal folds movement.<xref rid="dad270195-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="dad270195-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="dad270195-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> The association with &#8220;local absolute jitter,&#8221; which precisely captures these cycle&#8208;to&#8208;cycle variations in the fundamental frequency of the vocal fold vibrations, remained significant even after BH correction, emphasizing its importance in the acoustic profile of depression. Finally, depression severity as measured by GDS negatively correlated with a few pitch&#8208;related variables, aligning with the literature and supporting the presence of prosodic abnormalities in depression.<xref rid="dad270195-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="dad270195-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>
</p><p>Although apathy is a frequent NPS in older adults, we found no significant correlations with linguistic markers, while only two acoustic features presented significant correlations, with directions inconsistent with the literature. The lack of severe symptomatology in our cohort may have contributed to these results and the general nature of the free&#8208;speech question, which may not have been emotionally or cognitively demanding enough to elicit distinct linguistic alterations. Language features reflect higher order cognitive processes, which may remain relatively unaffected in individuals with low NPS severity or those in early/mild stages of cognitive decline, like in our cohort. Moreover, comorbidities between apathy, depression, and anxiety, which are common in older adults, were not accounted for, despite recent evidence indicating that comorbid NPSs may share distinct speech patterns from single symptoms.<xref rid="dad270195-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>
</p><p>We additionally identified limited negative associations between anxiety and lexical diversity/richness indices (Brunet index, Honore statistic, and type token ratio). Despite the scarcity of related literature, our findings converge with a large study by Teferra et&#160;al.,<xref rid="dad270195-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> which linked anxiety severity in a large population of younger to older adults to the production of fewer words, shorter sentences, and reduced speaking length. These results indicate a narrower lexical range produced by anxious participants, which was also captured by our indices of lexical richness. An important consideration is that both anxiety and depression exhibited diminished lexical diversity, likely explained by their high comorbidity in older adults.<xref rid="dad270195-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> However, we could clearly differentiate between the two by the distinct acoustic indicators associated only with depression severity. While further validation in larger and longitudinal cohorts is necessary, this observation illustrates the importance of speech analysis in automatizing the measurement and characterization of NPS.</p><p>This study presents limitations. First, the small sample size in the present cohort precludes the ability to perform more robust statistical analyses. Moreover, the results should be interpreted with caution due to the short recording time of the free&#8208;speech task. Despite the prompt's potential ecological validity, its general nature may not have elicited emotionally charged responses. Data were collected during the COVID&#8208;19 pandemic, rendering the question difficult for some participants due to applied restrictions. These factors might have affected speech output and cognitive engagement, as seen by the limited associations between language&#8208;related markers and NPSs and limited findings with apathy despite being a prominent NPS in our cohort. Due to data availability NPI, GDS, and MMSE were used as gold&#8208;standard assessments in our study. While these tools still remain the best available measures in our cohort, we acknowledge their subjective nature and, specifically for MMSE, the reduced sensitivity in early cognitive impairment. Future research should explore how different free&#8208;speech tasks impact the assessment of NPSs in NCDs in relation also to different clinical scales, and exploit multiple time&#8208;point recordings, given the proven variability of NPSs over time. Future research should also explore and distinguish the speech&#8208;based markers in relation to comorbid NPSs. Finally, the results are exclusively based on a Dutch population, predominantly from Limburg, and on single time&#8208;point recordings, limiting their generalizability.</p><p>Despite the limitations, this study illustrates that automatic speech analysis can offer an objective approach to assessing NPSs in patients with NCD. Few studies have directly examined associations between several NPS in NCD and both acoustic and linguistic markers. Promisingly, we identified significant correlations between apathy, depression, anxiety, and agitation and distinct speech/language features in a cohort with limited NPS severity, underscoring the potential sensitivity of speech&#8208;based markers to subtle NPS manifestations. Well&#8208;established studies support the use of computed acoustic and linguistic markers in the field of psychiatry and even predict treatment responses.<xref rid="dad270195-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> However, there is a notable lack of similar directly observable measures tailored for the screening of NPSs in NCDs, which can overcome the barriers of classical questionnaires and self&#8208;assessments. Despite tools like the NPI and GDS remaining widely used, they are still time consuming and prone to subjectivity, highlighting the need for complementary and data&#8208;driven methods. Therefore, automated computational methods can provide an opportunity window for objectively quantifying and monitoring subtle behavioral changes in patients with early cognitive deterioration, playing a pivotal role in improving NPS management and optimizing treatment outcomes.</p></sec><sec sec-type="COI-statement" id="dad270195-sec-0180"><title>CONFLICT OF INTEREST STATEMENT</title><p>Alexandra K&#246;nig, Johannes Tr&#246;ger, and Elisa Mallick are employed by the company ki:elements, which developed the application for the speech&#8208;based assessment and extracted the speech features. Johannes Tr&#246;ger owns shares in the ki:elements company. Zampeta&#8208;Sofia Alexopoulou, Nina Possemis, Daphne ter Huurne, Valeria Manera, and Inez Ramakers have nothing to disclose. Author disclosures are available in the <xref rid="dad270195-supinfo-0001" ref-type="">supporting information</xref>.</p></sec><sec id="dad270195-sec-0190"><title>CONSENT STATEMENT</title><p>All human subjects provided informed consent.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="dad270195-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="dad270195-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="DAD2-17-e70195-s002.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="dad270195-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="DAD2-17-e70195-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="dad270195-sec-0170"><title>ACKNOWLEDGMENTS</title><p>The authors extend their gratitude to all investigators involved in the DeepSpA study and their teams involved in all efforts. The work of author Zampeta&#8208;Sofia Alexopoulou was supported by funding received from the European Union's HORIZON&#8208;MSCA Doctoral Networks 2021 program under grant agreement No 101071485. DeepSpA has been funded by EIT&#8208;Health project grant agreement number 19249, as well as supported by Janssen Pharmaceutical NV through a collaboration agreement (award/grant number is not applicable).</p></ack><ref-list id="dad270195-bibl-0001"><title>References</title><ref id="dad270195-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="dad270195-cite-0002"><string-name name-style="western"><surname>Lyketsos</surname><given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Carrillo</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Ryan</surname><given-names>JM</given-names></string-name>, et&#160;al. <article-title>Neuropsychiatric symptoms in Alzheimer's disease</article-title>. <source>Alzheimers Dement J Alzheimers Assoc</source>. <year>2011</year>;<volume>7</volume>(<issue>5</issue>):<fpage>532</fpage>&#8208;<lpage>539</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jalz.2011.05.2410</pub-id><pub-id pub-id-type="pmcid">PMC3299979</pub-id><pub-id pub-id-type="pmid">21889116</pub-id></mixed-citation></ref><ref id="dad270195-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="dad270195-cite-0003"><string-name name-style="western"><surname>Santacruz Escudero</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Beltr&#225;n</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Palacios</surname><given-names>&#193;</given-names></string-name>, et&#160;al. <article-title>Neuropsychiatric symptoms as predictors of clinical course in neurodegeneration. A longitudinal study</article-title>. <source>Front Aging Neurosci</source>. <year>2019</year>;<volume>11</volume>:<fpage>176</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fnagi.2019.00176</pub-id><pub-id pub-id-type="pmid">31396074</pub-id><pub-id pub-id-type="pmcid">PMC6668630</pub-id></mixed-citation></ref><ref id="dad270195-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dad270195-cite-0004"><string-name name-style="western"><surname>Gallagher</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Fischer</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Iaboni</surname><given-names>A</given-names></string-name>. <article-title>Neuropsychiatric symptoms in mild cognitive impairment: an update on prevalence, mechanisms, and clinical significance</article-title>. <source>Can J Psychiatry</source>. <year>2017</year>;<volume>62</volume>(<issue>3</issue>):<fpage>161</fpage>&#8208;<lpage>169</lpage>. doi:<pub-id pub-id-type="doi">10.1177/0706743716648296</pub-id><pub-id pub-id-type="pmid">28212495</pub-id><pub-id pub-id-type="pmcid">PMC5317015</pub-id></mixed-citation></ref><ref id="dad270195-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dad270195-cite-0005"><string-name name-style="western"><surname>Geda</surname><given-names>YE</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>RO</given-names></string-name>, <string-name name-style="western"><surname>Mielke</surname><given-names>MM</given-names></string-name>, et&#160;al. <article-title>Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: a population&#8208;based study</article-title>. <source>Am J Psychiatry</source>. <year>2014</year>;<volume>171</volume>(<issue>5</issue>):<fpage>572</fpage>&#8208;<lpage>581</lpage>. doi:<pub-id pub-id-type="doi">10.1176/appi.ajp.2014.13060821</pub-id><pub-id pub-id-type="pmid">24700290</pub-id><pub-id pub-id-type="pmcid">PMC4057095</pub-id></mixed-citation></ref><ref id="dad270195-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="dad270195-cite-0006"><string-name name-style="western"><surname>Wilson</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Boyle</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Arnold</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></string-name>. <article-title>Chronic distress and incidence of mild cognitive impairment</article-title>. <source>Neurology</source>. <year>2007</year>;<volume>68</volume>(<issue>24</issue>):<fpage>2085</fpage>&#8208;<lpage>2092</lpage>. doi:<pub-id pub-id-type="doi">10.1212/01.wnl.0000264930.97061.82</pub-id><pub-id pub-id-type="pmid">17562829</pub-id></mixed-citation></ref><ref id="dad270195-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="dad270195-cite-0007"><string-name name-style="western"><surname>Krell&#8208;Roesch</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rakusa</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Syrjanen</surname><given-names>JA</given-names></string-name>, et&#160;al. <article-title>Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: mayo clinic study of aging</article-title>. <source>Alzheimers Dement</source>. <year>2023</year>;<volume>19</volume>(<issue>10</issue>):<fpage>4498</fpage>&#8208;<lpage>4506</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.12557</pub-id><pub-id pub-id-type="pmid">35142047</pub-id><pub-id pub-id-type="pmcid">PMC10433790</pub-id></mixed-citation></ref><ref id="dad270195-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dad270195-cite-0008"><string-name name-style="western"><surname>Banning</surname><given-names>LCP</given-names></string-name>, <string-name name-style="western"><surname>Ramakers</surname><given-names>IHGB</given-names></string-name>, <string-name name-style="western"><surname>Deckers</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Verhey</surname><given-names>FRJ</given-names></string-name>, <string-name name-style="western"><surname>Aalten</surname><given-names>P</given-names></string-name>. <article-title>Affective symptoms and AT(N) biomarkers in mild cognitive impairment and Alzheimer's disease: a systematic literature review</article-title>. <source>Neurosci Biobehav Rev</source>. <year>2019</year>;<volume>107</volume>:<fpage>346</fpage>&#8208;<lpage>359</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neubiorev.2019.09.014</pub-id><pub-id pub-id-type="pmid">31525387</pub-id></mixed-citation></ref><ref id="dad270195-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dad270195-cite-0009"><string-name name-style="western"><surname>Livingston</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Huntley</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>KY</given-names></string-name>, et&#160;al. <article-title>Dementia prevention, intervention, and care: 2024 report of the lancet standing commission</article-title>. <source>The Lancet</source>. <year>2024</year>;<volume>404</volume>(<issue>10452</issue>):<fpage>572</fpage>&#8208;<lpage>628</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(24)01296-0</pub-id><pub-id pub-id-type="pmid">39096926</pub-id></mixed-citation></ref><ref id="dad270195-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dad270195-cite-0010"><string-name name-style="western"><surname>Tochel</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Baldwin</surname><given-names>H</given-names></string-name>, et&#160;al. <article-title>What outcomes are important to patients with mild cognitive impairment or Alzheimer's disease, their caregivers, and health&#8208;care professionals? A systematic review</article-title>. <source>Alzheimers Dement Amst Neth</source>. <year>2019</year>;<volume>11</volume>:<fpage>231</fpage>&#8208;<lpage>247</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.dadm.2018.12.003</pub-id><pub-id pub-id-type="pmcid">PMC6411507</pub-id><pub-id pub-id-type="pmid">30906845</pub-id></mixed-citation></ref><ref id="dad270195-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dad270195-cite-0011"><string-name name-style="western"><surname>Gitlin</surname><given-names>LN</given-names></string-name>, <string-name name-style="western"><surname>Marx</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Stanley</surname><given-names>IH</given-names></string-name>, <string-name name-style="western"><surname>Hansen</surname><given-names>BR</given-names></string-name>, <string-name name-style="western"><surname>Van Haitsma</surname><given-names>KS</given-names></string-name>. <article-title>Assessing neuropsychiatric symptoms in people with dementia: a systematic review of measures</article-title>. <source>Int Psychogeriatr</source>. <year>2014</year>;<volume>26</volume>(<issue>11</issue>):<fpage>1805</fpage>&#8208;<lpage>1848</lpage>. doi:<pub-id pub-id-type="doi">10.1017/S1041610214001537</pub-id><pub-id pub-id-type="pmid">25096416</pub-id><pub-id pub-id-type="pmcid">PMC4435793</pub-id></mixed-citation></ref><ref id="dad270195-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dad270195-cite-0012"><string-name name-style="western"><surname>Tsoukra</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Velakoulis</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wibawa</surname><given-names>P</given-names></string-name>, et&#160;al. <article-title>The diagnostic challenge of young&#8208;onset dementia syndromes and primary psychiatric diseases: results from a retrospective 20&#8208;year cross&#8208;sectional study</article-title>. <source>J Neuropsychiatry Clin Neurosci</source>. <year>2022</year>;<volume>34</volume>(<issue>1</issue>):<fpage>44</fpage>&#8208;<lpage>52</lpage>. doi:<pub-id pub-id-type="doi">10.1176/appi.neuropsych.20100266</pub-id><pub-id pub-id-type="pmid">34538074</pub-id></mixed-citation></ref><ref id="dad270195-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dad270195-cite-0013"><string-name name-style="western"><surname>Low</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Bentley</surname><given-names>KH</given-names></string-name>, <string-name name-style="western"><surname>Ghosh</surname><given-names>SS</given-names></string-name>. <article-title>Automated assessment of psychiatric disorders using speech: a systematic review</article-title>. <source>Laryngoscope Investig Otolaryngol</source>. <year>2020</year>;<volume>5</volume>(<issue>1</issue>):<fpage>96</fpage>&#8208;<lpage>116</lpage>. doi:<pub-id pub-id-type="doi">10.1002/lio2.354</pub-id><pub-id pub-id-type="pmcid">PMC7042657</pub-id><pub-id pub-id-type="pmid">32128436</pub-id></mixed-citation></ref><ref id="dad270195-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="dad270195-cite-0014"><string-name name-style="western"><surname>Cummins</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Scherer</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Krajewski</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Schnieder</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Epps</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Quatieri</surname><given-names>TF</given-names></string-name>. <article-title>A review of depression and suicide risk assessment using speech analysis</article-title>. <source>Speech Commun</source>. <year>2015</year>;<volume>71</volume>:<fpage>10</fpage>&#8208;<lpage>49</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.specom.2015.03.004</pub-id></mixed-citation></ref><ref id="dad270195-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="dad270195-cite-0015"><string-name name-style="western"><surname>Levy</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Cummings</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Fairbanks</surname><given-names>LA</given-names></string-name>, et&#160;al. <article-title>Apathy Is not depression</article-title>. <source>J Neuropsychiatry Clin Neurosci</source>. <year>1998</year>;<volume>10</volume>(<issue>3</issue>):<fpage>314</fpage>&#8208;<lpage>319</lpage>. doi:<pub-id pub-id-type="doi">10.1176/jnp.10.3.314</pub-id><pub-id pub-id-type="pmid">9706539</pub-id></mixed-citation></ref><ref id="dad270195-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="dad270195-cite-0016"><string-name name-style="western"><surname>Cummings</surname><given-names>J</given-names></string-name>. <article-title>The neuropsychiatric inventory: development and applications</article-title>. <source>J Geriatr Psychiatry Neurol</source>. <year>2020</year>;<volume>33</volume>(<issue>2</issue>):<fpage>73</fpage>&#8208;<lpage>84</lpage>. doi:<pub-id pub-id-type="doi">10.1177/0891988719882102</pub-id><pub-id pub-id-type="pmid">32013737</pub-id><pub-id pub-id-type="pmcid">PMC8505128</pub-id></mixed-citation></ref><ref id="dad270195-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="dad270195-cite-0017"><string-name name-style="western"><surname>Cummings</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Mega</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gray</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Rosenberg&#8208;Thompson</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Carusi</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Gornbein</surname><given-names>J</given-names></string-name>. <article-title>The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia</article-title>. <source>Neurology</source>. <year>1994</year>;<volume>44</volume>(<issue>12</issue>):<fpage>2308</fpage>&#8208;<lpage>2314</lpage>. doi:<pub-id pub-id-type="doi">10.1212/wnl.44.12.2308</pub-id><pub-id pub-id-type="pmid">7991117</pub-id></mixed-citation></ref><ref id="dad270195-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="dad270195-cite-0018"><string-name name-style="western"><surname>de</surname><given-names>MedeirosK</given-names></string-name>, <string-name name-style="western"><surname>P</surname><given-names>Robert</given-names></string-name>, <string-name name-style="western"><surname>Gauthier</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>The Neuropsychiatric Inventory&#8208;Clinician rating scale (NPI&#8208;C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia</article-title>. <source>Int Psychogeriatr</source>. <year>2010</year>;<volume>22</volume>(<issue>6</issue>):<fpage>984</fpage>&#8208;<lpage>994</lpage>. doi:<pub-id pub-id-type="doi">10.1017/S1041610210000876</pub-id><pub-id pub-id-type="pmid">20594384</pub-id><pub-id pub-id-type="pmcid">PMC3314709</pub-id></mixed-citation></ref><ref id="dad270195-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="dad270195-cite-0019"><string-name name-style="western"><surname>Ismail</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Ag&#252;era&#8208;Ortiz</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Brodaty</surname><given-names>H</given-names></string-name>, et&#160;al. <article-title>The mild behavioral impairment checklist (MBI&#8208;C): a rating scale for neuropsychiatric symptoms in pre&#8208;dementia populations</article-title>. <source>J Alzheimers Dis JAD</source>. <year>2017</year>;<volume>56</volume>(<issue>3</issue>):<fpage>929</fpage>&#8208;<lpage>938</lpage>. doi:<pub-id pub-id-type="doi">10.3233/JAD-160979</pub-id><pub-id pub-id-type="pmid">28059789</pub-id><pub-id pub-id-type="pmcid">PMC5652315</pub-id></mixed-citation></ref><ref id="dad270195-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="dad270195-cite-0020"><string-name name-style="western"><surname>Hecker</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Steckhan</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Eyben</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Schuller</surname><given-names>BW</given-names></string-name>, <string-name name-style="western"><surname>Arnrich</surname><given-names>B</given-names></string-name>. <article-title>Voice analysis for neurological disorder recognition&#8211;a systematic review and perspective on emerging trends</article-title>. <source>Front Digit Health</source>. <year>2022</year>;<volume>4</volume>:<elocation-id>842301</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fdgth.2022.842301</pub-id><pub-id pub-id-type="pmid">35899034</pub-id><pub-id pub-id-type="pmcid">PMC9309252</pub-id></mixed-citation></ref><ref id="dad270195-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="dad270195-cite-0021"><string-name name-style="western"><surname>K&#246;nig</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mallick</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Tr&#246;ger</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Measuring neuropsychiatric symptoms in patients with early cognitive decline using speech analysis</article-title>. <source>Eur Psychiatry</source>. <year>2021</year>;<volume>64</volume>(<issue>1</issue>):<elocation-id>e64</elocation-id>. doi:<pub-id pub-id-type="doi">10.1192/j.eurpsy.2021.2236</pub-id><pub-id pub-id-type="pmid">34641989</pub-id><pub-id pub-id-type="pmcid">PMC8581700</pub-id></mixed-citation></ref><ref id="dad270195-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="dad270195-cite-0022"><string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Xue</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>. <article-title>Developing a machine learning model for detecting depression, anxiety, and apathy in older adults with mild cognitive impairment using speech and facial expressions: a cross&#8208;sectional observational study</article-title>. <source>Int J Nurs Stud</source>. <year>2023</year>;<volume>146</volume>:<elocation-id>104562</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.ijnurstu.2023.104562</pub-id><pub-id pub-id-type="pmid">37531702</pub-id></mixed-citation></ref><ref id="dad270195-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="dad270195-cite-0023"><string-name name-style="western"><surname>Fresnais</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Humble</surname><given-names>MB</given-names></string-name>, <string-name name-style="western"><surname>Bejerot</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Meehan</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Fure</surname><given-names>B</given-names></string-name>. <article-title>Apathy as a predictor for conversion from mild cognitive impairment to dementia: a systematic review and meta&#8208;analysis of longitudinal studies</article-title>. <source>J Geriatr Psychiatry Neurol</source>. <year>2023</year>;<volume>36</volume>(<issue>1</issue>):<fpage>3</fpage>&#8208;<lpage>17</lpage>. doi:<pub-id pub-id-type="doi">10.1177/08919887221093361</pub-id><pub-id pub-id-type="pmid">35446723</pub-id><pub-id pub-id-type="pmcid">PMC9755689</pub-id></mixed-citation></ref><ref id="dad270195-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="dad270195-cite-0024"><string-name name-style="western"><surname>K&#246;nig</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Linz</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Zeghari</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Detecting apathy in older adults with cognitive disorders using automatic speech analysis</article-title>. <source>J Alzheimers Dis</source>. <year>2019</year>;<volume>69</volume>(<issue>4</issue>):<fpage>1183</fpage>&#8208;<lpage>1193</lpage>. doi:<pub-id pub-id-type="doi">10.3233/JAD-181033</pub-id><pub-id pub-id-type="pmid">31127764</pub-id></mixed-citation></ref><ref id="dad270195-bib-0024"><label>24</label><mixed-citation publication-type="book" id="dad270195-cite-0025"><collab collab-type="authors">American Psychiatric Association</collab>
. <source>Diagnostic and Statistical Manual of Mental Disorders</source>. 5th ed. <publisher-name>American Psychiatric Association</publisher-name>; <year>2013</year>. doi:<pub-id pub-id-type="doi">10.1176/appi.books.9780890425596</pub-id></mixed-citation></ref><ref id="dad270195-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="dad270195-cite-0026"><string-name name-style="western"><surname>Yesavage</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Brink</surname><given-names>TL</given-names></string-name>, <string-name name-style="western"><surname>Rose</surname><given-names>TL</given-names></string-name>, et&#160;al. <article-title>Development and validation of a geriatric depression screening scale: a preliminary report</article-title>. <source>J Psychiatr Res</source>. <year>1982</year>;<volume>17</volume>(<issue>1</issue>):<fpage>37</fpage>&#8208;<lpage>49</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0022-3956(82)90033-4</pub-id><pub-id pub-id-type="pmid">7183759</pub-id></mixed-citation></ref><ref id="dad270195-bib-0026"><label>26</label><mixed-citation publication-type="miscellaneous" id="dad270195-cite-0027"><article-title>Mili Platform &#8211; ki:elements</article-title>. Accessed August 26, 2025. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ki-elements.de/mili-platform/" ext-link-type="uri">https://ki&#8208;elements.de/mili&#8208;platform/</ext-link></mixed-citation></ref><ref id="dad270195-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="dad270195-cite-0028"><string-name name-style="western"><surname>Menne</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>D&#246;rr</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Schr&#228;der</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>The voice of depression: speech features as biomarkers for major depressive disorder</article-title>. <source>BMC Psychiatry</source>. <year>2024</year>;<volume>24</volume>(<issue>1</issue>):<fpage>794</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12888-024-06253-6</pub-id><pub-id pub-id-type="pmid">39533239</pub-id><pub-id pub-id-type="pmcid">PMC11559157</pub-id></mixed-citation></ref><ref id="dad270195-bib-0028"><label>28</label><mixed-citation publication-type="book" id="dad270195-cite-0029"><collab collab-type="authors">R Core Team</collab>
. <part-title><italic toggle="yes">R: a language and environment for statistical computing</italic></part-title>. <source>R Foundation for Statistical Computing</source>. <publisher-name>R Core Team</publisher-name>; <year>2023</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.R-project.org/" ext-link-type="uri">https://www.R&#8208;project.org/</ext-link></mixed-citation></ref><ref id="dad270195-bib-0029"><label>29</label><mixed-citation publication-type="miscellaneous" id="dad270195-cite-0030"><string-name name-style="western"><surname>Pedregosa</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Varoquaux</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Gramfort</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Scikit&#8208;learn: Machine Learning in Python. Mach Learn PYTHON</article-title>.</mixed-citation></ref><ref id="dad270195-bib-0030"><label>30</label><mixed-citation publication-type="book" id="dad270195-cite-0031"><string-name name-style="western"><surname>Bie</surname><given-names>SE</given-names></string-name>. <source>Standaardvragen 1987: voorstellen voor uniformering van vraagstellingen naar achtergrondkenmerken in interviews</source>. <publisher-name>VOI, Stuurgroep Dataverzameling</publisher-name>; <year>1987</year>.</mixed-citation></ref><ref id="dad270195-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="dad270195-cite-0032"><string-name name-style="western"><surname>Honor&#233;</surname><given-names>A</given-names></string-name>. <article-title>Some simple measures of richness of vocabulary</article-title>. <source>Assoc Lit Linguist Comput Bull</source>. <year>1979</year>;<volume>7</volume>(<issue>2</issue>):<fpage>172</fpage>&#8208;<lpage>177</lpage>.</mixed-citation></ref><ref id="dad270195-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="dad270195-cite-0033"><string-name name-style="western"><surname>Tournier</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>&#201;tienne</surname><given-names>B</given-names></string-name>runet, <article-title>Le vocabulaire de Jean Giraudoux.Structure et &#233;volution. Statistique et informatique appliqu&#233;es &#225; l'etude des textes, Gen&#232;ve, &#233;ditions Slatkine, 197</article-title>. <source>Mots</source>. <year>1981</year>;<volume>3</volume>(<issue>1</issue>):<fpage>154</fpage>&#8208;<lpage>155</lpage>.</mixed-citation></ref><ref id="dad270195-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="dad270195-cite-0034"><string-name name-style="western"><surname>Cohen&#8208;mansfield</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Marx</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Rosenthal</surname><given-names>AS</given-names></string-name>. <article-title>A description of agitation in a nursing home</article-title>. <source>J Gerontol</source>. <year>1989</year>;<volume>44</volume>(<issue>3</issue>):<fpage>M77</fpage>&#8208;<lpage>M84</lpage>. doi:<pub-id pub-id-type="doi">10.1093/geronj/44.3.M77</pub-id><pub-id pub-id-type="pmid">2715584</pub-id></mixed-citation></ref><ref id="dad270195-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="dad270195-cite-0035"><string-name name-style="western"><surname>Banse</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Scherer</surname><given-names>KR</given-names></string-name>. <article-title>Acoustic profiles in vocal emotion expression</article-title>. <source>J Pers Soc Psychol</source>. <year>1996</year>;<volume>70</volume>(<issue>3</issue>):<fpage>614</fpage>&#8208;<lpage>636</lpage>. doi:<pub-id pub-id-type="doi">10.1037/0022-3514.70.3.614</pub-id><pub-id pub-id-type="pmid">8851745</pub-id></mixed-citation></ref><ref id="dad270195-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="dad270195-cite-0036"><string-name name-style="western"><surname>Lemay</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Landreville</surname><given-names>P</given-names></string-name>. <article-title>Review: Verbal Agitation in Dementia: The Role of Discomfort</article-title>. <source>Am J Alzheimers Dis Other Demen</source>. <year>2010</year>;<volume>25</volume>(<issue>3</issue>): <fpage>193</fpage>&#8208;<lpage>201</lpage>. doi:<pub-id pub-id-type="doi">10.1177/1533317509356687</pub-id><pub-id pub-id-type="pmid">20142626</pub-id><pub-id pub-id-type="pmcid">PMC10845377</pub-id></mixed-citation></ref><ref id="dad270195-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="dad270195-cite-0037"><string-name name-style="western"><surname>B&#228;nziger</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Scherer</surname><given-names>KR</given-names></string-name>. <article-title>The role of intonation in emotional expressions</article-title>. <source>Speech Commun</source>. <year>2005</year>;<volume>46</volume>(<issue>3</issue>):<fpage>252</fpage>&#8208;<lpage>267</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.specom.2005.02.016</pub-id></mixed-citation></ref><ref id="dad270195-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="dad270195-cite-0038"><string-name name-style="western"><surname>Kraepelin</surname><given-names>E</given-names></string-name>. <article-title>Manic depressive insanity and paranoia</article-title>. <source>J Nerv Ment Dis</source>. <year>1921</year>;<volume>53</volume>(<issue>4</issue>):<fpage>350</fpage>.</mixed-citation></ref><ref id="dad270195-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="dad270195-cite-0039"><string-name name-style="western"><surname>DeSouza</surname><given-names>DD</given-names></string-name>, <string-name name-style="western"><surname>Robin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gumus</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yeung</surname><given-names>A</given-names></string-name>. <article-title>Natural language processing as an emerging tool to detect late&#8208;life depression</article-title>. <source>Front Psychiatry</source>. <year>2021</year>;<volume>12</volume>:<elocation-id>719125</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fpsyt.2021.719125</pub-id><pub-id pub-id-type="pmid">34552519</pub-id><pub-id pub-id-type="pmcid">PMC8450440</pub-id></mixed-citation></ref><ref id="dad270195-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="dad270195-cite-0040"><string-name name-style="western"><surname>T&#248;lb&#248;ll</surname><given-names>KB</given-names></string-name>. <article-title>Linguistic features in depression: a meta&#8208;analysis</article-title>. <source>J Lang Works&#8212;Sprogvidenskabeligt Stud</source>. <year>2019</year>;<volume>4</volume>(<issue>2</issue>):<fpage>39</fpage>.</mixed-citation></ref><ref id="dad270195-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="dad270195-cite-0041"><string-name name-style="western"><surname>Teixeira</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Oliveira</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lopes</surname><given-names>C</given-names></string-name>. <article-title>Vocal acoustic analysis &#8211; jitter, shimmer and HNR parameters</article-title>. <source>Procedia Technol</source>. <year>2013</year>;<volume>9</volume>:<fpage>1112</fpage>&#8208;<lpage>1122</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.protcy.2013.12.124</pub-id></mixed-citation></ref><ref id="dad270195-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="dad270195-cite-0042"><string-name name-style="western"><surname>Almaghrabi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Clark</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Baumert</surname><given-names>M</given-names></string-name>. <article-title>Bio&#8208;acoustic features of depression: a review</article-title>. <source>Biomed Signal Process Control</source>. <year>2023</year>;<volume>85</volume>:<elocation-id>105020</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.bspc.2023.105020</pub-id></mixed-citation></ref><ref id="dad270195-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="dad270195-cite-0043"><string-name name-style="western"><surname>Teferra</surname><given-names>BG</given-names></string-name>, <string-name name-style="western"><surname>Borwein</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>DeSouza</surname><given-names>DD</given-names></string-name>, <string-name name-style="western"><surname>Simpson</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Rheault</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Rose</surname><given-names>J</given-names></string-name>. <article-title>Acoustic and linguistic features of impromptu speech and their association with anxiety: validation study</article-title>. <source>JMIR Ment Health</source>. <year>2022</year>;<volume>9</volume>(<issue>7</issue>):<elocation-id>e36828</elocation-id>. doi:<pub-id pub-id-type="doi">10.2196/36828</pub-id><pub-id pub-id-type="pmid">35802401</pub-id><pub-id pub-id-type="pmcid">PMC9308078</pub-id></mixed-citation></ref><ref id="dad270195-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="dad270195-cite-0044"><string-name name-style="western"><surname>Beekman</surname><given-names>ATF</given-names></string-name>, <string-name name-style="western"><surname>de Beurs</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>van Balkom</surname><given-names>AJLM</given-names></string-name>, <string-name name-style="western"><surname>Deeg</surname><given-names>DJH</given-names></string-name>, <string-name name-style="western"><surname>van Dyck</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>van Tilburg</surname><given-names>W</given-names></string-name>. <article-title>Anxiety and depression in later life: co&#8208;occurrence and communality of risk factors</article-title>. <source>Am J Psychiatry</source>. <year>2000</year>;<volume>157</volume>(<issue>1</issue>):<fpage>89</fpage>&#8208;<lpage>95</lpage>. doi:<pub-id pub-id-type="doi">10.1176/ajp.157.1.89</pub-id><pub-id pub-id-type="pmid">10618018</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="acel70190" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Aging Cell</journal-id><journal-id journal-id-type="iso-abbrev">Aging Cell</journal-id><journal-id journal-id-type="pmc-domain-id">2481</journal-id><journal-id journal-id-type="pmc-domain">acel</journal-id><journal-id journal-id-type="publisher-id">ACEL</journal-id><journal-title-group><journal-title>Aging Cell</journal-title></journal-title-group><issn pub-type="ppub">1474-9718</issn><issn pub-type="epub">1474-9726</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12507415</article-id><article-id pub-id-type="pmcid-ver">PMC12507415.1</article-id><article-id pub-id-type="pmcaid">12507415</article-id><article-id pub-id-type="pmcaiid">12507415</article-id><article-id pub-id-type="pmid">40785275</article-id><article-id pub-id-type="doi">10.1111/acel.70190</article-id><article-id pub-id-type="publisher-id">ACEL70190</article-id><article-id pub-id-type="other">ACE-25-0516-RAr</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Associations of Skin Biomechanical Properties With Biological Aging Clocks and Longitudinal Changes in Intrinsic Capacity in Adults Aged 20&#8211;93: The <styled-content style="fixed-case" toggle="no">INSPIRE</styled-content>&#8208;T Project</article-title></title-group><contrib-group><contrib id="acel70190-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Lu</surname><given-names initials="WH">Wan&#8208;Hsuan</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7824-4214</contrib-id><xref rid="acel70190-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="acel70190-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>wanhsuanlu@gmail.com</email></address></contrib><contrib id="acel70190-cr-0002" contrib-type="author"><name name-style="western"><surname>Guyonnet</surname><given-names initials="S">Sophie</given-names></name><xref rid="acel70190-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="acel70190-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="acel70190-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="acel70190-cr-0003" contrib-type="author"><name name-style="western"><surname>Raffin</surname><given-names initials="J">J&#233;r&#233;my</given-names></name><xref rid="acel70190-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="acel70190-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="acel70190-cr-0004" contrib-type="author"><name name-style="western"><surname>Bessou&#8208;Touya</surname><given-names initials="S">Sandrine</given-names></name><xref rid="acel70190-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="acel70190-cr-0005" contrib-type="author"><name name-style="western"><surname>Helffer</surname><given-names initials="KR">Katia Ravard</given-names></name><xref rid="acel70190-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="acel70190-cr-0006" contrib-type="author"><name name-style="western"><surname>Bianchi</surname><given-names initials="P">Pascale</given-names></name><xref rid="acel70190-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="acel70190-cr-0007" contrib-type="author"><name name-style="western"><surname>Digabel</surname><given-names initials="JL">Jimmy Le</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4970-4466</contrib-id><xref rid="acel70190-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="acel70190-cr-0008" contrib-type="author"><name name-style="western"><surname>Bensadoun</surname><given-names initials="P">Paul</given-names></name><xref rid="acel70190-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="acel70190-cr-0009" contrib-type="author"><name name-style="western"><surname>Lemaitre</surname><given-names initials="JM">Jean&#8208;Marc</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6492-5219</contrib-id><xref rid="acel70190-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="acel70190-cr-0010" contrib-type="author"><name name-style="western"><surname>Barreto</surname><given-names initials="PDS">Philipe de Souto</given-names></name><xref rid="acel70190-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="acel70190-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="acel70190-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="acel70190-cr-0011" contrib-type="author"><name name-style="western"><surname>Vellas</surname><given-names initials="B">Bruno</given-names></name><xref rid="acel70190-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="acel70190-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="acel70190-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="acel70190-cr-0012" contrib-type="author"><collab collab-type="authors">the IHU HealthAge INSPIRE/Open Science study group<contrib-group><contrib id="acel70190-cr-0013" contrib-type="author"><name name-style="western"><surname>Guyonnet</surname><given-names initials="S">Sophie</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0014" contrib-type="author"><name name-style="western"><surname>Vellas</surname><given-names initials="B">Bruno</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0015" contrib-type="author"><name name-style="western"><surname>Brigitte</surname><given-names initials="L">Laur&#233;ane</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0016" contrib-type="author"><name name-style="western"><surname>Milhet</surname><given-names initials="A">Agathe</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0017" contrib-type="author"><name name-style="western"><surname>Paez</surname><given-names initials="E">Elodie</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0018" contrib-type="author"><name name-style="western"><surname>Muller</surname><given-names initials="E">Emeline</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0019" contrib-type="author"><name name-style="western"><surname>Le Floch</surname><given-names initials="S">Sabine</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0020" contrib-type="author"><name name-style="western"><surname>Takeda</surname><given-names initials="C">Catherine</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0021" contrib-type="author"><name name-style="western"><surname>Faisant</surname><given-names initials="C">Catherine</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0022" contrib-type="author"><name name-style="western"><surname>Lala</surname><given-names initials="F">Fran&#231;oise</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0023" contrib-type="author"><name name-style="western"><surname>Van Kan</surname><given-names initials="GA">Gabor Abellan</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0024" contrib-type="author"><name name-style="western"><surname>Steinmeyer</surname><given-names initials="Z">Zara</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0025" contrib-type="author"><name name-style="western"><surname>Piau</surname><given-names initials="A">Antoine</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0026" contrib-type="author"><name name-style="western"><surname>Macaron</surname><given-names initials="T">Tony</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0027" contrib-type="author"><name name-style="western"><surname>Angioni</surname><given-names initials="D">Davide</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0028" contrib-type="author"><name name-style="western"><surname>Ousset</surname><given-names initials="PJ">Pierre&#8208;Jean</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0029" contrib-type="author"><name name-style="western"><surname>Comt&#233;</surname><given-names initials="M">M&#233;lanie</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0030" contrib-type="author"><name name-style="western"><surname>Daniaud</surname><given-names initials="N">Nathalie</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0031" contrib-type="author"><name name-style="western"><surname>Boissou&#8208;Parachaud</surname><given-names initials="F">Fanny</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0032" contrib-type="author"><name name-style="western"><surname>Andrieu</surname><given-names initials="S">Sandrine</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0033" contrib-type="author"><name name-style="western"><surname>Cantet</surname><given-names initials="C">Christelle</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0034" contrib-type="author"><name name-style="western"><surname>Rolland</surname><given-names initials="Y">Yves</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0035" contrib-type="author"><name name-style="western"><surname>Barreto</surname><given-names initials="PDS">Philipe de Souto</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0036" contrib-type="author"><name name-style="western"><surname>Pillard</surname><given-names initials="F">Fabien</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0037" contrib-type="author"><name name-style="western"><surname>Teysseyre</surname><given-names initials="B">Bernard</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0038" contrib-type="author"><name name-style="western"><surname>Faruch</surname><given-names initials="M">Marie</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0039" contrib-type="author"><name name-style="western"><surname>Payoux</surname><given-names initials="P">Pierre</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0040" contrib-type="author"><name name-style="western"><surname>Takeda</surname><given-names initials="C">Catherine</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0041" contrib-type="author"><name name-style="western"><surname>Tavassoli</surname><given-names initials="N">Neda</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0042" contrib-type="author"><name name-style="western"><surname>Dorard</surname><given-names initials="M">Marie</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0043" contrib-type="author"><name name-style="western"><surname>Razat</surname><given-names initials="B">B&#233;n&#233;dicte</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0044" contrib-type="author"><name name-style="western"><surname>Champigny</surname><given-names initials="C">Camille</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0045" contrib-type="author"><name name-style="western"><surname>Guyonnet</surname><given-names initials="S">Sophie</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0046" contrib-type="author"><name name-style="western"><surname>Dray</surname><given-names initials="C">C&#233;dric</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0047" contrib-type="author"><name name-style="western"><surname>Prad&#232;re</surname><given-names initials="JP">Jean&#8208;Philippe</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0048" contrib-type="author"><name name-style="western"><surname>Parini</surname><given-names initials="A">Angelo</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0049" contrib-type="author"><name name-style="western"><surname>Santin</surname><given-names initials="Y">Yohan</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0050" contrib-type="author"><name name-style="western"><surname>Langin</surname><given-names initials="D">Dominique</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0051" contrib-type="author"><name name-style="western"><surname>Gourdy</surname><given-names initials="P">Pierre</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0052" contrib-type="author"><name name-style="western"><surname>Martinez</surname><given-names initials="LO">Laurent O.</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0053" contrib-type="author"><name name-style="western"><surname>Bouloumi&#233;</surname><given-names initials="A">Anne</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0054" contrib-type="author"><name name-style="western"><surname>Parini</surname><given-names initials="A">Angelo</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0055" contrib-type="author"><name name-style="western"><surname>Fazilleau</surname><given-names initials="N">Nicolas</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0056" contrib-type="author"><name name-style="western"><surname>Liblau</surname><given-names initials="R">Roland</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0057" contrib-type="author"><name name-style="western"><surname>Gu&#233;ry</surname><given-names initials="JC">Jean&#8208;Charles</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0058" contrib-type="author"><name name-style="western"><surname>Simon</surname><given-names initials="M">Michel</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0059" contrib-type="author"><name name-style="western"><surname>Gaudenzio</surname><given-names initials="N">Nicolas</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0060" contrib-type="author"><name name-style="western"><surname>Bostan</surname><given-names initials="L">Luciana</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0061" contrib-type="author"><name name-style="western"><surname>El Costa</surname><given-names initials="H">Hicham</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0062" contrib-type="author"><name name-style="western"><surname>Jabrane Ferrat</surname><given-names initials="N">Nabila</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0063" contrib-type="author"><name name-style="western"><surname>Valet</surname><given-names initials="P">Philippe</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0064" contrib-type="author"><name name-style="western"><surname>Dray</surname><given-names initials="C">Cedric</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0065" contrib-type="author"><name name-style="western"><surname>Ader</surname><given-names initials="I">Isabelle</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0066" contrib-type="author"><name name-style="western"><surname>Planat</surname><given-names initials="V">Val&#233;rie</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0067" contrib-type="author"><name name-style="western"><surname>Casteilla</surname><given-names initials="L">Louis</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0068" contrib-type="author"><name name-style="western"><surname>Payoux</surname><given-names initials="P">Pierre</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0069" contrib-type="author"><name name-style="western"><surname>Peran</surname><given-names initials="P">Patrice</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0070" contrib-type="author"><name name-style="western"><surname>Delpierre</surname><given-names initials="C">Cyrille</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0071" contrib-type="author"><name name-style="western"><surname>Andrieu</surname><given-names initials="S">Sandrine</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0072" contrib-type="author"><name name-style="western"><surname>Rampon</surname><given-names initials="C">Claire</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0073" contrib-type="author"><name name-style="western"><surname>Davezac</surname><given-names initials="N">Noelie</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0074" contrib-type="author"><name name-style="western"><surname>Guiard</surname><given-names initials="B">Bruno</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0075" contrib-type="author"><name name-style="western"><surname>Vergnolle</surname><given-names initials="N">Nathalie</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0076" contrib-type="author"><name name-style="western"><surname>Motta</surname><given-names initials="JP">Jean&#8208;Paul</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0077" contrib-type="author"><name name-style="western"><surname>Djebali</surname><given-names initials="S">Sara</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0078" contrib-type="author"><name name-style="western"><surname>Floch</surname><given-names initials="P">Pauline</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0079" contrib-type="author"><name name-style="western"><surname>Deraison</surname><given-names initials="C">C&#233;line</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0080" contrib-type="author"><name name-style="western"><surname>Bonnart</surname><given-names initials="C">Chrystelle</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0081" contrib-type="author"><name name-style="western"><surname>Sarry</surname><given-names initials="JE">Jean&#8208;Emmanuel</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0082" contrib-type="author"><name name-style="western"><surname>Coley</surname><given-names initials="N">Nicola</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0083" contrib-type="author"><name name-style="western"><surname>Guyonnet</surname><given-names initials="S">Sophie</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0084" contrib-type="author"><name name-style="western"><surname>Cantet</surname><given-names initials="C">Christelle</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0085" contrib-type="author"><name name-style="western"><surname>Pontary</surname><given-names initials="J">Jessica</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib><contrib id="acel70190-cr-0086" contrib-type="author"><name name-style="western"><surname>Andrieu</surname><given-names initials="S">Sandrine</given-names></name><xref rid="acel70190-cr-0012" ref-type="contrib"/></contrib></contrib-group>
</collab></contrib></contrib-group><aff id="acel70190-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>IHU HealthAge</institution>
<city>Toulouse</city>
<country country="FR">France</country>
</aff><aff id="acel70190-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Institute on Aging</named-content>
<institution>Toulouse University Hospital (CHU Toulouse)</institution>
<city>Toulouse</city>
<country country="FR">France</country>
</aff><aff id="acel70190-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">CERPOP, UMR 1295</named-content>
<institution>Universit&#233; Paul Sabatier</institution>
<city>Toulouse</city>
<country country="FR">France</country>
</aff><aff id="acel70190-aff-0004">
<label>
<sup>4</sup>
</label>
<institution>R&amp;D Pierre Fabre Dermo&#8208;Cosm&#233;tique &amp; Personal Care</institution>
<city>Toulouse</city>
<country country="FR">France</country>
</aff><aff id="acel70190-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">INSERM IRMB UMR1183, H&#244;pital Saint Eloi</named-content>
<institution>Universit&#233; de Montpellier</institution>
<city>Montpellier</city>
<country country="FR">France</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Wan&#8208;Hsuan Lu (<email>wanhsuanlu@gmail.com</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>24</volume><issue seq="180">10</issue><issue-id pub-id-type="pmc-issue-id">498575</issue-id><issue-id pub-id-type="doi">10.1111/acel.v24.10</issue-id><elocation-id>e70190</elocation-id><history><date date-type="rev-recd"><day>17</day><month>6</month><year>2025</year></date><date date-type="received"><day>09</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>21</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>10</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Aging Cell</italic> published by Anatomical Society and John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ACEL-24-e70190.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ACEL-24-e70190.pdf"/><abstract><title>ABSTRACT</title><p>Evidence connecting skin aging to functional decline and systemic aging biomarkers is lacking. This study investigated how skin&#8208;aging biomechanics were associated with changes in intrinsic capacity (IC), a marker of healthy aging. We also explored their links with biological aging clocks (epigenetic and inflammatory clocks) and potential moderating effects on the skin&#8208;IC relationship. Baseline skin elasticity and viscoelasticity were measured in 441 INSPIRE&#8208;T participants aged 20 to 93 (59.9% women) using Cutometer parameters. IC was evaluated over 3&#8201;years as a five&#8208;domain score covering cognition, locomotion, psychology, vitality, and sensory (a higher score indicated better). Biological aging was measured at baseline using six epigenetic clocks (Horvath pan&#8208;tissue, Horvath skin &amp; blood, Hannum, PhenoAge, GrimAge, and DunedinPACE) and inflammatory clock (iAge). Poor skin elasticity and viscoelasticity in older adults were associated with lower baseline IC after controlling for demographic, medical, and lifestyle factors. Longitudinally, older men with a higher viscoelastic ratio (R6) experienced a faster decline in IC (a standardized coefficient [95% CI] ranged from &#8722;0.37 [&#8722;0.72, &#8722;0.03] at age 62 to &#8722;1.32 [&#8722;1.91, &#8722;0.73] at age 93). Accelerated iAge was associated with reduced skin elasticity (R2, R5, R7). Moreover, the association between parameters related to elastic recovery (R5, R7) and baseline IC became more pronounced as accelerated iAge increased. This is the first study demonstrating the association between skin&#8208;aging biomechanics and IC. Poor skin elasticity was associated with higher systemic inflammation. Therefore, skin biomechanical properties may reflect overall functional aging, with inflammation serving as a common underlying factor.</p></abstract><abstract abstract-type="graphical"><p>This study assessed skin biomechanics using the Cutometer in 441 community&#8208;dwelling adults aged 20&#8211;93 from the INSPIRE&#8208;T cohort. We demonstrated that skin elasticity and viscoelasticity parameters were associated with the intrinsic capacity (IC) score, a functional marker of healthy aging encompassing cognition, locomotion, psychology, vitality, and sensory functions. The relationships between skin parameters and biological aging clocks (epigenetic and inflammatory) were also investigated.<boxed-text position="anchor" content-type="graphic" id="acel70190-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ACEL-24-e70190-g002.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="acel70190-kwd-0001">biomarkers</kwd><kwd id="acel70190-kwd-0002">biomechanical phenomena</kwd><kwd id="acel70190-kwd-0003">epigenesis</kwd><kwd id="acel70190-kwd-0005">healthy aging</kwd><kwd id="acel70190-kwd-0006">inflammation</kwd><kwd id="acel70190-kwd-0007">intrinsic capacity</kwd><kwd id="acel70190-kwd-0008">skin aging</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>the Agence Nationale de la Recherche under the France 2030 program</institution></institution-wrap></funding-source><award-id>ANR&#8208;23&#8208;IAHU&#8208;0011</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Region Occitanie/Pyr&#233;n&#233;es&#8208;M&#233;diterran&#233;e</institution></institution-wrap></funding-source><award-id>1901175</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>European Regional Development Fund</institution><institution-id institution-id-type="doi">10.13039/501100008530</institution-id></institution-wrap></funding-source><award-id>MP0022856</award-id></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>Alzheimer Prevention in Occitania and Catalonia (APOC)</institution></institution-wrap></funding-source></award-group><award-group id="funding-0005"><funding-source><institution-wrap><institution>EDENIS</institution></institution-wrap></funding-source></award-group><award-group id="funding-0006"><funding-source><institution-wrap><institution>KORIAN</institution></institution-wrap></funding-source></award-group><award-group id="funding-0007"><funding-source><institution-wrap><institution>Pfizer</institution><institution-id institution-id-type="doi">10.13039/100004319</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0008"><funding-source><institution-wrap><institution>Pierre&#8208;Fabre</institution></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="4"/><table-count count="3"/><page-count count="13"/><word-count count="8700"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:08.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="acel70190-ntgp-0001"><fn fn-type="funding" id="acel70190-note-0001"><p>
<bold>Funding:</bold> This work was supported by the Agence Nationale de la Recherche under the France 2030 program, ANR&#8208;23&#8208;IAHU&#8208;0011. Region Occitanie/Pyr&#233;n&#233;es&#8208;M&#233;diterran&#233;e, 1901175. European Regional Development Fund, MP0022856. Alzheimer Prevention in Occitania and Catalonia (APOC). EDENIS. KORIAN. Pfizer. Pierre&#8208;Fabre.</p></fn><fn fn-type="equal" id="acel70190-note-0002"><p>Philipe de Souto Barreto and Bruno Vellas contributed equally to this study.</p></fn><fn fn-type="generalState" id="acel70190-note-0003"><p>IHU HealthAge INSPIRE/Open Science study group members are listed in the acknowledgements.</p></fn></fn-group></notes></front><body id="acel70190-body-0001"><sec id="acel70190-sec-0001"><label>1</label><title>Introduction</title><p>Aging is associated with the gradual accumulation of molecular and cellular damage from early life, manifesting as physiological changes; in advanced stages, biological damage may lead to functional impairments affecting daily life (Ferrucci et&#160;al.&#160;<xref rid="acel70190-bib-0014" ref-type="bibr">2018</xref>). To delay or prevent loss of function during aging, the World Health Organization (WHO) elaborated the integrated care for older people (ICOPE; World Health Organization&#160;<xref rid="acel70190-bib-0043" ref-type="bibr">2019</xref>), a function&#8208;centered healthcare pathway dedicated to maximizing intrinsic capacity (IC) &#8211; the ensemble of all physical and mental capacities of an individual (Beard et&#160;al.&#160;<xref rid="acel70190-bib-0003" ref-type="bibr">2016</xref>) &#8211; throughout older adulthood. IC comprises key body domains contributing to healthy aging: cognition, locomotion, psychology, vitality, and sensory (Cesari et&#160;al.&#160;<xref rid="acel70190-bib-0005" ref-type="bibr">2018</xref>). The decline in IC can be detected earlier than disability in older adults (S&#225;nchez&#8208;S&#225;nchez et&#160;al.&#160;<xref rid="acel70190-bib-0038" ref-type="bibr">2024</xref>), allowing for timely interventions to reverse functional decline in the early stages (Beard et&#160;al.&#160;<xref rid="acel70190-bib-0003" ref-type="bibr">2016</xref>; de Souto Barreto et&#160;al.&#160;<xref rid="acel70190-bib-0009" ref-type="bibr">2024</xref>). IC is also important in basic research to understand the cellular and molecular mechanisms underlying functional decline during aging (de Souto Barreto et&#160;al.&#160;<xref rid="acel70190-bib-0011" ref-type="bibr">2023</xref>).</p><p>Aging of the skin is the most visible sign of human aging, commonly characterized by wrinkling, sagging, dryness, and loss of elasticity (Wong and Chew&#160;<xref rid="acel70190-bib-0042" ref-type="bibr">2021</xref>; Gruber et&#160;al.&#160;<xref rid="acel70190-bib-0018" ref-type="bibr">2020</xref>). Intrinsic skin aging refers to the inevitable physiological alterations over time, in contrast to damages caused by environmental exposure (i.e., extrinsic skin aging; Csekes and Ra&#269;kov&#225;&#160;<xref rid="acel70190-bib-0007" ref-type="bibr">2021</xref>). At the cellular level, intrinsic skin aging involves reduced cell proliferation caused by stem cell dysfunction and attrition, along with the accumulation of senescent dermal fibroblasts and epidermal keratinocytes (Russell&#8208;Goldman and Murphy&#160;<xref rid="acel70190-bib-0036" ref-type="bibr">2020</xref>; Gruber et&#160;al.&#160;<xref rid="acel70190-bib-0018" ref-type="bibr">2020</xref>). The structural integrity of the extracellular matrix also deteriorates, mainly resulting from age&#8208;related reduction in collagen synthesis as well as the increase in enzymatic degradation and fragmentation of both collagen and elastin fibers (Wilkinson and Hardman&#160;<xref rid="acel70190-bib-0041" ref-type="bibr">2021</xref>; Lee et&#160;al.&#160;<xref rid="acel70190-bib-0027" ref-type="bibr">2021</xref>). Notably, biological mechanisms underlying the changes in intrinsically aged skin, particularly cellular senescence, epigenetic alteration, and inflammation (Gruber et&#160;al.&#160;<xref rid="acel70190-bib-0018" ref-type="bibr">2020</xref>; D'Arino et&#160;al.&#160;<xref rid="acel70190-bib-0008" ref-type="bibr">2023</xref>; Lemaitre&#160;<xref rid="acel70190-bib-0028" ref-type="bibr">2024</xref>), are also implicated in age&#8208;associated deteriorations and diseases across multiple tissues and organs (Kennedy et&#160;al.&#160;<xref rid="acel70190-bib-0025" ref-type="bibr">2014</xref>; L&#243;pez&#8208;Ot&#237;n et&#160;al.&#160;<xref rid="acel70190-bib-0030" ref-type="bibr">2023</xref>). The skin thus represents an ideal model for studying systematic biological aging due to its ease of sampling and phenotyping (Holzscheck et&#160;al.&#160;<xref rid="acel70190-bib-0022" ref-type="bibr">2020</xref>). For example, skin elasticity and viscoelasticity, attributed to the stability of the elastin and collagen fiber network, significantly change with aging and can be assessed using noninvasive methods. However, evidence supporting a direct relationship between skin aging and age&#8208;related phenotypes/disorders remains limited (Zouboulis and Makrantonaki&#160;<xref rid="acel70190-bib-0044" ref-type="bibr">2019</xref>). To the best of our knowledge, no study has explored functional outcomes, including IC&#8212;an indicator of healthy aging.</p><p>In the present study, we aimed to investigate the association between skin biomechanical properties, serving as a marker of skin aging, and functional aging across adulthood. This study had two main objectives. First, we investigated if skin elasticity and viscoelasticity, measured using Cutometer parameters, were associated with IC over three years in community&#8208;dwelling adults aged from 20 to 93&#8201;years. Second, we evaluated the association of skin elasticity and viscoelasticity with biological aging, measured through epigenetic clocks (Oblak et&#160;al.&#160;<xref rid="acel70190-bib-0034" ref-type="bibr">2021</xref>) and the inflammatory clock (Sayed et&#160;al.&#160;<xref rid="acel70190-bib-0040" ref-type="bibr">2021</xref>). As an exploratory analysis, we examined whether biological aging moderated the skin&#8208;IC relationship.</p></sec><sec sec-type="methods" id="acel70190-sec-0002"><label>2</label><title>Methods</title><sec id="acel70190-sec-0003"><label>2.1</label><title>Study Population</title><p>The current study used data from the Human Translational Research Cohort of the INSPIRE program (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://clinicaltrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> [NCT04224038]; version 1.0 of the INSPIRE&#8208;T database), which is an ongoing, observational, and longitudinal cohort established in 2019 to explore biomarkers of aging, age&#8208;related conditions, and IC evolution in humans (de Souto Barreto et&#160;al.&#160;<xref rid="acel70190-bib-0010" ref-type="bibr">2021</xref>; Guyonnet et&#160;al.&#160;<xref rid="acel70190-bib-0020" ref-type="bibr">2020</xref>). The details of the INSPIRE&#8208;T cohort are provided in <xref rid="acel70190-supitem-0001" ref-type="supplementary-material">Supporting Information&#8212;Methods</xref>. Until 2024, the INSPIRE&#8208;T program has included 1132 subjects, most completing up to 3&#8201;years of follow&#8208;up visits. Among them, 518 people recruited before April 2021 received Cutometer measurements at baseline on a voluntary basis. Data from 77 individuals were excluded due to poor quality, as evaluated by a skin data specialist unaffiliated with the nurses responsible for Cutometer assessments. Finally, a sample of 441 individuals (aged 20&#8211;93) was used for analysis. Within this population, 440 subjects had available data on IC over 3&#8201;years. Data on blood&#8208;derived epigenetic clocks and inflammatory clock were accessible for 434 and 436 subjects, respectively (Figure&#160;<xref rid="acel70190-supitem-0001" ref-type="supplementary-material">S1</xref>).</p></sec><sec id="acel70190-sec-0004"><label>2.2</label><title>Skin Biomechanical Properties</title><p>Skin elasticity and viscoelasticity were measured on the day of study enrollment using Cutometer Dual MPA 580 (Courage &amp; Khazaka Electronic GmbH, Cologne, Germany) with a 2&#8208;mm&#8208;diameter probe. Participants sat with the probe placed on the inner side of their upper arm (sun&#8208;unexposed area). A 450&#8208;mbar vacuum was applied to evaluate the skin deformation; the assessment comprised five successive cycles, each including a 5&#8208;s suction followed by 5&#8201;s of relaxation. The software of Cutometer later generated mechanical parameters based on data from five cycles.</p><p>We analyzed five Cutometer parameters frequently investigated in prior studies (Ahn et&#160;al.&#160;<xref rid="acel70190-bib-0002" ref-type="bibr">2007</xref>; Fujimoto et&#160;al.&#160;<xref rid="acel70190-bib-0017" ref-type="bibr">2023</xref>; Huang et&#160;al.&#160;<xref rid="acel70190-bib-0023" ref-type="bibr">2024</xref>): (1) Skin distensibility&#8212;R0, the total distension during the suction phase, measured in mm. (2) Gross elasticity&#8212;R2, the ratio of final recovery (at the end of the relaxation) to total distension. (3) Net elasticity&#8212;R5, which excludes viscous distension and recovery compared to R2. (4) Biological elasticity&#8212;R7, the ratio of immediate recovery (within the first 0.1&#8201;s during the relaxation phase) to total distension, excluding viscous recovery compared to R2. (5) Viscoelastic ratio&#8212;R6, the ratio of viscoelastic to elastic distension.</p><p>R2, R5, and R7 are markers of skin elasticity, with higher values indicating better elasticity; R5 and R7 primarily reflect the extent of elastic recovery, whereas R2 encompasses both elastic and viscous recovery. R6 serves as the parameter for viscoelasticity, representing the proportion of viscous deformation during the suction phase, which usually increases with age. Unlike R0, the parameters R2, R5, R6, and R7 are dimensionless and independent of skin thickness, enabling a direct comparison between individuals (Abbas et&#160;al.&#160;<xref rid="acel70190-bib-0001" ref-type="bibr">2022</xref>). Moreover, R2, R5, R6, and R7 were suggested as indicators of &#8220;skin elasticity age&#8221; due to their strong correlation with age compared to other R parameters from Cutometer (Ryu et&#160;al.&#160;<xref rid="acel70190-bib-0037" ref-type="bibr">2008</xref>).</p></sec><sec id="acel70190-sec-0005"><label>2.3</label><title>Intrinsic Capacity (<styled-content style="fixed-case" toggle="no">IC</styled-content>)</title><p>IC was operationalized as a composite score of five functional domains involving cognition (assessed by the Mini&#8208;Mental State Examination [MMSE] (Folstein et&#160;al.&#160;<xref rid="acel70190-bib-0016" ref-type="bibr">1975</xref>)), locomotion (measured by the Short Physical Performance Battery [SPPB] (Guralnik et&#160;al.&#160;<xref rid="acel70190-bib-0019" ref-type="bibr">1994</xref>)), psychology (examined by the 9&#8208;item Patient Health Questionnaire for depression [PHQ&#8208;9] (Kroenke et&#160;al.&#160;<xref rid="acel70190-bib-0026" ref-type="bibr">2001</xref>)), vitality (evaluated as grip strength in the dominant hand), and sensory (including distance vision assessment and whisper test). Each domain was assessed by trained staff at baseline and then annually for up to 3&#8201;years. Following the methods in the prior INSPIRE&#8208;T publication (Lu et&#160;al.&#160;<xref rid="acel70190-bib-0031" ref-type="bibr">2023</xref>), the original scores from the domain assessments were rescaled to a range of 0&#8211;100 points, with higher indicating better performance. The final IC score was calculated as the average of the five domains.</p></sec><sec id="acel70190-sec-0006"><label>2.4</label><title>Biological Aging Clocks</title><p>Six epigenetic clocks were examined at baseline, including first&#8208;generation clocks (Horvath pan&#8208;tissue, Horvath skin &amp; blood, Hannum; trained on chronological age), second&#8208;generation clocks (PhenoAge and GrimAge; trained on lifespan and mortality risk), and a third&#8208;generation clock (DunedinPACE; trained on pace of aging; Oblak et&#160;al.&#160;<xref rid="acel70190-bib-0034" ref-type="bibr">2021</xref>). Details of epigenetic clock assessments are provided in <xref rid="acel70190-supitem-0001" ref-type="supplementary-material">Supporting Information&#8212;Methods</xref>. For the first&#8208; and second&#8208;generation clocks, we calculated age acceleration (AA) for each individual, defined as the residuals from regressing chronological age against DNA methylation ages (DNAmAge). A positive AA value indicated that epigenetic age exceeded chronological age, whereas a negative AA value indicated that epigenetic age was lower than chronological age. DunedinPACE reflected the pace of biological aging per year of time; a value &gt;&#8201;1 indicated accelerated biological aging.</p><p>The inflammatory clock (iAge), developed by Sayed et&#160;al.&#160;(<xref rid="acel70190-bib-0040" ref-type="bibr">2021</xref>), measures age&#8208;related systemic inflammation using a set of blood immune molecules identified through a deep learning method. In this study, iAge was estimated from the baseline blood sample following the procedures outlined in Sayed et&#160;al.'s work. To align with epigenetic AA, we calculated residuals from the regression of chronological age and iAge (referred hereafter as iAgeAA), where positive values indicated an estimated iAge exceeding chronological age.</p></sec><sec id="acel70190-sec-0007"><label>2.5</label><title>Covariates</title><p>Factors influencing individuals' skin elasticity were collected at the baseline visit, including age, sex (Firooz et&#160;al.&#160;<xref rid="acel70190-bib-0015" ref-type="bibr">2012</xref>), hormone replacement therapy (HRT) use (Sator et&#160;al.&#160;<xref rid="acel70190-bib-0039" ref-type="bibr">2001</xref>), and long&#8208;term sun exposure (Bernstein et&#160;al.&#160;<xref rid="acel70190-bib-0004" ref-type="bibr">1996</xref>). HRT users were identified if participants reported taking oral or topical HRT medications due to menopause symptoms. Factors related to sun exposure included previous residence in high daily solar exposure regions, use of ultraviolet (UV) protection products, and the frequency of sun exposure on the lower limbs (detailed in <xref rid="acel70190-supitem-0001" ref-type="supplementary-material">Supporting Information&#8212;Methods</xref>).</p></sec><sec id="acel70190-sec-0008"><label>2.6</label><title>Statistical Analysis</title><sec id="acel70190-sec-0009"><label>2.6.1</label><title>Descriptive Analysis</title><p>We performed descriptive statistics on the participants' characteristics, R parameters, and biological aging clocks; the results were presented as means with standard deviations (SDs) or as numbers with percentages, as appropriate. Correlations between age and R parameters were illustrated using scatter plots and analyzed using Spearman's rank order correlation coefficients.</p></sec><sec id="acel70190-sec-0010"><label>2.6.2</label><title>Association Between R Parameters and <styled-content style="fixed-case" toggle="no">IC</styled-content>
</title><p>We applied linear mixed&#8208;effect models with random intercepts and random time slopes at the participants' level. Each R parameter was analyzed in a separate model as a predictor. To allow for comparison across models, all R parameters were standardized (mean&#8201;=&#8201;0, SD&#8201;=&#8201;1), such that coefficients could be interpreted as the effect of a one&#8208;SD increase in the R parameter on IC.</p><p>We ran both unadjusted models (including only R, time, and their interaction as independent variables) and adjusted models that controlled for age, sex, and the aforementioned covariates. Since both R parameters and IC vary with age, it is plausible that their associations also change throughout the lifespan. Therefore, interaction terms involving time, the R parameter, and age were tested in the adjusted models; significant interaction terms were retained, and their coefficients and <italic toggle="yes">p</italic> values were reported.</p><p>We took two approaches to facilitate the interpretation of models with significant age interactions. First, we applied the Johnson&#8208;Neyman technique (Johnson and Fay&#160;<xref rid="acel70190-bib-0024" ref-type="bibr">1950</xref>; Hayes and Matthes&#160;<xref rid="acel70190-bib-0021" ref-type="bibr">2009</xref>) to identify age intervals where the association between R and IC was statistically significant, and then reported the conditional effects of R on IC at the lower and upper boundaries of this interval. Second, we created interaction plots to visualize the effect of R on IC, holding age constant at 40, 65, and 80&#8201;years, respectively. These age points were selected to represent young, old, and very old adults.</p><p>All analyses regarding IC were conducted on the whole population and then separately by sex to explore potential sex differences.</p></sec><sec id="acel70190-sec-0011"><label>2.6.3</label><title>Association Between R Parameters and Biological Aging Clocks</title><p>The association of R parameters with epigenetic aging and iAgeAA was evaluated using linear regression. A total of 35 models were examined, each testing a separate R parameter (as a dependent variable) and biomarker (as a predictor). Results from both unadjusted models and models adjusted for age, age<sup>2</sup> (when appropriate), sex, and covariates were reported. Furthermore, to test whether the associations between biological aging clocks and R parameters varied by age or sex, we included interaction terms between biomarkers and age as well as between biomarkers and sex in the linear models. To ensure comparability across models, standardized regression coefficients were reported, indicating the expected change (in SD units) in the R parameter for each one SD increase in epigenetic aging or iAgeAA.</p></sec><sec id="acel70190-sec-0012"><label>2.6.4</label><title>Exploratory Analyses</title><p>We conducted two exploratory analyses. First, we ran linear mixed&#8208;effect models using each IC domain score (on a scale of 0&#8211;100 points) as an outcome to investigate the effects of R parameters on individual IC domains. Second, given that some R parameters were significantly associated with both IC and biological aging clocks, we investigated whether the association between R parameters and IC was moderated by biological aging. To do so, we added biological aging clocks and their interaction terms to the mixed&#8208;effect models previously applied to assess the R&#8211;IC association. Interaction plots were used to illustrate the R&#8211;IC relationship at different levels of biological aging, as defined by quartiles; the plots held age constant at 40, 65, or 80&#8201;years, respectively, to highlight potential age differences. This exploratory analysis was conducted only for the R parameters and biomarkers that showed statistical significance in the main analyses.</p><p>Our analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC) and R Studio version 2024.9.0.375, with a significance level of 0.05. Listwise deletion was applied to observations with any missing data on the variables required for regression models (IC, biomarkers, or covariates).</p></sec></sec></sec><sec sec-type="results" id="acel70190-sec-0013"><label>3</label><title>Results</title><sec id="acel70190-sec-0014"><label>3.1</label><title>Descriptive Analysis of Population Characteristics and Skin Biomechanics</title><p>Table&#160;<xref rid="acel70190-tbl-0001" ref-type="table">1</xref> and Table&#160;<xref rid="acel70190-supitem-0001" ref-type="supplementary-material">S1</xref> display the baseline characteristics of 441 participants, with a mean (SD) age of 61.3 (17.5) years and the majority being women (59.9%). Figure&#160;<xref rid="acel70190-fig-0001" ref-type="fig">1</xref> presents the distribution of R parameters across age (Figure&#160;<xref rid="acel70190-fig-0001" ref-type="fig">1A&#8211;E</xref>) and their Spearman's rank correlation coefficients (Figure&#160;<xref rid="acel70190-fig-0001" ref-type="fig">1F</xref>). R0 (skin distensibility) showed a weak correlation with age (<italic toggle="yes">r</italic>&#8201;=&#8201;&#8722;0.19; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) and did not follow a consistent trend (Figure&#160;<xref rid="acel70190-fig-0001" ref-type="fig">1A</xref>). Skin elasticity parameters, including R2 (gross elasticity), R5 (net elasticity), and R7 (biological elasticity), exhibited significant negative correlations with age (Figure&#160;<xref rid="acel70190-fig-0001" ref-type="fig">1B,C,E</xref>), with Spearman's rank correlation coefficients ranging from &#8722;0.31 to &#8722;0.56 (all <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; Figure&#160;<xref rid="acel70190-fig-0001" ref-type="fig">1F</xref>). In contrast, R6 (viscoelastic ratio) tended to increase in older age (<italic toggle="yes">r</italic>&#8201;=&#8201;0.43; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; Figure&#160;<xref rid="acel70190-fig-0001" ref-type="fig">1D</xref>).</p><table-wrap position="float" id="acel70190-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Baseline characteristics of 441 INSPIRE&#8208;T participants with skin elasticity and viscoelasticity data.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Whole population (<italic toggle="yes">n</italic>&#8201;=&#8201;441)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Women (<italic toggle="yes">n</italic>&#8201;=&#8201;264 [59.9%])</th><th align="center" valign="bottom" rowspan="1" colspan="1">Men (<italic toggle="yes">n</italic>&#8201;=&#8201;177 [40.1%])</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, year</td><td align="center" valign="top" rowspan="1" colspan="1">61.3 (17.5)</td><td align="center" valign="top" rowspan="1" colspan="1">59.9 (18.2)</td><td align="center" valign="top" rowspan="1" colspan="1">63.4 (16.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Baseline IC score, 0&#8211;100 (<italic toggle="yes">n</italic>&#8201;=&#8201;431)</td><td align="center" valign="top" rowspan="1" colspan="1">85.5 (7.4)</td><td align="center" valign="top" rowspan="1" colspan="1">85.2 (7.7)</td><td align="center" valign="top" rowspan="1" colspan="1">86.0 (7.1)</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">Skin Cutometer parameters</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">R0&#8212;skin distensibility, mm</td><td align="center" valign="top" rowspan="1" colspan="1">0.45 (0.10)</td><td align="center" valign="top" rowspan="1" colspan="1">0.46 (0.10)</td><td align="center" valign="top" rowspan="1" colspan="1">0.42 (0.10)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">R2&#8212;gross elasticity, %</td><td align="center" valign="top" rowspan="1" colspan="1">0.63 (0.14)</td><td align="center" valign="top" rowspan="1" colspan="1">0.63 (0.14)</td><td align="center" valign="top" rowspan="1" colspan="1">0.62 (0.14)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">R5&#8212;net elasticity, %</td><td align="center" valign="top" rowspan="1" colspan="1">0.58 (0.20)</td><td align="center" valign="top" rowspan="1" colspan="1">0.59 (0.20)</td><td align="center" valign="top" rowspan="1" colspan="1">0.57 (0.19)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">R6&#8212;viscoelastic ratio, %</td><td align="center" valign="top" rowspan="1" colspan="1">0.37 (0.11)</td><td align="center" valign="top" rowspan="1" colspan="1">0.37 (0.11)</td><td align="center" valign="top" rowspan="1" colspan="1">0.37 (0.12)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">R7&#8212;biological elasticity, %</td><td align="center" valign="top" rowspan="1" colspan="1">0.42 (0.15)</td><td align="center" valign="top" rowspan="1" colspan="1">0.43 (0.15)</td><td align="center" valign="top" rowspan="1" colspan="1">0.41 (0.14)</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">Biological aging clocks</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">HorvathAA pan&#8208;tissue (<italic toggle="yes">n</italic>&#8201;=&#8201;434)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.45 (4.47)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;1.23 (4.42)</td><td align="center" valign="top" rowspan="1" colspan="1">0.71 (4.31)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">HorvathAA skin&#8208;blood (<italic toggle="yes">n</italic>&#8201;=&#8201;434)</td><td align="center" valign="top" rowspan="1" colspan="1">0.03 (3.22)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.35 (3.26)</td><td align="center" valign="top" rowspan="1" colspan="1">0.60 (3.07)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">HannumAA (<italic toggle="yes">n</italic>&#8201;=&#8201;434)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.11 (3.34)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.66 (3.25)</td><td align="center" valign="top" rowspan="1" colspan="1">0.71 (3.30)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">PhenoAA (<italic toggle="yes">n</italic>&#8201;=&#8201;434)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.35 (4.82)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.68 (4.62)</td><td align="center" valign="top" rowspan="1" colspan="1">0.15 (5.08)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">GrimAA (<italic toggle="yes">n</italic>&#8201;=&#8201;434)</td><td align="center" valign="top" rowspan="1" colspan="1">0.53 (3.49)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.54 (3.09)</td><td align="center" valign="top" rowspan="1" colspan="1">2.11 (3.46)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">DunedinPACE (<italic toggle="yes">n</italic>&#8201;=&#8201;434)</td><td align="center" valign="top" rowspan="1" colspan="1">0.93 (0.11)</td><td align="center" valign="top" rowspan="1" colspan="1">0.93 (0.12)</td><td align="center" valign="top" rowspan="1" colspan="1">0.93 (0.11)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">iAgeAA (<italic toggle="yes">n</italic>&#8201;=&#8201;436)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.62 (8.32)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.13 (8.28)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;1.34 (8.36)</td></tr></tbody></table><table-wrap-foot id="acel70190-ntgp-0002"><fn id="acel70190-note-0004"><p>
<italic toggle="yes">Note:</italic> Values are displayed as mean (SD).</p></fn><fn id="acel70190-note-0005"><p>Abbreviations: AA, age acceleration obtained using the corresponding biological aging clocks (unit: year); IC, intrinsic capacity.</p></fn></table-wrap-foot></table-wrap><fig position="float" fig-type="FIGURE" id="acel70190-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Correlations between skin elasticity/viscoelasticity parameters and age. (A&#8211;E) Scatterplots show how Cutometer R parameters varied by age. Blue points represent men, and red points represent women. R0, skin distensibility; R2, gross elasticity; R5, net elasticity; R6, viscoelastic ratio; R7, biological elasticity. (F) A correlation matrix representing Spearman's rank correlation coefficients between age and R parameters. All <italic toggle="yes">p</italic> values for the correlations were statistically significant (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05), except for the comparison between parameters R5 and R6 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.05).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="ACEL-24-e70190-g003.jpg"/></fig></sec><sec id="acel70190-sec-0015"><label>3.2</label><title>Associations Between Skin Biomechanics and <styled-content style="fixed-case" toggle="no">IC</styled-content>
</title><p>In unadjusted analyses, we observed significant associations between IC and the R parameters, except for R0 (skin distensibility) (Table&#160;<xref rid="acel70190-tbl-0002" ref-type="table">2</xref>). Higher values of R2, R5, and R7, which indicate better skin elasticity, were associated with higher IC scores at baseline (R2: &#946; [SE]&#8201;=&#8201;1.83 [0.33], <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; R5: &#946; [SE]&#8201;=&#8201;2.07 [0.32], <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; R7: &#946; [SE]&#8201;=&#8201;2.50 [0.32], <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Longitudinally, better skin elasticity predicted improvement in IC over time (time&#8201;&#215;&#8201;R2: &#946; [SE]&#8201;=&#8201;0.30 [0.10], <italic toggle="yes">p</italic>&#8201;=&#8201;0.004; time&#8201;&#215;&#8201;R5: &#946; [SE]&#8201;=&#8201;0.31 [0.10], <italic toggle="yes">p</italic>&#8201;=&#8201;0.003; time&#8201;&#215;&#8201;R7: &#946; [SE]&#8201;=&#8201;0.37 [0.10], <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) (Table&#160;<xref rid="acel70190-tbl-0002" ref-type="table">2</xref>). On the other hand, a higher R6 (viscoelastic ratio) was associated with lower baseline IC (R6: &#946; [SE]&#8201;=&#8201;&#8722;2.23 [0.32], <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) and a faster IC decline over time (time&#8201;&#215;&#8201;R6: &#946; [SE]&#8201;=&#8201;&#8722;0.30 [0.10], <italic toggle="yes">p</italic>&#8201;=&#8201;0.005) (Table&#160;<xref rid="acel70190-tbl-0002" ref-type="table">2</xref>).</p><table-wrap position="float" id="acel70190-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Linear mixed&#8208;effects model results for IC, based on the whole population.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1"/><th align="center" colspan="3" valign="bottom" rowspan="1">R0 (skin distensibility)</th><th align="center" colspan="3" valign="bottom" rowspan="1">R2 (gross elasticity)</th><th align="center" colspan="3" valign="bottom" rowspan="1">R5 (net elasticity)</th><th align="center" colspan="3" valign="bottom" rowspan="1">R6 (viscoelastic ratio)</th><th align="center" colspan="3" valign="bottom" rowspan="1">R7 (biological elasticity)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">&#946;</th><th align="center" valign="bottom" rowspan="1" colspan="1">SE</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">&#946;</th><th align="center" valign="bottom" rowspan="1" colspan="1">SE</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">&#946;</th><th align="center" valign="bottom" rowspan="1" colspan="1">SE</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">&#946;</th><th align="center" valign="bottom" rowspan="1" colspan="1">SE</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">&#946;</th><th align="center" valign="bottom" rowspan="1" colspan="1">SE</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="16" valign="top" rowspan="1">Unadjusted model</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">R</td><td align="center" valign="top" rowspan="1" colspan="1">0.59</td><td align="center" valign="top" rowspan="1" colspan="1">0.34</td><td align="center" valign="top" rowspan="1" colspan="1">0.079</td><td align="center" valign="top" rowspan="1" colspan="1">1.83</td><td align="center" valign="top" rowspan="1" colspan="1">0.33</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">2.07</td><td align="center" valign="top" rowspan="1" colspan="1">0.32</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;2.23</td><td align="center" valign="top" rowspan="1" colspan="1">0.32</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">2.50</td><td align="center" valign="top" rowspan="1" colspan="1">0.32</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Time</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.15</td><td align="center" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">0.145</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.16</td><td align="center" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">0.120</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.15</td><td align="center" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">0.132</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.15</td><td align="center" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">0.136</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.15</td><td align="center" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">0.132</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Time&#8201;&#215;&#8201;R</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td><td align="center" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">0.620</td><td align="center" valign="top" rowspan="1" colspan="1">0.30</td><td align="center" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">0.004</td><td align="center" valign="top" rowspan="1" colspan="1">0.31</td><td align="center" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">0.003</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.30</td><td align="center" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">0.005</td><td align="center" valign="top" rowspan="1" colspan="1">0.37</td><td align="center" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="16" valign="top" rowspan="1">Adjusted model<xref rid="acel70190-note-0007" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">R</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.18</td><td align="center" valign="top" rowspan="1" colspan="1">0.29</td><td align="center" valign="top" rowspan="1" colspan="1">0.521</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;4.79</td><td align="center" valign="top" rowspan="1" colspan="1">1.03</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;5.43</td><td align="center" valign="top" rowspan="1" colspan="1">0.99</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">3.69</td><td align="center" valign="top" rowspan="1" colspan="1">1.14</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;6.21</td><td align="center" valign="top" rowspan="1" colspan="1">0.96</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Age</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.23</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.20</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.21</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.24</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.22</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">R&#8201;&#215;&#8201;age</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;<xref rid="acel70190-note-0008" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">0.08</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.09</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.06</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.11</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Time</td><td align="center" valign="top" rowspan="1" colspan="1">1.91</td><td align="center" valign="top" rowspan="1" colspan="1">0.39</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1.44</td><td align="center" valign="top" rowspan="1" colspan="1">0.38</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1.44</td><td align="center" valign="top" rowspan="1" colspan="1">0.40</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">2.27</td><td align="center" valign="top" rowspan="1" colspan="1">0.46</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1.35</td><td align="center" valign="top" rowspan="1" colspan="1">0.42</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Time&#8201;&#215;&#8201;R</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.81</td><td align="center" valign="top" rowspan="1" colspan="1">0.35</td><td align="center" valign="top" rowspan="1" colspan="1">0.020</td><td align="center" valign="top" rowspan="1" colspan="1">0.17</td><td align="center" valign="top" rowspan="1" colspan="1">0.11</td><td align="center" valign="top" rowspan="1" colspan="1">0.101</td><td align="center" valign="top" rowspan="1" colspan="1">0.12</td><td align="center" valign="top" rowspan="1" colspan="1">0.11</td><td align="center" valign="top" rowspan="1" colspan="1">0.266</td><td align="center" valign="top" rowspan="1" colspan="1">1.29</td><td align="center" valign="top" rowspan="1" colspan="1">0.42</td><td align="center" valign="top" rowspan="1" colspan="1">0.002</td><td align="center" valign="top" rowspan="1" colspan="1">0.15</td><td align="center" valign="top" rowspan="1" colspan="1">0.12</td><td align="center" valign="top" rowspan="1" colspan="1">0.205</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Time&#8201;&#215;&#8201;age</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.03</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.03</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.03</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.04</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.02</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Time&#8201;&#215;&#8201;R&#8201;&#215;&#8201;age</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.023</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;<xref rid="acel70190-note-0009" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;<xref rid="acel70190-note-0009" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.02</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;<xref rid="acel70190-note-0009" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr></tbody></table><table-wrap-foot id="acel70190-ntgp-0003"><fn id="acel70190-note-0006"><p>
<italic toggle="yes">Note:</italic> Analyses were conducted on 440 individuals for unadjusted models and on 431 individuals for adjusted models. The values of R parameters were first standardized to have a mean of 0 and a SD of 1 before performing the linear mixed&#8208;effect models, allowing for comparisons across models. A year was used as the unit of time.</p></fn><fn id="acel70190-note-0007"><label>
<sup>a</sup>
</label><p>The models were additionally adjusted for sex, use of hormone replacement therapy (HRT), previous residence in high&#8208;solar&#8208;exposure regions, use of ultraviolet (UV) protection products, and sun exposure frequency.</p></fn><fn id="acel70190-note-0008"><label>
<sup>b</sup>
</label><p>The interaction term &#8220;R0 &#215; age&#8221; was not retained in the model due to its insignificance.</p></fn><fn id="acel70190-note-0009"><label>
<sup>c</sup>
</label><p>The interaction terms &#8220;time &#215; R2 &#215; age,&#8221; &#8220;time &#215; R5 &#215; age,&#8221; &#8220;time &#215; R7 &#215; age&#8221; were not retained in the models due to their insignificance.</p></fn></table-wrap-foot></table-wrap><p>R2, R5, R6, and R7 remained associated with baseline IC scores after adjusting for covariates, with significant interactions between age and R (Table&#160;<xref rid="acel70190-tbl-0002" ref-type="table">2</xref>). The Johnson&#8208;Neyman technique revealed that the associations between R and baseline IC were significant only at younger and older ages (Table&#160;<xref rid="acel70190-supitem-0001" ref-type="supplementary-material">S2</xref>). Figure&#160;<xref rid="acel70190-fig-0002" ref-type="fig">2A&#8211;D</xref> illustrates the age&#8208;moderating association between the R parameters and baseline IC, presenting ages 40, 65, and 80 as examples: the relationship between R and baseline IC at age 40 was in the opposite direction compared to those at ages 65 and 80.</p><fig position="float" fig-type="FIGURE" id="acel70190-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Effect of skin elasticity (R2, R5, R7) and viscoelasticity (R6) parameters on baseline IC at ages 40, 65, and 80. The interaction plots illustrate how the effects of Cutometer R parameters on baseline IC scores varied by age, using 40, 65, and 80&#8201;years as examples. Results are presented for the whole population (A&#8211;D), women (E&#8211;H), and men (I&#8211;L). The slopes of R parameters were estimated by holding time&#8201;=&#8201;0 and ages&#8201;=&#8201;40, 65, and 80, respectively, using the linear mixed&#8208;effect models in Table&#160;<xref rid="acel70190-tbl-0002" ref-type="table">2</xref> (for the whole population) and Table&#160;<xref rid="acel70190-tbl-0003" ref-type="table">3</xref> (for women and men). Overall, the association between baseline IC and R parameters differed between younger (age 40; in red) and older individuals (age 65 and 80; in blue and green), as indicated by the opposite slope directions in the plots. R2, gross elasticity; R5, net elasticity; R6, viscoelastic ratio; R7, biological elasticity.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="ACEL-24-e70190-g001.jpg"/></fig><p>R6 (viscoelastic ratio) was longitudinally associated with IC change in the adjusted model, and this association was moderated by age (time&#8201;&#215;&#8201;R6: &#946; [SE]&#8201;=&#8201;1.29 [0.42], <italic toggle="yes">p</italic>&#8201;=&#8201;0.002; time&#8201;&#215;&#8201;R6&#8201;<italic toggle="yes">&#215;</italic>&#8201;age: &#946; [SE]&#8201;=&#8201;&#8722;0.02 [0.01]; <italic toggle="yes">p</italic>&#8201;=&#8201;0.001; Table&#160;<xref rid="acel70190-tbl-0002" ref-type="table">2</xref>). Higher R6 was associated with a faster decline in IC at older ages (from 75 to 93&#8201;years), with the conditional effect on the IC change ranging from &#8722;0.25 (95% CI, &#8722;0.50 to &#8722;0.01) at age 75 to &#8722;0.62 (&#8722;1.01 to &#8722;0.23) at age 93. In contrast, opposite associations between R6 and overtime IC change were found at age &#8804;&#8201;47 (Table&#160;<xref rid="acel70190-supitem-0001" ref-type="supplementary-material">S3</xref>). Figure&#160;<xref rid="acel70190-fig-0003" ref-type="fig">3A</xref> presents how the impact of R6 on IC trajectories differs at ages 40, 65, and 80 in the whole population. Skin distensibility (R0) was also associated with overtime IC change after adjusting for covariates (time&#8201;&#215;&#8201;R0: &#946; [SE]&#8201;=&#8201;&#8722;0.81 [0.35], <italic toggle="yes">p</italic>&#8201;=&#8201;0.020; time&#8201;&#215;&#8201;R0&#8201;&#215;&#8201;age: &#946; [SE]&#8201;=&#8201;0.01 [0.01], <italic toggle="yes">p</italic>&#8201;=&#8201;0.023; Table&#160;<xref rid="acel70190-tbl-0002" ref-type="table">2</xref>). This association was mainly observed in adults aged &#8804;&#8201;43, with an increased R0 being associated with worse IC over time (&#946; [95% CI] ranged from &#8722;0.56 [&#8722;1.05, &#8722;0.08] at age 20 to &#8722;0.28 [&#8722;0.56, &#8722;0.00] at age 43; Table&#160;<xref rid="acel70190-supitem-0001" ref-type="supplementary-material">S3</xref>).</p><fig position="float" fig-type="FIGURE" id="acel70190-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Predicted IC over 3&#8201;years by different levels of R6 and ages. The interaction plots illustrate how the effect of the viscoelastic ratio R6 on the overtime IC change varied by ages, using age&#8201;=&#8201;40, 65, and 80&#8201;years and standardized R6 values&#8201;=&#8201;&#8722;1, 0, and 1 as examples. The slopes of time (referring to the overtime IC change) were estimated using the linear mixed&#8208;effect models in Table&#160;<xref rid="acel70190-tbl-0002" ref-type="table">2</xref> (for the whole population) and Table&#160;<xref rid="acel70190-tbl-0003" ref-type="table">3</xref> (for women and men). (A) IC tended to be improved over time in individuals aged 40 (positive slopes in the plots) and relatively stable or declining at ages 65 and 80. (B, C) Women aged 40 with increased R6 were associated with a higher IC initially and a greater improvement in IC over three years. On the contrary, in older people, especially men, an increased R6 was associated with a lower baseline IC and a faster IC decline.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="ACEL-24-e70190-g004.jpg"/></fig><p>In the sex&#8208;stratified analysis, IC was cross&#8208;sectionally associated with R5 (net elasticity) and R7 (biological elasticity) in both women and men, whereas significant associations with R2 (gross elasticity) and R6 (viscoelastic ratio) were observed only in women (Table&#160;<xref rid="acel70190-tbl-0003" ref-type="table">3</xref>, Table&#160;<xref rid="acel70190-supitem-0001" ref-type="supplementary-material">S2</xref>, Figure&#160;<xref rid="acel70190-fig-0002" ref-type="fig">2E&#8211;2L</xref>). A higher R6 predicted a faster IC decline in older men (&#946; [95% CI] ranging from &#8722;0.37 [&#8722;0.72, &#8722;0.03] at age 62 to &#8722;1.32 [&#8722;1.91, &#8722;0.73] at age 93) but not in older women (Table&#160;<xref rid="acel70190-supitem-0001" ref-type="supplementary-material">S3</xref>, Figure&#160;<xref rid="acel70190-fig-0003" ref-type="fig">3B&#8211;C</xref>). The results of the exploratory analysis on individual IC domains were consistent with the main findings. Skin elasticity parameters R2, R5, and R7 were cross&#8208;sectionally associated with all IC domains. Longitudinally, associations with R6 were primarily observed in the cognition, locomotion, and sensory domains (Table&#160;<xref rid="acel70190-supitem-0001" ref-type="supplementary-material">S4</xref>).</p><table-wrap position="float" id="acel70190-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Linear mixed&#8208;effects model results for IC, stratified by sex.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1"/><th align="center" colspan="3" valign="bottom" rowspan="1">R0 (skin distensibility)</th><th align="center" colspan="3" valign="bottom" rowspan="1">R2 (gross elasticity)</th><th align="center" colspan="3" valign="bottom" rowspan="1">R5 (net elasticity)</th><th align="center" colspan="3" valign="bottom" rowspan="1">R6 (viscoelastic ratio)</th><th align="center" colspan="3" valign="bottom" rowspan="1">R7 (biological elasticity)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">&#946;</th><th align="center" valign="bottom" rowspan="1" colspan="1">SE</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">&#946;</th><th align="center" valign="bottom" rowspan="1" colspan="1">SE</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">&#946;</th><th align="center" valign="bottom" rowspan="1" colspan="1">SE</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">&#946;</th><th align="center" valign="bottom" rowspan="1" colspan="1">SE</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">&#946;</th><th align="center" valign="bottom" rowspan="1" colspan="1">SE</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="16" valign="top" rowspan="1">Women (<italic toggle="yes">n</italic>&#8201;=&#8201;259)<xref rid="acel70190-note-0011" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">R</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.08</td><td align="center" valign="top" rowspan="1" colspan="1">0.39</td><td align="center" valign="top" rowspan="1" colspan="1">0.826</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;6.17</td><td align="center" valign="top" rowspan="1" colspan="1">1.30</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;6.48</td><td align="center" valign="top" rowspan="1" colspan="1">1.23</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">5.20</td><td align="center" valign="top" rowspan="1" colspan="1">1.45</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;7.19</td><td align="center" valign="top" rowspan="1" colspan="1">1.19</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Age</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.24</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.19</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.21</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.26</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.22</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">R&#8201;&#215;&#8201;age</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;<xref rid="acel70190-note-0012" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">0.11</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.12</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.09</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.13</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Time</td><td align="center" valign="top" rowspan="1" colspan="1">1.90</td><td align="center" valign="top" rowspan="1" colspan="1">0.50</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1.30</td><td align="center" valign="top" rowspan="1" colspan="1">0.45</td><td align="center" valign="top" rowspan="1" colspan="1">0.004</td><td align="center" valign="top" rowspan="1" colspan="1">1.32</td><td align="center" valign="top" rowspan="1" colspan="1">0.47</td><td align="center" valign="top" rowspan="1" colspan="1">0.005</td><td align="center" valign="top" rowspan="1" colspan="1">2.52</td><td align="center" valign="top" rowspan="1" colspan="1">0.58</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1.39</td><td align="center" valign="top" rowspan="1" colspan="1">0.51</td><td align="center" valign="top" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Time &#215; R</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.75</td><td align="center" valign="top" rowspan="1" colspan="1">0.45</td><td align="center" valign="top" rowspan="1" colspan="1">0.096</td><td align="center" valign="top" rowspan="1" colspan="1">0.16</td><td align="center" valign="top" rowspan="1" colspan="1">0.13</td><td align="center" valign="top" rowspan="1" colspan="1">0.229</td><td align="center" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">0.14</td><td align="center" valign="top" rowspan="1" colspan="1">0.472</td><td align="center" valign="top" rowspan="1" colspan="1">1.17</td><td align="center" valign="top" rowspan="1" colspan="1">0.51</td><td align="center" valign="top" rowspan="1" colspan="1">0.023</td><td align="center" valign="top" rowspan="1" colspan="1">0.04</td><td align="center" valign="top" rowspan="1" colspan="1">0.14</td><td align="center" valign="top" rowspan="1" colspan="1">0.778</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Time &#215; age</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.03</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.02</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.03</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.04</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.03</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Time &#215; R&#8201;&#215;&#8201;age</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.210</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;<xref rid="acel70190-note-0013" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;<xref rid="acel70190-note-0013" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.085</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;<xref rid="acel70190-note-0013" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" colspan="16" valign="top" rowspan="1">Men (<italic toggle="yes">n</italic>&#8201;=&#8201;172)<xref rid="acel70190-note-0014" ref-type="table-fn">
<sup>d</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">R</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.21</td><td align="center" valign="top" rowspan="1" colspan="1">0.42</td><td align="center" valign="top" rowspan="1" colspan="1">0.619</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;2.80</td><td align="center" valign="top" rowspan="1" colspan="1">1.64</td><td align="center" valign="top" rowspan="1" colspan="1">0.088</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;3.82</td><td align="center" valign="top" rowspan="1" colspan="1">1.64</td><td align="center" valign="top" rowspan="1" colspan="1">0.020</td><td align="center" valign="top" rowspan="1" colspan="1">0.58</td><td align="center" valign="top" rowspan="1" colspan="1">1.84</td><td align="center" valign="top" rowspan="1" colspan="1">0.752</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;4.34</td><td align="center" valign="top" rowspan="1" colspan="1">1.64</td><td align="center" valign="top" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Age</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.21</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.20</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.21</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.20</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.22</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">R&#8201;&#215;&#8201;age</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;<xref rid="acel70190-note-0012" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">0.04</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">0.098</td><td align="center" valign="top" rowspan="1" colspan="1">0.06</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">0.018</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td><td align="center" valign="top" rowspan="1" colspan="1">0.590</td><td align="center" valign="top" rowspan="1" colspan="1">0.07</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">0.007</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Time</td><td align="center" valign="top" rowspan="1" colspan="1">1.98</td><td align="center" valign="top" rowspan="1" colspan="1">0.65</td><td align="center" valign="top" rowspan="1" colspan="1">0.002</td><td align="center" valign="top" rowspan="1" colspan="1">1.79</td><td align="center" valign="top" rowspan="1" colspan="1">0.67</td><td align="center" valign="top" rowspan="1" colspan="1">0.007</td><td align="center" valign="top" rowspan="1" colspan="1">1.74</td><td align="center" valign="top" rowspan="1" colspan="1">0.70</td><td align="center" valign="top" rowspan="1" colspan="1">0.013</td><td align="center" valign="top" rowspan="1" colspan="1">2.29</td><td align="center" valign="top" rowspan="1" colspan="1">0.74</td><td align="center" valign="top" rowspan="1" colspan="1">0.002</td><td align="center" valign="top" rowspan="1" colspan="1">1.35</td><td align="center" valign="top" rowspan="1" colspan="1">0.74</td><td align="center" valign="top" rowspan="1" colspan="1">0.069</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Time &#215; R</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.80</td><td align="center" valign="top" rowspan="1" colspan="1">0.57</td><td align="center" valign="top" rowspan="1" colspan="1">0.161</td><td align="center" valign="top" rowspan="1" colspan="1">0.20</td><td align="center" valign="top" rowspan="1" colspan="1">0.17</td><td align="center" valign="top" rowspan="1" colspan="1">0.250</td><td align="center" valign="top" rowspan="1" colspan="1">0.17</td><td align="center" valign="top" rowspan="1" colspan="1">0.19</td><td align="center" valign="top" rowspan="1" colspan="1">0.366</td><td align="center" valign="top" rowspan="1" colspan="1">1.51</td><td align="center" valign="top" rowspan="1" colspan="1">0.70</td><td align="center" valign="top" rowspan="1" colspan="1">0.031</td><td align="center" valign="top" rowspan="1" colspan="1">0.36</td><td align="center" valign="top" rowspan="1" colspan="1">0.20</td><td align="center" valign="top" rowspan="1" colspan="1">0.080</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Time &#215; age</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.03</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.002</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.03</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.003</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.03</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.007</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.04</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.02</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.046</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Time &#215; R&#8201;&#215;&#8201;age</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.085</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;<xref rid="acel70190-note-0013" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;<xref rid="acel70190-note-0013" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.03</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.003</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;<xref rid="acel70190-note-0013" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr></tbody></table><table-wrap-foot id="acel70190-ntgp-0004"><fn id="acel70190-note-0010"><p>
<italic toggle="yes">Note:</italic> The values of R parameters were first standardized to have a mean of 0 and a SD of 1 before performing the linear mixed&#8208;effect models, allowing for comparisons across models. A year was used as the unit of time.</p></fn><fn id="acel70190-note-0011"><label>
<sup>a</sup>
</label><p>The models were additionally adjusted for use of hormone replacement therapy (HRT), previous residence in high&#8208;solar&#8208;exposure regions, use of ultraviolet (UV) protection products, and sun exposure frequency.</p></fn><fn id="acel70190-note-0012"><label>
<sup>b</sup>
</label><p>The interaction term &#8220;R0 &#215; age&#8221; was not retained in the model due to its insignificance.</p></fn><fn id="acel70190-note-0013"><label>
<sup>c</sup>
</label><p>The interaction terms &#8220;time &#215; R2 &#215; age,&#8221; &#8220;time &#215; R5 &#215; age,&#8221; &#8220;time &#215; R7 &#215; age&#8221; were not retained in the models due to their insignificance.</p></fn><fn id="acel70190-note-0014"><label>
<sup>d</sup>
</label><p>The models were additionally adjusted for previous residence in high&#8208;solar&#8208;exposure regions, use of ultraviolet (UV) protection products, and sun exposure frequency.</p></fn></table-wrap-foot></table-wrap></sec><sec id="acel70190-sec-0016"><label>3.3</label><title>Association Between Skin Biomechanics and Biological Aging Clocks</title><p>Table&#160;<xref rid="acel70190-supitem-0001" ref-type="supplementary-material">S5</xref> presents the association between R parameters and biological aging based on epigenetic clocks and iAge. We observed inconsistent results for R0 (skin distensibility). After adjusting for covariates, AA in first&#8208;generation epigenetic clocks showed a positive association with R0 (HorvathAA pan&#8208;tissue: S.&#946;&#8201;=&#8201;0.12, <italic toggle="yes">p</italic>&#8201;=&#8201;0.014; HorvathAA skin&#8208;blood: S.&#946;&#8201;=&#8201;0.12, <italic toggle="yes">p</italic>&#8201;=&#8201;0.023; HannumAA: S.&#946;&#8201;=&#8201;0.09, <italic toggle="yes">p</italic>&#8201;=&#8201;0.053). In contrast, GrimAA, a second&#8208;generation clock, exhibited a reverse association with R0, although it did not reach statistical significance (S.&#946;&#8201;=&#8201;&#8722;0.10; <italic toggle="yes">p</italic>&#8201;=&#8201;0.056). A trend between higher DunedinPACE and increased R6 (viscoelastic ratio) was observed without reaching statistical significance (S.&#946;&#8201;=&#8201;0.08, <italic toggle="yes">p</italic>&#8201;=&#8201;0.062), indicating that a faster pace of biological aging was associated with poor viscoelasticity. Finally, individuals with iAgeAA were associated with poor skin elasticity, indicating decreased R2, R5, and R7 (iAgeAA: standardized regression coefficient [S.&#946;]&#8201;=&#8201;&#8722;0.10, <italic toggle="yes">p</italic>&#8201;=&#8201;0.018 for R2; S.&#946;&#8201;=&#8201;&#8722;0.11, <italic toggle="yes">p</italic>&#8201;=&#8201;0.010 for R5; S.&#946;&#8201;=&#8201;&#8722;0.10, <italic toggle="yes">p</italic>&#8201;=&#8201;0.012 for R7). No interaction with age or sex was involved in the association between biological aging clocks and R parameters (Tables&#160;<xref rid="acel70190-supitem-0001" ref-type="supplementary-material">S6</xref> and <xref rid="acel70190-supitem-0001" ref-type="supplementary-material">S7</xref>).</p></sec><sec id="acel70190-sec-0017"><label>3.4</label><title>Moderating Effect of Biological Aging on the Association Between Skin Biomechanics and <styled-content style="fixed-case" toggle="no">IC</styled-content>
</title><p>Since skin elasticity parameters R2, R5, and R7 demonstrated associations with baseline IC and iAgeAA, respectively, we explored whether iAgeAA moderated the relationship between these three R parameters and IC (Table&#160;<xref rid="acel70190-supitem-0001" ref-type="supplementary-material">S8</xref>). Significant interactions with iAgeAA (i.e., R&#8201;&#215;&#8201;iAgeAA and R&#8201;&#215;&#8201;age&#8201;&#215;&#8201;iAgeAA) were observed for parameters reflecting elastic recovery&#8212;R5 (net elasticity) and R7 (biological elasticity). The results suggested that a higher iAgeAA enhanced the effect of R5 and R7 on baseline IC in young and very old individuals. As illustrated in Figure&#160;<xref rid="acel70190-supitem-0001" ref-type="supplementary-material">S2</xref>, older people with a higher iAgeAA tended to have a lower initial IC when their R5 and R7 parameters were decreased. Conversely, the association between a higher baseline IC and reduced R5 and R7 in younger adults became more pronounced with elevated iAgeAA. Sex&#8208;stratified results are provided in Table&#160;<xref rid="acel70190-supitem-0001" ref-type="supplementary-material">S8</xref>, where significant associations were primarily observed in women.</p></sec></sec><sec sec-type="discussion" id="acel70190-sec-0018"><label>4</label><title>Discussion</title><p>This study demonstrated that biomarkers of skin aging&#8212;measured through skin biomechanical properties&#8212;were associated with functional outcomes across the adult lifespan. Older adults, particularly women, with decreased skin elasticity (R2, R5, R7) and increased viscoelastic part of the deformation (R6) tended to have lower initial IC levels. Higher R6 in older men was associated with faster IC decline over 3&#8201;years. On the other hand, the relationship between skin biomechanics and IC was reversed in younger adults. Increased systemic inflammation, indicated by accelerated iAge, was associated with reduced skin elasticity and strengthened the relationship between elastic recovery parameters (R5, R7) and IC.</p><p>The association between skin biomechanics and IC in older adults suggested that reduced skin elasticity and viscoelasticity occurred parallel to functional aging. This aligns with the geroscience perspective, which posits that aging&#8208;related pathophysiology in different body organs is connected and represents, at least in part, the consequences and manifestations of the same fundamental mechanisms (Kennedy et&#160;al.&#160;<xref rid="acel70190-bib-0025" ref-type="bibr">2014</xref>). In other words, biological aging is a systemic process despite being heterogeneous inter&#8208;individually and intra&#8208;individually (different organs age at different paces). Although this hypothesis warrants further investigation, our findings indicated that skin aging may mirror the holistic aging state of the body (as measured by IC). Evidence from non&#8208;invasive, low&#8208;cost, and less harmful skin markers like elasticity and viscoelasticity is particularly valuable due to its clinical feasibility.</p><p>Our analysis of biological aging clocks provides the investigation associating skin markers with the biomarkers derived from the hallmarks of aging, that is, the main biological drivers of the aging process (Kennedy et&#160;al.&#160;<xref rid="acel70190-bib-0025" ref-type="bibr">2014</xref>; L&#243;pez&#8208;Ot&#237;n et&#160;al.&#160;<xref rid="acel70190-bib-0030" ref-type="bibr">2023</xref>). Indeed, chronic inflammation and its contributing factors (such as oxidative stress and cellular senescence) act as important mechanisms of intrinsic skin aging (D'Arino et&#160;al.&#160;<xref rid="acel70190-bib-0008" ref-type="bibr">2023</xref>; Lemaitre&#160;<xref rid="acel70190-bib-0028" ref-type="bibr">2024</xref>), which could collectively impair skin strength and elasticity by promoting the degradation of collagen and elastin fibers (Pilkington et&#160;al.&#160;<xref rid="acel70190-bib-0035" ref-type="bibr">2021</xref>). The accelerated inflammatory age in this study was calculated based on circulating immune proteins, implying that changes in skin biomechanics may result from systemic inflammation. Cutaneous inflammation from a weakened epidermal barrier in aging has also been proposed to contribute back to systemic inflammation (Man and Elias&#160;<xref rid="acel70190-bib-0032" ref-type="bibr">2019</xref>). Although these findings indicate a connection between skin and systemic inflammation, the direction of this relationship remains inconclusive and requires further investigation. The association between the first&#8208;generation epigenetic clocks and skin distensibility (R0) is unknown. Interpreting R0 values can be challenging since both an increase (due to higher immediate extensibility; Chen et&#160;al.&#160;<xref rid="acel70190-bib-0006" ref-type="bibr">2024</xref>; Nedelec et&#160;al.&#160;<xref rid="acel70190-bib-0033" ref-type="bibr">2016</xref>) and a decrease (indicating improved skin firmness; Chen et&#160;al.&#160;<xref rid="acel70190-bib-0006" ref-type="bibr">2024</xref>; Huang et&#160;al.&#160;<xref rid="acel70190-bib-0023" ref-type="bibr">2024</xref>) have been linked to a healthy skin condition. In addition, as mentioned above, the non&#8208;standardized nature of R0 makes it less comparable among individuals (Abbas et&#160;al.&#160;<xref rid="acel70190-bib-0001" ref-type="bibr">2022</xref>). Additional research is needed to better understand the function of the R0 parameter as an indicator of skin aging.</p><p>We observed the reverse association between skin elasticity and IC in younger adults. This paradox may arise because the maximum IC peaked around age 30 (Lu et&#160;al.&#160;<xref rid="acel70190-bib-0031" ref-type="bibr">2023</xref>), whereas skin elasticity was suggested to decline from the early 20s (Lephart and Naftolin&#160;<xref rid="acel70190-bib-0029" ref-type="bibr">2022</xref>). Our additional analysis of individual IC trajectories from the baseline to the three&#8208;year visit supports this paradox. As illustrated in Figure&#160;<xref rid="acel70190-supitem-0001" ref-type="supplementary-material">S3</xref>, many younger participants continued to improve their IC, whereas significant changes in IC were more commonly observed among older people. Furthermore, the current IC metric was primarily evaluated through geriatric assessments (such as MMSE and SPPB), which may have limitations in distinguishing functional differences in younger adults due to ceiling effects in some variables. This is evident from the smaller individual differences in IC trajectories for younger individuals in Figure&#160;<xref rid="acel70190-supitem-0001" ref-type="supplementary-material">S3</xref>. Finally, this study included a relatively small number of participants aged 20&#8211;40 (accounting for 15.4% of the sample). As a result, further research focusing on young individuals is required to clarify the relationship between skin biomechanics and functional capacity in this population, perhaps using maximum tests (e.g., maximum volume of oxygen&#8212;<mml:math id="jats-math-1" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>VO</mml:mi><mml:mi>max</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mrow></mml:math>) since these tests do not have ceiling effects.</p><p>Our study demonstrated how skin mechanical parameters of the Cutometer varied throughout adulthood, using a larger sample than previous research. Consistent with the literature, we found that R7 (biological elasticity) had the strongest correlation with chronological age, supporting its potential to serve as the &#8220;age of skin elasticity&#8221; (Ahn et&#160;al.&#160;<xref rid="acel70190-bib-0002" ref-type="bibr">2007</xref>; Ryu et&#160;al.&#160;<xref rid="acel70190-bib-0037" ref-type="bibr">2008</xref>; Chen et&#160;al.&#160;<xref rid="acel70190-bib-0006" ref-type="bibr">2024</xref>). Interestingly, this study discovered the longitudinal association with IC only for R6 (viscoelastic ratio). Why R6 outperformed other R parameters in terms of predicting IC evolution remains to be elucidated since higher R6 can result from increased viscous distension, decreased elastic distension, or both (Dobrev&#160;<xref rid="acel70190-bib-0012" ref-type="bibr">2000</xref>). More investigation is also required to understand sex&#8208;specific differences in the longitudinal IC&#8208;R6 association in older adults, namely why R6 predicted IC decline in older men but not women. In addition, studies involving longitudinal and multisite skin elasticity measurements are encouraged to explore how these parameters evolve over time and whether the associations identified in the current studies show regional differences. Furthermore, despite the advantages of being non&#8208;invasive and less harmful, Cutometer data has limitations in providing information at the molecular and cellular levels of the skin. Therefore, additional evidence from skin biopsies is needed to elucidate the connection between systemic and skin&#8208;specific aging. For example, studies incorporating skin biopsy data could use omics techniques to identify aging&#8208;related inflammatory molecules in the skin microenvironment and examine how they interact with the systemic inflammatory clock.</p><p>This is the first study exploring the association of skin&#8208;derived biomarkers with global body functions and aging biomarkers, using novel measurements in the field including IC, epigenetic clocks, and iAge. Furthermore, we provided evidence of skin elasticity differences across adulthood in a relatively large, community&#8208;dwelling cohort involving an extended age range and functional status. Nevertheless, some limitations should be raised. First, due to data availability, this study was conducted in a subset of the INSPIRE&#8208;T cohort. Second, only the skin biomechanics of the sun&#8208;unexposed area were assessed in the INSPIRE&#8208;T cohort. Further investigation comparing results from sun&#8208;exposed and sun&#8208;unexposed skin areas is required to provide insight into the role of UV radiation in the relationship between age&#8208;related elasticity decline and IC. Third, the current study lacks data on other aspects of skin biomechanical properties, such as skin induration measured by Durometer and skin echogenicity evaluated via ultrasound. It is plausible that these properties may reveal different relationships with IC and biological aging clocks compared to skin elasticity and viscoelasticity. Fourth, the analysis of skin biomechanics and biological aging clocks was performed using a cross&#8208;sectional design, so we could not establish a causal relationship between them. Yet, the risk of reverse causation is low since skin elasticity is more likely to be a consequence rather than the cause of biological aging. In addition, type I error was expected to increase due to examining several skin parameters and aging biomarkers. Finally, although we controlled for the medical and photoaging factors affecting skin elasticity and viscoelasticity, our findings could be biased by other unmeasured variables, such as skin color (Everett and Sommers&#160;<xref rid="acel70190-bib-0013" ref-type="bibr">2013</xref>) and collagen supplements.</p><p>In conclusion, our work demonstrated that skin biomechanical properties may reflect overall functional capacity during aging. Reduced skin elasticity and increased viscoelastic ratio were associated with a lower baseline and an accelerated decline in IC in older adults. Higher levels of systemic inflammation were related to poor skin elasticity, which might serve as the common cause of both organ&#8208;specific (i.e., skin) and whole&#8208;body (i.e., IC) aging. Future research targeting younger individuals and employing suitable functional assessments will provide insight into this topic.</p></sec><sec id="acel70190-sec-0019"><title>Author Contributions</title><p>W.&#8208;H.L., S.G., P.S.B., and B.V. contributed to the study design. P.S.B. and B.V. supervised the study. S.G. contributed to data collection and verification. S.B.&#8208;T., K.R.H., P.B., and J.L.D. contributed to Cutometer data verification. P.B. and J.&#8208;M.L. managed data of epigenetic clocks. W.&#8208;H.L. analyzed the data. All authors contributed to data interpretation. W.&#8208;H.L. wrote the first version of the manuscript. All authors revised the manuscript with important intellectual content and agreed with the final version to be submitted.</p></sec><sec sec-type="COI-statement" id="acel70190-sec-0021"><title>Conflicts of Interest</title><p>P.S.B. declares to have received research grant and consultancy fees from Pfizer. B.V. is the founder president of IHU HealthAge, Toulouse University Hospital, and an investigator in clinical trials sponsored by several industry partners (IHU, CRC, and Inspire gerosicence platforms). S.B.T., K.R.H., P.B., and J.L.D. work for Pierre Fabre Dermo&#8208;Cosm&#233;tique &amp; Personal Care. All the other authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="acel70190-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Figure S1:</bold> Flowchart of sample identification.</p><p>
<bold>Figure S2:</bold> Interaction plots illustrating the moderating effect of AgeAA on the relationship between IC, R5 (net elasticity) and R7 (biological elasticity) across different ages.</p><p>
<bold>Figure S3:</bold> Individual IC trajectories over 3&#8201;years.</p><p>
<bold>Table&#160;S1:</bold> Descriptive analysis of covariates.</p><p>
<bold>Table&#160;S2:</bold> Conditional effects of R parameters on baseline IC.</p><p>
<bold>Table&#160;S3:</bold> Conditional effects of R parameters on the overtime IC change.</p><p>
<bold>Table&#160;S4:</bold> Linear mixed&#8208;effects model results for individual IC domains.</p><p>
<bold>Table&#160;S5:</bold> Association between R parameters and biological aging clocks.</p><p>
<bold>Table&#160;S6:</bold> Associations of biological age acceleration with R parameters using multiple linear regression included age interaction.</p><p>
<bold>Table&#160;S7:</bold> Associations of biological age acceleration with R parameters using multiple linear regression included sex interaction.</p><p>
<bold>Table&#160;S8:</bold> Summary of coefficients from linear mixed&#8208;effect models for IC, introducing the interaction terms with iAgeAA.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ACEL-24-e70190-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="acel70190-sec-0020"><title>Acknowledgments</title><p>We would like to thank the INSPIRE&#8208;T participants and all of the research and clinical staff who contributed to the study. This work was performed within the context of the IHU HealthAge, which has benefited from funding by the Agence Nationale de la Recherche under the France 2030 program (reference number: ANR&#8208;23&#8208;IAHU&#8208;0011). The INSPIRE&#8208;T study was supported by grants from the Region Occitanie/Pyr&#233;n&#233;es&#8208;M&#233;diterran&#233;e (reference no.: 1901175) and the European Regional Development Fund (ERDF) (project no.: MP0022856) and the Inspire Chairs of Excellence funded by: Alzheimer Prevention in Occitania and Catalonia (APOC), EDENIS, KORIAN, Pfizer, Pierre&#8208;Fabre, and the IHU HealthAge, which received funding from the French National Research Agency (ANR) as part of the France 2030 program (reference number: ANR&#8208;23&#8208;IAHU&#8208;0011). The IHU HealthAge Open Science initiative was supported by the French National Research Agency (ANR) as part of the France 2030 program (reference number: ANR&#8208;23&#8208;IAHU&#8208;0011) and builds on the work conducted in the Data Sharing Alzheimer project. The funders had no role in study design, data collection, and analysis.</p><p>
<bold>Members of the IHU HealthAge INSPIRE/Open Science Group:</bold>
</p><p>
<italic toggle="yes">IHU HealthAge INSPIRE platform group:</italic>
</p><p>INSPIRE&#8208;T human cohort group: Coordinators: Sophie Guyonnet, Bruno Vellas; Project managers: Laur&#233;ane Brigitte, Agathe Milhet; Clinical Research Assistants: Elodie Paez, Emeline Muller, Sabine Le Floch; Investigators: Catherine Takeda, Catherine Faisant, Fran&#231;oise Lala, Gabor Abellan Van Kan, Zara Steinmeyer, Antoine Piau, Tony Macaron, Davide Angioni, Pierre&#8208;Jean Ousset; Nurses: M&#233;lanie Comt&#233;, Nathalie Daniaud, Fanny Boissou&#8208;Parachaud; Methodology, statistical analysis, and data management subgroup: Sandrine Andrieu, Christelle Cantet; Body composition, VO2 max, isocinetism subgroup: Yves Rolland, Philipe de Souto Barreto, Fabien Pillard; Technician DXA&#8212;Bernard Teysseyre; MRI subgroup: Marie Faruch, Pierre Payoux; ICOPE subgroup: Catherine Takeda, Neda Tavassoli, Maria Eugenia Soto Mart&#237;n; Biological sample collection subgroup: Marie Dorard, B&#233;n&#233;dicte Razat, Camille Champigny, Sophie Guyonnet.</p><p>Inspire animal cohort groups: C&#233;dric Dray, Jean&#8208;Philippe Prad&#232;re (Fish colony); Angelo Parini, Yohan Santin (Murine cohort).</p><p>Associated research teams: Dominique Langin, Pierre Gourdy, Laurent O. Martinez, Anne Bouloumi&#233;, Angelo Parini (I2MC lab); Nicolas Fazilleau, Roland Liblau, Jean&#8208;Charles Gu&#233;ry, Michel Simon, Nicolas Gaudenzio, Luciana Bostan, Hicham El Costa, Nabila Jabrane Ferrat (Infinity lab); Philippe Valet, Cedric Dray, Isabelle Ader, Val&#233;rie Planat, Louis Casteilla (Restore); Pierre Payoux, Patrice Peran (Tonic lab); Cyrille Delpierre, Sandrine Andrieu (CERPOP lab); Claire Rampon, Noelie Davezac, Bruno Guiard (CRCA/CBI lab); Nathalie Vergnolle, Jean&#8208;Paul Motta, Sara Djebali, Pauline Floch, C&#233;line Deraison, Chrystelle Bonnart (IRSD lab); Jean&#8208;Emmanuel Sarry (CRCT lab).</p><p>IHU HealthAge Open Science group: Nicola Coley, Sophie Guyonnet, Christelle Cantet, Jessica Pontary, Sandrine Andrieu (contact: <email>ihuos_inspiredataaccess@chu-toulouse.fr</email>).</p></ack><sec sec-type="data-availability" id="acel70190-sec-0023"><title>Data Availability Statement</title><p>Request for de&#8208;identified data related to the results reported in this article (i.e., text, tables, figures, and <xref rid="acel70190-supitem-0001" ref-type="supplementary-material">Supporting Information</xref>) and a data dictionary will be evaluated by the INSPIRE data&#8208;sharing committee, which can be contacted at the following address: <email>ihuos_inspiredataaccess@chu-toulouse.fr</email>. Data will be made available for investigators upon request for a pre&#8208;identified scientific purpose developed in a research proposal with sound methodology, subject to the approval of the appropriate Committees; a data use agreement must also be signed.</p><p>Given the ongoing nature of the INSPIRE&#8208;T study, the authors are unable to make the dataset publicly accessible at this time. In addition, according to the INSPIRE policy, all analyses using INSPIRE&#8208;T data (including the present study) must be evaluated and approved by the committee after the submission of a comprehensive analysis proposal. Therefore, for researchers interested in accessing the data used for the current study, the same evaluation procedure must be followed.</p></sec><ref-list content-type="cited-references" id="acel70190-bibl-0001"><title>References</title><ref id="acel70190-bib-0001"><mixed-citation publication-type="journal" id="acel70190-cit-0001"><string-name name-style="western"><surname>Abbas</surname>, <given-names>D. B.</given-names></string-name>, <string-name name-style="western"><given-names>C. V.</given-names><surname>Lavin</surname></string-name>, <string-name name-style="western"><given-names>E. J.</given-names><surname>Fahy</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>Standardizing Dimensionless Cutometer Parameters to Determine In&#160;Vivo Elasticity of Human Skin</article-title>.&#8221; <source>Advanced Wound Care</source><volume>11</volume>: <fpage>297</fpage>&#8211;<lpage>310</lpage>.</mixed-citation></ref><ref id="acel70190-bib-0002"><mixed-citation publication-type="journal" id="acel70190-cit-0002"><string-name name-style="western"><surname>Ahn</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Kim</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Lee</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Moon</surname></string-name>, and <string-name name-style="western"><given-names>I.</given-names><surname>Chang</surname></string-name>. <year>2007</year>. &#8220;<article-title>Correlation Between a Cutometer and Quantitative Evaluation Using Moire Topography in Age&#8208;Related Skin Elasticity</article-title>.&#8221; <source>Skin Research and Technology</source><volume>13</volume>: <fpage>280</fpage>&#8211;<lpage>284</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-0846.2007.00224.x</pub-id>.<pub-id pub-id-type="pmid">17610649</pub-id></mixed-citation></ref><ref id="acel70190-bib-0003"><mixed-citation publication-type="journal" id="acel70190-cit-0003"><string-name name-style="western"><surname>Beard</surname>, <given-names>J. R.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Officer</surname></string-name>, <string-name name-style="western"><given-names>I. A.</given-names><surname>de Carvalho</surname></string-name>, et&#160;al. <year>2016</year>. &#8220;<article-title>The World Report on Ageing and Health: A Policy Framework for Healthy Ageing</article-title>.&#8221; <source>Lancet</source><volume>387</volume>: <fpage>2145</fpage>&#8211;<lpage>2154</lpage>.<pub-id pub-id-type="pmid">26520231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(15)00516-4</pub-id><pub-id pub-id-type="pmcid">PMC4848186</pub-id></mixed-citation></ref><ref id="acel70190-bib-0004"><mixed-citation publication-type="journal" id="acel70190-cit-0004"><string-name name-style="western"><surname>Bernstein</surname>, <given-names>E. F.</given-names></string-name>, <string-name name-style="western"><given-names>Y. Q.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>J. B.</given-names><surname>Kopp</surname></string-name>, et&#160;al. <year>1996</year>. &#8220;<article-title>Long&#8208;Term Sun Exposure Alters the Collagen of the Papillary Dermis: Comparison of Sun&#8208;Protected and Photoaged Skin by Northern Analysis Immunohistochemical Staining, and Confocal Laser Scanning Microscopy</article-title>.&#8221; <source>Journal of the American Academy of Dermatology</source><volume>34</volume>: <fpage>209</fpage>&#8211;<lpage>218</lpage>.<pub-id pub-id-type="pmid">8642084</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0190-9622(96)80114-9</pub-id></mixed-citation></ref><ref id="acel70190-bib-0005"><mixed-citation publication-type="journal" id="acel70190-cit-0005"><string-name name-style="western"><surname>Cesari</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Araujo de Carvalho</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Amuthavalli Thiyagarajan</surname></string-name>, et&#160;al. <year>2018</year>. &#8220;<article-title>Evidence for the Domains Supporting the Construct of Intrinsic Capacity</article-title>.&#8221; <source>Journals of Gerontology. Series A, Biological Sciences and Medical Sciences</source><volume>73</volume>: <fpage>1653</fpage>&#8211;<lpage>1660</lpage>.<pub-id pub-id-type="pmid">29408961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/gerona/gly011</pub-id></mixed-citation></ref><ref id="acel70190-bib-0006"><mixed-citation publication-type="journal" id="acel70190-cit-0006"><string-name name-style="western"><surname>Chen</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Yin</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Lu</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Fu</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Gao</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Zhang</surname></string-name>. <year>2024</year>. &#8220;<article-title>Research on the Correlation Between Skin Elasticity Evaluation Parameters and Age</article-title>.&#8221; <source>Cosmetics</source><volume>11</volume>: <fpage>205</fpage>.</mixed-citation></ref><ref id="acel70190-bib-0007"><mixed-citation publication-type="journal" id="acel70190-cit-0007"><string-name name-style="western"><surname>Csekes</surname>, <given-names>E.</given-names></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Ra&#269;kov&#225;</surname></string-name>. <year>2021</year>. &#8220;<article-title>Skin Aging, Cellular Senescence and Natural Polyphenols</article-title>.&#8221; <source>International Journal of Molecular Sciences</source><volume>22</volume>: <elocation-id>12641</elocation-id>.<pub-id pub-id-type="pmid">34884444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms222312641</pub-id><pub-id pub-id-type="pmcid">PMC8657738</pub-id></mixed-citation></ref><ref id="acel70190-bib-0008"><mixed-citation publication-type="journal" id="acel70190-cit-0008"><string-name name-style="western"><surname>D'Arino</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Caputo</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Eibenschutz</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>Skin Cancer Microenvironment: What we Can Learn From Skin Aging?</article-title>&#8221; <source>International Journal of Molecular Sciences</source><volume>24</volume>, no. <issue>18</issue>: <elocation-id>14043</elocation-id>.<pub-id pub-id-type="pmid">37762344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms241814043</pub-id><pub-id pub-id-type="pmcid">PMC10531546</pub-id></mixed-citation></ref><ref id="acel70190-bib-0009"><mixed-citation publication-type="journal" id="acel70190-cit-0009"><string-name name-style="western"><surname>de Souto Barreto</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Gonzalez&#8208;Bautista</surname></string-name>, <string-name name-style="western"><given-names>H. A.</given-names><surname>Bischoff&#8208;Ferrari</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Real&#8208;Life Intrinsic Capacity Screening Data From the ICOPE&#8208;Care Program</article-title>.&#8221; <source>Nature Aging</source><volume>4</volume>: <fpage>1279</fpage>&#8211;<lpage>1289</lpage>.<pub-id pub-id-type="pmid">39122839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-024-00684-2</pub-id></mixed-citation></ref><ref id="acel70190-bib-0010"><mixed-citation publication-type="journal" id="acel70190-cit-0010"><string-name name-style="western"><surname>de Souto Barreto</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Guyonnet</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Ader</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>The Inspire Research Initiative: A Program for Geroscience and Healthy Aging Research Going From Animal Models to Humans and the Healthcare System</article-title>.&#8221; <source>Journal of Frailty &amp; Aging</source><volume>10</volume>: <fpage>86</fpage>&#8211;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.14283/jfa.2020.18</pub-id>.<pub-id pub-id-type="pmid">33575696</pub-id></mixed-citation></ref><ref id="acel70190-bib-0011"><mixed-citation publication-type="journal" id="acel70190-cit-0011"><string-name name-style="western"><surname>de Souto Barreto</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Rolland</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Ferrucci</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>Looking at Frailty and Intrinsic Capacity Through a Geroscience Lens: The ICFSR &amp; Geroscience Task Force</article-title>.&#8221; <source>Nature Aging</source><volume>3</volume>: <fpage>1474</fpage>&#8211;<lpage>1479</lpage>.<pub-id pub-id-type="pmid">37985720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-023-00531-w</pub-id><pub-id pub-id-type="pmcid">PMC12159420</pub-id></mixed-citation></ref><ref id="acel70190-bib-0012"><mixed-citation publication-type="journal" id="acel70190-cit-0012"><string-name name-style="western"><surname>Dobrev</surname>, <given-names>H.</given-names></string-name><year>2000</year>. &#8220;<article-title>Use of Cutometer to Assess Epidermal Hydration</article-title>.&#8221; <source>Skin Research and Technology</source><volume>6</volume>: <fpage>239</fpage>&#8211;<lpage>244</lpage>. <pub-id pub-id-type="doi">10.1034/j.1600-0846.2000.006004239.x</pub-id>.<pub-id pub-id-type="pmid">11428963</pub-id></mixed-citation></ref><ref id="acel70190-bib-0013"><mixed-citation publication-type="journal" id="acel70190-cit-0013"><string-name name-style="western"><surname>Everett</surname>, <given-names>J. S.</given-names></string-name>, and <string-name name-style="western"><given-names>M. S.</given-names><surname>Sommers</surname></string-name>. <year>2013</year>. &#8220;<article-title>Skin Viscoelasticity: Physiologic Mechanisms, Measurement Issues, and Application to Nursing Science</article-title>.&#8221; <source>Biological Research for Nursing</source><volume>15</volume>: <fpage>338</fpage>&#8211;<lpage>346</lpage>.<pub-id pub-id-type="pmid">22544517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1099800411434151</pub-id><pub-id pub-id-type="pmcid">PMC3465619</pub-id></mixed-citation></ref><ref id="acel70190-bib-0014"><mixed-citation publication-type="journal" id="acel70190-cit-0014"><string-name name-style="western"><surname>Ferrucci</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><given-names>M. E.</given-names><surname>Levine</surname></string-name>, <string-name name-style="western"><given-names>P. L.</given-names><surname>Kuo</surname></string-name>, and <string-name name-style="western"><given-names>E. M.</given-names><surname>Simonsick</surname></string-name>. <year>2018</year>. &#8220;<article-title>Time and the Metrics of Aging</article-title>.&#8221; <source>Circulation Research</source><volume>123</volume>: <fpage>740</fpage>&#8211;<lpage>744</lpage>.<pub-id pub-id-type="pmid">30355074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCRESAHA.118.312816</pub-id><pub-id pub-id-type="pmcid">PMC6205734</pub-id></mixed-citation></ref><ref id="acel70190-bib-0015"><mixed-citation publication-type="journal" id="acel70190-cit-0015"><string-name name-style="western"><surname>Firooz</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Sadr</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Babakoohi</surname></string-name>, et&#160;al. <year>2012</year>. &#8220;<article-title>Variation of Biophysical Parameters of the Skin With Age, Gender, and Body Region</article-title>.&#8221; <source>Scientific World Journal</source><volume>2012</volume>: <elocation-id>386936</elocation-id>.<pub-id pub-id-type="pmid">22536139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1100/2012/386936</pub-id><pub-id pub-id-type="pmcid">PMC3317612</pub-id></mixed-citation></ref><ref id="acel70190-bib-0016"><mixed-citation publication-type="journal" id="acel70190-cit-0016"><string-name name-style="western"><surname>Folstein</surname>, <given-names>M. F.</given-names></string-name>, <string-name name-style="western"><given-names>S. E.</given-names><surname>Folstein</surname></string-name>, and <string-name name-style="western"><given-names>P. R.</given-names><surname>McHugh</surname></string-name>. <year>1975</year>. &#8220;<article-title>&#8220;Mini&#8208;Mental State&#8221;: A Practical Method for Grading the Cognitive State of Patients for the Clinician</article-title>.&#8221; <source>Journal of Psychiatric Research</source><volume>12</volume>: <fpage>189</fpage>&#8211;<lpage>198</lpage>.<pub-id pub-id-type="pmid">1202204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0022-3956(75)90026-6</pub-id></mixed-citation></ref><ref id="acel70190-bib-0017"><mixed-citation publication-type="journal" id="acel70190-cit-0017"><string-name name-style="western"><surname>Fujimoto</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Yuri</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Kato</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Kinoshita</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Tamiya</surname></string-name>. <year>2023</year>. &#8220;<article-title>Intra&#8208; and Inter&#8208;Rater Reliabilities of Skin Mechanical Properties Measured in Healthy Individuals Using Skin Elasticity Meter</article-title>.&#8221; <source>Annals of Medicine</source><volume>55</volume>: <elocation-id>2279747</elocation-id>. <pub-id pub-id-type="doi">10.1080/07853890.2023.2279747</pub-id>.<pub-id pub-id-type="pmid">37967233</pub-id><pub-id pub-id-type="pmcid">PMC10653741</pub-id></mixed-citation></ref><ref id="acel70190-bib-0018"><mixed-citation publication-type="journal" id="acel70190-cit-0018"><string-name name-style="western"><surname>Gruber</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Kremslehner</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Eckhart</surname></string-name>, and <string-name name-style="western"><given-names>E.</given-names><surname>Tschachler</surname></string-name>. <year>2020</year>. &#8220;<article-title>Cell Aging and Cellular Senescence in Skin Aging&#8212;Recent Advances in Fibroblast and Keratinocyte Biology</article-title>.&#8221; <source>Experimental Gerontology</source><volume>130</volume>: <elocation-id>110780</elocation-id>.<pub-id pub-id-type="pmid">31794850</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.exger.2019.110780</pub-id></mixed-citation></ref><ref id="acel70190-bib-0019"><mixed-citation publication-type="journal" id="acel70190-cit-0019"><string-name name-style="western"><surname>Guralnik</surname>, <given-names>J. M.</given-names></string-name>, <string-name name-style="western"><given-names>E. M.</given-names><surname>Simonsick</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Ferrucci</surname></string-name>, et&#160;al. <year>1994</year>. &#8220;<article-title>A Short Physical Performance Battery Assessing Lower Extremity Function: Association With Self&#8208;Reported Disability and Prediction of Mortality and Nursing Home Admission</article-title>.&#8221; <source>Journal of Gerontology</source><volume>49</volume>: <fpage>M85</fpage>&#8211;<lpage>M94</lpage>.<pub-id pub-id-type="pmid">8126356</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/geronj/49.2.m85</pub-id></mixed-citation></ref><ref id="acel70190-bib-0020"><mixed-citation publication-type="journal" id="acel70190-cit-0020"><string-name name-style="western"><surname>Guyonnet</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Rolland</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Takeda</surname></string-name>, et&#160;al. <year>2020</year>. &#8220;<article-title>The INSPIRE Bio&#8208;Resource Research Platform for Healthy Aging and Geroscience: Focus on the Human Translational Research Cohort (The INSPIRE&#8208;T Cohort)</article-title>.&#8221; <source>Journal of Frailty &amp; Aging</source><volume>10</volume>: <fpage>1</fpage>&#8211;<lpage>11</lpage>.</mixed-citation></ref><ref id="acel70190-bib-0021"><mixed-citation publication-type="journal" id="acel70190-cit-0021"><string-name name-style="western"><surname>Hayes</surname>, <given-names>A. F.</given-names></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Matthes</surname></string-name>. <year>2009</year>. &#8220;<article-title>Computational Procedures for Probing Interactions in OLS and Logistic Regression: SPSS and SAS Implementations</article-title>.&#8221; <source>Behavior Research Methods</source><volume>41</volume>: <fpage>924</fpage>&#8211;<lpage>936</lpage>.<pub-id pub-id-type="pmid">19587209</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3758/BRM.41.3.924</pub-id></mixed-citation></ref><ref id="acel70190-bib-0022"><mixed-citation publication-type="journal" id="acel70190-cit-0022"><string-name name-style="western"><surname>Holzscheck</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>S&#246;hle</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Kristof</surname></string-name>, et&#160;al. <year>2020</year>. &#8220;<article-title>Multi&#8208;Omics Network Analysis Reveals Distinct Stages in the Human Aging Progression in Epidermal Tissue</article-title>.&#8221; <source>Aging (Albany NY)</source><volume>12</volume>: <fpage>12393</fpage>&#8211;<lpage>12409</lpage>.<pub-id pub-id-type="pmid">32554863</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.103499</pub-id><pub-id pub-id-type="pmcid">PMC7343460</pub-id></mixed-citation></ref><ref id="acel70190-bib-0023"><mixed-citation publication-type="journal" id="acel70190-cit-0023"><string-name name-style="western"><surname>Huang</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Zhang</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Correlating Facial Skin Parameters With Age and Gender in Population of Shaanxi Province, China</article-title>.&#8221; <source>Journal of Cosmetic Dermatology</source><volume>23</volume>: <fpage>1386</fpage>&#8211;<lpage>1395</lpage>.<pub-id pub-id-type="pmid">38093505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jocd.16113</pub-id></mixed-citation></ref><ref id="acel70190-bib-0024"><mixed-citation publication-type="journal" id="acel70190-cit-0024"><string-name name-style="western"><surname>Johnson</surname>, <given-names>P. O.</given-names></string-name>, and <string-name name-style="western"><given-names>L. C.</given-names><surname>Fay</surname></string-name>. <year>1950</year>. &#8220;<article-title>The Johnson&#8208;Neyman Technique, Its Theory and Practice</article-title>.&#8221; <source>Psychometrika</source><volume>15</volume>: <fpage>349</fpage>&#8211;<lpage>367</lpage>.<pub-id pub-id-type="pmid">14797902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF02288864</pub-id></mixed-citation></ref><ref id="acel70190-bib-0025"><mixed-citation publication-type="journal" id="acel70190-cit-0025"><string-name name-style="western"><surname>Kennedy</surname>, <given-names>B. K.</given-names></string-name>, <string-name name-style="western"><given-names>S. L.</given-names><surname>Berger</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Brunet</surname></string-name>, et&#160;al. <year>2014</year>. &#8220;<article-title>Geroscience: Linking Aging to Chronic Disease</article-title>.&#8221; <source>Cell</source><volume>159</volume>: <fpage>709</fpage>&#8211;<lpage>713</lpage>.<pub-id pub-id-type="pmid">25417146</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2014.10.039</pub-id><pub-id pub-id-type="pmcid">PMC4852871</pub-id></mixed-citation></ref><ref id="acel70190-bib-0026"><mixed-citation publication-type="journal" id="acel70190-cit-0026"><string-name name-style="western"><surname>Kroenke</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><given-names>R. L.</given-names><surname>Spitzer</surname></string-name>, and <string-name name-style="western"><given-names>J. B. W.</given-names><surname>Williams</surname></string-name>. <year>2001</year>. &#8220;<article-title>The PHQ&#8208;9: Validity of a Brief Depression Severity Measure</article-title>.&#8221; <source>Journal of General Internal Medicine</source><volume>16</volume>: <fpage>606</fpage>&#8211;<lpage>613</lpage>.<pub-id pub-id-type="pmid">11556941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1525-1497.2001.016009606.x</pub-id><pub-id pub-id-type="pmcid">PMC1495268</pub-id></mixed-citation></ref><ref id="acel70190-bib-0027"><mixed-citation publication-type="journal" id="acel70190-cit-0027"><string-name name-style="western"><surname>Lee</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Hong</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Kim</surname></string-name>. <year>2021</year>. &#8220;<article-title>Structural and Functional Changes and Possible Molecular Mechanisms in Aged Skin</article-title>.&#8221; <source>International Journal of Molecular Sciences</source><volume>22</volume>: <elocation-id>12489</elocation-id>.<pub-id pub-id-type="pmid">34830368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms222212489</pub-id><pub-id pub-id-type="pmcid">PMC8624050</pub-id></mixed-citation></ref><ref id="acel70190-bib-0028"><mixed-citation publication-type="journal" id="acel70190-cit-0028"><string-name name-style="western"><surname>Lemaitre</surname>, <given-names>J. M.</given-names></string-name><year>2024</year>. &#8220;<article-title>Looking for the Philosopher's Stone: Emerging Approaches to Target the Hallmarks of Aging in the Skin</article-title>.&#8221; <source>Journal of the European Academy of Dermatology and Venereology</source><volume>38</volume>: <fpage>5</fpage>&#8211;<lpage>14</lpage>.</mixed-citation></ref><ref id="acel70190-bib-0029"><mixed-citation publication-type="journal" id="acel70190-cit-0029"><string-name name-style="western"><surname>Lephart</surname>, <given-names>E. D.</given-names></string-name>, and <string-name name-style="western"><given-names>F.</given-names><surname>Naftolin</surname></string-name>. <year>2022</year>. &#8220;<article-title>Factors Influencing Skin Aging and the Important Role of Estrogens and Selective Estrogen Receptor Modulators (SERMs)</article-title>.&#8221; <source>Clinical, Cosmetic and Investigational Dermatology</source><volume>15</volume>: <fpage>1695</fpage>&#8211;<lpage>1709</lpage>.<pub-id pub-id-type="pmid">36017417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/CCID.S333663</pub-id><pub-id pub-id-type="pmcid">PMC9397534</pub-id></mixed-citation></ref><ref id="acel70190-bib-0030"><mixed-citation publication-type="journal" id="acel70190-cit-0030"><string-name name-style="western"><surname>L&#243;pez&#8208;Ot&#237;n</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Blasco</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Partridge</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Serrano</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Kroemer</surname></string-name>. <year>2023</year>. &#8220;<article-title>Hallmarks of Aging: An Expanding Universe</article-title>.&#8221; <source>Cell</source><volume>186</volume>: <fpage>243</fpage>&#8211;<lpage>278</lpage>.<pub-id pub-id-type="pmid">36599349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2022.11.001</pub-id></mixed-citation></ref><ref id="acel70190-bib-0031"><mixed-citation publication-type="journal" id="acel70190-cit-0031"><string-name name-style="western"><surname>Lu</surname>, <given-names>W.</given-names></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Rolland</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Guyonnet</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>de Souto Barreto</surname></string-name>, and <string-name name-style="western"><given-names>B.</given-names><surname>Vellas</surname></string-name>. <year>2023</year>. &#8220;<article-title>Reference Centiles for Intrinsic Capacity Throughout Adulthood and Their Association With Clinical Outcomes: A Cross&#8208;Sectional Analysis From the INSPIRE&#8208;T Cohort</article-title>.&#8221; <source>Nature Aging</source><volume>3</volume>: <fpage>1521</fpage>&#8211;<lpage>1528</lpage>.<pub-id pub-id-type="pmid">37946044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-023-00522-x</pub-id></mixed-citation></ref><ref id="acel70190-bib-0032"><mixed-citation publication-type="journal" id="acel70190-cit-0032"><string-name name-style="western"><surname>Man</surname>, <given-names>M. Q.</given-names></string-name>, and <string-name name-style="western"><given-names>P. M.</given-names><surname>Elias</surname></string-name>. <year>2019</year>. &#8220;<article-title>Could Inflammaging and Its Sequelae Be Prevented or Mitigated?</article-title>&#8221; <source>Clinical Interventions in Aging</source><volume>14</volume>: <fpage>2301</fpage>&#8211;<lpage>2304</lpage>.<pub-id pub-id-type="pmid">31920294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/CIA.S235595</pub-id><pub-id pub-id-type="pmcid">PMC6941699</pub-id></mixed-citation></ref><ref id="acel70190-bib-0033"><mixed-citation publication-type="journal" id="acel70190-cit-0033"><string-name name-style="western"><surname>Nedelec</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><given-names>N. J.</given-names><surname>Forget</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Hurtubise</surname></string-name>, et&#160;al. <year>2016</year>. &#8220;<article-title>Skin Characteristics: Normative Data for Elasticity, Erythema, Melanin, and Thickness at 16 Different Anatomical Locations</article-title>.&#8221; <source>Skin Research and Technology</source><volume>22</volume>: <fpage>263</fpage>&#8211;<lpage>275</lpage>.<pub-id pub-id-type="pmid">26333046</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/srt.12256</pub-id></mixed-citation></ref><ref id="acel70190-bib-0034"><mixed-citation publication-type="journal" id="acel70190-cit-0034"><string-name name-style="western"><surname>Oblak</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>van der Zaag</surname></string-name>, <string-name name-style="western"><given-names>A. T.</given-names><surname>Higgins&#8208;Chen</surname></string-name>, <string-name name-style="western"><given-names>M. E.</given-names><surname>Levine</surname></string-name>, and <string-name name-style="western"><given-names>M. P.</given-names><surname>Boks</surname></string-name>. <year>2021</year>. &#8220;<article-title>A Systematic Review of Biological, Social and Environmental Factors Associated With Epigenetic Clock Acceleration</article-title>.&#8221; <source>Ageing Research Reviews</source><volume>69</volume>: <elocation-id>101348</elocation-id>.<pub-id pub-id-type="pmid">33930583</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2021.101348</pub-id></mixed-citation></ref><ref id="acel70190-bib-0035"><mixed-citation publication-type="journal" id="acel70190-cit-0035"><string-name name-style="western"><surname>Pilkington</surname>, <given-names>S. M.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Bulfone&#8208;Paus</surname></string-name>, <string-name name-style="western"><given-names>C. E. M.</given-names><surname>Griffiths</surname></string-name>, and <string-name name-style="western"><given-names>R. E. B.</given-names><surname>Watson</surname></string-name>. <year>2021</year>. &#8220;<article-title>Inflammaging and the Skin</article-title>.&#8221; <source>Journal of Investigative Dermatology</source><volume>141</volume>: <fpage>1087</fpage>&#8211;<lpage>1095</lpage>.<pub-id pub-id-type="pmid">33358020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jid.2020.11.006</pub-id></mixed-citation></ref><ref id="acel70190-bib-0036"><mixed-citation publication-type="journal" id="acel70190-cit-0036"><string-name name-style="western"><surname>Russell&#8208;Goldman</surname>, <given-names>E.</given-names></string-name>, and <string-name name-style="western"><given-names>G. F.</given-names><surname>Murphy</surname></string-name>. <year>2020</year>. &#8220;<article-title>The Pathobiology of Skin Aging: New Insights Into an Old Dilemma</article-title>.&#8221; <source>American Journal of Pathology</source><volume>190</volume>: <fpage>1356</fpage>&#8211;<lpage>1369</lpage>.<pub-id pub-id-type="pmid">32246919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajpath.2020.03.007</pub-id><pub-id pub-id-type="pmcid">PMC7481755</pub-id></mixed-citation></ref><ref id="acel70190-bib-0037"><mixed-citation publication-type="journal" id="acel70190-cit-0037"><string-name name-style="western"><surname>Ryu</surname>, <given-names>H. S.</given-names></string-name>, <string-name name-style="western"><given-names>Y. H.</given-names><surname>Joo</surname></string-name>, <string-name name-style="western"><given-names>S. O.</given-names><surname>Kim</surname></string-name>, <string-name name-style="western"><given-names>K. C.</given-names><surname>Park</surname></string-name>, and <string-name name-style="western"><given-names>S. W.</given-names><surname>Youn</surname></string-name>. <year>2008</year>. &#8220;<article-title>Influence of Age and Regional Differences on Skin Elasticity as Measured by the Cutometer</article-title>.&#8221; <source>Skin Research and Technology</source><volume>14</volume>: <fpage>354</fpage>&#8211;<lpage>358</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-0846.2008.00302.x</pub-id>.<pub-id pub-id-type="pmid">19159383</pub-id></mixed-citation></ref><ref id="acel70190-bib-0038"><mixed-citation publication-type="journal" id="acel70190-cit-0038"><string-name name-style="western"><surname>S&#225;nchez&#8208;S&#225;nchez</surname>, <given-names>J. L.</given-names></string-name>, <string-name name-style="western"><given-names>W.&#8208;H.</given-names><surname>Lu</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Gallardo&#8208;G&#243;mez</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Association of Intrinsic Capacity With Functional Decline and Mortality in Older Adults: A Systematic Review and Meta&#8208;Analysis of Longitudinal Studies</article-title>.&#8221; <source>Lancet. Healthy Longevity</source><volume>5</volume>: <fpage>e480</fpage>&#8211;<lpage>e492</lpage>.<pub-id pub-id-type="pmid">38945130</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2666-7568(24)00092-8</pub-id></mixed-citation></ref><ref id="acel70190-bib-0039"><mixed-citation publication-type="journal" id="acel70190-cit-0039"><string-name name-style="western"><surname>Sator</surname>, <given-names>P. G.</given-names></string-name>, <string-name name-style="western"><given-names>J. B.</given-names><surname>Schmidt</surname></string-name>, <string-name name-style="western"><given-names>M. O.</given-names><surname>Sator</surname></string-name>, <string-name name-style="western"><given-names>J. C.</given-names><surname>Huber</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>H&#246;nigsmann</surname></string-name>. <year>2001</year>. &#8220;<article-title>The Influence of Hormone Replacement Therapy on Skin Ageing: A Pilot Study</article-title>.&#8221; <source>Maturitas</source><volume>39</volume>: <fpage>43</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="pmid">11451620</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0378-5122(00)00225-5</pub-id></mixed-citation></ref><ref id="acel70190-bib-0040"><mixed-citation publication-type="journal" id="acel70190-cit-0040"><string-name name-style="western"><surname>Sayed</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Nguyen</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>An Inflammatory Aging Clock (iAge) Based on Deep Learning Tracks Multimorbidity, Immunosenescence, Frailty and Cardiovascular Aging</article-title>.&#8221; <source>Nature Aging</source><volume>1</volume>: <fpage>598</fpage>&#8211;<lpage>615</lpage>.<pub-id pub-id-type="pmid">34888528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-021-00082-y</pub-id><pub-id pub-id-type="pmcid">PMC8654267</pub-id></mixed-citation></ref><ref id="acel70190-bib-0041"><mixed-citation publication-type="journal" id="acel70190-cit-0041"><string-name name-style="western"><surname>Wilkinson</surname>, <given-names>H. N.</given-names></string-name>, and <string-name name-style="western"><given-names>M. J.</given-names><surname>Hardman</surname></string-name>. <year>2021</year>. &#8220;<article-title>A Role for Estrogen in Skin Ageing and Dermal Biomechanics</article-title>.&#8221; <source>Mechanisms of Ageing and Development</source><volume>197</volume>: <elocation-id>111513</elocation-id>.<pub-id pub-id-type="pmid">34044023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mad.2021.111513</pub-id></mixed-citation></ref><ref id="acel70190-bib-0042"><mixed-citation publication-type="journal" id="acel70190-cit-0042"><string-name name-style="western"><surname>Wong</surname>, <given-names>Q. Y. A.</given-names></string-name>, and <string-name name-style="western"><given-names>F. T.</given-names><surname>Chew</surname></string-name>. <year>2021</year>. &#8220;<article-title>Defining Skin Aging and Its Risk Factors: A Systematic Review and Meta&#8208;Analysis</article-title>.&#8221; <source>Scientific Reports</source><volume>11</volume>: <fpage>1</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">33414495</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-020-79139-8</pub-id><pub-id pub-id-type="pmcid">PMC7791137</pub-id></mixed-citation></ref><ref id="acel70190-bib-0043"><mixed-citation publication-type="book" id="acel70190-cit-0043"><collab collab-type="authors">World Health Organization</collab>
. <year>2019</year>. <source>Integrated Care for Older People (ICOPE): Guidance for Person&#8208;Centred Assessment and Pathways in Primary Care</source>. <publisher-name>World Health Organization</publisher-name>.</mixed-citation></ref><ref id="acel70190-bib-0044"><mixed-citation publication-type="journal" id="acel70190-cit-0044"><string-name name-style="western"><surname>Zouboulis</surname>, <given-names>C. C.</given-names></string-name>, and <string-name name-style="western"><given-names>E.</given-names><surname>Makrantonaki</surname></string-name>. <year>2019</year>. &#8220;<article-title>Clinical and Laboratory Skin Biomarkers of Organ&#8208;Specific Diseases</article-title>.&#8221; <source>Mechanisms of Ageing and Development</source><volume>177</volume>: <fpage>144</fpage>&#8211;<lpage>149</lpage>.<pub-id pub-id-type="pmid">30118721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mad.2018.08.003</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="acel70208" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Aging Cell</journal-id><journal-id journal-id-type="iso-abbrev">Aging Cell</journal-id><journal-id journal-id-type="pmc-domain-id">2481</journal-id><journal-id journal-id-type="pmc-domain">acel</journal-id><journal-id journal-id-type="publisher-id">ACEL</journal-id><journal-title-group><journal-title>Aging Cell</journal-title></journal-title-group><issn pub-type="ppub">1474-9718</issn><issn pub-type="epub">1474-9726</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12507404</article-id><article-id pub-id-type="pmcid-ver">PMC12507404.1</article-id><article-id pub-id-type="pmcaid">12507404</article-id><article-id pub-id-type="pmcaiid">12507404</article-id><article-id pub-id-type="pmid">40888555</article-id><article-id pub-id-type="doi">10.1111/acel.70208</article-id><article-id pub-id-type="publisher-id">ACEL70208</article-id><article-id pub-id-type="other">ACE-25-0444-RAr</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Association Between Plasma Metabolomic Profile and Machine Learning&#8208;Based Brain Age</article-title></title-group><contrib-group><contrib id="acel70208-cr-0001" contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="Y">Yang</given-names></name><xref rid="acel70208-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="acel70208-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="acel70208-cr-0002" contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="J">Jiao</given-names></name><xref rid="acel70208-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="acel70208-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="acel70208-cr-0003" contrib-type="author"><name name-style="western"><surname>Miao</surname><given-names initials="Y">Yuyang</given-names></name><xref rid="acel70208-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="acel70208-cr-0004" contrib-type="author"><name name-style="western"><surname>Dunk</surname><given-names initials="MM">Michelle M.</given-names></name><xref rid="acel70208-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="acel70208-cr-0005" contrib-type="author" corresp="yes"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yan</given-names></name><xref rid="acel70208-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><address><email>neoyen3011@126.com</email></address></contrib><contrib id="acel70208-cr-0006" contrib-type="author" corresp="yes"><name name-style="western"><surname>Fang</surname><given-names initials="Z">Zhongze</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0002-3773-9207</contrib-id><xref rid="acel70208-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="acel70208-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>fang_zhongze@163.com</email></address></contrib><contrib id="acel70208-cr-0007" contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhang</surname><given-names initials="Q">Qiang</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5686-9253</contrib-id><xref rid="acel70208-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>zhangqiangyulv@163.com</email></address></contrib><contrib id="acel70208-cr-0008" contrib-type="author"><name name-style="western"><surname>Xu</surname><given-names initials="W">Weili</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6140-2968</contrib-id><xref rid="acel70208-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="acel70208-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="acel70208-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Aging Research Center, Department of Geriatrics</named-content>
<institution>Tianjin Medical University General Hospital, Tianjin Geriatrics Institute</institution>
<city>Tianjin</city>
<country country="CN">China</country>
</aff><aff id="acel70208-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Toxicology and Health Inspection and Quarantine</named-content>
<institution>School of Public Health, Tianjin Medical University</institution>
<city>Tianjin</city>
<country country="CN">China</country>
</aff><aff id="acel70208-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">National Clinical Research Center for Geriatrics</named-content>
<institution>West China Hospital, Sichuan University</institution>
<city>Chengdu</city>
<country country="CN">China</country>
</aff><aff id="acel70208-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Aging Research Center, Department of Neurobiology, Care Sciences and Society</named-content>
<institution>Karolinska Institute</institution>
<city>Stockholm</city>
<country country="SE">Sweden</country>
</aff><aff id="acel70208-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Health Care, the Second Medical Center</named-content>
<institution>Chinese PLA General Hospital</institution>
<city>Beijing</city>
<country country="CN">China</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Yan Liu (<email>neoyen3011@126.com</email>)<break/>
Zhongze Fang (<email>fang_zhongze@163.com</email>)<break/>
Qiang Zhang (<email>zhangqiangyulv@163.com</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>01</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>24</volume><issue seq="290">10</issue><issue-id pub-id-type="pmc-issue-id">498575</issue-id><issue-id pub-id-type="doi">10.1111/acel.v24.10</issue-id><elocation-id>e70208</elocation-id><history><date date-type="rev-recd"><day>22</day><month>7</month><year>2025</year></date><date date-type="received"><day>28</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>23</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Aging Cell</italic> published by Anatomical Society and John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ACEL-24-e70208.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ACEL-24-e70208.pdf"/><abstract><title>ABSTRACT</title><p>Metabolomics has been associated with cognitive decline and dementia, but the relationship between metabolites and brain aging remains unclear. We aimed to investigate the associations of metabolomics with brain age assessed by neuroimaging and to explore whether these relationships vary according to apolipoprotein E (<italic toggle="no">APOE</italic>) &#949;4. This study included 17,770 chronic brain disorder&#8208;free participants aged 40&#8211;69&#8201;years from UK Biobank who underwent neuroimaging scans an average of 9&#8201;years after baseline. A total of 249 plasma metabolites were measured using nuclear magnetic resonance spectroscopy at baseline. Brain age was estimated using LASSO regression and 1079 brain MRI phenotypes and brain age gap (BAG; i.e., brain age minus chronological age) was calculated. Data were analyzed using linear regression. We identified 64 and 77 metabolites associated with brain age and BAG, respectively, of which 55 overlapped. Lipids (including cholesterol, cholesteryl esters, free cholesterol, phospholipids, and total lipids) in S/M&#8208;HDL, as well as phospholipids and triglycerides as a percentage of total lipids in different&#8208;density lipoproteins, were associated with larger BAG. The percentages of cholesterol, cholesteryl esters, and free cholesterol to total lipids in VLDL, LDL, and HDL of different particle sizes were associated with smaller BAG. The associations of LA/FA, omega&#8208;6/FA, SFA/FA, and phospholipids to total lipids in L&#8208;HDL with brain age were consistent across <italic toggle="no">APOE</italic> &#949;4 carriers and non&#8208;carriers (all <italic toggle="no">p</italic> for interaction &gt;&#8201;0.05). Plasma metabolites show remarkably widespread associations with brain aging regardless of <italic toggle="no">APOE</italic> &#949;4 genetic risk. Metabolic profiles could serve as an early indicator of accelerated brain aging.</p></abstract><abstract abstract-type="graphical"><p>Plasma metabolites show remarkably widespread associations with brain aging regardless of <italic toggle="no">APOE</italic> &#949;4 genetic risk. Metabolic profiles could serve as an early indicator of accelerated brain aging.<boxed-text position="anchor" content-type="graphic" id="acel70208-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ACEL-24-e70208-g004.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="acel70208-kwd-0001">brain age</kwd><kwd id="acel70208-kwd-0002">machine learning</kwd><kwd id="acel70208-kwd-0003">magnetic resonance imaging</kwd><kwd id="acel70208-kwd-0004">metabolites</kwd><kwd id="acel70208-kwd-0005">UK biobank</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>National Key Research and Development Program of China</institution><institution-id institution-id-type="doi">10.13039/501100012166</institution-id></institution-wrap></funding-source><award-id>2021YFA1301202</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>National Natural Science Foundation of China</institution><institution-id institution-id-type="doi">10.13039/501100001809</institution-id></institution-wrap></funding-source><award-id>82473677</award-id><award-id>82273676</award-id><award-id>32400963</award-id><award-id>92357305</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Natural Science Foundation of Chongqing Municipality</institution><institution-id institution-id-type="doi">10.13039/501100005230</institution-id></institution-wrap></funding-source><award-id>2024NSCQ&#8208;MSX3537</award-id></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>Swedish Research Council</institution><institution-id institution-id-type="doi">10.13039/501100004359</institution-id></institution-wrap></funding-source><award-id>2021&#8208;01647</award-id></award-group><award-group id="funding-0005"><funding-source><institution-wrap><institution>Swedish Council for Health Working Life and Welfare</institution></institution-wrap></funding-source><award-id>2021&#8208;01826</award-id></award-group><award-group id="funding-0006"><funding-source><institution-wrap><institution>Loo and Hans Osterman Foundation for Medical Research</institution><institution-id institution-id-type="doi">10.13039/100010771</institution-id></institution-wrap></funding-source><award-id>2025&#8208;01809</award-id></award-group><award-group id="funding-0007"><funding-source><institution-wrap><institution>Sigurd and Elsa Goljes Memorial Foundation</institution></institution-wrap></funding-source><award-id>2025&#8208;0123</award-id></award-group><award-group id="funding-0008"><funding-source><institution-wrap><institution>Forte</institution><institution-id institution-id-type="doi">10.13039/501100006636</institution-id></institution-wrap></funding-source><award-id>2024&#8208;01820</award-id></award-group><award-group id="funding-0009"><funding-source><institution-wrap><institution>Strategic Research Programm in Diabetes 2025, and the Karolinska Institutet Research Foundation</institution></institution-wrap></funding-source><award-id>2024&#8208;02959</award-id></award-group></funding-group><counts><fig-count count="4"/><table-count count="1"/><page-count count="11"/><word-count count="7600"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:08.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="acel70208-cit-1001"><string-name name-style="western"><surname>Li</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Miao</surname></string-name>, et al. <year>2025</year>. &#8220;<article-title>Association Between Plasma Metabolomic Profile and Machine Learning&#8208;Based Brain Age</article-title>.&#8221; <source>Aging Cell</source><volume>24</volume>, no. <issue>10</issue>: <elocation-id>e70208</elocation-id>. <pub-id pub-id-type="doi">10.1111/acel.70208</pub-id>.</mixed-citation>
</p><fn-group id="acel70208-ntgp-0001"><fn fn-type="funding" id="acel70208-note-0001"><p>
<bold>Funding:</bold> The study was supported by the National Key Research and Development Program of China [2021YFA1301202], the National Natural Science Foundation of China [82473677, 82273676, 32400963, 92357305], the Natural Science Foundation of Chongqing Municipality [2024NSCQ&#8208;MSX3537], Swedish Research Council [No. 2021&#8208;01647], Swedish Council for Health Working Life and Welfare [2021&#8208;01826], Forte [2024&#8208;01820], Strategic Research Programm in Diabetes 2025, and the Karolinska Institutet Research Foundation [2024&#8208;02959], Loo and Hans Osterman Foundation for Medical Research [2025&#8208;01809], and the Sigurd and Elsa Goljes Memorial Foundation [2025&#8208;0123].</p></fn><fn fn-type="equal" id="acel70208-note-0002"><p>Yang Li and Jiao Wang contributed equally as the first author.</p></fn><fn fn-type="equal" id="acel70208-note-0003"><p>Yan Liu, Zhongze Fang, and Qiang Zhang Contributed equally as the last authors.</p></fn></fn-group></notes></front><body id="acel70208-body-0001"><def-list list-content="abbreviations" id="acel70208-dl-0001"><title>Abbreviations</title><def-item><term id="acel70208-li-0001">Apo</term><def id="acel70208-li-0002"><p>apolipoprotein</p></def></def-item><def-item><term id="acel70208-li-0003">BAG</term><def id="acel70208-li-0004"><p>brain age gap</p></def></def-item><def-item><term id="acel70208-li-0005">BCAAs</term><def id="acel70208-li-0006"><p>branched&#8208;chain amino acids</p></def></def-item><def-item><term id="acel70208-li-0007">BMI</term><def id="acel70208-li-0008"><p>body mass index</p></def></def-item><def-item><term id="acel70208-li-0009">CI</term><def id="acel70208-li-0010"><p>confidence interval</p></def></def-item><def-item><term id="acel70208-li-0011">DHA</term><def id="acel70208-li-0012"><p>docosahexaenoic acid</p></def></def-item><def-item><term id="acel70208-li-0013">FA</term><def id="acel70208-li-0014"><p>fatty acid</p></def></def-item><def-item><term id="acel70208-li-0015">FDR</term><def id="acel70208-li-0016"><p>False discovery rate</p></def></def-item><def-item><term id="acel70208-li-0017">HDL</term><def id="acel70208-li-0018"><p>high&#8208;density lipoprotein</p></def></def-item><def-item><term id="acel70208-li-0019">HDL&#8208;AD</term><def id="acel70208-li-0020"><p>average diameter for HDL particles</p></def></def-item><def-item><term id="acel70208-li-0021">IDL</term><def id="acel70208-li-0022"><p>intermediate&#8208;density lipoprotein</p></def></def-item><def-item><term id="acel70208-li-0023">LA</term><def id="acel70208-li-0024"><p>linoleic acid</p></def></def-item><def-item><term id="acel70208-li-0025">LASSO</term><def id="acel70208-li-0026"><p>Least Absolute Shrinkage and Selection Operator</p></def></def-item><def-item><term id="acel70208-li-0027">LDL</term><def id="acel70208-li-0028"><p>low&#8208;density lipoprotein</p></def></def-item><def-item><term id="acel70208-li-0029">LDL&#8208;AD</term><def id="acel70208-li-0030"><p>average diameter for LDL particles</p></def></def-item><def-item><term id="acel70208-li-0031">MRI</term><def id="acel70208-li-0032"><p>magnetic resonance imaging</p></def></def-item><def-item><term id="acel70208-li-0033">MUFA</term><def id="acel70208-li-0034"><p>monounsaturated fatty acid</p></def></def-item><def-item><term id="acel70208-li-0035">NMR</term><def id="acel70208-li-0036"><p>nuclear magnetic resonance</p></def></def-item><def-item><term id="acel70208-li-0037">PUFA</term><def id="acel70208-li-0038"><p>polyunsaturated fatty acid</p></def></def-item><def-item><term id="acel70208-li-0039">SFA</term><def id="acel70208-li-0040"><p>saturated fatty acid</p></def></def-item><def-item><term id="acel70208-li-0041">TDI</term><def id="acel70208-li-0042"><p>Townsend Deprivation Index</p></def></def-item><def-item><term id="acel70208-li-0043">TG</term><def id="acel70208-li-0044"><p>triglycerides</p></def></def-item><def-item><term id="acel70208-li-0045">VLDL</term><def id="acel70208-li-0046"><p>very low&#8208;density lipoprotein</p></def></def-item><def-item><term id="acel70208-li-0047">VLDL&#8208;AD</term><def id="acel70208-li-0048"><p>average diameter for VLDL particles</p></def></def-item></def-list><sec id="acel70208-sec-0001"><label>1</label><title>Introduction</title><p>Metabolomics has been used to identify novel biomarkers for the diagnosis and monitoring of chronic diseases (Griffin et&#160;al.&#160;<xref rid="acel70208-bib-0016" ref-type="bibr">2011</xref>; Hasin et&#160;al.&#160;<xref rid="acel70208-bib-0019" ref-type="bibr">2017</xref>). In addition, metabolomics can provide valuable insights into the pathophysiology of age&#8208;related diseases by sensitively capturing metabolic alterations even at the pre&#8208;clinical stage (Tynkkynen et&#160;al.&#160;<xref rid="acel70208-bib-0048" ref-type="bibr">2018</xref>). In brain magnetic resonance imaging (MRI) studies, blood metabolites, including lipid subclasses, fatty acids, amino acids, and inflammatory biomarkers, have been linked to regional brain volumes, white matter microstructure, cortical thickness, and microstructural lesions (Harshfield and Markus&#160;<xref rid="acel70208-bib-0018" ref-type="bibr">2023</xref>; Sliz et&#160;al.&#160;<xref rid="acel70208-bib-0041" ref-type="bibr">2022</xref>, <xref rid="acel70208-bib-0042" ref-type="bibr">2020</xref>, <xref rid="acel70208-bib-0043" ref-type="bibr">2021</xref>).</p><p>In recent years, machine learning has been utilized to model brain age from an aggregation of multimodal brain MRI phenotypes. By integrating multiple MRI measures, brain age captures subtle structural changes and intricate connections among various brain regions, thus providing a comprehensive picture of the individual's brain aging process (Bzdok&#160;<xref rid="acel70208-bib-0004" ref-type="bibr">2017</xref>; Cole&#160;<xref rid="acel70208-bib-0008" ref-type="bibr">2020</xref>). Brain age gap (BAG), the difference between predicted brain age and chronological age, further reveals whether an individual's brain age deviates from the norm and is recognized as a significant biomarker of neurological health and aging (Baecker et&#160;al.&#160;<xref rid="acel70208-bib-0002" ref-type="bibr">2021</xref>).</p><p>To date, three landmark studies have explored the association of metabolic signatures with MRI&#8208;derived brain aging measures (Gordon et&#160;al.&#160;<xref rid="acel70208-bib-0014" ref-type="bibr">2024</xref>; Kim et&#160;al.&#160;<xref rid="acel70208-bib-0024" ref-type="bibr">2023</xref>; Tian et&#160;al.&#160;<xref rid="acel70208-bib-0046" ref-type="bibr">2023</xref>). Gordon et&#160;al.&#160;(<xref rid="acel70208-bib-0014" ref-type="bibr">2024</xref>) and Kim et&#160;al.&#160;(<xref rid="acel70208-bib-0024" ref-type="bibr">2023</xref>) established brain age using T1&#8208;weighted structural MRI data without considering phenotypes from other MRI modalities. Tian et&#160;al.&#160;(<xref rid="acel70208-bib-0046" ref-type="bibr">2023</xref>) made significant strides by developing multiorgan aging clocks including the brain age using the multimodal neuroimaging phenotypes and the metabolic system integrating blood biomarkers associated with lipids and glucose metabolites, and then suggested metabolic perturbation and accelerated brain aging. However, this study assessed the health of the metabolic system with limited metabolites and did not explore a wider range of metabolites as well as assess individual metabolites in relation to brain age. Thus, we still need to further explore the association of broad metabolites with brain age/BAG.</p><p>The apolipoprotein E (<italic toggle="yes">APOE</italic>) &#949;4 allele&#8212;the greatest genetic risk factor for Alzheimer's dementia&#8212;has been associated with brain health (such as brain microstructure, gray matter, and hippocampal volume) (Malek&#8208;Ahmadi et&#160;al.&#160;<xref rid="acel70208-bib-0028" ref-type="bibr">2023</xref>). Beyond its established links to brain health, emerging epidemiological evidence reveals that <italic toggle="yes">APOE</italic> &#949;4 carriers exhibit distinct plasma metabolomic profiles characterized by altered lipid metabolism (e.g., lower high&#8208;density lipoprotein cholesterol, elevated triglyceride&#8208;rich lipoproteins) and neuroinflammation, which may accelerate brain aging independently of amyloid <italic toggle="yes">&#946;</italic> deposition (Montagne et&#160;al.&#160;<xref rid="acel70208-bib-0030" ref-type="bibr">2021</xref>; Nakamura et&#160;al.&#160;<xref rid="acel70208-bib-0031" ref-type="bibr">2023</xref>). Critically, <italic toggle="yes">APOE</italic> &#949;4 carriers exhibit metabolic shifts decades before clinical dementia onset, positioning these profiles as potential early indicators of neurobiological decline. However, there is a lack of direct evidence on whether metabolites alter the risk of <italic toggle="yes">APOE</italic>&#8208;associated brain aging.</p><p>To fill these knowledge gaps, we conducted a comprehensive examination of the association between circulating metabolites and brain age in over 30,000 middle&#8208;aged and older adults, utilizing detailed neuroimaging data from the UK Biobank covering 6 different MRI modalities. Specifically, we aimed to (1) assess the associations of metabolites with brain age and BAG, and (2) explore the role of <italic toggle="yes">APOE</italic> &#949;4 carrier status in these associations.</p></sec><sec sec-type="methods" id="acel70208-sec-0002"><label>2</label><title>Methods</title><sec id="acel70208-sec-0003"><label>2.1</label><title>Study Design and Participants</title><p>The UK Biobank recruited 502,412 participants aged 37&#8211;73&#8201;years between 2006 and 2010 from 22 assessment centers. The UK Biobank study received ethical approval from the North West Multi&#8208;Centre Research Ethics Committee (Ref 11/NW/0382) and all registered participants provided informed and written consent. This research was conducted using the UK Biobank resource (Application Number 67048).</p><p>Following baseline assessment, a subsample of 42,806 participants consented to undergo MRI assessment from 2014 to 2020. Following the exclusion of participants with incomplete brain MRI (<italic toggle="yes">n</italic>&#8201;=&#8201;8510), we used the remaining individuals with complete brain MRI data (<italic toggle="yes">n</italic>&#8201;=&#8201;34,296) for subsequent analysis. We then further excluded those with ICD&#8208;10 diagnosed somatic disease (UK Biobank&#8208;field ID 41270), self&#8208;reported long&#8208;term illness, disability, or frailty (field ID 2188), or self&#8208;reported fair or poor health (field ID 2178), yielding a sample of 4355 healthy participants. These participants were randomly allocated in a 4:1 ratio to a training set (<italic toggle="yes">n</italic>&#8201;=&#8201;3484, for training the brain age model) and a validation set (<italic toggle="yes">n</italic>&#8201;=&#8201;871, for validating model performance). The remaining 29,941 participants were included in the testing set.</p><p>After further excluding 16,526 participants with chronic brain diseases (<italic toggle="yes">n</italic>&#8201;=&#8201;1459; detailed code is available in Table&#160;<xref rid="acel70208-supitem-0001" ref-type="supplementary-material">S1</xref>) and missing information on metabolites (<italic toggle="yes">n</italic>&#8201;=&#8201;15,067), a total of 17,770 participants were included in the final study sample (Figure&#160;<xref rid="acel70208-fig-0001" ref-type="fig">1</xref>). The study population included 17,770 participants, among whom 51.95% were female, with a mean (SD) age of 54.73 (7.48) years. Participant characteristics are detailed in Table&#160;<xref rid="acel70208-tbl-0001" ref-type="table">1</xref>.</p><fig position="float" fig-type="FIGURE" id="acel70208-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>(a) Study overview. Six MRI modalities used to estimate brain age, namely T1&#8208;weighted MRI, T2*, Resting&#8208;state fMRI, Diffusion&#8208;MRI, Task fMRI, and T2&#8208;FLAIR. Top 10 IDPs for LASSO modeling; (b) Flowchart of participants included in the study.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="ACEL-24-e70208-g002.jpg"/></fig><table-wrap position="float" id="acel70208-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Baseline characteristics of the study population (<italic toggle="no">n</italic>&#8201;=&#8201;17,770).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Characteristics</th><th align="center" valign="bottom" rowspan="1" colspan="1">Total participants</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (year)</td><td align="center" valign="top" rowspan="1" colspan="1">54.73&#8201;&#177;&#8201;7.48</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">9232 (51.95)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Race&#8208;White</td><td align="center" valign="top" rowspan="1" colspan="1">16,490 (92.80)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TDI</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;2.69 (&#8722;3.94, &#8722;0.69)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Education&#8208;College</td><td align="center" valign="top" rowspan="1" colspan="1">8180 (46.03)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">26.57&#8201;&#177;&#8201;4.17</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Smoking status</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Never</td><td align="center" valign="top" rowspan="1" colspan="1">10,853 (61.07)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Former</td><td align="center" valign="top" rowspan="1" colspan="1">5793 (32.60)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Current</td><td align="center" valign="top" rowspan="1" colspan="1">1088 (6.13)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Alcohol drinking status</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Never</td><td align="center" valign="top" rowspan="1" colspan="1">440 (2.48)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Former</td><td align="center" valign="top" rowspan="1" colspan="1">353 (1.99)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Current</td><td align="center" valign="top" rowspan="1" colspan="1">16,971 (95.50)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Regular physical activity</td><td align="center" valign="top" rowspan="1" colspan="1">12,797 (72.01)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">High social connection</td><td align="center" valign="top" rowspan="1" colspan="1">13,685 (77.01)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hypertension</td><td align="center" valign="top" rowspan="1" colspan="1">7902 (44.47)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diabetes</td><td align="center" valign="top" rowspan="1" colspan="1">462 (2.60)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Heart disease</td><td align="center" valign="top" rowspan="1" colspan="1">641 (3.61)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Medication</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Beta&#8208;blockers</td><td align="center" valign="top" rowspan="1" colspan="1">669 (3.76)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Calcium blockers</td><td align="center" valign="top" rowspan="1" colspan="1">593 (3.34)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Lipid&#8208;lowering</td><td align="center" valign="top" rowspan="1" colspan="1">1789 (10.07)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> &#949;4 carrier</td><td align="center" valign="top" rowspan="1" colspan="1">4155 (23.38)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Brain age (year)</td><td align="center" valign="top" rowspan="1" colspan="1">63.82&#8201;&#177;&#8201;9.07</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Brain age gap (year)</td><td align="center" valign="top" rowspan="1" colspan="1">0.35&#8201;&#177;&#8201;5.16</td></tr></tbody></table><table-wrap-foot id="acel70208-ntgp-0002"><fn id="acel70208-note-0004"><p>
<italic toggle="yes">Note:</italic> Data are presented as mean&#8201;&#177;&#8201;standard deviations, median (interquartile range), or <italic toggle="yes">n</italic> (%). Missing data: Education&#8201;=&#8201;56; Race&#8201;=&#8201;46; TDI&#8201;=&#8201;16; Smoking status&#8201;=&#8201;36; Alcohol drinking status&#8201;=&#8201;6; BMI&#8201;=&#8201;15; Physical activity&#8201;=&#8201;573; Social connection&#8201;=&#8201;43; <italic toggle="yes">APOE</italic> &#949;4 carrier status&#8201;=&#8201;2670.</p></fn><fn id="acel70208-note-0005"><p>Abbreviations: <italic toggle="yes">APOE</italic> &#949;4, apolipoprotein E epsilon; BMI, body mass index; TDI, Townsend Deprivation Index.</p></fn></table-wrap-foot></table-wrap></sec><sec id="acel70208-sec-0004"><label>2.2</label><title>Measurement of Metabolomics</title><p>Ethylenediaminetetraacetic acid (EDTA) plasma samples were collected in a non&#8208;fasting state, following the UK Biobank protocol. However, the sampling time was 4&#8201;h after the last meal, so the effect on metabolite concentrations was minor. Metabolites in EDTA plasma samples collected at baseline were quantified using a high&#8208;throughput nuclear magnetic resonance (NMR)&#8208;based metabolic biomarker analysis platform developed by Nightingale Health Ltd. Detailed information on metabolite processing can be found online (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://biobank.ctsu.ox.ac.uk/ukb/ukb/docs/nmrm_companion_doc" ext-link-type="uri">https://biobank.ctsu.ox.ac.uk/ukb/ukb/docs/nmrm_companion_doc</ext-link>). In this study, we included 249 metabolic biomarkers, including 168 absolute levels and 81 derived ratios. The comprehensive biomarker profile included cholesterol, fatty acids, and low&#8208;molecular&#8208;weight metabolites, such as ketone bodies, amino acids, and glycolysis&#8208;related metabolites. All metabolites were Z&#8208;transformed before analysis.</p></sec><sec id="acel70208-sec-0005"><label>2.3</label><title>
<styled-content style="fixed-case" toggle="no">MRI</styled-content> Data Acquisition and Pre&#8208;Processing</title><p>Brain MRI scans were performed between 2014 and 2020 at 4 MRI assessment centers using standard Siemens Skyra 3&#8201;T scanners running VD13A. Details on the UK Biobank brain MRI data protocol and processing pipeline are available on the UK Biobank website in the brain scan protocol and brain imaging documentation (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://biobank.ndph.ox.ac.uk" ext-link-type="uri">biobank.ndph.ox.ac.uk</ext-link>/crystal/ukb/docs/brain_mri.pdf). Summary measurements of imaging&#8208;derived phenotypes were generated with an image&#8208;processing pipeline developed and run on behalf of the UK Biobank, using publicly available image processing tools FSL (the FMRIB Software Library, version 5.0.10, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://fsl.fmrib.ox.ac.uk/fsl" ext-link-type="uri">http://fsl.fmrib.ox.ac.uk/fsl</ext-link>) and FreeSurfer (version 6.0). A total of 1079 neuroimaging phenotypes were generated from six modalities, including T1&#8208;weighted (<italic toggle="yes">n</italic>&#8201;=&#8201;165), T2&#8208;FLAIR (<italic toggle="yes">n</italic>&#8201;=&#8201;1; total volume of white&#8208;matter hyperintensities), SWI (<italic toggle="yes">n</italic>&#8201;=&#8201;14), diffusion&#8208;MRI (<italic toggle="yes">n</italic>&#8201;=&#8201;675), task fMRI (<italic toggle="yes">n</italic>&#8201;=&#8201;14), and resting&#8208;state fMRI (<italic toggle="yes">n</italic>&#8201;=&#8201;210) (Table&#160;<xref rid="acel70208-supitem-0001" ref-type="supplementary-material">S2</xref>).</p></sec><sec id="acel70208-sec-0006"><label>2.4</label><title>Assessment of Brain Age and <styled-content style="fixed-case" toggle="no">BAG</styled-content>
</title><p>A total of 1079 MRI phenotypes were first Z&#8208;transformed, followed by training of nine machine learning models to calculate brain age in the training dataset. These models included least absolute shrinkage and selection operator (LASSO) regression, eXtreme gradient boosting, and support vector regression, each combined with one of three feature selection approaches: no feature selection, FeatureWiz, or recursive feature elimination with cross&#8208;validation. To identify the best hyperparameter, Bayesian optimization was employed across 100 epochs (Tables&#160;<xref rid="acel70208-supitem-0001" ref-type="supplementary-material">S3</xref> and <xref rid="acel70208-supitem-0001" ref-type="supplementary-material">S4</xref>). After optimizing the hyperparameters, each model was tested on the validation set for performance comparison. Finally, the LASSO model without feature selection performed best (with mean absolute error&#8201;=&#8201;3.232, <italic toggle="yes">R</italic>
<sup>2</sup>&#8201;=&#8201;0.690, and Pearson's <italic toggle="yes">r</italic>&#8201;=&#8201;0.830) (Table&#160;<xref rid="acel70208-supitem-0001" ref-type="supplementary-material">S5</xref>) and was therefore selected for predicting brain age across the entire population. Among the 1079 imaging&#8208;derived phenotypes (IDPs), 285 were found to have a significant contribution to the brain age estimation, and their details are provided in Table&#160;<xref rid="acel70208-supitem-0001" ref-type="supplementary-material">S6</xref>.</p><p>In addition, we corrected for the age bias commonly observed in brain age prediction, that is corrected brain age&#8201;=&#8201;(original brain age&#8208;<italic toggle="yes">&#946;</italic>)/&#945;, where the coefficients <italic toggle="yes">&#945;</italic> and <italic toggle="yes">&#946;</italic> are the slope and intercept, respectively, of the linear regression model for estimating brain age from chronological age in the training set (brain age <sub>training set</sub>&#8201;=&#8201;<italic toggle="yes">&#945;</italic> * chronological age <sub>training set</sub>&#8201;&#177;&#8201;<italic toggle="yes">&#946;</italic>). BAG was calculated by subtracting chronological age from corrected brain age. A positive BAG indicates accelerated brain age, and a negative BAG reflects a younger, healthier brain than expected based on chronological age. This correction adjusts for residual age correlations but does not alter the model's intrinsic performance metrics, which were finalized before correction.</p></sec><sec id="acel70208-sec-0007"><label>2.5</label><title>Assessment of Covariates</title><p>Upon study entry, participants underwent a comprehensive physical examination and clinical evaluation. In addition, information on demographic characteristics, socioeconomic status, and lifestyle factors was collected via a computerized touchscreen questionnaire.</p><p>Education was categorized as college or non&#8208;college. Race was dichotomized as white or non&#8208;white (including Asian, Black, and mixed background). Townsend Deprivation Index (TDI), which combined information on housing, employment, and car availability, was calculated based on census and postcode before participant recruitment, reflecting the subject's socioeconomic status. Smoking and alcohol drinking status were both categorized as never, former, or current. Body mass index (BMI) was calculated as weight (kg) divided by height (m<sup>2</sup>). Regular physical activity was defined as &#8805;&#8201;150&#8201;min of moderate&#8208;intensity activity per week, or &#8805;&#8201;75&#8201;min of vigorous&#8208;intensity activity per week or its equivalent. Social connection was evaluated based on responses to the question &#8220;How often do you visit friends or have them visit you?&#8221; and classified as high (&#8220;almost daily&#8221;, &#8220;2&#8211;4 times a week&#8221;, and &#8220;about once a week&#8221;) and low levels (&#8220;about once a month&#8221;, &#8220;once every few months&#8221;, &#8220;never or almost never&#8221;, and &#8220;no friends/family outside household&#8221;).</p><p>Hypertension was defined as systolic blood pressure &#8805;&#8201;140&#8201;mmHg, diastolic blood pressure &#8805;&#8201;90&#8201;mmHg, use of antihypertensive drugs, or a history of hypertension. Heart disease including coronary artery disease, congestive heart failure, and atrial fibrillation was assessed based on self&#8208;reported and registered medical history. Diabetes was defined as hemoglobin A1c &#8805;&#8201;6.5%, fasting plasma glucose &#8805;&#8201;126&#8201;mg/dL, a history of diabetes, or the use of glucose&#8208;lowering medications.</p><p>
<italic toggle="yes">APOE</italic> was genotyped from blood samples, and a detailed genotyping process can be found at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.ukbiobank.ac.uk/scientists-3/genetic-data" ext-link-type="uri">http://www.ukbiobank.ac.uk/scientists&#8208;3/genetic&#8208;data</ext-link>. Single nucleotide polymorphism data for rs429358 and rs7412 were used to determine the <italic toggle="yes">APOE</italic> genotype. <italic toggle="yes">APOE</italic> genotypes were classified as &#949;2 carriers (genotypes &#949;2&#949;2), &#949;3 homozygotes (&#949;3&#949;3), &#949;4 heterozygotes (&#949;3&#949;4), or &#949;4 homozygotes (&#949;4&#949;4). The <italic toggle="yes">APOE</italic> gene was genotyped and dichotomized as carriers versus non&#8208;carriers of the &#949;4 allele.</p></sec><sec id="acel70208-sec-0008"><label>2.6</label><title>Statistical Analysis</title><p>Baseline characteristics of study participants were described as mean (SD) and median (25th&#8211;75th percentiles) for continuous variables and number (%) for qualitative variables. All statistical analyses were performed using R (version 4.1.0). With two&#8208;tailed testing, a <italic toggle="yes">p&#8208;</italic>value &lt;&#8201;0.05 was considered statistically significant.</p><p>Linear regression models were used to estimate <italic toggle="yes">&#946;</italic> coefficients and 95% confidence intervals (CIs) for the association of metabolites with brain age and BAG. The basic models were adjusted for age, sex, and education. Multivariable&#8208;adjusted models were further adjusted for race, socioeconomic status, body mass index, smoking status, alcohol drinking status, physical activity, social contact, hypertension, diabetes, heart disease, <italic toggle="yes">&#946;</italic>&#8208;blockers, calcium blockers, lipid&#8208;lowering medications, and <italic toggle="yes">APOE</italic> &#949;4 carrier status. Stratified analyses were performed to explore the role of <italic toggle="yes">APOE</italic> &#949;4 in the association of metabolites with brain age and BAG. Statistical interaction was examined by creating an indicator variable with the cross&#8208;product of two variables. Benjamini&#8208;Hochberg for false discovery rate (FDR) was used to correct for the <italic toggle="yes">p</italic>&#8208;value.</p><p>In sensitivity analysis, we repeated the analyses after (1) using chained&#8208;equation multiple imputation to impute the missing values or covariates (including race, education, TDI, BMI, smoking status, alcohol drinking status, physical activity, social connection, and <italic toggle="yes">APOE</italic> &#949;4 carrier status) and (2) using BAG calculated based on brain age estimated from other candidate machine learning models.</p></sec></sec><sec sec-type="results" id="acel70208-sec-0009"><label>3</label><title>Results</title><sec id="acel70208-sec-0010"><label>3.1</label><title>Association of Individual Metabolites With Brain Age and <styled-content style="fixed-case" toggle="no">BAG</styled-content>
</title><p>The association of individual metabolites with brain age and BAG was assessed with the use of linear regression models. In the multi&#8208;variable models, 64 (25.70%) and 77 (30.92%) metabolites were associated with brain age and BAG, respectively (Tables&#160;<xref rid="acel70208-supitem-0001" ref-type="supplementary-material">S7</xref> and <xref rid="acel70208-supitem-0001" ref-type="supplementary-material">S8</xref>), and the overlap of significant metabolites between brain age and BAG was 55 (22.09%) (Figure&#160;<xref rid="acel70208-fig-0002" ref-type="fig">2</xref> and Figure&#160;<xref rid="acel70208-supitem-0001" ref-type="supplementary-material">S1</xref>).</p><fig position="float" fig-type="FIGURE" id="acel70208-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Benjamini&#8208;Hochberg for false discovery rate&#8208;corrected metabolites significantly associated with (a) brain age and (b) brain age gap. Orange point and line: Metabolite associated with brain age/BAG with &#946; and 95% confidence interval (CI) of &gt;&#8201;0; gray point and line: Metabolite associated with brain age/BAG with &#946; and 95% CI of &lt;&#8201;0. All models adjusted for age, sex, education, race, socioeconomic status, body mass index, smoking status, alcohol drinking status, physical activity, social connection, hypertension, diabetes, heart disease, beta&#8208;blockers, calcium blockers, lipid&#8208;lowering, and <italic toggle="yes">APOE</italic> &#949;4 status. Apo, apolipoprotein; CE, cholesteryl esters; CHOL, cholesterol; FA, fatty acid; HDL, high&#8208;density lipoprotein; IDL, intermediate&#8208;density lipoprotein; L, large; LA, linoleic acid; LDL, low&#8208;density lipoprotein; LDL&#8208;AD, average diameter for LDL particles; M, medium; MUFA, monounsaturated fatty acid; n&#8208;6, omega&#8208;6 fatty acid; PUFA, polyunsaturated fatty acid; S, small; SFA, saturated fatty acid; TG, triglycerides; VL, very large; VLDL, very low&#8208;density lipoprotein; XL, extremely large.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="ACEL-24-e70208-g001.jpg"/></fig><p>Cholesterol, cholesteryl esters, free cholesterol, phospholipids, and total lipids in S/M&#8208;HDL (e.g., brain age: <italic toggle="yes">&#946;</italic>
<sub>CHOL in S&#8208;HDL</sub>&#8201;=&#8201;0.160, 95% confidence interval [CI]&#8201;=&#8201;0.069&#8211;0.252; BAG: <italic toggle="yes">&#946;</italic>
<sub>CHOL in S&#8208;HDL</sub>&#8201;=&#8201;0.186, 95% CI&#8201;=&#8201;0.103&#8211;0.270), as well as phospholipids and triglycerides as a percentage of total lipids in different density lipoproteins, were associated with older brain age and larger BAG (e.g., <italic toggle="yes">&#946;</italic> and 95% CI of TG/Total lipids in S&#8208;LDL, 0.154 [0.057, 0.250] for brain age; 0.123 [0.035, 0.212] for BAG). Meanwhile, tyrosine, glucose, ApoA1, phosphatidylcholine, phosphoglycerides, monounsaturated fatty acid (MUFA), SFA, SFA/FA, glycoprotein acetyls, and three ketone bodies (e.g., brain age: <italic toggle="yes">&#946;</italic>
<sub>Acetoacetate</sub>&#8201;=&#8201;0.159, 95% CI&#8201;=&#8201;0.068&#8211;0.249; BAG: <italic toggle="yes">&#946;</italic>
<sub>Acetoacetate</sub>&#8201;=&#8201;0.118, 95% CI&#8201;=&#8201;0.035&#8211;0.201) also were related to older brain age and larger BAG. However, glutamine, ApoB/ApoA1, certain fatty acid ratios (e.g., <italic toggle="yes">&#946;</italic> and 95% CI of LA/FA, &#8722;0.291 [&#8722;0.392, &#8722;0.190] for brain age; <italic toggle="yes">&#946;</italic> and 95% CI of &#8722;0.333 [&#8722;0.425, &#8722;0.240] for BAG), and the percentages of cholesterol, cholesteryl esters, and free cholesterol to total lipids in VLDL, LDL, and HDL of different particle sizes were associated with younger brain age and smaller BAG.</p></sec><sec id="acel70208-sec-0011"><label>3.2</label><title>Role of <styled-content style="fixed-case" toggle="no">
<italic toggle="no">APOE</italic>
</styled-content> &#949;4 Status</title><p>Among <italic toggle="yes">APOE</italic> &#949;4 non&#8208;carriers, 43 and 45 metabolites were associated with brain age and BAG, respectively. In contrast, only four metabolites were related to BAG among <italic toggle="yes">APOE</italic> &#949;4 carriers (Tables&#160;<xref rid="acel70208-supitem-0001" ref-type="supplementary-material">S9&#8211;S12</xref>).</p><p>Among <italic toggle="yes">APOE</italic> &#949;4 non&#8208;carriers, 8 identical and all absolute effect values &gt;&#8201;0.25 metabolites were related to both brain age and BAG (Figure&#160;<xref rid="acel70208-fig-0003" ref-type="fig">3a,c</xref>). Interestingly, 4 metabolites associated with BAG among <italic toggle="yes">APOE</italic> &#949;4 carriers (i.e., LA/FA, omega&#8208;6/FA, SFA/FA, and phospholipids to total lipids in L&#8208;HDL) were similarly identified among non&#8208;<italic toggle="yes">APOE</italic> &#949;4 carriers (Figure&#160;<xref rid="acel70208-fig-0003" ref-type="fig">3d</xref>). SFA/FA and phospholipids to total lipids in L&#8208;HDL had positive effects on brain aging, whereas LA/FA and omega&#8208;6/FA exerted negative effects. There were no statistical interactions of LA/FA, omega&#8208;6/FA, SFA/FA, and phospholipids to total lipids in L&#8208;HDL with <italic toggle="yes">APOE</italic> &#949;4 in relation to brain age or BAG in the multi&#8208;variable adjusted models (all <italic toggle="yes">p</italic>&#8208;interactions &gt;&#8201;0.05). However, we observed significant associations of DHA (<italic toggle="yes">p</italic>&#8201;=&#8201;0.031), DHA/FA (<italic toggle="yes">p</italic>&#8201;=&#8201;0.012), omega&#8208;3/FA (<italic toggle="yes">p</italic>&#8201;=&#8201;0.019), and omega&#8208;6/omega&#8208;3 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.023) with <italic toggle="yes">APOE</italic> &#949;4 on BAG before multiple testing correction, while these associations were not significant after FDR adjustment (Table&#160;<xref rid="acel70208-supitem-0001" ref-type="supplementary-material">S13</xref>).</p><fig position="float" fig-type="FIGURE" id="acel70208-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Association of metabolites with brain age and BAG stratified by <italic toggle="yes">APOE</italic> &#949;4 carrier status. (a/b) <italic toggle="yes">APOE</italic> &#949;4 non&#8208;carriers/carriers and brain age; (c/d) <italic toggle="yes">APOE</italic> &#949;4 non&#8208;carriers/carriers and BAG. All models adjusted for age, sex, education, race, socioeconomic status, body mass index, smoking status, alcohol drinking status, physical activity, social connection, hypertension, diabetes, heart disease, beta&#8208;blockers, calcium blockers, and lipid&#8208;lowering. FA, fatty acid; HDL, high&#8208;density lipoprotein; LA, linoleic acid; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid. * indicates no significant interaction effect of LA/FA, omega&#8208;6/FA, SFA/FA, and phospholipids to total lipids in L&#8208;HDL with <italic toggle="yes">APOE</italic> &#949;4 on brain age/BAG (<italic toggle="yes">P</italic>&#8208;interaction &gt;&#8201;0.05)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="ACEL-24-e70208-g003.jpg"/></fig></sec><sec id="acel70208-sec-0012"><label>3.3</label><title>Sensitivity Analysis</title><p>The associations of metabolites with brain age and BAG were not greatly altered when we repeated the analyses after (1) performing multiple imputations to account for missing values of covariates (including race, education, TDI, BMI, smoking status, alcohol drinking status, physical activity, and social connection; Tables&#160;<xref rid="acel70208-supitem-0001" ref-type="supplementary-material">S14</xref> and <xref rid="acel70208-supitem-0001" ref-type="supplementary-material">S15</xref>), (2) using brain age and BAG calculated from 8 other machine learning models (Table&#160;<xref rid="acel70208-supitem-0001" ref-type="supplementary-material">S16</xref>).</p></sec></sec><sec sec-type="discussion" id="acel70208-sec-0013"><label>4</label><title>Discussion</title><p>In this large neuroimaging study with multimodal MRI measures, we constructed a brain age prediction model based on LASSO regression and found that (1) 64 and 77 metabolites were associated with brain age and BAG respectively, including lipoprotein subclasses, fatty acids, glucose, inflammatory biomarkers, ketone bodies, and tyrosine; and (2) regardless of <italic toggle="yes">APOE</italic> &#949;4 carrier status, the significant relationship of fatty acids and lipoprotein subclasses with brain age remained.</p><sec id="acel70208-sec-0014"><label>4.1</label><title>Comparison With Previous Research and Interpretation of Our Findings</title><p>Previous studies have identified higher specific lipid components (such as phospholipids and cholesteryl esters) in S/M&#8208;HDL to be associated with neuroimaging signatures (white matter hyperintensities, mean diffusivity, higher mean diffusivity, and fractional anisotropy) (Harshfield and Markus&#160;<xref rid="acel70208-bib-0018" ref-type="bibr">2023</xref>; Sun et&#160;al.&#160;<xref rid="acel70208-bib-0045" ref-type="bibr">2023</xref>) and clinical endpoints (dementia and stroke) (de Leeuw et&#160;al.&#160;<xref rid="acel70208-bib-0011" ref-type="bibr">2021</xref>; Huang et&#160;al.&#160;<xref rid="acel70208-bib-0020" ref-type="bibr">2023</xref>; van der Lee et&#160;al.&#160;<xref rid="acel70208-bib-0049" ref-type="bibr">2018</xref>), which is consistent with our findings. However, these studies predominantly relied on unidimensional assessments of cerebral integrity, potentially overlooking the multidimensional nature of brain health. Current understanding of metabolomic correlates of brain age remains nascent, with only three prior studies systematically evaluating this relationship (Gordon et&#160;al.&#160;<xref rid="acel70208-bib-0014" ref-type="bibr">2024</xref>; Kim et&#160;al.&#160;<xref rid="acel70208-bib-0024" ref-type="bibr">2023</xref>). Among these, two research&#8208;derived brain age estimates solely from T1&#8208;weighted structural MRI, inherently limit their capacity to capture the multiscale aging process spanning microstructural and functional decline. Tian et&#160;al. used multimodal neuroimaging to estimate brain age, linking BAG to specific lipid and glucose metabolites. Our work builds on this by estimating brain age/BAG from multiple neuroimaging phenotypes across six MRI modalities and incorporating 249 plasma metabolites. We found that multiple lipids in S/M&#8208;HDL are associated with larger brain age and BAG. Additionally, this study identified cholesterol&#8208;like substances in VLDL, LDL, and HDL as a percentage of lipids that were likewise related to brain age and BAG. This phenomenon may be caused by differences in the function and ability of various lipoprotein subclasses to promote cholesterol&#8208;like efflux (Navab et&#160;al.&#160;<xref rid="acel70208-bib-0032" ref-type="bibr">2005</xref>; Rader and Hovingh&#160;<xref rid="acel70208-bib-0035" ref-type="bibr">2014</xref>).</p><p>The present study observed that higher MUFA, SFA, total FA, MUFA/FA, and SFA/FA as well as lower LA, n&#8208;6/FA, PUFA/FA, degree of unsaturation, and PUFA/MUFA are associated with higher brain age, consistent with previous studies on dementia risk and brain structure (e.g., mean diffusivity, white matter hyperintensities, and fractional anisotropy). While mechanistic pathways cannot be directly inferred from observational data, evidence from preclinical and clinical studies contextualizes these findings. PUFA modulates neurogenesis, neuroplasticity, and neurotransmitter metabolism to exert properties that reduce neurodegeneration and maintain cognitive function in aging (Daiello et&#160;al.&#160;<xref rid="acel70208-bib-0010" ref-type="bibr">2015</xref>). Conversely, elevated SFA levels may promote neuroinflammation through ceramide accumulation (Gupta et&#160;al.&#160;<xref rid="acel70208-bib-0017" ref-type="bibr">2012</xref>). In preclinical dementia studies, neuroinflammation leads to a reduction in inhibitory activity by impairing inhibitory GABAergic signaling (Crowley et&#160;al.&#160;<xref rid="acel70208-bib-0009" ref-type="bibr">2016</xref>), thereby triggering hyperexcitability (Maest&#250; et&#160;al.&#160;<xref rid="acel70208-bib-0027" ref-type="bibr">2021</xref>). Current research on the association of MUFA with brain health is limited and inconsistent. The majority of studies link higher MUFA based on dietary assessments to better cognitive performance and lower risk of dementia (Zhang et&#160;al.&#160;<xref rid="acel70208-bib-0051" ref-type="bibr">2020</xref>). However, some studies observe positive associations of MUFA in the metabolic profile with the risk of aging&#8208;related disease (Lian and Vardhanabhuti&#160;<xref rid="acel70208-bib-0025" ref-type="bibr">2024</xref>), which is in line with our finding that MUFA is linked to higher brain age/BAG. Notably, animal studies have found that MUFA disrupts insulin homeostasis via its toxic effects on <italic toggle="yes">&#946;</italic> cells (Pl&#246;tz et&#160;al.&#160;<xref rid="acel70208-bib-0033" ref-type="bibr">2017</xref>; Zhang et&#160;al.&#160;<xref rid="acel70208-bib-0052" ref-type="bibr">2005</xref>) and in turn is associated with brain aging (Chen et&#160;al.&#160;<xref rid="acel70208-bib-0006" ref-type="bibr">2022</xref>).</p><p>This study found an association between higher glucose levels and larger brain age and BAG. Substantial evidence suggests that higher glucose is strongly associated with abnormal brain functional connectivity, WMH, brain atrophy, and cortical thinning (Chen et&#160;al.&#160;<xref rid="acel70208-bib-0007" ref-type="bibr">2014</xref>; de Leeuw et&#160;al.&#160;<xref rid="acel70208-bib-0011" ref-type="bibr">2021</xref>; Qiang et&#160;al.&#160;<xref rid="acel70208-bib-0034" ref-type="bibr">2024</xref>; Wennberg et&#160;al.&#160;<xref rid="acel70208-bib-0050" ref-type="bibr">2016</xref>). Higher glucose accelerates the aging of the brain through several mechanisms, including glucose neurotoxicity (Sommerfield et&#160;al.&#160;<xref rid="acel70208-bib-0044" ref-type="bibr">2004</xref>), insulin resistance (Candeias et&#160;al.&#160;<xref rid="acel70208-bib-0005" ref-type="bibr">2012</xref>), inflammation (Schmidt et&#160;al.&#160;<xref rid="acel70208-bib-0039" ref-type="bibr">1999</xref>), and cardiovascular events (Kalmijn et&#160;al.&#160;<xref rid="acel70208-bib-0022" ref-type="bibr">2000</xref>). Additionally, the study identified a novel NMR&#8208;derived biomarker of systemic inflammation, namely glycoprotein acetyls (GlycA), which is associated with higher brain age and BAG. The association of GlycA with WMH and poorer cognitive performance is in line with our findings. Beyond glucose and inflammatory markers, ketone bodies exhibit significant associations with energy metabolism. Dysregulated energy metabolism is a modifier or even proximate cause of brain aging (Kapogiannis&#160;<xref rid="acel70208-bib-0023" ref-type="bibr">2015</xref>). Our findings that ketone bodies are associated with higher brain age are consistent with other research that links elevated ketone bodies to decreased hippocampal volume and an increased risk of dementia (de Leeuw et&#160;al.&#160;<xref rid="acel70208-bib-0011" ref-type="bibr">2021</xref>; Huang et&#160;al.&#160;<xref rid="acel70208-bib-0020" ref-type="bibr">2023</xref>). However, several studies have also found that ketone bodies are related to improved cognitive performance and a lower risk of dementia (Reger et&#160;al.&#160;<xref rid="acel70208-bib-0036" ref-type="bibr">2004</xref>; Shippy et&#160;al.&#160;<xref rid="acel70208-bib-0040" ref-type="bibr">2020</xref>). This apparent paradox may arise from context&#8208;dependent effects: ketone bodies are an effective alternative energy substrate for the brain under physiological conditions (e.g., fasting), which can strengthen mitochondrial function and reduce inflammatory mediators (Rusek et&#160;al.&#160;<xref rid="acel70208-bib-0038" ref-type="bibr">2019</xref>). Conversely, persistently elevated circulating ketone bodies in non&#8208;fasting states (e.g., insulin resistance) may indicate metabolic dysregulation, thereby contributing to neurovascular damage (Meneilly and Tessier&#160;<xref rid="acel70208-bib-0029" ref-type="bibr">2016</xref>). The role of ketone bodies in the mechanisms of brain aging is limited, and further studies are needed to clarify the molecular mechanisms involved.</p><p>Kim et&#160;al.&#160;(<xref rid="acel70208-bib-0024" ref-type="bibr">2023</xref>) reported significant associations of glucose and lipid metabolites with BAG derived from T1&#8208;weighted structural imaging information. Building on this, we developed a more comprehensive brain age model by integrating multimodal IDPs encompassing brain structure, function, and connectivity. While our model exhibits a higher MAE than that reported by Kim et&#160;al. the integration of multimodal information enhances our ability to gain deeper insights into the complexity of brain aging, thereby extending and advancing the findings of Kim et&#160;al.</p></sec><sec id="acel70208-sec-0015"><label>4.2</label><title>Role of <styled-content style="fixed-case" toggle="no">
<italic toggle="no">APOE</italic>
</styled-content> &#949;4</title><p>The role of <italic toggle="yes">APOE</italic> &#949;4 as a key genetic risk factor in brain age has been extensively studied. <italic toggle="yes">APOE</italic> &#949;4 has been associated with poor microstructure and functional networks in the brain (Malek&#8208;Ahmadi et&#160;al.&#160;<xref rid="acel70208-bib-0028" ref-type="bibr">2023</xref>; Turney et&#160;al.&#160;<xref rid="acel70208-bib-0047" ref-type="bibr">2020</xref>), and a higher risk of dementia (Graff&#8208;Radford et&#160;al.&#160;<xref rid="acel70208-bib-0015" ref-type="bibr">2021</xref>). The <italic toggle="yes">APOE</italic> &#949;4 allele also affects the level of metabolites in the body, including inflammation, oxidative stress, small molecules related to glucose metabolism, and lipid homeostasis (Ahmad et&#160;al.&#160;<xref rid="acel70208-bib-0001" ref-type="bibr">2024</xref>; Liu et&#160;al.&#160;<xref rid="acel70208-bib-0026" ref-type="bibr">2013</xref>; Reiman et&#160;al.&#160;<xref rid="acel70208-bib-0037" ref-type="bibr">2004</xref>). The higher brain age observed in <italic toggle="yes">APOE</italic> &#949;4 carriers (BAG: 0.48&#8201;&#177;&#8201;5.42 vs. 0.25&#8201;&#177;&#8201;5.10&#8201;years in non&#8208;carriers, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.005) likely reflects both amyloid&#8208;dependent and amyloid&#8208;independent pathways (Frick et&#160;al.&#160;<xref rid="acel70208-bib-0012" ref-type="bibr">2024</xref>). <italic toggle="yes">APOE</italic> &#949;4 disrupts astrocytic lipid metabolism and mitochondrial function, driving neuroinflammation and synaptic loss even in A<italic toggle="yes">&#946;</italic>&#8208;negative models (Bell et&#160;al.&#160;<xref rid="acel70208-bib-0003" ref-type="bibr">2012</xref>). For instance, <italic toggle="yes">APOE</italic> &#949;4 impairs cholesterol transport across the blood&#8211;brain barrier, exacerbating oxidative stress independent of the amyloid pathway (Montagne et&#160;al.&#160;<xref rid="acel70208-bib-0030" ref-type="bibr">2021</xref>). We found that fatty acid and lipoprotein subclasses were associated with brain health irrespective of <italic toggle="yes">APOE</italic> &#949;4 status, with no significant interaction between these metabolites and <italic toggle="yes">APOE</italic> on brain age. This discrepancy may reflect a dual mechanism of gene&#8208;metabolism interaction. Among <italic toggle="yes">APOE</italic> &#949;4 carriers, the dominant role of <italic toggle="yes">APOE</italic> &#949;4 driven pathological cascades (e.g., amyloid aggregation) overshadowed metabolic contributions in carriers. Conversely, in non&#8208;carriers, peripheral metabolic dysregulation (e.g., lipid proportion imbalance) may directly exacerbate neuroinflammation and mitochondrial dysfunction, thereby accelerating brain aging. These findings underscore the need for genotype&#8208;stratified interventions targeting metabolic pathways in brain aging.</p></sec><sec id="acel70208-sec-0016"><label>4.3</label><title>Strength and Limitations</title><p>Strengths of this study include exploring for the first time the associations of various metabolites with predicted brain age using data from multiple imaging modalities in a large&#8208;scale community&#8208;based population with a comprehensive data collection procedure. Nevertheless, some limitations should be acknowledged. Firstly, participants in the UK Biobank cohort are healthier than the general population (Fry et&#160;al.&#160;<xref rid="acel70208-bib-0013" ref-type="bibr">2017</xref>). Additionally, our study's analytical sample consisted of participants who underwent brain MRI scans and were free of chronic brain diseases, which is a relatively healthier subset of the overall UK Biobank population. This may result in an overestimation or underestimation of the extent of the associations between certain metabolites and brain health. Second, the approach used in this study to calculate brain age vis multi&#8208;modal IDPs information may reduce model performance compared to methods relying on intuitive imaging information. Third, plasma from the UK Biobank was extracted in a non&#8208;fasting state but an average of 4&#8201;h from the last meal (Julkunen et&#160;al.&#160;<xref rid="acel70208-bib-0021" ref-type="bibr">2023</xref>), suggesting minimal bias in our findings. However, future studies with fasting samples could further validate our results. Fourth, while the metabolomics platform captured a wide range of lipids and lipid subspecies, it provided limited coverage of low&#8208;molecular&#8208;weight metabolites. Fifth, although our findings suggest the potential effects of metabolites on brain aging, causality cannot be inferred due to the observational design. Future work using repeat brain imaging data now available in the UK Biobank will allow longitudinal assessment of brain aging trajectories and their metabolic correlates. Moreover, while our study provides important associations, we did not perform Mendelian randomization (MR) analyses to examine potential causal links. Although we acknowledge that MR is a powerful tool for causal inference, the current availability of large&#8208;scale GWAS summary statistics for brain age phenotypes is limited. Future studies leveraging well&#8208;powered GWAS data for both brain aging and metabolomic traits are needed to establish causality more robustly. Finally, caution must be taken when generalizing our findings to other ethnic groups because the majority of participants in the UK Biobank were white. Emerging evidence indicates cardiometabolic risks (e.g., obesity, hypertension) disproportionately accelerate brain aging in Global South populations due to compounded health disparities. Future multi&#8208;ethnic studies should validate findings and optimize precision prevention strategies.</p></sec></sec><sec sec-type="conclusions" id="acel70208-sec-0017"><label>5</label><title>Conclusion</title><p>In conclusion, we employed a novel study method to identify multiple metabolomic biomarkers&#8212;namely lipoprotein subclasses, fatty acids, glucose, inflammatory biomarkers, ketone bodies, and amino acids&#8212;that were significantly associated with brain age. Furthermore, we observed that the association of fatty acids and lipoprotein subclasses with brain age was consistent across <italic toggle="yes">APOE</italic> &#949;4 carriers' status. The metabolites identified in this study may complement future hypotheses explaining the intricate relationships of lipid homeostasis and energy metabolism with brain health.</p></sec><sec id="acel70208-sec-0018"><title>Author Contributions</title><p>
<bold>Yang Li:</bold> formal analysis, visualization, writing &#8211; original draft. <bold>Jiao Wang:</bold> conceptualization, data curation, writing &#8211; review and editing, funding acquisition. <bold>Yuyang Miao:</bold> writing &#8211; review and editing. <bold>Michelle M. Dunk:</bold> writing &#8211; review and editing. <bold>Yan Liu:</bold> writing &#8211; review and editing. <bold>Zhongze Fang:</bold> writing &#8211; review and editing, funding acquisition. <bold>Qiang Zhang:</bold> writing &#8211; review and editing. <bold>Weili Xu:</bold> conceptualization, funding acquisition. All authors reviewed the manuscript.</p></sec><sec sec-type="COI-statement" id="acel70208-sec-0020"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="acel70208-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Table&#160;S1:</bold> Self&#8208;reported health variable codes used for exclusion criteria on initial population.</p><p>
<bold>Table&#160;S2:</bold> Missing number for brain imaging&#8208;derived phenotypes.</p><p>
<bold>Table&#160;S3:</bold> Coefficients for 285 IDPs that significantly contribute to brain age estimation in the LASSO regression without feature selection.</p><p>
<bold>Table&#160;S4:</bold> Hyperparameter spaces of 9 models in Bayesian optimization.</p><p>
<bold>Table&#160;S5:</bold> The chosen hyperparameters of 9 models.</p><p>
<bold>Table&#160;S6:</bold> Model evaluation of 9 models in the validation set and testing set.</p><p>
<bold>Table&#160;S7:</bold>
<italic toggle="yes">&#946;</italic> coefficients and 95% confidence intervals (CIs) for the association between metabolites and brain age: results from linear regression models.</p><p>
<bold>Table&#160;S8:</bold>
<italic toggle="yes">&#946;</italic> coefficients and 95% confidence intervals (CIs) for the association between metabolites and brain age gap (BAG): results from linear regression models.</p><p>
<bold>Table&#160;S9:</bold>
<italic toggle="yes">&#946;</italic> coefficients and 95% confidence intervals (CIs) for the association between metabolites and brain age among non&#8208;<italic toggle="yes">APOE</italic> &#949;4 carriers: results from linear regression models.</p><p>
<bold>Table&#160;S10:</bold>
<italic toggle="yes">&#946;</italic> coefficients and 95% confidence intervals (CIs) for the association between metabolites and brain age gap (BAG) among non&#8208;<italic toggle="yes">APOE</italic> &#949;4 carriers: results from linear regression models.</p><p>
<bold>Table&#160;S11:</bold>
<italic toggle="yes">&#946;</italic> coefficients and 95% confidence intervals (CIs) for the association between metabolites and brain age among <italic toggle="yes">APOE</italic> &#949;4 carriers: results from linear regression models.</p><p>
<bold>Table&#160;S12:</bold>
<italic toggle="yes">&#946;</italic> coefficients and 95% confidence intervals (CIs) for the association between metabolites and brain age gap (BAG) among <italic toggle="yes">APOE</italic> &#949;4 carriers: results from linear regression models.</p><p>
<bold>Table&#160;S13:</bold>. The interaction effect of metabolites with <italic toggle="yes">APOE</italic> &#949;4 status on brain age gap (BAG).</p><p>
<bold>Table&#160;S14:</bold>
<italic toggle="yes">&#946;</italic> coefficients and 95% confidence intervals (CIs) for the association between metabolites and brain age after multiple imputation of covariates: results from linear regression models.</p><p>
<bold>Table&#160;S15:</bold>
<italic toggle="yes">&#946;</italic> coefficients and 95% confidence intervals (CIs) for the association between metabolites and brain age gap (BAG) after multiple imputation of covariates: results from linear regression models.</p><p>
<bold>Table&#160;S16:</bold>
<italic toggle="yes">&#946;</italic> coefficients and 95% confidence intervals (CIs) for the association between metabolites and brain age gap (BAG) within eight other candidate machine learning models: results from linear regression models.</p><p>
<bold>Figure S1:</bold> 249 individual metabolites in relation to (a) brain age and (b) brain age gap.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ACEL-24-e70208-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="acel70208-sec-0019"><title>Acknowledgements</title><p>This research has been conducted using the UK Biobank Resource under Application Number 67048, and this work uses data provided by patients and collected by the NHS as part of their care and support. The authors thank all participants of the UK Biobank study who have dedicated their valuable time to this project, as well as the UK Biobank team for collecting, preparing, and providing data used in this work.</p></ack><sec sec-type="data-availability" id="acel70208-sec-0022"><title>Data Availability Statement</title><p>Data from this study are available through the UK Biobank (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ukbiobank.ac.uk/" ext-link-type="uri" specific-use="software is-supplemented-by">https://www.ukbiobank.ac.uk/</ext-link>).</p></sec><ref-list content-type="cited-references" id="acel70208-bibl-0001"><title>References</title><ref id="acel70208-bib-0001"><mixed-citation publication-type="journal" id="acel70208-cit-0001"><string-name name-style="western"><surname>Ahmad</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Orellana</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Association of Oxidative Stress and Inflammatory Metabolites With Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment</article-title>.&#8221; <source>Alzheimer's Research &amp; Therapy</source><volume>16</volume>, no. <issue>1</issue>: <elocation-id>171</elocation-id>. <pub-id pub-id-type="doi">10.1186/s13195-024-01542-4</pub-id>.</mixed-citation></ref><ref id="acel70208-bib-0002"><mixed-citation publication-type="journal" id="acel70208-cit-0002"><string-name name-style="western"><surname>Baecker</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Garcia&#8208;Dias</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Vieira</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Scarpazza</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Mechelli</surname></string-name>. <year>2021</year>. &#8220;<article-title>Machine Learning for Brain Age Prediction: Introduction to Methods and Clinical Applications</article-title>.&#8221; <source>eBioMedicine</source><volume>72</volume>: <elocation-id>103600</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2021.103600</pub-id>.<pub-id pub-id-type="pmid">34614461</pub-id><pub-id pub-id-type="pmcid">PMC8498228</pub-id></mixed-citation></ref><ref id="acel70208-bib-0003"><mixed-citation publication-type="journal" id="acel70208-cit-0003"><string-name name-style="western"><surname>Bell</surname>, <given-names>R. D.</given-names></string-name>, <string-name name-style="western"><given-names>E. A.</given-names><surname>Winkler</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Singh</surname></string-name>, et&#160;al. <year>2012</year>. &#8220;<article-title>Apolipoprotein E Controls Cerebrovascular Integrity via Cyclophilin A</article-title>.&#8221; <source>Nature</source><volume>485</volume>, no. <issue>7399</issue>: <fpage>512</fpage>&#8211;<lpage>516</lpage>. <pub-id pub-id-type="doi">10.1038/nature11087</pub-id>.<pub-id pub-id-type="pmid">22622580</pub-id><pub-id pub-id-type="pmcid">PMC4047116</pub-id></mixed-citation></ref><ref id="acel70208-bib-0004"><mixed-citation publication-type="journal" id="acel70208-cit-0004"><string-name name-style="western"><surname>Bzdok</surname>, <given-names>D.</given-names></string-name><year>2017</year>. &#8220;<article-title>Classical Statistics and Statistical Learning in Imaging Neuroscience</article-title>.&#8221; <source>Frontiers in Neuroscience</source><volume>11</volume>: <elocation-id>543</elocation-id>. <pub-id pub-id-type="doi">10.3389/fnins.2017.00543</pub-id>.<pub-id pub-id-type="pmid">29056896</pub-id><pub-id pub-id-type="pmcid">PMC5635056</pub-id></mixed-citation></ref><ref id="acel70208-bib-0005"><mixed-citation publication-type="journal" id="acel70208-cit-0005"><string-name name-style="western"><surname>Candeias</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><given-names>A. I.</given-names><surname>Duarte</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Carvalho</surname></string-name>, et&#160;al. <year>2012</year>. &#8220;<article-title>The Impairment of Insulin Signaling in Alzheimer's Disease</article-title>.&#8221; <source>IUBMB Life</source><volume>64</volume>, no. <issue>12</issue>: <fpage>951</fpage>&#8211;<lpage>957</lpage>. <pub-id pub-id-type="doi">10.1002/iub.1098</pub-id>.<pub-id pub-id-type="pmid">23129399</pub-id></mixed-citation></ref><ref id="acel70208-bib-0006"><mixed-citation publication-type="journal" id="acel70208-cit-0006"><string-name name-style="western"><surname>Chen</surname>, <given-names>W.</given-names></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Cai</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Hoover</surname></string-name>, and <string-name name-style="western"><given-names>C. R.</given-names><surname>Kahn</surname></string-name>. <year>2022</year>. &#8220;<article-title>Insulin Action in the Brain: Cell Types, Circuits, and Diseases</article-title>.&#8221; <source>Trends in Neurosciences</source><volume>45</volume>, no. <issue>5</issue>: <fpage>384</fpage>&#8211;<lpage>400</lpage>. <pub-id pub-id-type="doi">10.1016/j.tins.2022.03.001</pub-id>.<pub-id pub-id-type="pmid">35361499</pub-id><pub-id pub-id-type="pmcid">PMC9035105</pub-id></mixed-citation></ref><ref id="acel70208-bib-0007"><mixed-citation publication-type="journal" id="acel70208-cit-0007"><string-name name-style="western"><surname>Chen</surname>, <given-names>Y. C.</given-names></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Jiao</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Cui</surname></string-name>, et&#160;al. <year>2014</year>. &#8220;<article-title>Aberrant Brain Functional Connectivity Related to Insulin Resistance in Type 2 Diabetes: A Resting&#8208;State fMRI Study</article-title>.&#8221; <source>Diabetes Care</source><volume>37</volume>, no. <issue>6</issue>: <fpage>1689</fpage>&#8211;<lpage>1696</lpage>. <pub-id pub-id-type="doi">10.2337/dc13-2127</pub-id>.<pub-id pub-id-type="pmid">24658392</pub-id></mixed-citation></ref><ref id="acel70208-bib-0008"><mixed-citation publication-type="journal" id="acel70208-cit-0008"><string-name name-style="western"><surname>Cole</surname>, <given-names>J. H.</given-names></string-name><year>2020</year>. &#8220;<article-title>Multimodality Neuroimaging Brain&#8208;Age in UK Biobank: Relationship to Biomedical, Lifestyle, and Cognitive Factors</article-title>.&#8221; <source>Neurobiology of Aging</source><volume>92</volume>: <fpage>34</fpage>&#8211;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2020.03.014</pub-id>.<pub-id pub-id-type="pmid">32380363</pub-id><pub-id pub-id-type="pmcid">PMC7280786</pub-id></mixed-citation></ref><ref id="acel70208-bib-0009"><mixed-citation publication-type="journal" id="acel70208-cit-0009"><string-name name-style="western"><surname>Crowley</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><given-names>J. F.</given-names><surname>Cryan</surname></string-name>, <string-name name-style="western"><given-names>E. J.</given-names><surname>Downer</surname></string-name>, and <string-name name-style="western"><given-names>O. F.</given-names><surname>O'Leary</surname></string-name>. <year>2016</year>. &#8220;<article-title>Inhibiting Neuroinflammation: The Role and Therapeutic Potential of GABA in Neuro&#8208;Immune Interactions</article-title>.&#8221; <source>Brain, Behavior, and Immunity</source><volume>54</volume>: <fpage>260</fpage>&#8211;<lpage>277</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2016.02.001</pub-id>.<pub-id pub-id-type="pmid">26851553</pub-id></mixed-citation></ref><ref id="acel70208-bib-0010"><mixed-citation publication-type="journal" id="acel70208-cit-0010"><string-name name-style="western"><surname>Daiello</surname>, <given-names>L. A.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Gongvatana</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Dunsiger</surname></string-name>, <string-name name-style="western"><given-names>R. A.</given-names><surname>Cohen</surname></string-name>, and <string-name name-style="western"><given-names>B. R.</given-names><surname>Ott</surname></string-name>. <year>2015</year>. &#8220;<article-title>Association of Fish Oil Supplement Use With Preservation of Brain Volume and Cognitive Function</article-title>.&#8221; <source>Alzheimer's &amp; Dementia</source><volume>11</volume>, no. <issue>2</issue>: <fpage>226</fpage>&#8211;<lpage>235</lpage>. <pub-id pub-id-type="doi">10.1016/j.jalz.2014.02.005</pub-id>.</mixed-citation></ref><ref id="acel70208-bib-0011"><mixed-citation publication-type="journal" id="acel70208-cit-0011"><string-name name-style="western"><surname>de Leeuw</surname>, <given-names>F. A.</given-names></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Karamuji&#263;&#8208;&#268;omi&#263;</surname></string-name>, <string-name name-style="western"><given-names>B. M.</given-names><surname>Tijms</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>Circulating Metabolites Are Associated With Brain Atrophy and White Matter Hyperintensities</article-title>.&#8221; <source>Alzheimer's &amp; Dementia</source><volume>17</volume>, no. <issue>2</issue>: <fpage>205</fpage>&#8211;<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1002/alz.12180</pub-id>.</mixed-citation></ref><ref id="acel70208-bib-0012"><mixed-citation publication-type="journal" id="acel70208-cit-0012"><string-name name-style="western"><surname>Frick</surname>, <given-names>E. A.</given-names></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Emilsson</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Jonmundsson</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Serum Proteomics Reveal APOE&#8208;&#949;4&#8208;Dependent and APOE&#8208;&#949;4&#8208;Independent Protein Signatures in Alzheimer's Disease</article-title>.&#8221; <source>Nature Aging</source><volume>4</volume>, no. <issue>10</issue>: <fpage>1446</fpage>&#8211;<lpage>1464</lpage>. <pub-id pub-id-type="doi">10.1038/s43587-024-00693-1</pub-id>.<pub-id pub-id-type="pmid">39169269</pub-id><pub-id pub-id-type="pmcid">PMC11485263</pub-id></mixed-citation></ref><ref id="acel70208-bib-0013"><mixed-citation publication-type="journal" id="acel70208-cit-0013"><string-name name-style="western"><surname>Fry</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>T. J.</given-names><surname>Littlejohns</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Sudlow</surname></string-name>, et&#160;al. <year>2017</year>. &#8220;<article-title>Comparison of Sociodemographic and Health&#8208;Related Characteristics of UK Biobank Participants With Those of the General Population</article-title>.&#8221; <source>American Journal of Epidemiology</source><volume>186</volume>, no. <issue>9</issue>: <fpage>1026</fpage>&#8211;<lpage>1034</lpage>. <pub-id pub-id-type="doi">10.1093/aje/kwx246</pub-id>.<pub-id pub-id-type="pmid">28641372</pub-id><pub-id pub-id-type="pmcid">PMC5860371</pub-id></mixed-citation></ref><ref id="acel70208-bib-0014"><mixed-citation publication-type="journal" id="acel70208-cit-0014"><string-name name-style="western"><surname>Gordon</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>J. S.</given-names><surname>Lee</surname></string-name>, <string-name name-style="western"><given-names>T. M.</given-names><surname>Scott</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Metabolites and MRI&#8208;Derived Markers of AD/ADRD Risk in a Puerto Rican Cohort</article-title>.&#8221; <source>Research Square</source><volume>13</volume>: <elocation-id>3941791/v1</elocation-id>. <pub-id pub-id-type="doi">10.21203/rs.3.rs-3941791/v1</pub-id>.</mixed-citation></ref><ref id="acel70208-bib-0015"><mixed-citation publication-type="journal" id="acel70208-cit-0015"><string-name name-style="western"><surname>Graff&#8208;Radford</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><given-names>K. X. X.</given-names><surname>Yong</surname></string-name>, <string-name name-style="western"><given-names>L. G.</given-names><surname>Apostolova</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>New Insights Into Atypical Alzheimer's Disease in the Era of Biomarkers</article-title>.&#8221; <source>Lancet Neurology</source><volume>20</volume>, no. <issue>3</issue>: <fpage>222</fpage>&#8211;<lpage>234</lpage>. <pub-id pub-id-type="doi">10.1016/s1474-4422(20)30440-3</pub-id>.<pub-id pub-id-type="pmid">33609479</pub-id><pub-id pub-id-type="pmcid">PMC8056394</pub-id></mixed-citation></ref><ref id="acel70208-bib-0016"><mixed-citation publication-type="journal" id="acel70208-cit-0016"><string-name name-style="western"><surname>Griffin</surname>, <given-names>J. L.</given-names></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Atherton</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Shockcor</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Atzori</surname></string-name>. <year>2011</year>. &#8220;<article-title>Metabolomics as a Tool for Cardiac Research</article-title>.&#8221; <source>Nature Reviews. Cardiology</source><volume>8</volume>, no. <issue>11</issue>: <fpage>630</fpage>&#8211;<lpage>643</lpage>. <pub-id pub-id-type="doi">10.1038/nrcardio.2011.138</pub-id>.<pub-id pub-id-type="pmid">21931361</pub-id></mixed-citation></ref><ref id="acel70208-bib-0017"><mixed-citation publication-type="journal" id="acel70208-cit-0017"><string-name name-style="western"><surname>Gupta</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>A. G.</given-names><surname>Knight</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Gupta</surname></string-name>, <string-name name-style="western"><given-names>J. N.</given-names><surname>Keller</surname></string-name>, and <string-name name-style="western"><given-names>A. J.</given-names><surname>Bruce&#8208;Keller</surname></string-name>. <year>2012</year>. &#8220;<article-title>Saturated Long&#8208;Chain Fatty Acids Activate Inflammatory Signaling in Astrocytes</article-title>.&#8221; <source>Journal of Neurochemistry</source><volume>120</volume>, no. <issue>6</issue>: <fpage>1060</fpage>&#8211;<lpage>1071</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2012.07660.x</pub-id>.<pub-id pub-id-type="pmid">22248073</pub-id><pub-id pub-id-type="pmcid">PMC3296820</pub-id></mixed-citation></ref><ref id="acel70208-bib-0018"><mixed-citation publication-type="journal" id="acel70208-cit-0018"><string-name name-style="western"><surname>Harshfield</surname>, <given-names>E. L.</given-names></string-name>, and <string-name name-style="western"><given-names>H. S.</given-names><surname>Markus</surname></string-name>. <year>2023</year>. &#8220;<article-title>Association of Baseline Metabolomic Profiles With Incident Stroke and Dementia and With Imaging Markers of Cerebral Small Vessel Disease</article-title>.&#8221; <source>Neurology</source><volume>101</volume>, no. <issue>5</issue>: <fpage>e489</fpage>&#8211;<lpage>e501</lpage>. <pub-id pub-id-type="doi">10.1212/wnl.0000000000207458</pub-id>.<pub-id pub-id-type="pmid">37290969</pub-id><pub-id pub-id-type="pmcid">PMC10401678</pub-id></mixed-citation></ref><ref id="acel70208-bib-0019"><mixed-citation publication-type="journal" id="acel70208-cit-0019"><string-name name-style="western"><surname>Hasin</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Seldin</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Lusis</surname></string-name>. <year>2017</year>. &#8220;<article-title>Multi&#8208;Omics Approaches to Disease</article-title>.&#8221; <source>Genome Biology</source><volume>18</volume>, no. <issue>1</issue>: <fpage>83</fpage>. <pub-id pub-id-type="doi">10.1186/s13059-017-1215-1</pub-id>.<pub-id pub-id-type="pmid">28476144</pub-id><pub-id pub-id-type="pmcid">PMC5418815</pub-id></mixed-citation></ref><ref id="acel70208-bib-0020"><mixed-citation publication-type="journal" id="acel70208-cit-0020"><string-name name-style="western"><surname>Huang</surname>, <given-names>S. Y.</given-names></string-name>, <string-name name-style="western"><given-names>Y. R.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Yang</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>Circulating Metabolites and Risk of Incident Dementia: A Prospective Cohort Study</article-title>.&#8221; <source>Journal of Neurochemistry</source><volume>167</volume>, no. <issue>5</issue>: <fpage>668</fpage>&#8211;<lpage>679</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.15997</pub-id>.<pub-id pub-id-type="pmid">37908051</pub-id></mixed-citation></ref><ref id="acel70208-bib-0021"><mixed-citation publication-type="journal" id="acel70208-cit-0021"><string-name name-style="western"><surname>Julkunen</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Cicho&#324;ska</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Tiainen</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>Atlas of Plasma NMR Biomarkers for Health and Disease in 118,461 Individuals From the UK Biobank</article-title>.&#8221; <source>Nature Communications</source><volume>14</volume>, no. <issue>1</issue>: <elocation-id>604</elocation-id>. <pub-id pub-id-type="doi">10.1038/s41467-023-36231-7</pub-id>.</mixed-citation></ref><ref id="acel70208-bib-0022"><mixed-citation publication-type="journal" id="acel70208-cit-0022"><string-name name-style="western"><surname>Kalmijn</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Foley</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>White</surname></string-name>, et&#160;al. <year>2000</year>. &#8220;<article-title>Metabolic Cardiovascular Syndrome and Risk of Dementia in Japanese&#8208;American Elderly Men. The Honolulu&#8208;Asia Aging Study</article-title>.&#8221; <source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>20</volume>, no. <issue>10</issue>: <fpage>2255</fpage>&#8211;<lpage>2260</lpage>. <pub-id pub-id-type="doi">10.1161/01.atv.20.10.2255</pub-id>.<pub-id pub-id-type="pmid">11031212</pub-id></mixed-citation></ref><ref id="acel70208-bib-0023"><mixed-citation publication-type="journal" id="acel70208-cit-0023"><string-name name-style="western"><surname>Kapogiannis</surname>, <given-names>D.</given-names></string-name><year>2015</year>. &#8220;<article-title>Energy Metabolism and the Brain: A Bidirectional Relationship</article-title>.&#8221; <source>Ageing Research Reviews</source><volume>20</volume>: <fpage>35</fpage>&#8211;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.arr.2015.02.002</pub-id>.<pub-id pub-id-type="pmid">25728594</pub-id><pub-id pub-id-type="pmcid">PMC5456290</pub-id></mixed-citation></ref><ref id="acel70208-bib-0024"><mixed-citation publication-type="journal" id="acel70208-cit-0024"><string-name name-style="western"><surname>Kim</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Lee</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Nam</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Lee</surname></string-name>. <year>2023</year>. &#8220;<article-title>Investigation of Genetic Variants and Causal Biomarkers Associated With Brain Aging</article-title>.&#8221; <source>Scientific Reports</source><volume>13</volume>, no. <issue>1</issue>: <fpage>1526</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-023-27903-x</pub-id>.<pub-id pub-id-type="pmid">36707530</pub-id><pub-id pub-id-type="pmcid">PMC9883521</pub-id></mixed-citation></ref><ref id="acel70208-bib-0025"><mixed-citation publication-type="journal" id="acel70208-cit-0025"><string-name name-style="western"><surname>Lian</surname>, <given-names>J.</given-names></string-name>, and <string-name name-style="western"><given-names>V.</given-names><surname>Vardhanabhuti</surname></string-name>. <year>2024</year>. &#8220;<article-title>Metabolic Biomarkers Using Nuclear Magnetic Resonance Metabolomics Assay for the Prediction of Aging&#8208;Related Disease Risk and Mortality: A Prospective, Longitudinal, Observational, Cohort Study Based on the UK Biobank</article-title>.&#8221; <source>Geroscience</source><volume>46</volume>, no. <issue>2</issue>: <fpage>1515</fpage>&#8211;<lpage>1526</lpage>. <pub-id pub-id-type="doi">10.1007/s11357-023-00918-y</pub-id>.<pub-id pub-id-type="pmid">37648937</pub-id><pub-id pub-id-type="pmcid">PMC10828466</pub-id></mixed-citation></ref><ref id="acel70208-bib-0026"><mixed-citation publication-type="journal" id="acel70208-cit-0026"><string-name name-style="western"><surname>Liu</surname>, <given-names>C. C.</given-names></string-name>, <string-name name-style="western"><given-names>C. C.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Kanekiyo</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Xu</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Bu</surname></string-name>. <year>2013</year>. &#8220;<article-title>Apolipoprotein E and Alzheimer Disease: Risk, Mechanisms and Therapy</article-title>.&#8221; <source>Nature Reviews. Neurology</source><volume>9</volume>, no. <issue>2</issue>: <fpage>106</fpage>&#8211;<lpage>118</lpage>. <pub-id pub-id-type="doi">10.1038/nrneurol.2012.263</pub-id>.<pub-id pub-id-type="pmid">23296339</pub-id><pub-id pub-id-type="pmcid">PMC3726719</pub-id></mixed-citation></ref><ref id="acel70208-bib-0027"><mixed-citation publication-type="journal" id="acel70208-cit-0027"><string-name name-style="western"><surname>Maest&#250;</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>de Haan</surname></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Busche</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>DeFelipe</surname></string-name>. <year>2021</year>. &#8220;<article-title>Neuronal Excitation/Inhibition Imbalance: Core Element of a Translational Perspective on Alzheimer Pathophysiology</article-title>.&#8221; <source>Ageing Research Reviews</source><volume>69</volume>: <elocation-id>101372</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.arr.2021.101372</pub-id>.<pub-id pub-id-type="pmid">34029743</pub-id></mixed-citation></ref><ref id="acel70208-bib-0028"><mixed-citation publication-type="journal" id="acel70208-cit-0028"><string-name name-style="western"><surname>Malek&#8208;Ahmadi</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Su</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Ghisays</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>Plasma NfL Is Associated With the APOE &#949;4 Allele, Brain Imaging Measurements of Neurodegeneration, and Lower Recall Memory Scores in Cognitively Unimpaired Late&#8208;Middle&#8208;Aged and Older Adults</article-title>.&#8221; <source>Alzheimer's Research &amp; Therapy</source><volume>15</volume>, no. <issue>1</issue>: <elocation-id>74</elocation-id>. <pub-id pub-id-type="doi">10.1186/s13195-023-01221-w</pub-id>.</mixed-citation></ref><ref id="acel70208-bib-0029"><mixed-citation publication-type="journal" id="acel70208-cit-0029"><string-name name-style="western"><surname>Meneilly</surname>, <given-names>G. S.</given-names></string-name>, and <string-name name-style="western"><given-names>D. M.</given-names><surname>Tessier</surname></string-name>. <year>2016</year>. &#8220;<article-title>Diabetes, Dementia and Hypoglycemia</article-title>.&#8221; <source>Canadian Journal of Diabetes</source><volume>40</volume>, no. <issue>1</issue>: <fpage>73</fpage>&#8211;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcjd.2015.09.006</pub-id>.<pub-id pub-id-type="pmid">26778684</pub-id></mixed-citation></ref><ref id="acel70208-bib-0030"><mixed-citation publication-type="journal" id="acel70208-cit-0030"><string-name name-style="western"><surname>Montagne</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>A. M.</given-names><surname>Nikolakopoulou</surname></string-name>, <string-name name-style="western"><given-names>M. T.</given-names><surname>Huuskonen</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>APOE4 Accelerates Advanced&#8208;Stage Vascular and Neurodegenerative Disorder in Old Alzheimer's Mice via Cyclophilin A Independently of Amyloid&#8208;&#946;</article-title>.&#8221; <source>Nature Aging</source><volume>1</volume>, no. <issue>6</issue>: <fpage>506</fpage>&#8211;<lpage>520</lpage>. <pub-id pub-id-type="doi">10.1038/s43587-021-00073-z</pub-id>.<pub-id pub-id-type="pmid">35291561</pub-id><pub-id pub-id-type="pmcid">PMC8920485</pub-id></mixed-citation></ref><ref id="acel70208-bib-0031"><mixed-citation publication-type="journal" id="acel70208-cit-0031"><string-name name-style="western"><surname>Nakamura</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Kawarabayashi</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Ueda</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>Plasma ApoE4 Levels Are Lower Than ApoE2 and ApoE3 Levels, and not Associated With Plasma A&#946;40/42 Ratio as a Biomarker of Amyloid&#8208;&#946; Amyloidosis in Alzheimer's Disease</article-title>.&#8221; <source>Journal of Alzheimer's Disease</source><volume>93</volume>, no. <issue>1</issue>: <fpage>333</fpage>&#8211;<lpage>348</lpage>. <pub-id pub-id-type="doi">10.3233/jad-220996</pub-id>.</mixed-citation></ref><ref id="acel70208-bib-0032"><mixed-citation publication-type="journal" id="acel70208-cit-0032"><string-name name-style="western"><surname>Navab</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>G. M.</given-names><surname>Ananthramaiah</surname></string-name>, <string-name name-style="western"><given-names>S. T.</given-names><surname>Reddy</surname></string-name>, et&#160;al. <year>2005</year>. &#8220;<article-title>The Double Jeopardy of HDL</article-title>.&#8221; <source>Annals of Medicine</source><volume>37</volume>, no. <issue>3</issue>: <fpage>173</fpage>&#8211;<lpage>178</lpage>. <pub-id pub-id-type="doi">10.1080/07853890510007322</pub-id>.<pub-id pub-id-type="pmid">16019715</pub-id></mixed-citation></ref><ref id="acel70208-bib-0033"><mixed-citation publication-type="journal" id="acel70208-cit-0033"><string-name name-style="western"><surname>Pl&#246;tz</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Kr&#252;mmel</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Laporte</surname></string-name>, et&#160;al. <year>2017</year>. &#8220;<article-title>The Monounsaturated Fatty Acid Oleate Is the Major Physiological Toxic Free Fatty Acid for Human Beta Cells</article-title>.&#8221; <source>Nutrition &amp; Diabetes</source><volume>7</volume>, no. <issue>12</issue>: <elocation-id>305</elocation-id>. <pub-id pub-id-type="doi">10.1038/s41387-017-0005-x</pub-id>.<pub-id pub-id-type="pmid">29269872</pub-id><pub-id pub-id-type="pmcid">PMC5865546</pub-id></mixed-citation></ref><ref id="acel70208-bib-0034"><mixed-citation publication-type="journal" id="acel70208-cit-0034"><string-name name-style="western"><surname>Qiang</surname>, <given-names>Y. X.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>You</surname></string-name>, <string-name name-style="western"><given-names>X. Y.</given-names><surname>He</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Plasma Metabolic Profiles Predict Future Dementia and Dementia Subtypes: A Prospective Analysis of 274,160 Participants</article-title>.&#8221; <source>Alzheimer's Research &amp; Therapy</source><volume>16</volume>, no. <issue>1</issue>: <fpage>16</fpage>. <pub-id pub-id-type="doi">10.1186/s13195-023-01379-3</pub-id>.</mixed-citation></ref><ref id="acel70208-bib-0035"><mixed-citation publication-type="journal" id="acel70208-cit-0035"><string-name name-style="western"><surname>Rader</surname>, <given-names>D. J.</given-names></string-name>, and <string-name name-style="western"><given-names>G. K.</given-names><surname>Hovingh</surname></string-name>. <year>2014</year>. &#8220;<article-title>HDL and Cardiovascular Disease</article-title>.&#8221; <source>Lancet</source><volume>384</volume>, no. <issue>9943</issue>: <fpage>618</fpage>&#8211;<lpage>625</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(14)61217-4</pub-id>.<pub-id pub-id-type="pmid">25131981</pub-id></mixed-citation></ref><ref id="acel70208-bib-0036"><mixed-citation publication-type="journal" id="acel70208-cit-0036"><string-name name-style="western"><surname>Reger</surname>, <given-names>M. A.</given-names></string-name>, <string-name name-style="western"><given-names>S. T.</given-names><surname>Henderson</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Hale</surname></string-name>, et&#160;al. <year>2004</year>. &#8220;<article-title>Effects of Beta&#8208;Hydroxybutyrate on Cognition in Memory&#8208;Impaired Adults</article-title>.&#8221; <source>Neurobiology of Aging</source><volume>25</volume>, no. <issue>3</issue>: <fpage>311</fpage>&#8211;<lpage>314</lpage>. <pub-id pub-id-type="doi">10.1016/s0197-4580(03)00087-3</pub-id>.<pub-id pub-id-type="pmid">15123336</pub-id></mixed-citation></ref><ref id="acel70208-bib-0037"><mixed-citation publication-type="journal" id="acel70208-cit-0037"><string-name name-style="western"><surname>Reiman</surname>, <given-names>E. M.</given-names></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>G. E.</given-names><surname>Alexander</surname></string-name>, et&#160;al. <year>2004</year>. &#8220;<article-title>Functional Brain Abnormalities in Young Adults at Genetic Risk for Late&#8208;Onset Alzheimer's Dementia</article-title>.&#8221; <source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>101</volume>, no. <issue>1</issue>: <fpage>284</fpage>&#8211;<lpage>289</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.2635903100</pub-id>.<pub-id pub-id-type="pmid">14688411</pub-id><pub-id pub-id-type="pmcid">PMC314177</pub-id></mixed-citation></ref><ref id="acel70208-bib-0038"><mixed-citation publication-type="journal" id="acel70208-cit-0038"><string-name name-style="western"><surname>Rusek</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Pluta</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>U&#322;amek&#8208;Kozio&#322;</surname></string-name>, and <string-name name-style="western"><given-names>S. J.</given-names><surname>Czuczwar</surname></string-name>. <year>2019</year>. &#8220;<article-title>Ketogenic Diet in Alzheimer's Disease</article-title>.&#8221; <source>International Journal of Molecular Sciences</source><volume>20</volume>, no. <issue>16</issue>: <elocation-id>3892</elocation-id>. <pub-id pub-id-type="doi">10.3390/ijms20163892</pub-id>.<pub-id pub-id-type="pmid">31405021</pub-id><pub-id pub-id-type="pmcid">PMC6720297</pub-id></mixed-citation></ref><ref id="acel70208-bib-0039"><mixed-citation publication-type="journal" id="acel70208-cit-0039"><string-name name-style="western"><surname>Schmidt</surname>, <given-names>M. I.</given-names></string-name>, <string-name name-style="western"><given-names>B. B.</given-names><surname>Duncan</surname></string-name>, <string-name name-style="western"><given-names>A. R.</given-names><surname>Sharrett</surname></string-name>, et&#160;al. <year>1999</year>. &#8220;<article-title>Markers of Inflammation and Prediction of Diabetes Mellitus in Adults (Atherosclerosis Risk in Communities Study): A Cohort Study</article-title>.&#8221; <source>Lancet</source><volume>353</volume>, no. <issue>9165</issue>: <fpage>1649</fpage>&#8211;<lpage>1652</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(99)01046-6</pub-id>.<pub-id pub-id-type="pmid">10335783</pub-id></mixed-citation></ref><ref id="acel70208-bib-0040"><mixed-citation publication-type="journal" id="acel70208-cit-0040"><string-name name-style="western"><surname>Shippy</surname>, <given-names>D. C.</given-names></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Wilhelm</surname></string-name>, <string-name name-style="western"><given-names>P. A.</given-names><surname>Viharkumar</surname></string-name>, <string-name name-style="western"><given-names>T. J.</given-names><surname>Raife</surname></string-name>, and <string-name name-style="western"><given-names>T. K.</given-names><surname>Ulland</surname></string-name>. <year>2020</year>. &#8220;<article-title>&#946;&#8208;Hydroxybutyrate Inhibits Inflammasome Activation to Attenuate Alzheimer's Disease Pathology</article-title>.&#8221; <source>Journal of Neuroinflammation</source><volume>17</volume>, no. <issue>1</issue>: <fpage>280</fpage>. <pub-id pub-id-type="doi">10.1186/s12974-020-01948-5</pub-id>.<pub-id pub-id-type="pmid">32958021</pub-id><pub-id pub-id-type="pmcid">PMC7507727</pub-id></mixed-citation></ref><ref id="acel70208-bib-0041"><mixed-citation publication-type="journal" id="acel70208-cit-0041"><string-name name-style="western"><surname>Sliz</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Shin</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Ahmad</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>Circulating Metabolome and White Matter Hyperintensities in Women and Men</article-title>.&#8221; <source>Circulation</source><volume>145</volume>, no. <issue>14</issue>: <fpage>1040</fpage>&#8211;<lpage>1052</lpage>. <pub-id pub-id-type="doi">10.1161/circulationaha.121.056892</pub-id>.<pub-id pub-id-type="pmid">35050683</pub-id><pub-id pub-id-type="pmcid">PMC9645366</pub-id></mixed-citation></ref><ref id="acel70208-bib-0042"><mixed-citation publication-type="journal" id="acel70208-cit-0042"><string-name name-style="western"><surname>Sliz</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Shin</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Syme</surname></string-name>, et&#160;al. <year>2020</year>. &#8220;<article-title>Thickness of the Cerebral Cortex Shows Positive Association With Blood Levels of Triacylglycerols Carrying 18&#8208;Carbon Fatty Acids</article-title>.&#8221; <source>Communications Biology</source><volume>3</volume>, no. <issue>1</issue>: <fpage>456</fpage>. <pub-id pub-id-type="doi">10.1038/s42003-020-01189-5</pub-id>.<pub-id pub-id-type="pmid">32820227</pub-id><pub-id pub-id-type="pmcid">PMC7441395</pub-id></mixed-citation></ref><ref id="acel70208-bib-0043"><mixed-citation publication-type="journal" id="acel70208-cit-0043"><string-name name-style="western"><surname>Sliz</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Shin</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Syme</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>A Variant Near DHCR24 Associates With Microstructural Properties of White Matter and Peripheral Lipid Metabolism in Adolescents</article-title>.&#8221; <source>Molecular Psychiatry</source><volume>26</volume>, no. <issue>8</issue>: <fpage>3795</fpage>&#8211;<lpage>3805</lpage>. <pub-id pub-id-type="doi">10.1038/s41380-019-0640-9</pub-id>.<pub-id pub-id-type="pmid">31900429</pub-id><pub-id pub-id-type="pmcid">PMC7332371</pub-id></mixed-citation></ref><ref id="acel70208-bib-0044"><mixed-citation publication-type="journal" id="acel70208-cit-0044"><string-name name-style="western"><surname>Sommerfield</surname>, <given-names>A. J.</given-names></string-name>, <string-name name-style="western"><given-names>I. J.</given-names><surname>Deary</surname></string-name>, and <string-name name-style="western"><given-names>B. M.</given-names><surname>Frier</surname></string-name>. <year>2004</year>. &#8220;<article-title>Acute Hyperglycemia Alters Mood State and Impairs Cognitive Performance in People With Type 2 Diabetes</article-title>.&#8221; <source>Diabetes Care</source><volume>27</volume>, no. <issue>10</issue>: <fpage>2335</fpage>&#8211;<lpage>2340</lpage>. <pub-id pub-id-type="doi">10.2337/diacare.27.10.2335</pub-id>.<pub-id pub-id-type="pmid">15451897</pub-id></mixed-citation></ref><ref id="acel70208-bib-0045"><mixed-citation publication-type="journal" id="acel70208-cit-0045"><string-name name-style="western"><surname>Sun</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Guo</surname></string-name>, <string-name name-style="western"><given-names>H. Q.</given-names><surname>Li</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>Associations of Circulating Metabolites With Cerebral White Matter Hyperintensities</article-title>.&#8221; <source>Journal of Neurochemistry</source><volume>166</volume>, no. <issue>2</issue>: <fpage>414</fpage>&#8211;<lpage>423</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.15845</pub-id>.<pub-id pub-id-type="pmid">37222503</pub-id></mixed-citation></ref><ref id="acel70208-bib-0046"><mixed-citation publication-type="journal" id="acel70208-cit-0046"><string-name name-style="western"><surname>Tian</surname>, <given-names>Y. E.</given-names></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Cropley</surname></string-name>, <string-name name-style="western"><given-names>A. B.</given-names><surname>Maier</surname></string-name>, <string-name name-style="western"><given-names>N. T.</given-names><surname>Lautenschlager</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Breakspear</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Zalesky</surname></string-name>. <year>2023</year>. &#8220;<article-title>Heterogeneous Aging Across Multiple Organ Systems and Prediction of Chronic Disease and Mortality</article-title>.&#8221; <source>Nature Medicine</source><volume>29</volume>, no. <issue>5</issue>: <fpage>1221</fpage>&#8211;<lpage>1231</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-023-02296-6</pub-id>.</mixed-citation></ref><ref id="acel70208-bib-0047"><mixed-citation publication-type="journal" id="acel70208-cit-0047"><string-name name-style="western"><surname>Turney</surname>, <given-names>I. C.</given-names></string-name>, <string-name name-style="western"><given-names>A. G.</given-names><surname>Chesebro</surname></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Renter&#237;a</surname></string-name>, et&#160;al. <year>2020</year>. &#8220;<article-title>APOE &#949;4 and Resting&#8208;State Functional Connectivity in Racially/Ethnically Diverse Older Adults</article-title>.&#8221; <source>Alzheimer's &amp; Dementia: Diagnosis, Assessment &amp; Disease Monitoring</source><volume>12</volume>, no. <issue>1</issue>: <elocation-id>e12094</elocation-id>. <pub-id pub-id-type="doi">10.1002/dad2.12094</pub-id>.</mixed-citation></ref><ref id="acel70208-bib-0048"><mixed-citation publication-type="journal" id="acel70208-cit-0048"><string-name name-style="western"><surname>Tynkkynen</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Chouraki</surname></string-name>, <string-name name-style="western"><given-names>S. J.</given-names><surname>van der Lee</surname></string-name>, et&#160;al. <year>2018</year>. &#8220;<article-title>Association of Branched&#8208;Chain Amino Acids and Other Circulating Metabolites With Risk of Incident Dementia and Alzheimer's Disease: A Prospective Study in Eight Cohorts</article-title>.&#8221; <source>Alzheimer's &amp; Dementia</source><volume>14</volume>, no. <issue>6</issue>: <fpage>723</fpage>&#8211;<lpage>733</lpage>. <pub-id pub-id-type="doi">10.1016/j.jalz.2018.01.003</pub-id>.</mixed-citation></ref><ref id="acel70208-bib-0049"><mixed-citation publication-type="journal" id="acel70208-cit-0049"><string-name name-style="western"><surname>van der Lee</surname>, <given-names>S. J.</given-names></string-name>, <string-name name-style="western"><given-names>C. E.</given-names><surname>Teunissen</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Pool</surname></string-name>, et&#160;al. <year>2018</year>. &#8220;<article-title>Circulating Metabolites and General Cognitive Ability and Dementia: Evidence From 11 Cohort Studies</article-title>.&#8221; <source>Alzheimer's &amp; Dementia</source><volume>14</volume>, no. <issue>6</issue>: <fpage>707</fpage>&#8211;<lpage>722</lpage>. <pub-id pub-id-type="doi">10.1016/j.jalz.2017.11.012</pub-id>.</mixed-citation></ref><ref id="acel70208-bib-0050"><mixed-citation publication-type="journal" id="acel70208-cit-0050"><string-name name-style="western"><surname>Wennberg</surname>, <given-names>A. M.</given-names></string-name>, <string-name name-style="western"><given-names>A. P.</given-names><surname>Spira</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Pettigrew</surname></string-name>, et&#160;al. <year>2016</year>. &#8220;<article-title>Blood Glucose Levels and Cortical Thinning in Cognitively Normal, Middle&#8208;Aged Adults</article-title>.&#8221; <source>Journal of the Neurological Sciences</source><volume>365</volume>: <fpage>89</fpage>&#8211;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1016/j.jns.2016.04.017</pub-id>.<pub-id pub-id-type="pmid">27206882</pub-id><pub-id pub-id-type="pmcid">PMC4876973</pub-id></mixed-citation></ref><ref id="acel70208-bib-0051"><mixed-citation publication-type="journal" id="acel70208-cit-0051"><string-name name-style="western"><surname>Zhang</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Han</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Mi</surname></string-name>, and <string-name name-style="western"><given-names>X.</given-names><surname>Gou</surname></string-name>. <year>2020</year>. &#8220;<article-title>Dietary Fatty Acid Factors in Alzheimer's Disease: A Review</article-title>.&#8221; <source>Journal of Alzheimer's Disease</source><volume>78</volume>, no. <issue>3</issue>: <fpage>887</fpage>&#8211;<lpage>904</lpage>. <pub-id pub-id-type="doi">10.3233/jad-200558</pub-id>.</mixed-citation></ref><ref id="acel70208-bib-0052"><mixed-citation publication-type="journal" id="acel70208-cit-0052"><string-name name-style="western"><surname>Zhang</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Xiao</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Niu</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Tan</surname></string-name>. <year>2005</year>. &#8220;<article-title>Mechanisms of Oleic Acid Deterioration in Insulin Secretion: Role in the Pathogenesis of Type 2 Diabetes</article-title>.&#8221; <source>Life Sciences</source><volume>77</volume>, no. <issue>17</issue>: <fpage>2071</fpage>&#8211;<lpage>2081</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2004.12.047</pub-id>.<pub-id pub-id-type="pmid">15935394</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Fluids Barriers CNS</journal-id><journal-id journal-id-type="iso-abbrev">Fluids Barriers CNS</journal-id><journal-id journal-id-type="pmc-domain-id">1454</journal-id><journal-id journal-id-type="pmc-domain">fbcns</journal-id><journal-title-group><journal-title>Fluids and Barriers of the CNS</journal-title></journal-title-group><issn pub-type="epub">2045-8118</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12506263</article-id><article-id pub-id-type="pmcid-ver">PMC12506263.1</article-id><article-id pub-id-type="pmcaid">12506263</article-id><article-id pub-id-type="pmcaiid">12506263</article-id><article-id pub-id-type="pmid">41057861</article-id><article-id pub-id-type="doi">10.1186/s12987-025-00716-y</article-id><article-id pub-id-type="publisher-id">716</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Evidence for reduced choroid plexus volume in the aged brain</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Youh</surname><given-names initials="R">R.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Perera</surname><given-names initials="C">C.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Katsiva</surname><given-names initials="C">C.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Harrison</surname><given-names initials="IF">I. F.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lythgoe</surname><given-names initials="MF">M. F.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wright</surname><given-names initials="DK">D. K.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nizari</surname><given-names initials="S">S.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wells</surname><given-names initials="JA">Jack A.</given-names></name><address><email>jack.wells@ucl.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02jx3x895</institution-id><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2190 1201</institution-id><institution>UCL Centre for Advanced Biomedical Imaging, Division of Medicine, </institution><institution>University College London, </institution></institution-wrap>London, UK </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02bfwt286</institution-id><institution-id institution-id-type="GRID">grid.1002.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7857</institution-id><institution>Department of Neuroscience, The School of Translational Medicine, </institution><institution>Monash University, </institution></institution-wrap>Melbourne, Australia </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>22</volume><issue-id pub-id-type="pmc-issue-id">478386</issue-id><elocation-id>97</elocation-id><history><date date-type="received"><day>12</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>26</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12987_2025_Article_716.pdf"/><abstract id="Abs1" abstract-type="structured"><sec><title>Background</title><p id="Par1">The choroid plexus plays an important role in brain homeostasis, including the active secretion of cerebrospinal fluid. Its function and structure have been reported to be affected by normal ageing. However, existing measures of choroid plexus volume may be complicated by partial volume (in vivo MRI) and tissue fixation artefacts (histology). In this study, we investigate possible changes in choroid plexus volume within the lateral ventricles of aged mice utilising two structural MRI protocols explicitly designed for time-efficient, high-resolution in vivo imaging of the choroid plexus.</p></sec><sec><title>Methods</title><p id="Par2">Two MRI sequences were utilised to examine in vivo choroid plexus volume in the lateral ventricles of young (&#8764;&#8201;6 months) and aged (&#8764;&#8201;24 months) mouse brains: (1) an ultra-long echo-time T2 weighted fast-spin-echo and (2) a multi-TE T2* mapping protocol. A test-retest study was performed on a subset of the data to examine the reproducibility of choroid plexus volume estimation based on manual segmentation. A two-way ANOVA test was performed to determine possible differences in choroid plexus volume in young and aged mouse groups across the two distinct MRI protocols.</p></sec><sec><title>Results</title><p id="Par3">Reproducibility tests showed a low test-retest variability of the manual segmentation pipeline for both MRI protocols. A statistically significant reduction of in vivo choroid plexus volume was found in the aged mouse brain. This finding is concordant with previous histological observations of a reduction in epithelial cell height with ageing across a wide range of species.</p></sec><sec><title>Conclusions</title><p id="Par4">We present an in vivo investigation of changes to lateral ventricle choroid plexus volume in the mouse brain utilising a manual segmentation approach based on two bespoke MRI protocols designed for time-efficient high resolution imaging of the choroid plexus. Based on these protocols, we provide evidence for a reduction in choroid plexus volume in the aged brain. This research provides insight for studies utilising MRI measurements of choroid plexus volume as a biomarker of age-related neurologic conditions as it indicates that the ageing process itself does not result in hypertrophy of the choroid plexus, but a decrease in tissue volume.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12987-025-00716-y.</p></sec></abstract><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100010269</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>225345/Z/22/Z</award-id><principal-award-recipient><name name-style="western"><surname>Perera</surname><given-names>C.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100000304</institution-id><institution>Parkinson's UK</institution></institution-wrap></funding-source><award-id>F-1902</award-id><principal-award-recipient><name name-style="western"><surname>Harrison</surname><given-names>I. F.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100002283</institution-id><institution>Alzheimer&#8217;s Research UK</institution></institution-wrap></funding-source><award-id>ARUK-RF2019A-003</award-id><principal-award-recipient><name name-style="western"><surname>Harrison</surname><given-names>I. F.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100000833</institution-id><institution>Rosetrees Trust</institution></institution-wrap></funding-source><award-id>A2200</award-id><principal-award-recipient><name name-style="western"><surname>Lythgoe</surname><given-names>M. F.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100002203</institution-id><institution>Brain Tumour Charity</institution></institution-wrap></funding-source><award-id>QfC_2018_10387</award-id><principal-award-recipient><name name-style="western"><surname>Lythgoe</surname><given-names>M. F.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Edinburgh-UCL CRUK Brain Tumour Centre of Excellence</institution></funding-source><award-id>C7893/A27590</award-id><principal-award-recipient><name name-style="western"><surname>Lythgoe</surname><given-names>M. F.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source><award-id>1174040</award-id><principal-award-recipient><name name-style="western"><surname>Wright</surname><given-names>D. K.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">The choroid plexus (ChP) resides in the lateral, third, and fourth ventricles of the brain and forms the blood-cerebrospinal fluid barrier (BCSFB). The ChP performs several key roles in service of normal brain function including the active secretion of cerebrospinal fluid (CSF) which may in turn support the efficacy of CSF-mediated brain-clearance mechanisms such as the glymphatic pathway [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Given this multifaceted and unique physiology, the ChP has been proposed as a hitherto underexplored site of mechanistic significance in age-related conditions such as multiple sclerosis (MS) and Alzheimer&#8217;s disease (AD) [<xref ref-type="bibr" rid="CR3">3</xref>&#8211;<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par6">Towards the goal of developing novel imaging biomarkers of ChP derangement, there has been an emergence of publications reporting changes in ChP volume associated with disease, based on segmentation of high-resolution structural MRI scans [<xref ref-type="bibr" rid="CR7">7</xref>&#8211;<xref ref-type="bibr" rid="CR15">15</xref>]. One notable observation in the context of age-related neurodegenerative disease, are reports of increased lateral ventricle (LV) ChP volume in the aged human brain [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Interestingly, this finding would appear to contradict direct histological assessment where ChP epithelial atrophy has been reported with age in both mice and rats as well as in the human brain [<xref ref-type="bibr" rid="CR18">18</xref>&#8211;<xref ref-type="bibr" rid="CR20">20</xref>]. These reports are further complicated by possible methodological limitations associated with both approaches such as partial volume effects exacerbated by the retrospective analysis of structural MRI scans that were not explicitly designed for reliable ChP segmentation as well as possible artefacts due to tissue fixation procedures required in histology. Thus, we aimed to help disambiguate the relationship between LV ChP volume and ageing by acquiring in vivo measurements of ChP volume using two bespoke time-efficient MRI protocols designed for high-resolution in vivo imaging of the ChP: (i) an ultra-long echo-time (TE) T2 weighted fast-spin echo (FSE) scan and (ii) a multi-TE T2* mapping protocol. We demonstrate that both MRI protocols provide measures of ChP volume with low test-retest manual-segmentation variability. We then apply both imaging protocols to aged and young-adult control mice for non-invasive, in vivo estimation of ChP volume. Doing so returns evidence for a reduction in ChP volume in the aged brain, suggesting that the ageing process results in a decreased volume of ChP tissue.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Animal preparation</title><p id="Par7">All experiments were conducted in accordance with the European Commission Directive 86/609/EEC (European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes) and the United Kingdom&#8217;s Home Office Animals (Scientific Procedures) Act (1986). Prior to data collection, mice were acclimatized in an animal facility with a 12-hour light/12-hour dark cycle, and food and water were provided ad libitum.</p><p id="Par8">Imaging was performed using a horizontal-bore 9.4T Bruker preclinical system (BioSpec 94/20 USR; Bruker) equipped with a 440-mT/m gradient set featuring outer and inner diameters of 205 mm and 116 mm, respectively (BioSpec B-GA 12S2). An 86-mm volume transit RF coil and a four-channel receiver-array coil, specifically designed for mouse brain imaging (Bruker), were used for data acquisition. Mice were anesthetized with a 2% isoflurane mixture (4:1 room air/O<sub>2</sub>), adjusted to 1.5% to maintain a respiratory rate of approximately 150 bpm, which was continuously monitored using a pressure pad throughout the scan. The mouse&#8217;s head was rigidly fixed using blunt ear bars. Core body temperature was measured with a rectal probe (SA Instruments, Stony Brook, NY) and kept at 37.0 &#177; 0.5 &#176;C, regulated by an adjustable water bath connected to a mouse heating pad (Bruker BioSpec; Bruker, Kontich, Belgium). MRI experiments were performed on male C57BL/6JRj mice at 6 and 24 months of age (Janvier labs) (<italic toggle="yes">n</italic> = 10 and <italic toggle="yes">n</italic> = 12 respectively). This corresponds to an age in human years of approximately 30 and 70 years respectively [<xref ref-type="bibr" rid="CR21">21</xref>].</p></sec><sec id="Sec4"><title>Data acquisition</title><p id="Par9">In this study, two structural MRI protocols designed for high resolution/contrast imaging of mouse ChP were applied in separate scan sessions: (1) 3D FSE ultra-long TE readout with the following parameters: FOV&#8201;=&#8201;19.6&#8201;&#215;&#8201;19.6&#8201;&#215;&#8201;3.6&#160;mm (centred around the LVs, see Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>); matrix size&#8201;=&#8201;196&#8201;&#215;&#8201;196&#8201;&#215;&#8201;36; 0.1&#160;mm isotropic resolution; echo train length&#8201;=&#8201;64; effective TE&#8201;=&#8201;176.2ms; TR&#8201;=&#8201;5000ms; 1 average; acquisition time&#8201;&#8764;&#8201;6.5&#160;min; (2) 3D multi-TE gradient echo with the following parameters; FOV&#8201;=&#8201;16&#8201;&#215;&#8201;19.25&#8201;&#215;&#8201;12&#160;mm; matrix size&#8201;=&#8201;128&#8201;&#215;&#8201;154&#8201;&#215;&#8201;96; TEs&#8201;=&#8201;2.19, 5,25, 8.31, 11.37, 14.43, 17.49, 20.55, 23.61, 26.67, 29.73, 32.79, 35.85 ms; TR&#8201;=&#8201;66ms; flip angle&#8201;=&#8201;15<sup>o</sup>;1 average; 0.125&#160;mm isotropic resolution; acquisition time&#8201;&#8764;&#8201;16&#160;min.</p><p id="Par10">Both imaging datasets were collected to estimate the volume of ChP. The raw MRI images of the 3D FSE h-T2w readout were directly utilised, while the 3D multi-TE GRE T2*w readout was then used to generate T2* map images for ChP volume estimation by fitting the data to a simple mono-exponential model using Matlab (Mathsworks, Massachusetts, USA).</p></sec><sec id="Sec5"><title>ChP volume estimation</title><p id="Par11">A manual segmentation pipeline was conducted for in vivo ChP volume estimation in young and aged mouse brains among all image datasets (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). For each slice, the ChP was manually segmented based on visual inspection of the T2w images/ T2* maps. The segmentations were carried out using the Volume Segmenter toolbox in MATLAB. The manual segmentation was performed blind to the animal group (aged vs. young control). To investigate the reproducibility of ChP volume estimation using the manual segmentation pipeline, the segmentation pipeline was repeated on 3 randomly selected subjects within a one-day interval. This was performed separately for both MRI protocols. The mean absolute % difference in volume measurements was calculated for each subject.</p><p id="Par12">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Schematic of manual segmentation pipeline. Top: The LV images were extracted from the mouse brain (upper left and upper middle) using MRI protocols that are explicitly designed for ChP segmentation, where the ChP is viewed and manually segmented slice by slice (upper middle). The ChP (upper right) is then labelled within the LV and is highlighted in purple. Bottom: Representative datasets from the same subject utilising two different imaging protocols (T2w and T2* map, <italic toggle="yes">n</italic>&#8201;=&#8201;1 representative), which demonstrates a collection of sequential slices that capture the LV for ChP volume estimation</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e325" position="float" orientation="portrait" xlink:href="12987_2025_716_Fig1_HTML.jpg"/></fig>
</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par13">The effect of age and imaging protocol (ultra-long TE T2w &amp; T2*maps) on ChP volume was investigated using a two-way analysis of variance (ANOVA) test using GraphPad Prism (GraphPad Software, Boston, Massachusetts USA). Errors are reported as standard deviations from the mean.</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>ChP segmentation reproducibility test</title><p id="Par14">Reproducibility tests were carried out to investigate the consistency of the manual ChP volume segmentation methods (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). An average absolute change of 9.38% was observed between the repeatedly segmented datasets using high-resolution ultra-long TE T2w MRI images (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>(A)), while an average absolute change of 7.07% was observed using T2* map images (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>(B)). A representative example of the reproducibility test is shown in Fig. <xref rid="Fig3" ref-type="fig">3</xref>(C)(D), where we observe a high degree of segmentation agreement for both protocols. Here, we established that the manual segmentation method yielded reproducible estimates of ChP volume.</p><p id="Par15">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Segmentation pipeline reproducibility tests. (<bold>A</bold>) ChP volume segmentation reproducibility test based on T2w datasets. (<italic toggle="yes">n</italic>&#8201;=&#8201;3, randomly selected) (<bold>B</bold>) ChP volume segmentation reproducibility test based on T2* map datasets. (<italic toggle="yes">n</italic>&#8201;=&#8201;3, randomly selected) (<bold>C</bold>) Representative example of visual comparison of sequential manual segmentation based on a T2w MRI image obtained from the reproducibility test. (<bold>D</bold>) Representative example of visual comparison of sequential manual segmentation based on a T2* map image obtained from the reproducibility test. For (<bold>C</bold>) and (<bold>D</bold>), the green areas indicate the regions segmented on both the first and second days. The purple areas represent the segmentations made on the first day that were not included on the second day. Conversely, the blue areas represent the segmentations made on the second day that were absent on the first day</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e383" position="float" orientation="portrait" xlink:href="12987_2025_716_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec9"><title>In vivo choroid plexus volume in the aged mouse brain</title><p id="Par16">A two-way ANOVA test was conducted to compare the main effects of age and MRI protocol as well as the interaction effects on the ChP volume. Prior to unblinding, one mouse was excluded from all T2* map analyses due to MRI artifacts within the LV that affected the segmentation. No other animals were excluded from the analysis. The age effect was statistically significant (<inline-formula id="IEq1"><alternatives><tex-math id="d33e389">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:P&lt;0.01$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12987_2025_716_Article_IEq1.gif"/></alternatives></inline-formula>). The effect of imaging datasets was statistically significant (<inline-formula id="IEq2"><alternatives><tex-math id="d33e395">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:P&lt;0.05$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12987_2025_716_Article_IEq2.gif"/></alternatives></inline-formula>). The interaction effects showed no significance (<inline-formula id="IEq3"><alternatives><tex-math id="d33e401">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:P&gt;0.05$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12987_2025_716_Article_IEq3.gif"/></alternatives></inline-formula>). A comparison of ChP volume between young (<inline-formula id="IEq4"><alternatives><tex-math id="d33e407">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:N=10$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12987_2025_716_Article_IEq4.gif"/></alternatives></inline-formula>, <inline-formula id="IEq5"><alternatives><tex-math id="d33e413">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:0.405\:{\pm\:\:0.076mm}^{3}$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12987_2025_716_Article_IEq5.gif"/></alternatives></inline-formula>) and aged mice (<inline-formula id="IEq6"><alternatives><tex-math id="d33e420">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:N=12$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12987_2025_716_Article_IEq6.gif"/></alternatives></inline-formula>, <inline-formula id="IEq7"><alternatives><tex-math id="d33e426">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:0.356\pm\:0.036\:{mm}^{3}$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12987_2025_716_Article_IEq7.gif"/></alternatives></inline-formula>) from ultra-long TE T2-weighted MRI images is shown in Fig. <xref rid="Fig3" ref-type="fig">3</xref>(A). A comparison of ChP volume between young (<inline-formula id="IEq8"><alternatives><tex-math id="d33e435">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:N=10$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12987_2025_716_Article_IEq4.gif"/></alternatives></inline-formula>, <inline-formula id="IEq9"><alternatives><tex-math id="d33e441">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:0.481\pm\:0.129\:{mm}^{3}$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12987_2025_716_Article_IEq9.gif"/></alternatives></inline-formula>) and aged mice (<inline-formula id="IEq10"><alternatives><tex-math id="d33e447">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:N=11$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12987_2025_716_Article_IEq10.gif"/></alternatives></inline-formula>, <inline-formula id="IEq11"><alternatives><tex-math id="d33e454">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:0.383\pm\:0.050\:{mm}^{3}$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12987_2025_716_Article_IEq11.gif"/></alternatives></inline-formula>) from T2* map images is shown in Fig. <xref rid="Fig3" ref-type="fig">3</xref>(B). These findings indicate a statistically significant difference in ChP volume between the young and old groups.</p><p id="Par17">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Comparison of the ChP volume estimated in young and old groups from high-resolution T2-weighted MRI images (<bold>A</bold>) and T2* map MRI images (<bold>B</bold>). Each dot represents an individual mouse</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e478" position="float" orientation="portrait" xlink:href="12987_2025_716_Fig3_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec10"><title>Discussion</title><p id="Par18">In this study we applied two time-efficient MRI protocols designed for robust estimation of ChP volume in the LVs of the mouse brain. The protocols employed were an ultra-long TE FSE and a multi-TE gradient echo T2* mapping sequence. We then evaluated the reproducibility of ChP volume estimates from manual segmentation of the images which returned a mean absolute difference of 9% and 7% for each protocol respectively, providing a solid foundation to detect putative group-wise differences in ChP volume in mouse models. We then applied the protocols to a cohort of aged and young mice to investigate possible changes in ChP volume in the ageing brain, given conflicting reports in the literature. Doing so, we found evidence for reduced ChP volume in the aged mouse brain, a finding concordant with observations of ChP epithelial atrophy from direct histological assessment [<xref ref-type="bibr" rid="CR18">18</xref>&#8211;<xref ref-type="bibr" rid="CR20">20</xref>]. This finding suggests that ageing causes atrophy of the ChP and highlights that this can be readily detected using non-invasive in vivo structural MRI. An important limitation of the current work is that the effect of age on ChP volume was investigated only in a single sex (male), thus limiting the relevance of our findings [<xref ref-type="bibr" rid="CR19">19</xref>]. Scarpetta and colleagues reported no differences due to sex in their recent histological characterisation of ChP changes in the aged mouse brain, suggesting that our observations are likely to extend to female mice. Future work, however, should be performed to characterise putative sex differences in structural alterations of the ChP with ageing.</p><p id="Par19">It is important to note that some strains of mice such as BALB/c or DBA/2 have much smaller lateral ventricles in comparison to the C57BL/6 strain examined in this work [<xref ref-type="bibr" rid="CR22">22</xref>]. This can make it challenging to accurately measure ChP volume using the protocols employed here. This is illustrated in Supplementary Fig. <xref rid="MOESM1" ref-type="media">1</xref> where example images taken from a 5-week-old BALB/C mouse are compared against equivalent scans from the C57BL/6 strain. We were unable to identify ChP tissue on images acquired in the BALB/c strain despite confirming the presence of ChP tissue on histology (see Supplementary Fig. <xref rid="MOESM1" ref-type="media">1</xref>). Therefore, future studies should carefully consider the background strain of their mice when intending to apply non-invasive MRI protocols for in-vivo assessment of ChP volume.</p><p id="Par20">The concept of the ultra-long FSE sequence for time-efficient imaging of ChP volume is a simple one that has been used before in MRI studies primarily designed to image the CSF [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. This employs a long echo train (in this case 64) which allows the acquisition of multiple lines of k-space after a single excitation for time-efficient data capture (in this case giving 0.1 mm isotropic resolution images in &#8764; 6 min). The resultant long echo time (TEeff = 176ms) will highly attenuate the signal from all tissue types within the brain with the exception of CSF due to its uniquely long T2 relaxation time (&#8764; 300ms [<xref ref-type="bibr" rid="CR25">25</xref>]). Thus, in these images, negative contrast is employed where the CSF appears bright and the ChP tissue is dark. Accordingly, a downside of this approach is that all extra-ventricular tissue signal is nulled in these images meaning that this protocol will only inform about ventricular and ChP structure and not other grey/white matter regions for example. Here we implemented a 3D FSE sequence as image quality was found to be poor using an equivalent 2D sequence with matched geometry likely due to the cumulative effect of multiple refocusing pulses when using 0.1 mm slice thickness (data not shown). The multi-echo gradient echo 3D sequence is designed for time-efficient T2* mapping using a short TR and reduced flip angle. Similarly, this exploits the marked difference in T2* between the ChP and adjacent CSF. Unlike the ultra-long TE FSE sequence however, this also yields T2* maps across the extra-ventricular tissue which could be useful for detection of other radiological markers of pathology, such as micro-hemorrhages.</p><p id="Par21">In regards to employing a more automated and objective approach to ChP volume estimation, within the ultra-long TE FSE data we explored using signal-intensity based thresholding across the LVs under the premise that there would be two distinct signal populations at &#8764; 0 signal (ChP) and &gt; &gt;0 signal (CSF). However, the distribution of signal intensities within the LVs was found to more continuous and not as bi-modal as we initially surmised meaning that it was challenging to define a &#8216;cut-off&#8217; signal intensity to accurately separate ChP and CSF voxels. We suspect that this principally reflects the partial volume of the CSF with tissue at the edge of the ventricles and ChP respectively, in addition to some subtle Gibbs ringing artefacts in the CSF (whose characteristic pattern can be distinguished by eye). Thus, we proceeded with a manual segmentation approach which further benefits from the experience of the rater to recognise the characteristic morphology of the ChP within the LVs (see Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Indeed, this approach returned a mean absolute error in ChP volume estimation of 9% (ultra-long TE FSE) and 7% (multi-TE GE T2* maps) following test-retest ChP segmentations suggesting that this approach can yield reliable estimates of ChP volume. Moving forward, the use of more automated approaches may alleviate the need for the time-consuming manual segmentation [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Interestingly, the estimates of ChP volume based on the T2* maps were greater than those using the ultra-long TE FSE protocol which likely stems from a &#8216;blurring&#8217; of the ChP tissue due to the macro time-invariant susceptibility effects that are present with T2* vs. T2 contrast.</p><p id="Par22">Our finding of reduced ChP volume in the aged brain is consistent with histological observations of epithelial cell atrophy in the aged mouse, rat and human brain [<xref ref-type="bibr" rid="CR18">18</xref>&#8211;<xref ref-type="bibr" rid="CR20">20</xref>]. Although, it is important to point out that a recent study in rats found no evidence for ChP cell atrophy at 24 months of age [<xref ref-type="bibr" rid="CR28">28</xref>]. The precise reasons why, based on in vivo structural MRI data, we find a reduction in ChP volume in the aged mouse brain whereas others have reported an increase in ChP volume with ageing in the human brain [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>], remains unknown at this time. Here, we speculate the following methodological/physiological factors may be at play: (i) the limited spatial resolution of in vivo structural MRI scans to accurately spatially resolve the fine structure of the ChP may lead to systematic errors that influence the accuracy of ChP volume measurement. This may be impacted by changes in the volume of the LVs that occur with ageing, in turn altering the expanse of fluid in which the ChP tissue can float within. ChP tissue that is diffusely present in a larger volume of ventricular CSF could be misinterpreted as possessing a greater volume than ChP tissue more densely packed into a small volume of lateral ventricular CSF due to partial volume effects given the limited spatial resolution of the images. In the mice examined here, no significant differences in our in vivo measurements of ventricular volume were detected between the aged and young adult groups, as found in our previous study [<xref ref-type="bibr" rid="CR29">29</xref>] (data not shown). It could also be related to the presence of ChP cysts that were recently captured with high resolution imaging of the human brain at 7T [<xref ref-type="bibr" rid="CR30">30</xref>]. These cysts which would likely act to artificially enhance measures of ChP volume from in-vivo structural MRI scans, where the outer surface of the CP tissue is typically segmented to estimate it&#8217;s volume. (ii) earlier studies have reported an increased volume of ChP tissue in a range of neurological conditions (e.g [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR31">31</xref>&#8211;<xref ref-type="bibr" rid="CR35">35</xref>]). Of note, to our knowledge a <italic toggle="yes">decrease</italic> in ChP volume associated with a disease has yet to be reported. Therefore, the increased ChP volume observed in the aged human brain may reflect undiagnosed comorbidities with human ageing that are not necessarily recapitulated in the aged mouse brain, highlighting the limitations of the mouse to model the complex multifaceted co-morbidities that come with human ageing. (iii) the ChP is known to undergo marked movement due to cardiac and respiratory pulsation. As, to our knowledge, none of the previous studies of ChP volume have been gated to cardiac or respiratory signals (including the present work), this movement may introduce a degree of inaccuracy into the structural images where ChP tissue that undergoes a greater degree of motion presents with a spurious increase in volume due to blurring during the acquisition (which typically takes several minutes). This possible artefact may have an age dependence where, in the case of cardiac pulsation, upstream stiffening of the vessels leads to greater pulse wave propagation to the downstream cerebral vessels [<xref ref-type="bibr" rid="CR36">36</xref>]. Our preliminary investigation into the degree of ChP motion with cardiac and respiratory cycles suggested that this motion was subtle however and will thus have relatively little influence on our ChP volume measurements (data not shown).</p><p id="Par23">To our knowledge, the weight of the mouse ChP has not been reported in the literature (and by extension the weight of the mouse brain ChP in the LVs). Interpolating the rat ChP weight of 2.9 mg [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>] and assuming that the weight/volume of the mouse brain is 20% of the rat brain, this gives an approximate weight of the mouse ChP of 0.58 mg. Based on prior measurements of the surface area of the ChP in the mouse brain [<xref ref-type="bibr" rid="CR39">39</xref>] the ChP in the LVs represents 43% of the total ChP tissue giving an estimated mass of 0.25 mg. We estimate ChP volume to be 0.40 and 0.48 mm<sup>3</sup> for our two MRI protocols in the young mouse brain. Therefore, assuming the ChP tissue has the density of water, there is an approximately two-fold overestimation in the volume of the ChP using our MRI protocol. This is perhaps not surprising as partial volume effects are notoriously challenging using non-invasive in-vivo imaging of the ChP, given it&#8217;s fine and delicate structure which is microscopically intertwined with the CSF and often directly proximal to the ventricular wall. Nonetheless, this inaccuracy does not necessarily confound measures of <italic toggle="yes">differences</italic> in ChP volume between different groups (here young vs. old), but reinforces the need to carefully consider the imaging methods (spatial resolution/ contrast etc.) when comparing MRI-derived estimates of in-vivo ChP volume from different studies. In their recent examination of ChP morphology in the aged mouse brain, Scarpetta and colleagues found a &#8764; 10% and &#8764; 30% decrease in epithelial cell area and microvilli length when comparing 2 and 20 month old mice [<xref ref-type="bibr" rid="CR19">19</xref>]. Similarly Serot et al., reported a 15% decrease in epithelial cell height when comparing 30 and 6 month old rats [<xref ref-type="bibr" rid="CR18">18</xref>]. Here, we measure a 12% and 20% decrease in ChP volume with age for the ultra-long TE T2-weighted and T2* map scans respectively (when comparing mice at 6 and 24 months of age). Thus, the volume changes are broadly consistent with decreases in ChP cell dimensions previously reported.</p><p id="Par24">Recently, studies have reported an association between ChP volume and neurological disorders such as AD, MS, and Parkinson&#8217;s disease (PD). An earlier investigation found that an increased ChP volume is associated with patients with AD, as determined by T1-weighted (T1w) MRI scans [<xref ref-type="bibr" rid="CR35">35</xref>]. This investigation also emphasised the need for more accurate measurement techniques to delineate ChP volume in MRI scans, alongside the development of effective segmentation methods [<xref ref-type="bibr" rid="CR35">35</xref>]. In addition, a retrospective analysis indicated that the ChP volume within the LV is greater in individuals with Alzheimer&#8217;s disease compared to those experiencing subjective cognitive impairment (SCI) or mild cognitive impairment (MCI), as assessed through 3D T1w imaging [<xref ref-type="bibr" rid="CR15">15</xref>]. Apart from AD, a previous study has shown that patients with MS, particularly those with the relapsing-remitting form, exhibit a larger ChP volume compared to healthy individuals based on 3D T1w images and that this enlargement is speculated to be partially related to inflammatory processes [<xref ref-type="bibr" rid="CR40">40</xref>]. Another retrospective study reported ChP enlargement, based on T1w MRI images, may indicate a higher risk of developing dementia with PD [<xref ref-type="bibr" rid="CR41">41</xref>]. Apart from studies related to neurological disorders, other human studies also reported an increase in ChP volume with normal ageing. For example, a cross-sectional study reported that larger ChP volume in the LVs was associated with older age. In addition, this cross-sectional study also emphasises the need for enhanced image resolution and improved segmentation techniques to more precisely evaluate ChP volume [<xref ref-type="bibr" rid="CR16">16</xref>]. Another study developed a deep learning segmentation method to assess the ChP volume in the human brain utilizing T1w MRI, T2w MRI, and T2w FLAIR MRI images and reported a positive association between ChP volume and age in all three MRI protocols [<xref ref-type="bibr" rid="CR17">17</xref>]. Further studies, including longitudinal studies and functional investigations of ChP, are warranted to elucidate the complex interplay between ChP morphology, function, and ageing. In addition, preclinical studies including mouse models of AD, PD, MS, and other conditions, could utilise the MRI acquisition and analysis methods presented in this study. These approaches may enhance the understanding of the utility of MRI measurement of ChP volume as biomarkers of disease processes, with additional comparison with invasive assessment techniques.</p><p id="Par25">To conclude, in this work we aimed to better understand the impact of ageing on ChP volume, captured using simple, translational, structural MRI scans. We did this by applying two MRI protocols specifically designed for efficient, high resolution, high contrast imaging of the ChP, to the young and aged mouse brain. We find evidence for a reduction in ChP volume in the aged brain, with both methods returning similar findings. This provides evidence that ageing itself results in atrophy and not hypertrophy of the ChP.</p></sec><sec id="Sec11" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12987_2025_716_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>R. Youh and C. Perera joint first authors.</p></fn></fn-group><ack><title>Acknowledgements</title><p>JAW, CP, CK and SN are supported by the Wellcome Trust (225345/Z/22/Z). IH is supported by a Parkinson&#8217;s UK senior fellowship (SFEL-19-02). M.J.P. van Osch reports support from the Leducq Foundation and the Leducq Foundation for Cardiovascular Research (23CVD03), a NWO-Human Measurement Models 2.0 grant (18969) as well as support from the Dutch Research Council (NWO), European Community, the Dutch Heart Foundation, and the Dutch Brain Foundation. DLT is supported by the National Institute for Health and Care Research University College London Hospital Biomedical Research Centre (NIHR UCLH BRC), the Alzheimer&#8217;s Society, and UK Research and Innovation (UKRI). LH is supported by an EU Joint programme&#8211;Neurodegenerative Disease Research (JPND) project (HCBI: &#8220;Human brain clearance imaging: a window on physiological disturbances in the prediagnostic phase of neurodegenerative diseases&#8221;). The project has received funding from the European Union&#8217;s Horizon 2020 Research and Innovation Programme under grant agreement number 825664. Additional funding was received by Alzheimer Netherland (MJPvO, LH).</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>RY: Project lead, data analysis, data acquisition, Writing&#8212;original draft. CP: Supervision, data acquisition, Methodology, Writing&#8212;review and editing. CK: data analysis; IFH: Project Licence; Writing&#8212;review and editing. ML: Project licence, Writing&#8212;review and editing. DW: methodology, Writing&#8212;review and editing. SN: Supervision, data acquisition, Writing&#8212;review and editing. JW: Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Investigation, Writing&#8212;review and editing, Project administration.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>JAW, CP, CK and SN are supported by the Wellcome Trust (225345/Z/22/Z). DW is supported by the National Health and Medical Research Council to DKW [grant number: 1174040]. IFH is supported by both Parkinson&#8217;s UK (F-1902) and Alzheimer&#8217;s Research UK (ARUK-RF2019A-003). MFL is supported by Rosetrees Trust and the John Black Charitable Foundation (Grant No. A2200); Medical Research Council (MR/M009092/1); the Brain Tumour Charity (Grant No. QfC_2018_10387); the Edinburgh-UCL CRUK Brain Tumour Centre of Excellence (Grant No. C7893/A27590);</p><p>the CRUK &amp; EPSRC Comprehensive Cancer Imaging Centre at KCL and UCL (Grant No. C1519/A16463 and C1519/A10331).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Upon publication, the MRI data will be made freely available to download from the UCL data repository (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://rdr.ucl.ac.uk/authors/Jack_Wells/6768476">https://rdr.ucl.ac.uk/authors/Jack_Wells/6768476</ext-link>).</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par26">All experiments were conducted in accordance with the European Commission Directive 86/609/EEC (European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes) and the United Kingdom&#8217;s Home Office Animals (Scientific Procedures) Act (1986).</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par27">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Courtney Y, Hochstetler A, Lehtinen MK. Choroid plexus pathophysiology. Annu Rev Pathol. 2024.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-pathmechdis-051222-114051</pub-id><pub-id pub-id-type="pmcid">PMC11884907</pub-id><pub-id pub-id-type="pmid">39383438</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacAulay</surname><given-names>N</given-names></name><name name-style="western"><surname>Keep</surname><given-names>RF</given-names></name><name name-style="western"><surname>Zeuthen</surname><given-names>T</given-names></name></person-group><article-title>Cerebrospinal fluid production by the choroid plexus: a century of barrier research revisited</article-title><source>Fluids Barriers CNS</source><year>2022</year><volume>19</volume><issue>1</issue><fpage>26</fpage><pub-id pub-id-type="doi">10.1186/s12987-022-00323-1</pub-id><pub-id pub-id-type="pmid">35317823</pub-id><pub-id pub-id-type="pmcid">PMC8941821</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">MacAulay N, Keep RF, Zeuthen T. Cerebrospinal fluid production by the choroid plexus: a century of barrier research revisited. Fluids Barriers CNS. 2022;19(1):26.<pub-id pub-id-type="pmid">35317823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12987-022-00323-1</pub-id><pub-id pub-id-type="pmcid">PMC8941821</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Choroid plexus volume as a novel candidate neuroimaging marker of the alzheimer&#8217;s continuum</article-title><source>Alzheimers Res Ther</source><year>2024</year><volume>16</volume><issue>1</issue><fpage>149</fpage><pub-id pub-id-type="doi">10.1186/s13195-024-01520-w</pub-id><pub-id pub-id-type="pmid">38961406</pub-id><pub-id pub-id-type="pmcid">PMC11221040</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Jiang J, et al. Choroid plexus volume as a novel candidate neuroimaging marker of the alzheimer&#8217;s continuum. Alzheimers Res Ther. 2024;16(1):149.<pub-id pub-id-type="pmid">38961406</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-024-01520-w</pub-id><pub-id pub-id-type="pmcid">PMC11221040</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#268;arna</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pathogenesis of alzheimer&#8217;s disease: involvement of the choroid plexus</article-title><source>Alzheimers Dement</source><year>2023</year><volume>19</volume><issue>8</issue><fpage>3537</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1002/alz.12970</pub-id><pub-id pub-id-type="pmid">36825691</pub-id><pub-id pub-id-type="pmcid">PMC10634590</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">&#268;arna M, et al. Pathogenesis of alzheimer&#8217;s disease: involvement of the choroid plexus. Alzheimers Dement. 2023;19(8):3537&#8211;54.<pub-id pub-id-type="pmid">36825691</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12970</pub-id><pub-id pub-id-type="pmcid">PMC10634590</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Magliozzi R, et al. Neuropathological and cerebrospinal fluid correlates of choroid plexus inflammation in progressive multiple sclerosis. Brain Pathol. 2024;e13322.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bpa.13322</pub-id><pub-id pub-id-type="pmcid">PMC12145902</pub-id><pub-id pub-id-type="pmid">39617422</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Hochstetler A, Lehtinen MK. Choroid plexus as a mediator of CNS inflammation in multiple sclerosis. Mult Scler. 2024:13524585241292974.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/13524585241292974</pub-id><pub-id pub-id-type="pmcid">PMC11634642</pub-id><pub-id pub-id-type="pmid">39503321</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Choroid plexus aging: structural and vascular insights from the HCP-aging dataset</article-title><source>Fluids Barriers CNS</source><year>2024</year><volume>21</volume><issue>1</issue><fpage>98</fpage><pub-id pub-id-type="doi">10.1186/s12987-024-00603-y</pub-id><pub-id pub-id-type="pmid">39639335</pub-id><pub-id pub-id-type="pmcid">PMC11619641</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Sun Z, et al. Choroid plexus aging: structural and vascular insights from the HCP-aging dataset. Fluids Barriers CNS. 2024;21(1):98.<pub-id pub-id-type="pmid">39639335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12987-024-00603-y</pub-id><pub-id pub-id-type="pmcid">PMC11619641</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Associations between the choroid plexus and Tau in alzheimer&#8217;s disease using an active learning segmentation pipeline</article-title><source>Fluids Barriers CNS</source><year>2024</year><volume>21</volume><issue>1</issue><fpage>56</fpage><pub-id pub-id-type="doi">10.1186/s12987-024-00554-4</pub-id><pub-id pub-id-type="pmid">38997764</pub-id><pub-id pub-id-type="pmcid">PMC11245807</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Li J, et al. Associations between the choroid plexus and Tau in alzheimer&#8217;s disease using an active learning segmentation pipeline. Fluids Barriers CNS. 2024;21(1):56.<pub-id pub-id-type="pmid">38997764</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12987-024-00554-4</pub-id><pub-id pub-id-type="pmcid">PMC11245807</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pearson</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Wagstaff</surname><given-names>R</given-names></name><name name-style="western"><surname>Williams</surname><given-names>RJ</given-names></name></person-group><article-title>Choroid plexus volumes and auditory verbal learning scores are associated with conversion from mild cognitive impairment to alzheimer&#8217;s disease</article-title><source>Brain Behav</source><year>2024</year><volume>14</volume><issue>7</issue><fpage>e3611</fpage><pub-id pub-id-type="doi">10.1002/brb3.3611</pub-id><pub-id pub-id-type="pmid">38956818</pub-id><pub-id pub-id-type="pmcid">PMC11219301</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Pearson MJ, Wagstaff R, Williams RJ. Choroid plexus volumes and auditory verbal learning scores are associated with conversion from mild cognitive impairment to alzheimer&#8217;s disease. Brain Behav. 2024;14(7):e3611.<pub-id pub-id-type="pmid">38956818</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/brb3.3611</pub-id><pub-id pub-id-type="pmcid">PMC11219301</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>T</given-names></name><etal/></person-group><article-title>Choroid plexus enlargement in amyotrophic lateral sclerosis patients and its correlation with clinical disability and blood-CSF barrier permeability</article-title><source>Fluids Barriers CNS</source><year>2024</year><volume>21</volume><issue>1</issue><fpage>36</fpage><pub-id pub-id-type="doi">10.1186/s12987-024-00536-6</pub-id><pub-id pub-id-type="pmid">38632611</pub-id><pub-id pub-id-type="pmcid">PMC11025206</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Dai T, et al. Choroid plexus enlargement in amyotrophic lateral sclerosis patients and its correlation with clinical disability and blood-CSF barrier permeability. Fluids Barriers CNS. 2024;21(1):36.<pub-id pub-id-type="pmid">38632611</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12987-024-00536-6</pub-id><pub-id pub-id-type="pmcid">PMC11025206</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Jeong SH, et al. Choroid Plexus Volume, Amyloid Burden, and Cognition in the Alzheimer&#8217;s Disease Continuum. Aging Dis; 2024.<pub-id pub-id-type="doi" assigning-authority="pmc">10.14336/AD.2024.0118</pub-id><pub-id pub-id-type="pmcid">PMC11745423</pub-id><pub-id pub-id-type="pmid">38300638</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Umemura</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Choroid plexus enlargement in mild cognitive impairment on MRI: a large cohort study</article-title><source>Eur Radiol</source><year>2024</year><volume>34</volume><issue>8</issue><fpage>5297</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1007/s00330-023-10572-9</pub-id><pub-id pub-id-type="pmid">38221583</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Umemura Y, et al. Choroid plexus enlargement in mild cognitive impairment on MRI: a large cohort study. Eur Radiol. 2024;34(8):5297&#8211;304.<pub-id pub-id-type="pmid">38221583</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00330-023-10572-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Assogna</surname><given-names>M</given-names></name><etal/></person-group><article-title>Association of choroid plexus volume with serum Biomarkers, clinical Features, and disease severity in patients with frontotemporal Lobar degeneration spectrum</article-title><source>Neurology</source><year>2023</year><volume>101</volume><issue>12</issue><fpage>e1218</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000207600</pub-id><pub-id pub-id-type="pmid">37500561</pub-id><pub-id pub-id-type="pmcid">PMC10516270</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Assogna M, et al. Association of choroid plexus volume with serum Biomarkers, clinical Features, and disease severity in patients with frontotemporal Lobar degeneration spectrum. Neurology. 2023;101(12):e1218&#8211;30.<pub-id pub-id-type="pmid">37500561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000207600</pub-id><pub-id pub-id-type="pmcid">PMC10516270</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Novakova Martinkova</surname><given-names>J</given-names></name><etal/></person-group><article-title>Longitudinal progression of choroid plexus enlargement is associated with female sex, cognitive decline and ApoE E4 homozygote status</article-title><source>Front Psychiatry</source><year>2023</year><volume>14</volume><fpage>1039239</fpage><pub-id pub-id-type="doi">10.3389/fpsyt.2023.1039239</pub-id><pub-id pub-id-type="pmid">36970283</pub-id><pub-id pub-id-type="pmcid">PMC10031049</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Novakova Martinkova J, et al. Longitudinal progression of choroid plexus enlargement is associated with female sex, cognitive decline and ApoE E4 homozygote status. Front Psychiatry. 2023;14:1039239.<pub-id pub-id-type="pmid">36970283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyt.2023.1039239</pub-id><pub-id pub-id-type="pmcid">PMC10031049</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Choroid plexus volume and permeability at brain MRI within the alzheimer disease clinical spectrum</article-title><source>Radiology</source><year>2022</year><volume>304</volume><issue>3</issue><fpage>635</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1148/radiol.212400</pub-id><pub-id pub-id-type="pmid">35579521</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Choi JD, et al. Choroid plexus volume and permeability at brain MRI within the alzheimer disease clinical spectrum. Radiology. 2022;304(3):635&#8211;45.<pub-id pub-id-type="pmid">35579521</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/radiol.212400</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alisch</surname><given-names>JSR</given-names></name><etal/></person-group><article-title>Characterization of Age-Related differences in the human choroid plexus Volume, microstructural Integrity, and blood perfusion using multiparameter magnetic resonance imaging</article-title><source>Front Aging Neurosci</source><year>2021</year><volume>13</volume><fpage>734992</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2021.734992</pub-id><pub-id pub-id-type="pmid">34603011</pub-id><pub-id pub-id-type="pmcid">PMC8485051</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Alisch JSR, et al. Characterization of Age-Related differences in the human choroid plexus Volume, microstructural Integrity, and blood perfusion using multiparameter magnetic resonance imaging. Front Aging Neurosci. 2021;13:734992.<pub-id pub-id-type="pmid">34603011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2021.734992</pub-id><pub-id pub-id-type="pmcid">PMC8485051</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eisma</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Deep learning segmentation of the choroid plexus from structural magnetic resonance imaging (MRI): validation and normative ranges across the adult lifespan</article-title><source>Fluids Barriers CNS</source><year>2024</year><volume>21</volume><issue>1</issue><fpage>21</fpage><pub-id pub-id-type="doi">10.1186/s12987-024-00525-9</pub-id><pub-id pub-id-type="pmid">38424598</pub-id><pub-id pub-id-type="pmcid">PMC10903155</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Eisma JJ, et al. Deep learning segmentation of the choroid plexus from structural magnetic resonance imaging (MRI): validation and normative ranges across the adult lifespan. Fluids Barriers CNS. 2024;21(1):21.<pub-id pub-id-type="pmid">38424598</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12987-024-00525-9</pub-id><pub-id pub-id-type="pmcid">PMC10903155</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serot</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Choroid plexus and ageing in rats: a morphometric and ultrastructural study</article-title><source>Eur J Neurosci</source><year>2001</year><volume>14</volume><issue>5</issue><fpage>794</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1046/j.0953-816x.2001.01693.x</pub-id><pub-id pub-id-type="pmid">11576183</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Serot JM, et al. Choroid plexus and ageing in rats: a morphometric and ultrastructural study. Eur J Neurosci. 2001;14(5):794&#8211;8.<pub-id pub-id-type="pmid">11576183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.0953-816x.2001.01693.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scarpetta</surname><given-names>V</given-names></name><etal/></person-group><article-title>Morphological and mitochondrial changes in murine choroid plexus epithelial cells during healthy aging</article-title><source>Fluids Barriers CNS</source><year>2023</year><volume>20</volume><issue>1</issue><fpage>19</fpage><pub-id pub-id-type="doi">10.1186/s12987-023-00420-9</pub-id><pub-id pub-id-type="pmid">36918889</pub-id><pub-id pub-id-type="pmcid">PMC10012601</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Scarpetta V, et al. Morphological and mitochondrial changes in murine choroid plexus epithelial cells during healthy aging. Fluids Barriers CNS. 2023;20(1):19.<pub-id pub-id-type="pmid">36918889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12987-023-00420-9</pub-id><pub-id pub-id-type="pmcid">PMC10012601</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serot</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Morphological alterations of the choroid plexus in late-onset alzheimer&#8217;s disease</article-title><source>Acta Neuropathol</source><year>2000</year><volume>99</volume><issue>2</issue><fpage>105</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/PL00007412</pub-id><pub-id pub-id-type="pmid">10672315</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Serot JM, et al. Morphological alterations of the choroid plexus in late-onset alzheimer&#8217;s disease. Acta Neuropathol. 2000;99(2):105&#8211;8.<pub-id pub-id-type="pmid">10672315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/pl00007412</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Flurkey CH, D E, American College of Laboratory Animal Medicine Series. 2007.</mixed-citation></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hino</surname><given-names>K</given-names></name><etal/></person-group><article-title>Strain differences of cerebral ventricles in mice: can the MRL/MpJ mouse be a model for hydrocephalus?</article-title><source>Jpn J Vet Res</source><year>2009</year><volume>57</volume><issue>1</issue><fpage>3</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">19593983</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Hino K, et al. Strain differences of cerebral ventricles in mice: can the MRL/MpJ mouse be a model for hydrocephalus? Jpn J Vet Res. 2009;57(1):3&#8211;11.<pub-id pub-id-type="pmid">19593983</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Harrison IF, et al. Non-invasive imaging of CSF-mediated brain clearance pathways via assessment of perivascular fluid movement with diffusion tensor MRI. Elife. 2018;7.<pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.34028</pub-id><pub-id pub-id-type="pmcid">PMC6117153</pub-id><pub-id pub-id-type="pmid">30063207</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petitclerc</surname><given-names>L</given-names></name><etal/></person-group><article-title>Ultra-long-TE arterial spin labeling reveals rapid and brain-wide blood-to-CSF water transport in humans</article-title><source>NeuroImage</source><year>2021</year><volume>245</volume><fpage>118755</fpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2021.118755</pub-id><pub-id pub-id-type="pmid">34826596</pub-id><pub-id pub-id-type="pmcid">PMC7612938</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Petitclerc L, et al. Ultra-long-TE arterial spin labeling reveals rapid and brain-wide blood-to-CSF water transport in humans. NeuroImage. 2021;245:118755.<pub-id pub-id-type="pmid">34826596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2021.118755</pub-id><pub-id pub-id-type="pmcid">PMC7612938</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name><etal/></person-group><article-title>Choroid plexus tissue perfusion and blood to CSF barrier function in rats measured with continuous arterial spin labeling</article-title><source>NeuroImage</source><year>2022</year><volume>261</volume><fpage>119512</fpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2022.119512</pub-id><pub-id pub-id-type="pmid">35882269</pub-id><pub-id pub-id-type="pmcid">PMC9969358</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Lee H, et al. Choroid plexus tissue perfusion and blood to CSF barrier function in rats measured with continuous arterial spin labeling. NeuroImage. 2022;261:119512.<pub-id pub-id-type="pmid">35882269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2022.119512</pub-id><pub-id pub-id-type="pmcid">PMC9969358</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yazdan-Panah</surname><given-names>A</given-names></name><etal/></person-group><article-title>Automatic segmentation of the choroid plexuses: method and validation in controls and patients with multiple sclerosis</article-title><source>Neuroimage Clin</source><year>2023</year><volume>38</volume><fpage>103368</fpage><pub-id pub-id-type="doi">10.1016/j.nicl.2023.103368</pub-id><pub-id pub-id-type="pmid">36913908</pub-id><pub-id pub-id-type="pmcid">PMC10011049</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Yazdan-Panah A, et al. Automatic segmentation of the choroid plexuses: method and validation in controls and patients with multiple sclerosis. Neuroimage Clin. 2023;38:103368.<pub-id pub-id-type="pmid">36913908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2023.103368</pub-id><pub-id pub-id-type="pmcid">PMC10011049</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Storelli</surname><given-names>L</given-names></name><etal/></person-group><article-title>A fully automatic method to segment choroid plexuses in multiple sclerosis using conventional MRI sequences</article-title><source>J Magn Reson Imaging</source><year>2024</year><volume>59</volume><issue>5</issue><fpage>1643</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1002/jmri.28937</pub-id><pub-id pub-id-type="pmid">37530734</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Storelli L, et al. A fully automatic method to segment choroid plexuses in multiple sclerosis using conventional MRI sequences. J Magn Reson Imaging. 2024;59(5):1643&#8211;52.<pub-id pub-id-type="pmid">37530734</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmri.28937</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lolansen</surname><given-names>SD</given-names></name><etal/></person-group><article-title>Choroid plexus-mediated CSF secretion remains stable in aging rats via high and age-resistant metabolic activity</article-title><source>Nat Commun</source><year>2025</year><volume>16</volume><issue>1</issue><fpage>6778</fpage><pub-id pub-id-type="doi">10.1038/s41467-025-61889-6</pub-id><pub-id pub-id-type="pmid">40701965</pub-id><pub-id pub-id-type="pmcid">PMC12287394</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Lolansen SD, et al. Choroid plexus-mediated CSF secretion remains stable in aging rats via high and age-resistant metabolic activity. Nat Commun. 2025;16(1):6778.<pub-id pub-id-type="pmid">40701965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-025-61889-6</pub-id><pub-id pub-id-type="pmcid">PMC12287394</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Evans PG, et al. Non-invasive MRI of blood-cerebrospinal fluid barrier function. Nat Commun. 2020;11(1):2081.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-16002-4</pub-id><pub-id pub-id-type="pmcid">PMC7190825</pub-id><pub-id pub-id-type="pmid">32350278</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhen</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Choroid plexus cysts on 7T MRI: relationship to aging and neurodegenerative diseases</article-title><source>Alzheimers Dement</source><year>2025</year><volume>21</volume><issue>2</issue><fpage>e14484</fpage><pub-id pub-id-type="doi">10.1002/alz.14484</pub-id><pub-id pub-id-type="pmid">39732521</pub-id><pub-id pub-id-type="pmcid">PMC11848175</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Zhen Z, et al. Choroid plexus cysts on 7T MRI: relationship to aging and neurodegenerative diseases. Alzheimers Dement. 2025;21(2):e14484.<pub-id pub-id-type="pmid">39732521</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.14484</pub-id><pub-id pub-id-type="pmcid">PMC11848175</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>S</given-names></name><etal/></person-group><article-title>Elevated peripheral inflammation is associated with choroid plexus enlargement in independent sporadic amyotrophic lateral sclerosis cohorts</article-title><source>Fluids Barriers CNS</source><year>2024</year><volume>21</volume><issue>1</issue><fpage>83</fpage><pub-id pub-id-type="doi">10.1186/s12987-024-00586-w</pub-id><pub-id pub-id-type="pmid">39434103</pub-id><pub-id pub-id-type="pmcid">PMC11492712</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Sun S, et al. Elevated peripheral inflammation is associated with choroid plexus enlargement in independent sporadic amyotrophic lateral sclerosis cohorts. Fluids Barriers CNS. 2024;21(1):83.<pub-id pub-id-type="pmid">39434103</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12987-024-00586-w</pub-id><pub-id pub-id-type="pmcid">PMC11492712</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kolahi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Choroid plexus volume changes in multiple sclerosis: insights from a systematic review and meta-analysis of magnetic resonance imaging studies</article-title><source>Neuroradiology</source><year>2024</year><volume>66</volume><issue>11</issue><fpage>1869</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1007/s00234-024-03439-3</pub-id><pub-id pub-id-type="pmid">39105769</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Kolahi S, et al. Choroid plexus volume changes in multiple sclerosis: insights from a systematic review and meta-analysis of magnetic resonance imaging studies. Neuroradiology. 2024;66(11):1869&#8211;86.<pub-id pub-id-type="pmid">39105769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00234-024-03439-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Deus Vieira</surname><given-names>G</given-names></name><name name-style="western"><surname>Ant&#244;nio</surname><given-names>FF</given-names></name><name name-style="western"><surname>Damasceno</surname><given-names>A</given-names></name></person-group><article-title>Enlargement of the choroid plexus in pediatric multiple sclerosis</article-title><source>Neuroradiology</source><year>2024</year><volume>66</volume><issue>7</issue><fpage>1199</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1007/s00234-024-03366-3</pub-id><pub-id pub-id-type="pmid">38668802</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">de Deus Vieira G, Ant&#244;nio FF, Damasceno A. Enlargement of the choroid plexus in pediatric multiple sclerosis. Neuroradiology. 2024;66(7):1199&#8211;202.<pub-id pub-id-type="pmid">38668802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00234-024-03366-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ota</surname><given-names>M</given-names></name><etal/></person-group><article-title>Relationship between the Tau protein and choroid plexus volume in alzheimer&#8217;s disease</article-title><source>NeuroReport</source><year>2023</year><volume>34</volume><issue>11</issue><fpage>546</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1097/WNR.0000000000001923</pub-id><pub-id pub-id-type="pmid">37384934</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Ota M, et al. Relationship between the Tau protein and choroid plexus volume in alzheimer&#8217;s disease. NeuroReport. 2023;34(11):546&#8211;50.<pub-id pub-id-type="pmid">37384934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WNR.0000000000001923</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tadayon</surname><given-names>E</given-names></name><etal/></person-group><article-title>Choroid plexus volume is associated with levels of CSF proteins: relevance for alzheimer&#8217;s and parkinson&#8217;s disease</article-title><source>Neurobiol Aging</source><year>2020</year><volume>89</volume><fpage>108</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2020.01.005</pub-id><pub-id pub-id-type="pmid">32107064</pub-id><pub-id pub-id-type="pmcid">PMC9094632</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Tadayon E, et al. Choroid plexus volume is associated with levels of CSF proteins: relevance for alzheimer&#8217;s and parkinson&#8217;s disease. Neurobiol Aging. 2020;89:108&#8211;17.<pub-id pub-id-type="pmid">32107064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2020.01.005</pub-id><pub-id pub-id-type="pmcid">PMC9094632</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aquaro</surname><given-names>GD</given-names></name><etal/></person-group><article-title>Age-dependent changes in elastic properties of thoracic aorta evaluated by magnetic resonance in normal subjects</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2013</year><volume>17</volume><issue>4</issue><fpage>674</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/icvts/ivt261</pub-id><pub-id pub-id-type="pmid">23760356</pub-id><pub-id pub-id-type="pmcid">PMC3781791</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Aquaro GD, et al. Age-dependent changes in elastic properties of thoracic aorta evaluated by magnetic resonance in normal subjects. Interact Cardiovasc Thorac Surg. 2013;17(4):674&#8211;9.<pub-id pub-id-type="pmid">23760356</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/icvts/ivt261</pub-id><pub-id pub-id-type="pmcid">PMC3781791</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keep</surname><given-names>RF</given-names></name><name name-style="western"><surname>Jones</surname><given-names>HC</given-names></name></person-group><article-title>A morphometric study on the development of the lateral ventricle choroid plexus, choroid plexus capillaries and ventricular ependyma in the rat</article-title><source>Brain Res Dev Brain Res</source><year>1990</year><volume>56</volume><issue>1</issue><fpage>47</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/0165-3806(90)90163-S</pub-id><pub-id pub-id-type="pmid">2279331</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Keep RF, Jones HC. A morphometric study on the development of the lateral ventricle choroid plexus, choroid plexus capillaries and ventricular ependyma in the rat. Brain Res Dev Brain Res. 1990;56(1):47&#8211;53.<pub-id pub-id-type="pmid">2279331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0165-3806(90)90163-s</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quay</surname><given-names>WB</given-names></name></person-group><article-title>Regional and quantitative differences in the postweaning development of choroid plexuses in the rat brain</article-title><source>Brain Res</source><year>1972</year><volume>36</volume><issue>1</issue><fpage>37</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/0006-8993(72)90764-0</pub-id><pub-id pub-id-type="pmid">5008383</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Quay WB. Regional and quantitative differences in the postweaning development of choroid plexuses in the rat brain. Brain Res. 1972;36(1):37&#8211;45.<pub-id pub-id-type="pmid">5008383</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0006-8993(72)90764-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knudsen</surname><given-names>PA</given-names></name></person-group><article-title>THE SURFACE AREA OF CHOROID PLEXUS IN NORMAL MOUSE EMBRYOS</article-title><source>Acta Anat (Basel)</source><year>1964</year><volume>58</volume><fpage>355</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1159/000142595</pub-id><pub-id pub-id-type="pmid">14250383</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Knudsen PA. THE SURFACE AREA OF CHOROID PLEXUS IN NORMAL MOUSE EMBRYOS. Acta Anat (Basel). 1964;58:355&#8211;64.<pub-id pub-id-type="pmid">14250383</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000142595</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ricigliano</surname><given-names>VAG</given-names></name><etal/></person-group><article-title>Choroid plexus enlargement in inflammatory multiple sclerosis: 3.0-T MRI and translocator protein PET evaluation</article-title><source>Radiology</source><year>2021</year><volume>301</volume><issue>1</issue><fpage>166</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1148/radiol.2021204426</pub-id><pub-id pub-id-type="pmid">34254858</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Ricigliano VAG, et al. Choroid plexus enlargement in inflammatory multiple sclerosis: 3.0-T MRI and translocator protein PET evaluation. Radiology. 2021;301(1):166&#8211;77.<pub-id pub-id-type="pmid">34254858</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/radiol.2021204426</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeong</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Association between choroid plexus volume and cognition in Parkinson disease</article-title><source>Eur J Neurol</source><year>2023</year><volume>30</volume><issue>10</issue><fpage>3114</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1111/ene.15999</pub-id><pub-id pub-id-type="pmid">37498202</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Jeong SH, et al. Association between choroid plexus volume and cognition in Parkinson disease. Eur J Neurol. 2023;30(10):3114&#8211;23.<pub-id pub-id-type="pmid">37498202</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ene.15999</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="alz70722" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement</journal-id><journal-id journal-id-type="pmc-domain-id">4549</journal-id><journal-id journal-id-type="pmc-domain">alzdem</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Alzheimer's &amp; Dementia</journal-title></journal-title-group><issn pub-type="ppub">1552-5260</issn><issn pub-type="epub">1552-5279</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12504061</article-id><article-id pub-id-type="pmcid-ver">PMC12504061.1</article-id><article-id pub-id-type="pmcaid">12504061</article-id><article-id pub-id-type="pmcaiid">12504061</article-id><article-id pub-id-type="doi">10.1002/alz.70722</article-id><article-id pub-id-type="publisher-id">ALZ70722</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Development of a web platform to advance data&#8208;driven recruitment for ADRD research</article-title><alt-title alt-title-type="left-running-head">FULL <sc>et&#160;al</sc>.</alt-title></title-group><contrib-group><contrib id="alz70722-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Full</surname><given-names initials="KM">Kelsie M.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6264-0228</contrib-id><xref rid="alz70722-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70722-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>k.full@vumc.org</email></address></contrib><contrib id="alz70722-cr-0002" contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="D">Dandan</given-names></name><xref rid="alz70722-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70722-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="alz70722-cr-0003" contrib-type="author"><name name-style="western"><surname>Ibarra&#8208;Scurr</surname><given-names initials="DC">Daniel C.</given-names></name><xref rid="alz70722-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70722-cr-0004" contrib-type="author"><name name-style="western"><surname>Wilkins</surname><given-names initials="CH">Consuelo H.</given-names></name><xref rid="alz70722-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70722-cr-0005" contrib-type="author"><name name-style="western"><surname>Burns</surname><given-names initials="JM">Jeffrey M.</given-names></name><xref rid="alz70722-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70722-cr-0006" contrib-type="author"><name name-style="western"><surname>Lewandowski</surname><given-names initials="TM">Tina M.</given-names></name><xref rid="alz70722-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70722-cr-0007" contrib-type="author"><name name-style="western"><surname>Vidoni</surname><given-names initials="ED">Eric D.</given-names></name><xref rid="alz70722-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70722-cr-0008" contrib-type="author"><name name-style="western"><surname>Jefferson</surname><given-names initials="AL">Angela L.</given-names></name><xref rid="alz70722-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70722-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib></contrib-group><aff id="alz70722-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Vanderbilt Memory and Alzheimer's Center</named-content>
<institution>Vanderbilt University Medical Center</institution>
<city>Nashville</city>
<named-content content-type="country-part">Tennessee</named-content>
<country country="US">USA</country>
</aff><aff id="alz70722-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<institution>Vanderbilt University Medical Center</institution>
<city>Nashville</city>
<named-content content-type="country-part">Tennessee</named-content>
<country country="US">USA</country>
</aff><aff id="alz70722-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Biostatistics</named-content>
<institution>Vanderbilt University Medical Center</institution>
<city>Nashville</city>
<named-content content-type="country-part">Tennessee</named-content>
<country country="US">USA</country>
</aff><aff id="alz70722-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Alzheimer's Disease Research Center</named-content>
<institution>University of Kansas Medical Center</institution>
<city>Kansas City</city>
<named-content content-type="country-part">Kansas</named-content>
<country country="US">USA</country>
</aff><aff id="alz70722-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Vanderbilt University Medical Center Nashville</institution>
<city>Nashville</city>
<named-content content-type="country-part">Tennessee</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Kelsie M. Full, Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, 2525 West End Ave, Nashville, TN 37203, USA.<break/> Email: <email>k.full@vumc.org</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>21</volume><issue seq="340">10</issue><issue-id pub-id-type="pmc-issue-id">497699</issue-id><issue-id pub-id-type="doi">10.1002/alz.v21.10</issue-id><elocation-id>e70722</elocation-id><history><date date-type="received"><day>24</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>09</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Alzheimer's &amp; Dementia</italic> published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ALZ-21-e70722.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ALZ-21-e70722.pdf"/><abstract><title>Abstract</title><sec id="alz70722-sec-0010"><title>INTRODUCTION</title><p>To meet increasing investments in research on Alzheimer's disease (AD) and related dementias (ADRD), investigators must efficiently recruit diverse and representative participant samples. To address this challenge, the Vanderbilt Alzheimer's Disease Research Center (ADRC) sought to develop an integrated digital research infrastructure with a web&#8208;based platform.</p></sec><sec id="alz70722-sec-0020"><title>METHODS</title><p>In Fall 2021, we partnered with collaborators and developed the Participant Information Tracking and Coordinating Hub (PITCH). PITCH was developed with a novel iterative user&#8208;centered design, allowing for continuous platform development and enhancement.</p></sec><sec id="alz70722-sec-0030"><title>RESULTS</title><p>With PITCH we evaluate community&#8208;based recruitment strategies, monitor participant progression through the study enrollment pipeline, and simultaneously enrich multiple ADRD studies. The PITCH platform has improved ADRC recruitment efficiency and effectiveness in meeting enrollment goals for two ongoing ADRD cohort studies.</p></sec><sec id="alz70722-sec-0040"><title>DISCUSSION</title><p>With PITCH and data&#8208;driven recruitment we will centralize all institutional ADRD research recruitment and successfully enroll more representative samples of research participants.</p></sec><sec id="alz70722-sec-0050"><title>Highlights</title><p>
<list list-type="bullet" id="alz70722-list-0001"><list-item><p>Researchers face challenges recruiting diverse samples with limited recruitment budgets.</p></list-item><list-item><p>The Vanderbilt ADRC developed a web platform to enhance recruitment and retention.</p></list-item><list-item><p>PITCH builds on previous centralized, data&#8208;driven research recruitment models.</p></list-item><list-item><p>PITCH has expedited recruitment and study timelines and ensured better inclusion of underrepresented groups.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="alz70722-kwd-0001">database</kwd><kwd id="alz70722-kwd-0002">diversity</kwd><kwd id="alz70722-kwd-0003">recruitment</kwd><kwd id="alz70722-kwd-0004">virtual</kwd><kwd id="alz70722-kwd-0005">website</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>National Institutes of Health</institution><institution-id institution-id-type="doi">10.13039/100000002</institution-id></institution-wrap></funding-source><award-id>R01&#8208;AG034962</award-id><award-id>K24&#8208;AG04637</award-id><award-id>P20&#8208;AG068082</award-id><award-id>R24&#8208;AG063724</award-id><award-id>P30&#8208;AG072973</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Alzheimer's Association</institution><institution-id institution-id-type="doi">10.13039/100000957</institution-id></institution-wrap></funding-source><award-id>IIRG&#8208;08&#8208;88733</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Vanderbilt Institute for Clinical &amp; Translational Research Intramural</institution></institution-wrap></funding-source><award-id>VR4328</award-id></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>Vanderbilt Clinical Translational Science</institution></institution-wrap></funding-source><award-id>UL1&#8208;TR000445</award-id><award-id>UL1&#8208;TR002243</award-id></award-group><award-group id="funding-0005"><funding-source><institution-wrap><institution>National Institute on Aging</institution><institution-id institution-id-type="doi">10.13039/100000049</institution-id></institution-wrap></funding-source><award-id>K01AG083223</award-id></award-group></funding-group><counts><fig-count count="8"/><table-count count="0"/><page-count count="11"/><word-count count="5335"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:07.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="alz70722-cite-0001"><string-name name-style="western"><surname>Full</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ibarra&#8208;Scurr</surname><given-names>DC</given-names></string-name>, et&#160;al. <article-title>Development of a web platform to advance data&#8208;driven recruitment for ADRD research</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>21</volume>:<elocation-id>e70722</elocation-id>. <pub-id pub-id-type="doi">10.1002/alz.70722</pub-id><pub-id pub-id-type="pmid">41058004</pub-id></mixed-citation>
</p></notes></front><body><sec id="alz70722-sec-0060"><label>1</label><title>BACKGROUND</title><p>In recent years, efforts to advance dementia care and research initiatives have rapidly grown across institutions and healthcare settings. Improved diagnostic tools, identified risk factors, and more accurate evaluation of the financial, social, and medical burden of Alzheimer's disease (AD) and related dementias (ADRD) have stemmed from this investment.<xref rid="alz70722-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> In particular, the recent discovery of multiple disease modifying treatments has the potential to transform clinical practice and reduce the burden of ADRD.<xref rid="alz70722-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>
</p><p>These many transformative developments are increasing interest in ADRD clinical research participation. The AD drug pipeline is well&#8208;stocked.<xref rid="alz70722-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> To appropriately support the evaluation of these investigational medications, not to mention the many ongoing non&#8208;pharmaceutical trials and observational studies, ADRD researchers are now faced with the challenge of recruiting diverse and representative samples of eligible participants as efficiently as possible. The pace of recruitment directly impacts the cost of studies and their time to completion.<xref rid="alz70722-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> In the rush to enroll participants, many ADRD studies have lacked adequate representation across socioeconomic, geographic, racial, and language lines.<xref rid="alz70722-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="alz70722-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> Additionally, research has been hampered by the generally slow pace of recruitment,<xref rid="alz70722-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> insufficient recruitment budgets,<xref rid="alz70722-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> and inadequate personnel resources or expertise needed to support recruitment,<xref rid="alz70722-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> all in turn slowing the pace of discovery.</p><p>Despite some improvements,<xref rid="alz70722-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="alz70722-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="alz70722-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> recruitment efforts continue to emphasize the efforts of a local study coordinator drawing participants from a medical institution or principal investigator's clinical practice and by investing time in community settings focusing on education and benefits of research participation (e.g., talks and presentations). This existing recruitment model has been inadequate to meet enrollment needs to date<xref rid="alz70722-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> and will only fall further behind in the coming years. A multifaceted, centralized commitment to community engagement, awareness and education, and recruitment is essential to improve the speed to complete AD studies.<xref rid="alz70722-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="alz70722-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="alz70722-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="alz70722-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>
</p><p>We previously argued that centralized, data&#8208;driven research recruitment models accelerate study enrollment bottlenecks, especially at academic medical centers that are responsible for a broad portfolio of observational studies and intervention trials.<xref rid="alz70722-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> At the University of Kansas ADRC, this concept was implemented through the development of a robust recruitment infrastructure grounded in dedicated staffing, a participant&#8208;centered philosophy, streamlined intake workflows, and ongoing evaluation of recruitment processes &#8211; all supported by a tailored REDCap&#8208;based infrastructure and custom&#8208;coded analytics tools.<xref rid="alz70722-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>
</p><p>Building on this foundation, the Vanderbilt Alzheimer's Disease Research Center (ADRC) recently advanced the model further through the development of the Participant Information Tracking and Coordinating Hub (PITCH). Based on the recognition that data&#8208;driven approaches are needed to better utilize staff resources and ensure maximum return on research funding, PITCH was developed to support all ADRC Outreach, Recruitment, and Engagement activities, including enriching a centralized ADRD participant registry with individuals interested in ADRD research. Using PITCH, the ADRC team can evaluate the effectiveness of community&#8208;based recruitment strategies, monitor participant progression through the enrollment pipeline, and leverage research interest to simultaneously enrich multiple ADRD studies. PITCH not only expedites recruitment of participants into the center's ADRD participant registry but also offers a web platform for external Institutional Review Board&#8208;approved research study investigators to access registry participants, centralizing ADRD recruitment across the institution. In this paper, we describe the development of the PITCH digital research infrastructure and detail the advancements of PITCH compared to the previously deployed data&#8208;driven, open&#8208;source, and centralized recruitment models.<xref rid="alz70722-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> We demonstrate proof of concept and discuss the broader deployment in the context of the ADRD recruitment science research field.</p></sec><sec id="alz70722-sec-0070"><label>2</label><title>METHODS</title><sec id="alz70722-sec-0080"><label>2.1</label><title>PITCH development</title><p>PITCH was developed through user&#8208;centered design,<xref rid="alz70722-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="alz70722-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> where feedback from end users is iteratively incorporated into the web platform development and updates. Each iteration of PITCH user&#8208;centered design involves four distinct phases: (1) understand the context, (2) specify user requirements, (3) design solution, and (4) evaluate against requirements. End users for this project include local institution ADRD investigators and staff, users based at other ADRCs, and the broader ADRD research community.</p><boxed-text position="float" content-type="box" orientation="portrait"><sec id="alz70722-sec-0090"><title>RESEARCH IN CONTEXT</title><p>
<list list-type="order" id="alz70722-list-0002"><list-item><p>
<bold>Systematic review</bold>: The authors reviewed the current literature using traditional sources like PubMed. Recent Alzheimer's research has focused on evaluating recruitment methods, particularly for more representative inclusion of underrepresented groups. This manuscript cites many relevant and appropriate articles.</p></list-item><list-item><p>
<bold>Interpretation</bold>: The article details the development and implementation of PITCH, a web&#8208;based data platform. PITCH enables the Vanderbilt Alzheimer's Disease Research Center (ADRC) to effectively and efficiently assess recruitment strategies, track participant progress through the study enrollment pipeline, and simultaneously enrich multiple ADRD studies.</p></list-item><list-item><p>
<bold>Future directions</bold>: The manuscript presents the PITCH platform as a model to enhance centralized, data&#8208;driven research recruitment. The PITCH model is scalable for broader application within other ADRCs, health systems, and fields of study.</p></list-item></list>
</p></sec></boxed-text><p>In Fall 2021, our team conducted context&#8208;of&#8208;use and requirement&#8208;gathering sessions with identified key users and collaborators, including ADRD investigators, ADRC Outreach, Recruitment, and Engagement Core team members, and clinic study staff. These collaborative sessions were the first two phases of PITCH development. The goal of these sessions was to guide the design and specifications of an efficient and effective digital research platform. Building a platform to meet the complex and growing recruitment needs of the ADRC requires a comprehensive understanding of the context of use from different end users (Phase 1). Upon discussing how PITCH is expected to support recruitment needs, the team then focused on collecting requirements from different key collaborators (Phase 2). At the end of these sessions, it was decided that PITCH should be used to capture outreach and engagement event statistics, track participant recruitment and referral processes, and summarize eligible study participant characteristics. It was also decided that PITCH should use data pulled in real time, be dynamic with changing eligibility criteria or study needs, and be interactive and useful in the participant referral process by allowing external study coordinators to update participant referral status (Phase 2). These capabilities, in particular, have the potential to significantly extend and advance recruitment work over prior data management models we have described.<xref rid="alz70722-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>
</p><p>For Phase 3 (design solution), we partnered with the Vanderbilt Biostatistics Data Coordinating Center (VBDCC) to develop the envisioned platform. Our ADRC research team took the information and specifications collected in Phases 1 and 2 and developed a series of user interface platform mockups. In partnership with a VBDCC information technology (IT) project manager and team of application developers as well as key collaborators, the mockups were iteratively reviewed and refined. Key collaborators involved in this step included (1) ADRC Administrative Core leadership and leadership and members of the Outreach, Recruitment, and Engagement Core team, Clinical Core team, and Data Management and Statistics Core team; (2) the VBDCC application development team including a project manager, two developers, and a quality assurance (QA) specialist; and (3) leadership from the University of Kansas ADRC with expertise and contextual knowledge of prior recruitment data models and structures. After mockups were approved and agreed upon, the VBDCC team developed the platform, conducted QA checks within the development database, and provided post&#8208;production support including bug remediation and optimization. The ADRC database team managed all required database configurations and data integrity to meet user requirements of real&#8208;time data pull and the interactive referral process.</p><p>The PITCH's web&#8208;based platform was coded in PHP, HTML, CSS3, Ruby on Rails, and JavaScript using responsive web design to ensure effective page rendering on all screen sizes regardless of operating system. CSS employed Block Element Modifier and Inverted Triangle methodologies. Google Tag Manager was used to enable web analytics data collection using Google Analytics (Mountain View, CA, USA). The web&#8208;based platform utilizes Alchemy to populate summaries and statistics and the Javascript Highcharts library, R Shiny tool, and Python for interactive data visualization.</p><p>For Phase 4 (evaluation against user requirements), beta testing was systematically performed by ADRC staff over several months, and feedback was delivered with revised user requirements (iteration for Phase 2) and implemented in design solution (iteration for Phase 3) to refine the platform and ensure its utility across ADRC study recruitment and enrollment activities. The novel approach of this iterative user&#8208;centered design allows for continuous platform development with regular ongoing platform feature enhancements that target specific user needs.</p></sec><sec id="alz70722-sec-0100"><label>2.2</label><title>PITCH data infrastructure</title><p>The feasibility of the PITCH platform relies on the consolidated and integrated data infrastructure of the ADRC. Figure&#160;<xref rid="alz70722-fig-0001" ref-type="fig">1</xref> displays the ADRC data infrastructure that supports the PITCH platform. Data collected across all ADRC activities, including outreach and recruitment events, study referrals and enrollments, clinical data collection, and study participant scheduling and touchpoints, are securely entered into center&#8208;wide relational REDCap databases. These databases were intentionally developed for use by faculty and staff across the ADRC, including the Administrative Core, Clinical Core, and Outreach, Recruitment, and Engagement Core teams (black boxes in Figure&#160;<xref rid="alz70722-fig-0001" ref-type="fig">1</xref>). The center&#8208;wide databases are continuously managed by the ADRC Data Management and Biostatistics Core team. We followed the Findable, Accessible, Interoperable, and Reusable (FAIR) guiding principles for our ADRC data management to ensure transparency, reproducibility, and reusability.<xref rid="alz70722-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Rigorous data quality checking and cleaning are conducted on a regular basis.</p><fig position="float" fig-type="FIGURE" id="alz70722-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Vanderbilt Alzheimer's Disease Research Center data infrastructure.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ALZ-21-e70722-g005.jpg"/></fig><p>The PITCH data integration process relies on two essential REDCap features: SQL fields and repeating instruments. REDCap SQL fields allow for dynamic data retrieval across various linked databases. SQL queries automatically pull data from one database to another (e.g., into a dropdown menu or auto&#8208;populated text box) minimizing data entry errors and the need for repetitive data entry. The repeating instruments allow for multiple records to be generated for one participant, allowing for comprehensive and detailed participant history tracking over time. This feature enables the monitoring of participants&#8217; journey throughout their research experience (from enrollment into the ADRD participant registry to study referral and consent).</p><p>Data from this integrated network of relational REDCap databases are aggregated into the PITCH web platform via an Application Programming Interface (API). API access to REDCap allows automated real&#8208;time generation of data summaries and statistics that are easily accessible in PITCH in a series of dashboards and reports. All available information provided through PITCH is retrieved from REDCap databases in real time.</p></sec><sec id="alz70722-sec-0110"><label>2.3</label><title>PITCH functionality</title><p>PITCH is composed of four primary dashboards, which we continue to update and improve through the user&#8208;centered design approach detailed previously. In what follows, each dashboard is briefly described:</p><p>The <italic toggle="yes">Outreach Events and Referral Dashboard</italic> provides data on ADRC outreach and engagement events as well as recruitment and retention strategies to maintain diverse and representative participant samples in ADRC&#8208;affiliated studies. Data summaries are reviewed monthly by the center Outreach, Recruitment, and Engagement Core team to identify best practices and evaluate effectiveness and efficiency in recruitment activities to support local ADRD research.</p><p>The <italic toggle="yes">Participant Information and Status Dashboard</italic> pulls real&#8208;time information on the participants enrolled in the ADRD participant registry (e.g., demographic characteristics, study enrollment and referral statuses, and communication touchpoints such as last contact). This dashboard is used by the Outreach, Recruitment and Engagement Core team to monitor continuous registry enrollment and identify participants who are eligible for approved ADRC&#8208;affiliated research studies.</p><p>
<italic toggle="yes">The Participant Study Request Dashboard</italic> is the central location for ADRC&#8208;affiliated investigators to request eligible individuals from the ADRD participant registry for their studies and (upon ADRC Scientific Review Committee approval) view referral status information. Approved study teams only have access to registry participants who meet prespecified eligibility criteria and have consented to their information being shared. External study coordinators are able to update participants&#8217; status (e.g., study accepted, ineligible, not interested), which then automatically update in the ADRD participant registry REDCap database.</p><p>
<italic toggle="yes">The Internal Report Dashboard</italic> also pulls real&#8208;time data from the ADRD participant registry, but this dashboard focuses on information specific to each ADRC&#8208;affiliated study. The internal report dashboard provides detailed breakdowns by age (and age categories), sex, race, ethnicity, and clinical diagnosis for eligible ADRD participant registry participants who can be or have been referred to their study.</p><p>The power of PITCH lies in its integrated data infrastructure, which enables the interactivity of the four PITCH dashboards (Figure&#160;<xref rid="alz70722-fig-0002" ref-type="fig">2</xref>). The interconnectedness of the PITCH dashboards drives recruitment efficiency and effectiveness, reduces unnecessary data entry and errors across different teams and end users, saving countless hours of research staff time, and, most importantly, minimizes the burden on all research participants.</p><fig position="float" fig-type="FIGURE" id="alz70722-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Interactivity of Participant Information Tracking and Coordinating Hub for different Alzheimer's Disease Research Centers and affiliated users.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="ALZ-21-e70722-g006.jpg"/></fig></sec></sec><sec id="alz70722-sec-0120"><label>3</label><title>RESULTS</title><p>PITCH was designed to facilitate (1) the evaluation of outreach and recruitment strategies, (2) the identification of eligible participants for study referral, (3) the simultaneous tracking of progress on study recruitment timelines and goals, and (4) external ADRD investigators in identifying and engaging eligible research participants.</p><sec id="alz70722-sec-0130"><label>3.1</label><title>Outcome 1: Evaluation of outreach and recruitment strategies</title><p>Utilizing PITCH, the ADRC Outreach, Recruitment, and Engagement Core team is able to identify the recruitment strategies that are most effective and efficient in recruiting research participants. In particular, PITCH is critical to evaluating the team's efficacy in recruiting population subgroups that we have been less successful at reaching in the past (e.g., community groups underrepresented in medical research underrepresented groups [URG] and individuals with cognitive impairment).</p><p>For example, the Vanderbilt Memory and Aging Project (VMAP) is a community&#8208;based cohort of older adults free of clinical stroke or dementia that launched initial cohort recruitment between 2012 and 2014. In the first 2 years of enrollment, 335 participants were enrolled, approximately 13% of whom identified as URG.<xref rid="alz70722-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Study enrollment was expanded in 2021. Since the deployment of PITCH in September 2022, the proportion of URG participants enrolled in the VMAP cohort has increased to &#8805;18%. In Figure&#160;<xref rid="alz70722-fig-0003" ref-type="fig">3</xref>, the <italic toggle="yes">Outreach Events and Referral Dashboard</italic> Study Status by Event Report allows the Outreach, Recruitment, and Engagement Core team to examine participants enrolled in various studies by recruitment strategy. In this report, there is the option to filter by variables including date, demographics, and diagnosis, allowing the team to investigate recruitment strategy effectiveness within specified subgroups. Figure&#160;<xref rid="alz70722-fig-0004" ref-type="fig">4</xref> provides the VMAP&#8208;enrolled participants by recruitment strategies filtered by URG status. Using these data, we were able to identify that for VMAP, the most effective recruitment strategies to reaching and enrolling unimpaired URG participants were directed postal mailings, passive media and press coverage, and non&#8208;provider referrals (word of mouth).</p><fig position="float" fig-type="FIGURE" id="alz70722-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Outreach dashboard: study status by event report.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="ALZ-21-e70722-g008.jpg"/></fig><fig position="float" fig-type="FIGURE" id="alz70722-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Vanderbilt Memory and Aging Project participants by recruitment strategy (underrepresented groups [URG] vs non&#8208;Hispanic White).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="ALZ-21-e70722-g002.jpg"/></fig><p>In another example of effective PITCH support, the Tennessee Alzheimer's Project (TAP), which represents the Vanderbilt ADRC Clinical Core cohort, began recruitment in 2021. The goal of this cohort was to maintain approximately one&#8208;third of participants with an AD diagnosis. Leveraging PITCH, we were able to meet and surpass this goal by identifying strategies that were effective in reaching participants with AD (Figure&#160;<xref rid="alz70722-fig-0005" ref-type="fig">5</xref>). When evaluating recruitment strategies by clinical diagnosis, we were not surprised that Vanderbilt University Medical Center provider referral and patient panels were effective strategies to recruit impaired participants; however, we were surprised that other strategies were equally effective, including postal mailings and website engagement.</p><fig position="float" fig-type="FIGURE" id="alz70722-fig-0005" orientation="portrait"><label>FIGURE 5</label><caption><p>Study status by event report by Tennessee Alzheimer's Project participant diagnosis (no impairment vs participants with Alzheimer's disease).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="ALZ-21-e70722-g001.jpg"/></fig><p>Additionally, the <italic toggle="yes">Participant Information and Status Dashboard</italic> includes reports that enable the Outreach, Recruitment, and Engagement Core team to maintain a consistent flow of individuals interested in ADRD research through the study enrollment pipeline. The recruitment report provides an adjustable week&#8208;by&#8208;week timeline view of the recruitment pipeline from the prescreen phone call to enrollment into an ADRC&#8208;affiliated study (Figure&#160;<xref rid="alz70722-fig-0006" ref-type="fig">6</xref>). The outreach team uses this report to adjust planned recruitment activities and staff work responsibilities to maintain a consistent number of prescreen calls and ADRD participant registry enrollment calls per week. The various registry health reports allow the outreach team to evaluate the characteristics of participants in the ADRD participant registry, including real&#8208;time updates on sex, race, ethnicity, and cognitive diagnosis breakdowns to ensure the ADRD research registry is enriched with eligible participants to meet all affiliated study inclusion criteria. Future plans include the integration of additional demographic measures and participant characteristics of interest, such as living arrangements, caregiver status, and Area Deprivation Index.<xref rid="alz70722-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>
</p><fig position="float" fig-type="FIGURE" id="alz70722-fig-0006" orientation="portrait"><label>FIGURE 6</label><caption><p>Weekly recruitment report filtered to past year.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-11" orientation="portrait" xlink:href="ALZ-21-e70722-g003.jpg"/></fig><sec id="alz70722-sec-0140"><label>3.1.1</label><title>Outcome 2: Identifying eligible participants for study referral</title><p>By pulling real&#8208;time data on participants in the ADRD participant registry, the <italic toggle="yes">Participant Information and Status Dashboard</italic> is used to monitor the number and characteristics of registry participants who are eligible for referral to ADRC&#8208;affiliated studies. The registry eligibility report and the study short list report were created to search and review all eligible registry participants and filter participant information based on variables of interest (e.g., age, sex, clinical diagnosis, and race/ethnicity). Together these reports can be used to efficiently identify a list of available eligible participants that meet study criteria. Additionally, these reports include the most recent contact (&#8220;touch point&#8221;) with ADRC recruitment staff, participant history of involvement in other ADRC&#8208;affiliated studies, and if the staff flagged the participant as a high&#8208;priority referral based on current study recruitment needs. In Figure&#160;<xref rid="alz70722-fig-0007" ref-type="fig">7</xref>, using the study short list report, eligible participants were filtered to females between the ages of 65 and 70 years with mild cognitive impairment (MCI) or AD. The <italic toggle="yes">Internal Report Dashboard</italic> also features this information summarized by age, sex, and race categories for investigators to see the overall availability of eligible participants for their study. Leveraging this data&#8208;driven recruitment pipeline, we have referred over 400 participants from the ADRD participant registry to external ADRC&#8208;affiliated studies.</p><fig position="float" fig-type="FIGURE" id="alz70722-fig-0007" orientation="portrait"><label>FIGURE 7</label><caption><p>Study short list report with eligibility filters applied.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-13" orientation="portrait" xlink:href="ALZ-21-e70722-g004.jpg"/></fig></sec></sec><sec id="alz70722-sec-0150"><label>3.2</label><title>Outcome 3: Track progress on study recruitment timelines and goals</title><p>As the ADRC Outreach, Recruitment, and Engagement Core team increases its recruitment goals across ADRC&#8208;affiliated studies, the <italic toggle="yes">Participant Information and Status Dashboard</italic> aids in tracking recruitment progress toward multiple study goals. For example, the study status report provides a real&#8208;time snapshot of recruitment progress across select studies, including pending eligible participants who are in the ADRD participant registry and meet eligibility criteria; accepted participants who have been scheduled for a study enrollment visit; enrolled participants who have been accepted and started study procedures; and participants who were deemed ineligible after recruitment conversations (Figure&#160;<xref rid="alz70722-fig-0008" ref-type="fig">8</xref>). For study&#8208;specific recruitment progress tracking, the study status external reports allow external ADRC&#8208;affiliated study research teams to see summaries of participants who are marked as referred for their studies. Study staff will be given access to reports in PITCH to track in real time how the Outreach, Recruitment, and Engagement Core team is progressing toward their study&#8208;specific recruitment goals and breakdowns of eligible and enrolled participant demographics.</p><fig position="float" fig-type="FIGURE" id="alz70722-fig-0008" orientation="portrait"><label>FIGURE 8</label><caption><p>Study status report.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-15" orientation="portrait" xlink:href="ALZ-21-e70722-g007.jpg"/></fig></sec><sec id="alz70722-sec-0160"><label>3.3</label><title>Outcome 4: Facilitating external ADRD investigators in identifying participants</title><p>ADRD investigators interested in leveraging the ADRD participant registry can complete a participant request form on the <italic toggle="yes">Participant Study Request Dashboard</italic>. The participant request form asks for information on IRB approval, study funding, goals, inclusion and exclusion criteria for participants, and study timelines. Submitted requests are reviewed by the ADRC Scientific Review Committee. Once approved, study investigators can use the <italic toggle="yes">Participant Study Request Dashboard</italic> to manage their study staff access to PITCH, access their study status external reports, view eligible participant information, update the enrollment or eligibility status of participants into their study, and visualize and download data for progress reports or for inclusion in other study documentation materials. This ability for staff to provide updated information through dashboards is key to maintaining accuracy of our ADRC participant tracking. Staff recognized the importance of returning this information to ensure accurate evaluation of potential participants and provides them with equitable opportunities for research participation.</p></sec></sec><sec id="alz70722-sec-0170"><label>4</label><title>DISCUSSION</title><p>With recent congressional approvals, National Institutes of Health NIH funding allocations include approximately $3.8 billion annually for ADRD research.<xref rid="alz70722-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> This investment will drive much needed continued growth in the number of ADRD clinical trials and studies to advance disease knowledge, discover new diagnostic biomarkers, and develop and implement effective treatments. ADRD recruitment efforts will need to adapt to match this rapid pace of research investment. We have outlined the development and deployment of a web&#8208;based platform, PITCH, a centralized hub for data&#8208;driven participant recruitment that tracks the participant life cycle from initial outreach to multiple study referrals. Innovative centralized data&#8208;driven approaches to ADRD recruitment are paramount to help investigators (1) recruit more efficiently within recruitment budgets, (2) improve the effectiveness of reaching the community members they want to reach to enhance representation and inclusion in ADRD research, and (3) be accountable to their study participants and the community they intend to serve.</p><p>Data&#8208;driven research participation registries are not new. Their description in the literature began in earnest in the early 2000s and benefitted from sales and marketing &#8220;customer relations management&#8221; software tools developed in the late 1990s. Within the ADRD research field, several prominent registries and accompanying tools have been developed and deployed with considerable success (e.g., Alzheimer's Association TrialMatch,<xref rid="alz70722-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> Alzheimer's Prevention Registry,<xref rid="alz70722-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> and the Brain Health Registry<xref rid="alz70722-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>). Inspired by these data&#8208;driven models, we previously described the custom development of a set of software tools to track and facilitate ADRD research participation at an institutional level.<xref rid="alz70722-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> The Vanderbilt ADRC PITCH digital research infrastructure and web&#8208;based platform represents a significant extension (and enhancement) of prior data&#8208;driven recruitment model capabilities and has the potential to significantly advance the recruitment and management of participants for ADRD research.</p><p>In this article, we provided specific examples of how we leverage PITCH and our centralized, data&#8208;driven approach to enhance the effectiveness of ADRC recruitment efforts and the efficiency of recruitment processes. This approach has facilitated the engagement of a more diverse and representative sample of participants in our center's ADRD participant registry and streamlined data management across multiple ADRC&#8208;affiliated studies. Just as our prior tools provided improved tracking of participants and efficiency over paper &#8220;chart&#8221;&#8208;based recruitment, PITCH's real&#8208;time accuracy and interactivity provide numerous enhancements for all end users and key ADRC collaborators.</p><p>The need for greater efficiency in clinical trial recruitment is well documented, with most researchers often exceeding allocated recruitment budgets, resources, and timelines. Traditional recruitment methods are time&#8208;consuming, costly, and often undervalued by sponsors. Staff time spent in recruitment is under&#8208;reimbursed compared to activities of enrollment and post&#8208;enrollment (e.g., data collection, analysis, and dissemination). By centralizing recruitment tracking and evaluation and providing detailed information on an interactive and accessible web&#8208;based platform, PITCH significantly reduces recruitment burden on study staff, recruitment teams, and ADRD investigators. A centralized data&#8208;driven model and adaptable data platform allow researchers to do more with less, optimizing their focus on scientific inquiry rather than the logistics of participant recruitment. The centralization of recruitment processes ensures that resources are utilized more effectively across the center and institution, potentially lowering the overall cost and duration of ADRD studies. If participants are efficiently and effectively enrolled faster, it ensures a more rapid pace of study completion and potential discovery.</p><p>The effectiveness of PITCH is evidenced by its ability to expedite recruitment processes and meet critical timelines, for example, in the TAP project. The Vanderbilt ADRC was able to enroll an initial proof&#8208;of&#8208;concept Clinical Core cohort of 150 people (33% unimpaired, 33% MCI, and 33% AD) ahead of the specified recruitment period. This recruitment goal was met while the Outreach, Recruitment, and Engagement Core team was also responsible for meeting the recruitment goals of several additional external ADRC&#8208;affiliated studies. By integrating real&#8208;time data management and participant tracking, PITCH enables the ADRC to respond quickly to recruitment needs across multiple studies, effortlessly aligning eligible participants with appropriate studies. This capability not only enhances the pace of enrolling participants but also contributes directly to the timely progression of research projects by reducing recruitment burden on staff.</p><p>One of the transformative aspects of PITCH is its increased accountability to participants. Traditionally, participants enrolled in research registries might miss out on opportunities for study inclusion. An eager eligible participant may be enrolled in a registry and never be contacted again. With the real&#8208;time data and participant history tracking capabilities of PITCH, eligible participants may be promptly identified and matched with ongoing studies, addressing the challenge of participants &#8220;sitting&#8221; unnoticed in the registry. Moreover, PITCH serves as a model for accountability and transparency in participant management, demonstrating a commitment to respecting and valuing the contributions of community members to research. Data&#8208;driven platforms, such as PITCH, increase the likelihood that eligible and interested community members will become active, engaged, and sustained research participants.</p><sec id="alz70722-sec-0180"><label>4.1</label><title>Future directions</title><p>We envision many possible additional and expanded functionalities for PITCH. For example, we believe PITCH is flexible enough to eventually accommodate a participant's own &#8220;My Research Program&#8221; dashboard, allowing participants to log in and check on the status of their screening and enrollment, or request they be considered for a particular study. The scalability of the PITCH model presents opportunities for broader application within other research centers, health systems, and fields of study. Its success at the Vanderbilt ADRC highlights its potential as a resource&#8208;sharing tool that can be adapted to various institutional contexts. We focused on using technologies and software platforms that were standard, low&#8208;cost, and open source or source&#8208;available. With the appropriate data infrastructure and mapping of institutional servers, PITCH could be deployed at many institutions with the same recruitment needs, both encouraging collaboration across different research settings and creating the potential for mass recruitment data sharing that would transform the science of research recruitment. This sharing of technological resources and best practices can significantly enhance the operational capacity of ADRCs nationwide, fostering a more connected and efficient network of ADRD research institutions.</p></sec></sec><sec id="alz70722-sec-0190"><label>5</label><title>CONCLUSIONS</title><p>The evolution of our early recruitment tools, originally developed at the University of Kansas ADRC, laid the groundwork for subsequent advancements &#8211; including the development and implementation of PITCH at the Vanderbilt ADRC &#8211; setting a new standard for the use of technology in data&#8208;driven and responsive research recruitment. By facilitating more efficient and inclusive recruitment strategies, PITCH has the potential to significantly enhance the quality and impact of ADRD research, on both the science and the participant experience. Through its focus on efficiency, effectiveness, and accountability, PITCH ensures that recruitment processes will be not only expedient but also equitable and participant&#8208;centered.</p></sec><sec sec-type="COI-statement" id="alz70722-sec-0210"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors declare no conflicts of interest. Author disclosures are available in the <xref rid="alz70722-supinfo-0001" ref-type="">supporting information</xref>.</p></sec><sec id="alz70722-sec-0220"><title>CONSENT STATEMENT</title><p>Consent was not necessary for this work.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="alz70722-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="alz70722-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70722-s001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="alz70722-sec-0200"><title>ACKNOWLEDGMENTS</title><p>This work was supported by the National Institutes of Health (R01&#8208;AG034962, K24&#8208;AG04637, P20&#8208;AG068082, R24&#8208;AG063724, and P30&#8208;AG072973), the Alzheimer's Association (IIRG&#8208;08&#8208;88733), the Vanderbilt Institute for Clinical &amp; Translational Research Intramural Award (VR4328), and Vanderbilt Clinical Translational Science Award (UL1&#8208;TR000445 and UL1&#8208;TR002243). Dr. Full was supported by the National Institute on Aging (K01AG083223). The funding sources had no involvement in the design, analysis, writing, or preparation for publication involved in this manuscript.</p></ack><ref-list id="alz70722-bibl-0001"><title>REFERENCES</title><ref id="alz70722-bib-0001"><label>1</label><mixed-citation publication-type="book" id="alz70722-cite-0002"><collab collab-type="authors">NIH</collab><source>Progress Report: Alzheimer's Disease and Related Dementias Research</source>. <publisher-name>National Institute of Health</publisher-name>; <year>2022</year>.</mixed-citation></ref><ref id="alz70722-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="alz70722-cite-0003"><string-name name-style="western"><surname>Cummings</surname><given-names>JL</given-names></string-name>. <article-title>Anti&#8208;amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer's disease therapeutics</article-title>. <source>Drugs</source>. <year>2023</year>;<volume>83</volume>(<issue>7</issue>):<fpage>569</fpage>&#8208;<lpage>576</lpage>.<pub-id pub-id-type="pmid">37060386</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40265-023-01858-9</pub-id><pub-id pub-id-type="pmcid">PMC10195708</pub-id></mixed-citation></ref><ref id="alz70722-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="alz70722-cite-0004"><string-name name-style="western"><surname>Cummings</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Zhong</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Fonseca</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>F</given-names></string-name>. <article-title>Alzheimer's disease drug development pipeline: 2023</article-title>. <source>Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions</source>. <year>2023</year>;<volume>9</volume>(<issue>2</issue>):<elocation-id>e12385</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/trc2.12385</pub-id><pub-id pub-id-type="pmcid">PMC10210334</pub-id><pub-id pub-id-type="pmid">37251912</pub-id></mixed-citation></ref><ref id="alz70722-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="alz70722-cite-0005"><string-name name-style="western"><surname>Cummings</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Zhong</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kinney</surname><given-names>JW</given-names></string-name>, et&#160;al. <article-title>Double&#8208;blind, placebo&#8208;controlled, proof&#8208;of&#8208;concept trial of bexarotene Xin moderate Alzheimer's disease</article-title>. <source>Alzheimers Res Ther</source>. <year>2016</year>:<fpage>4</fpage>.<pub-id pub-id-type="pmid">26822146</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-016-0173-2</pub-id><pub-id pub-id-type="pmcid">PMC4731943</pub-id></mixed-citation></ref><ref id="alz70722-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="alz70722-cite-0006"><string-name name-style="western"><surname>Babulal</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Quiroz</surname><given-names>YT</given-names></string-name>, <string-name name-style="western"><surname>Albensi</surname><given-names>BC</given-names></string-name>, et&#160;al. <article-title>Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: update and areas of immediate need</article-title>. <source>Alzheimers Dement</source>. <year>2019</year>;<volume>15</volume>(<issue>2</issue>):<fpage>292</fpage>&#8208;<lpage>312</lpage>.<pub-id pub-id-type="pmid">30555031</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2018.09.009</pub-id><pub-id pub-id-type="pmcid">PMC6368893</pub-id></mixed-citation></ref><ref id="alz70722-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="alz70722-cite-0007"><string-name name-style="western"><surname>Elliott</surname><given-names>CL</given-names></string-name>. <article-title>Together we make the difference: national strategy for recruitment and participation in Alzheimer's and related dementias clinical research</article-title>. <source>Ethn Dis</source>. <year>2020</year>;<volume>30</volume>(<issue>2</issue>):<fpage>705</fpage>&#8208;<lpage>708</lpage>.<pub-id pub-id-type="pmid">33250617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18865/ed.30.S2.705</pub-id><pub-id pub-id-type="pmcid">PMC7683031</pub-id></mixed-citation></ref><ref id="alz70722-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="alz70722-cite-0008"><string-name name-style="western"><surname>Cummings</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Aisen</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Barton</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Re&#8208;engineering Alzheimer clinical trials: global Alzheimer's platform network</article-title>. <source>J Prev Alzheimers Dis</source>. <year>2016</year>;<volume>3</volume>(<issue>2</issue>):<fpage>114</fpage>&#8208;<lpage>120</lpage>.<pub-id pub-id-type="pmid">28459045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14283/jpad.2016.93</pub-id><pub-id pub-id-type="pmcid">PMC5408881</pub-id></mixed-citation></ref><ref id="alz70722-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="alz70722-cite-0009"><string-name name-style="western"><surname>Amorrortu</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Arevalo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Vernon</surname><given-names>SW</given-names></string-name>, et&#160;al. <article-title>Recruitment of racial and ethnic minorities to clinical trials conducted within specialty clinics: an intervention mapping approach</article-title>. <source>Trials</source>. <year>2018</year>;<volume>19</volume>(<issue>1</issue>):<fpage>115</fpage>.<pub-id pub-id-type="pmid">29454389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13063-018-2507-9</pub-id><pub-id pub-id-type="pmcid">PMC5816509</pub-id></mixed-citation></ref><ref id="alz70722-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="alz70722-cite-0010"><string-name name-style="western"><surname>Vidoni</surname><given-names>ED</given-names></string-name>, <string-name name-style="western"><surname>Bothwell</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Burns</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Dwyer</surname><given-names>JR</given-names></string-name>. <article-title>Novel recruitment models will drive Alzheimer's trial success</article-title>. <source>Alzheimers Dement</source>. <year>2018</year>;<volume>14</volume>(<issue>1</issue>):<fpage>117</fpage>&#8208;<lpage>119</lpage>.<pub-id pub-id-type="pmid">29156221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2017.10.004</pub-id><pub-id pub-id-type="pmcid">PMC5750126</pub-id></mixed-citation></ref><ref id="alz70722-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="alz70722-cite-0011"><string-name name-style="western"><surname>Langbaum</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>High</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Nichols</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kettenhoven</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Reiman</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Tariot</surname><given-names>PN</given-names></string-name>. <article-title>The Alzheimer's prevention registry: a large internet&#8208;based participant recruitment registry to accelerate referrals to Alzheimer's&#8208;focused studies</article-title>. <source>J Prev Alzheimers Dis</source>. <year>2020</year>;<volume>7</volume>(<issue>4</issue>):<fpage>242</fpage>&#8208;<lpage>250</lpage>.<pub-id pub-id-type="pmid">32920626</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14283/jpad.2020.31</pub-id><pub-id pub-id-type="pmcid">PMC7534299</pub-id></mixed-citation></ref><ref id="alz70722-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="alz70722-cite-0012"><string-name name-style="western"><surname>Ta Park</surname><given-names>VM</given-names></string-name>, <string-name name-style="western"><surname>Meyer</surname><given-names>OL</given-names></string-name>, <string-name name-style="western"><surname>Tsoh</surname><given-names>JY</given-names></string-name>, et&#160;al. <article-title>The collaborative approach for Asian Americans and pacific islanders research and education (CARE): a recruitment registry for Alzheimer's disease and related dementias, aging, and caregiver&#8208;related research</article-title>. <source>Alzheimers Dement</source>. <year>2023</year>;<volume>19</volume>(<issue>2</issue>):<fpage>433</fpage>&#8208;<lpage>443</lpage>.<pub-id pub-id-type="pmid">35420258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12667</pub-id><pub-id pub-id-type="pmcid">PMC9562598</pub-id></mixed-citation></ref><ref id="alz70722-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="alz70722-cite-0013"><string-name name-style="western"><surname>Dabiri</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Raman</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Grooms</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Molina&#8208;Henry</surname><given-names>D</given-names></string-name>. <article-title>Examining the role of community engagement in enhancing the participation of racial and ethnic minoritized communities in Alzheimer's disease clinical trials; a rapid review</article-title>. <source>J Prev Alzheimers Dis</source>. <year>2024</year>;<volume>11</volume>(<issue>6</issue>):<fpage>1647</fpage>&#8208;<lpage>1672</lpage>.<pub-id pub-id-type="pmid">39559877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14283/jpad.2024.149</pub-id><pub-id pub-id-type="pmcid">PMC11573826</pub-id></mixed-citation></ref><ref id="alz70722-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="alz70722-cite-0014"><string-name name-style="western"><surname>Szabo&#8208;Reed</surname><given-names>AN</given-names></string-name>, <string-name name-style="western"><surname>Hall</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Vidoni</surname><given-names>ED</given-names></string-name>, et&#160;al. <article-title>Recruitment methods and yield rates for a multisite clinical trial exploring risk reduction for Alzheimer's disease (rrAD)</article-title>. <source>Alzheimers Dement (N Y)</source>. <year>2023</year>;<volume>9</volume>(<issue>4</issue>):<elocation-id>e12422</elocation-id>.<pub-id pub-id-type="pmid">37841653</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/trc2.12422</pub-id><pub-id pub-id-type="pmcid">PMC10576444</pub-id></mixed-citation></ref><ref id="alz70722-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="alz70722-cite-0015"><string-name name-style="western"><surname>Altman</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>TTK</given-names></string-name>, <string-name name-style="western"><surname>Breland</surname><given-names>JY</given-names></string-name>. <article-title>Design thinking in health care</article-title>. <source>Prev Chronic Dis</source>. <year>2018</year>;<volume>15</volume>:<fpage>E117</fpage>.<pub-id pub-id-type="pmid">30264690</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5888/pcd15.180128</pub-id><pub-id pub-id-type="pmcid">PMC6178900</pub-id></mixed-citation></ref><ref id="alz70722-bib-0015"><label>15</label><mixed-citation publication-type="book" id="alz70722-cite-0016"><string-name name-style="western"><surname>Norman</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Draper</surname><given-names>SW</given-names></string-name>. <source>User Centered System Design; New Perspectives on Human&#8208;Computer Interaction</source>. <publisher-name>L. Erlbaum Associates Inc</publisher-name>; <year>1986</year>.</mixed-citation></ref><ref id="alz70722-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="alz70722-cite-0017"><string-name name-style="western"><surname>Wilkinson</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Dumontier</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Aalbersberg</surname><given-names>IJ</given-names></string-name>, et&#160;al. <article-title>The FAIR Guiding Principles for scientific data management and stewardship</article-title>. <source>Scientific Data</source>. <year>2016</year>;<volume>3</volume>(<issue>1</issue>):<elocation-id>160018</elocation-id>.<pub-id pub-id-type="pmid">26978244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sdata.2016.18</pub-id><pub-id pub-id-type="pmcid">PMC4792175</pub-id></mixed-citation></ref><ref id="alz70722-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="alz70722-cite-0018"><string-name name-style="western"><surname>Jefferson</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Gifford</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Acosta</surname><given-names>LM</given-names></string-name>, et&#160;al. <article-title>The Vanderbilt Memory &amp; Aging Project: study design and baseline cohort overview</article-title>. <source>J Alzheimers Dis</source>. <year>2016</year>;<volume>52</volume>(<issue>2</issue>):<fpage>539</fpage>&#8208;<lpage>559</lpage>.<pub-id pub-id-type="pmid">26967211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-150914</pub-id><pub-id pub-id-type="pmcid">PMC4866875</pub-id></mixed-citation></ref><ref id="alz70722-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="alz70722-cite-0019"><string-name name-style="western"><surname>Kind</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Jencks</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Brock</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Neighborhood socioeconomic disadvantage and 30&#8208;day rehospitalization: a retrospective cohort study</article-title>. <source>Ann Intern Med</source>. <year>2014</year>;<volume>161</volume>(<issue>11</issue>):<fpage>765</fpage>&#8208;<lpage>774</lpage>.<pub-id pub-id-type="pmid">25437404</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M13-2946</pub-id><pub-id pub-id-type="pmcid">PMC4251560</pub-id></mixed-citation></ref><ref id="alz70722-bib-0019"><label>19</label><mixed-citation publication-type="book" id="alz70722-cite-0020"><collab collab-type="authors">RePORT NIH</collab>
. <source><italic toggle="yes">Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC</italic>)</source>. <publisher-name>US Department of Health and Human Services</publisher-name>; <year>2024</year>; Accessed March 19th, 2025. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://report.nih.gov/funding/categorical-spending#/" ext-link-type="uri">https://report.nih.gov/funding/categorical&#8208;spending#/</ext-link></mixed-citation></ref><ref id="alz70722-bib-0020"><label>20</label><mixed-citation publication-type="book" id="alz70722-cite-0021"><collab collab-type="authors">Alzheimer's Association</collab>
. <source>TrialMatch: Find Clinical Trials for Alzheimer's and Other Dementia</source>. <year>2025</year>; Accessed March 19th 2025. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.alz.org/alzheimers-dementia/research_progress/clinical-trials/trialmatch" ext-link-type="uri">https://www.alz.org/alzheimers&#8208;dementia/research_progress/clinical&#8208;trials/trialmatch</ext-link></mixed-citation></ref><ref id="alz70722-bib-0021"><label>21</label><mixed-citation publication-type="book" id="alz70722-cite-0022"><collab collab-type="authors">Banner Alzheimer's Institute</collab>
. <source>The Alzheimer's Prevention Registry</source>. <year>2025</year>; Accessed March 19th 2025. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.endalznow.org/" ext-link-type="uri">https://www.endalznow.org/</ext-link></mixed-citation></ref><ref id="alz70722-bib-0022"><label>22</label><mixed-citation publication-type="book" id="alz70722-cite-0023"><collab collab-type="authors">University of California San Francisco</collab>
. <source>BrainHealth Registry</source>. <publisher-name>The Regents of the University of California</publisher-name>; <year>2025</year>; Accessed March 19th, 2025.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.brainhealthregistry.org/" ext-link-type="uri">https://www.brainhealthregistry.org/</ext-link></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="alz70761" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement</journal-id><journal-id journal-id-type="pmc-domain-id">4549</journal-id><journal-id journal-id-type="pmc-domain">alzdem</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Alzheimer's &amp; Dementia</journal-title></journal-title-group><issn pub-type="ppub">1552-5260</issn><issn pub-type="epub">1552-5279</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12505026</article-id><article-id pub-id-type="pmcid-ver">PMC12505026.1</article-id><article-id pub-id-type="pmcaid">12505026</article-id><article-id pub-id-type="pmcaiid">12505026</article-id><article-id pub-id-type="doi">10.1002/alz.70761</article-id><article-id pub-id-type="publisher-id">ALZ70761</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Variability of longitudinal sleep monitoring in amyloid&#8208;negative and amyloid&#8208;positive cognitively unimpaired and mildly impaired older adults</article-title><alt-title alt-title-type="left-running-head">PEDERSEN <sc>et&#160;al</sc>.</alt-title></title-group><contrib-group><contrib id="alz70761-cr-0001" contrib-type="author"><name name-style="western"><surname>Pedersen</surname><given-names initials="TJ">Taylor J.</given-names></name><xref rid="alz70761-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70761-cr-0002" contrib-type="author"><name name-style="western"><surname>Lu</surname><given-names initials="R">Ruijin</given-names></name><xref rid="alz70761-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70761-cr-0003" contrib-type="author"><name name-style="western"><surname>Toedebusch</surname><given-names initials="C">Cristina</given-names></name><xref rid="alz70761-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="alz70761-cr-0004" contrib-type="author"><name name-style="western"><surname>Hess</surname><given-names initials="A">Ashley</given-names></name><xref rid="alz70761-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="alz70761-cr-0005" contrib-type="author"><name name-style="western"><surname>Richardson</surname><given-names initials="R">Rachel</given-names></name><xref rid="alz70761-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="alz70761-cr-0006" contrib-type="author"><name name-style="western"><surname>Quigley</surname><given-names initials="A">Allyson</given-names></name><xref rid="alz70761-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="alz70761-cr-0007" contrib-type="author"><name name-style="western"><surname>Robinson</surname><given-names initials="CG">Carling G.</given-names></name><xref rid="alz70761-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70761-cr-0008" contrib-type="author"><name name-style="western"><surname>Morris</surname><given-names initials="JC">John C.</given-names></name><xref rid="alz70761-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="alz70761-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70761-cr-0009" contrib-type="author"><name name-style="western"><surname>Holtzman</surname><given-names initials="DM">David M.</given-names></name><xref rid="alz70761-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="alz70761-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70761-cr-0010" contrib-type="author"><name name-style="western"><surname>Xiong</surname><given-names initials="C">Chengjie</given-names></name><xref rid="alz70761-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="alz70761-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70761-cr-0011" contrib-type="author"><name name-style="western"><surname>Gordon</surname><given-names initials="BA">Brian A.</given-names></name><xref rid="alz70761-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70761-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="alz70761-cr-0012" contrib-type="author" corresp="yes"><name name-style="western"><surname>Lucey</surname><given-names initials="BP">Brendan P.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5400-825X</contrib-id><xref rid="alz70761-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="alz70761-aff-0006" ref-type="aff">
<sup>6</sup>
</xref><address><email>luceyb@wustl.edu</email></address></contrib></contrib-group><aff id="alz70761-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Psychological &amp; Brain Sciences</named-content>
<institution>Washington University in St. Louis</institution>
<city>St Louis</city>
<named-content content-type="country-part">Missouri</named-content>
<country country="US">USA</country>
</aff><aff id="alz70761-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Biostatistics</named-content>
<institution>Washington University in St. Louis</institution>
<city>St Louis</city>
<named-content content-type="country-part">Missouri</named-content>
<country country="US">USA</country>
</aff><aff id="alz70761-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Washington University in St. Louis</institution>
<city>St Louis</city>
<named-content content-type="country-part">Missouri</named-content>
<country country="US">USA</country>
</aff><aff id="alz70761-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Knight Alzheimer Disease Research Center</named-content>
<institution>Washington University in St. Louis</institution>
<city>St Louis</city>
<named-content content-type="country-part">Missouri</named-content>
<country country="US">USA</country>
</aff><aff id="alz70761-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Radiology</named-content>
<institution>Washington University in St. Louis</institution>
<city>St Louis</city>
<named-content content-type="country-part">Missouri</named-content>
<country country="US">USA</country>
</aff><aff id="alz70761-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Center On Biological Rhythms and Sleep</named-content>
<institution>Washington University in St. Louis</institution>
<city>St Louis</city>
<named-content content-type="country-part">Missouri</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Brendan P. Lucey, MD, MSCI, Washington University School of Medicine, Campus Box 8111, 660 S Euclid Ave, St Louis, MO 63108, USA.<break/> Email: <email>luceyb@wustl.edu</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>21</volume><issue seq="450">10</issue><issue-id pub-id-type="pmc-issue-id">497699</issue-id><issue-id pub-id-type="doi">10.1002/alz.v21.10</issue-id><elocation-id>e70761</elocation-id><history><date date-type="rev-recd"><day>02</day><month>9</month><year>2025</year></date><date date-type="received"><day>17</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>02</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Alzheimer's &amp; Dementia</italic> published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ALZ-21-e70761.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ALZ-21-e70761.pdf"/><abstract><title>Abstract</title><sec id="alz70761-sec-0010"><title>INTRODUCTION</title><p>Sleep disturbances are associated with Alzheimer's disease (AD) pathology and cognitive symptoms, but few studies have longitudinally assessed sleep, AD biomarkers, and cognition. Understanding how sleep changes over time in older adults with and without AD pathology is crucial for appropriately designing longitudinal studies of aging and AD.</p></sec><sec id="alz70761-sec-0020"><title>METHODS</title><p>Sleep was measured over &#8776;3.5 years in older adults using self&#8208;reported questionnaires and an at&#8208;home single&#8208;channel electroencephalography (scEEG) device. Participants also underwent amyloid imaging and cognitive testing. Longitudinal change of multiple sleep parameters was determined and sample sizes estimated for future clinical trials using sleep as an outcome.</p></sec><sec id="alz70761-sec-0030"><title>RESULTS</title><p>In both amyloid groups, EEG spectral power measures demonstrated minimal longitudinal change, whereas self&#8208;reported and sleep parameters such as sleep efficiency demonstrated greater variability over time.</p></sec><sec id="alz70761-sec-0040"><title>DISCUSSION</title><p>This study characterized how sleep parameters change in older adults with and without AD pathology, offering important guidance for future longitudinal studies targeting sleep and neurodegeneration.</p></sec><sec id="alz70761-sec-0050"><title>Highlights</title><p>
<list list-type="bullet" id="alz70761-list-0001"><list-item><p>Low variability in electroencephalography (EEG) spectral power metrics, including delta, theta, and alpha power.</p></list-item><list-item><p>Greater variability in self&#8208;report sleep metrics, including self&#8208;reported time to fall asleep and EEG&#8208;derived metrics such as sleep duration and N2 sleep.</p></list-item><list-item><p>Understanding the variability in sleep measures over time will offer important guidance for designing future longitudinal studies targeting sleep and neurodegeneration.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="alz70761-kwd-0001">Alzheimer's disease</kwd><kwd id="alz70761-kwd-0002">amyloid</kwd><kwd id="alz70761-kwd-0003">single&#8208;channel electroencephalography</kwd><kwd id="alz70761-kwd-0004">sleep</kwd><kwd id="alz70761-kwd-0005">sleep logs</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>National Institutes of Health</institution><institution-id institution-id-type="doi">10.13039/100000002</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>National Institute on Aging</institution><institution-id institution-id-type="doi">10.13039/100000049</institution-id></institution-wrap></funding-source><award-id>P01 AG03991</award-id><award-id>P01 AG026276</award-id><award-id>P30 AG066444</award-id></award-group></funding-group><counts><fig-count count="2"/><table-count count="5"/><page-count count="13"/><word-count count="7624"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:08.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="alz70761-cite-0001"><string-name name-style="western"><surname>Pedersen</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Toedebusch</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>Variability of longitudinal sleep monitoring in amyloid&#8208;negative and amyloid&#8208;positive cognitively unimpaired and mildly impaired older adults</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>21</volume>:<elocation-id>e70761</elocation-id>. <pub-id pub-id-type="doi">10.1002/alz.70761</pub-id></mixed-citation>
</p></notes></front><body><sec id="alz70761-sec-0060"><label>1</label><title>BACKGROUND</title><p>Alzheimer's disease (AD) has grown increasingly prevalent as a major cause of dementia and death in elderly individuals.<xref rid="alz70761-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="alz70761-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> AD has a long preclinical phase that precedes clinical diagnosis, where pathology begins to develop but cognition remains unimpaired.<xref rid="alz70761-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="alz70761-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="alz70761-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Changes in blood, cerebrospinal fluid (CSF), and positron emission tomography (PET) AD biomarkers provide early indication of AD pathology before clinical symptoms arise. Levels of amyloid beta (A&#946;) plaques, captured by blood, CSF, or PET biomarkers, begin to develop a decade or more before the onset of symptoms.<xref rid="alz70761-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> These pathological changes in the brain are expected to precede other larger alterations due to AD, including neuronal injury, cell death, and ultimately clinical changes, including memory and cognitive decline.<xref rid="alz70761-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> The preclinical stage serves as a crucial window for intervention to target progression from asymptomatic to symptomatic AD.<xref rid="alz70761-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>
</p><p>Sleep disturbances are commonly seen in both the &#8220;preclinical&#8221; asymptomatic period of AD, when AD pathology is accumulating without cognitive dysfunction, and in symptomatic AD.<xref rid="alz70761-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Alterations in sleep efficiency, duration, and time spent in certain sleep stages while in the preclinical phase have been shown to be associated with cognitive decline and A&#946; deposition.<xref rid="alz70761-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="alz70761-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Disrupted sleep affects 25% of people with mild dementia and up to 50% of those with moderate or severe dementia.<xref rid="alz70761-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> It was previously thought that sleep changes were due to underlying AD pathology, but there has been mounting evidence that sleep disturbances also contribute to an increased risk of AD.<xref rid="alz70761-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> This bidirectional relationship is poorly understood due to a lack of research on sleep, AD biomarkers, and cognitive assessments collected longitudinally.</p><p>There are a multitude of reported sleep&#8208;monitoring paradigms, including polysomnography and self&#8208;reports. For example, self&#8208;report data&#8212;such as sleep diaries and surveys like the Epworth Sleepiness Scale and Pittsburgh Sleep Quality Index&#8212;are often used to measure sleep quality and disturbances due to ease of implementation.<xref rid="alz70761-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>&#8208;<sup>&#8208;</sup>
<xref rid="alz70761-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Alternatively, multiple sleep parameters measured by single&#8208;channel electroencephalography (scEEG) are comparable to those produced from polysomnography, including time spent in different sleep stages and EEG spectral power.<xref rid="alz70761-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Each approach produces numerous individual measurements that vary in sensitivity and specificity, leading to different studies potentially yielding varying results based on the chosen measurement methods.<xref rid="alz70761-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="alz70761-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> Change over time serves as the foundation for assessing the sensitivity and predictability of a measure.<xref rid="alz70761-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> Therefore, it is critical to understand how sleep metrics change over time when planning clinical research studies.</p><p>Currently there is a lack of research examining longitudinal sleep measures, AD biomarkers, and cognitive data. Many studies have relied on cross&#8208;sectional data for sleep measures, which capture only a single timepoint for sleep's role in AD progression.<xref rid="alz70761-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> This study sought to examine longitudinal sleep changes in a cohort of cognitively unimpaired amyloid&#8208;negative and amyloid&#8208;positive individuals to inform future sleep studies in older adults, particularly in the setting of AD.</p></sec><sec id="alz70761-sec-0070"><label>2</label><title>METHODS</title><sec id="alz70761-sec-0080"><label>2.1</label><title>Participants</title><p>Sixty community&#8208;living participants enrolled in longitudinal studies at the Charles F. and Joanne Knight Alzheimer's Disease Research Center (ADRC) at Washington University in St. Louis were included in the study. All participants underwent annual standardized clinical and cognitive assessments by a clinician. For inclusion in this study, participants were required to have: (1) two separate study visits with six nights of sleep monitoring from an scEEG device and sleep logs; (2) an amyloid PET scan within 2 years of sleep monitoring; and (3) a cognitive assessment of their Clinical Dementia Rating (CDR) within 1 year of sleep monitoring. Age, sex, race, years of education, and medical history were also collected. This study was approved by the Washington University Institutional Review Board. Each participant provided written informed consent and was compensated for their participation.</p></sec><sec id="alz70761-sec-0090"><label>2.2</label><title>Sleep monitoring</title><p>Sleep was monitored at two timepoints with an average 3.49&#8208;year difference between visits. At each timepoint, sleep was assessed up to six nights at home using an scEEG device (Sleep Profiler, Advanced Brain Monitoring, Carlsbad, CA). Bed and rise times were confirmed with sleep logs and actigraphy. The scEEG device was worn on the forehead and recorded 256 samples per second from three frontal sensors placed at approximately AF7, AF8, and Fpz. Only the AF7&#8208;AF8 channel was used for scoring sleep stages in 30 s epochs in Polysmith (Nihon Kohden, Tokyo, Japan) by registered polysomnographic technologists using modified American Academy of Sleep Medicine (AASM) criteria.<xref rid="alz70761-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Summary sleep measures from the scored scEEG epochs were calculated using Polysmith. Nights were excluded if&#160;&gt;10% of the recording was artifactual and/or if the bed and rise times did not match the sleep log and/or actigraphy. Participants needed a minimum of two nights that met this criterion to be included in the analyses. Average total sleep duration, wake after sleep onset, sleep efficiency, rapid eye movement (REM) onset latency, and time in different sleep stages (non&#8208;REM (NREM) sleep Stages 1, 2, 3, and REM) were calculated for each study night and used in all analyses. Sleep efficiency was calculated based on the lights&#8208;off and lights&#8208;on times for the scEEG studies. Sleep stages and measures derived from the scEEG are referred to as scEEG&#8208;derived metrics throughout the article.</p><boxed-text position="float" content-type="box" orientation="portrait"><sec id="alz70761-sec-0100"><title>RESEARCH IN CONTEXT</title><p>
<list list-type="order" id="alz70761-list-0002"><list-item><p>
<bold>Systematic review</bold>: We used PubMed to perform a literature search for studies examining sleep in the context of Alzheimer's disease. The majority of prior work has examined sleep cross&#8208;sectionally, and there is limited knowledge on the test&#8211;retest reliability of widely utilized sleep measures in amyloid&#8208;negative and amyloid&#8208;positive older adults.</p></list-item><list-item><p>
<bold>Interpretation</bold>: Objective sleep measures, primarily electroencephalography spectral power, reflected the lowest longitudinal variability over &#8776;3.5 years. Objective sleep measures provide greater reliability when studying sleep longitudinally when compared to self&#8208;report measures in both amyloid&#8208;negative and amyloid&#8208;positive individuals.</p></list-item><list-item><p>
<bold>Future directions</bold>: Future studies are needed to examine longitudinal sleep in those who convert from amyloid&#8208;negative to amyloid&#8208;positive.</p></list-item></list>
</p></sec></boxed-text><p>Spectral analysis was performed to quantify EEG power within different frequency bins. As described previously,<xref rid="alz70761-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>&#160;a band&#8208;pass (two&#8208;way least&#8208;squares finite impulse response) filter between 0.5 and 40&#8201;Hz was applied to the scEEG data. Spectral analysis was performed in consecutive 5 s epochs (Welch method, Hamming window, no overlap). Power bands during NREM sleep were calculated by averaging the power in the frequency bins of 0.5&#8211;1.0&#8201;Hz for&#160;&lt;1&#160;Hz slow&#8208;wave activity (SWA), 1.0&#8211;4.5&#8201;Hz for SWA, 4&#8211;8&#160;Hz for theta, 8&#8211;12&#160;Hz for alpha, 12&#8211;16&#160;Hz for spindles, 15&#8211;25&#160;Hz for beta, and 25&#8211;50&#160;Hz for gamma waves. To semi&#8208;automatically remove artifactual epochs, power in the 20&#8211;30 and 0.5&#8211;4.5&#8201;Hz bands for each electrode across all epochs of a recording was displayed. The operator (B.P.L.) then selected a threshold between the 95% and 99.5% threshold of power to remove artifactual epochs. Each frequency range was calculated for each single&#8208;channel EEG study using MATLAB (MathWorks, Natick, MA), and the average NREM frequency range was used in the analysis.</p><p>As mentioned previously, participants completed daily logs and questionnaires. These included the Epworth Sleepiness Scale,<xref rid="alz70761-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> the Insomnia Severity Index,<xref rid="alz70761-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> daytime napping, time to fall asleep, and self&#8208;reported sleep duration. Data derived from these reports are referred to as self&#8208;reported data in all analyses. Participants also underwent one night of home sleep apnea testing as described previously (HSAT; Alice PDx, Philips Respironics, Inc., Murrysville, PA).<xref rid="alz70761-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> The Alice PDx is a type III HSAT device that monitors oxygen saturation (SpO<sub>2</sub>) and pulse rate from an oximeter finger probe, nasal pressure&#8208;based airflow monitor and thermistor, thoracic and abdominal effort via inductance plethysmography, and body position. A minimum of 4&#160;h of artifact&#8208;free recording was obtained for all participants, and participants not meeting this criterion were asked to repeat monitoring. Respiratory events were scored by registered polysomnographic technologists using AASM criteria<xref rid="alz70761-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> and were reviewed by a board&#8208;certified sleep medicine physician (B.P.L.). Hypopneas were scored using 4% oxygen desaturation criteria. The apnea&#8208;hypopnea index (AHI) was calculated per hour of monitoring time for each participant. Participants using positive airway pressure (PAP) therapy or dental devices were asked to use them as usual during the HSAT.</p></sec><sec id="alz70761-sec-0110"><label>2.3</label><title>Neuroimaging</title><p>Participants underwent PET imaging with amyloid tracers. Amyloid PET imaging was performed using Pittsburgh compound B (PiB) or [18F]AV&#8208;45 (florbetapir) and data from the 30 to 60 and 50&#8208; to 70&#8208;min post&#8208;injection window, respectively. To obtain a global measure of amyloid burden, the magnetic resonance imaging (MRI)&#8211;free PET processing pipeline was run for all amyloid PET scans.<xref rid="alz70761-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> The pipeline uses Statistical Parametric Mapping 12's (SPM12)N1 normalization module to non&#8208;linearly warp the PET data into alignment with a pre&#8208;defined template PET image. The PET data are then spatially smoothed using a Gaussian filter to a full width at half maximum (FWHM) of 8&#160;mm. A mean cortical standard uptake value ratio (MCSUVR) is calculated from the resulting image using the standard Centiloid (CL) cortical volume of interest (VOI) with the whole cerebellum VOI as the reference region.<xref rid="alz70761-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> These SUVRs are then converted to the Centiloid scale. MCSUVRs from the MRI&#8208;free PET pipeline are non&#8208;partial volume corrected. Participants were considered amyloid&#8208;negative by PET if their Centiloid value was less than 19 at Visit 1.<xref rid="alz70761-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>
</p></sec><sec id="alz70761-sec-0120"><label>2.4</label><title>Cognitive assessments</title><p>Cognitive assessment protocols were consistent with the National Alzheimer's Coordinating Center (NACC) Uniform Data Set (UDS).<xref rid="alz70761-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> The CDR was performed at each clinical assessment to determine the presence or absence of dementia, and when present, its severity. CDR is used in longitudinal studies and clinical trials for staging dementia in general and in dementia due to AD, with an overall score ranging from 0 to 3 and a sum of boxes (SB) ranging from 0 to 18.<xref rid="alz70761-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="alz70761-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> Participants included in the study were classified as either cognitively unimpaired (CDR&#160;=&#160;0, <italic toggle="yes">n</italic>&#160;=&#160;55) or mildly impaired (CDR&#160;=&#160;0.5, <italic toggle="yes">n</italic>&#160;=&#160;4; CDR&#160;=&#160;1, <italic toggle="yes">n</italic>&#160;=&#160;1). We did not assess the differences between CDR&#160;=&#160;0 and CDR&#160;&gt;0 due to the limited number of CDR&#160;&gt;0 participants.</p></sec><sec id="alz70761-sec-0130"><label>2.5</label><title>Statistical analysis</title><p>To determine if the sleep metrics changed over time, intraclass correlation coefficients (ICC) were calculated. The R Package <italic toggle="yes">irr</italic> was used.<xref rid="alz70761-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> General linear models were used to determine the longitudinal change of sleep parameters computed at the subject level as the ratio of the difference in each parameter over the time difference in years (i.e., rate of change per year), whereas controlling for Centiloid value, age, sex, race, and if participants were positive for one apolipoprotein E (<italic toggle="yes">APOE</italic>) &#949;4 allele (ApoE4+). We also conducted power calculations for two types of studies: (1) a one&#8208;sample longitudinal observational study monitoring change from baseline with participants serving as their own controls; and (2) a two&#8208;arm clinical trial with both treated and untreated groups. For the one&#8208;sample power analysis, we computed the mean and SD of this estimated rate of change for each sleep parameter and then determined the sample size necessary to detect longitudinal change in the sleep measures. The power analysis was based on a one&#8208;sample <italic toggle="yes">t</italic>&#8208;test with a two&#8208;sided alternative hypothesis. We defined the detectable rate of change as 0.5, 0.8, 1, 1.2, 1.5, and 2 times the observed rate of change, targeting 80% power, and determined the corresponding sample sizes. For the two&#8208;sample power analysis, we used a two&#8208;sample <italic toggle="yes">t</italic>&#8208;test on the rate of change with a two&#8208;sided alternative hypothesis. We treated the observed data as representing the control group and assumed the treatment group would exhibit a rate of change (i.e., change/year) equal to 1%, 3%, 5%, and 7% of the baseline value. For each assumed effect size, we calculated the required sample size to achieve 80% power at a significance level of 0.05. The power analyses were conducted using R 4.4.0.<xref rid="alz70761-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>
</p></sec><sec id="alz70761-sec-0140"><label>2.6</label><title>Data and material availability</title><p>All of the data that support the findings of this study are available from the corresponding author upon reasonable request or via the Washington University in St. Louis Charles F. and Joanne Knight Alzheimer's Disease Research Center's data request portal.<xref rid="alz70761-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> All code associated with this analysis is freely available from the corresponding author upon reasonable request.</p></sec></sec><sec id="alz70761-sec-0150"><label>3</label><title>RESULTS</title><sec id="alz70761-sec-0160"><label>3.1</label><title>Participant characteristics</title><p>Table&#160;<xref rid="alz70761-tbl-0001" ref-type="table">1</xref> shows the breakdown of participants between groups and characteristics associated with sleep. This includes sleep apnea and related metrics (AHI and average saturated oxygen percentage), and medical history including insomnia, restless leg syndrome, and depression. The number of participants who reported using a sleep medication is also shown. Participants were listed as on a sleep medication if they were taking at least one of the following medications: benzodiazepine receptor agonists (zolpidem, zaleplon, eszopiclone), benzodiazepines (triazolam, temazepam, alprazolam), suvorexant, ramelteon, gabapentin, dopamine agonists (ropinirole, pramipexole, rotigotine), doxepin, antihistamines, antidepressants, and narcotics. In order to be more representative of the general population, participants were not excluded if they had a sleep&#8208;related disorder or used sleep medications.<xref rid="alz70761-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> Comparisons between groups and visits were made using a two&#8208;sample <italic toggle="yes">t</italic>&#8208;test for age, visit interval, AHI, and average SaO<sub>2</sub>%. All other comparisons were made using a chi&#8208;square test. Amyloid Centiloid value was the only metric that showed a significant difference between amyloid groups at each visit. Notably, there were no significant differences in Centiloid value within amyloid groups and between visits (amyloid&#8208;negative <italic toggle="yes">p</italic>&#8208;value&#160;=&#160;0.416, amyloid&#8208;positive <italic toggle="yes">p</italic>&#8208;value&#160;=&#160;0.119). This aligned with the other demographics and sleep characteristics, as there were no significant differences within or between amyloid groups. No participants changed amyloid groups or CDR status between visits. Differences between amyloid groups for all sleep metrics are shown in Tables <xref rid="alz70761-supinfo-0001" ref-type="">S1&#8211;S3</xref>.</p><table-wrap position="float" id="alz70761-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Participant characteristics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Demographics</th><th align="left" rowspan="1" colspan="1">Amyloid negative</th><th align="left" rowspan="1" colspan="1">Amyloid positive</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;value<xref rid="alz70761-tbl1-note-0002" ref-type="table-fn">
<sup>*</sup>
</xref>
</th><th align="left" rowspan="1" colspan="1">Overall</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sample size</td><td align="char" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#160;= 37</td><td align="char" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#160;= 23</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#160;= 60</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (at first visit)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Mean (SD)</td><td align="char" rowspan="1" colspan="1">72.48 (4.16)</td><td align="char" rowspan="1" colspan="1">73.66 (4.08)</td><td align="char" rowspan="1" colspan="1">0.740 (0.962)</td><td align="char" rowspan="1" colspan="1">72.96 (4.13)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Median [Min, Max]</td><td align="left" rowspan="1" colspan="1">71.96 [64.0, 83.4]</td><td align="left" rowspan="1" colspan="1">73.76 [65.7, 82.3]</td><td align="char" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">72.50 [64.1, 83.4]</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Female</td><td align="char" rowspan="1" colspan="1">19 (51.4%)</td><td align="char" rowspan="1" colspan="1">13 (56.5%)</td><td align="char" rowspan="1" colspan="1">0.901 (0.976)</td><td align="char" rowspan="1" colspan="1">32 (53.3%)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Male</td><td align="char" rowspan="1" colspan="1">18 (48.6%)</td><td align="char" rowspan="1" colspan="1">10 (43.5%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">28 (46.7%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Race, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Black</td><td align="char" rowspan="1" colspan="1">6 (16.2%)</td><td align="char" rowspan="1" colspan="1">2 (8.7%)</td><td align="char" rowspan="1" colspan="1">0.405 (0.962)</td><td align="char" rowspan="1" colspan="1">8 (13.3%)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">White</td><td align="char" rowspan="1" colspan="1">31 (83.8%)</td><td align="char" rowspan="1" colspan="1">21 (91.3%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">52 (86.7%)</td></tr><tr><td align="left" rowspan="1" colspan="1">CDR&#160;= 0</td><td align="char" rowspan="1" colspan="1">34 (91.9%)</td><td align="char" rowspan="1" colspan="1">21 (91.3%)</td><td align="char" rowspan="1" colspan="1">0.946 (0.976)</td><td align="char" rowspan="1" colspan="1">55 (91.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">CDR&#160;&gt;0</td><td align="char" rowspan="1" colspan="1">3 (0.08%)</td><td align="char" rowspan="1" colspan="1">2 (0.09%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">5 (0.08%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Centiloid value</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Visit 1, mean (SD)</td><td align="char" rowspan="1" colspan="1">5.00 (6.10)</td><td align="char" rowspan="1" colspan="1">45.88 (24.08)</td><td align="char" rowspan="1" colspan="1">7.59e&#8208;14 (6.07e&#8208;13)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Visit interval, years</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Mean (SD)</td><td align="char" rowspan="1" colspan="1">3.45 (0.79)</td><td align="char" rowspan="1" colspan="1">3.54 (0.87)</td><td align="char" rowspan="1" colspan="1">0.688 (0.962)</td><td align="char" rowspan="1" colspan="1">3.49 (0.814)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Median [Min, Max]</td><td align="left" rowspan="1" colspan="1">3.30 [2.48, 5.80]</td><td align="left" rowspan="1" colspan="1">3.35 [2.45, 6.01]</td><td align="char" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3.32 [2.45, 6.01]</td></tr><tr><td align="left" rowspan="1" colspan="1">Sleep apnea (AHI &#8805;5)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Visit 1</td><td align="char" rowspan="1" colspan="1">6 (16.2%)</td><td align="char" rowspan="1" colspan="1">5 (21.7%)</td><td align="char" rowspan="1" colspan="1">0.726 (0.962)</td><td align="char" rowspan="1" colspan="1">11 (18.3%)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Visit 2</td><td align="char" rowspan="1" colspan="1">14 (37.8%)</td><td align="char" rowspan="1" colspan="1">9 (39.1%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">23 (38.3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">AHI (events/h)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Visit 1, mean (SD)</td><td align="char" rowspan="1" colspan="1">8.75 (7.65)</td><td align="char" rowspan="1" colspan="1">7.17 (9.44)</td><td align="char" rowspan="1" colspan="1">0.616 (0.962)</td><td align="char" rowspan="1" colspan="1">&#8211;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Visit 2, mean (SD)</td><td align="char" rowspan="1" colspan="1">8.48 (8.89)</td><td align="char" rowspan="1" colspan="1">4.62 (7.5)</td><td align="char" rowspan="1" colspan="1">0.154 (0.810)</td><td align="char" rowspan="1" colspan="1">&#8211;</td></tr><tr><td align="left" rowspan="1" colspan="1">Average SaO<sub>2</sub> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Visit 1, mean (SD)</td><td align="char" rowspan="1" colspan="1">92.91 (1.85)</td><td align="char" rowspan="1" colspan="1">93.39 (1.58)</td><td align="char" rowspan="1" colspan="1">0.640 (0.962)</td><td align="char" rowspan="1" colspan="1">&#8208;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Visit 2, mean (SD)</td><td align="char" rowspan="1" colspan="1">92.97 (1.51)</td><td align="char" rowspan="1" colspan="1">93.78 (1.52)</td><td align="char" rowspan="1" colspan="1">0.053 (0.695)</td><td align="char" rowspan="1" colspan="1">&#8208;</td></tr><tr><td align="left" rowspan="1" colspan="1">Insomnia</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Visit 1</td><td align="char" rowspan="1" colspan="1">2 (5.4%)</td><td align="char" rowspan="1" colspan="1">4 (17.4%)</td><td align="char" rowspan="1" colspan="1">1.00 (1.00)</td><td align="char" rowspan="1" colspan="1">6 (10.0%)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Visit 2</td><td align="char" rowspan="1" colspan="1">2 (5.4%)</td><td align="char" rowspan="1" colspan="1">4 (17.4%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">6 (10.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Restless leg syndrome, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Visit 1</td><td align="char" rowspan="1" colspan="1">4 (10.8%)</td><td align="char" rowspan="1" colspan="1">2 (8.7%)</td><td align="char" rowspan="1" colspan="1">0.533 (0.962)</td><td align="char" rowspan="1" colspan="1">6 (10.0%)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Visit 2</td><td align="char" rowspan="1" colspan="1">4 (10.8%)</td><td align="char" rowspan="1" colspan="1">4 (17.4%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">8 (13.3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Depression, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Visit 1</td><td align="char" rowspan="1" colspan="1">4 (10.8%)</td><td align="char" rowspan="1" colspan="1">1 (4.3%)</td><td align="char" rowspan="1" colspan="1">0.187 (0.810)</td><td align="char" rowspan="1" colspan="1">5 (8.3%)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Visit 2</td><td align="char" rowspan="1" colspan="1">1 (2.7%)</td><td align="char" rowspan="1" colspan="1">2 (8.7%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">3 (5.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1"># PTs using sleep medication (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Visit 1</td><td align="char" rowspan="1" colspan="1">9 (24.3%)</td><td align="char" rowspan="1" colspan="1">7 (30.4%)</td><td align="char" rowspan="1" colspan="1">0.870 (0.976)</td><td align="char" rowspan="1" colspan="1">16 (26.7%)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Visit 2</td><td align="char" rowspan="1" colspan="1">8 (21.6%)</td><td align="char" rowspan="1" colspan="1">7 (30.4%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">15 (25.0%)</td></tr></tbody></table><table-wrap-foot><fn id="alz70761-tbl1-note-0001"><p>Abbreviations: AHI, Apnea&#8208;Hypopnea Index; CDR, Clinical Dementia Rating; Max, maximum; Min, minimum; PTs, participants; SaO<sub>2</sub>, arterial oxygen saturation; SD, standard deviation.</p></fn><fn id="alz70761-tbl1-note-0002"><label>*</label><p>Included both original and adjusted for multiple comparison <italic toggle="yes">p</italic>&#8208;values: original (adjusted). Bolded values&#160;=&#160;<italic toggle="yes">p</italic>&#8208;value&#160;&lt;&#160;0.05.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="alz70761-sec-0170"><label>3.2</label><title>Longitudinal variability of sleep metrics</title><p>Figure&#160;<xref rid="alz70761-fig-0001" ref-type="fig">1</xref> shows the ICC values for each sleep metric in amyloid&#8208;negative (Figure&#160;<xref rid="alz70761-fig-0001" ref-type="fig">1A</xref>) and amyloid&#8208;positive (Figure&#160;<xref rid="alz70761-fig-0001" ref-type="fig">1B</xref>) individuals. The ICC is a measure of agreement over time, and the interpretation is as follows: below 0.5 indicates poor agreement, 0.5&#8211;0.75 represents moderate agreement, 0.75&#8211;0.9 shows good agreement, and above 0.9 reflects excellent agreement.<xref rid="alz70761-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>
</p><fig position="float" fig-type="FIGURE" id="alz70761-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Intraclass Correlation Coefficients. The ICC for each sleep metric is shown. (A) ICC values for the amyloid&#8208;negative group. (B) ICC values for the amyloid&#8208;positive group. Error bars represent the confidence interval around the ICC value. Variables labeled represent self&#8208;reported (red), scEEG&#8208;derived (blue), and EEG spectral power measures (green). EEG, electroencephalography; Hz, hertz; ICC, intraclass correlation coefficient; N1, NREM Stage 1 sleep; N2, NREM Stage 2 sleep; N3, NREM Stage 3 sleep; NREM, non&#8208;rapid eye movement; REM, rapid eye movement; scEEG: single&#8208;channel EEG; SWA, slow&#8208;wave activity.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ALZ-21-e70761-g002.jpg"/></fig><p>For both amyloid groups, the EEG spectral power metrics had the lowest longitudinal variability and the greatest agreement between visits. In the amyloid&#8208;negative group, EEG spectral power reflected the highest ICC values (mean ICC&#160;=&#160;0.719) compared to the scEEG&#8208;based measures (mean&#160;=&#160;0.542) and self&#8208;report data (mean&#160;=&#160;0.538). A similar trend is seen in amyloid&#8208;positive individuals: EEG spectral power measures also reflected the greatest ICC values (mean ICC&#160;=&#160;0.695), compared to self&#8208;report (mean ICC&#160;=&#160;0.463) and scEEG&#8208;derived metrics (mean ICC&#160;=&#160;0.367).</p><p>Within both amyloid groups, certain sleep metrics stood out in their level of agreement. In the scEEG&#8208;derived metrics, average NREM Stage 3 (N3) sleep time showed the lowest longitudinal variability (amyloid&#8208;negative ICC&#160;=&#160;0.869; amyloid&#8208;positive ICC&#160;=&#160;0.664). This aligns with the ICC values derived from EEG spectral power measures, considering that N3 sleep is characterized by slow&#8208;wave sleep and increased SWA. Slow&#8208;wave sleep measures, which included average NREM SWA (&lt;1&#160;Hz), NREM SWA (1&#8211;4.5&#160;Hz), and the ratio of NREM SWA (&lt;1&#160;Hz) to NREM SWA (1&#8211;4.5&#160;Hz), all showed good to excellent agreement (amyloid&#8208;negative ICC&#160;=&#160;0.841, 0.818, and 0.775, respectively; amyloid&#8208;positive ICC&#160;=&#160;0.867, 0.910, and 0.613, respectively). Average NREM theta (4&#8211;8&#160;Hz) and NREM alpha (8&#8211;12&#160;Hz) also reflected EEG spectral power bands with good to excellent longitudinal agreement (amyloid&#8208;negative ICC&#160;=&#160;0.820 and 0.890, respectively; amyloid&#8208;positive ICC&#160;=&#160;0.826 and 0.953, respectively), which is consistent between amyloid groups. As for the self&#8208;report sleep metrics, no metric surpassed the threshold of ICC&#160;=&#160;0.75, but daytime napping and self&#8208;reported sleep duration approached it. Of note, the variability of self&#8208;reported sleep duration was markedly higher in the amyloid&#8208;positive group compared to the amyloid&#8208;negative group (amyloid&#8208;negative ICC&#160;=&#160;0.601; amyloid&#8208;positive ICC&#160;=&#160;0.237).</p><p>To better gauge how these sleep metrics perform on the individual level, longitudinal change for one sleep metric was graphed within each sleep metric category (Figures <xref rid="alz70761-supinfo-0001" ref-type="">S1&#8211;S3</xref>) and reflects the longitudinal change of self&#8208;reported minutes of daytime napping, sleep duration, and NREM slow&#8208;wave activity. These metrics were chosen out of interest due to their current use in studies examining the role of sleep in AD.<xref rid="alz70761-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>, <xref rid="alz70761-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>, <xref rid="alz70761-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>, <xref rid="alz70761-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref> The average deviation from Visit 1 (depicted by the dashed line) indicated that these measures showed minimal change over time, on average. On the individual level, there is a distribution of deviations, with the majority reflecting minor changes between visits.</p></sec><sec id="alz70761-sec-0180"><label>3.3</label><title>Longitudinal variability adjusting for potential confounders</title><p>Because multiple factors could affect sleep over time, generalized linear modeling was used to determine the annual change of each sleep metric after adjusting for Centiloid, age, sex, race, and ApoE4+ status. The annual rate of change was defined as the metric at Visit 2 minus the metric at Visit 1 divided by the time between visits in years. Table&#160;<xref rid="alz70761-tbl-0002" ref-type="table">2</xref> includes model outputs from self&#8208;report measures, Table&#160;<xref rid="alz70761-tbl-0003" ref-type="table">3</xref> shows scEEG&#8208;derived measures, and Table&#160;<xref rid="alz70761-tbl-0004" ref-type="table">4</xref> includes EEG spectral power measures. Results from the linear models indicated low longitudinal change across sleep metrics, even after accounting for Centiloid, sex, age, race, and ApoE4+ status. None of the covariates were significant predicators (<italic toggle="yes">p</italic>&#160;&gt;&#160;0.05) of the annualized rate of change per sleep metric after correcting for multiple comparisons. These findings were consistent with the findings of the ICC analyses.</p><table-wrap position="float" id="alz70761-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Annual rate of change of self&#8208;report metrics adjusting for potential confounders.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Sleep variable annualized rate of change</th><th align="left" rowspan="1" colspan="1">Covariate</th><th align="left" rowspan="1" colspan="1">Estimate</th><th align="left" rowspan="1" colspan="1">SE</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">t</italic>&#8208;statistic</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;value</th><th align="left" rowspan="1" colspan="1">Adjusted <italic toggle="yes">p</italic>&#8208;value</th></tr></thead><tbody><tr><td rowspan="5" align="left" colspan="1">
<bold>Epworth Sleepiness Scale</bold>
</td><td align="left" rowspan="1" colspan="1">Centiloid value</td><td align="char" rowspan="1" colspan="1">1.9 &#215; 10&#8315;&#8308;</td><td align="char" rowspan="1" colspan="1">0.01</td><td align="char" rowspan="1" colspan="1">0.03</td><td align="char" rowspan="1" colspan="1">0.979</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">0.02</td><td align="char" rowspan="1" colspan="1">0.05</td><td align="char" rowspan="1" colspan="1">0.44</td><td align="char" rowspan="1" colspan="1">0.659</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">&#8722;0.44</td><td align="char" rowspan="1" colspan="1">0.39</td><td align="char" rowspan="1" colspan="1">&#8722;1.13</td><td align="char" rowspan="1" colspan="1">0.265</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="char" rowspan="1" colspan="1">&#8722;0.38</td><td align="char" rowspan="1" colspan="1">0.56</td><td align="char" rowspan="1" colspan="1">&#8722;0.68</td><td align="char" rowspan="1" colspan="1">0.502</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> &#949;4 status</td><td align="char" rowspan="1" colspan="1">0.17</td><td align="char" rowspan="1" colspan="1">0.40</td><td align="char" rowspan="1" colspan="1">0.43</td><td align="char" rowspan="1" colspan="1">0.676</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="5" align="left" colspan="1">
<bold>Insomnia Severity Index</bold>
</td><td align="left" rowspan="1" colspan="1">Centiloid value</td><td align="char" rowspan="1" colspan="1">4.3 &#215; 10&#8315;<sup>3</sup>
</td><td align="char" rowspan="1" colspan="1">0.01</td><td align="char" rowspan="1" colspan="1">0.73</td><td align="char" rowspan="1" colspan="1">0.470</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">0.03</td><td align="char" rowspan="1" colspan="1">0.04</td><td align="char" rowspan="1" colspan="1">0.79</td><td align="char" rowspan="1" colspan="1">0.435</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">&#8722;0.39</td><td align="char" rowspan="1" colspan="1">0.31</td><td align="char" rowspan="1" colspan="1">&#8722;1.28</td><td align="char" rowspan="1" colspan="1">0.206</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="char" rowspan="1" colspan="1">0.55</td><td align="char" rowspan="1" colspan="1">0.44</td><td align="char" rowspan="1" colspan="1">1.25</td><td align="char" rowspan="1" colspan="1">0.216</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> &#949;4 status</td><td align="char" rowspan="1" colspan="1">0.18</td><td align="char" rowspan="1" colspan="1">0.31</td><td align="char" rowspan="1" colspan="1">0.58</td><td align="char" rowspan="1" colspan="1">0.565</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="5" align="left" colspan="1">
<bold>Daytime napping</bold>
</td><td align="left" rowspan="1" colspan="1">Centiloid value</td><td align="char" rowspan="1" colspan="1">&#8722;0.02</td><td align="char" rowspan="1" colspan="1">0.03</td><td align="char" rowspan="1" colspan="1">&#8722;0.61</td><td align="char" rowspan="1" colspan="1">0.543</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">0.04</td><td align="char" rowspan="1" colspan="1">0.20</td><td align="char" rowspan="1" colspan="1">0.18</td><td align="char" rowspan="1" colspan="1">0.861</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">&#8722;1.93</td><td align="char" rowspan="1" colspan="1">1.64</td><td align="char" rowspan="1" colspan="1">&#8722;1.17</td><td align="char" rowspan="1" colspan="1">0.246</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="char" rowspan="1" colspan="1">&#8722;0.31</td><td align="char" rowspan="1" colspan="1">2.35</td><td align="char" rowspan="1" colspan="1">&#8722;0.13</td><td align="char" rowspan="1" colspan="1">0.897</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> &#949;4 status</td><td align="char" rowspan="1" colspan="1">&#8722;0.81</td><td align="char" rowspan="1" colspan="1">1.68</td><td align="char" rowspan="1" colspan="1">&#8722;0.48</td><td align="char" rowspan="1" colspan="1">0.632</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="5" align="left" colspan="1">
<bold>Time to fall asleep</bold>
</td><td align="left" rowspan="1" colspan="1">Centiloid value</td><td align="char" rowspan="1" colspan="1">&#8722;0.02</td><td align="char" rowspan="1" colspan="1">0.04</td><td align="char" rowspan="1" colspan="1">&#8722;0.48</td><td align="char" rowspan="1" colspan="1">0.635</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">&#8722;0.32</td><td align="char" rowspan="1" colspan="1">0.22</td><td align="char" rowspan="1" colspan="1">&#8722;1.47</td><td align="char" rowspan="1" colspan="1">0.147</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">&#8722;2.80</td><td align="char" rowspan="1" colspan="1">1.77</td><td align="char" rowspan="1" colspan="1">&#8722;1.58</td><td align="char" rowspan="1" colspan="1">0.119</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="char" rowspan="1" colspan="1">0.39</td><td align="char" rowspan="1" colspan="1">2.71</td><td align="char" rowspan="1" colspan="1">0.14</td><td align="char" rowspan="1" colspan="1">0.886</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> &#949;4 status</td><td align="char" rowspan="1" colspan="1">&#8722;1.37</td><td align="char" rowspan="1" colspan="1">1.82</td><td align="char" rowspan="1" colspan="1">&#8722;0.75</td><td align="char" rowspan="1" colspan="1">0.454</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="5" align="left" colspan="1">
<bold>Self&#8208;reported sleep duration</bold>
</td><td align="left" rowspan="1" colspan="1">Centiloid value</td><td align="char" rowspan="1" colspan="1">4.0 &#215; 10&#8315;<sup>3</sup>
</td><td align="char" rowspan="1" colspan="1">1.6 &#215; 10&#8315;<sup>3</sup>
</td><td align="char" rowspan="1" colspan="1">2.54</td><td align="char" rowspan="1" colspan="1">0.014</td><td align="char" rowspan="1" colspan="1">0.35</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">4.8 &#215; 10&#8315;<sup>3</sup>
</td><td align="char" rowspan="1" colspan="1">0.01</td><td align="char" rowspan="1" colspan="1">0.48</td><td align="char" rowspan="1" colspan="1">0.631</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">4.7 &#215; 10&#8315;&#8308;</td><td align="char" rowspan="1" colspan="1">0.08</td><td align="char" rowspan="1" colspan="1">0.01</td><td align="char" rowspan="1" colspan="1">0.995</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="char" rowspan="1" colspan="1">0.14</td><td align="char" rowspan="1" colspan="1">0.12</td><td align="char" rowspan="1" colspan="1">1.21</td><td align="char" rowspan="1" colspan="1">0.230</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> &#949;4 status</td><td align="char" rowspan="1" colspan="1">&#8722;0.05</td><td align="char" rowspan="1" colspan="1">0.08</td><td align="char" rowspan="1" colspan="1">&#8722;0.63</td><td align="char" rowspan="1" colspan="1">0.525</td><td align="char" rowspan="1" colspan="1">1.00</td></tr></tbody></table><table-wrap-foot><fn id="alz70761-tbl2-note-0001"><p>Abbreviations: <italic toggle="yes">APOE</italic> &#949;4, apolipoprotein E &#949;4 allele4; SE, standard error.</p></fn><fn id="alz70761-tbl2-note-0002"><p>Adjusted <italic toggle="yes">p</italic>&#8208;values are after Bonferroni correction for multiple comparisons.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="alz70761-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Annual rate of change of scEEG&#8208;derived measures adjusting for potential confounders.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Sleep variable annualized rate of change</th><th align="left" rowspan="1" colspan="1">Covariate</th><th align="left" rowspan="1" colspan="1">Estimate</th><th align="left" rowspan="1" colspan="1">SE</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">t</italic>&#8208;statistic</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;value</th><th align="left" rowspan="1" colspan="1">Adjusted <italic toggle="yes">p</italic>&#8208;value</th></tr></thead><tbody><tr><td rowspan="5" align="left" colspan="1">
<bold>Sleep duration</bold>
</td><td align="left" rowspan="1" colspan="1">Centiloid value</td><td align="char" rowspan="1" colspan="1">&#8722;0.04</td><td align="char" rowspan="1" colspan="1">0.10</td><td align="char" rowspan="1" colspan="1">&#8722;0.40</td><td align="char" rowspan="1" colspan="1">0.694</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">0.46</td><td align="char" rowspan="1" colspan="1">0.62</td><td align="char" rowspan="1" colspan="1">0.74</td><td align="char" rowspan="1" colspan="1">0.465</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">&#8722;2.05</td><td align="char" rowspan="1" colspan="1">5.07</td><td align="char" rowspan="1" colspan="1">&#8722;0.41</td><td align="char" rowspan="1" colspan="1">0.687</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="char" rowspan="1" colspan="1">1.28</td><td align="char" rowspan="1" colspan="1">7.25</td><td align="char" rowspan="1" colspan="1">0.18</td><td align="char" rowspan="1" colspan="1">0.861</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> &#949;4 status</td><td align="char" rowspan="1" colspan="1">&#8722;2.00</td><td align="char" rowspan="1" colspan="1">5.18</td><td align="char" rowspan="1" colspan="1">&#8722;0.39</td><td align="char" rowspan="1" colspan="1">0.700</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="5" align="left" colspan="1">
<bold>Average wake time</bold>
</td><td align="left" rowspan="1" colspan="1">Centiloid value</td><td align="char" rowspan="1" colspan="1">0.17</td><td align="char" rowspan="1" colspan="1">0.85</td><td align="char" rowspan="1" colspan="1">0.20</td><td align="char" rowspan="1" colspan="1">0.731</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">0.17</td><td align="char" rowspan="1" colspan="1">0.85</td><td align="char" rowspan="1" colspan="1">0.20</td><td align="char" rowspan="1" colspan="1">0.746</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">1.87</td><td align="char" rowspan="1" colspan="1">1.31</td><td align="char" rowspan="1" colspan="1">1.43</td><td align="char" rowspan="1" colspan="1">0.750</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="char" rowspan="1" colspan="1">5.84</td><td align="char" rowspan="1" colspan="1">2.31</td><td align="char" rowspan="1" colspan="1">2.53</td><td align="char" rowspan="1" colspan="1">0.621</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> &#949;4 status</td><td align="char" rowspan="1" colspan="1">2.00</td><td align="char" rowspan="1" colspan="1">0.03</td><td align="char" rowspan="1" colspan="1">66.67</td><td align="char" rowspan="1" colspan="1">0.637</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="5" align="left" colspan="1">
<bold>Sleep efficiency</bold>
</td><td align="left" rowspan="1" colspan="1">Centiloid value</td><td align="char" rowspan="1" colspan="1">&#8722;0.02</td><td align="char" rowspan="1" colspan="1">0.02</td><td align="char" rowspan="1" colspan="1">&#8722;1.38</td><td align="char" rowspan="1" colspan="1">0.172</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">&#8722;0.05</td><td align="char" rowspan="1" colspan="1">0.11</td><td align="char" rowspan="1" colspan="1">&#8722;0.45</td><td align="char" rowspan="1" colspan="1">0.654</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">&#8722;0.05</td><td align="char" rowspan="1" colspan="1">0.88</td><td align="char" rowspan="1" colspan="1">&#8722;0.06</td><td align="char" rowspan="1" colspan="1">0.953</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="char" rowspan="1" colspan="1">&#8722;0.67</td><td align="char" rowspan="1" colspan="1">1.26</td><td align="char" rowspan="1" colspan="1">&#8722;0.53</td><td align="char" rowspan="1" colspan="1">0.599</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> &#949;4 status</td><td align="char" rowspan="1" colspan="1">&#8722;0.62</td><td align="char" rowspan="1" colspan="1">0.90</td><td align="char" rowspan="1" colspan="1">&#8722;0.69</td><td align="char" rowspan="1" colspan="1">0.490</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="5" align="left" colspan="1">
<bold>Average N1 time</bold>
</td><td align="left" rowspan="1" colspan="1">Centiloid value</td><td align="char" rowspan="1" colspan="1">0.01</td><td align="char" rowspan="1" colspan="1">0.02</td><td align="char" rowspan="1" colspan="1">0.40</td><td align="char" rowspan="1" colspan="1">0.690</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">0.02</td><td align="char" rowspan="1" colspan="1">0.15</td><td align="char" rowspan="1" colspan="1">0.12</td><td align="char" rowspan="1" colspan="1">0.908</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">0.18</td><td align="char" rowspan="1" colspan="1">1.20</td><td align="char" rowspan="1" colspan="1">0.15</td><td align="char" rowspan="1" colspan="1">0.884</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="char" rowspan="1" colspan="1">0.16</td><td align="char" rowspan="1" colspan="1">1.71</td><td align="char" rowspan="1" colspan="1">0.09</td><td align="char" rowspan="1" colspan="1">0.926</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> &#949;4 status</td><td align="char" rowspan="1" colspan="1">&#8722;0.31</td><td align="char" rowspan="1" colspan="1">1.22</td><td align="char" rowspan="1" colspan="1">&#8722;0.25</td><td align="char" rowspan="1" colspan="1">0.800</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="5" align="left" colspan="1">
<bold>Average N2 time</bold>
</td><td align="left" rowspan="1" colspan="1">Centiloid value</td><td align="char" rowspan="1" colspan="1">0.08</td><td align="char" rowspan="1" colspan="1">0.12</td><td align="char" rowspan="1" colspan="1">0.69</td><td align="char" rowspan="1" colspan="1">0.493</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">&#8722;0.18</td><td align="char" rowspan="1" colspan="1">0.76</td><td align="char" rowspan="1" colspan="1">&#8722;0.24</td><td align="char" rowspan="1" colspan="1">0.810</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">&#8722;9.81</td><td align="char" rowspan="1" colspan="1">6.17</td><td align="char" rowspan="1" colspan="1">&#8722;1.59</td><td align="char" rowspan="1" colspan="1">0.118</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="char" rowspan="1" colspan="1">&#8722;1.79</td><td align="char" rowspan="1" colspan="1">8.82</td><td align="char" rowspan="1" colspan="1">&#8722;0.20</td><td align="char" rowspan="1" colspan="1">0.840</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> &#949;4 status</td><td align="char" rowspan="1" colspan="1">&#8722;1.28</td><td align="char" rowspan="1" colspan="1">6.31</td><td align="char" rowspan="1" colspan="1">&#8722;0.20</td><td align="char" rowspan="1" colspan="1">0.840</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="5" align="left" colspan="1">
<bold>Average N3 time</bold>
</td><td align="left" rowspan="1" colspan="1">Centiloid value</td><td align="char" rowspan="1" colspan="1">&#8722;2.5 &#215; 10&#8315;&#8308;</td><td align="char" rowspan="1" colspan="1">0.02</td><td align="char" rowspan="1" colspan="1">&#8722;0.02</td><td align="char" rowspan="1" colspan="1">0.988</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">&#8722;0.22</td><td align="char" rowspan="1" colspan="1">0.10</td><td align="char" rowspan="1" colspan="1">&#8722;2.15</td><td align="char" rowspan="1" colspan="1">0.037</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">0.92</td><td align="char" rowspan="1" colspan="1">0.85</td><td align="char" rowspan="1" colspan="1">1.08</td><td align="char" rowspan="1" colspan="1">0.285</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="char" rowspan="1" colspan="1">0.35</td><td align="char" rowspan="1" colspan="1">1.22</td><td align="char" rowspan="1" colspan="1">0.29</td><td align="char" rowspan="1" colspan="1">0.776</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> &#949;4 status</td><td align="char" rowspan="1" colspan="1">&#8722;0.46</td><td align="char" rowspan="1" colspan="1">0.87</td><td align="char" rowspan="1" colspan="1">&#8722;0.53</td><td align="char" rowspan="1" colspan="1">0.595</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="5" align="left" colspan="1">Average N2+N3 time</td><td align="left" rowspan="1" colspan="1">Centiloid value</td><td align="char" rowspan="1" colspan="1">0.082</td><td align="char" rowspan="1" colspan="1">0.120</td><td align="char" rowspan="1" colspan="1">0.683</td><td align="char" rowspan="1" colspan="1">0.497</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">&#8722;0.408</td><td align="char" rowspan="1" colspan="1">0.765</td><td align="char" rowspan="1" colspan="1">&#8722;0.533</td><td align="char" rowspan="1" colspan="1">0.596</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">&#8722;8.89</td><td align="char" rowspan="1" colspan="1">6.22</td><td align="char" rowspan="1" colspan="1">&#8722;1.43</td><td align="char" rowspan="1" colspan="1">0.159</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="char" rowspan="1" colspan="1">&#8722;1.44</td><td align="char" rowspan="1" colspan="1">8.90</td><td align="char" rowspan="1" colspan="1">&#8722;0.162</td><td align="char" rowspan="1" colspan="1">0.872</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> &#949;4 status</td><td align="char" rowspan="1" colspan="1">&#8722;1.74</td><td align="char" rowspan="1" colspan="1">6.36</td><td align="char" rowspan="1" colspan="1">&#8722;0.274</td><td align="char" rowspan="1" colspan="1">0.785</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="5" align="left" colspan="1">
<bold>Average REM time</bold>
</td><td align="left" rowspan="1" colspan="1">Centiloid value</td><td align="char" rowspan="1" colspan="1">0.00</td><td align="char" rowspan="1" colspan="1">0.04</td><td align="char" rowspan="1" colspan="1">0.10</td><td align="char" rowspan="1" colspan="1">0.918</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">0.34</td><td align="char" rowspan="1" colspan="1">0.27</td><td align="char" rowspan="1" colspan="1">1.29</td><td align="char" rowspan="1" colspan="1">0.202</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">&#8722;1.16</td><td align="char" rowspan="1" colspan="1">2.17</td><td align="char" rowspan="1" colspan="1">&#8722;0.53</td><td align="char" rowspan="1" colspan="1">0.595</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="char" rowspan="1" colspan="1">2.99</td><td align="char" rowspan="1" colspan="1">3.10</td><td align="char" rowspan="1" colspan="1">0.96</td><td align="char" rowspan="1" colspan="1">0.340</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> &#949;4 status</td><td align="char" rowspan="1" colspan="1">&#8722;3.21</td><td align="char" rowspan="1" colspan="1">2.21</td><td align="char" rowspan="1" colspan="1">&#8722;1.45</td><td align="char" rowspan="1" colspan="1">0.153</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="5" align="left" colspan="1">
<bold>REM latency</bold>
</td><td align="left" rowspan="1" colspan="1">Centiloid value</td><td align="char" rowspan="1" colspan="1">&#8722;0.04</td><td align="char" rowspan="1" colspan="1">0.07</td><td align="char" rowspan="1" colspan="1">&#8722;0.49</td><td align="char" rowspan="1" colspan="1">0.629</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">&#8722;0.08</td><td align="char" rowspan="1" colspan="1">0.48</td><td align="char" rowspan="1" colspan="1">&#8722;0.16</td><td align="char" rowspan="1" colspan="1">0.872</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">1.60</td><td align="char" rowspan="1" colspan="1">3.89</td><td align="char" rowspan="1" colspan="1">0.41</td><td align="char" rowspan="1" colspan="1">0.683</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="char" rowspan="1" colspan="1">&#8722;2.36</td><td align="char" rowspan="1" colspan="1">5.57</td><td align="char" rowspan="1" colspan="1">&#8722;0.42</td><td align="char" rowspan="1" colspan="1">0.673</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> &#949;4 status</td><td align="char" rowspan="1" colspan="1">1.27</td><td align="char" rowspan="1" colspan="1">3.98</td><td align="char" rowspan="1" colspan="1">0.32</td><td align="char" rowspan="1" colspan="1">0.752</td><td align="char" rowspan="1" colspan="1">1.00</td></tr></tbody></table><table-wrap-foot><fn id="alz70761-tbl3-note-0001"><p>Abbreviations: <italic toggle="yes">APOE</italic> &#949;4, apolipoprotein E &#949;4 allele4; N1, nonrapid eye movement sleep stage 1; N2, nonrapid eye movement sleep stage 2; N3, nonrapid eye movement sleep stage 3; REM, rapid eye movement; SE, standard error.</p></fn><fn id="alz70761-tbl3-note-0002"><p>Adjusted <italic toggle="yes">p</italic>&#8208;values are after Bonferroni correction for multiple comparisons.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="alz70761-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>Annual rate of change of EEG spectral power measures adjusting for potential confounders.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Sleep variable annual rate of change</th><th align="left" rowspan="1" colspan="1">Covariate</th><th align="left" rowspan="1" colspan="1">Estimate</th><th align="left" rowspan="1" colspan="1">SE</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">t</italic>&#8208;statistic</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;value</th><th align="left" rowspan="1" colspan="1">Adjusted <italic toggle="yes">p</italic>&#8208;value</th></tr></thead><tbody><tr><td rowspan="5" align="left" colspan="1">Average NREM SWA (&lt;1&#160;Hz)</td><td align="left" rowspan="1" colspan="1">Centiloid value</td><td align="char" rowspan="1" colspan="1">&#8722;0.04</td><td align="char" rowspan="1" colspan="1">0.04</td><td align="char" rowspan="1" colspan="1">&#8722;0.92</td><td align="char" rowspan="1" colspan="1">0.361</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">0.10</td><td align="char" rowspan="1" colspan="1">0.29</td><td align="char" rowspan="1" colspan="1">0.35</td><td align="char" rowspan="1" colspan="1">0.730</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">1.85</td><td align="char" rowspan="1" colspan="1">2.33</td><td align="char" rowspan="1" colspan="1">0.80</td><td align="char" rowspan="1" colspan="1">0.430</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="char" rowspan="1" colspan="1">&#8722;1.68</td><td align="char" rowspan="1" colspan="1">3.33</td><td align="char" rowspan="1" colspan="1">&#8722;0.51</td><td align="char" rowspan="1" colspan="1">0.615</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> &#949;4 status</td><td align="char" rowspan="1" colspan="1">0.64</td><td align="char" rowspan="1" colspan="1">2.38</td><td align="char" rowspan="1" colspan="1">0.27</td><td align="char" rowspan="1" colspan="1">0.788</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="5" align="left" colspan="1">
<p>Average NREM SWA</p>
<p>(1&#8211;4.5&#160;Hz)</p>
</td><td align="left" rowspan="1" colspan="1">Centiloid value</td><td align="char" rowspan="1" colspan="1">&#8722;0.01</td><td align="char" rowspan="1" colspan="1">0.01</td><td align="char" rowspan="1" colspan="1">&#8722;1.13</td><td align="char" rowspan="1" colspan="1">0.264</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">0.06</td><td align="char" rowspan="1" colspan="1">0.07</td><td align="char" rowspan="1" colspan="1">0.92</td><td align="char" rowspan="1" colspan="1">0.361</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">0.17</td><td align="char" rowspan="1" colspan="1">0.53</td><td align="char" rowspan="1" colspan="1">0.33</td><td align="char" rowspan="1" colspan="1">0.743</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="char" rowspan="1" colspan="1">&#8722;0.31</td><td align="char" rowspan="1" colspan="1">0.76</td><td align="char" rowspan="1" colspan="1">&#8722;0.41</td><td align="char" rowspan="1" colspan="1">0.686</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> &#949;4 status</td><td align="char" rowspan="1" colspan="1">0.25</td><td align="char" rowspan="1" colspan="1">0.54</td><td align="char" rowspan="1" colspan="1">0.46</td><td align="char" rowspan="1" colspan="1">0.640</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="5" align="left" colspan="1">
<p>Ratio of&#160;&lt;1&#160;Hz SWA/1&#8211;4.5&#160;Hz SWA</p>
</td><td align="left" rowspan="1" colspan="1">Centiloid value</td><td align="char" rowspan="1" colspan="1">2.4 &#215; 10&#8315;&#8308;</td><td align="char" rowspan="1" colspan="1">6.1 &#215; 10&#8315;&#8308;</td><td align="char" rowspan="1" colspan="1">0.398</td><td align="char" rowspan="1" colspan="1">0.692</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">&#8722;2.9 &#215; 10&#8315;<sup>3</sup>
</td><td align="char" rowspan="1" colspan="1">0.289</td><td align="char" rowspan="1" colspan="1">0.790</td><td align="char" rowspan="1" colspan="1">0.433</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">0.180</td><td align="char" rowspan="1" colspan="1">0.032</td><td align="char" rowspan="1" colspan="1">0.570</td><td align="char" rowspan="1" colspan="1">0.571</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="char" rowspan="1" colspan="1">0.028</td><td align="char" rowspan="1" colspan="1">0.046</td><td align="char" rowspan="1" colspan="1">0.613</td><td align="char" rowspan="1" colspan="1">0.543</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> &#949;4 status</td><td align="char" rowspan="1" colspan="1">0.052</td><td align="char" rowspan="1" colspan="1">0.326</td><td align="char" rowspan="1" colspan="1">1.58</td><td align="char" rowspan="1" colspan="1">0.119</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="5" align="left" colspan="1">
<p>Average NREM theta</p>
<p>(4&#8211;8&#160;Hz)</p>
</td><td align="left" rowspan="1" colspan="1">Centiloid value</td><td align="char" rowspan="1" colspan="1">&#8722;1.6 &#215; 10&#8315;<sup>3</sup>
</td><td align="char" rowspan="1" colspan="1">1.0 &#215; 10&#8315;<sup>3</sup>
</td><td align="char" rowspan="1" colspan="1">&#8722;1.55</td><td align="char" rowspan="1" colspan="1">0.127</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">0.01</td><td align="char" rowspan="1" colspan="1">0.01</td><td align="char" rowspan="1" colspan="1">1.70</td><td align="char" rowspan="1" colspan="1">0.095</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">&#8722;0.02</td><td align="char" rowspan="1" colspan="1">0.05</td><td align="char" rowspan="1" colspan="1">&#8722;0.31</td><td align="char" rowspan="1" colspan="1">0.759</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="char" rowspan="1" colspan="1">&#8722;0.06</td><td align="char" rowspan="1" colspan="1">0.08</td><td align="char" rowspan="1" colspan="1">&#8722;0.81</td><td align="char" rowspan="1" colspan="1">0.421</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> &#949;4 status</td><td align="char" rowspan="1" colspan="1">0.05</td><td align="char" rowspan="1" colspan="1">0.06</td><td align="char" rowspan="1" colspan="1">0.83</td><td align="char" rowspan="1" colspan="1">0.377</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="5" align="left" colspan="1">
<p>Average NREM alpha</p>
<p>(8&#8211;12&#160;Hz)</p>
</td><td align="left" rowspan="1" colspan="1">Centiloid value</td><td align="char" rowspan="1" colspan="1">&#8722;7.3 &#215; 10&#8315;&#8309;</td><td align="char" rowspan="1" colspan="1">4.9 &#215; 10&#8315;&#8308;</td><td align="char" rowspan="1" colspan="1">&#8722;0.15</td><td align="char" rowspan="1" colspan="1">0.881</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">4.0 &#215; 10&#8315;<sup>3</sup>
</td><td align="char" rowspan="1" colspan="1">3.1 &#215; 10&#8315;<sup>3</sup>
</td><td align="char" rowspan="1" colspan="1">1.27</td><td align="char" rowspan="1" colspan="1">0.209</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">&#8722;0.04</td><td align="char" rowspan="1" colspan="1">0.03</td><td align="char" rowspan="1" colspan="1">&#8722;1.55</td><td align="char" rowspan="1" colspan="1">0.127</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="char" rowspan="1" colspan="1">&#8722;0.04</td><td align="char" rowspan="1" colspan="1">0.04</td><td align="char" rowspan="1" colspan="1">&#8722;1.04</td><td align="char" rowspan="1" colspan="1">0.302</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> &#949;4 status</td><td align="char" rowspan="1" colspan="1">&#8722;0.03</td><td align="char" rowspan="1" colspan="1">0.03</td><td align="char" rowspan="1" colspan="1">&#8722;1.00</td><td align="char" rowspan="1" colspan="1">0.331</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="5" align="left" colspan="1">Average NREM spindles (12&#8211;16&#160;Hz)</td><td align="left" rowspan="1" colspan="1">Centiloid value</td><td align="char" rowspan="1" colspan="1">&#8722;0.01</td><td align="char" rowspan="1" colspan="1">2.2 &#215; 10&#8315;<sup>3</sup>
</td><td align="char" rowspan="1" colspan="1">&#8722;2.43</td><td align="char" rowspan="1" colspan="1">0.019</td><td align="char" rowspan="1" colspan="1">0.76</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">&#8722;3.7 &#215; 10&#8315;<sup>3</sup>
</td><td align="char" rowspan="1" colspan="1">0.01</td><td align="char" rowspan="1" colspan="1">&#8722;0.26</td><td align="char" rowspan="1" colspan="1">0.793</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">&#8722;0.07</td><td align="char" rowspan="1" colspan="1">0.11</td><td align="char" rowspan="1" colspan="1">&#8722;0.59</td><td align="char" rowspan="1" colspan="1">0.558</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="char" rowspan="1" colspan="1">&#8722;0.48</td><td align="char" rowspan="1" colspan="1">0.16</td><td align="char" rowspan="1" colspan="1">&#8722;2.96</td><td align="char" rowspan="1" colspan="1">0.005</td><td align="char" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> &#949;4 status</td><td align="char" rowspan="1" colspan="1">&#8722;0.03</td><td align="char" rowspan="1" colspan="1">0.12</td><td align="char" rowspan="1" colspan="1">&#8722;0.25</td><td align="char" rowspan="1" colspan="1">0.772</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="5" align="left" colspan="1">Average NREM beta (15&#8211;25&#160;Hz)</td><td align="left" rowspan="1" colspan="1">Centiloid value</td><td align="char" rowspan="1" colspan="1">&#8722;0.01</td><td align="char" rowspan="1" colspan="1">2.1 &#215; 10&#8315;<sup>3</sup>
</td><td align="char" rowspan="1" colspan="1">&#8722;2.58</td><td align="char" rowspan="1" colspan="1">0.013</td><td align="char" rowspan="1" colspan="1">0.52</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">&#8722;4.7 &#215; 10&#8315;<sup>3</sup>
</td><td align="char" rowspan="1" colspan="1">0.01</td><td align="char" rowspan="1" colspan="1">&#8722;0.36</td><td align="char" rowspan="1" colspan="1">0.721</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">&#8722;0.05</td><td align="char" rowspan="1" colspan="1">0.11</td><td align="char" rowspan="1" colspan="1">&#8722;0.46</td><td align="char" rowspan="1" colspan="1">0.650</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="char" rowspan="1" colspan="1">&#8722;0.46</td><td align="char" rowspan="1" colspan="1">0.15</td><td align="char" rowspan="1" colspan="1">&#8722;2.98</td><td align="char" rowspan="1" colspan="1">0.004</td><td align="char" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> &#949;4 status</td><td align="char" rowspan="1" colspan="1">&#8722;0.02</td><td align="char" rowspan="1" colspan="1">0.11</td><td align="char" rowspan="1" colspan="1">&#8722;0.18</td><td align="char" rowspan="1" colspan="1">0.882</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="5" align="left" colspan="1">Average NREM gamma (25&#8211;40&#160;Hz)</td><td align="left" rowspan="1" colspan="1">Centiloid value</td><td align="char" rowspan="1" colspan="1">&#8722;2.4 &#215; 10&#8315;&#8309;</td><td align="char" rowspan="1" colspan="1">3.8 &#215; 10&#8315;&#8309;</td><td align="char" rowspan="1" colspan="1">&#8722;0.63</td><td align="char" rowspan="1" colspan="1">0.531</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">2.9 &#215; 10&#8315;&#8308;</td><td align="char" rowspan="1" colspan="1">2.5 &#215; 10&#8315;&#8308;</td><td align="char" rowspan="1" colspan="1">1.19</td><td align="char" rowspan="1" colspan="1">0.240</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">&#8722;4.4 &#215; 10&#8315;&#8308;</td><td align="char" rowspan="1" colspan="1">2.0 &#215; 10&#8315;<sup>3</sup>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.22</td><td align="char" rowspan="1" colspan="1">0.828</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="char" rowspan="1" colspan="1">7.5 &#215; 10&#8315;&#8308;</td><td align="char" rowspan="1" colspan="1">2.9 &#215; 10&#8315;<sup>3</sup>
</td><td align="char" rowspan="1" colspan="1">0.26</td><td align="char" rowspan="1" colspan="1">0.796</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> &#949;4 status</td><td align="char" rowspan="1" colspan="1">2.7 &#215; 10&#8315;<sup>3</sup>
</td><td align="char" rowspan="1" colspan="1">2.1 &#215; 10&#8315;<sup>3</sup>
</td><td align="char" rowspan="1" colspan="1">0.00</td><td align="char" rowspan="1" colspan="1">0.191</td><td align="char" rowspan="1" colspan="1">1.00</td></tr></tbody></table><table-wrap-foot><fn id="alz70761-tbl4-note-0001"><p>Abbreviations: <italic toggle="yes">APOE</italic> &#949;4, apolipoprotein E &#949;4 allele; Hz, hertz; NREM, non&#8208;rapid eye movement; SE, standard error; SWA, slow&#8208;wave activity.</p></fn><fn id="alz70761-tbl4-note-0002"><p>Adjusted <italic toggle="yes">p</italic>&#8208;values are after Bonferroni correction for multiple comparisons.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="alz70761-sec-0190"><label>3.4</label><title>Sample size estimates</title><p>To assess how these findings may be applicable to different clinical study designs, power analyses were conducted to estimate the sample sizes necessary to detect both within&#8208;individual and between&#8208;individual longitudinal change of different sleep metrics depending on the study design. For a one&#8208;sample (within&#8208;individual) longitudinal observational study monitoring change from baseline with participants serving as their own controls, the detectable rate of change was used to calculate the sample size needed to detect the following proportions of the observed rate of change: 0.5, 0.8, 1.0, 1.2, 1.5, and 2.0. Tables <xref rid="alz70761-supinfo-0001" ref-type="">S4&#8211;S6</xref> show the sample sizes needed for using self&#8208;reported, scEEG&#8208;derived, and EEG power sleep metrics. Each table includes the average rate of change per year and the SD of the rate of change per metric. To test a two&#8208;arm clinical trial (between&#8208;individual) comparing treated and untreated groups, we used the baseline value, observed rate of change, and SD of the rate of change to calculate the sample sizes needed to measure group differences of 1%, 3%, 5%, and 7% (Tables <xref rid="alz70761-supinfo-0001" ref-type="">S7&#8211;S9</xref>). Figure&#160;<xref rid="alz70761-fig-0002" ref-type="fig">2</xref> shows examples of these two types of studies.</p><fig position="float" fig-type="FIGURE" id="alz70761-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Outcomes of Potential Clinical Study Designs. (A) Example of the outcomes from a study measuring one&#8208;sample within&#8208;individual change in a sleep metric from baseline with participants serving as their own controls. The within&#8208;individual change from baseline at 1 year is shown. (B) Example of the outcomes from a two&#8208;arm clinical trial measuring between&#8208;individual change comparing treated and untreated groups. The untreated group shows a low rate of change at 1 year, similar to our findings. The treated group increases the sleep metric, and the between&#8208;individual group differences at 1 year are shown. The x&#8208;axis shows time from the baseline study start to 1 year. The y&#8208;axis indicates the sleep metric. The horizontal dotted line shows no change from baseline.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="ALZ-21-e70761-g001.jpg"/></fig><p>In Table&#160;<xref rid="alz70761-tbl-0005" ref-type="table">5</xref>, we show example sample size calculations for both studies of within&#8208;individual (one&#8208;sample) change from baseline and between&#8208;individual (two&#8208;arm clinical trial) change, comparing treated and untreated groups with self&#8208;reported minutes of daytime napping, sleep duration measured by scEEG, and average 1&#8211;4.5&#160;Hz NREM SWA. For the within&#8208;individual study design, we used 5% change from baseline as a minimum clinically meaningful change in the sleep metrics. Sleep metrics from Visit 1 in Tables <xref rid="alz70761-supinfo-0001" ref-type="">S1&#8211;S3</xref> were used for baseline values. For sleep duration and average NREM SWA, the sample size necessary to detect a significant change at 80% power is&#160;&lt;40 participants. In comparison, the self&#8208;reported daytime napping measure calls for 574 amyloid&#8208;negative participants and 120 amyloid&#8208;positive participants, respectively. In the between&#8208;individual study design, the 5% and 7% change between groups are shown in Table&#160;<xref rid="alz70761-tbl-0005" ref-type="table">5</xref>, and all measures can be differentiated with sample sizes between 5 and 156 participants per group.</p><table-wrap position="float" id="alz70761-tbl-0005" content-type="TABLE" orientation="portrait"><label>TABLE 5</label><caption><p>Example sample size calculations.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><thead><tr><th align="left" colspan="9" style="border-bottom:solid 1px #000000" rowspan="1">
<italic toggle="yes">Within&#8208;individual sample sizes to detect a 5% change from baseline</italic>
</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" colspan="4" style="border-bottom:solid 1px #000000" rowspan="1">Amyloid negative</th><th align="left" colspan="4" style="border-bottom:solid 1px #000000" rowspan="1">Amyloid positive</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Sleep metric</th><th align="left" rowspan="1" colspan="1">Baseline value</th><th align="left" rowspan="1" colspan="1">5% change from baseline</th><th align="left" rowspan="1" colspan="1">SD of rate of change</th><th align="left" rowspan="1" colspan="1">Sample size (<italic toggle="yes">n</italic>)</th><th align="left" rowspan="1" colspan="1">Baseline value</th><th align="left" rowspan="1" colspan="1">5% change from baseline</th><th align="left" rowspan="1" colspan="1">SD of rate of change</th><th align="left" rowspan="1" colspan="1">Sample size (<italic toggle="yes">n</italic>)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Self&#8208;reported daytime napping (min)</td><td align="char" rowspan="1" colspan="1">14.04</td><td align="char" rowspan="1" colspan="1">0.70</td><td align="char" rowspan="1" colspan="1">5.99</td><td align="char" rowspan="1" colspan="1">574</td><td align="char" rowspan="1" colspan="1">23.12</td><td align="char" rowspan="1" colspan="1">1.16</td><td align="char" rowspan="1" colspan="1">4.54</td><td align="char" rowspan="1" colspan="1">120</td></tr><tr><td align="left" rowspan="1" colspan="1">Sleep duration (min)</td><td align="char" rowspan="1" colspan="1">371.6</td><td align="char" rowspan="1" colspan="1">18.58</td><td align="char" rowspan="1" colspan="1">19.5</td><td align="char" rowspan="1" colspan="1">7</td><td align="char" rowspan="1" colspan="1">367.4</td><td align="char" rowspan="1" colspan="1">18.37</td><td align="char" rowspan="1" colspan="1">16.2</td><td align="char" rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>Average</p>
<p>NREM SWA</p>
<p>(1&#8211;4.5&#160;Hz)</p>
</td><td align="char" rowspan="1" colspan="1">19.15</td><td align="char" rowspan="1" colspan="1">0.96</td><td align="char" rowspan="1" colspan="1">2.06</td><td align="char" rowspan="1" colspan="1">36</td><td align="char" rowspan="1" colspan="1">19.09</td><td align="char" rowspan="1" colspan="1">0.95</td><td align="char" rowspan="1" colspan="1">1.75</td><td align="char" rowspan="1" colspan="1">27</td></tr></tbody></table><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><thead><tr><th align="left" colspan="13" style="border-bottom:solid 1px #000000" rowspan="1">
<italic toggle="yes">Between&#8208;individual sample sizes comparing treated and untreated groups</italic>
</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" colspan="6" style="border-bottom:solid 1px #000000" rowspan="1">Amyloid negative</th><th align="left" colspan="6" style="border-bottom:solid 1px #000000" rowspan="1">Amyloid positive</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="char" rowspan="1" colspan="1"/><th align="char" rowspan="1" colspan="1"/><th align="char" rowspan="1" colspan="1"/><th align="char" rowspan="1" colspan="1"/><th colspan="2" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Sample size per group (<italic toggle="yes">n</italic>)</th><th align="char" rowspan="1" colspan="1"/><th align="char" rowspan="1" colspan="1"/><th align="char" rowspan="1" colspan="1"/><th align="char" rowspan="1" colspan="1"/><th colspan="2" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Sample size per group (<italic toggle="yes">n</italic>)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Sleep metric</th><th align="left" rowspan="1" colspan="1">Observed rate of change</th><th align="left" rowspan="1" colspan="1">SD of rate of change</th><th align="left" rowspan="1" colspan="1">Baseline value</th><th align="left" rowspan="1" colspan="1">Observed rate of change/baseline</th><th align="left" rowspan="1" colspan="1">5% change</th><th align="left" rowspan="1" colspan="1">7% change</th><th align="left" rowspan="1" colspan="1">Observed rate of change</th><th align="left" rowspan="1" colspan="1">SD of rate of change</th><th align="left" rowspan="1" colspan="1">Baseline value</th><th align="left" rowspan="1" colspan="1">Observed rate of change/baseline</th><th align="left" rowspan="1" colspan="1">5% change</th><th align="left" rowspan="1" colspan="1">7% change</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Self&#8208;reported daytime napping (min)</td><td align="char" rowspan="1" colspan="1">&#8722;0.017</td><td align="char" rowspan="1" colspan="1">0.268</td><td align="char" rowspan="1" colspan="1">7.250</td><td align="char" rowspan="1" colspan="1">&#8722;0.23%</td><td align="char" rowspan="1" colspan="1">9</td><td align="char" rowspan="1" colspan="1">6</td><td align="char" rowspan="1" colspan="1">&#8722;4.37x10<sup>&#8722;2</sup>
</td><td align="char" rowspan="1" colspan="1">0.251</td><td align="char" rowspan="1" colspan="1">7.346</td><td align="char" rowspan="1" colspan="1">&#8722;0.06%</td><td align="char" rowspan="1" colspan="1">9</td><td align="char" rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">Sleep duration (min)</td><td align="char" rowspan="1" colspan="1">5.245</td><td align="char" rowspan="1" colspan="1">19.46</td><td align="char" rowspan="1" colspan="1">370.1</td><td align="char" rowspan="1" colspan="1">1.42%</td><td align="char" rowspan="1" colspan="1">35</td><td align="char" rowspan="1" colspan="1">15</td><td align="char" rowspan="1" colspan="1">&#8722;0.9685</td><td align="char" rowspan="1" colspan="1">16.24</td><td align="char" rowspan="1" colspan="1">375.7</td><td align="char" rowspan="1" colspan="1">&#8722;0.26%</td><td align="char" rowspan="1" colspan="1">12</td><td align="char" rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>Average NREM SWA</p>
<p>(1&#8211;4.5&#160;Hz)</p>
</td><td align="char" rowspan="1" colspan="1">0.2607</td><td align="char" rowspan="1" colspan="1">2.060</td><td align="char" rowspan="1" colspan="1">18.33</td><td align="char" rowspan="1" colspan="1">1.42%</td><td align="char" rowspan="1" colspan="1">156</td><td align="char" rowspan="1" colspan="1">65</td><td align="char" rowspan="1" colspan="1">&#8722;6.00x10<sup>&#8722;3</sup>
</td><td align="char" rowspan="1" colspan="1">1.749</td><td align="char" rowspan="1" colspan="1">20.26</td><td align="char" rowspan="1" colspan="1">&#8722;0.03%</td><td align="char" rowspan="1" colspan="1">48</td><td align="char" rowspan="1" colspan="1">25</td></tr></tbody></table><table-wrap-foot><fn id="alz70761-tbl5-note-0001"><p>Abbreviations: Hz, hertz; <italic toggle="yes">n</italic>&#160;=&#160;sample size, min, minutes; NREM, non&#8208;rapid eye movement; SD, standard deviation; SWA, slow&#8208;wave activity.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec></sec><sec id="alz70761-sec-0200"><label>4</label><title>DISCUSSION</title><p>Sleep disturbances have been associated with numerous disease states including AD, Parkinson's disease, major mental illnesses such as depression and anxiety, as well as cardiovascular disease and obesity.<xref rid="alz70761-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref>, <xref rid="alz70761-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>, <xref rid="alz70761-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>, <xref rid="alz70761-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> Despite evidence supporting sleep's role in the onset and progression of certain diseases, there are few studies that follow sleep longitudinally while also collecting longitudinal cognitive and AD biomarker data. This study aimed to fill that gap by examining self&#8208;reported sleep measures, scEEG&#8208;derived sleep metrics, and EEG spectral power in a cohort of cognitively unimpaired to mildly impaired amyloid&#8208;negative and amyloid&#8208;positive individuals over the span of &#8776;3.5 years. The longitudinal change of sleep metrics within each amyloid group was estimated using an ICC, and findings were confirmed using general linear modeling that adjusted for the presence of covariates that may influence longitudinal change.</p><p>We observed that EEG spectral power measures had the least longitudinal change over time in both amyloid&#8208;negative and amyloid&#8208;positive individuals. EEG power measures from&#160;&lt;1 to 12&#160;Hz showed the greatest stability. This is consistent with prior findings in healthy individuals that EEG spectral power had a strong correlation (<italic toggle="yes">r</italic>&#160;=&#160;0.84) over a 12&#8208; to 16&#8208;week interval.<xref rid="alz70761-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> In comparison, the scEEG&#8208;derived measures and self&#8208;reported sleep data demonstrated relatively greater longitudinal change over time, with metrics ranging from low to moderate change between visits. However, certain metrics stood out for their greater stability within these categories. Minutes of daytime napping, average N3 time, and REM latency each exhibited lower longitudinal change (amyloid&#8208;negative ICC&#160;=&#160;0.674, 0.869, and 0.721, respectively; amyloid&#8208;positive ICC&#160;=&#160;0.640, 0.664, and 0.764, respectively). The annual rate of change of each sleep measure was also not associated with Centiloid value, sex, age, race, or ApoE4+ status.</p><p>Overall, the evaluated sleep metrics reflected generally low rates of change across the &#8776;3.5&#8208;year interval. A possible explanation for these findings is the lack of significant change in amyloid Centiloid values or cognitive status between visits. For example, neither participant's overall CDR scores nor amyloid PET Centiloid values changed significantly over the follow&#8208;up period. We hypothesize that the lack of change observed in the different sleep metrics may be due to the lack of change in AD symptoms or pathology. If so, this suggests that relatively small sample sizes with longitudinal sleep, AD biomarker, and cognitive measures are needed to establish if sleep changes over time as amyloid plaques accumulate or cognition worsens. Alternatively, our study may be underpowered to detect changes in sleep over &#8776;3.5 years in cognitively unimpaired and mildly impaired amyloid&#8208;negative and amyloid&#8208;positive older adults. Future studies with larger sample sizes that capture changes in amyloid and/or cognitive status are needed to establish if sleep changes with AD progression and if sleep measures may serve as a functional biomarker in early AD.</p><p>As a result of these small rates of change combined with small variances, the sample sizes for within&#8208;individual change from baseline were very large for some measures to detect even <italic toggle="yes">k</italic>&#160;=&#160;2.0 change (Tables <xref rid="alz70761-supinfo-0001" ref-type="">S4&#8211;S6</xref>). However, such a small rate of change may not be considered clinically meaningful. For example, sleep duration in the amyloid&#8208;positive group has an average rate of change of &#8722;0.969 min/year. A 50% change in this metric is equal to 0.485 min/year and requires 8831 participants to detect this change with 80% power. Although the sample size in this scenario is markedly large, the example highlights the importance of choosing a clinically meaningful effect for a study outcome. A randomized clinical trial of suvorexant to treat insomnia in patients with mild&#8208;to&#8208;moderate AD found a significant increase in sleep duration of 28 min,<xref rid="alz70761-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> strongly supporting that this is a clinically meaningful increase. Our data show that only three cognitively unimpaired amyloid&#8208;positive participants are needed to see a 30 min/year change in sleep duration in 1 year using the one&#8208;sample within&#8208;individual study design. This example underscores the critical importance of selecting the appropriate study outcome measure when choosing an experimental study design.</p><p>The study findings suggest that the majority of sleep metrics require sample sizes too large to use as primary outcomes in randomized controlled trials. However, these sample sizes, which may also be adjusted based on hypothesized effect size, may be more appropriate for longitudinal observational studies or as a covariate to follow an intervention when AD pathology and cognitive function may change. An example of how our findings may be applicable to a &#8220;real world&#8221; study would be to assess sleep longitudinally in AD patients receiving anti&#8208;amyloid immunotherapy (e.g., lecanemab, donanemab). A potential sleep metric to follow is 1&#8211;4.5&#160;Hz NREM SWA, a measure of sleep homeostasis that has been proposed to track both AD pathology and cognitive performance.<xref rid="alz70761-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> If we assume a longitudinal change similar to what we found in amyloid&#8208;positive older adults, only 27 amyloid&#8208;positive individuals would be needed to adequately power a study with an outcome of a 5% change in NREM SWA from baseline in patients treated with anti&#8208;amyloid therapy using the one&#8208;sample within&#8208;individual study design (Figure&#160;<xref rid="alz70761-fig-0002" ref-type="fig">2A</xref>, Table&#160;<xref rid="alz70761-tbl-0005" ref-type="table">5</xref>). To detect 5% or 7% differences in NREM SWA between treated and untreated groups, a greater number of participants would be required than in the one&#8208;sample study example, and a different sleep metric may serve as a better outcome measure depending on the study hypothesis and expected effect size. The above examples are for illustrative purposes and do not account for other factors that may impact sleep such as underlying cognitive impairment and other medical comorbidities.</p><p>The strengths of this study included well&#8208;characterized participants and the large amount of sleep data acquired using different methods. Participants were assessed for longitudinal AD biomarkers, standardized cognitive assessments, and sleep monitored with both EEG and self&#8208;reported methods. A limitation of this study was the lack of participants who changed amyloid or CDR status. A future direction will be to examine the longitudinal change of sleep metrics in those who convert in cognitive status or amyloid status, as the study is still ongoing. Although we have found that sleep measures derived from scEEG are comparable to those from polysomnography,<xref rid="alz70761-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> it is important to note that there are important differences, including low agreement for N1. In addition, these findings apply only to an older adult cohort. Participant ages ranged from 64 to 83 years (Table <xref rid="alz70761-tbl-0001" ref-type="table">1</xref>). There are unique changes in sleep&#8208;related architecture that occur in young adults as well as in mid&#8208;life that are not captured in this study.<xref rid="alz70761-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref>
</p><p>In summary, this study serves as a resource to inform future longitudinal sleep studies in the setting of AD. EEG spectral power measures showed the least longitudinal change and required generally smaller sample sizes to detect longitudinal changes in sleep. Future studies of sleep and AD will need to select the sleep metric and study design to be appropriately powered to detect meaningful effect sizes.</p></sec><sec sec-type="COI-statement" id="alz70761-sec-0220"><title>CONFLICT OF INTEREST STATEMENT</title><p>Brendan P. Lucey receives consulting fees from Eisai, Eli Lilly, and the Weston Family Foundation; serves on data safety and monitoring boards for Eli Lilly; serves on the scientific advisory board for Beacon Biosignals; and receives compensation as a scientific advisor to Applied Cognition. He receives drug/matched placebo from Merck for a clinical trial funded by a private foundation and drug/matched placebo from Eisai for a clinical trial funded by the National Institute on Aging (NIA). David M. Holtzman is a cofounder of C2N Diagnostics; he has an equity ownership interest and may receive income based on technology licensed by Washington University to C2N Diagnostics. He reports serving on the scientific advisory board of C2N Diagnostics, Denali, Genentech, Cajal Neuroscience, and Switch Therapeutics, and consults for Roche. John C. Morris is funded by NIH grants # P30 AG066444, P01AG003991, and P01AG026276. Neither Dr. Morris nor his family owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company.</p><p>Authors Taylor J. Pedersen, Ruijin Lu, Cristina Toedebusch, Ashley Hess, Rachel Richardson, Allyson Quigley, Carling G. Robinson, Chengjie Xiong, and Brian A. Gordon have no disclosures. Any author disclosures are available in the <xref rid="alz70761-supinfo-0001" ref-type="">Supporting Information</xref>.</p></sec><sec id="alz70761-sec-0230"><title>CONSENT STATEMENT</title><p>This study was approved by the Washington University Institutional Review Board. Each participant provided written informed consent and were compensated for their participation.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="alz70761-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="alz70761-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70761-s002.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70761-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70761-s001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="alz70761-sec-0210"><title>ACKNOWLEDGMENTS</title><p>We are grateful to the participants for their valuable contributions to this study. This work was funded by the National Institutes of Health (NIH) and National Institute on Aging (NIA) grants P01 AG03991, P01 AG026276, and P30 AG066444. This manuscript is the result of funding in whole or in part by the NIH. It is subject to the NIH Public Access Policy. Through acceptance of this federal funding, The NIH has been given the right to make this manuscript publicly available in PubMed Central upon the Official Date of Publication, as defined by the NIH.</p></ack><ref-list id="alz70761-bibl-0001"><title>REFERENCES</title><ref id="alz70761-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="alz70761-cite-0002"><string-name name-style="western"><surname>Scheltens</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Blennow</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Breteler</surname><given-names>MM</given-names></string-name>, et&#160;al. <article-title>Alzheimer's disease</article-title>. <source>Lancet</source>. <year>2016</year>;<volume>388</volume>:<fpage>505</fpage>&#8208;<lpage>517</lpage>.<pub-id pub-id-type="pmid">26921134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(15)01124-1</pub-id></mixed-citation></ref><ref id="alz70761-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="alz70761-cite-0003"><string-name name-style="western"><surname>Fargo</surname><given-names>KN</given-names></string-name>, <string-name name-style="western"><surname>Aisen</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Albert</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Report on the milestones for the US national plan to address Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2014</year>;<volume>10</volume>:<fpage>S430</fpage>&#8208;<lpage>52</lpage>.<pub-id pub-id-type="pmid">25341459</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2014.08.103</pub-id></mixed-citation></ref><ref id="alz70761-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="alz70761-cite-0004"><string-name name-style="western"><surname>Price</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Morris</surname><given-names>JC</given-names></string-name>. <article-title>Tangles and plaques in nondemented aging and &#8220;preclinical&#8221; Alzheimer's disease</article-title>. <source>Ann Neurol</source>. <year>1999</year>;<volume>45</volume>:<fpage>358</fpage>&#8208;<lpage>368</lpage>.<pub-id pub-id-type="pmid">10072051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1531-8249(199903)45:3&lt;358::aid-ana12&gt;3.0.co;2-x</pub-id></mixed-citation></ref><ref id="alz70761-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="alz70761-cite-0005"><string-name name-style="western"><surname>Hulette</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Welsh&#8208;Bohmer</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Murray</surname><given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>Saunders</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Mash</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>McIntyre</surname><given-names>LM</given-names></string-name>. <article-title>Neuropathological and neuropsychological changes in &#8220;normal&#8221; aging: evidence for preclinical Alzheimer disease in cognitively normal individuals</article-title>. <source>J Neuropathol Exp Neurol</source>. <year>1998</year>;<volume>57</volume>:<fpage>1168</fpage>&#8208;<lpage>1174</lpage>.<pub-id pub-id-type="pmid">9862640</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00005072-199812000-00009</pub-id></mixed-citation></ref><ref id="alz70761-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="alz70761-cite-0006"><string-name name-style="western"><surname>Braak</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Braak</surname><given-names>E</given-names></string-name>. <article-title>Frequency of stages of Alzheimer&#8208;related lesions in different age categories</article-title>. <source>Neurobiol Aging</source>. <year>1997</year>;<volume>18</volume>:<fpage>351</fpage>&#8208;<lpage>357</lpage>.<pub-id pub-id-type="pmid">9330961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0197-4580(97)00056-0</pub-id></mixed-citation></ref><ref id="alz70761-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="alz70761-cite-0007"><string-name name-style="western"><surname>Hampel</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hardy</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Blennow</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>The Amyloid&#8208;&#946; pathway in Alzheimer's disease</article-title>. <source>Mol Psychiatry</source>. <year>2021</year>;<volume>26</volume>:<fpage>5481</fpage>&#8208;<lpage>5503</lpage>.<pub-id pub-id-type="pmid">34456336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-021-01249-0</pub-id><pub-id pub-id-type="pmcid">PMC8758495</pub-id></mixed-citation></ref><ref id="alz70761-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="alz70761-cite-0008"><string-name name-style="western"><surname>Dubois</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Hampel</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Feldman</surname><given-names>HH</given-names></string-name>, et&#160;al. <article-title>Alzheimer's disease: definition, natural history, and diagnostic criteria</article-title>. <source>Alzheimers Dement</source>. <year>2016</year>;<volume>12</volume>:<fpage>292</fpage>&#8208;<lpage>323</lpage>.<pub-id pub-id-type="pmid">27012484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2016.02.002</pub-id><pub-id pub-id-type="pmcid">PMC6417794</pub-id></mixed-citation></ref><ref id="alz70761-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="alz70761-cite-0009"><string-name name-style="western"><surname>Sperling</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Aisen</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Beckett</surname><given-names>LA</given-names></string-name>, et&#160;al. <article-title>Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging&#8208;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2011</year>;<volume>7</volume>:<fpage>280</fpage>&#8208;<lpage>292</lpage>.<pub-id pub-id-type="pmid">21514248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2011.03.003</pub-id><pub-id pub-id-type="pmcid">PMC3220946</pub-id></mixed-citation></ref><ref id="alz70761-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="alz70761-cite-0010"><string-name name-style="western"><surname>Brzecka</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Leszek</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ashraf</surname><given-names>GM</given-names></string-name>, et&#160;al. <article-title>Sleep disorders associated with Alzheimer's disease: a perspective</article-title>. <source>Front Neurosci</source>. <year>2018</year>;<volume>12</volume>:<fpage>330</fpage>.<pub-id pub-id-type="pmid">29904334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2018.00330</pub-id><pub-id pub-id-type="pmcid">PMC5990625</pub-id></mixed-citation></ref><ref id="alz70761-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="alz70761-cite-0011"><string-name name-style="western"><surname>Lucey</surname><given-names>BP</given-names></string-name>, <string-name name-style="western"><surname>Wisch</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Boerwinkle</surname><given-names>AH</given-names></string-name>, et&#160;al. <article-title>Sleep and longitudinal cognitive performance in preclinical and early symptomatic Alzheimer's disease</article-title>. <source>Brain</source>. <year>2021</year>;<volume>144</volume>:<fpage>2852</fpage>&#8208;<lpage>2862</lpage>.<pub-id pub-id-type="pmid">34668959</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awab272</pub-id><pub-id pub-id-type="pmcid">PMC8536939</pub-id></mixed-citation></ref><ref id="alz70761-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="alz70761-cite-0012"><string-name name-style="western"><surname>Ju</surname><given-names>Y&#8208;E</given-names></string-name>, <string-name name-style="western"><surname>McLeland</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Toedebusch</surname><given-names>CD</given-names></string-name>, et&#160;al. <article-title>Sleep quality and preclinical Alzheimer's disease</article-title>. <source>JAMA Neurol</source>. <year>2013</year>;<volume>70</volume>:<fpage>587</fpage>&#8208;<lpage>593</lpage>.<pub-id pub-id-type="pmid">23479184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2013.2334</pub-id><pub-id pub-id-type="pmcid">PMC3676720</pub-id></mixed-citation></ref><ref id="alz70761-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="alz70761-cite-0013"><string-name name-style="western"><surname>Koren</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Fisher</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Webster</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Livingston</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Rapaport</surname><given-names>P</given-names></string-name>. <article-title>Prevalence of sleep disturbances in people with dementia living in the community: a systematic review and meta&#8208;analysis</article-title>. <source>Ageing Res Rev</source>. <year>2023</year>;<volume>83</volume>:<elocation-id>101782</elocation-id>.<pub-id pub-id-type="pmid">36356799</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2022.101782</pub-id></mixed-citation></ref><ref id="alz70761-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="alz70761-cite-0014"><string-name name-style="western"><surname>Lucey</surname><given-names>BP</given-names></string-name>. <article-title>It's complicated: the relationship between sleep and Alzheimer's disease in humans</article-title>. <source>Neurobiol Dis</source>. <year>2020</year>;<volume>144</volume>:<elocation-id>105031</elocation-id>.<pub-id pub-id-type="pmid">32738506</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2020.105031</pub-id><pub-id pub-id-type="pmcid">PMC7484285</pub-id></mixed-citation></ref><ref id="alz70761-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="alz70761-cite-0015"><string-name name-style="western"><surname>Robbins</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Quan</surname><given-names>SF</given-names></string-name>, <string-name name-style="western"><surname>Barger</surname><given-names>LK</given-names></string-name>, et&#160;al. <article-title>Self&#8208;reported sleep duration and timing: a methodological review of event definitions, context, and timeframe of related questions</article-title>. <source>Sleep Epidemiol</source>. <year>2021</year>;<volume>1</volume>:<elocation-id>100016</elocation-id>.<pub-id pub-id-type="pmid">35761957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.sleepe.2021.100016</pub-id><pub-id pub-id-type="pmcid">PMC9233860</pub-id></mixed-citation></ref><ref id="alz70761-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="alz70761-cite-0016"><string-name name-style="western"><surname>Johns</surname><given-names>MW</given-names></string-name>. <article-title>A new method for measuring daytime sleepiness: the Epworth sleepiness scale</article-title>. <source>Sleep</source>. <year>1991</year>;<volume>14</volume>:<fpage>540</fpage>&#8208;<lpage>545</lpage>.<pub-id pub-id-type="pmid">1798888</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/sleep/14.6.540</pub-id></mixed-citation></ref><ref id="alz70761-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="alz70761-cite-0017"><string-name name-style="western"><surname>Buysse</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Reynolds</surname><given-names>CF</given-names></string-name>, <string-name name-style="western"><surname>Monk</surname><given-names>TH</given-names></string-name>, <string-name name-style="western"><surname>Berman</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Kupfer</surname><given-names>DJ</given-names></string-name>. <article-title>The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research</article-title>. <source>Psych Res</source>. <year>1989</year>;<volume>28</volume>:<fpage>193</fpage>&#8208;<lpage>213</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0165-1781(89)90047-4</pub-id><pub-id pub-id-type="pmid">2748771</pub-id></mixed-citation></ref><ref id="alz70761-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="alz70761-cite-0018"><string-name name-style="western"><surname>Lucey</surname><given-names>BP</given-names></string-name>, <string-name name-style="western"><surname>McLeland</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Toedebusch</surname><given-names>CD</given-names></string-name>, et&#160;al. <article-title>Comparison of a single&#8208;channel EEG sleep study to polysomnography</article-title>. <source>J Sleep Res</source>. <year>2016</year>;<volume>25</volume>:<fpage>625</fpage>&#8208;<lpage>635</lpage>.<pub-id pub-id-type="pmid">27252090</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jsr.12417</pub-id><pub-id pub-id-type="pmcid">PMC5135638</pub-id></mixed-citation></ref><ref id="alz70761-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="alz70761-cite-0019"><string-name name-style="western"><surname>Biasiucci</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Franceschiello</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><given-names>Murray MM</given-names></string-name>. <string-name name-style="western"><surname>Electroencephalography</surname></string-name>. <source>Curr Biol</source>. <year>2019</year>;<volume>29</volume>:<fpage>R80</fpage>&#8208;<lpage>r5</lpage>.<pub-id pub-id-type="pmid">30721678</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cub.2018.11.052</pub-id></mixed-citation></ref><ref id="alz70761-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="alz70761-cite-0020"><string-name name-style="western"><surname>Girschik</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fritschi</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Heyworth</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Waters</surname><given-names>F</given-names></string-name>. <article-title>Validation of self&#8208;reported sleep against actigraphy</article-title>. <source>J Epidemiol</source>. <year>2012</year>;<volume>22</volume>:<fpage>462</fpage>&#8208;<lpage>468</lpage>.<pub-id pub-id-type="pmid">22850546</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2188/jea.JE20120012</pub-id><pub-id pub-id-type="pmcid">PMC3798642</pub-id></mixed-citation></ref><ref id="alz70761-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="alz70761-cite-0021"><string-name name-style="western"><surname>Fosgerau</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Karlstr&#246;m</surname><given-names>A</given-names></string-name>. <article-title>The value of reliability</article-title>. <source>Transp Res B: Methodol</source>. <year>2010</year>;<volume>44</volume>:<fpage>38</fpage>&#8208;<lpage>49</lpage>.</mixed-citation></ref><ref id="alz70761-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="alz70761-cite-0022"><string-name name-style="western"><surname>Bastien</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Vallieres</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Morin</surname><given-names>CM</given-names></string-name>. <article-title>Validation of the Insomnia Severity Index as an outcome measure for insomnia research</article-title>. <source>Sleep Med</source>. <year>2001</year>;<volume>2</volume>:<fpage>297</fpage>&#8208;<lpage>307</lpage>.<pub-id pub-id-type="pmid">11438246</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1389-9457(00)00065-4</pub-id></mixed-citation></ref><ref id="alz70761-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="alz70761-cite-0023"><string-name name-style="western"><surname>Doherty</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Roe</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Murphy</surname><given-names>SA</given-names></string-name>, et&#160;al. <article-title>Adverse driving behaviors are associated with sleep apnea severity and age in cognitively normal older adults at risk for Alzheimer's disease</article-title>. <source>Sleep</source>. <year>2022</year>;<volume>45</volume>:<elocation-id>zsac070</elocation-id>.<pub-id pub-id-type="pmid">35303111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/sleep/zsac070</pub-id><pub-id pub-id-type="pmcid">PMC9189946</pub-id></mixed-citation></ref><ref id="alz70761-bib-0023"><label>23</label><mixed-citation publication-type="book" id="alz70761-cite-0024"><string-name name-style="western"><surname>Iber</surname><given-names>C</given-names></string-name>. <source>The AASM Manual for Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications: version 3</source>. <publisher-name>American Academy of Sleep Medicine</publisher-name>; <year>2023</year>.</mixed-citation></ref><ref id="alz70761-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="alz70761-cite-0025"><string-name name-style="western"><surname>Landau</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Ward</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Murphy</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Quantification of amyloid beta and tau PET without a structural MRI</article-title>. <source>Alzheimers Dement</source>. <year>2023</year>;<volume>19</volume>:<fpage>444</fpage>&#8208;<lpage>455</lpage>.<pub-id pub-id-type="pmid">35429219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12668</pub-id></mixed-citation></ref><ref id="alz70761-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="alz70761-cite-0026"><string-name name-style="western"><surname>Klunk</surname><given-names>WE</given-names></string-name>, <string-name name-style="western"><surname>Koeppe</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Price</surname><given-names>JC</given-names></string-name>, et&#160;al. <article-title>The Centiloid project: standardizing quantitative amyloid plaque estimation by PET</article-title>. <source>Alzheimers Dement</source>. <year>2015</year>;<volume>11</volume>:<fpage>1</fpage>&#8208;<lpage>15</lpage>.<pub-id pub-id-type="pmid">25443857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2014.07.003</pub-id><pub-id pub-id-type="pmcid">PMC4300247</pub-id></mixed-citation></ref><ref id="alz70761-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="alz70761-cite-0027"><string-name name-style="western"><surname>Jack</surname><given-names>CR</given-names>, <suffix>Jr.</suffix></string-name>, <string-name name-style="western"><surname>Wiste</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Weigand</surname><given-names>SD</given-names></string-name>, et&#160;al. <article-title>Defining imaging biomarker cut points for brain aging and Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2017</year>;<volume>13</volume>:<fpage>205</fpage>&#8208;<lpage>216</lpage>.<pub-id pub-id-type="pmid">27697430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2016.08.005</pub-id><pub-id pub-id-type="pmcid">PMC5344738</pub-id></mixed-citation></ref><ref id="alz70761-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="alz70761-cite-0028"><string-name name-style="western"><surname>Beekly</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Ramos</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>WW</given-names></string-name>, et&#160;al. <article-title>The National Alzheimer's Coordinating Center (NACC) database: the uniform data set</article-title>. <source>Alzheimer Dis Assoc Disord</source>. <year>2007</year>;<volume>21</volume>:<fpage>249</fpage>&#8208;<lpage>258</lpage>.<pub-id pub-id-type="pmid">17804958</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WAD.0b013e318142774e</pub-id></mixed-citation></ref><ref id="alz70761-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="alz70761-cite-0029"><string-name name-style="western"><surname>O'Bryant</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Waring</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Cullum</surname><given-names>CM</given-names></string-name>, et&#160;al. <article-title>Staging dementia using clinical dementia rating scale sum of boxes scores: a Texas Alzheimer's research consortium study</article-title>. <source>Arch Neurol</source>. <year>2008</year>;<volume>65</volume>:<fpage>1091</fpage>&#8208;<lpage>1095</lpage>.<pub-id pub-id-type="pmid">18695059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneur.65.8.1091</pub-id><pub-id pub-id-type="pmcid">PMC3409562</pub-id></mixed-citation></ref><ref id="alz70761-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="alz70761-cite-0030"><string-name name-style="western"><surname>Morris</surname><given-names>JC</given-names></string-name>. <article-title>The clinical dementia rating (CDR): current version and scoring rules</article-title>. <source>Neurology</source>. <year>1993</year>;<volume>43</volume>:<fpage>2412</fpage>&#8208;<lpage>2414</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.43.11.2412-a</pub-id><pub-id pub-id-type="pmid">8232972</pub-id></mixed-citation></ref><ref id="alz70761-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="alz70761-cite-0031"><string-name name-style="western"><surname>Gamer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lemon</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fellows</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>P</given-names></string-name>. <article-title>irr: Various coefficients of Interrater Reliability and Agreement</article-title>. Published online January <volume>26</volume>, <elocation-id>20192019</elocation-id>.</mixed-citation></ref><ref id="alz70761-bib-0031"><label>31</label><mixed-citation publication-type="miscellaneous" id="alz70761-cite-0032"><article-title>Team RC. R: A Language and Environment for Statistical Computing</article-title>. <year>2024</year>.</mixed-citation></ref><ref id="alz70761-bib-0032"><label>32</label><mixed-citation publication-type="miscellaneous" id="alz70761-cite-0033"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://knightadrc.wustl.edu/data-request-form/" ext-link-type="uri">https://knightadrc.wustl.edu/data&#8208;request&#8208;form/</ext-link></mixed-citation></ref><ref id="alz70761-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="alz70761-cite-0034"><string-name name-style="western"><surname>Miner</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Kryger</surname><given-names>MH</given-names></string-name>. <article-title>Sleep in the aging population</article-title>. <source>Sleep Med Clin</source>. <year>2017</year>;<volume>12</volume>:<fpage>31</fpage>&#8208;<lpage>38</lpage>.<pub-id pub-id-type="pmid">28159095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsmc.2016.10.008</pub-id><pub-id pub-id-type="pmcid">PMC5300306</pub-id></mixed-citation></ref><ref id="alz70761-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="alz70761-cite-0035"><string-name name-style="western"><surname>Bobak</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Barr</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>O'Malley</surname><given-names>AJ</given-names></string-name>. <article-title>Estimation of an inter&#8208;rater intra&#8208;class correlation coefficient that overcomes common assumption violations in the assessment of health measurement scales</article-title>. <source>BMC Med Res Methodol</source>. <year>2018</year>;<volume>18</volume>:<fpage>93</fpage>.<pub-id pub-id-type="pmid">30208858</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12874-018-0550-6</pub-id><pub-id pub-id-type="pmcid">PMC6134634</pub-id></mixed-citation></ref><ref id="alz70761-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="alz70761-cite-0036"><string-name name-style="western"><surname>Li</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>X</given-names></string-name>, et&#160;al. <article-title>Daytime napping and Alzheimer's dementia: a potential bidirectional relationship</article-title>. <source>Alzheimers Dement</source>. <year>2023</year>;<volume>19</volume>:<fpage>158</fpage>&#8208;<lpage>168</lpage>.<pub-id pub-id-type="pmid">35297533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12636</pub-id><pub-id pub-id-type="pmcid">PMC9481741</pub-id></mixed-citation></ref><ref id="alz70761-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="alz70761-cite-0037"><string-name name-style="western"><surname>Sabia</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Fayosse</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Dumurgier</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Association of sleep duration in middle and old age with incidence of dementia</article-title>. <source>Nat Commun</source>. <year>2021</year>;<volume>12</volume>:<fpage>2289</fpage>.<pub-id pub-id-type="pmid">33879784</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-22354-2</pub-id><pub-id pub-id-type="pmcid">PMC8058039</pub-id></mixed-citation></ref><ref id="alz70761-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="alz70761-cite-0038"><string-name name-style="western"><surname>Westwood</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Beiser</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Jain</surname><given-names>N</given-names></string-name>, et&#160;al. <article-title>Prolonged sleep duration as a marker of early neurodegeneration predicting incident dementia</article-title>. <source>Neurology</source>. <year>2017</year>;<volume>88</volume>:<fpage>1</fpage>&#8208;<lpage>8</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000003732</pub-id><pub-id pub-id-type="pmcid">PMC5373785</pub-id><pub-id pub-id-type="pmid">28228567</pub-id></mixed-citation></ref><ref id="alz70761-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="alz70761-cite-0039"><string-name name-style="western"><surname>Lee</surname><given-names>YF</given-names></string-name>, <string-name name-style="western"><surname>Gerashchenko</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Timofeev</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Bacskai</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Kastanenka</surname><given-names>KV</given-names></string-name>. <article-title>Slow wave sleep is a promising intervention target for Alzheimer's disease</article-title>. <source>Front Neurosci</source>. <year>2020</year>;<volume>14</volume>:<fpage>705</fpage>.<pub-id pub-id-type="pmid">32714142</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2020.00705</pub-id><pub-id pub-id-type="pmcid">PMC7340158</pub-id></mixed-citation></ref><ref id="alz70761-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="alz70761-cite-0040"><string-name name-style="western"><surname>Parish</surname><given-names>JM</given-names></string-name>. <article-title>Sleep&#8208;related problems in common medical conditions</article-title>. <source>Chest</source>. <year>2009</year>;<volume>135</volume>:<fpage>563</fpage>&#8208;<lpage>572</lpage>.<pub-id pub-id-type="pmid">19201722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1378/chest.08-0934</pub-id></mixed-citation></ref><ref id="alz70761-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="alz70761-cite-0041"><string-name name-style="western"><surname>Stefani</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>H&#246;gl</surname><given-names>B</given-names></string-name>. <article-title>Sleep in Parkinson's disease</article-title>. <source>Neuropsychopharmacology</source>. <year>2020</year>;<volume>45</volume>:<fpage>121</fpage>&#8208;<lpage>128</lpage>.<pub-id pub-id-type="pmid">31234200</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41386-019-0448-y</pub-id><pub-id pub-id-type="pmcid">PMC6879568</pub-id></mixed-citation></ref><ref id="alz70761-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="alz70761-cite-0042"><string-name name-style="western"><surname>Krystal</surname><given-names>AD</given-names></string-name>. <article-title>Psychiatric disorders and sleep</article-title>. <source>Neurol Clin</source>. <year>2012</year>;<volume>30</volume>:<fpage>1389</fpage>&#8208;<lpage>1413</lpage>.<pub-id pub-id-type="pmid">23099143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ncl.2012.08.018</pub-id><pub-id pub-id-type="pmcid">PMC3493205</pub-id></mixed-citation></ref><ref id="alz70761-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="alz70761-cite-0043"><string-name name-style="western"><surname>Nagai</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hoshide</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kario</surname><given-names>K</given-names></string-name>. <article-title>Sleep duration as a risk factor for cardiovascular disease&#8208; a review of the recent literature</article-title>. <source>Curr Cardiol Rev</source>. <year>2010</year>;<volume>6</volume>:<fpage>54</fpage>&#8208;<lpage>61</lpage>.<pub-id pub-id-type="pmid">21286279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/157340310790231635</pub-id><pub-id pub-id-type="pmcid">PMC2845795</pub-id></mixed-citation></ref><ref id="alz70761-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="alz70761-cite-0044"><string-name name-style="western"><surname>Salinsky</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Oken</surname><given-names>BS</given-names></string-name>, <string-name name-style="western"><surname>Morehead</surname><given-names>L</given-names></string-name>. <article-title>Test&#8208;retest reliability in EEG frequency analysis</article-title>. <source>Electroencephalogr Clin Neurophysiol</source>. <year>1991</year>;<volume>79</volume>:<fpage>382</fpage>&#8208;<lpage>392</lpage>.<pub-id pub-id-type="pmid">1718711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0013-4694(91)90203-g</pub-id></mixed-citation></ref><ref id="alz70761-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="alz70761-cite-0045"><string-name name-style="western"><surname>Herring</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Ceesay</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Snyder</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial</article-title>. <source>Alzheimers Dement</source>. <year>2020</year>;<volume>16</volume>:<fpage>541</fpage>&#8208;<lpage>551</lpage>.<pub-id pub-id-type="pmid">31944580</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12035</pub-id><pub-id pub-id-type="pmcid">PMC7984350</pub-id></mixed-citation></ref><ref id="alz70761-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="alz70761-cite-0046"><string-name name-style="western"><surname>Lucey</surname><given-names>BP</given-names></string-name>, <string-name name-style="western"><surname>McCullough</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Landsness</surname><given-names>EC</given-names></string-name>, et&#160;al. <article-title>Reduced non&#8208;rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease</article-title>. <source>Sci Transl Med</source>. <year>2019</year>;<volume>11</volume>:<elocation-id>eaau6550</elocation-id>.<pub-id pub-id-type="pmid">30626715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aau6550</pub-id><pub-id pub-id-type="pmcid">PMC6342564</pub-id></mixed-citation></ref><ref id="alz70761-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="alz70761-cite-0047"><string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Vitiello</surname><given-names>MV</given-names></string-name>, <string-name name-style="western"><surname>Gooneratne</surname><given-names>NS</given-names></string-name>. <article-title>Sleep in normal aging</article-title>. <source>Sleep Med Clin</source>. <year>2018</year>;<volume>13</volume>:<fpage>1</fpage>&#8208;<lpage>11</lpage>.<pub-id pub-id-type="pmid">29412976</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsmc.2017.09.001</pub-id><pub-id pub-id-type="pmcid">PMC5841578</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Front Psychiatry</journal-id><journal-id journal-id-type="pmc-domain-id">1463</journal-id><journal-id journal-id-type="pmc-domain">frontpsychiat</journal-id><journal-id journal-id-type="publisher-id">Front. Psychiatry</journal-id><journal-title-group><journal-title>Frontiers in Psychiatry</journal-title></journal-title-group><issn pub-type="epub">1664-0640</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12504309</article-id><article-id pub-id-type="pmcid-ver">PMC12504309.1</article-id><article-id pub-id-type="pmcaid">12504309</article-id><article-id pub-id-type="pmcaiid">12504309</article-id><article-id pub-id-type="doi">10.3389/fpsyt.2025.1653998</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Psychiatry</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Investigating biomarkers of mitochondrial and aging-related genes in major depressive disorder through bioinformatics analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="Z">Zhiyuan</given-names></name><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3112811/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tang</surname><given-names initials="X">Xiaoxiao</given-names></name><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gu</surname><given-names initials="C">Chao</given-names></name><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zou</surname><given-names initials="S">Shaohong</given-names></name><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1257831/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<institution>Department of Clinical Psychology, People&#8217;s Hospital of Xinjiang Uygur Autonomous Region</institution>, <addr-line>Urumqi</addr-line>,&#160;<country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/926343/overview" ext-link-type="uri">Hongbao Cao</ext-link>, George Mason University, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/673902/overview" ext-link-type="uri">Kuanjun He</ext-link>, Inner Mongolia University for Nationalities, China</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2076788/overview" ext-link-type="uri">Wenlong Du</ext-link>, Xuzhou Medical University, China</p></fn><corresp id="fn001">*Correspondence: Shaohong Zou, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:zoushaohong@126.com">zoushaohong@126.com</email></corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">480913</issue-id><elocation-id>1653998</elocation-id><history><date date-type="received"><day>25</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>08</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Chen, Tang, Gu and Zou.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Chen, Tang, Gu and Zou</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fpsyt-16-1653998.pdf"/><abstract><sec><title>Background</title><p>Major depressive disorder (MDD) is a prevalent mental health condition in which mitochondrial dysfunction and cellular senescence contribute to its pathogenesis. This study aims to identify biomarkers related to mitochondria-associated genes (MRGs) and aging-related genes (ARGs) in MDD using bioinformatics.</p></sec><sec><title>Methods</title><p>This study utilized data from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE201332">GSE201332</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE52790">GSE52790</ext-link>, including 1,136 MRGs and 866 ARGs. Initially, candidate genes were selected by intersecting MRGs, ARGs, and differentially expressed genes (DEGs) derived from differential expression analysis in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE201332">GSE201332</ext-link>. Biomarkers were identified through LASSO regression analysis of the candidate genes. The biomarkers were then evaluated using ROC curves, and artificial neural network (ANN) models were constructed. Subsequently, functional enrichment, immune-related analyses, drug predictions, and molecular docking were performed. Finally, the expression of biomarkers was validated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR).</p></sec><sec><title>Results</title><p>Seven candidate genes were identified from the intersection of 4,041 DEGs, 1,136 MRGs, and 866 ARGs, with SLC25A5, ALDH2, CPT1C, and IMMT identified as potential biomarkers for MDD through LASSO regression analysis. ROC curve analysis in both <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE201332">GSE201332</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE52790">GSE52790</ext-link> showed that these biomarkers effectively distinguished between MDD and control samples, with AUC values exceeding 0.7. ANN models further confirmed the diagnostic potential of these biomarkers. Gene set enrichment analysis (GSEA) revealed significant enrichment of SLC25A5, CPT1C, and IMMT in pathways related to cellular protein complex assembly and chromatin organization. Immune infiltration analysis demonstrated significant positive correlations between SLC25A5, ALDH2, and IMMT and most of the 18 immune cell types. Molecular docking predictions identified ALDH2 and SLC25A5 as potential targets for specific drugs, with NITROGLYCERIN showing the best binding affinity to ALDH2 (-6.4 kcal/mol). RT-qPCR validation showed significantly lower expression of SLC25A5 and IMMT, and higher expression of CPT1C, in patients with MDD compared to controls (p &lt; 0.05), consistent with bioinformatics predictions.</p></sec><sec><title>Conclusion</title><p>This study identified SLC25A5, ALDH2, CPT1C, and IMMT as biomarkers associated with MDD, offering insights into its molecular mechanisms.</p></sec></abstract><kwd-group><kwd>major depressive disorder</kwd><kwd>mitochondria-related genes</kwd><kwd>aging-related genes</kwd><kwd>biomarker</kwd><kwd>molecular docking</kwd></kwd-group><funding-group><award-group><funding-source id="cn001"><institution-wrap><institution>Science and Technology Department of Xinjiang Uygur Autonomous Region
</institution><institution-id institution-id-type="doi">10.13039/100016079</institution-id></institution-wrap></funding-source></award-group><funding-statement>The author(s) declare financial support was received for the research and/or publication of this article. The research reported in this project was generously supported by (&#8220;Tianshan Talent&#8221; Medical and Health Leading Talent Training Program: *Research on the Mechanisms of Neuroimaging, Genetics, and Psychosocial Factors in Mood Disorders and Development of a Data Network Platform) under grant agreement number (TSYC202401A004). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="9"/><table-count count="1"/><equation-count count="0"/><ref-count count="38"/><page-count count="17"/><word-count count="6724"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Mood Disorders</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1</label><title>Introduction</title><p>Major depressive disorder (MDD) is a prevalent mental health condition characterized by persistent feelings of sadness, hopelessness, and a loss of interest or pleasure in daily activities. Affecting millions globally, MDD has an estimated lifetime prevalence of around 16.6% in adults, representing a significant public health issue (<xref rid="B1" ref-type="bibr">1</xref>). The etiology of MDD is complex, involving a combination of genetic, environmental, and psychological factors that contribute to its onset (<xref rid="B2" ref-type="bibr">2</xref>). Its clinical presentation is highly variable, encompassing emotional disturbances, cognitive impairments, and somatic symptoms, all of which can severely affect an individual&#8217;s quality of life and functional capacity (<xref rid="B3" ref-type="bibr">3</xref>). Recent epidemiological studies have revealed that MDD disproportionately impacts certain groups, including women, individuals with a family history of depression, and those exposed to chronic stress or traumatic events (<xref rid="B4" ref-type="bibr">4</xref>). Despite advancements in understanding the core processes of MDD, the precise mechanisms remain elusive, complicating both diagnosis and treatment (<xref rid="B5" ref-type="bibr">5</xref>).</p><p>The treatment of MDD includes pharmacotherapy, psychotherapy, and lifestyle changes. However, these approaches are often hindered by challenges such as delayed therapeutic onset, limited response rates, and side effects (<xref rid="B3" ref-type="bibr">3</xref>). These obstacles underscore the urgent need for novel therapeutic strategies and biomarkers to facilitate earlier diagnosis and more effective management of MDD. Identifying new biological markers and elucidating the molecular mechanisms underlying MDD may offer critical insights into its pathophysiology, potentially leading to improved diagnostic and therapeutic approaches (<xref rid="B2" ref-type="bibr">2</xref>).</p><p>Mitochondria, the powerhouse of the cell, play a pivotal role not only in energy production but also in regulating essential processes such as apoptosis (programmed cell death), calcium homeostasis, and cellular metabolism (<xref rid="B6" ref-type="bibr">6</xref>). Disruption of mitochondrial function has been implicated in various diseases, including neurodegenerative disorders and metabolic syndromes, suggesting that such dysfunctions may contribute significantly to the pathophysiology of MDD (<xref rid="B7" ref-type="bibr">7</xref>). Mitochondrial dysfunction in aging is marked by increased oxidative stress, reduced bioenergetics, and impaired mitochondrial dynamics, which may promote the onset and progression of depressive symptoms (<xref rid="B8" ref-type="bibr">8</xref>). Recent studies have indicated that mitochondrial dysfunction and age-related pathways are closely linked to MDD development, although the exact molecular mechanisms remain unclear (<xref rid="B9" ref-type="bibr">9</xref>).</p><p>This study utilizes bioinformatics techniques to analyze transcriptomic data from patients with MDD and healthy controls obtained from the GEO database. Differential expression analysis is employed to identify mitochondrial and aging-related biomarkers associated with MDD. Additionally, an artificial neural network (ANN) model is constructed to evaluate the diagnostic potential of these biomarkers. Through functional enrichment analysis, immune cell infiltration studies, and molecular docking, the study aims to elucidate the complex roles of these biomarkers in MDD pathogenesis, highlighting their therapeutic potential.</p><p>Exploring the relationship between mitochondrial function, aging, and MDD is crucial for enhancing our understanding of the disorder. By investigating the molecular foundations of these interactions, the goal is to provide valuable insights into MDD pathophysiology and identify potential biomarkers that could improve clinical management and treatment outcomes.</p></sec><sec sec-type="materials|methods" id="s2"><label>2</label><title>Materials and methods</title><sec id="s2_1"><label>2.1</label><title>Data sources</title><p>This study utilized MDD-related datasets obtained from GEO (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.ncbi.nlm.nih.gov/geo/" ext-link-type="uri">http://www.ncbi.nlm.nih.gov/geo/</ext-link>). The <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE201332">GSE201332</ext-link> dataset, serving as the training set, included whole blood samples from 20 patients with MDD and 20 healthy controls (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Table&#160;1</bold>
</xref>), while <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE52790">GSE52790</ext-link>, used as the validation set, comprised whole blood samples from 10 patients with MDD and 12 healthy controls. MitoCarta3.0 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.broadinstitute.org/mitocarta" ext-link-type="uri">https://www.broadinstitute.org/mitocarta</ext-link>) and the HAGR database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://genomics.senescence.info/" ext-link-type="uri">https://genomics.senescence.info/</ext-link>) were used to extract 1,136 mitochondria-related genes (MRGs) and 866 aging-related genes (ARGs), respectively. A flowchart of the study is provided in <xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>.</p><fig position="float" id="f1" orientation="portrait"><label>Figure&#160;1</label><caption><p>Flowchart of the research process for biomarker screening.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fpsyt-16-1653998-g001.jpg"><alt-text content-type="machine-generated">Flowchart illustrating a research process. MitoCarta3.0, <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE201332">GSE201332</ext-link>, and HAGR lead to MRGs, DEGs, and ARGs respectively, which converge into candidate genes. These undergo GO and KEGG analysis and form a PPI network. LASSO and ROC analyses refine biomarkers. These are validated by ANN, <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE201332">GSE201332</ext-link>, <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE52790">GSE52790</ext-link>, expression verification, and RT-qPCR. Outcomes include GSEA, GGI, immune analysis, regulatory networks, molecular docking, and localization analysis.</alt-text></graphic></fig></sec><sec id="s2_2"><label>2.2</label><title>Differential expression analysis and functional enrichment analysis</title><p>Differential expression analysis was performed to identify disease-related genes by screening for differentially expressed genes (DEGs) between the MDD and control groups using the Limma package (v 3.44.3) in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE201332">GSE201332</ext-link>, applying thresholds of an adjusted p-value &lt; 0.05 and |Log<sub>2</sub>FC| &gt; 0.5 (<xref rid="B10" ref-type="bibr">10</xref>). The intersection of MRGs, ARGs, and DEGs was then analyzed to pinpoint potential biomarkers. GO and KEGG functional enrichment analyses were conducted using the clusterProfiler package (v 4.0.2) (p-value &lt; 0.05, count &gt; 1) (<xref rid="B11" ref-type="bibr">11</xref>). The candidate genes were further analyzed using the STRING database to construct a protein-protein interaction (PPI) network with a threshold of 0.2.</p></sec><sec id="s2_3"><label>2.3</label><title>Identification of biomarkers and construction of ANN</title><p>For biomarker screening, LASSO logistic regression was performed on the candidate genes using the glmnet package (v 4.0-2) (<xref rid="B12" ref-type="bibr">12</xref>), with family = &#8220;binomial&#8221; to accommodate the binary outcome variable. To ensure reproducibility, set.seed (<xref rid="B30" ref-type="bibr">30</xref>) was used to fix random number generation, and a maximum of 5,000 iterations was allowed to ensure algorithm convergence. Ten-fold cross-validation (nfolds = 10) was employed to evaluate model performance and determine the optimal regularization strength (&#955;). The &#955; value with the smallest cross-validation error (lambda.min) was chosen for model fitting, and genes with non-zero coefficients were identified as potential biomarkers. The diagnostic performance of these biomarkers was further evaluated through Receiver Operating Characteristic (ROC) curves in both <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE201332">GSE201332</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE52790">GSE52790</ext-link>. The ROC curve plotted the false positive rate on the x-axis and the true positive rate on the y-axis, with the Area Under the Curve (AUC) serving as the quantitative measure. An AUC of 0.5 indicated random guessing, an AUC &gt; 0.7 indicated good discriminative ability, and an AUC &gt; 0.9 suggested excellent diagnostic performance. Genes with an AUC &gt; 0.7 were selected for further analysis. Finally, an ANN model based on the biomarkers was developed using the neuralnet package to further assess their diagnostic performance. The ROC curves for the ANN models were also evaluated in both datasets.</p></sec><sec id="s2_4"><label>2.4</label><title>Functional analysis of biomarkers</title><p>To elucidate the regulatory mechanisms and biological functions of biomarkers, gene set enrichment analysis (GSEA) was performed using the clusterProfiler package (v 4.0.2) (<xref rid="B11" ref-type="bibr">11</xref>). GO gene sets were sourced from the org.Hs.eg.db database <italic toggle="yes">via</italic> the gseGO function, and KEGG gene sets were retrieved using the gseKEGG function with the organism parameter set to &#8220;hsa&#8221;. First, correlation coefficients between each biomarker and the expression levels of all genes were calculated, and genes were ranked based on these coefficients, from high to low. Enrichment scores were determined using the classic permutation method of GSEA (gene set permutation), with significantly enriched gene sets identified using a threshold of p-value &lt; 0.05. In addition, GeneMANIA (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://genemania.org/" ext-link-type="uri">https://genemania.org/</ext-link>) was used to predict the genes and functions associated with the biomarkers.</p></sec><sec id="s2_5"><label>2.5</label><title>Immune-related analyses</title><p>To explore immune cell-related variations, the study investigated the differences in ssGSEA scores for 29 immune cell types between individuals with neurodegenerative diseases (NDD) and control subjects in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE201332">GSE201332</ext-link> dataset (<xref rid="B13" ref-type="bibr">13</xref>). The associations between differentially expressed immune cells and the biomarkers were then analyzed. Moreover, to assess the relationship between biomarkers and immunological factors, various immunomodulators and chemokines were retrieved from the ISIDB database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://cis.hku.hk/TISIDB/" ext-link-type="uri">http://cis.hku.hk/TISIDB/</ext-link>), and their correlations with biomarkers were evaluated using Spearman&#8217;s method (|cor| &gt; 0.3, p-value &lt; 0.05).</p></sec><sec id="s2_6"><label>2.6</label><title>Regulatory network analysis</title><p>To examine the molecular regulatory mechanisms of the biomarkers, the NetworkAnalyst platform was used to access the &#8220;CORE vertebrates&#8221; dataset from the JASPAR database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.networkanalyst.ca/" ext-link-type="uri">https://www.networkanalyst.ca/</ext-link>). Transcription factors (TFs) with potential binding affinity to the biomarkers were identified using a motif matching score &#8805; 800 and a corresponding p-value &#8804; 1e-4. miRNAs related to the biomarkers were then predicted using the miRWalk 3.0 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://mirwalk.umm.uni-heidelberg.de/" ext-link-type="uri">http://mirwalk.umm.uni-heidelberg.de/</ext-link>) and Starbase v3.0 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://starbase.sysu.edu.cn/" ext-link-type="uri">http://starbase.sysu.edu.cn/</ext-link>) databases, with Starbase requiring a &#8220;Pan-Cancer Conservation&#8221; score &#8805; 3. The miRNAs identified from both databases were intersected to determine the target miRNAs. Next, lncRNAs corresponding to these miRNAs were predicted using the miRNet 2.0 database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mirnet.ca/" ext-link-type="uri">https://www.mirnet.ca/</ext-link>), with the screening condition set as CancerNum &gt; 0 in Starbase v3.0. The lncRNAs identified by both databases were intersected to establish the final set of target lncRNAs. Finally, a TF-gene and lncRNA-miRNA-mRNA regulatory network was constructed using Cytoscape software to visually depict these complex molecular interactions.</p></sec><sec id="s2_7"><label>2.7</label><title>Drug prediction and molecular docking</title><p>To assess the effects of chemotherapeutic drugs on biomarkers, a drug-gene network was constructed using the DSigDB database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://dsigdb.tanlab.org/DSigDBv1.0/" ext-link-type="uri">https://dsigdb.tanlab.org/DSigDBv1.0/</ext-link>). The structural information for the chemotherapeutic drugs in this network was sourced from PubChem (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubchem.ncbi.nlm.nih.gov/" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/</ext-link>). Concurrently, protein sequences and functional data for the key genes were retrieved from the Uniprot database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.uniprot.org/" ext-link-type="uri">https://www.uniprot.org/</ext-link>), and their three-dimensional structures were obtained from the PDB database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.rcsb.org/" ext-link-type="uri">https://www.rcsb.org/</ext-link>). These protein and drug structures were uploaded to the CB-Dock2 platform (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cadd.labshare.cn/cb-dock2/php/index.php" ext-link-type="uri">https://cadd.labshare.cn/cb-dock2/php/index.php</ext-link>) for molecular docking analysis. The platform standardized protonation states and automatically identified and defined binding sites using its built-in algorithm. Binding affinity between the proteins and ligands was evaluated based on binding energy, with lower values indicating stronger binding. To validate the stability and reliability of the docking results, additional docking experiments were performed using alternative receptor structures of known binders to assess the binding interactions.</p></sec><sec id="s2_8"><label>2.8</label><title>Drug prediction and molecular docking</title><p>To further elucidate the mechanism of action of drugs and evaluate the stability of drug-biomarker complexes as well as the kinetic characteristics of drug binding, molecular dynamics simulations were conducted using GROMACS 2024.4 software. The simulations followed the AMBER99SB-ILDN force field and utilized the TIP3P water model. A cubic system box was set, ensuring the box edges were 1 nm away from the protein edges, and 0.15 mol/L Na<sup>+</sup>/Cl&#8315; ions were added to maintain electrical neutrality. Energy minimization was first performed using the steepest descent method. Subsequently, both a heat bath (NVT, with fixed particles, volume, and temperature) and a pressure bath (NPT, with fixed particles, pressure, and temperature) were applied, employing the V-rescale method for temperature coupling. The reference temperature was set to 300 K, with a time step of 2 femtoseconds, and each simulation phase lasted 100 picoseconds. The final molecular dynamics simulation ran for 20 nanoseconds. To quantify binding characteristics, the root-mean-square deviation (RMSD) of backbone atoms in the protein-ligand complex was calculated to assess conformational stability. The root-mean-square fluctuation (RMSF) of protein backbone atoms was analyzed to observe changes in residue flexibility, and fluctuations in total system energy were monitored to evaluate thermodynamic stability. Additionally, the number of hydrogen bonds and their occupancy between the drug and target were counted to quantify the strength of binding interactions. The distance between the small molecule binding site and the amino acid residues of the protein was measured to evaluate binding stability, interaction mechanisms, and conformational changes.</p></sec><sec id="s2_9"><label>2.9</label><title>Subcellular localization, chromosomal localization, and association analysis with disease risk of biomarkers</title><p>The position of the biomarker on the chromosome was visualized using the RCircos package (v 1.2.2) (<xref rid="B14" ref-type="bibr">14</xref>). Gene sequences for the biomarkers were retrieved from the NCBI database, and subcellular localization was assessed using the mRNALocator database. The relationship between the biomarkers and MDD risk was explored using the CTD database.</p></sec><sec id="s2_10"><label>2.10</label><title>Biomarker expression analysis</title><p>To further validate biomarker expression in MDD and control groups, expression levels were analyzed in both the training and validation sets, followed by RT-qPCR validation. Five pairs of whole blood samples were obtained from patients with MDD and healthy controls (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Table&#160;2</bold>
</xref>) at the People&#8217;s Hospital of Xinjiang Uygur Autonomous Region for qRT-PCR analysis.</p><p>The study cohort consisted of female patients aged 40 to 50 years, diagnosed with depression, who sought care at the Department of Clinical Psychology, People&#8217;s Hospital of Xinjiang Uygur Autonomous Region, in June 2024. A control group of healthy females in the same age range was also included. Inclusion criteria were as follows: (1) Diagnosis: Participants met DSM-5 criteria for MDD, confirmed through structured clinical interviews; (2) Symptom severity: A baseline score &#8805;18 on the 17-item Hamilton Depression Rating Scale (HAMD-17), indicating moderate-to-severe depression; (3) Age: Adults aged 18&#8211;65 years; (4) Treatment status: Participants were not receiving any medication or psychological treatment at the time of enrollment. Exclusion criteria were as follows: (1) Comorbid psychiatric disorders: Axis I disorders (e.g., bipolar disorder, psychosis, primary anxiety disorders) or substance use disorders (within 6 months); (2) High suicide risk: Defined by HAMD item 3 score &#8805;3, recent suicide attempt, or active ideation with intent; (3) Unstable medical conditions (e.g., neurological disorders, uncontrolled diabetes) or medications influencing mood (e.g., corticosteroids). Participants were required to fast overnight for at least 8 hours before blood collection, which was performed between 8:00 AM and 10:00 AM under controlled temperature and lighting conditions. Blood was drawn by a trained phlebotomist using sterile techniques, and aliquots were stored at -20&#176;C for no more than 2 weeks.</p><p>This study was approved by the Clinical Research Ethics Committee of the People&#8217;s Hospital of Xinjiang Uygur Autonomous Region (KY2024070801), and all patients provided signed informed consent. To validate biomarker expression, total RNA was extracted from the samples using TRIZOL, according to the manufacturer&#8217;s instructions. The first strand of complementary DNA (cDNA) was synthesized from 2 &#956;g of total RNA using the SureScript First Strand cDNA Synthesis Kit (Servicebio, Wuhan, China). RT-qPCR was performed with the 2xUniversal Blue SYBR Green qPCR Master Mix (Servicebio, Wuhan, China). The reaction protocol was as follows: 1 minute at 95&#176;C, followed by 40 cycles of 20 seconds at 95&#176;C, 20 seconds at 55&#176;C, and 30 seconds at 72&#176;C. Primer sequences are listed in <xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref> and were validated for specificity using BLAST. GAPDH was used as the internal reference gene. Gene expression levels were calculated using the 2<sup>-&#9651;&#9651;Ct</sup> method (<xref rid="B15" ref-type="bibr">15</xref>). Data analysis and visualization were performed using GraphPad Prism 5 (GraphPad Software Inc., USA).</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table&#160;1</label><caption><p>Primer sequences.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">Primers</th><th valign="middle" align="center" rowspan="1" colspan="1">Sequences (5&#8217;-3&#8217;)</th><th valign="middle" align="center" rowspan="1" colspan="1">Amplification size (bp)</th></tr></thead><tbody><tr><td valign="middle" align="center" rowspan="1" colspan="1">CPT1C-F</td><td valign="middle" align="center" rowspan="1" colspan="1">GGCTAGGGACACGAGAGAGA</td><td valign="middle" rowspan="2" align="center" colspan="1">112</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">CPT1C-R</td><td valign="middle" align="center" rowspan="1" colspan="1">CCAATCCCAGTGCAAGGAGT</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">SLC25A5-F</td><td valign="middle" align="center" rowspan="1" colspan="1">AGACTGCGTGGTCCGTATTC</td><td valign="middle" rowspan="2" align="center" colspan="1">190</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">SLC25A5-R</td><td valign="middle" align="center" rowspan="1" colspan="1">TGCCAGATTCCCTGCAAAGT</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">ALDH2-F</td><td valign="middle" align="center" rowspan="1" colspan="1">GCATGGACGCATCACACAG</td><td valign="middle" rowspan="2" align="center" colspan="1">103</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">ALDH2-R</td><td valign="middle" align="center" rowspan="1" colspan="1">TTGCCATTGTCCAGGGTCTC</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">IMMT-F</td><td valign="middle" align="center" rowspan="1" colspan="1">CACCTACAGAAGCGGCTCAA</td><td valign="middle" rowspan="2" align="center" colspan="1">139</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">IMMT-R</td><td valign="middle" align="center" rowspan="1" colspan="1">TCTGAAAGTGCAGGTGTGGG</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">GAPDH-F</td><td valign="middle" align="center" rowspan="1" colspan="1">CGAAGGTGGAGTCAACGGATTT</td><td valign="middle" rowspan="2" align="center" colspan="1">148</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">GAPDH-R</td><td valign="middle" align="center" rowspan="1" colspan="1">ATGGGTGGAATCATATTGGAAC</td></tr></tbody></table></table-wrap></sec><sec id="s2_11"><label>2.11</label><title>Statistical analysis</title><p>Bioinformatics analysis was performed using R software. Statistical significance was set at p &lt; 0.05. Due to the small sample size, non-parametric tests (Mann&#8211;Whitney U test) were used for group comparisons in PCR experiments to ensure the robustness of the results.</p></sec></sec><sec sec-type="results" id="s3"><label>3</label><title>Results</title><sec id="s3_1"><label>3.1</label><title>A total of 7 candidate genes were subjected to functional enrichment analysis</title><p>A total of 4,041 DEGs were identified in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE201332">GSE201332</ext-link>, comprising 2,154 upregulated genes and 1,887 downregulated genes (<xref rid="f2" ref-type="fig">
<bold>Figures&#160;2A, B</bold>
</xref>). Seven candidate genes were further selected by intersecting DEGs with 1,136 MRGs and 866 ARGs (<xref rid="f2" ref-type="fig">
<bold>Figure&#160;2C</bold>
</xref>). GO enrichment analysis revealed that these candidate genes were associated with 47 functional categories, including mitochondrial outer membrane, organelle outer membrane, and other relevant terms (<xref rid="f2" ref-type="fig">
<bold>Figure&#160;2D</bold>
</xref>). KEGG pathway analysis highlighted the involvement of these genes in 10 signaling pathways, such as fatty acid degradation and NOD-like receptor signaling (<xref rid="f2" ref-type="fig">
<bold>Figure&#160;2E</bold>
</xref>). The PPI network analysis identified key PPIs, including MAVS-BCL2 and NBR1-MMT (<xref rid="f2" ref-type="fig">
<bold>Figure&#160;2F</bold>
</xref>).</p><fig position="float" id="f2" orientation="portrait"><label>Figure&#160;2</label><caption><p>Differential expression analysis and functional enrichment analysis. <bold>(A)</bold> Volcano plot of differentially expressed genes between MDD and control groups. <bold>(B)</bold> Heat map of differentially expressed genes between MDD and control groups. <bold>(C)</bold> Venn diagram identifying candidate genes. <bold>(D)</bold> GO enrichment analysis results of candidate genes. <bold>(E)</bold> KEGG enrichment analysis results of candidate genes. <bold>(F)</bold> Protein interaction network of candidate genes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fpsyt-16-1653998-g002.jpg"><alt-text content-type="machine-generated">Panel A displays a volcano plot illustrating gene expression with log fold change versus negative log p-value. Panel B presents a heatmap showing gene expression density across samples, with a color gradient from blue to red indicating expression levels. Panel C is a Venn diagram overlapping DEG_mrna, ARGs, and MRGs groups, showing shared and unique elements. Panel D is a treemap showing biological processes, with size representing count and color indicating relevance. Panel E is a treemap displaying disease associations, with p-values. Panel F is a network diagram of protein interactions with nodes indicating proteins.</alt-text></graphic></fig></sec><sec id="s3_2"><label>3.2</label><title>SLC25A5, ALDH2, CPT1C, and IMMT had excellent diagnostic performance for MDD</title><p>In LASSO regression analysis, the lowest error during cross-validation was achieved with a lambda.min of 0.0115, which led to the selection of four biomarkers: SLC25A5, ALDH2, CPT1C, and IMMT (<xref rid="f3" ref-type="fig">
<bold>Figure&#160;3A</bold>
</xref>). The ROC curve analysis showed AUC values greater than 0.7 in both <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE201332">GSE201332</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE52790">GSE52790</ext-link>, indicating that these biomarkers could effectively differentiate between MDD and control samples (<xref rid="f3" ref-type="fig">
<bold>Figures&#160;3B, C</bold>
</xref>). The ANN model built using these biomarkers demonstrated excellent diagnostic performance in both the training and validation sets, with AUC values of 1 and 0.95, respectively (<xref rid="f3" ref-type="fig">
<bold>Figures&#160;3D, E</bold>
</xref>).</p><fig position="float" id="f3" orientation="portrait"><label>Figure&#160;3</label><caption><p>SLC25A5, ALDH2, CPT1C, and IMMT had excellent diagnostic performance for MDD. <bold>(A)</bold> LASSO regression analysis was used to screen biomarkers. The left panel depicted the coefficient trajectory plot of genes. The horizontal axis represented the logarithm of the regularization parameter &#955; (Log Lambdas), and the vertical axis denoted the regression coefficients of genes. Lines of different colors corresponded to the coefficient trajectories of candidate genes as &#955; varied: blue for SLC25A5, red for ALDH2, yellow for CPT1C, and gray for IMMT. The right panel showed the cross - validation error curve. The shaded area indicated the standard error of the error, and the red curve represented the binomial deviance. <bold>(B, C)</bold> ROC curve analysis of biomarkers (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE201332">GSE201332</ext-link> training set and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE52790">GSE52790</ext-link> validation set). The horizontal axis stood for 1&#8722;Specificity, and the vertical axis represented Sensitivity. <bold>(D)</bold> Artificial neural network diagnostic model constructed based on biomarkers. Red-colored connections indicated positive corresponding weights, while gray - colored ones indicated negative weights. <bold>(E)</bold> ROC was used to evaluate the performance of the artificial neural network in the training set and validation set.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fpsyt-16-1653998-g003.jpg"><alt-text content-type="machine-generated">Chart A shows a Lasso regression with coefficient paths and binomial deviance against log lambda. Charts B and C are ROC curves with AUC values for SLC25A5, ALDH2, CPT1C, and IMMT, indicating model performance. Diagram D illustrates a network of SLC25A5, ALDH2, CPT1C, and IMMT connections with an emphasis on MDD and control. Charts E and F are ROC curves for training and test sets, showing AUC values of 1.000 and 0.950, respectively.</alt-text></graphic></fig></sec><sec id="s3_3"><label>3.3</label><title>Biomarkers had different biological functions</title><p>GO enrichment analysis indicated that SLC25A5, CPT1C, and IMMT were significantly associated with processes such as cellular protein-containing complex assembly, chromatin organization, and chromosome organization (<xref rid="f4" ref-type="fig">
<bold>Figures&#160;4A&#8211;C</bold>
</xref>). Additionally, CPT1C was linked to the detection of chemical stimuli and sensory perception (<xref rid="f4" ref-type="fig">
<bold>Figure&#160;4D</bold>
</xref>). In KEGG pathway analysis, SLC25A5, CPT1C, and IMMT were implicated in various biological processes, including ATP-dependent chromatin remodeling, neutrophil extracellular trap formation, and protein processing in the endoplasmic reticulum (<xref rid="f4" ref-type="fig">
<bold>Figures&#160;4E&#8211;G</bold>
</xref>). Moreover, CPT1C was involved in pathways such as cortisol synthesis and secretion, and focal adhesion (<xref rid="f4" ref-type="fig">
<bold>Figure&#160;4H</bold>
</xref>). The gene-gene interaction (GGI) network revealed additional genes related to biomarkers, including ACSS1 and SLC25A6, which are involved in functions such as organelle outer membrane composition, fatty acid transmembrane transport, and other processes (<xref rid="f4" ref-type="fig">
<bold>Figure&#160;4I</bold>
</xref>). GO and KEGG pathway enrichment analysis results for the four biomarkers are provided in <xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Table&#160;3</bold>
</xref>.</p><fig position="float" id="f4" orientation="portrait"><label>Figure&#160;4</label><caption><p>Biomarkers had different biological functions. GO enrichment analysis results for <bold>(A)</bold> SLC25A5, <bold>(B)</bold> CPT1C, <bold>(C)</bold> IMMT, and <bold>(D)</bold> CPT1C. KEGG enrichment analysis results for <bold>(E)</bold> SLC25A5, <bold>(F)</bold> CPT1C, <bold>(G)</bold> IMMT, and <bold>(H)</bold> CPT1C. <bold>(I)</bold> Gene-gene interaction of biomarkers.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fpsyt-16-1653998-g004.jpg"><alt-text content-type="machine-generated">Nine-panel figure showcasing various gene set enrichment analysis (GSEA) plots and a network diagram. Panels A to H display enrichment scores for different biological conditions, with colorful line graphs and barcodes representing ranked genes. Panel I features a circular network diagram illustrating relationships among different gene functions and networks, connected by lines of varying weights and colors. Each panel highlights distinct conditions and pathways, with legends indicating specific gene sets and pathways involved.</alt-text></graphic></fig></sec><sec id="s3_4"><label>3.4</label><title>Biomarkers correlated with both different immune cells and immune factors</title><p>The ssGSEA algorithm revealed significant differences in the scores of 18 immune cells between the MDD and control groups. For example, activated B cells, activated CD8 T cells, and activated dendritic cells (DCs) displayed reduced expression levels in the MDD group (<xref rid="f5" ref-type="fig">
<bold>Figure&#160;5A</bold>
</xref>). Most of these immune cell types were positively correlated with one another (<xref rid="f5" ref-type="fig">
<bold>Figure&#160;5B</bold>
</xref>). Additionally, SLC25A5, ALDH2, and IMMT showed positive correlations with several differential immune cells, including activated B cells, activated CD8 T cells, and activated DCs. In contrast, CPT1C exhibited an inverse relationship with most immune cells, except for Immature B cells and Type 1 T helper cells (<xref rid="f5" ref-type="fig">
<bold>Figure&#160;5C</bold>
</xref>). Correlation analysis with immune factors demonstrated significant associations between the biomarkers and XCL1, CXCL9, CXCL8, CXCL5, CXCL1, and CCL8 (<xref rid="f5" ref-type="fig">
<bold>Figure&#160;5D</bold>
</xref>).</p><fig position="float" id="f5" orientation="portrait"><label>Figure&#160;5</label><caption><p>Biomarkers correlate with both different immune cells and immune factors. <bold>(A)</bold> The ssGSEA algorithm revealed substantial differences in the scores of 18 immune cells between the MDD and control groups. ns represented no significance, ****p-value&lt;0.0001. <bold>(B)</bold> Heat map showing the correlation analysis of differential immune cells. *p-value&lt;0.05, **p-value&lt;0.01, ***p-value&lt;0.001. <bold>(C)</bold> Correlation analysis between differential immune cells and biomarkers. <bold>(D)</bold> Heat map of correlation between biomarkers and immune factors.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fpsyt-16-1653998-g005.jpg"><alt-text content-type="machine-generated">Panel A shows a violin plot comparing immune cell percentages between MCD (blue) and control (red) groups across various cell types, with significant differences marked. Panel B is a heatmap showing correlation coefficients among immune cell types, with color representing correlation strength. Panel C presents a heatmap of gene expression correlations with specific immune cell types, with significant values indicated by asterisks. Panel D displays a heatmap of cytokine expression correlations, with significant levels similarly marked. The color gradient indicates the strength of correlation in panels B, C, and D.</alt-text></graphic></fig></sec><sec id="s3_5"><label>3.5</label><title>Regulatory networks and molecular docking of biomarkers were performed</title><p>A total of 27 TFs were predicted in this study. Bioinformatics analysis suggested that STAT1 may target the promoter regions of ALDH2 and SLC25A5, while NKX3&#8211;2 may regulate the transcription of IMMT and SLC25A5 (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Figure&#160;1A</bold>
</xref>). Nine target miRNAs were identified by intersecting the predicted miRNAs from the miRWalk and Starbase databases. Based on this, 79 target lncRNAs were predicted, with the following regulatory pairs: HCP5-hsa-miR-27b-3p-SLC25A5, LINC02535-hsa-miR-30b-5p-ALDH2, among others (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Figures&#160;1B&#8211;D</bold>
</xref>). Furthermore, drugs corresponding to ALDH2 and SLC25A5 were predicted in the DSigDB database, including four compounds (acetaldehyde, denatured ethanol, nitroglycerin, disulfiram) and two drugs (clodronic acid, butyric acid) (<xref rid="f6" ref-type="fig">
<bold>Figure&#160;6A</bold>
</xref>). Molecular docking of these drugs with the biomarkers was performed, with ALDH2 (PDB ID: 1nzw) and nitroglycerin showing the most favorable results, exhibiting a docking energy of -6.4 kcal/mol (<xref rid="f6" ref-type="fig">
<bold>Figure&#160;6B</bold>
</xref>). To validate the docking results, further analysis revealed that the docking energy between ALDH2 and selective serotonin reuptake inhibitors (SSRIs) was 8.2 kcal/mol (<xref rid="f6" ref-type="fig">
<bold>Figure&#160;6C</bold>
</xref>). When the 3D structure of ALDH2 was replaced with 1CW3, its binding energy with nitroglycerin was 6.3 kcal/mol (<xref rid="f6" ref-type="fig">
<bold>Figure&#160;6D</bold>
</xref>), which showed minimal change from the original result, further confirming the accuracy of the docking analysis.</p><fig position="float" id="f6" orientation="portrait"><label>Figure&#160;6</label><caption><p>Drug prediction and molecular docking results. <bold>(A)</bold> Drug-gene interaction network. Red circles represent genes, green diamonds represent drug names, and lines connecting drugs and genes indicate regulatory interactions between them. <bold>(B)</bold> Molecular docking of ALDH2 and NITROGLYCERIN. <bold>(C)</bold> Molecular docking of ALDH2 and Selective Serotonin Reuptake Inhibitor. <bold>(D)</bold> Molecular docking of ALDH2 (1CW3) and NITROGLYCERIN.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fpsyt-16-1653998-g006.jpg"><alt-text content-type="machine-generated">Panel A depicts a chemical interaction network with ALDH2 and SLC25A5 as central nodes, connected to substances like acetaldehyde and butyric acid. Panels B, C, and D show detailed protein structures in various colors, highlighting intricate coiled and folded configurations, with specific sites marked by amino acid labels and residue numbers, emphasizing structural complexity and possible interaction sites.</alt-text></graphic></fig></sec><sec id="s3_6"><label>3.6</label><title>Molecular dynamics validation of ALDH2</title><p>This study investigated the conformational changes and energy stability of ALDH2 upon binding to nitroglycerin using 100 ns molecular dynamics simulations. The results showed that the RMSD value of the ALDH2-nitroglycerin system fluctuated between 0.45 and 0.6 nm, indicating that the protein structure reached dynamic equilibrium between 25 and 100 ns and maintained a stable conformation (<xref rid="f7" ref-type="fig">
<bold>Figure&#160;7A</bold>
</xref>). RMSF analysis revealed that the flexibility of individual residues ranged from 0.05 to 0.4 nm, reflecting local flexibility while ensuring the overall stability of the binding (<xref rid="f7" ref-type="fig">
<bold>Figure&#160;7B</bold>
</xref>). Energy monitoring demonstrated that the total system energy remained low with minimal fluctuations, and combined with Gibbs free energy landscape analysis, this further confirmed the thermodynamic stability of the complex (<xref rid="f7" ref-type="fig">
<bold>Figures&#160;7C, D</bold>
</xref>). Hydrogen bond analysis revealed that nitroglycerin formed 1&#8211;2 stable hydrogen bonds with the active site of ALDH2, occasionally increasing to 3&#8211;4 bonds, highlighting the significance of non-covalent interactions in maintaining binding stability (<xref rid="f7" ref-type="fig">
<bold>Figure&#160;7E</bold>
</xref>). Additionally, spatial distance monitoring showed that the distances between key binding sites (Residues 150/179) and nitroglycerin stabilized within the ranges of 0.6-0.8 nm and 0.45-0.65 nm, respectively, without a consistent directional change, further confirming the sustained stability of the binding state (<xref rid="f7" ref-type="fig">
<bold>Figure&#160;7F</bold>
</xref>). In summary, the ALDH2-nitroglycerin complex exhibited stable conformation, favorable thermodynamic properties, and sustained interactions, demonstrating the robustness of their binding.</p><fig position="float" id="f7" orientation="portrait"><label>Figure&#160;7</label><caption><p>Molecular dynamics validation of ALDH2-NITROGLYCERIN. <bold>(A)</bold> RMSD plot of protein ALDH2. <bold>(B)</bold> RMSF plot of protein ALDH2. <bold>(C)</bold> Energy fluctuation plot between the small molecule drug and the protein. <bold>(D)</bold> Gibbs Free Energy Landscape Diagram of the Interaction between ALDH2 and NITROGLYCERIN. <bold>(E)</bold> Hydrogen bond count plot between the small molecule drug and the protein active site. <bold>(F)</bold> Distance plot between the small molecule drug and the binding site.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fpsyt-16-1653998-g007.jpg"><alt-text content-type="machine-generated">Graphical analysis of ALDH2 interacting with nitroglycerin: A. Line graph showing RMSD vs. time indicating fluctuations over 100 ns. B. Line graph depicting RMSF vs. residue number, highlighting variable flexibility across residues. C. Energy plot showing fluctuations in energy over 100,000 ps. D. Gibbs energy landscape heat map contrasting gyrate and RMSD. E. Plot showing hydrogen bond numbers over 100,000 ps. F. Distance plot comparing binding site-ALDH2 distances for two residues over time. Each data visualization examines molecular dynamics in the ALDH2-nitroglycerin interaction.</alt-text></graphic></fig></sec><sec id="s3_7"><label>3.7</label><title>Biomarkers were localized to different chromosomes and subcellular compartments</title><p>Chromosomal localization analysis indicated that SLC25A5 is located on chromosome X, ALDH2 on chromosome 12, CPT1C on chromosome 19, and IMMT on chromosome 2 (<xref rid="f8" ref-type="fig">
<bold>Figure&#160;8A</bold>
</xref>). In subcellular localization analysis, IMMT was localized to the nucleus, while SLC25A5, ALDH2, and CPT1C were localized to the cytoplasm (<xref rid="f8" ref-type="fig">
<bold>Figure&#160;8B</bold>
</xref>). Furthermore, based on the CTD database, the biomarkers displayed higher scores in depression-related diseases, suggesting that they play a pivotal role in depression pathogenesis (<xref rid="f8" ref-type="fig">
<bold>Figure&#160;8C</bold>
</xref>).</p><fig position="float" id="f8" orientation="portrait"><label>Figure&#160;8</label><caption><p>Subcellular localization of biomarkers and chromosome localization analysis. <bold>(A)</bold> The location of biomarkers on chromosomes. <bold>(B)</bold> Subcellular localization scoring of biomarkers. <bold>(C)</bold> The relationship between biomarkers and disease risk. Different colors represented specific diseases respectively: cyan represented Learning Disabilities, orange represented Cognition Disorders, purple represented Depressive Disorder, rose red represented Anxiety Disorders, green represented Alzheimer Disease, yellow represented Mental Disorders, and brown represented Sleep Wake Disorders.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fpsyt-16-1653998-g008.jpg"><alt-text content-type="machine-generated">Panel A shows a circos plot displaying the genomic locations of four genes (ALDH2, CPT1C, IMMT, SLC25A5) on human chromosomes. Panel B presents a stacked bar chart comparing localization scores for the genes across different cell parts, including the nucleus, mitochondria, and more, with varying color codes. Panel C contains bar charts depicting inference scores for each gene related to different disorders, such as learning disabilities and cognition disorders, with ALDH2, CPT1C, IMMT, and SLC25A5 individually highlighted.</alt-text></graphic></fig></sec><sec id="s3_8"><label>3.8</label><title>Biomarker expression levels were verified</title><p>The expression levels of the biomarkers were further validated. In both the training and validation sets, SLC25A5 and IMMT expression were significantly decreased in the MDD group, while CPT1C showed an opposite expression trend. ALDH2 was downregulated in the MDD group in both datasets, although this change was not statistically significant in the validation set (<xref rid="f9" ref-type="fig">
<bold>Figures&#160;9A, B</bold>
</xref>). RT-qPCR validation revealed that in patients with MDD, IMMT and SLC25A5 expression were significantly lower, while CPT1C expression was markedly elevated compared to controls (p &lt; 0.05) (<xref rid="f9" ref-type="fig">
<bold>Figure&#160;9C</bold>
</xref>). These findings were consistent with the bioinformatics analysis. Only ALDH2 expression did not show a significant difference (p &gt; 0.05) (<xref rid="f9" ref-type="fig">
<bold>Figure&#160;9C</bold>
</xref>).</p><fig position="float" id="f9" orientation="portrait"><label>Figure&#160;9</label><caption><p>Biomarker expression levels were verified. <bold>(A)</bold> Expression of biomarkers in the training set. ****p-value&lt;0.0001. <bold>(B)</bold> Expression of biomarkers in the validation set. ns represented no significance, *p-value&lt;0.05, **p-value&lt;0.01. <bold>(C)</bold> Validation of biomarker expression in clinical samples by RT-qPCR.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fpsyt-16-1653998-g009.jpg"><alt-text content-type="machine-generated">Box plots and bar graphs illustrating gene expression and relative levels of various genes, comparing Major Depressive Disorder (MDD) and control groups. Panel A shows significant differences in SLC25A5, ALDH2, CPT1C, and IMMT gene expressions. Panel B highlights SLC25A5, ALDH2, CPT1C, and IMMT gene expression with some non-significant results. Panel C displays bar graphs with relative levels of IMMT, SLC25A5, CPT1C, and ALDH2, indicating significant differences in some genes between MDD and control groups. Statistical significance is marked with asterisks.</alt-text></graphic></fig></sec></sec><sec sec-type="discussion" id="s4"><label>4</label><title>Discussion</title><p>MDD is a debilitating mental disorder characterized by persistent sadness, reduced interest in activities, and various cognitive impairments, which significantly affect the quality of life and functioning of affected individuals. The multifactorial nature of MDD involves genetic, environmental, and neurobiological factors, including changes in brain volume and function, particularly in areas like the hippocampus, which plays a key role in memory and mood regulation (<xref rid="B16" ref-type="bibr">16</xref>). Current treatment approaches primarily include psychotherapy and pharmacotherapy, yet a substantial number of patients remain resistant to standard treatments. This underscores the urgent need for novel therapeutic strategies and biomarkers to better understand the complex pathophysiology of MDD (<xref rid="B17" ref-type="bibr">17</xref>). Mitochondrial damage and the release of mitochondrial DNA are important markers of age-related inflammation, potentially contributing to the development of depression. Additionally, the age-associated decline in mitochondrial function has been linked to an increased risk of depression (<xref rid="B18" ref-type="bibr">18</xref>). Therefore, exploring mitochondrial and aging-related biomarkers may uncover new antidepressant therapies that target the mitochondrial-inflammation axis, offering strategies to reduce the risk of MDD.</p><p>This study aims to investigate the role of MRGs and ARGs in MDD using a comprehensive bioinformatics approach. By integrating transcriptomic data from the GEO database, this study identified several candidate biomarkers associated with MDD and conducted functional enrichment analyses to explore their potential roles in the disease&#8217;s mechanisms. Among the findings, four key biomarkers&#8212;SLC25A5, ALDH2, CPT1C, and IMMT&#8212;emerged as significant. These biomarkers could provide valuable insights into the molecular mechanisms underlying MDD, particularly in relation to mitochondrial dysfunction and cellular senescence (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>). The results of this study contribute to the existing literature and emphasize the need for further research into the molecular pathways influenced by these biomarkers. Such investigations may pave the way for the development of novel treatment strategies and ultimately improve patient outcomes in MDD (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>).</p><p>This study highlights the important link between mitochondrial dysfunction and aging in the pathophysiology of MDD. Our findings indicate that the biomarkers SLC25A5, ALDH2, CPT1C, and IMMT exhibit significant expression differences in patients with MDD and are strongly associated with pathways related to mitochondrial dysfunction and aging.</p><p>The ANT2 protein, encoded by the SLC25A5 gene, is a key transporter located in the inner mitochondrial membrane, responsible for facilitating the exchange of ADP from the cytosol with ATP from the mitochondrial matrix <italic toggle="yes">via</italic> an &#8220;alternate access mechanism&#8221; (<xref rid="B23" ref-type="bibr">23</xref>). ANT2 plays a key role in the formation and opening of the mitochondrial permeability transition pore (MPTP). Its conformational changes regulate MPTP activity, which, in turn, influences apoptosis. For instance, abnormal activation of ANT2 exacerbates mitochondrial membrane rupture during myocardial ischemia-reperfusion injury (<xref rid="B24" ref-type="bibr">24</xref>). In mouse models of anxiety and depression induced by chronic social defeat stress, ANT2 expression in the hippocampus and hypothalamus was significantly upregulated, correlating with mitochondrial dysfunction and the activation of inflammatory pathways (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>). In contrast, our PCR results revealed significantly downregulated ANT2 expression in patients with MDD, suggesting that reduced ADP/ATP transport efficiency may impair energy metabolism and compromise neuronal function in brain regions responsible for emotion regulation. The discrepancy between increased ANT2 levels in animal models and decreased levels in patients could stem from differences in disease stages (acute stress versus chronic depression), specific brain regions, or variations in compensatory mechanisms. These findings highlight that ANT2&#8217;s role in depression is microenvironment-dependent, and its dysregulated expression could serve as a potential diagnostic biomarker and therapeutic target for MDD through modulation of energy metabolism.</p><p>CPT1C (carnitine palmitoyltransferase 1C) is a member of the CPT1 family and is predominantly expressed in the brain, especially in the hypothalamus, hippocampus, and cerebral cortex. It is essential for long-chain fatty acid metabolism, energy homeostasis, lipid regulation, and modulation of neuronal activity (<xref rid="B27" ref-type="bibr">27</xref>). CPT1C facilitates the transport of fatty acids into mitochondria for &#946;-oxidation and also regulates neuronal synaptic plasticity, including AMPAR trafficking, through non-catalytic mechanisms, thus influencing neural signal transmission (<xref rid="B28" ref-type="bibr">28</xref>). In CPT1C knockout mouse models, researchers observed impaired dendritic spine maturation in the hippocampus, disrupting AMPAR synthesis and trafficking and ultimately compromising spatial learning ability (<xref rid="B27" ref-type="bibr">27</xref>). Interestingly, our study found that CPT1C expression was upregulated in patients with MDD. Depression is often associated with synaptic loss in the prefrontal cortex and hippocampus. However, this study observed elevated CPT1C levels, suggesting that this increase may represent a compensatory mechanism to counteract weakened synaptic transmission by enhancing AMPAR synthesis and membrane localization. However, CPT1C&#8217;s palmitoyl thioesterase activity must be tightly regulated, as overexpression could disrupt the balance of AMPAR palmitoylation and impair synaptic signaling. CPT1C participates in AMPAR regulation through the BDNF-mTOR pathway, with aberrant BDNF signaling being a core pathological mechanism in depression. The observed upregulation of CPT1C may reflect a compensatory response to reduced BDNF signaling. Nevertheless, under pathological conditions, CPT1C may fail to adequately activate downstream mTOR pathways, preventing functional compensation despite its elevated expression. This contrast underscores the complex and context-dependent roles of CPT1C in synaptic plasticity regulation and the pathology of depression.</p><p>ALDH2, a key biomarker identified in this study, plays a pivotal role in managing oxidative stress and detoxifying aldehydes, thereby contributing to neuroprotection. Dysregulation of ALDH2 has been linked to various mood disorders, highlighting its potential relevance in MDD (<xref rid="B29" ref-type="bibr">29</xref>). IMMT, involved in mitochondrial dynamics and integrity, has not been extensively studied in the context of MDD, making our findings a novel contribution to understanding its role in depressive pathology (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B30" ref-type="bibr">30</xref>).</p><p>Further GSEA revealed significant involvement of the identified biomarkers in pathways such as ATP-dependent chromatin remodeling and neutrophil extracellular trap formation. These pathways are associated with cellular stress responses and inflammation, both of which are increasingly recognized as key factors in the development of MDD. Notably, ATP-dependent chromatin remodeling is essential for regulating gene expression in response to stress. Disruptions in this process may lead to changes in neuronal plasticity and function, potentially contributing to the mechanisms underlying depression (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>). The presence of neutrophil extracellular traps points to an immune-related component in MDD. These structures can influence neuroinflammatory responses and may contribute to the neurodegenerative processes associated with depression (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>). These findings suggest that targeting these pathways could offer new therapeutic avenues for treating MDD.</p><p>Our drug prediction analysis identified several promising therapeutic agents, with nitroglycerin emerging as a particularly noteworthy candidate due to its favorable molecular docking results with ALDH2. This finding is of particular interest, as nitroglycerin, known for its vasodilatory properties, could potentially influence cerebral blood flow. Additionally, it has been suggested as a possible treatment for certain depressive symptoms, further emphasizing its relevance in this context (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>). However, molecular docking alone is insufficient to fully substantiate the therapeutic potential of nitroglycerin in NDD and psychiatric disorders. To bolster the reliability of these findings, further validation through <italic toggle="yes">in vitro</italic> cell experiments and <italic toggle="yes">in vivo</italic> animal models is necessary. Such studies would confirm the interaction between nitroglycerin and its molecular targets, as well as its therapeutic effects from an experimental standpoint. Strengthening the biological relevance of these conclusions through multidimensional experimental data&#8212;such as biochemical assays, cellular investigations, and animal behavior analyses&#8212;will provide solid scientific support for the potential repurposing of nitroglycerin in treating NDD and psychiatric conditions.</p><p>The correlation between the identified biomarkers and immune cell profiles further underscores the critical role of immune dysregulation in the development of MDD. Our immunoinfiltration analysis revealed significantly lower levels of activated B cells, CD8<sup>+</sup> T cells, and DCs in the peripheral blood of patients with MDD, offering new insights into immune dysfunction in MDD. Notably, this finding mirrors observations in multiple sclerosis (MS), where B cells contribute to neuronal cell death by secreting pro-inflammatory cytokines, such as IL-6 and TNF-&#945; (<xref rid="B37" ref-type="bibr">37</xref>). Existing literature supports the association between MDD and abnormal distribution of B cell subsets, characterized by an increase in MHC-II<sup>+</sup> B cells and a decrease in regulatory B cells (Bregs) and na&#239;ve B cells (<xref rid="B38" ref-type="bibr">38</xref>), suggesting that B cell dysfunction may represent a common neuroimmune regulatory mechanism in both MDD and MS. Furthermore, a significant positive correlation was found between the expression of the SLC25A5 gene, which encodes mitochondrial adenine nucleotide translocase 2 (ANT2), and the count of activated B cells. This correlation suggests that activated B cells may modulate MPTP opening through ANT2 regulation, potentially disrupting mitochondrial membrane potential and ATP synthesis. Such mitochondrial dysfunction could exacerbate energy metabolism deficits in neural circuits that regulate emotions, thereby intensifying depressive symptoms. These findings highlight the critical interplay between adaptive immunity and mitochondrial bioenergetics in MDD pathogenesis. Our research uncovers novel biomarkers related to mitochondrial function and aging in MDD, emphasizing their potential to guide future treatment strategies and deepen our understanding of the molecular mechanisms underlying this complex disorder. While these results are promising, further validation in larger cohorts and mechanistic studies are required to clarify the significance of these biomarkers in MDD and explore their potential clinical applications.</p><p>Despite the preliminary nature of this study, certain limitations remain. First, the sample size validated by RT-qPCR is relatively small, which may restrict the generalizability of the findings. Additionally, only transcriptional validation has been conducted, with no functional validation at the protein level, and the mechanism linking the identified biomarkers to depression remains unexplored. Second, the clinical data of the cohort are incomplete, with missing information such as medication status and body mass index, which may introduce potential confounding factors. Furthermore, the regulatory relationships between TFs, miRNAs, and lncRNAs predicted by bioinformatics tools are hypothetical and require experimental validation.</p><p>To address these limitations, future plans involve expanding the sample size and incorporating cohorts with detailed clinical characteristics (such as diagnostic criteria, depression severity, and comorbidities) to enhance the robustness of the results. Protein-level validation will be performed using Western blotting or immunofluorescence, alongside functional studies like gene knockout and animal models to clarify the mechanisms underlying the biomarkers in depression. Additionally, the predicted regulatory relationships will be validated through ChIP assays and overexpression/downregulation functional studies. Longitudinal studies will also be conducted to investigate the dynamic effects of biomarkers on the onset and progression of depressive symptoms. These efforts will provide a stronger theoretical foundation for the diagnosis and intervention of depression.</p><p>In conclusion, this study highlights the significant potential of SLC25A5, ALDH2, CPT1C, and IMMT as biomarkers for MDD, elucidating their roles in mitochondrial dysfunction and aging processes. The regulatory networks and immune interactions associated with these biomarkers deepen our understanding of the complex mechanisms underlying MDD. Although certain limitations exist, these findings provide a critical foundation for future studies focused on identifying clinically relevant biomarkers and developing therapeutic targets. Further research into these genes may enhance our understanding of MDD and facilitate the development of more effective treatments for individuals affected by this debilitating condition.</p></sec></body><back><ack><title>Acknowledgments</title><p>We would like to express our sincere gratitude to all individuals and organizations who supported and assisted us throughout this research. We extend our thanks to everyone who has supported and assisted us along the way. Without your support, this research would not have been possible.</p></ack><fn-group><title>Abbreviations</title><fn fn-type="abbr" id="abbrev1"><p>MDD, Major depressive disorder; MRGs, Mitochondria-related genes; ARGs, Aging-related genes; DEGs, Differentially expressed genes; RT-qPCR, Reverse transcription-quantitative polymerase chain reaction; ANN, Artificial neural network; PPI, Protein-protein interactions; ROC, Receiver Operating Characteristic; LASSO, Least Absolute Shrinkage and Selection Operator; NDD, Neurodegenerative diseases; TFs, Transcription factors; AUC, Area under the curve.</p></fn></fn-group><sec sec-type="data-availability" id="s5"><title>Data availability statement</title><p>The original contributions presented in the study are included in the article/<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Material</bold>
</xref>. Further inquiries can be directed to the corresponding author.</p></sec><sec sec-type="ethics-statement" id="s6"><title>Ethics statement</title><p>The studies involving humans were approved by Clinical Research Ethics Committee of the People&#8217;s Hospital of Xinjiang Uygur Autonomous Region. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p></sec><sec sec-type="author-contributions" id="s7"><title>Author contributions</title><p>ZC: Writing &#8211; original draft, Writing &#8211; review &amp; editing, Conceptualization, Data curation, Validation, Visualization. XT: Data curation, Validation, Visualization, Writing &#8211; review &amp; editing. CG: Visualization, Writing &#8211; review &amp; editing. SZ: Conceptualization, Project administration, Supervision, Writing &#8211; review &amp; editing.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s10"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p><p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="s12"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.frontiersin.org/articles/10.3389/fpsyt.2025.1653998/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fpsyt.2025.1653998/full#supplementary-material</ext-link>
</p><supplementary-material id="SM1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table1.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="SM2" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table2.xlsx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="SM3" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table3.xlsx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="SM4" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table4.xlsx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="SM5" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table5.doc" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="SF1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Image1.tif" position="float" orientation="portrait"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Otte</surname><given-names>C</given-names></name><name name-style="western"><surname>Gold</surname><given-names>SM</given-names></name><name name-style="western"><surname>Penninx</surname><given-names>BW</given-names></name><name name-style="western"><surname>Pariante</surname><given-names>CM</given-names></name><name name-style="western"><surname>Etkin</surname><given-names>A</given-names></name><name name-style="western"><surname>Fava</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Major depressive disorder</article-title>. <source>Nat Rev Dis Primers</source>. (<year>2016</year>) <volume>2</volume>:<fpage>16065</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nrdp.2016.65</pub-id>, PMID: <pub-id pub-id-type="pmid">27629598</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharp</surname><given-names>LK</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>SL</given-names></name><name name-style="western"><surname>Williams</surname><given-names>RW</given-names></name></person-group>. <article-title>Improving screening for major depressive disorder</article-title>. <source>J Am Assoc Nurse Pract</source>. (<year>2023</year>) <volume>35</volume>:<page-range>71&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1097/jxx.0000000000000817</pub-id>, PMID: <pub-id pub-id-type="pmid">36490264</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belmaker</surname><given-names>RH</given-names></name><name name-style="western"><surname>Agam</surname><given-names>G</given-names></name></person-group>. <article-title>Major depressive disorder</article-title>. <source>N Engl J Med</source>. (<year>2008</year>) <volume>358</volume>:<fpage>55</fpage>&#8211;<lpage>68</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMra073096</pub-id>, PMID: <pub-id pub-id-type="pmid">18172175</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>P</given-names></name><name name-style="western"><surname>DC</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CF</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>RF</given-names></name><name name-style="western"><surname>Armitage</surname><given-names>R</given-names></name><name name-style="western"><surname>Deldin</surname><given-names>PJ</given-names></name></person-group>. <article-title>Sleep-disordered breathing in major depressive disorder</article-title>. <source>J Sleep Res</source>. (<year>2013</year>) <volume>22</volume>:<page-range>459&#8211;62</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/jsr.12029</pub-id>, PMID: <pub-id pub-id-type="pmid">23350718</pub-id><pub-id pub-id-type="pmcid">PMC3689852</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirschfeld</surname><given-names>RM</given-names></name></person-group>. <article-title>Differential diagnosis of bipolar disorder and major depressive disorder</article-title>. <source>J Affect Disord</source>. (<year>2014</year>) <volume>169 Suppl 1</volume>:<page-range>S12&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/s0165-0327(14)70004-7</pub-id>, PMID: <pub-id pub-id-type="pmid">25533909</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>J</given-names></name><name name-style="western"><surname>Hong</surname><given-names>D</given-names></name><name name-style="western"><surname>Lang</surname><given-names>W</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name><name name-style="western"><surname>Qian</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Differently tagged probes for protein profiling of mitochondria</article-title>. <source>Chembiochem</source>. (<year>2019</year>) <volume>20</volume>:<page-range>1155&#8211;60</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/cbic.201800735</pub-id>, PMID: <pub-id pub-id-type="pmid">30600897</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Bliek</surname><given-names>AM</given-names></name><name name-style="western"><surname>Sedensky</surname><given-names>MM</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>PG</given-names></name></person-group>. <article-title>Cell biology of the mitochondrion</article-title>. <source>Genetics</source>. (<year>2017</year>) <volume>207</volume>:<page-range>843&#8211;71</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1534/genetics.117.300262</pub-id>, PMID: <pub-id pub-id-type="pmid">29097398</pub-id><pub-id pub-id-type="pmcid">PMC5676242</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moriya</surname><given-names>J</given-names></name><name name-style="western"><surname>Minamino</surname><given-names>T</given-names></name></person-group>. <article-title>Angiogenesis, cancer, and vascular aging</article-title>. <source>Front Cardiovasc Med</source>. (<year>2017</year>) <volume>4</volume>:<elocation-id>65</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fcvm.2017.00065</pub-id>, PMID: <pub-id pub-id-type="pmid">29114540</pub-id><pub-id pub-id-type="pmcid">PMC5660731</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Segu&#237;-Simarro</surname><given-names>JM</given-names></name><name name-style="western"><surname>Coronado</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Staehelin</surname><given-names>LA</given-names></name></person-group>. <article-title>The mitochondrial cycle of Arabidopsis shoot apical meristem and leaf primordium meristematic cells is defined by a perinuclear tentaculate/cage-like mitochondrion</article-title>. <source>Plant Physiol</source>. (<year>2008</year>) <volume>148</volume>:<page-range>1380&#8211;93</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1104/pp.108.126953</pub-id>, PMID: <pub-id pub-id-type="pmid">18799659</pub-id><pub-id pub-id-type="pmcid">PMC2577259</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ritchie</surname><given-names>ME</given-names></name><name name-style="western"><surname>Phipson</surname><given-names>B</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Law</surname><given-names>CW</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title>. <source>Nucleic Acids Res</source>. (<year>2015</year>) <volume>43</volume>:<elocation-id>e47</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id>, PMID: <pub-id pub-id-type="pmid">25605792</pub-id><pub-id pub-id-type="pmcid">PMC4402510</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>T</given-names></name><name name-style="western"><surname>Hu</surname><given-names>E</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Guo</surname><given-names>P</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>clusterProfiler 4.0: A universal enrichment tool for interpreting omics data</article-title>. <source>Innovation (Camb)</source>. (<year>2021</year>) <volume>2</volume>:<elocation-id>100141</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.xinn.2021.100141</pub-id>, PMID: <pub-id pub-id-type="pmid">34557778</pub-id><pub-id pub-id-type="pmcid">PMC8454663</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engebretsen</surname><given-names>S</given-names></name><name name-style="western"><surname>Bohlin</surname><given-names>J</given-names></name></person-group>. <article-title>Statistical predictions with glmnet</article-title>. <source>Clin Epigenetics</source>. (<year>2019</year>) <volume>11</volume>:<fpage>123</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s13148-019-0730-1</pub-id>, PMID: <pub-id pub-id-type="pmid">31443682</pub-id><pub-id pub-id-type="pmcid">PMC6708235</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Yin</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cai</surname><given-names>L</given-names></name><name name-style="western"><surname>Geng</surname><given-names>R</given-names></name><name name-style="western"><surname>Du</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>A comprehensive prognostic and immune analysis of enhancer RNA identifies IGFBP7-AS1 as a novel prognostic biomarker in Uterine Corpus Endometrial Carcinoma</article-title>. <source>Biol Proced Online</source>. (<year>2022</year>) <volume>24</volume>:<fpage>9</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12575-022-00172-0</pub-id>, PMID: <pub-id pub-id-type="pmid">35836132</pub-id><pub-id pub-id-type="pmcid">PMC9284715</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Meltzer</surname><given-names>P</given-names></name><name name-style="western"><surname>Davis</surname><given-names>S</given-names></name></person-group>. <article-title>RCircos: an R package for Circos 2D track plots</article-title>. <source>BMC Bioinf</source>. (<year>2013</year>) <volume>14</volume>:<elocation-id>244</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1186/1471-2105-14-244</pub-id>, PMID: <pub-id pub-id-type="pmid">23937229</pub-id><pub-id pub-id-type="pmcid">PMC3765848</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Livak</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group>. <article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method</article-title>. <source>Methods</source>. (<year>2001</year>) <volume>25</volume>:<page-range>402&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id>, PMID: <pub-id pub-id-type="pmid">11846609</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sacchet</surname><given-names>MD</given-names></name><name name-style="western"><surname>Livermore</surname><given-names>EE</given-names></name><name name-style="western"><surname>Iglesias</surname><given-names>JE</given-names></name><name name-style="western"><surname>Glover</surname><given-names>GH</given-names></name><name name-style="western"><surname>Gotlib</surname><given-names>IH</given-names></name></person-group>. <article-title>Subcortical volumes differentiate Major Depressive Disorder, Bipolar Disorder, and remitted Major Depressive Disorder</article-title>. <source>J Psychiatr Res</source>. (<year>2015</year>) <volume>68</volume>:<page-range>91&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jpsychires.2015.06.002</pub-id>, PMID: <pub-id pub-id-type="pmid">26228406</pub-id><pub-id pub-id-type="pmcid">PMC11887997</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beach</surname><given-names>SR</given-names></name><name name-style="western"><surname>Whisman</surname><given-names>MA</given-names></name></person-group>. <article-title>Affective disorders</article-title>. <source>J Marital Fam Ther</source>. (<year>2012</year>) <volume>38</volume>:<page-range>201&#8211;19</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1752-0606.2011.00243.x</pub-id>, PMID: <pub-id pub-id-type="pmid">22283387</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>J</given-names></name><name name-style="western"><surname>Beroncal</surname><given-names>EL</given-names></name><name name-style="western"><surname>Chernega</surname><given-names>T</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>JL</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>CE</given-names></name><etal/></person-group>. <article-title>Exploring mitochondrial blood-based and genetic markers in older adults with mild cognitive impairment and remitted major depressive disorder</article-title>. <source>Transl Psychiatry</source>. (<year>2024</year>) <volume>14</volume>:<fpage>457</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41398-024-03155-9</pub-id>, PMID: <pub-id pub-id-type="pmid">39468012</pub-id><pub-id pub-id-type="pmcid">PMC11519657</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Hong</surname><given-names>WF</given-names></name><name name-style="western"><surname>Liu</surname><given-names>ML</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X</given-names></name><name name-style="western"><surname>Yu</surname><given-names>YY</given-names></name><name name-style="western"><surname>Cui</surname><given-names>YH</given-names></name><etal/></person-group>. <article-title>An integrated bioinformatic investigation of mitochondrial solute carrier family 25 (SLC25) in colon cancer followed by preliminary validation of member 5 (SLC25A5) in tumorigenesis</article-title>. <source>Cell Death Dis</source>. (<year>2022</year>) <volume>13</volume>:<fpage>237</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41419-022-04692-1</pub-id>, PMID: <pub-id pub-id-type="pmid">35288533</pub-id><pub-id pub-id-type="pmcid">PMC8921248</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>S</given-names></name><name name-style="western"><surname>Yin</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>H</given-names></name><name name-style="western"><surname>Bi</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>ALDH2 is a prognostic biomarker and related with immune infiltrates in HCC</article-title>. <source>Am J Cancer Res</source>. (<year>2021</year>) <volume>11</volume>:<page-range>5319&#8211;37</page-range>., PMID: <pub-id pub-id-type="pmid">34873463</pub-id><pub-id pub-id-type="pmcid">PMC8640816</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fad&#243;</surname><given-names>R</given-names></name><name name-style="western"><surname>Zagmutt</surname><given-names>S</given-names></name><name name-style="western"><surname>Herrero</surname><given-names>L</given-names></name><name name-style="western"><surname>Muley</surname><given-names>H</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Rodr&#237;guez</surname><given-names>R</given-names></name><name name-style="western"><surname>Bi</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>To be or not to be a fat burner, that is the question for cpt1c in cancer cells</article-title>. <source>Cell Death Dis</source>. (<year>2023</year>) <volume>14</volume>:<fpage>57</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41419-023-05599-1</pub-id>, PMID: <pub-id pub-id-type="pmid">36693836</pub-id><pub-id pub-id-type="pmcid">PMC9873675</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>CC</given-names></name><name name-style="western"><surname>Chu</surname><given-names>PY</given-names></name><name name-style="western"><surname>Lin</surname><given-names>HY</given-names></name></person-group>. <article-title>Supervised learning and multi-omics integration reveals clinical significance of inner membrane mitochondrial protein (IMMT) in prognostic prediction, tumor immune microenvironment and precision medicine for kidney renal clear cell carcinoma</article-title>. <source>Int J Mol Sci</source>. (<year>2023</year>) <volume>24</volume>:<elocation-id>8807</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/ijms24108807</pub-id>, PMID: <pub-id pub-id-type="pmid">37240154</pub-id><pub-id pub-id-type="pmcid">PMC10218256</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cl&#233;men&#231;on</surname><given-names>B</given-names></name><name name-style="western"><surname>Babot</surname><given-names>M</given-names></name><name name-style="western"><surname>Tr&#233;z&#233;guet</surname><given-names>V</given-names></name></person-group>. <article-title>The mitochondrial ADP/ATP carrier (SLC25 family): pathological implications of its dysfunction</article-title>. <source>Mol Aspects Med</source>. (<year>2013</year>) <volume>34</volume>:<page-range>485&#8211;93</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.mam.2012.05.006</pub-id>, PMID: <pub-id pub-id-type="pmid">23506884</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kokoszka</surname><given-names>JE</given-names></name><name name-style="western"><surname>Waymire</surname><given-names>KG</given-names></name><name name-style="western"><surname>Flierl</surname><given-names>A</given-names></name><name name-style="western"><surname>Sweeney</surname><given-names>KM</given-names></name><name name-style="western"><surname>Angelin</surname><given-names>A</given-names></name><name name-style="western"><surname>MacGregor</surname><given-names>GR</given-names></name><etal/></person-group>. <article-title>Deficiency in the mouse mitochondrial adenine nucleotide translocator isoform 2 gene is associated with cardiac noncompaction</article-title>. <source>Biochim Biophys Acta</source>. (<year>2016</year>) <volume>1857</volume>:<page-range>1203&#8211;12</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.bbabio.2016.03.026</pub-id>, PMID: <pub-id pub-id-type="pmid">27048932</pub-id><pub-id pub-id-type="pmcid">PMC5100012</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>J</given-names></name><name name-style="western"><surname>Seo</surname><given-names>J</given-names></name><name name-style="western"><surname>Lim</surname><given-names>CH</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Shiratsuchi</surname><given-names>T</given-names></name><name name-style="western"><surname>Lee</surname><given-names>MH</given-names></name><etal/></person-group>. <article-title>Mitochondrial ATP transporter Ant2 depletion impairs erythropoiesis and B lymphopoiesis</article-title>. <source>Cell Death Differ</source>. (<year>2015</year>) <volume>22</volume>:<page-range>1437&#8211;50</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/cdd.2014.230</pub-id>, PMID: <pub-id pub-id-type="pmid">25613378</pub-id><pub-id pub-id-type="pmcid">PMC4532771</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Babenko</surname><given-names>VN</given-names></name><name name-style="western"><surname>Smagin</surname><given-names>DA</given-names></name><name name-style="western"><surname>Galyamina</surname><given-names>AG</given-names></name><name name-style="western"><surname>Kovalenko</surname><given-names>IL</given-names></name><name name-style="western"><surname>Kudryavtseva</surname><given-names>NN</given-names></name></person-group>. <article-title>Altered Slc25 family gene expression as markers of mitochondrial dysfunction in brain regions under experimental mixed anxiety/depression-like disorder</article-title>. <source>BMC Neurosci</source>. (<year>2018</year>) <volume>19</volume>:<fpage>79</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12868-018-0480-6</pub-id>, PMID: <pub-id pub-id-type="pmid">30537945</pub-id><pub-id pub-id-type="pmcid">PMC6288882</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Casals</surname><given-names>N</given-names></name><name name-style="western"><surname>Zammit</surname><given-names>V</given-names></name><name name-style="western"><surname>Herrero</surname><given-names>L</given-names></name><name name-style="western"><surname>Fad&#243;</surname><given-names>R</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Rodr&#237;guez</surname><given-names>R</given-names></name><name name-style="western"><surname>Serra</surname><given-names>D</given-names></name></person-group>. <article-title>Carnitine palmitoyltransferase 1C: From cognition to cancer</article-title>. <source>Prog Lipid Res</source>. (<year>2016</year>) <volume>61</volume>:<page-range>134&#8211;48</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.plipres.2015.11.004</pub-id>, PMID: <pub-id pub-id-type="pmid">26708865</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwenk</surname><given-names>J</given-names></name><name name-style="western"><surname>Boudkkazi</surname><given-names>S</given-names></name><name name-style="western"><surname>Kocylowski</surname><given-names>MK</given-names></name><name name-style="western"><surname>Brechet</surname><given-names>A</given-names></name><name name-style="western"><surname>Zolles</surname><given-names>G</given-names></name><name name-style="western"><surname>Bus</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>An ER assembly line of AMPA-receptors controls excitatory neurotransmission and its plasticity</article-title>. <source>Neuron</source>. (<year>2019</year>) <volume>104</volume>:<fpage>680</fpage>&#8211;<lpage>92.e9</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.neuron.2019.08.033</pub-id>, PMID: <pub-id pub-id-type="pmid">31604597</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>CH</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>JCB</given-names></name><name name-style="western"><surname>Mochly-Rosen</surname><given-names>D</given-names></name></person-group>. <article-title>ALDH2 and cardiovascular disease</article-title>. <source>Adv Exp Med Biol</source>. (<year>2019</year>) <volume>1193</volume>:<fpage>53</fpage>&#8211;<lpage>67</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/978-981-13-6260-6_3</pub-id>, PMID: <pub-id pub-id-type="pmid">31368097</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hiyoshi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ichinoe</surname><given-names>M</given-names></name><name name-style="western"><surname>Nagashio</surname><given-names>R</given-names></name><name name-style="western"><surname>Hagiuda</surname><given-names>D</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Prognostic significance of IMMT expression in surgically-resected lung adenocarcinoma</article-title>. <source>Thorac Cancer</source>. (<year>2019</year>) <volume>10</volume>:<page-range>2142&#8211;51</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/1759-7714.13200</pub-id>, PMID: <pub-id pub-id-type="pmid">31583841</pub-id><pub-id pub-id-type="pmcid">PMC6825906</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hota</surname><given-names>SK</given-names></name><name name-style="western"><surname>Bruneau</surname><given-names>BG</given-names></name></person-group>. <article-title>ATP-dependent chromatin remodeling during mammalian development</article-title>. <source>Development</source>. (<year>2016</year>) <volume>143</volume>:<page-range>2882&#8211;97</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1242/dev.128892</pub-id>, PMID: <pub-id pub-id-type="pmid">27531948</pub-id><pub-id pub-id-type="pmcid">PMC5004879</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crosswhite</surname><given-names>PL</given-names></name></person-group>. <article-title>ATP-dependent chromatin remodeling complexes in embryonic vascular development and hypertension</article-title>. <source>Am J Physiol Heart Circ Physiol</source>. (<year>2019</year>) <volume>317</volume>:<page-range>H575&#8211;h80</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1152/ajpheart.00147.2019</pub-id>, PMID: <pub-id pub-id-type="pmid">31398060</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ravindran</surname><given-names>M</given-names></name><name name-style="western"><surname>Khan</surname><given-names>MA</given-names></name><name name-style="western"><surname>Palaniyar</surname><given-names>N</given-names></name></person-group>. <article-title>Neutrophil extracellular trap formation: physiology, pathology, and pharmacology</article-title>. <source>Biomolecules</source>. (<year>2019</year>) <volume>9</volume>:<elocation-id>365</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/biom9080365</pub-id>, PMID: <pub-id pub-id-type="pmid">31416173</pub-id><pub-id pub-id-type="pmcid">PMC6722781</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><name name-style="western"><surname>Jin</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Gut microbiome dysbiosis contributes to abdominal aortic aneurysm by promoting neutrophil extracellular trap formation</article-title>. <source>Cell Host Microbe</source>. (<year>2022</year>) <volume>30</volume>:<fpage>1450</fpage>&#8211;<lpage>63.e8</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.chom.2022.09.004</pub-id>, PMID: <pub-id pub-id-type="pmid">36228585</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heer</surname><given-names>T</given-names></name><name name-style="western"><surname>Reiter</surname><given-names>S</given-names></name><name name-style="western"><surname>Tri&#223;ler</surname><given-names>M</given-names></name><name name-style="western"><surname>H&#246;fling</surname><given-names>B</given-names></name></person-group>. <article-title>von knobelsdorff-brenkenhoff F, pilz G. Effect of nitroglycerin on the performance of MR coronary angiography</article-title>. <source>J Magn Reson Imaging</source>. (<year>2017</year>) <volume>45</volume>:<page-range>1419&#8211;28</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/jmri.25483</pub-id>, PMID: <pub-id pub-id-type="pmid">27731913</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tfelt-Hansen</surname><given-names>PC</given-names></name><name name-style="western"><surname>Tfelt-Hansen</surname><given-names>J</given-names></name></person-group>. <article-title>Nitroglycerin headache and nitroglycerin-induced primary headaches from 1846 and onwards: a historical overview and an update</article-title>. <source>Headache</source>. (<year>2009</year>) <volume>49</volume>:<page-range>445&#8211;56</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1526-4610.2009.01342.x</pub-id>, PMID: <pub-id pub-id-type="pmid">19267787</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lisak</surname><given-names>RP</given-names></name><name name-style="western"><surname>Nedelkoska</surname><given-names>L</given-names></name><name name-style="western"><surname>Benjamins</surname><given-names>JA</given-names></name><name name-style="western"><surname>Schalk</surname><given-names>D</given-names></name><name name-style="western"><surname>Bealmear</surname><given-names>B</given-names></name><name name-style="western"><surname>Touil</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons <italic toggle="yes">in vitro</italic>
</article-title>. <source>J Neuroimmunol</source>. (<year>2017</year>) <volume>309</volume>:<fpage>88</fpage>&#8211;<lpage>99</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jneuroim.2017.05.004</pub-id>, PMID: <pub-id pub-id-type="pmid">28601295</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corrigan</surname><given-names>M</given-names></name><name name-style="western"><surname>O&#8217;Rourke</surname><given-names>AM</given-names></name><name name-style="western"><surname>Moran</surname><given-names>B</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>JM</given-names></name><name name-style="western"><surname>Harkin</surname><given-names>A</given-names></name></person-group>. <article-title>Inflammation in the pathogenesis of depression: a disorder of neuroimmune origin</article-title>. <source>Neuronal Signal</source>. (<year>2023</year>) <volume>7</volume>:<fpage>Ns20220054</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1042/ns20220054</pub-id>, PMID: <pub-id pub-id-type="pmid">37457896</pub-id><pub-id pub-id-type="pmcid">PMC10345431</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="dad270197" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement (Amst)</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement (Amst)</journal-id><journal-id journal-id-type="pmc-domain-id">3002</journal-id><journal-id journal-id-type="pmc-domain">dadm</journal-id><journal-id journal-id-type="publisher-id">DAD2</journal-id><journal-title-group><journal-title>Alzheimer's &amp; Dementia : Diagnosis, Assessment &amp; Disease Monitoring</journal-title></journal-title-group><issn pub-type="epub">2352-8729</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12505024</article-id><article-id pub-id-type="pmcid-ver">PMC12505024.1</article-id><article-id pub-id-type="pmcaid">12505024</article-id><article-id pub-id-type="pmcaiid">12505024</article-id><article-id pub-id-type="doi">10.1002/dad2.70197</article-id><article-id pub-id-type="publisher-id">DAD270197</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Discovering subtypes with imaging signatures in the Motoric Cognitive Risk Syndrome Consortium using weakly supervised clustering</article-title><alt-title alt-title-type="left-running-head">NALLAPU <sc>et&#160;al.</sc></alt-title></title-group><contrib-group><contrib id="dad270197-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Nallapu</surname><given-names initials="BT">Bhargav Teja</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6368-8509</contrib-id><xref rid="dad270197-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="dad270197-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>b.t.nallapu@tudelft.nl</email></address></contrib><contrib id="dad270197-cr-0002" contrib-type="author"><name name-style="western"><surname>Ezzati</surname><given-names initials="A">Ali</given-names></name><xref rid="dad270197-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="dad270197-cr-0003" contrib-type="author"><name name-style="western"><surname>Blumen</surname><given-names initials="HM">Helena M.</given-names></name><xref rid="dad270197-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="dad270197-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="dad270197-cr-0004" contrib-type="author"><name name-style="western"><surname>Petersen</surname><given-names initials="KK">Kellen K.</given-names></name><xref rid="dad270197-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="dad270197-cr-0005" contrib-type="author"><name name-style="western"><surname>Lipton</surname><given-names initials="RB">Richard B.</given-names></name><xref rid="dad270197-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="dad270197-cr-0006" contrib-type="author"><name name-style="western"><surname>Ayers</surname><given-names initials="E">Emmeline</given-names></name><xref rid="dad270197-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="dad270197-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="dad270197-cr-0007" contrib-type="author"><name name-style="western"><surname>Kumar</surname><given-names initials="VGP">V G Pradeep</given-names></name><xref rid="dad270197-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="dad270197-cr-0008" contrib-type="author"><name name-style="western"><surname>Velandai</surname><given-names initials="S">Srikanth</given-names></name><xref rid="dad270197-aff-0008" ref-type="aff">
<sup>8</sup>
</xref><xref rid="dad270197-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="dad270197-cr-0009" contrib-type="author"><name name-style="western"><surname>Beare</surname><given-names initials="R">Richard</given-names></name><xref rid="dad270197-aff-0008" ref-type="aff">
<sup>8</sup>
</xref><xref rid="dad270197-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="dad270197-cr-0010" contrib-type="author"><name name-style="western"><surname>Beauchet</surname><given-names initials="O">Olivier</given-names></name><xref rid="dad270197-aff-0011" ref-type="aff">
<sup>11</sup>
</xref><xref rid="dad270197-aff-0012" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib id="dad270197-cr-0011" contrib-type="author"><name name-style="western"><surname>Doi</surname><given-names initials="T">Takehiko</given-names></name><xref rid="dad270197-aff-0013" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib id="dad270197-cr-0012" contrib-type="author"><name name-style="western"><surname>Shimada</surname><given-names initials="H">Hiroyuki</given-names></name><xref rid="dad270197-aff-0013" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib id="dad270197-cr-0013" contrib-type="author"><name name-style="western"><surname>Callisaya</surname><given-names initials="M">Michele</given-names></name><xref rid="dad270197-aff-0014" ref-type="aff">
<sup>14</sup>
</xref><xref rid="dad270197-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="dad270197-cr-0014" contrib-type="author"><name name-style="western"><surname>Milman</surname><given-names initials="S">Sofiya</given-names></name><xref rid="dad270197-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="dad270197-cr-0015" contrib-type="author"><name name-style="western"><surname>Aleksic</surname><given-names initials="S">Sandra</given-names></name><xref rid="dad270197-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="dad270197-cr-0016" contrib-type="author"><name name-style="western"><surname>Verghese</surname><given-names initials="J">Joe</given-names></name><xref rid="dad270197-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="dad270197-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="dad270197-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Albert Einstein College of Medicine</institution>
<city>Bronx</city>
<named-content content-type="country-part">New York</named-content>
<country country="US">USA</country>
</aff><aff id="dad270197-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Cognitive Robotics</named-content>
<institution>Delft University of Technology</institution>
<city>Delft</city>
<named-content content-type="country-part">Zuid&#8208;Holland</named-content>
<country country="NL">The Netherlands</country>
</aff><aff id="dad270197-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>University of California, Irvine (UCI), Irvine</institution>
<city>Orange</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><aff id="dad270197-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Stony Brook University</institution>
<city>Stony Brook</city>
<named-content content-type="country-part">New York</named-content>
<country country="US">USA</country>
</aff><aff id="dad270197-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Departments of Medicine</named-content>
<institution>Albert Einstein College of Medicine</institution>
<city>Bronx</city>
<named-content content-type="country-part">New York</named-content>
<country country="US">USA</country>
</aff><aff id="dad270197-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Washington University in St. Louis</institution>
<city>St. Louis</city>
<named-content content-type="country-part">Missouri</named-content>
<country country="US">USA</country>
</aff><aff id="dad270197-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Baby Memorial Hospital</institution>
<city>Kozhikode</city>
<named-content content-type="country-part">Kerala</named-content>
<country country="IN">India</country>
</aff><aff id="dad270197-aff-0008">
<label>
<sup>8</sup>
</label>
<institution>National Centre for Healthy Ageing</institution>
<city>Frankston</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><aff id="dad270197-aff-0009">
<label>
<sup>9</sup>
</label>
<named-content content-type="organisation-division">School of Translational Medicine</named-content>
<institution>Monash University</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><aff id="dad270197-aff-0010">
<label>
<sup>10</sup>
</label>
<named-content content-type="organisation-division">Developmental Imaging Group</named-content>
<institution>Murdoch Children's Research Institute</institution>
<city>Parkville</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><aff id="dad270197-aff-0011">
<label>
<sup>11</sup>
</label>
<institution>Centre de Recherche de l'Institut Universitaire de G&#233;riatrie de Montr&#233;al (CRIUGM)</institution>
<city>Montr&#233;al</city>
<named-content content-type="country-part">Quebec</named-content>
<country country="CA">Canada</country>
</aff><aff id="dad270197-aff-0012">
<label>
<sup>12</sup>
</label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<institution>University of Montreal</institution>
<city>Montr&#233;al</city>
<named-content content-type="country-part">Quebec</named-content>
<country country="CA">Canada</country>
</aff><aff id="dad270197-aff-0013">
<label>
<sup>13</sup>
</label>
<named-content content-type="organisation-division">Department of Preventive Gerontology</named-content>
<named-content content-type="organisation-division">Center for Gerontology and Social Science</named-content>
<institution>Research Institute, National Centre for Geriatrics and Gerontology</institution>
<city>Obu City Aichi Prefecture</city>
<country country="JP">Japan</country>
</aff><aff id="dad270197-aff-0014">
<label>
<sup>14</sup>
</label>
<named-content content-type="organisation-division">Menzies Institute for Medical Research</named-content>
<institution>University of Tasmania</institution>
<city>Hobart</city>
<named-content content-type="country-part">Tasmania</named-content>
<country country="AU">Australia</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Bhargav T. Nallapu, Address: Building 34, Mekelweg 2, 2628 CD Delft, The Netherlands.<break/> Email: <email>b.t.nallapu@tudelft.nl</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><season>Oct-Dec</season><year>2025</year></pub-date><volume>17</volume><issue seq="40">4</issue><issue-id pub-id-type="pmc-issue-id">497563</issue-id><issue-id pub-id-type="doi">10.1002/dad2.v17.4</issue-id><elocation-id>e70197</elocation-id><history><date date-type="rev-recd"><day>12</day><month>9</month><year>2025</year></date><date date-type="received"><day>15</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>15</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Alzheimer's &amp; Dementia: Diagnosis, Assessment &amp; Disease Monitoring</italic> published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="DAD2-17-e70197.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:DAD2-17-e70197.pdf"/><abstract><title>ABSTRACT</title><sec id="dad270197-sec-0010"><title>INTRODUCTION</title><p>Understanding the heterogeneity of brain structure in individuals with the Motoric Cognitive Risk Syndrome (MCR) may improve the current risk assessments of dementia.</p></sec><sec id="dad270197-sec-0020"><title>METHODS</title><p>We used data from six cohorts from the <italic toggle="yes">MCR consortium</italic> (<italic toggle="yes">N</italic>&#160;=&#160;1987). A weakly&#8208;supervised clustering algorithm called HYDRA (Heterogeneity through Discriminative Analysis) was applied to volumetric magnetic resonance imaging (MRI) measures to identify distinct subgroups in the population with gait speeds lower than one standard deviation (1SD) above mean.</p></sec><sec id="dad270197-sec-0030"><title>RESULTS</title><p>Three subgroups (Groups A, B, and C) were identified through MRI&#8208;based clustering with significant differences in regional brain volumes, gait speeds, and performance on Trail Making (Part&#8208;B) and Free and Cued Selective Reminding Tests.</p></sec><sec id="dad270197-sec-0040"><title>DISCUSSION</title><p>Based on structural MRI, our results reflect heterogeneity in the population with moderate and slow gait, including those with MCR. Such a data&#8208;driven approach could help pave new pathways toward dementia at&#8208;risk stratification and have implications for precision health for patients.</p></sec><sec id="dad270197-sec-0050"><title>Highlights</title><p>
<list list-type="bullet" id="dad270197-list-0001"><list-item><p>Different patterns of brain atrophy were observed among the people with moderate and slow gait speeds</p></list-item><list-item><p>Slower gait speeds were associated with substantial cortical atrophy, higher rates of Motoric Cognitive Risk Syndrome (MCR), and worse cognitive performance</p></list-item><list-item><p>This approach can aid patient stratification at early asymptomatic stages and have implications for precision health.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dad270197-kwd-0001">cognitive complaints</kwd><kwd id="dad270197-kwd-0002">dementia</kwd><kwd id="dad270197-kwd-0003">gait</kwd><kwd id="dad270197-kwd-0004">machine learning</kwd><kwd id="dad270197-kwd-0005">MCR</kwd><kwd id="dad270197-kwd-0006">volumetric imaging</kwd><kwd id="dad270197-kwd-0007">weakly&#8208;supervised clustering</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Alzheimer's Association</institution><institution-id institution-id-type="doi">10.13039/100000957</institution-id></institution-wrap></funding-source><award-id>SG&#8208;24&#8208;988292</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>NIH/NIA</institution></institution-wrap></funding-source><award-id>1R56AG057548&#8208;01</award-id><award-id>R01AG057548&#8208;01</award-id><award-id>2R01AG039330</award-id><award-id>DK129320&#8208;01 2021&#8208;2026</award-id><award-id>R01AG062659&#8208;01A1</award-id><award-id>K23 AG063993</award-id><award-id>AG080635</award-id><award-id>AG003949</award-id><award-id>1R56AG057548&#8208;01</award-id><award-id>R01AG057548&#8208;01</award-id><award-id>2R01AG039330</award-id><award-id>DK129320&#8208;01 2021&#8208;2026</award-id><award-id>R01AG062659&#8208;01A1</award-id><award-id>K23 AG063993</award-id><award-id>AG080635</award-id><award-id>AG003949</award-id><award-id>1K76AG083274</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Cure Alzheimer's Fund</institution><institution-id institution-id-type="doi">10.13039/100007625</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>NIH (US)</institution></institution-wrap></funding-source></award-group><award-group id="funding-0005"><funding-source><institution-wrap><institution>National Institute on Aging</institution><institution-id institution-id-type="doi">10.13039/100000049</institution-id></institution-wrap></funding-source><award-id>1K76AG083274&#8208;01</award-id></award-group><award-group id="funding-0006"><funding-source><institution-wrap><institution>Leonard and Sylvia Marx Foundation</institution></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="3"/><page-count count="11"/><word-count count="6999"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October-December 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:08.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="dad270197-cite-0001"><string-name name-style="western"><surname>Nallapu</surname><given-names>BT</given-names></string-name>, <string-name name-style="western"><surname>Ezzati</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Blumen</surname><given-names>HM</given-names></string-name>, et&#160;al. <article-title>Discovering subtypes with imaging signatures in the Motoric Cognitive Risk Syndrome Consortium using weakly supervised clustering</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>17</volume>:<elocation-id>e70197</elocation-id>. <pub-id pub-id-type="doi">10.1002/dad2.70197</pub-id></mixed-citation>
</p></notes></front><body><sec id="dad270197-sec-0060"><label>1</label><title>INTRODUCTION</title><p>Dementia is marked by a progressive cognitive and functional decline. Accessible and informative clinical indicators for identifying individuals at risk of incident dementia could enable targeted, earlier and more effective interventions. Like mild cognitive impairment (MCI), Motoric Cognitive Risk Syndrome (MCR) is a pre&#8208;dementia state characterized by subjective cognitive complaints and objectively measured impairment.<xref rid="dad270197-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> While MCI is characterized by reduced performance on objective cognitive tests, MCR is characterized by slow gait speed and subjective cognitive impairment.<xref rid="dad270197-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Studies show that MCR is a significant risk factor for dementia in older adults.<xref rid="dad270197-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> Compared to MCI, MCR does not require neuropsychological assessments, which are time&#8208;consuming. This makes MCR a more efficient and accessible solution for dementia risk stratification in community&#8208;dwelling adults and across various settings, from primary care to specialized neurology clinics <xref rid="dad270197-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>. Both components of MCR, slow gait and subjective cognitive impairment are independently predictive of future cognitive decline and incident dementia &#8211; but the MCR phenotype has higher predictive validity for dementia than either component alone.<xref rid="dad270197-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="dad270197-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>
</p><p>In older adults, slow gait speed can stem from various factors such as neurological issues, muscle&#8208;related conditions, arthritis, or a combination of these factors. Neurodegeneration caused by various dementia etiologies, such as Alzheimer's disease (AD) is considered one of the primary reasons behind declines in both gait speed and cognitive function.<xref rid="dad270197-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> The brain regions known to mediate executive functions (EFs), such as the frontal and prefrontal&#8208;lobe networks also control gait ability.<xref rid="dad270197-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="dad270197-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> These brain regions are involved in integrating information from many cortical sensory systems, and producing goal&#8208;directed actions and behavior.<xref rid="dad270197-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Atrophy in these regions causes both cognitive and gait decline concurrently with the aging process.<xref rid="dad270197-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="dad270197-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Preliminary intervention trials using cognitive training or brain stimulation to enhance EF have also shown improvements in gait velocity.<xref rid="dad270197-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> MCR, despite these shared neuroanatomical pathways, describes people who are still cognitively intact but with cognitive complaints and slowing of gait. The precise neuroanatomical signatures that correspond to the clinical manifestations in MCR, however are unknown. To study the biological underpinnings of MCR, an MCR&#8208;neuroimaging consortium was established across seven cohorts across five different countries and three continents, collecting structural MRIs, gait speeds, cognitive assessments, and other clinical symptoms. This consortium provides a valuable opportunity to study neurodegeneration patterns as identified through structural MRIs and to connect these findings with MCR, its components, and other clinical symptoms.</p><p>There is substantial neuroanatomical heterogeneity in preclinical stages of dementia.<xref rid="dad270197-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> Several studies have linked MCR to specific patterns of brain atrophy, specifically in prefrontal, supplementary motor, insular and motor cortices.<xref rid="dad270197-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="dad270197-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> However, very few data&#8208;driven studies have explored the variability of neuroanatomical patterns in MCR and its components.<xref rid="dad270197-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Therefore, in this study, we adopted a data&#8208;driven machine learning (ML) approach to investigate structural brain differences among participants in the MCR consortium using volumetric imaging. We employed a novel semi&#8208;supervised clustering approach called HYDRA (Heterogeneity through Discriminative Analysis)<xref rid="dad270197-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> to identify subgroups with distinct structural brain patterns within the MCR Consortium. Several other approaches were previously proposed to reveal the inherent disease heterogeneity. But most of these methods either relied on predefined clinical subgroups, ignoring multivariate relationships in the data,<xref rid="dad270197-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="dad270197-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> or applied clustering directly to brain anatomies, risking the identification of normal inter&#8208;individual variability which could be due to confounding factors like sex and age rather than disease&#8208;specific heterogeneity.<xref rid="dad270197-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> The HYDRA method enables us to mitigate these challenges and disentangles the heterogeneity in a population, using another reference population. This was achieved by leveraging data from a reference group composed of individuals with faster gait speeds (population FG, those with gait speed faster than 1 standard deviation (SD) above the population mean within each cohort). Identifying subgroups with homogenous neuroanatomical patterns in a cohort population with gait variability has a potential to further our understanding of biological underpinnings of MCR and in developing interventions for dementia.</p></sec><sec id="dad270197-sec-0070"><label>2</label><title>METHODS</title><sec id="dad270197-sec-0080"><label>2.1</label><title>Participants</title><p>Data from 2007 older adults in the MCR consortium was examined. The data were obtained from seven different cohorts and five different countries. The cohorts were:(i) the Central Control of Mobility in Aging Study (CCMA)<xref rid="dad270197-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="dad270197-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> in the United States, (ii) the LonGenity study<xref rid="dad270197-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> in the United States, (iii) the Einstein Aging Study (EAS)<xref rid="dad270197-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> in the United States, (iv) the Tasmanian Study of Cognition and Gait (TASCOG)<xref rid="dad270197-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="dad270197-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> in Australia, (v) the National Center for Geriatrics and Gerontology&#8211;Study of Geriatric Syndromes (NCGG&#8208;SGS)<xref rid="dad270197-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="dad270197-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> in Japan, (vi) the Kerala&#8208;Einstein Study (KES)<xref rid="dad270197-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> in India, and (vii) the Gait and Alzheimer's Interactions Tracking study (GAIT)<xref rid="dad270197-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> in France. All procedures were approved by the local institutional review boards. All cohorts excluded individuals with prevalent dementia.</p><boxed-text position="float" content-type="box" orientation="portrait"><sec id="dad270197-sec-0090"><title>RESEARCH IN CONTEXT</title><p>
<list list-type="order" id="dad270197-list-0002"><list-item><p>
<bold>Systematic review</bold>: A comprehensive literature review using traditional sources (like PubMed) was conducted. It has been shown that abnormal gait has been shown to be a reliable predictor of non&#8208;Alzheimer dementia. The brain regions that are known to control gait ability are also involved in mediating executive function. Cohort&#8208;based population studies of the Motoric Cognitive Risk Syndrome (MCR), which is characterized both slow gait speed and subjective cognitive complaints, highlight neuroanatomical heterogeneity in older adults.</p></list-item><list-item><p>
<bold>Interpretation</bold>: Our results indicated that different gait speeds can be associated with distinct neuroanatomical patterns and that there could be a negative association between gait speed and impairment in executive function and global cognition.</p></list-item><list-item><p>
<bold>Future directions</bold>: Our results describe the distinct neuroanatomical patterns in a cross&#8208;sectional cohort data. These results should be further validated and explored in longitudinal data to understand the patterns of neurodegeneration over time. The analyses must be further developed considering a more detailed account of comorbidities.</p></list-item></list>
</p></sec></boxed-text><p>Data from all cohorts were used in the analyses. We reserved a subset of population from each cohort as the reference population for the clustering model, that had faster gait speeds (FG).</p><p>This analysis was approved by the institutional review board of the Albert Einstein College of Medicine (Bronx, NY). All participating cohorts have received approval from their local ethics committees.</p></sec><sec id="dad270197-sec-0100"><label>2.2</label><title>Study measures</title><p>Data from all cohorts included population demographics. To harmonize these data and address cohort variability, we followed a standardized process for the preparation of each data modality.</p><sec id="dad270197-sec-0110"><label>2.2.1</label><title>Gait speeds</title><p>Gait speed (cm/s) was available in all studies. In all cohorts, except NCGG&#8208;SGS, it was quantified over 609.6&#160;cm with GAITRite instrumented walkways (GAITRite System &#174; Clifton, NJ). In NCGG&#8208;SGS, it was quantified over 240&#160;cm with the WalkWay MW&#8208;1000 instrumented walkway (Anima Co., Tokyo, Japan). Details of gait speed measurements and quantification were presented in previous studies.<xref rid="dad270197-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="dad270197-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> After normalizing gait speed within each study, individuals with the normalized gait speed greater than 1 SD above the mean were labeled as FG, as 1SD provides clear separation from the &#8220;normal to slower gait&#8221; study population and a balanced sample size. The study population included the remaining individuals with gait speeds less than 1 SD above population mean (normal and slower gait speeds). The FG participants from all the studies were used as the reference population for the HYDRA clustering algorithm.</p></sec><sec id="dad270197-sec-0120"><label>2.2.2</label><title>Volumetric MRI</title><p>Magnetic resonance imaging (MRI) measures were collected at the respective study sites and harmonized at a single site using the Free Surfer pipeline version 6.0. Details on the specific scanner at each site are provided in <xref rid="dad270197-supinfo-0001" ref-type="">Supporting Information</xref>. Images were harmonized for the volumetric measures, using the standard parcellation and correction methods, as described in our previous work.<xref rid="dad270197-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> For this study, we used the volumetric measures of 41 brain regions (Table <xref rid="dad270197-supinfo-0001" ref-type="">S1</xref>), and total intracranial volume (tICV). To account for the individual differences in tICV, within each cohort the volume of each region (VR) was normalized according to the mean tICV of the population within that cohort. The adjusted volume (VRa) of a brain region of an individual was calculated as
<disp-formula id="dad270197-disp-0001"><mml:math id="jats-math-1" display="block"><mml:mrow><mml:mrow><mml:mi>VRa</mml:mi><mml:mo linebreak="badbreak">=</mml:mo><mml:mfenced separators="" open="(" close=")"><mml:mrow><mml:mi>VR</mml:mi><mml:mo>/</mml:mo><mml:mi>tICV</mml:mi></mml:mrow></mml:mfenced><mml:mo>&#8727;</mml:mo><mml:mi>mean</mml:mi><mml:mfenced open="(" close=")"><mml:mi>tICV</mml:mi></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula>
</p></sec><sec id="dad270197-sec-0130"><label>2.2.3</label><title>Neuropsychological evaluations</title><p>For the post&#8208;hoc analyses of objective cognitive scores of different subgroups obtained in our analyses, we used available neuropsychological scores from different studies, normalized per study wherever applicable. The following were the neuropsychological tests that were used: Trail Making Test, Part B (TMT&#8208;B),<xref rid="dad270197-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> Stroop Color Word test,<xref rid="dad270197-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> and Free and Cued Selective Reminding Test (FCSRT).<xref rid="dad270197-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> The details of each test and specific versions are reported in <xref rid="dad270197-supinfo-0001" ref-type="">Supporting Information</xref>.</p></sec><sec id="dad270197-sec-0140"><label>2.2.4</label><title>Diagnosis of MCR</title><p>MCR is characterized by slow gait and cognitive complaints. Slow gait was defined as gait speed lesser than 1 SD below the age and sex&#8208;specific means in each cohort <xref rid="dad270197-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> (see <xref rid="dad270197-supinfo-0001" ref-type="">Supporting Information</xref>). For our study, subjective cognitive complaint was determined using the memory item from Geriatric Depression Scale (GDS) uniformly in all cohorts<xref rid="dad270197-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> or the instrumental activities of daily living (I&#8208;ADL),<xref rid="dad270197-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> where available in cohorts CCMA and KES.</p></sec></sec><sec id="dad270197-sec-0150"><label>2.3</label><title>Analytic approach</title><p>Figure&#160;<xref rid="dad270197-fig-0001" ref-type="fig">1</xref> depicts the study s analytic pipeline. There were 41 brain region volumes available from structural MRI preprocessing using the Free Surfer pipeline. We used factor analyses (FA) to reduce the number of input variables to the clustering model, since some of the brain region volumes are highly correlated and using all of them together in a clustering model may skew and bias the results. FA was performed on the entire study cohort (the combined population of FG and the remaining study population) to ensure that the identified latent factors and their representative regions captured the overall structural variance present across all participants included in the analysis.</p><fig position="float" fig-type="FIGURE" id="dad270197-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Plan of our study. CCMA, Central Control of Mobility in Aging Study in the United States; the LonGenity study in the United States; EAS, Einstein Aging Study in the United States; TASCOG, Tasmanian Study of Cognition and Gait in Australia; NCGG&#8208;SGS, the National Center for Geriatrics and Gerontology&#8211;Study of Geriatric Syndromes in Japan; KES, Kerala&#8208;Einstein Study in India; and GAIT, the Gait and Alzheimer's Interactions Tracking study; ICV, intracranial volume; MRI, magnetic resonance imaging; SD, standard deviation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="DAD2-17-e70197-g001.jpg"/></fig><sec id="dad270197-sec-0160"><label>2.3.1</label><title>FA and weakly&#8208;supervised clustering</title><p>For the FA, we used maximum likelihood estimation and varimax rotation with the 41 regions available as input variables to obtain fewer latent factors relying on a matrix of weights or factor loadings. We choose one variable within each factor that had the highest loading to make the feature set (Regions<sub>Factor</sub>) for the subsequent clustering model. Though other methods exist using representative loadings from each factor, using one high factor loading (e.g., |0.4| or higher) indicates that a variable strongly represents the underlying factor<xref rid="dad270197-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> simplifying inputs to the downstream model and balancing dimensionality reduction with anatomical interpretability. We used a variant of clustering model, a weakly&#8208;supervised algorithm called HYDRA, that also considers the characteristics of the FG group with faster gait speeds as reference, such that the population to be clustered can be simultaneously separated from the controls FG while quantifying the heterogeneity within the population through their association to the sub&#8208;classifiers that separate them from the reference group.<xref rid="dad270197-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Age and sex were added as covariates in HYDRA, due to their well&#8208;established influence on both brain structure and gait speed.<xref rid="dad270197-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> More details are reported under <xref rid="dad270197-supinfo-0001" ref-type="">Supporting Information</xref>.</p></sec><sec id="dad270197-sec-0170"><label>2.3.2</label><title>Statistical analyses</title><p>We examined the descriptive features of the entire population, each cohort, and subgroups resulted from clustering. The demographic variables such as age, sex, education, and ethnicity were included in the descriptive characteristics (see <xref rid="dad270197-supinfo-0001" ref-type="">Supporting Information</xref> for details).</p><p>All the data preprocessing, FA, and HYDRA clustering were performed using Python with scikit&#8208;learn library for FA and mlni package for HYDRA clustering.<xref rid="dad270197-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Statistical analyses used R statistical software, version 4.2.2 for MacOS.</p></sec></sec></sec><sec id="dad270197-sec-0180"><label>3</label><title>RESULTS</title><sec id="dad270197-sec-0190"><label>3.1</label><title>Population characteristics</title><p>A total of 1987 participants were included in the final clustering model after excluding those with missing volumetric MRI data or outliers (mean age [MA], 71.73&#160;&#177;&#160;6.87 years; 47.7% female). There were 294 participants in the reference FG group (MA, 69.30&#160;&#177;&#160;5.52 years; 47.3% female) and 1693 participants in the remaining study population (MA, 72.15&#160;&#177;&#160;6.99 years; 47.8% female). The FG group had younger population compared to the study population (<italic toggle="yes">p</italic>&#160;&lt;&#160;0.001, effect size of &#8208;0.52). Both groups differed in the mean years of education of the population (<italic toggle="yes">p</italic>&#160;=&#160;0.03, effect size of 0.14). There was no sex differences found between the groups. Both groups did not significantly differ in cohort membership. The reference group FG differed from the study population in the proportion of participants with MCR diagnosis as defined by &#8216;slow gait&#8217;, depending on threshold specific to the cohort, and subjective cognitive complaint as determined by either GDS or ADL (3.3% in the FG group, 13.3% in the study population, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001) (see Table&#160;<xref rid="dad270197-tbl-0001" ref-type="table">1</xref>).</p><table-wrap position="float" id="dad270197-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Study characteristics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">All participants</th><th align="left" rowspan="1" colspan="1">FG</th><th align="left" rowspan="1" colspan="1">Group A</th><th align="left" rowspan="1" colspan="1">Group B</th><th align="left" rowspan="1" colspan="1">Group C</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>
</td><td align="left" rowspan="1" colspan="1">1987</td><td align="left" rowspan="1" colspan="1">294</td><td align="left" rowspan="1" colspan="1">585</td><td align="left" rowspan="1" colspan="1">455</td><td align="left" rowspan="1" colspan="1">653</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age, mean (SD), y</td><td align="left" rowspan="1" colspan="1">71.73(&#177;&#160;6.87)</td><td align="left" rowspan="1" colspan="1">69.30(&#177;&#160;5.52)</td><td align="left" rowspan="1" colspan="1">72.07(&#177;&#160;6.80)</td><td align="left" rowspan="1" colspan="1">70.94(&#177;&#160;6.77)</td><td align="left" rowspan="1" colspan="1">73.06(&#177;&#160;7.18)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex, female (%)</td><td align="left" rowspan="1" colspan="1">948(47.7%)</td><td align="left" rowspan="1" colspan="1">139(47.3%)</td><td align="left" rowspan="1" colspan="1">277(47.4%)</td><td align="left" rowspan="1" colspan="1">229(50.3%)</td><td align="left" rowspan="1" colspan="1">303(46.4%)</td><td align="left" rowspan="1" colspan="1">0.625</td></tr><tr><td align="left" rowspan="1" colspan="1">Education, mean (SD), y<xref rid="dad270197-tbl1-note-0002" ref-type="table-fn">
<sup>#</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">12.30(&#177;&#160;3.50)</td><td align="left" rowspan="1" colspan="1">12.73(&#177;&#160;3.70)</td><td align="left" rowspan="1" colspan="1">12.27(&#177;&#160;3.51)</td><td align="left" rowspan="1" colspan="1">12.39(&#177;&#160;3.22)</td><td align="left" rowspan="1" colspan="1">12.08(&#177;&#160;3.56)</td><td align="left" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" rowspan="1" colspan="1">Race/ethnicity, N(%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.016</td></tr><tr><td align="left" rowspan="1" colspan="1">Asian</td><td align="left" rowspan="1" colspan="1">1146(57.7%)</td><td align="left" rowspan="1" colspan="1">176(59.9%)</td><td align="left" rowspan="1" colspan="1">329(56.2%)</td><td align="left" rowspan="1" colspan="1">282(62.0%)</td><td align="left" rowspan="1" colspan="1">359(55.0%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">White</td><td align="left" rowspan="1" colspan="1">769(38.7%)</td><td align="left" rowspan="1" colspan="1">112(38.1%)</td><td align="left" rowspan="1" colspan="1">225(38.5%)</td><td align="left" rowspan="1" colspan="1">160(35.2%)</td><td align="left" rowspan="1" colspan="1">272(41.7%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Other<xref rid="dad270197-tbl1-note-0003" ref-type="table-fn">
<sup>*</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">59(3.6%)</td><td align="left" rowspan="1" colspan="1">2(2.0%)</td><td align="left" rowspan="1" colspan="1">27(5.3%)</td><td align="left" rowspan="1" colspan="1">9(2.8%)</td><td align="left" rowspan="1" colspan="1">21(3.3%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Gait speed, cm/s</td><td align="left" rowspan="1" colspan="1">108.42(&#177;&#160;22.85)</td><td align="left" rowspan="1" colspan="1">141.21(&#177;&#160;11.52)</td><td align="left" rowspan="1" colspan="1">104.91(&#177;&#160;17.05)</td><td align="left" rowspan="1" colspan="1">103.79(&#177;&#160;18.28)</td><td align="left" rowspan="1" colspan="1">100.04(&#177;&#160;21.34)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">MCR, Positive<xref rid="dad270197-tbl1-note-0004" ref-type="table-fn">
<sup>**</sup>
</xref>, N(%)</td><td align="left" rowspan="1" colspan="1">117(6.6%,N&#160;=&#160;1778)</td><td align="left" rowspan="1" colspan="1">&#8211;</td><td align="left" rowspan="1" colspan="1">38(7.4%,N&#160;=&#160;515)</td><td align="left" rowspan="1" colspan="1">26(6.4%,N&#160;=&#160;405)</td><td align="left" rowspan="1" colspan="1">53(9%,N&#160;=&#160;588)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn id="dad270197-tbl1-note-0001"><p>Abbreviations: FG, fast gait, a subgroup of participants with gait speed greater than 1 standard deviation above mean; Groups A,B, and C, gait speed lower than 1 SD above cohort specific mean; Subgroups obtained by the clustering model. <italic toggle="yes">p</italic>&#8208;Values reported for significant differences between FG and Subgroups</p></fn><fn id="dad270197-tbl1-note-0002"><label>
<sup>#</sup>
</label><p>Education was not available for the GAIT cohort.</p></fn><fn id="dad270197-tbl1-note-0003"><label>*</label><p>Other in race/ethnicity included primarily Black (3.0% of total population), Hispanic Black, Hispanic White and others.</p></fn><fn id="dad270197-tbl1-note-0004"><label>**</label><p>MCR positive is defined as slow gait (as defined by a cohort specific threshold) and any cognitive complaint in Geriatric Depression Scale (GDS) or activities of daily living (ADL) questionnaire.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="dad270197-sec-0200"><label>3.2</label><title>Factor analyses</title><p>We found 8 factors and conducted FA with them. Table <xref rid="dad270197-supinfo-0001" ref-type="">S1</xref> summarizes the factor loadings of each variable for all eight factors. For simplicity, we presented only those variables which had loadings of at least 0.4 in any factor. We chose one variable (region) from each factor that had the highest loading as the input for clustering model. The eight regions that were chosen to be the input features for the clustering model, Regions<sub>Factor</sub> were the following: accumbens area, caudate, banks of the superior temporal sulcus (banksSTS), caudal anterior cingulate, entorhinal cortex, pars triangularis, pericalcarine, and precentral gyrus.</p></sec><sec id="dad270197-sec-0210"><label>3.3</label><title>HYDRA clustering analyses</title><p>We obtained three subgroups within the study population from HYDRA, with an adjusted Rand index (ARI) of 0.1. We performed statistical analyses to assess the differences across the three subgroups, Group A, Group B, and Group C, between each of them as well as with respect to the FG group. Table&#160;<xref rid="dad270197-tbl-0001" ref-type="table">1</xref> summarizes population characteristics in each subgroup. Of the 1693 individuals, 585 were grouped under Group A (mean age, 72.07&#160;&#177;&#160;6.80 years; 47.4% female), 455 were grouped under Group B (mean age&#160;&#177;&#160;SD, 70.94&#160;&#177;&#160;6.77 years; 50.3% female), and 653 under Group C (mean age, 73.06&#160;&#177;&#160;7.18 years; 46.4% female). The mean gait speed (&#177;&#160;SD) in Group A was 104.91(&#177;&#160;17.05), 103.79(&#177;&#160;18.28) in Group B and 100.04(&#177;&#160;21.34) in Group C.</p></sec><sec id="dad270197-sec-0220"><label>3.4</label><title>Heterogeneity in brain patterns in the MCR Consortium participants</title><p>Post&#8208;hoc pairwise group comparisons revealed significant differences across the subgroups for most of the regions (Table <xref rid="dad270197-supinfo-0001" ref-type="">S2</xref> and Figure&#160;<xref rid="dad270197-fig-0002" ref-type="fig">S2</xref>, Factors). Among all the subgroups, Group A had the highest volumes of accumbens area (mean <italic toggle="yes">z</italic>&#8208;score of 0.481&#160;&#177;&#160;0.140), followed by group FG (0.434&#160;&#177;&#160;0.126), Group B (0.425&#160;&#177;&#160;0.106) and Group C (0.329&#160;&#177;&#160;0.106). Group A had the highest volumes of caudal anterior cingulate (mean <italic toggle="yes">z</italic>&#8208;score of 0.513&#160;&#177;&#160;0.117), followed by Group B (0.478&#160;&#177;&#160;0.113), FG (0.465&#160;&#177;&#160;0.126), and Group C (0.392&#160;&#177;&#160;0.118). Except Groups FG and B, all the pairs of groups differed significantly in their volumes of accumbens area and caudal anterior cingulate (<italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001). All the pairs of subgroups differed significantly in their volumes of banksSTS, parstriangularis, pericalcarine, and precentral gyrus. While Group A had the highest volume of banksSTS and precentral gyrus, Group B had the highest volume of parstriangularis and pericalcarine. Group B and FG did not differ significantly in their precentral gyrus volumes.</p><fig position="float" fig-type="FIGURE" id="dad270197-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Subgroup differences in MRI volumes by regions: group differences in MRI volumes. PreCen, precentral gyrus; EC,&#160;entorhinal cortex; ParsTri,&#160;pars triangularis; BanksSTS,&#160;banks of superior temporal sulcus; PeriCal,&#160;pericalcarine; Cau,&#160;caudate nucleus; CauACC,&#160;caudal anterior cingulate; AccArea,&#160;nucleus accumbens; FRO,&#160;frontal cortex; PAR,&#160;parietal cortex; TEM,&#160;temporal lobe; OCC,&#160;occipital lobe; HIPP,&#160;hippocampus; CEREB, cerebellar cortex; SUBCORT,&#160;subcortical regions (basal ganglia nuclei, amygdala, thalamus.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="DAD2-17-e70197-g002.jpg"/></fig><p>Next, we combined the brain region volumes into respective cortical, subcortical, and other regions that were generally implied in MCR and dementia, that is, cortical/subcortical (C/S) regions of interest (ROIs) are frontal, temporal, parietal, occipital, hippocampus, cerebellum, and subcortical (basal ganglia nuclei, amygdala, and thalamus). We repeated the analysis of covariance (ANCOVA) analyses and post&#8208;hoc pairwise comparisons to examine the differences across the subgroups. Differences in the C/S ROIs between the subgroups are reported in Table <xref rid="dad270197-supinfo-0001" ref-type="">S3</xref>; Figure&#160;<xref rid="dad270197-fig-0002" ref-type="fig">S2</xref>, Cortical). Group B did not show any significant differences in the volumes of C/S ROIs compared to FG, except in the occipital lobe. Group A showed significant differences in all the C/S ROI volumes compared to Group B, except in the occipital lobe. Group A had the highest volumes across all the C/S ROIs while Group C had the least. Group C showed significant differences in all the C/S ROI volumes compared to FG, except in the subcortical regions. Group C showed significant differences in the all the C/S ROI volumes compared to Group B, except in the cerebellum and subcortical regions. Finally, Group C and Group A differed across all the C/S ROI volumes.</p></sec><sec id="dad270197-sec-0230"><label>3.5</label><title>Heterogeneity in gait speeds and cognition in the MCR Consortium participants</title><p>Analysis of Covariance (ANCOVA) analyses showed that the subgroups differed in their gait speeds. A post&#8208;hoc analysis was performed to evaluate subgroups differences. While Group B did not show a significant difference with either Group A or Group C, the mean gait speed of Group A was higher than that of Group C (&#8722;0.192&#160;&#177;&#160;0.739&#160;vs. &#8722;0.364&#160;&#177;&#160;0.864, <italic toggle="yes">p</italic>&#160;=&#160;0.003). In the ANCOVA analyses with each cognitive score as the outcome, all subgroups differed in their TMT&#8208;B and FR96 scores but not in their Stroop&#8208;INT scores. For TMT&#8208;B, the FG group had better scores (mean&#160;&#177;&#160;SD: &#8722;0.354&#160;&#177;&#160;0.892) compared to Group B (&#8722;0.066&#160;&#177;&#160;0.906, <italic toggle="yes">p</italic>&#160;=&#160;0.03), Group A (&#8722;0.044&#160;&#177;&#160;0.905, <italic toggle="yes">p</italic>&#160;=&#160;0.05), and Group C (0.174&#160;&#177;&#160;1.153, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001). Within the subgroups, only Groups A and C showed a significant difference (<italic toggle="yes">p</italic>&#160;=&#160;0.02). Regarding FR96 scores, the FG group had higher scores (0.599&#160;&#177;&#160;0.716) compared to Group C (&#8722;0.125&#160;&#177;&#160;1.136, <italic toggle="yes">p</italic>&#160;=&#160;0.02). Group A also had higher scores (0.389&#160;&#177;&#160;0.778) compared to Group C (<italic toggle="yes">p</italic>&#160;=&#160;0.01). The groups did not show significant differences in their Stroop&#8208;Int scores. Table&#160;<xref rid="dad270197-tbl-0002" ref-type="table">2</xref> and Figure&#160;<xref rid="dad270197-fig-0003" ref-type="fig">3</xref> summarize the ANCOVA and post&#8208;hoc pairwise comparison results for gait speed and cognitive scores across the subgroups.</p><table-wrap position="float" id="dad270197-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Pairwise subgroup differences in gait speed and cognition.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Measure</th><th align="left" rowspan="1" colspan="1">FG</th><th align="left" rowspan="1" colspan="1">Group A</th><th align="left" rowspan="1" colspan="1">Group B</th><th align="left" rowspan="1" colspan="1">Group C</th><th align="left" rowspan="1" colspan="1">P&#8208;value</th><th align="left" rowspan="1" colspan="1">Group A&#8212;FG</th><th align="left" rowspan="1" colspan="1">Group B&#8212;FG</th><th align="left" rowspan="1" colspan="1">Group C&#8212;FG</th><th align="left" rowspan="1" colspan="1">Group A&#8212;group B</th><th align="left" rowspan="1" colspan="1">Group C&#8212;Group A</th><th align="left" rowspan="1" colspan="1">Group C&#8212;group B</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gait speed (Z&#8208;score)</td><td align="left" rowspan="1" colspan="1">1.531 (&#177;&#160;0.466)</td><td align="left" rowspan="1" colspan="1">&#8722;0.192 (&#177;&#160;0.739)</td><td align="left" rowspan="1" colspan="1">&#8722;0.223 (&#177;&#160;0.793)</td><td align="left" rowspan="1" colspan="1">&#8722;0.364 (&#177;&#160;0.864)</td><td align="left" rowspan="1" colspan="1">
<xref rid="dad270197-tbl2-note-0002" ref-type="table-fn">
<sup>***</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="dad270197-tbl2-note-0002" ref-type="table-fn">
<sup>***</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="dad270197-tbl2-note-0002" ref-type="table-fn">
<sup>***</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="dad270197-tbl2-note-0002" ref-type="table-fn">
<sup>***</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">0.58</td><td align="left" rowspan="1" colspan="1">0.003<xref rid="dad270197-tbl2-note-0003" ref-type="table-fn">
<sup>**</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">0.22</td></tr><tr><td align="left" rowspan="1" colspan="1">Cognition</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TMT&#8208;B</td><td align="left" rowspan="1" colspan="1">&#8722;0.354 (&#177;&#160;0.892)</td><td align="left" rowspan="1" colspan="1">&#8722;0.044 (&#177;&#160;0.905)</td><td align="left" rowspan="1" colspan="1">&#8722;0.066 (&#177;&#160;0.906)</td><td align="left" rowspan="1" colspan="1">0.174 (&#177;&#160;1.153)</td><td align="left" rowspan="1" colspan="1">
<xref rid="dad270197-tbl2-note-0002" ref-type="table-fn">
<sup>***</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">0.05<xref rid="dad270197-tbl2-note-0004" ref-type="table-fn">
<sup>*</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">0.03<xref rid="dad270197-tbl2-note-0004" ref-type="table-fn">
<sup>*</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="dad270197-tbl2-note-0002" ref-type="table-fn">
<sup>***</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">0.98</td><td align="left" rowspan="1" colspan="1">0.02<xref rid="dad270197-tbl2-note-0004" ref-type="table-fn">
<sup>*</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="1" colspan="1">FR96</td><td align="left" rowspan="1" colspan="1">0.599 (&#177;&#160;0.716)</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">0.148 (&#177;&#160;0.871)</td><td align="left" rowspan="1" colspan="1">&#8722;0.125 (&#177;&#160;1.136)</td><td align="left" rowspan="1" colspan="1">0.005<xref rid="dad270197-tbl2-note-0003" ref-type="table-fn">
<sup>**</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">0.95</td><td align="left" rowspan="1" colspan="1">0.23</td><td align="left" rowspan="1" colspan="1">0.02<xref rid="dad270197-tbl2-note-0004" ref-type="table-fn">
<sup>*</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">0.31</td><td align="left" rowspan="1" colspan="1">0.01<xref rid="dad270197-tbl2-note-0004" ref-type="table-fn">
<sup>*</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">0.61</td></tr><tr><td align="left" rowspan="1" colspan="1">Stroop&#8208;INT</td><td align="left" rowspan="1" colspan="1">&#8722;0.025 (&#177;&#160;0.918)</td><td align="left" rowspan="1" colspan="1">0.069 (&#177;&#160;1.175)</td><td align="left" rowspan="1" colspan="1">0.061 (&#177;&#160;0.923)</td><td align="left" rowspan="1" colspan="1">0.076 (&#177;&#160;1.122)</td><td align="left" rowspan="1" colspan="1">0.99</td><td align="left" rowspan="1" colspan="1">&#8211;</td><td align="left" rowspan="1" colspan="1">&#8211;</td><td align="left" rowspan="1" colspan="1">&#8211;</td><td align="left" rowspan="1" colspan="1">&#8211;</td><td align="left" rowspan="1" colspan="1">&#8211;</td><td align="left" rowspan="1" colspan="1">&#8211;</td></tr></tbody></table><table-wrap-foot><fn id="dad270197-tbl2-note-0001"><p>Abbreviation FG, population with fast gait, gait speed greater than 1SD above population&#8208;mean; Groups A, B, and C, result of HYDRA Clustering of the remaining population (gait speed slower than 1 SD above population&#8208;mean); <italic toggle="yes">p</italic>&#8208;value, significance Pr(&gt;&#160;F) in ANCOVA corrected for age and sex; Pairwise comparisons: Multiple Comparisons of Means with Tukey Contrasts. TMT&#8208;B: Trail Making Test, Part B, log&#8208;transformed, z&#8208;score normalized, available in CCMA, LonGenity, EAS, NCGG&#8208;SGS, Kes and GAIT, Stroop&#8208;INT:Stroop Color Word test, consisting of subtests measuring time required to name the colors seen (COLOR), read the given words (WORD) and name the color of the printed word (COLOR_WORD); Stroop&#8208;INTthe difference between the third subtask and the first task (COLOR_WORD&#8212;COLOR), available in EAS, TASCOG, and GAIT; FR96, Free and Cued Selective Reminding Test (FCSRT), a recall test that uses either words or images. Scores include the sum of free recall (FR) alone (range 0&#8208;48) and combined with cued recall as total recall (TR); FR96, the sum of FR and TR (range 0&#8208;96); available in CCMA, EAS, and LonGenity.</p></fn><fn id="dad270197-tbl2-note-0002"><label>***</label><p>
<italic toggle="yes">p</italic>&#8208;values&#160;&lt;&#160;0.0001.</p></fn><fn id="dad270197-tbl2-note-0003"><label>**</label><p>
<italic toggle="yes">p</italic>&#8208;values &lt; 0.001.</p></fn><fn id="dad270197-tbl2-note-0004"><label>*</label><p>
<italic toggle="yes">p</italic>&#8208;values &lt; 0.01</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><fig position="float" fig-type="FIGURE" id="dad270197-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Subgroup differences in cognition by regions: group differences in gait speed and cognition. TMT&#8208;B, Trail Making Test, Part B; log&#8208;transformed, z&#8208;score normalized, available in CCMA, LonGenity, EAS, NCGG&#8208;SGS, KES, and GAIT; FR96, Free and Cued Selective Reminding Test (FCSRT), a recall test that uses either words or images. Scores include the sum of free recall (FR) alone (range 0&#8208;48) and combined with cued recall as total recall (TR). FR96: the sum of FR and TR (range 0&#8208;96); available in CCMA, EAS, and LonGenity; Stroop&#8208;INT, Stroop color word test, consisting of subtests measuring time required to name the colors seen (COLOR), read the given words (WORD), and name the color of the printed word (COLOR_WORD); Stroop&#8208;INT: the difference between the third subtask and the first task (COLOR_WORD&#8212;COLOR) available in EAS, TASCOG, and GAIT.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="DAD2-17-e70197-g003.jpg"/></fig></sec></sec><sec id="dad270197-sec-0240"><label>4</label><title>DISCUSSION</title><p>The MCR Consortium includes over 2000 MRIs from older adults without dementia from multiple locations worldwide. It provides a valuable repository of neuroimaging and other measures for understanding MCR as a crucial risk factor for dementia. Using a novel data&#8208;driven ML approach, we explored the heterogeneity among those with fast and normative gait speeds (slower than 1 SD above the population mean), while accounting for the distinct neuroanatomical patterns that separate each subgroup from the population with fast gait speeds. Among the participants without dementia and gait speeds in the normal to slow range, we found three subgroups which significantly differed in the patterns of brain regional volumes, gait speeds, and cognitive performance (Table&#160;<xref rid="dad270197-tbl-0003" ref-type="table">3</xref>). Group A had slower gait speeds compared to the reference FG group and largest volumes of cortical and subcortical regions. Group B had intermediate gait speeds and cortical volumes like the reference group. Group C had the slowest gait speeds, the smallest overall regional brain volumes in most brain regions and the highest prevalence of MCR. The subgroups also differed in their performance in TMT&#8208;B and FCSRT.</p><table-wrap position="float" id="dad270197-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>MCR Consortium participant subgroup characteristics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Group</th><th align="left" rowspan="1" colspan="1">Gait speed, imaging, and cognition</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Fast gait (FG)</td><td align="left" rowspan="1" colspan="1">Reference group, used by the clustering algorithm</td></tr><tr><td align="left" rowspan="1" colspan="1">Gait speed&#160;&gt; mean+1SD</td><td align="left" rowspan="1" colspan="1">Best scores in FCSRT and TMT&#8208;B, No cortical or subcortical atrophy</td></tr><tr><td align="left" rowspan="1" colspan="1">Study Population Gait Speed&#160;&lt; mean+1SD</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Group A</td><td align="left" rowspan="1" colspan="1">Fastest gait, largest volumes across almost all ROIs</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Group B</td><td align="left" rowspan="1" colspan="1">Intermediate gait speed, similar cortical volumes as reference group</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">
<italic toggle="yes">&#8195;Group C</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">Slowest gait, lowest cortical volumes, highest prevalence of MCR</italic>
</td></tr></tbody></table><table-wrap-foot><fn id="dad270197-tbl3-note-0001"><p>Abbreviation: FG, population with fast gait, gait speed greater than 1SD above population&#8208;mean; Groups A,B&amp;C, result of HYDRA Clustering of the remaining population (gait speed slower than 1 SD above population&#8208;mean); <italic toggle="yes">p</italic>&#8208;value, significance Pr(&gt;&#160;F) in ANCOVA corrected for age and sex; pairwise comparisons, multiple comparisons of means with Tukey contrasts; SD, standard deviation; TMT&#8208;B, Trail Making Test, Part B; log&#8208;transformed, z&#8208;score normalized, available in CCMA, LonGenity, EAS, NCGG&#8208;SGS, KES, and GAIT; FCSRT, Free and Cued Selective Reminding Test (FCSRT), a recall test that uses either words or images. Scores include the sum of free recall (FR) alone (range 0&#8208;48) and combined with cued recall as total recall (TR); FR96, the sum of FR and TR (range 0&#8208;96); available in CCMA, EAS, and LonGenity.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>Abnormal gait has been shown to be a reliable predictor of non&#8208;Alzheimer's dementia.<xref rid="dad270197-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> Since slowing of gait speed precedes cognitive decline,<xref rid="dad270197-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> understanding the heterogeneity related to gait speed patterns can be very valuable in characterizing predementia syndromes such as MCR. MCR, which is characterized by slow gait and subjective cognitive impairment, depends on varying thresholds to determine slow gait ranging from 44.4 to101.9&#160;cm/s among men and 36.9 to 97.4&#160;cm/s among women as observed across different study locations.<xref rid="dad270197-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> In our analyses, instead of studying abnormal gait using fixed thresholds, we considered a broader group of older population without dementia with gait speeds that are fast or normative (less than 1 SD above population mean). We were interested in studying neuroanatomical patterns within this population in relation to their gait speed and in exploring possible differences in their cognition. As hypothesized, we found homogenous subgroups that showed significant differences in their mean gait speeds accompanied by corresponding distinct neuroanatomical patterns as shown by differences in their brain region volumes. The subgroup with the slowest mean gait speed (Group C) had the least volumes across the prefrontal, temporal, and parietal cortex regions, hippocampus and cerebellar cortex than any other subgroups, resembling a pathological pattern of an MCR subtype accompanied by olfactory dysfunction that is more likely to be associated with Alzheimer and Lewy body dementias.<xref rid="dad270197-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> Our results were consistent with the previous MCR studies that showed higher association of lower cortical gray matter volumes and total hippocampal volumes with incident MCR.<xref rid="dad270197-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="dad270197-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="dad270197-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> Similar results were observed across the regions that were used in the clustering model, except for the caudate nucleus, for which no significant difference was found across any of the groups. Interestingly, Group A, which had a slower mean gait speed compared to the reference fast gait group had higher brain region volumes across prefrontal, hippocampal, temporal, parietal regions. We could not find a specific neuroanatomical pattern that could explain why Group A had slower gait speeds and greater brain region volumes than the reference group FG. This finding might be explainable by other comorbidities. However, due to the lack of detailed data on these comorbidities, we could not study them in the context of the current study.</p><p>Prior studies link MCR syndrome to poorer performance in attention, memory, and global cognition with gait attributes like speed and stride length associated with specific cognitive domains adults.<xref rid="dad270197-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>, <xref rid="dad270197-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> In our analysis, all slow&#8208;gait subgroups performed worse than the faster gait group on TMT&#8208;B and FCSRT (FR96). TMT&#8208;B scores differed across most subgroups (except A vs. B), reinforcing the link between executive function and gait.<xref rid="dad270197-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="dad270197-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> Only the slowest subgroup (C) showed significantly lower FR96 scores. No subgroup differences were observed in cued recall or Stroop&#8208;Interference likely due to the dementia&#8208;free baseline. This aligns with prior evidence linking slower gait to executive and global cognitive decline.<xref rid="dad270197-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>, <xref rid="dad270197-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>, <xref rid="dad270197-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>
</p><p>There are few notable limitations in our study. We did not have consistent data across cohorts on musculoskeletal or peripheral contributors to gait slowing (e.g., joint pain, arthritis), limiting our ability to adjust for these potential confounders. Future studies should incorporate such measures to better isolate neuroanatomical contributions from peripheral ones. While the cross&#8208;sectional design limits causal inference, future longitudinal analyses could reveal whether neuroanatomic subgroups with distinct gait patterns follow different cognitive or motor trajectories. A future direction of study could be whether these subgroups that differ in their neuroanatomic and gait speed patterns, show different trajectories in their gait speed slowdown or cognitive decline. Although in the case of MCR it was shown that cortical thickness detected neurodegeneration easier than cortical volumes,<xref rid="dad270197-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> it was shown that cortical volume can be more sensitive to detecting changes in brain structure associated with aging and neurodegenerative processes<xref rid="dad270197-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> and numerous studies have successfully used cortical volumes in ML models for various neurological conditions.<xref rid="dad270197-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref>, <xref rid="dad270197-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> The effects of using cortical thickness on the resulting subgroups should be further explored. While the novel approach combining factor analysis with weakly&#8208;supervised clustering is not tailored specifically for gait&#8208;neuroanatomy associations, it effectively addresses collinearity in brain volumes. However, the adding only one region from each factor as a feature to the HYDRA algorithm, while clinically interpretable may lose crucial information from the variance of regions not included. Finally, as the data used in our study is from various cohorts/study sites, within&#8208;study normalization of gait speeds does not account for differences in demographic and clinical characteristics across these study sites<xref rid="dad270197-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref>, <xref rid="dad270197-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref> (See Table <xref rid="dad270197-supinfo-0001" ref-type="">S4</xref> for differences in demographic, clinical characteristics, and gait speeds across study sites.) and therefore we accounted for age and sex differences in our model. Similarly, since the images were not collected particularly for our study focusing on MCR, harmonization, and standardization of acquisition protocols are needed to further address the challenges related to consistency of measurements. While this is indeed a well&#8208;recognized and complex challenge in multi&#8208;site neuroimaging studies,<xref rid="dad270197-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref> the image processing pipeline used to obtain the volumetric data used in our study &#8211; Free Surfer 6.0 has been shown to be quite reliable across scans and centers.<xref rid="dad270197-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>, <xref rid="dad270197-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> In addition, cognitive performance comparisons across subgroups may lack generalizability due to variability in test types and availability across cohorts. Future work using harmonized, longitudinal cognitive data and other recent generative methods <xref rid="dad270197-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> could better characterize heterogeneity, subtypes, and disease progression in gait impairments and MCR.</p><p>Our work highlights the potential of uncovering hidden heterogeneity in individuals with slow gait, an at&#8208;risk group for MCR and dementia. By identifying distinct subgroups based on brain volume patterns and related biomarkers, we enhance the understanding of the underlying pathophysiology and support early, stratified intervention strategies. Our methodology effectively handles complex multi&#8208;site neuroimaging data, offering a robust framework for precision health in aging and dementia research. This contributes to more targeted approaches for early detection and prevention of cognitive decline.</p></sec><sec sec-type="COI-statement" id="dad270197-sec-0260"><title>CONFLICTS OF INTEREST STATEMENT</title><p>H.M.B. serves as a consultant for Neural+. R.B.L. is the Edwin S. Lowe Professor of Neurology at the Albert Einstein College of Medicine in New York. He also receives support from the Migraine Research Foundation and the National Headache Foundation and research grants from TEVA, Satsuma and Amgen. He serves on the editorial board of Neurology, senior advisor to Headache, and associate editor to Cephalalgia. He has reviewed for the NIA and NINDS, holds stock and stock options in Axon, Biohaven Holdings, CoolTech and Manistee; serves as consultant, advisory board member, or has received honoraria from: Abbvie (Allergan), American Academy of Neurology, American Headache Society, Amgen, Avanir, Axon, Axsome, Biohaven, Biovision, Boston Scientific, Dr. Reddy's (Promius), Electrocore, Eli Lilly, eNeura Therapeutics, Equinox, GlaxoSmithKline, Grifols, Lundbeck (Alder), Manistee, Merck, Pernix, Pfizer, Satsuma, Supernus, Teva, Trigemina, Vector, Vedanta. He receives royalties from Wolff's Headache 7th and 8th Edition, Oxford Press University, 2009, Wiley and Informa. J.V. serves as an Advisory Committee Member for MedRhythms, and a holds an uncompensated voluntary position at CatchU. Authors B.T.N., A.E., K.K.P., E.A., V.G.P.K., S.V., R.B., O.B., T.D., H.S., M.C., S.M., and S.A. do not have any conflicts of interest to disclose. Author disclosures are available in the <xref rid="dad270197-supinfo-0001" ref-type="">Supporting Information</xref>
</p></sec><sec id="dad270197-sec-0270"><title>CONSENT STATEMENT</title><p>All human subjects across all the study locations provided informed consent.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="dad270197-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="dad270197-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="DAD2-17-e70197-s001.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="dad270197-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="DAD2-17-e70197-s002.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="dad270197-sec-0250"><title>ACKNOWLEDGMENTS</title><p>The authors gratefully acknowledge the contributions of the participants, families, and study staff from all the studies in the consortium that provided the data for this research. We also thank the funding agencies and institutions that have supported these studies. This study was supported by NIH/NIAgrants: 1R56AG057548&#8208;01, R01AG057548&#8208;01A1 and 2R01AG039330 (J.V.), NIH RO1 DK129320&#8208;01 2021&#8208;2026 (R.B.), NIA R01AG062659&#8208;01A1 (H.B.), NIA K23 AG063993, AG080635, AG003949, the Alzheimer's Association (SG&#8208;24&#8208;988292 ISAVRAD); Cure Alzheimer's Fund, the Leonard and Sylvia Marx Foundation (A.E., R.L.), NIH/NIA 1K76AG083274 (S.A.). None of the funding sources had any role in the</p></ack><ref-list id="dad270197-bibl-0001"><title>REFERENCES</title><ref id="dad270197-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="dad270197-cite-0002"><string-name name-style="western"><surname>Campbell</surname><given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>Unverzagt</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>LaMantia</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Boustani</surname><given-names>MA</given-names></string-name>. <article-title>Risk Factors for the Progression of Mild Cognitive Impairment to Dementia</article-title>. <source>Clin Geriatr Med</source>. <year>2013</year>;<volume>29</volume>(<issue>4</issue>):<fpage>873</fpage>&#8208;<lpage>893</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cger.2013.07.009</pub-id><pub-id pub-id-type="pmid">24094301</pub-id><pub-id pub-id-type="pmcid">PMC5915285</pub-id></mixed-citation></ref><ref id="dad270197-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="dad270197-cite-0003"><string-name name-style="western"><surname>Verghese</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lipton</surname><given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Holtzer</surname><given-names>R</given-names></string-name>. <article-title>Motoric cognitive risk syndrome and the risk of dementia</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2013</year>;<volume>68</volume>(<issue>4</issue>):<fpage>412</fpage>&#8208;<lpage>418</lpage>. doi:<pub-id pub-id-type="doi">10.1093/gerona/gls191</pub-id><pub-id pub-id-type="pmid">22987797</pub-id><pub-id pub-id-type="pmcid">PMC3593614</pub-id></mixed-citation></ref><ref id="dad270197-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dad270197-cite-0004"><string-name name-style="western"><surname>Meiner</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Ayers</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Verghese</surname><given-names>J</given-names></string-name>. <article-title>Motoric Cognitive Risk Syndrome: a Risk Factor for Cognitive Impairment and Dementia in Different Populations</article-title>. <source>Ann Geriatr Med Res</source>. <year>2020</year>;<volume>24</volume>(<issue>1</issue>):<fpage>3</fpage>&#8208;<lpage>14</lpage>. doi:<pub-id pub-id-type="doi">10.4235/agmr.20.0001</pub-id><pub-id pub-id-type="pmid">32743316</pub-id><pub-id pub-id-type="pmcid">PMC7370775</pub-id></mixed-citation></ref><ref id="dad270197-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dad270197-cite-0005"><string-name name-style="western"><surname>Belleville</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Fouquet</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hudon</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zomahoun</surname><given-names>HTV</given-names></string-name>, <string-name name-style="western"><surname>Croteau</surname><given-names>J</given-names></string-name>. <article-title>Disease&#8208;Quebec CftEIoAs. Neuropsychological measures that predict progression from mild cognitive impairment to Alzheimer's type dementia in older adults: a systematic review and meta&#8208;analysis</article-title>. <source>Neuropsychol Rev</source>. <year>2017</year>;<volume>27</volume>:<fpage>328</fpage>&#8208;<lpage>353</lpage>.<pub-id pub-id-type="pmid">29019061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11065-017-9361-5</pub-id><pub-id pub-id-type="pmcid">PMC5754432</pub-id></mixed-citation></ref><ref id="dad270197-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="dad270197-cite-0006"><string-name name-style="western"><surname>Verghese</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ayers</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Barzilai</surname><given-names>N</given-names></string-name>, et&#160;al. <article-title>Motoric cognitive risk syndrome</article-title>. <source>Neurology</source>. <year>2014</year>;<volume>83</volume>(<issue>24</issue>):<fpage>2278</fpage>&#8208;<lpage>2284</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000001084</pub-id><pub-id pub-id-type="pmid">25361778</pub-id><pub-id pub-id-type="pmcid">PMC4277675</pub-id></mixed-citation></ref><ref id="dad270197-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="dad270197-cite-0007"><string-name name-style="western"><surname>Semba</surname><given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Carlson</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Xue</surname><given-names>Q&#8208;L</given-names></string-name>, <string-name name-style="western"><surname>Ferrucci</surname><given-names>L</given-names></string-name>. <article-title>Motoric cognitive risk syndrome: integration of two early harbingers of dementia in older adults</article-title>. <source>Ageing Research Reviews</source>. <year>2020</year>;<volume>58</volume>:<elocation-id>101022</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.arr.2020.101022</pub-id><pub-id pub-id-type="pmid">31996326</pub-id><pub-id pub-id-type="pmcid">PMC7697173</pub-id></mixed-citation></ref><ref id="dad270197-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dad270197-cite-0008"><string-name name-style="western"><surname>Holtzer</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Mahoney</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Verghese</surname><given-names>J</given-names></string-name>. <article-title>Intraindividual variability in executive functions but not speed of processing or conflict resolution predicts performance differences in gait speed in older adults</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2014</year>;<volume>69</volume>(<issue>8</issue>):<fpage>980</fpage>&#8208;<lpage>986</lpage>. doi:<pub-id pub-id-type="doi">10.1093/gerona/glt180</pub-id><pub-id pub-id-type="pmid">24285744</pub-id><pub-id pub-id-type="pmcid">PMC4111295</pub-id></mixed-citation></ref><ref id="dad270197-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dad270197-cite-0009"><string-name name-style="western"><surname>Ezzati</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Katz</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Lipton</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Lipton</surname><given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Verghese</surname><given-names>J</given-names></string-name>. <article-title>The association of brain structure with gait velocity in older adults: a quantitative volumetric analysis of brain MRI</article-title>. <source>Neuroradiology</source>. <year>2015</year>;<volume>57</volume>(<issue>8</issue>):<fpage>851</fpage>&#8208;<lpage>861</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00234-015-1536-2</pub-id><pub-id pub-id-type="pmid">25921321</pub-id><pub-id pub-id-type="pmcid">PMC4553137</pub-id></mixed-citation></ref><ref id="dad270197-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dad270197-cite-0010"><string-name name-style="western"><surname>Beauchet</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Allali</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Annweiler</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Verghese</surname><given-names>J</given-names></string-name>. <article-title>Association of Motoric Cognitive Risk Syndrome With Brain Volumes: results From the GAIT Study</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2016</year>;<volume>71</volume>(<issue>8</issue>):<fpage>1081</fpage>&#8208;<lpage>1088</lpage>. doi:<pub-id pub-id-type="doi">10.1093/gerona/glw012</pub-id><pub-id pub-id-type="pmid">26946101</pub-id></mixed-citation></ref><ref id="dad270197-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dad270197-cite-0011"><string-name name-style="western"><surname>Holtzer</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lipton</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Verghese</surname><given-names>J</given-names></string-name>. <article-title>The protective effects of executive functions and episodic memory on gait speed decline in aging defined in the context of cognitive reserve</article-title>. <source>J Am Geriatr Soc</source>. <year>2012</year>;<volume>60</volume>(<issue>11</issue>):<fpage>2093</fpage>&#8208;<lpage>2098</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1532-5415.2012.04193.x</pub-id><pub-id pub-id-type="pmid">23039200</pub-id><pub-id pub-id-type="pmcid">PMC3498524</pub-id></mixed-citation></ref><ref id="dad270197-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dad270197-cite-0012"><string-name name-style="western"><surname>Nagamalla</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Verghese</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ayers</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>Distinct patterns of brain atrophy in amnestic mild cognitive impairment and motoric cognitive risk syndromes</article-title>. <source>Neurodegener Dis</source>. <year>2024</year>;<volume>24</volume>(<issue>3&#8208;4</issue>):<fpage>117</fpage>&#8208;<lpage>128</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000540512</pub-id><pub-id pub-id-type="pmid">39102797</pub-id><pub-id pub-id-type="pmcid">PMC11794591</pub-id></mixed-citation></ref><ref id="dad270197-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dad270197-cite-0013"><string-name name-style="western"><surname>Blumen</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Allali</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Beauchet</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Lipton</surname><given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Verghese</surname><given-names>J</given-names></string-name>, <article-title>A gray matter volume covariance network associated with the Motoric Cognitive Risk Syndrome: a multicohort MRI study</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2019</year>;<volume>74</volume>(<issue>6</issue>):<fpage>884</fpage>&#8208;<lpage>889</lpage>. doi:<pub-id pub-id-type="doi">10.1093/gerona/gly158</pub-id><pub-id pub-id-type="pmid">29985983</pub-id></mixed-citation></ref><ref id="dad270197-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="dad270197-cite-0014"><string-name name-style="western"><surname>Marusic</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Verghese</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Mahoney</surname><given-names>JR</given-names></string-name>. <article-title>Cognitive&#8208;Based interventions to improve mobility: a systematic review and meta&#8208;analysis</article-title>. <source>J Am Med Dir Assoc</source>. <year>2018</year>;<volume>19</volume>(<issue>6</issue>):<fpage>484</fpage>&#8208;<lpage>491.e3</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jamda.2018.02.002</pub-id><pub-id pub-id-type="pmid">29680203</pub-id><pub-id pub-id-type="pmcid">PMC6361514</pub-id></mixed-citation></ref><ref id="dad270197-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="dad270197-cite-0015"><string-name name-style="western"><surname>Ezzati</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Zammit</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Habeck</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hall</surname><given-names>CB</given-names></string-name>, <article-title>Lipton RB, for the Alzheimer's Disease Neuroimaging I. Detecting biological heterogeneity patterns in ADNI amnestic mild cognitive impairment based on volumetric MRI</article-title>. <source>Brain Imaging Behav</source>. <year>2020</year>;<volume>14</volume>(<issue>5</issue>):<fpage>1792</fpage>&#8208;<lpage>1804</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11682-019-00115-6</pub-id><pub-id pub-id-type="pmid">31104279</pub-id><pub-id pub-id-type="pmcid">PMC7203761</pub-id></mixed-citation></ref><ref id="dad270197-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="dad270197-cite-0016"><string-name name-style="western"><surname>Blumen</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Schwartz</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Allali</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>Cortical thickness, volume, and surface area in the Motoric Cognitive Risk Syndrome</article-title>. <source>J Alzheimers Dis</source>. <year>2021</year>;<volume>81</volume>(<issue>2</issue>):<fpage>651</fpage>&#8208;<lpage>665</lpage>. doi:<pub-id pub-id-type="doi">10.3233/jad-201576</pub-id><pub-id pub-id-type="pmid">33867359</pub-id><pub-id pub-id-type="pmcid">PMC8768501</pub-id></mixed-citation></ref><ref id="dad270197-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="dad270197-cite-0017"><string-name name-style="western"><surname>Varol</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Sotiras</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Davatzikos</surname><given-names>C</given-names></string-name>. <article-title>HYDRA: revealing heterogeneity of imaging and genetic patterns through a multiple max&#8208;margin discriminative analysis framework</article-title>. <source>Neuroimage</source>. <year>2017</year>;<volume>145</volume>:<fpage>346</fpage>&#8208;<lpage>364</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neuroimage.2016.02.041</pub-id><pub-id pub-id-type="pmid">26923371</pub-id><pub-id pub-id-type="pmcid">PMC5408358</pub-id></mixed-citation></ref><ref id="dad270197-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="dad270197-cite-0018"><string-name name-style="western"><surname>Whitwell</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Dickson</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Murray</surname><given-names>ME</given-names></string-name>, et&#160;al. <article-title>Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case&#8208;control study</article-title>. <source>The Lancet Neurology</source>. <year>2012</year>;<volume>11</volume>(<issue>10</issue>):<fpage>868</fpage>&#8208;<lpage>877</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422(12)70200-4</pub-id><pub-id pub-id-type="pmid">22951070</pub-id><pub-id pub-id-type="pmcid">PMC3490201</pub-id></mixed-citation></ref><ref id="dad270197-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="dad270197-cite-0019"><string-name name-style="western"><surname>Zhang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Koutsouleris</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Meisenzahl</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Davatzikos</surname><given-names>C</given-names></string-name>. <article-title>Heterogeneity of structural brain changes in subtypes of schizophrenia revealed using magnetic resonance imaging pattern analysis</article-title>. <source>Schizophr Bull</source>. <year>2014</year>;<volume>41</volume>(<issue>1</issue>):<fpage>74</fpage>&#8208;<lpage>84</lpage>. doi:<pub-id pub-id-type="doi">10.1093/schbul/sbu136</pub-id><pub-id pub-id-type="pmid">25261565</pub-id><pub-id pub-id-type="pmcid">PMC4266302</pub-id></mixed-citation></ref><ref id="dad270197-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="dad270197-cite-0020"><string-name name-style="western"><surname>Noh</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jeon</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>JM</given-names></string-name>, et&#160;al. <article-title>Anatomical heterogeneity of Alzheimer disease</article-title>. <source>Neurology</source>. <year>2014</year>;<volume>83</volume>(<issue>21</issue>):<fpage>1936</fpage>&#8208;<lpage>1944</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000001003</pub-id><pub-id pub-id-type="pmid">25344382</pub-id><pub-id pub-id-type="pmcid">PMC4248459</pub-id></mixed-citation></ref><ref id="dad270197-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="dad270197-cite-0021"><string-name name-style="western"><surname>Blumen</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Holtzer</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Brown</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Gazes</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Verghese</surname><given-names>J</given-names></string-name>. <article-title>Behavioral and neural correlates of imagined walking and walking&#8208;while&#8208;talking in the elderly</article-title>. <source>Hum Brain Mapp</source>. <year>2014</year>;<volume>35</volume>(<issue>8</issue>):<fpage>4090</fpage>&#8208;<lpage>4104</lpage>. doi:<pub-id pub-id-type="doi">10.1002/hbm.22461</pub-id><pub-id pub-id-type="pmid">24522972</pub-id><pub-id pub-id-type="pmcid">PMC4106989</pub-id></mixed-citation></ref><ref id="dad270197-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="dad270197-cite-0022"><string-name name-style="western"><surname>Rajpathak</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ben&#8208;David</surname><given-names>O</given-names></string-name>, et&#160;al. <article-title>Lifestyle factors of people with exceptional longevity</article-title>. <source>J Am Geriatr Soc</source>. <year>2011</year>;<volume>59</volume>(<issue>8</issue>):<fpage>1509</fpage>&#8208;<lpage>1512</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1532-5415.2011.03498.x</pub-id><pub-id pub-id-type="pmid">21812767</pub-id><pub-id pub-id-type="pmcid">PMC6034120</pub-id></mixed-citation></ref><ref id="dad270197-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="dad270197-cite-0023"><string-name name-style="western"><surname>Callisaya</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Beare</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Phan</surname><given-names>TG</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Srikanth</surname><given-names>VK</given-names></string-name>. <article-title>Global and regional associations of smaller cerebral gray and white matter volumes with gait in older people</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>1</issue>):<elocation-id>e84909</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0084909</pub-id><pub-id pub-id-type="pmid">24416309</pub-id><pub-id pub-id-type="pmcid">PMC3885624</pub-id></mixed-citation></ref><ref id="dad270197-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="dad270197-cite-0024"><string-name name-style="western"><surname>Srikanth</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Phan</surname><given-names>TG</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Beare</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Stapleton</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Reutens</surname><given-names>DC</given-names></string-name>. <article-title>The location of white matter lesions and gait&#8211;a voxel&#8208;based study</article-title>. <source>Ann Neurol</source>. <year>2010</year>;<volume>67</volume>(<issue>2</issue>):<fpage>265</fpage>&#8208;<lpage>269</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.21826</pub-id><pub-id pub-id-type="pmid">20225293</pub-id></mixed-citation></ref><ref id="dad270197-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="dad270197-cite-0025"><string-name name-style="western"><surname>Doi</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Blumen</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Verghese</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Gray matter volume and dual&#8208;task gait performance in mild cognitive impairment</article-title>. <source>Brain Imaging Behav</source>. <year>2017</year>;<volume>11</volume>(<issue>3</issue>):<fpage>887</fpage>&#8208;<lpage>898</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11682-016-9562-1</pub-id><pub-id pub-id-type="pmid">27392792</pub-id><pub-id pub-id-type="pmcid">PMC5266675</pub-id></mixed-citation></ref><ref id="dad270197-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="dad270197-cite-0026"><string-name name-style="western"><surname>Shimada</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Tsutsumimoto</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Driving continuity in cognitively impaired older drivers</article-title>. <source>Geriatr Gerontol Int</source>. <year>2016</year>;<volume>16</volume>(<issue>4</issue>):<fpage>508</fpage>&#8208;<lpage>514</lpage>. doi:<pub-id pub-id-type="doi">10.1111/ggi.12504</pub-id><pub-id pub-id-type="pmid">25953032</pub-id></mixed-citation></ref><ref id="dad270197-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="dad270197-cite-0027"><string-name name-style="western"><surname>Wang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Allali</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Kesavadas</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>Cerebral small vessel disease and Motoric Cognitive Risk Syndrome: results from the Kerala&#8208;einstein study</article-title>. <source>J. Alzheimer's Disease</source>. <year>2016</year>;<volume>50</volume>:<fpage>699</fpage>&#8208;<lpage>707</lpage>. doi:<pub-id pub-id-type="doi">10.3233/JAD-150523</pub-id><pub-id pub-id-type="pmid">26757037</pub-id><pub-id pub-id-type="pmcid">PMC5292924</pub-id></mixed-citation></ref><ref id="dad270197-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="dad270197-cite-0028"><string-name name-style="western"><surname>Mielke</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>RO</given-names></string-name>, <string-name name-style="western"><surname>Savica</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Assessing the temporal relationship between cognition and gait: slow gait predicts cognitive decline in the Mayo Clinic Study of Aging</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2013</year>;<volume>68</volume>(<issue>8</issue>):<fpage>929</fpage>&#8208;<lpage>937</lpage>. doi:<pub-id pub-id-type="doi">10.1093/gerona/gls256</pub-id><pub-id pub-id-type="pmid">23250002</pub-id><pub-id pub-id-type="pmcid">PMC3712358</pub-id></mixed-citation></ref><ref id="dad270197-bib-0028"><label>28</label><mixed-citation publication-type="book" id="dad270197-cite-0029"><string-name name-style="western"><surname>Army</surname><given-names>U</given-names></string-name>. <article-title>Army individual test battery</article-title>. <source>Manual of directions and scoring. War Department, Adjutant General 's Office</source>, <publisher-loc>Washington DC</publisher-loc>. <year>1944</year>;</mixed-citation></ref><ref id="dad270197-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="dad270197-cite-0030"><string-name name-style="western"><surname>Stroop</surname><given-names>JR</given-names></string-name>. <article-title>Studies of interference in serial verbal reactions</article-title>. <source>J Exp Psychol</source>. <year>1935</year>;<volume>18</volume>(<issue>6</issue>):<fpage>643</fpage>.</mixed-citation></ref><ref id="dad270197-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="dad270197-cite-0031"><string-name name-style="western"><surname>Grober</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Buschke</surname><given-names>H</given-names></string-name>. <article-title>Genuine memory deficits in dementia</article-title>. <source>Developmental Neuropsychology</source>. <year>1987</year>;<volume>3</volume>(<issue>1</issue>):<fpage>13</fpage>&#8208;<lpage>36</lpage>. doi:<pub-id pub-id-type="doi">10.1080/87565648709540361</pub-id></mixed-citation></ref><ref id="dad270197-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="dad270197-cite-0032"><string-name name-style="western"><surname>Verghese</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Annweiler</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ayers</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>Motoric Cognitive Risk Syndrome: multicountry prevalence and dementia risk</article-title>. <source>Neurology</source>. <year>2014</year>;<volume>83</volume>(<issue>8</issue>):<fpage>718</fpage>&#8208;<lpage>726</lpage>. doi:<pub-id pub-id-type="doi">10.1212/wnl.0000000000000717</pub-id><pub-id pub-id-type="pmid">25031288</pub-id><pub-id pub-id-type="pmcid">PMC4150127</pub-id></mixed-citation></ref><ref id="dad270197-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="dad270197-cite-0033"><string-name name-style="western"><surname>Yesavage</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Brink</surname><given-names>TL</given-names></string-name>, <string-name name-style="western"><surname>Rose</surname><given-names>TL</given-names></string-name>, et&#160;al. <article-title>Development and validation of a geriatric depression screening scale: a preliminary report</article-title>. <source>J Psychiatr Res</source>. <year>1982</year>;<volume>17</volume>(<issue>1</issue>):<fpage>37</fpage>&#8208;<lpage>49</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0022-3956(82)90033-4</pub-id><pub-id pub-id-type="pmid">7183759</pub-id></mixed-citation></ref><ref id="dad270197-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="dad270197-cite-0034"><string-name name-style="western"><surname>Depp</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Jeste</surname><given-names>DV</given-names></string-name>. <article-title>Definitions and predictors of successful aging: a comprehensive review of larger quantitative studies</article-title>. <source>Am J Geriatr Psychiatry</source>. <year>2006</year>;<volume>14</volume>(<issue>1</issue>):<fpage>6</fpage>&#8208;<lpage>20</lpage>. doi:<pub-id pub-id-type="doi">10.1097/01.JGP.0000192501.03069.bc</pub-id><pub-id pub-id-type="pmid">16407577</pub-id></mixed-citation></ref><ref id="dad270197-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="dad270197-cite-0035"><string-name name-style="western"><surname>Alavi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Visentin</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Thapa</surname><given-names>DK</given-names></string-name>, <string-name name-style="western"><surname>Hunt</surname><given-names>GE</given-names></string-name>, <string-name name-style="western"><surname>Watson</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Cleary</surname><given-names>M</given-names></string-name>. <article-title>Exploratory factor analysis and principal component analysis in clinical studies: which one should you use?</article-title><source>J Adv Nurs</source>. <year>2020</year>;<volume>76</volume>(<issue>8</issue>):<fpage>1886</fpage>&#8208;<lpage>1889</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jan.14377</pub-id><pub-id pub-id-type="pmid">32255218</pub-id></mixed-citation></ref><ref id="dad270197-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="dad270197-cite-0036"><string-name name-style="western"><surname>Kasovi&#263;</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>&#352;tefan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>&#352;tefan</surname><given-names>A</given-names></string-name>. <article-title>Normative data for gait speed and height norm speed in &#8805; 60&#8208;year&#8208;old men and women</article-title>. <source>Clin Interv Aging</source>. <year>2021</year>;<volume>16</volume>:<fpage>225</fpage>&#8208;<lpage>230</lpage>. doi:<pub-id pub-id-type="doi">10.2147/cia.S290071</pub-id><pub-id pub-id-type="pmid">33568903</pub-id><pub-id pub-id-type="pmcid">PMC7869711</pub-id></mixed-citation></ref><ref id="dad270197-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="dad270197-cite-0037"><string-name name-style="western"><surname>Kerminen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Marzetti</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>D'Angelo</surname><given-names>E</given-names></string-name>. <article-title>Biological and physical performance markers for early detection of cognitive impairment in older adults</article-title>. <source>Journal of Clinical Medicine</source>. <year>2024</year>;<volume>13</volume>(<issue>3</issue>):<fpage>806</fpage>.<pub-id pub-id-type="pmid">38337499</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm13030806</pub-id><pub-id pub-id-type="pmcid">PMC10856537</pub-id></mixed-citation></ref><ref id="dad270197-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="dad270197-cite-0038"><string-name name-style="western"><surname>Kravatz</surname><given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>Ayers</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Verghese</surname><given-names>J</given-names></string-name>. <article-title>Olfactory dysfunction and incidence of Motoric Cognitive Risk Syndrome: a prospective clinical&#8208;pathologic study</article-title>. <source>Neurology</source>. <year>2022</year>;<volume>99</volume>(<issue>17</issue>):<fpage>e1886</fpage>&#8208;<lpage>e1896</lpage>. doi:<pub-id pub-id-type="doi">10.1212/wnl.0000000000201030</pub-id><pub-id pub-id-type="pmid">36240083</pub-id><pub-id pub-id-type="pmcid">PMC9620808</pub-id></mixed-citation></ref><ref id="dad270197-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="dad270197-cite-0039"><string-name name-style="western"><surname>Maguire</surname><given-names>FJ</given-names></string-name>, <string-name name-style="western"><surname>Killane</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Creagh</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Donoghue</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Kenny</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Reilly</surname><given-names>RB</given-names></string-name>. <article-title>Baseline association of Motoric Cognitive Risk Syndrome with sustained attention, memory, and global cognition</article-title>. <source>J Am Med Dir Assoc</source>. <year>2018</year>;<volume>19</volume>(<issue>1</issue>):<fpage>53</fpage>&#8208;<lpage>58</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jamda.2017.07.016</pub-id><pub-id pub-id-type="pmid">28899662</pub-id></mixed-citation></ref><ref id="dad270197-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="dad270197-cite-0040"><string-name name-style="western"><surname>Allali</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Ayers</surname><given-names>EI</given-names></string-name>, <string-name name-style="western"><surname>Verghese</surname><given-names>J</given-names></string-name>. <article-title>Motoric Cognitive Risk Syndrome subtypes and cognitive profiles</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2016</year>;<volume>71</volume>(<issue>3</issue>):<fpage>378</fpage>&#8208;<lpage>384</lpage>. doi:<pub-id pub-id-type="doi">10.1093/gerona/glv092</pub-id><pub-id pub-id-type="pmid">26248559</pub-id><pub-id pub-id-type="pmcid">PMC5864158</pub-id></mixed-citation></ref><ref id="dad270197-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="dad270197-cite-0041"><string-name name-style="western"><surname>Sekhon</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Launay</surname><given-names>CP</given-names></string-name>, <string-name name-style="western"><surname>Chabot</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Allali</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Beauchet</surname><given-names>O</given-names></string-name>. <article-title>Motoric Cognitive Risk Syndrome: could it be defined through increased five&#8208;times&#8208;sit&#8208;to&#8208;stand test time, rather than slow walking speed? original research</article-title>. <source>Front. Age. Neurosci.</source>. <year>2019</year>;<volume>10</volume>:<fpage>434</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fnagi.2018.00434</pub-id><pub-id pub-id-type="pmcid">PMC6366305</pub-id><pub-id pub-id-type="pmid">30766485</pub-id></mixed-citation></ref><ref id="dad270197-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="dad270197-cite-0042"><string-name name-style="western"><surname>Shim</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Won</surname><given-names>CW</given-names></string-name>. <article-title>Motoric cognitive risk syndrome is associated with processing speed and executive function, but not delayed free recall memory: the Korean frailty and aging cohort study (KFACS)</article-title>. <source>Arch Gerontol Geriatr</source>. <year>2020</year>;<volume>87</volume>:<elocation-id>103990</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.archger.2019.103990</pub-id><pub-id pub-id-type="pmid">31786409</pub-id></mixed-citation></ref><ref id="dad270197-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="dad270197-cite-0043"><string-name name-style="western"><surname>Kim</surname><given-names>M&#8208;J</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Yum</surname><given-names>M&#8208;S</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>Y&#8208;J</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ko</surname><given-names>T&#8208;S</given-names></string-name>. <article-title>Deep learning&#8208;based, fully automated, pediatric brain segmentation</article-title>. <source>Scientific Reports</source>. <year>2024</year>;<volume>14</volume>(<issue>1</issue>):<fpage>4344</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-024-54663-z</pub-id><pub-id pub-id-type="pmid">38383725</pub-id><pub-id pub-id-type="pmcid">PMC10881508</pub-id></mixed-citation></ref><ref id="dad270197-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="dad270197-cite-0044"><string-name name-style="western"><surname>Mateos&#8208;P&#233;rez</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Dadar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lacalle&#8208;Aurioles</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Iturria&#8208;Medina</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zeighami</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Evans</surname><given-names>AC</given-names></string-name>. <article-title>Structural neuroimaging as clinical predictor: a review of machine learning applications</article-title>. <source>NeuroImage: Clinical</source>. <year>2018</year>;<volume>20</volume>:<fpage>506</fpage>&#8208;<lpage>522</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.nicl.2018.08.019</pub-id><pub-id pub-id-type="pmid">30167371</pub-id><pub-id pub-id-type="pmcid">PMC6108077</pub-id></mixed-citation></ref><ref id="dad270197-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="dad270197-cite-0045"><string-name name-style="western"><surname>Jang</surname><given-names>J&#8208;W</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>S&#8208;W</given-names></string-name>, et&#160;al. <article-title>Machine learning&#8208;based automatic estimation of cortical atrophy using brain computed tomography images</article-title>. <source>Scientific Reports</source>. <year>2022</year>;<volume>12</volume>(<issue>1</issue>):<elocation-id>14740</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/s41598-022-18696-6</pub-id><pub-id pub-id-type="pmid">36042322</pub-id><pub-id pub-id-type="pmcid">PMC9427760</pub-id></mixed-citation></ref><ref id="dad270197-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="dad270197-cite-0046"><string-name name-style="western"><surname>Boulifard</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Ayers</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Verghese</surname><given-names>J</given-names></string-name>. <article-title>Home&#8208;based gait speed assessment: normative data and racial/ethnic correlates among older adults</article-title>. <source>J Am Med Dir Assoc</source>. <year>2019</year>;<volume>20</volume>(<issue>10</issue>):<fpage>1224</fpage>&#8208;<lpage>1229</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jamda.2019.06.002</pub-id><pub-id pub-id-type="pmid">31395494</pub-id><pub-id pub-id-type="pmcid">PMC6768753</pub-id></mixed-citation></ref><ref id="dad270197-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="dad270197-cite-0047"><string-name name-style="western"><surname>Capistrant</surname><given-names>BD</given-names></string-name>, <string-name name-style="western"><surname>Glymour</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Berkman</surname><given-names>LF</given-names></string-name>. <article-title>Assessing mobility difficulties for cross&#8208;national comparisons: results from the world health organization study on global ageing and adult health</article-title>. <source>J Am Geriatr Soc</source>. <year>2014</year>;<volume>62</volume>(<issue>2</issue>):<fpage>329</fpage>&#8208;<lpage>335</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jgs.12633</pub-id><pub-id pub-id-type="pmid">24438515</pub-id><pub-id pub-id-type="pmcid">PMC3945402</pub-id></mixed-citation></ref><ref id="dad270197-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="dad270197-cite-0048"><string-name name-style="western"><surname>Maikusa</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Uematsu</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Comparison of traveling&#8208;subject and ComBat harmonization methods for assessing structural brain characteristics</article-title>. <source>Hum Brain Mapp</source>. <year>2021</year>;<volume>42</volume>(<issue>16</issue>):<fpage>5278</fpage>&#8208;<lpage>5287</lpage>. doi:<pub-id pub-id-type="doi">10.1002/hbm.25615</pub-id><pub-id pub-id-type="pmid">34402132</pub-id><pub-id pub-id-type="pmcid">PMC8519865</pub-id></mixed-citation></ref><ref id="dad270197-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="dad270197-cite-0049"><string-name name-style="western"><surname>Jovicich</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Marizzoni</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sala&#8208;Llonch</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Brain morphometry reproducibility in multi&#8208;center 3T MRI studies: a comparison of cross&#8208;sectional and longitudinal segmentations</article-title>. <source>Neuroimage</source>. <year>2013</year>;<volume>83</volume>:<fpage>472</fpage>&#8208;<lpage>484</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neuroimage.2013.05.007</pub-id><pub-id pub-id-type="pmid">23668971</pub-id></mixed-citation></ref><ref id="dad270197-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="dad270197-cite-0050"><string-name name-style="western"><surname>Jovicich</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Czanner</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>X</given-names></string-name>, et&#160;al. <article-title>MRI&#8208;derived measurements of human subcortical, ventricular and intracranial brain volumes: reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths</article-title>. <source>Neuroimage</source>. <year>2009</year>;<volume>46</volume>(<issue>1</issue>):<fpage>177</fpage>&#8208;<lpage>192</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neuroimage.2009.02.010</pub-id><pub-id pub-id-type="pmid">19233293</pub-id><pub-id pub-id-type="pmcid">PMC2866077</pub-id></mixed-citation></ref><ref id="dad270197-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="dad270197-cite-0051"><string-name name-style="western"><surname>Yang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Nasrallah</surname><given-names>IM</given-names></string-name>, <string-name name-style="western"><surname>Shou</surname><given-names>H</given-names></string-name>, et&#160;al. <article-title>A deep learning framework identifies dimensional representations of Alzheimer's Disease from brain structure</article-title>. <source>Nature Communications</source>. <year>2021</year>;<volume>12</volume>(<issue>1</issue>):<fpage>7065</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-021-26703-z</pub-id><pub-id pub-id-type="pmcid">PMC8642554</pub-id><pub-id pub-id-type="pmid">34862382</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="dad270178" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement (Amst)</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement (Amst)</journal-id><journal-id journal-id-type="pmc-domain-id">3002</journal-id><journal-id journal-id-type="pmc-domain">dadm</journal-id><journal-id journal-id-type="publisher-id">DAD2</journal-id><journal-title-group><journal-title>Alzheimer's &amp; Dementia : Diagnosis, Assessment &amp; Disease Monitoring</journal-title></journal-title-group><issn pub-type="epub">2352-8729</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12504057</article-id><article-id pub-id-type="pmcid-ver">PMC12504057.1</article-id><article-id pub-id-type="pmcaid">12504057</article-id><article-id pub-id-type="pmcaiid">12504057</article-id><article-id pub-id-type="doi">10.1002/dad2.70178</article-id><article-id pub-id-type="publisher-id">DAD270178</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>An online vignette study of diagnostic testing: Racial and ethnic differences in Alzheimer's disease diagnosis confidence and stigma</article-title><alt-title alt-title-type="left-running-head">STITES <sc>et&#160;al.</sc></alt-title></title-group><contrib-group><contrib id="dad270178-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Stites</surname><given-names initials="SD">Shana D.</given-names></name><xref rid="dad270178-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="dad270178-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="dad270178-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>Stites@UPenn.edu</email></address></contrib><contrib id="dad270178-cr-0002" contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="BN">Brian N.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6090-4306</contrib-id><xref rid="dad270178-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="dad270178-cr-0003" contrib-type="author"><name name-style="western"><surname>Kuz</surname><given-names initials="C">Carolyn</given-names></name><xref rid="dad270178-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="dad270178-cr-0004" contrib-type="author"><name name-style="western"><surname>Adams</surname><given-names initials="M">Morgann</given-names></name><xref rid="dad270178-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="dad270178-cr-0005" contrib-type="author"><name name-style="western"><surname>Harkins</surname><given-names initials="K">Kristin</given-names></name><xref rid="dad270178-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="dad270178-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="dad270178-cr-0006" contrib-type="author"><name name-style="western"><surname>Xie</surname><given-names initials="SX">Sharon X.</given-names></name><xref rid="dad270178-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="dad270178-cr-0007" contrib-type="author"><name name-style="western"><surname>Walke</surname><given-names initials="L">Lisa</given-names></name><xref rid="dad270178-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="dad270178-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="dad270178-cr-0008" contrib-type="author"><name name-style="western"><surname>Sankar</surname><given-names initials="P">Pamela</given-names></name><xref rid="dad270178-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="dad270178-cr-0009" contrib-type="author"><name name-style="western"><surname>Hamilton</surname><given-names initials="R">Roy</given-names></name><xref rid="dad270178-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="dad270178-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib></contrib-group><aff id="dad270178-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Psychiatry, Perelman School of Medicine</named-content>
<institution>University of Pennsylvania</institution>
<city>Philadelphia</city>
<named-content content-type="country-part">Pennsylvania</named-content>
<country country="US">USA</country>
</aff><aff id="dad270178-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Penn Memory Center</named-content>
<institution>University of Pennsylvania</institution>
<city>Philadelphia</city>
<named-content content-type="country-part">Pennsylvania</named-content>
<country country="US">USA</country>
</aff><aff id="dad270178-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Division of Geriatrics, Perelman School of Medicine</named-content>
<institution>University of Pennsylvania</institution>
<city>Philadelphia</city>
<named-content content-type="country-part">Pennsylvania</named-content>
<country country="US">USA</country>
</aff><aff id="dad270178-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine</named-content>
<institution>University of Pennsylvania</institution>
<city>Philadelphia</city>
<named-content content-type="country-part">Pennsylvania</named-content>
<country country="US">USA</country>
</aff><aff id="dad270178-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Medical Ethics and Health Policy</named-content>
<named-content content-type="organisation-division">Perelman School of Medicine</named-content>
<institution>University of Pennsylvania</institution>
<city>Philadelphia</city>
<named-content content-type="country-part">Pennsylvania</named-content>
<country country="US">USA</country>
</aff><aff id="dad270178-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<named-content content-type="organisation-division">Perelman School of Medicine</named-content>
<institution>University of Pennsylvania</institution>
<city>Philadelphia</city>
<named-content content-type="country-part">Pennsylvania</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Shana Stites, University of Pennsylvania, 3615 Chestnut Street, Philadelphia, PA 19104, USA.<break/> Email: <email>Stites@UPenn.edu</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><season>Oct-Dec</season><year>2025</year></pub-date><volume>17</volume><issue seq="30">4</issue><issue-id pub-id-type="pmc-issue-id">497563</issue-id><issue-id pub-id-type="doi">10.1002/dad2.v17.4</issue-id><elocation-id>e70178</elocation-id><history><date date-type="rev-recd"><day>30</day><month>7</month><year>2025</year></date><date date-type="received"><day>21</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>12</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Alzheimer's &amp; Dementia: Diagnosis, Assessment &amp; Disease Monitoring</italic> published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="DAD2-17-e70178.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:DAD2-17-e70178.pdf"/><abstract><title>Abstract</title><sec id="dad270178-sec-0010"><title>INTRODUCTION</title><p>Understanding how biomarker testing affects Alzheimer's disease (AD) diagnosis confidence and AD stigma among race and ethnicity groups is essential for supporting early diagnosis and treatment.</p></sec><sec id="dad270178-sec-0020"><title>METHODS</title><p>Adults (<italic toggle="yes">N</italic>&#160;=&#160;3548) rated confidence in an AD diagnosis based on four diagnostic evaluations and answered questions about AD stigma based on a clinical vignette. The sample reflects response and completion rates of 53% and 91.3%, respectively. Bivariate and multivariable regression analyses were conducted.</p></sec><sec id="dad270178-sec-0030"><title>RESULTS</title><p>Black participants showed the smallest increase (11.86 points) in diagnosis confidence of all race groups when a brain scan was included in the diagnostic evaluation. AD diagnosis confidence changed across diagnostic evaluation categories based on level and type of AD stigma domain and race group.</p></sec><sec id="dad270178-sec-0040"><title>DISCUSSION</title><p>Use of brain scans in evaluations can heighten diagnosis confidence in all race groups. Yet, no group had 100% confidence in an AD diagnosis with any evaluation. Recommendations are discussed.</p></sec><sec id="dad270178-sec-0050"><title>Highlights</title><p>
<list list-type="bullet" id="dad270178-list-0001"><list-item><p>Confidence in an Alzheimer's disease (AD) diagnosis varies across racial groups.</p></list-item><list-item><p>Within racial groups, AD diagnosis confidence differs with diagnostics.</p></list-item><list-item><p>Even with cutting&#8208;edge biomarker testing, no racial group had 100% confidence in an AD diagnosis.</p></list-item><list-item><p>Patient&#8208;centered care and systemic changes are needed to widen distribution of diagnostic technologies and improve access to care.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dad270178-kwd-0001">Alzheimer's disease</kwd><kwd id="dad270178-kwd-0002">biomarkers</kwd><kwd id="dad270178-kwd-0003">diagnosis confidence</kwd><kwd id="dad270178-kwd-0004">ethnicity</kwd><kwd id="dad270178-kwd-0005">race</kwd><kwd id="dad270178-kwd-0006">stigma</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>National Institutes of Health</institution><institution-id institution-id-type="doi">10.13039/100000002</institution-id></institution-wrap></funding-source><award-id>1K23AG065442</award-id><award-id>1K23AG065442&#8208;03S1</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Alzheimer's Association</institution><institution-id institution-id-type="doi">10.13039/100000957</institution-id></institution-wrap></funding-source><award-id>AARF&#8208;17&#8208;528934</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Alzheimer's Foundation of America</institution><institution-id institution-id-type="doi">10.13039/100010473</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>National Institute on Aging</institution><institution-id institution-id-type="doi">10.13039/100000049</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="4"/><page-count count="11"/><word-count count="8089"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October-December 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:07.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="dad270178-cite-0001"><string-name name-style="western"><surname>Stites</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>BN</given-names></string-name>, <string-name name-style="western"><surname>Kuz</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>An online vignette study of diagnostic testing: Racial and ethnic differences in Alzheimer's disease diagnosis confidence and stigma</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>17</volume>:<elocation-id>e70178</elocation-id>. <pub-id pub-id-type="doi">10.1002/dad2.70178</pub-id></mixed-citation>
</p></notes></front><body><sec id="dad270178-sec-0060"><label>1</label><title>INTRODUCTION</title><p>Alzheimer's disease (AD) affects &gt; 5 million people in the United States. Early diagnosis and treatment are critical to reducing AD burden by affording patients and their families opportunities to access supportive therapies to slow disease progression. Whether patients can avail themselves of early interventions is, in turn, influenced by their confidence in an AD diagnosis.<xref rid="dad270178-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Patients and families with confidence in a diagnosis may address current care needs and future life planning promptly, may accept the risks of possible treatments, and actively seek treatments. Conversely, patients and families with low confidence in an AD diagnosis may pursue multiple time&#8208;consuming clinical evaluations for alternative diagnoses and show reduced adherence to AD medications and treatments.</p><p>Confidence in an AD diagnosis has been shown to vary between Black and White adults, with White adults generally reporting more confidence.<xref rid="dad270178-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> This is notable given that diagnosis confidence affects clinical outcomes and that Black and Latino populations are among those who experience the greatest burdens of AD.<xref rid="dad270178-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="dad270178-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> Research shows members of these populations meet clinical criteria for AD dementia at higher rates, are less likely to be diagnosed, are diagnosed at later stages of the disease, receive lower quality of care, and have worse mortality rates than their White, non&#8208;Latino counterparts.<xref rid="dad270178-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="dad270178-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> Studies have not described AD diagnosis confidence among Asian Americans, multiracial or multiethnic individuals, American Indian or Alaskan Natives, or other race groups.</p><p>Findings from prior studies point to a possible association between higher confidence in an AD diagnosis and greater AD stigma,<xref rid="dad270178-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="dad270178-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> which refers to the negative perceptions, attitudes, emotions, and reactions related to AD.<xref rid="dad270178-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Quantifying this association and understanding whether it may differ in racial and ethnic groups is important as stigma has been considered by some to have utility in motivating certain behaviors, such as diagnosis seeking.<xref rid="dad270178-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="dad270178-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="dad270178-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Yet, AD stigma can also lower quality of life.<xref rid="dad270178-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> If AD diagnosis confidence and AD stigma are inextricably linked, it would underscore the importance of addressing stigma during diagnosis. However, this may not be the case for all patients and families, and understanding the variance in this regard that exists in the population is likely to help clinicians better formulate effective approaches for conveying this life&#8208;altering diagnosis.</p><p>Clinicians often make an AD diagnosis using clinical data from a clinical history, physical examination, and cognitive testing; to date there is no single test that can definitively diagnose&#160;AD.<xref rid="dad270178-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="dad270178-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> However, prior studies have shown that AD biomarker results, such as neuroimaging data or a laboratory test, can have measurable effects on the general public's AD diagnosis confidence and AD stigma.<xref rid="dad270178-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="dad270178-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> In one study, older adults read a vignette that described either a positive or negative brain scan result. Those who read about the positive result both reported higher AD stigma and demonstrated a psychological priming effect, whereby when asked later to rate their confidence in a hypothetical AD diagnosis, their ratings were higher than those who read about a negative brain scan result.</p><boxed-text position="float" content-type="box" orientation="portrait"><sec id="dad270178-sec-0070"><title>RESEARCH IN CONTEXT</title><p>
<bold>Systematic review</bold>: The authors reviewed the literature (journal articles, abstracts, presentations) using traditional databases (i.e., PubMed). While trends in diagnostic confidence and stigma have not been thoroughly studied in all listed racial/ethnic groups, some recent publications have explored diagnostic confidence in Black and White adults. Relevant sources are cited and discussed.</p><p>
<bold>Interpretation</bold>: We identify differences in diagnostic confidence trends between racial/ethnic groups. These differences can be explained by sociocultural influences and systematic biases. They signal a need for patient&#8208;centered practices in the disclosure of dementia diagnoses and biomarker test results to address diagnosis confidence and stigma. Our hypotheses are consistent with prior reported findings and extend what is known in the literature.</p><p>
<bold>Future directions</bold>: The current work has explored trends in diagnostic confidence within White, Black, Asian, and multirace individuals. More work must be done to explore trends in diagnostic confidence and stigma in the Native Hawaiian/Pacific Islander and American Indian/Alaskan Native racial/ethnic groups and evaluating effects of patient&#8208;centered practices on diagnosis confidence. The article's methodology can serve as a framework with which to extend this work.</p></sec></boxed-text><p>It would be conceptually consistent for AD diagnosis confidence to be closely related to the stigma surrounding the condition. Higher confidence in a diagnosis conveys more certainty that the disease label is applicable to the individual. Goffman's<xref rid="dad270178-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> stigma theory poses that the stigmatized individual has an attribute that is immediately both apparent and discrediting. In this case, the AD diagnosis is the discrediting attribute. The more confidence in that diagnosis, the stronger the AD stigma.</p><p>Emerging tests, such as brain scans and blood tests, that identify AD&#8208;specific pathologies may radically improve diagnosis accuracy and timeliness.<xref rid="dad270178-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="dad270178-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> Studies suggest brain scans increase physicians&#8217; diagnosis confidence and have sensitivity and specificity superior to cognitive testing.<xref rid="dad270178-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="dad270178-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="dad270178-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> The addition of AD biomarker testing to routine AD diagnosis may also improve AD diagnosis confidence in the public. It is important to know whether this is in fact the case, and, if so, whether it is consistent across racial and ethnic groups.</p><p>The purpose of this study is to examine the relationship between AD diagnosis confidence and AD stigma among select race and ethnicity groups in the American adult public. We also explore interactions between AD diagnosis confidence and AD stigma. Based on prior studies,<xref rid="dad270178-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="dad270178-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="dad270178-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="dad270178-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> we hypothesized that each category of diagnostic tests used in a hypothetical evaluation would increase AD diagnosis confidence. Findings from this study may help inform efforts to advance early AD diagnosis and treatment among groups that are often underrepresented in research and that experience health&#8208;care disparities.</p></sec><sec id="dad270178-sec-0080"><label>2</label><title>METHODS</title><sec id="dad270178-sec-0090"><label>2.1</label><title>Study design</title><p>The study is a vignette&#8208;based online experiment.<xref rid="dad270178-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> Data collection occurred between June 11 and July 3, 2019.</p></sec><sec id="dad270178-sec-0100"><label>2.2</label><title>Setting and participant eligibility</title><p>Adults able to read English were invited at random from a large research panel maintained by Qualtrics, which was chosen to achieve our goals of selecting a random sample with key characteristics of the US general population with oversampling of Black Americans and older adults. The response rate was 53%. The completion rate was 91.3%. Data from participants in this sample have been analyzed previously.<xref rid="dad270178-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="dad270178-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="dad270178-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="dad270178-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> Randomly invited panel members consented to participate. After consent participants were asked to complete a biomarker education question and had two opportunities to answer it correctly (supporting information, Appendix <xref rid="dad270178-supinfo-0001" ref-type="">A</xref>).</p><p>The sample for this current study, comprising 3548 participants, is a combination of individuals who were either in a sample that was demographically similar to the US adult population (<italic toggle="yes">n</italic>&#160;=&#160;1831) or from oversamples of Black adults (<italic toggle="yes">n</italic>&#160;=&#160;862) and older adults (<italic toggle="yes">n</italic>&#160;=&#160;855). In this full sample of 3548, we examine older adults of White (<italic toggle="yes">n</italic>&#160;=&#160;2143), Black (<italic toggle="yes">n</italic>&#160;=&#160;1094), Asian (<italic toggle="yes">n</italic>&#160;=&#160;116), American Indian or Alaskan Native (<italic toggle="yes">n</italic>&#160;=&#160;29), and Native Hawaiian or Pacific Islander (<italic toggle="yes">n</italic>&#160;=&#160;6) race. We also include adults that identify with another racial category (<italic toggle="yes">n</italic>&#160;=&#160;61) and two or more races (<italic toggle="yes">n</italic>&#160;=&#160;99).</p></sec><sec id="dad270178-sec-0110"><label>2.3</label><title>AD diagnosis confidence measure</title><p>AD diagnosis confidence was measured with a scale from Baumann et&#160;al.<xref rid="dad270178-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> We modified the diagnostic evaluations for relevance to current clinical practices in diagnosing AD and emerging advances in blood and imaging AD biomarkers. Participants rated the confidence that they would have if given an AD diagnosis based on each of four categories of medical evaluations:
<list list-type="order" id="dad270178-list-0002"><list-item><p>Clinical history interview and physical exam;</p></list-item><list-item><p>Clinical history interview, physical exam, and memory tests;</p></list-item><list-item><p>Clinical history interview, physical exam, memory tests, and blood tests; or</p></list-item><list-item><p>Clinical history interview, physical exam, memory tests, blood tests, and a brain scan.</p></list-item></list>
</p><p>Participants rated their confidence from 0 to 100 on a visual analog scale, with higher scores indicating more confidence. No additional anchors or narrative instructions were given.</p></sec><sec id="dad270178-sec-0120"><label>2.4</label><title>AD stigma measure</title><p>All participants read a vignette about fictional person who presented for a new patient visit at a memory center accompanied by an adult daughter (supporting information, Appendix <xref rid="dad270178-supinfo-0001" ref-type="">B</xref>). The vignettes were randomized to create equal groups who read about: a positive or negative AD biomarker test result, available versus unavailable disease&#8208;modifying treatment for AD, and dementia symptom stage (Clinical Dementia Rating [CDR; no symptoms (CDR 0), mild dementia symptoms (CDR 1), moderate dementia symptoms (CDR 2)]).<xref rid="dad270178-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> The effects of patient age at three levels (60, 70, or 80 years old) and sex at two levels (man or woman) are also held constant in our analyses as the number of vignettes was balanced to control for the effects that could be attributed to these characteristics.</p><p>Immediately after reading the vignette, participants were asked to answer a modified Family Stigma in Alzheimer's Disease Scale (FS&#8208;ADS), a validated scale that measures AD stigma across a range of cognitive, emotional, and behavioral attributions.<xref rid="dad270178-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> These attributions align with Link and Phelan's theory of stigma,<xref rid="dad270178-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> modified labeling theory,<xref rid="dad270178-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> and the social&#8208;cognitive model of stigma.<xref rid="dad270178-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> Items on the original assessment were adapted for relevance to the vignettes.<xref rid="dad270178-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> The overall internal consistency of the adapted form appeared similar to that of the original scale (Cronbach alpha&#160;=&#160;0.91).<xref rid="dad270178-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> Cronbach alphas for all individual domains were &gt; 0.80, suggesting &#8220;better than good&#8221; internal reliability, except for the Pity scale, which had a score of 0.77, suggesting &#8220;good&#8221; internal reliability.</p><p>The modified FS&#8208;ADS comprises 41 items that load onto seven empirically derived domains. Items ask the extent to which the participant believes that the person described in the vignette: (1) should worry about encountering discrimination by insurance companies or employers and being excluded from voting or medical decision making (structural discrimination); (2) would be expected to have certain symptoms like speaking repetitively or suffering incontinence (negative severity attributions); (3) should be expected to have poor hygiene, neglected self&#8208;care, and appear in other ways that provoke negative judgments (negative aesthetic attributions); (4) would evoke feelings of disgust or repulsion (antipathy); (5) would evoke feelings of concern, compassion, or willingness to help from others (support); (6) would evoke feelings of sympathy, sadness, or pity from others (pity); and (7) would be ignored or have social relationships limited by others (social distance). We framed items on domains that pertained to negative or unpleasant attributes to be about the actions of &#8220;others&#8221; to minimize social desirability bias.<xref rid="dad270178-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> Responses were recorded on a 5 point Likert scale arranged on the screen horizontally from left to right, and analyzed by domain using established methods,<xref rid="dad270178-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> with higher scores indicating stronger endorsement.</p><p>Demographic data were collected using US Census categories. The University of Pennsylvania Institutional Review Board (IRB) deemed exempt all procedures involving human subjects for the &#8220;Health Beliefs Study&#8221; (#828348).</p></sec><sec id="dad270178-sec-0130"><label>2.5</label><title>Statistical analysis</title><p>Means and proportions were used to characterize the sample and study outcomes. Ninety&#8208;five percent confidence intervals (95% CIs) were used to estimate uncertainty in the study estimates. Graphical depictions are presented to aid characterization of the study data. Linear regression was used to estimate the adjusted mean confidence in an AD diagnosis in each of four categories of diagnostic evaluations by race and ethnicity group. These models adjusted for participant age,<xref rid="dad270178-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> which can interact with the biomarker condition that was balanced across study groups. Responses of 4 and 5 on the FS&#8208;ADS were considered a positive result in the present study. This cut point was consistent with the 85th percentile or above on all domains. Percentages and their respective 95% CIs were used to describe participants who strongly endorsed each FS&#8208;ADS domain by race and ethnicity group. In these analyses, estimates with pairs of 95% CIs that do not overlap are statistically significant at <italic toggle="yes">P</italic>&#160;&lt;&#160;0.05. To mitigate type 1 error, only variables that showed statistically significant differences in bivariate analyses were carried forward for further analysis:<xref rid="dad270178-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> race groups and FS&#8208;ADS domains were carried forward.</p><p>Statistical tests were two&#8208;sided. <italic toggle="yes">P</italic> values&#160;&lt;&#160;0.05 were considered statistically significant. Analyses were performed in Stata 17.</p></sec></sec><sec id="dad270178-sec-0140"><label>3</label><title>RESULTS</title><sec id="dad270178-sec-0150"><label>3.1</label><title>Participant characteristics</title><p>In the sample of 3548 adults, the mean age was 50.5 years (standard deviation 18.9, Table&#160;<xref rid="dad270178-tbl-0001" ref-type="table">1</xref>). Approximately half of participants were women (54.2%). Participants self&#8208;identified as White (60.4%), Black (30.8%), Asian (3.3%), American Indian or Alaskan Native (0.8%), Native Hawaiian or Pacific Islander (0.2%), other racial category (1.7%), and two or more races (2.8%). Approximately 11% identified as of Hispanic or Latino ethnicity. Similar proportions had either a high school education or less (34.1%) or some college or 2 year degree (34.5%).</p><table-wrap position="float" id="dad270178-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Participant characteristics (<italic toggle="yes">N</italic>&#160;=&#160;3548).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Participant characteristic&#160;</th><th align="left" rowspan="1" colspan="1">Sample (<italic toggle="yes">N</italic>&#160;=&#160;3548)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, mean (SD)&#160;</td><td align="char" rowspan="1" colspan="1">50.5 (18.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Women, % (<italic toggle="yes">n</italic>)&#160;</td><td align="char" rowspan="1" colspan="1">54.2 (1922)</td></tr><tr><td align="left" rowspan="1" colspan="1">Race/Ethnicity, % (<italic toggle="yes">n</italic>)&#160;</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">White&#160;</td><td align="char" rowspan="1" colspan="1">60.4 (2143)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Black&#160;</td><td align="char" rowspan="1" colspan="1">30.8 (1094)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Asian</td><td align="char" rowspan="1" colspan="1">3.3 (116)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">American Indian or Alaskan Native</td><td align="char" rowspan="1" colspan="1">0.8 (29)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Native Hawaiian or Pacific Islander</td><td align="char" rowspan="1" colspan="1">0.2 (6)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Some other race</td><td align="char" rowspan="1" colspan="1">1.7 (61)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Two or more races</td><td align="char" rowspan="1" colspan="1">2.8 (99)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Hispanic or Latina/o/x</td><td align="char" rowspan="1" colspan="1">11.4 (404)</td></tr><tr><td align="left" rowspan="1" colspan="1">Education, % (<italic toggle="yes">n</italic>)&#160;</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">High school/GED or less&#160;</td><td align="char" rowspan="1" colspan="1">34.1 (1221)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Some college or 2 year degree&#160;</td><td align="char" rowspan="1" colspan="1">34.5 (1223)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">4 year college degree or beyond<sup>a</sup>&#160;</td><td align="char" rowspan="1" colspan="1">31.1&#160;(1104)</td></tr></tbody></table><table-wrap-foot><fn id="dad270178-tbl1-note-0001"><p>
<italic toggle="yes">Note</italic>. Column percentages may not total 100 due to rounding.&#160;</p></fn><fn id="dad270178-tbl1-note-0002"><label>
<sup>a</sup>
</label><p>4&#8208;year college, master's, doctorate, or professional degree.</p></fn><fn id="dad270178-tbl1-note-0003"><p>Abbreviations: GED, General Educational Development text; SD, standard deviation.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="dad270178-sec-0160"><label>3.2</label><title>Confidence in an AD diagnosis by evaluation category and participant race and ethnicity</title><p>White participants had the lowest mean confidence in an AD diagnosis that was determined based on a clinical history interview and physical exam only (adjusted mean&#160;=&#160;36.34, 95% CI 36.13 to 36.55). In this group, mean confidence in an AD diagnosis increased linearly across the four categories of evaluations, with a slightly larger increase from 54.5 points (95% CI 54.36 to 54.68) in the evaluation that included clinical history interview and physical exam, memory tests, and blood tests to 77.86 points (95% CI 77.81 to 77.92) in the evaluation that includes those prior tests plus a brain scan, which was a mean difference of 41.52 points. This pattern was similar across most race and ethnicity groups, with the exception of those who identified as either Black or Native Hawaiian or Pacific Islander. No additional effects were identified in analyses of race effects by ethnicity (Table&#160;<xref rid="dad270178-tbl-0002" ref-type="table">2</xref>).</p><table-wrap position="float" id="dad270178-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Confidence in an AD diagnosis by evaluation categories and participant race and ethnicity (<italic toggle="yes">N</italic>&#160;=&#160;3548).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th colspan="4" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Evaluation categories<xref rid="dad270178-tbl2-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>
</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<p>Clinical history interview and physical exam [i]</p>
</th><th align="left" rowspan="1" colspan="1">
<p>&#8230; and memory tests [ii]</p>
</th><th align="left" rowspan="1" colspan="1">
<p>&#8230; and blood tests [iii]</p>
</th><th align="left" rowspan="1" colspan="1">
<p>&#8230; and a brain scan [iv]</p>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Participant race</th><th colspan="4" align="center" style="border-bottom:solid 1px #000000" rowspan="1">
<p>Adjusted mean (95% CI)</p>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">White</td><td align="left" rowspan="1" colspan="1">36.34 (36.13 to 36.55)</td><td align="left" rowspan="1" colspan="1">45.26 (45.10 to 45.42)</td><td align="left" rowspan="1" colspan="1">54.52 (54.36 to 54.68)</td><td align="left" rowspan="1" colspan="1">77.86 (77.81 to 77.92)</td></tr><tr><td align="left" rowspan="1" colspan="1">Black</td><td align="left" rowspan="1" colspan="1">46.95 (46.66 to 47.23)</td><td align="left" rowspan="1" colspan="1">54.06 (53.84 to 54.28)</td><td align="left" rowspan="1" colspan="1">60.35 (60.13 to 60.57)</td><td align="left" rowspan="1" colspan="1">72.21 (72.13 to 72.29)</td></tr><tr><td align="left" rowspan="1" colspan="1">Asian</td><td align="left" rowspan="1" colspan="1">43.56 (42.67 to 44.45)</td><td align="left" rowspan="1" colspan="1">51.01 (50.32 to 51.70)</td><td align="left" rowspan="1" colspan="1">59.63 (58.95 to 60.31)</td><td align="left" rowspan="1" colspan="1">77.51 (77.26 to 77.76)</td></tr><tr><td align="left" rowspan="1" colspan="1">AIAN</td><td align="left" rowspan="1" colspan="1">41.66 (39.77 to 43.54)</td><td align="left" rowspan="1" colspan="1">50.38 (48.92 to 51.84)</td><td align="left" rowspan="1" colspan="1">56.55 (55.11 to 57.99)</td><td align="left" rowspan="1" colspan="1">78.72 (78.19 to 79.25)</td></tr><tr><td align="left" rowspan="1" colspan="1">NHPI</td><td align="left" rowspan="1" colspan="1">70.33 (66.18 to 74.49)</td><td align="left" rowspan="1" colspan="1">60.17 (56.95 to 63.38)</td><td align="left" rowspan="1" colspan="1">75.17 (72.00 to 78.33)</td><td align="left" rowspan="1" colspan="1">77.50 (76.33 to 78.67)</td></tr><tr><td align="left" rowspan="1" colspan="1">Other racial Category</td><td align="left" rowspan="1" colspan="1">41.25 (39.72 to 42.77)</td><td align="left" rowspan="1" colspan="1">43.84 (42.66 to 45.02)</td><td align="left" rowspan="1" colspan="1">49.64 (48.48 to 50.80)</td><td align="left" rowspan="1" colspan="1">67.62 (67.19 to 68.05)</td></tr><tr><td align="left" rowspan="1" colspan="1">Two or more races</td><td align="left" rowspan="1" colspan="1">36.47 (35.39 to 37.56)</td><td align="left" rowspan="1" colspan="1">44.52 (43.67 to 45.36)</td><td align="left" rowspan="1" colspan="1">56.71 (55.88 to 57.54)</td><td align="left" rowspan="1" colspan="1">77.51 (77.20 to 77.81)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hispanic or Latina/o/x</td><td align="left" rowspan="1" colspan="1">45.27 (44.77 to 45.77)</td><td align="left" rowspan="1" colspan="1">52.43 (52.04 to 52.82)</td><td align="left" rowspan="1" colspan="1">59.66 (59.31 to 60.01)</td><td align="left" rowspan="1" colspan="1">75.45 (75.26 to 75.64)</td></tr><tr><td align="left" rowspan="1" colspan="1">Not Hispanic or Latina/o/x</td><td align="left" rowspan="1" colspan="1">39.36 (39.15 to 39.58)</td><td align="left" rowspan="1" colspan="1">47.64 (47.47 to 47.80)</td><td align="left" rowspan="1" colspan="1">56.11 (55.96 to 56.26)</td><td align="left" rowspan="1" colspan="1">75.99 (75.91 to 76.07)</td></tr></tbody></table><table-wrap-foot><fn id="dad270178-tbl2-note-0001"><p>
<italic toggle="yes">Note</italic>. Analyses adjust for participant age.</p></fn><fn id="dad270178-tbl2-note-0002"><p>Abbreviations: AD,&#160;Alzheimer's disease; AIAN,&#160;American Indian or Alaskan Native; CI,&#160; confidence interval; NHPI,&#160;Native Hawaiian or Pacific Islander.</p></fn><fn id="dad270178-tbl2-note-0003"><p>Non&#8208;overlapping confidence intervals are significant at <italic toggle="yes">P</italic>&#160;&lt;&#160;0.05.</p></fn><fn id="dad270178-tbl2-note-0004"><label>
<sup>a</sup>
</label><p>Evaluation Categories: (i) clinical history interview and physical exam; (ii) clinical history interview, physical exam, and memory tests; (iii) clinical history interview, physical exam, memory tests, and blood tests; or (iv) clinical history interview, physical exam, memory tests, blood tests, and a brain scan.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>Black participants had relatively high confidence in a diagnosis based on the evaluation that included clinical history interview and physical exam (adjusted mean&#160;=&#160;46.95, 95% CI 46.66 to 47.23). Confidence in a diagnosis based on the evaluation that included a brain scan was an adjusted mean of 72.21 points (95% CI 72.13 to 72.29). This was 11.86 points higher than the evaluation that included clinical history interview and physical exam, memory tests, and blood tests and reflected a smaller difference than what was observed among most of the other race groups (Figure&#160;<xref rid="dad270178-fig-0001" ref-type="fig">1</xref>).</p><fig position="float" fig-type="FIGURE" id="dad270178-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Adjusted mean confidence rating in an Alzheimer's disease diagnosis by evaluation category and participant race and ethnicity (<italic toggle="yes">N</italic>&#160;=&#160;3548). Analyses control for participant age. A&#160;=&#160;Clinical history interview and physical exam only. B&#160;=&#160;Clinical history interview and physical exam and memory tests. C&#160;=&#160;Clinical history interview and physical exam, memory tests, and blood tests. D&#160;=&#160;Clinical history interview and physical exam, memory tests, and blood tests, and brain scan.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="DAD2-17-e70178-g001.jpg"/></fig></sec><sec id="dad270178-sec-0170"><label>3.3</label><title>AD stigma by race and ethnicity</title><p>The percentages of participants reporting high AD stigma by race and ethnicity groups are reported in Table&#160;<xref rid="dad270178-tbl-0003" ref-type="table">3</xref>. Willingness to support persons with AD, potentially to the level of paternalism (i.e., overprotective decision making); strong feelings of pity; and worries about structural discrimination were the most reported aspects of stigma across all race and ethnicity groups. For example, among Asian participants, 29% (95% CI 21% to 38%) reported high willingness to support persons with AD, 16% (95% CI 16% to 20%) strong feelings of pity, and 14% (95% CI 7% to 20%) strong worries about structural discrimination.</p><table-wrap position="float" id="dad270178-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Age adjusted percentage of participants (95% CI) reporting high AD stigma by race and ethnicity group (<italic toggle="yes">N</italic>&#160;=&#160;3548).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><thead><tr><th align="left" colspan="8" style="border-bottom:solid 1px #000000" rowspan="1">FS&#8208;ADS domain [%, (95% CI)]</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Participant race and ethnicity</th><th align="left" rowspan="1" colspan="1">Structural discrim&#8208;ination</th><th align="left" rowspan="1" colspan="1">Negative severity attributions</th><th align="left" rowspan="1" colspan="1">Negative aesthetic attributions</th><th align="left" rowspan="1" colspan="1">Pity</th><th align="left" rowspan="1" colspan="1">Support</th><th align="left" rowspan="1" colspan="1">Antipathy</th><th align="left" rowspan="1" colspan="1">Social distance</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">White</td><td align="char" rowspan="1" colspan="1">15.9 (14.4 to 17.5)</td><td align="char" rowspan="1" colspan="1">4.8 (3.9 to 5.7)</td><td align="char" rowspan="1" colspan="1">2.1 (1.5 to 2.7)</td><td align="char" rowspan="1" colspan="1">18.0 (16.4 to 19.6)</td><td align="char" rowspan="1" colspan="1">35.4 (33.4 to 37.4)</td><td align="char" rowspan="1" colspan="1">2.4 (1.8 to 3.1)</td><td align="char" rowspan="1" colspan="1">6.5 (5.4 to 7.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Black</td><td align="char" rowspan="1" colspan="1">22.3 (19.8 to 24.8)</td><td align="char" rowspan="1" colspan="1">15.4 (13.2 to 17.5)</td><td align="char" rowspan="1" colspan="1">10.0 (8.2 to 11.7)</td><td align="char" rowspan="1" colspan="1">30.2 (27.4 to 32.9)</td><td align="char" rowspan="1" colspan="1">53.0 (50.1 to 56.0)</td><td align="char" rowspan="1" colspan="1">8.6 (6.9 to 10.3)</td><td align="char" rowspan="1" colspan="1">11.2 (9.4 to 13.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Asian</td><td align="char" rowspan="1" colspan="1">13.8 (7.5 to 20.1)</td><td align="char" rowspan="1" colspan="1">2.6 (&#8211;0.3 to 5.5)</td><td align="char" rowspan="1" colspan="1">0.9 (&#8211;0.9 to 2.6)</td><td align="char" rowspan="1" colspan="1">16.4 (9.6 to 23.1)</td><td align="char" rowspan="1" colspan="1">29.3 (21.0 to 37.6)</td><td align="char" rowspan="1" colspan="1">3.4 (0.1 to 6.8)</td><td align="char" rowspan="1" colspan="1">7.8 (2.9 to 12.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">AIAN</td><td align="char" rowspan="1" colspan="1">27.6 (11.0 to 44.1)</td><td align="char" rowspan="1" colspan="1">6.9 (&#8211;2.5 to 16.3)</td><td align="char" rowspan="1" colspan="1">3.4 (&#8211;3.3 to 10.2)</td><td align="char" rowspan="1" colspan="1">34.5 (16.9 to 52.1)</td><td align="char" rowspan="1" colspan="1">41.4 (23.1 to 59.6)</td><td align="char" rowspan="1" colspan="1">3.4 (&#8211;3.3 to 10.2)</td><td align="char" rowspan="1" colspan="1">13.8 (1.0 to 26.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">NHPI</td><td align="char" rowspan="1" colspan="1">66.7 (25.3 to 108.0)</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="char" rowspan="1" colspan="1">50.0 (6.2 to 93.8)</td><td align="char" rowspan="1" colspan="1">66.7 (25.3 to 108.0)</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" rowspan="1" colspan="1">Other racial category</td><td align="char" rowspan="1" colspan="1">18.0 (8.3 to 27.8)</td><td align="char" rowspan="1" colspan="1">3.3 (&#8211;1.2 to 7.8)</td><td align="char" rowspan="1" colspan="1">4.9 (&#8211;0.6 to 10.4)</td><td align="char" rowspan="1" colspan="1">13.1 (4.6 to 21.7)</td><td align="char" rowspan="1" colspan="1">27.9 (16.5 to 39.2)</td><td align="char" rowspan="1" colspan="1">3.3 (&#8211;1.2 to 7.8)</td><td align="char" rowspan="1" colspan="1">4.9 (&#8211;0.6 to 10.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Two or more races</td><td align="char" rowspan="1" colspan="1">15.2 (8.1 to 22.3)</td><td align="char" rowspan="1" colspan="1">9.1 (3.4 to 14.8)</td><td align="char" rowspan="1" colspan="1">8.1 (2.7 to 13.5)</td><td align="char" rowspan="1" colspan="1">27.3 (18.5 to 36.1)</td><td align="char" rowspan="1" colspan="1">42.4 (32.6 to 52.2)</td><td align="char" rowspan="1" colspan="1">6.1 (1.3 to 10.8)</td><td align="char" rowspan="1" colspan="1">10.1 (4.1 to 16.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hispanic or Latina/o/x</td><td align="char" rowspan="1" colspan="1">23.3 (19.1 to 27.4)</td><td align="char" rowspan="1" colspan="1">9.7 (6.8 to 12.5)</td><td align="char" rowspan="1" colspan="1">7.7 (5.1 to 10.3)</td><td align="char" rowspan="1" colspan="1">25.7 (21.5 to 30.0)</td><td align="char" rowspan="1" colspan="1">43.3 (38.5 to 48.2)</td><td align="char" rowspan="1" colspan="1">5.4 (3.2 to 7.7)</td><td align="char" rowspan="1" colspan="1">9.7 (6.8 to 12.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Not Hispanic or Latina/o/x</td><td align="char" rowspan="1" colspan="1">17.3 (16.0 to 18.7)</td><td align="char" rowspan="1" colspan="1">7.9 (6.9 to 8.8)</td><td align="char" rowspan="1" colspan="1">4.3 (3.6 to 5.0)</td><td align="char" rowspan="1" colspan="1">21.6 (20.2 to 23.0)</td><td align="char" rowspan="1" colspan="1">40.5 (38.8 to 42.2)</td><td align="char" rowspan="1" colspan="1">4.4 (3.6 to 5.1)</td><td align="char" rowspan="1" colspan="1">7.9 (7.0 to 8.9)</td></tr></tbody></table><table-wrap-foot><fn id="dad270178-tbl3-note-0001"><p>
<italic toggle="yes">Note</italic>. Models adjusted for participant age (years).</p></fn><fn id="dad270178-tbl3-note-0002"><p>Abbreviations: AD,&#160;Alzheimer's disease; AIAN,&#160;American Indian or Alaskan Native; FS&#8208;ADS,&#160;Family Stigma Alzheimer's Disease Scale; CI,&#160; confidence interval; N/A,&#160;data not available; NHPI,&#160;Native Hawaiian or Pacific Islander.</p></fn><fn id="dad270178-tbl3-note-0003"><p>Higher stigma is defined as ratings of &gt; 3.4 on the FS&#8208;ADS domains. Non&#8208;overlapping confidence intervals are significant at <italic toggle="yes">P</italic>&#160;&lt;&#160;0.05.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>The pattern of results for willingness to support persons with AD, strong feelings of pity, and worries about structural discrimination was similar among groups of Black participants: willingness to support (53%, 95% CI 50% to 56%), pity (30%, 95% CI 27% to 33%), and structural discrimination (22%, 95% CI 20% to 25%). Black participants were also more likely to make high negative severity attributions (15%, 95% CI 13% to 17%) and strong expectations of social distance (11%, 95% CI 9% to 13%) compared to all other race groups.</p><p>Strong worries of high structural discrimination (23%, 95% CI 8% to 22%) and negative aesthetic attributions (8%, 95% CI 5% to 10%) were more frequent among Hispanic/Latino participants than non&#8208;Hispanic/Latino participants. Strong endorsements for all other FS&#8208;ADS domains were statistically similar (all <italic toggle="yes">P</italic>&#160;&gt;&#160;0.05) between Hispanic/Latino participants and non&#8208;Hispanic/Latino participants.</p><p>Confidence in an AD diagnosis was generally higher among those who endorse high AD stigma. Asked to rate their confidence in an AD diagnosis based on an evaluation that included a clinical interview and physical examination, White participants with high worries about structural discrimination had an adjusted mean confidence in an AD diagnosis of 40.18 points (95% CI 37.03 to 43.34). In comparison, White participants with lower worries about structural discrimination had an adjusted mean confidence in an AD diagnosis of 35.61 points (95% CI 34.34 to 36.88) in the same evaluation category (Table&#160;<xref rid="dad270178-tbl-0004" ref-type="table">4</xref>).</p><table-wrap position="float" id="dad270178-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>Age&#8208;adjusted mean (95% CI) confidence rating in AD diagnosis by high and low AD stigma domain and race group.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" colspan="10" style="border-bottom:solid 1px #000000" rowspan="1">FS&#8208;ADS domain [adjusted mean, (95% CI)]</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Structural discrimination</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Negative severity attributions</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Pity</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Support</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Social distance</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Evaluation categories<xref rid="dad270178-tbl4-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="left" rowspan="1" colspan="1">Low</th><th align="left" rowspan="1" colspan="1">High</th><th align="left" rowspan="1" colspan="1">Low</th><th align="left" rowspan="1" colspan="1">High</th><th align="left" rowspan="1" colspan="1">Low</th><th align="left" rowspan="1" colspan="1">High</th><th align="left" rowspan="1" colspan="1">Low</th><th align="left" rowspan="1" colspan="1">High</th><th align="left" rowspan="1" colspan="1">Low</th><th align="left" rowspan="1" colspan="1">High</th></tr></thead><tbody><tr><td colspan="11" align="left" rowspan="1">White (<italic toggle="yes">n</italic>&#160;=&#160;2143)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>Clinical history interview and physical exam [i]</p>
</td><td align="char" rowspan="1" colspan="1">35.6 (34.3 to 36.9)</td><td align="char" rowspan="1" colspan="1">40.2 (37.0 to 43.3)</td><td align="char" rowspan="1" colspan="1">35.3 (34.1 to 36.5)</td><td align="char" rowspan="1" colspan="1">56.4 (50.9 to 61.8)</td><td align="char" rowspan="1" colspan="1">34.9 (33.6 to 36.2)</td><td align="char" rowspan="1" colspan="1">42.8 (39.8 to 45.8)</td><td align="char" rowspan="1" colspan="1">33.6 (32.2 to 35.0)</td><td align="char" rowspan="1" colspan="1">41.3 (39.1 to 43.4)</td><td align="char" rowspan="1" colspan="1">35.8 (34.6 to 37.0)</td><td align="char" rowspan="1" colspan="1">44.4 (39.4 to 49.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>&#8230;and memory tests [ii]</p>
</td><td align="char" rowspan="1" colspan="1">44.6 (43.4 to 45.9)</td><td align="char" rowspan="1" colspan="1">48.5 (45.5 to 51.5)</td><td align="char" rowspan="1" colspan="1">44.4 (43.2 to 45.5)</td><td align="char" rowspan="1" colspan="1">62.6 (57.5 to 67.6)</td><td align="char" rowspan="1" colspan="1">44.1 (42.8 to 45.3)</td><td align="char" rowspan="1" colspan="1">50.8 (48.0 to 53.5)</td><td align="char" rowspan="1" colspan="1">42.9 (41.6 to 44.3)</td><td align="char" rowspan="1" colspan="1">49.5 (47.5 to 51.5)</td><td align="char" rowspan="1" colspan="1">44.8 (43.6 to 45.9)</td><td align="char" rowspan="1" colspan="1">52.3 (47.7 to 56.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>&#8230;and blood tests [iii]</p>
</td><td align="char" rowspan="1" colspan="1">54.0 (53.8 to 55.2)</td><td align="char" rowspan="1" colspan="1">57.4 (54.4 to 60.5)</td><td align="char" rowspan="1" colspan="1">54.0 (52.8 to 55.1)</td><td align="char" rowspan="1" colspan="1">65.4 (60.6 to 70.1)</td><td align="char" rowspan="1" colspan="1">53.5 (52.3 to 54.8)</td><td align="char" rowspan="1" colspan="1">59.0 (56.3 to 61.7)</td><td align="char" rowspan="1" colspan="1">52.3 (51.0 to 53.7)</td><td align="char" rowspan="1" colspan="1">58.5 (56.6 to 60.4)</td><td align="char" rowspan="1" colspan="1">54.1 (52.9 to 55.2)</td><td align="char" rowspan="1" colspan="1">61.2 (57.1 to 65.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>&#8230;and a brain scan [iv]</p>
</td><td align="char" rowspan="1" colspan="1">77.8 (76.8 to 78.8)</td><td align="char" rowspan="1" colspan="1">78.2 (75.6 to 80.7)</td><td align="char" rowspan="1" colspan="1">78.0 (77.1 to 79.0)</td><td align="char" rowspan="1" colspan="1">75.1 (71.0 to 79.3)</td><td align="char" rowspan="1" colspan="1">77.4 (76.4 to 78.4)</td><td align="char" rowspan="1" colspan="1">80.0 (77.9 to 82.2)</td><td align="char" rowspan="1" colspan="1">76.5 (75.3 to 77.7)</td><td align="char" rowspan="1" colspan="1">80.4 (78.9 to 81.9)</td><td align="char" rowspan="1" colspan="1">78.1 (77.2 to 79.1)</td><td align="char" rowspan="1" colspan="1">74.1 (70.3 to 77.8)</td></tr><tr><td colspan="11" align="left" rowspan="1">Black (<italic toggle="yes">n</italic>&#160;=&#160;1094)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>Clinical history interview and physical exam [i]</p>
</td><td align="char" rowspan="1" colspan="1">45.1 (43.1 to 47.0)</td><td align="char" rowspan="1" colspan="1">53.5 (49.8 to 57.2)</td><td align="char" rowspan="1" colspan="1">44.4 (42.5 to 46.3)</td><td align="char" rowspan="1" colspan="1">60.8 (56.7 to 64.9)</td><td align="char" rowspan="1" colspan="1">43.4 (41.3 to 45.5)</td><td align="char" rowspan="1" colspan="1">55.2 (52.0 to 58.4)</td><td align="char" rowspan="1" colspan="1">42.4 (39.9 to 44.9)</td><td align="char" rowspan="1" colspan="1">51.0 (48.5 to 53.4)</td><td align="char" rowspan="1" colspan="1">45.3 (43.4 to 47.1)</td><td align="char" rowspan="1" colspan="1">60.1 (55.2 to 65.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>&#8230;and memory tests [ii]</p>
</td><td align="char" rowspan="1" colspan="1">52.4 (50.6 to 54.3)</td><td align="char" rowspan="1" colspan="1">59.7 (56.4 to 63.0)</td><td align="char" rowspan="1" colspan="1">52.3 (50.5 to 54.0)</td><td align="char" rowspan="1" colspan="1">63.9 (60.0 to 67.8)</td><td align="char" rowspan="1" colspan="1">51.1 (49.2 to 53.0)</td><td align="char" rowspan="1" colspan="1">61.0 (58.1 to 64.0)</td><td align="char" rowspan="1" colspan="1">48.5 (46.1 to 50.8)</td><td align="char" rowspan="1" colspan="1">59.0 (56.8 to 61.2)</td><td align="char" rowspan="1" colspan="1">53.3 (51.5 to 55.0)</td><td align="char" rowspan="1" colspan="1">60.4 (55.6 to 65.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>&#8230;and blood tests [iii]</p>
</td><td align="char" rowspan="1" colspan="1">58.8 (56.9 to 60.6)</td><td align="char" rowspan="1" colspan="1">65.9 (62.7 to 69.1)</td><td align="char" rowspan="1" colspan="1">58.9 (57.1 to 60.6)</td><td align="char" rowspan="1" colspan="1">68.6 (65.0 to 72.2)</td><td align="char" rowspan="1" colspan="1">57.8 (56.0 to 59.7)</td><td align="char" rowspan="1" colspan="1">66.2 (63.3 to 69.0)</td><td align="char" rowspan="1" colspan="1">56.1 (53.8 to 58.4)</td><td align="char" rowspan="1" colspan="1">64.1 (61.9 to 66.3)</td><td align="char" rowspan="1" colspan="1">59.8 (58.1 to 61.5)</td><td align="char" rowspan="1" colspan="1">64.5 (60.0 to 69.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>&#8230;and a brain scan [iv]</p>
</td><td align="char" rowspan="1" colspan="1">72.3 (70.5 to 74.0)</td><td align="char" rowspan="1" colspan="1">72.0 (68.9 to 75.2)</td><td align="char" rowspan="1" colspan="1">72.7 (71.0 to 74.3)</td><td align="char" rowspan="1" colspan="1">69.8 (66.0 to 73.5)</td><td align="char" rowspan="1" colspan="1">71.8 (70.0 to 73.6)</td><td align="char" rowspan="1" colspan="1">73.1 (70.4 to 75.9)</td><td align="char" rowspan="1" colspan="1">70.7 (68.5 to 72.8)</td><td align="char" rowspan="1" colspan="1">73.6 (71.5 to 75.7)</td><td align="char" rowspan="1" colspan="1">72.6 (71.0 to 74.3)</td><td align="char" rowspan="1" colspan="1">68.9 (64.6 to 73.2)</td></tr><tr><td colspan="11" align="left" rowspan="1">Asian (<italic toggle="yes">n</italic>&#160;=&#160;116)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>Clinical history interview and physical exam [i]</p>
</td><td align="char" rowspan="1" colspan="1">41.9 (36.9 to 46.9)</td><td align="char" rowspan="1" colspan="1">54.1 (37.56 to 70.7)</td><td align="char" rowspan="1" colspan="1">42.4 (37.5 to 47.2)</td><td align="char" rowspan="1" colspan="1">88.3 (76.7 to 100.0)</td><td align="char" rowspan="1" colspan="1">40.8 (35.7 to 45.9)</td><td align="char" rowspan="1" colspan="1">57.8 (44.5 to 71.1)</td><td align="char" rowspan="1" colspan="1">41.1 (35.5 to 46.7)</td><td align="char" rowspan="1" colspan="1">49.5 (39.6 to 59.4)</td><td align="char" rowspan="1" colspan="1">42.7 (37.7 to 47.7)</td><td align="char" rowspan="1" colspan="1">54.0 (32.2 to 75.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>&#8230;and memory tests [ii]</p>
</td><td align="char" rowspan="1" colspan="1">48.9 (44.2 to 53.7)</td><td align="char" rowspan="1" colspan="1">63.9 (50.1 to 77.8)</td><td align="char" rowspan="1" colspan="1">50.1 (45.5 to 54.7)</td><td align="char" rowspan="1" colspan="1">84.3 (67.6 to 101.1)</td><td align="char" rowspan="1" colspan="1">48.1 (43.4 to 52.8)</td><td align="char" rowspan="1" colspan="1">65.7 (53.1 to 78.3)</td><td align="char" rowspan="1" colspan="1">47.8 (42.7 to 53.0)</td><td align="char" rowspan="1" colspan="1">58.7 (49.5 to 67.9)</td><td align="char" rowspan="1" colspan="1">50.4 (45.7 to 55.1)</td><td align="char" rowspan="1" colspan="1">58.7 (39.1 to 78.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>&#8230;and blood tests [iii]</p>
</td><td align="char" rowspan="1" colspan="1">58.2 (53.4 to 62.9)</td><td align="char" rowspan="1" colspan="1">68.8 (56.9 to 80.8)</td><td align="char" rowspan="1" colspan="1">58.8 (54.4 to 63.3)</td><td align="char" rowspan="1" colspan="1">90.0 (77.3 to 102.7)</td><td align="char" rowspan="1" colspan="1">57.1 (52.4 to 61.7)</td><td align="char" rowspan="1" colspan="1">72.6 (60.8 to 84.4)</td><td align="char" rowspan="1" colspan="1">55.6 (50.3 to 60.4)</td><td align="char" rowspan="1" colspan="1">69.9 (61.8 to 78.0)</td><td align="char" rowspan="1" colspan="1">59.7 (55.2 to 64.2)</td><td align="char" rowspan="1" colspan="1">58.6 (36.2 to 80.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>&#8230;and a brain scan [iv]</p>
</td><td align="char" rowspan="1" colspan="1">76.5 (72.3 to 80.6)</td><td align="char" rowspan="1" colspan="1">84.1 (73.7 to 94.4)</td><td align="char" rowspan="1" colspan="1">77.2 (73.2 to 81.1)</td><td align="char" rowspan="1" colspan="1">91.0 (73.2 to 108.8)</td><td align="char" rowspan="1" colspan="1">76.4 (72.1 to 80.6)</td><td align="char" rowspan="1" colspan="1">83.4 (74.3 to 92.5)</td><td align="char" rowspan="1" colspan="1">76.8 (72.5 to 81.2)</td><td align="char" rowspan="1" colspan="1">79.1 (71.1 to 87.2)</td><td align="char" rowspan="1" colspan="1">77.6 (73.6 to 81.5)</td><td align="char" rowspan="1" colspan="1">76.9 (59.0 to 94.8)</td></tr><tr><td colspan="11" align="left" rowspan="1">AIAN (<italic toggle="yes">n</italic>&#160;=&#160;29)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>Clinical history interview and physical exam [i]</p>
</td><td align="char" rowspan="1" colspan="1">39.5 (26.1 to 52.9)</td><td align="char" rowspan="1" colspan="1">47.3 (26.5 to 68.0)</td><td align="char" rowspan="1" colspan="1">39.9 (28.2 to 51.5)</td><td align="char" rowspan="1" colspan="1">66.0 (N/A)</td><td align="char" rowspan="1" colspan="1">36.6 (22.6 to 50.6)</td><td align="char" rowspan="1" colspan="1">51.3 (33.6 to 69.0)</td><td align="char" rowspan="1" colspan="1">45.4 (31.6 to 59.1)</td><td align="char" rowspan="1" colspan="1">36.4 (17.6 to 55.3)</td><td align="char" rowspan="1" colspan="1">38.1 (25.9 to 50.4)</td><td align="char" rowspan="1" colspan="1">63.8 (52.2 to 75.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>&#8230;and memory tests [ii]</p>
</td><td align="char" rowspan="1" colspan="1">48.3 (34.6 to 62.0)</td><td align="char" rowspan="1" colspan="1">55.9 (36.1 to 75.6)</td><td align="char" rowspan="1" colspan="1">47.8 (36.4 to 59.1)</td><td align="char" rowspan="1" colspan="1">85.5 (84.5 to 86.5)</td><td align="char" rowspan="1" colspan="1">50.9 (36.9 to 64.9)</td><td align="char" rowspan="1" colspan="1">49.4 (29.7 to 69.1)</td><td align="char" rowspan="1" colspan="1">50.2 (37.0 to 63.4)</td><td align="char" rowspan="1" colspan="1">50.7 (30.3 to 71.0)</td><td align="char" rowspan="1" colspan="1">45.9 (34.0 to 57.9)</td><td align="char" rowspan="1" colspan="1">78.3 (69.0 to 87.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>&#8230;and blood tests [iii]</p>
</td><td align="char" rowspan="1" colspan="1">56.7 (42.9 to 70.4)</td><td align="char" rowspan="1" colspan="1">56.3 (38.9 to 73.6)</td><td align="char" rowspan="1" colspan="1">56.7 (45.1 to 68.4)</td><td align="char" rowspan="1" colspan="1">54.0 (31.5 to 76.5)</td><td align="char" rowspan="1" colspan="1">55.8 (41.6 to 70.0)</td><td align="char" rowspan="1" colspan="1">58.0 (40.6 to 75.4)</td><td align="char" rowspan="1" colspan="1">61.9 (47.3 to 76.6)</td><td align="char" rowspan="1" colspan="1">48.9 (33.1 to 64.7)</td><td align="char" rowspan="1" colspan="1">54.7 (42.5 to 66.9)</td><td align="char" rowspan="1" colspan="1">68.0 (48.2 to 87.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>&#8230;and a brain scan [iv]</p>
</td><td align="char" rowspan="1" colspan="1">78.7 (66.9 to 90.5)</td><td align="char" rowspan="1" colspan="1">78.9 (65.2 to 92.6)</td><td align="char" rowspan="1" colspan="1">79.4 (69.6 to 89.2)</td><td align="char" rowspan="1" colspan="1">69.5 (52.1 to 86.9)</td><td align="char" rowspan="1" colspan="1">77.1 (64.3 to 89.9)</td><td align="char" rowspan="1" colspan="1">81.8 (70.0 to 93.6)</td><td align="char" rowspan="1" colspan="1">78.0 (66.5 to 89.5)</td><td align="char" rowspan="1" colspan="1">79.8 (64.0 to 95.5)</td><td align="char" rowspan="1" colspan="1">78.3 (67.8 to 88.7)</td><td align="char" rowspan="1" colspan="1">81.5 (64.7 to 98.3)</td></tr><tr><td colspan="11" align="left" rowspan="1">NHPI (<italic toggle="yes">n</italic>&#160;=&#160;6)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>Clinical history interview and physical exam [i]</p>
</td><td align="char" rowspan="1" colspan="1">92.5 (73.2 to 111.8)</td><td align="char" rowspan="1" colspan="1">59.3 (37.7 to 80.8)</td><td align="char" rowspan="1" colspan="1">70.3 (47.2 to 93.5)</td><td align="left" rowspan="1" colspan="1">(N/A)</td><td align="char" rowspan="1" colspan="1">65.7 (30.3 to 101.1)</td><td align="char" rowspan="1" colspan="1">75.0 (39.3 to 110.7)</td><td align="char" rowspan="1" colspan="1">56.0 (12.3 to 99.7)</td><td align="char" rowspan="1" colspan="1">77.5 (51.4 to 103.6)</td><td align="char" rowspan="1" colspan="1">70.3 (47.2 to 93.5)</td><td align="left" rowspan="1" colspan="1">(N/A)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>&#8230;and memory tests [ii]</p>
</td><td align="char" rowspan="1" colspan="1">66.0 (22.3 to 109.7)</td><td align="char" rowspan="1" colspan="1">57.3 (42.0 to 72.5)</td><td align="char" rowspan="1" colspan="1">60.2 (44.6 to 75.8)</td><td align="left" rowspan="1" colspan="1">(N/A)</td><td align="char" rowspan="1" colspan="1">54.0 (31.5 to 76.5)</td><td align="char" rowspan="1" colspan="1">66.3 (44.9 to 87.8)</td><td align="char" rowspan="1" colspan="1">50.5 (28.7 to 72.4)</td><td align="char" rowspan="1" colspan="1">65.0 (45.7 to 84.4)</td><td align="char" rowspan="1" colspan="1">60.2 (44.6 to 75.8)</td><td align="left" rowspan="1" colspan="1">(N/A)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>&#8230;and blood tests [iii]</p>
</td><td align="char" rowspan="1" colspan="1">95.0 (82.2 to 107.9)</td><td align="char" rowspan="1" colspan="1">65.3 (63.3 to 67.2)</td><td align="char" rowspan="1" colspan="1">75.2 (58.7 to 91.7)</td><td align="left" rowspan="1" colspan="1">(N/A)</td><td align="char" rowspan="1" colspan="1">76.3 (45.8 to 106.8)</td><td align="char" rowspan="1" colspan="1">74.0 (53.4 to 94.6)</td><td align="char" rowspan="1" colspan="1">64.5 (60.6 to 68.4)</td><td align="char" rowspan="1" colspan="1">80.5 (58.4 to 102.7)</td><td align="char" rowspan="1" colspan="1">75.2 (58.7 to 91.7)</td><td align="left" rowspan="1" colspan="1">(N/A)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>&#8230;and a brain scan [iv]</p>
</td><td align="char" rowspan="1" colspan="1">91.0 (67.9 to 114.1)</td><td align="char" rowspan="1" colspan="1">70.8 (58.6 to 82.9)</td><td align="char" rowspan="1" colspan="1">77.5 (62.8 to 92.2)</td><td align="left" rowspan="1" colspan="1">(N/A)</td><td align="char" rowspan="1" colspan="1">77.0 (45.9 to 108.1)</td><td align="char" rowspan="1" colspan="1">78.0 (67.7 to 88.3)</td><td align="char" rowspan="1" colspan="1">64.5 (50.4 to 78.6)</td><td align="char" rowspan="1" colspan="1">84.0 (69.0 to 99.0)</td><td align="char" rowspan="1" colspan="1">77.5 (62.8 to 92.2)</td><td align="left" rowspan="1" colspan="1">(N/A)</td></tr><tr><td colspan="11" align="left" rowspan="1">Other racial category (<italic toggle="yes">n</italic>&#160;=&#160;61)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>Clinical history interview and physical exam [i]</p>
</td><td align="char" rowspan="1" colspan="1">38.3 (29.3 to 47.3)</td><td align="char" rowspan="1" colspan="1">54.6 (36.1 to 73.1)</td><td align="char" rowspan="1" colspan="1">40.7 (32.5 to 48.9)</td><td align="char" rowspan="1" colspan="1">57.5 (&#8211;27.5 to 142.5)</td><td align="char" rowspan="1" colspan="1">41.5 (32.5 to 50.5)</td><td align="char" rowspan="1" colspan="1">39.5 (20.6 to 58.5)</td><td align="char" rowspan="1" colspan="1">40.3 (30.7 to 49.9)</td><td align="char" rowspan="1" colspan="1">43.7 (27.6 to 59.8)</td><td align="char" rowspan="1" colspan="1">41.4 (33.2 to 49.6)</td><td align="char" rowspan="1" colspan="1">38.3 (&#8211;23.4 to 100.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>&#8230;and memory tests [ii]</p>
</td><td align="char" rowspan="1" colspan="1">42.0 (33.5 to 50.6)</td><td align="char" rowspan="1" colspan="1">52.1 (35.2 to 69.0)</td><td align="char" rowspan="1" colspan="1">43.2 (35.6 to 50.8)</td><td align="char" rowspan="1" colspan="1">63.0 (&#8211;11.0 to 137.0)</td><td align="char" rowspan="1" colspan="1">43.1 (34.9 to 51.3)</td><td align="char" rowspan="1" colspan="1">48.8 (26.5 to 71.0)</td><td align="char" rowspan="1" colspan="1">41.2 (32.2 to 50.1)</td><td align="char" rowspan="1" colspan="1">50.8 (36.3 to 65.3)</td><td align="char" rowspan="1" colspan="1">44.1 (36.5 to 51.6)</td><td align="char" rowspan="1" colspan="1">39.7 (&#8211;21.7 to 101.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>&#8230;and blood tests [iii]</p>
</td><td align="char" rowspan="1" colspan="1">47.5 (40.2 to 54.9)</td><td align="char" rowspan="1" colspan="1">59.2 (45.0 to 73.3)</td><td align="char" rowspan="1" colspan="1">50.0 (43.3 to 56.7)</td><td align="char" rowspan="1" colspan="1">38.5 (3.5 to 73.5)</td><td align="char" rowspan="1" colspan="1">49.6 (42.5 to 56.6)</td><td align="char" rowspan="1" colspan="1">50.1 (31.7 to 68.6)</td><td align="char" rowspan="1" colspan="1">46.0 (38.8 to 53.3)</td><td align="char" rowspan="1" colspan="1">59.1 (45.4 to 72.7)</td><td align="char" rowspan="1" colspan="1">50.1 (43.3 to 57.0)</td><td align="char" rowspan="1" colspan="1">40.3 (19.0 to 61.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>&#8230;and a brain scan [iv]</p>
</td><td align="char" rowspan="1" colspan="1">68.0 (60.2 to 75.9)</td><td align="char" rowspan="1" colspan="1">65.8 (49.6 to 82.1)</td><td align="char" rowspan="1" colspan="1">68.0 (60.9 to 75.2)</td><td align="char" rowspan="1" colspan="1">55.5 (6.5 to 104.5)</td><td align="char" rowspan="1" colspan="1">69.3 (61.8 to 76.8)</td><td align="char" rowspan="1" colspan="1">56.5 (37.6 to 75.5)</td><td align="char" rowspan="1" colspan="1">66.0 (57.8 to 74.2)</td><td align="char" rowspan="1" colspan="1">71.8 (58.2 to 85.4)</td><td align="char" rowspan="1" colspan="1">67.3 (59.9 to 74.7)</td><td align="char" rowspan="1" colspan="1">73.8 (67.1 to 80.2)</td></tr><tr><td colspan="11" align="left" rowspan="1">Two or more races (<italic toggle="yes">n</italic>&#160;=&#160;99)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>Clinical history interview and physical exam [i]</p>
</td><td align="char" rowspan="1" colspan="1">37.1 (30.8 to 43.4)</td><td align="char" rowspan="1" colspan="1">33.1 (27.0 to 39.1)</td><td align="char" rowspan="1" colspan="1">34.6 (29.0 to 40.3)</td><td align="char" rowspan="1" colspan="1">55.0 (39.6 to 70.4)</td><td align="char" rowspan="1" colspan="1">34.2 (27.9 to 40.5)</td><td align="char" rowspan="1" colspan="1">42.6 (32.2 to 53.1)</td><td align="char" rowspan="1" colspan="1">32.3 (25.5 to 39.0)</td><td align="char" rowspan="1" colspan="1">42.2 (33.5 to 50.9)</td><td align="char" rowspan="1" colspan="1">34.2 (28.7 to 39.7)</td><td align="char" rowspan="1" colspan="1">56.7 (39.5 to 73.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>&#8230;and memory tests [ii]</p>
</td><td align="char" rowspan="1" colspan="1">46.1 (40.0 to 52.3)</td><td align="char" rowspan="1" colspan="1">35.5 (27.6 to 43.5)</td><td align="char" rowspan="1" colspan="1">43.6 (37.8 to 49.4)</td><td align="char" rowspan="1" colspan="1">53.6 (42.4 to 64.7)</td><td align="char" rowspan="1" colspan="1">41.3 (35.0 to 47.7)</td><td align="char" rowspan="1" colspan="1">53.0 (43.5 to 62.6)</td><td align="char" rowspan="1" colspan="1">41.6 (34.7 to 48.5)</td><td align="char" rowspan="1" colspan="1">48.5 (40.0 to 57.0)</td><td align="char" rowspan="1" colspan="1">42.5 (36.9 to 48.0)</td><td align="char" rowspan="1" colspan="1">62.9 (46.1 to 79.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>&#8230;and blood tests [iii]</p>
</td><td align="char" rowspan="1" colspan="1">57.2 (51.6 to 62.9)</td><td align="char" rowspan="1" colspan="1">53.9 (41.7 to 66.0)</td><td align="char" rowspan="1" colspan="1">56.2 (50.8 to 61.6)</td><td align="char" rowspan="1" colspan="1">62.0 (45.8 to 78.2)</td><td align="char" rowspan="1" colspan="1">52.8 (46.4 to 59.1)</td><td align="char" rowspan="1" colspan="1">67.3 (60.7 to 73.8)</td><td align="char" rowspan="1" colspan="1">53.1 (46.3 to 59.9)</td><td align="char" rowspan="1" colspan="1">62.0 (54.0 to 69.2)</td><td align="char" rowspan="1" colspan="1">55.4 (50.0 to 60.9)</td><td align="char" rowspan="1" colspan="1">68.2 (54.7 to 81.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>&#8230;and a brain scan [iv]</p>
</td><td align="char" rowspan="1" colspan="1">79.0 (74.1 to 83.8)</td><td align="char" rowspan="1" colspan="1">69.4 (58.0 to 80.8)</td><td align="char" rowspan="1" colspan="1">78.6 (74.0 to 83.2)</td><td align="char" rowspan="1" colspan="1">66.4 (48.3 to 84.6)</td><td align="char" rowspan="1" colspan="1">76.3 (70.7 to 81.9)</td><td align="char" rowspan="1" colspan="1">80.7 (74.0 to 87.5)</td><td align="char" rowspan="1" colspan="1">75.5 (69.4 to 81.5)</td><td align="char" rowspan="1" colspan="1">80.3 (73.6 to 87.0)</td><td align="char" rowspan="1" colspan="1">77.8 (73.0 to 82.6)</td><td align="char" rowspan="1" colspan="1">75.2 (62.2 to 88.)</td></tr></tbody></table><table-wrap-foot><fn id="dad270178-tbl4-note-0001"><p>
<italic toggle="yes">Note</italic>. Models adjusted for participant age (years). Low&#160;=&#160;score on FS&#8208;ADS scale of&#160;&lt;&#160;3.5. High&#160;=&#160;score on FS&#8208;ADS scale of&#160;&gt;&#160;3.4.</p></fn><fn id="dad270178-tbl4-note-0002"><p>Abbreviations: AD,&#160;Alzheimer's disease; AIAN,&#160;American Indian or Alaskan Native; FS&#8208;ADS,&#160;Family Stigma Alzheimer's Disease Scale; CI,&#160; confidence interval; N/A,&#160;data not available; NHPI,&#160;Native Hawaiian or Pacific Islander.</p></fn><fn id="dad270178-tbl4-note-0003"><p>Non&#8208;overlapping confidence intervals are significant at <italic toggle="yes">P</italic>&#160;&lt;&#160;0.05.</p></fn><fn id="dad270178-tbl4-note-0004"><label>
<sup>a</sup>
</label><p>Evaluation categories: (i) clinical history interview and physical exam; (ii) clinical history interview, physical exam, and memory tests; (iii) clinical history interview, physical exam, memory tests, and blood tests; (iv) clinical history interview, physical exam, memory tests, blood tests, and a brain scan.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>How confidence in an AD diagnosis changed across the evaluation categories varied by AD stigma domain and level as well as race group (Figure&#160;<xref rid="dad270178-fig-0002" ref-type="fig">2</xref>). For example, among Asian participants, adjusted mean confidence rating was statistically similar across the four evaluation categories in those reporting higher AD stigma as defined by negative symptom severity attributions. In contrast, among those reporting lower negative symptom severity attributions, adjusted mean confidence in an AD diagnosis increased linearly across the evaluation categories.</p><fig position="float" fig-type="FIGURE" id="dad270178-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Confidence in an AD diagnosis by participant race and ethnicity group, high and low AD stigma and evaluation category (<italic toggle="yes">N</italic>&#160;=&#160;3548). Race groups and FS&#8208;ADS domains that showed statistically significant differences in bivariate analyses (see Table&#160;<xref rid="dad270178-tbl-0003" ref-type="table">3</xref>) were carried forward to the interaction analyses with AD diagnosis confidence. A&#160;=&#160;Clinical history interview and physical exam only. B&#160;=&#160;Clinical history interview and physical exam and memory tests. C&#160;=&#160;Clinical history interview and physical exam, memory tests, and blood tests. D&#160;=&#160;Clinical history interview and physical exam, memory tests, and blood tests, and brain scan. AD, Alzheimer's disease; FS&#8208;ADS, Family Stigma Alzheimer's Disease Scale.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="DAD2-17-e70178-g002.jpg"/></fig></sec></sec><sec id="dad270178-sec-0180"><label>4</label><title>DISCUSSION</title><p>The goal of this study was to examine how use of AD biomarkers in diagnostic evaluations may impact AD diagnosis confidence and AD stigma among race and ethnicity groups in American adults. In this study, we found the association between AD diagnosis confidence and AD stigma differs by AD stigma level and racial group, suggesting AD stigma perceptions and AD testing translate variably into AD diagnosis confidence. This variability may be due to the degree to which individuals attribute confidence in the applicability of a diagnosis to components of the clinical evaluation. It may reflect the interplay of several factors, including their personal experiences, and their beliefs about health, illness, and medicine.</p><sec id="dad270178-sec-0190"><label>4.1</label><title>Differences in AD diagnosis confidence signal the need for patient&#8208;centered care</title><p>The study results indicate that understanding how AD biomarker tests are received by patients is a crucial part of the scientific process. While substantial resources are invested in establishing sensitive, specific, and clinically relevant AD biomarkers, this foundational work does not supersede the need for patient&#8208;centered discussions with patients and families. Patterns in diagnostic confidence varied widely across the race groups in this study, underscoring the importance of culturally informed clinical conversations that center on the preferences and values of patients and their families.</p><p>White participants showed a large increase in AD diagnosis confidence with the addition of a brain scan to the evaluation while Black participants showed a more modest increase. As a group, Black participants were not only less swayed by the addition of the brain scan, they were also more confident in their diagnosis based on the doctor's clinical interview. This juxtaposition raises questions about how rapid, technological advances in care may come with trade&#8208;offs to the patient&#8211;physician relationship. This finding aligns with prior data that suggest that Black adults may generally report high trust in physicians&#8217; technical competence.<xref rid="dad270178-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="dad270178-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> Prioritizing trust and technical competence is consistent with values and goals for dementia diagnosis that can be priorities for Black Americans, which include knowing what is wrong with their relative and facilitating connections with appropriate community resources.<xref rid="dad270178-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>
</p></sec><sec id="dad270178-sec-0200"><label>4.2</label><title>Systemic practices</title><p>Fundamental cause theory (FCT) poses that inequitable access to resources is the fundamental cause of health disparities. Inequities can include limited access to diagnostic testing, health&#8208;care systems&#8217; reliance on diagnostic tools predominantly validated in White populations, and insufficient integration of culturally informed approaches to diagnosis and education. Thus, differences in diagnosis confidence may reflect social inequities and cultural differences. For example, as a group, Black Americans are more likely than White Americans to be diagnosed in settings with limited access to diagnostic testing<xref rid="dad270178-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>, <xref rid="dad270178-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>, <xref rid="dad270178-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>, <xref rid="dad270178-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref> and less likely to receive diagnostic tests at all.<xref rid="dad270178-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> Existing disparities may worsen as diagnostic testing advances and becomes further consolidated in specialty care centers.</p><p>Addressing these disparities requires improving access to specialty care centers and expanding access to biomarker testing. Comprehensive patient education and specialist referrals are crucial for populations who have limited access to advanced diagnostic technologies while also expanding care pathways and the sociocultural inclusiveness of specialty care settings. Efforts to do this might include pilot programs with insurance companies and outreach to medical providers through professional organizations, practices, and conferences.</p></sec><sec id="dad270178-sec-0210"><label>4.3</label><title>AD stigma: common concerns about support, pity, and structural discrimination</title><p>Our findings partially support our hypothesis that concerns about discrimination and over&#8208;attribution of symptom severity would be among the most prevalent forms of AD stigma. We found support, pity, and structural discrimination were universally the most reported AD stigma domains across racial groups. Efforts are needed to reduce these common concerns. For instance, discussions with patients about beliefs, worries, and experiences related to AD can both correct misinformation and provide patients resources for social support; foster dignity using person&#8208;centered language; or improve self&#8208;care strategies.</p><p>Asian participants showed relatively high concerns about social distance. This is consistent with prior studies that show, specifically among groups of Chinese&#8208;American adults, there are cultural concerns about loneliness that relate to fear of losing face.<xref rid="dad270178-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> &#8216;Losing face' reflects a loss of family honor and collective standing.<xref rid="dad270178-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> Some individuals may avoid early diagnosis to protect family reputation. Exploring this possibility with direct, respectful inquiry that validates worries of losing face and offers resources to preserve family honor may best support individuals concerned about losing face because of early diagnosis.</p><p>We found that as diagnosis confidence increases with the category and number of diagnostic tests, AD stigma is simultaneously diminished. This finding has clinical implications as it underscores the importance that patients and families are confident in an AD diagnosis. Given that prior studies have also shown positive AD biomarker results can heighten AD stigma,<xref rid="dad270178-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="dad270178-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> further study is warranted to understand the nuance in how confidence contributes to higher versus lower AD stigma.</p></sec><sec id="dad270178-sec-0220"><label>4.4</label><title>Future directions</title><p>No racial or ethnic group approached 100% confidence in a diagnosis. This persistent uncertainty amplifies challenges for resource&#8208;limited patients who cannot pursue additional testing when confidence is low. Patient confidence in a provider's conclusions, when warranted, may help to improve diagnosis confidence, and mitigate the consequences of socioeconomic disparities due to low diagnostic confidence. Future research should investigate factors contributing to the &#8220;uncertainty gap&#8221; to improve AD diagnosis communication and develop care plans to address uncertainty.</p><p>Our study used a vignette experiment to examine how the use of AD biomarkers in diagnostic evaluations may impact AD diagnosis confidence and AD stigma among American racial and ethnic groups. While vignette studies can show excellent internal validity, it is unclear whether their results can generalize to in vivo experiences,<xref rid="dad270178-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> as this rests on their accurate portrayal of the situation under study and the factors that can influence that situation. The primary utility of vignette studies may be in contributing to the understanding of a specific scenario and its correlates to guide more resource&#8208;intensive in vivo studies.</p></sec><sec id="dad270178-sec-0230"><label>4.5</label><title>Study strengths and limitations</title><p>While our randomly drawn sample of 3548 individuals from a large national panel is a strength, it inadequately reflects the diversity of the United States. More work is needed to understand the interaction between stigma and diagnostic confidence within under&#8208;sampled populations including American Indian or Alaskan Native and Native Hawaiian or Pacific Islander communities. Data on these groups are infrequently reported in AD research,<xref rid="dad270178-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>, <xref rid="dad270178-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> despite high dementia prevalence in these groups.<xref rid="dad270178-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>, <xref rid="dad270178-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> Findings from these groups presented in this study are novel to the literature, and conclusions from these data should be made cautiously and may not generalize broadly. Participant responses may not reflect awareness of newer diagnostic techniques that, while increasingly common, are not yet widely used.<xref rid="dad270178-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref>
</p><p>Participation in our study required reading in English (fifth/sixth grade level; SMOG [simple measure of gobbledygook] index 5.9; automated readability index 5.1). Of the 258.3 million adults in the United States, 4.3% are non&#8208;literate in English. Approximately two thirds of these individuals read below the fifth grade level and one third (36%) experience language barriers<xref rid="dad270178-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref> whereby Spanish or Chinese are their primary languages.<xref rid="dad270178-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref> While the percentage appears numerically small, it affects 11 million people, who, as a consequence, are more likely to experience health&#8208;care disparities as a consequence of language barriers, including those specific to dementia diagnosis.<xref rid="dad270178-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref>
</p></sec></sec><sec id="dad270178-sec-0240"><label>5</label><title>CONCLUSION</title><p>Racial groups show varying levels of AD diagnosis confidence, potentially reflecting differences in health&#8208;care access, exposure to medical advances, and cultural perspectives on medicine. While additional diagnostic testing generally increases confidence, group differences indicate the importance of the provider&#8211;patient relationship. Patient&#8208;centered care should address families&#8217; perspectives on AD testing and the values that guide their decision making. Further consolidation of advanced testing in specialty care centers may widen existing disparities. Addressing these issues requires systemic improvements facilitating early diagnosis and culturally informed clinical practices.</p></sec><sec sec-type="COI-statement" id="dad270178-sec-0260"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors have no conflicts of interest to disclose. Author disclosures are available in the <xref rid="dad270178-supinfo-0001" ref-type="">supporting information</xref>
</p></sec><sec id="dad270178-sec-0270"><title>CONSENT STATEMENT</title><p>Informed consent was obtained from all participants prior to survey engagement. The University of Pennsylvania Institutional Review Board (IRB) deemed exempt all procedures involving human subjects for the &#8220;Health Beliefs Study&#8221; (#828348).</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="dad270178-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="dad270178-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="DAD2-17-e70178-s001.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="dad270178-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="DAD2-17-e70178-s002.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="dad270178-sec-0250"><title>ACKNOWLEDGMENTS</title><p>This work was supported by the National Institutes of Health (grant numbers NIA 1K23AG065442, 1K23AG065442&#8208;03S1), the Alzheimer's Association (grant number AARF&#8208;17&#8208;528934), the Alzheimer's Foundation of America and National Institute on Aging.</p></ack><ref-list id="dad270178-bibl-0001"><title>REFERENCES</title><ref id="dad270178-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="dad270178-cite-0002"><string-name name-style="western"><surname>Fantoni</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Chalkidou</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>O&#8217; Brien</surname><given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>Farrar</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Hammers</surname><given-names>A</given-names></string-name>. <article-title>A systematic review and aggregated analysis on the impact of amyloid PET brain imaging on the diagnosis, diagnostic confidence, and management of patients being evaluated for Alzheimer's disease</article-title>. <source>J Alzheimers Dis JAD</source>. <year>2018</year>;<volume>63</volume>(<issue>2</issue>):<fpage>783</fpage>&#8208;<lpage>796</lpage>. doi:<pub-id pub-id-type="doi">10.3233/JAD-171093</pub-id><pub-id pub-id-type="pmid">29689725</pub-id><pub-id pub-id-type="pmcid">PMC5929301</pub-id></mixed-citation></ref><ref id="dad270178-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="dad270178-cite-0003"><string-name name-style="western"><surname>Stites</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Largent</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Schumann</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Harkins</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sankar</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Krieger</surname><given-names>A</given-names></string-name>. <article-title>How reactions to a brain scan result differ for adults based on self&#8208;identified Black and White race</article-title>. <source>Alzheimers Dement</source>. <year>2024</year>;<volume>20</volume>:<fpage>1527</fpage>&#8208;<lpage>1537</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.13558</pub-id><pub-id pub-id-type="pmid">38029367</pub-id><pub-id pub-id-type="pmcid">PMC10984417</pub-id></mixed-citation></ref><ref id="dad270178-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dad270178-cite-0004"><string-name name-style="western"><surname>Barnes</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></string-name>. <article-title>Alzheimer's disease in African Americans: risk factors and challenges for the future</article-title>. <source>Health Aff Proj Hope</source>. <year>2014</year>;<volume>33</volume>(<issue>4</issue>):<fpage>580</fpage>&#8208;<lpage>586</lpage>. doi:<pub-id pub-id-type="doi">10.1377/hlthaff.2013.1353</pub-id><pub-id pub-id-type="pmcid">PMC4084964</pub-id><pub-id pub-id-type="pmid">24711318</pub-id></mixed-citation></ref><ref id="dad270178-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dad270178-cite-0005"><string-name name-style="western"><surname>Castora&#8208;Binkley</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Peronto</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Edwards</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Small</surname><given-names>BJ</given-names></string-name>. <article-title>A longitudinal analysis of the influence of race on cognitive performance</article-title>. <source>J Gerontol B Psychol Sci Soc Sci</source>. <year>2015</year>;<volume>70</volume>(<issue>4</issue>):<fpage>512</fpage>&#8208;<lpage>518</lpage>. doi:<pub-id pub-id-type="doi">10.1093/geronb/gbt112</pub-id><pub-id pub-id-type="pmid">24184780</pub-id></mixed-citation></ref><ref id="dad270178-bib-0005"><label>5</label><mixed-citation publication-type="book" id="dad270178-cite-0006"><string-name name-style="western"><surname>Lines</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Wiener</surname><given-names>JM</given-names></string-name>. <source>Racial and Ethnic Disparities in Alzheimer's Disease: A Literature Review</source>. <publisher-name>Research Triangle Institute International</publisher-name>; <publisher-name>U.S. Department of Health and Human Services Assistant Secretary for Planning and Evaluation Office of Disability, Aging and Long&#8208;Term Care Policy</publisher-name>; <year>2014</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://aspe.hhs.gov/sites/default/files/migrated_legacy_files//138596/RacEthDis.pdf" ext-link-type="uri">https://aspe.hhs.gov/sites/default/files/migrated_legacy_files//138596/RacEthDis.pdf</ext-link></mixed-citation></ref><ref id="dad270178-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="dad270178-cite-0007"><string-name name-style="western"><surname>Lennon</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Aita</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Bene</surname><given-names>VAD</given-names></string-name>, et&#160;al. <article-title>Black and White individuals differ in dementia prevalence, risk factors, and symptomatic presentation</article-title>. <source>Alzheimers Dement J Alzheimers Assoc</source>. <year>2021</year>;<volume>18</volume>(<issue>8</issue>):<fpage>1461</fpage>&#8208;<lpage>1471</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.12509</pub-id><pub-id pub-id-type="pmcid">PMC9160212</pub-id><pub-id pub-id-type="pmid">34854531</pub-id></mixed-citation></ref><ref id="dad270178-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dad270178-cite-0008"><string-name name-style="western"><surname>Stites</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>BN</given-names></string-name>, <string-name name-style="western"><surname>Largent</surname><given-names>EA</given-names></string-name>, et&#160;al. <article-title>Double&#8208;Edged Sword: a Positive Brain Scan Result Heightens Confidence in an Alzheimer's Diagnosis But Also Leads to Higher Stigma Among Older Adults in a Vignette&#8208;Based Experiment</article-title>. <source>J Gerontol B Psychol Sci Soc Sci</source>. <year>2024</year>;<volume>79</volume>(<issue>8</issue>):<elocation-id>gbae109</elocation-id>. doi:<pub-id pub-id-type="doi">10.1093/geronb/gbae109</pub-id><pub-id pub-id-type="pmid">38869988</pub-id><pub-id pub-id-type="pmcid">PMC11237985</pub-id></mixed-citation></ref><ref id="dad270178-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dad270178-cite-0009"><string-name name-style="western"><surname>Werner</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Heinik</surname><given-names>J</given-names></string-name>. <article-title>Stigma by association and Alzheimer's disease</article-title>. <source>Aging Ment Health</source>. <year>2008</year>;<volume>12</volume>(<issue>1</issue>):<fpage>92</fpage>&#8208;<lpage>99</lpage>. doi:<pub-id pub-id-type="doi">10.1080/13607860701616325</pub-id><pub-id pub-id-type="pmid">18297483</pub-id></mixed-citation></ref><ref id="dad270178-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dad270178-cite-0010"><string-name name-style="western"><surname>Corner</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bond</surname><given-names>J</given-names></string-name>. <article-title>Being at risk of dementia: fears and anxieties of older adults</article-title>. <source>J Aging Stud</source>. <year>2004</year>;<volume>18</volume>(<issue>2</issue>):<fpage>143</fpage>&#8208;<lpage>155</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jaging.2004.01.007</pub-id></mixed-citation></ref><ref id="dad270178-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dad270178-cite-0011"><string-name name-style="western"><surname>Werner</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Giveon</surname><given-names>SM</given-names></string-name>. <article-title>Discriminatory behavior of family physicians toward a person with Alzheimer's disease</article-title>. <source>Int Psychogeriatr</source>. <year>2008</year>;<volume>20</volume>(<issue>4</issue>):<fpage>824</fpage>&#8208;<lpage>839</lpage>. doi:<pub-id pub-id-type="doi">10.1017/S1041610208007060</pub-id><pub-id pub-id-type="pmid">18341751</pub-id></mixed-citation></ref><ref id="dad270178-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dad270178-cite-0012"><collab collab-type="authors">Alzheimer's Association National Plan Milestone Workgroup</collab>
, <string-name name-style="western"><surname>Fargo</surname><given-names>KN</given-names></string-name>, <string-name name-style="western"><surname>Aisen</surname><given-names>P</given-names></string-name>, et&#160;al, <collab collab-type="authors">Alzheimer's Association National Plan Milestone Workgroup</collab>
. <article-title>2014 Report on the milestones for the US national plan to address Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2014</year>;<volume>10</volume>(<issue>5S</issue>):<fpage>S430</fpage>&#8208;<lpage>S452</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jalz.2014.08.103</pub-id><pub-id pub-id-type="pmid">25341459</pub-id></mixed-citation></ref><ref id="dad270178-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dad270178-cite-0013"><string-name name-style="western"><surname>Stites</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Milne</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Karlawish</surname><given-names>J</given-names></string-name>. <article-title>Advances in Alzheimer's imaging are changing the experience of Alzheimer's disease</article-title>. <source>Alzheimers Dement Diagn Assess Dis Monit</source>. <year>2018</year>;<volume>10</volume>:<fpage>285</fpage>&#8208;<lpage>300</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.dadm.2018.02.006</pub-id><pub-id pub-id-type="pmcid">PMC5956938</pub-id><pub-id pub-id-type="pmid">29780873</pub-id></mixed-citation></ref><ref id="dad270178-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="dad270178-cite-0014"><string-name name-style="western"><surname>Atri</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Dickerson</surname><given-names>BC</given-names></string-name>, <string-name name-style="western"><surname>Clevenger</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>The Alzheimer's Association clinical practice guideline for the diagnostic evaluation, testing, counseling, and disclosure of suspected Alzheimer's disease and related disorders (DETeCD&#8208;ADRD): validated clinical assessment instruments</article-title>. <source>Alzheimers Dement</source>. <year>2025</year>;<volume>21</volume>(<issue>1</issue>):<elocation-id>e14335</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/alz.14335</pub-id>. Published online December 23, 2024:alz.14335.<pub-id pub-id-type="pmid">39713939</pub-id><pub-id pub-id-type="pmcid">PMC11772712</pub-id></mixed-citation></ref><ref id="dad270178-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="dad270178-cite-0015"><string-name name-style="western"><surname>Khoury</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ghossoub</surname><given-names>E</given-names></string-name>. <article-title>Diagnostic biomarkers of Alzheimer's disease: a state&#8208;of&#8208;the&#8208;art review</article-title>. <source>Biomark Neuropsychiatry</source>. <year>2019</year>;<volume>1</volume>:<elocation-id>100005</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.bionps.2019.100005</pub-id></mixed-citation></ref><ref id="dad270178-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="dad270178-cite-0016"><string-name name-style="western"><surname>Stites</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Gill</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Largent</surname><given-names>EA</given-names></string-name>, et&#160;al. <article-title>The relative contributions of biomarkers, disease modifying treatment, and dementia severity to Alzheimer's stigma: a vignette&#8208;based experiment</article-title>. <source>Soc Sci Med</source>. <year>2022</year>;<volume>292</volume>:<elocation-id>114620</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.socscimed.2021.114620</pub-id><pub-id pub-id-type="pmid">34883313</pub-id><pub-id pub-id-type="pmcid">PMC8748419</pub-id></mixed-citation></ref><ref id="dad270178-bib-0016"><label>16</label><mixed-citation publication-type="book" id="dad270178-cite-0017"><string-name name-style="western"><surname>Goffman</surname><given-names>E</given-names></string-name>. <source>Stigma: Notes on the Management of Spoiled Identity</source>. <publisher-name>Simon &amp; Schuster, Inc</publisher-name>; <year>1963</year>. Accessed July 23, 2025. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://archive.org/details/stigmanotesonman0000goff" ext-link-type="uri">http://archive.org/details/stigmanotesonman0000goff</ext-link></mixed-citation></ref><ref id="dad270178-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="dad270178-cite-0018"><string-name name-style="western"><surname>Betthauser</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Koscik</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Jonaitis</surname><given-names>EM</given-names></string-name>, et&#160;al. <article-title>Amyloid and tau imaging biomarkers explain cognitive decline from late middle&#8208;age</article-title>. <source>Brain</source>. <year>2020</year>;<volume>143</volume>(<issue>1</issue>):<fpage>320</fpage>&#8208;<lpage>335</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awz378</pub-id><pub-id pub-id-type="pmid">31886494</pub-id><pub-id pub-id-type="pmcid">PMC6935717</pub-id></mixed-citation></ref><ref id="dad270178-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="dad270178-cite-0019"><string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Schindler</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Bollinger</surname><given-names>JG</given-names></string-name>, et&#160;al. <article-title>Validation of Plasma Amyloid&#8208;&#946; 42/40 for Detecting Alzheimer Disease Amyloid Plaques</article-title>. <source>Neurology</source>. <year>2022</year>;<volume>98</volume>(<issue>7</issue>):<fpage>e688</fpage>&#8208;<lpage>e699</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000013211</pub-id><pub-id pub-id-type="pmid">34906975</pub-id><pub-id pub-id-type="pmcid">PMC8865895</pub-id></mixed-citation></ref><ref id="dad270178-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="dad270178-cite-0020"><string-name name-style="western"><surname>Boccardi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Altomare</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ferrari</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>Assessment of the incremental diagnostic value of florbetapir F 18 imaging in patients with cognitive impairment: the incremental diagnostic value of amyloid PET with [18F]&#8208;florbetapir (INDIA&#8208;FBP) study</article-title>. <source>JAMA Neurol</source>. <year>2016</year>;<volume>73</volume>(<issue>12</issue>):<fpage>1417</fpage>&#8208;<lpage>1424</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaneurol.2016.3751</pub-id><pub-id pub-id-type="pmid">27802513</pub-id></mixed-citation></ref><ref id="dad270178-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="dad270178-cite-0021"><string-name name-style="western"><surname>Ossenkoppele</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Prins</surname><given-names>ND</given-names></string-name>, <string-name name-style="western"><surname>Pijnenburg</surname><given-names>YAL</given-names></string-name>, et&#160;al. <article-title>Impact of molecular imaging on the diagnostic process in a memory clinic</article-title>. <source>Alzheimers Dement</source>. <year>2013</year>;<volume>9</volume>(<issue>4</issue>):<fpage>414</fpage>&#8208;<lpage>421</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jalz.2012.07.003</pub-id><pub-id pub-id-type="pmid">23164552</pub-id></mixed-citation></ref><ref id="dad270178-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="dad270178-cite-0022"><string-name name-style="western"><surname>Stites</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Harkins</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sankar</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Karlawish</surname><given-names>J</given-names></string-name>, <article-title>Identifiable Characteristics and Potentially Malleable Beliefs Predict Stigmatizing Attributions Toward Persons With Alzheimer's Disease Dementia: results of a Survey of the U.S. General Public</article-title>. <source>Health Commun</source>. <year>2018</year>;<volume>33</volume>(<issue>3</issue>):<fpage>264</fpage>&#8208;<lpage>273</lpage>. doi:<pub-id pub-id-type="doi">10.1080/10410236.2016.1255847</pub-id>. Published online December 29, 2016:1&#8208;10<pub-id pub-id-type="pmid">28033471</pub-id><pub-id pub-id-type="pmcid">PMC5898816</pub-id></mixed-citation></ref><ref id="dad270178-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="dad270178-cite-0023"><string-name name-style="western"><surname>Johnson</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Harkins</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Cary</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sankar</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Karlawish</surname><given-names>J</given-names></string-name>. <article-title>The relative contributions of disease label and disease prognosis to Alzheimer's stigma: a vignette&#8208;based experiment</article-title>. <source>Soc Sci Med</source>. <year>2015</year>;<volume>143</volume>:<fpage>117</fpage>&#8208;<lpage>127</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.socscimed.2015.08.031</pub-id><pub-id pub-id-type="pmid">26356823</pub-id></mixed-citation></ref><ref id="dad270178-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="dad270178-cite-0024"><string-name name-style="western"><surname>Stites</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Midgett</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Largent</surname><given-names>EA</given-names></string-name>, et&#160;al. <article-title>A survey study of Alzheimer's stigma among Black adults: intersectionality of Black identity and biomarker diagnosis</article-title>. <source>Ethn Health</source>. <year>2024</year>;<volume>30</volume>:<fpage>1</fpage>&#8208;<lpage>17</lpage>. doi:<pub-id pub-id-type="doi">10.1080/13557858.2024.2385110</pub-id>. Published online July.<pub-id pub-id-type="pmid">39079935</pub-id><pub-id pub-id-type="pmcid">PMC11560502</pub-id></mixed-citation></ref><ref id="dad270178-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="dad270178-cite-0025"><string-name name-style="western"><surname>Baumann</surname><given-names>BM</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>EH</given-names></string-name>, <string-name name-style="western"><surname>Mills</surname><given-names>AM</given-names></string-name>, et&#160;al. <article-title>Patient perceptions of computed tomographic imaging and their understanding of radiation risk and exposure</article-title>. <source>Ann Emerg Med</source>. <year>2011</year>;<volume>58</volume>(<issue>1</issue>):<fpage>1</fpage>&#8208;<lpage>7</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.annemergmed.2010.10.018</pub-id><pub-id pub-id-type="pmid">21146900</pub-id></mixed-citation></ref><ref id="dad270178-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="dad270178-cite-0026"><string-name name-style="western"><surname>Hughes</surname><given-names>CP</given-names></string-name>, <string-name name-style="western"><surname>Berg</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Danziger</surname><given-names>WL</given-names></string-name>, <string-name name-style="western"><surname>Coben</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname><given-names>RL</given-names></string-name>. <article-title>A new clinical scale for the staging of dementia</article-title>. <source>Br J Psychiatry J Ment Sci</source>. <year>1982</year>;<volume>140</volume>:<fpage>566</fpage>&#8208;<lpage>572</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1192/bjp.140.6.566</pub-id><pub-id pub-id-type="pmid">7104545</pub-id></mixed-citation></ref><ref id="dad270178-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="dad270178-cite-0027"><string-name name-style="western"><surname>Werner</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Goldstein</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Heinik</surname><given-names>J</given-names></string-name>. <article-title>Development and validity of the family stigma in Alzheimer's disease scale (FS&#8208;ADS)</article-title>. <source>Alzheimer Dis Assoc Disord</source>. <year>2011</year>;<volume>25</volume>(<issue>1</issue>):<fpage>42</fpage>&#8208;<lpage>48</lpage>. doi:<pub-id pub-id-type="doi">10.1097/WAD.0b013e3181f32594</pub-id><pub-id pub-id-type="pmid">20921880</pub-id></mixed-citation></ref><ref id="dad270178-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="dad270178-cite-0028"><string-name name-style="western"><surname>Link</surname><given-names>BG</given-names></string-name>, <string-name name-style="western"><surname>Phelan</surname><given-names>JC</given-names></string-name>. <article-title>Conceptualizing stigma</article-title>. <source>Annu Rev Sociol</source>. <year>2001</year>;<volume>27</volume>(<issue>1</issue>):<fpage>363</fpage>&#8208;<lpage>385</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev.soc.27.1.363</pub-id></mixed-citation></ref><ref id="dad270178-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="dad270178-cite-0029"><string-name name-style="western"><surname>Link</surname><given-names>BG</given-names></string-name>, <string-name name-style="western"><surname>Cullen</surname><given-names>FT</given-names></string-name>, <string-name name-style="western"><surname>Struening</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Shrout</surname><given-names>PE</given-names></string-name>, <string-name name-style="western"><surname>Dohrenwend</surname><given-names>BP</given-names></string-name>. <article-title>A modified labeling theory approach to mental disorders: an empirical assessment</article-title>. <source>Am Sociol Rev</source>. <year>1989</year>;<volume>54</volume>(<issue>3</issue>):<fpage>400</fpage>. doi:<pub-id pub-id-type="doi">10.2307/2095613</pub-id></mixed-citation></ref><ref id="dad270178-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="dad270178-cite-0030"><string-name name-style="western"><surname>Corrigan</surname><given-names>PW</given-names></string-name>. <article-title>How clinical diagnosis might exacerbate the stigma of mental illness</article-title>. <source>Soc Work</source>. <year>2007</year>;<volume>52</volume>(<issue>1</issue>):<fpage>31</fpage>&#8208;<lpage>39</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sw/52.1.31</pub-id><pub-id pub-id-type="pmid">17388081</pub-id></mixed-citation></ref><ref id="dad270178-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="dad270178-cite-0031"><string-name name-style="western"><surname>Fisher</surname><given-names>RJ</given-names></string-name>. <article-title>Social Desirability Bias and the Validity of Indirect Questioning</article-title>. <source>J Consum Res</source>. <year>1993</year>;<volume>20</volume>(<issue>2</issue>):<fpage>303</fpage>. doi:<pub-id pub-id-type="doi">10.1086/209351</pub-id></mixed-citation></ref><ref id="dad270178-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="dad270178-cite-0032"><string-name name-style="western"><surname>Cox</surname><given-names>D</given-names></string-name>. <article-title>Statistical significance tests</article-title>. <source>Br J Clin Pharmacol</source>. <year>1982</year>;<volume>14</volume>(<issue>3</issue>):<fpage>325</fpage>&#8208;<lpage>331</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2125.1982.tb01987.x</pub-id><pub-id pub-id-type="pmid">6751362</pub-id><pub-id pub-id-type="pmcid">PMC1427620</pub-id></mixed-citation></ref><ref id="dad270178-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="dad270178-cite-0033"><string-name name-style="western"><surname>Jacobs</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Rolle</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Ferrans</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Whitaker</surname><given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Warnecke</surname><given-names>RB</given-names></string-name>. <article-title>Understanding African Americans&#8217; Views of the Trustworthiness of Physicians</article-title>. <source>J Gen Intern Med</source>. <year>2006</year>;<volume>21</volume>(<issue>6</issue>):<fpage>642</fpage>&#8208;<lpage>647</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1525-1497.2006.00485.x</pub-id><pub-id pub-id-type="pmid">16808750</pub-id><pub-id pub-id-type="pmcid">PMC1924632</pub-id></mixed-citation></ref><ref id="dad270178-bib-0033"><label>33</label><mixed-citation publication-type="miscellaneous" id="dad270178-cite-0034"><string-name name-style="western"><surname>Funk</surname><given-names>C</given-names></string-name>. <article-title>Black Americans&#8217; trust in medical scientists and views about the potential for researcher misconduct. Pew Research Center</article-title>. <year>2022</year>. Accessed December 18. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pewresearch.org/science/2022/04/07/black-americans-trust-in-medical-scientists-and-views-about-the-potential-for-researcher-misconduct/" ext-link-type="uri">https://www.pewresearch.org/science/2022/04/07/black&#8208;americans&#8208;trust&#8208;in&#8208;medical&#8208;scientists&#8208;and&#8208;views&#8208;about&#8208;the&#8208;potential&#8208;for&#8208;researcher&#8208;misconduct/</ext-link></mixed-citation></ref><ref id="dad270178-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="dad270178-cite-0035"><string-name name-style="western"><surname>Connell</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>McLaughlin</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Carpenter</surname><given-names>BD</given-names></string-name>. <article-title>Black and White Adult Family Members&#8217; Attitudes Toward a Dementia Diagnosis</article-title>. <source>J Am Geriatr Soc</source>. <year>2009</year>;<volume>57</volume>(<issue>9</issue>):<fpage>1562</fpage>&#8208;<lpage>1568</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1532-5415.2009.02395.x</pub-id><pub-id pub-id-type="pmid">19682136</pub-id><pub-id pub-id-type="pmcid">PMC6312886</pub-id></mixed-citation></ref><ref id="dad270178-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="dad270178-cite-0036"><string-name name-style="western"><surname>Hasnain&#8208;Wynia</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Baker</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Nerenz</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Disparities in Health Care Are Driven by Where Minority Patients Seek Care: examination of the Hospital Quality Alliance Measures</article-title>. <source>Arch Intern Med</source>. <year>2007</year>;<volume>167</volume>(<issue>12</issue>):<fpage>1233</fpage>&#8208;<lpage>1239</lpage>. doi:<pub-id pub-id-type="doi">10.1001/archinte.167.12.1233</pub-id><pub-id pub-id-type="pmid">17592095</pub-id></mixed-citation></ref><ref id="dad270178-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="dad270178-cite-0037"><string-name name-style="western"><surname>Barnato</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Lucas</surname><given-names>FL</given-names></string-name>, <string-name name-style="western"><surname>Staiger</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wennberg</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Chandra</surname><given-names>A</given-names></string-name>. <article-title>Hospital&#8208;level Racial Disparities in Acute Myocardial Infarction Treatment and Outcomes</article-title>. <source>Med Care</source>. <year>2005</year>;<volume>43</volume>(<issue>4</issue>):<fpage>308</fpage>. doi:<pub-id pub-id-type="doi">10.1097/01.mlr.0000156848.62086.06</pub-id><pub-id pub-id-type="pmid">15778634</pub-id><pub-id pub-id-type="pmcid">PMC2121607</pub-id></mixed-citation></ref><ref id="dad270178-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="dad270178-cite-0038"><string-name name-style="western"><surname>Coffey</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Andrews</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Moy</surname><given-names>E</given-names></string-name>. <article-title>Racial, ethnic, and socioeconomic disparities in estimates of AHRQ patient safety indicators</article-title>. <source>Med Care</source>. <year>2005</year>;<volume>43</volume>(<issue>3</issue>):<fpage>I48</fpage>&#8208;<lpage>57</lpage>. doi:<pub-id pub-id-type="doi">10.1097/00005650-200503001-00008</pub-id>. Suppl.<pub-id pub-id-type="pmid">15746591</pub-id></mixed-citation></ref><ref id="dad270178-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="dad270178-cite-0039"><string-name name-style="western"><surname>Hasnain&#8208;Wynia</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Landrum</surname><given-names>MB</given-names></string-name>, <string-name name-style="western"><surname>Vogeli</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Baker</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Weissman</surname><given-names>JS</given-names></string-name>. <article-title>Racial and ethnic disparities within and between hospitals for inpatient quality of care: an examination of patient&#8208;level Hospital Quality Alliance measures</article-title>. <source>J Health Care Poor Underserved</source>. <year>2010</year>;<volume>21</volume>(<issue>2</issue>):<fpage>629</fpage>&#8208;<lpage>648</lpage>. doi:<pub-id pub-id-type="doi">10.1353/hpu.0.0281</pub-id><pub-id pub-id-type="pmid">20453362</pub-id></mixed-citation></ref><ref id="dad270178-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="dad270178-cite-0040"><string-name name-style="western"><surname>Ellenbogen</surname><given-names>MI</given-names></string-name>, <string-name name-style="western"><surname>Weygandt</surname><given-names>PL</given-names></string-name>, <string-name name-style="western"><surname>Newman&#8208;Toker</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rim</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Brotman</surname><given-names>DJ</given-names></string-name>. <article-title>Race and Ethnicity and Diagnostic Testing for Common Conditions in the Acute Care Setting</article-title>. <source>JAMA Netw Open</source>. <year>2024</year>;<volume>7</volume>(<issue>8</issue>):<elocation-id>e2430306</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2024.30306</pub-id><pub-id pub-id-type="pmid">39190305</pub-id><pub-id pub-id-type="pmcid">PMC11350469</pub-id></mixed-citation></ref><ref id="dad270178-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="dad270178-cite-0041"><string-name name-style="western"><surname>Lwi</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Ford</surname><given-names>BQ</given-names></string-name>, <string-name name-style="western"><surname>Levenson</surname><given-names>RW</given-names></string-name>. <article-title>Cultural differences in caring for people with dementia: a pilot study of concern about losing face and loneliness in Chinese American and European American caregivers</article-title>. <source>Clin Gerontol</source>. <year>2023</year>;<volume>46</volume>(<issue>2</issue>):<fpage>207</fpage>&#8208;<lpage>222</lpage>. doi:<pub-id pub-id-type="doi">10.1080/07317115.2022.2137448</pub-id><pub-id pub-id-type="pmid">36309843</pub-id><pub-id pub-id-type="pmcid">PMC9928887</pub-id></mixed-citation></ref><ref id="dad270178-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="dad270178-cite-0042"><string-name name-style="western"><surname>Matza</surname><given-names>LS</given-names></string-name>, <string-name name-style="western"><surname>Stewart</surname><given-names>KD</given-names></string-name>, <string-name name-style="western"><surname>Lloyd</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Rowen</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Brazier</surname><given-names>JE</given-names></string-name>. <article-title>Vignette&#8208;based utilities: usefulness, limitations, and methodological recommendations</article-title>. <source>Value Health J Int Soc Pharmacoeconomics Outcomes Res</source>. <year>2021</year>;<volume>24</volume>(<issue>6</issue>):<fpage>812</fpage>&#8208;<lpage>821</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jval.2020.12.017</pub-id><pub-id pub-id-type="pmid">34119079</pub-id></mixed-citation></ref><ref id="dad270178-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="dad270178-cite-0043"><string-name name-style="western"><surname>Ashford</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Raman</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>Screening and enrollment of underrepresented ethnocultural and educational populations in the Alzheimer's Disease Neuroimaging Initiative (ADNI)</article-title>. <source>Alzheimers Dement J Alzheimers Assoc</source>. <year>2022</year>;<volume>18</volume>(<issue>12</issue>):<fpage>2603</fpage>&#8208;<lpage>2613</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.12640</pub-id><pub-id pub-id-type="pmcid">PMC9402812</pub-id><pub-id pub-id-type="pmid">35213778</pub-id></mixed-citation></ref><ref id="dad270178-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="dad270178-cite-0044"><string-name name-style="western"><surname>Lim</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Barnes</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Weissberger</surname><given-names>GH</given-names></string-name>, et&#160;al. <article-title>Quantification of race/ethnicity representation in Alzheimer's disease neuroimaging research in the USA: a systematic review</article-title>. <source>Commun Med</source>. <year>2023</year>;<volume>3</volume>(<issue>1</issue>):<fpage>1</fpage>&#8208;<lpage>12</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s43856-023-00333-6</pub-id><pub-id pub-id-type="pmid">37491471</pub-id><pub-id pub-id-type="pmcid">PMC10368705</pub-id></mixed-citation></ref><ref id="dad270178-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="dad270178-cite-0045"><string-name name-style="western"><surname>Mayeda</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Glymour</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Quesenberry</surname><given-names>CP</given-names></string-name>, <string-name name-style="western"><surname>Whitmer</surname><given-names>RA</given-names></string-name>. <article-title>Inequalities in dementia incidence between six racial and ethnic groups over 14 years</article-title>. <source>Alzheimers Dement</source>. <year>2016</year>;<volume>12</volume>(<issue>3</issue>):<fpage>216</fpage>&#8208;<lpage>224</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jalz.2015.12.007</pub-id><pub-id pub-id-type="pmid">26874595</pub-id><pub-id pub-id-type="pmcid">PMC4969071</pub-id></mixed-citation></ref><ref id="dad270178-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="dad270178-cite-0046"><string-name name-style="western"><surname>Apostolou</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kennedy</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Person</surname><given-names>MK</given-names></string-name>, et&#160;al. <article-title>Alzheimer's disease and related dementia diagnoses among American Indian and Alaska Native adults aged &#8805;45 years, Indian Health Service System, 2016&#8211;2020</article-title>. <source>J Am Geriatr Soc</source>. <year>2024</year>;<volume>72</volume>(<issue>9</issue>):<fpage>2834</fpage>&#8208;<lpage>2841</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jgs.19058</pub-id><pub-id pub-id-type="pmid">39115437</pub-id><pub-id pub-id-type="pmcid">PMC11875228</pub-id></mixed-citation></ref><ref id="dad270178-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="dad270178-cite-0047"><string-name name-style="western"><surname>Mielke</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ashford</surname><given-names>JW</given-names></string-name>, et&#160;al. <article-title>Recommendations for clinical implementation of blood&#8208;based biomarkers for Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2024</year>;<volume>20</volume>(<issue>11</issue>):<fpage>8216</fpage>&#8208;<lpage>8224</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.14184</pub-id><pub-id pub-id-type="pmid">39351838</pub-id><pub-id pub-id-type="pmcid">PMC11567872</pub-id></mixed-citation></ref><ref id="dad270178-bib-0047"><label>47</label><mixed-citation publication-type="miscellaneous" id="dad270178-cite-0048"><collab collab-type="authors">American Library Association</collab>
. <article-title>Literacy for all: Adult literacy @ your library&#8212;Adult literacy in the U.S</article-title>. ALA. <year>2025</year>. Accessed July 20, 2025. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ala.org/aboutala/offices/literacy-all-adult-literacy-your-library-adult-literacy-us" ext-link-type="uri">https://www.ala.org/aboutala/offices/literacy&#8208;all&#8208;adult&#8208;literacy&#8208;your&#8208;library&#8208;adult&#8208;literacy&#8208;us</ext-link></mixed-citation></ref><ref id="dad270178-bib-0048"><label>48</label><mixed-citation publication-type="miscellaneous" id="dad270178-cite-0049"><collab collab-type="authors">United States Census Bureau</collab>
. <article-title>Population and housing unit estimates Censusgov</article-title>. <year>2025</year>. Accessed July 23, 2025. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.census.gov/programs-surveys/popest.html" ext-link-type="uri">https://www.census.gov/programs&#8208;surveys/popest.html</ext-link></mixed-citation></ref><ref id="dad270178-bib-0049"><label>49</label><mixed-citation publication-type="book" id="dad270178-cite-0050"><string-name name-style="western"><surname>Morais</surname><given-names>JA</given-names></string-name>. <part-title>Sex, gender and cultural factors</part-title>. In: <source>World Alzheimer Report 2021: Journey to a Diagnosis of Dementia</source>. <publisher-name>Alzheimer's Disease International</publisher-name>; <year>2021</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.alzint.org/resource/world-alzheimer-report-2021/" ext-link-type="uri">https://www.alzint.org/resource/world&#8208;alzheimer&#8208;report&#8208;2021/</ext-link></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Brain Commun</journal-id><journal-id journal-id-type="iso-abbrev">Brain Commun</journal-id><journal-id journal-id-type="pmc-domain-id">3915</journal-id><journal-id journal-id-type="pmc-domain">braincomms</journal-id><journal-id journal-id-type="publisher-id">braincomms</journal-id><journal-title-group><journal-title>Brain Communications</journal-title></journal-title-group><issn pub-type="epub">2632-1297</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12507083</article-id><article-id pub-id-type="pmcid-ver">PMC12507083.1</article-id><article-id pub-id-type="pmcaid">12507083</article-id><article-id pub-id-type="pmcaiid">12507083</article-id><article-id pub-id-type="doi">10.1093/braincomms/fcaf365</article-id><article-id pub-id-type="publisher-id">fcaf365</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00310</subject><subject>AcademicSubjects/SCI01870</subject></subj-group></article-categories><title-group><article-title>Glymphatic dysfunction as a potential driver of cerebral iron deposition in Parkinson's disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="K">Kaidong</given-names></name><aff>
<institution>Department of Radiology, The Affiliated Wuxi People's Hospital of Nanjing Medical University</institution>, <addr-line>Wuxi 214023</addr-line>, <country country="CN">China</country></aff><xref rid="FM1" ref-type="author-notes"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ji</surname><given-names initials="Y">Yi</given-names></name><aff>
<institution>Department of Radiology, The Affiliated Wuxi People's Hospital of Nanjing Medical University</institution>, <addr-line>Wuxi 214023</addr-line>, <country country="CN">China</country></aff><xref rid="FM1" ref-type="author-notes"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="L">Li</given-names></name><aff>
<institution>Department of Neurology, The Affiliated Wuxi People's Hospital of Nanjing Medical University</institution>, <addr-line>Wuxi 214023</addr-line>, <country country="CN">China</country></aff><xref rid="FM1" ref-type="author-notes"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="R">Ruixuan</given-names></name><aff>
<institution>Department of Radiology, The Affiliated Wuxi People's Hospital of Nanjing Medical University</institution>, <addr-line>Wuxi 214023</addr-line>, <country country="CN">China</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="J">Jianqi</given-names></name><aff>
<institution>Shanghai Key Laboratory of Magnetic Resonance, School of Physics and Electronic Science, East China Normal University</institution>, <addr-line>Shanghai 200062</addr-line>, <country country="CN">China</country></aff><aff>
<institution>Institute of Magnetic Resonance and Molecular Imaging in Medicine, East China Normal University</institution>, <addr-line>Shanghai 200062</addr-line>, <country country="CN">China</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lu</surname><given-names initials="L">Liujia</given-names></name><aff>
<institution>Department of Radiology, The Affiliated Wuxi People's Hospital of Nanjing Medical University</institution>, <addr-line>Wuxi 214023</addr-line>, <country country="CN">China</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tang</surname><given-names initials="Y">Ying</given-names></name><aff>
<institution>Shanghai Key Laboratory of Magnetic Resonance, School of Physics and Electronic Science, East China Normal University</institution>, <addr-line>Shanghai 200062</addr-line>, <country country="CN">China</country></aff><aff>
<institution>Institute of Magnetic Resonance and Molecular Imaging in Medicine, East China Normal University</institution>, <addr-line>Shanghai 200062</addr-line>, <country country="CN">China</country></aff></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Hu</surname><given-names initials="X">Xiaoyun</given-names></name><aff>
<institution>Department of Radiology, The Affiliated Wuxi People's Hospital of Nanjing Medical University</institution>, <addr-line>Wuxi 214023</addr-line>, <country country="CN">China</country></aff><xref rid="fcaf365-cor2" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="F">Feng</given-names></name><aff>
<institution>Department of Neurology, The Affiliated Wuxi People's Hospital of Nanjing Medical University</institution>, <addr-line>Wuxi 214023</addr-line>, <country country="CN">China</country></aff><xref rid="FM1" ref-type="author-notes"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8818-5382</contrib-id><name name-style="western"><surname>Fang</surname><given-names initials="X">Xiangming</given-names></name><aff>
<institution>Department of Radiology, The Affiliated Wuxi People's Hospital of Nanjing Medical University</institution>, <addr-line>Wuxi 214023</addr-line>, <country country="CN">China</country></aff><xref rid="fcaf365-cor1" ref-type="corresp"/></contrib></contrib-group><author-notes><corresp id="fcaf365-cor1">Correspondence to: Xiangming Fang Department of Radiology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, 299 Qingyang Road Liangxi District, Wuxi 214023, China E-mail: <email>xiangming_fang@njmu.edu.cn</email></corresp><corresp id="fcaf365-cor2">Correspondence may also be addressed to: Xiaoyun Hu Department of Radiology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, 299 Qingyang Road Liangxi District, Wuxi 214023, China E-mail: <email>drxyh@foxmail.com</email></corresp><fn id="FM1"><p>Kaidong Chen, Yi Ji, Li Zhang and Feng Wang contributed equally to this work.</p></fn></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2025-09-23"><day>23</day><month>9</month><year>2025</year></pub-date><volume>7</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">495905</issue-id><elocation-id>fcaf365</elocation-id><history><date date-type="received"><day>29</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>26</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>21</day><month>9</month><year>2025</year></date><date date-type="corrected-typeset"><day>08</day><month>10</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>23</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025. Published by Oxford University Press on behalf of the Guarantors of Brain.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fcaf365.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fcaf365.pdf"/><abstract><title>Abstract</title><p>Cerebral iron deposition is a pathological hallmark of Parkinson's disease. Notably, Parkinson's disease patients exhibit the characteristic neuroimaging features of enlarged choroid plexus volume (CPV) and diminished glymphatic function. While previous research has focused on potential iron influx dysregulation in Parkinson's disease, the critical question of whether impaired iron clearance stemming from choroid plexus and glymphatic system dysfunction constitutes a key mechanism underlying pathological iron accumulation remains unexplored. Therefore, the aim of this study was to investigate the relationship between cerebral iron deposition and glymphatic dysfunction in Parkinson's disease, and explored its clinical relevance. We hypothesized that impaired glymphatic clearance contributes to pathological iron accumulation in Parkinson's disease. This cross-sectional study enrolled 65 patients with mild-to-moderate Parkinson's disease and 38 age- and sex-matched healthy controls. Multimodal MRI was used to assess the CPV, diffusion tensor imaging analysis along the perivascular space (ALPS) index (indirectly reflecting glymphatic function) and quantitative susceptibility mapping-derived iron levels. The clinical evaluations included motor, cognitive and psychiatric assessments. Statistical analyses compared group differences, correlations, mediation effects and diagnostic performance via receiver operating characteristic analysis. Compared to healthy controls, Parkinson's disease patients exhibited bilateral CPV enlargement (<italic toggle="yes">P</italic> &lt; 0.01), reduced ALPS indices (<italic toggle="yes">P</italic> &lt; 0.05) and elevated iron deposition in the substantia nigra, red nucleus and putamen (<italic toggle="yes">P</italic> &lt; 0.05). CPV negatively correlated with ALPS index (left hemisphere: <italic toggle="yes">r</italic> = &#8722;0.305, <italic toggle="yes">P</italic> = 0.014; right hemisphere: <italic toggle="yes">r</italic> = &#8722;0.357, <italic toggle="yes">P</italic> = 0.004). Notably, the degree of glymphatic dysfunction, manifested by either choroid plexus enlargement or a reduced ALPS index, was significantly correlated with regional iron deposition patterns, especially between the CPV and substantia nigra iron deposition (left hemisphere: <italic toggle="yes">r</italic> = 0.236, <italic toggle="yes">P</italic> = 0.029; right hemisphere: <italic toggle="yes">r</italic> = 0.233, <italic toggle="yes">P</italic> = 0.031). Mediation analysis revealed that ALPS and putamen iron deposition-mediated CPV affected daily living impairments and psychiatric symptoms. A comprehensive diagnostic model integrating neuroimaging, cognitive and psychiatric variables achieved near-perfect discrimination for mild-to-moderate Parkinson's disease (area under the receiver operating characteristic curve = 0.972, sensitivity = 100%, specificity = 97.4%). In conclusion, our results suggest that CPV enlargement and reduced ALPS index are closely linked to pathological iron deposition in Parkinson's disease. These biomarkers correlate with motor deficits, cognitive decline and psychiatric symptoms, highlighting their roles in disease progression. The integrated diagnostic model demonstrated exceptional accuracy, advocating multimodal approaches for Parkinson's disease management. These findings suggest that glymphatic modulation and iron chelation are potential therapeutic targets that warrant further longitudinal validation.</p></abstract><abstract abstract-type="teaser"><p>Chen <italic toggle="yes">et al.</italic> reported the possible new mechanism underlying cerebral iron deposition in Parkinson's disease that impairment in the glymphatic system, which removes waste and toxins from the brain, may contribute to the iron deposition, providing a new potential target for treating patients with Parkinson's disease.</p></abstract><abstract abstract-type="graphical"><title>Graphical Abstract</title><p>
<fig position="anchor" id="fcaf365-fcaf365_ga" orientation="portrait"><label>Graphical Abstract</label><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcaf365_ga.jpg"/></fig>
</p></abstract><kwd-group><kwd>Parkinson's disease</kwd><kwd>glymphatic system</kwd><kwd>cerebral iron deposition</kwd><kwd>choroid plexus volume</kwd><kwd>quantitative susceptibility mapping</kwd></kwd-group><funding-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Jiangsu Province Natural Science Foundation</institution><institution-id institution-id-type="DOI">10.13039/501100004608</institution-id></institution-wrap></funding-source><award-id>BK20191143</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>National Natural Science Foundation of China</institution><institution-id institution-id-type="DOI">10.13039/501100001809</institution-id></institution-wrap></funding-source><award-id>81271629</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Medical Expert Team Program of the Wuxi Taihu Talent Plan</institution></institution-wrap></funding-source><award-id>YXKZDZK2</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Nanjing Medical University</institution><institution-id institution-id-type="DOI">10.13039/501100007289</institution-id></institution-wrap></funding-source><award-id>WMCC202402</award-id></award-group></funding-group><counts><page-count count="15"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="fcaf365-s1"><title>Introduction</title><p>Parkinson's disease is the second most common neurodegenerative disease and is characterized by motor disorders including tremors, rigidity and bradykinesia.<sup><xref rid="fcaf365-B1" ref-type="bibr">1</xref></sup> In the past decade, the global burden of Parkinson's disease has rapidly increased with an increasing number and proportion of elderly people.<sup><xref rid="fcaf365-B2" ref-type="bibr">2</xref></sup> However, the mechanisms underlying the neurodegeneration in Parkinson's disease remain unclear.</p><p>In recent years, the pathogenic significance of cerebral iron deposition has been increasingly recognized as a central mechanistic contributor to neurodegeneration in Parkinson's disease.<sup><xref rid="fcaf365-B3" ref-type="bibr">3-5</xref></sup> In A53T PD mouse models, iron dyshomeostasis in the substantia nigra (SN) exhibits chronological precedence over both dopaminergic neuronal silencing and motor phenotype emergence.<sup><xref rid="fcaf365-B6" ref-type="bibr">6</xref></sup> Notably, iron chelation interventions during this prodromal phase delay neurodegeneration, suggesting that SN iron deposition may be an upstream regulator of &#945;-synucleinopathy (&#945;-syn) progression.<sup><xref rid="fcaf365-B6" ref-type="bibr">6</xref></sup> Moreover, neuropathological progression in Parkinson's disease demonstrates a spatiotemporal expansion of cerebral iron deposition, exhibiting increased anatomical involvement and an amplified iron load in the affected brain regions.<sup><xref rid="fcaf365-B7" ref-type="bibr">7</xref></sup> Although advanced quantitative MRI techniques, such as quantitative susceptibility mapping (QSM),<sup><xref rid="fcaf365-B8" ref-type="bibr">8</xref>,<xref rid="fcaf365-B9" ref-type="bibr">9</xref></sup> have been used to detect cerebral iron deposition, the neurobiological drivers underlying progressive brain iron accumulation in Parkinson's disease remain unclear.</p><p>The progression of brain iron deposition is often associated with excessive input and clearance disorders.<sup><xref rid="fcaf365-B10" ref-type="bibr">10</xref></sup> Accumulating evidence suggests that the pathological elevation of cerebral iron levels in Parkinson's disease may originate from dysregulated brain iron import mechanisms.<sup><xref rid="fcaf365-B11" ref-type="bibr">11</xref></sup> Decreased serum iron coupled with elevated transferrin levels in Parkinson's disease may drive the pathological redistribution of peripheral iron into the brain, particularly into the SN, via systemic circulation.<sup><xref rid="fcaf365-B10" ref-type="bibr">10</xref>,<xref rid="fcaf365-B12" ref-type="bibr">12</xref></sup> Parkinson's disease models exhibit divergent regulation of nigral iron transporters; increased expression of divalent metal transporter 1 coupled with decreased ferroportin 1 levels creates a unidirectional iron flux into the SN,<sup><xref rid="fcaf365-B13" ref-type="bibr">13</xref></sup> establishing a redox imbalance through Fenton reaction-mediated oxidative damage.<sup><xref rid="fcaf365-B14" ref-type="bibr">14</xref>,<xref rid="fcaf365-B15" ref-type="bibr">15</xref></sup> In addition, neuroimaging research has revealed a characteristic spatiotemporal trajectory of iron redistribution in Parkinson's disease, progressing from initial SN accumulation to basal ganglia involvement and culminating in cortical dissemination, which parallels clinical deterioration.<sup><xref rid="fcaf365-B7" ref-type="bibr">7</xref></sup> Nevertheless, few studies have discussed whether defective cerebral iron clearance exists in Parkinson's disease, with current research predominantly focusing on iron influx dysregulation rather than impaired efflux pathways.</p><p>The cerebral iron homeostasis framework delineates the following regulatory systems: iron influx is predominantly governed by transferrin receptor-mediated transcytosis at the blood&#8211;brain barrier (BBB), whereas efflux is orchestrated through the glymphatic system mediated by the blood&#8211;cerebrospinal fluid barrier (BCSFB).<sup><xref rid="fcaf365-B13" ref-type="bibr">13</xref>,<xref rid="fcaf365-B16" ref-type="bibr">16-19</xref></sup> The BCSFB, composed of choroid plexus epithelial cells, regulates cerebral iron homeostasis through passive paracellular clearance via interstitial fluid convection along the glymphatic routes.<sup><xref rid="fcaf365-B13" ref-type="bibr">13</xref></sup> Therefore, the choroid plexus volume (CPV) indirectly reflects choroid plexus function, which is negatively correlated with choroid plexus permeability.<sup><xref rid="fcaf365-B20" ref-type="bibr">20</xref></sup> The diffusion tensor image analysis along the perivascular space (DTI-ALPS) index reflects brain glymphatic function and may be a key indicator for measuring the brain iron clearance ability.<sup><xref rid="fcaf365-B13" ref-type="bibr">13</xref>,<xref rid="fcaf365-B21" ref-type="bibr">21</xref></sup> According to neuroimaging evidence, patients with Parkinson's disease often exhibit increased CPV and a reduced ALPS index, both of which indicate severe glymphatic clearance dysfunction.<sup><xref rid="fcaf365-B22" ref-type="bibr">22-26</xref></sup> However, few studies have explored the relationship between choroid plexus dysfunction, glymphatic dysfunction and brain iron deposition in Parkinson's disease.</p><p>We hypothesized that cerebral iron deposition in patients with Parkinson's disease is associated with impaired brain iron clearance mechanisms mediated by glymphatic dysfunction. In this study, we investigated the differences in the CPV, ALPS index and cerebral iron deposition detected using QSM between patients with Parkinson's disease and healthy control (HC). Subsequently, we examined the correlations between abnormally elevated iron deposition in key deep grey matter nuclei in patients with Parkinson's disease using both the CPV and ALPS indices. Overall, this study aimed to employ multimodal neuroimaging approaches to investigate the role of cerebral iron clearance dysfunction in driving pathological cerebral iron deposition progression in Parkinson's disease and the clinical correlates of these neuroimaging abnormalities.</p></sec><sec sec-type="materials|methods" id="fcaf365-s2"><title>Materials and methods</title><sec id="fcaf365-s2.1"><title>Subjects</title><p>A total of 70 patients with Parkinson's disease were enrolled consecutively through the Movement Disorders Clinic, Affiliated Wuxi People's Hospital of Nanjing Medical University (Wuxi, China), from August 2021 to August 2023. This study included an age- and sex-matched control group of 38 older adults. Further, this study strictly followed the ethical guidelines of the Declaration of Helsinki and was approved by the Ethics Committee of the Affiliated Wuxi People's Hospital of Nanjing Medical University. All participants provided written informed consent before the study began.</p><p>The inclusion criteria for patients with Parkinson's disease were as follows: (i) diagnosis confirmed per the clinical diagnostic criteria for Parkinson's disease<sup><xref rid="fcaf365-B27" ref-type="bibr">27</xref></sup>; (ii) age &gt; 40 years at enrolment, (iii) right hand dominance and (iv) willingness to participate with signed consent documentation.</p><p>The exclusion criteria for patients with Parkinson's disease were as follows: (i) history of severe head trauma or any neurological/psychiatric disorders; (ii) inability to complete MRI examinations or clinical evaluations; (iii) abnormal findings detected on routine MRI; (iv) educational attainment below the primary school level and (v) poor imaging quality precluding postprocessing analysis.</p></sec><sec id="fcaf365-s2.2"><title>Clinical features</title><p>Following MRI, demographic and clinical data, including age, sex, educational attainment, disease duration, and the levodopa equivalent daily dose, were systematically recorded for all patients with Parkinson's disease. Two highly experienced neurologists specializing in Parkinson's disease administered the following assessments to the patients with Parkinson's disease: Unified Parkinson's Disease Rating Scale (UPDRS) Parts II and III, Hoehn &amp; Yahr Staging (H&amp;Y Scale), Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Freezing of Gait Questionnaire (FOG-Q), REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ), Hamilton Anxiety Rating Scale (HAM-A) and Hamilton Depression Rating Scale (HAM-D). A similar battery of assessments was administered to HCs.</p></sec><sec id="fcaf365-s2.3"><title>MRI data</title><p>All participants underwent 3.0 T MRI (Siemens Prisma, Germany) in the morning using a 20-channel head coil. To minimize motion artefacts and acoustic noise, each subject was fitted with foam padding and MRI-compatible headphones prior to scanning. Patients with Parkinson's disease underwent brain MRI in the off-medication state following 12-h of withdrawal of dopaminergic therapy.</p><p>The parameters of the three-dimensional T1-weighted magnetization prepared rapid acquisition gradient echo (3D-T1 MP-RAGE) sequence, the DTI sequence and the QSM sequence were available in <xref rid="sup1" ref-type="supplementary-material">Supplementary Material 1</xref>.</p></sec><sec id="fcaf365-s2.4"><title>Choroid plexus volume calculation</title><p>FastSurfer (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/Deep-MI/FastSurfer" ext-link-type="uri">https://github.com/Deep-MI/FastSurfer</ext-link>) employed 3D-T1 MP-RAGE images for segmentation to obtain masks of the lateral ventricles and choroid plexus, with concurrent calculation of the total intracranial volume (TIV). Subsequently, a Gaussian mixture model was applied to refine the choroid plexus segmentation.<sup><xref rid="fcaf365-B28" ref-type="bibr">28</xref></sup> Furthermore, all delineation results of choroid plexus segmentation were reviewed and manually corrected by two independent raters. Finally, choroid plexus volumetry was performed using ITK-SNAP (version 4.2.2; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.itksnap.org" ext-link-type="uri">www.itksnap.org</ext-link>), with inter-rater discrepancies exceeding 15% resolved through a consensus review by a senior neuroradiologist. To mitigate the influence of interindividual differences in TIV on CPV measurements, CP was defined as the ratio of CPV/TIV, which represented the relative value of CPV for subsequent statistical analyses.</p></sec><sec id="fcaf365-s2.5"><title>ALPS analysis</title><sec id="fcaf365-s2.5.1"><title>DTI preprocessing</title><p>Diffusion data were processed using the FMRIB Software Library (FSL, version 6.0.1; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fmrib.ox.ac.uk/fsl" ext-link-type="uri">www.fmrib.ox.ac.uk/fsl</ext-link>) with standard pipelines: (i) TOPUP for field inhomogeneity correction (b0 images, AP/PA encoding); (ii) EDDY for eddy current and motion correction; (iii) MP-PCA denoising and Gibbs unringing for artefact reduction; (iv) DTIFIT for tensor calculation [generating fractional anisotropy (FA), Dxx, Dyy, Dzz maps] and (v) non-linear registration to the Montreal Neurological Institute (MNI) space (JHU-ICBM-FA template via FLIRT/FNIRT) and spatial normalization.</p></sec><sec id="fcaf365-s2.5.2"><title>Region of interest definition</title><p>Standardized 5-mm spherical regions of interest (ROIs) were placed at the ventricular body level in the normalized MNI space, targeting (i) projection fibres: Bilateral superior corona radiata (SCR); and (ii) association fibres: Bilateral superior longitudinal fasciculus (SLF). The template coordinates were as follows: Left SCR (116,110,99), right SCR (64,110,99), left SLF (128,110,99) and right SLF (51,110,99).</p></sec><sec id="fcaf365-s2.5.3"><title>ALPS quantification</title><p>The ALPS index was computed as:</p><disp-formula id="UM0001"><mml:math id="UM1" display="block" overflow="scroll"><mml:mrow><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">ALPS</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">index</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mrow><mml:mi mathvariant="normal">mean</mml:mi></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="normal">Dx</mml:mi></mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">proj</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mrow><mml:mo>,</mml:mo><mml:mi mathvariant="normal">Dx</mml:mi></mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">assoc</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">mean</mml:mi></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="normal">Dy</mml:mi></mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">y</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">proj</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mrow><mml:mo>,</mml:mo><mml:mi mathvariant="normal">Dz</mml:mi></mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">z</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">assoc</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula><p>The terms are defined as follows: Dxx_proj, left&#8211;right diffusivity (projection fibers); Dxx_assoc, left&#8211;right diffusivity (association fibers); Dyy_proj, anterior&#8211;posterior diffusivity (projection fibers); Dzz_assoc, superior&#8211;inferior diffusivity (association fibers).</p></sec></sec><sec id="fcaf365-s2.6"><title>Quantitative susceptibility mapping</title><sec id="fcaf365-s2.6.1"><title>QSM postprocessing</title><p>QSM postprocessing was performed to obtain QSM maps using the MEDI_GUI toolbox (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pre.weill.cornell.edu/mri/pages/qsm.html" ext-link-type="uri">https://pre.weill.cornell.edu/mri/pages/qsm.html</ext-link>) in MATLAB R2024b,<sup><xref rid="fcaf365-B29" ref-type="bibr">29</xref></sup> as follows: (i) run mode: advanced mode was selected to access all parameterization options; (ii) brain mask generation: extracted the binary brain mask from the first echo magnitude image using the brain extraction tool (BET) from FSL; (iii) phase fitting: estimated the local frequency shift from multi-echo phase data via linear least-squares fitting across echoes; (iv) phase unwrapping: phase images were unwrapped via the region growth algorithm; (v) background field removal: performed using projection onto dipole fields and (vi) susceptibility inversion: conducted with morphology enabled dipole inversion (<italic toggle="yes">&#955;</italic> = 1000, edge = 0.9) incorporating the modified error reduction algorithm with iterative Tikhonov regularization and spherical mean value (Kernel radius = 5&#8197;mm) to QSM accuracy.</p></sec><sec id="fcaf365-s2.6.2"><title>Susceptibility value extraction</title><p>Two neuroradiologists specializing in neuroimaging manually delineated the ROI on QSM maps using ITK-SNAP to extract mean susceptibility values from the following iron-rich brain regions implicated in Parkinson's disease pathophysiology: bilateral SN, red nucleus (RN), caudate nucleus (CN), putamen (PUT) and globus pallidus (GP).<sup><xref rid="fcaf365-B30" ref-type="bibr">30</xref>,<xref rid="fcaf365-B31" ref-type="bibr">31</xref></sup> Inter-rater discrepancies exceeding 15% were resolved by a third senior neuroradiologist through a consensus review.</p></sec></sec><sec id="fcaf365-s2.7"><title>Statistical analysis</title><p>All the statistical analyses were performed using SPSS (version 26.0, IBM Corp., Armonk, NY, USA). The significance threshold was set at <italic toggle="yes">P</italic> &lt; 0.05, with the Bonferroni correction applied for multiple comparisons when applicable. Demographic and clinical characteristics are summarized as mean &#177; standard deviation for continuous variables.</p><p>Normality of the data distribution was assessed using the Shapiro&#8211;Wilk test. Group comparisons (Parkinson's disease versus HC) were conducted using the two-sample <italic toggle="yes">t</italic>-test or Mann&#8211;Whitney U-test (for continuous variables, based on normality) or the chi-square exact test (for categorical variables).</p><p>Adjusting for age, gender and educational attainment as covariates, partial correlation analyses were performed to assess relationships among neuroimaging biomarkers (CP, ALPS index and QSM values) within the Parkinson's disease group, HC group and combined cohort. Correlations between age and neuroimaging biomarkers of Parkinson's disease patients were assessed using the Pearson method. Then, we used the partial correlation analyses to evaluate correlations between neuroimaging biomarkers and clinical characteristics in Parkinson's disease cohort with age, gender and educational attainment as covariates. Simple mediation models were constructed using the PROCESS macro to explore whether glymphatic dysfunction (ALPS index) or iron deposition (QSM values) mediated the effects of CP on the clinical outcomes. Bootstrapping with 5000 iterations was used to estimate 95% confidence intervals for the indirect effects.</p><p>Finally, receiver operating characteristic (ROC) curve analysis was performed to evaluate the discriminatory power of the neuroimaging biomarkers and clinical variables with statistical differences for Parkinson's disease diagnosis, reporting the area under the curve (AUC), 95% confidence interval (CI), sensitivity and specificity (determined by maximizing the Youden Index). DeLong's test was used to compare the AUCs of the models. All visualizations were generated using GraphPad Prism (version 8.0.2).</p></sec></sec><sec sec-type="results" id="fcaf365-s3"><title>Results</title><sec id="fcaf365-s3.1"><title>Population and participant characteristics</title><p>The final cohort comprised 65 patients with Parkinson's disease and 38 HCs after excluding five participants due to suboptimal MRI image quality. All enrolled patients with Parkinson's disease were at mild-to-moderate disease stages (H&amp;Y stage &#8804; 3), since advanced-stage patients (H&amp;Y stage &gt; 3) often cannot meet the rigorous requirements for multimodal MRI acquisition. The sex distribution, age and educational attainment of the Parkinson's disease cohort were comparable to the HCs (all <italic toggle="yes">P</italic> &gt; 0.05). However, significant between-group differences were observed in the cognitive assessments, with patients with Parkinson's disease showing markedly lower MoCA and MMSE scores (<italic toggle="yes">P</italic> &lt; 0.001 and <italic toggle="yes">P</italic> = 0.049, respectively). Additionally, the Parkinson's disease group exhibited significantly higher severity scores for both depression and anxiety symptoms compared to controls (both <italic toggle="yes">P</italic> &lt; 0.001). Further details are presented in <xref rid="fcaf365-T1" ref-type="table">Table 1</xref>.</p><table-wrap position="float" id="fcaf365-T1" orientation="portrait"><label>Table 1</label><caption><p>Comparative analysis of the demographic and clinical characteristics between groups</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Parkinson's disease (<italic toggle="yes">n</italic> = 65)</th><th align="center" rowspan="1" colspan="1">HC (<italic toggle="yes">n</italic> = 38)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Sex (M/F)</td><td rowspan="1" colspan="1">39/26</td><td rowspan="1" colspan="1">19/19</td><td rowspan="1" colspan="1">0.323</td></tr><tr><td rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1">64.29 &#177; 8.68</td><td rowspan="1" colspan="1">62.61 &#177; 7.99</td><td rowspan="1" colspan="1">0.330</td></tr><tr><td rowspan="1" colspan="1">Education (years)</td><td rowspan="1" colspan="1">9.75 &#177; 2.97</td><td rowspan="1" colspan="1">9.55 &#177; 3.96</td><td rowspan="1" colspan="1">0.787</td></tr><tr><td rowspan="1" colspan="1">Disease duration (years)</td><td rowspan="1" colspan="1">4.08 &#177; 3.05</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">H&amp;Y</td><td rowspan="1" colspan="1">2.03 &#177; 0.73</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">LEDD (mg)</td><td rowspan="1" colspan="1">404.81 &#177; 228.91</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">UPDRS-II</td><td rowspan="1" colspan="1">9.66 &#177; 4.67</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">UPDRS-III</td><td rowspan="1" colspan="1">21.88 &#177; 10.45</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">FOG-Q</td><td rowspan="1" colspan="1">3.12 &#177; 5.15</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">RBDSQ</td><td rowspan="1" colspan="1">3.14 &#177; 3.72</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">MoCA</td><td rowspan="1" colspan="1">25.18 &#177; 2.94</td><td rowspan="1" colspan="1">28.18 &#177; 1.37</td><td rowspan="1" colspan="1">&lt;0.001***</td></tr><tr><td rowspan="1" colspan="1">MMSE</td><td rowspan="1" colspan="1">28.48 &#177; 1.53</td><td rowspan="1" colspan="1">28.97 &#177; 1.00</td><td rowspan="1" colspan="1">0.049*</td></tr><tr><td rowspan="1" colspan="1">HAM-D</td><td rowspan="1" colspan="1">12.43 &#177; 5.84</td><td rowspan="1" colspan="1">3.05 &#177; 1.97</td><td rowspan="1" colspan="1">&lt;0.001***</td></tr><tr><td rowspan="1" colspan="1">HAM-A</td><td rowspan="1" colspan="1">19.52 &#177; 4.85</td><td rowspan="1" colspan="1">2.61 &#177; 1.76</td><td rowspan="1" colspan="1">&lt;0.001***</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>Abbreviations: HC, healthy controls; H&amp;Y, Hoehn &amp; Yahr scale; LEDD, levodopa equivalent daily dose; UPDRS, Unified Parkinson's Disease Rating Scale; FOG-Q, Freezing of Gait Questionnaire; RBDSQ, REM Sleep Behavior Disorder Screening Questionnaire; MoCA, Montreal Cognitive Assessment; MMSE, Mini-Mental State Examination; HAM-D, 17-item Hamilton Depression Rating Scale; HAM-A, Hamilton Anxiety Rating Scale; NA, not applicable.</p></fn><fn id="tblfn2"><p>Significance levels: *<italic toggle="yes">P</italic> &#160;<italic toggle="yes">&lt;</italic> 0.05, ***<italic toggle="yes">P</italic> &#160;<italic toggle="yes">&lt;</italic> 0.001 (Parkinson's disease versus HCs), Bonferroni-corrected.</p></fn></table-wrap-foot></table-wrap></sec><sec id="fcaf365-s3.2"><title>Neuroimaging biomarkers</title><sec id="fcaf365-s3.2.1"><title>Choroid plexus volume</title><p>Quantification of the CPV revealed bilateral enlargement in patients with Parkinson's disease compared to that in HCs (left hemisphere: <italic toggle="yes">P</italic> = 0.003; right hemisphere: <italic toggle="yes">P</italic> &#160;<italic toggle="yes">&lt;</italic> 0.001, using Bonferroni correction). The TIV did not differ significantly between patients with Parkinson's disease and HCs (<italic toggle="yes">P</italic> = 0.246). To control for interindividual differences in TIV, CP was defined as the ratio of CPV/TIV. Comparative analysis revealed significantly elevated CP values in patients with Parkinson's disease relative to HCs, with bilateral significance (left hemisphere, <italic toggle="yes">P</italic> = 0.002; right hemisphere, <italic toggle="yes">P</italic> &#160;<italic toggle="yes">&lt;</italic> 0.001). The results are presented in <xref rid="fcaf365-T2" ref-type="table">Table 2</xref> and <xref rid="fcaf365-F1" ref-type="fig">Fig. 1A</xref>.</p><fig position="float" id="fcaf365-F1" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><p>
<bold>Comparison of neuroimaging biomarkers between Parkinson's disease (<italic toggle="yes">N</italic> = 65) and HC (<italic toggle="yes">N</italic> = 38) with two-sample <italic toggle="yes">t</italic>-test.</bold> (<bold>A</bold>) CP; (<bold>B</bold>) DTI-ALPS index; (<bold>C</bold>) susceptibility value in the SN, RN, CN, PUT and GP. Error bars represent the standard error of the mean. Asterisks indicate statistically significant group differences (*<italic toggle="yes">P</italic> &lt; 0.05, **<italic toggle="yes">P</italic> &lt; 0.01, ***<italic toggle="yes">P</italic> &lt; 0.01). Abbreviations: CP, ratio of choroid plexus volume/total intracranial volume; L, left-hemispheric; R, right-hemispheric.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcaf365f1.jpg"/></fig><table-wrap position="float" id="fcaf365-T2" orientation="portrait"><label>Table 2</label><caption><p>Comparative analysis of neuroimaging biomarkers between groups</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Parkinson's disease (<italic toggle="yes">n</italic> = 65)</th><th align="center" rowspan="1" colspan="1">HC (<italic toggle="yes">n</italic> = 38)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td colspan="4" rowspan="1">Choroid plexus volume</td></tr><tr><td rowspan="1" colspan="1">&#8195;CPV<sub>L</sub> (mm<sup>3</sup>)</td><td rowspan="1" colspan="1">1099.97 &#177; 411.96</td><td rowspan="1" colspan="1">871.79 &#177; 251.82</td><td rowspan="1" colspan="1">0.003**</td></tr><tr><td rowspan="1" colspan="1">&#8195;CPV<sub>R</sub> (mm<sup>3</sup>)</td><td rowspan="1" colspan="1">1054.34 &#177; 333.03</td><td rowspan="1" colspan="1">816.42 &#177; 182.96</td><td rowspan="1" colspan="1">&lt;0.001***</td></tr><tr><td rowspan="1" colspan="1">&#8195;TIV (mm<sup>3</sup>)</td><td rowspan="1" colspan="1">1 484 074.75 &#177; 165 924.37</td><td rowspan="1" colspan="1">1 446 202.89 &#177; 146 299.30</td><td rowspan="1" colspan="1">0.246</td></tr><tr><td rowspan="1" colspan="1">&#8195;CP<sub>L</sub> (&#8240;)</td><td rowspan="1" colspan="1">0.73 &#177; 0.23</td><td rowspan="1" colspan="1">0.60 &#177; 0.15</td><td rowspan="1" colspan="1">0.002**</td></tr><tr><td rowspan="1" colspan="1">&#8195;CP<sub>R</sub> (&#8240;)</td><td rowspan="1" colspan="1">0.71 &#177; 0.19</td><td rowspan="1" colspan="1">0.56 &#177; 0.11</td><td rowspan="1" colspan="1">&lt;0.001***</td></tr><tr><td colspan="4" rowspan="1">DTI-ALPS index</td></tr><tr><td rowspan="1" colspan="1">&#8195;ALPS<sub>L</sub></td><td rowspan="1" colspan="1">1.29 &#177; 0.11</td><td rowspan="1" colspan="1">1.34 &#177; 0.13</td><td rowspan="1" colspan="1">0.025*</td></tr><tr><td rowspan="1" colspan="1">&#8195;ALPS<sub>R</sub></td><td rowspan="1" colspan="1">1.28 &#177; 0.12</td><td rowspan="1" colspan="1">1.33 &#177; 0.11</td><td rowspan="1" colspan="1">0.024*</td></tr><tr><td colspan="4" rowspan="1">QSM</td></tr><tr><td rowspan="1" colspan="1">&#8195;SN<sub>L</sub></td><td rowspan="1" colspan="1">121.01 &#177; 28.09</td><td rowspan="1" colspan="1">99.32 &#177; 39.72</td><td rowspan="1" colspan="1">0.002**</td></tr><tr><td rowspan="1" colspan="1">&#8195;SN<sub>R</sub></td><td rowspan="1" colspan="1">124.98 &#177; 37.95</td><td rowspan="1" colspan="1">103.89 &#177; 41.39</td><td rowspan="1" colspan="1">0.012*</td></tr><tr><td rowspan="1" colspan="1">&#8195;RN<sub>L</sub></td><td rowspan="1" colspan="1">111.23 &#177; 35.78</td><td rowspan="1" colspan="1">94.46 &#177; 33.74</td><td rowspan="1" colspan="1">0.021*</td></tr><tr><td rowspan="1" colspan="1">&#8195;RN<sub>R</sub></td><td rowspan="1" colspan="1">115.37 &#177; 33.63</td><td rowspan="1" colspan="1">97.40 &#177; 34.06</td><td rowspan="1" colspan="1">0.011*</td></tr><tr><td rowspan="1" colspan="1">&#8195;CN<sub>L</sub></td><td rowspan="1" colspan="1">68.13 &#177; 21.83</td><td rowspan="1" colspan="1">62.04 &#177; 17.84</td><td rowspan="1" colspan="1">0.148</td></tr><tr><td rowspan="1" colspan="1">&#8195;CN<sub>R</sub></td><td rowspan="1" colspan="1">69.04 &#177; 20.22</td><td rowspan="1" colspan="1">69.57 &#177; 17.95</td><td rowspan="1" colspan="1">0.895</td></tr><tr><td rowspan="1" colspan="1">&#8195;PUT<sub>L</sub></td><td rowspan="1" colspan="1">59.78 &#177; 24.69</td><td rowspan="1" colspan="1">47.66 &#177; 20.51</td><td rowspan="1" colspan="1">0.009**</td></tr><tr><td rowspan="1" colspan="1">&#8195;PUT<sub>R</sub></td><td rowspan="1" colspan="1">59.61 &#177; 23.05</td><td rowspan="1" colspan="1">50.98 &#177; 18.42</td><td rowspan="1" colspan="1">0.039*</td></tr><tr><td rowspan="1" colspan="1">&#8195;GP<sub>L</sub></td><td rowspan="1" colspan="1">126.34 &#177; 39.99</td><td rowspan="1" colspan="1">117.87 &#177; 32.91</td><td rowspan="1" colspan="1">0.272</td></tr><tr><td rowspan="1" colspan="1">&#8195;GP<sub>R</sub></td><td rowspan="1" colspan="1">136.49 &#177; 44.13</td><td rowspan="1" colspan="1">127.71 &#177; 32.59</td><td rowspan="1" colspan="1">0.289</td></tr></tbody></table><table-wrap-foot><fn id="tblfn3"><p>Abbreviations: HC, healthy controls; CPV, choroid plexus volume; TIV, total intracranial volume; CP, ratio of CPV/TIV; DTI-ALPS, diffusion tensor image analysis along the perivascular space; QSM, quantitative susceptibility mapping; SN, substantia nigra; RN, red nucleus; CN, caudate nucleus; PUT, putamen; GP, globus pallidus; L, left-hemispheric; R, right-hemispheric.</p></fn><fn id="tblfn4"><p>Significance levels: *<italic toggle="yes">P</italic> &#160;<italic toggle="yes">&lt;</italic> 0.05, **<italic toggle="yes">P</italic> &#160;<italic toggle="yes">&lt;</italic> 0.01, ***<italic toggle="yes">P</italic> &#160;<italic toggle="yes">&lt;</italic> 0.001 (Parkinson's disease versus HC), Bonferroni-corrected.</p></fn></table-wrap-foot></table-wrap></sec><sec id="fcaf365-s3.2.2"><title>DTI-ALPS index</title><p>Patients with Parkinson's disease exhibited significantly reduced ALPS indices in both hemispheres compared to HCs (left hemisphere, <italic toggle="yes">P</italic> = 0.025; right hemisphere, <italic toggle="yes">P</italic> = 0.024, using Bonferroni correction). See <xref rid="fcaf365-T2" ref-type="table">Table 2</xref> and <xref rid="fcaf365-F1" ref-type="fig">Fig. 1B</xref> for details.</p></sec><sec id="fcaf365-s3.2.3"><title>Quantitative susceptibility mapping</title><p>QSM revealed significantly higher susceptibility values in the SN (left hemisphere: <italic toggle="yes">P</italic> = 0.002; right hemisphere: <italic toggle="yes">P</italic> = 0.012, using Bonferroni correction), RN (left hemisphere: <italic toggle="yes">P</italic> = 0.021; right hemisphere: <italic toggle="yes">P</italic> = 0.011) and PUT (left hemisphere: <italic toggle="yes">P</italic> = 0.009; right hemisphere: <italic toggle="yes">P</italic> = 0.039) bilaterally in patients with Parkinson's disease compared with controls. No between-group differences were observed in susceptibility values for CN or GP (both <italic toggle="yes">P</italic> &gt; 0.05). Quantitative comparisons of the regional susceptibility values are provided in <xref rid="fcaf365-T2" ref-type="table">Table 2</xref> and <xref rid="fcaf365-F1" ref-type="fig">Fig. 1C</xref>.</p></sec></sec><sec id="fcaf365-s3.3"><title>Cross-modal relationships between neuroimaging biomarkers</title><sec id="fcaf365-s3.3.1"><title>Correlations between CP and the ALPS index</title><p>At the left hemispheric level, the CP exhibited significant negative correlations with the ALPS index in both the Parkinson's disease group (<italic toggle="yes">r</italic> = &#8722;0.305, <italic toggle="yes">P</italic> = 0.014) and the combined cohort (<italic toggle="yes">r</italic> = &#8722;0.341, <italic toggle="yes">P</italic> &#160;<italic toggle="yes">&lt;</italic> 0.001), whereas only a non-significant trend was observed in the HC group (<italic toggle="yes">r</italic> = &#8722;0.310, <italic toggle="yes">P</italic> = 0.058). The results are presented in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 1</xref> and <xref rid="fcaf365-F2" ref-type="fig">Fig. 2A</xref>.</p><fig position="float" id="fcaf365-F2" fig-type="figure" orientation="portrait"><label>Figure 2</label><caption><p>
<bold>Cross-modal correlations between neuroimaging biomarkers.</bold> (<bold>A, B</bold>) Partial correlation analysis between CP and the DTI-ALPS index in Parkinson's disease cohort (<italic toggle="yes">N</italic> = 65); (<bold>C</bold>) partial correlation analysis between glymphatic biomarkers and regional susceptibility values in Parkinson's disease cohort (<italic toggle="yes">N</italic> = 65). QSM represents the QSM values of the corresponding brain regions. Asterisks indicate statistically significant group differences (*<italic toggle="yes">P</italic> &lt; 0.05, **<italic toggle="yes">P</italic> &lt; 0.01, ***<italic toggle="yes">P</italic> &lt; 0.01). Abbreviations: All, all participants; CP, ratio of choroid plexus volume/total intracranial volume; L, left-hemispheric; R, right-hemispheric.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcaf365f2.jpg"/></fig><p>At the right hemispheric level, the CP demonstrated significant negative correlations with the ALPS index across all cohorts: the Parkinson's disease group (<italic toggle="yes">r</italic> = &#8722;0.357, <italic toggle="yes">P</italic> = 0.004), the HC group (<italic toggle="yes">r</italic> = &#8722;0.512, <italic toggle="yes">P</italic> = 0.001) and the entire sample (<italic toggle="yes">r</italic> = &#8722;0.434, <italic toggle="yes">P</italic> &#160;<italic toggle="yes">&lt;</italic> 0.001). The results are presented in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 1</xref> and <xref rid="fcaf365-F2" ref-type="fig">Fig. 2B</xref>.</p></sec><sec id="fcaf365-s3.3.2"><title>Correlations between glymphatic markers and regional iron accumulation</title><p>Our analyses revealed distinct patterns of glymphatic susceptibility relationships across the groups. We observed consistent positive associations between SN susceptibility and CP across all study groups, with bilateral significance (Parkinson's disease group: left hemisphere: <italic toggle="yes">r</italic> = 0.236, <italic toggle="yes">P</italic> = 0.029; right hemisphere: <italic toggle="yes">r</italic> = 0.233, <italic toggle="yes">P</italic> = 0.031; HC group: left hemisphere: <italic toggle="yes">r</italic> = 0.367, <italic toggle="yes">P</italic> = 0.012; right hemisphere: <italic toggle="yes">r</italic> = 0.373, <italic toggle="yes">P</italic> = 0.011; combined cohort: left hemisphere: <italic toggle="yes">r</italic> = 0.333, <italic toggle="yes">P</italic> &#160;<italic toggle="yes">&lt;</italic> 0.001; right hemisphere: <italic toggle="yes">r</italic> = 0.332, <italic toggle="yes">P</italic> &#160;<italic toggle="yes">&lt;</italic> 0.001). Additionally, in the HC group, left PUT susceptibility showed a significant positive correlation with ipsilateral CP (<italic toggle="yes">r</italic> = 0.32, <italic toggle="yes">P</italic> = 0.025), whereas right RN susceptibility was inversely associated with the right ALPS index in both the HC group (<italic toggle="yes">r</italic> = &#8722;0.466, <italic toggle="yes">P</italic> = 0.002) and the combined cohort (<italic toggle="yes">r</italic> = &#8722;0.25, <italic toggle="yes">P</italic> = 0.005). Patients with Parkinson's disease exhibited more complex right-hemisphere glymphatic susceptibility associations; CN susceptibility demonstrated a positive correlation with CP (<italic toggle="yes">r</italic> = 0.25, <italic toggle="yes">P</italic> = 0.029) and a negative correlation with the ALPS index (<italic toggle="yes">r</italic> = &#8722;0.22, <italic toggle="yes">P</italic> = 0.038). Right PUT susceptibility displayed consistent positive correlations with the right CP in patients with Parkinson's disease (<italic toggle="yes">r</italic> = 0.325, <italic toggle="yes">P</italic> = 0.004) and all participants (<italic toggle="yes">r</italic> = 0.304, <italic toggle="yes">P</italic> = 0.001), and showed uniformly negative associations with the right ALPS index across the Parkinson's disease group (<italic toggle="yes">r</italic> = &#8722;0.278, <italic toggle="yes">P</italic> = 0.012), HC group (<italic toggle="yes">r</italic> = &#8722;0.329, <italic toggle="yes">P</italic> = 0.022) and the full sample (<italic toggle="yes">r</italic> = &#8722;0.301, <italic toggle="yes">P</italic> = 0.001). Finally, right GP susceptibility was negatively correlated with the right ALPS index in the patients with Parkinson's disease (<italic toggle="yes">r</italic> = &#8722;0.212, <italic toggle="yes">P</italic> = 0.045), whereas it showed a positive correlation with the right CP in the HC group (<italic toggle="yes">r</italic> = 0.319, <italic toggle="yes">P</italic> = 0.025). No significant correlations were observed between other glymphatic markers and regional susceptibility values (<italic toggle="yes">P</italic> &gt; 0.05). The details are presented in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 1</xref> and <xref rid="fcaf365-F2" ref-type="fig">Fig. 2C</xref>.</p></sec></sec><sec id="fcaf365-s3.4"><title>Correlation between neuroimaging biomarkers and clinical characteristics related to Parkinson's disease</title><p>In Parkinson's disease patients, age was negatively correlated with bilateral ALPS indices (left hemisphere: <italic toggle="yes">r</italic> = &#8722;0.396, <italic toggle="yes">P</italic> &lt; 0.001; right hemisphere: <italic toggle="yes">r</italic> = &#8722;0.438, <italic toggle="yes">P</italic> &lt; 0.001), while showing positive associations with CP (left hemisphere: <italic toggle="yes">r</italic> = 0.264, <italic toggle="yes">P</italic> = 0.017; right hemisphere: <italic toggle="yes">r</italic> = 0.487, <italic toggle="yes">P</italic> &lt; 0.001), CN susceptibility (left hemisphere: <italic toggle="yes">r</italic> = 0.348, <italic toggle="yes">P</italic> = 0.002; right hemisphere: <italic toggle="yes">r</italic> = 0.314, <italic toggle="yes">P</italic> = 0.005), PUT susceptibility (left hemisphere: <italic toggle="yes">r</italic> = 0.483, <italic toggle="yes">P</italic> &lt; 0.001; right hemisphere: <italic toggle="yes">r</italic> = 0.419, <italic toggle="yes">P</italic> &lt; 0.001) and right GP susceptibility (<italic toggle="yes">r</italic> = 0.235, <italic toggle="yes">P</italic> = 0.03). Disease duration was inversely associated with the right ALPS index (<italic toggle="yes">r</italic> = &#8722;0.207, <italic toggle="yes">P</italic> = 0.049) but positively correlated with left putaminal susceptibility (<italic toggle="yes">r</italic> = 0.215, <italic toggle="yes">P</italic> = 0.042). UPDRS-II scores were negatively correlated with bilateral ALPS indices (left hemisphere: <italic toggle="yes">r</italic> = &#8722;0.292, <italic toggle="yes">P</italic> = 0.009; right hemisphere: <italic toggle="yes">r</italic> = &#8722;0.269, <italic toggle="yes">P</italic> = 0.015) and left GP susceptibility (<italic toggle="yes">r</italic> = &#8722;0.208, <italic toggle="yes">P</italic> = 0.048), whereas UPDRS-III scores were associated with a reduced right ALPS index (<italic toggle="yes">r</italic> = &#8722;0.265, <italic toggle="yes">P</italic> = 0.016) and elevated right SN susceptibility (<italic toggle="yes">r</italic> = 0.309, <italic toggle="yes">P</italic> = 0.006). FOG assessments revealed positive associations with bilateral CP (left hemisphere: <italic toggle="yes">r</italic> = 0.229, <italic toggle="yes">P</italic> = 0.033; right hemisphere: <italic toggle="yes">r</italic> = 0.277, <italic toggle="yes">P</italic> = 0.013), PUT susceptibility (left hemisphere: <italic toggle="yes">r</italic> = 0.285, <italic toggle="yes">P</italic> = 0.011; right hemisphere: <italic toggle="yes">r</italic> = 0.263, <italic toggle="yes">P</italic> = 0.017) and left CN susceptibility (<italic toggle="yes">r</italic> = 0.213, <italic toggle="yes">P</italic> = 0.044), alongside negative correlations with bilateral ALPS indices (left hemisphere: <italic toggle="yes">r</italic> = &#8722;0.243, <italic toggle="yes">P</italic> = 0.025; right hemisphere: <italic toggle="yes">r</italic> = &#8722;0.280, <italic toggle="yes">P</italic> = 0.012). RBD severity was positively correlated with left CP (<italic toggle="yes">r</italic> = 0.238, <italic toggle="yes">P</italic> = 0.028). The MMSE scores were inversely related to bilateral CN (left hemisphere: <italic toggle="yes">r</italic> = &#8722;0.272, <italic toggle="yes">P</italic> = 0.014; right hemisphere: <italic toggle="yes">r</italic> = &#8722;0.216, <italic toggle="yes">P</italic> = 0.042) and PUT susceptibility (left hemisphere: <italic toggle="yes">r</italic> = &#8722;0.281, <italic toggle="yes">P</italic> = 0.012; right hemisphere: <italic toggle="yes">r</italic> = &#8722;0.271, <italic toggle="yes">P</italic> = 0.015). Depression severity was positively correlated with bilateral CN (left hemisphere: <italic toggle="yes">r</italic> = 0.293, <italic toggle="yes">P</italic> = 0.009; right hemisphere: <italic toggle="yes">r</italic> = 0.241, <italic toggle="yes">P</italic> = 0.027) and putaminal susceptibility (left hemisphere: <italic toggle="yes">r</italic> = 0.334, <italic toggle="yes">P</italic> = 0.003; right hemisphere: <italic toggle="yes">r</italic> = 0.234, <italic toggle="yes">P</italic> = 0.03) but negatively correlated with ALPS indices (left hemisphere: <italic toggle="yes">r</italic> = &#8722;0.308, <italic toggle="yes">P</italic> = 0.006; right hemisphere: <italic toggle="yes">r</italic> = &#8722;0.367, <italic toggle="yes">P</italic> &lt; 0.001). Finally, anxiety scores were positively associated with bilateral CP (left: <italic toggle="yes">r</italic> = 0.228, <italic toggle="yes">P</italic> = 0.034; right: <italic toggle="yes">r</italic> = 0.212, <italic toggle="yes">P</italic> = 0.045), PUT susceptibility (left hemisphere: <italic toggle="yes">r</italic> = 0.386, <italic toggle="yes">P</italic> &lt; 0.001; right hemisphere: <italic toggle="yes">r</italic> = 0.303, <italic toggle="yes">P</italic> = 0.007) and left CN susceptibility (<italic toggle="yes">r</italic> = 0.301, <italic toggle="yes">P</italic> = 0.007), and negatively correlated with bilateral ALPS indices (left hemisphere: <italic toggle="yes">r</italic> = &#8722;0.259, <italic toggle="yes">P</italic> = 0.006; right hemisphere: <italic toggle="yes">r</italic> = &#8722;0.363, <italic toggle="yes">P</italic> &lt; 0.001). All other neuroimaging-clinical correlations were below the predefined significance threshold (<italic toggle="yes">P</italic> &gt; 0.05). Detailed information is presented in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 2</xref> and <xref rid="fcaf365-F3" ref-type="fig">Fig. 3</xref>.</p><fig position="float" id="fcaf365-F3" fig-type="figure" orientation="portrait"><label>Figure 3</label><caption><p>
<bold>Partial correlation analysis between neuroimaging biomarkers and clinical characteristics related to Parkinson's disease (<italic toggle="yes">N</italic> = 65).</bold> QSM represents the QSM values of the corresponding brain regions. Asterisks indicate statistically significant group differences (*<italic toggle="yes">P</italic> &lt; 0.05, **<italic toggle="yes">P</italic> &lt; 0.01, ***<italic toggle="yes">P</italic> &lt; 0.01). Abbreviations: CP, ratio of choroid plexus volume/total intracranial volume; LEDD, levodopa equivalent daily dose; L, left-hemispheric; R, right-hemispheric.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcaf365f3.jpg"/></fig></sec><sec id="fcaf365-s3.5"><title>Mediation analysis</title><sec id="fcaf365-s3.5.1"><title>CP influenced UPDRS-II scores through modulation of the ALPS index in patients with Parkinson's disease</title><p>A significant indirect effect of the right CP on UPDRS-II scores (used to assess impairments in activities of daily living) via the right ALPS index was observed (effect = 2.61, SE = 1.80, 95% CI [0.23, 7.12]). Right CP negatively predicted right ALPS (<italic toggle="yes">&#946;</italic> = &#8722;0.22, <italic toggle="yes">P</italic> = 0.004), which in turn was associated with lower UPDRS-II scores (<italic toggle="yes">&#946;</italic> = &#8722;11.81, <italic toggle="yes">P</italic> = 0.028). The absence of significant direct or total effects (<italic toggle="yes">P</italic> &gt; 0.59) supported full mediation, as illustrated in <xref rid="fcaf365-F4" ref-type="fig">Fig. 4A</xref>.</p><fig position="float" id="fcaf365-F4" fig-type="figure" orientation="portrait"><label>Figure 4</label><caption><p>
<bold>Mediation analysis using simple mediation models in patients with Parkinson's disease (<italic toggle="yes">N</italic> = 65).</bold> (<bold>A</bold>) The mediation effects of the right ALPS index between the right CPV and UPDRS-II score; (<bold>B</bold>) the mediation effects of right PUT iron deposition between the right CPV and HAM-A score; (<bold>C</bold>) the mediation effects of right PUT iron deposition between the right CPV and HAM-D score. Abbreviations: QSM-PUT, susceptibility value of the putamen.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcaf365f4.jpg"/></fig></sec><sec id="fcaf365-s3.5.2"><title>CP contributed to neuropsychiatric symptoms via modulation of PUT iron deposition in Parkinson's disease</title><p>Mediation analysis demonstrated a significant indirect effect of the right CP on anxiety and depression symptoms through iron deposition in the right PUT in patients with Parkinson's disease. Right CP positively predicted right PUT susceptibility (<italic toggle="yes">&#946;</italic> = 39.85, <italic toggle="yes">P</italic> = 0.008), which in turn was associated with higher HAM-A scores (<italic toggle="yes">&#946;</italic> = 0.09, <italic toggle="yes">P</italic> = 0.047), with a significant indirect effect (effect = 3.49, SE = 2.12, 95% CI [0.30, 8.51]), as illustrated in <xref rid="fcaf365-F4" ref-type="fig">Fig. 4B</xref>.</p><p>Similarly, right PUT susceptibility mediated the relationship between right CP and HAM-D scores (<italic toggle="yes">&#946;</italic> = 0.07, <italic toggle="yes">P</italic> = 0.046), showing a significant indirect effect (effect = 2.62, SE = 1.59, 95% CI [0.19, 6.44]). The absence of significant direct or total effects (both <italic toggle="yes">P</italic> &gt; 0.39) in both models supported full mediation, as illustrated in <xref rid="fcaf365-F4" ref-type="fig">Fig. 4C</xref>.</p></sec></sec><sec id="fcaf365-s3.6"><title>Neuroimaging biomarkers, cognitive scores and psychiatric symptoms in the combined diagnostic efficacy for Parkinson's disease</title><p>ROC curve analysis was used to evaluate the diagnostic performance of multiple models for mild-to-moderate stage Parkinson's disease. The ALPS model demonstrated modest performance (AUC = 0.621, 95% CI: 0.508&#8211;0.735), a sensitivity of 66.2% and a specificity of 50.0%. The CP model showed improved discrimination (AUC = 0.730, 95% CI: 0.634&#8211;0.826), with 60.0% sensitivity and 73.7% specificity. Further enhancement was observed with the QSM model (AUC = 0.747, 95% CI: 0.647&#8211;0.847), with 73.8% sensitivity with 55.3% specificity. Neuroimaging-based models comprising neuroimaging biomarkers exhibited strong diagnostic utility. The multiparametric neuroimaging model achieved an AUC of 0.817 (95% CI: 0.734&#8211;0.899) with 80.0% sensitivity and 65.8% specificity. The MoCA score (AUC = 0.821; 95% CI, 0.743&#8211;0.899) had high specificity (89.5%), but limited sensitivity (40.0%), while the neuropsychiatric variable model incorporating the HAM-D and HAM-A scores (AUC = 0.828, 95% CI: 0.751&#8211;0.905) prioritized sensitivity (81.5%) over specificity (42.1%). Notably, the comprehensive model incorporating all variables outperformed all other models with near-perfect discrimination (AUC = 0.972, 95% CI: 0.947&#8211;0.997). It achieved 100% sensitivity and 97.4% specificity, demonstrating a robust ability to identify true cases while minimizing the number of false positives. DeLong's test revealed that the comprehensive model surpassed all other models (<italic toggle="yes">P</italic> &lt; 0.001 versus ALPS, CP, QSM, multiparametric neuroimaging model, MoCA-only and neuropsychiatric variables). The results are shown in <xref rid="fcaf365-F5" ref-type="fig">Fig. 5</xref>.</p><fig position="float" id="fcaf365-F5" fig-type="figure" orientation="portrait"><label>Figure 5</label><caption><p>
<bold>Diagnostic performance of multiple models for mild-to-moderate-stage Parkinson's disease using ROC curve analysis (<italic toggle="yes">N</italic> = 65).</bold> The diagnostic model for Parkinson's disease incorporating all variables significantly outperformed all univariate models, achieving near-perfect discriminative capability (AUC = 0.972). The multiparametric neuroimaging model integrated ALPS + CP + QSM. The neuropsychiatric variables model integrated HAM-D + HAM-A. Abbreviations: CP, ratio of choroid plexus volume/total intracranial volume.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcaf365f5.jpg"/></fig></sec></sec><sec sec-type="discussion" id="fcaf365-s4"><title>Discussion</title><p>This study applied multimodal neuroimaging techniques to systematically elucidate the relationship between cerebral iron deposition and glymphatic dysfunction in Parkinson's disease, revealing significant associations between an enlarged CPV, reduced ALPS index and pathological iron accumulation. Furthermore, these neuroimaging biomarkers demonstrated robust correlations with clinical symptomatology, and edition analyses demonstrated that glymphatic dysfunction and iron deposition mediate the relationship between CPV and clinical symptoms. Finally, the integrated diagnostic model, which incorporated comprehensive cognitive assessments, psychiatric symptom evaluations and neuroimaging biomarkers, exhibited remarkable diagnostic efficacy for mild-to-moderate-stage Parkinson's disease. These findings provide new insights into the mechanisms underlying iron dyshomeostasis in Parkinson's disease and highlight potential therapeutic targets.</p><sec id="fcaf365-s4.1"><title>Choroid plexus enlargement may contribute to glymphatic dysfunction in Parkinson's disease</title><p>Our observation of bilateral CPV enlargement in patients with Parkinson's disease is consistent with previous neuroimaging studies that reported choroid plexus hypertrophy in neurodegenerative diseases, including Alzheimer's disease and PD,<sup><xref rid="fcaf365-B20" ref-type="bibr">20</xref>,<xref rid="fcaf365-B22" ref-type="bibr">22</xref></sup> which usually supports that the increase of choroid plexus volume usually represents compensatory tissue hypertrophy or oedema, thus reflecting the decline of choroid plexus function. Recently, it has been proposed that choroid plexus enlargement in Alzheimer's disease may reflect compensatory mechanisms due to impaired cerebrospinal fluid (CSF) clearance,<sup><xref rid="fcaf365-B20" ref-type="bibr">20</xref></sup> a hypothesis that may extend to Parkinson's disease. Some review articles conceptualized CPV as a key regulator in maintaining central nervous system homeostasis, establishing it as a crucial biomarker for evaluating glymphatic system functionality.<sup><xref rid="fcaf365-B32" ref-type="bibr">32</xref>,<xref rid="fcaf365-B33" ref-type="bibr">33</xref></sup> Notably, our study directly linked CPV enlargement to glymphatic dysfunction (reduced ALPS index) in Parkinson's disease, which has been consistently reported in both Alzheimer's disease and multiple sclerosis.<sup><xref rid="fcaf365-B34" ref-type="bibr">34</xref>,<xref rid="fcaf365-B35" ref-type="bibr">35</xref></sup> This suggests that choroid plexus pathology may disrupt interstitial fluid convection along the perivascular spaces, a critical pathway for brain iron clearance.<sup><xref rid="fcaf365-B13" ref-type="bibr">13</xref></sup> This finding complements recent studies, which reported glymphatic impairment in Parkinson's disease using DTI-ALPS analysis but did not explore its relationship with CPV, and uniquely established a direct negative correlation between CPV and the ALPS index, suggesting that choroid plexus enlargement may exacerbate glymphatic dysfunction by altering CSF turnover or interstitial fluid dynamics.<sup><xref rid="fcaf365-B24" ref-type="bibr">24</xref>,<xref rid="fcaf365-B25" ref-type="bibr">25</xref></sup></p></sec><sec id="fcaf365-s4.2"><title>Iron deposition in Parkinson's disease may be associated with impaired glymphatic clearance function</title><p>The elevated iron deposition in the SN, RN and PUT of patients with Parkinson's disease is consistent with prior QSM studies.<sup><xref rid="fcaf365-B7" ref-type="bibr">7</xref>,<xref rid="fcaf365-B30" ref-type="bibr">30</xref>,<xref rid="fcaf365-B31" ref-type="bibr">31</xref></sup> However, the absence of significant iron accumulation in the GP contrasted with some reports,<sup><xref rid="fcaf365-B31" ref-type="bibr">31</xref></sup> possibly attributable to the exclusion of advanced-stage Parkinson's disease patients (H-Y stage &gt; 3) in our cohort. Additionally, our study is the first to demonstrate that iron accumulation in parts of these regions correlates positively with CPV and negatively with the ALPS index. This aligns with the theory that brain iron homeostasis depends on a balanced influx (via transferrin receptors) and efflux (via glymphatic clearance). While previous studies have attributed Parkinson's disease iron dysregulation primarily to upregulated BBB iron influx,<sup><xref rid="fcaf365-B11" ref-type="bibr">11</xref></sup> our findings provide the first systematic evidence implicating glymphatic-mediated iron clearance failure as a driver of pathological iron deposition.</p><p>Furthermore, only iron deposition in the SN demonstrated a positive correlation with bilateral CPV, and the susceptibility of other regions exhibited right hemisphere predominance in association with impaired glymphatic clearance function, which may reflect the characteristic clinical and pathological asymmetries observed in Parkinson's disease,<sup><xref rid="fcaf365-B36" ref-type="bibr">36</xref></sup> but unfortunately, this study did not record the lateralization information of Parkinson's disease patients in detail. In addition, compared with Parkinson's disease group, a higher correlation was found between CPV and SN iron deposition in HC group, which may be because of the imbalance between the input and output of SN iron and the greater compensatory effect of choroid plexus in Parkinson's disease. A recent study employed both the ALPS and QSM multimodal neuroimaging approaches to investigate Parkinson's disease.<sup><xref rid="fcaf365-B37" ref-type="bibr">37</xref></sup> However, their analysis was restricted to iron deposition in the SN alone and overlooked the potential relationship between the glymphatic system and SN iron accumulation; correlation analysis between these measures was not performed. Our findings demonstrate that SN iron deposition in patients with Parkinson's disease was more closely associated with choroid plexus function than with the ALPS index. Finally, the animal study had demonstrated that glymphatic dysfunction contributes to &#945;-syn accumulation in Parkinson's disease,<sup><xref rid="fcaf365-B38" ref-type="bibr">38</xref></sup> which was consistent with our findings because of previous reports of frequent iron-&#945;-syn co-deposition in the SN of Parkinson's disease.<sup><xref rid="fcaf365-B11" ref-type="bibr">11</xref></sup></p></sec><sec id="fcaf365-s4.3"><title>The association between neuroimaging biomarkers and clinical manifestations in Parkinson's disease</title><p>Age exhibited robust correlations with multiple neuroimaging measures, including negative associations with the ALPS index and positive correlations with CPV and iron deposition in the CN and PUT groups. These observations are consistent with previous studies demonstrating an age-related decline in glymphatic function and choroid plexus hypertrophy.<sup><xref rid="fcaf365-B39" ref-type="bibr">39-41</xref></sup> Notably, our data extend these findings by showing that age-associated glymphatic dysfunction may exacerbate iron accumulation in regions vulnerable to Parkinson's disease, suggesting a synergistic effect of aging and Parkinson's disease pathology on brain iron homeostasis. This supports the &#8216;two-hit&#8217; hypothesis, where aging (hit one) primes the brain for Parkinson's disease-specific iron dysregulation (hit two).<sup><xref rid="fcaf365-B10" ref-type="bibr">10</xref>,<xref rid="fcaf365-B30" ref-type="bibr">30</xref></sup></p><p>Longer disease duration was correlated with higher PUT iron deposition and a reduced right ALPS index, reinforcing the role of glymphatic impairment in progressive iron accumulation. This parallels the neuropathological evidence of spatiotemporal iron expansion in Parkinson's disease.<sup><xref rid="fcaf365-B7" ref-type="bibr">7</xref></sup> However, our study uniquely links this progression to declining glymphatic efficiency. The lack of a significant association between disease duration and CPV implies that choroid plexus hypertrophy may occur early in Parkinson's disease, preceding measurable glymphatic function decline, a hypothesis that warrants longitudinal validation.</p><p>The UPDRS-III scores correlated with right SN iron deposition and the right ALPS index, consistent with the role of the SN in motor dysfunction reported in previous studies.<sup><xref rid="fcaf365-B42" ref-type="bibr">42</xref></sup> Mediation analysis further revealed that the right ALPS index fully mediated the effect of CPV on UPDRS-II scores, underscoring glymphatic dysfunction as a potential key driver of impaired QoL in patients with Parkinson's disease, a finding aligned with established research evidence.<sup><xref rid="fcaf365-B43" ref-type="bibr">43</xref></sup></p><p>The severity of FOG was associated with bilateral glymphatic dysfunction and PUT iron deposition, highlighting the pivotal role of PUT in the pathogenesis of FOG in Parkinson's disease. Previous studies have suggested that FOG may be associated with aberrantly enhanced functional connectivity between the PUT and amygdala, suggesting that this pathological mechanism may be mediated through iron deposition-induced functional disruption of the PUT.<sup><xref rid="fcaf365-B44" ref-type="bibr">44</xref></sup> However, in contrast to our findings, some studies have reported no significant differences in the ALPS index between patients with Parkinson's disease with and without FOG.<sup><xref rid="fcaf365-B45" ref-type="bibr">45</xref></sup> This may be because Parkinson's disease with FOG additionally involves abnormalities in basal ganglia-cortical circuits and degeneration of the noradrenergic system, thereby attenuating the observed association with glymphatic dysfunction.<sup><xref rid="fcaf365-B46" ref-type="bibr">46</xref>,<xref rid="fcaf365-B47" ref-type="bibr">47</xref></sup></p><p>Higher CN and PUT iron deposition were found to correlate with lower MMSE scores and higher HAM-D/HAM-A scores, supporting the role of striatal iron, not just the cortex, in cognitive impairment and psychiatric symptoms.<sup><xref rid="fcaf365-B23" ref-type="bibr">23</xref>,<xref rid="fcaf365-B48" ref-type="bibr">48-50</xref></sup> Similarly, several studies have reported a negative relationship between striatal iron deposition and cognitive scores in patients with Parkinson's disease.<sup><xref rid="fcaf365-B51" ref-type="bibr">51</xref>,<xref rid="fcaf365-B52" ref-type="bibr">52</xref></sup> Regarding mental disorders, the previous research identified a correlation between anxiety scores and reduced functional connectivity between the PUT and amygdala in Parkinson's disease.<sup><xref rid="fcaf365-B53" ref-type="bibr">53</xref></sup> In contrast, previous PET studies demonstrated that reduced striatal dopamine transporter density predicts more severe psychiatric symptoms in patients with Parkinson's disease,<sup><xref rid="fcaf365-B54" ref-type="bibr">54</xref></sup> a finding replicated in animal models.<sup><xref rid="fcaf365-B55" ref-type="bibr">55</xref></sup> This study provides further evidence regarding the potential mechanisms related to PUT ferroptosis leading to mental disorders in Parkinson's disease, which were completely regulated by choroid plexus function according to mediation analysis.</p></sec><sec id="fcaf365-s4.4"><title>Diagnostic superiority of integrating multimodal neuroimaging biomarkers with clinical variables</title><p>The comprehensive model combining the CPV, ALPS index, QSM-derived iron deposition and neuropsychiatric assessments achieved near-perfect discrimination between mild-to-moderate-stage Parkinson's disease and HCs (AUC = 0.972), surpassing individual neuroimaging biomarker models such as the QSM (AUC = 0.747) or ALPS index alone (AUC = 0.621). This aligns with emerging evidence advocating for multimodal approaches in neurodegenerative disease diagnostics,<sup><xref rid="fcaf365-B26" ref-type="bibr">26</xref>,<xref rid="fcaf365-B37" ref-type="bibr">37</xref></sup> as single biomarkers often fail to capture the multifactorial nature of Parkinson's disease pathology.<sup><xref rid="fcaf365-B22" ref-type="bibr">22</xref>,<xref rid="fcaf365-B24" ref-type="bibr">24</xref></sup> Previous studies have also employed a combination of neuroimaging biomarkers (bilateral perivascular spaces and the ALPS index or the QSM of the bilateral SN and ALPS index) for ROC analysis in Parkinson's disease, yet achieved only moderate diagnostic accuracy (AUC = 0.85 and 0.801), likely due to the exclusion of crucial clinical parameters.<sup><xref rid="fcaf365-B25" ref-type="bibr">25</xref>,<xref rid="fcaf365-B37" ref-type="bibr">37</xref></sup> The exceptional sensitivity (100%) and specificity (97.4%) of this model contrasted with the trade-offs observed in isolated assessments&#8212;the high specificity (89.5%) but limited sensitivity (40%) of the MoCA and inverse profile of neuropsychiatric variables&#8212;emphasizing the clinical value of integrated evaluation. Notably, the synergistic performance of CPV, the ALPS index and QSM highlighted their complementary roles: CPV enlargement reflected choroid plexus dysfunction, whereas ALPS index reduction directly quantified glymphatic impairment, providing a holistic proxy for iron clearance failure. While prior studies independently linked CPV to &#945;-synucleinopathy or the ALPS index to Parkinson's disease severity,<sup><xref rid="fcaf365-B22" ref-type="bibr">22</xref>,<xref rid="fcaf365-B24" ref-type="bibr">24</xref></sup> this study pioneered their combined use, demonstrating unprecedented diagnostic precision. These results underscore the diagnostic advantage of integrating multimodal data, and the exceptional performance of the combined model highlights its potential for clinical applications in mild-to-moderate-stage Parkinson's disease detection. Future validation in prodromal cohorts could further refine the utility of this model for early intervention, thereby addressing the critical unmet need in Parkinson's disease management.</p></sec><sec id="fcaf365-s4.5"><title>Limitations</title><p>This study has some limitations, as follows. (i) Sample size and generalizability: Since this was a single-centre exploratory investigation with a limited sample size, there are constraints on generalizability. The preliminary nature of these findings necessitates validation through multicentre studies with larger cohorts to establish broader clinical applicability. The exclusion of advanced-stage patients with Parkinson's disease further restricted applicability to mild-to-moderate cases, and the diagnostic model requires external validation in independent cohorts for clinical translation. In addition, the lack of lateralization information made it difficult to explain the rightization of the results in this paper. (ii) Cross-sectional design: the observational nature of the study precludes causal inferences between glymphatic dysfunction, iron deposition and clinical symptoms. Longitudinal studies are needed to validate temporal relationships, such as tracking prodromal Parkinson's disease cohorts (e.g. idiopathic RBD) to test directional relationships among baseline CPV, follow-up ALPS decline and follow-up iron accumulation,<sup><xref rid="fcaf365-B56" ref-type="bibr">56</xref></sup> or applying Parkinson's disease animal models with damaged glymphatic system to explore its effect on brain iron deposition. (iii) Differential analysis: glymphatic dysfunction and brain iron deposition are common in nearly all neurodegenerative diseases, but the relationship between glymphoid dysfunction and brain iron deposition in other neurodegenerative diseases was not discussed in this paper to determine whether it is a unique mechanism in Parkinson's disease. In the future, similar research can be considered in other neurodegenerative diseases such as Alzheimer's disease or multiple system atrophy. (iv) Potential measurement bias: manual delineation of QSM ROIs by neuroradiologists, despite consensus resolution, may have introduced subjectivity. Additionally, the ALPS index indirectly assessed glymphatic function, lacking direct measurement of CSF dynamics. Although previous studies have supported the robustness of ALPS by studying the high correlation between traditional glymphatic imaging and ALPS index,<sup><xref rid="fcaf365-B57" ref-type="bibr">57</xref></sup> the recent study suggest that age-related white matter degeneration may increase the false positive rate of ALPS by 30% due to the ROI dependence of methodology,<sup><xref rid="fcaf365-B58" ref-type="bibr">58</xref></sup> which was an unavoidable limitation even if age had been used as a covariate to assess the correlation. In future research, more robust methods to evaluate glymphatic system, such as traditional enhanced glymphatic MRI, could be applied to solve this problem. (v) Technical limitations: Although motion artefacts were minimized, subtle movements in patients with Parkinson's disease during MRI scanning may have affected data accuracy.</p></sec></sec><sec id="fcaf365-s5"><title>Conclusion</title><p>This study demonstrated that impaired glymphatic clearance, as evidenced by choroid plexus enlargement and a reduced ALPS index, was closely associated with pathological iron deposition in key brain regions of patients with Parkinson's disease, suggesting a mechanistic link between glymphatic dysfunction and iron dyshomeostasis. The identified correlations between neuroimaging biomarkers (CPV, ALPS index and QSM-derived iron levels) and clinical manifestations, including motor deficits, cognitive decline and psychiatric symptoms, highlight their potential roles in tracking Parkinson's disease progression. Notably, the integrative diagnostic model, combining multimodal neuroimaging, cognitive assessments and psychiatric evaluations, achieved exceptional accuracy (AUC = 0.972), underscoring the clinical value of holistic approaches for Parkinson's disease diagnosis. These findings not only advance our understanding of iron clearance failure in Parkinson's disease pathogenesis but also suggest therapeutic targets, such as glymphatic modulation and iron chelation, to mitigate neurodegeneration. Future longitudinal and mechanistic studies are warranted to validate these associations and to provide insights into clinical interventions.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sup1" position="float" content-type="local-data" orientation="portrait"><label>fcaf365_Supplementary_Data</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fcaf365_supplementary_data.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ack1"><title>Acknowledgements</title><p>The authors express their gratitude to all participants and collaborators who contributed to this study. We also acknowledge Editage (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.editage.cn" ext-link-type="uri">www.editage.cn</ext-link>) for providing professional language editing services.</p></ack><sec id="fcaf365-s6"><title>Supplementary material</title><p>Supplementary material is available at <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Brain Communications</xref></italic> online.</p></sec><sec id="fcaf365-s7"><title>Funding</title><p>This research was financially supported by the Jiangsu Province Natural Science Foundation (No. BK20191143, awarded to X.F.), National Natural Science Foundation of China (No. 81271629, awarded to X.F.), Medical Expert Team Program of the Wuxi Taihu Talent Plan (No. THRC-TD-YXYXK-2021, awarded to X.F.) and the Specialized Disease Queue Project of Wuxi Medical Center affiliated with Nanjing Medical University 2024 (No. WMCC202402, awarded to X.F.).</p></sec><sec sec-type="COI-statement" id="fcaf365-s8"><title>Competing interests</title><p>The authors report no competing interests.</p></sec><sec sec-type="data-availability" id="fcaf365-s9"><title>Data availability</title><p>The corresponding authors will provide the raw data upon request without reservation. All code applied for data analysis in this manuscript could be found in <xref rid="sup1" ref-type="supplementary-material">Supplementary Material 2</xref>.</p></sec><ref-list id="ref1"><title>References</title><ref id="fcaf365-B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Armstrong</surname> &#160;<given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Okun</surname> &#160;<given-names>MS</given-names></string-name></person-group>. <article-title>Diagnosis and treatment of Parkinson&#8217;s disease</article-title>. <source>JAMA</source>. <year>2020</year>;<volume>323</volume>(<issue>6</issue>):<fpage>548</fpage>&#8211;<lpage>560</lpage>.<pub-id pub-id-type="pmid">32044947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2019.22360</pub-id></mixed-citation></ref><ref id="fcaf365-B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tanner</surname> &#160;<given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Ostrem</surname> &#160;<given-names>JL</given-names></string-name></person-group>. <article-title>Parkinson's disease</article-title>. <source>N Engl J Med</source>. <year>2024</year>;<volume>391</volume>(<issue>5</issue>):<fpage>442</fpage>&#8211;<lpage>452</lpage>.<pub-id pub-id-type="pmid">39083773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra2401857</pub-id></mixed-citation></ref><ref id="fcaf365-B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ding</surname> &#160;<given-names>XS</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname> &#160;<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Han</surname> &#160;<given-names>Z</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Ferroptosis in Parkinson's disease: Molecular mechanisms and therapeutic potential</article-title>. <source>Ageing Res Rev</source>. <year>2023</year>;<volume>91</volume>:<fpage>102077</fpage>.<pub-id pub-id-type="pmid">37742785</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2023.102077</pub-id></mixed-citation></ref><ref id="fcaf365-B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Riederer</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Nagatsu</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Youdim</surname> &#160;<given-names>MB</given-names></string-name>, <string-name name-style="western"><surname>Wulf</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dijkstra</surname> &#160;<given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Sian-Huelsmann</surname> &#160;<given-names>J</given-names></string-name></person-group>. <article-title>Lewy bodies, iron, inflammation and neuromelanin: Pathological aspects underlying Parkinson's disease</article-title>. <source>J Neural Transm (Vienna)</source>. <year>2023</year>;<volume>130</volume>(<issue>5</issue>):<fpage>627</fpage>&#8211;<lpage>646</lpage>.<pub-id pub-id-type="pmid">37062012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00702-023-02630-9</pub-id><pub-id pub-id-type="pmcid">PMC10121516</pub-id></mixed-citation></ref><ref id="fcaf365-B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huenchuguala</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Segura-Aguilar</surname> &#160;<given-names>J</given-names></string-name></person-group>. <article-title>On the role of iron in idiopathic Parkinson's disease</article-title>. <source>Biomedicines</source>. <year>2023</year>;<volume>11</volume>(<issue>11</issue>):<fpage>3094</fpage>.<pub-id pub-id-type="pmid">38002094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines11113094</pub-id><pub-id pub-id-type="pmcid">PMC10669582</pub-id></mixed-citation></ref><ref id="fcaf365-B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shen</surname> &#160;<given-names>QQ</given-names></string-name>, <string-name name-style="western"><surname>Jv</surname> &#160;<given-names>XH</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname> &#160;<given-names>XZ</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Cell senescence induced by toxic interaction between &#945;-synuclein and iron precedes nigral dopaminergic neuron loss in a mouse model of Parkinson's disease</article-title>. <source>Acta Pharmacol Sin</source>. <year>2024</year>;<volume>45</volume>(<issue>2</issue>):<fpage>268</fpage>&#8211;<lpage>281</lpage>.<pub-id pub-id-type="pmid">37674042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41401-023-01153-z</pub-id><pub-id pub-id-type="pmcid">PMC10789811</pub-id></mixed-citation></ref><ref id="fcaf365-B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname> &#160;<given-names>KR</given-names></string-name>, <string-name name-style="western"><surname>Avecillas-Chasin</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Nguyen</surname> &#160;<given-names>TD</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Quantitative evaluation of brain iron accumulation in different stages of Parkinson's disease</article-title>. <source>J Neuroimaging</source>. <year>2022</year>;<volume>32</volume>(<issue>2</issue>):<fpage>363</fpage>&#8211;<lpage>371</lpage>.<pub-id pub-id-type="pmid">34904328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jon.12957</pub-id></mixed-citation></ref><ref id="fcaf365-B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname> &#160;<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mao</surname> &#160;<given-names>H</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>The impact of iron deposition on the fear circuit of the brain in patients with Parkinson's disease and anxiety</article-title>. <source>Front Aging Neurosci</source>. <year>2023</year>;<volume>15</volume>:<fpage>1116516</fpage>.<pub-id pub-id-type="pmid">36845658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2023.1116516</pub-id><pub-id pub-id-type="pmcid">PMC9951615</pub-id></mixed-citation></ref><ref id="fcaf365-B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Uchida</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kan</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sakurai</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Oishi</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Matsukawa</surname> &#160;<given-names>N</given-names></string-name></person-group>. <article-title>Quantitative susceptibility mapping as an imaging biomarker for Alzheimer's disease: The expectations and limitations</article-title>. <source>Front Neurosci</source>. <year>2022</year>;<volume>16</volume>:<fpage>938092</fpage>.<pub-id pub-id-type="pmid">35992906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2022.938092</pub-id><pub-id pub-id-type="pmcid">PMC9389285</pub-id></mixed-citation></ref><ref id="fcaf365-B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mills</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname> &#160;<given-names>XP</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname> &#160;<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname> &#160;<given-names>H</given-names></string-name></person-group>. <article-title>Mechanisms of brain iron transport: Insight into neurodegeneration and CNS disorders</article-title>. <source>Future Med Chem</source>. <year>2010</year>;<volume>2</volume>(<issue>1</issue>):<fpage>51</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">20161623</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4155/fmc.09.140</pub-id><pub-id pub-id-type="pmcid">PMC2812924</pub-id></mixed-citation></ref><ref id="fcaf365-B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mochizuki</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Choong</surname> &#160;<given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Baba</surname> &#160;<given-names>K</given-names></string-name></person-group>. <article-title>Parkinson's disease and iron</article-title>. <source>J Neural Transm (Vienna)</source>. <year>2020</year>;<volume>127</volume>(<issue>2</issue>):<fpage>181</fpage>&#8211;<lpage>187</lpage>.<pub-id pub-id-type="pmid">32025811</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00702-020-02149-3</pub-id></mixed-citation></ref><ref id="fcaf365-B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Costa-Mallen</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Gatenby</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Friend</surname> &#160;<given-names>S</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Brain iron concentrations in regions of interest and relation with serum iron levels in Parkinson disease</article-title>. <source>J Neurol Sci</source>. <year>2017</year>;<volume>378</volume>:<fpage>38</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="pmid">28566175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jns.2017.04.035</pub-id><pub-id pub-id-type="pmcid">PMC5609675</pub-id></mixed-citation></ref><ref id="fcaf365-B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Campos-Escamilla</surname> &#160;<given-names>C</given-names></string-name></person-group>. <article-title>The role of transferrins and iron-related proteins in brain iron transport: Applications to neurological diseases</article-title>. <source>Adv Protein Chem Struct Biol</source>. <year>2021</year>;<volume>123</volume>:<fpage>133</fpage>&#8211;<lpage>162</lpage>.<pub-id pub-id-type="pmid">33485481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.apcsb.2020.09.002</pub-id></mixed-citation></ref><ref id="fcaf365-B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Song</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname> &#160;<given-names>J</given-names></string-name></person-group>. <article-title>Ferroportin 1 but not hephaestin contributes to iron accumulation in a cell model of Parkinson's disease</article-title>. <source>Free Radic Biol Med</source>. <year>2010</year>;<volume>48</volume>(<issue>2</issue>):<fpage>332</fpage>&#8211;<lpage>341</lpage>.<pub-id pub-id-type="pmid">19913091</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.freeradbiomed.2009.11.004</pub-id></mixed-citation></ref><ref id="fcaf365-B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Song</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname> &#160;<given-names>J</given-names></string-name></person-group>. <article-title>Pro-inflammatory cytokines modulate iron regulatory protein 1 expression and iron transportation through reactive oxygen/nitrogen species production in ventral mesencephalic neurons</article-title>. <source>Biochim Biophys Acta</source>. <year>2013</year>;<volume>1832</volume>(<issue>5</issue>):<fpage>618</fpage>&#8211;<lpage>625</lpage>.<pub-id pub-id-type="pmid">23376588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbadis.2013.01.021</pub-id></mixed-citation></ref><ref id="fcaf365-B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ficiar&#224;</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Stura</surname> &#160;<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Vernone</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Silvagno</surname> &#160;<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Cavalli</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Guiot</surname> &#160;<given-names>C</given-names></string-name></person-group>. <article-title>Iron overload in brain: Transport mismatches, microbleeding events, and how nanochelating therapies may counteract their effects</article-title>. <source>Int J Mol Sci</source>. <year>2024</year>;<volume>25</volume>(<issue>4</issue>):<fpage>2337</fpage>.<pub-id pub-id-type="pmid">38397013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms25042337</pub-id><pub-id pub-id-type="pmcid">PMC10889007</pub-id></mixed-citation></ref><ref id="fcaf365-B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Uchida</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kan</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sakurai</surname> &#160;<given-names>K</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>APOE &#603;4 dose associates with increased brain iron and &#946;-amyloid via blood-brain barrier dysfunction</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2022;jnnp(2021):328519</year>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2021-328519</pub-id><pub-id pub-id-type="pmid">35483916</pub-id></mixed-citation></ref><ref id="fcaf365-B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Uchida</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kan</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sakurai</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Oishi</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Matsukawa</surname> &#160;<given-names>N</given-names></string-name></person-group>. <article-title>Contributions of blood-brain barrier imaging to neurovascular unit pathophysiology of Alzheimer's disease and related dementias</article-title>. <source>Front Aging Neurosci</source>. <year>2023</year>;<volume>15</volume>:<fpage>1111448</fpage>.<pub-id pub-id-type="pmid">36861122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2023.1111448</pub-id><pub-id pub-id-type="pmcid">PMC9969807</pub-id></mixed-citation></ref><ref id="fcaf365-B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Uchida</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kan</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Furukawa</surname> &#160;<given-names>G</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Relationship between brain iron dynamics and blood-brain barrier function during childhood: A quantitative magnetic resonance imaging study</article-title>. <source>Fluids Barriers CNS</source>. <year>2023</year>;<volume>20</volume>(<issue>1</issue>):<fpage>60</fpage>.<pub-id pub-id-type="pmid">37592310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12987-023-00464-x</pub-id><pub-id pub-id-type="pmcid">PMC10433620</pub-id></mixed-citation></ref><ref id="fcaf365-B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Choi</surname> &#160;<given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Moon</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname> &#160;<given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Yim</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Moon</surname> &#160;<given-names>WJ</given-names></string-name></person-group>. <article-title>Choroid plexus volume and permeability at brain MRI within the Alzheimer disease clinical spectrum</article-title>. <source>Radiology</source>. <year>2022</year>;<volume>304</volume>(<issue>3</issue>):<fpage>635</fpage>&#8211;<lpage>645</lpage>.<pub-id pub-id-type="pmid">35579521</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/radiol.212400</pub-id></mixed-citation></ref><ref id="fcaf365-B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname> &#160;<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ren</surname> &#160;<given-names>Q</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Glymphatic dysfunction in patients with early-stage amyotrophic lateral sclerosis</article-title>. <source>Brain</source>. <year>2024</year>;<volume>147</volume>(<issue>1</issue>):<fpage>100</fpage>&#8211;<lpage>108</lpage>.<pub-id pub-id-type="pmid">37584389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awad274</pub-id></mixed-citation></ref><ref id="fcaf365-B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jeong</surname> &#160;<given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Park</surname> &#160;<given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Jeong</surname> &#160;<given-names>HJ</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Association of choroid plexus volume with motor symptoms and dopaminergic degeneration in Parkinson's disease</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2023</year>;<volume>94</volume>(<issue>12</issue>):<fpage>1047</fpage>&#8211;<lpage>1055</lpage>.<pub-id pub-id-type="pmid">37399288</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2023-331170</pub-id></mixed-citation></ref><ref id="fcaf365-B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>He</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname> &#160;<given-names>L</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>The association of CSF biomarkers and cognitive decline with choroid plexus volume in early Parkinson's disease</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2024</year>;<volume>120</volume>:<fpage>105987</fpage>.<pub-id pub-id-type="pmid">38183890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.parkreldis.2023.105987</pub-id></mixed-citation></ref><ref id="fcaf365-B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Si</surname> &#160;<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname> &#160;<given-names>Z</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Neuroimaging evidence of glymphatic system dysfunction in possible REM sleep behavior disorder and Parkinson's disease</article-title>. <source>NPJ Parkinsons Dis</source>. <year>2022</year>;<volume>8</volume>(<issue>1</issue>):<fpage>54</fpage>.<pub-id pub-id-type="pmid">35487930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41531-022-00316-9</pub-id><pub-id pub-id-type="pmcid">PMC9055043</pub-id></mixed-citation></ref><ref id="fcaf365-B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shen</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Yue</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ba</surname> &#160;<given-names>F</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Diffusion along perivascular spaces as marker for impairment of glymphatic system in Parkinson's disease</article-title>. <source>NPJ Parkinsons Dis</source>. <year>2022</year>;<volume>8</volume>(<issue>1</issue>):<fpage>174</fpage>.<pub-id pub-id-type="pmid">36543809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41531-022-00437-1</pub-id><pub-id pub-id-type="pmcid">PMC9772196</pub-id></mixed-citation></ref><ref id="fcaf365-B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhou</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname> &#160;<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Guan</surname> &#160;<given-names>X</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Glymphatic system dysfunction and risk of clinical milestones in patients with Parkinson disease</article-title>. <source>Eur J Neurol</source>. <year>2024</year>;<volume>31</volume>(<issue>12</issue>):<fpage>e16521</fpage>.<pub-id pub-id-type="pmid">39425566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ene.16521</pub-id><pub-id pub-id-type="pmcid">PMC11554988</pub-id></mixed-citation></ref><ref id="fcaf365-B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Postuma</surname> &#160;<given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Berg</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Stern</surname> &#160;<given-names>M</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>MDS clinical diagnostic criteria for Parkinson's disease</article-title>. <source>Mov Disord</source>. <year>2015</year>;<volume>30</volume>(<issue>12</issue>):<fpage>1591</fpage>&#8211;<lpage>1601</lpage>.<pub-id pub-id-type="pmid">26474316</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.26424</pub-id></mixed-citation></ref><ref id="fcaf365-B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tadayon</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Moret</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Sprugnoli</surname> &#160;<given-names>G</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Improving choroid plexus segmentation in the healthy and diseased brain: Relevance for Tau-PET imaging in dementia</article-title>. <source>J Alzheimers Dis</source>. <year>2020</year>;<volume>74</volume>(<issue>4</issue>):<fpage>1057</fpage>&#8211;<lpage>1068</lpage>.<pub-id pub-id-type="pmid">32144979</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-190706</pub-id><pub-id pub-id-type="pmcid">PMC9094634</pub-id></mixed-citation></ref><ref id="fcaf365-B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname> &#160;<given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname> &#160;<given-names>C</given-names></string-name></person-group>. <article-title>Quantitative susceptibility mapping of human brain reflects spatial variation in tissue composition</article-title>. <source>Neuroimage</source>. <year>2011</year>;<volume>55</volume>(<issue>4</issue>):<fpage>1645</fpage>&#8211;<lpage>1656</lpage>.<pub-id pub-id-type="pmid">21224002</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2010.11.088</pub-id><pub-id pub-id-type="pmcid">PMC3062654</pub-id></mixed-citation></ref><ref id="fcaf365-B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yao</surname> &#160;<given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Jiao</surname> &#160;<given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Du</surname> &#160;<given-names>X</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Ferroptosis in Parkinson's disease&#8212;The iron-related degenerative disease</article-title>. <source>Ageing Res Rev</source>. <year>2024</year>;<volume>101</volume>:<fpage>102477</fpage>.<pub-id pub-id-type="pmid">39218077</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2024.102477</pub-id></mixed-citation></ref><ref id="fcaf365-B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jin</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Su</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lam</surname> &#160;<given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname> &#160;<given-names>T</given-names></string-name></person-group>. <article-title>Iron deposition in subcortical nuclei of Parkinson's disease: A meta-analysis of quantitative iron-sensitive magnetic resonance imaging studies</article-title>. <source>Chin Med J (Engl)</source>. <year>2025</year>;<volume>138</volume>(<issue>6</issue>):<fpage>678</fpage>&#8211;<lpage>692</lpage>.<pub-id pub-id-type="pmid">38809051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CM9.0000000000003167</pub-id><pub-id pub-id-type="pmcid">PMC11925423</pub-id></mixed-citation></ref><ref id="fcaf365-B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Courtney</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hochstetler</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lehtinen</surname> &#160;<given-names>MK</given-names></string-name></person-group>. <article-title>Choroid plexus pathophysiology</article-title>. <source>Annu Rev Pathol</source>. <year>2025</year>;<volume>20</volume>(<issue>1</issue>):<fpage>193</fpage>&#8211;<lpage>220</lpage>.<pub-id pub-id-type="pmid">39383438</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-pathmechdis-051222-114051</pub-id><pub-id pub-id-type="pmcid">PMC11884907</pub-id></mixed-citation></ref><ref id="fcaf365-B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hutton</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Fadelalla</surname> &#160;<given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>Kanodia</surname> &#160;<given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Hossain-Ibrahim</surname> &#160;<given-names>K</given-names></string-name></person-group>. <article-title>Choroid plexus and CSF: An updated review</article-title>. <source>Br J Neurosurg</source>. <year>2022</year>;<volume>36</volume>(<issue>3</issue>):<fpage>307</fpage>&#8211;<lpage>315</lpage>.<pub-id pub-id-type="pmid">33821737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/02688697.2021.1903390</pub-id></mixed-citation></ref><ref id="fcaf365-B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hong</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname> &#160;<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname> &#160;<given-names>X</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>The relationship between amyloid pathology, cerebral small vessel disease, glymphatic dysfunction, and cognition: A study based on Alzheimer's disease continuum participants</article-title>. <source>Alzheimers Res Ther</source>. <year>2024</year>;<volume>16</volume>(<issue>1</issue>):<fpage>43</fpage>.<pub-id pub-id-type="pmid">38378607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-024-01407-w</pub-id><pub-id pub-id-type="pmcid">PMC10877805</pub-id></mixed-citation></ref><ref id="fcaf365-B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xie</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname> &#160;<given-names>Y</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Enlarged choroid plexus in relapsing-remitting multiple sclerosis may lead to brain structural changes through the glymphatic impairment</article-title>. <source>Mult Scler Relat Disord</source>. <year>2024</year>;<volume>85</volume>:<fpage>105550</fpage>.<pub-id pub-id-type="pmid">38493535</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.msard.2024.105550</pub-id></mixed-citation></ref><ref id="fcaf365-B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Seuthe</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hermanns</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hulzinga</surname> &#160;<given-names>F</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Gait asymmetry and symptom laterality in Parkinson's disease: Two of a kind?</article-title> &#160;<source>J Neurol</source>. <year>2024</year>;<volume>271</volume>(<issue>7</issue>):<fpage>4373</fpage>&#8211;<lpage>4382</lpage>.<pub-id pub-id-type="pmid">38652262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-024-12379-0</pub-id><pub-id pub-id-type="pmcid">PMC11233399</pub-id></mixed-citation></ref><ref id="fcaf365-B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ni</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname> &#160;<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname> &#160;<given-names>R</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Diffusion tensor image analysis along the perivascular space and quantitative susceptibility mapping in the diagnosis and severity assessment of Parkinson's disease</article-title>. <source>Quant Imaging Med Surg</source>. <year>2025</year>;<volume>15</volume>(<issue>2</issue>):<fpage>1411</fpage>&#8211;<lpage>1424</lpage>.<pub-id pub-id-type="pmid">39995711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/qims-24-1605</pub-id><pub-id pub-id-type="pmcid">PMC11847189</pub-id></mixed-citation></ref><ref id="fcaf365-B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>He</surname> &#160;<given-names>XZ</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Interaction between the glymphatic system and &#945;-synuclein in Parkinson's disease</article-title>. <source>Mol Neurobiol</source>. <year>2023</year>;<volume>60</volume>(<issue>4</issue>):<fpage>2209</fpage>&#8211;<lpage>2222</lpage>.<pub-id pub-id-type="pmid">36637746</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-023-03212-2</pub-id></mixed-citation></ref><ref id="fcaf365-B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname> &#160;<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jiao</surname> &#160;<given-names>B</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Glymphatic system impairment in Alzheimer's disease: Associations with perivascular space volume and cognitive function</article-title>. <source>Eur Radiol</source>. <year>2024</year>;<volume>34</volume>(<issue>2</issue>):<fpage>1314</fpage>&#8211;<lpage>1323</lpage>.<pub-id pub-id-type="pmid">37610441</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00330-023-10122-3</pub-id></mixed-citation></ref><ref id="fcaf365-B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tadayon</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Pascual-Leone</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Press</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Santarnecchi</surname> &#160;<given-names>E</given-names></string-name>, <collab>Alzheimer's Disease Neuroimaging Initiative</collab></person-group>. <article-title>Choroid plexus volume is associated with levels of CSF proteins: Relevance for Alzheimer's and Parkinson's disease</article-title>. <source>Neurobiol Aging</source>. <year>2020</year>;<volume>89</volume>:<fpage>108</fpage>&#8211;<lpage>117</lpage>.<pub-id pub-id-type="pmid">32107064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2020.01.005</pub-id><pub-id pub-id-type="pmcid">PMC9094632</pub-id></mixed-citation></ref><ref id="fcaf365-B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Braun</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Iliff</surname> &#160;<given-names>JJ</given-names></string-name></person-group>. <article-title>The impact of neurovascular, blood-brain barrier, and glymphatic dysfunction in neurodegenerative and metabolic diseases</article-title>. <source>Int Rev Neurobiol</source>. <year>2020</year>;<volume>154</volume>:<fpage>413</fpage>&#8211;<lpage>436</lpage>.<pub-id pub-id-type="pmid">32739013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.irn.2020.02.006</pub-id></mixed-citation></ref><ref id="fcaf365-B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>He</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ling</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname> &#160;<given-names>B</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Region-specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping</article-title>. <source>Hum Brain Mapp</source>. <year>2015</year>;<volume>36</volume>(<issue>11</issue>):<fpage>4407</fpage>&#8211;<lpage>4420</lpage>.<pub-id pub-id-type="pmid">26249218</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hbm.22928</pub-id><pub-id pub-id-type="pmcid">PMC6869507</pub-id></mixed-citation></ref><ref id="fcaf365-B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McKnight</surname> &#160;<given-names>CD</given-names></string-name>, <string-name name-style="western"><surname>Trujillo</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Lopez</surname> &#160;<given-names>AM</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Diffusion along perivascular spaces reveals evidence supportive of glymphatic function impairment in Parkinson disease</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2021</year>;<volume>89</volume>:<fpage>98</fpage>&#8211;<lpage>104</lpage>.<pub-id pub-id-type="pmid">34271425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.parkreldis.2021.06.004</pub-id><pub-id pub-id-type="pmcid">PMC8429254</pub-id></mixed-citation></ref><ref id="fcaf365-B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gilat</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ehgoetz Martens</surname> &#160;<given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Miranda-Dom&#237;nguez</surname> &#160;<given-names>O</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Dysfunctional limbic circuitry underlying freezing of gait in Parkinson's disease</article-title>. <source>Neuroscience</source>. <year>2018</year>;<volume>374</volume>:<fpage>119</fpage>&#8211;<lpage>132</lpage>.<pub-id pub-id-type="pmid">29408498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroscience.2018.01.044</pub-id><pub-id pub-id-type="pmcid">PMC6390849</pub-id></mixed-citation></ref><ref id="fcaf365-B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ruan</surname> &#160;<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname> &#160;<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Li</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname> &#160;<given-names>X</given-names></string-name></person-group>. <article-title>Diffusion tensor imaging analysis along the perivascular space index in primary Parkinson's disease patients with and without freezing of gait</article-title>. <source>Neuroscience</source>. <year>2022</year>;<volume>506</volume>:<fpage>51</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="pmid">36341724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroscience.2022.10.013</pub-id></mixed-citation></ref><ref id="fcaf365-B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shine</surname> &#160;<given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Matar</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ward</surname> &#160;<given-names>PB</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Freezing of gait in Parkinson's disease is associated with functional decoupling between the cognitive control network and the basal ganglia</article-title>. <source>Brain</source>. <year>2013</year>;<volume>136</volume>(<issue>Pt 12</issue>):<fpage>3671</fpage>&#8211;<lpage>3681</lpage>.<pub-id pub-id-type="pmid">24142148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awt272</pub-id></mixed-citation></ref><ref id="fcaf365-B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sun</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Gan</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname> &#160;<given-names>X</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Microstructural and functional abnormalities of the locus coeruleus in freezing of gait in Parkinson's disease</article-title>. <source>Neurobiol Dis</source>. <year>2025</year>;<volume>208</volume>:<fpage>106868</fpage>.<pub-id pub-id-type="pmid">40068723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2025.106868</pub-id></mixed-citation></ref><ref id="fcaf365-B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cheng</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname> &#160;<given-names>S</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Brain network localization of gray matter atrophy and neurocognitive and social cognitive dysfunction in schizophrenia</article-title>. <source>Biol Psychiatry</source>. <year>2025</year>;<volume>97</volume>(<issue>2</issue>):<fpage>148</fpage>&#8211;<lpage>156</lpage>.<pub-id pub-id-type="pmid">39103010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopsych.2024.07.021</pub-id></mixed-citation></ref><ref id="fcaf365-B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname> &#160;<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname> &#160;<given-names>S</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Brain structural damage networks at different stages of schizophrenia</article-title>. <source>Psychol Med</source>. <year>2024</year>;<volume>54</volume>:<fpage>4809</fpage>&#8211;<lpage>4819</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S0033291724003088</pub-id><pub-id pub-id-type="pmid">39660416</pub-id></mixed-citation></ref><ref id="fcaf365-B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shen</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname> &#160;<given-names>X</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Structural connectome architecture shapes cortical atrophy in major depression disorder: A Chinese DIRECT consortium study</article-title>. <source>Biol Psychiatry</source>. <year>2025</year>;S0006-3223(25):01304-6.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopsych.2025.06.030</pub-id><pub-id pub-id-type="pmid">40675428</pub-id></mixed-citation></ref><ref id="fcaf365-B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Uchida</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kan</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sakurai</surname> &#160;<given-names>K</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Voxel-based quantitative susceptibility mapping in Parkinson's disease with mild cognitive impairment</article-title>. <source>Mov Disord</source>. <year>2019</year>;<volume>34</volume>(<issue>8</issue>):<fpage>1164</fpage>&#8211;<lpage>1173</lpage>.<pub-id pub-id-type="pmid">31091347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.27717</pub-id></mixed-citation></ref><ref id="fcaf365-B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thomas</surname> &#160;<given-names>GE</given-names></string-name>, <string-name name-style="western"><surname>Leyland</surname> &#160;<given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Schrag</surname> &#160;<given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Lees</surname> &#160;<given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Acosta-Cabronero</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Weil</surname> &#160;<given-names>RS</given-names></string-name></person-group>. <article-title>Brain iron deposition is linked with cognitive severity in Parkinson's disease</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2020</year>;<volume>91</volume>(<issue>4</issue>):<fpage>418</fpage>&#8211;<lpage>425</lpage>.<pub-id pub-id-type="pmid">32079673</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2019-322042</pub-id><pub-id pub-id-type="pmcid">PMC7147185</pub-id></mixed-citation></ref><ref id="fcaf365-B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname> &#160;<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname> &#160;<given-names>F</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Altered functional connectivity within the brain fear circuit in Parkinson's disease with anxiety: A seed-based functional connectivity study</article-title>. <source>Heliyon</source>. <year>2023</year>;<volume>9</volume>(<issue>5</issue>):<fpage>e15871</fpage>.<pub-id pub-id-type="pmid">37305477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2023.e15871</pub-id><pub-id pub-id-type="pmcid">PMC10256910</pub-id></mixed-citation></ref><ref id="fcaf365-B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Erro</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Pappat&#224;</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Amboni</surname> &#160;<given-names>M</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson's disease patients</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2012</year>;<volume>18</volume>(<issue>9</issue>):<fpage>1034</fpage>&#8211;<lpage>1038</lpage>.<pub-id pub-id-type="pmid">22789824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.parkreldis.2012.05.022</pub-id></mixed-citation></ref><ref id="fcaf365-B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Taylor</surname> &#160;<given-names>TN</given-names></string-name>, <string-name name-style="western"><surname>Caudle</surname> &#160;<given-names>WM</given-names></string-name>, <string-name name-style="western"><surname>Shepherd</surname> &#160;<given-names>KR</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity</article-title>. <source>J Neurosci</source>. <year>2009</year>;<volume>29</volume>(<issue>25</issue>):<fpage>8103</fpage>&#8211;<lpage>8113</lpage>.<pub-id pub-id-type="pmid">19553450</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.1495-09.2009</pub-id><pub-id pub-id-type="pmcid">PMC2813143</pub-id></mixed-citation></ref><ref id="fcaf365-B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname> &#160;<given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname> &#160;<given-names>C</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Disease progression in proposed brain-first and body-first Parkinson's disease subtypes</article-title>. <source>NPJ Parkinsons Dis</source>. <year>2024</year>;<volume>10</volume>(<issue>1</issue>):<fpage>111</fpage>.<pub-id pub-id-type="pmid">38834646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41531-024-00730-1</pub-id><pub-id pub-id-type="pmcid">PMC11150376</pub-id></mixed-citation></ref><ref id="fcaf365-B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname> &#160;<given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname> &#160;<given-names>J</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Glymphatic clearance function in patients with cerebral small vessel disease</article-title>. <source>Neuroimage</source>. <year>2021</year>;<volume>238</volume>:<fpage>118257</fpage>.<pub-id pub-id-type="pmid">34118396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2021.118257</pub-id></mixed-citation></ref><ref id="fcaf365-B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Keil</surname> &#160;<given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Jansson</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Braun</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Iliff</surname> &#160;<given-names>JJ</given-names></string-name></person-group>. <article-title>Glymphatic dysfunction in Alzheimer's disease: A critical appraisal</article-title>. <source>Science</source>. <year>2025</year>;<volume>389</volume>(<issue>6756</issue>):<comment>eadv8269</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.adv8269</pub-id><pub-id pub-id-type="pmid">40638744</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">World J Mens Health</journal-id><journal-id journal-id-type="iso-abbrev">World J Mens Health</journal-id><journal-id journal-id-type="pmc-domain-id">2051</journal-id><journal-id journal-id-type="pmc-domain">wjmh</journal-id><journal-id journal-id-type="publisher-id">WJMH</journal-id><journal-title-group><journal-title>The World Journal of Men's Health</journal-title></journal-title-group><issn pub-type="ppub">2287-4208</issn><issn pub-type="epub">2287-4690</issn><publisher><publisher-name>Korean Society for Sexual Medicine and Andrology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12505482</article-id><article-id pub-id-type="pmcid-ver">PMC12505482.1</article-id><article-id pub-id-type="pmcaid">12505482</article-id><article-id pub-id-type="pmcaiid">12505482</article-id><article-id pub-id-type="pmid">39743217</article-id><article-id pub-id-type="doi">10.5534/wjmh.240191</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject><subj-group subj-group-type="subheading"><subject>Prostate Cancer</subject></subj-group></subj-group></article-categories><title-group><article-title>Coping with Complications that Occur after Prostate Biopsy for Satisfactory Evaluation of Call Service Using Artificial Intelligence: A Pilot Randomized Controlled Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8732-327X</contrib-id><name name-style="western"><surname>Gwon</surname><given-names initials="YN">Yong Nam</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0000-0242-303X</contrib-id><name name-style="western"><surname>Cho</surname><given-names initials="U">Ukrae</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0001-7148-0860</contrib-id><name name-style="western"><surname>Chong</surname><given-names initials="SR">Seung Ryong</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0001-0984-0714</contrib-id><name name-style="western"><surname>Han</surname><given-names initials="JY">Ji Yeon</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3696-8756</contrib-id><name name-style="western"><surname>Kim</surname><given-names initials="DK">Do Kyung</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5924-6908</contrib-id><name name-style="western"><surname>Doo</surname><given-names initials="SW">Seung Whan</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7356-4312</contrib-id><name name-style="western"><surname>Yang</surname><given-names initials="WJ">Won Jae</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4814-9264</contrib-id><name name-style="western"><surname>Kim</surname><given-names initials="K">Kyeongmin</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4143-7383</contrib-id><name name-style="western"><surname>Shim</surname><given-names initials="SR">Sung Ryul</given-names></name><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4856-3668</contrib-id><name name-style="western"><surname>Jung</surname><given-names initials="J">Jaehun</given-names></name><xref rid="A6" ref-type="aff">6</xref><xref rid="A7" ref-type="aff">7</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4490-3610</contrib-id><name name-style="western"><surname>Kim</surname><given-names initials="JH">Jae Heon</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Urology, Soonchunhyang University Seoul Hospital, Soonchunhyang University Medical College, Seoul, <country>Korea</country>.</aff><aff id="A2"><label>2</label>AI Product Biz Team, AI Service Division, SK Telecom, Seoul, <country>Korea</country>.</aff><aff id="A3"><label>3</label>Social Safety Net Team, ESG Office, SK Telecom, Seoul, <country>Korea</country>.</aff><aff id="A4"><label>4</label>Department of Engineering, University of Hong Kong, Hong Kong, <country>China</country>.</aff><aff id="A5"><label>5</label>Department of Biomedical Informatics, College of Medicine, Konyang University, Daejeon, <country>Korea</country>.</aff><aff id="A6"><label>6</label>Artificial Intelligence and Big-Data Convergence Center, Gil Medical Center, Gachon University College of Medicine, Incheon, <country>Korea</country>.</aff><aff id="A7"><label>7</label>Department of Preventive Medicine, Gachon University College of Medicine, Incheon, <country>Korea</country>.</aff><author-notes><corresp>Correspondence to: Jaehun Jung. Department of Preventive Medicine, Korea University College of Medicine, 73 Goryeodae-ro, Seongbuk-gu, Seoul 02841, Korea. Tel: +82-2-2286-1170, Fax: +82-2-2286-1569, <email>eastside1st@gmail.com</email></corresp><corresp>Correspondence to: Jae Heon Kim. Department of Urology, Soonchunhyang University Seoul Hospital, Soonchunhyang University Medical College, 59 Daesagwan-ro, Yongsan-gu, Seoul 04401, Korea. Tel: +82-2-709-9378, Fax: +82-2-710-9130, <email>piacekjh@hanmail.net</email></corresp><fn id="FN1" fn-type="current-aff"><p><sup>*</sup>Current affiliation: Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea.</p></fn></author-notes><pub-date pub-type="ppub"><month>10</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>25</day><month>11</month><year>2024</year></pub-date><volume>43</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">498540</issue-id><fpage>934</fpage><lpage>943</lpage><history><date date-type="received"><day>30</day><month>7</month><year>2024</year></date><date date-type="rev-recd"><day>19</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>06</day><month>10</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Korean Society for Sexual Medicine and Andrology</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Korean Society for Sexual Medicine and Andrology</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="wjmh-43-934.pdf"/><abstract><sec><title>Purpose</title><p>To assess whether an artificial intelligence (AI)-based reassurance-call can inform patients about potential complications and provides reassurance following a prostate biopsy.</p></sec><sec><title>Materials and Methods</title><p>From October 2022 to December 2023, 42 patients aged 40 to 70 years undergoing their first prostate biopsy were recruited. The &#8216;Reassurance-call&#8217; service was utilized to inform and monitor patients for complications. Participants were randomized into three groups: AI-assisted Reassurance-call service (Group 1), human-assisted Reassurance-call service (Group 2), and no call (Group 3). The primary outcome measured was patient satisfaction with the Reassurance-call service, assessed using a Likert scale. Secondary outcomes included satisfaction with complication management and anxiety levels, evaluated using the Likert scale, visual analog scale (VAS), and the state-trait anxiety inventory (STAI).</p></sec><sec><title>Results</title><p>Satisfaction with Reassurance-call averaged 4.20 (standard deviation [SD] 0.56) for Group 1 and 4.71 (SD 0.47) for Group 2, showing a statistically significant difference. Satisfaction regarding complication management using Likert scale was 4.13 (SD 0.52) for Group 1, 4.43 (SD 0.76) for Group 2, and 3.79 (SD 0.80) for Group 3 with no statistically significant differences. Satisfaction regarding complication management using VAS averaged 8.33 (SD 1.23) for Group 1, 8.57 (SD 1.45) for Group 2, and 7.07 (SD 1.86) for Group 3, indicating significant differences. Anxiety levels using STAI averaged 40.00 (SD 10.54) for Group 1, 39.14 (SD 8.29) for Group 2, and 35.00 (SD 9.46) for Group 3, showing no significant differences. Anxiety levels using VAS averaged 5.07 (SD 2.79) for Group 1, 2.21 (SD 2.64) for Group 2, and 3.50 (SD 2.28) for Group 3, with significant differences observed.</p></sec><sec><title>Conclusions</title><p>AI demonstrated potential in enhancing patient reassurance and managing complications post-prostate biopsy, although human interaction proved superior in certain aspects. Further studies with larger cohorts are necessary to verify the effectiveness of AI-based tools.</p></sec></abstract><kwd-group><kwd>Artificial intelligence</kwd><kwd>Biopsy</kwd><kwd>Postoperative complications</kwd><kwd>Prostatic neoplasms</kwd></kwd-group><funding-group><award-group><funding-source country="KR"><institution-wrap><institution>Soonchunhyang University</institution><institution-id institution-id-type="CrossRef">http://doi.org/10.13039/501100002560</institution-id></institution-wrap></funding-source><award-id>10.13039/501100002560</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>It is well-established that the benchmark diagnostic test for males suspected of having prostate carcinoma, following suspicious findings on digital rectal examination (DRE) or elevated serum prostate-specific antigen (PSA) levels, is the trans-rectal ultrasound (TRUS)-guided biopsy of the prostate [<xref rid="B1" ref-type="bibr">1</xref><xref rid="B2" ref-type="bibr">2</xref>]. Although generally conducted in an outpatient facility and commonly without incident, the potential complication rate remains approximately 5% or less [<xref rid="B3" ref-type="bibr">3</xref><xref rid="B4" ref-type="bibr">4</xref>]. A prospective study in the United Kingdom documented moderate to major issues within 35 days in men undergoing the procedure; hospitalization was required for 1.4% of the 1,147 males studied [<xref rid="B5" ref-type="bibr">5</xref>]. Research has shown that nearly half of the patients undergoing this biopsy experienced anxiety related to the procedure [<xref rid="B6" ref-type="bibr">6</xref>], even when no physical adverse events occurred. Therefore, undergoing a TRUS-guided prostate biopsy can have significant psychological impacts. To date, no research has been conducted on predicting potential complications prior to the procedure, reassuring patients, or identifying those who may need immediate follow-up and additional management.</p><p>The notion that machines could exhibit human intelligence was first proposed in the 1950s, embodying aspects such as the capacity to learn, engage in rational thought, and solve problems [<xref rid="B7" ref-type="bibr">7</xref>]. The significant increase in computational power, decreasing costs of data storage, advancements in algorithm refinements, and the accessibility of vast data through electronic clinical records have all contributed to the implementation of artificial intelligence (AI) across various clinical fields [<xref rid="B8" ref-type="bibr">8</xref><xref rid="B9" ref-type="bibr">9</xref><xref rid="B10" ref-type="bibr">10</xref>]. AI has been employed to enhance diagnostic [<xref rid="B11" ref-type="bibr">11</xref>], therapeutic, and prognostic endeavors [<xref rid="B12" ref-type="bibr">12</xref><xref rid="B13" ref-type="bibr">13</xref>]. However, there is a paucity of data concerning the utility of AI tools in providing information and reassurance to patients about the likelihood of experiencing complications from a prostatic biopsy and determining which patients could benefit from earlier follow-up and potential treatment.</p><p>A pilot randomized controlled trial (RCT) was conducted to determine whether the reassurance-call based on AI could effectively reassure patients about potential complications following a TRUS-guided prostatic biopsy and identify those needing immediate treatment. This represents the first study addressing this subject.</p></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title>1. Study population</title><p>From October 2022 to December 2023, 42 patients who underwent transrectal prostate biopsy were consecutively included in the single-institution study. Patients who underwent transrectal prostate biopsy due to suspicious signs of prostate cancer which were defined as a PSA value of 3 ng/mL or higher or the detection of a nodule on DRE, those undergoing their first prostate biopsy, individuals able to communicate and aged &#8805;40 and &lt;70 years, those without a history of psychological illness, and those without cognitive impairments were included. Patients deemed unsuitable for participation in the study, those with cognitive impairments, and those who had undergone the same procedure in the past were excluded. Those diagnosed with dementia or taking related medications, or those with a history of cerebrovascular disease, neurological disease, or psychiatric disease were excluded from the study. Korean version of the Alzheimer disease 8 (K-AD8), which is a brief informant-based measure that distinguishes individuals with very mild dementia and mild cognitive impairment from those with normal cognition, was performed on all patients to exclude patients with cognitive impairment who had not been previously diagnosed, and those with a score of 2 or higher were excluded from the study.</p></sec><sec><title>2. Methodology</title><p>A call service named &#8216;Reassurance-call&#8217; was established to provide patients with information about the procedure and post-procedure care, to monitor the presence and severity of complications, and to guide future treatments in case of complications. The algorithm of reassurance-call is detailed in <xref rid="S1" ref-type="supplementary-material">Supplement Fig. 1</xref>.</p><p>&#8216;Reassurance-call&#8217; is a voice recognition-based AI service that relies on Natural Language Processing (NLP) technology, rather than Large Language Model (LLM), to reduce hallucinations and conduct surveys accurately. It leverages Natural Language Understanding (NLU) technology to comprehend user intent and employs dialogue management techniques to facilitate smooth communication with patients.</p><p>The &#8216;Reassurance-call&#8217; service is trained in the following ways: voice recognition training, NLU training, and dialogue management training.</p><p>Firstly, the &#8216;Reassurance-call&#8217; service improves its ability to recognize patients&#8217; voices through voice recognition training. This process involves analyzing patients&#8217; voices to update the voice recognition model. Particularly in the pilot trial using the &#8216;Reassurance-call&#8217;, accurate recognition of numbers was crucial due to the use of the Likert scale. SK Telecom has experience providing voice-based services like Tmap (navigation) and Btv (media), which gave them expertise in number recognition. However, for this pilot, additional training and tuning were conducted using voices from various age groups and genders.</p><p>Secondly, the &#8216;Reassurance-call&#8217; service enhances its ability to understand patients&#8217; intentions through NLU training. This involves analyzing patients&#8217; speech to update the NLU model. During the pilot trial using the &#8216;Reassurance-call&#8217;, additional intent lists were defined and trained to accurately handle responses when patients answered with text rather than numbers (<italic toggle="yes">e.g.</italic>, if the first option for a question about pain frequency was &#8220;often,&#8221; and the patient responded with &#8220;often,&#8221; &#8220;first one,&#8221; <italic toggle="yes">etc.</italic>, instead of &#8220;1&#8221;).</p><p>Thirdly, the &#8216;Reassurance-call&#8217; service improves its ability to manage conversations with patients through dialogue management training. This involves understanding the patient&#8217;s intent to provide appropriate responses. In the pilot trial using the&#8216;Reassurance-call&#8217;, scenarios were additionally defined for situations where patients wanted to revise a previously answered question. And dialogue algorithm was trained to handle these scenarios smoothly.</p><p>The 42 patients who underwent transrectal prostate biopsy were divided into three groups of 14 individuals each [<xref rid="B14" ref-type="bibr">14</xref><xref rid="B15" ref-type="bibr">15</xref>]. The power was determined to be 14, considering a dropout rate of 10% based on the minimum target number of 12 to confirm significance [<xref rid="B15" ref-type="bibr">15</xref>]. The groups were categorized as the reassurance-call service group managed by AI (Group 1), the reassurance-call service group managed by human personnel (Group 2), and a control group without reassurance-call access (Group 3) (<xref rid="F1" ref-type="fig">Fig. 1</xref>). The human personnel in Group 2 were well-trained nurses capable of providing consultations about complications. However, regardless of whether the call was made by AI or a human, patients were advised to seek outpatient specialist care in case of complications, and all conversation contents were recorded. Allocation was achieved through random permutation. A single sequence of random assignments was done using compute generated random numbers.</p><p>Procedure consent and cognitive questionnaires were obtained prior to the procedure. During the biopsy, a third-generation cephalosporin was administered, and intra-rectal administration of jelly containing disinfectant and lidocaine. Upon discharge, patients were prescribed oral antibiotics, and painkillers were provided as needed. On the day after, Group 1, 2, and 3 were randomly assigned. All questionnaires translated into Korean were conducted on the 7th day post-discharge, during the last outpatient visit, and before the meeting with the urologist.</p></sec><sec><title>3. Statistics</title><p>The primary outcome was patient satisfaction with the reassurance-call service, assessed using a 5-point Likert scale. Secondary outcomes included satisfaction with how complications were managed and anxiety regarding possible complications. Satisfaction for managing complications was evaluated using a 5-point Likert scale and a 10-point visual analog scale (VAS), a measurement instrument for subjective characteristics or attitudes that cannot be directly measured, while anxiety was assessed using the state-trait anxiety inventory (STAI), a 20-item self-report instrument that utilizes a 4-point Likert-type scale for each item, and VAS [<xref rid="B16" ref-type="bibr">16</xref>].</p><p>Continuous variables were represented by mean and standard deviation (SD), while categorical variables were represented by frequency and percentage. We performed chi-squared tests and t-tests to confirm the absence of significant selection bias at baseline between the AI (Group 1) and human (Group 2) groups. To identify the variables influencing the differences between the two groups, we initially analyzed various outcomes (Reassurance-call by AI satisfaction.Likert, Complication. satisfaction.Likert, Complication.satisfaction.VAS, Complication.anxiety.STAI, and Complication.anxiety. VAS) using t-tests. Due to the small sample sizes per group, non-parametric tests (Mann&#8211;Whitney U test) were also conducted. Subsequently, multiple regression analysis was performed to identify the factors associated with satisfaction and anxiety outcomes. The significance of multicollinearity was assessed by comparing the variance inflation factors among the independent variables. Statistical analysis was conducted using R version 4.2.1 (The R Foundation for Statistical Computing). All statistical tests were two-tailed, and p-values &lt;0.05 were considered significant. This study was reported in accordance with the Consolidated Standards of Reporting Trials (CONSORT) Guidelines [<xref rid="B17" ref-type="bibr">17</xref>].</p></sec><sec><title>4. Ethics statement</title><p>The study protocol was approved by the institutional review board of Soonchunhyang University Seoul Hospital (IRB No. 2022-07-013). Informed consent was confirmed by the IRB.</p><p>This is a pilot randomized clinical trial, registered at the Clinical Research Information Service (CRIS, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cris.nih.go.kr" ext-link-type="uri">http://cris.nih.go.kr</ext-link>), number KCT0008062.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>A total of 42 patients provided informed consent and were subsequently enrolled in the study. These participants were then randomly divided into three groups. There were no patients confirmed to have a score of 2 or higher after screening with K-AD8. One patient from Group 3, however, dropped out due to refusal to complete the questionnaire. The baseline characteristics of the patients are detailed in (<xref rid="T1" ref-type="table">Table 1</xref>). Mean height/weight for Group 1 patients was 168.27 cm/68.60 kg, Group 2 was 167.66 cm/68.99 kg, and Group 3 was 167.87 cm/70.42 kg. Also, the mean age was 66.80, 66.00, and 66.36, respectively. The average PSA levels were 9.33 in Group 1, 9.76 in Group 2, and 25.59 in Group 3. Each group had two, three, and two patients, respectively, who did not undergo imaging tests. The average Gleason score of diagnosed cancer was 7.00, 7.83 and 7.64, respectively, while the Gleason grade group was 2.50, 3.50, and 3.00 for each group. Among the patients diagnosed with prostate cancer, stages were evaluated as T2 for five, five, and eight patients, respectively, and T3 for two, one, and three patients, respectively. The presence of metastasis was documented in two, one, and seven patients in each group accordingly. All the characteristics displayed were statistically insignificant. Primary and secondary outcomes are presented in (<xref rid="T2" ref-type="table">Table 2</xref>, <xref rid="F2" ref-type="fig">Fig. 2</xref>). Satisfaction with reassurance-call exhibited a mean of 4.20 and a SD of 0.56 in Group 1, and a mean of 4.71 and an SD of 0.47 in Group 2. reassurance-call moderated by human operators scored significantly higher on satisfaction compared to reassurance-call facilitated by AI. When evaluating the satisfaction with the use of AI in the reassurance-call, it showed a mean of 4.00 and an SD of 0.65. Satisfaction regarding the management of complications, as measured on the Likert scale, resulted in a mean of 4.13 and an SD of 0.52 in Group 1, a mean of 4.43 and an SD of 0.76 in Group 2, and a mean of 3.79 and an SD of 0.80 in Group 3. No significant difference was noted on the Likert scale. However, a significant difference was observed among the three groups when employing the VAS, with a mean of 8.33 and an SD of 1.23 in Group 1, a mean of 8.57 and an SD of 1.45 in Group 2, and a mean of 7.07 and an SD of 1.86 in Group 3, while no significant difference was found between Group 1 and Group 2. Anxiety related to complications, as assessed using the STAI, was recorded with a mean score of 40.00 and an SD of 10.54 in Group 1, a mean of 39.14 and an SD of 8.29 in Group 2, and a mean of 35.00 and an SD of 9.46 in Group 3, showing no significant difference across or between groups. Anxiety related to anxiety, measured using the VAS, resulted in a mean score of 5.07 and an SD of 2.79 in Group 1, a mean of 2.21 and an SD of 2.64 in Group 2, and a mean of 3.50 and an SD of 2.28 in Group 3. Reassurance-call via AI was significantly superior to the other two groups.</p><p>Multiple regression analysis was conducted on all outcomes and presented in (<xref rid="T3" ref-type="table">Table 3</xref>). Regarding satisfaction with the reassurance-call service measured via the Likert scale, patients who were staged at T1 reported significantly higher satisfaction with Reassurance-call compared to patients staged at T2. Moreover, patients staged at T1 experienced less anxiety regarding complications compared to those staged at T2, according to both STAI and VAS assessments. Reassurance-call facilitated by AI demonstrated a significantly higher anxiety score on the VAS than reassurance-call operated by humans; no other significant differences among the variables were observed.</p><p>Some patients experienced actual complications. Dysuria was reported in four patients in Group 1 and two patients in Group 2, with most of these patients experiencing dysuria rarely or occasionally. However, one patient in Group 1 reported experiencing it often. Voiding difficulty was reported in three patients in Group 1 and five patients in Group 2. Among these patients, the one who often experienced dysuria reported moderate voiding difficulty, while the others reported mild or very mild difficulty. Five patients in Group 1 complained of discomfort in daily life, and two patients, including the one with moderate complications, reported a moderate degree of discomfort. However, no patients reported fever or complications severe enough to require additional treatment.</p><p>Three patients in Group 1 offered feedback on potential improvements for the AI-assisted reassurance-call service. One patient highlighted the inadequacy of the voice recognition technology, another pointed out the lack of response options for symptoms affecting other body parts, and the third patient commented that the information and questions from reassurance-call were unclear regarding what they were intended to ascertain.</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The reassurance-call, made with context-based AI, has demonstrated potential in providing patients with reassurance and satisfaction regarding the incidence of complications following a prostatic biopsy. In some areas, patients appeared to be less satisfied with the AI-based tool compared to human contact, but overall, this pilot study, the first of its kind, has shown that safety checks could be conducted using an AI-based tool rather than a human. When comparing Group 1 and Group 2, patients were more satisfied with calls made by a human than those made by AI. However, Group 1 also received a score exceeding 4 out of 5, achieving a sufficiently high score. About complications, the reasurance-call groups showed notably better score for satisfaction and anxiety about complications than no call group, and call by human scored better than call by AI. When comparing only Group 1 and Group 2, there was no significant difference in satisfaction measured by Likert scale and VAS, and anxiety measured by STAI, but anxiety measured by VAS was significantly lower in Group 2. This inconsistency might have been due to the fact that the STAI has more detailed questions and a more comprehensive scoring system, while the VAS is a more general subjective score. Despite demonstrating potential in these areas, a recognized need exists for further enhancements, especially in terms of reducing patient anxiety.</p><p>Over the past thirty years, TRUS-guided prostatic biopsy has been the primary diagnostic procedure for prostatic carcinoma. However, patients may experience post-procedure symptoms such as pain and distress. More than 100 RCTs have been conducted to evaluate potential analgesic methods to alleviate these symptoms [<xref rid="B18" ref-type="bibr">18</xref>]. A prostatic nerve block (PNB) has been established as the most efficacious method, allowing the majority of men to tolerate the procedure. Numerical rating scales for pain following a PNB have indicated average pain scores ranging from 2 to 4 [<xref rid="B19" ref-type="bibr">19</xref><xref rid="B20" ref-type="bibr">20</xref><xref rid="B21" ref-type="bibr">21</xref><xref rid="B22" ref-type="bibr">22</xref><xref rid="B23" ref-type="bibr">23</xref>].</p><p>Clinical utility of AI-based tools within this domain has predominantly focused on promoting an accurate diagnosis of prostatic malignancy. AI has been utilized to support statistical analyses and computer functionality, aiming to reduce the subjectivity of the diagnosis and improve its accuracy [<xref rid="B24" ref-type="bibr">24</xref><xref rid="B25" ref-type="bibr">25</xref>]. The use of AI-supported instruments has recently been demonstrated in routine clinical domains [<xref rid="B26" ref-type="bibr">26</xref>]. Among the 13 clinical disciplines where RCTs concerning AI-based tools have been conducted, gastroenterology remains the most common; AI-assisted endoscopy, predominantly through biosignal-based tools, has been the focus of 15 studies. In a study involving cancer patients randomly assigned to either an intervention group with access to a novel AI-based smartphone application or a control group, it was observed that the former group exhibited more positive attitudes toward their cancer therapy (&#223;=&#8722;0.037, p=0.042) and experienced lower pain levels (&#223;=&#8722;0.09, p=0.034) [<xref rid="B27" ref-type="bibr">27</xref>].</p><p>As previously mentioned, it is feasible to perform a prostate biopsy on an outpatient basis. However, it is crucial to have a standardized procedure for monitoring patients in order to identify any complications that may arise post-procedure. Typically, this monitoring involves telephoning each patient the day after the biopsy, which allows for ongoing surveillance and the early detection of potential complications [<xref rid="B28" ref-type="bibr">28</xref>]. Nevertheless, this follow-up method consumes a significant amount of &#8216;healthcare professionals&#8217; time, especially given the increasing number of patients utilizing day surgery services. This time could be better allocated toward direct patient care. Currently, the organization of ambulatory surgery is the focus of a national study called OPERA, conducted by the French Society of Anesthesia and Intensive Care. It has been reported that the average percentage of patients who do not receive a follow-up call is 15%; this percentage increases to as much as 55% on Saturday mornings [<xref rid="B29" ref-type="bibr">29</xref>]. The staff contacting the patients predominantly consists of nursing staff (70%), along with administrative (5%) and medical (1%) staff. Introducing automated methods for patient communication could greatly enhance the efficient use of clinical staff. The current study has yielded important insights by demonstrating that an AI-based safety tool, which directly interacts with patients and is more advanced than standard automated text messages, provides a level of patient satisfaction comparable to human follow-up.</p><p>Deciding to directly contact patients to monitor their progress represented a significant strength of this study. Whether utilizing an AI-based tool or a person, the process involved engaging with the patient and asking about their symptoms using a specific checklist. Critical data, such as difficulties with bladder empty and signs of significant fever, were collected to help rule out major complications. Not only did the tool in question reassure patients about potential postoperative issues, but it also facilitated the detection of severe complications that the patient might not have been aware of. It is imperative to quickly identify potential sepsis, for example by verifying significant pyrexia, to ensure that timely and appropriate treatment can be initiated.</p><p>Although the patients were less satisfied when interacting with the AI used in the study compared to human interaction, mainly because the AI was not generative, the study&#8217;s findings highlight considerable potential for the system employed. Due to small sample size, Group 3 showed a higher proportion of patients with more advanced prostate cancer, characterized by elevated PSA levels or metastasis, although this difference was not statistically significant. Therefore, further RCTs with a larger sample size are needed in the future.</p></sec><sec sec-type="conclusions"><title>CONCLUSIONS</title><p>TRUS-guided prostate biopsy is likely to remain the benchmark diagnostic test for prostate carcinoma. To date, no approaches have been proposed to reassure patients and monitor potential post-procedural complications. The majority of studies on AI-based tools in prostate cancer have concentrated on the diagnostic aspects of the disease. Thus, this is the first study to apply AI in identifying post-procedural complications and enhancing patient reassurance. Although the number of participants in this pilot study was limited, the findings are encouraging, indicating that satisfaction levels from follow-ups using the AI tool or a human were comparable. Further research, involving larger patient cohorts and conducted prospectively, is needed to verify the effectiveness of this AI-based tool.</p></sec></body><back><ack><title>Acknowledgements</title><p>None.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Conflict of Interest:</bold> The authors have nothing to disclose.</p></fn><fn fn-type="supported-by"><p><bold>Funding:</bold> This study was supported by the Soonchunhyang University (10.13039/501100002560) Research Fund (2024).</p></fn><fn fn-type="con"><p><bold>Author Contribution:</bold>
<list list-type="simple"><list-item><p><bold>Conceptualization:</bold> JJ, JHK.</p></list-item><list-item><p><bold>Data curation:</bold> YNG, UC, SRC.</p></list-item><list-item><p><bold>Formal analysis:</bold> YNG, JYH, DKK.</p></list-item><list-item><p><bold>Funding acquisition:</bold> JHK.</p></list-item><list-item><p><bold>Investigation:</bold> UC, SRC, JYH, DKK, SWD, WJY, KK, SRS.</p></list-item><list-item><p><bold>Software:</bold> UC, SRC.</p></list-item><list-item><p><bold>Writing &#8211; original draft:</bold> YNG, JHK.</p></list-item><list-item><p><bold>Writing &#8211; review &amp; editing:</bold> JJ, JHK.</p></list-item></list>
</p></fn></fn-group><sec sec-type="data-availability"><title>Data Sharing Statement</title><p>The data analyzed for this study have been deposited in HARVARD Dataverse and are available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.7910/DVN/ALVSGP" ext-link-type="uri">https://doi.org/10.7910/DVN/ALVSGP</ext-link>.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hodge</surname><given-names>KK</given-names></name><name name-style="western"><surname>McNeal</surname><given-names>JE</given-names></name><name name-style="western"><surname>Stamey</surname><given-names>TA</given-names></name></person-group><article-title>Ultrasound guided transrectal core biopsies of the palpably abnormal prostate</article-title><source>J Urol</source><year>1989</year><volume>142</volume><fpage>66</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">2659826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0022-5347(17)38663-9</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hodge</surname><given-names>KK</given-names></name><name name-style="western"><surname>McNeal</surname><given-names>JE</given-names></name><name name-style="western"><surname>Terris</surname><given-names>MK</given-names></name><name name-style="western"><surname>Stamey</surname><given-names>TA</given-names></name></person-group><article-title>Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate</article-title><source>J Urol</source><year>1989</year><volume>142</volume><fpage>71</fpage><lpage>74</lpage><comment>discussion 4-5</comment><pub-id pub-id-type="pmid">2659827</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0022-5347(17)38664-0</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loeb</surname><given-names>S</given-names></name><name name-style="western"><surname>Carter</surname><given-names>HB</given-names></name><name name-style="western"><surname>Berndt</surname><given-names>SI</given-names></name><name name-style="western"><surname>Ricker</surname><given-names>W</given-names></name><name name-style="western"><surname>Schaeffer</surname><given-names>EM</given-names></name></person-group><article-title>Complications after prostate biopsy: data from SEER-Medicare</article-title><source>J Urol</source><year>2011</year><volume>186</volume><fpage>1830</fpage><lpage>1834</lpage><pub-id pub-id-type="pmid">21944136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.juro.2011.06.057</pub-id><pub-id pub-id-type="pmcid">PMC9840843</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loeb</surname><given-names>S</given-names></name><name name-style="western"><surname>van den Heuvel</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name><name name-style="western"><surname>Bangma</surname><given-names>CH</given-names></name><name name-style="western"><surname>Schr&#246;der</surname><given-names>FH</given-names></name><name name-style="western"><surname>Roobol</surname><given-names>MJ</given-names></name></person-group><article-title>Infectious complications and hospital admissions after prostate biopsy in a European randomized trial</article-title><source>Eur Urol</source><year>2012</year><volume>61</volume><fpage>1110</fpage><lpage>1114</lpage><pub-id pub-id-type="pmid">22244150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2011.12.058</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosario</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Lane</surname><given-names>JA</given-names></name><name name-style="western"><surname>Metcalfe</surname><given-names>C</given-names></name><name name-style="western"><surname>Donovan</surname><given-names>JL</given-names></name><name name-style="western"><surname>Doble</surname><given-names>A</given-names></name><name name-style="western"><surname>Goodwin</surname><given-names>L</given-names></name><etal/></person-group><article-title>Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study</article-title><source>BMJ</source><year>2012</year><volume>344</volume><elocation-id>d7894</elocation-id><pub-id pub-id-type="pmid">22232535</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.d7894</pub-id><pub-id pub-id-type="pmcid">PMC3253765</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macefield</surname><given-names>RC</given-names></name><name name-style="western"><surname>Metcalfe</surname><given-names>C</given-names></name><name name-style="western"><surname>Lane</surname><given-names>JA</given-names></name><name name-style="western"><surname>Donovan</surname><given-names>JL</given-names></name><name name-style="western"><surname>Avery</surname><given-names>KN</given-names></name><name name-style="western"><surname>Blazeby</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result</article-title><source>Br J Cancer</source><year>2010</year><volume>102</volume><fpage>1335</fpage><lpage>1340</lpage><pub-id pub-id-type="pmid">20372151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.bjc.6605648</pub-id><pub-id pub-id-type="pmcid">PMC2865757</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCarthy</surname><given-names>J</given-names></name><name name-style="western"><surname>Minsky</surname><given-names>ML</given-names></name><name name-style="western"><surname>Rochester</surname><given-names>N</given-names></name><name name-style="western"><surname>Shannon</surname><given-names>CE</given-names></name></person-group><article-title>A proposal for the dartmouth summer research project on artificial intelligence, august 31, 1955</article-title><source>AI Mag</source><year>2006</year><volume>27</volume><fpage>12</fpage><lpage>14</lpage></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamamoto</surname><given-names>R</given-names></name></person-group><article-title>Application of artificial intelligence for medical research</article-title><source>Biomolecules</source><year>2021</year><volume>11</volume><elocation-id>90</elocation-id><pub-id pub-id-type="pmid">33445802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biom11010090</pub-id><pub-id pub-id-type="pmcid">PMC7828229</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shung</surname><given-names>DL</given-names></name><name name-style="western"><surname>Sung</surname><given-names>JJY</given-names></name></person-group><article-title>Challenges of developing artificial intelligence-assisted tools for clinical medicine</article-title><source>J Gastroenterol Hepatol</source><year>2021</year><volume>36</volume><fpage>295</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">33624889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jgh.15378</pub-id><pub-id pub-id-type="pmcid">PMC11874508</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>CL</given-names></name><name name-style="western"><surname>Freedman</surname><given-names>B</given-names></name></person-group><article-title>Artificial intelligence in health care: preparing for the fifth Industrial Revolution</article-title><source>Med J Aust</source><year>2020</year><volume>213</volume><fpage>253</fpage><lpage>255.e1</lpage><pub-id pub-id-type="pmid">32892395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5694/mja2.50755</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>JM</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>JP</given-names></name><name name-style="western"><surname>Beers</surname><given-names>A</given-names></name><name name-style="western"><surname>Chang</surname><given-names>K</given-names></name><name name-style="western"><surname>Ostmo</surname><given-names>S</given-names></name><name name-style="western"><surname>Chan</surname><given-names>RVP</given-names></name><etal/></person-group><collab>Imaging and Informatics in Retinopathy of Prematurity (i-ROP) Research Consortium</collab><article-title>Automated diagnosis of plus disease in retinopathy of prematurity using deep convolutional neural networks</article-title><source>JAMA Ophthalmol</source><year>2018</year><volume>136</volume><fpage>803</fpage><lpage>810</lpage><pub-id pub-id-type="pmid">29801159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaophthalmol.2018.1934</pub-id><pub-id pub-id-type="pmcid">PMC6136045</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Labovitz</surname><given-names>DL</given-names></name><name name-style="western"><surname>Shafner</surname><given-names>L</given-names></name><name name-style="western"><surname>Reyes Gil</surname><given-names>M</given-names></name><name name-style="western"><surname>Virmani</surname><given-names>D</given-names></name><name name-style="western"><surname>Hanina</surname><given-names>A</given-names></name></person-group><article-title>Using artificial intelligence to reduce the risk of nonadherence in patients on anticoagulation therapy</article-title><source>Stroke</source><year>2017</year><volume>48</volume><fpage>1416</fpage><lpage>1419</lpage><pub-id pub-id-type="pmid">28386037</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.116.016281</pub-id><pub-id pub-id-type="pmcid">PMC5432369</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shung</surname><given-names>DL</given-names></name><name name-style="western"><surname>Au</surname><given-names>B</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>RA</given-names></name><name name-style="western"><surname>Tay</surname><given-names>JK</given-names></name><name name-style="western"><surname>Laursen</surname><given-names>SB</given-names></name><name name-style="western"><surname>Stanley</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Validation of a machine learning model that outperforms clinical risk scoring systems for upper gastrointestinal bleeding</article-title><source>Gastroenterology</source><year>2020</year><volume>158</volume><fpage>160</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">31562847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2019.09.009</pub-id><pub-id pub-id-type="pmcid">PMC7004228</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="book"><collab>U.S. Department of Health and Human Services</collab><collab>U.S. Food and Drug Administration</collab><collab>Center for Drug Evaluation and Research (CDER)</collab><source>Guidance for Industry: food-effect bioavailability and fed bioequivalence studies</source><publisher-name>U.S. Food and Drug Administration</publisher-name><year>2002</year></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Julious</surname><given-names>SA</given-names></name></person-group><article-title>Sample size of 12 per group rule of thumb for a pilot study</article-title><source>Pharmaceut Statist</source><year>2005</year><volume>4</volume><fpage>287</fpage><lpage>291</lpage></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knowles</surname><given-names>KA</given-names></name><name name-style="western"><surname>Olatunji</surname><given-names>BO</given-names></name></person-group><article-title>Specificity of trait anxiety in anxiety and depression: meta-analysis of the State-Trait Anxiety Inventory</article-title><source>Clin Psychol Rev</source><year>2020</year><volume>82</volume><elocation-id>101928</elocation-id><pub-id pub-id-type="pmid">33091745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cpr.2020.101928</pub-id><pub-id pub-id-type="pmcid">PMC7680410</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="book"><source>CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials [Internet]</source><publisher-name>EQUATOR network</publisher-name><year>c2024</year><date-in-citation content-type="access-date">cited 2023 Oct 1</date-in-citation><comment>Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.equator-network.org/reporting-guidelines/consort/" ext-link-type="uri">https://www.equator-network.org/reporting-guidelines/consort/</ext-link></comment></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>C</given-names></name><name name-style="western"><surname>Woo</surname><given-names>HH</given-names></name></person-group><article-title>Current methods of analgesia for transrectal ultrasonography (TRUS)-guided prostate biopsy &#8211; a systematic review</article-title><source>BJU Int</source><year>2014</year><volume>113</volume><issue>Suppl 2</issue><fpage>48</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">24053451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bju.12433</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leibovici</surname><given-names>D</given-names></name><name name-style="western"><surname>Zisman</surname><given-names>A</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>YI</given-names></name><name name-style="western"><surname>Sella</surname><given-names>A</given-names></name><name name-style="western"><surname>Kleinmann</surname><given-names>J</given-names></name><name name-style="western"><surname>Lindner</surname><given-names>A</given-names></name></person-group><article-title>Local anesthesia for prostate biopsy by periprostatic lidocaine injection: a double-blind placebo controlled study</article-title><source>J Urol</source><year>2002</year><volume>167</volume><fpage>563</fpage><lpage>565</lpage><pub-id pub-id-type="pmid">11792919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0022-5347(01)69086-4</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moussa</surname><given-names>AS</given-names></name><name name-style="western"><surname>El-Shafei</surname><given-names>A</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>E</given-names></name><name name-style="western"><surname>Gao</surname><given-names>T</given-names></name><name name-style="western"><surname>Zaytoun</surname><given-names>OM</given-names></name><name name-style="western"><surname>Fareed</surname><given-names>K</given-names></name><etal/></person-group><article-title>Identification of the variables associated with pain during transrectal ultrasonography-guided prostate biopsy in the era of periprostatic nerve block: the role of transrectal probe configuration</article-title><source>BJU Int</source><year>2013</year><volume>111</volume><fpage>1281</fpage><lpage>1286</lpage><pub-id pub-id-type="pmid">23465033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1464-410X.2012.11689.x</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nambirajan</surname><given-names>T</given-names></name><name name-style="western"><surname>Woolsey</surname><given-names>S</given-names></name><name name-style="western"><surname>Mahendra</surname><given-names>V</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>IK</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>TH</given-names></name><name name-style="western"><surname>Keane</surname><given-names>PF</given-names></name></person-group><article-title>Efficacy and safety peri-prostatic local anaesthetic injection in trans-rectal biopsy of the prostrate: a prospective randomised study</article-title><source>Surgeon</source><year>2004</year><volume>2</volume><fpage>221</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">15570830</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1479-666x(04)80004-0</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>SH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JK</given-names></name><name name-style="western"><surname>Song</surname><given-names>K</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>H</given-names></name><name name-style="western"><surname>Kim</surname><given-names>CS</given-names></name></person-group><article-title>Effectiveness of local anaesthesia techniques in patients undergoing transrectal ultrasound-guided prostate biopsy: a prospective randomized study</article-title><source>Int J Urol</source><year>2006</year><volume>13</volume><fpage>707</fpage><lpage>710</lpage><pub-id pub-id-type="pmid">16834647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1442-2042.2006.01390.x</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stirling</surname><given-names>BN</given-names></name><name name-style="western"><surname>Shockley</surname><given-names>KF</given-names></name><name name-style="western"><surname>Carothers</surname><given-names>GG</given-names></name><name name-style="western"><surname>Maatman</surname><given-names>TJ</given-names></name></person-group><article-title>Pain perception during transrectal ultrasound guided prostate needle biopsy: an objective analysis of local anesthesia use</article-title><source>Prostate Cancer Prostatic Dis</source><year>2002</year><volume>5</volume><fpage>209</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">12496983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.pcan.4500598</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osses</surname><given-names>DF</given-names></name><name name-style="western"><surname>Roobol</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Schoots</surname><given-names>IG</given-names></name></person-group><article-title>Prediction medicine: biomarkers, risk calculators and magnetic resonance imaging as risk stratification tools in prostate cancer diagnosis</article-title><source>Int J Mol Sci</source><year>2019</year><volume>20</volume><elocation-id>1637</elocation-id><pub-id pub-id-type="pmid">30986955</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms20071637</pub-id><pub-id pub-id-type="pmcid">PMC6480079</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Tai</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Liang</surname><given-names>C</given-names></name></person-group><article-title>A calculator based on prostate imaging reporting and data system version 2 (PI-RADS V2) is a promising prostate cancer predictor</article-title><source>Sci Rep</source><year>2019</year><volume>9</volume><elocation-id>6870</elocation-id><pub-id pub-id-type="pmid">31053749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-019-43427-9</pub-id><pub-id pub-id-type="pmcid">PMC6499813</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lam</surname><given-names>TYT</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>MFK</given-names></name><name name-style="western"><surname>Munro</surname><given-names>YL</given-names></name><name name-style="western"><surname>Lim</surname><given-names>KM</given-names></name><name name-style="western"><surname>Shung</surname><given-names>D</given-names></name><name name-style="western"><surname>Sung</surname><given-names>JJY</given-names></name></person-group><article-title>Randomized controlled trials of artificial intelligence in clinical practice: systematic review</article-title><source>J Med Internet Res</source><year>2022</year><volume>24</volume><elocation-id>e37188</elocation-id><pub-id pub-id-type="pmid">35904087</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/37188</pub-id><pub-id pub-id-type="pmcid">PMC9459941</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamdar</surname><given-names>M</given-names></name><name name-style="western"><surname>Centi</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Agboola</surname><given-names>S</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>N</given-names></name><name name-style="western"><surname>Rinaldi</surname><given-names>S</given-names></name><name name-style="western"><surname>Strand</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>A randomized controlled trial of a novel artificial intelligence-based smartphone application to optimize the management of cancer-related pain</article-title><source>J Clin Oncol</source><year>2019</year><volume>37</volume><issue>15 Supple</issue><elocation-id>11514</elocation-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hwa</surname><given-names>K</given-names></name><name name-style="western"><surname>Wren</surname><given-names>SM</given-names></name></person-group><article-title>Telehealth follow-up in lieu of postoperative clinic visit for ambulatory surgery: results of a pilot program</article-title><source>JAMA Surg</source><year>2013</year><volume>148</volume><fpage>823</fpage><lpage>827</lpage><pub-id pub-id-type="pmid">23842982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamasurg.2013.2672</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beaussier</surname><given-names>M</given-names></name><name name-style="western"><surname>Albaladejo</surname><given-names>P</given-names></name><name name-style="western"><surname>Sciard</surname><given-names>D</given-names></name><name name-style="western"><surname>Jouffroy</surname><given-names>L</given-names></name><name name-style="western"><surname>Benhamou</surname><given-names>D</given-names></name><name name-style="western"><surname>Ecoffey</surname><given-names>C</given-names></name><etal/></person-group><collab>SFAR Committee of Ambulatory Anaesthesia</collab><article-title>Operation and organisation of ambulatory surgery in France. Results of a nationwide survey; The OPERA study</article-title><source>Anaesth Crit Care Pain Med</source><year>2017</year><volume>36</volume><fpage>353</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">28826981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.accpm.2017.07.003</pub-id></element-citation></ref></ref-list><sec sec-type="supplementary-material"><title>Supplementary Materials</title><p>Supplementary materials can be found via <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.5534/wjmh.240191" ext-link-type="uri">https://doi.org/10.5534/wjmh.240191</ext-link>.</p><supplementary-material id="S1" position="float" content-type="local-data" orientation="portrait"><caption><title>Supplement Fig. 1</title><p>Algorithm of the reassurance call</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="wjmh-43-934-s001.pdf" id="d67e1274" position="anchor" orientation="portrait"/></supplementary-material></sec></back><floats-group><fig position="float" id="F1" orientation="portrait"><label>Fig. 1</label><caption><title>Box plots for satisfaction or anxiety after reassurance-call service. AI: artificial intelligence.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="wjmh-43-934-g001.jpg"/></fig><fig position="float" id="F2" orientation="portrait"><label>Fig. 2</label><caption><title>Flow diagram of patient selection. <xref rid="F2" ref-type="fig">Fig. 2</xref> does not include the non-group to aid understanding. The p-value for the statistics is based on a comparison among all three groups, including the non-group, so it may differ. VAS: visual analog scale, STAI: state-trait anxiety inventory, AI: artificial intelligence.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="wjmh-43-934-g002.jpg"/></fig><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><title>Baseline characteristics of patients</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="wjmh-43-934-i001.jpg"/><table frame="hsides" rules="rows"><col width="2.02%" span="1"/><col width="28.86%" span="1"/><col width="18.75%" span="1"/><col width="18.75%" span="1"/><col width="18.75%" span="1"/><col width="12.87%" span="1"/><thead><tr><th valign="middle" align="center" rowspan="1" colspan="2" style="background-color:rgb(179,217,215)"/><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">AI</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">Human</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">None</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">p-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="2">Number</td><td valign="top" align="center" rowspan="1" colspan="1">14</td><td valign="top" align="center" rowspan="1" colspan="1">14</td><td valign="top" align="center" rowspan="1" colspan="1">14</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="2">Height (cm)</td><td valign="top" align="center" rowspan="1" colspan="1">168.27&#177;3.97</td><td valign="top" align="center" rowspan="1" colspan="1">167.66&#177;3.80</td><td valign="top" align="center" rowspan="1" colspan="1">167.87&#177;4.66</td><td valign="top" align="center" rowspan="1" colspan="1">0.680</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="2">Weight (kg)</td><td valign="top" align="center" rowspan="1" colspan="1">68.60&#177;7.00</td><td valign="top" align="center" rowspan="1" colspan="1">68.99&#177;7.34</td><td valign="top" align="center" rowspan="1" colspan="1">70.42&#177;8.06</td><td valign="top" align="center" rowspan="1" colspan="1">0.886</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="2">Age (y)</td><td valign="top" align="center" rowspan="1" colspan="1">66.80&#177;8.63</td><td valign="top" align="center" rowspan="1" colspan="1">66.00&#177;5.22</td><td valign="top" align="center" rowspan="1" colspan="1">66.36&#177;5.46</td><td valign="top" align="center" rowspan="1" colspan="1">0.767</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="2">PSA (ng/mL)</td><td valign="top" align="center" rowspan="1" colspan="1">9.33&#177;9.13</td><td valign="top" align="center" rowspan="1" colspan="1">9.76&#177;8.51</td><td valign="top" align="center" rowspan="1" colspan="1">25.59&#177;42.22</td><td valign="top" align="center" rowspan="1" colspan="1">0.897</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="2">Image</td><td valign="bottom" align="center" rowspan="1" colspan="1"/><td valign="bottom" align="center" rowspan="1" colspan="1"/><td valign="bottom" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.607</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">2 (14.3)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (21.4)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (14.3)</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">MRI or CT only</td><td valign="top" align="center" rowspan="1" colspan="1">5 (35.7)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (35.7)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (7.1)</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">MRI with bone scan or PET-CT</td><td valign="top" align="center" rowspan="1" colspan="1">7 (50.0)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (42.9)</td><td valign="top" align="center" rowspan="1" colspan="1">11 (78.6)</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="2">Gleason score</td><td valign="bottom" align="center" rowspan="1" colspan="1"/><td valign="bottom" align="center" rowspan="1" colspan="1"/><td valign="bottom" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.063</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Benign</td><td valign="top" align="center" rowspan="1" colspan="1">6 (42.9)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (57.1)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (21.4)</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#8804;6</td><td valign="top" align="center" rowspan="1" colspan="1">1 (7.1)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (14.3)</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">7 (3+4)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (21.4)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (14.3)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (28.6)</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">7 (4+3)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (21.4)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (7.1)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (7.1)</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="center" rowspan="1" colspan="1">1 (7.1)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (7.1)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">9&#8211;10</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (14.3)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (28.6)</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="2">Gleason grade group</td><td valign="bottom" align="center" rowspan="1" colspan="1"/><td valign="bottom" align="center" rowspan="1" colspan="1"/><td valign="bottom" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.129</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Benign</td><td valign="top" align="center" rowspan="1" colspan="1">6 (42.9)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (57.1)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (21.4)</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Low</td><td valign="top" align="center" rowspan="1" colspan="1">1 (7.1)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (14.3)</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Intermediate (favorable)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (21.4)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (14.3)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (28.6)</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Intermediate (unfavorable)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (21.4)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (7.1)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (7.1)</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">High</td><td valign="top" align="center" rowspan="1" colspan="1">1 (7.1)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (7.1)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Very high</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (14.3)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (28.6)</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="2">PI-RADS</td><td valign="bottom" align="center" rowspan="1" colspan="1"/><td valign="bottom" align="center" rowspan="1" colspan="1"/><td valign="bottom" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.724</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">5 (35.7)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (21.4)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (42.9)</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1&#8211;3</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (14.3)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">5 (35.7)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (21.4)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (28.6)</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="center" rowspan="1" colspan="1">4 (28.6)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (42.9)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (28.6)</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="2">Stage</td><td valign="bottom" align="center" rowspan="1" colspan="1"/><td valign="bottom" align="center" rowspan="1" colspan="1"/><td valign="bottom" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.713</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Benign</td><td valign="top" align="center" rowspan="1" colspan="1">6 (42.9)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (57.1)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (21.4)</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">T1</td><td valign="top" align="center" rowspan="1" colspan="1">1 (7.1)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0.0)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0.0)</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">T2</td><td valign="top" align="center" rowspan="1" colspan="1">5 (35.7)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (35.7)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (57.1)</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">T3-4</td><td valign="top" align="center" rowspan="1" colspan="1">2 (14.3)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (7.1)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (21.4)</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="2">Metastasis</td><td valign="bottom" align="center" rowspan="1" colspan="1"/><td valign="bottom" align="center" rowspan="1" colspan="1"/><td valign="bottom" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.291</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Unknown</td><td valign="top" align="center" rowspan="1" colspan="1">2 (14.3)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0.0)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0.0)</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">11 (78.6)</td><td valign="top" align="center" rowspan="1" colspan="1">13 (92.9)</td><td valign="top" align="center" rowspan="1" colspan="1">7 (50.0)</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">2 (14.3)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (7.1)</td><td valign="top" align="center" rowspan="1" colspan="1">7 (50.0)</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn><p>Values are presented as mean&#177;standard deviation or number (%).</p><p>AI: artificial intelligence, PSA: prostate-specific antigen, N/A: not assessed, MRI: magnetic resonance imaging, CT: computed tomography, PET-CT: positron emission tomography and computed tomography, PI-RADS: prostate imaging reporting and data system.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><title>Satisfaction or anxiety after reassurance-call service</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="wjmh-43-934-i002.jpg"/><table frame="hsides" rules="rows"><col width="28.5%" span="1"/><col width="17.88%" span="1"/><col width="17.88%" span="1"/><col width="17.88%" span="1"/><col width="17.88%" span="1"/><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)"/><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">AI</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">Human</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">None</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">p-value (non-parametric)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Number</td><td valign="top" align="center" rowspan="1" colspan="1">14</td><td valign="top" align="center" rowspan="1" colspan="1">14</td><td valign="top" align="center" rowspan="1" colspan="1">13</td><td valign="bottom" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Height (cm)</td><td valign="top" align="center" rowspan="1" colspan="1">168.27 (3.97)</td><td valign="top" align="center" rowspan="1" colspan="1">167.66 (3.80)</td><td valign="top" align="center" rowspan="1" colspan="1">167.75 (4.52)</td><td valign="top" align="center" rowspan="1" colspan="1">0.825</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Weight (kg)</td><td valign="top" align="center" rowspan="1" colspan="1">68.60 (7.00)</td><td valign="top" align="center" rowspan="1" colspan="1">68.99 (7.34)</td><td valign="top" align="center" rowspan="1" colspan="1">70.53 (7.77)</td><td valign="top" align="center" rowspan="1" colspan="1">0.716</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (y)</td><td valign="top" align="center" rowspan="1" colspan="1">66.80 (8.63)</td><td valign="top" align="center" rowspan="1" colspan="1">66.00 (5.22)</td><td valign="top" align="center" rowspan="1" colspan="1">66.80 (5.53)</td><td valign="top" align="center" rowspan="1" colspan="1">0.535</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Reassurance-call satisfaction.Likert</td><td valign="top" align="center" rowspan="1" colspan="1">4.20 (0.56)</td><td valign="top" align="center" rowspan="1" colspan="1">4.71 (0.47)</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">0.015</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Reassurance-call by AI satisfaction.Likert</td><td valign="top" align="center" rowspan="1" colspan="1">4.00 (0.65)</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Complication.satisfaction.Likert</td><td valign="top" align="center" rowspan="1" colspan="1">4.13 (0.52)</td><td valign="top" align="center" rowspan="1" colspan="1">4.43 (0.76)</td><td valign="top" align="center" rowspan="1" colspan="1">3.79 (0.80)</td><td valign="top" align="center" rowspan="1" colspan="1">0.067</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Complication.satisfaction.VAS</td><td valign="top" align="center" rowspan="1" colspan="1">8.33 (1.23)</td><td valign="top" align="center" rowspan="1" colspan="1">8.57 (1.45)</td><td valign="top" align="center" rowspan="1" colspan="1">7.07 (1.86)</td><td valign="top" align="center" rowspan="1" colspan="1">0.042</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Complication.anxiety.STAI</td><td valign="top" align="center" rowspan="1" colspan="1">40.00 (10.54)</td><td valign="top" align="center" rowspan="1" colspan="1">39.14 (8.29)</td><td valign="top" align="center" rowspan="1" colspan="1">35.00 (9.46)</td><td valign="top" align="center" rowspan="1" colspan="1">0.428</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Complication.anxiety.VAS</td><td valign="top" align="center" rowspan="1" colspan="1">5.07 (2.79)</td><td valign="top" align="center" rowspan="1" colspan="1">2.21 (2.64)</td><td valign="top" align="center" rowspan="1" colspan="1">3.50 (2.28)</td><td valign="top" align="center" rowspan="1" colspan="1">0.024</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>Values are presented as mean (standard deviation).</p><p>AI: artificial intelligence, VAS: visual analog scale, STAI: state-trait anxiety inventory.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><title>Regression analysis for identifying risk factors</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="wjmh-43-934-i003.jpg"/><table frame="hsides" rules="rows"><col width="1.18%" span="1"/><col width="6.24%" span="1"/><col width="4.63%" span="1"/><col width="4.63%" span="1"/><col width="4.63%" span="1"/><col width="4.63%" span="1"/><col width="4.63%" span="1"/><col width="4.63%" span="1"/><col width="4.63%" span="1"/><col width="4.63%" span="1"/><col width="4.63%" span="1"/><col width="4.63%" span="1"/><col width="4.63%" span="1"/><col width="4.63%" span="1"/><col width="4.63%" span="1"/><col width="4.63%" span="1"/><col width="4.63%" span="1"/><col width="4.63%" span="1"/><col width="4.63%" span="1"/><col width="4.63%" span="1"/><col width="4.63%" span="1"/><col width="4.63%" span="1"/><thead><tr><th valign="middle" align="center" rowspan="2" colspan="2" style="background-color:rgb(179,217,215)">Variable</th><th valign="middle" align="center" rowspan="1" colspan="4" style="background-color:rgb(179,217,215)">Satisfaction A</th><th valign="middle" align="center" rowspan="1" colspan="4" style="background-color:rgb(179,217,215)">Satisfaction B</th><th valign="middle" align="center" rowspan="1" colspan="4" style="background-color:rgb(179,217,215)">Satisfaction C</th><th valign="middle" align="center" rowspan="1" colspan="4" style="background-color:rgb(179,217,215)">Anxiety A</th><th valign="middle" align="center" rowspan="1" colspan="4" style="background-color:rgb(179,217,215)">Anxiety B</th></tr><tr><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">Coef</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">CIL</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">CIH</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">p</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">Coef</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">CIL</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">CIH</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">p</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">Coef</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">CIL</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">CIH</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">p</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">Coef</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">CIL</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">CIH</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">p</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">Coef</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">CIL</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">CIH</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(179,217,215)">p</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="2">AI <italic toggle="yes">vs.</italic> human</td><td valign="top" align="center" rowspan="1" colspan="1">-0.63</td><td valign="top" align="center" rowspan="1" colspan="1">-1.16</td><td valign="top" align="center" rowspan="1" colspan="1">-0.10</td><td valign="top" align="center" rowspan="1" colspan="1">0.052</td><td valign="top" align="center" rowspan="1" colspan="1">-0.45</td><td valign="top" align="center" rowspan="1" colspan="1">-0.98</td><td valign="top" align="center" rowspan="1" colspan="1">0.08</td><td valign="top" align="center" rowspan="1" colspan="1">0.138</td><td valign="top" align="center" rowspan="1" colspan="1">-0.45</td><td valign="top" align="center" rowspan="1" colspan="1">-1.82</td><td valign="top" align="center" rowspan="1" colspan="1">0.92</td><td valign="top" align="center" rowspan="1" colspan="1">0.538</td><td valign="top" align="center" rowspan="1" colspan="1">12.6</td><td valign="top" align="center" rowspan="1" colspan="1">0.29</td><td valign="top" align="center" rowspan="1" colspan="1">24.91</td><td valign="top" align="center" rowspan="1" colspan="1">0.085</td><td valign="top" align="center" rowspan="1" colspan="1">5.28</td><td valign="top" align="center" rowspan="1" colspan="1">1.99</td><td valign="top" align="center" rowspan="1" colspan="1">8.57</td><td valign="top" align="center" rowspan="1" colspan="1">0.016</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="2">Weight</td><td valign="top" align="center" rowspan="1" colspan="1">0.01</td><td valign="top" align="center" rowspan="1" colspan="1">-0.01</td><td valign="top" align="center" rowspan="1" colspan="1">0.03</td><td valign="top" align="center" rowspan="1" colspan="1">0.346</td><td valign="top" align="center" rowspan="1" colspan="1">-0.02</td><td valign="top" align="center" rowspan="1" colspan="1">-0.04</td><td valign="top" align="center" rowspan="1" colspan="1">0.00</td><td valign="top" align="center" rowspan="1" colspan="1">0.185</td><td valign="top" align="center" rowspan="1" colspan="1">-0.05</td><td valign="top" align="center" rowspan="1" colspan="1">-0.13</td><td valign="top" align="center" rowspan="1" colspan="1">0.03</td><td valign="top" align="center" rowspan="1" colspan="1">0.187</td><td valign="top" align="center" rowspan="1" colspan="1">-0.47</td><td valign="top" align="center" rowspan="1" colspan="1">-1.10</td><td valign="top" align="center" rowspan="1" colspan="1">0.16</td><td valign="top" align="center" rowspan="1" colspan="1">0.180</td><td valign="top" align="center" rowspan="1" colspan="1">-0.11</td><td valign="top" align="center" rowspan="1" colspan="1">-0.28</td><td valign="top" align="center" rowspan="1" colspan="1">0.06</td><td valign="top" align="center" rowspan="1" colspan="1">0.237</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="2">Age</td><td valign="top" align="center" rowspan="1" colspan="1">-0.04</td><td valign="top" align="center" rowspan="1" colspan="1">-0.08</td><td valign="top" align="center" rowspan="1" colspan="1">0.00</td><td valign="top" align="center" rowspan="1" colspan="1">0.087</td><td valign="top" align="center" rowspan="1" colspan="1">-0.02</td><td valign="top" align="center" rowspan="1" colspan="1">-0.06</td><td valign="top" align="center" rowspan="1" colspan="1">0.02</td><td valign="top" align="center" rowspan="1" colspan="1">0.225</td><td valign="top" align="center" rowspan="1" colspan="1">-0.05</td><td valign="top" align="center" rowspan="1" colspan="1">-0.15</td><td valign="top" align="center" rowspan="1" colspan="1">0.05</td><td valign="top" align="center" rowspan="1" colspan="1">0.330</td><td valign="top" align="center" rowspan="1" colspan="1">-0.05</td><td valign="top" align="center" rowspan="1" colspan="1">-0.89</td><td valign="top" align="center" rowspan="1" colspan="1">0.79</td><td valign="top" align="center" rowspan="1" colspan="1">0.911</td><td valign="top" align="center" rowspan="1" colspan="1">-0.01</td><td valign="top" align="center" rowspan="1" colspan="1">-0.23</td><td valign="top" align="center" rowspan="1" colspan="1">0.21</td><td valign="top" align="center" rowspan="1" colspan="1">0.963</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="2">Stage</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">T2</td><td valign="top" align="center" rowspan="1" colspan="1">-1.1</td><td valign="top" align="center" rowspan="1" colspan="1">-2.00</td><td valign="top" align="center" rowspan="1" colspan="1">-0.20</td><td valign="top" align="center" rowspan="1" colspan="1">0.047</td><td valign="top" align="center" rowspan="1" colspan="1">-0.69</td><td valign="top" align="center" rowspan="1" colspan="1">-1.59</td><td valign="top" align="center" rowspan="1" colspan="1">0.21</td><td valign="top" align="center" rowspan="1" colspan="1">0.174</td><td valign="top" align="center" rowspan="1" colspan="1">-1.42</td><td valign="top" align="center" rowspan="1" colspan="1">-3.73</td><td valign="top" align="center" rowspan="1" colspan="1">0.89</td><td valign="top" align="center" rowspan="1" colspan="1">0.268</td><td valign="top" align="center" rowspan="1" colspan="1">25.30</td><td valign="top" align="center" rowspan="1" colspan="1">4.49</td><td valign="top" align="center" rowspan="1" colspan="1">46.12</td><td valign="top" align="center" rowspan="1" colspan="1">0.049</td><td valign="top" align="center" rowspan="1" colspan="1">6.78</td><td valign="top" align="center" rowspan="1" colspan="1">1.21</td><td valign="top" align="center" rowspan="1" colspan="1">12.35</td><td valign="top" align="center" rowspan="1" colspan="1">0.048</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">T3</td><td valign="top" align="center" rowspan="1" colspan="1">-1.05</td><td valign="top" align="center" rowspan="1" colspan="1">-1.97</td><td valign="top" align="center" rowspan="1" colspan="1">-0.13</td><td valign="top" align="center" rowspan="1" colspan="1">0.060</td><td valign="top" align="center" rowspan="1" colspan="1">-0.56</td><td valign="top" align="center" rowspan="1" colspan="1">-1.48</td><td valign="top" align="center" rowspan="1" colspan="1">0.36</td><td valign="top" align="center" rowspan="1" colspan="1">0.268</td><td valign="top" align="center" rowspan="1" colspan="1">0.17</td><td valign="top" align="center" rowspan="1" colspan="1">-2.20</td><td valign="top" align="center" rowspan="1" colspan="1">2.54</td><td valign="top" align="center" rowspan="1" colspan="1">0.892</td><td valign="top" align="center" rowspan="1" colspan="1">8.2</td><td valign="top" align="center" rowspan="1" colspan="1">-13.16</td><td valign="top" align="center" rowspan="1" colspan="1">29.56</td><td valign="top" align="center" rowspan="1" colspan="1">0.476</td><td valign="top" align="center" rowspan="1" colspan="1">3.16</td><td valign="top" align="center" rowspan="1" colspan="1">-2.56</td><td valign="top" align="center" rowspan="1" colspan="1">8.88</td><td valign="top" align="center" rowspan="1" colspan="1">0.315</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="2">Gleason score</td><td valign="top" align="center" rowspan="1" colspan="1">-0.08</td><td valign="top" align="center" rowspan="1" colspan="1">-0.35</td><td valign="top" align="center" rowspan="1" colspan="1">0.19</td><td valign="top" align="center" rowspan="1" colspan="1">0.593</td><td valign="top" align="center" rowspan="1" colspan="1">0.01</td><td valign="top" align="center" rowspan="1" colspan="1">-0.26</td><td valign="top" align="center" rowspan="1" colspan="1">0.28</td><td valign="top" align="center" rowspan="1" colspan="1">0.952</td><td valign="top" align="center" rowspan="1" colspan="1">0.51</td><td valign="top" align="center" rowspan="1" colspan="1">-0.22</td><td valign="top" align="center" rowspan="1" colspan="1">1.24</td><td valign="top" align="center" rowspan="1" colspan="1">0.213</td><td valign="top" align="center" rowspan="1" colspan="1">1.16</td><td valign="top" align="center" rowspan="1" colspan="1">-5.35</td><td valign="top" align="center" rowspan="1" colspan="1">7.67</td><td valign="top" align="center" rowspan="1" colspan="1">0.737</td><td valign="top" align="center" rowspan="1" colspan="1">0.94</td><td valign="top" align="center" rowspan="1" colspan="1">-0.80</td><td valign="top" align="center" rowspan="1" colspan="1">2.68</td><td valign="top" align="center" rowspan="1" colspan="1">0.325</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>Satisfaction A: Satisfaction for reassurance-call service using Likert, Satisfaction B: Satisfaction for complication handling using Likert, Satisfaction C: Satisfaction for complication handling using visual analog scale (VAS), Anxiety A: Anxiety of complications using state-trait anxiety inventory (STAI), Anxiety B: Anxiety of complications using VAS.</p><p>Coef: regression coefficient, CIL: 95% confidence interval low limit, CIH: 95% confidence interval upper limit.</p></fn></table-wrap-foot></table-wrap></floats-group></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="alz70629" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement</journal-id><journal-id journal-id-type="pmc-domain-id">4549</journal-id><journal-id journal-id-type="pmc-domain">alzdem</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Alzheimer's &amp; Dementia</journal-title></journal-title-group><issn pub-type="ppub">1552-5260</issn><issn pub-type="epub">1552-5279</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12505200</article-id><article-id pub-id-type="pmcid-ver">PMC12505200.1</article-id><article-id pub-id-type="pmcaid">12505200</article-id><article-id pub-id-type="pmcaiid">12505200</article-id><article-id pub-id-type="doi">10.1002/alz.70629</article-id><article-id pub-id-type="publisher-id">ALZ70629</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Novel differentially expressed genes and multiple biological pathways for Alzheimer's disease identified in brain tissue from African American donors</article-title><alt-title alt-title-type="left-running-head">LOGUE <sc>et&#160;al</sc>.</alt-title></title-group><contrib-group><contrib id="alz70629-cr-0001" contrib-type="author"><name name-style="western"><surname>Logue</surname><given-names initials="MW">Mark W.</given-names></name><xref rid="alz70629-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70629-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="alz70629-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="alz70629-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70629-cr-0002" contrib-type="author"><name name-style="western"><surname>Labadorf</surname><given-names initials="A">Adam</given-names></name><xref rid="alz70629-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><xref rid="alz70629-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="alz70629-cr-0003" contrib-type="author"><name name-style="western"><surname>O'Neill</surname><given-names initials="NK">Nicholas K.</given-names></name><xref rid="alz70629-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="alz70629-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="alz70629-cr-0004" contrib-type="author"><name name-style="western"><surname>Dickson</surname><given-names initials="DW">Dennis W.</given-names></name><xref rid="alz70629-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="alz70629-cr-0005" contrib-type="author"><name name-style="western"><surname>Dugger</surname><given-names initials="BN">Brittany N.</given-names></name><xref rid="alz70629-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="alz70629-cr-0006" contrib-type="author"><name name-style="western"><surname>Flanagan</surname><given-names initials="ME">Margaret E.</given-names></name><xref rid="alz70629-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="alz70629-cr-0007" contrib-type="author"><name name-style="western"><surname>Frosch</surname><given-names initials="MP">Matthew P.</given-names></name><xref rid="alz70629-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib id="alz70629-cr-0008" contrib-type="author"><name name-style="western"><surname>Gearing</surname><given-names initials="M">Marla</given-names></name><xref rid="alz70629-aff-0012" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib id="alz70629-cr-0009" contrib-type="author"><name name-style="western"><surname>Jin</surname><given-names initials="LW">Lee&#8208;Way</given-names></name><xref rid="alz70629-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="alz70629-cr-0010" contrib-type="author"><name name-style="western"><surname>Kofler</surname><given-names initials="J">Julia</given-names></name><xref rid="alz70629-aff-0013" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib id="alz70629-cr-0011" contrib-type="author"><name name-style="western"><surname>Mayeux</surname><given-names initials="R">Richard</given-names></name><xref rid="alz70629-aff-0014" ref-type="aff">
<sup>14</sup>
</xref></contrib><contrib id="alz70629-cr-0012" contrib-type="author"><name name-style="western"><surname>McKee</surname><given-names initials="A">Ann</given-names></name><xref rid="alz70629-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><xref rid="alz70629-aff-0015" ref-type="aff">
<sup>15</sup>
</xref><xref rid="alz70629-aff-0017" ref-type="aff">
<sup>17</sup>
</xref><xref rid="alz70629-aff-0018" ref-type="aff">
<sup>18</sup>
</xref><xref rid="alz70629-aff-0019" ref-type="aff">
<sup>19</sup>
</xref><xref rid="alz70629-aff-0020" ref-type="aff">
<sup>20</sup>
</xref></contrib><contrib id="alz70629-cr-0013" contrib-type="author"><name name-style="western"><surname>Miller</surname><given-names initials="CA">Carol A.</given-names></name><xref rid="alz70629-aff-0021" ref-type="aff">
<sup>21</sup>
</xref></contrib><contrib id="alz70629-cr-0014" contrib-type="author"><name name-style="western"><surname>Murray</surname><given-names initials="ME">Melissa E.</given-names></name><xref rid="alz70629-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="alz70629-cr-0015" contrib-type="author"><name name-style="western"><surname>Nelson</surname><given-names initials="PT">Peter T.</given-names></name><xref rid="alz70629-aff-0022" ref-type="aff">
<sup>22</sup>
</xref></contrib><contrib id="alz70629-cr-0016" contrib-type="author"><name name-style="western"><surname>Perrin</surname><given-names initials="RJ">Richard J.</given-names></name><xref rid="alz70629-aff-0023" ref-type="aff">
<sup>23</sup>
</xref></contrib><contrib id="alz70629-cr-0017" contrib-type="author"><name name-style="western"><surname>Schneider</surname><given-names initials="JA">Julie A.</given-names></name><xref rid="alz70629-aff-0024" ref-type="aff">
<sup>24</sup>
</xref></contrib><contrib id="alz70629-cr-0018" contrib-type="author"><name name-style="western"><surname>Stein</surname><given-names initials="TD">Thor D.</given-names></name><xref rid="alz70629-aff-0015" ref-type="aff">
<sup>15</sup>
</xref><xref rid="alz70629-aff-0017" ref-type="aff">
<sup>17</sup>
</xref><xref rid="alz70629-aff-0018" ref-type="aff">
<sup>18</sup>
</xref><xref rid="alz70629-aff-0019" ref-type="aff">
<sup>19</sup>
</xref><xref rid="alz70629-aff-0020" ref-type="aff">
<sup>20</sup>
</xref></contrib><contrib id="alz70629-cr-0019" contrib-type="author"><name name-style="western"><surname>Teich</surname><given-names initials="AF">Andrew F.</given-names></name><xref rid="alz70629-aff-0014" ref-type="aff">
<sup>14</sup>
</xref><xref rid="alz70629-aff-0025" ref-type="aff">
<sup>25</sup>
</xref></contrib><contrib id="alz70629-cr-0020" contrib-type="author"><name name-style="western"><surname>Tobunluepop</surname><given-names initials="K">Katarnut</given-names></name><xref rid="alz70629-aff-0016" ref-type="aff">
<sup>16</sup>
</xref></contrib><contrib id="alz70629-cr-0021" contrib-type="author"><name name-style="western"><surname>Troncoso</surname><given-names initials="JC">Juan C.</given-names></name><xref rid="alz70629-aff-0026" ref-type="aff">
<sup>26</sup>
</xref></contrib><contrib id="alz70629-cr-0022" contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="SH">Shih&#8208;Hsiu</given-names></name><xref rid="alz70629-aff-0027" ref-type="aff">
<sup>27</sup>
</xref></contrib><contrib id="alz70629-cr-0023" contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Z">Zihan</given-names></name><xref rid="alz70629-aff-0016" ref-type="aff">
<sup>16</sup>
</xref></contrib><contrib id="alz70629-cr-0024" contrib-type="author"><name name-style="western"><surname>Wolozin</surname><given-names initials="B">Benjamin</given-names></name><xref rid="alz70629-aff-0016" ref-type="aff">
<sup>16</sup>
</xref></contrib><contrib id="alz70629-cr-0025" contrib-type="author"><name name-style="western"><surname>Mez</surname><given-names initials="J">Jesse</given-names></name><xref rid="alz70629-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><xref rid="alz70629-aff-0017" ref-type="aff">
<sup>17</sup>
</xref><xref rid="alz70629-aff-0018" ref-type="aff">
<sup>18</sup>
</xref></contrib><contrib id="alz70629-cr-0026" contrib-type="author" corresp="yes"><name name-style="western"><surname>Farrer</surname><given-names initials="LA">Lindsay A.</given-names></name><xref rid="alz70629-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="alz70629-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="alz70629-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><xref rid="alz70629-aff-0007" ref-type="aff">
<sup>7</sup>
</xref><xref rid="alz70629-aff-0017" ref-type="aff">
<sup>17</sup>
</xref><xref rid="alz70629-aff-0028" ref-type="aff">
<sup>28</sup>
</xref><xref rid="alz70629-aff-0029" ref-type="aff">
<sup>29</sup>
</xref><address><email>farrer@bu.edu</email></address></contrib></contrib-group><aff id="alz70629-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Psychiatry</named-content>
<institution>Boston University Chobanian &amp; Avedisian School of Medicine</institution>
<city>Boston</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Medicine (Biomedical Genetics)</named-content>
<institution>Boston University Chobanian &amp; Avedisian School of Medicine</institution>
<city>Boston</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Department of Biostatistics and Boston University School of Public Health</institution>
<city>Boston</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">National Center for PTSD</named-content>
<named-content content-type="organisation-division">Behavioral Sciences Division</named-content>
<institution>VA Boston Healthcare System</institution>
<city>Boston</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Boston University Chobanian &amp; Avedisian School of Medicine</institution>
<city>Boston</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Bioinformatics Hub</named-content>
<institution>Boston University</institution>
<city>Boston</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Bioinformatics Program</named-content>
<institution>Boston University</institution>
<city>Boston</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">Departments of Neuroscience and Laboratory Medicine &amp; Pathology</named-content>
<institution>Mayo Clinic</institution>
<city>Jacksonville</city>
<named-content content-type="country-part">Florida</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0009">
<label>
<sup>9</sup>
</label>
<named-content content-type="organisation-division">Departments of Pathology and Laboratory Medicine</named-content>
<institution>UC Davis School of Medicine</institution>
<city>Sacramento</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0010">
<label>
<sup>10</sup>
</label>
<institution>Northwestern University Feinberg School of Medicine</institution>
<city>Chicago</city>
<named-content content-type="country-part">Illinois</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0011">
<label>
<sup>11</sup>
</label>
<named-content content-type="organisation-division">C.S. Kubik Laboratory for Neuropathology</named-content>
<institution>Massachusetts General Hospital &amp; Harvard Medical School</institution>
<city>Boston</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0012">
<label>
<sup>12</sup>
</label>
<named-content content-type="organisation-division">GADRC and Departments of Pathology &amp; Laboratory Medicine and Neurology</named-content>
<institution>Emory University</institution>
<city>Atlanta</city>
<named-content content-type="country-part">Georgia</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0013">
<label>
<sup>13</sup>
</label>
<named-content content-type="organisation-division">Division of Neuropathology</named-content>
<institution>University of Pittsburgh</institution>
<city>Pittsburgh</city>
<named-content content-type="country-part">Pennsylvania</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0014">
<label>
<sup>14</sup>
</label>
<named-content content-type="organisation-division">Taub Institute for Research on Alzheimer's Disease and the Aging Brain</named-content>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Columbia University</institution>
<city>New York</city>
<named-content content-type="country-part">New York</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0015">
<label>
<sup>15</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology &amp; Laboratory Medicine</named-content>
<institution>Boston University Chobanian &amp; Avedisian School of Medicine</institution>
<city>Boston</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0016">
<label>
<sup>16</sup>
</label>
<named-content content-type="organisation-division">Department of Anatomy &amp; Neurobiology</named-content>
<institution>Boston University Chobanian &amp; Avedisian School of Medicine</institution>
<city>Boston</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0017">
<label>
<sup>17</sup>
</label>
<named-content content-type="organisation-division">Boston University Alzheimer's Disease Research Center</named-content>
<institution>Boston University Chobanian &amp; Avedisian School of Medicine</institution>
<city>Boston</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0018">
<label>
<sup>18</sup>
</label>
<named-content content-type="organisation-division">Chronic Traumatic Encephalopathy Center</named-content>
<institution>Boston University Chobanian &amp; Avedisian School of Medicine</institution>
<city>Boston</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0019">
<label>
<sup>19</sup>
</label>
<institution>VA Boston Healthcare System</institution>
<city>Boston</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0020">
<label>
<sup>20</sup>
</label>
<institution>Department of Veterans Affairs Medical Center</institution>
<city>Bedford</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0021">
<label>
<sup>21</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>University of Southern California</institution>
<city>Los Angeles</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0022">
<label>
<sup>22</sup>
</label>
<named-content content-type="organisation-division">Sanders&#8208;Brown Center on Aging and Department of Pathology &amp; Laboratory Medicine</named-content>
<institution>University of Kentucky</institution>
<city>Lexington</city>
<named-content content-type="country-part">Kentucky</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0023">
<label>
<sup>23</sup>
</label>
<named-content content-type="organisation-division">Departments of Neurology and Pathology and Immunology</named-content>
<institution>Washington University School of Medicine</institution>
<city>St. Louis</city>
<named-content content-type="country-part">Missouri</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0024">
<label>
<sup>24</sup>
</label>
<named-content content-type="organisation-division">Departments of Pathology (Neuropathology) and Neurological Sciences</named-content>
<institution>Rush University Medical Center</institution>
<city>Chicago</city>
<named-content content-type="country-part">Illinois</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0025">
<label>
<sup>25</sup>
</label>
<named-content content-type="organisation-division">Departments of Pathology and Cell Biology and Neurology</named-content>
<institution>Columbia University</institution>
<city>New York</city>
<named-content content-type="country-part">New York</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0026">
<label>
<sup>26</sup>
</label>
<named-content content-type="organisation-division">Departments of Pathology and Neurology</named-content>
<institution>Johns Hopkins University School of Medicine</institution>
<city>Baltimore</city>
<named-content content-type="country-part">Maryland</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0027">
<label>
<sup>27</sup>
</label>
<institution>Duke University Medical Center</institution>
<city>Durham</city>
<named-content content-type="country-part">North Carolina</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0028">
<label>
<sup>28</sup>
</label>
<named-content content-type="organisation-division">Department of Ophthalmology</named-content>
<institution>Boston University Chobanian &amp; Avedisian School of Medicine</institution>
<city>Boston</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff id="alz70629-aff-0029">
<label>
<sup>29</sup>
</label>
<named-content content-type="organisation-division">Department of Epidemiology</named-content>
<institution>Boston University School of Public Health</institution>
<city>Boston</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Lindsay A. Farrer, Department of Medicine (Biomedical Genetics), Boston University Chobanian &amp; Avedisian School of Medicine, 72 East Concord Street E200, Boston, MA 02118, USA.<break/> Email: <email>farrer@bu.edu</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>21</volume><issue seq="100">10</issue><issue-id pub-id-type="pmc-issue-id">497699</issue-id><issue-id pub-id-type="doi">10.1002/alz.v21.10</issue-id><elocation-id>e70629</elocation-id><history><date date-type="rev-recd"><day>15</day><month>7</month><year>2025</year></date><date date-type="received"><day>22</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>23</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Alzheimer's &amp; Dementia</italic> published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ALZ-21-e70629.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ALZ-21-e70629.pdf"/><abstract><title>Abstract</title><sec id="alz70629-sec-0010"><title>INTRODUCTION</title><p>Few African American (AA) donors have been included in <italic toggle="yes">post mortem</italic> Alzheimer's disease (AD) studies compared to European&#8208;ancestry (EA) individuals.</p></sec><sec id="alz70629-sec-0020"><title>METHODS</title><p>We generated transcriptome&#8208;wide bulk pre&#8208;frontal cortex (PFC) gene expression data from 125 AA donors with neuropathologically determined AD and 82 AA controls.</p></sec><sec id="alz70629-sec-0030"><title>RESULTS</title><p>Transcriptome&#8208;wide significant differential expression was observed with 482 genes. The most significant, <italic toggle="yes">ADAMTS2</italic>, showed 1.52 times higher expression in AD cases (<italic toggle="yes">p</italic>&#160;=&#160;2.96x10<sup>&#8722;8</sup>). Comparison of findings with those from a recent gene expression study of EA brain donors revealed substantial concordance, including <italic toggle="yes">ADAMTS2</italic>. Other associations not observed in EA results may be especially relevant to AD risk in the AA population. Examination of AA AD GWAS&#8208;implicated variants identified several expression quantitative trait loci.</p></sec><sec id="alz70629-sec-0040"><title>CONCLUSION</title><p>This first large&#8208;scale AA brain AD gene expression study identified many differentially expressed genes, including <italic toggle="yes">ADAMTS2</italic>, and supports gene expression as a molecular pathway underlying the impact of several AA AD risk variants.</p></sec><sec id="alz70629-sec-0050"><title>Highlights</title><p>
<list list-type="bullet" id="alz70629-list-0001"><list-item><p>We performed the largest African American brain tissue Alzheimer's disease (AD) gene expression study.</p></list-item><list-item><p>Expression differences for 482 genes, notably <italic toggle="yes">ADAMTS2</italic>, were study&#8208;wide significant.</p></list-item><list-item><p>Many significant differentially expressed genes are involved in energy metabolism.</p></list-item><list-item><p>Several previously known AD&#8208;associated variants in African Americans are eQTLs.</p></list-item><list-item><p>These results advance knowledge of the genetic basis of AD in the AA population.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="alz70629-kwd-0001">ADAMTS2</kwd><kwd id="alz70629-kwd-0002">African American</kwd><kwd id="alz70629-kwd-0003">Alzheimer disease</kwd><kwd id="alz70629-kwd-0004">differential gene expression</kwd><kwd id="alz70629-kwd-0005">eQTL</kwd><kwd id="alz70629-kwd-0006">gene network analysis</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>National Institutes of Health</institution><institution-id institution-id-type="doi">10.13039/100000002</institution-id></institution-wrap></funding-source><award-id>R01&#8208;AG048927</award-id><award-id>U01&#8208;AG058654</award-id><award-id>U54&#8208;AG052427</award-id><award-id>U19&#8208;AG068753</award-id><award-id>U01&#8208;AG062602</award-id><award-id>P30&#8208;AG072978</award-id><award-id>U01&#8208;081230</award-id><award-id>P01&#8208;AG003949</award-id><award-id>P30&#8208;AG062677</award-id><award-id>P30&#8208;AG062421</award-id><award-id>P30&#8208;AG 066507</award-id><award-id>P30&#8208;AG066511</award-id><award-id>P30&#8208;AG 072972</award-id><award-id>P30&#8208;AG066468</award-id><award-id>R01&#8208;AG072474</award-id><award-id>RF1&#8208;AG066107</award-id><award-id>U24&#8208;AG056270</award-id><award-id>P01&#8208;AG003949</award-id><award-id>RF1&#8208;AG082339</award-id><award-id>RF1&#8208;NS118584</award-id><award-id>P30&#8208;AG072946</award-id><award-id>P01&#8208;AG003991</award-id><award-id>P30&#8208;AG066444</award-id><award-id>P01&#8208;AG026276</award-id><award-id>P30&#8208;AG066462</award-id><award-id>P30&#8208;AG072958</award-id><award-id>P30&#8208;AG072978</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Florida Department of Health</institution><institution-id institution-id-type="doi">10.13039/100006827</institution-id></institution-wrap></funding-source><award-id>8AZ06</award-id><award-id>20A22</award-id></award-group></funding-group><counts><fig-count count="1"/><table-count count="3"/><page-count count="10"/><word-count count="7598"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:08.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="alz70629-cite-0001"><string-name name-style="western"><surname>Logue</surname><given-names>MW</given-names></string-name>, <string-name name-style="western"><surname>Labadorf</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>O'Neill</surname><given-names>NK</given-names></string-name>, et&#160;al. <article-title>Novel differentially expressed genes and multiple biological pathways for Alzheimer's disease identified in brain tissue from African American donors</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>21</volume>:<elocation-id>e70629</elocation-id>. <pub-id pub-id-type="doi">10.1002/alz.70629</pub-id></mixed-citation>
</p></notes></front><body><sec id="alz70629-sec-0060"><label>1</label><title>BACKGROUND</title><p>The prevalence of Alzheimer's disease (AD) is about two times higher in the Black/African American (AA) population compared to White/European&#8208;ancestry (EA) individuals living in the United States.<xref rid="alz70629-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Some of this difference is due to social determinants of health such as disparities in health care access and quality of education,<xref rid="alz70629-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="alz70629-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> biases in testing,<xref rid="alz70629-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="alz70629-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> and higher rates of AD risk factors such as cardiovascular disease<xref rid="alz70629-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> and diabetes<xref rid="alz70629-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> in those who identify as AA, although the mechanisms underlying these risk factors and contribution to differential rates of AD are not completely known.<xref rid="alz70629-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Group differences have also been noted in the pattern of association with AD risk variants.<xref rid="alz70629-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> For example, apolipoprotein E (<italic toggle="yes">APOE)</italic> &#949;4 is more frequent in the AA population, but the reported AD risk associated with <italic toggle="yes">APOE</italic> &#949;4 heterozygosity and especially homozygosity is smaller in AA compared to EA cohorts.<xref rid="alz70629-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>
</p><p>Much of our understanding of the genetic basis of AD in AA individuals is derived from candidate gene and genome&#8208;wide association studies (GWAS), although with much smaller sample sizes than those included in genetic studies of EA cohorts.<xref rid="alz70629-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> For example, a recent large AD GWAS in EA cohorts including approximately 85,000 AD cases and 296,000 controls as well as information about proxy AD (reported parental dementia) cases identified genome&#8208;wide significant associations with 75+ loci.<xref rid="alz70629-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> By comparison, the largest GWAS of AD and AD&#8208;related dementia (ADRD) in AA cohorts<xref rid="alz70629-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> included 4012 ADRD cases, 18,435 controls, and 52,611 AD proxy cases and controls from the Million Veteran Program<xref rid="alz70629-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> and an additional 2784 AD cases and 5222 controls assembled by the Alzheimer's Disease Genetics Consortium (ADGC).<xref rid="alz70629-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> That study confirmed associations previously established in EA studies (i.e., <italic toggle="yes">APOE</italic>, <italic toggle="yes">ABCA7</italic>, <italic toggle="yes">CD2AP</italic>, and <italic toggle="yes">TREM2</italic>) and identified highly significant novel associations with variants in <italic toggle="yes">ROBO1</italic> and <italic toggle="yes">RP11&#8208;340A13.2</italic>. In addition, associations have been identified with rare pathogenic variants in AA cohorts that are rare or absent in EA populations, suggesting that some AD&#8208;related mechanisms may be more easily discernable in particular ancestry groups.<xref rid="alz70629-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>
</p><p>Although many studies have examined differential gene expression (DGE) in brain tissue from AD cases and controls in EA or mixed ancestry cohorts using bulk tissue, single&#8208;cell sequencing, and individual cell types (e.g.,<xref rid="alz70629-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="alz70629-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="alz70629-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>), the number of AA individuals in these studies was unspecified or too small to identify significant findings within this group alone. In this study, we evaluated RNAseq data derived from <italic toggle="yes">post mortem</italic> prefrontal cortex (PFC) tissue from 207 AA brain donors (125 pathologically confirmed AD cases and 82 controls). The most significant differentially expressed gene, <italic toggle="yes">ADAMTS2</italic>, was also one of the top&#8208;ranked genes in a concurrent study comparing gene expression in brain tissue from EA AD cases and controls,<xref rid="alz70629-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> and the most significant differentially expressed gene between the pathologically confirmed AD cases with and without clinical AD symptoms prior to death.<xref rid="alz70629-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> We also found evidence suggesting modulation of gene expression as a potential mechanism for some AD risk variants implicated in a recent AA AD/dementia GWAS.<xref rid="alz70629-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>
</p></sec><sec id="alz70629-sec-0070"><label>2</label><title>METHODS</title><sec id="alz70629-sec-0080"><label>2.1</label><title>Participants, specimens, and diagnostic procedures</title><p>We obtained frozen brain tissue specimens from 229 donors identified as AA individuals from 13 Alzheimer's Disease Research Center (ADRC) brain banks: (1) Boston University ADRC (BU), (2) Goizueta ADRC at Emory University (GADRC), (3) Johns Hopkins ADRC (JH), (4) University of Kentucky Alzheimer's Disease Center Tissue Bank (UKY), (5) Florida Brain Bank and ADRC at the Mayo Clinic (Jacksonville, FL), (6) Rush Alzheimer's Disease Core Center (RUSH), (7) University of Pittsburgh ADRC (PITT), (8) Carroll A. Campbell, Jr. Neuropathology Laboratory at the Medical University of Southern California (USC), (9) The Charles F. and Joanne Knight ADRC at Washington University in Saint Louis (WASHU), (10) Massachusetts ADRC (MGH), (11) University of California&#8208;Davis ADRC (UCD), (12) Bryan Brain Bank and Biorepository at the Duke&#8208;UNC ADRC (DUKE), and (13) the Northwestern ADC Neuropathology Core (NW). In addition, we received previously generated RNAseq data for 28 donors (18 cases and 10 controls) from the Columbia University ADRC (CU). Scores measuring the severity of neurofibrillary tangle involvement (Braak) and neuritic amyloid deposition (Consortium to Establish a Registry for Alzheimer's Disease [CERAD]) scores obtained from the brain banks were harmonized using the ADRC data dictionary to the standard 0&#8211;6 coding for Braak and 0&#8211;3 coding for CERAD. We used National Institute on Aging&#8212;Alzheimer Association guidelines<xref rid="alz70629-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> and standard NIA Reagan scoring criteria to classify the donors as AD cases (intermediate likelihood or high likelihood of AD) and controls (not AD or low likelihood of AD). This study was approved by the Boston University Institutional Review Board. Informed consent obtained from the brain donors covers the research performed in this study using their <italic toggle="yes">post mortem</italic> tissue.</p></sec><sec id="alz70629-sec-0090"><label>2.2</label><title>RNA sequencing data generation and quality control</title><p>RNA was extracted from the PFC tissue using the Maxwell RSC simplyRNA Tissue Kit from Promega according to the manufacturer's instructions. RNA integrity number (RIN) values were assessed using Agilent 2100 Bioanalyzer RNA Chip (Santa Clara). RNAseq was performed on samples with RIN scores&#160;&gt;&#160;2 by the Yale Center for Genome Analysis in two batches of 90 and 99 samples, respectively. RNAseq data were successfully generated for all but one sample. Initial QC was performed using FastQC (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bioinformatics.babraham.ac.uk/projects/fastqc/" ext-link-type="uri">http://www.bioinformatics.babraham.ac.uk/projects/fastqc/</ext-link>). Adapter trimming and removal of low&#8208;quality reads was performed using Trimmomatic<xref rid="alz70629-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> based on the Trueseq 2 Universal Adapter reference sequence. BAM files containing paired&#8208;end RNAseq read data were obtained for the CU participants. Generation of RNAseq data for the CU donors is described in detail elsewhere.<xref rid="alz70629-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> Reads were extracted using BEDTools<xref rid="alz70629-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> and aligned to the genome jointly with the other cohorts as follows. Paired&#8208;end reads were aligned to the hg38 human reference genome using STAR.<xref rid="alz70629-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> Quantification at the gene and transcript level was performed using RSEM.<xref rid="alz70629-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> Post&#8208;alignment QC was performed using RSeQC,<xref rid="alz70629-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> and aggregation of the QC across samples was performed using MultiQC.<xref rid="alz70629-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> Two samples with mapping rates&#160;&lt;&#160;50% were excluded from subsequent analysis. All of the remaining samples had mapping rates&#160;&gt;&#160;80%. A principal component (PC) analysis of the rLog samples using R did not reveal any outliers (&gt;&#160;6 SD), but examination of the PCs indicated clustering by batch (Batch 1, Batch 2, CU); hence, batch was included as a covariate in the differential expression analyses. Sex concordance was checked by examining the total number of reads mapped to four Y&#8208;chromosome genes: <italic toggle="yes">KDM5D</italic>, <italic toggle="yes">DDX3Y</italic>, <italic toggle="yes">USP9Y</italic>, and <italic toggle="yes">UTY</italic>. We identified one mismatch, which was excluded. Cell&#8208;type estimates for use as covariates were generated using the DeTREM method<xref rid="alz70629-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> with single&#8208;nuclei reference data from a PFC AD study.<xref rid="alz70629-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> The estimated cell proportions in AD cases and controls are shown in Table <xref rid="alz70629-supinfo-0001" ref-type="">S1</xref>.</p><boxed-text position="float" content-type="box" orientation="portrait"><sec id="alz70629-sec-0100"><title>RESEARCH IN CONTEXT</title><p>
<list list-type="order" id="alz70629-list-0002"><list-item><p>
<bold>Systematic review</bold>: The authors reviewed the literature using traditional (e.g., PubMed) as well as preprinted (e.g., medRxiv) sources on Alzheimer's disease (AD), focusing on genetic associations in African American (AA) ancestry and mechanisms of cognitive resilience in individuals with AD pathology.</p></list-item><list-item><p>
<bold>Interpretation</bold>: We showed that 482 genes are differentially expressed in the pre&#8208;frontal cortex of AA brain donors with pathologically confirmed AD compared to those without neurodegenerative disease. These include <italic toggle="yes">ADAMTS2</italic>, a finding that is supported by a recent differential gene expression study of cognitive resilience in EA brain donors comparing pathologically confirmed AD cases with and without clinical symptoms prior to death.</p></list-item><list-item><p>
<bold>Future directions</bold>: These results suggest genes and pathways as potential intervention targets. <italic toggle="yes">ADAMTS2</italic> was previously linked to AD pathology and many of the identified differentially expressed genes are involved in mitochondrial energy production. Additionally, this study highlights the need to include large ancestrally diverse cohorts in AD research.</p></list-item></list>
</p></sec></boxed-text></sec><sec id="alz70629-sec-0110"><label>2.3</label><title>Genotype data</title><p>DNA was extracted from brain tissue using Maxwell RSC Blood DNA capture kits l. Samples were sent to The Children's Hospital of Philadelphia Center for Applied Genomics for genotyping using the Illumina Global Diversity Array (&#8764;1.8 million variants). Post&#8208;genotyping QC was performed using plink v1.90b3.36 and v2.00a2.3.<xref rid="alz70629-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> Two samples were excluded for high missing rates (&gt;&#160;5%). X&#8208;Chromosome heterozygosity was examined to identify potential sex mismatches. Two samples were removed due to discordant sex. Imputation of variants not on the array was performed using the Michigan Imputation Server (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://imputationserver.sph.umich.edu/" ext-link-type="uri">https://imputationserver.sph.umich.edu/</ext-link>) based on 1000 Genomes phase 3v5 reference data.<xref rid="alz70629-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> Genotype calls were made with an 80% certainty threshold. After cleaning, genotype data, valid RNAseq data, and non&#8208;missing covariates were available for 177 donors. PC analysis was performed using Plink to identify potential ancestry outliers in the autopsy cohort based on comparison with multi&#8208;ancestry GWAS data from the ADGC. This analysis included 100K randomly selected non&#8208;ambiguously genotyped single nucleotide polymorphisms (SNPs) with minor allele frequency (MAF)&#160;&gt;&#160;1% and missing rate&#160;&lt;&#160;1%.</p></sec><sec id="alz70629-sec-0120"><label>2.4</label><title>Differential gene expression analysis</title><p>DGE analysis was performed using DEseq2<xref rid="alz70629-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> for genes with&#160;&#8805;&#160;1 read in half of the sequenced cohort as previously suggested.<xref rid="alz70629-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> A Benjamini Hochberg false discovery rate (FDR) corrected <italic toggle="yes">p</italic>&#8208;value (<italic toggle="yes">p</italic>
<sub>adj</sub>, often called a q&#8208;value)<xref rid="alz70629-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> was computed to adjust for 33,611 genes examined. Regression models included covariates for age at death, sex, batch, RIN, and the estimated proportions of inhibitory neurons, excitatory neurons, microglia, oligodendrocytes, astrocytes, and endothelial cells. <italic toggle="yes">Post mortem</italic> interval (PMI) was not included as a covariate because this information was missing for 20 samples, however, we did perform sensitivity analyses to confirm that excluding PMI did not substantially bias the results. Volcano plots were generated using the EnhancedVolcano R package (<underline underline-style="single">https://github.com/kevinblighe/EnhancedVolcano</underline>). Expression differences are reported as log<sub>2</sub> fold change (L2FC). We also examined differential expression of <italic toggle="yes">APOE</italic> and other genes implicated in EA AD GWAS,<xref rid="alz70629-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> AA dementia GWAS,<xref rid="alz70629-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> and in other AA AD genetic studies.<xref rid="alz70629-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> DGE results from the AA cohort were then compared to those obtained from frontal cortex tissue of 526 autopsy&#8208;confirmed AD cases and 456 controls from four EA cohorts<xref rid="alz70629-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> using a &#967;<sup>2</sup> test.</p></sec><sec id="alz70629-sec-0130"><label>2.5</label><title>Over&#8208;representation and gene network analyses</title><p>Over&#8208;representation analysis was conducted to identify gene ontology (GO) terms (biological processes and pathways) that are enriched for the top&#8208;ranked DEGs using Goseq,<xref rid="alz70629-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> a method that adjusts for any differential likelihood of significance due to gene size. To increase interpretability and limit multiple testing, we only tested for overrepresentation within GO Biological Process and GO Molecular Function categories. Gene network analysis was performed using Weighted Gene Co&#8208;Expression Network Analysis (WGCNA).<xref rid="alz70629-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> Because WGCNA does not allow for covariates, prior to performing gene network analyses, RNA&#8208;seq data were corrected using COMBAT&#8208;SEQ<xref rid="alz70629-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> to adjust for batch effects but preserve age, sex, and AD effects. The batch&#8208;corrected counts were normalized and log transformed using the DEseq2<xref rid="alz70629-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> package, and networks of correlated genes were identified by analysis of the resulting rLog values using WGCNA. This analysis was performed using the blockwiseModules function in the WGCNA R package to generate signed networks with power&#160;=&#160;15 and options cut height&#160;=&#160;0.75, min module of 30, max block of 4000, reassign threshold&#160;=&#160;0, mergeCutHieght&#160;=&#160;0.25, and the rest of the options left at the default. Only highly expressed genes (&gt;&#160;10 reads in half of the cohort) were included in this analysis to reduce computational complexity.</p></sec><sec id="alz70629-sec-0140"><label>2.6</label><title>eQTL analysis of AD&#8208;associated variants</title><p>We assessed by linear regression potential regulatory effects of variants previously associated with AD in AA cohorts<xref rid="alz70629-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> with MAF&#160;<underline underline-style="single">&gt;</underline>&#160;5% and associated on expression of genes within 200&#160;kb of the variant according to the ensemble v 75 (GRCH37) database accessed via the R biomaRt library. The model included covariates for age at death, sex, batch, RIN, and the estimated cell&#8208;type proportions. FDR&#8208;corrected <italic toggle="yes">p</italic> values were calculated for each variant adjusting for the number of genes examined. We computed the association between gene expression and all of the MAF&#160;&gt;&#160;5% SNPs within 200&#160;kb of the top&#8208;ranked findings in order to compare the associations findings from AA ADRD GWAS<xref rid="alz70629-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> with the strength of the eQTL effect on genes under the association peaks. These comparisons were visualized using R, LocusZoom (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://my.locuszoom.org/" ext-link-type="uri">https://my.locuszoom.org/</ext-link>), and the UCSC Genome Browser (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://genome.ucsc.edu/" ext-link-type="uri">http://genome.ucsc.edu/</ext-link>).</p></sec></sec><sec id="alz70629-sec-0150"><label>3</label><title>RESULTS</title><sec id="alz70629-sec-0160"><label>3.1</label><title>Demographics</title><p>After excluding 34 samples that were obtained from non&#8208;PFC regions or had RNA quality or sequencing issues, and 1 sex mismatched sample, 212 participants (including 82 controls, 125 AD cases, and 5 subjects lacking sufficient neuropathological data to determine AD status) remained for subsequent analyses (Table&#160;<xref rid="alz70629-tbl-0001" ref-type="table">1</xref>). Participants with undetermined neuropathological AD status were excluded from the DGE analysis but included in eQTL analysis. The sex ratio is approximately 1 among the controls, but a higher proportion of cases are women. The mean age at death was 5.3 years greater in AD cases than controls (<italic toggle="yes">p</italic>&#160;=&#160;0.0040). PC analysis of genotyped subjects in the AA autopsy cohort in conjunction with ADGC GWAS data indicated that the population structure of the AA cohort is concordant with the ADGC AA cluster (Figure <xref rid="alz70629-supinfo-0001" ref-type="">S1</xref>).</p><table-wrap position="float" id="alz70629-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Subject characteristics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th colspan="4" style="border-bottom:solid 1px #000000" align="left" rowspan="1">AD cases</th><th colspan="4" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Controls</th><th colspan="4" style="border-bottom:solid 1px #000000" align="left" rowspan="1">AD status unknown</th><th colspan="4" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Total</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Available data</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>
</th><th align="left" rowspan="1" colspan="1">% Women</th><th align="left" rowspan="1" colspan="1">% &#949;4 carriers</th><th align="left" rowspan="1" colspan="1">Mean age (SD)</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>
</th><th align="left" rowspan="1" colspan="1">% Women</th><th align="left" rowspan="1" colspan="1">% &#949;4 carriers</th><th align="left" rowspan="1" colspan="1">Mean age (SD)</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>
</th><th align="left" rowspan="1" colspan="1">% Women</th><th align="left" rowspan="1" colspan="1">% &#949;4 carriers</th><th align="left" rowspan="1" colspan="1">Mean age (SD)</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>
</th><th align="left" rowspan="1" colspan="1">% Women</th><th align="left" rowspan="1" colspan="1">% &#949;4 carriers</th><th align="left" rowspan="1" colspan="1">Mean age (SD)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">RNA&#8208;seq only</td><td align="left" rowspan="1" colspan="1">125</td><td align="left" rowspan="1" colspan="1">61.6</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">83.0 (9.9)</td><td align="left" rowspan="1" colspan="1">82</td><td align="left" rowspan="1" colspan="1">52.4</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">77.7 (14.4)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">&#8211;</td><td align="left" rowspan="1" colspan="1">&#8211;</td><td align="left" rowspan="1" colspan="1">&#8211;</td><td align="left" rowspan="1" colspan="1">207</td><td align="left" rowspan="1" colspan="1">58.0</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">80.9 (12.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">RNA&#8208;seq + SNP array</td><td align="left" rowspan="1" colspan="1">104</td><td align="left" rowspan="1" colspan="1">61.5</td><td align="left" rowspan="1" colspan="1">71.2</td><td align="left" rowspan="1" colspan="1">82.4 (10.2)</td><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">51.5</td><td align="left" rowspan="1" colspan="1">33.8</td><td align="left" rowspan="1" colspan="1">76.6 (15.1)</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">20.0</td><td align="left" rowspan="1" colspan="1">60.0</td><td align="left" rowspan="1" colspan="1">61.6 (26.3)</td><td align="left" rowspan="1" colspan="1">177</td><td align="left" rowspan="1" colspan="1">56.5</td><td align="left" rowspan="1" colspan="1">56.5</td><td align="left" rowspan="1" colspan="1">79.5 (13.5)</td></tr></tbody></table><table-wrap-foot><fn id="alz70629-tbl1-note-0001"><p>Abbreviations: AD, Alzheimer's disease; APOE, apolipoprotein E; NA, <italic toggle="yes">APOE</italic> genotype information not available for subjects missing SNP array data; SNP, single nucleotide polymorphism.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="alz70629-sec-0170"><label>3.2</label><title>Genes differentially expressed between AD cases and controls</title><p>Transcriptome&#8208;wide significant (TWS) differences were observed for 482 of the 33,611 sufficiently expressed genes, among which 174 had higher and 308 had lower expression in AD cases than controls (Figure&#160;<xref rid="alz70629-fig-0001" ref-type="fig">1</xref>, Table <xref rid="alz70629-supinfo-0001" ref-type="">S2</xref>). The most significant DEG, <italic toggle="yes">ADAMTS2</italic>, was expressed 1.52 times higher in AD cases than controls (L2FC&#160;=&#160;0.60, <italic toggle="yes">p</italic>&#160;=&#160;2.96x10<sup>&#8722;8</sup>, Table&#160;<xref rid="alz70629-tbl-0002" ref-type="table">2</xref>, Figure <xref rid="alz70629-supinfo-0001" ref-type="">S2</xref>). Sensitivity analyses showed that excluding PMI as a covariate and excluding younger (age&#160;&lt;&#160;60 at time of death) donors did not substantively impact the results (Figure <xref rid="alz70629-supinfo-0001" ref-type="">S3, Table S3</xref>). By comparison, none of the AD loci established by the largest GWAS in EA and AA cohorts<xref rid="alz70629-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="alz70629-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> were differentially expressed at a level that would survive a multiple test correction (Table <xref rid="alz70629-supinfo-0001" ref-type="">S4</xref>). The most significant differentially expressed gene among the previously known AD loci, <italic toggle="yes">IG1FR</italic>, was implicated in an AA AD GWAS<xref rid="alz70629-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> due to a rare variant association (rs570487962), had higher expression in AD cases (L2FC&#160;=&#160;0.11, <italic toggle="yes">p</italic>&#160;=&#160;0.0013).<xref rid="alz70629-fig-0001" ref-type="fig">&#8195;</xref>
</p><fig position="float" fig-type="FIGURE" id="alz70629-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Volcano plot of a transcriptome&#8208;wide differential gene expression analysis of 125 neuropathologically determined African American AD cases and 82 neuropathologically determined African American controls. Color&#8208;coding denotes genes that passed multiple testing corrected significance thresholds (blue dots), L2FC&#160;&gt;&#160;|0.5| (green dots), or both (red dots). AD, Alzheimer's disease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ALZ-21-e70629-g001.jpg"/></fig><table-wrap position="float" id="alz70629-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Twenty genes most significantly differentially expressed between African American AD cases and controls.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Gene</th><th align="left" rowspan="1" colspan="1">L2FC</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
<sub>adj</sub>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">ADAMTS2</italic>
</td><td align="char" rowspan="1" colspan="1">0.60</td><td align="left" rowspan="1" colspan="1">2.96E&#8208;08</td><td align="left" rowspan="1" colspan="1">0.0010</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="AP002360.1">AP002360.1</ext-link></italic>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.35</td><td align="left" rowspan="1" colspan="1">8.71E&#8208;08</td><td align="left" rowspan="1" colspan="1">0.0012</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">EFR3B</italic>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.25</td><td align="left" rowspan="1" colspan="1">1.11E&#8208;07</td><td align="left" rowspan="1" colspan="1">0.0012</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">IRS4</italic>
</td><td align="char" rowspan="1" colspan="1">0.47</td><td align="left" rowspan="1" colspan="1">2.18E&#8208;07</td><td align="left" rowspan="1" colspan="1">0.0014</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">CA12</italic>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.78</td><td align="left" rowspan="1" colspan="1">2.33E&#8208;07</td><td align="left" rowspan="1" colspan="1">0.0014</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">ITPKB</italic>
</td><td align="char" rowspan="1" colspan="1">0.31</td><td align="left" rowspan="1" colspan="1">2.70E&#8208;07</td><td align="left" rowspan="1" colspan="1">0.0014</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">PDE10A</italic>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.47</td><td align="left" rowspan="1" colspan="1">2.89E&#8208;07</td><td align="left" rowspan="1" colspan="1">0.0014</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">TDRKH</italic>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.17</td><td align="left" rowspan="1" colspan="1">9.62E&#8208;07</td><td align="left" rowspan="1" colspan="1">0.0040</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">LINC01182</italic>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.64</td><td align="left" rowspan="1" colspan="1">1.13E&#8208;06</td><td align="left" rowspan="1" colspan="1">0.0040</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">TFCP2</italic>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.17</td><td align="left" rowspan="1" colspan="1">1.31E&#8208;06</td><td align="left" rowspan="1" colspan="1">0.0040</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="AL158071.3">AL158071.3</ext-link></italic>
</td><td align="char" rowspan="1" colspan="1">0.52</td><td align="left" rowspan="1" colspan="1">1.34E&#8208;06</td><td align="left" rowspan="1" colspan="1">0.0040</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">EHHADH</italic>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.30</td><td align="left" rowspan="1" colspan="1">1.42E&#8208;06</td><td align="left" rowspan="1" colspan="1">0.0040</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">PIEZO2</italic>
</td><td align="char" rowspan="1" colspan="1">0.41</td><td align="left" rowspan="1" colspan="1">1.84E&#8208;06</td><td align="left" rowspan="1" colspan="1">0.0047</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">P2RY1</italic>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.43</td><td align="left" rowspan="1" colspan="1">1.97E&#8208;06</td><td align="left" rowspan="1" colspan="1">0.0047</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="AC018647.2">AC018647.2</ext-link></italic>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.25</td><td align="left" rowspan="1" colspan="1">2.64E&#8208;06</td><td align="left" rowspan="1" colspan="1">0.0059</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">NOX4</italic>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.42</td><td align="left" rowspan="1" colspan="1">3.02E&#8208;06</td><td align="left" rowspan="1" colspan="1">0.0062</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">ECHS1</italic>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.18</td><td align="left" rowspan="1" colspan="1">3.21E&#8208;06</td><td align="left" rowspan="1" colspan="1">0.0062</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">ZCCHC14</italic>
</td><td align="char" rowspan="1" colspan="1">0.14</td><td align="left" rowspan="1" colspan="1">3.38E&#8208;06</td><td align="left" rowspan="1" colspan="1">0.0062</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">LINC01094</italic>
</td><td align="char" rowspan="1" colspan="1">0.43</td><td align="left" rowspan="1" colspan="1">3.48E&#8208;06</td><td align="left" rowspan="1" colspan="1">0.0062</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="AP001180.1">AP001180.1</ext-link></italic>
</td><td align="char" rowspan="1" colspan="1">1.35</td><td align="left" rowspan="1" colspan="1">3.89E&#8208;06</td><td align="left" rowspan="1" colspan="1">0.0063</td></tr></tbody></table><table-wrap-foot><fn id="alz70629-tbl2-note-0001"><p>Abbreviations: AD, Alzheimer's disease; L2FC, log<sub>2</sub> fold change.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>Four of the most significant DEGs in our AA autopsy cohort (<italic toggle="yes">ADAMTS2</italic>, <italic toggle="yes">ITPKB</italic>, <italic toggle="yes">TDRKH</italic>, and <italic toggle="yes">LINC0194</italic>) were also differentially expressed between AD cases and controls at a TWS level in a large EA sample.<xref rid="alz70629-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Additionally, the most significant DEG in the EA study, <italic toggle="yes">EMP3</italic>, was also significant in the AA cohort with a similar effect direction (L2FC&#160;=&#160;0.33, <italic toggle="yes">p</italic>&#160;=&#160;0.00037). The overlap in TWS associations was more than would be expected by chance (<italic toggle="yes">p</italic>&#160;&lt;&#160;2.2x10<sup>&#8722;16</sup>), with 6% of TWS DEGs in the EA sample also TWS in the AA cohort (65/1092) versus 1.4% TWS significant in the overall AA cohort. Importantly, the direction of effect is the same for the 65 DEGs that are TWS in both studies.</p></sec><sec id="alz70629-sec-0180"><label>3.3</label><title>Enrichment of DEGs involved in mitochondrial function, phosphorylation, DNA binding, and transcription</title><p>Enrichment analysis of the differentially expressed genes yielded 71 significant Enriched GO terms, especially those involving oxidative reduction processes and mitochondrial energy generation. All of the top 10 GO terms include 11 nuclear&#8208;encoded NDUF (NADH:ubiquinone oxidoreductase core subunit) genes (<italic toggle="yes">NDUFA1</italic>, <italic toggle="yes">NDUFA2</italic>, <italic toggle="yes">NDUFA3</italic>, <italic toggle="yes">NDUFA6</italic>, <italic toggle="yes">NDUFA7</italic>, <italic toggle="yes">NDUFB1</italic>, <italic toggle="yes">NDUFB2</italic>, <italic toggle="yes">NDUFB3</italic>, <italic toggle="yes">NDUFB8</italic>, <italic toggle="yes">NDUFS3</italic>, and <italic toggle="yes">NDUFS5</italic>) and cytochrome c oxidase genes (<italic toggle="yes">COX15</italic>, <italic toggle="yes">COX4I1</italic>, <italic toggle="yes">COX6B1</italic>) which were all expressed less in AD cases compared controls (Table <xref rid="alz70629-supinfo-0001" ref-type="">S5</xref>). Because <italic toggle="yes">NADH&#8208;</italic> and <italic toggle="yes">COX</italic>&#8208;gene encoded molecules form parts of the mitochondrial respiratory chain, we also examined but did not find differential expression of 16 mitochondrial DNA genes (<italic toggle="yes">p</italic>&#160;&gt;&#160;0.07). Gene network analysis identified 27 networks ranging in size from 44 to 2944 genes. Eigengenes (PCs representing gene activity) for three networks (light yellow, magenta, salmon) remained significant after correction for multiple testing (Table <xref rid="alz70629-supinfo-0001" ref-type="">S5</xref>). The light yellow network included 111 genes and was enriched for those involved in regulation of developmental processes or phosphorylation. Expression for most (7/9) of the AD&#8208;associated (<italic toggle="yes">p</italic>&#160;&lt;&#160;0.05) genes in this network was higher in AD cases than controls. The magenta network was enriched for genes involved in DNA binding, transcription regulation, and cilium organization. Salmon was the most significantly associated network with AD (<italic toggle="yes">p</italic>&#160;=&#160;5.19x10<sup>&#8722;6</sup>, <italic toggle="yes">p</italic>
<sub>adj&#160;</sub>=&#160;0.00014) and was enriched for genes related to protein complexes, oxidative phosphorylation, and metabolic processes.<xref rid="alz70629-tbl-0002" ref-type="table">&#8195;</xref>
</p></sec><sec id="alz70629-sec-0190"><label>3.4</label><title>eQTLs among AD&#8208;associated variants identified by GWAS in AA cohorts</title><p>SNP association and gene expression data were available for 177 AA brain donors. Ten of 12 SNPs with a MAF&#160;&gt;&#160;0.05 which were significantly associated with AD/ADRD in the large AA GWAS<xref rid="alz70629-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> were located within 200&#160;kb of at least one gene (range 1&#8211;15, mean&#160;=&#160;5.5). After correction for multiple testing, significant eQTL associations were observed with five variants (Table&#160;<xref rid="alz70629-tbl-0003" ref-type="table">3</xref>). The minor alleles of two highly correlated SNPs (rs2234253 and rs73427293) in the <italic toggle="yes">TREM2</italic>/<italic toggle="yes">TREML2</italic> region (D&#8217;&#160;=&#160;1, <italic toggle="yes">R</italic>
<sup>2&#160;</sup>=&#160;0.99 in the 1000 Genomes AFR reference data) were associated with higher expression of <italic toggle="yes">ADCY10P1</italic> (<italic toggle="yes">p</italic>&#160;=&#160;0.0048 and 0.0080, respectively) and <italic toggle="yes">TREML2</italic> (<italic toggle="yes">p</italic>&#160;=&#160;0.0038 and 0.0044, respectively). Of note, rs2234253 is a missense mutation in <italic toggle="yes">TREM2</italic> (T96M) that is relatively common (MAF&#160;=&#160;0.046) in the AA population. Although the frequency of this variant is rare in EA individuals (MAF&#160;=&#160;0.00083), it has been associated with frontotemporal dementia in a German cohort.<xref rid="alz70629-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> The minor allele of <italic toggle="yes">CD2AP</italic> SNP rs7738720 was associated with reduced <italic toggle="yes">CD2AP</italic> expression (<italic toggle="yes">p</italic>&#160;=&#160;0.026). The minor allele of <italic toggle="yes">MSRA</italic> intronic SNP rs4607615 was associated with expression of <italic toggle="yes">MSRA</italic> (<italic toggle="yes">p</italic>&#160;=&#160;0.026), <italic toggle="yes">RP1L1</italic> (<italic toggle="yes">p</italic>&#160;=&#160;0.041), and most strongly with <italic toggle="yes">PRSS51</italic> (<italic toggle="yes">p</italic>&#160;=&#160;6.11x10<sup>&#8722;7</sup>) even though rs4607615 is 61&#160;kb downstream of that gene. The minor allele <italic toggle="yes">APOE</italic> SNP rs429358, which encodes the &#603;4 isoform, was associated with reduced expression of <italic toggle="yes">APOE</italic> (<italic toggle="yes">p</italic>&#160;=&#160;5.61x10<sup>&#8722;4</sup>) and adjacent genes <italic toggle="yes">APOC2</italic> and <italic toggle="yes">CLPTM1</italic> (<italic toggle="yes">p</italic>&#160;=&#160;0.017 for both). More detailed comparisons of the AA ADRD GWAS findings in each region excluding <italic toggle="yes">APOE</italic>
<xref rid="alz70629-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> with the strength of effect of each SNP on expression of genes (i.e., eQTLs) underlying the association peaks are shown in Figures <xref rid="alz70629-supinfo-0001" ref-type="">S4&#8211;S6</xref>.</p><table-wrap position="float" id="alz70629-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Association of AA GWAS&#8208;implicated variants and expression of nearby (&lt;&#160;200&#160;kb) genes.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">SNP</th><th align="left" rowspan="1" colspan="1">Gene</th><th align="left" rowspan="1" colspan="1">&#946;<xref rid="alz70629-tbl3-note-0001" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
<sub>cor</sub>
</th></tr></thead><tbody><tr><td rowspan="2" align="left" colspan="1">rs2234253</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">ADCY10P1</italic>
</td><td align="char" rowspan="1" colspan="1">0.11</td><td align="left" rowspan="1" colspan="1">0.0048</td><td align="left" rowspan="1" colspan="1">0.026</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">TREML2</italic>
</td><td align="char" rowspan="1" colspan="1">0.18</td><td align="left" rowspan="1" colspan="1">0.0038</td><td align="left" rowspan="1" colspan="1">0.026</td></tr><tr><td rowspan="2" align="left" colspan="1">rs73427293</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">ADCY10P1</italic>
</td><td align="char" rowspan="1" colspan="1">0.11</td><td align="left" rowspan="1" colspan="1">0.0080</td><td align="left" rowspan="1" colspan="1">0.044</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">TREML2</italic>
</td><td align="char" rowspan="1" colspan="1">0.17</td><td align="left" rowspan="1" colspan="1">0.0044</td><td align="left" rowspan="1" colspan="1">0.044</td></tr><tr><td align="left" rowspan="1" colspan="1">rs7738720</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">CD2AP</italic>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.09</td><td align="left" rowspan="1" colspan="1">0.013</td><td align="left" rowspan="1" colspan="1">0.026</td></tr><tr><td rowspan="3" align="left" colspan="1">rs4607615</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">MSRA</italic>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.04</td><td align="left" rowspan="1" colspan="1">0.026</td><td align="left" rowspan="1" colspan="1">0.041</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">RP1L1</italic>
</td><td align="char" rowspan="1" colspan="1">0.10</td><td align="left" rowspan="1" colspan="1">0.031</td><td align="left" rowspan="1" colspan="1">0.041</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">PRSS51</italic>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.20</td><td align="left" rowspan="1" colspan="1">1.53E&#8208;07</td><td align="left" rowspan="1" colspan="1">6.11E&#8208;07</td></tr><tr><td rowspan="3" align="left" colspan="1">rs429358</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.13</td><td align="left" rowspan="1" colspan="1">5.61E&#8208;04</td><td align="left" rowspan="1" colspan="1">8.42E&#8208;03</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOC2</italic>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.15</td><td align="left" rowspan="1" colspan="1">0.0033</td><td align="left" rowspan="1" colspan="1">0.017</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">CLPTM1</italic>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.06</td><td align="left" rowspan="1" colspan="1">0.0023</td><td align="left" rowspan="1" colspan="1">0.017</td></tr></tbody></table><table-wrap-foot><fn id="alz70629-tbl3-note-0001"><label>
<sup>a</sup>
</label><p>Effect of each minor allele on gene expression.</p></fn><fn id="alz70629-tbl3-note-0002"><p>Abbreviations: AA, African American; GWAS, genome&#8208;wide association studies; SNP, single nucleotide polymorphism.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>We examined the Genotype&#8208;Tissue Expression (GTEx) Portal (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.gtexportal.org/" ext-link-type="uri">https://www.gtexportal.org/</ext-link> accessed April 02, 2025) for evidence that the associations observed in our AA sample are present in an independent largely EA cohort. We confirmed most of these variants as eSNPs in the cortex or frontal cortex at a nominal significance level (<italic toggle="yes">p</italic>&#160;&lt;&#160;0.05). Although results for <italic toggle="yes">TREML2</italic> were not available, the two <italic toggle="yes">TREML2</italic> variants in high LD, rs2234253 and rs73427293, are eSNPs for <italic toggle="yes">ADCY10P1</italic> (<italic toggle="yes">p</italic>&#160;=&#160;6.38x10<sup>&#8722;4</sup> and 5.99x10<sup>&#8722;3</sup>, respectively), even though these variants are uncommon in EA populations. Rs4607615 was associated with expression of <italic toggle="yes">MSRA</italic> (<italic toggle="yes">p</italic>&#160;=&#160;0.04) and <italic toggle="yes">PRSS51</italic> (1.54x10<sup>&#8722;3</sup>) in the frontal cortex. Notably, the <italic toggle="yes">PRSS51</italic> association was more significant in our smaller AA autopsy cohort (<italic toggle="yes">p</italic>&#160;=&#160;6.11x10<sup>&#8722;7</sup>), perhaps indicating a larger effect in AAs or AD cases. The <italic toggle="yes">CD2AP</italic> SNP rs7738720 was nominally associated with reduced <italic toggle="yes">CD2AP</italic> expression (<italic toggle="yes">p</italic>&#160;=&#160;0.0030) in the nucleus accumbens, but not the frontal cortex. However, this may be due to the small number of minor alleles (6) observed in the frontal cortex data.</p></sec></sec><sec id="alz70629-sec-0200"><label>4</label><title>DISCUSSION</title><p>We performed the largest to date transcriptome&#8208;wide study of AD using brain tissue from AA donors. This is an important step in deciphering the genetic architecture and underlying mechanisms of AD risk in this population, in light of evidence that nearly all of the established AD risk variants are population&#8208;specific or have divergent frequencies across populations.<xref rid="alz70629-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="alz70629-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="alz70629-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> Additionally, because exposure to some AD risk factors differ between White and Black Americans including those that disproportionally affect the Black population in the United States (e.g., vascular disease, diabetes, low education, and others linked to diet, income and occupation),<xref rid="alz70629-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="alz70629-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> the degree to which some biological pathways lead to AD likely varies across populations. In spite of such expected differences, we found high correspondence of differential expression of many genes in the pre&#8208;frontal cortex from AA and EA brain donors.</p><p>
<italic toggle="yes">ADAMTS2</italic> was the most significant DEG in our study and among the top&#8208;ranked DEGs assessed in PFC tissue in a very recent study of 982 EA brain donors (<italic toggle="yes">p</italic>&#160;=&#160;5.1x10<sup>&#8722;13</sup>)<xref rid="alz70629-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> with the same effect direction in both populations. In addition, the study by Li et&#160;al. <xref rid="alz70629-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> found that <italic toggle="yes">ADAMTS2</italic> was the most significant DEG between AD cases who had an <italic toggle="yes">ante mortem</italic> clinical AD diagnosis versus AD cases who were cognitively healthy prior to death (i.e., cognitively resilient). Taken together, these findings suggest that lower <italic toggle="yes">ADAMTS2</italic> expression reduces the risk of cognitive impairment among those who develop hallmark AD pathology.</p><p>
<italic toggle="yes">ADAMTS2</italic> is a member of the disintegrin and metalloproteinase with thrombospondin motifs (<italic toggle="yes">ADAMTS</italic>) family of genes that perform a diverse set of functions.<xref rid="alz70629-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref> The most well studied role of ADAMTS2 relates to its proteolytically processed form resulting in a procollagen N&#8208;proteinase. In humans, <italic toggle="yes">ADAMTS2</italic> mutations cause a recessive form of Ehlers&#8208;Danlos syndrome.<xref rid="alz70629-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> Other studies have implicated ADAMTS2 in neurological processes related to AD risk. Yamakage et&#160;al. demonstrated in <italic toggle="yes">ADAMTS2</italic> knockout mice that ADAMTS2 induces cleavage of Reelin in the PFC and hippocampus, impairing its function.<xref rid="alz70629-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> Mouse studies suggest Reelin is protective and found that its level is negatively associated with tau phosphorylation and amyloid plaque formation.<xref rid="alz70629-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>, <xref rid="alz70629-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> A recent study of resilience in a 67&#8208;year&#8208;old cognitively intact individual carrying a highly penetrant <italic toggle="yes">PSEN1</italic> mutation that causes autosomal dominant early&#8208;onset AD identified a putatively protective gain of function variant (H3447R) in <italic toggle="yes">RELN</italic> (the gene encoding reelin), which contributed to reduced Tau phosphorylation in mouse AD models.<xref rid="alz70629-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> Results of human studies of Reelin levels and <italic toggle="yes">RELN</italic> expression in brain tissue are less consistent, showing increased,<xref rid="alz70629-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>, <xref rid="alz70629-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> reduced,<xref rid="alz70629-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>, <xref rid="alz70629-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> or no difference<xref rid="alz70629-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref> in reelin levels and RELN expression in AD versus control tissue. In this cohort, we did not observe an association of <italic toggle="yes">RELN</italic> expression with AD in PFC tissue (<italic toggle="yes">p</italic>&#160;=&#160;0.35). Nevertheless, our observation of higher expression of <italic toggle="yes">ADAMTS2</italic> in PFC from AD cases and its role in the Reelin pathway supports the hypothesis that <italic toggle="yes">ADAMTS2</italic> inhibition might be an AD therapeutic strategy.<xref rid="alz70629-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>
</p><p>Four of the other six most significant (<italic toggle="yes">p</italic>&#160;&lt;&#160;3.0x10<sup>&#8722;7</sup>) DEGs (<italic toggle="yes">ITPKB, IRS4, CA12</italic>, and <italic toggle="yes">PDE10A</italic>) were previously implicated in AD&#8208;related processes noting that the differential expression of <italic toggle="yes">IRS4</italic> and <italic toggle="yes">CA12</italic> appears to be either specific to brain tissue from AA donors or much less prominent in EA brain tissue.<xref rid="alz70629-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>
<italic toggle="yes">ITPKB</italic> expression measured in cDNA microarray experiments was shown to be higher in an EA sample of 61 AD cases compared to 53 controls,<xref rid="alz70629-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref> which is consistent with our result in AA brain specimens. Mouse studies have linked ITPKB activation and higher <italic toggle="yes">ITPKB</italic> expression to AD pathology.<xref rid="alz70629-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>, <xref rid="alz70629-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref>
<italic toggle="yes">IRS4</italic>, which encodes insulin receptor substrate 4, is known to function in several processes relevant to AD including interacting with endosomes to control A&#946; levels in neurons.<xref rid="alz70629-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> In addition, insulin signaling and resistance, and diabetes more generally, have been strongly implicated in AD risk (e.g.,<xref rid="alz70629-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref>, <xref rid="alz70629-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref>). <italic toggle="yes">Irs4</italic> expression was reduced in B6.<italic toggle="yes">APB<sup>Tg</sup>
</italic> mice in the early stages of AD pathology,<xref rid="alz70629-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> which does not match our observation of higher <italic toggle="yes">IRS4</italic> expression in AD cases, but this may be due to the later stage of disease in the <italic toggle="yes">post mortem</italic> human brain. IRS&#8208;4 interacts with IRS&#8208;2,<xref rid="alz70629-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref> which is also among the TWS DEGs in our AA study, and disruption of IRS&#8208;2 impacts tau phosphorylation, although the direction of effect is not consistent across studies.<xref rid="alz70629-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref>, <xref rid="alz70629-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref>
</p><p>
<italic toggle="yes">CA12</italic> is part of the carbonic anhydrase (CA) family which has been linked to learning and memory.<xref rid="alz70629-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref>
<italic toggle="yes">CA12</italic> expression in the caudate nucleus was identified as regulated by rs117618017, a SNP in the neighboring gene <italic toggle="yes">APH1B</italic>,<xref rid="alz70629-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref> which was robustly associated with AD risk in GWAS (e.g.,<xref rid="alz70629-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>). Repurposing existing FDA&#8208;approved CA inhibitors has been suggested as a potential dementia treatment.<xref rid="alz70629-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref> PDE10A is member of the phosphodiesterase (PDE) family of enzymes involved in the breakdown of cAMP and/or cGMP.<xref rid="alz70629-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref> PDE inhibitors have been shown to increase memory task performance in animals (e.g.,<xref rid="alz70629-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref>, <xref rid="alz70629-bib-0061" ref-type="bibr">
<sup>61</sup>
</xref>) and have been investigated as potential treatments for autism spectrum disorder,<xref rid="alz70629-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref> schizophrenia,<xref rid="alz70629-bib-0063" ref-type="bibr">
<sup>63</sup>
</xref> and Parkinson disease.<xref rid="alz70629-bib-0064" ref-type="bibr">
<sup>64</sup>
</xref>, <xref rid="alz70629-bib-0065" ref-type="bibr">
<sup>65</sup>
</xref> A clinical trial of a PDE1 inhibitor in AD cases did not find a benefit,<xref rid="alz70629-bib-0066" ref-type="bibr">
<sup>66</sup>
</xref> but other PDE inhibitors may have efficacy.<xref rid="alz70629-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref> Here and in a recent DGE study conducted in tissue from EA brain donors,<xref rid="alz70629-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>
<italic toggle="yes">PDE10A</italic> expression is lower in AD brain tissue, which is perhaps counter to the notion that PDE10A inhibition is an effective treatment strategy. However, prior expression studies of multiple PDE genes yielded conflicting results.<xref rid="alz70629-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref>
</p><p>Several other TWS DEGs have strong connections to AD. <italic toggle="yes">PSENEN</italic> encodes a subunit of the gamma&#8208;secretase complex including presenilin.<xref rid="alz70629-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref>
<italic toggle="yes">ROBO3</italic> is a homolog of <italic toggle="yes">ROBO1</italic> which emerged as a genome&#8208;wide significant locus in an AA AD GWAS.<xref rid="alz70629-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
<italic toggle="yes">HDAC4</italic> is one of several histone deacetylases previously implicated in AD and identified as potential targets for AD treatment.<xref rid="alz70629-bib-0068" ref-type="bibr">
<sup>68</sup>
</xref>
</p><p>Analyses of pathways enriched for significant DEGs highlighted the importance of many nuclear genes involved in mitochondrial energy production, including 3 cytochrome c oxidase genes and 11 genes encoding <italic toggle="yes">NUDF</italic> subunits, all of which were expressed at a lower level in AD cases than controls. NDUF subunits form part of mitochondrial respiratory complex I, a multimeric enzyme composed of 44 subunits encoded by both nuclear and mtDNA genes. AD&#8208;related impairments in mitochondrial complex I in the brain and platelets have been observed.<xref rid="alz70629-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref> These findings in our AA sample overlap with evidence from many studies for mitochondrial energy pathway involvement in AD<xref rid="alz70629-bib-0070" ref-type="bibr">
<sup>70</sup>
</xref> and are supported by results from an AD DGE study in a large EA sample.<xref rid="alz70629-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Multiple groups have identified mitochondrial dysfunction as an important cause of increased oxidative stress in brain tissue and suggest that this pathway is a potential druggable target for AD treatment and prevention.<xref rid="alz70629-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref>, <xref rid="alz70629-bib-0072" ref-type="bibr">
<sup>72</sup>
</xref>
</p><p>This study has several notable limitations. It should be acknowledged that this cohort of brain donors may not be representative of AA AD cases and controls more broadly. Although this is the largest study of <italic toggle="yes">post mortem</italic> brain tissue from AA AD cases and controls, the sample is much smaller than other DGE studies conducted in EA autopsy samples (e.g.,<xref rid="alz70629-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="alz70629-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>). Additionally, there is substantial variability in the collection and availability of neuropathological data and <italic toggle="yes">ante mortem</italic> information including cognitive test data and history of relevant conditions (e.g., cardiovascular and transient ischemic attacks [TIA] events, diabetes, or other medical complications) that precluded incorporation of these factors in our analyses. Finally, because this study was performed using bulk RNA sequencing data, we could not ascribe observed gene expression association to particular cell types or detect associations evident only in underrepresented cell types. Subsequent studies could overcome this limitation through single&#8208;cell sequencing technology<xref rid="alz70629-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> or deconvolution methods.<xref rid="alz70629-bib-0073" ref-type="bibr">
<sup>73</sup>
</xref>
</p><p>In summary, we identified many genes that are differentially expressed in PFC tissue obtained from AA AD cases and controls. Several of the most significant DEGs were observed in EA brain donors, most notably <italic toggle="yes">ADAMTS2</italic>, whereas other novel DEGs and eQTLs were identified in AA individuals only. Asymmetrical findings in the two groups may be due to population differences in the frequency of genetic variants, modifying effects of other genes or other risk factors. Our findings support the hypothesis that reelin and poor bioenergetics due to mitochondrial dysfunction play a role in AD susceptibility, and may lead to new hypotheses about pathogenic mechanisms, targets for drug development, and biomarkers for risk assessment and profiling subjects for clinical trials. The inclusion of AA participants in AD research is important not only to ensure that predictions made based on genetic and &#8216;omic data are accurate in this population,<xref rid="alz70629-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> but also because of the potential it will lead to new and important advances in knowledge about AD risk that will benefit everyone.</p></sec><sec sec-type="COI-statement" id="alz70629-sec-0220"><title>CONFLICT OF INTEREST STATEMENT</title><p>Mark Logue received grants from the NIH and Department of Veterans Affairs. Marla Gearing, Lee&#8208;Way Jin, Richard Mayeux, Richard Perrin, Shih&#8208;Hsiu Wang and Lindsay Farrer received grants from the NIH. Melissa Murray received grants from NIH, was a paid consultant for Biogen Pharmaceuticals, and served on committees for the Alzheimer's Association and International Conference on Alzheimer's and Parkinson's Diseases. Thor Stein received grants from the NIH and Department of Veterans Affairs, and an honorarium from Brown University. Andrew Teich received grants from the NIH, a contract from Regeneron Pharmaceuticals and an honorarium from Ono Pharmaceuticals, owns stock in Ionis Pharmaceuticals and Biogen Pharmaceuticals, and served on committees for the Department of Defense and the Alzheimer's Association. The effort of Katarnut Tobunluepop and Zihan Wang was supported by NIH grants. Benjamin Wolozin received grants from the NIH, consulting fees from Aquinnah Pharmaceuticals and Abbingworth Ventures, honoraria for several lectures, and owns stock and is Co&#8208;Founder and CSO of Aquinnah Pharmaceuticals Inc. Other authors have no competing interests to report. Author disclosures are available in the <xref rid="alz70629-supinfo-0001" ref-type="">supporting information</xref>.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="alz70629-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="alz70629-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70629-s002.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70629-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70629-s001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="alz70629-sec-0210"><title>ACKNOWLEDGMENTS</title><p>The authors acknowledge the contributions of Dr. Sambhavi Puri, Dr. Rachel Whitmer, Dr. Charles DeCarli, Erin E. Franklin, and Dr. Oscar Lopez. This study was supported by National Institute of Health grants R01&#8208;AG048927, U01&#8208;AG058654, U54&#8208;AG052427, U19&#8208;AG068753, U01&#8208;AG062602, P30&#8208;AG072978, U01&#8208;081230, P01&#8208;AG003949, P30&#8208;AG062677, P30&#8208;AG062421; P30&#8208;AG 066507, P30&#8208;AG066511, P30&#8208;AG 072972, P30&#8208;AG066468, R01&#8208;AG072474, RF1&#8208;AG066107, U24&#8208;AG056270, P01&#8208;AG003949, RF1&#8208;AG082339, RF1&#8208;NS118584, P30&#8208;AG072946; P01&#8208;AG003991, P30&#8208;AG066444, P01&#8208;AG026276, P30&#8208;AG066462, P30&#8208;AG072958, and P30&#8208;AG072978, and by Florida Department of Health awards 8AZ06 and 20A22. The funding sources had no role in study design; in the collection, analysis or interpretation of data; in the writing of this article; or in the decision to submit this article for publication. Consent from human subjects for inclusion in this study was unnecessary.</p></ack><sec sec-type="data-availability" id="alz70629-sec-0240"><title>DATA AVAILABILITY STATEMENT</title><p>RNA sequencing data are available at the National Institute on Aging Genetics of&#160;Alzheimer's Disease Data Storage Site (NIAGADS;&#160;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.niagads.org" ext-link-type="uri" specific-use="software is-supplemented-by">https://www.niagads.org</ext-link>).</p></sec><ref-list id="alz70629-bibl-0001"><title>REFERENCES</title><ref id="alz70629-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="alz70629-cite-0002"><collab collab-type="authors">Alzheimer's Association</collab>
. <article-title>2010 Alzheimer's disease facts and figures</article-title>. <source>Alzheimers Dement</source>. <year>2010</year>;<volume>6</volume>:<fpage>158</fpage>&#8208;<lpage>194</lpage>.<pub-id pub-id-type="pmid">20298981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2010.01.009</pub-id></mixed-citation></ref><ref id="alz70629-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="alz70629-cite-0003"><string-name name-style="western"><surname>Chin</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Negash</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Arnold</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Hamilton</surname><given-names>R</given-names></string-name>. <article-title>Quality, and not just quantity, of education accounts for differences in psychometric performance between African Americans and white non&#8208;Hispanics with Alzheimer's disease</article-title>. <source>J Int Neuropsychol Soc</source>. <year>2012</year>;<volume>18</volume>:<fpage>277</fpage>&#8208;<lpage>285</lpage>.<pub-id pub-id-type="pmid">22300593</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1355617711001688</pub-id><pub-id pub-id-type="pmcid">PMC3685288</pub-id></mixed-citation></ref><ref id="alz70629-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="alz70629-cite-0004"><string-name name-style="western"><surname>Sisco</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gross</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Shih</surname><given-names>RA</given-names></string-name>, et&#160;al. <article-title>The role of early&#8208;life educational quality and literacy in explaining racial disparities in cognition in late life</article-title>. <source>J Gerontol B Psychol Sci Soc Sci</source>. <year>2015</year>;<volume>70</volume>:<fpage>557</fpage>&#8208;<lpage>567</lpage>.<pub-id pub-id-type="pmid">24584038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/geronb/gbt133</pub-id><pub-id pub-id-type="pmcid">PMC4462668</pub-id></mixed-citation></ref><ref id="alz70629-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="alz70629-cite-0005"><string-name name-style="western"><surname>Gross</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Mungas</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Crane</surname><given-names>PK</given-names></string-name>, et&#160;al. <article-title>Effects of education and race on cognitive decline: an integrative study of generalizability versus study&#8208;specific results</article-title>. <source>Psychol Aging</source>. <year>2015</year>;<volume>30</volume>:<fpage>863</fpage>&#8208;<lpage>880</lpage>.<pub-id pub-id-type="pmid">26523693</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037/pag0000032</pub-id><pub-id pub-id-type="pmcid">PMC4679562</pub-id></mixed-citation></ref><ref id="alz70629-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="alz70629-cite-0006"><string-name name-style="western"><surname>Zahodne</surname><given-names>LB</given-names></string-name>, <string-name name-style="western"><surname>Manly</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Azar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Brickman</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Glymour</surname><given-names>MM</given-names></string-name>. <article-title>Racial disparities in cognitive performance in mid&#8208; and late adulthood: analyses of two cohort studies</article-title>. <source>J Am Geriatr Soc</source>. <year>2016</year>;<volume>64</volume>:<fpage>959</fpage>&#8208;<lpage>964</lpage>.<pub-id pub-id-type="pmid">27225354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jgs.14113</pub-id><pub-id pub-id-type="pmcid">PMC4883591</pub-id></mixed-citation></ref><ref id="alz70629-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="alz70629-cite-0007"><string-name name-style="western"><surname>Clark</surname><given-names>LR</given-names></string-name>, <string-name name-style="western"><surname>Norton</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Berman</surname><given-names>SE</given-names></string-name>, et&#160;al. <article-title>Association of cardiovascular and Alzheimer's disease risk factors with intracranial arterial blood flow in Whites and African Americans</article-title>. <source>J Alzheimers Dis</source>. <year>2019</year>;<volume>72</volume>:<fpage>919</fpage>&#8208;<lpage>929</lpage>.<pub-id pub-id-type="pmid">31658057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-190645</pub-id><pub-id pub-id-type="pmcid">PMC7081660</pub-id></mixed-citation></ref><ref id="alz70629-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="alz70629-cite-0008"><string-name name-style="western"><surname>Harris</surname><given-names>MI</given-names></string-name>, <string-name name-style="western"><surname>Flegal</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Cowie</surname><given-names>CC</given-names></string-name>, et&#160;al. <article-title>Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988&#8208;1994</article-title>. <source>Diabetes Care</source>. <year>1998</year>;<volume>21</volume>:<fpage>518</fpage>&#8208;<lpage>524</lpage>.<pub-id pub-id-type="pmid">9571335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/diacare.21.4.518</pub-id></mixed-citation></ref><ref id="alz70629-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="alz70629-cite-0009"><string-name name-style="western"><surname>Barnes</surname><given-names>LL</given-names></string-name>. <article-title>Alzheimer disease in African American individuals: increased incidence or not enough data?</article-title>. <source>Nat Rev Neurol</source>. <year>2022</year>;<volume>18</volume>:<fpage>56</fpage>&#8208;<lpage>62</lpage>.<pub-id pub-id-type="pmid">34873310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-021-00589-3</pub-id><pub-id pub-id-type="pmcid">PMC8647782</pub-id></mixed-citation></ref><ref id="alz70629-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="alz70629-cite-0010"><string-name name-style="western"><surname>Logue</surname><given-names>MW</given-names></string-name>, <string-name name-style="western"><surname>Dasgupta</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Farrer</surname><given-names>LA</given-names></string-name>. <article-title>Genetics of Alzheimer's disease in the African American population</article-title>. <source>J Clin Med</source>. <year>2023</year>;<volume>12</volume>:<fpage>5189</fpage>.<pub-id pub-id-type="pmid">37629231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm12165189</pub-id><pub-id pub-id-type="pmcid">PMC10455208</pub-id></mixed-citation></ref><ref id="alz70629-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="alz70629-cite-0011"><string-name name-style="western"><surname>Bellenguez</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kucukali</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Jansen</surname><given-names>IE</given-names></string-name>, et&#160;al. <article-title>New insights into the genetic etiology of Alzheimer's disease and related dementias</article-title>. <source>Nat Genet</source>. <year>2022</year>;<volume>54</volume>:<fpage>412</fpage>&#8208;<lpage>436</lpage>.<pub-id pub-id-type="pmid">35379992</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-022-01024-z</pub-id><pub-id pub-id-type="pmcid">PMC9005347</pub-id></mixed-citation></ref><ref id="alz70629-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="alz70629-cite-0012"><string-name name-style="western"><surname>Sherva</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Sahelijo</surname><given-names>N</given-names></string-name>, et&#160;al. <article-title>African ancestry GWAS of dementia in a large military cohort identifies significant risk loci</article-title>. <source>Mol Psychiatry</source>. <year>2023</year>;<volume>28</volume>:<fpage>1293</fpage>&#8208;<lpage>1302</lpage>.<pub-id pub-id-type="pmid">36543923</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-022-01890-3</pub-id><pub-id pub-id-type="pmcid">PMC10066923</pub-id></mixed-citation></ref><ref id="alz70629-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="alz70629-cite-0013"><string-name name-style="western"><surname>Gaziano</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Concato</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Brophy</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Million Veteran Program: a mega&#8208;biobank to study genetic influences on health and disease</article-title>. <source>J Clin Epidemiol</source>. <year>2016</year>;<volume>70</volume>:<fpage>214</fpage>&#8208;<lpage>223</lpage>.<pub-id pub-id-type="pmid">26441289</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jclinepi.2015.09.016</pub-id></mixed-citation></ref><ref id="alz70629-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="alz70629-cite-0014"><string-name name-style="western"><surname>Kunkle</surname><given-names>BW</given-names></string-name>, <string-name name-style="western"><surname>Schmidt</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Klein</surname><given-names>HU</given-names></string-name>, et&#160;al. <article-title>Novel Alzheimer disease risk loci and pathways in African American individuals using the African Genome Resources Panel: a meta&#8208;analysis</article-title>. <source>JAMA Neurol</source>. <year>2021</year>;<volume>78</volume>:<fpage>102</fpage>&#8208;<lpage>113</lpage>.<pub-id pub-id-type="pmid">33074286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2020.3536</pub-id><pub-id pub-id-type="pmcid">PMC7573798</pub-id></mixed-citation></ref><ref id="alz70629-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="alz70629-cite-0015"><string-name name-style="western"><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Roussos</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>McKenzie</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer's disease</article-title>. <source>Genome Med</source>. <year>2016</year>;<volume>8</volume>:<fpage>104</fpage>.<pub-id pub-id-type="pmid">27799057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13073-016-0355-3</pub-id><pub-id pub-id-type="pmcid">PMC5088659</pub-id></mixed-citation></ref><ref id="alz70629-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="alz70629-cite-0016"><string-name name-style="western"><surname>Narayanan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Huynh</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>Common dysregulation network in the human prefrontal cortex underlies two neurodegenerative diseases</article-title>. <source>Mol Syst Biol</source>. <year>2014</year>;<volume>10</volume>:<fpage>743</fpage>.<pub-id pub-id-type="pmid">25080494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/msb.20145304</pub-id><pub-id pub-id-type="pmcid">PMC4299500</pub-id></mixed-citation></ref><ref id="alz70629-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="alz70629-cite-0017"><string-name name-style="western"><surname>Mathys</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Davila&#8208;Velderrain</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>Z</given-names></string-name>, et&#160;al. <article-title>Single&#8208;cell transcriptomic analysis of Alzheimer's disease</article-title>. <source>Nature</source>. <year>2019</year>;<volume>570</volume>:<fpage>332</fpage>&#8208;<lpage>337</lpage>.<pub-id pub-id-type="pmid">31042697</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-019-1195-2</pub-id><pub-id pub-id-type="pmcid">PMC6865822</pub-id></mixed-citation></ref><ref id="alz70629-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="alz70629-cite-0018"><string-name name-style="western"><surname>Panitch</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chung</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Integrative brain transcriptome analysis links complement component 4 and HSPA2 to the APOE epsilon2 protective effect in Alzheimer disease</article-title>. <source>Mol Psychiatry</source>. <year>2021</year>;<volume>26</volume>:<fpage>6054</fpage>&#8208;<lpage>6064</lpage>.<pub-id pub-id-type="pmid">34480088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-021-01266-z</pub-id><pub-id pub-id-type="pmcid">PMC8758485</pub-id></mixed-citation></ref><ref id="alz70629-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="alz70629-cite-0019"><string-name name-style="western"><surname>Li</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Farrer</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Stein</surname><given-names>TD</given-names></string-name>, <string-name name-style="western"><surname>Jun</surname><given-names>GR</given-names></string-name>. <article-title>Transcriptome signatures for cognitive resilience among individuals with pathologically confirmed Alzheimer disease</article-title>. <source>MedRxiv</source>. doi: <pub-id pub-id-type="doi">10.1101/2024.11.12.24317218v1</pub-id></mixed-citation></ref><ref id="alz70629-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="alz70629-cite-0020"><string-name name-style="western"><surname>Montine</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Phelps</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Beach</surname><given-names>TG</given-names></string-name>, et&#160;al. <article-title>National Institute on Aging&#8208;Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach</article-title>. <source>Acta Neuropathol</source>. <year>2012</year>;<volume>123</volume>:<fpage>1</fpage>&#8208;<lpage>11</lpage>.<pub-id pub-id-type="pmid">22101365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-011-0910-3</pub-id><pub-id pub-id-type="pmcid">PMC3268003</pub-id></mixed-citation></ref><ref id="alz70629-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="alz70629-cite-0021"><string-name name-style="western"><surname>Bolger</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Lohse</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Usadel</surname><given-names>B</given-names></string-name>. <article-title>Trimmomatic: a flexible trimmer for Illumina sequence data</article-title>. <source>Bioinformatics</source>. <year>2014</year>;<volume>30</volume>:<fpage>2114</fpage>&#8208;<lpage>2120</lpage>.<pub-id pub-id-type="pmid">24695404</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btu170</pub-id><pub-id pub-id-type="pmcid">PMC4103590</pub-id></mixed-citation></ref><ref id="alz70629-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="alz70629-cite-0022"><string-name name-style="western"><surname>Reddy</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Heath</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Linden</surname><given-names>AV</given-names></string-name>, et&#160;al. <article-title>Bridging the gap: multi&#8208;omics profiling of brain tissue in Alzheimer's disease and older controls in multi&#8208;ethnic populations</article-title>. <source>Alzheimers Dement</source>. <year>2024</year>;<volume>20</volume>:<fpage>7174</fpage>&#8208;<lpage>7192</lpage>.<pub-id pub-id-type="pmid">39215503</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.14208</pub-id><pub-id pub-id-type="pmcid">PMC11485084</pub-id></mixed-citation></ref><ref id="alz70629-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="alz70629-cite-0023"><string-name name-style="western"><surname>Quinlan</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Hall</surname><given-names>IM</given-names></string-name>. <article-title>BEDTools: a flexible suite of utilities for comparing genomic features</article-title>. <source>Bioinformatics</source>. <year>2010</year>;<volume>26</volume>:<fpage>841</fpage>&#8208;<lpage>842</lpage>.<pub-id pub-id-type="pmid">20110278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btq033</pub-id><pub-id pub-id-type="pmcid">PMC2832824</pub-id></mixed-citation></ref><ref id="alz70629-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="alz70629-cite-0024"><string-name name-style="western"><surname>Dobin</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Schlesinger</surname><given-names>F</given-names></string-name>, et&#160;al. <article-title>STAR: ultrafast universal RNA&#8208;seq aligner</article-title>. <source>Bioinformatics</source>. <year>2013</year>;<volume>29</volume>:<fpage>15</fpage>&#8208;<lpage>21</lpage>.<pub-id pub-id-type="pmid">23104886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmcid">PMC3530905</pub-id></mixed-citation></ref><ref id="alz70629-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="alz70629-cite-0025"><string-name name-style="western"><surname>Li</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Dewey</surname><given-names>CN</given-names></string-name>. <article-title>RSEM: accurate transcript quantification from RNA&#8208;Seq data with or without a reference genome</article-title>. <source>BMC Bioinformatics</source>. <year>2011</year>;<volume>12</volume>:<fpage>323</fpage>.<pub-id pub-id-type="pmid">21816040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2105-12-323</pub-id><pub-id pub-id-type="pmcid">PMC3163565</pub-id></mixed-citation></ref><ref id="alz70629-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="alz70629-cite-0026"><string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>W</given-names></string-name>. <article-title>RSeQC: quality control of RNA&#8208;seq experiments</article-title>. <source>Bioinformatics</source>. <year>2012</year>;<volume>28</volume>:<fpage>2184</fpage>&#8208;<lpage>2185</lpage>.<pub-id pub-id-type="pmid">22743226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/bts356</pub-id></mixed-citation></ref><ref id="alz70629-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="alz70629-cite-0027"><string-name name-style="western"><surname>Ewels</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Magnusson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lundin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kaller</surname><given-names>M</given-names></string-name>. <article-title>MultiQC: summarize analysis results for multiple tools and samples in a single report</article-title>. <source>Bioinformatics</source>. <year>2016</year>;<volume>32</volume>:<fpage>3047</fpage>&#8208;<lpage>3048</lpage>.<pub-id pub-id-type="pmid">27312411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btw354</pub-id><pub-id pub-id-type="pmcid">PMC5039924</pub-id></mixed-citation></ref><ref id="alz70629-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="alz70629-cite-0028"><string-name name-style="western"><surname>O'Neill</surname><given-names>NK</given-names></string-name>, <string-name name-style="western"><surname>Stein</surname><given-names>TD</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Bulk brain tissue cell&#8208;type deconvolution with bias correction for single&#8208;nuclei RNA sequencing data using DeTREM</article-title>. <source>BMC Bioinformatics</source>. <year>2023</year>;<volume>24</volume>:<fpage>349</fpage>.<pub-id pub-id-type="pmid">37726653</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12859-023-05476-w</pub-id><pub-id pub-id-type="pmcid">PMC10507917</pub-id></mixed-citation></ref><ref id="alz70629-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="alz70629-cite-0029"><string-name name-style="western"><surname>Lau</surname><given-names>SF</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>AKY</given-names></string-name>, <string-name name-style="western"><surname>Ip</surname><given-names>NY</given-names></string-name>. <article-title>Single&#8208;nucleus transcriptome analysis reveals dysregulation of angiogenic endothelial cells and neuroprotective glia in Alzheimer's disease</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2020</year>;<volume>117</volume>:<fpage>25800</fpage>&#8208;<lpage>25809</lpage>.<pub-id pub-id-type="pmid">32989152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2008762117</pub-id><pub-id pub-id-type="pmcid">PMC7568283</pub-id></mixed-citation></ref><ref id="alz70629-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="alz70629-cite-0030"><string-name name-style="western"><surname>Chang</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Chow</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Tellier</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Vattikuti</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Purcell</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>JJ</given-names></string-name>. <article-title>Second&#8208;generation PLINK: rising to the challenge of larger and richer datasets</article-title>. <source>Gigascience</source>. <year>2015</year>;<volume>4</volume>:<fpage>7</fpage>.<pub-id pub-id-type="pmid">25722852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13742-015-0047-8</pub-id><pub-id pub-id-type="pmcid">PMC4342193</pub-id></mixed-citation></ref><ref id="alz70629-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="alz70629-cite-0031"><collab collab-type="authors">1000 Genomes Project Consortium</collab>
, <string-name name-style="western"><surname>Auton</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Brooks</surname><given-names>LD</given-names></string-name>, <string-name name-style="western"><surname>Durbin</surname><given-names>RM</given-names></string-name>, et&#160;al, <collab collab-type="authors">1000 Genomes Project Consortium</collab>
. <article-title>A global reference for human genetic variation</article-title>. <source>Nature</source>. <year>2015</year>;<volume>526</volume>:<fpage>68</fpage>&#8208;<lpage>74</lpage>.<pub-id pub-id-type="pmid">26432245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature15393</pub-id><pub-id pub-id-type="pmcid">PMC4750478</pub-id></mixed-citation></ref><ref id="alz70629-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="alz70629-cite-0032"><string-name name-style="western"><surname>Love</surname><given-names>MI</given-names></string-name>, <string-name name-style="western"><surname>Huber</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Anders</surname><given-names>S</given-names></string-name>. <article-title>Moderated estimation of fold change and dispersion for RNA&#8208;seq data with DESeq2</article-title>. <source>Genome Biol</source>. <year>2014</year>;<volume>15</volume>:<fpage>550</fpage>.<pub-id pub-id-type="pmid">25516281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmcid">PMC4302049</pub-id></mixed-citation></ref><ref id="alz70629-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="alz70629-cite-0033"><string-name name-style="western"><surname>Yu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Dawe</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Boyle</surname><given-names>PA</given-names></string-name>, et&#160;al. <article-title>Association between brain gene expression, DNA methylation, and qlteration of ex vivo magnetic resonance imaging transverse relaxation in late&#8208;life cognitive decline</article-title>. <source>JAMA Neurol</source>. <year>2017</year>;<volume>74</volume>:<fpage>1473</fpage>&#8208;<lpage>1480</lpage>.<pub-id pub-id-type="pmid">29084334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2017.2807</pub-id><pub-id pub-id-type="pmcid">PMC5729739</pub-id></mixed-citation></ref><ref id="alz70629-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="alz70629-cite-0034"><string-name name-style="western"><surname>Storey</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Tibshirani</surname><given-names>R</given-names></string-name>. <article-title>Statistical significance for genomewide studies</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2003</year>;<volume>100</volume>:<fpage>9440</fpage>&#8208;<lpage>9445</lpage>.<pub-id pub-id-type="pmid">12883005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1530509100</pub-id><pub-id pub-id-type="pmcid">PMC170937</pub-id></mixed-citation></ref><ref id="alz70629-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="alz70629-cite-0035"><string-name name-style="western"><surname>Young</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Wakefield</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Smyth</surname><given-names>GK</given-names></string-name>, <string-name name-style="western"><surname>Oshlack</surname><given-names>A</given-names></string-name>. <article-title>Gene ontology analysis for RNA&#8208;seq: accounting for selection bias</article-title>. <source>Genome Biol</source>. <year>2010</year>;<volume>11</volume>:<fpage>R14</fpage>.<pub-id pub-id-type="pmid">20132535</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/gb-2010-11-2-r14</pub-id><pub-id pub-id-type="pmcid">PMC2872874</pub-id></mixed-citation></ref><ref id="alz70629-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="alz70629-cite-0036"><string-name name-style="western"><surname>Langfelder</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Horvath</surname><given-names>S</given-names></string-name>. <article-title>WGCNA: an R package for weighted correlation network analysis</article-title>. <source>BMC Bioinformatics</source>. <year>2008</year>;<volume>9</volume>:<fpage>559</fpage>.<pub-id pub-id-type="pmid">19114008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2105-9-559</pub-id><pub-id pub-id-type="pmcid">PMC2631488</pub-id></mixed-citation></ref><ref id="alz70629-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="alz70629-cite-0037"><string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Parmigiani</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname><given-names>WE</given-names></string-name>. <article-title>ComBat&#8208;seq: batch effect adjustment for RNA&#8208;seq count data</article-title>. <source>NAR Genom Bioinform</source>. <year>2020</year>;<volume>2</volume>:<elocation-id>lqaa078</elocation-id>.<pub-id pub-id-type="pmid">33015620</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nargab/lqaa078</pub-id><pub-id pub-id-type="pmcid">PMC7518324</pub-id></mixed-citation></ref><ref id="alz70629-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="alz70629-cite-0038"><string-name name-style="western"><surname>Thelen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Razquin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hernandez</surname><given-names>I</given-names></string-name>, et&#160;al. <article-title>Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes</article-title>. <source>Neurobiol Aging</source>. <year>2014</year>;<volume>35</volume>:<elocation-id>2657</elocation-id> e13&#8208; e19.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2014.06.018</pub-id><pub-id pub-id-type="pmid">25042114</pub-id></mixed-citation></ref><ref id="alz70629-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="alz70629-cite-0039"><string-name name-style="western"><surname>Kelwick</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Desanlis</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Wheeler</surname><given-names>GN</given-names></string-name>, <string-name name-style="western"><surname>Edwards</surname><given-names>DR</given-names></string-name>. <article-title>The ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) family</article-title>. <source>Genome Biol</source>. <year>2015</year>;<volume>16</volume>:<fpage>113</fpage>.<pub-id pub-id-type="pmid">26025392</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13059-015-0676-3</pub-id><pub-id pub-id-type="pmcid">PMC4448532</pub-id></mixed-citation></ref><ref id="alz70629-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="alz70629-cite-0040"><string-name name-style="western"><surname>Colige</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sieron</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>SW</given-names></string-name>, et&#160;al. <article-title>Human Ehlers&#8208;Danlos syndrome type VII C and bovine dermatosparaxis are caused by mutations in the procollagen I N&#8208;proteinase gene</article-title>. <source>Am J Hum Genet</source>. <year>1999</year>;<volume>65</volume>:<fpage>308</fpage>&#8208;<lpage>317</lpage>.<pub-id pub-id-type="pmid">10417273</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/302504</pub-id><pub-id pub-id-type="pmcid">PMC1377929</pub-id></mixed-citation></ref><ref id="alz70629-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="alz70629-cite-0041"><string-name name-style="western"><surname>Yamakage</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kato</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hongo</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>A disintegrin and metalloproteinase with thrombospondin motifs 2 cleaves and inactivates Reelin in the postnatal cerebral cortex and hippocampus, but not in the cerebellum</article-title>. <source>Mol Cell Neurosci</source>. <year>2019</year>;<volume>100</volume>:<elocation-id>103401</elocation-id>.<pub-id pub-id-type="pmid">31491533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mcn.2019.103401</pub-id></mixed-citation></ref><ref id="alz70629-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="alz70629-cite-0042"><string-name name-style="western"><surname>Botella&#8208;Lopez</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Burgaya</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Gavin</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Reelin expression and glycosylation patterns are altered in Alzheimer's disease</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2006</year>;<volume>103</volume>:<fpage>5573</fpage>&#8208;<lpage>5578</lpage>.<pub-id pub-id-type="pmid">16567613</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0601279103</pub-id><pub-id pub-id-type="pmcid">PMC1414634</pub-id></mixed-citation></ref><ref id="alz70629-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="alz70629-cite-0043"><string-name name-style="western"><surname>Chin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Massaro</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Palop</surname><given-names>JJ</given-names></string-name>, et&#160;al. <article-title>Reelin depletion in the entorhinal cortex of human amyloid precursor protein transgenic mice and humans with Alzheimer's disease</article-title>. <source>J Neurosci</source>. <year>2007</year>;<volume>27</volume>:<fpage>2727</fpage>&#8208;<lpage>2733</lpage>.<pub-id pub-id-type="pmid">17360894</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.3758-06.2007</pub-id><pub-id pub-id-type="pmcid">PMC6672562</pub-id></mixed-citation></ref><ref id="alz70629-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="alz70629-cite-0044"><string-name name-style="western"><surname>Lopera</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Marino</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chandrahas</surname><given-names>AS</given-names></string-name>, et&#160;al. <article-title>Resilience to autosomal dominant Alzheimer's disease in a Reelin&#8208;COLBOS heterozygous man</article-title>. <source>Nat Med</source>. <year>2023</year>;<volume>29</volume>:<fpage>1243</fpage>&#8208;<lpage>1252</lpage>.<pub-id pub-id-type="pmid">37188781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-023-02318-3</pub-id><pub-id pub-id-type="pmcid">PMC10202812</pub-id></mixed-citation></ref><ref id="alz70629-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="alz70629-cite-0045"><string-name name-style="western"><surname>Botella&#8208;Lopez</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cuchillo&#8208;Ibanez</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Cotrufo</surname><given-names>T</given-names></string-name>, et&#160;al. <article-title>Beta&#8208;amyloid controls altered Reelin expression and processing in Alzheimer's disease</article-title>. <source>Neurobiol Dis</source>. <year>2010</year>;<volume>37</volume>:<fpage>682</fpage>&#8208;<lpage>691</lpage>.<pub-id pub-id-type="pmid">20025970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2009.12.006</pub-id></mixed-citation></ref><ref id="alz70629-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="alz70629-cite-0046"><string-name name-style="western"><surname>Herring</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Donath</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Steiner</surname><given-names>KM</given-names></string-name>, et&#160;al. <article-title>Reelin depletion is an early phenomenon of Alzheimer's pathology</article-title>. <source>J Alzheimers Dis</source>. <year>2012</year>;<volume>30</volume>:<fpage>963</fpage>&#8208;<lpage>979</lpage>.<pub-id pub-id-type="pmid">22495348</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-2012-112069</pub-id></mixed-citation></ref><ref id="alz70629-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="alz70629-cite-0047"><string-name name-style="western"><surname>Ignatova</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Sindic</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Goffinet</surname><given-names>AM</given-names></string-name>. <article-title>Characterization of the various forms of the Reelin protein in the cerebrospinal fluid of normal subjects and in neurological diseases</article-title>. <source>Neurobiol Dis</source>. <year>2004</year>;<volume>15</volume>:<fpage>326</fpage>&#8208;<lpage>330</lpage>.<pub-id pub-id-type="pmid">15006702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2003.11.008</pub-id></mixed-citation></ref><ref id="alz70629-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="alz70629-cite-0048"><string-name name-style="western"><surname>Emilsson</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Saetre</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Jazin</surname><given-names>E</given-names></string-name>. <article-title>Alzheimer's disease: mRNA expression profiles of multiple patients show alterations of genes involved with calcium signaling</article-title>. <source>Neurobiol Dis</source>. <year>2006</year>;<volume>21</volume>:<fpage>618</fpage>&#8208;<lpage>625</lpage>.<pub-id pub-id-type="pmid">16257224</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2005.09.004</pub-id></mixed-citation></ref><ref id="alz70629-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="alz70629-cite-0049"><string-name name-style="western"><surname>Stygelbout</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Leroy</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Pouillon</surname><given-names>V</given-names></string-name>, et&#160;al. <article-title>Inositol trisphosphate 3&#8208;kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology</article-title>. <source>Brain</source>. <year>2014</year>;<volume>137</volume>:<fpage>537</fpage>&#8208;<lpage>552</lpage>.<pub-id pub-id-type="pmid">24401760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awt344</pub-id></mixed-citation></ref><ref id="alz70629-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="alz70629-cite-0050"><string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Nan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Nan</surname><given-names>S</given-names></string-name>. <article-title>Microglia&#8208;derived extracellular vesicles carrying miR&#8208;711 alleviate neurodegeneration in a murine Alzheimer's disease model by binding to Itpkb</article-title>. <source>Front Cell Dev Biol</source>. <year>2020</year>;<volume>8</volume>:<elocation-id>566530</elocation-id>.<pub-id pub-id-type="pmid">33240878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcell.2020.566530</pub-id><pub-id pub-id-type="pmcid">PMC7677138</pub-id></mixed-citation></ref><ref id="alz70629-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="alz70629-cite-0051"><string-name name-style="western"><surname>Jackson</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Soto</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Graham</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Carter</surname><given-names>GW</given-names></string-name>, <string-name name-style="western"><surname>Howell</surname><given-names>GR</given-names></string-name>. <article-title>Clustering of transcriptional profiles identifies changes to insulin signaling as an early event in a mouse model of Alzheimer's disease</article-title>. <source>BMC Genomics</source>. <year>2013</year>;<volume>14</volume>:<fpage>831</fpage>.<pub-id pub-id-type="pmid">24274089</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2164-14-831</pub-id><pub-id pub-id-type="pmcid">PMC3907022</pub-id></mixed-citation></ref><ref id="alz70629-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="alz70629-cite-0052"><string-name name-style="western"><surname>Barbiellini Amidei</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fayosse</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Dumurgier</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Association between age at diabetes onset and subsequent risk of dementia</article-title>. <source>JAMA</source>. <year>2021</year>;<volume>325</volume>:<fpage>1640</fpage>&#8208;<lpage>1649</lpage>.<pub-id pub-id-type="pmid">33904867</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2021.4001</pub-id><pub-id pub-id-type="pmcid">PMC8080220</pub-id></mixed-citation></ref><ref id="alz70629-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="alz70629-cite-0053"><string-name name-style="western"><surname>Sedzikowska</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Szablewski</surname><given-names>L</given-names></string-name>. <article-title>Insulin and insulin resistance in Alzheimer's disease</article-title>. <source>Int J Mol Sci</source>. <year>2021</year>;<volume>22</volume>:<fpage>9987</fpage>.<pub-id pub-id-type="pmid">34576151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22189987</pub-id><pub-id pub-id-type="pmcid">PMC8472298</pub-id></mixed-citation></ref><ref id="alz70629-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="alz70629-cite-0054"><string-name name-style="western"><surname>Tsuruzoe</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Emkey</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kriauciunas</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Ueki</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kahn</surname><given-names>CR</given-names></string-name>. <article-title>Insulin receptor substrate 3 (IRS&#8208;3) and IRS&#8208;4 impair IRS&#8208;1&#8208; and IRS&#8208;2&#8208;mediated signaling</article-title>. <source>Molec Cell Biol</source>. <year>2001</year>;<volume>21</volume>:<fpage>26</fpage>&#8208;<lpage>38</lpage>.<pub-id pub-id-type="pmid">11113178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/MCB.21.1.26-38.2001</pub-id><pub-id pub-id-type="pmcid">PMC86565</pub-id></mixed-citation></ref><ref id="alz70629-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="alz70629-cite-0055"><string-name name-style="western"><surname>Killick</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Scales</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Leroy</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2009</year>;<volume>386</volume>:<fpage>257</fpage>&#8208;<lpage>262</lpage>.<pub-id pub-id-type="pmid">19523444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2009.06.032</pub-id><pub-id pub-id-type="pmcid">PMC2726921</pub-id></mixed-citation></ref><ref id="alz70629-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="alz70629-cite-0056"><string-name name-style="western"><surname>Schubert</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Brazil</surname><given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Burks</surname><given-names>DJ</given-names></string-name>, et&#160;al. <article-title>Insulin receptor substrate&#8208;2 deficiency impairs brain growth and promotes tau phosphorylation</article-title>. <source>J Neurosci</source>. <year>2003</year>;<volume>23</volume>:<fpage>7084</fpage>&#8208;<lpage>7092</lpage>.<pub-id pub-id-type="pmid">12904469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.23-18-07084.2003</pub-id><pub-id pub-id-type="pmcid">PMC6740672</pub-id></mixed-citation></ref><ref id="alz70629-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="alz70629-cite-0057"><string-name name-style="western"><surname>Provensi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Carta</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Nocentini</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>A new kid on the block? Carbonic anhydrases as possible new targets in Alzheimer's disease</article-title>. <source>Int J Mol Sci</source>. <year>2019</year>;<volume>20</volume>:<fpage>4724</fpage>.<pub-id pub-id-type="pmid">31554165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms20194724</pub-id><pub-id pub-id-type="pmcid">PMC6801497</pub-id></mixed-citation></ref><ref id="alz70629-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="alz70629-cite-0058"><string-name name-style="western"><surname>He</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Loika</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kulminski</surname><given-names>AM</given-names></string-name>. <article-title>Allele&#8208;specific analysis reveals exon&#8208; and cell&#8208;type&#8208;specific regulatory effects of Alzheimer's disease&#8208;associated genetic variants</article-title>. <source>Transl Psychiatry</source>. <year>2022</year>;<volume>12</volume>:<fpage>163</fpage>.<pub-id pub-id-type="pmid">35436980</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-022-01913-1</pub-id><pub-id pub-id-type="pmcid">PMC9016079</pub-id></mixed-citation></ref><ref id="alz70629-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="alz70629-cite-0059"><string-name name-style="western"><surname>Canepa</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Parodi&#8208;Rullan</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Vazquez&#8208;Torres</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>FDA&#8208;approved carbonic anhydrase inhibitors reduce amyloid beta pathology and improve cognition, by ameliorating cerebrovascular health and glial fitness</article-title>. <source>Alzheimers Dement</source>. <year>2023</year>;<volume>19</volume>:<fpage>5048</fpage>&#8208;<lpage>5073</lpage>.<pub-id pub-id-type="pmid">37186121</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13063</pub-id><pub-id pub-id-type="pmcid">PMC10600328</pub-id></mixed-citation></ref><ref id="alz70629-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="alz70629-cite-0060"><string-name name-style="western"><surname>Garcia&#8208;Osta</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cuadrado&#8208;Tejedor</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Garcia&#8208;Barroso</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Oyarzabal</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Franco</surname><given-names>R</given-names></string-name>. <article-title>Phosphodiesterases as therapeutic targets for Alzheimer's disease</article-title>. <source>ACS Chem Neurosci</source>. <year>2012</year>;<volume>3</volume>:<fpage>832</fpage>&#8208;<lpage>844</lpage>.<pub-id pub-id-type="pmid">23173065</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/cn3000907</pub-id><pub-id pub-id-type="pmcid">PMC3503343</pub-id></mixed-citation></ref><ref id="alz70629-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="alz70629-cite-0061"><string-name name-style="western"><surname>Gong</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Vitolo</surname><given-names>OV</given-names></string-name>, <string-name name-style="western"><surname>Trinchese</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shelanski</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Arancio</surname><given-names>O</given-names></string-name>. <article-title>Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment</article-title>. <source>J Clin Invest</source>. <year>2004</year>;<volume>114</volume>:<fpage>1624</fpage>&#8208;<lpage>1634</lpage>.<pub-id pub-id-type="pmid">15578094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI22831</pub-id><pub-id pub-id-type="pmcid">PMC529285</pub-id></mixed-citation></ref><ref id="alz70629-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="alz70629-cite-0062"><string-name name-style="western"><surname>Rutten</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Prickaerts</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hendrix</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>van der Staay</surname><given-names>FJ</given-names></string-name>, <string-name name-style="western"><surname>Sik</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Blokland</surname><given-names>A</given-names></string-name>. <article-title>Time&#8208;dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors</article-title>. <source>Eur J Pharmacol</source>. <year>2007</year>;<volume>558</volume>:<fpage>107</fpage>&#8208;<lpage>112</lpage>.<pub-id pub-id-type="pmid">17207788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2006.11.041</pub-id></mixed-citation></ref><ref id="alz70629-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="alz70629-cite-0063"><string-name name-style="western"><surname>Padovan&#8208;Neto</surname><given-names>FE</given-names></string-name>, <string-name name-style="western"><surname>Cerveira</surname><given-names>AJO</given-names></string-name>, <string-name name-style="western"><surname>da Silva</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ribeiro</surname><given-names>DL</given-names></string-name>. <article-title>Beyond traditional pharmacology: evaluating phosphodiesterase inhibitors in autism spectrum disorder</article-title>. <source>Neuropsychopharmacology</source>. <year>2024</year>;<volume>49</volume>:<fpage>1359</fpage>&#8208;<lpage>1360</lpage>.<pub-id pub-id-type="pmid">38605185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41386-024-01860-z</pub-id><pub-id pub-id-type="pmcid">PMC11251265</pub-id></mixed-citation></ref><ref id="alz70629-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="alz70629-cite-0064"><string-name name-style="western"><surname>Snyder</surname><given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>Vanover</surname><given-names>KE</given-names></string-name>. <article-title>PDE inhibitors for the treatment of schizophrenia</article-title>. <source>Adv Neurobiol</source>. <year>2017</year>;<volume>17</volume>:<fpage>385</fpage>&#8208;<lpage>409</lpage>.<pub-id pub-id-type="pmid">28956340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-319-58811-7_14</pub-id></mixed-citation></ref><ref id="alz70629-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="alz70629-cite-0065"><string-name name-style="western"><surname>Rodefer</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Murphy</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Baxter</surname><given-names>MG</given-names></string-name>. <article-title>PDE10A inhibition reverses subchronic PCP&#8208;induced deficits in attentional set&#8208;shifting in rats</article-title>. <source>Eur J Neurosci</source>. <year>2005</year>;<volume>21</volume>:<fpage>1070</fpage>&#8208;<lpage>1076</lpage>.<pub-id pub-id-type="pmid">15787711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1460-9568.2005.03937.x</pub-id></mixed-citation></ref><ref id="alz70629-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="alz70629-cite-0066"><string-name name-style="western"><surname>Erro</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Mencacci</surname><given-names>NE</given-names></string-name>, <string-name name-style="western"><surname>Bhatia</surname><given-names>KP</given-names></string-name>. <article-title>The emerging role of phosphodiesterases in movement disorders</article-title>. <source>Mov Disord</source>. <year>2021</year>;<volume>36</volume>:<fpage>2225</fpage>&#8208;<lpage>2243</lpage>.<pub-id pub-id-type="pmid">34155691</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.28686</pub-id><pub-id pub-id-type="pmcid">PMC8596847</pub-id></mixed-citation></ref><ref id="alz70629-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="alz70629-cite-0067"><string-name name-style="western"><surname>Thal</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Salmon</surname><given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Lasker</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Bower</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Klauber</surname><given-names>MR</given-names></string-name>. <article-title>The safety and lack of efficacy of vinpocetine in Alzheimer's disease</article-title>. <source>J Am Geriatr Soc</source>. <year>1989</year>;<volume>37</volume>:<fpage>515</fpage>&#8208;<lpage>520</lpage>.<pub-id pub-id-type="pmid">2715559</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1532-5415.1989.tb05682.x</pub-id></mixed-citation></ref><ref id="alz70629-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="alz70629-cite-0068"><string-name name-style="western"><surname>Serneels</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bammens</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zwijsen</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tolia</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chavez&#8208;Gutierrez</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>De Strooper</surname><given-names>B</given-names></string-name>. <article-title>Functional and topological analysis of PSENEN, the fourth subunit of the gamma&#8208;secretase complex</article-title>. <source>J Biol Chem</source>. <year>2024</year>;<volume>300</volume>:<elocation-id>105533</elocation-id>.<pub-id pub-id-type="pmid">38072061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbc.2023.105533</pub-id><pub-id pub-id-type="pmcid">PMC10790097</pub-id></mixed-citation></ref><ref id="alz70629-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="alz70629-cite-0069"><string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>B</given-names></string-name>. <article-title>Zinc&#8208;dependent deacetylases (HDACs) as potential targets for treating Alzheimer's disease</article-title>. <source>Bioorg Med Chem Lett</source>. <year>2022</year>;<volume>76</volume>:<elocation-id>129015</elocation-id>.<pub-id pub-id-type="pmid">36208870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bmcl.2022.129015</pub-id></mixed-citation></ref><ref id="alz70629-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="alz70629-cite-0070"><string-name name-style="western"><surname>Giachin</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Bouverot</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Acajjaoui</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pantalone</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Soler&#8208;Lopez</surname><given-names>M</given-names></string-name>. <article-title>Dynamics of human mitochondrial complex I assembly: implications for neurodegenerative diseases</article-title>. <source>Front Mol Biosci</source>. <year>2016</year>;<volume>3</volume>:<fpage>43</fpage>.<pub-id pub-id-type="pmid">27597947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmolb.2016.00043</pub-id><pub-id pub-id-type="pmcid">PMC4992684</pub-id></mixed-citation></ref><ref id="alz70629-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="alz70629-cite-0071"><string-name name-style="western"><surname>Bano</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ehninger</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bagetta</surname><given-names>G</given-names></string-name>. <article-title>Decoding metabolic signatures in Alzheimer's disease: a mitochondrial perspective</article-title>. <source>Cell Death Discov</source>. <year>2023</year>;<volume>9</volume>:<fpage>432</fpage>.<pub-id pub-id-type="pmid">38040687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41420-023-01732-3</pub-id><pub-id pub-id-type="pmcid">PMC10692234</pub-id></mixed-citation></ref><ref id="alz70629-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="alz70629-cite-0072"><string-name name-style="western"><surname>Strope</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Birky</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Wilkins</surname><given-names>HM</given-names></string-name>. <article-title>The role of bioenergetics in neurodegeneration</article-title>. <source>Int J Mol Sci</source>. <year>2022</year>;<volume>23</volume>:<fpage>9212</fpage>.<pub-id pub-id-type="pmid">36012480</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23169212</pub-id><pub-id pub-id-type="pmcid">PMC9409169</pub-id></mixed-citation></ref><ref id="alz70629-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="alz70629-cite-0073"><string-name name-style="western"><surname>Ashleigh</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Swerdlow</surname><given-names>RH</given-names></string-name>, <string-name name-style="western"><surname>Beal</surname><given-names>MF</given-names></string-name>. <article-title>The role of mitochondrial dysfunction in Alzheimer's disease pathogenesis</article-title>. <source>Alzheimers Dement</source>. <year>2023</year>;<volume>19</volume>:<fpage>333</fpage>&#8208;<lpage>342</lpage>.<pub-id pub-id-type="pmid">35522844</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12683</pub-id></mixed-citation></ref><ref id="alz70629-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="alz70629-cite-0074"><string-name name-style="western"><surname>Jaakkola</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Elo</surname><given-names>LL</given-names></string-name>. <article-title>Estimating cell type&#8208;specific differential expression using deconvolution</article-title>. <source>Brief Bioinform</source>. <year>2022</year>;<volume>23</volume>:<elocation-id>bbab433</elocation-id>.<pub-id pub-id-type="pmid">34651640</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bib/bbab433</pub-id><pub-id pub-id-type="pmcid">PMC8769698</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="pmc-domain-id">440</journal-id><journal-id journal-id-type="pmc-domain">plosone</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS One</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>PLOS</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12507304</article-id><article-id pub-id-type="pmcid-ver">PMC12507304.1</article-id><article-id pub-id-type="pmcaid">12507304</article-id><article-id pub-id-type="pmcaiid">12507304</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0333029</article-id><article-id pub-id-type="publisher-id">PONE-D-25-07673</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical Compounds</subject><subj-group><subject>Ammonia</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Gastroenterology and Hepatology</subject><subj-group><subject>Liver Diseases</subject><subj-group><subject>Cirrhosis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biomechanics</subject><subj-group><subject>Hand Strength</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Biomarkers</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Biological Locomotion</subject><subj-group><subject>Gait Analysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Clinical Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Cognitive Science</subject><subj-group><subject>Cognitive Neuroscience</subject><subj-group><subject>Cognitive Neurology</subject><subj-group><subject>Cognitive Impairment</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Cognitive Neuroscience</subject><subj-group><subject>Cognitive Neurology</subject><subj-group><subject>Cognitive Impairment</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Cognitive Neurology</subject><subj-group><subject>Cognitive Impairment</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Motor performance as a predictor of blood levels of ammonia and inflammatory biomarkers in patients with liver cirrhosis</article-title><alt-title alt-title-type="running-head">Motor impairment as predictor of inflammation in cirrhosis</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0347-5442</contrib-id><name name-style="western"><surname>San Mart&#237;n Valenzuela</surname><given-names initials="C">Constanza</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4368-5284</contrib-id><name name-style="western"><surname>Gallego</surname><given-names initials="JJ">Juan Jos&#233;</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Urios</surname><given-names initials="A">Amparo</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Correa-Ghisays</surname><given-names initials="P">Patricia</given-names></name><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1089-2204</contrib-id><name name-style="western"><surname>Tabares-Seisdedos</surname><given-names initials="R">Rafael</given-names></name><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4740-4788</contrib-id><name name-style="western"><surname>Montoliu</surname><given-names initials="C">Carmina</given-names></name><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff005" ref-type="aff">
<sup>5</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Unit of Personal Autonomy, Dependency, and Mental Disorders Assessment, Faculty of Medicine, University of Valencia - INCLIVA Biomedical Research Institute, Valencia, Spain</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Physiotherapy, Faculty of Physiotherapy, University of Valencia, Valencia, Spain</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Centro de Investigaci&#243;n Biom&#233;dica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Department of Pathology, Faculty of Medicine, University of Valencia, Valencia, Spain</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>INCLIVA, Biomedical Research Institute, Valencia, Spain</addr-line></aff><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Elshaarawy</surname><given-names initials="GAA">Ghada Abdrabo Abdellatif</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>National Research Centre, EGYPT</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>rafael.tabares@uv.es</email> (RT); <email>carmina.montoliu@uv.es</email> (CM)</corresp></author-notes><pub-date pub-type="epub"><day>8</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>20</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">498120</issue-id><elocation-id>e0333029</elocation-id><history><date date-type="received"><day>14</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>8</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 San Mart&#237;n Valenzuela et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>San Mart&#237;n Valenzuela et al</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pone.0333029.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="pone.0333029.pdf"/><abstract><p>Liver cirrhosis can present with complications such as hyperammonemia and inflammation, and the consequent appearance of minimal hepatic encephalopathy (MHE), which has been associated with poorer motor performance. Our aim was to analyze whether motor impairment would predict blood levels of ammonia and inflammatory factors in cirrhotic patients, independently of cognitive impairment. Blood was extracted from 67 cirrhotic patients from two hospitals in Valencia (Spain) (41.79% with MHE, diagnosis by Psychometric Hepatic Encephalopathy Score). Blood ammonia and plasma levels of interleukins (IL-6, IL-13, IL-18, IL-21, IL-22, IL-23, TNF-&#945;, TGF-&#946;) and chemokines (CCL20, CX3CL1, CXCL13, CCL2) were measured by micro-diffusion and ELISA, respectively. Gait, balance, hand strength, and manual motor speed were evaluated with biomechanical tools. All measurements were performed at University of Valencia, Spain. Motor outcomes were used as predictors in multiple linear regression analysis to determine their predictive capacity on blood ammonia and inflammatory factors. We found that levels of blood ammonia and TNF-&#945; were significantly predicted by the set of motor parameters with a coefficient of determination (R<sup>2</sup>)&gt;0.50, particularly by balance performance through the movement and velocity of Center of Pressure across the balance test. On the other hand, the models for IL-13, IL-21, CX3CL1, IL-6, CCL2, yielded an R<sup>2</sup> varying between 0.31&#8211;0.39. Lastly, R<sup>2</sup> was between 0.29 and 0.16 for the cytokines CXCL13, IL-22, CCL20, IL-18, and TGF-&#946;. Beside balance outcomes, gait speed and swing phase, as well as grip and lateral pinch strength, and hand motor speed, were frequent predictors in the models calculated. In conclusion, motor performance can predict blood levels of ammonia and cytokines in patients with liver cirrhosis, independently of the cognitive impairment present. Motor impairment could serve as an early, non-invasive indicator of disease severity, indicating the utility of conducting these tests in daily clinical practice and in follow-up studies.</p></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100004837</institution-id><institution>Ministerio de Ciencia e Innovaci&#195;&#179;n</institution></institution-wrap></funding-source><award-id>Instituto de Salud Carlos III (FIS PI23/00062), co-funded with European Regional Development Funds (ERDF)</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4740-4788</contrib-id><name name-style="western"><surname>Montoliu</surname><given-names>Carmina</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution>F. Sarabia Donation </institution></funding-source><award-id>PRV00225</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4740-4788</contrib-id><name name-style="western"><surname>Montoliu</surname><given-names>Carmina</given-names></name></principal-award-recipient></award-group><award-group id="award003"><funding-source><institution>Universidad de Valencia</institution></funding-source><award-id>Ayudas para Acciones Especiales (UV-INV_AE-2633839)</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4740-4788</contrib-id><name name-style="western"><surname>Montoliu</surname><given-names>Carmina</given-names></name></principal-award-recipient></award-group><award-group id="award004"><funding-source><institution>INCLIVA and Universidad de Valencia,</institution></funding-source><award-id>Programa de Proyectos de Investigaci&#243;n Traslacional VLC-Bioclinic (PI-2023-001)</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4740-4788</contrib-id><name name-style="western"><surname>Montoliu</surname><given-names>Carmina</given-names></name></principal-award-recipient></award-group><award-group id="award005"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100003359</institution-id><institution>Generalitat Valenciana</institution></institution-wrap></funding-source><award-id>PROMETEO/CIPROM/2022/58</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1089-2204</contrib-id><name name-style="western"><surname>Tabares-Seisdedos</surname><given-names>Rafael</given-names></name></principal-award-recipient></award-group><award-group id="award006"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100003359</institution-id><institution>Generalitat Valenciana</institution></institution-wrap></funding-source><award-id>CIPROM2021/082</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4740-4788</contrib-id><name name-style="western"><surname>Montoliu</surname><given-names>Carmina</given-names></name></principal-award-recipient></award-group><award-group id="award007"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100014440</institution-id><institution>Ministerio de Ciencia, Innovaci&#195;&#179;n y Universidades</institution></institution-wrap></funding-source><award-id>PID2021-129099OB-I00</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1089-2204</contrib-id><name name-style="western"><surname>Tabares-Seisdedos</surname><given-names>Rafael</given-names></name></principal-award-recipient></award-group><award-group id="award008"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100004587</institution-id><institution>Instituto de Salud Carlos III</institution></institution-wrap></funding-source><award-id>CIBERSAM</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1089-2204</contrib-id><name name-style="western"><surname>Tabares-Seisdedos</surname><given-names>Rafael</given-names></name></principal-award-recipient></award-group><award-group id="award009"><funding-source><institution>European Union </institution></funding-source><award-id>Operational Program of the European Regional Development Fund (FEDER) of the Comunidad Valenciana 2014&#8211;2020</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4740-4788</contrib-id><name name-style="western"><surname>Montoliu</surname><given-names>Carmina</given-names></name></principal-award-recipient></award-group><funding-statement>This research was funded by Ministerio de Ciencia e Innovaci&#243;n&#8212;Instituto de Salud Carlos III (FIS PI23/00062) to CM, co-funded with European Regional Development Funds (ERDF); F. Sarabia Donation (PRV00225) to CM; Universidad de Valencia, Ayudas para Acciones Especiales (UV-INV_AE-2633839) to CM; Donation from Fundaci&#243;n Raminatrans (president of Foundation, Larissa Milla) to CM. In addition, the authors also received support from Ministry of Education of the Valencian Regional Government (PROMETEO/CIPROM/2022/58 to RT-S, CIPROM2021/082 to CM); Spanish Ministry of Science, Innovation and Universities (PID2021-129099OB-I00) to RT-S. RT-S is funded by CIBERSAM/Institute of Health Carlos III. Action was cofinanced by the European Union through the Operational Program of the European Regional Development Fund (FEDER) of the Comunidad Valenciana 2014&#8211;2020 to CM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="0"/><table-count count="4"/><page-count count="13"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>The data generated and analyzed during this study are included within this article, and its <xref rid="sec010" ref-type="sec">Supporting information</xref>. Data of motor variables and cytokine levels are available from the Zenodo.org repository at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.5281/zenodo.15695221" ext-link-type="uri">https://doi.org/10.5281/zenodo.15695221</ext-link> (accessed on 19 June 2025).</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>The data generated and analyzed during this study are included within this article, and its <xref rid="sec010" ref-type="sec">Supporting information</xref>. Data of motor variables and cytokine levels are available from the Zenodo.org repository at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.5281/zenodo.15695221" ext-link-type="uri">https://doi.org/10.5281/zenodo.15695221</ext-link> (accessed on 19 June 2025).</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Liver cirrhosis is widely prevalent worldwide, and is associated with high morbidity and mortality [<xref rid="pone.0333029.ref001" ref-type="bibr">1</xref>]. Cirrhosis is characterized by fibrosis and nodule formation of the liver secondary to chronic injury [<xref rid="pone.0333029.ref002" ref-type="bibr">2</xref>], and it evolves from an asymptomatic phase (compensated cirrhosis) to a symptomatic phase (decompensated cirrhosis), with complications such as ascites, oesophageal variceal bleeding, and hepatic encephalopathy (HE) [<xref rid="pone.0333029.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0333029.ref003" ref-type="bibr">3</xref>]. HE encompasses a broad spectrum of cognitive, psychomotor, and psychiatric disturbances [<xref rid="pone.0333029.ref004" ref-type="bibr">4</xref>], ranging from minimal hepatic encephalopathy (MHE), to grade IV according to symptoms severity by West Haven criteria [<xref rid="pone.0333029.ref003" ref-type="bibr">3</xref>]. Another common system, from the International Society for Hepatic Encephalopathy and Nitrogen Metabolism, divides HE into covert (MHE and grade I) and overt (grades II to IV) forms [<xref rid="pone.0333029.ref005" ref-type="bibr">5</xref>]. Overt HE is present in 10&#8211;14% of patients at cirrhosis diagnosis [<xref rid="pone.0333029.ref003" ref-type="bibr">3</xref>] and occurs in 30&#8211;40% over the disease course, often recurrently [<xref rid="pone.0333029.ref006" ref-type="bibr">6</xref>]. MHE is the mildest form of HE, and includes a spectrum of brain-related symptoms [<xref rid="pone.0333029.ref007" ref-type="bibr">7</xref>], such as impairment in attention, executive function, visuo-construction, processing speed, motor speed, and motor accuracy [<xref rid="pone.0333029.ref008" ref-type="bibr">8</xref>]. Since these neuropsychiatric features are not exclusive to MHE, diagnosis relies on neurocognitive tests, of which the psychometric hepatic encephalopathy score (PHES) is the gold standard [<xref rid="pone.0333029.ref009" ref-type="bibr">9</xref>] where normative values are available. In our studies, we found that 42% of cirrhotic patients have MHE according to PHES score [<xref rid="pone.0333029.ref010" ref-type="bibr">10</xref>], which is similar to that found in a multicenter study from Europe and the United States [<xref rid="pone.0333029.ref011" ref-type="bibr">11</xref>] reporting a MHE prevalence of 35%, which varied substantially between diseases stages. A study form India showed a MHE prevalence of 59.7% [<xref rid="pone.0333029.ref012" ref-type="bibr">12</xref>] and the prevalence of covert HE in cirrhotic patients in China was 50.4%, gradually increasing with the severity of impaired liver function [<xref rid="pone.0333029.ref013" ref-type="bibr">13</xref>].</p><p>Motor impairments have also been reported in patients with HE and MHE, which correlated with their cognitive performance [<xref rid="pone.0333029.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0333029.ref014" ref-type="bibr">14</xref>,<xref rid="pone.0333029.ref015" ref-type="bibr">15</xref>]. Although there are not reported the prevalence of motor impairment in patients with MHE, we found that 80% of MHE patients and 43% of patients without MHE show alterations in motor coordination tests [<xref rid="pone.0333029.ref010" ref-type="bibr">10</xref>]. Moreover, compared to individuals without MHE, MHE patients exhibit poorer gait and balance performance, as well as motor slowing and worse hand strength variability [<xref rid="pone.0333029.ref014" ref-type="bibr">14</xref>]. In addition, both myosteatosis (excessive fat infiltration in the skeletal muscle), and sarcopenia (loss of skeletal muscle mass and strength) seem to be strongly associated with the presence of MHE, as well as with the development of overt HE [<xref rid="pone.0333029.ref016" ref-type="bibr">16</xref>]. Due to this disease pattern, MHE is associated with decreased survival and high risk of recurrence [<xref rid="pone.0333029.ref017" ref-type="bibr">17</xref>], and impacts the lives of both patients and caregivers by worsening daily function, socioeconomic status, and quality of life [<xref rid="pone.0333029.ref018" ref-type="bibr">18</xref>]. Lastly, cognitive decline and psychomotor alterations (e.g., asterixis, dyspraxia) themselves also entail a high risk of progression to overt HE [<xref rid="pone.0333029.ref017" ref-type="bibr">17</xref>].</p><p>The major mechanisms implicated in the pathogenesis of HE in cirrhosis include the effects of toxins and pro-inflammatory processes, which are significant for structural and functional brain integrity [<xref rid="pone.0333029.ref004" ref-type="bibr">4</xref>]. Ammonia is one of the main factors related to HE. Due to liver failure, other organs take on roles in the transformation of ammonia into glutamine, such as skeletal muscle, kidneys and brain [<xref rid="pone.0333029.ref019" ref-type="bibr">19</xref>]. In the brain, astrocytes undergo a series of morphological changes compatible with Alzheimer&#8217;s disease [<xref rid="pone.0333029.ref020" ref-type="bibr">20</xref>,<xref rid="pone.0333029.ref021" ref-type="bibr">21</xref>], and subsequent elevation of intracellular glutamine. This generates osmotic stress that causes astrocytes to swell [<xref rid="pone.0333029.ref022" ref-type="bibr">22</xref>], dysregulation of metabolic pathways in astrocytes, oxidative stress, and cerebral edema [<xref rid="pone.0333029.ref023" ref-type="bibr">23</xref>].</p><p>Besides ammonia, circulating chemokines and cytokines are also increased following liver injury, leading to activation of microglia and a subsequent neuroinflammatory response [<xref rid="pone.0333029.ref023" ref-type="bibr">23</xref>]. The systemic release of pro-inflammatory cytokines and mediators including but not limited to Tumour Necrosis Factor alpha (TNF-&#945;) and interleukins (IL) such as IL-1&#946;, IL-6, IL-8 and IL-12, may aggravate the condition of patients with cirrhosis and precipitate or exacerbate HE [<xref rid="pone.0333029.ref019" ref-type="bibr">19</xref>]. Therefore, peripheral inflammation and hyperammonemia play synergistic roles in inducing MHE in cirrhotic patients [<xref rid="pone.0333029.ref024" ref-type="bibr">24</xref>,<xref rid="pone.0333029.ref025" ref-type="bibr">25</xref>], indicating that inflammation exacerbates the neuropsychological alterations induced by hyperammonemia [<xref rid="pone.0333029.ref026" ref-type="bibr">26</xref>]. The prevalence of high ammonia and ILs levels in MHE patients is not reported, but some studies showed that patients with MHE have elevated levels of proinflammatory interleukins in plasma compared to patients without MHE [<xref rid="pone.0333029.ref024" ref-type="bibr">24</xref>,<xref rid="pone.0333029.ref025" ref-type="bibr">25</xref>,<xref rid="pone.0333029.ref027" ref-type="bibr">27</xref>,<xref rid="pone.0333029.ref028" ref-type="bibr">28</xref>]. Moreover, MHE appearance is associated with specific changes in the immune system and peripheral inflammation [<xref rid="pone.0333029.ref029" ref-type="bibr">29</xref>].</p><p>Studies have demonstrated that arterial and venous ammonia is significantly correlated with HE severity, as measured by the West Haven Criteria [<xref rid="pone.0333029.ref030" ref-type="bibr">30</xref>], yet no significant relationship between the PHES score and blood ammonia has been found [<xref rid="pone.0333029.ref031" ref-type="bibr">31</xref>]. In this way, Gim&#233;nez et al. reported that PHES is not sensitive enough to detect early neurological alterations in a significant proportion of cirrhotic patients [<xref rid="pone.0333029.ref010" ref-type="bibr">10</xref>]. Due to the previously demonstrated association of motor decline with onset of MHE [<xref rid="pone.0333029.ref014" ref-type="bibr">14</xref>], in this work we aimed to analyze whether motor performance in cirrhotic patients with and without MHE could be a statistical predictor of plasma biomarker levels such as ammonia and inflammatory factors. Our hypothesis was that motor impairment is progressive and is related to toxicity and inflammation in patients with liver cirrhosis, regardless of whether they have cognitive impairment diagnosed via PHES. If so, motor impairment may represent a new area indicating the ammonia and inflammatory stage of patients with liver cirrhosis. Given that this motor impairment is easily observable and reportable in daily clinical practice without the need for test batteries or laboratory analysis, this could potentially enhance early diagnosis and treatment of MHE, by helping clinicians prioritize specific diagnostic tests for patients with motor impairment.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and methods</title><sec id="sec003"><title>Study design, setting, and participants</title><p>This study is cross-sectional with a convenience sampling approach (specifically, modal instance sampling, i.e., volunteers with the pathology for study). It was designed following STROBE guidelines (<xref rid="pone.0333029.s001" ref-type="supplementary-material">S1 Table</xref>). A total of 67 participants with liver cirrhosis were consecutively recruited from 4 March 2018&#8211;12 November 2024, at the outpatient clinics of Hospital Cl&#237;nico and Hospital Arnau de Vilanova in Valencia, Spain. Diagnosis of cirrhosis was based on clinical, biochemical and ultrasonographic data. Inclusion criteria were (i) compensated liver cirrhosis, (ii) able to stand and walk without use of assistive devices, (iii) stable medication and (iv) over 18 years old. Exclusion criteria were (i) overt HE or history of overt HE, (ii) recent (&lt;6 months) alcohol intake, (iii) history of abuse or drug-dependence of any another substances besides alcohol, (iv) history of disease or secondary trauma that could influence cognitive or motor deterioration, (v) chronic disease without normative treatment (visual problems, high blood pressure, diabetes, hypercholesterolemia), (vi) established neurological or psychiatric disorders. All participants were included after giving written informed consent. Study protocols were approved by the Scientific and Research Ethics Committees of Hospital Cl&#237;nico Universitario and Arnau de Vilanova Hospital of Valencia, Spain (approval code: 2018.051; approval date: 27 February 2018; approval code: 2023/130; approval date: 29 February 2024) and were in accordance with the principles of the World Medical Association&#8217;s Declaration of Helsinki, the Council of Europe Convention regarding human rights and the requirements established in Spanish legislation in the field of Biomedical research, personal data protection and bioethics.</p></sec><sec id="sec004"><title>Variables and measurement</title><p>Recruited study participants who had signed informed consent underwent blood extraction after fasting. On the same day, a clinical interview was performed to record participants&#8217; baseline characteristics, such as weight, height, and cognitive status. Thereafter, venous blood ammonia level was measured immediately after blood extraction with the Ammonia Test Kit II for the PocketChem BA system (Arkray, Inc., Kyoto, Japan) following the manufacturer&#8217;s instructions. Blood samples were centrifuged for 10&#8201;min at 1500&#8201;g, and plasma was kept at &#8722;80 &#176;C for subsequent cytokine analysis. Concentrations of cytokines were measured by ELISA (R&amp;D Systems, Minneapolis, MN, USA) according to the manufacturer&#8217;s instructions. Beside ammonia (&#956;M), the inflammatory parameters (pg/mL) studied were TNF-&#945;, interleukins IL-6, IL-13, IL-18, IL-21, and IL-22; fractalkine (CX3CL1); chemokines CCL2 and CCL20; chemokine ligand 13 (CXCL13), and transforming growth factor beta (TGF-&#946;). The relevance of these parameters in liver cirrhosis has been previously reported [<xref rid="pone.0333029.ref027" ref-type="bibr">27</xref>,<xref rid="pone.0333029.ref029" ref-type="bibr">29</xref>]. Blood analytical parameters, including glucose levels, electrolytes, and hepatic enzymes, were collected to characterize the participants.</p><p>Additionally, cognitive status was also assessed on the same day as the blood collection in order to characterize the sample. All participants completed the Psychometric Hepatic Encephalopathy Score (PHES) [<xref rid="pone.0333029.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0333029.ref032" ref-type="bibr">32</xref>,<xref rid="pone.0333029.ref033" ref-type="bibr">33</xref>], which was calculated, adjusting for age and educational level, using Spanish normality tables (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.redeh.org/TEST_phes.htm" ext-link-type="uri">www.redeh.org/TEST_phes.htm</ext-link>, accessed on 19 July 2023). Patients were classified as MHE when the score was&#8201;&#8804;&#8722;4 [<xref rid="pone.0333029.ref032" ref-type="bibr">32</xref>]. Severity of liver disease indicators was calculated using the Child-Pugh score and the model end-stage liver disease (MELD) score after etiology data related to the liver disease and analytical values were collected.</p><p>All patients performed the motor tests in the morning, at the same time (9:00 am) and under the same conditions (non-fasting). Given the time required to carry out motor tests, motor performance was assessed in a different session, but no later than one week after blood extraction, depending on the availability of the participant, in order to avoid possible progression of the pathology and distortion of the results. Gait, balance, hand strength, and manual motor speed were evaluated with instrumental and biomechanical tools. Motor outcomes (shown in <xref rid="pone.0333029.t001" ref-type="table">Table 1</xref>) were used as predictor variables in the analyses. First, gait was measured using two photocells and two force platforms (Dinascan/IBV Biomechanical Institute of Valencia, Valencia, Spain; and NedAMH/IBV software version 5.1.0, 2013, Biomechanical Institute of Valencia, Valencia, Spain). Participants walked barefoot along a 10 m-long corridor at a self-selected comfortable speed. The platforms were located at the center of the corridor to record the central step and avoid acceleration and deceleration at the start and end of the gait cycle. Secondly, functional postural balance was assessed using a single force platform and NedSVE&#174;/IBV software (version 5.1.0, 2013, Biomechanical Institute of Valencia, Valencia, Spain) [<xref rid="pone.0333029.ref034" ref-type="bibr">34</xref>]. Center of Pressure (CoP) displacement was recorded during Romberg tests for 30&#8201;s under four different stability conditions (eyes open or closed, standing on a firm surface or on a 10 cm-thick foam pad) [<xref rid="pone.0333029.ref035" ref-type="bibr">35</xref>]. During the tests, participants maintained a standing position and marks were used on the pad to standardize foot position [<xref rid="pone.0333029.ref014" ref-type="bibr">14</xref>].</p><table-wrap position="float" id="pone.0333029.t001" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0333029.t001</object-id><label>Table 1</label><caption><title>Motor outcome parameters measured used as predictors in the study.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0333029.t001g" position="float" orientation="portrait" xlink:href="pone.0333029.t001.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">
<italic toggle="yes">Gait assessment</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gait velocity (m/s)</td><td align="left" rowspan="1" colspan="1">Distance traveled during a period of time</td></tr><tr><td align="left" rowspan="1" colspan="1">Stance time (s)</td><td align="left" rowspan="1" colspan="1">Period of time when the foot is in contact with the ground</td></tr><tr><td align="left" rowspan="1" colspan="1">Braking force (N)</td><td align="left" rowspan="1" colspan="1">Minimum registered anteroposterior GRF corresponding to heel strike</td></tr><tr><td align="left" rowspan="1" colspan="1">Propulsive force (N)</td><td align="left" rowspan="1" colspan="1">Maximum registered anteroposterior GRF corresponding to take-off</td></tr><tr><td align="left" rowspan="1" colspan="1">Swing force (N)</td><td align="left" rowspan="1" colspan="1">Minimum registered vertical GRF occurring during contralateral foot oscillation</td></tr><tr><td align="left" rowspan="1" colspan="1">Push-off force (N)</td><td align="left" rowspan="1" colspan="1">Second highest registered of vertical component of GRF between heel-off and toe-off</td></tr><tr><td align="left" colspan="2" rowspan="1">
<italic toggle="yes">Static balance assessment</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">CoP velocity (m/s)</td><td align="left" rowspan="1" colspan="1">Mean velocity of CoP projection from start to end of test (total distance traveled by the CoP/ time elapsed)</td></tr><tr><td align="left" rowspan="1" colspan="1">CoP displacement angle (&#186;)</td><td align="left" rowspan="1" colspan="1">Displacement vector orientation extending from the starting point to the end position of the subject</td></tr><tr><td align="left" rowspan="1" colspan="1">CoP displacement (mm)</td><td align="left" rowspan="1" colspan="1">Total distance of the CoP reached from the origin. Maximum anteroposterior and mediolateral distance reached by the CoP</td></tr><tr><td align="left" rowspan="1" colspan="1">CoP dispersion (mm)</td><td align="left" rowspan="1" colspan="1">Dispersion of the point cloud described by the CoP in the mediolateral and anteroposterior directions</td></tr><tr><td align="left" rowspan="1" colspan="1">CoP force (N)</td><td align="left" rowspan="1" colspan="1">Maximum force in mediolateral and anteroposterior directions exerted by the CoP during the test</td></tr><tr><td align="left" rowspan="1" colspan="1">CoP swept area (mm<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1">Area of subject&#8217;s swing, calculated from beginning until end of the test</td></tr><tr><td align="left" colspan="2" rowspan="1">
<italic toggle="yes">Manual motor speed assessment</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">FTT right and left (freq.)</td><td align="left" rowspan="1" colspan="1">Number of times the key is pressed with the right and left hand</td></tr><tr><td align="left" rowspan="1" colspan="1">FTT2 right and left (freq.)</td><td align="left" rowspan="1" colspan="1">Number of times the key is pressed with the right and left hand while the test is performed with both hands</td></tr><tr><td align="left" colspan="2" rowspan="1">
<italic toggle="yes">Hand strength assessment</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Grip strength (N)</td><td align="left" rowspan="1" colspan="1">Average of grip strength repetitions, for right and left hand individually</td></tr><tr><td align="left" rowspan="1" colspan="1">Lateral pinch strength (N)</td><td align="left" rowspan="1" colspan="1">Average of lateral pinch strength repetitions, for right and left hand individually</td></tr><tr><td align="left" rowspan="1" colspan="1">Tip pinch strength (N)</td><td align="left" rowspan="1" colspan="1">Average of tip pinch strength repetitions, for right and left hand individually</td></tr><tr><td align="left" rowspan="1" colspan="1">Coefficient of variation (%)</td><td align="left" rowspan="1" colspan="1">Standard deviation ratio to mean hand strength during each task, which indicates variability in hand force strength performance and strength stability control</td></tr><tr><td align="left" rowspan="1" colspan="1">Index of Difference (ID)</td><td align="left" rowspan="1" colspan="1">Difference in performance between right and left hand</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>Motor outcomes registered per test: m/s, meter/second; s, second; N, newton; GRF, ground reaction force; CoP, center of pressure; mm, millimeters; mm<sup>2</sup>, square millimeters; FTT, finger tapping test; freq., frequency.</p></fn></table-wrap-foot></table-wrap><p>After gait and balance, participants performed hand motor tests sitting upright in a chair with a backrest but without armrests. Feet were supported on the floor with 90&#186; knee flexion, and arms positioned with 90&#186; elbow flexion. First, motor speed was assessed through the Finger Tapping Test (FTT). Each subject was required to tap a key as many times as possible using the index finger of each hand, and the number of taps within 30&#8201;s was recorded [<xref rid="pone.0333029.ref036" ref-type="bibr">36</xref>]. Participants completed the test once with the right hand, again with the left hand and lastly performed the test with both hands at the same time. Finally, grip strength was measured with an electronic dynamometer (NedVEP/IBV Biomechanical Institute of Valencia, Valencia, Spain) and NedDiscapacidad/IBV software (version 4.1.1, Biomechanical Institute of Valencia, Valencia, Spain) [<xref rid="pone.0333029.ref037" ref-type="bibr">37</xref>,<xref rid="pone.0333029.ref038" ref-type="bibr">38</xref>]. The forearm was placed in neutral pronosupination position [<xref rid="pone.0333029.ref039" ref-type="bibr">39</xref>] to perform three functional force gestures for 30 s: a) handgrip, b) lateral pinch (thumb pad and side of index finger), and c) tip pinch (thumb and index finger) [<xref rid="pone.0333029.ref014" ref-type="bibr">14</xref>]. For each gesture, three repetitions of maximum force were obtained, ensuring they did not differ by more than 10% [<xref rid="pone.0333029.ref040" ref-type="bibr">40</xref>].</p></sec><sec id="sec005"><title>Bias and study size</title><p>The main bias detected in the study was the presence of comorbidities adding an inflammatory burden beyond that generated exclusively by the disease. This bias was controlled through the participation criteria, the clinical interview conducted and participants&#8217; medical history. Sample size estimation was performed for the statistical analysis presented in this manuscript. For this purpose, the G*Power software (Universit&#228;t Kiel, Germany, Version 3.1) [<xref rid="pone.0333029.ref041" ref-type="bibr">41</xref>] was used, applying and alpha level of 0.05 and a power of 0.8. The expected effect size was set at R&#178;&#8201;=&#8201;0.5, indicating that at least 50% of the variance in the biological variables would be explained by the 19 motor predictors included in the analysis. Based on this calculation, a total of 58 participants were required.</p></sec><sec id="sec006"><title>Statistical analysis</title><p>Statistical analyses were performed using IBM SPSS V26 (SPSS Inc., Chicago, IL, USA). All motor outcomes served as the independent variables in this study and were used as predictors in the analyses discussed below. In contrast, the registered biochemical variables (from blood test) constituted the dependent variables, that is, the predicted outcomes for which a separate regression model was generated. Descriptive data (mean, standard deviation, and range) were used to inform the continuous outcomes with normal distribution. Variables not meeting this assumption were reported using median and range. Categorical variables were reported through frequencies. As the assumption of normality was met in the variables analyzed and residuals, a stepwise multiple linear regression analysis model was used for the ammonia and biochemical markers measured. Given the large number of predictors relative to the number of participants, stepwise regression was employed to obtain a regression model with the minimum number of statistically significant predictors [<xref rid="pone.0333029.ref042" ref-type="bibr">42</xref>]. The multiple correlation coefficient squared value (R<sup>2</sup>) was calculated for each regression model to demonstrate goodness of fit. Beta coefficient values (&#946;), standard error (SE), and significance values for each regression model were also reported.</p></sec></sec><sec sec-type="results" id="sec007"><title>Results</title><p>The assessments of the study were completed for 67 participants, whose characteristics, etiology of cirrhosis and analytical parameters are shown in <xref rid="pone.0333029.t002" ref-type="table">Table 2</xref>. Across the whole sample, 28 patients (41.79%) were classified as having MHE versus 39 patients (58.21%) without MHE, according to PHES score. Blood ammonia and plasma levels of interleukins (IL-6, IL-13, IL-18, IL-21, IL-22, IL-23, TNF-&#945;, TGF-&#946;) and chemokines (CCL20, CX3CL1, CXCL13, CCL2) tested are shown in <xref rid="pone.0333029.s002" ref-type="supplementary-material">S2 Table</xref>, as well as their comparison with reference data. Cirrhotic patients showed significantly higher blood ammonia levels (p&#8201;&lt;&#8201;0.05) and altered plasma levels of ILs measured, in contrast with non-diseased blood levels data.</p><table-wrap position="float" id="pone.0333029.t002" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0333029.t002</object-id><label>Table 2</label><caption><title>Clinical and demographic characteristics of the participants.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0333029.t002g" position="float" orientation="portrait" xlink:href="pone.0333029.t002.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Demographical and Clinical variables</th><th align="left" rowspan="1" colspan="1">Cirrhotic patients (n&#8201;=&#8201;67)</th><th align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sex (Male/Female)<sup>a</sup></td><td align="left" rowspan="1" colspan="1">52 (77.61%)/15 (22.39%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)<sup>b</sup></td><td align="left" rowspan="1" colspan="1">62.31&#8201;&#177;&#8201;8.82 (46-86)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg)<sup>b</sup></td><td align="left" rowspan="1" colspan="1">80.35&#8201;&#177;&#8201;13.85 (54.5-113.1)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Height (m)<sup>b</sup></td><td align="left" rowspan="1" colspan="1">166.56&#8201;&#177;&#8201;7.75 (148-184)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">BMI<sup>b</sup></td><td align="left" rowspan="1" colspan="1">29.01&#8201;&#177;&#8201;4.55 (19.50-38.79)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Child-Pugh score (A/B/C)<sup>a</sup></td><td align="left" rowspan="1" colspan="1">49/16/2</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">MELD score<sup>b</sup></td><td align="left" rowspan="1" colspan="1">9.49&#8201;&#177;&#8201;2.78 (5-17)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age at diagnosis of cirrhosis<sup>c</sup></td><td align="left" rowspan="1" colspan="1">55 (49-63)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Time from diagnosis of cirrhosis to inclusion in the study (years)</td><td align="left" rowspan="1" colspan="1">3 (1-7.5)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Etiology of cirrhosis<sup>a</sup></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Alcohol</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">HBV/HCV/HCV&#8201;+&#8201;alcohol</td><td align="left" rowspan="1" colspan="1">1/17/3</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">MASH</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Analytical parameters<sup>b</sup></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Normal range</td></tr><tr><td align="left" rowspan="1" colspan="1">Glucose (mg/dL)</td><td align="left" rowspan="1" colspan="1">114&#8201;&#177;&#8201;39</td><td align="left" rowspan="1" colspan="1">64-106</td></tr><tr><td align="left" rowspan="1" colspan="1">Sodium (mmol/L)</td><td align="left" rowspan="1" colspan="1">139&#8201;&#177;&#8201;3</td><td align="left" rowspan="1" colspan="1">135-145</td></tr><tr><td align="left" rowspan="1" colspan="1">Potassium (mmol/L)</td><td align="left" rowspan="1" colspan="1">4.3&#8201;&#177;&#8201;0.6</td><td align="left" rowspan="1" colspan="1">3.5-5.1</td></tr><tr><td align="left" rowspan="1" colspan="1">AST (U/L)</td><td align="left" rowspan="1" colspan="1">41&#8201;&#177;&#8201;21</td><td align="left" rowspan="1" colspan="1">11-34</td></tr><tr><td align="left" rowspan="1" colspan="1">ALT (U/L)</td><td align="left" rowspan="1" colspan="1">31.6&#8201;&#177;&#8201;13.5</td><td align="left" rowspan="1" colspan="1">&lt;34</td></tr><tr><td align="left" rowspan="1" colspan="1">GGT (U/L)</td><td align="left" rowspan="1" colspan="1">92&#8201;&#177;&#8201;78</td><td align="left" rowspan="1" colspan="1">9-36</td></tr><tr><td align="left" rowspan="1" colspan="1">PHES<sup>b</sup></td><td align="left" rowspan="1" colspan="1">&#8722;3.98&#8201;&#177;&#8201;4.50 (&#8722;14&#8722;3)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">MHE/ No MHE<sup>a</sup></td><td align="left" rowspan="1" colspan="1">28/ 39</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p><sup>a</sup>Values are expressed as frequency. <sup>b</sup>Values are expressed as mean&#8201;&#177;&#8201;standard deviation (range).<sup>c</sup>data expressed as median (Interquartile range). AST, aspartate transaminase; ALT, alanine transaminase; BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus; GGT, &#947;-glutamyl transpeptidase; MASH, metabolic dysfunction-associated steatohepatitis; MELD: model end-stage liver disease. PHES: Psychometric Hepatic Encephalopathy Score. MHE, no MHE: patients with and without minimal hepatic encephalopathy, respectively, according to PHES score.</p></fn></table-wrap-foot></table-wrap><p>We previously evaluated whether some potential confounders such as blood electrolytes and the presence of diabetes, produced differences in motor performance and in the values of the blood parameters measured. As shown in <xref rid="pone.0333029.t002" ref-type="table">Table 2</xref>, all patients in this study showed normal levels of sodium and potassium, and these variables would not influence motor function in the patients in our study.</p><p>We also analyzed whether the presence of diabetes could influence differences in motor performance and in the values of the blood parameters measured. The presence of diabetes did not lead to statistically significant differences in either motor performance or the blood biomarkers analyzed (<xref rid="pone.0333029.s003" ref-type="supplementary-material">S3</xref> and <xref rid="pone.0333029.s004" ref-type="supplementary-material">S4 Tables</xref>). Therefore, we consider that the presence of diabetes is unlikely to have influenced our results.</p><p>Other possible confounder could be the alcoholic etiology, however we previously showed that there were no significant differences in parameters of motor performance measured between cirrhotic patients of alcoholic etiology and other etiologies [<xref rid="pone.0333029.ref014" ref-type="bibr">14</xref>].</p><p>The model that explained the greatest variance in each biomarker was selected from stepwise analysis. For IL-23, no statistically significant model was found (p&#8201;&gt;&#8201;0.05). For the biomarkers with a significant result (p&#8201;&lt;&#8201;0.05), the regression models calculated explained between 16 and 59% of the biomarker data dispersion. <xref rid="pone.0333029.t003" ref-type="table">Table 3</xref> shows the results for each model. Ammonia (F<sub>(8.56)</sub> = 10.20, p&#8201;&lt;&#8201;0.01) and TNF-&#945; (F<sub>(7.57)</sub> = 8.25, p&#8201;&lt;&#8201;0.01) outcomes achieved models with an R<sup>2</sup>&#8201;&gt;&#8201;0.50 (<xref rid="pone.0333029.t003" ref-type="table">Table 3</xref>). In the ammonia model, variables related to balance and gait functioned as predictors, while in the TNF-&#945; model gait, balance and hand strength variables were significant outcome predictors. From the ammonia model, the most meaningful outcomes were CoP force (SBeta&#8201;=&#8201;0.75, p&#8201;&lt;&#8201;0.01) and dispersion (SBeta&#8201;=&#8201;0.91, p&#8201;&lt;&#8201;0.01) in the anteroposterior direction during the Romberg test with eyes open (<xref rid="pone.0333029.t004" ref-type="table">Table 4</xref>). According to the unstandardized coefficients reported in <xref rid="pone.0333029.t004" ref-type="table">Table 4</xref>, a one-unit increase in CoP dispersion in the anteroposterior direction during the Romberg test with eyes open is associated with an average increase of 13.54 units in ammonia concentration, holding all other variables from the model constant. Likewise, a one-unit increase in CoP force in the anteroposterior direction during the same Romberg test is associated with an average increase of 8.14 units in ammonia concentration.</p><table-wrap position="float" id="pone.0333029.t003" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0333029.t003</object-id><label>Table 3</label><caption><title>Summary of multiple linear regression models for each biomarker measured.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0333029.t003g" position="float" orientation="portrait" xlink:href="pone.0333029.t003.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Biomarker</th><th align="left" rowspan="1" colspan="1">R</th><th align="left" rowspan="1" colspan="1">R<sup>2</sup></th><th align="left" rowspan="1" colspan="1">F</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="left" rowspan="1" colspan="1">&#946;<sub>0</sub></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Ammonia</td><td align="left" rowspan="1" colspan="1">0.77</td><td align="left" rowspan="1" colspan="1">0.59</td><td align="left" rowspan="1" colspan="1">10.20</td><td align="left" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">105.51</td></tr><tr><td align="left" rowspan="1" colspan="1">TNF-&#945;</td><td align="left" rowspan="1" colspan="1">0.71</td><td align="left" rowspan="1" colspan="1">0.50</td><td align="left" rowspan="1" colspan="1">8.25</td><td align="left" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">4.98</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-13</td><td align="left" rowspan="1" colspan="1">0.63</td><td align="left" rowspan="1" colspan="1">0.39</td><td align="left" rowspan="1" colspan="1">7.62</td><td align="left" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">8.65</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-21</td><td align="left" rowspan="1" colspan="1">0.61</td><td align="left" rowspan="1" colspan="1">0.38</td><td align="left" rowspan="1" colspan="1">9.08</td><td align="left" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">1078.15</td></tr><tr><td align="left" rowspan="1" colspan="1">CX3CL1</td><td align="left" rowspan="1" colspan="1">0.60</td><td align="left" rowspan="1" colspan="1">0.36</td><td align="left" rowspan="1" colspan="1">11.62</td><td align="left" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">4011.32</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-6</td><td align="left" rowspan="1" colspan="1">0.56</td><td align="left" rowspan="1" colspan="1">0.32</td><td align="left" rowspan="1" colspan="1">14.64</td><td align="left" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">10.45</td></tr><tr><td align="left" rowspan="1" colspan="1">CCL2</td><td align="left" rowspan="1" colspan="1">0.56</td><td align="left" rowspan="1" colspan="1">0.31</td><td align="left" rowspan="1" colspan="1">6.80</td><td align="left" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">41.84</td></tr><tr><td align="left" rowspan="1" colspan="1">CXCL13</td><td align="left" rowspan="1" colspan="1">0.54</td><td align="left" rowspan="1" colspan="1">0.29</td><td align="left" rowspan="1" colspan="1">8.35</td><td align="left" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">209.29</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-22</td><td align="left" rowspan="1" colspan="1">0.53</td><td align="left" rowspan="1" colspan="1">0.28</td><td align="left" rowspan="1" colspan="1">11.87</td><td align="left" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">67.92</td></tr><tr><td align="left" rowspan="1" colspan="1">CCL20</td><td align="left" rowspan="1" colspan="1">0.51</td><td align="left" rowspan="1" colspan="1">0.26</td><td align="left" rowspan="1" colspan="1">7.09</td><td align="left" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">87.73</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-18</td><td align="left" rowspan="1" colspan="1">0.41</td><td align="left" rowspan="1" colspan="1">0.18</td><td align="left" rowspan="1" colspan="1">6.56</td><td align="left" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">1423.93</td></tr><tr><td align="left" rowspan="1" colspan="1">TGF-&#946;</td><td align="left" rowspan="1" colspan="1">0.40</td><td align="left" rowspan="1" colspan="1">0.16</td><td align="left" rowspan="1" colspan="1">5.97</td><td align="left" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">8756.13</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>The regression models for each biomarker are shown in order of explained variance. The multiple correlation coefficient (R) and squared value (R<sup>2</sup>) are indicated. The Fisher F ratio and its significance value (<italic toggle="yes">p</italic>) from the ANOVA analysis, as well as the &#946;<sub>0</sub> coefficient are also reported.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pone.0333029.t004" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0333029.t004</object-id><label>Table 4</label><caption><title>Outcome predictors from the multiple regression models that explain over 50% of the variance in the biomarkers analyzed.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0333029.t004g" position="float" orientation="portrait" xlink:href="pone.0333029.t004.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Biomarker</th><th align="left" rowspan="2" colspan="1">Predictor</th><th align="left" colspan="2" rowspan="1">Unstandardized</th><th align="left" rowspan="2" colspan="1">Stand.</th><th align="left" rowspan="2" colspan="1">CI</th><th align="left" rowspan="2" colspan="1">t</th><th align="left" rowspan="2" colspan="1">
<italic toggle="yes">p</italic>
</th></tr><tr><th align="left" rowspan="1" colspan="1">&#946;</th><th align="left" rowspan="1" colspan="1">SE</th></tr></thead><tbody><tr><td align="left" rowspan="8" colspan="1">AMMONIA</td><td align="left" rowspan="1" colspan="1">AP CoP Force in REO</td><td align="left" rowspan="1" colspan="1">8.14</td><td align="left" rowspan="1" colspan="1">1.39</td><td align="left" rowspan="1" colspan="1">0.75</td><td align="left" rowspan="1" colspan="1">5.36; 10.93</td><td align="left" rowspan="1" colspan="1">5.86</td><td align="left" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" rowspan="1" colspan="1">AP CoP Dispersion in REO</td><td align="left" rowspan="1" colspan="1">13.54</td><td align="left" rowspan="1" colspan="1">2.47</td><td align="left" rowspan="1" colspan="1">0.91</td><td align="left" rowspan="1" colspan="1">8.58; 18.49</td><td align="left" rowspan="1" colspan="1">5.47</td><td align="left" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Displacement CoP angle in RFC</td><td align="left" rowspan="1" colspan="1">0.06</td><td align="left" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">0.21</td><td align="left" rowspan="1" colspan="1">0.00; 0.13</td><td align="left" rowspan="1" colspan="1">2.10</td><td align="left" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">AP CoP Force in RFC</td><td align="left" rowspan="1" colspan="1">0.54</td><td align="left" rowspan="1" colspan="1">0.16</td><td align="left" rowspan="1" colspan="1">0.30</td><td align="left" rowspan="1" colspan="1">0.22; 0.86</td><td align="left" rowspan="1" colspan="1">3.38</td><td align="left" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" rowspan="1" colspan="1">AP CoP Force in RFO</td><td align="left" rowspan="1" colspan="1">1.57</td><td align="left" rowspan="1" colspan="1">0.42</td><td align="left" rowspan="1" colspan="1">0.35</td><td align="left" rowspan="1" colspan="1">0.71; 2.42</td><td align="left" rowspan="1" colspan="1">3.67</td><td align="left" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Swing GRF during gait</td><td align="left" rowspan="1" colspan="1">0.09</td><td align="left" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">0.36</td><td align="left" rowspan="1" colspan="1">0.15; 0.03</td><td align="left" rowspan="1" colspan="1">&#8722;3.00</td><td align="left" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Propulsive GRF during gait</td><td align="left" rowspan="1" colspan="1">&#8722;0.31</td><td align="left" rowspan="1" colspan="1">0.11</td><td align="left" rowspan="1" colspan="1">&#8722;0.30</td><td align="left" rowspan="1" colspan="1">&#8722;0.53; &#8722;0.09</td><td align="left" rowspan="1" colspan="1">&#8722;2.83</td><td align="left" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" rowspan="1" colspan="1">ML CoP Force in REO</td><td align="left" rowspan="1" colspan="1">4.27</td><td align="left" rowspan="1" colspan="1">2.03</td><td align="left" rowspan="1" colspan="1">0.44</td><td align="left" rowspan="1" colspan="1">0.19; 8.34</td><td align="left" rowspan="1" colspan="1">2.09</td><td align="left" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="7" colspan="1">TNF-&#945;</td><td align="left" rowspan="1" colspan="1">Push-off GRF during gait</td><td align="left" rowspan="1" colspan="1">&#8722;0.02</td><td align="left" rowspan="1" colspan="1">0.01</td><td align="left" rowspan="1" colspan="1">&#8722;0.19</td><td align="left" rowspan="1" colspan="1">&#8722;0.00; 0.00</td><td align="left" rowspan="1" colspan="1">&#8722;1.96</td><td align="left" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">CoP Velocity in RGC</td><td align="left" rowspan="1" colspan="1">17.03</td><td align="left" rowspan="1" colspan="1">4.85</td><td align="left" rowspan="1" colspan="1">0.34</td><td align="left" rowspan="1" colspan="1">7.31; 26.75</td><td align="left" rowspan="1" colspan="1">3.50</td><td align="left" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Total CoP displacement in REC</td><td align="left" rowspan="1" colspan="1">0.08</td><td align="left" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">0.34</td><td align="left" rowspan="1" colspan="1">0.03; 0.13</td><td align="left" rowspan="1" colspan="1">3.53</td><td align="left" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Total CoP displacement in RFC</td><td align="left" rowspan="1" colspan="1">0.45</td><td align="left" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">0.27</td><td align="left" rowspan="1" colspan="1">0.01; 0.07</td><td align="left" rowspan="1" colspan="1">2.85</td><td align="left" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Tip pinch strength (left hand)</td><td align="left" rowspan="1" colspan="1">&#8722;0.03</td><td align="left" rowspan="1" colspan="1">0.01</td><td align="left" rowspan="1" colspan="1">&#8722;0.35</td><td align="left" rowspan="1" colspan="1">&#8722;0.05; &#8722;0.01</td><td align="left" rowspan="1" colspan="1">&#8722;3.46</td><td align="left" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Lateral pinch difference index</td><td align="left" rowspan="1" colspan="1">&#8722;0.02</td><td align="left" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">&#8722;0.27</td><td align="left" rowspan="1" colspan="1">&#8722;0.03; &#8722;0.01</td><td align="left" rowspan="1" colspan="1">&#8722;2.78</td><td align="left" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Lateral pinch (left) variation coeff.</td><td align="left" rowspan="1" colspan="1">&#8722;0.07</td><td align="left" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">&#8722;0.24</td><td align="left" rowspan="1" colspan="1">&#8722;0.13; &#8722;0.02</td><td align="left" rowspan="1" colspan="1">&#8722;2.56</td><td align="left" rowspan="1" colspan="1">0.01</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t004fn001"><p>The standardized and unstandardized &#946; coefficients, their standard error (SE), t values, significance, and confidence interval (CI) are reported for each predictor. CoP, center of pressure; AP, anteroposterior direction; ML, mediolateral direction; GRF, ground reaction force; REC, Romberg test with eyes closed; REO, Romberg test with eyes open; REC, Romberg test with eyes closed; RFO, Romberg with foam pad and eyes open; RFC, Romberg test with foam pad and eyes closed.</p></fn></table-wrap-foot></table-wrap><p>In the TNF-&#945; model, while multiple predictors were statistically significant (p&#8201;&lt;&#8201;0.05), CoP velocity during the Romberg test with foam and eyes closed was the only variable with an unstandardized coefficient of meaningful magnitude (SBeta&#8201;=&#8201;0.34, p&#8201;&lt;&#8201;0.01). Accordingly, a one-unit increase in CoP velocity during the aforementioned balance test is associated with a mean increase of 17.03 units in ammonia concentration.</p><p>For biomarkers whose models explained less than 50% of variance, the full list of predictors in provided in <xref rid="pone.0333029.s005" ref-type="supplementary-material">S5 Table</xref>. The most consistently identified predictor across within these models was gait speed, which played a significant role in the models for IL-21 (SBeta&#8201;=&#8201;&#8722;0.40, p&#8201;&lt;&#8201;0.01), IL-6 (SBeta&#8201;=&#8201;&#8722;0.50, p&#8201;&lt;&#8201;0.01), CCL20 (SBeta&#8201;=&#8201;&#8722;0.24, p&#8201;&lt;&#8201;0.05), CXCL13 (SBeta&#8201;=&#8201;&#8722;0.33, p&#8201;&lt;&#8201;0.01), and IL-18 (SBeta&#8201;=&#8201;&#8722;0.44, p&#8201;&lt;&#8201;0.01). A negative coefficient for walking speed was observed in all models mentioned, indicating that lower gait speed was consistently linked with higher levels of the interleukins and cytokines analyzed.</p><p>Balance performance was also a significant predictor in all the models tested with an R<sup>2</sup> below 0.50, but Romberg tests and balance outcomes varied between them. From this data set, the most consistently identified predictive outcomes were derived from the Romberg test with eyes closed and subjects standing on a foam pad. These outcomes were included in the models for IL-21, CX3CL1, IL-6, CCL2, CXCL13, and CCL20. The most frequently recurring predictor was the CoP velocity displacement during the test, which showed a positive association with IL-6 (SBeta&#8201;=&#8201;.26, p&#8201;&lt;&#8201;.01), CCL2 (SBeta&#8201;=&#8201;.31, p&#8201;&lt;&#8201;.01), and CCL20 (SBeta&#8201;=&#8201;.26, p&#8201;&lt;&#8201;.05) levels. An increase in CoP velocity was associated with elevated concentrations of these biomarkers. Finally, hand motor performance was statistically predictive variable in the IL-21, CX3CL1, CCL2 and TGF-&#946; models (p&#8201;&lt;&#8201;.05). As shown in <xref rid="pone.0333029.s005" ref-type="supplementary-material">S5 Table</xref>, while the coefficient of variation and the hand force difference index were positively associated with increased levels of IL-21 (SBeta.25, p&#8201;=&#8201;.01), CCL2 (SBeta&#8201;=&#8201;.29, p&#8201;=&#8201;0.01), and TGF-&#946; (SBeta&#8201;=&#8201;.30, p&#8201;=&#8201;0.01), both hand strength and manual speed exhibited a negative relationship with the measured blood parameters.</p></sec><sec sec-type="conclusions" id="sec008"><title>Discussion</title><p>This study aimed to analyze whether motor performance in patients with liver cirrhosis (with and without MHE) could predict levels of biomarkers such as ammonia and inflammatory factors. Although previous studies have investigated the association of motor outcomes with MHE [<xref rid="pone.0333029.ref014" ref-type="bibr">14</xref>], to our best knowledge, this is the first work to predict blood parameter levels based solely on motor performance in cirrhosis patients with and without cognitive impairment. We found that ammonia and TNF-&#945; levels were predicted with a coefficient of determination higher than 0.50 by the set of motor predictors. First, we observed that blood ammonia and TNF-&#945; were predicted mainly by balance performance, by both movement and velocity of the CoP across the Romberg tests explored. CoP velocity displacement also had a predictive role in IL-6, CCL2 and CCL20 cytokines, although with a lower percentage of variance. Several structures across the brain intervene in postural balance control; however, the cerebellum has a key role in balance acquisition and ability [<xref rid="pone.0333029.ref043" ref-type="bibr">43</xref>]. Our results could indicate that the accumulation of ammonia and inflammatory factors may affect specific brain locations responsible for balance, a theory which has not been previously described. The results of previous research could support this hypothesis. A previous study reported that ammonia and proinflammatory cytokine levels correlated with alterations in posturographic parameters such as RFO and limits of stability in MHE patients [<xref rid="pone.0333029.ref034" ref-type="bibr">34</xref>], highlighting the relationship between hyperammonaemia and inflammation and impaired postural control in patients with MHE. Studies in animal model for MHE showed that plasma extracellular vesicles from hyperammonemic rats were enriched in TNF-&#945; and induced neuroinflammation in cerebellum, as well as motor incoordination in control rats. These effects were reversed by blocking the action of TNF-&#945; [<xref rid="pone.0333029.ref044" ref-type="bibr">44</xref>,<xref rid="pone.0333029.ref045" ref-type="bibr">45</xref>]. Moreover, Felipo et al. reported significantly increased cerebral blood flow in the cerebellar vermis in patients with MHE compared with non-MHE patients, and also observed increased blood flow in cerebellar hemispheres in cirrhotic patients, irrespective of the presence of MHE [<xref rid="pone.0333029.ref046" ref-type="bibr">46</xref>], pointing to the cerebellum as a sensitive region in cirrhosis. Similarly, neuronal cell loss from cerebellum, among other areas, has been reported in hepatocerebral degeneration [<xref rid="pone.0333029.ref004" ref-type="bibr">4</xref>]. Nonetheless, that balance impairment is a predictor in all of the biomarkers tested could also be explained by deterioration in balance-related systems of non-cerebellar causes. One such example is sarcopenia, a common cirrhotic complication which could hamper the inability to respond successfully to challenging postures [<xref rid="pone.0333029.ref047" ref-type="bibr">47</xref>].</p><p>Regarding gait speed, this aspect was a predictor for IL-21, IL-6, CCL20, CXCL13 and IL-18, but not for ammonia or TNF-&#945;. In the latter two biomarkers, predictive outcomes from gait were related to the swing phase of the gait cycle and the forces that propel the foot just before the swing. Walking speed has become an indicator of health in many pathologies and is currently widely considered a sixth vital sign [<xref rid="pone.0333029.ref048" ref-type="bibr">48</xref>,<xref rid="pone.0333029.ref049" ref-type="bibr">49</xref>]. The beta coefficients reported in the results section indicate a negative association in which the slower the measured walking speed, the higher the estimated inflammatory factor. Several authors have previously referenced walking speed as an independent risk factor for mortality in people with cirrhosis [<xref rid="pone.0333029.ref050" ref-type="bibr">50</xref>,<xref rid="pone.0333029.ref051" ref-type="bibr">51</xref>], so it was among the variables we expected to be predictive. However, the gait predictors in ammonia and TNF-&#945; showed that a worse stance phase is associated with high values of these biomarkers in blood. This characteristic is extremely important in patients with physical impairment because worse gait quality is directly linked to a higher risk of falls [<xref rid="pone.0333029.ref052" ref-type="bibr">52</xref>], which becomes especially problematic in people with impaired balance, and is reported in patients with MHE [<xref rid="pone.0333029.ref053" ref-type="bibr">53</xref>]. Furthermore, reduced leg swing in gait is related to worse kinematic performance, which in turn may be conditioned by both muscle strength deficiency and neural impairment in gait pattern. Although not evaluated in this study, the sarcopenia characteristic in cirrhotic patients could potentially impact on the importance of this gait milestone in the regression analysis.</p><p>Lastly, we observed that strength and speed, along with their difference index and coefficient of variation, play a relevant role as predictors in the models for IL-21, CCL2, and TGF-&#946;. Although handgrip strength has been shown to be decreased in cirrhotic patients in previous studies [<xref rid="pone.0333029.ref054" ref-type="bibr">54</xref>,<xref rid="pone.0333029.ref055" ref-type="bibr">55</xref>], other motor performance outcomes such as hand speed have not been previously informed. In line with our findings, Lai et al<italic toggle="yes">.</italic> [<xref rid="pone.0333029.ref056" ref-type="bibr">56</xref>] developed a liver-specific frailty index in patients with liver disease, which include three performance-based tests of physical frailty: grip strength, chair stands, and balance testing. This index was especially true for those who were older, obese, or had HE or medical co-morbidities [<xref rid="pone.0333029.ref056" ref-type="bibr">56</xref>]. As shown in our results, the hand-related predictors were included in the models with the lowest explained variance, but they still played a relevant role alongside gait speed and balance parameters, which supports this frailty profile as a good reflection of participants&#8217; physiological reserve.</p><p>In terms of clinical application, motor assessment should be included in cirrhotic patient exams even prior to cognitive manifestations. Our results suggest that balance assessment should examine both the amplitude of CoP movement and the speed of displacement, an important factor in falls due to balance impairment. Previous studies have reported that falls are prevalent in people with cirrhosis, and commonly lead to loss of independence, reduced quality of life, and mortality [<xref rid="pone.0333029.ref047" ref-type="bibr">47</xref>]. The physical exam should also include gait speed, swing phase of gait cycle and hand grip strength. These physical tests have the advantage of being noninvasive, low cost, and with immediate results that can alert medical professionals to worsening blood biomarkers. Our data support the evidence that impairment of motor variables may represent an early marker of dysfunction in patients with liver cirrhosis, even prior to detectable neuropsychometric changes [<xref rid="pone.0333029.ref014" ref-type="bibr">14</xref>,<xref rid="pone.0333029.ref046" ref-type="bibr">46</xref>]. Follow-up studies should determine the timing of systemic signs and symptoms (both motor and cognitive) occurring in people with cirrhosis as liver disease worsens.</p><p>The limitations of our work are that the regression models proposed in this manuscript were made with a local sample, so their external validity must be verified in samples with other sociodemographic characteristics. Likewise, the study lacks a secondary sample percentage to test the regression models generated in the initial sample. This omission prevents the completion of a cross-validation procedure, which is necessary to determine whether the original models can be generalized to other samples. Future studies should incorporate this procedure if they intend to analyze how motor performance are related to inflammation in people with liver cirrhosis.</p></sec><sec sec-type="conclusions" id="sec009"><title>Conclusions</title><p>The blood levels of ammonia and cytokines in patients with liver cirrhosis can be predicted through clinical motor deterioration, independently of patients&#8217; cognitive impairment. Blood ammonia and TNF-&#945; levels can be predicted by motor variables with more than 50% of variance explained. Movement and velocity of CoP during balance tests, gait speed and swing phase, as well as grip and lateral pinch strength, in addition to hand motor speed, were repeated predictors in the models calculated for the different parameters analyzed in blood. Motor impairment may represent an alternative area to provide useful information on the pathophysiological state associated with liver cirrhosis, thus warranting evaluation in daily clinical practice and future follow-up studies.</p></sec><sec id="sec010" sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pone.0333029.s001" position="float" content-type="local-data" orientation="portrait"><label>S1 Table</label><caption><title>STROBE Checklist.</title><p>Items reported in cross-sectional study manuscripts, with corresponding page and line references where each item is covered.</p><p>(DOCX)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0333029.s001.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0333029.s002" position="float" content-type="local-data" orientation="portrait"><label>S2 Table</label><caption><title>Blood ammonia and plasma levels of interleukins and chemokines tested in the sample of participants and a control group as a reference.</title><p>(DOCX)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0333029.s002.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0333029.s003" position="float" content-type="local-data" orientation="portrait"><label>S3 Table</label><caption><title>Differences between sample participants with and without diabetes on parameters from blood test.</title><p>(DOCX)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0333029.s003.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0333029.s004" position="float" content-type="local-data" orientation="portrait"><label>S4 Table</label><caption><title>Differences between sample participants with and without diabetes on motor outcomes.</title><p>(DOCX)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0333029.s004.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0333029.s005" position="float" content-type="local-data" orientation="portrait"><label>S5 Table</label><caption><title>Outcome predictors from the multiple regression models that explain less 50% of the variance in the biomarkers analyzed.</title><p>(DOCX)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0333029.s005.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack><p>The authors would like to thank the institutions that supported this research and the participants who volunteered their time. We want to thank to Fundaci&#243;n Raminatrans, and to its president, Larissa Milla, for supporting this research. </p></ack><ref-list><title>References</title><ref id="pone.0333029.ref001"><label>1</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sepanlou</surname><given-names>SG</given-names></name>, <name name-style="western"><surname>Safiri</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bisignano</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Ikuta</surname><given-names>KS</given-names></name>, <name name-style="western"><surname>Merat</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Saberifiroozi</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017</article-title>. <source>Lancet Gastroenterol Hepatol</source>. <year>2020</year>;<volume>5</volume>:<fpage>245</fpage>&#8211;<lpage>66</lpage>.<pub-id pub-id-type="pmid">31981519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-1253(19)30349-8</pub-id><pub-id pub-id-type="pmcid">PMC7026710</pub-id></mixed-citation></ref><ref id="pone.0333029.ref002"><label>2</label><mixed-citation publication-type="book"><name name-style="western"><surname>Sharma</surname><given-names>B</given-names></name>, <name name-style="western"><surname>John</surname><given-names>S</given-names></name>. <source>Hepatic Cirrhosis</source>. <publisher-loc>Treasure Island (FL)</publisher-loc>: <publisher-name>StatPearls StatPearls Publishing</publisher-name>; <year>2024</year>.</mixed-citation></ref><ref id="pone.0333029.ref003"><label>3</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Vilstrup</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Amodio</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Bajaj</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Cordoba</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ferenci</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Mullen</surname><given-names>KD</given-names></name>, <etal>et al</etal>. <article-title>Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver</article-title>. <source>Hepatology</source>. <year>2014</year>;<volume>60</volume>(<issue>2</issue>):<fpage>715</fpage>&#8211;<lpage>35</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/hep.27210</pub-id><pub-id pub-id-type="pmid">25042402</pub-id></mixed-citation></ref><ref id="pone.0333029.ref004"><label>4</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Butterworth</surname><given-names>RF</given-names></name>. <article-title>Hepatic encephalopathy in cirrhosis: pathology and pathophysiology</article-title>. <source>Drugs</source>. <year>2019</year>;<volume>79</volume>:<fpage>17</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">30706423</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40265-018-1017-0</pub-id><pub-id pub-id-type="pmcid">PMC6416236</pub-id></mixed-citation></ref><ref id="pone.0333029.ref005"><label>5</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bajaj</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Cordoba</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mullen</surname><given-names>KD</given-names></name>, <name name-style="western"><surname>Amodio</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Shawcross</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Butterworth</surname><given-names>RF</given-names></name>, <etal>et al</etal>. <article-title>Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2011</year>;<volume>33</volume>(<issue>7</issue>):<fpage>739</fpage>&#8211;<lpage>47</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1365-2036.2011.04590.x</pub-id><pub-id pub-id-type="pmid">21306407</pub-id><pub-id pub-id-type="pmcid">PMC3971432</pub-id></mixed-citation></ref><ref id="pone.0333029.ref006"><label>6</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Amodio</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Del Piccolo</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Petten&#242;</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Mapelli</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Angeli</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Iemmolo</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients</article-title>. <source>J Hepatol</source>. <year>2001</year>;<volume>35</volume>(<issue>1</issue>):<fpage>37</fpage>&#8211;<lpage>45</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0168-8278(01)00129-5</pub-id><pub-id pub-id-type="pmid">11495040</pub-id></mixed-citation></ref><ref id="pone.0333029.ref007"><label>7</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Patidar</surname><given-names>KR</given-names></name>, <name name-style="western"><surname>Bajaj</surname><given-names>JS</given-names></name>. <article-title>Covert and Overt Hepatic Encephalopathy: Diagnosis and Management</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2015</year>;<volume>13</volume>(<issue>12</issue>):<fpage>2048</fpage>&#8211;<lpage>61</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cgh.2015.06.039</pub-id><pub-id pub-id-type="pmid">26164219</pub-id><pub-id pub-id-type="pmcid">PMC4618040</pub-id></mixed-citation></ref><ref id="pone.0333029.ref008"><label>8</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Weissenborn</surname><given-names>K</given-names></name>. <article-title>Minimal/covert hepatic encephalopathy - impact of comorbid conditions</article-title>. <source>J Clin Exp Hepatol</source>. <year>2019</year>;<volume>9</volume>:<fpage>109</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">30765943</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jceh.2018.08.010</pub-id><pub-id pub-id-type="pmcid">PMC6363959</pub-id></mixed-citation></ref><ref id="pone.0333029.ref009"><label>9</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ferenci</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Lockwood</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Mullen</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Tarter</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Weissenborn</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Blei</surname><given-names>AT</given-names></name>. <article-title>Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998</article-title>. <source>Hepatology</source>. <year>2002</year>;<volume>35</volume>:<fpage>716</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">11870389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/jhep.2002.31250</pub-id></mixed-citation></ref><ref id="pone.0333029.ref010"><label>10</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gim&#233;nez-Garz&#243;</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Garc&#233;s</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Urios</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Mangas-Losada</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Garc&#237;a-Garc&#237;a</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Gonz&#225;lez-L&#243;pez</surname><given-names>O</given-names></name>. <article-title>The PHES battery does not detect all cirrhotic patients with early neurological deficits, which are different in different patients</article-title>. <source>PLoS One</source>. <year>2017</year>;<volume>12</volume>:e0171211.</mixed-citation></ref><ref id="pone.0333029.ref011"><label>11</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gairing</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Mangini</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Zarantonello</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Gioia</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Nielsen</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Danneberg</surname><given-names>S</given-names></name>. <article-title>Prevalence of Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis: A Multicenter Study</article-title>. <source>Am J Gastroenterol</source>. <year>2023</year>;<volume>118</volume>:<fpage>2191</fpage>&#8211;<lpage>200</lpage>.<pub-id pub-id-type="pmid">36940426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14309/ajg.0000000000002251</pub-id></mixed-citation></ref><ref id="pone.0333029.ref012"><label>12</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rathi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chopra</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Chouduri</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Sharma</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Madan</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Chhabra</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Prevalence of Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis: A Cross-Sectional, Clinicoepidemiological, Multicenter, Nationwide Study in India: The PREDICT Study</article-title>. <source>J Clin Exp Hepatol</source>. <year>2019</year>;<volume>9</volume>(<issue>4</issue>):<fpage>476</fpage>&#8211;<lpage>83</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jceh.2018.09.009</pub-id><pub-id pub-id-type="pmid">31516264</pub-id><pub-id pub-id-type="pmcid">PMC6728606</pub-id></mixed-citation></ref><ref id="pone.0333029.ref013"><label>13</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zeng</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Yin</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>CY</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>XH</given-names></name>, <etal>et al</etal>. <article-title>Prevalence and risk factors of covert hepatic encephalopathy in cirrhotic patients: A multicenter study in China</article-title>. <source>J Dig Dis</source>. <year>2023</year>;<volume>24</volume>(<issue>2</issue>):<fpage>122</fpage>&#8211;<lpage>32</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/1751-2980.13171</pub-id><pub-id pub-id-type="pmid">37032126</pub-id></mixed-citation></ref><ref id="pone.0333029.ref014"><label>14</label><mixed-citation publication-type="journal"><name name-style="western"><surname>San Mart&#237;n-Valenzuela</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Borras-Barrachina</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gallego</surname><given-names>J-J</given-names></name>, <name name-style="western"><surname>Urios</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Mestre-Salvador</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Correa-Ghisays</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Motor and Cognitive Performance in Patients with Liver Cirrhosis with Minimal Hepatic Encephalopathy</article-title>. <source>J Clin Med</source>. <year>2020</year>;<volume>9</volume>(<issue>7</issue>):<fpage>2154</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/jcm9072154</pub-id><pub-id pub-id-type="pmid">32650464</pub-id><pub-id pub-id-type="pmcid">PMC7408738</pub-id></mixed-citation></ref><ref id="pone.0333029.ref015"><label>15</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Butz</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Timmermann</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Braun</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Groiss</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Wojtecki</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ostrowski</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Motor impairment in liver cirrhosis without and with minimal hepatic encephalopathy</article-title>. <source>Acta Neurol Scand</source>. <year>2010</year>;<volume>122</volume>(<issue>1</issue>):<fpage>27</fpage>&#8211;<lpage>35</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1600-0404.2009.01246.x</pub-id><pub-id pub-id-type="pmid">20003084</pub-id></mixed-citation></ref><ref id="pone.0333029.ref016"><label>16</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Nardelli</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gioia</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Faccioli</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Riggio</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Ridola</surname><given-names>L</given-names></name>. <article-title>Sarcopenia and cognitive impairment in liver cirrhosis: A viewpoint on the clinical impact of minimal hepatic encephalopathy</article-title>. <source>World J Gastroenterol</source>. <year>2019</year>;<volume>25</volume>(<issue>35</issue>):<fpage>5257</fpage>&#8211;<lpage>65</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3748/wjg.v25.i35.5257</pub-id><pub-id pub-id-type="pmid">31558871</pub-id><pub-id pub-id-type="pmcid">PMC6761233</pub-id></mixed-citation></ref><ref id="pone.0333029.ref017"><label>17</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Redfield</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Latt</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Munoz</surname><given-names>SJ</given-names></name>. <article-title>Minimal hepatic encephalopathy</article-title>. <source>Clin Liver Dis</source>. <year>2024</year>;<volume>28</volume>:<fpage>237</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="pmid">38548436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cld.2024.01.004</pub-id></mixed-citation></ref><ref id="pone.0333029.ref018"><label>18</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Faccioli</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Nardelli</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gioia</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Riggio</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Ridola</surname><given-names>L</given-names></name>. <article-title>Minimal Hepatic Encephalopathy Affects Daily Life of Cirrhotic Patients: A Viewpoint on Clinical Consequences and Therapeutic Opportunities</article-title>. <source>J Clin Med</source>. <year>2022</year>;<volume>11</volume>(<issue>23</issue>):<fpage>7246</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/jcm11237246</pub-id><pub-id pub-id-type="pmid">36498820</pub-id><pub-id pub-id-type="pmcid">PMC9736966</pub-id></mixed-citation></ref><ref id="pone.0333029.ref019"><label>19</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Aldridge</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Tranah</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Shawcross</surname><given-names>DL</given-names></name>. <article-title>Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation</article-title>. <source>J Clin Exp Hepatol</source>. <year>2015</year>;<volume>5</volume>(Suppl 1):S7&#8211;<lpage>20</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jceh.2014.06.004</pub-id><pub-id pub-id-type="pmid">26041962</pub-id><pub-id pub-id-type="pmcid">PMC4442852</pub-id></mixed-citation></ref><ref id="pone.0333029.ref020"><label>20</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Brumback</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Lapham</surname><given-names>LW</given-names></name>. <article-title>DNA synthesis in Alzheimer type II astrocytosis. The question of astrocytic proliferation and mitosis in experimentally induced hepatic encephalopathy</article-title>. <source>Arch Neurol</source>. <year>1989</year>;<volume>46</volume>(<issue>8</issue>):<fpage>845</fpage>&#8211;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/archneur.1989.00520440027016</pub-id><pub-id pub-id-type="pmid">2757524</pub-id></mixed-citation></ref><ref id="pone.0333029.ref021"><label>21</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Norenberg</surname><given-names>MD</given-names></name>. <article-title>A light and electron microscopic study of experimental portal-systemic (ammonia) encephalopathy. Progression and reversal of the disorder</article-title>. <source>Lab Invest</source>. <year>1977</year>;<volume>36</volume>(<issue>6</issue>):<fpage>618</fpage>&#8211;<lpage>27</lpage>. <pub-id pub-id-type="pmid">559221</pub-id></mixed-citation></ref><ref id="pone.0333029.ref022"><label>22</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Brusilow</surname><given-names>SW</given-names></name>, <name name-style="western"><surname>Koehler</surname><given-names>RC</given-names></name>, <name name-style="western"><surname>Traystman</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Cooper</surname><given-names>AJL</given-names></name>. <article-title>Astrocyte glutamine synthetase: importance in hyperammonemic syndromes and potential target for therapy</article-title>. <source>Neurotherapeutics</source>. <year>2010</year>;<volume>7</volume>(<issue>4</issue>):<fpage>452</fpage>&#8211;<lpage>70</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.nurt.2010.05.015</pub-id><pub-id pub-id-type="pmid">20880508</pub-id><pub-id pub-id-type="pmcid">PMC2975543</pub-id></mixed-citation></ref><ref id="pone.0333029.ref023"><label>23</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jaeger</surname><given-names>V</given-names></name>, <name name-style="western"><surname>DeMorrow</surname><given-names>S</given-names></name>, <name name-style="western"><surname>McMillin</surname><given-names>M</given-names></name>. <article-title>The direct contribution of astrocytes and microglia to the pathogenesis of hepatic encephalopathy</article-title>. <source>J Clin Transl Hepatol</source>. <year>2019</year>;<volume>7</volume>:<fpage>352</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">31915605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14218/JCTH.2019.00025</pub-id><pub-id pub-id-type="pmcid">PMC6943208</pub-id></mixed-citation></ref><ref id="pone.0333029.ref024"><label>24</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Felipo</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Urios</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Montesinos</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Molina</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Garcia-Torres</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Civera</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy</article-title>. <source>Metab Brain Dis</source>. <year>2012</year>;<volume>27</volume>(<issue>1</issue>):<fpage>51</fpage>&#8211;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s11011-011-9269-3</pub-id><pub-id pub-id-type="pmid">22072427</pub-id></mixed-citation></ref><ref id="pone.0333029.ref025"><label>25</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Shawcross</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Wright</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Olde Damink</surname><given-names>SWM</given-names></name>, <name name-style="western"><surname>Jalan</surname><given-names>R</given-names></name>. <article-title>Role of ammonia and inflammation in minimal hepatic encephalopathy</article-title>. <source>Metab Brain Dis</source>. <year>2007</year>;<volume>22</volume>:<fpage>125</fpage>&#8211;<lpage>38</lpage>.<pub-id pub-id-type="pmid">17260161</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11011-006-9042-1</pub-id></mixed-citation></ref><ref id="pone.0333029.ref026"><label>26</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Shawcross</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Davies</surname><given-names>NA</given-names></name>, <name name-style="western"><surname>Williams</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Jalan</surname><given-names>R</given-names></name>. <article-title>Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis</article-title>. <source>J Hepatol</source>. <year>2004</year>;<volume>40</volume>:<fpage>247</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="pmid">14739095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2003.10.016</pub-id></mixed-citation></ref><ref id="pone.0333029.ref027"><label>27</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Montoliu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Piedrafita</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Serra</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>del Olmo</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Urios</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Rodrigo</surname><given-names>JM</given-names></name>, <etal>et al</etal>. <article-title>IL-6 and IL-18 in blood may discriminate cirrhotic patients with and without minimal hepatic encephalopathy</article-title>. <source>J Clin Gastroenterol</source>. <year>2009</year>;<volume>43</volume>(<issue>3</issue>):<fpage>272</fpage>&#8211;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/MCG.0b013e31815e7f58</pub-id><pub-id pub-id-type="pmid">18562979</pub-id></mixed-citation></ref><ref id="pone.0333029.ref028"><label>28</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jain</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Sharma</surname><given-names>BC</given-names></name>, <name name-style="western"><surname>Sharma</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Srivastava</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Agrawal</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sarin</surname><given-names>SK</given-names></name>. <article-title>Serum endotoxin and inflammatory mediators in patients with cirrhosis and hepatic encephalopathy</article-title>. <source>Dig Liver Dis</source>. <year>2012</year>;<volume>44</volume>(<issue>12</issue>):<fpage>1027</fpage>&#8211;<lpage>31</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.dld.2012.07.002</pub-id><pub-id pub-id-type="pmid">22883217</pub-id></mixed-citation></ref><ref id="pone.0333029.ref029"><label>29</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mangas-Losada</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Garc&#237;a-Garc&#237;a</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Urios</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Escudero-Garc&#237;a</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Tosca</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Giner-Dur&#225;n</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Minimal hepatic encephalopathy is associated with expansion and activation of CD4+CD28-, Th22 and Tfh and B lymphocytes</article-title>. <source>Sci Rep</source>. <year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>6683</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-017-05938-1</pub-id><pub-id pub-id-type="pmid">28751644</pub-id><pub-id pub-id-type="pmcid">PMC5532287</pub-id></mixed-citation></ref><ref id="pone.0333029.ref030"><label>30</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ong</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Aggarwal</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Krieger</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Easley</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Karafa</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Van Lente</surname><given-names>F</given-names></name>. <article-title>Correlation Between Ammonia Levels and the Severity of Hepatic Encephalopathy</article-title>. <source>Nutr Clin Pract</source>. <year>2004</year>;<volume>19</volume>:<fpage>413</fpage>&#8211;<lpage>4</lpage>.</mixed-citation></ref><ref id="pone.0333029.ref031"><label>31</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kimer</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Gluud</surname><given-names>LL</given-names></name>, <name name-style="western"><surname>Pedersen</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Tavenier</surname><given-names>J</given-names></name>, <name name-style="western"><surname>M&#248;ller</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bendtsen</surname><given-names>F</given-names></name>. <article-title>The Psychometric Hepatic Encephalopathy Syndrome score does not correlate with blood ammonia, endotoxins or markers of inflammation in patients with cirrhosis</article-title>. <source>Transl Gastroenterol Hepatol</source>. <year>2021</year>;<volume>6</volume>:<fpage>8</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.21037/tgh.2020.02.14</pub-id><pub-id pub-id-type="pmid">33409402</pub-id><pub-id pub-id-type="pmcid">PMC7724176</pub-id></mixed-citation></ref><ref id="pone.0333029.ref032"><label>32</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Weissenborn</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ennen</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Schomerus</surname><given-names>H</given-names></name>, <name name-style="western"><surname>R&#252;ckert</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Hecker</surname><given-names>H</given-names></name>. <article-title>Neuropsychological characterization of hepatic encephalopathy</article-title>. <source>J Hepatol</source>. <year>2001</year>;<volume>34</volume>(<issue>5</issue>):<fpage>768</fpage>&#8211;<lpage>73</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0168-8278(01)00026-5</pub-id><pub-id pub-id-type="pmid">11434627</pub-id></mixed-citation></ref><ref id="pone.0333029.ref033"><label>33</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Romero G&#243;mez</surname><given-names>M</given-names></name>, <name name-style="western"><surname>C&#243;rdoba</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Jover</surname><given-names>R</given-names></name>, <name name-style="western"><surname>del Olmo</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Fern&#225;ndez</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Flavi&#224;</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Normality tables in the Spanish population for psychometric tests used in the diagnosis of minimal hepatic encephalopathy</article-title>. <source>Med Clin (Barc)</source>. <year>2006</year>;<volume>127</volume>(<issue>7</issue>):<fpage>246</fpage>&#8211;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1157/13091264</pub-id><pub-id pub-id-type="pmid">16942726</pub-id></mixed-citation></ref><ref id="pone.0333029.ref034"><label>34</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Urios</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Mangas-Losada</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gimenez-Garz&#243;</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Gonz&#225;lez-L&#243;pez</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Giner-Dur&#225;n</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Serra</surname><given-names>MA</given-names></name>, <etal>et al</etal>. <article-title>Altered postural control and stability in cirrhotic patients with minimal hepatic encephalopathy correlate with cognitive deficits</article-title>. <source>Liver Int</source>. <year>2017</year>;<volume>37</volume>(<issue>7</issue>):<fpage>1013</fpage>&#8211;<lpage>22</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/liv.13345</pub-id><pub-id pub-id-type="pmid">27988985</pub-id></mixed-citation></ref><ref id="pone.0333029.ref035"><label>35</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Balaguer Garc&#237;a</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Pitarch Corresa</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Baydal Bertomeu</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Morales Su&#225;rez-Varela</surname><given-names>MM</given-names></name>. <article-title>Static posturography with dynamic tests. Usefulness of biomechanical parameters in assessing vestibular patients</article-title>. <source>Acta Otorrinolaringol Esp</source>. <year>2012</year>;<volume>63</volume>(<issue>5</issue>):<fpage>332</fpage>&#8211;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.otorri.2012.03.006</pub-id><pub-id pub-id-type="pmid">22633316</pub-id></mixed-citation></ref><ref id="pone.0333029.ref036"><label>36</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Matuoka</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Kurita</surname><given-names>GP</given-names></name>, <name name-style="western"><surname>Nordly</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sj&#248;gren</surname><given-names>P</given-names></name>, <name name-style="western"><surname>de Mattos-Pimenta</surname><given-names>CA</given-names></name>. <article-title>Validation of a Battery of Neuropsychological Tests for Patients With Metastatic Cancer</article-title>. <source>Clin Nurs Res</source>. <year>2020</year>;<volume>29</volume>(<issue>8</issue>):<fpage>607</fpage>&#8211;<lpage>15</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/1054773819831210</pub-id><pub-id pub-id-type="pmid">30793636</pub-id></mixed-citation></ref><ref id="pone.0333029.ref037"><label>37</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lorenzo-Agudo</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Santos-Garc&#237;a</surname><given-names>P</given-names></name>, <name name-style="western"><surname>S&#225;nchez-Beliz&#243;n</surname><given-names>D</given-names></name>. <article-title>Determinaci&#243;n de los valores normales de fuerza muscular de pu&#241;o y pinza en una poblaci&#243;n laboral</article-title>. <source>Rehabilitaci&#243;n</source>. <year>2007</year>;<volume>41</volume>:<fpage>220</fpage>&#8211;<lpage>7</lpage>.</mixed-citation></ref><ref id="pone.0333029.ref038"><label>38</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Montero Vilela</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Baydal Bertomeu</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Garrido Ja&#233;n</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Bermejo Bosch</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Page</surname><given-names>&#193;</given-names></name>, <name name-style="western"><surname>Porcar Seder</surname><given-names>R</given-names></name>. <article-title>Objetivamos los gestos caracter&#237;sticos de la mano</article-title>. <source>Revista de biomec&#225;nica</source>. <year>2012</year>:<fpage>47</fpage>&#8211;<lpage>50</lpage>.</mixed-citation></ref><ref id="pone.0333029.ref039"><label>39</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Su</surname><given-names>CY</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Chien</surname><given-names>TH</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>KF</given-names></name>, <name name-style="western"><surname>Sung</surname><given-names>YT</given-names></name>. <article-title>Grip strength in different positions of elbow and shoulder</article-title>. <source>Arch Phys Med Rehabil</source>. <year>1994</year>;<volume>75</volume>(<issue>7</issue>):<fpage>812</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="pmid">8024431</pub-id></mixed-citation></ref><ref id="pone.0333029.ref040"><label>40</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mathiowetz</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Weber</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Volland</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Kashman</surname><given-names>N</given-names></name>. <article-title>Reliability and validity of grip and pinch strength evaluations</article-title>. <source>J Hand Surg Am</source>. <year>1984</year>;<volume>9</volume>(<issue>2</issue>):<fpage>222</fpage>&#8211;<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0363-5023(84)80146-x</pub-id><pub-id pub-id-type="pmid">6715829</pub-id></mixed-citation></ref><ref id="pone.0333029.ref041"><label>41</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Faul</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Erdfelder</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Lang</surname><given-names>A-G</given-names></name>, <name name-style="western"><surname>Buchner</surname><given-names>A</given-names></name>. <article-title>G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences</article-title>. <source>Behav Res Methods</source>. <year>2007</year>;<volume>39</volume>(<issue>2</issue>):<fpage>175</fpage>&#8211;<lpage>91</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3758/bf03193146</pub-id><pub-id pub-id-type="pmid">17695343</pub-id></mixed-citation></ref><ref id="pone.0333029.ref042"><label>42</label><mixed-citation publication-type="book"><name name-style="western"><surname>Tabachnick</surname><given-names>BG</given-names></name>, <name name-style="western"><surname>Fidell</surname><given-names>LS</given-names></name>. <source>Using Multivariate Statistics</source>. <edition designator="7">7th Edition.</edition><publisher-name>Pearson</publisher-name>; <year>2018</year>.</mixed-citation></ref><ref id="pone.0333029.ref043"><label>43</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Surgent</surname><given-names>OJ</given-names></name>, <name name-style="western"><surname>Dadalko</surname><given-names>OI</given-names></name>, <name name-style="western"><surname>Pickett</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Travers</surname><given-names>BG</given-names></name>. <article-title>Balance and the brain: A review of structural brain correlates of postural balance and balance training in humans</article-title>. <source>Gait Posture</source>. <year>2019</year>;<volume>71</volume>:<fpage>245</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="pmid">31082657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gaitpost.2019.05.011</pub-id><pub-id pub-id-type="pmcid">PMC6594858</pub-id></mixed-citation></ref><ref id="pone.0333029.ref044"><label>44</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Izquierdo-Altarejos</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Mart&#237;nez-Garc&#237;a</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Felipo</surname><given-names>V</given-names></name>. <article-title>Extracellular Vesicles From Hyperammonemic Rats Induce Neuroinflammation in Cerebellum of Normal Rats: Role of Increased TNF&#945; Content</article-title>. <source>Front Immunol</source>. <year>2022</year>;<volume>13</volume>:<fpage>921947</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fimmu.2022.921947</pub-id><pub-id pub-id-type="pmid">35911759</pub-id><pub-id pub-id-type="pmcid">PMC9325972</pub-id></mixed-citation></ref><ref id="pone.0333029.ref045"><label>45</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Izquierdo-Altarejos</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Cabrera-Pastor</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gonzalez-King</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Montoliu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Felipo</surname><given-names>V</given-names></name>. <article-title>Extracellular Vesicles from Hyperammonemic Rats Induce Neuroinflammation and Motor Incoordination in Control Rats</article-title>. <source>Cells</source>. <year>2020</year>;<volume>9</volume>(<issue>3</issue>):<fpage>572</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/cells9030572</pub-id><pub-id pub-id-type="pmid">32121257</pub-id><pub-id pub-id-type="pmcid">PMC7140428</pub-id></mixed-citation></ref><ref id="pone.0333029.ref046"><label>46</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Felipo</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Urios</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gim&#233;nez-Garz&#243;</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Cauli</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Andr&#233;s-Costa</surname><given-names>M-J</given-names></name>, <name name-style="western"><surname>Gonz&#225;lez</surname><given-names>O</given-names></name>, <etal>et al</etal>. <article-title>Non invasive blood flow measurement in cerebellum detects minimal hepatic encephalopathy earlier than psychometric tests</article-title>. <source>World J Gastroenterol</source>. <year>2014</year>;<volume>20</volume>(<issue>33</issue>):<fpage>11815</fpage>&#8211;<lpage>25</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3748/wjg.v20.i33.11815</pub-id><pub-id pub-id-type="pmid">25206287</pub-id><pub-id pub-id-type="pmcid">PMC4155373</pub-id></mixed-citation></ref><ref id="pone.0333029.ref047"><label>47</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Murphy</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Tapper</surname><given-names>EB</given-names></name>, <name name-style="western"><surname>Blackwood</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Richardson</surname><given-names>JK</given-names></name>. <article-title>Why Do Individuals with Cirrhosis Fall? A Mechanistic Model for Fall Assessment, Treatment, and Research</article-title>. <source>Dig Dis Sci</source>. <year>2019</year>;<volume>64</volume>(<issue>2</issue>):<fpage>316</fpage>&#8211;<lpage>23</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s10620-018-5333-8</pub-id><pub-id pub-id-type="pmid">30327964</pub-id></mixed-citation></ref><ref id="pone.0333029.ref048"><label>48</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Fritz</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lusardi</surname><given-names>M</given-names></name>. <article-title>White Paper: &#8220;Walking Speed: the Sixth Vital Sign&#8221;</article-title>. <source>Journal of Geriatric Physical Therapy</source>. <year>2009</year>;<volume>32</volume>(<issue>2</issue>):<fpage>2</fpage>&#8211;<lpage>5</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1519/00139143-200932020-00002</pub-id><pub-id pub-id-type="pmid">19856629</pub-id></mixed-citation></ref><ref id="pone.0333029.ref049"><label>49</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Middleton</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Fritz</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Lusardi</surname><given-names>M</given-names></name>. <article-title>Walking speed: the functional vital sign</article-title>. <source>J Aging Phys Act</source>. <year>2015</year>;<volume>23</volume>(<issue>2</issue>):<fpage>314</fpage>&#8211;<lpage>22</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1123/japa.2013-0236</pub-id><pub-id pub-id-type="pmid">24812254</pub-id><pub-id pub-id-type="pmcid">PMC4254896</pub-id></mixed-citation></ref><ref id="pone.0333029.ref050"><label>50</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Soto</surname><given-names>R</given-names></name>, <name name-style="western"><surname>D&#237;az</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Rivas</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Fuentes-L&#243;pez</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Zalaquett</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bruera</surname><given-names>MJ</given-names></name>, <etal>et al</etal>. <article-title>Frailty and reduced gait speed are independently related to mortality of cirrhotic patients in long-term follow-up</article-title>. <source>Ann Hepatol</source>. <year>2021</year>;<volume>25</volume>:<fpage>100327</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.aohep.2021.100327</pub-id><pub-id pub-id-type="pmid">33596465</pub-id></mixed-citation></ref><ref id="pone.0333029.ref051"><label>51</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Deng</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Fan</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Cui</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Hou</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Incorporation of frailty estimated by gait speed within MELD-Na and the predictive potential for mortality in cirrhosis</article-title>. <source>Ther Adv Chronic Dis</source>. <year>2020</year>;<volume>11</volume>:<fpage>2040622320922023</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/2040622320922023</pub-id><pub-id pub-id-type="pmid">32489574</pub-id><pub-id pub-id-type="pmcid">PMC7238306</pub-id></mixed-citation></ref><ref id="pone.0333029.ref052"><label>52</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Verghese</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Holtzer</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Lipton</surname><given-names>RB</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>C</given-names></name>. <article-title>Quantitative gait markers and incident fall risk in older adults</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2009</year>;<volume>64</volume>(<issue>8</issue>):<fpage>896</fpage>&#8211;<lpage>901</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/gerona/glp033</pub-id><pub-id pub-id-type="pmid">19349593</pub-id><pub-id pub-id-type="pmcid">PMC2709543</pub-id></mixed-citation></ref><ref id="pone.0333029.ref053"><label>53</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rom&#225;n</surname><given-names>E</given-names></name>, <name name-style="western"><surname>C&#243;rdoba</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Torrens</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Torras</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Villanueva</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Vargas</surname><given-names>V</given-names></name>, <etal>et al</etal>. <article-title>Minimal hepatic encephalopathy is associated with falls</article-title>. <source>Am J Gastroenterol</source>. <year>2011</year>;<volume>106</volume>(<issue>3</issue>):<fpage>476</fpage>&#8211;<lpage>82</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/ajg.2010.413</pub-id><pub-id pub-id-type="pmid">20978484</pub-id></mixed-citation></ref><ref id="pone.0333029.ref054"><label>54</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Haraguchi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Miyaaki</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Nakamura</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Narita</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Matsumoto</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Fukushima</surname><given-names>M</given-names></name>. <article-title>Assessment of the association between dysphagia and sarcopenia among elderly patients with cirrhosis: Usefulness of the finger-ring test</article-title>. <source>Arch Gerontol Geriatr</source>. <year>2021</year>;<volume>95</volume>:<fpage>104430</fpage>.<pub-id pub-id-type="pmid">34004488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.archger.2021.104430</pub-id></mixed-citation></ref><ref id="pone.0333029.ref055"><label>55</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Majeed</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Shaikh</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Rasheed</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Khalid</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Qazi Arisa</surname><given-names>FA</given-names></name>, <name name-style="western"><surname>Ghias</surname><given-names>H</given-names></name>. <article-title>Prevalence And Risk Factors Of Sarcopenia In Patients With Cirrhosis: An Observational Study</article-title>. <source>J Pak Med Assoc</source>. <year>2023</year>;<volume>73</volume>(<issue>10</issue>):<fpage>2004</fpage>&#8211;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.47391/JPMA.8461</pub-id><pub-id pub-id-type="pmid">37876060</pub-id></mixed-citation></ref><ref id="pone.0333029.ref056"><label>56</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lai</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Covinsky</surname><given-names>KE</given-names></name>, <name name-style="western"><surname>Dodge</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Boscardin</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Segev</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Roberts</surname><given-names>JP</given-names></name>, <etal>et al</etal>. <article-title>Development of a novel frailty index to predict mortality in patients with end-stage liver disease</article-title>. <source>Hepatology</source>. <year>2017</year>;<volume>66</volume>(<issue>2</issue>):<fpage>564</fpage>&#8211;<lpage>74</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/hep.29219</pub-id><pub-id pub-id-type="pmid">28422306</pub-id><pub-id pub-id-type="pmcid">PMC5519430</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Res Ther</journal-id><journal-id journal-id-type="pmc-domain-id">943</journal-id><journal-id journal-id-type="pmc-domain">alzreth</journal-id><journal-title-group><journal-title>Alzheimer's Research &amp; Therapy</journal-title></journal-title-group><issn pub-type="epub">1758-9193</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12505654</article-id><article-id pub-id-type="pmcid-ver">PMC12505654.1</article-id><article-id pub-id-type="pmcaid">12505654</article-id><article-id pub-id-type="pmcaiid">12505654</article-id><article-id pub-id-type="pmid">41057930</article-id><article-id pub-id-type="doi">10.1186/s13195-025-01823-6</article-id><article-id pub-id-type="publisher-id">1823</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Anti-tau VHH therapy against PHF6: a safe approach to slowing the phenotype of tau pathology</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6804-9586</contrib-id><name name-style="western"><surname>Caillierez</surname><given-names initials="R">Raphaelle</given-names></name><address><email>raphaelle.caillierez@inserm.fr</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Leboullenger</surname><given-names initials="C">Cl&#233;mence</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Leclercq</surname><given-names initials="S">Sarah</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Besegher</surname><given-names initials="M">M&#233;lanie</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>B&#233;gard</surname><given-names initials="S">S&#233;verine</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Auger</surname><given-names initials="F">Florent</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Maurage</surname><given-names initials="CA">Claude-Alain</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Accart</surname><given-names initials="B">Bertrand</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mortelecque</surname><given-names initials="J">Justine</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dupr&#233;</surname><given-names initials="E">Elian</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Danis</surname><given-names initials="C">Cl&#233;ment</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Landrieu</surname><given-names initials="I">Isabelle</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6261-4230</contrib-id><name name-style="western"><surname>Bu&#233;e</surname><given-names initials="L">Luc</given-names></name><address><email>luc.buee@inserm.fr</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0611-4167</contrib-id><name name-style="western"><surname>Colin</surname><given-names initials="M">Morvane</given-names></name><address><email>morvane.colin@inserm.fr</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.523375.5</institution-id><institution>University Lille, Inserm, CHU-Lille, U1172 - LilNCog - Lille Neuroscience &amp; Cognition, </institution></institution-wrap>Lille, F-59000 France </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02kzqn938</institution-id><institution-id institution-id-type="GRID">grid.503422.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2242 6780</institution-id><institution>University Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US41-UAR 2014-PLBS, </institution></institution-wrap>Lille, F-59000 France </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02kzqn938</institution-id><institution-id institution-id-type="GRID">grid.503422.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2242 6780</institution-id><institution>University Lille, CHU-Lille, CRB/CIC1403, Centre de Ressources Biologiques du Centre d&#8217;Investigation Clinique, </institution></institution-wrap>Lille, F-59000, France </aff><aff id="Aff4"><label>4</label>CNRS EMR9002 BSI Integrative Structural Biology , Lille, F-59000 France </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02ppyfa04</institution-id><institution-id institution-id-type="GRID">grid.410463.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0471 8845</institution-id><institution>University Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Risk Factors and Molecular Determinants of Aging-Related Diseases, </institution></institution-wrap>Lille, F-59000 France </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>17</volume><issue-id pub-id-type="pmc-issue-id">478170</issue-id><elocation-id>221</elocation-id><history><date date-type="received"><day>15</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>16</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="13195_2025_Article_1823.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Tauopathies share common features, including tau aggregation, which plays a central role in neurodegeneration. However, these disorders are highly heterogeneous, particularly in the spread of pathological tau species between cells. In Alzheimer&#8217;s disease, intracellular tau aggregation is followed by a propagation between cells leading to a hierarchical pathway of neurodegeneration, whereas in other tauopathies, such as progressive supranuclear palsy (PSP), pathological tau remains largely confined within neurons and exhibits more limited spread. This variability raises the question of whether tailored treatments for each tauopathy might offer more therapeutic benefit. Hence, we designed two different immunological approaches using single domain antibody fragments, also called VHHs, to target intracellular and extracellular tau. This study aims to first evaluate the safety of these immunological tools on physiological tau and then their potential to slow disease progression.</p></sec><sec><title>Methods</title><p id="Par2">We selected the pro-aggregative tau hexapeptide PHF6 as a common target for the VHHs. These VHHs were cloned in viral vectors allowing to compare two different expression systems: 1) intracytosolic expression to prevent tau accumulation (intraVHH) and 2) secretion into the interstitial fluid, to prevent tau spreading (extraVHH). By stereotactic injection of viral vectors, these VHHs were expressed in the brain of transgenic or wild-type mice and three readouts were studied: behavior, brain imaging and tau lesions.</p></sec><sec><title>Results</title><p id="Par3">We validated the correct addressing of intra- and extraVHHs. These two constructs were not associated with adverse effects, even in the absence of tau overexpression, in wild-type mice. Their efficacy was demonstrated in transgenic mouse tau models, either chronic long-term or in acute seeding with injections of human brain homogenates from Alzheimer's disease patients. They both can slow down several pathological effects (i.e. cognitive deficits, cerebral atrophy and neuronal hyperphosphorylation of tau).</p></sec><sec><title>Conclusions</title><p id="Par4">This study is a proof of concept demonstrating that VHHs can be engineered to reduce both intra- and extracellular tau pathologies without major adverse effects, making them of interest for therapeutic applications.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s13195-025-01823-6.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Tauopathies</kwd><kwd>VHH</kwd><kwd>Single domain antibodies</kwd><kwd>PHF6</kwd><kwd>Tau spreading</kwd><kwd>Immunotherapy</kwd><kwd>Alzheimer&#8217;s disease</kwd><kwd>PSP</kwd></kwd-group><funding-group><award-group><funding-source><institution>Rainwater Charitable Foundation &amp; Alzheimer&#8217;s Association</institution></funding-source><award-id>T-PEP-23-969176</award-id><award-id>T-PEP-23-969176</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Union-HORIZON-MSCA-2022-DN-01</institution></funding-source><award-id>TAME, GA101119596</award-id><award-id>TAME, GA101119596</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>French National Research Agency</institution></funding-source><award-id>LabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary Approach to Alzheimer&#8217;s Disease,&#160;ANR-11-LABX-01</award-id><award-id>LabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary Approach to Alzheimer&#8217;s Disease,&#160;ANR-11-LABX-01</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>French regional funding : R&#233;gion Hauts de France</institution></funding-source><award-id>StartAIRR&#160;BONUS DRESS-2020-023479</award-id><award-id>StartAIRR&#160;BONUS DRESS-2020-023479</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>IR INFRANALYTICS FR2054</institution></funding-source><award-id>FR2054 CNRS</award-id><award-id>FR2054 CNRS</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par43">Tauopathies are a heterogenous group of neurodegenerative diseases that share a common feature: the intracellular accumulation of tau protein [<xref ref-type="bibr" rid="CR1">1</xref>]. During the pathological time course, this microtubule-associated protein assembles into fibrillar structures, leading to neurofibrillary degeneration (NFD) in Alzheimer&#8217;s disease (AD), which is a correlated with cognitive decline [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. These intraneuronal lesions are composed of paired helical and straight tau filaments. Their composition, defined by cryoEM studies, revealed an ordered core of paired protofilaments comprising residues 306&#8211;378, and disordered amino- and carboxy-termini forming the fuzzy coat [<xref ref-type="bibr" rid="CR4">4</xref>]. Additionally, tau oligomers are now considered to be the toxic tau species in several neurodegenerative disorders such as AD [<xref ref-type="bibr" rid="CR5">5</xref>]. These intraTau species, in their fibrillar and/or oligomeric structures, are now considered to be very important targets in AD. The appearance of tau lesions in AD follows a hierarchical progression in a pattern that is similar among patients. This stereotypical progression is known in the literature as the Braak stages [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>], which are now considered to be steps in the &#8216;prion-like&#8217; propagation of neurodegeneration, thus identifying pathological extraTau as a potential target [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par44">Anti-tau therapies, particularly immunotherapies, have since been developed [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>], and peripheral injection of monoclonal antibodies is already used in clinical trials [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Unfortunately, they poorly penetrate the brain, with only 0.1% to 0.2% crossing the blood&#8211;brain barrier [<xref ref-type="bibr" rid="CR11">11</xref>], and therefore have great difficulty reaching their target in the interstitial fluid that surrounds cells. In this context, antibody engineering represents an alternative approach to target the tau protein. Several studies in mouse models of tau pathology have demonstrated the potential of anti-tau antibody fragments (variable fragment of single chain antibodies or scFv) to reduce pathology [<xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR15">15</xref>]. In addition, the development of other single-domain antibody fragments, such as the variable domain of the heavy chain of heavy chain-only antibodies (VHHs), is also promising. Since their discovery in 1993 [<xref ref-type="bibr" rid="CR16">16</xref>], VHHs, which correspond to the variable fragment of antibodies without a light chain, have proved to be powerful not only in research applications but also in medicine and have attracted intense preclinical and clinical interest over the past two decades [<xref ref-type="bibr" rid="CR17">17</xref>]. Their entry into the neurodegenerative field began in the 2010s and they are now widely studied in the hope of addressing the challenges of antibody-based therapy targeting the central nervous system. Their high solubility facilitates intracellular protein targeting, they are easy to produce in bacteria, induce less immunogenicity than classical immunoglobulin G (IgG) antibodies, and exhibit good antigen binding capabilities and strong tissue penetration [<xref ref-type="bibr" rid="CR18">18</xref>]. Additionally, their small size (12 to 15 kDa) and the structure of their antigen-binding loops facilitate access to some epitopes that are difficult to reach with conventional antibodies [<xref ref-type="bibr" rid="CR19">19</xref>]. Some anti-tau VHHs have demonstrated the ability to target intraTau [<xref ref-type="bibr" rid="CR20">20</xref>&#8211;<xref ref-type="bibr" rid="CR26">26</xref>] and, when modified for secretion, to target extraTau [<xref ref-type="bibr" rid="CR27">27</xref>]. They are then invaluable, readily adaptable tools in the fight against tauopathies where specific toxic species are known in the brain parenchyma [<xref ref-type="bibr" rid="CR28">28</xref>] as well as in biological fluids [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>].</p><p id="Par45">Previously, we developed an anti-tau VHH called Z70 that targets tau, specifically the PHF6 epitope [<xref ref-type="bibr" rid="CR22">22</xref>]. This PHF6 hexapeptide (<sub>306</sub>VQIVYK<sub>311</sub>) is located in the third microtubule binding domain (MTBD) of tau and plays a central role in its aggregation [<xref ref-type="bibr" rid="CR31">31</xref>&#8211;<xref ref-type="bibr" rid="CR33">33</xref>]. Indeed, early filamentous assemblies of tau have been shown to be predominantly composed of the PHF6 peptide arranged in cross-&#946; sheet structures [<xref ref-type="bibr" rid="CR33">33</xref>]. We have previously shown that neutralizing intraTau species reduces tau nucleation in vitro, but also in an acute mouse model of tau seeding [<xref ref-type="bibr" rid="CR22">22</xref>]. Although a proof of concept of great interest, several limitations of this study remain, as the seeding model and lentiviral delivery used in this experiment that limit the assessment of larger (whole brain) and longer (ageing of tauopathy mouse models) effects of treatment. In addition, studying extended spatial and temporal effects raise the related question of safety under these conditions of increased exposure. Indeed, the PHF6 is not a specific epitope for pathological tau and it remains to be shown that the VHHs do not affect brain function.</p><p id="Par46">In this study, three main sections are highlighted: development of the tools, their safety and their efficacy. First, the safety of AAV viral vectors expressing anti-PHF6 VHH intracellularly or extracellularly was extensively evaluated using several complementary assays. We then tested the efficacy of targeting extraTau or intraTau and reducing different aspects of tau pathology on a mouse time scale that may be related to ageing. We demonstrated the efficacy of VHHs in preventing cognitive deficits or cerebral atrophy and reducing neuronal tau hyperphosphorylation, while the overall safety of the approach was strongly supported by multiple indicators. The comparison of the intraTau and extraTau VHH approaches allowed a better mechanistic understanding of their activities, which is of general interest for the development of anti-tau bio-therapies.</p></sec><sec id="Sec2"><title>Material and methods</title><sec id="Sec3"><title>VHH and adeno-associated vectors (AAVs)</title><p id="Par47">As previously performed in our laboratories, VHHs were selected from the screen of a synthetic phage-display library of humanized llama single-domain antibody [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Here, VHHs were produced using plasmids encoding a C-terminal mCherry protein fused with Z70 to target intraTau (intraZ70) or fused with a VHH against GFP as a control (intraCtrl). To target extraTau, plasmids encoding an N-terminal interleukin-2 secretion sequence and a C-terminal mouse mIgG-Fc2 [<xref ref-type="bibr" rid="CR34">34</xref>] was fused to Z70 to target extraTau (extraZ70) or fused with a VHH against GFP as a control (extraCtrl) were used (Fig. <xref rid="Fig1" ref-type="fig">1</xref>A). AAVs vectors driven by a cytomegalovirus promotor were purchased from VectorBuilder. AAV serotypes and cerebral injection sites were tested for maximal brain coverage [<xref ref-type="bibr" rid="CR35">35</xref>]. To insure the greatest dispersion of our vector, we evaluated four AAV serotypes already described for their central nervous system tropism [<xref ref-type="bibr" rid="CR36">36</xref>] (AAV2/7, AAV2/8, AAV2/9 and AAV2/10; encoding GFP protein, Fig. S1A). Intra-cerebroventricular delivery is not efficient regardless of the serotype used (Fig. S1B). Contrary, GFP is expressed after intra-hippocampal injections with AAV2/8 significantly less efficient than AAV2/7, AAV2/9 and AAV2/10 (Fig. S1C). To discriminate these three candidates, and because the tau transgenic mice used in this study (THY-Tau30 named Tg30) present tau pathology in the spinal cord [<xref ref-type="bibr" rid="CR37">37</xref>], immunostaining of GFP in this area was also performed. AAV2/9 allowed the best GFP expression in the spinal cord in wild-type mice (Fig. S1D) and is expressed in the dorsal, cervical and thoracic part of the spinal cord (Fig. S1E, left part) where tau pathology is present (Fig. S1E, right part) and was therefore selected for the further study.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>VHH constructs- (<bold>A</bold>, <bold>B</bold>) AAV2/9 constructs encoding under the expression control of a CMV promoter. <bold>A</bold>&#160;intraZ70 or intraCtrl&#8212;VHHs fused to a mCherry tag protein or (<bold>B</bold>) extraZ70 or extraCtrl&#8212;VHHs fused to an IL2 secretion signal and a Fc portion of mouse IgG2 (<bold>C</bold>) HEK293T cells were transfected with intraCtrl, intraZ70, extraCtrl and extraZ70 plasmids and VHH expression was detected by Western blot in cell lysate (C) or media (M) using anti-bodies against VHHs (upper panel) or antibodies against Fc (lower panel). The black star indicates the presence of cell culture medium contaminants, which are also present in non-transfected cells (NT). The black arrows point to the VHHs. <bold>D</bold> AAVs encoding VHHs were injected into the hippocampus of Tg30, and the viral DNA episome from the hippocampus were detected by qPCR, 1 or 9 months after injection. <bold>E</bold>&#160;Immuno-fluorescence detection of extraVHH (anti-VHH) and the endoplasmic reticulum (anti-calreticulin) was done using hippocampal sagittal sections of mice, 9 months post-injection. ExtraVHH is visualized in green and the ER in purple. Fluorochrome overlays are analyzed in cells and illustrated on the right part of the figure</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="13195_2025_1823_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec4"><title>Cell culture and cell transfection</title><p id="Par48">HEK293T cells were cultivated in Dulbecco&#8217;s modified Eagle&#8217;s medium with 10% fetal bovine serum, 1% penicillin/streptomycin, 1% GlutaMAX, and without HEPES. The cells were maintained in a humidified incubator with 5% CO<sub>2</sub>. All cell lines were passaged twice a week. Cells were seeded in 24-well plates (0.8.10<sup>6</sup> cells per well); 24 h later, cells were transfected with 500 ng of plasmids encoding intraZ70, intraCtrl, extraZ70 or extraCtrl together with lipofectamine in opti-MEM, as recommended by the manufacturer (Invitrogen). 48 h later, supernatants were collected and cells lysed in RIPA 1X buffer (150 mM NaCl, 0.1% SDS, 0.5% Sodium deoxycholate, 1% NP-40, EDTA free protease inhibitor, 50 mM Tris base at pH 8), homogenate was sonicated and samples were stored at &#8722;80 &#176;C.</p></sec><sec id="Sec5"><title>Biochemical analyses</title><p id="Par49">Protein concentrations were evaluated using a BCA assay (Pierce), subsequently diluted with lithium dodecyl sulfate 2X supplemented with reducing agents (Invitrogen) and then separated on 4&#8211;12% NuPAGE Bis&#8211;Tris Gels (Invitrogen). Proteins were transferred to nitrocellulose membrane, then saturated in TNT (Tris 15 mM pH8, NaCl 140 mM, 0.05% Tween) with 5% non-fat dry milk or 5% BSA and incubated with primary antibodies (see Table <xref rid="Tab1" ref-type="table">1</xref>) overnight at 4 &#176;C and with the corresponding secondary antibodies: peroxidase labeled horse anti-rabbit and anti-mouse (1/5,000 and 1/50,000 respectively, Vector Laboratories). Signals were revealed using a chemiluminescence assay (ECL, Amersham Bioscience) and visualized using a LAS4000 imaging system (GE Healthcare). Results were quantified using ImageQuant software to allow normalization. For synaptosome preparation, a mouse hippocampus was homogenized in Tris buffer (pH 7.4) containing 10% sucrose using a Potter&#8211;Elvehjem on ice. Syn-PER&#8482; Synaptic Protein Extraction Reagent (#87,793; Thermofisher, France) was then added to 100 &#956;L of brain homogenate. The samples were homogenized again using a Potter&#8211;Elvehjem and then centrifuged (1200 g; 10 min at 4 &#176;C). Cell debris were discarded, supernatants centrifuged (15,000 g; 20 min at 4 &#176;C) and the resulting pellets suspended in 100 &#956;L of Syn-PER&#8482; solution. For induction of ATF4 and EIF2&#945;, SH-SY5Y cells were incubated with 20 &#181;M of sodium arsenic for 6 h at 37 &#176;C.
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>List of primary and secondary antibodies used for western blot, immunohistochemistry or immunohistofluorescence</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Antibody</th><th align="left" colspan="1" rowspan="1">Application</th><th align="left" colspan="1" rowspan="1">Manufacturer&#8217;s reference</th><th align="left" colspan="1" rowspan="1">Dilution</th><th align="left" colspan="1" rowspan="1">Host species</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1"><italic toggle="yes">Primary antibodies</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Tau C-ter</td><td align="left" colspan="1" rowspan="1">WB</td><td align="left" colspan="1" rowspan="1">Home-made, 993-S1</td><td align="left" colspan="1" rowspan="1">1/4,000</td><td align="left" colspan="1" rowspan="1">Rabbit</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;NeuN</td><td align="left" colspan="1" rowspan="1">WB</td><td align="left" colspan="1" rowspan="1">Abcam, ab177487</td><td align="left" colspan="1" rowspan="1">1/5,000</td><td align="left" colspan="1" rowspan="1">Rabbit</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;GFAP</td><td align="left" colspan="1" rowspan="1">WB</td><td align="left" colspan="1" rowspan="1">Sigma-Aldrich, G3893</td><td align="left" colspan="1" rowspan="1">1/1,000</td><td align="left" colspan="1" rowspan="1">Mouse</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Iba1</td><td align="left" colspan="1" rowspan="1">WB</td><td align="left" colspan="1" rowspan="1">Abcam, ab178846</td><td align="left" colspan="1" rowspan="1">1/1,000</td><td align="left" colspan="1" rowspan="1">Rabbit</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;pEIF2&#945;</td><td align="left" colspan="1" rowspan="1">WB</td><td align="left" colspan="1" rowspan="1">Thermofischer, MA5-15133</td><td align="left" colspan="1" rowspan="1">1/1,000</td><td align="left" colspan="1" rowspan="1">Rabbit</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;EIF2&#945;</td><td align="left" colspan="1" rowspan="1">WB</td><td align="left" colspan="1" rowspan="1">Cell Signaling, 5324</td><td align="left" colspan="1" rowspan="1">1/1,000</td><td align="left" colspan="1" rowspan="1">Rabbit</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;ATF4</td><td align="left" colspan="1" rowspan="1">WB</td><td align="left" colspan="1" rowspan="1">Cell Signaling, 11815</td><td align="left" colspan="1" rowspan="1">1/1,000</td><td align="left" colspan="1" rowspan="1">Rabbit</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;pErk</td><td align="left" colspan="1" rowspan="1">WB</td><td align="left" colspan="1" rowspan="1">Cell Signaling, 9106</td><td align="left" colspan="1" rowspan="1">1/2,000</td><td align="left" colspan="1" rowspan="1">Mouse</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Erk</td><td align="left" colspan="1" rowspan="1">WB</td><td align="left" colspan="1" rowspan="1">Cell Signaling, 9102</td><td align="left" colspan="1" rowspan="1">1/1,000</td><td align="left" colspan="1" rowspan="1">Rabbit</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Snap25</td><td align="left" colspan="1" rowspan="1">WB</td><td align="left" colspan="1" rowspan="1">SantaCruz, sc-376713</td><td align="left" colspan="1" rowspan="1">1/1,000</td><td align="left" colspan="1" rowspan="1">Mouse</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;PSD95</td><td align="left" colspan="1" rowspan="1">WB</td><td align="left" colspan="1" rowspan="1">Cell Signaling, 2507</td><td align="left" colspan="1" rowspan="1">1/1,000</td><td align="left" colspan="1" rowspan="1">Rabbit</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;LC3b</td><td align="left" colspan="1" rowspan="1">WB</td><td align="left" colspan="1" rowspan="1">Cell Signaling, 2775</td><td align="left" colspan="1" rowspan="1">1/2,000</td><td align="left" colspan="1" rowspan="1">Rabbit</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;MBP</td><td align="left" colspan="1" rowspan="1">WB</td><td align="left" colspan="1" rowspan="1">Sigma Aldrich AB15542</td><td align="left" colspan="1" rowspan="1">1/5,000</td><td align="left" colspan="1" rowspan="1">Rabbit</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;CPNPase</td><td align="left" colspan="1" rowspan="1">WB</td><td align="left" colspan="1" rowspan="1">Abcam, ab6319</td><td align="left" colspan="1" rowspan="1">1/1,000</td><td align="left" colspan="1" rowspan="1">Mouse</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;GAPDH</td><td align="left" colspan="1" rowspan="1">WB</td><td align="left" colspan="1" rowspan="1">Sigma Aldrich, G9545</td><td align="left" colspan="1" rowspan="1">1/50,000</td><td align="left" colspan="1" rowspan="1">Rabbit</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Actin</td><td align="left" colspan="1" rowspan="1">WB</td><td align="left" colspan="1" rowspan="1">Sigma Aldrich, A5441</td><td align="left" colspan="1" rowspan="1">1/25,000</td><td align="left" colspan="1" rowspan="1">Mouse</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;AT8biot</td><td align="left" colspan="1" rowspan="1">IHC/IF</td><td align="left" colspan="1" rowspan="1">Invitrogen, MN1020B</td><td align="left" colspan="1" rowspan="1">1/500</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;AT100</td><td align="left" colspan="1" rowspan="1">IHC</td><td align="left" colspan="1" rowspan="1">Invitrogen MN1060</td><td align="left" colspan="1" rowspan="1">1/500</td><td align="left" colspan="1" rowspan="1">Mouse</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;MC1</td><td align="left" colspan="1" rowspan="1">IHC</td><td align="left" colspan="1" rowspan="1">Peter Davies lab</td><td align="left" colspan="1" rowspan="1">1/500</td><td align="left" colspan="1" rowspan="1">Mouse</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Iba1</td><td align="left" colspan="1" rowspan="1">IHC</td><td align="left" colspan="1" rowspan="1">Wako, 019&#8211;19741</td><td align="left" colspan="1" rowspan="1">1/1000</td><td align="left" colspan="1" rowspan="1">Rabbit</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;AT8</td><td align="left" colspan="1" rowspan="1">IF</td><td align="left" colspan="1" rowspan="1">Invitrogen, MN1020</td><td align="left" colspan="1" rowspan="1">1/500</td><td align="left" colspan="1" rowspan="1">Mouse</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;VHH</td><td align="left" colspan="1" rowspan="1">IF</td><td align="left" colspan="1" rowspan="1">Eurogentec EG-VHH001</td><td align="left" colspan="1" rowspan="1">1/1,000</td><td align="left" colspan="1" rowspan="1">Rabbit</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;RFP</td><td align="left" colspan="1" rowspan="1">IF</td><td align="left" colspan="1" rowspan="1">Rockland, 600&#8211;401-379</td><td align="left" colspan="1" rowspan="1">1/1,000</td><td align="left" colspan="1" rowspan="1">Rabbit</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Calreticulin</td><td align="left" colspan="1" rowspan="1">IF</td><td align="left" colspan="1" rowspan="1">Thermo, PA3-900</td><td align="left" colspan="1" rowspan="1">1/500</td><td align="left" colspan="1" rowspan="1">Rabbit</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;GFP</td><td align="left" colspan="1" rowspan="1">IF</td><td align="left" colspan="1" rowspan="1">Synaptic System 132002</td><td align="left" colspan="1" rowspan="1">&#160;1/1,000</td><td align="left" colspan="1" rowspan="1">Rabbit</td></tr><tr><td align="left" colspan="5" rowspan="1"><italic toggle="yes">Secondary antibodies</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Anti-mouse IgG Fc cross-adsorbed HRP</td><td align="left" colspan="1" rowspan="1">WB</td><td align="left" colspan="1" rowspan="1">Invitrogen 31439</td><td align="left" colspan="1" rowspan="1">1/20,000</td><td align="left" colspan="1" rowspan="1">Goat</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Anti-rabbit IgG (H&#8201;+&#8201;L) peroxidase</td><td align="left" colspan="1" rowspan="1">WB</td><td align="left" colspan="1" rowspan="1">Vector Laboratories, PI-1000</td><td align="left" colspan="1" rowspan="1">1/5,000</td><td align="left" colspan="1" rowspan="1">Goat</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Anti-mouse IgG (H&#8201;+&#8201;L) peroxidase</td><td align="left" colspan="1" rowspan="1">WB</td><td align="left" colspan="1" rowspan="1">Vector Laboratories, PI-2000</td><td align="left" colspan="1" rowspan="1">1/50,000</td><td align="left" colspan="1" rowspan="1">Horse</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Anti-mouse IgG (H&#8201;+&#8201;L) biotinylated</td><td align="left" colspan="1" rowspan="1">IHC</td><td align="left" colspan="1" rowspan="1">Vector Laboratories, BA-2001</td><td align="left" colspan="1" rowspan="1">1/400</td><td align="left" colspan="1" rowspan="1">Goat</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Anti-rabbit IgG (H&#8201;+&#8201;L) biotinylated</td><td align="left" colspan="1" rowspan="1">IHC</td><td align="left" colspan="1" rowspan="1">Vector Laboratories, BA-1000</td><td align="left" colspan="1" rowspan="1">1/400</td><td align="left" colspan="1" rowspan="1">Goat</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Anti-mouse IgG, Fc&#947; fragment specific Alexa Fluor 488</td><td align="left" colspan="1" rowspan="1">IF</td><td align="left" colspan="1" rowspan="1">Jackson ImmunoResearch, 115&#8211;545-008</td><td align="left" colspan="1" rowspan="1">1/500</td><td align="left" colspan="1" rowspan="1">Goat</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Anti-mouse IgG (H&#8201;+&#8201;L), Alexa fluor 488</td><td align="left" colspan="1" rowspan="1">IF</td><td align="left" colspan="1" rowspan="1">Invitrogen, A11001</td><td align="left" colspan="1" rowspan="1">1/1,000</td><td align="left" colspan="1" rowspan="1">Goat</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Anti-rabbit IgG (H&#8201;+&#8201;L), Alexa fluor 647</td><td align="left" colspan="1" rowspan="1">IF</td><td align="left" colspan="1" rowspan="1">Invitrogen, A21245</td><td align="left" colspan="1" rowspan="1">1/1,000</td><td align="left" colspan="1" rowspan="1">Goat</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Streptavidine, conjugued Alexa Fluor 647</td><td align="left" colspan="1" rowspan="1">IF</td><td align="left" colspan="1" rowspan="1">Invitrogen S21374</td><td align="left" colspan="1" rowspan="1">1/500</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Streptavidine conjugued Alexa Fluor 568</td><td align="left" colspan="1" rowspan="1">IF</td><td align="left" colspan="1" rowspan="1">Invitrogen S11226</td><td align="left" colspan="1" rowspan="1">1/500</td><td align="left" colspan="1" rowspan="1">-</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec6"><title>Animals</title><p id="Par50">The study was performed in accordance with French and European Community rules. The experimental research was performed with the approval of an ethics committee (agreement APAFIS #43474&#8211;2023050714441306 v6) and follows European guidelines for the use of animals. The animals (males and females) were housed in a temperature controlled (20&#8211;22&#176;C) room maintained on a 12 h (h) day/night cycle with food (SAFE R04-25) and water provided ad libitum in a specific pathogen-free animal facility (<italic toggle="yes">n</italic>&#8201;=&#8201;5 mice per cage). Animals were allocated to experimental groups by randomization. THY-tau30 transgenic mice (Tg30) express human 1N4R tau protein with two pathogenic mutations (P301S and G272V) under the control of the neuron-specific Thy1.2 promoter [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Animals used in this study are detailed in Table <xref rid="Tab2" ref-type="table">2</xref>. Whereas considering Sex As a Biological Variable (SABV) is of interest, this study grouped male and female mice together for ethical reasons, primarily to minimize the number of animals sacrificed. This approach also ensured statistical power, particularly for our imaging and behavioral assays.
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Animal groups</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" rowspan="5" colspan="1">Injection site &amp; AAV selection</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Injection-ICV</td><td align="left" colspan="1" rowspan="1">Injection-HIPP</td><td align="left" colspan="1" rowspan="1">IHF</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">AAV2/7</td><td align="left" colspan="1" rowspan="1">3 &#9792;</td><td align="left" colspan="1" rowspan="1">3 &#9792;</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">AAV2/8</td><td align="left" colspan="1" rowspan="1">3 &#9794;</td><td align="left" colspan="1" rowspan="1">3 &#9794;</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">AAV2/9</td><td align="left" colspan="1" rowspan="1">3 &#9792;</td><td align="left" colspan="1" rowspan="1">3 &#9792;</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">AAV2/10</td><td align="left" colspan="1" rowspan="1">3 &#9794;</td><td align="left" colspan="1" rowspan="1">3 &#9794;</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" rowspan="9" colspan="1">WT &amp; Tg30</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Injection</td><td align="left" colspan="1" rowspan="1">Behavior</td><td align="left" colspan="1" rowspan="1">Imaging</td><td align="left" colspan="1" rowspan="1">qPCR</td><td align="left" colspan="1" rowspan="1">IHC</td><td align="left" colspan="1" rowspan="1">IHF</td><td align="left" colspan="1" rowspan="1">WB</td></tr><tr><td align="left" colspan="1" rowspan="1">Tg30 intraCtrl</td><td align="left" colspan="1" rowspan="1">15 (9&#9794;&#8201;+&#8201;6&#9792;)</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Tg30 intraZ70</td><td align="left" colspan="1" rowspan="1">15 (10&#9794;&#8201;+&#8201;5&#9792;)</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Tg30 extraCtrl</td><td align="left" colspan="1" rowspan="1">15 (6&#9794;&#8201;+&#8201;9&#9792;)</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Tg30 extraZ70</td><td align="left" colspan="1" rowspan="1">15 (6&#9794;&#8201;+&#8201;9&#9792;)</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">WT AAV2/9</td><td align="left" colspan="1" rowspan="1">15 (5&#9794;&#8201;+&#8201;10&#9792;)</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">15</td></tr><tr><td align="left" colspan="1" rowspan="1">WT GFP</td><td align="left" colspan="1" rowspan="1">15 (6&#9794;&#8201;+&#8201;9&#9792;)</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">15</td></tr><tr><td align="left" colspan="1" rowspan="1">WT intraZ70</td><td align="left" colspan="1" rowspan="1">15 (6&#9794;&#8201;+&#8201;9&#9792;)</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">14</td></tr><tr><td align="left" colspan="1" rowspan="1">WT extraZ70</td><td align="left" colspan="1" rowspan="1">14 (8&#9794;&#8201;+&#8201;6&#9792;)</td><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">12</td></tr><tr><td align="left" rowspan="5" colspan="1">VHH episome</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Injection</td><td align="left" colspan="1" rowspan="1">qPCR</td><td align="left" colspan="1" rowspan="1">IHF</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Tg30 intraCtrl</td><td align="left" colspan="1" rowspan="1">5 (3&#9794;&#8201;+&#8201;2&#9792;)</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Tg30 intraZ70</td><td align="left" colspan="1" rowspan="1">5 (3&#9794;&#8201;+&#8201;2&#9792;)</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Tg30 extraCtrl</td><td align="left" colspan="1" rowspan="1">5 (2&#9794;&#8201;+&#8201;3&#9792;)</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Tg30 extraZ70</td><td align="left" colspan="1" rowspan="1"> 5(3&#9794;&#8201;+&#8201;2&#9792;)</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p>The number and sex of mice injected and among them the number of animal used for separate experiment are shown</p><p>Difference between a few groups and pathological assessment is due to premature death of animals</p><p><italic toggle="yes">ICV </italic>intracerebroventricular, <italic toggle="yes">HIPP </italic>hippocampus, <italic toggle="yes">IHF </italic>immunofluorescence, <italic toggle="yes">IHC </italic>immunohistochemistry, <italic toggle="yes">WB </italic>western-blot, <italic toggle="yes">qPCR </italic>quantitative polymerase chain reaction</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec7"><title>AD brain homogenate (hAD) preparation</title><p id="Par51">Two human AD brain samples (Braak 6, frontal cortex) were obtained from the Lille Neurobank (fulfilling criteria of the French law on biological resources and declared to competent authority under the number DC-2008&#8211;642) with donor consent, data protection and ethical committee review. Samples were managed by the CRB/CIC1403 Biobank, BB0033-00030. Extract was homogenized on ice with a glass potter in five volumes (w/v) of phosphate-buffered saline (PBS) and then sonicated (50 runs, amplitude 60, VibraCell 72405, Bioblock Scientific). Protein concentration was determined using a BCA assay. Sonicated h-AD was centrifuged at 4 &#176;C 3,000 g for 5 min and then the supernatant was aliquoted and kept at &#8722;80 &#176;C until use.</p></sec><sec id="Sec8"><title>Stereotaxic injection</title><p id="Par52">One month-old anesthetized Tg30 or littermate mice were submitted to stereotaxic intracranial injections of AAV at 1.5.10<sup>13</sup> genome copies/mL in 2 &#181;L at 250 nL/minutes (min) with a Hamilton glass syringe. For AAV serotype selection, bilateral stereotaxic injections were performed in the hippocampus of Tg30 mice (coordinates from bregma anterio-posterior (AP): &#8722;2.5; medio-lateral (ML):&#8201;&#177;&#8201;1; dorso-ventral (DV): &#8722;1.8) or in cerebral ventricle (coordinates from bregma AP: &#8722;0.4; ML:&#8201;&#177;&#8201;1; DV: &#8722;2.2) with AAV serotype 2/7, 2/8, 2/9 or 2/rh10 expressing GFP protein under a CMV promotor (VectorBuilder). For VHH efficiency assays, Tg30 mice were bilaterally injected at the same hippocampal coordinates with AAV2/9 expressing either intraZ70, intraCtrl, extraZ70 or extraCtrl (Fig. <xref rid="Fig1" ref-type="fig">1</xref>A and B). Littermate mice were injected at the same hippocampal coordinates with either control AAV (AAV2/9) or with AAVs expressing GFP protein, or with intra or extraZ70. For the seeding mouse model, one month-old Tg30 animals were injected at the same coordinates (AP: &#8722;2.5, ML:&#8201;&#177;&#8201;1; DV: &#8722;1.8) with lentiviral vectors expressing intraCtrl, intraZ70, extraCtrl, extraZ70 as previously done [<xref ref-type="bibr" rid="CR22">22</xref>]. Two weeks later, 2 &#181;L (5 &#181;g/&#181;L) of human h-AD were inoculated at the same injection site.</p></sec><sec id="Sec9"><title>Behavioral tests</title><p id="Par53">The behavioral tests were done during the rodent light cycle.</p><sec id="Sec10"><title>Y-maze</title><p id="Par54">Seven months after stereotaxic injections, mice were tested for short-term hippocampus-dependent spatial working memory using a two-trial Y-maze task [<xref ref-type="bibr" rid="CR39">39</xref>]. The arms of the maze were 22 cm long, 6.4 cm wide and 15 cm deep. The floor of the maze was covered with sawdust that was mixed after each trial in order to eliminate olfactory cues. Various extra-maze visual clues were placed on the surrounding walls. Experiments were conducted with an ambient light level of 7 lx. During the exposure phase, mice were assigned to two arms (the &#8220;start arm&#8221; and the &#8220;other arm&#8221;), which can be freely explored during 5 min, without access to the third arm of the maze (the &#8220;novel arm&#8221;), blocked by an opaque door. The assignment of arms was counterbalanced within each experimental group. Mice were then removed from the maze and returned to their home cage for 2 min. During the test phase, mice were placed at the end of the same &#8220;start arm&#8221; and allowed to freely explore all three arms during 5 min. The amount of time spent in each of the arms in the first minute was recorded using EthovisionXT (Noldus, Netherlands). A discrimination index is applied on the test phase, corresponding to the time in the novel arm&#8201;&#215;&#8201;100/(time in novel arm&#8201;+&#8201;time in other arm). The distance travelled and the velocity were determined on the 5 min of exploration.</p></sec><sec id="Sec11"><title>OpenField</title><p id="Par55">Seven months after injections, exploratory activity and anxiety-like behavior without predator stimuli was assessed in an openField arena (49&#8201;&#215;&#8201;49 cm) under medium-light intensity (60 lx) [<xref ref-type="bibr" rid="CR40">40</xref>]. Plastic walls were always cleaned with 30% ethanol between each trial. Mice were placed in the center and were allowed to explore the arena for 10 min. The distance travelled and the velocity were considered as the main parameters of locomotion. The inner zone was considered as center and time spent in the center was compared to the time near the walls. The amount of time spent in each zone was recorded using EthovisionXT (Noldus, Netherlands).</p></sec></sec><sec id="Sec12"><title>Magnetic resonance imaging (MRI)</title><sec id="Sec13"><title>Acquisition</title><p id="Par56">The images are taken on a 7 T MRI (Bruker, Biospec, Etlingen, Germany). A cylindrical transmitting coil 86 mm diameter coupled to a surface receiving coil dedicated to the mouse brain allows data recording. The animals are anesthetized during the acquisitions with isoflurane (1.5%) and their temperature is kept constant thanks to a hot water circuit integrated into the bed on which the animal is positioned. A pressure sensor is placed under the abdomen to monitor breathing during the various acquisitions, and a pulse oximetry sensor is placed on its leg. The procedure lasts approximately 1 h 25 min per animal and includes a total of 6 sequences acquired successively. The imaging protocol begins with a gradient echo sequence which allows control of the positioning of the brain at the center of the magnetic field of the MRI, 15 images are then acquired (5 images for each of the three reference planes, axial, coronal and sagittal). A second 2D identification sequence is carried out, in spin echo of 10 contiguous coronal sections of 0.7 mm thickness, T2 weighted, making it possible to control the transverse orientation of the brain. The sequence parameters are as follows: A time repetition (TR) of 2500 millisecondes (ms), an echo time (TE) of 33 ms, the field of view (FOV) is a 2-cm square, coded by a matrix of 256 by 256, i.e. a resolution of 78 microns per pixel. A 2D diffusion tensor imaging (DTI) sequence of 30 0.5 mm axial sections is applied using the echo planar imaging (EPI) acquisition method in order to measure the mobility parameters of water molecules, such as the Fractional Anisotropy (FA) and the Mean Diffusivity (MD). The sequence parameters are as follows: A TR of 2500 ms, an echo time (ET) of 30 ms, the FOV is a rectangle of 2.2&#8201;&#215;&#8201;1.5 cm, coded by a matrix of 220 by 150, i.e. a pixel of 100 microns of side. This sequence is coded in 30 directions with a b-value of 850 s/mm2. Homogenization of the magnetic field is obtained by the MAP-SHIM method by placing a narrowed voxel around the brain. In addition, a reverse-phase image acquired for DTI sequence is duplicated by adjusting its inverted phase coding direction parameters, without gradient diffusion, in order to correct in a post-processing analyze the distortions due to the EPI method. Then an anatomical T2 weighting sequence geometrically recalled to the DTI is carried out with the following parameters: A TR of 5000 ms, an ET of 33 ms, with a geometry identical to the DTI sequence. Finally, a 3D anatomical sequence of the brain is acquired in order to carry out volumetric calculations of brain structures. It is T2 weighted with a TR of 1800 ms, an ET of 36 ms, the FOV is a voxel of 20&#8201;&#215;&#8201;15.5&#8201;&#215;&#8201;12 cm, coded by a matrix of 154 by 119 by 92, i.e. an isotropic resolution of 130 microns per pixel.</p></sec><sec id="Sec14"><title>Data processing</title><p id="Par57">First, bias field inhomogeneity is corrected from T2-weighted images using N4 algorithm [<xref ref-type="bibr" rid="CR41">41</xref>]. Then images were denoised with a multiresolution non-local means filter [<xref ref-type="bibr" rid="CR42">42</xref>]. Brain mask and label segmentation were extracted in using multi-atlas label fusion [<xref ref-type="bibr" rid="CR43">43</xref>] and from the National University of Singapore (NUS) mouse atlas [<xref ref-type="bibr" rid="CR44">44</xref>]. Thirty-nine bilateral Regions of Interest (ROIs) were extracted and their volume was calculated (Whole Brain, CA1, Dentate Gyrus, Hippocampus, Amygdala, Caudoputamen, Corpus callosum, Lateral ventricle, Motor cortex, Perirhinal cortex, Visual cortex, Thalamus). On 3D T2 weighted images, a voxel-wise <italic toggle="yes">p</italic>-values method was performed to compare volumes of the cerebral regions of WT-AAV2/9 mice to the three other groups in using an approximate two-sample Fisher-Pitman permutation test with resample&#8201;=&#8201;10,000 [<xref ref-type="bibr" rid="CR45">45</xref>]<italic toggle="yes">.</italic> For <italic toggle="yes">p</italic>-value&#8201;&lt;&#8201;0.05, a -log10(<italic toggle="yes">p</italic>-value) was applied. Label values were modified with those <italic toggle="yes">p</italic>-values were then applied on their atlas ROIs and overlapped to the MRI template<italic toggle="yes">.</italic></p></sec><sec id="Sec15"><title>DTI images statical analysis</title><p id="Par58">First, DTI images were corrected for motion using AFNI (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://afni.nimh.nih.gov/">https://afni.nimh.nih.gov/</ext-link>) function. Then, TOPUP function was applied to the pair of phase image. DTI data were denoise with Mrtrix package (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.mrtrix.org/">https://www.mrtrix.org/</ext-link>) and bias field inhomogeneity is corrected from T2-weighted images using N4 algorithm. T2 weighted image and mask and label images were rigidely co-registered over the B0 image with functional source license FSL. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://fsl.fmrib.ox.ac.uk">https://fsl.fmrib.ox.ac.uk</ext-link>). Eddy correction were applied on diffusion image using FSL. <italic toggle="yes">Different</italic> diffusion tensor parametric maps were generated with FSL, including FA, MD, Longitudinal (LD) and Radial (RD) diffusivities. Data from all the animals were averaged/ROI and presented as mean standard deviation (SD).</p></sec></sec></sec><sec id="Sec16"><title>[18 F]-fluorodeoxyglucose positron emission tomography (PET) acquisitions</title><p id="Par59">Glucose cerebral metabolism was studied by performing a PET-computed tomography (CT) scan (Inveon, Siemens, Knoxville, TN, USA) with an intraperitoneal injection of 18-fluorinated glucose analogue ([18 F] fluorodeoxyglucose, (0.5 MBq / g; 0.3 ml in volume, Curium, Glisy, France). A 15-min PET scan was initiated 45 min after radiotracer injection. All CT scans were registered to an in-house CT template and brain masks were extracted and applied to PET images with ANTS (Advanced Normalization package <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.fil.ion.ucl.ac.uk/spm/">http://www.fil.ion.ucl.ac.uk/spm/</ext-link> Normalization Tools package). PET images were then registered to NUS mouse atlas [<xref ref-type="bibr" rid="CR44">44</xref>]<italic toggle="yes">.</italic>
<sup>18</sup>FDG brain uptake values were expressed as Standardized Uptake Values (SUV). SUV were then extracted in brain areas using NUS atlas. Elected regions SUV values were normalized with cerebellum SUV values.</p><sec id="Sec17"><title>Tissue processing</title><p id="Par60">For AAVs serotype selection and the seeding model, 1 month after stereotaxic injection, Tg30 were deeply anesthetized with 100 mg/kg Ketamine and 10 mg/kg Xylazine, trans-cardially perfused with ice-cold 0.9% saline solution then 10 min with fresh 4% paraformaldehyde (PFA). The brains and spinal cords were immediately removed and post-fixed in 4% PFA over-night (ON). Brain was washed in phosphate-buffered saline (PBS), placed in 20% sucrose ON, and frozen 1 min in isopentane. Free-floating sagittal (AAVs selection) or coronal (seeding model) sections (40-&#181;m thickness) were obtained using a cryostat microtome. Spinal cord was incubated in 70% ETOH overnight, 80% ETOH 90 min, 95% ETOH 90 min, 100% ETOH 90 min, 100% Xylene 2 times 2 h each, paraffin 55 &#176;C 2 times 90 min each and embedded. 7 &#181;m sections were performed with Leica microtome. For VHH efficiency assays, 9 months after stereotaxic injection, WT or Tg30 were deeply anesthetized with 100 mg/kg Ketamine and 10 mg/kg Xylazine and trans-cardially perfused with ice-cold 0.9% saline solution. The brains were immediately removed and a brain hemisphere was post-fixed in 4% PFA for 7 days, washed in PBS, placed in 20% sucrose ON, and frozen 1 min in isopentane. Free-floating sagittal sections (40-&#181;m thickness) were obtained using a Leica cryostat. The second hemisphere was extracted, the hippocampus separated and frozen for biochemical analysis.</p></sec><sec id="Sec18"><title>DNA extraction from hippocampus and qPCR protocol</title><p id="Par61">One- and 9 months post-injection, hippocampi were lysed by sonication in 200 &#181;L in a tris base 10 mM pH 7.4 &#8211; sucrose 10% solution. The DNA was extracted using 15 &#181;L of lysate in the Nucleospin Tissue XS, Micro kit (740,901.50, Macherey Nagel) according to the manufacturer&#8217;s instructions. Quantitative real-time PCR analysis was performed on Applied Biosystems&#8482; QuantStudio3&#8482; Real-Time PCR Systems, using 2 &#956;L at 25 ng/&#956;L of the previously obtained products, 1 &#181;M oligonucleotides specific to VHH (reverse ATA CGT AGC TGT GTC CTC GG and forward GAG TTC GTT TCC GCC ATC TC), in a commercial SYBRGreen Master Mix (GoTaq Green Master Mix 2X, Promega). The thermal cycler conditions were as follows: 95 &#176;C for 10 min, then 40 cycles at 95 &#176;C for 15 s and 60 &#176;C for 1 min. Viral copies genome number were deducted from standard curve generated after QPCR of plasmid encoding VHH with the same experimental conditions.</p></sec><sec id="Sec19"><title>Immunohistofluorescence</title><p id="Par62">For extraVHH, brain sections were saturated in normal goat serum (1/100; S-1000, Vector), then incubated with the primary antibody anti-Fc conjugated with Alexa 488 (AffiniPure Goat Anti-mouse IgG, Fc&#947; fragment specific; 1/500; 115&#8211;545-008, Jackson ImmunoResearch) for 1 h at room temperature in PBS-0.2% Triton X-100. Then they were incubated with the antibody anti-tau AT8 biotinylated (1/500; MN1020B, Invitrogen) ON at 4 &#176;C in PBS-0.2% Triton X-100. Biotin of anti-AT8 were revealed using either Alexa 568-Streptavidin (1/500; S11226, Invitrogen) for mice sacrificed 9 months post-injection or with Alexa 647-Streptavidin (1/500; S21374, Invitrogen) for mice sacrificed 1 month post-injection. For intraVHH, brain sections were saturated in normal goat serum (1/100; S-1000, Vector laboratories), then incubated with the primary antibodies anti-tau AT8 (1/500; mouse; MN1020, Invitrogen) and anti-RFP (1/1,000; rabbit; 600&#8211;401-379, Rockland) ON at 4 &#176;C in PBS-0.2% Triton X-100. Labeling was detected using a goat anti-mouse secondary antibody conjugated with Alexa 488 (1/1,000; A11001, Invitrogen) and goat anti-rabbit antibody conjugated with Alexa 647 (1/1,000; A21244 or A21245, Invitrogen).</p><p id="Par63">For both extra- and intraVHH, slices were coverslipped with mounting medium supplemented with DAPI (H1200, Vector laboratories) to reveal nuclei. Acquisitions were performed using either a slide scanner (Axioscan Z1-Zeiss) with a&#8201;20X objective or an inverted confocal microscope (LSM 710, Zeiss, Jena, Germany) with a 20X or 63X oil-immersion lens. Mean intensity projection (merged of individual focal plans) or individual focal plan are shown. Profile superpositions are done using the ZEB blue software (3.6 blue edition). Co-localization studies were carried out on individual focal planes&#8201;&#8804;&#8201;to 1 &#181;m to demonstrate the proximity of the markers analyzed. The superposition of the two fluorochromes was detected using the &#8216;profile&#8217; tools of the ZEN blue software (3.6blue edition).</p><p id="Par64">For AAV serotype selection, spinal cord sections were deparaffinized and unmasked via citrate buffer (3.75 mM Acid citrate, 2.5 mM disodium phosphate, pH&#8239;6) for 10 min in a domestic microwave. Spinal cords and brain sections were saturated in normal goat serum (1/100; Vector), then incubated with the primary polyclonal antibodies anti-GFP (1/1,000, rabbit, Synaptic System) ON at 4 &#176;C in PBS-0.2% Triton X-100. Labeling was detected using a secondary anti-rabbit antibody conjugated with Alexa 568 (1/500; Invitrogen). Slices were coverslipped with mounted medium added with DAPI (Vector) to reveal nuclei. Section imaging was performed using a slide scanner (Axioscan Z1-Zeiss) with a&#8201;&#215;&#8201;20 objective. Quantification of the GFP staining and DAPI was performed using ImageJ.</p></sec><sec id="Sec20"><title>Immunohistochemistry and quantification</title><p id="Par65">Free-floating sagittal sections were used for immunohistochemistry. Nonspecific binding was blocked by using &#8220;Mouse in Mouse&#8221; reagent or normal goat serum (1/100; Vector Laboratories). Brain slices were next incubated with the biotinylated primary monoclonal antibody AT8 (1/500; Thermo MN1020b), AT100 (1/500; Thermo MN1060), MC1 (1/500; Peter Davies&#8217;s gift) or Iba1 (1/1000; Wako 019&#8211;19741) in PBS- 0.2% Triton X-100, ON at 4 &#176;C. For AT100 and MC1 staining, slices were incubated with biotinylated anti-mouse secondary antibody (1/400; Vector BA2001); for Iba1 slices were incubated with biotinylated anti-rabbit secondary antibody (1/400; Vector BA1000). The avidin/biotin-HRP complex (ABC kit, 1:400 in PBS, Vector) was used to amplify signals prior to addition of diaminobenzidine tetrahydrochloride (DAB, Vector) in Tris&#8211;HCl 0.1 mol/L, pH 7.6, containing H<sub>2</sub>O<sub>2</sub>. Brain sections were mounted, air-dried, steadily dehydrated in ethanol (30%, 70%, 95%, 100%), cleared in toluene, and coverslipped with VectaMount (Vector Laboratories). For blinded quantification, sagittal brain sections (10 to 17 slices per mouse) from ML bregma 0.3 to 3.5 (based on the Mouse Atlas, George Paxinos and Keith B.J. Franklin, Second Edition, Academic Press) (Fig. S2A) were analyzed using histology software (Mercator image analysis system; Explora Nova). Threshold was established manually to present a minimal background and remained constant throughout the analysis (Fig. S2B).</p></sec><sec id="Sec21"><title>Plasma analysis</title><p id="Par66">At sacrifice, blood samples were collected by cardiac puncture using Microvette CB 300 EDTA K2E (Sarstedt) and centrifuged at 2000 g for 10 min at 4 &#176;C. Plasma were then stored at&#8201;&#8722;&#8201;80 &#176;C. Simoa Neuro 4-Plex B (Quanterix) was used to quantify NF-light, tau, GFAP and UCH-L1. Mouse plasma was re-spun 5 min at 10 000 g at 4 &#176;C, diluted 8 times in the assay buffer and the experiment were next performed in duplicate using manufacturer&#8217;s instructions. Samples were analyzed on the Simoa SR-X analyser (Quanterix). Manufacter&#8217;s controls were in the specified range and samples were above LLOQ for each measurement (Analytical LLOQ&#8201;=&#8201;0.5 pg/mL for Tau, 2 pg/mL for NfL, 9.38 pg/mL for GFAP and 37.5 pg/mL for UCHL1).</p></sec><sec id="Sec22"><title>Statistics</title><p id="Par67">Statistics and plots were generated using GraphPad Prism 8 software (version 8.0.0). The normality of the distributions was assessed graphically and using the Shapiro&#8211;Wilk test. In the case of a non-Gaussian distribution, the Mann&#8211;Whitney U test was used for one-to-one comparisons, and ordinary one-way Analysis Of Variance (ANOVA) (non-parametric Kruskal&#8211;Wallis test) for multiple comparisons. In the case of a Gaussian distribution, the t-test was used for one-to-one comparisons or one-way ANOVA (parametric Dunnett&#8217;s multiple comparison test) for multiple comparisons. Data are reported as the mean&#8201;&#177;&#8201;standard deviation (SD). The statistical tests adopted a two-tailed &#945; level of 0.05.</p><p id="Par68">Statistical tests, inclusion or exclusion of outliers, post-hoc tests are presented in supplementary Table 1. For behavioral studies, identification of outliers was performed post hoc using Iterative Grubbs (Alpha&#8201;=&#8201;0.1) and outliers were removed from data analysis.</p></sec></sec><sec id="Sec23"><title>Results</title><sec id="Sec24"><title>The tools</title><sec id="Sec25"><title>Constructs encoding VHH mediate effectively the intra or extracellular localization</title><p id="Par69">Our VHHs were designed for either intracellular expression (intraVHH, Fig. <xref rid="Fig1" ref-type="fig">1</xref>A) or secretion into the extracellular environment (extraVHH, Fig. <xref rid="Fig1" ref-type="fig">1</xref>B) driven by a secretion consensus sequence. IntraVHHs are fused to a mCherry protein, whereas extraVHHs are fused to an interleukin-2 signal sequence (IL2ss) in their N-terminal parts, allowing their secretion, and a Fc portion in their C-terminal parts, to increase their sensitivity and/or affinity [<xref ref-type="bibr" rid="CR46">46</xref>].</p><p id="Par70">IntraZ70 was detected in the cell lysate of transfected HEK293T cells by immunoblotting with anti-VHH antibodies (Fig. <xref rid="Fig1" ref-type="fig">1</xref>C, upper panel). Conversely, as expected, extraZ70 was detected with anti-VHH antibodies (Fig. <xref rid="Fig1" ref-type="fig">1</xref>C, upper panel) and anti-Fc antibodies (Fig. <xref rid="Fig1" ref-type="fig">1</xref>C, lower panel) in both the cell lysate and the media. Intra and extraVHHs were detected at the expected molecular weights of 40 kDa (VHH&#8201;=&#8201;14 kDa, mCherry&#8201;=&#8201;26 kDa) and 42 KDa (IL2ss-VHH&#8201;=&#8201;17 kDa, mFc&#8201;=&#8201;25 kDa), respectively. This confirms the targeting of VHHs and demonstrates that VHH secretion into the extracellular space is driven by the secretion consensus sequence present in extraVHH. Following viral vector delivery into young Tg30 mice, the presence of viral DNA episome was confirmed by qPCR in the hippocampus of mice (Fig. <xref rid="Fig1" ref-type="fig">1</xref>D), which was further confirmed by VHH immunofluorescence detection on sagittal brain slices at these time points (Fig. S3). Finally, a specific colocalization between calreticulin (purple), an endoplasmic reticulum marker, and extraVHH (green) confirmed a secretory pathway for its extracellular localization (Fig. <xref rid="Fig1" ref-type="fig">1</xref>E). Taken together, these experiments verified the long-term production of Z70 VHHs following viral vector delivery and that their intended localization was achieved. Similar conclusions were drawn for the intended controls of our experiments, namely anti-GFP VHHs (intraCtrl and extraCtrl VHHs, Fig. <xref rid="Fig1" ref-type="fig">1</xref>C).</p></sec></sec><sec id="Sec26"><title>The safety</title><sec id="Sec27"><title>VHH safety</title><p id="Par71">Z70 targets the epitope PHF6, which is found in both human and murine proteomes, potentially disrupting normal tau function in mice. A long-term multi-assay was designed to evaluate potential Z70 adverse events in WT mice. Several outcome measures were analyzed: 1) body weight gain, 2) brain imaging (MRI and PET-FDG), 3) parenchymal and peripheral biomarkers and 4) behavior. As controls, we used AAV2/9 vectors expressing the GFP protein and empty AAV vectors. Data relating to the GFP protein should be viewed with caution, as its overexpression in cells can induce undesirable cellular events [<xref ref-type="bibr" rid="CR47">47</xref>]. In multivariate statistical analyses, the empty vector is used as a control.<list list-type="order"><list-item><p id="Par72"><italic toggle="yes">Body weight gain&#8212;</italic>AAV2/9 expressing intraZ70 or extraZ70 was injected into the hippocampus of 1-month-old WT mice and the mice were sacrificed 9 months later (Fig. <xref rid="Fig2" ref-type="fig">2</xref>A). We also injected AAV2/9 which does not express any protein, called AAV2/9, or expressing GFP as controls. No difference in weight gain was observed among groups, suggesting the safety of protein overexpression procedures on the global metabolism in WT mice (Fig. <xref rid="Fig2" ref-type="fig">2</xref>B).<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>VHH Safety: Brain imaging- (<bold>A</bold>) Scheme of the experimental design created with Biorender.com. (<bold>B</bold>) Mice were weighed monthly and the results are expressed as weight gain (=&#8201;% weight compared to weight before viral vector injections). (<bold>C</bold>) 8 months after injection, MRI scans were used to determine the following image aspects: 1) brain volume: the statistical difference between mice injected with AAV2/9 and mice injected with GFP, intraZ70 or extraZ70 is shown (left to right). These statistical values are color-coded on the NUS template used for segmentation. The brain volumes expressed in mm<sup>3</sup> are shown for the hippocampus (<bold>D</bold>) and for the visual cortex (<bold>H</bold>). 2) DTI signals (FA and MD) were quantified in the hippocampus (<bold>E</bold>, <bold>F</bold> respectively) and the visual cortex (<bold>I</bold>, <bold>J</bold> respectively). 3) Glucose uptake (FDG-PET) was also evaluated in the hippocampus (<bold>G</bold>) and visual cortex (<bold>K</bold>). Some examples of MBP and CNPase proteins detected by SDS-PAGE in hippocampal lysate are shown (<bold>L</bold>). Quantifications were done from all mice (<bold>M</bold> and <bold>N</bold> respectively). *: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; **: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; ****: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="13195_2025_1823_Fig2_HTML.jpg"/></fig></p></list-item><list-item><p id="Par73"><italic toggle="yes">Brain imaging-</italic> The mice also underwent in vivo MRI to quantify parenchyma volume in the hippocampus and visual cortex, regions where VHHs are most highly expressed (Fig. S1B). GFP overexpression affected the volume of a few regions (Fig. <xref rid="Fig2" ref-type="fig">2</xref>C, AAV2/9 versus (vs.) GFP, medium per group of <italic toggle="yes">p</italic> values indicating changes compared to the AAV2/9 group), with brain atrophy quantified in the hippocampus and the visual cortex (Fig. <xref rid="Fig2" ref-type="fig">2</xref>D, H, white and green bars). Conversely, no major changes were observed in the brain after injection of intra- or extraZ70 (Fig. <xref rid="Fig2" ref-type="fig">2</xref>C, AAV2/9 vs. ExtraZ70, medium per group of <italic toggle="yes">p</italic> values indicating changes compared to AAV2/9 group), except for a significant atrophy of the hippocampus in the mice expressing extraZ70 (Fig. <xref rid="Fig2" ref-type="fig">2</xref>D, white and hatched blue columns).</p><p id="Par74">Next, we used diffusion tensor imaging (DTI), a technique used to assess the microstructural properties of white matter, based on the water diffusivity. The diffusion of water in an unrestricted medium, and therefore identical in all directions, is called isotropic. This diffusion is affected by the presence of barriers, such as myelin fibers, resulting in a modification of isotropy, called anisotropy. Anisotropic water diffusion can be specified using indices of water diffusion (RD and LD), which define FA. FA is highly sensitive to microstructural changes that allow to determine how far the shape of the diffusion tensor deviates from spherical, but does not specify the type of changes (e.g., RD or LD) [<xref ref-type="bibr" rid="CR48">48</xref>].</p><p id="Par75">These key DTI metrics then provide insight into axonal integrity and were assessed in the hippocampus and visual cortex. A slight but significant increase of RD and LD was observed in the hippocampus and visual cortex of WT mice injected with VHHs compared to WT-AAV2/9 (Fig. S4). Interestingly, the absence of FA changes in both regions (Fig. <xref rid="Fig2" ref-type="fig">2</xref>E, I) indicated the preservation of axon integrity. To confirm the absence of a demyelination process due to oligodendrocyte dysfunction, two myelin proteins, myelin basic protein (MBP) and the early myelin 2&#8217;,3&#8217;-cyclic nucleotide 3&#8217;-phosphodiesterase (CPNAse), were quantified by biochemical assay (Fig. <xref rid="Fig2" ref-type="fig">2</xref>L-N). While a significant increase in MBP was observed in the GFP group, neither CNPAse nor MBP was affected after intra- or extraZ0 expression compared to AAV2/9.</p><p id="Par76">In addition, we used <sup>18</sup>F-fluoro-deoxyglucose positron emission tomography (FDG-PET) to evaluate cerebral glucose metabolism. This technology provides high spatial resolution of altered neural activity and reflects overall brain metabolism [<xref ref-type="bibr" rid="CR49">49</xref>]. No differences in glucose uptake were observed between groups compared to WT-AAV2/9 (Fig. <xref rid="Fig2" ref-type="fig">2</xref>G, K) suggesting a global neuronal integrity.</p></list-item><list-item><p id="Par77"><italic toggle="yes">Parenchymal and peripheral biomarkers-</italic> To confirm the absence of neuronal damage and to evaluate any other cellular brain lesions, we quantified specific markers of neuronal cells (Tau, NeuN, NfL, PSD95, Snap25), and glial cells (GFAP, Iba1, markers of astrocytes and microglia, respectively) in the parenchyma using brain lysate but also in the peripheral plasmatic system. We also added ubiquitous functional markers to assess intracellular degradation (LC3b, UCHL1) and cellular stress (pEI2&#945;, ATF4). No neuronal damage was found with stable levels of (TauCter, Fig. <xref rid="Fig3" ref-type="fig">3</xref>A), NeuN (Fig. <xref rid="Fig3" ref-type="fig">3</xref>B) and synaptic markers (PSD95, Snap25, Fig. <xref rid="Fig3" ref-type="fig">3</xref>C, D). We also examined the inflammatory response that may be associated with VHH delivery. The level of GFAP (Fig. <xref rid="Fig3" ref-type="fig">3</xref>E) in the parenchyma shows no difference, whereas Iba1 is increased in mice injected with intra- and extraZ70 compared to the AAV2/9 group (Fig. <xref rid="Fig3" ref-type="fig">3</xref>F). In the hippocampal anatomy, this increase is confirmed only for extraZ70 (Fig. <xref rid="Fig3" ref-type="fig">3</xref>J). Importantly, the VHH treatment has no effect on intracellular degradation pathways (LC3b, Fig. <xref rid="Fig3" ref-type="fig">3</xref>G) and the cellular integrated response to stress (pEI2&#945;, ATF4, Fig. <xref rid="Fig3" ref-type="fig">3</xref>H, I).<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>VHH Safety: Parenchymal and peripheral biomarkers- Brain lysates of 10-months-old WT mice were used to quantify hippocampal biomarkers by Western-blotting (<bold>A</bold>-<bold>I</bold>): TauCter (<bold>A</bold>), NeuN (<bold>B</bold>), PSD95 (<bold>C</bold>), Snap25 (<bold>D</bold>), GFAP (<bold>E</bold>), Iba1 (<bold>F</bold>), LC3b (<bold>G</bold>), pEIF2&#945; (<bold>H</bold>), ATF4 (<bold>I</bold>). The list of antibodies used is listed in Table <xref rid="Tab1" ref-type="table">1</xref>. Antibodies were validated against positive and negative controls, and some examples of mouse samples are shown (Fig. S5). Representative images of Iba1 immunostaining in the hippocampus are shown. Scale bars are indicated in the figure. Zoom areas (small black insert) are shown in the bottom right corner (large black insert) (<bold>J</bold>, left panels). Iba1 immunostaining was quantified blindly using Mercator software. Results are expressed as the percentage of Iba1-positive area relative to control (<bold>J</bold>, right panels) Plasma dosage using the Simoa technology are shown: Tau (<bold>K</bold>), NfL (<bold>L</bold>), GFAP (<bold>M</bold>) and UCH-L1 (<bold>N</bold>). *: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; **: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; ***: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="13195_2025_1823_Fig3_HTML.jpg"/></fig></p><p id="Par78">Finally, peripheral markers were also quantified from plasma by using ultra-sensitive and multiplexed immunodosage based instruments, a technology already validated for human biological fluids. No release of tau (Fig. <xref rid="Fig3" ref-type="fig">3</xref>K), NfL (Fig. <xref rid="Fig3" ref-type="fig">3</xref>L), GFAP (Fig. <xref rid="Fig3" ref-type="fig">3</xref>M) and UCHL1 (Fig. <xref rid="Fig3" ref-type="fig">3</xref>N) was noticed.</p><p id="Par79">Together, the evaluation of parenchymal and peripheral biomarkers dosages suggests that the injection of viral vectors encoding intraVHH or extraVHH was safe overall, with no significant risk of neuronal death, axonal or synaptic loss, cellular stress or inflammation.</p></list-item><list-item><p id="Par80"><italic toggle="yes">Behavior&#8212;</italic>To confirm this conclusion, two behavioral assays were performed (anxiety and spatial memory tests using OpenField and Y-maze, respectively). First, no problems with locomotion and velocity were observed (Fig. <xref rid="Fig4" ref-type="fig">4</xref>A-D). Regardless of the group, mice spent significantly more time near the wall than in the center of the arena (Fig. <xref rid="Fig4" ref-type="fig">4</xref>E, OpenField), but also in the new arm in the Y-maze assay (Fig. <xref rid="Fig4" ref-type="fig">4</xref>F), as would be expected for normal behavior. Thus, consistent with the molecular and cellular safety, no behavioral defect was observed.<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>VHH Safety: behavioral assays- The distance traveled (<bold>A</bold>, <bold>B</bold>) and velocity (<bold>C</bold>, <bold>D</bold>) of 9-month-old WT mice were monitored in a 10 min OpenField area and in a 5 min Y-maze assay. <bold>E</bold>&#160;OpenField test. Time near the wall (<italic toggle="yes">P</italic>&#8201;=&#8201;periphery) or in the center&#160;(C) is reported relative to the total time in the arena (10 min).&#160;<bold>F&#160;</bold>Y-maze test. Time in new arm was reported as the sum of time in new and other arms in the first minute. The <italic toggle="yes">p</italic> value is related to the % of time spent in the new arm in comparison to 50% (dotted line). *: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; **: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; ***: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; ****: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="13195_2025_1823_Fig4_HTML.jpg"/></fig></p></list-item></list></p></sec></sec><sec id="Sec28"><title>The efficacy</title><sec id="Sec29"><title>Effect on behavior of long term intra- and extraZ70 expression</title><p id="Par81">In the absence of safety concerns, we next evaluated the efficacy of VHHs in reducing tau pathology. Viral vectors encoding VHHs constructs (intraZ70, extraZ70, intraCtrl or extraCtrl) were injected into the brain of Tg30 or AAV2/9 was injected into the brain of WT mice as a control. Three outcomes were evaluated: 1) mouse behavior, 2) brain imaging, and 3) tau lesions (Fig. <xref rid="Fig5" ref-type="fig">5</xref>A).
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Behavioral tests&#8212;(<bold>A</bold>) Scheme of the experimental design created with Biorender.com. The motor abilities of 8-month-old Tg30 mice injected with intra- or extraVHHs, or WT mice injected with AAV2/9, were controlled by distance traveled (<bold>B</bold>, <bold>C</bold>) and the velocity (<bold>D</bold>, <bold>E</bold>) in a 10 min OpenField area or in a 5 min Y-maze assay. <bold>F</bold>&#160;OpenField test. Time spent near the wall (<italic toggle="yes">P</italic>&#8201;=&#8201;periphery) or in the center (<bold>C</bold>) is reported relative to the total time in the arena (10 min). <bold>G</bold>&#160;Y-maze test. Time in the new arm is reported relative to the sum of time in the new and other arms in the first minute. The <italic toggle="yes">p</italic> value is related to the % of time spent in the new arm in comparison to 50% (dotted line). <bold>F</bold>-<bold>G</bold>&#160;GraphPad Prism 8 software (version 8.0.0) was used to exclude outliers from the analysis. *: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; **: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; ****: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="13195_2025_1823_Fig5_HTML.jpg"/></fig></p><p id="Par82">We first assessed anxiety and spatial memory eight months after injection. First, we verified the absence of locomotor and velocity impairments in both the OpenField (Fig. <xref rid="Fig5" ref-type="fig">5</xref>B, D) and the Y-maze (Fig. <xref rid="Fig5" ref-type="fig">5</xref>C, E). Tg30-VHH mice exhibited similar travel patterns to WT-AAV2/9 mice in all tests, allowing us to proceed with further behavioral analyses. WT-AAV2/9 mice showed normal behavior by spending significantly more time near the walls (periphery) than in the center (Fig. <xref rid="Fig5" ref-type="fig">5</xref>F, white bars) in the open field. In contrast, Tg30 control groups (intraCtrl and extraCtrl) showed no preference between the two areas (Fig. <xref rid="Fig5" ref-type="fig">5</xref>F, gray and hatched gray bars). Similar to WT-AAV2/9 mice, Tg30 mice injected with either intraZ70 or extraZ70 spent more time near the walls (Fig. <xref rid="Fig5" ref-type="fig">5</xref>F, blue), indicating recovery. We also assessed short-term spatial memory during the test phase of the Y-maze. As expected for normal behavior, WT-AAV2/9 mice showed a significant discrimination index and spent more time in the novel arm (Fig. <xref rid="Fig5" ref-type="fig">5</xref>G, white bar) whereas mice injected with intraCtrl or extraCtrl showed no preference for the novel arm (Fig. <xref rid="Fig5" ref-type="fig">5</xref>G, grey and hatched gray bars). However, mice expressing intraZ70 and extraZ70 showed a significant discrimination index (Fig. <xref rid="Fig5" ref-type="fig">5</xref>G, blue and hatched blue bars). The effect on memory is slight and it is difficult to conclude about improvement since no significant difference was found between groups.</p><p id="Par83">Taken together, these tests demonstrated that injections of intraZ70 and extraZ70 restore normal mouse behavior in the OpenField task and maintain safety in all behavioral tests.</p></sec></sec><sec id="Sec30"><title>Prevention of brain atrophy with intra- and extraZ70</title><p id="Par84">Eight months after injection, the mice underwent MRI scans to evaluate total brain volume. Both the WT-AAV2/9 vs. Tg30-intraCtrl and WT-AAV2/9 vs. Tg30-extraCtrl comparisons showed an alteration of the brain volume in Tg30 mice in several regions (Fig. <xref rid="Fig6" ref-type="fig">6</xref>A), quantified as a brain atrophy in the hippocampus and visual cortex (Fig. <xref rid="Fig6" ref-type="fig">6</xref>B, C, white, grey, and hatched grey bars). Notably, the volume of these regions in Tg30 mice expressing extraZ70 are not significantly different from those observed in the control, WT-AAV2/9 mice (Fig. <xref rid="Fig6" ref-type="fig">6</xref>B, C, white, blue hatched bars) and a similar effect was observed with intraZ70, except in the hippocampus (Fig. <xref rid="Fig6" ref-type="fig">6</xref>B-C, white and blue bars).<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>MRI-brain volume evaluation- (<bold>A</bold>) MRI scans taken 8 months after injection were used to determine the statistical difference in the brain volume between AAV2/9-injected WT mice and Tg30 mice injected with intraCtrl, intraZ70, extraCtrl, or extraZ70 (left to right). These statistical values were color-coded on the NUS template used for segmentation. The brain volume expressed in mm3 is shown for the hippocampus (<bold>B</bold>) or visual cortex (<bold>C</bold>), quantified by MRI. *: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; **: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; ***: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, ns: non-significant</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO6" position="float" orientation="portrait" xlink:href="13195_2025_1823_Fig6_HTML.jpg"/></fig></p><p id="Par85">Taken together, these data suggested that both intracellular and extracellular targeting of tau prevents brain atrophy in Tg30 mice.</p></sec><sec id="Sec31"><title>Targeting intraTau in a chronic model of tau pathology reduces tau hyperphosphorylation</title><p id="Par86">Given the mode of action of Z70 in preventing tau seeding [<xref ref-type="bibr" rid="CR22">22</xref>], it is reasonable to hypothesize that the recoveries observed in behavioral tests and brain volume may be the consequence of reduced tau pathology. Immunological tools are available to distinguish the different biochemical forms of tau and to characterize pathological changes. We therefore assessed tau immunoreactivity using various antibodies: AT8 labels hyperphosphorylated tau [<xref ref-type="bibr" rid="CR50">50</xref>], whereas MC1 labels conformational changes [<xref ref-type="bibr" rid="CR51">51</xref>] and AT100 labels aggregated tau [<xref ref-type="bibr" rid="CR52">52</xref>]. Contrary to extraZ70, intraZ70 can reduce AT8 immunoreactivity in the hippocampus compared to intraCtrl (Fig. <xref rid="Fig7" ref-type="fig">7</xref>A, B), but not in the amygdala (Fig. S6A, B). These effects correlated with the stability of the AAVs episome in the hippocampus (Fig. <xref rid="Fig1" ref-type="fig">1</xref>D), which drives VHH expression in this brain area (Fig. S3), but not in the amygdala which contains hyperphosphorylated tau (Fig. S6B). Intracellular superimposition of AT8 phosphoTau (Fig. <xref rid="Fig7" ref-type="fig">7</xref>C, green) and VHH (Fig. <xref rid="Fig7" ref-type="fig">7</xref>C, purple) profiles showed target engagement between intraZ70 and AT8 in the hippocampus, with no specific co-localization between intraCtrl and AT8 phosphoTau (Fig. <xref rid="Fig7" ref-type="fig">7</xref>D). To better characterize the tau species targeted by the VHHs, MC1 and AT100 immunoreactivities were also evaluated in the hippocampus, but no significant effect of intraZ70 was detected (Fig. <xref rid="Fig7" ref-type="fig">7</xref>E, F respectively). These data suggest that intraZ70 binding to intracellular tau drives reduction of tau lesions.<fig id="Fig7" position="float" orientation="portrait"><label>Fig. 7</label><caption><p>Tau pathology in aged Tg30, a chronic model of tau pathology expressing intraZ70 or extraZ70- (<bold>A</bold>) Illustration of AT8 tau lesions in hippocampal sections. Scale bars are indicated in the figures. Immunoreactivity is detected and quantified using the AT8 antibody in the hippocampus (<bold>B</bold>). Immunohistofluorescence was done on sagittal brain sections to visualize phosphoTau (AT8, green) and VHH (purple). The specific location of phosphoTau and intraZ70 (<bold>C</bold>) or intraCtrl (<bold>D</bold>) was quantified across the cells (left profile). Fluorochrome overlays are analyzed in cells and illustrated on the right part of the figure. Quantification of MC1 (<bold>E</bold>) or AT100 (<bold>F</bold>) immunostaining in the hippocampus is also shown. For B, E and F, quantifications were done using Mercator software. Results are presented as the percentage of antibody stained surface relative to the control. **: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO7" position="float" orientation="portrait" xlink:href="13195_2025_1823_Fig7_HTML.jpg"/></fig></p></sec><sec id="Sec32"><title>ExtraZ70 reduces tau pathology in a mouse model of tau seeding</title><p id="Par87">Because extraZ70 was unable to reduce tau hyperphosphorylation in the chronic transgenic Tg30 model (Fig. <xref rid="Fig7" ref-type="fig">7</xref>), we speculated that the high intracellular accumulation of pathological tau at 8 months in this chronic transgenic model of tau pathology might not be offset by extraZ70, which targets extraTau species. To address this hypothesis, we tested the extraZ70 in our acute model of tau seeding, in which tau pathology is induced by intraparenchymal injection of human AD brain homogenate into young transgenic mice [<xref ref-type="bibr" rid="CR53">53</xref>]. We injected lentiviral vectors expressing extraZ70 or extraCtrl into the hippocampus of 1-month-old Tg30 and inoculated AD brain material 15 days later (Fig. <xref rid="Fig8" ref-type="fig">8</xref>A). Lentiviral vectors are non-diffusing vectors, thus concentrating the VHH action at the injection site as previously shown [<xref ref-type="bibr" rid="CR54">54</xref>]. One month later, animals were sacrificed and hyperphosphorylated tau was detected on brain slices using the AT8 antibody (Fig. <xref rid="Fig8" ref-type="fig">8</xref>B). Quantification of tau pathology throughout the hippocampus showed a decrease with extraZ70 compared to the extraCtrl (Fig. <xref rid="Fig8" ref-type="fig">8</xref>C). These data suggest that extraZ70 is effective in reducing the spread of nucleating agents present in the extracellular medium.<fig id="Fig8" position="float" orientation="portrait"><label>Fig. 8</label><caption><p>Tau pathology in young Tg30, an acute in vivo model of tau seeding expressing extraZ70- (<bold>A</bold>) Scheme of the experimental design created with Biorender.com. <bold>B</bold>&#160;Representative images of mice with AT8 immunostaining (AT8 intensity closest to the group mean value). The needle track is indicated with a black arrow. Scale bars are indicated in the figure. <bold>C</bold>&#160;AT8 immunoreactivity in the whole hippocampus were blindly quantified using the Mercator software. Results are expressed as the percentage of AT8-positive area relative to control. *: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO8" position="float" orientation="portrait" xlink:href="13195_2025_1823_Fig8_HTML.jpg"/></fig></p></sec></sec><sec id="Sec33"><title>Discussion</title><p id="Par88">The development of therapies to combat AD is still a real challenge today, as the drugs currently on the market have low efficacy, and many of phase 3 clinical trials in the last 25 years have been negative. Tau-based immunotherapy is mainly based on the prion-like paradigm, in which there is first an induction of misfolding of the physiological tau protein by pathological species, called seeding, leading to intraTau pathological species. Secondly, a cell-to-cell transfer of a misfolded tau species leads to the presence of extraTau pathological species in the interstitial fluid surrounding the cells. Both intra- and extraTau are very promising targets because blocking tau seeds inside or outside the neurons could slow the specific hierarchical progression of AD, in which certain regions of the brains are affected in a particular order.</p><p id="Par89">These hierarchical pathways have also been described in primary tauopathies such as progressive supranuclear palsy [<xref ref-type="bibr" rid="CR55">55</xref>&#8211;<xref ref-type="bibr" rid="CR59">59</xref>], argyrophilic grain disease [<xref ref-type="bibr" rid="CR60">60</xref>] and Pick disease [<xref ref-type="bibr" rid="CR61">61</xref>]. However, the relevance of extending the prion-like concept to these other tauopathies is still under debate [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Indeed, while specific tau peptides are abundant in the cerebrospinal fluid (CSF) of AD, their levels are relatively low and close to control groups in progressive supranuclear palsy and dementia with Lewy body [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR63">63</xref>], suggesting that tau secretion are not necessarily common features of all tauopathies, a point that should be considered in the future when designing appropriate therapies. Thus, targeting intracellular tau (intraTau) may be useful in the context of these primary tauopathies, whereas developing tools to block both intra- and extracellular tau may be more efficient in the context of AD. </p><p id="Par90">In this study, we investigated the ability of two VHHs to reduce tau pathology through tau target engagement inside hippocampal neurons or in the interstitial fluid. To this end, we designed two VHH constructs. One mediated the intracellular expression of VHH (IntraVHH), and the other mediated its secretion by the addition of an IL2ss and Fc portion of murine IgG2a (ExtraVHH). As expected, our data showed that only extraVHHs seem to be secreted and not intraVHHs. Contrary, Holtzmann and collaborators shown that ScFv when expressed in the cells may be secreted with some variabilities among them [<xref ref-type="bibr" rid="CR13">13</xref>]. Also, the extraCtrl VHH is present in greater quantities in the extracellular medium than the extraZ70, as detected both with the anti-VHH and anti-Fc antibodies. This suggests that it is either secreted more efficiently or has a longer extracellular half-life, indicating some variability in single-domain antibody secretion, as reported by Holtzmann and collaborators for ScFv [<xref ref-type="bibr" rid="CR13">13</xref>]. Despite this difference, the extraZ70 performs well in comparison to its extraCtrl VHH. Although, a fraction of extraVHHs is detected inside the cells (Fig. <xref rid="Fig1" ref-type="fig">1</xref>C), it is probably confined to the vesicles of the ER (Fig. <xref rid="Fig1" ref-type="fig">1</xref>E), preventing intra-cellular tau binding. In this configuration, the extraVHH resembles an antibody, albeit a small one, that can trigger the immune response, whereas the intraVHH is a tau mini-protein binder rather than an antibody. The additional Fc also provides a multivalent configuration, with two VHHs, which can provide a higher apparent affinity (also referred to as &#8220;avidity&#8221;) than the monovalent form.</p><p id="Par91">Both VHHs bind the tau peptide PHF6 [<xref ref-type="bibr" rid="CR22">22</xref>]. The PHF6 hexapeptide <sub>306</sub>VQIVYK<sub>311</sub> is capable of inducing tau aggregation through the formation of &#223;-sheet structures [<xref ref-type="bibr" rid="CR31">31</xref>], observed in early filamentous assemblies [<xref ref-type="bibr" rid="CR33">33</xref>], and tau proteoform analyzes have shown the presence of peptides containing this motif in the CSF of AD patients [<xref ref-type="bibr" rid="CR30">30</xref>]. Therefore, this tau epitope is not only a suitable target for intracellular but also for extracellular immunotherapies.</p><p id="Par92">The development of these anti-tau VHHs into new therapeutic modalities requires not only proof of efficacy, but also evidence of long-term stability and safety. In fact, the PHF6 epitope which is recognized by the VHH Z70 used in this study is not specific for a pathological form of tau, as it is also present in native tau. As tau is a pleiotropic protein with multiple functions in the cell [<xref ref-type="bibr" rid="CR64">64</xref>], controls were needed to test the safety of the delivered anti-tau VHHs. To this end, a long-term kinetic study was performed in WT mice. Whereas considering Sex As a Biological Variable (SABV) is of interest, this study grouped male and female mice together for ethical reasons, primarily to minimize the number of animals sacrificed. This approach also ensured statistical power, particularly for our imaging and behavioral assays. It should be noted that a few mice died during the continuous anesthesia procedure for brain imaging data acquisition and then we thought that this adverse effect is related to the isofluorane administration and not to VHHs. Indeed, the global metabolism of the mice was unaffected, and among parenchymal and peripheral markers, only Iba1 was elevated after intra- and extraVHH administration, suggesting the induction of neuroinflammation. This inflammation was expected with extraVHH because its Fc part could activate microglia by binding to Fc receptors that are highly expressed on brain macrophages [<xref ref-type="bibr" rid="CR65">65</xref>], and Fc&#947;RI, Fc&#947;RIIa, Fc&#947;RIIb, and Fc&#947;RIIIa are further upregulated in AD microglia [<xref ref-type="bibr" rid="CR66">66</xref>]. Indeed, studies investigating IgG antibody-tau immune complexes show that clearance can be achieved by Fc&#947;R-mediated endocytosis in primary mouse microglial cultures [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. Conversely, the Iba1 immunoreactivity observed with intraZ70 (but not validated by IHC) was not expected, but could be associated with the small DTI changes observed. However, this mild inflammation does not appear to be detrimental, as no neuronal damage or side effects on the brain volume and mouse behavior were observed with either intra- or extraVHH administration. This may be due to the fact that the DTI changes are small (fold enhancements ranging from 1.02 to 1.10 in our DTI metrics) compared to, for example, those described in a traumatic axonal injury model (fold enhancements ranging from 1.3 to 1.5) [<xref ref-type="bibr" rid="CR69">69</xref>] or in a tauopathy model (fold enhancements ranging from 1.14 to 1.33) [<xref ref-type="bibr" rid="CR70">70</xref>]. Accordingly, the absence of glucose metabolism variation indicated a non-inflamed state of the brain.</p><p id="Par93">The potential of VHHs to slow down tau pathology was then investigated. To effectively reduce tau pathology in the most affected cells of the hippocampus, we compared various AAVs for their broad distribution and selected AAV2/9, which drives VHH expression under a CMV promoter. Progress towards clinical applications may require a less invasive delivery route than intracranial injection. Advances in AAV engineering are promising in this regard and some have demonstrated the ability to transduce the brain after peripheral intravenous administration [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>].</p><p id="Par94">Using a series of indicators, both in a chronic and long-term tau transgenic mouse model (Tg30) [<xref ref-type="bibr" rid="CR38">38</xref>] and in an acute seeding model with injections of human brain homogenates from AD patients [<xref ref-type="bibr" rid="CR22">22</xref>], we evaluated the intra- and extraVHH strategies to reverse pathological phenotype. IntraVHH, was able to reduce neuronal tau hyperphosphorylation, brain atrophy and mouse behavior despite the continuous accumulation of pathological tau in the chronic and long-term tau transgenic mouse model (Tg30) [<xref ref-type="bibr" rid="CR38">38</xref>]. It is noteworthy that the markers AT100 and MC1, commonly used as indicators of the presence of tau fibrils, were not attenuated by intraVHHs, but the recovery of several other indicators of pathology were factual indications of a reduction in tau toxicity. This adds to the discussion that the tau fibrils alone are not, to some extent, the only toxic tau species [<xref ref-type="bibr" rid="CR73">73</xref>&#8211;<xref ref-type="bibr" rid="CR75">75</xref>]. The intraVHHs are rather likely to act by binding to soluble tau species and small oligomers, and we have demonstrated this target engagement (Fig. <xref rid="Fig7" ref-type="fig">7</xref>D, E) preventing prion-like conversion into a pathological tau in a mini-chaperone-like manner [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]. Such a mode of action is independently proposed for other anti-tau VHHs more recently developed that similarly bind the tau PHF sequences [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par95">ExtraVHH, which targets tau in the interstitial fluid, reduced most of the pathological phenotype but, as expected, did not avoid the intraneuronal tau pathology in the long-term Tg30 model. The extraVHH is more likely to be involved in the inflammatory response, stimulating clearance of the pathological tau species. Alternatively, VHH Z70 has been shown to reduce cellular uptake of tau, in primary neuronal cultures [<xref ref-type="bibr" rid="CR78">78</xref>], which may also be a mode of action of the extraVHH.</p><p id="Par96">In the chronic model (8 months-old mice), there is an intra-neuronal accumulation of tau pathology coming from the continuous expression of tau transgene that cannot be blocked by the extraZ70. In the acute model however [<xref ref-type="bibr" rid="CR53">53</xref>], the intra-neuronal lesions are coming from the seeding of soluble transgenic endogenous human tau by the AD human seeds captured by the neurons. ExtraVHHs present in the interstitial fluid may then block part of the pathological tau species in this case.</p><p id="Par97">Thus, the intra- and extraVHHs used in this study both reduced the tau pathology in a similar manner by acting on the prion-like mechanisms of the disease, albeit in different and complementary ways. Evaluating their combined effect is a perspective of interest, as well as improving their properties (such as the affinity for tau; [<xref ref-type="bibr" rid="CR79">79</xref>]), with the objective of increasing the effect on the various pathology indicators.</p></sec><sec id="Sec34"><title>Conclusion</title><p id="Par98">Taken together, these results provide proof of concept that anti-tau VHHs can be used to reduce both intra- and extraTau pathology without major adverse effects. They are of great interest for therapeutic applications, not only in AD pathology to target intra- and/or extraTau pathological species, but also in primary tauopathies such as PSP where the pathology is mainly intracellular. They are also of great interest for research, in view of understanding the complex mechanisms at play to block tau toxicity and/or pathology.</p></sec><sec id="Sec240" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="13195_2025_1823_MOESM1_ESM.xlsx" position="float" orientation="portrait"><caption><p>Supplementary Material 1.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="13195_2025_1823_MOESM2_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 2 [<xref ref-type="bibr" rid="CR80">80</xref>&#8211;<xref ref-type="bibr" rid="CR84">84</xref>].</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="13195_2025_1823_MOESM3_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 3.</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AAVs</term><def><p id="Par5">Adeno-Associated Vectors</p></def></def-item><def-item><term>AD</term><def><p id="Par6">Alzeimer disease</p></def></def-item><def-item><term>AP</term><def><p id="Par7">Antero-posterior</p></def></def-item><def-item><term>CSF</term><def><p id="Par8">Cerebrospinal fluid</p></def></def-item><def-item><term>CT</term><def><p id="Par9">Computed Tomography</p></def></def-item><def-item><term>CPNAse</term><def><p id="Par10">2&#8217;,3&#8217;-Cyclic nucleotide 3&#8217;-phosphodiesterase</p></def></def-item><def-item><term>DV</term><def><p id="Par11">Dorso-ventral</p></def></def-item><def-item><term>EPI</term><def><p id="Par12">Echo Planar Imaging</p></def></def-item><def-item><term>ET</term><def><p id="Par13">Echo Time</p></def></def-item><def-item><term>ExtraTau</term><def><p id="Par14">Extracellular tau</p></def></def-item><def-item><term>FOV</term><def><p id="Par15">Field of View</p></def></def-item><def-item><term>FSL</term><def><p id="Par16">Functional Source License</p></def></def-item><def-item><term>FA</term><def><p id="Par17">Fractional anisotropy</p></def></def-item><def-item><term>PET-FDG</term><def><p id="Par18">(18)F-fluorodeoxyglucose positron emission tomography</p></def></def-item><def-item><term>GFP</term><def><p id="Par19">Green Fluorescent Protein</p></def></def-item><def-item><term>IntraTau</term><def><p id="Par20">Intracellular Tau</p></def></def-item><def-item><term>IL2ss</term><def><p id="Par21">Interleukin-2 signal sequence</p></def></def-item><def-item><term>LD</term><def><p id="Par22">Longitudinal diffusivity</p></def></def-item><def-item><term>MRI</term><def><p id="Par23">Magnetic Resonance imaging</p></def></def-item><def-item><term>ML</term><def><p id="Par24">Medio-lateral</p></def></def-item><def-item><term>MTBD</term><def><p id="Par25">Microtubule Binding Domain</p></def></def-item><def-item><term>ms</term><def><p id="Par26">Milliseconds</p></def></def-item><def-item><term>MBP</term><def><p id="Par27">Myelin Basic Protein</p></def></def-item><def-item><term>NUS</term><def><p id="Par28">National University of Singapore</p></def></def-item><def-item><term>NFD</term><def><p id="Par29">NeuroFibrillary Degeneration</p></def></def-item><def-item><term>ON</term><def><p id="Par30">Over-Night</p></def></def-item><def-item><term>PHFs</term><def><p id="Par31">Paired-Helical Filaments</p></def></def-item><def-item><term>PFA</term><def><p id="Par32">Paraformaldehyde</p></def></def-item><def-item><term>PCA</term><def><p id="Par33">Principal Component Analysis</p></def></def-item><def-item><term>PROTAC</term><def><p id="Par34">Proteolysis Targeting Chimera</p></def></def-item><def-item><term>RD</term><def><p id="Par35">Radial Diffusivity</p></def></def-item><def-item><term>ROI</term><def><p id="Par36">Region of Interest</p></def></def-item><def-item><term>TR</term><def><p id="Par37">Time Repetition</p></def></def-item><def-item><term>SUV</term><def><p id="Par38">Standardized Uptake Values</p></def></def-item><def-item><term>Tg30</term><def><p id="Par39">THY-tau30 transgenic mice</p></def></def-item><def-item><term>VHH</term><def><p id="Par40">Variable domain of the Heavy chain of the Heavy chain only antibodies</p></def></def-item><def-item><term>vs.</term><def><p id="Par41">Versus</p></def></def-item><def-item><term>WT</term><def><p id="Par42">Wild-Type</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Isabelle Landrieu, Luc Bu&#233;e and Morvane Colin equal contributors.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We are grateful to M. Tardivel and A. Bongiovanni for their help on the Zeiss confocal microscope, from the Photonic Microscopy Core BioImaging Center (BiCeL). We also thanks Nicolas Durieux and Yann Lepage from the Lille In vivo Imaging and Functional Exploration-LIIFE, for their technical help in brain imagery (MRI and FDG-PET) processing. Thanks to Claire Regost and Agathe Launay for their help in arsenic treatment and synaptosome purification respectively and to Marie Oosterlynck for her professional writing services.
</p></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>Investigation: R.C., S.L., S.B. &amp; M.B. Methodology: R.C., L.B., R.C. &amp; C.L., J. M., F.A. (brain imaging). Formal analysis: R.C., M.C., C.L. &amp; F.A. (brain imaging analyzes). Resources: C.A.M. and B.A. (selection of the AD cases and sampling, Lille NeuroBank). Validation: R.C., L.B. &amp; M.C. Visualization: R.C. &amp; M.C. Supervision: I.L., M.C. &amp; L.B. Conceptualization: R.C., E.D., C.D., I.L., L.B. &amp; M.C. Project administration: I.L. &amp; L.B. Funding acquisition: I.L. &amp; L.B. Writing-original draft. R.C. &amp; M.C. Writing-review and editing. R.C., E.D., C.D., I.L., L.B. &amp; M.C.
</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This project was partially funded by the European Union (HORIZON-MSCA-2022-DN-01, Project TAME, GA101119596), the&#160;Rainwater Charitable Foundation &amp; Alzheimer&#8217;s Association&#160;(Project&#160;T-PEP-23&#8211;969176)&#160;and&#160;grants from the National Research Agency (ANR, France): LabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary Approach to Alzheimer&#8217;s Disease,&#160;ANR-11-LABX-01) &amp; ToNIC (ANR-18-CE44-0016),&#160;R&#233;gion Hauts de France (StartAIRR&#160;BONUS DRESS-2020&#8211;023479).&#160;Our laboratories are also supported by LiCEND (Lille Centre of Excellence in Neurodegenerative Disorders), the M&#233;tropole Europ&#233;enne de Lille, the&#160;Conseil R&#233;gional du Nord and the European Union (I-SITE,&#160;TUNABLE).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par99">The study was performed in accordance with French and European Community rules. The experimental research was performed with the approval of an ethics committee (agreement APAFIS #43474&#8211;2023050714441306 v6) and follows European guidelines for the use of animals.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests
</title><p id="Par100">E.D., C.D., I.L and L.B. are the inventors of a patent (WO2020/120644A1) that covers the use of VHH Z70 and VHHs derived from it. The remaining authors declare no competing interests.
</p></notes></notes><ref-list id="Bib1"><title>References
</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spillantini</surname><given-names>MG</given-names></name><name name-style="western"><surname>Goedert</surname><given-names>M</given-names></name></person-group><article-title>Tau pathology and neurodegeneration</article-title><source>Lancet Neurol</source><year>2013</year><volume>12</volume><issue>6</issue><fpage>609</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(13)70090-5</pub-id><pub-id pub-id-type="pmid">23684085</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12(6):609&#8211;22. 10.1016/S1474-4422(13)70090-5.<pub-id pub-id-type="pmid">23684085</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(13)70090-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanner</surname><given-names>JA</given-names></name><name name-style="western"><surname>Iaccarino</surname><given-names>L</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>L</given-names></name><name name-style="western"><surname>Asken</surname><given-names>BM</given-names></name><name name-style="western"><surname>Gorno-Tempini</surname><given-names>ML</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease</article-title><source>Brain</source><year>2022</year><volume>145</volume><issue>12</issue><fpage>4489</fpage><lpage>4505</lpage><pub-id pub-id-type="doi">10.1093/brain/awac229</pub-id><pub-id pub-id-type="pmid">35762829</pub-id><pub-id pub-id-type="pmcid">PMC10200306</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Tanner JA, Iaccarino L, Edwards L, Asken BM, Gorno-Tempini ML, Kramer JH, et al. Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer&#8217;s disease. Brain. 2022;145(12):4489&#8211;505. 10.1093/brain/awac229.<pub-id pub-id-type="pmid">35762829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awac229</pub-id><pub-id pub-id-type="pmcid">PMC10200306</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nelson</surname><given-names>PT</given-names></name><name name-style="western"><surname>Alafuzoff</surname><given-names>I</given-names></name><name name-style="western"><surname>Bigio</surname><given-names>EH</given-names></name><name name-style="western"><surname>Bouras</surname><given-names>C</given-names></name><name name-style="western"><surname>Braak</surname><given-names>H</given-names></name><name name-style="western"><surname>Cairns</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature</article-title><source>J Neuropathol Exp Neurol</source><year>2012</year><volume>71</volume><issue>5</issue><fpage>362</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1097/NEN.0b013e31825018f7</pub-id><pub-id pub-id-type="pmid">22487856</pub-id><pub-id pub-id-type="pmcid">PMC3560290</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5):362&#8211;81. 10.1097/NEN.0b013e31825018f7.<pub-id pub-id-type="pmid">22487856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/NEN.0b013e31825018f7</pub-id><pub-id pub-id-type="pmcid">PMC3560290</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fitzpatrick</surname><given-names>AWP</given-names></name><name name-style="western"><surname>Falcon</surname><given-names>B</given-names></name><name name-style="western"><surname>He</surname><given-names>S</given-names></name><name name-style="western"><surname>Murzin</surname><given-names>AG</given-names></name><name name-style="western"><surname>Murshudov</surname><given-names>G</given-names></name><name name-style="western"><surname>Garringer</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Cryo-EM structures of tau filaments from Alzheimer's disease</article-title><source>Nature</source><year>2017</year><volume>547</volume><issue>7662</issue><fpage>185</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1038/nature23002</pub-id><pub-id pub-id-type="pmid">28678775</pub-id><pub-id pub-id-type="pmcid">PMC5552202</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ, et al. Cryo-EM structures of tau filaments from Alzheimer&#8217;s disease. Nature. 2017;547(7662):185&#8211;90. 10.1038/nature23002.<pub-id pub-id-type="pmid">28678775</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature23002</pub-id><pub-id pub-id-type="pmcid">PMC5552202</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lasagna-Reeves</surname><given-names>CA</given-names></name><name name-style="western"><surname>Castillo-Carranza</surname><given-names>DL</given-names></name><name name-style="western"><surname>Sengupta</surname><given-names>U</given-names></name><name name-style="western"><surname>Sarmiento</surname><given-names>J</given-names></name><name name-style="western"><surname>Troncoso</surname><given-names>J</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>GR</given-names></name><etal/></person-group><article-title>Identification of oligomers at early stages of tau aggregation in Alzheimer's disease</article-title><source>FASEB J</source><year>2012</year><volume>26</volume><issue>5</issue><fpage>1946</fpage><lpage>1959</lpage><pub-id pub-id-type="doi">10.1096/fj.11-199851</pub-id><pub-id pub-id-type="pmid">22253473</pub-id><pub-id pub-id-type="pmcid">PMC4046102</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR, et al. Identification of oligomers at early stages of tau aggregation in Alzheimer&#8217;s disease. FASEB J. 2012;26(5):1946&#8211;59. 10.1096/fj.11-199851. doi: fj.11-199851 [pii].<pub-id pub-id-type="pmid">22253473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.11-199851</pub-id><pub-id pub-id-type="pmcid">PMC4046102</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braak</surname><given-names>H</given-names></name><name name-style="western"><surname>Braak</surname><given-names>E</given-names></name></person-group><article-title>Neuropathological stageing of Alzheimer-related changes</article-title><source>Acta Neuropathol</source><year>1991</year><volume>82</volume><issue>4</issue><fpage>239</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">1759558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00308809</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239&#8211;59.<pub-id pub-id-type="pmid">1759558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00308809</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delacourte</surname><given-names>A</given-names></name><name name-style="western"><surname>David</surname><given-names>JP</given-names></name><name name-style="western"><surname>Sergeant</surname><given-names>N</given-names></name><name name-style="western"><surname>Buee</surname><given-names>L</given-names></name><name name-style="western"><surname>Wattez</surname><given-names>A</given-names></name><name name-style="western"><surname>Vermersch</surname><given-names>P</given-names></name><etal/></person-group><article-title>The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease</article-title><source>Neurology</source><year>1999</year><volume>52</volume><issue>6</issue><fpage>1158</fpage><lpage>1165</lpage><pub-id pub-id-type="pmid">10214737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.52.6.1158</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Delacourte A, David JP, Sergeant N, Buee L, Wattez A, Vermersch P, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer&#8217;s disease. Neurology. 1999;52(6):1158&#8211;65.<pub-id pub-id-type="pmid">10214737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.52.6.1158</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colin</surname><given-names>M</given-names></name><name name-style="western"><surname>Dujardin</surname><given-names>S</given-names></name><name name-style="western"><surname>Schraen-Maschke</surname><given-names>S</given-names></name><name name-style="western"><surname>Meno-Tetang</surname><given-names>G</given-names></name><name name-style="western"><surname>Duyckaerts</surname><given-names>C</given-names></name><name name-style="western"><surname>Courade</surname><given-names>JP</given-names></name><etal/></person-group><article-title>From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy</article-title><source>Acta Neuropathol</source><year>2020</year><volume>139</volume><issue>1</issue><fpage>3</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1007/s00401-019-02087-9</pub-id><pub-id pub-id-type="pmid">31686182</pub-id><pub-id pub-id-type="pmcid">PMC6942016</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Colin M, Dujardin S, Schraen-Maschke S, Meno-Tetang G, Duyckaerts C, Courade JP, et al. From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy. Acta Neuropathol. 2020;139(1):3&#8211;25. 10.1007/s00401-019-02087-9.<pub-id pub-id-type="pmid">31686182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-019-02087-9</pub-id><pub-id pub-id-type="pmcid">PMC6942016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Courade</surname><given-names>JP</given-names></name><name name-style="western"><surname>Angers</surname><given-names>R</given-names></name><name name-style="western"><surname>Mairet-Coello</surname><given-names>G</given-names></name><name name-style="western"><surname>Pacico</surname><given-names>N</given-names></name><name name-style="western"><surname>Tyson</surname><given-names>K</given-names></name><name name-style="western"><surname>Lightwood</surname><given-names>D</given-names></name><etal/></person-group><article-title>Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau</article-title><source>Acta Neuropathol</source><year>2018</year><volume>136</volume><issue>5</issue><fpage>729</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1007/s00401-018-1911-2</pub-id><pub-id pub-id-type="pmid">30238240</pub-id><pub-id pub-id-type="pmcid">PMC6208734</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Courade JP, Angers R, Mairet-Coello G, Pacico N, Tyson K, Lightwood D, et al. Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau. Acta Neuropathol. 2018;136(5):729&#8211;45. 10.1007/s00401-018-1911-2.<pub-id pub-id-type="pmid">30238240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-018-1911-2</pub-id><pub-id pub-id-type="pmcid">PMC6208734</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhadane</surname><given-names>P</given-names></name><name name-style="western"><surname>Roul</surname><given-names>K</given-names></name><name name-style="western"><surname>Belemkar</surname><given-names>S</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>D</given-names></name></person-group><article-title>Immunotherapeutic approaches for Alzheimer's disease: Exploring active and passive vaccine progress</article-title><source>Brain Res</source><year>2024</year><volume>1840</volume><fpage>149018</fpage><pub-id pub-id-type="doi">10.1016/j.brainres.2024.149018</pub-id><pub-id pub-id-type="pmid">38782231</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Bhadane P, Roul K, Belemkar S, Kumar D. Immunotherapeutic approaches for Alzheimer&#8217;s disease: exploring active and passive vaccine progress. Brain Res. 2024;1840: 149018. 10.1016/j.brainres.2024.149018.<pub-id pub-id-type="pmid">38782231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainres.2024.149018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poduslo</surname><given-names>JF</given-names></name><name name-style="western"><surname>Curran</surname><given-names>GL</given-names></name><name name-style="western"><surname>Berg</surname><given-names>CT</given-names></name></person-group><article-title>Macromolecular permeability across the blood-nerve and blood-brain barriers</article-title><source>Proc Natl Acad Sci U S A</source><year>1994</year><volume>91</volume><issue>12</issue><fpage>5705</fpage><lpage>5709</lpage><pub-id pub-id-type="doi">10.1073/pnas.91.12.5705</pub-id><pub-id pub-id-type="pmid">8202551</pub-id><pub-id pub-id-type="pmcid">PMC44065</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Poduslo JF, Curran GL, Berg CT. Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc Natl Acad Sci U S A. 1994;91(12):5705&#8211;9. 10.1073/pnas.91.12.5705.<pub-id pub-id-type="pmid">8202551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.91.12.5705</pub-id><pub-id pub-id-type="pmcid">PMC44065</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gallardo</surname><given-names>G</given-names></name><name name-style="western"><surname>Wong</surname><given-names>CH</given-names></name><name name-style="western"><surname>Ricardez</surname><given-names>SM</given-names></name><name name-style="western"><surname>Mann</surname><given-names>CN</given-names></name><name name-style="western"><surname>Lin</surname><given-names>KH</given-names></name><name name-style="western"><surname>Leyns</surname><given-names>CEG</given-names></name><etal/></person-group><article-title>Targeting tauopathy with engineered tau-degrading intrabodies</article-title><source>Mol Neurodegener</source><year>2019</year><volume>14</volume><issue>1</issue><fpage>38</fpage><pub-id pub-id-type="doi">10.1186/s13024-019-0340-6</pub-id><pub-id pub-id-type="pmid">31640765</pub-id><pub-id pub-id-type="pmcid">PMC6805661</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Gallardo G, Wong CH, Ricardez SM, Mann CN, Lin KH, Leyns CEG, et al. Targeting tauopathy with engineered tau-degrading intrabodies. Mol Neurodegener. 2019;14(1):38. 10.1186/s13024-019-0340-6.<pub-id pub-id-type="pmid">31640765</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-019-0340-6</pub-id><pub-id pub-id-type="pmcid">PMC6805661</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ising</surname><given-names>C</given-names></name><name name-style="western"><surname>Gallardo</surname><given-names>G</given-names></name><name name-style="western"><surname>Leyns</surname><given-names>CEG</given-names></name><name name-style="western"><surname>Wong</surname><given-names>CH</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>F</given-names></name><etal/></person-group><article-title>AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy</article-title><source>J Exp Med</source><year>2017</year><volume>214</volume><issue>5</issue><fpage>1227</fpage><lpage>1238</lpage><pub-id pub-id-type="doi">10.1084/jem.20162125</pub-id><pub-id pub-id-type="pmid">28416651</pub-id><pub-id pub-id-type="pmcid">PMC5413341</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Ising C, Gallardo G, Leyns CEG, Wong CH, Jiang H, Stewart F, et al. AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy. J Exp Med. 2017;214(5):1227&#8211;38. 10.1084/jem.20162125.<pub-id pub-id-type="pmid">28416651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20162125</pub-id><pub-id pub-id-type="pmcid">PMC5413341</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodwin</surname><given-names>MS</given-names></name><name name-style="western"><surname>Sinyavskaya</surname><given-names>O</given-names></name><name name-style="western"><surname>Burg</surname><given-names>F</given-names></name><name name-style="western"><surname>O'Neal</surname><given-names>V</given-names></name><name name-style="western"><surname>Ceballos-Diaz</surname><given-names>C</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>PE</given-names></name><etal/></person-group><article-title>Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative Phenotypes</article-title><source>Mol Ther</source><year>2021</year><volume>29</volume><issue>2</issue><fpage>859</fpage><lpage>872</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2020.10.007</pub-id><pub-id pub-id-type="pmid">33128896</pub-id><pub-id pub-id-type="pmcid">PMC7854277</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Goodwin MS, Sinyavskaya O, Burg F, O&#8217;Neal V, Ceballos-Diaz C, Cruz PE, et al. Anti-tau scFvs targeted to the cytoplasm or secretory pathway variably modify pathology and neurodegenerative phenotypes. Mol Ther. 2021;29(2):859&#8211;72. 10.1016/j.ymthe.2020.10.007.<pub-id pub-id-type="pmid">33128896</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2020.10.007</pub-id><pub-id pub-id-type="pmcid">PMC7854277</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vitale</surname><given-names>F</given-names></name><name name-style="western"><surname>Giliberto</surname><given-names>L</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>S</given-names></name><name name-style="western"><surname>Steslow</surname><given-names>K</given-names></name><name name-style="western"><surname>Marambaud</surname><given-names>P</given-names></name><name name-style="western"><surname>d'Abramo</surname><given-names>C</given-names></name></person-group><article-title>Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice</article-title><source>Acta Neuropathol Commun</source><year>2018</year><volume>6</volume><issue>1</issue><fpage>82</fpage><pub-id pub-id-type="doi">10.1186/s40478-018-0585-2</pub-id><pub-id pub-id-type="pmid">30134961</pub-id><pub-id pub-id-type="pmcid">PMC6103963</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Vitale F, Giliberto L, Ruiz S, Steslow K, Marambaud P, d&#8217;Abramo C. Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice. Acta Neuropathol Commun. 2018;6(1):82. 10.1186/s40478-018-0585-2.<pub-id pub-id-type="pmid">30134961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40478-018-0585-2</pub-id><pub-id pub-id-type="pmcid">PMC6103963</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamers-Casterman</surname><given-names>C</given-names></name><name name-style="western"><surname>Atarhouch</surname><given-names>T</given-names></name><name name-style="western"><surname>Muyldermans</surname><given-names>S</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>G</given-names></name><name name-style="western"><surname>Hamers</surname><given-names>C</given-names></name><name name-style="western"><surname>Songa</surname><given-names>EB</given-names></name><etal/></person-group><article-title>Naturally occurring antibodies devoid of light chains</article-title><source>Nature</source><year>1993</year><volume>363</volume><issue>6428</issue><fpage>446</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1038/363446a0</pub-id><pub-id pub-id-type="pmid">8502296</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993;363(6428):446&#8211;8. 10.1038/363446a0.<pub-id pub-id-type="pmid">8502296</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/363446a0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>JY</given-names></name><name name-style="western"><surname>Sang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name></person-group><article-title>Nanobodies: robust miniprotein binders in biomedicine</article-title><source>Adv Drug Deliv Rev</source><year>2023</year><volume>195</volume><fpage>114726</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2023.114726</pub-id><pub-id pub-id-type="pmid">36754285</pub-id><pub-id pub-id-type="pmcid">PMC11725230</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Kim JY, Sang Z, Xiang Y, Shen Z, Shi Y. Nanobodies: robust miniprotein binders in biomedicine. Adv Drug Deliv Rev. 2023;195:114726. 10.1016/j.addr.2023.114726.<pub-id pub-id-type="pmid">36754285</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2023.114726</pub-id><pub-id pub-id-type="pmcid">PMC11725230</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>F</given-names></name><name name-style="western"><surname>Pang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Pang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Applications of nanobodies in brain diseases</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>978513</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.978513</pub-id><pub-id pub-id-type="pmid">36426363</pub-id><pub-id pub-id-type="pmcid">PMC9679430</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Zheng F, Pang Y, Li L, Pang Y, Zhang J, Wang X, et al. Applications of nanobodies in brain diseases. Front Immunol. 2022;13: 978513. 10.3389/fimmu.2022.978513.<pub-id pub-id-type="pmid">36426363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.978513</pub-id><pub-id pub-id-type="pmcid">PMC9679430</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Genst</surname><given-names>E</given-names></name><name name-style="western"><surname>Silence</surname><given-names>K</given-names></name><name name-style="western"><surname>Decanniere</surname><given-names>K</given-names></name><name name-style="western"><surname>Conrath</surname><given-names>K</given-names></name><name name-style="western"><surname>Loris</surname><given-names>R</given-names></name><name name-style="western"><surname>Kinne</surname><given-names>J</given-names></name><etal/></person-group><article-title>Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies</article-title><source>Proc Natl Acad Sci U S A</source><year>2006</year><volume>103</volume><issue>12</issue><fpage>4586</fpage><lpage>4591</lpage><pub-id pub-id-type="doi">10.1073/pnas.0505379103</pub-id><pub-id pub-id-type="pmid">16537393</pub-id><pub-id pub-id-type="pmcid">PMC1450215</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">De Genst E, Silence K, Decanniere K, Conrath K, Loris R, Kinne J, et al. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci U S A. 2006;103(12):4586&#8211;91. 10.1073/pnas.0505379103.<pub-id pub-id-type="pmid">16537393</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0505379103</pub-id><pub-id pub-id-type="pmcid">PMC1450215</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Krishnaswamy</surname><given-names>S</given-names></name><name name-style="western"><surname>Pan</surname><given-names>R</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Sandusky-Beltran</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Single-domain antibody-based noninvasive in vivo imaging of alpha-synuclein or tau pathology</article-title><source>Sci Adv</source><year>2023</year><volume>9</volume><issue>19</issue><fpage>eadf3775</fpage><pub-id pub-id-type="doi">10.1126/sciadv.adf3775</pub-id><pub-id pub-id-type="pmid">37163602</pub-id><pub-id pub-id-type="pmcid">PMC10171817</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Jiang Y, Lin Y, Krishnaswamy S, Pan R, Wu Q, Sandusky-Beltran LA, et al. Single-domain antibody-based noninvasive in vivo imaging of alpha-synuclein or tau pathology. Sci Adv. 2023;9(19):eadf3775. 10.1126/sciadv.adf3775.<pub-id pub-id-type="pmid">37163602</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.adf3775</pub-id><pub-id pub-id-type="pmcid">PMC10171817</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Vandesquille</surname><given-names>M</given-names></name><name name-style="western"><surname>Koukouli</surname><given-names>F</given-names></name><name name-style="western"><surname>Dudeffant</surname><given-names>C</given-names></name><name name-style="western"><surname>Youssef</surname><given-names>I</given-names></name><name name-style="western"><surname>Lenormand</surname><given-names>P</given-names></name><etal/></person-group><article-title>Camelid single-domain antibodies: A versatile tool for in vivo imaging of extracellular and intracellular brain targets</article-title><source>J Control Release</source><year>2016</year><volume>243</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2016.09.019</pub-id><pub-id pub-id-type="pmid">27671875</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Li T, Vandesquille M, Koukouli F, Dudeffant C, Youssef I, Lenormand P, et al. Camelid single-domain antibodies: a versatile tool for in vivo imaging of extracellular and intracellular brain targets. J Control Release. 2016;243:1&#8211;10. 10.1016/j.jconrel.2016.09.019.<pub-id pub-id-type="pmid">27671875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2016.09.019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Danis</surname><given-names>C</given-names></name><name name-style="western"><surname>Dupre</surname><given-names>E</given-names></name><name name-style="western"><surname>Zejneli</surname><given-names>O</given-names></name><name name-style="western"><surname>Caillierez</surname><given-names>R</given-names></name><name name-style="western"><surname>Arrial</surname><given-names>A</given-names></name><name name-style="western"><surname>Begard</surname><given-names>S</given-names></name><etal/></person-group><article-title>Inhibition of Tau seeding by targeting Tau nucleation core within neurons with a single domain antibody fragment</article-title><source>Mol Ther</source><year>2022</year><volume>30</volume><issue>4</issue><fpage>1484</fpage><lpage>1499</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2022.01.009</pub-id><pub-id pub-id-type="pmid">35007758</pub-id><pub-id pub-id-type="pmcid">PMC9077319</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Danis C, Dupre E, Zejneli O, Caillierez R, Arrial A, Begard S, et al. Inhibition of Tau seeding by targeting Tau nucleation core within neurons with a single domain antibody fragment. Mol Ther. 2022;30(4):1484&#8211;99. 10.1016/j.ymthe.2022.01.009.<pub-id pub-id-type="pmid">35007758</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2022.01.009</pub-id><pub-id pub-id-type="pmcid">PMC9077319</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dupre</surname><given-names>E</given-names></name><name name-style="western"><surname>Danis</surname><given-names>C</given-names></name><name name-style="western"><surname>Arrial</surname><given-names>A</given-names></name><name name-style="western"><surname>Hanoulle</surname><given-names>X</given-names></name><name name-style="western"><surname>Homa</surname><given-names>M</given-names></name><name name-style="western"><surname>Cantrelle</surname><given-names>FX</given-names></name><etal/></person-group><article-title>Single Domain Antibody Fragments as New Tools for the Detection of Neuronal Tau Protein in Cells and in Mice Studies</article-title><source>ACS Chem Neurosci</source><year>2019</year><volume>10</volume><issue>9</issue><fpage>3997</fpage><lpage>4006</lpage><pub-id pub-id-type="doi">10.1021/acschemneuro.9b00217</pub-id><pub-id pub-id-type="pmid">31380615</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Dupre E, Danis C, Arrial A, Hanoulle X, Homa M, Cantrelle FX, et al. Single domain antibody fragments as new tools for the detection of neuronal Tau protein in cells and in mice studies. ACS Chem Neurosci. 2019;10(9):3997&#8211;4006. 10.1021/acschemneuro.9b00217.<pub-id pub-id-type="pmid">31380615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acschemneuro.9b00217</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abskharon</surname><given-names>R</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H</given-names></name><name name-style="western"><surname>Sawaya</surname><given-names>MR</given-names></name><name name-style="western"><surname>Seidler</surname><given-names>PM</given-names></name><name name-style="western"><surname>Olivares</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Structure-based design of nanobodies that inhibit seeding of Alzheimer's patient-extracted tau fibrils</article-title><source>Proc Natl Acad Sci U S A</source><year>2023</year><volume>120</volume><issue>41</issue><fpage>e2300258120</fpage><pub-id pub-id-type="doi">10.1073/pnas.2300258120</pub-id><pub-id pub-id-type="pmid">37801475</pub-id><pub-id pub-id-type="pmcid">PMC10576031</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Abskharon R, Pan H, Sawaya MR, Seidler PM, Olivares EJ, Chen Y, et al. Structure-based design of nanobodies that inhibit seeding of Alzheimer&#8217;s patient-extracted tau fibrils. Proc Natl Acad Sci U S A. 2023;120(41): e2300258120. 10.1073/pnas.2300258120.<pub-id pub-id-type="pmid">37801475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2300258120</pub-id><pub-id pub-id-type="pmcid">PMC10576031</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nair</surname><given-names>S</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Marchal</surname><given-names>IS</given-names></name><name name-style="western"><surname>Chernobelsky</surname><given-names>E</given-names></name><name name-style="western"><surname>Huang</surname><given-names>HW</given-names></name><name name-style="western"><surname>Suh</surname><given-names>S</given-names></name><etal/></person-group><article-title>Anti-tau single domain antibodies clear pathological tau and attenuate its toxicity and related functional defects</article-title><source>Cell Death Dis</source><year>2024</year><volume>15</volume><issue>7</issue><fpage>543</fpage><pub-id pub-id-type="doi">10.1038/s41419-024-06927-9</pub-id><pub-id pub-id-type="pmid">39079958</pub-id><pub-id pub-id-type="pmcid">PMC11289317</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Nair S, Jiang Y, Marchal IS, Chernobelsky E, Huang HW, Suh S, et al. Anti-tau single domain antibodies clear pathological tau and attenuate its toxicity and related functional defects. Cell Death Dis. 2024;15(7):543. 10.1038/s41419-024-06927-9.<pub-id pub-id-type="pmid">39079958</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-024-06927-9</pub-id><pub-id pub-id-type="pmcid">PMC11289317</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benn</surname><given-names>J</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>S</given-names></name><name name-style="western"><surname>Keeling</surname><given-names>S</given-names></name><name name-style="western"><surname>Smith</surname><given-names>AE</given-names></name><name name-style="western"><surname>Vaysburd</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Boken</surname><given-names>D</given-names></name><etal/></person-group><article-title>Aggregate-selective removal of pathological tau by clustering-activated degraders</article-title><source>Science</source><year>2024</year><volume>385</volume><issue>6712</issue><fpage>1009</fpage><lpage>1016</lpage><pub-id pub-id-type="doi">10.1126/science.adp5186</pub-id><pub-id pub-id-type="pmid">39208111</pub-id><pub-id pub-id-type="pmcid">PMC7616837</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Benn J, Cheng S, Keeling S, Smith AE, Vaysburd MJ, Boken D, et al. Aggregate-selective removal of pathological tau by clustering-activated degraders. Science. 2024;385(6712):1009&#8211;16. 10.1126/science.adp5186.<pub-id pub-id-type="pmid">39208111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.adp5186</pub-id><pub-id pub-id-type="pmcid">PMC7616837</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Congdon</surname><given-names>EE</given-names></name><name name-style="western"><surname>Pan</surname><given-names>R</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sandusky-Beltran</surname><given-names>LA</given-names></name><name name-style="western"><surname>Dodge</surname><given-names>A</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Single domain antibodies targeting pathological tau protein: Influence of four IgG subclasses on efficacy and toxicity</article-title><source>EBioMedicine</source><year>2022</year><volume>84</volume><fpage>104249</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2022.104249</pub-id><pub-id pub-id-type="pmid">36099813</pub-id><pub-id pub-id-type="pmcid">PMC9475275</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Congdon EE, Pan R, Jiang Y, Sandusky-Beltran LA, Dodge A, Lin Y, et al. Single domain antibodies targeting pathological tau protein: influence of four IgG subclasses on efficacy and toxicity. EBioMedicine. 2022;84: 104249. 10.1016/j.ebiom.2022.104249.<pub-id pub-id-type="pmid">36099813</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2022.104249</pub-id><pub-id pub-id-type="pmcid">PMC9475275</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheres</surname><given-names>SH</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Falcon</surname><given-names>B</given-names></name><name name-style="western"><surname>Goedert</surname><given-names>M</given-names></name></person-group><article-title>Cryo-EM structures of tau filaments</article-title><source>Curr Opin Struct Biol</source><year>2020</year><volume>64</volume><fpage>17</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.sbi.2020.05.011</pub-id><pub-id pub-id-type="pmid">32603876</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Scheres SH, Zhang W, Falcon B, Goedert M. Cryo-EM structures of tau filaments. Curr Opin Struct Biol. 2020;64:17&#8211;25. 10.1016/j.sbi.2020.05.011.<pub-id pub-id-type="pmid">32603876</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.sbi.2020.05.011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barthelemy</surname><given-names>NR</given-names></name><name name-style="western"><surname>Fenaille</surname><given-names>F</given-names></name><name name-style="western"><surname>Hirtz</surname><given-names>C</given-names></name><name name-style="western"><surname>Sergeant</surname><given-names>N</given-names></name><name name-style="western"><surname>Schraen-Maschke</surname><given-names>S</given-names></name><name name-style="western"><surname>Vialaret</surname><given-names>J</given-names></name><etal/></person-group><article-title>Tau protein quantification in human cerebrospinal fluid by targeted mass spectrometry at high sequence coverage provides insights into its primary structure heterogeneity</article-title><source>J Proteome Res</source><year>2016</year><volume>15</volume><issue>2</issue><fpage>667</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1021/acs.jproteome.5b01001</pub-id><pub-id pub-id-type="pmid">26742856</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Barthelemy NR, Fenaille F, Hirtz C, Sergeant N, Schraen-Maschke S, Vialaret J, et al. Tau protein quantification in human cerebrospinal fluid by targeted mass spectrometry at high sequence coverage provides insights into its primary structure heterogeneity. J Proteome Res. 2016;15(2):667&#8211;76. 10.1021/acs.jproteome.5b01001.<pub-id pub-id-type="pmid">26742856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jproteome.5b01001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barthelemy</surname><given-names>NR</given-names></name><name name-style="western"><surname>Gabelle</surname><given-names>A</given-names></name><name name-style="western"><surname>Hirtz</surname><given-names>C</given-names></name><name name-style="western"><surname>Fenaille</surname><given-names>F</given-names></name><name name-style="western"><surname>Sergeant</surname><given-names>N</given-names></name><name name-style="western"><surname>Schraen-Maschke</surname><given-names>S</given-names></name><etal/></person-group><article-title>Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies</article-title><source>J Alzheimers Dis</source><year>2016</year><volume>51</volume><issue>4</issue><fpage>1033</fpage><lpage>1043</lpage><pub-id pub-id-type="doi">10.3233/JAD-150962</pub-id><pub-id pub-id-type="pmid">26923020</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Barthelemy NR, Gabelle A, Hirtz C, Fenaille F, Sergeant N, Schraen-Maschke S, et al. Differential mass spectrometry profiles of Tau protein in the cerebrospinal fluid of patients with Alzheimer&#8217;s disease, progressive supranuclear palsy, and dementia with Lewy bodies. J Alzheimers Dis. 2016;51(4):1033&#8211;43. 10.3233/JAD-150962.<pub-id pub-id-type="pmid">26923020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-150962</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>von Bergen</surname><given-names>M</given-names></name><name name-style="western"><surname>Friedhoff</surname><given-names>P</given-names></name><name name-style="western"><surname>Biernat</surname><given-names>J</given-names></name><name name-style="western"><surname>Heberle</surname><given-names>J</given-names></name><name name-style="western"><surname>Mandelkow</surname><given-names>EM</given-names></name><name name-style="western"><surname>Mandelkow</surname><given-names>E</given-names></name></person-group><article-title>Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure</article-title><source>Proc Natl Acad Sci U S A</source><year>2000</year><volume>97</volume><issue>10</issue><fpage>5129</fpage><lpage>5134</lpage><pub-id pub-id-type="pmid">10805776</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.97.10.5129</pub-id><pub-id pub-id-type="pmcid">PMC25793</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">von Bergen M, Friedhoff P, Biernat J, Heberle J, Mandelkow EM, Mandelkow E. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc Natl Acad Sci U S A. 2000;97(10):5129&#8211;34.<pub-id pub-id-type="pmid">10805776</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.97.10.5129</pub-id><pub-id pub-id-type="pmcid">PMC25793</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perez</surname><given-names>M</given-names></name><name name-style="western"><surname>Santa-Maria</surname><given-names>I</given-names></name><name name-style="western"><surname>Tortosa</surname><given-names>E</given-names></name><name name-style="western"><surname>Cuadros</surname><given-names>R</given-names></name><name name-style="western"><surname>Del Valle</surname><given-names>M</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>F</given-names></name><etal/></person-group><article-title>The role of the VQIVYK peptide in tau protein phosphorylation</article-title><source>J Neurochem</source><year>2007</year><volume>103</volume><issue>4</issue><fpage>1447</fpage><lpage>1460</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2007.04834.x</pub-id><pub-id pub-id-type="pmid">17680993</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Perez M, Santa-Maria I, Tortosa E, Cuadros R, Del Valle M, Hernandez F, et al. The role of the VQIVYK peptide in tau protein phosphorylation. J Neurochem. 2007;103(4):1447&#8211;60. 10.1111/j.1471-4159.2007.04834.x.<pub-id pub-id-type="pmid">17680993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1471-4159.2007.04834.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lovestam</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Wagstaff</surname><given-names>JL</given-names></name><name name-style="western"><surname>Kotecha</surname><given-names>A</given-names></name><name name-style="western"><surname>Kimanius</surname><given-names>D</given-names></name><name name-style="western"><surname>McLaughlin</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Disease-specific tau filaments assemble via polymorphic intermediates</article-title><source>Nature</source><year>2024</year><volume>625</volume><issue>7993</issue><fpage>119</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06788-w</pub-id><pub-id pub-id-type="pmid">38030728</pub-id><pub-id pub-id-type="pmcid">PMC10764278</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Lovestam S, Li D, Wagstaff JL, Kotecha A, Kimanius D, McLaughlin SH, et al. Disease-specific tau filaments assemble via polymorphic intermediates. Nature. 2024;625(7993):119&#8211;25. 10.1038/s41586-023-06788-w.<pub-id pub-id-type="pmid">38030728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-06788-w</pub-id><pub-id pub-id-type="pmcid">PMC10764278</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Moutel S, Bery N, Bernard V, Keller L, Lemesre E, de Marco A, et al. NaLi-H1: a universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies. Elife. 2016;5. 10.7554/eLife.16228.<pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.16228</pub-id><pub-id pub-id-type="pmcid">PMC4985285</pub-id><pub-id pub-id-type="pmid">27434673</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weber</surname><given-names>T</given-names></name></person-group><article-title>Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible Solutions</article-title><source>Front Immunol</source><year>2021</year><volume>12</volume><fpage>658399</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.658399</pub-id><pub-id pub-id-type="pmid">33815421</pub-id><pub-id pub-id-type="pmcid">PMC8010240</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Weber T. Anti-AAV antibodies in AAV gene therapy: current challenges and possible solutions. Front Immunol. 2021;12: 658399. 10.3389/fimmu.2021.658399.<pub-id pub-id-type="pmid">33815421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.658399</pub-id><pub-id pub-id-type="pmcid">PMC8010240</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Issa SS, Shaimardanova AA, Solovyeva VV, Rizvanov AA. Various AAV serotypes and their applications in gene therapy: an overview. Cells. 2023;12(5). 10.3390/cells12050785.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells12050785</pub-id><pub-id pub-id-type="pmcid">PMC10000783</pub-id><pub-id pub-id-type="pmid">36899921</pub-id></mixed-citation></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schindowski</surname><given-names>K</given-names></name><name name-style="western"><surname>Bretteville</surname><given-names>A</given-names></name><name name-style="western"><surname>Leroy</surname><given-names>K</given-names></name><name name-style="western"><surname>Begard</surname><given-names>S</given-names></name><name name-style="western"><surname>Brion</surname><given-names>JP</given-names></name><name name-style="western"><surname>Hamdane</surname><given-names>M</given-names></name><etal/></person-group><article-title>Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits</article-title><source>Am J Pathol</source><year>2006</year><volume>169</volume><issue>2</issue><fpage>599</fpage><lpage>616</lpage><pub-id pub-id-type="pmid">16877359</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2353/ajpath.2006.060002</pub-id><pub-id pub-id-type="pmcid">PMC1698785</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Schindowski K, Bretteville A, Leroy K, Begard S, Brion JP, Hamdane M, et al. Alzheimer&#8217;s disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol. 2006;169(2):599&#8211;616. doi: 169/2/599 [pii].<pub-id pub-id-type="pmid">16877359</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2353/ajpath.2006.060002</pub-id><pub-id pub-id-type="pmcid">PMC1698785</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leroy</surname><given-names>K</given-names></name><name name-style="western"><surname>Bretteville</surname><given-names>A</given-names></name><name name-style="western"><surname>Schindowski</surname><given-names>K</given-names></name><name name-style="western"><surname>Gilissen</surname><given-names>E</given-names></name><name name-style="western"><surname>Authelet</surname><given-names>M</given-names></name><name name-style="western"><surname>De Decker</surname><given-names>R</given-names></name><etal/></person-group><article-title>Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice</article-title><source>Am J Pathol</source><year>2007</year><volume>171</volume><issue>3</issue><fpage>976</fpage><lpage>992</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2007.070345</pub-id><pub-id pub-id-type="pmid">17690183</pub-id><pub-id pub-id-type="pmcid">PMC1959508</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Leroy K, Bretteville A, Schindowski K, Gilissen E, Authelet M, De Decker R, et al. Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice. Am J Pathol. 2007;171(3):976&#8211;92. 10.2353/ajpath.2007.070345. doi: ajpath.2007.070345 [pii].<pub-id pub-id-type="pmid">17690183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2353/ajpath.2007.070345</pub-id><pub-id pub-id-type="pmcid">PMC1959508</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holter</surname><given-names>SM</given-names></name><name name-style="western"><surname>Garrett</surname><given-names>L</given-names></name><name name-style="western"><surname>Einicke</surname><given-names>J</given-names></name><name name-style="western"><surname>Sperling</surname><given-names>B</given-names></name><name name-style="western"><surname>Dirscherl</surname><given-names>P</given-names></name><name name-style="western"><surname>Zimprich</surname><given-names>A</given-names></name><etal/></person-group><article-title>Assessing cognition in mice</article-title><source>Curr Protoc Mouse Biol</source><year>2015</year><volume>5</volume><issue>4</issue><fpage>331</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1002/9780470942390.mo150068</pub-id><pub-id pub-id-type="pmid">26629775</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Holter SM, Garrett L, Einicke J, Sperling B, Dirscherl P, Zimprich A, et al. Assessing cognition in mice. Curr Protoc Mouse Biol. 2015;5(4):331&#8211;58. 10.1002/9780470942390.mo150068.<pub-id pub-id-type="pmid">26629775</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/9780470942390.mo150068</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="other">Gould TD. Mood and Anxiety-related Phenotypes in Mice: Characterization Using Behavioral Tests. Genes, Brain and Behavior. 2010;9(5):449-544. 10.1111/j.1601-183X.2010.00592.</mixed-citation></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tustison</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Avants</surname><given-names>BB</given-names></name><name name-style="western"><surname>Cook</surname><given-names>PA</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Egan</surname><given-names>A</given-names></name><name name-style="western"><surname>Yushkevich</surname><given-names>PA</given-names></name><etal/></person-group><article-title>N4ITK: improved N3 bias correction</article-title><source>IEEE Trans Med Imaging</source><year>2010</year><volume>29</volume><issue>6</issue><fpage>1310</fpage><lpage>1320</lpage><pub-id pub-id-type="doi">10.1109/TMI.2010.2046908</pub-id><pub-id pub-id-type="pmid">20378467</pub-id><pub-id pub-id-type="pmcid">PMC3071855</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Tustison NJ, Avants BB, Cook PA, Zheng Y, Egan A, Yushkevich PA, et al. N4ITK: improved N3 bias correction. IEEE Trans Med Imaging. 2010;29(6):1310&#8211;20. 10.1109/TMI.2010.2046908.<pub-id pub-id-type="pmid">20378467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/TMI.2010.2046908</pub-id><pub-id pub-id-type="pmcid">PMC3071855</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coupe</surname><given-names>P</given-names></name><name name-style="western"><surname>Manjon</surname><given-names>JV</given-names></name><name name-style="western"><surname>Robles</surname><given-names>M</given-names></name><name name-style="western"><surname>Collins</surname><given-names>DL</given-names></name></person-group><article-title>Adaptive multiresolution non-local means filter for three-dimensional magnetic resonance image denoising</article-title><source>IET Image Proc</source><year>2012</year><volume>6</volume><issue>5</issue><fpage>558</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1049/iet-ipr.2011.0161</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Coupe P, Manjon JV, Robles M, Collins DL. Adaptive multiresolution non-local means filter for three-dimensional magnetic resonance image denoising. IET Image Proc. 2012;6(5):558&#8211;68. 10.1049/iet-ipr.2011.0161.</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>D</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Modat</surname><given-names>M</given-names></name><name name-style="western"><surname>Powell</surname><given-names>N</given-names></name><name name-style="western"><surname>Wells</surname><given-names>J</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>H</given-names></name><etal/></person-group><article-title>Automatic structural parcellation of mouse brain MRI using multi-atlas label fusion</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><issue>1</issue><fpage>e86576</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0086576</pub-id><pub-id pub-id-type="pmid">24475148</pub-id><pub-id pub-id-type="pmcid">PMC3903537</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Ma D, Cardoso MJ, Modat M, Powell N, Wells J, Holmes H, et al. Automatic structural parcellation of mouse brain MRI using multi-atlas label fusion. PLoS ONE. 2014;9(1): e86576. 10.1371/journal.pone.0086576.<pub-id pub-id-type="pmid">24475148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0086576</pub-id><pub-id pub-id-type="pmcid">PMC3903537</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>J</given-names></name><name name-style="western"><surname>Trinh</surname><given-names>TL</given-names></name><name name-style="western"><surname>Chuang</surname><given-names>KH</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>A</given-names></name></person-group><article-title>Atlas-based automatic mouse brain image segmentation revisited: model complexity vs. image registration</article-title><source>Magn Reson Imaging</source><year>2012</year><volume>30</volume><issue>6</issue><fpage>789</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.mri.2012.02.010</pub-id><pub-id pub-id-type="pmid">22464452</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Bai J, Trinh TL, Chuang KH, Qiu A. Atlas-based automatic mouse brain image segmentation revisited: model complexity vs. image registration. Magn Reson Imaging. 2012;30(6):789&#8211;98. 10.1016/j.mri.2012.02.010.<pub-id pub-id-type="pmid">22464452</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mri.2012.02.010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>S</given-names></name><name name-style="western"><surname>Pelletier</surname><given-names>D</given-names></name><name name-style="western"><surname>Sdika</surname><given-names>M</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Berman</surname><given-names>JI</given-names></name><name name-style="western"><surname>Henry</surname><given-names>RG</given-names></name></person-group><article-title>Whole brain voxel-wise analysis of single-subject serial DTI by permutation testing</article-title><source>Neuroimage</source><year>2008</year><volume>39</volume><issue>4</issue><fpage>1693</fpage><lpage>1705</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2007.10.039</pub-id><pub-id pub-id-type="pmid">18082426</pub-id><pub-id pub-id-type="pmcid">PMC2276665</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Chung S, Pelletier D, Sdika M, Lu Y, Berman JI, Henry RG. Whole brain voxel-wise analysis of single-subject serial DTI by permutation testing. Neuroimage. 2008;39(4):1693&#8211;705. 10.1016/j.neuroimage.2007.10.039.<pub-id pub-id-type="pmid">18082426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2007.10.039</pub-id><pub-id pub-id-type="pmcid">PMC2276665</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moutel</surname><given-names>S</given-names></name><name name-style="western"><surname>El Marjou</surname><given-names>A</given-names></name><name name-style="western"><surname>Vielemeyer</surname><given-names>O</given-names></name><name name-style="western"><surname>Nizak</surname><given-names>C</given-names></name><name name-style="western"><surname>Benaroch</surname><given-names>P</given-names></name><name name-style="western"><surname>Dubel</surname><given-names>S</given-names></name><etal/></person-group><article-title>A multi-Fc-species system for recombinant antibody production</article-title><source>BMC Biotechnol</source><year>2009</year><volume>9</volume><fpage>14</fpage><pub-id pub-id-type="doi">10.1186/1472-6750-9-14</pub-id><pub-id pub-id-type="pmid">19245715</pub-id><pub-id pub-id-type="pmcid">PMC2654441</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Moutel S, El Marjou A, Vielemeyer O, Nizak C, Benaroch P, Dubel S, et al. A multi-Fc-species system for recombinant antibody production. BMC Biotechnol. 2009;9:14. 10.1186/1472-6750-9-14.<pub-id pub-id-type="pmid">19245715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1472-6750-9-14</pub-id><pub-id pub-id-type="pmcid">PMC2654441</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klein</surname><given-names>RL</given-names></name><name name-style="western"><surname>Dayton</surname><given-names>RD</given-names></name><name name-style="western"><surname>Leidenheimer</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>K</given-names></name><name name-style="western"><surname>Golde</surname><given-names>TE</given-names></name><name name-style="western"><surname>Zweig</surname><given-names>RM</given-names></name></person-group><article-title>Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins</article-title><source>Mol Ther</source><year>2006</year><volume>13</volume><issue>3</issue><fpage>517</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2005.10.008</pub-id><pub-id pub-id-type="pmid">16325474</pub-id><pub-id pub-id-type="pmcid">PMC2987642</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Klein RL, Dayton RD, Leidenheimer NJ, Jansen K, Golde TE, Zweig RM. Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. Mol Ther. 2006;13(3):517&#8211;27. 10.1016/j.ymthe.2005.10.008.<pub-id pub-id-type="pmid">16325474</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2005.10.008</pub-id><pub-id pub-id-type="pmcid">PMC2987642</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexander</surname><given-names>AL</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JE</given-names></name><name name-style="western"><surname>Lazar</surname><given-names>M</given-names></name><name name-style="western"><surname>Field</surname><given-names>AS</given-names></name></person-group><article-title>Diffusion tensor imaging of the brain</article-title><source>Neurotherapeutics</source><year>2007</year><volume>4</volume><issue>3</issue><fpage>316</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1016/j.nurt.2007.05.011</pub-id><pub-id pub-id-type="pmid">17599699</pub-id><pub-id pub-id-type="pmcid">PMC2041910</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Alexander AL, Lee JE, Lazar M, Field AS. Diffusion tensor imaging of the brain. Neurotherapeutics. 2007;4(3):316&#8211;29. 10.1016/j.nurt.2007.05.011.<pub-id pub-id-type="pmid">17599699</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nurt.2007.05.011</pub-id><pub-id pub-id-type="pmcid">PMC2041910</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Platt</surname><given-names>B</given-names></name><name name-style="western"><surname>Welch</surname><given-names>A</given-names></name><name name-style="western"><surname>Riedel</surname><given-names>G</given-names></name></person-group><article-title>FDG-PET imaging, EEG and sleep phenotypes as translational biomarkers for research in Alzheimer's disease</article-title><source>Biochem Soc Trans</source><year>2011</year><volume>39</volume><issue>4</issue><fpage>874</fpage><lpage>880</lpage><pub-id pub-id-type="doi">10.1042/BST0390874</pub-id><pub-id pub-id-type="pmid">21787316</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Platt B, Welch A, Riedel G. FDG-PET imaging, EEG and sleep phenotypes as translational biomarkers for research in Alzheimer&#8217;s disease. Biochem Soc Trans. 2011;39(4):874&#8211;80. 10.1042/BST0390874.<pub-id pub-id-type="pmid">21787316</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BST0390874</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mercken</surname><given-names>M</given-names></name><name name-style="western"><surname>Vandermeeren</surname><given-names>M</given-names></name><name name-style="western"><surname>Lubke</surname><given-names>U</given-names></name><name name-style="western"><surname>Six</surname><given-names>J</given-names></name><name name-style="western"><surname>Boons</surname><given-names>J</given-names></name><name name-style="western"><surname>Van de Voorde</surname><given-names>A</given-names></name><etal/></person-group><article-title>Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes</article-title><source>Acta Neuropathol</source><year>1992</year><volume>84</volume><issue>3</issue><fpage>265</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">1384266</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00227819</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Mercken M, Vandermeeren M, Lubke U, Six J, Boons J, Van de Voorde A, et al. Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes. Acta Neuropathol. 1992;84(3):265&#8211;72.<pub-id pub-id-type="pmid">1384266</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00227819</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeganathan</surname><given-names>S</given-names></name><name name-style="western"><surname>Hascher</surname><given-names>A</given-names></name><name name-style="western"><surname>Chinnathambi</surname><given-names>S</given-names></name><name name-style="western"><surname>Biernat</surname><given-names>J</given-names></name><name name-style="western"><surname>Mandelkow</surname><given-names>EM</given-names></name><name name-style="western"><surname>Mandelkow</surname><given-names>E</given-names></name></person-group><article-title>Proline-directed pseudo-phosphorylation at AT8 and PHF1 epitopes induces a compaction of the paperclip folding of Tau and generates a pathological (MC-1) conformation</article-title><source>J Biol Chem</source><year>2008</year><volume>283</volume><issue>46</issue><fpage>32066</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1074/jbc.M805300200</pub-id><pub-id pub-id-type="pmid">18725412</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Jeganathan S, Hascher A, Chinnathambi S, Biernat J, Mandelkow EM, Mandelkow E. Proline-directed pseudo-phosphorylation at AT8 and PHF1 epitopes induces a compaction of the paperclip folding of Tau and generates a pathological (MC-1) conformation. J Biol Chem. 2008;283(46):32066&#8211;76. 10.1074/jbc.M805300200. M805300200 [pii].<pub-id pub-id-type="pmid">18725412</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M805300200</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>B</given-names></name><name name-style="western"><surname>Ingram</surname><given-names>E</given-names></name><name name-style="western"><surname>Takao</surname><given-names>M</given-names></name><name name-style="western"><surname>Smith</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Jakes</surname><given-names>R</given-names></name><name name-style="western"><surname>Virdee</surname><given-names>K</given-names></name><etal/></person-group><article-title>Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein</article-title><source>J Neurosci</source><year>2002</year><volume>22</volume><issue>21</issue><fpage>9340</fpage><lpage>9351</lpage><pub-id pub-id-type="pmid">12417659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.22-21-09340.2002</pub-id><pub-id pub-id-type="pmcid">PMC6758022</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci. 2002;22(21):9340&#8211;51. doi: 22/21/9340 [pii].<pub-id pub-id-type="pmid">12417659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.22-21-09340.2002</pub-id><pub-id pub-id-type="pmcid">PMC6758022</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albert</surname><given-names>M</given-names></name><name name-style="western"><surname>Mairet-Coello</surname><given-names>G</given-names></name><name name-style="western"><surname>Danis</surname><given-names>C</given-names></name><name name-style="western"><surname>Lieger</surname><given-names>S</given-names></name><name name-style="western"><surname>Caillierez</surname><given-names>R</given-names></name><name name-style="western"><surname>Carrier</surname><given-names>S</given-names></name><etal/></person-group><article-title>Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody</article-title><source>Brain</source><year>2019</year><volume>142</volume><issue>6</issue><fpage>1736</fpage><lpage>1750</lpage><pub-id pub-id-type="doi">10.1093/brain/awz100</pub-id><pub-id pub-id-type="pmid">31038156</pub-id><pub-id pub-id-type="pmcid">PMC6536853</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Albert M, Mairet-Coello G, Danis C, Lieger S, Caillierez R, Carrier S, et al. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody. Brain. 2019;142(6):1736&#8211;50. 10.1093/brain/awz100.<pub-id pub-id-type="pmid">31038156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awz100</pub-id><pub-id pub-id-type="pmcid">PMC6536853</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dujardin</surname><given-names>S</given-names></name><name name-style="western"><surname>Lecolle</surname><given-names>K</given-names></name><name name-style="western"><surname>Caillierez</surname><given-names>R</given-names></name><name name-style="western"><surname>Begard</surname><given-names>S</given-names></name><name name-style="western"><surname>Zommer</surname><given-names>N</given-names></name><name name-style="western"><surname>Lachaud</surname><given-names>C</given-names></name><etal/></person-group><article-title>Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies</article-title><source>Acta Neuropathol Commun</source><year>2014</year><volume>2</volume><issue>1</issue><fpage>14</fpage><pub-id pub-id-type="doi">10.1186/2051-5960-2-14</pub-id><pub-id pub-id-type="pmid">24479894</pub-id><pub-id pub-id-type="pmcid">PMC3922636</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Dujardin S, Lecolle K, Caillierez R, Begard S, Zommer N, Lachaud C, et al. Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies. Acta Neuropathol Commun. 2014;2(1):14. 10.1186/2051-5960-2-14. doi: 2051-5960-2-14 [pii].<pub-id pub-id-type="pmid">24479894</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/2051-5960-2-14</pub-id><pub-id pub-id-type="pmcid">PMC3922636</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="other">Verny M, Duyckaerts C, Agid Y, Hauw JJ. The significance of cortical pathology in progressive supranuclear palsy. Clinico-pathological data in 10 cases. Brain. 1996;119(Pt 4):1123&#8211;36.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/119.4.1123</pub-id><pub-id pub-id-type="pmid">8813277</pub-id></mixed-citation></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>DR</given-names></name><name name-style="western"><surname>Holton</surname><given-names>JL</given-names></name><name name-style="western"><surname>Strand</surname><given-names>C</given-names></name><name name-style="western"><surname>Pittman</surname><given-names>A</given-names></name><name name-style="western"><surname>de Silva</surname><given-names>R</given-names></name><name name-style="western"><surname>Lees</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome</article-title><source>Brain</source><year>2007</year><volume>130</volume><issue>Pt 6</issue><fpage>1566</fpage><lpage>1576</lpage><pub-id pub-id-type="doi">10.1093/brain/awm104</pub-id><pub-id pub-id-type="pmid">17525140</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Williams DR, Holton JL, Strand C, Pittman A, de Silva R, Lees AJ, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson&#8217;s syndrome. Brain. 2007;130(Pt 6):1566&#8211;76. 10.1093/brain/awm104.<pub-id pub-id-type="pmid">17525140</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awm104</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brendel</surname><given-names>M</given-names></name><name name-style="western"><surname>Schonecker</surname><given-names>S</given-names></name><name name-style="western"><surname>Hoglinger</surname><given-names>G</given-names></name><name name-style="western"><surname>Lindner</surname><given-names>S</given-names></name><name name-style="western"><surname>Havla</surname><given-names>J</given-names></name><name name-style="western"><surname>Blautzik</surname><given-names>J</given-names></name><etal/></person-group><article-title>[(18)F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy</article-title><source>Front Aging Neurosci</source><year>2017</year><volume>9</volume><fpage>440</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2017.00440</pub-id><pub-id pub-id-type="pmid">29387005</pub-id><pub-id pub-id-type="pmcid">PMC5776329</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Brendel M, Schonecker S, Hoglinger G, Lindner S, Havla J, Blautzik J, et al. [(18)F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy. Front Aging Neurosci. 2017;9:440. 10.3389/fnagi.2017.00440.<pub-id pub-id-type="pmid">29387005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2017.00440</pub-id><pub-id pub-id-type="pmcid">PMC5776329</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Radford</surname><given-names>RAW</given-names></name><name name-style="western"><surname>Rayner</surname><given-names>SL</given-names></name><name name-style="western"><surname>Szwaja</surname><given-names>P</given-names></name><name name-style="western"><surname>Morsch</surname><given-names>M</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>T</given-names></name><etal/></person-group><article-title>Identification of phosphorylated tau protein interactors in progressive supranuclear palsy (PSP) reveals networks involved in protein degradation, stress response, cytoskeletal dynamics, metabolic processes, and neurotransmission</article-title><source>J Neurochem</source><year>2023</year><volume>165</volume><issue>4</issue><fpage>563</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1111/jnc.15796</pub-id><pub-id pub-id-type="pmid">36847488</pub-id><pub-id pub-id-type="pmcid">PMC10953353</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Radford RAW, Rayner SL, Szwaja P, Morsch M, Cheng F, Zhu T, et al. Identification of phosphorylated tau protein interactors in progressive supranuclear palsy (PSP) reveals networks involved in protein degradation, stress response, cytoskeletal dynamics, metabolic processes, and neurotransmission. J Neurochem. 2023;165(4):563&#8211;86. 10.1111/jnc.15796.<pub-id pub-id-type="pmid">36847488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jnc.15796</pub-id><pub-id pub-id-type="pmcid">PMC10953353</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cope</surname><given-names>TE</given-names></name><name name-style="western"><surname>Rittman</surname><given-names>T</given-names></name><name name-style="western"><surname>Borchert</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Jones</surname><given-names>PS</given-names></name><name name-style="western"><surname>Vatansever</surname><given-names>D</given-names></name><name name-style="western"><surname>Allinson</surname><given-names>K</given-names></name><etal/></person-group><article-title>Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy</article-title><source>Brain</source><year>2018</year><volume>141</volume><issue>2</issue><fpage>550</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1093/brain/awx347</pub-id><pub-id pub-id-type="pmid">29293892</pub-id><pub-id pub-id-type="pmcid">PMC5837359</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Cope TE, Rittman T, Borchert RJ, Jones PS, Vatansever D, Allinson K, et al. Tau burden and the functional connectome in Alzheimer&#8217;s disease and progressive supranuclear palsy. Brain. 2018;141(2):550&#8211;67. 10.1093/brain/awx347.<pub-id pub-id-type="pmid">29293892</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awx347</pub-id><pub-id pub-id-type="pmcid">PMC5837359</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saito</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ruberu</surname><given-names>NN</given-names></name><name name-style="western"><surname>Sawabe</surname><given-names>M</given-names></name><name name-style="western"><surname>Arai</surname><given-names>T</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>N</given-names></name><name name-style="western"><surname>Kakuta</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Staging of argyrophilic grains: an age-associated tauopathy</article-title><source>J Neuropathol Exp Neurol</source><year>2004</year><volume>63</volume><issue>9</issue><fpage>911</fpage><lpage>918</lpage><pub-id pub-id-type="pmid">15453090</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnen/63.9.911</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Saito Y, Ruberu NN, Sawabe M, Arai T, Tanaka N, Kakuta Y, et al. Staging of argyrophilic grains: an age-associated tauopathy. J Neuropathol Exp Neurol. 2004;63(9):911&#8211;8.<pub-id pub-id-type="pmid">15453090</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnen/63.9.911</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irwin</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Brettschneider</surname><given-names>J</given-names></name><name name-style="western"><surname>McMillan</surname><given-names>CT</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>F</given-names></name><name name-style="western"><surname>Olm</surname><given-names>C</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Deep clinical and neuropathological phenotyping of Pick disease</article-title><source>Ann Neurol</source><year>2016</year><volume>79</volume><issue>2</issue><fpage>272</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1002/ana.24559</pub-id><pub-id pub-id-type="pmid">26583316</pub-id><pub-id pub-id-type="pmcid">PMC4755803</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Irwin DJ, Brettschneider J, McMillan CT, Cooper F, Olm C, Arnold SE, et al. Deep clinical and neuropathological phenotyping of Pick disease. Ann Neurol. 2016;79(2):272&#8211;87. 10.1002/ana.24559.<pub-id pub-id-type="pmid">26583316</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.24559</pub-id><pub-id pub-id-type="pmcid">PMC4755803</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leroux</surname><given-names>E</given-names></name><name name-style="western"><surname>Perbet</surname><given-names>R</given-names></name><name name-style="western"><surname>Caillierez</surname><given-names>R</given-names></name><name name-style="western"><surname>Richetin</surname><given-names>K</given-names></name><name name-style="western"><surname>Lieger</surname><given-names>S</given-names></name><name name-style="western"><surname>Espourteille</surname><given-names>J</given-names></name><etal/></person-group><article-title>Extracellular vesicles: Major actors of heterogeneity in tau spreading among human tauopathies</article-title><source>Mol Ther</source><year>2022</year><volume>30</volume><issue>2</issue><fpage>782</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2021.09.020</pub-id><pub-id pub-id-type="pmid">34563677</pub-id><pub-id pub-id-type="pmcid">PMC8821971</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Leroux E, Perbet R, Caillierez R, Richetin K, Lieger S, Espourteille J, et al. Extracellular vesicles: major actors of heterogeneity in tau spreading among human tauopathies. Mol Ther. 2022;30(2):782&#8211;97. 10.1016/j.ymthe.2021.09.020.<pub-id pub-id-type="pmid">34563677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2021.09.020</pub-id><pub-id pub-id-type="pmcid">PMC8821971</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><mixed-citation publication-type="other">Hansson K, Dahlen R, Hansson O, Pernevik E, Paterson R, Schott JM, et al. Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease. Clin Mass Spectrom. 2019;14 Pt B:74&#8211;82. 10.1016/j.clinms.2019.07.002.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinms.2019.07.002</pub-id><pub-id pub-id-type="pmcid">PMC8669449</pub-id><pub-id pub-id-type="pmid">34917763</pub-id></mixed-citation></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sotiropoulos</surname><given-names>I</given-names></name><name name-style="western"><surname>Galas</surname><given-names>MC</given-names></name><name name-style="western"><surname>Silva</surname><given-names>JM</given-names></name><name name-style="western"><surname>Skoulakis</surname><given-names>E</given-names></name><name name-style="western"><surname>Wegmann</surname><given-names>S</given-names></name><name name-style="western"><surname>Maina</surname><given-names>MB</given-names></name><etal/></person-group><article-title>Atypical, non-standard functions of the microtubule associated Tau protein</article-title><source>Acta Neuropathol Commun</source><year>2017</year><volume>5</volume><issue>1</issue><fpage>91</fpage><pub-id pub-id-type="doi">10.1186/s40478-017-0489-6</pub-id><pub-id pub-id-type="pmid">29187252</pub-id><pub-id pub-id-type="pmcid">PMC5707803</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Sotiropoulos I, Galas MC, Silva JM, Skoulakis E, Wegmann S, Maina MB, et al. Atypical, non-standard functions of the microtubule associated Tau protein. Acta Neuropathol Commun. 2017;5(1):91. 10.1186/s40478-017-0489-6.<pub-id pub-id-type="pmid">29187252</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40478-017-0489-6</pub-id><pub-id pub-id-type="pmcid">PMC5707803</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okun</surname><given-names>E</given-names></name><name name-style="western"><surname>Mattson</surname><given-names>MP</given-names></name><name name-style="western"><surname>Arumugam</surname><given-names>TV</given-names></name></person-group><article-title>Involvement of Fc receptors in disorders of the central nervous system</article-title><source>Neuromolecular Med</source><year>2010</year><volume>12</volume><issue>2</issue><fpage>164</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1007/s12017-009-8099-5</pub-id><pub-id pub-id-type="pmid">19844812</pub-id><pub-id pub-id-type="pmcid">PMC2878892</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Okun E, Mattson MP, Arumugam TV. Involvement of Fc receptors in disorders of the central nervous system. Neuromolecular Med. 2010;12(2):164&#8211;78. 10.1007/s12017-009-8099-5.<pub-id pub-id-type="pmid">19844812</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12017-009-8099-5</pub-id><pub-id pub-id-type="pmcid">PMC2878892</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fuller</surname><given-names>JP</given-names></name><name name-style="western"><surname>Stavenhagen</surname><given-names>JB</given-names></name><name name-style="western"><surname>Teeling</surname><given-names>JL</given-names></name></person-group><article-title>New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease</article-title><source>Front Neurosci</source><year>2014</year><volume>8</volume><fpage>235</fpage><pub-id pub-id-type="doi">10.3389/fnins.2014.00235</pub-id><pub-id pub-id-type="pmid">25191216</pub-id><pub-id pub-id-type="pmcid">PMC4139653</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Fuller JP, Stavenhagen JB, Teeling JL. New roles for Fc receptors in neurodegeneration-the impact on immunotherapy for Alzheimer&#8217;s Disease. Front Neurosci. 2014;8:235. 10.3389/fnins.2014.00235.<pub-id pub-id-type="pmid">25191216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2014.00235</pub-id><pub-id pub-id-type="pmcid">PMC4139653</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Funk</surname><given-names>KE</given-names></name><name name-style="western"><surname>Mirbaha</surname><given-names>H</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>DM</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>MI</given-names></name></person-group><article-title>Distinct Therapeutic Mechanisms of Tau Antibodies: Promoting Microglial Clearance Versus Blocking Neuronal Uptake</article-title><source>J Biol Chem</source><year>2015</year><volume>290</volume><issue>35</issue><fpage>21652</fpage><lpage>21662</lpage><pub-id pub-id-type="doi">10.1074/jbc.M115.657924</pub-id><pub-id pub-id-type="pmid">26126828</pub-id><pub-id pub-id-type="pmcid">PMC4571888</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Funk KE, Mirbaha H, Jiang H, Holtzman DM, Diamond MI. Distinct therapeutic mechanisms of Tau antibodies: promoting microglial clearance versus blocking neuronal uptake. J Biol Chem. 2015;290(35):21652&#8211;62. 10.1074/jbc.M115.657924.<pub-id pub-id-type="pmid">26126828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M115.657924</pub-id><pub-id pub-id-type="pmcid">PMC4571888</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andersson</surname><given-names>CR</given-names></name><name name-style="western"><surname>Falsig</surname><given-names>J</given-names></name><name name-style="western"><surname>Stavenhagen</surname><given-names>JB</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>S</given-names></name><name name-style="western"><surname>Kartberg</surname><given-names>F</given-names></name><name name-style="western"><surname>Rosenqvist</surname><given-names>N</given-names></name><etal/></person-group><article-title>Antibody-mediated clearance of tau in primary mouse microglial cultures requires Fcgamma-receptor binding and functional lysosomes</article-title><source>Sci Rep</source><year>2019</year><volume>9</volume><issue>1</issue><fpage>4658</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-41105-4</pub-id><pub-id pub-id-type="pmid">30874605</pub-id><pub-id pub-id-type="pmcid">PMC6420568</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Andersson CR, Falsig J, Stavenhagen JB, Christensen S, Kartberg F, Rosenqvist N, et al. Antibody-mediated clearance of tau in primary mouse microglial cultures requires Fcgamma-receptor binding and functional lysosomes. Sci Rep. 2019;9(1):4658. 10.1038/s41598-019-41105-4.<pub-id pub-id-type="pmid">30874605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-019-41105-4</pub-id><pub-id pub-id-type="pmcid">PMC6420568</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mac Donald</surname><given-names>CL</given-names></name><name name-style="western"><surname>Dikranian</surname><given-names>K</given-names></name><name name-style="western"><surname>Bayly</surname><given-names>P</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>D</given-names></name><name name-style="western"><surname>Brody</surname><given-names>D</given-names></name></person-group><article-title>Diffusion tensor imaging reliably detects experimental traumatic axonal injury and indicates approximate time of injury</article-title><source>J Neurosci</source><year>2007</year><volume>27</volume><issue>44</issue><fpage>11869</fpage><lpage>11876</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3647-07.2007</pub-id><pub-id pub-id-type="pmid">17978027</pub-id><pub-id pub-id-type="pmcid">PMC2562788</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Mac Donald CL, Dikranian K, Bayly P, Holtzman D, Brody D. Diffusion tensor imaging reliably detects experimental traumatic axonal injury and indicates approximate time of injury. J Neurosci. 2007;27(44):11869&#8211;76. 10.1523/JNEUROSCI.3647-07.2007.<pub-id pub-id-type="pmid">17978027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.3647-07.2007</pub-id><pub-id pub-id-type="pmcid">PMC2562788</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holmes</surname><given-names>HE</given-names></name><name name-style="western"><surname>Colgan</surname><given-names>N</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>O</given-names></name><name name-style="western"><surname>Ma</surname><given-names>D</given-names></name><name name-style="western"><surname>Powell</surname><given-names>NM</given-names></name><name name-style="western"><surname>O'Callaghan</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Imaging the accumulation and suppression of tau pathology using multiparametric MRI</article-title><source>Neurobiol Aging</source><year>2016</year><volume>39</volume><fpage>184</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2015.12.001</pub-id><pub-id pub-id-type="pmid">26923415</pub-id><pub-id pub-id-type="pmcid">PMC4782737</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Holmes HE, Colgan N, Ismail O, Ma D, Powell NM, O&#8217;Callaghan JM, et al. Imaging the accumulation and suppression of tau pathology using multiparametric MRI. Neurobiol Aging. 2016;39:184&#8211;94. 10.1016/j.neurobiolaging.2015.12.001.<pub-id pub-id-type="pmid">26923415</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2015.12.001</pub-id><pub-id pub-id-type="pmcid">PMC4782737</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foust</surname><given-names>KD</given-names></name><name name-style="western"><surname>Nurre</surname><given-names>E</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>CL</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>A</given-names></name><name name-style="western"><surname>Chan</surname><given-names>CM</given-names></name><name name-style="western"><surname>Kaspar</surname><given-names>BK</given-names></name></person-group><article-title>Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes</article-title><source>Nat Biotechnol</source><year>2009</year><volume>27</volume><issue>1</issue><fpage>59</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1038/nbt.1515</pub-id><pub-id pub-id-type="pmid">19098898</pub-id><pub-id pub-id-type="pmcid">PMC2895694</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2009;27(1):59&#8211;65. 10.1038/nbt.1515.<pub-id pub-id-type="pmid">19098898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.1515</pub-id><pub-id pub-id-type="pmcid">PMC2895694</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>H</given-names></name><name name-style="western"><surname>Dirosario</surname><given-names>J</given-names></name><name name-style="western"><surname>Killedar</surname><given-names>S</given-names></name><name name-style="western"><surname>Zaraspe</surname><given-names>K</given-names></name><name name-style="western"><surname>McCarty</surname><given-names>DM</given-names></name></person-group><article-title>Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery</article-title><source>Mol Ther</source><year>2011</year><volume>19</volume><issue>6</issue><fpage>1025</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1038/mt.2011.34</pub-id><pub-id pub-id-type="pmid">21386820</pub-id><pub-id pub-id-type="pmcid">PMC3129800</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Fu H, Dirosario J, Killedar S, Zaraspe K, McCarty DM. Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol Ther. 2011;19(6):1025&#8211;33. 10.1038/mt.2011.34.<pub-id pub-id-type="pmid">21386820</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mt.2011.34</pub-id><pub-id pub-id-type="pmcid">PMC3129800</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lasagna-Reeves</surname><given-names>CA</given-names></name><name name-style="western"><surname>Castillo-Carranza</surname><given-names>DL</given-names></name><name name-style="western"><surname>Sengupta</surname><given-names>U</given-names></name><name name-style="western"><surname>Guerrero-Munoz</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Kiritoshi</surname><given-names>T</given-names></name><name name-style="western"><surname>Neugebauer</surname><given-names>V</given-names></name><etal/></person-group><article-title>Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau</article-title><source>Sci Rep</source><year>2012</year><volume>2</volume><fpage>700</fpage><pub-id pub-id-type="doi">10.1038/srep00700</pub-id><pub-id pub-id-type="pmid">23050084</pub-id><pub-id pub-id-type="pmcid">PMC3463004</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, Neugebauer V, et al. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep. 2012;2:700. 10.1038/srep00700.<pub-id pub-id-type="pmid">23050084</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep00700</pub-id><pub-id pub-id-type="pmcid">PMC3463004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghag</surname><given-names>G</given-names></name><name name-style="western"><surname>Bhatt</surname><given-names>N</given-names></name><name name-style="western"><surname>Cantu</surname><given-names>DV</given-names></name><name name-style="western"><surname>Guerrero-Munoz</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Ellsworth</surname><given-names>A</given-names></name><name name-style="western"><surname>Sengupta</surname><given-names>U</given-names></name><etal/></person-group><article-title>Soluble tau aggregates, not large fibrils, are the toxic species that display seeding and cross-seeding behavior</article-title><source>Protein Sci</source><year>2018</year><volume>27</volume><issue>11</issue><fpage>1901</fpage><lpage>1909</lpage><pub-id pub-id-type="doi">10.1002/pro.3499</pub-id><pub-id pub-id-type="pmid">30125425</pub-id><pub-id pub-id-type="pmcid">PMC6201727</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Ghag G, Bhatt N, Cantu DV, Guerrero-Munoz MJ, Ellsworth A, Sengupta U, et al. Soluble tau aggregates, not large fibrils, are the toxic species that display seeding and cross-seeding behavior. Protein Sci. 2018;27(11):1901&#8211;9. 10.1002/pro.3499.<pub-id pub-id-type="pmid">30125425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pro.3499</pub-id><pub-id pub-id-type="pmcid">PMC6201727</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devous</surname><given-names>MD</given-names><suffix>Sr</suffix></name><name name-style="western"><surname>Fleisher</surname><given-names>AS</given-names></name><name name-style="western"><surname>Pontecorvo</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M</given-names></name><name name-style="western"><surname>Siderowf</surname><given-names>A</given-names></name><name name-style="western"><surname>Navitsky</surname><given-names>M</given-names></name><etal/></person-group><article-title>Relationships Between Cognition and Neuropathological Tau in Alzheimer's Disease Assessed by 18F Flortaucipir PET</article-title><source>J Alzheimers Dis</source><year>2021</year><volume>80</volume><issue>3</issue><fpage>1091</fpage><lpage>1104</lpage><pub-id pub-id-type="doi">10.3233/JAD-200808</pub-id><pub-id pub-id-type="pmid">33682705</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Devous MD Sr, Fleisher AS, Pontecorvo MJ, Lu M, Siderowf A, Navitsky M, et al. Relationships between cognition and neuropathological Tau in Alzheimer&#8217;s disease assessed by 18F Flortaucipir PET. J Alzheimers Dis. 2021;80(3):1091&#8211;104. 10.3233/JAD-200808.<pub-id pub-id-type="pmid">33682705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-200808</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreira</surname><given-names>GG</given-names></name><name name-style="western"><surname>Cantrelle</surname><given-names>FX</given-names></name><name name-style="western"><surname>Quezada</surname><given-names>A</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>FS</given-names></name><name name-style="western"><surname>Cristovao</surname><given-names>JS</given-names></name><name name-style="western"><surname>Sengupta</surname><given-names>U</given-names></name><etal/></person-group><article-title>Dynamic interactions and Ca(2+)-binding modulate the holdase-type chaperone activity of S100B preventing tau aggregation and seeding</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><issue>1</issue><fpage>6292</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-26584-2</pub-id><pub-id pub-id-type="pmid">34725360</pub-id><pub-id pub-id-type="pmcid">PMC8560819</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Moreira GG, Cantrelle FX, Quezada A, Carvalho FS, Cristovao JS, Sengupta U, et al. Dynamic interactions and Ca(2+)-binding modulate the holdase-type chaperone activity of S100B preventing tau aggregation and seeding. Nat Commun. 2021;12(1):6292. 10.1038/s41467-021-26584-2.<pub-id pub-id-type="pmid">34725360</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-26584-2</pub-id><pub-id pub-id-type="pmcid">PMC8560819</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mok</surname><given-names>SA</given-names></name><name name-style="western"><surname>Condello</surname><given-names>C</given-names></name><name name-style="western"><surname>Freilich</surname><given-names>R</given-names></name><name name-style="western"><surname>Gillies</surname><given-names>A</given-names></name><name name-style="western"><surname>Arhar</surname><given-names>T</given-names></name><name name-style="western"><surname>Oroz</surname><given-names>J</given-names></name><etal/></person-group><article-title>Mapping interactions with the chaperone network reveals factors that protect against tau aggregation</article-title><source>Nat Struct Mol Biol</source><year>2018</year><volume>25</volume><issue>5</issue><fpage>384</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1038/s41594-018-0057-1</pub-id><pub-id pub-id-type="pmid">29728653</pub-id><pub-id pub-id-type="pmcid">PMC5942583</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Mok SA, Condello C, Freilich R, Gillies A, Arhar T, Oroz J, et al. Mapping interactions with the chaperone network reveals factors that protect against tau aggregation. Nat Struct Mol Biol. 2018;25(5):384&#8211;93. 10.1038/s41594-018-0057-1.<pub-id pub-id-type="pmid">29728653</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41594-018-0057-1</pub-id><pub-id pub-id-type="pmcid">PMC5942583</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Danis</surname><given-names>C</given-names></name><name name-style="western"><surname>Dupre</surname><given-names>E</given-names></name><name name-style="western"><surname>Bouillet</surname><given-names>T</given-names></name><name name-style="western"><surname>Denechaud</surname><given-names>M</given-names></name><name name-style="western"><surname>Lefebvre</surname><given-names>C</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Inhibition of tau neuronal internalization using anti-tau single domain antibodies</article-title><source>Nat Commun</source><year>2025</year><volume>16</volume><issue>1</issue><fpage>3162</fpage><pub-id pub-id-type="doi">10.1038/s41467-025-58383-4</pub-id><pub-id pub-id-type="pmid">40175345</pub-id><pub-id pub-id-type="pmcid">PMC11965310</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Danis C, Dupre E, Bouillet T, Denechaud M, Lefebvre C, Nguyen M, et al. Inhibition of tau neuronal internalization using anti-tau single domain antibodies. Nat Commun. 2025;16(1):3162. 10.1038/s41467-025-58383-4.<pub-id pub-id-type="pmid">40175345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-025-58383-4</pub-id><pub-id pub-id-type="pmcid">PMC11965310</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mortelecque</surname><given-names>J</given-names></name><name name-style="western"><surname>Zejneli</surname><given-names>O</given-names></name><name name-style="western"><surname>Begard</surname><given-names>S</given-names></name><name name-style="western"><surname>Simoes</surname><given-names>MC</given-names></name><name name-style="western"><surname>ElHajjar</surname><given-names>L</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>M</given-names></name><etal/></person-group><article-title>A selection and optimization strategy for single-domain antibodies targeting the PHF6 linear peptide within the tau intrinsically disordered protein</article-title><source>J Biol Chem</source><year>2024</year><volume>300</volume><issue>4</issue><fpage>107163</fpage><pub-id pub-id-type="doi">10.1016/j.jbc.2024.107163</pub-id><pub-id pub-id-type="pmid">38484799</pub-id><pub-id pub-id-type="pmcid">PMC11007443</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Mortelecque J, Zejneli O, Begard S, Simoes MC, ElHajjar L, Nguyen M, et al. A selection and optimization strategy for single-domain antibodies targeting the PHF6 linear peptide within the tau intrinsically disordered protein. J Biol Chem. 2024;300(4): 107163. 10.1016/j.jbc.2024.107163.<pub-id pub-id-type="pmid">38484799</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbc.2024.107163</pub-id><pub-id pub-id-type="pmcid">PMC11007443</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><mixed-citation publication-type="other">Caillierez R, Begard S, Lecolle K, Deramecourt V, Zommer N, Dujardin S, et al. Lentiviral Delivery of the Human Wild-type Tau Protein Mediates a Slow and Progressive Neurodegenerative Tau Pathology in the Rat Brain. Mol Ther. 2013;21(7):1358-68. 10.1038/mt.2013.66.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mt.2013.66</pub-id><pub-id pub-id-type="pmcid">PMC3702115</pub-id><pub-id pub-id-type="pmid">23609018</pub-id></mixed-citation></ref><ref id="CR81"><label>81.</label><mixed-citation publication-type="other">Tucker KL, Meyer M, Barde YA. Neurotrophins are required for nerve growth during development. Nat Neurosci. 2001;4(1):29-37. 10.1038/82868.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/82868</pub-id><pub-id pub-id-type="pmid">11135642</pub-id></mixed-citation></ref><ref id="CR82"><label>82.</label><mixed-citation publication-type="other">Dujardin S, Begard S, Caillierez R, Lachaud C, Delattre L, Carrier S, et al. Ectosomes: a new mechanism for non-exosomal secretion of tau protein. PLoS One. 2014;9(6):e100760. 10.1371/journal.pone.0100760.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0100760</pub-id><pub-id pub-id-type="pmcid">PMC4074092</pub-id><pub-id pub-id-type="pmid">24971751</pub-id></mixed-citation></ref><ref id="CR83"><label>83.</label><mixed-citation publication-type="other">Perbet R, Zufferey V, Leroux E, Parietti E, Espourteille J, Culebras L, et al. Tau Transfer via Extracellular Vesicles Disturbs the Astrocytic Mitochondrial System. Cells. 2023;12(7). 10.3390/cells12070985.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells12070985</pub-id><pub-id pub-id-type="pmcid">PMC10093208</pub-id><pub-id pub-id-type="pmid">37048058</pub-id></mixed-citation></ref><ref id="CR84"><label>84.</label><mixed-citation publication-type="other">McEwen E, Kedersha N, Song B, Scheuner D, Gilks N, Han A, et al. Heme-regulated inhibitor kinase-mediated phosphorylation of eukaryotic translation initiation factor 2 inhibits translation, induces stress granule formation, and mediates survival upon arsenite exposure. J Biol Chem. 2005;280(17):16925-33. 10.1074/jbc.M412882200.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M412882200</pub-id><pub-id pub-id-type="pmid">15684421</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">1524</journal-id><journal-id journal-id-type="pmc-domain">frontpharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12504301</article-id><article-id pub-id-type="pmcid-ver">PMC12504301.1</article-id><article-id pub-id-type="pmcaid">12504301</article-id><article-id pub-id-type="pmcaiid">12504301</article-id><article-id pub-id-type="doi">10.3389/fphar.2025.1665715</article-id><article-id pub-id-type="publisher-id">1665715</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Beta-amyloid influences the content and trafficking of beta-amyloid precursor protein via Na,K-ATPase-Src kinase positive feedback loop</article-title><alt-title alt-title-type="left-running-head">Petrushanko et al.</alt-title><alt-title alt-title-type="right-running-head"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.3389/fphar.2025.1665715" ext-link-type="uri">10.3389/fphar.2025.1665715</ext-link></alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name name-style="western"><surname>Petrushanko</surname><given-names initials="IY">Irina Y.</given-names></name><xref rid="c001" ref-type="corresp">*</xref><xref rid="fn001" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/355525/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Lisitskii</surname><given-names initials="DR">Denis R.</given-names></name><xref rid="fn001" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2902980/overview"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Filonov</surname><given-names initials="FA">Filipp A.</given-names></name><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3210948/overview"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Leonova</surname><given-names initials="OG">Olga G.</given-names></name><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3210977/overview"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mitkevich</surname><given-names initials="VA">Vladimir A.</given-names></name><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/416494/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Strelkova</surname><given-names initials="MA">Maria A.</given-names></name><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2888583/overview"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Makarov</surname><given-names initials="AA">Alexander A.</given-names></name><xref rid="c001" ref-type="corresp">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/137313/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib></contrib-group><aff>
<institution>Engelhardt Institute of Molecular Biology Russian Academy of Sciences</institution>, <addr-line>Moscow</addr-line>, <country>Russia</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2738064/overview" ext-link-type="uri">Alexei Bagrov</ext-link>, Padakonn Pharma, Estonia</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1223563/overview" ext-link-type="uri">Rub&#233;n G. Contreras</ext-link>, National Polytechnic Institute of Mexico (CINVESTAV), Mexico</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3141507/overview" ext-link-type="uri">Irina Romanova</ext-link>, Sechenov Institute of Evolutionary Physiology and Biochemistry, Russia</p></fn><corresp id="c001">*Correspondence: Irina Yu Petrushanko, <email>irina-pva@mail.ru</email>; Alexander A. Makarov, <email>aamakarov@eimb.ru</email></corresp><fn fn-type="equal" id="fn001"><label>
<sup>&#8224;</sup>
</label><p>These authors have contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>24</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">480654</issue-id><elocation-id>1665715</elocation-id><history><date date-type="received"><day>14</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>08</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Petrushanko, Lisitskii, Filonov, Leonova, Mitkevich, Strelkova and Makarov.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Petrushanko, Lisitskii, Filonov, Leonova, Mitkevich, Strelkova and Makarov</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fphar-16-1665715.pdf"/><abstract><p>Beta-amyloid (A&#946;) is an important factor in the development of pathology in Alzheimer&#8217;s disease. Level of beta-amyloid precursor protein (APP) is increased in neurites with age and in Alzheimer&#8217;s disease model mice. However, it is unclear whether A&#946; can affect APP levels in cells. The aim of this study was to evaluate the effect of A&#946; on the level and trafficking of APP in human neuroblastoma cells and to identify the role of cardiotonic steroid (CTS) ouabain in this process. Western blot analysis revealed that 30-min incubation of the cells with 100&#160;nM&#160;A&#946; increased APP levels by 75%. Confocal microscopy showed that A&#946; alters APP trafficking, promoting its movement into neurites. This effect establishes a positive feedback loop that accelerates A&#946; formation in neurites. The rise in APP was associated with Src kinase activation triggered by A&#946; binding to Na,K-ATPase. Notably, Src kinase inhibition completely blocked the A&#946;-induced increase in APP, indicating that beta-amyloid effect on APP is mediated by Src kinase activation. Furthermore, 100&#160;nM CTS ouabain, a specific Na,K-ATPase ligand, significantly decreased A&#946;&#8242;s impact on APP and Src kinase activation. Given that CTS are naturally present in the human body, these findings are important for developing therapeutic strategies to counteract A&#946;-driven APP accumulation and for understanding the role of endogenous CTS in regulating A&#946; formation.</p></abstract><kwd-group><kwd>beta-amyloid</kwd><kwd>APP</kwd><kwd>Src kinase</kwd><kwd>ouabain</kwd><kwd>APP trafficking</kwd><kwd>Na,K-ATPase</kwd></kwd-group><funding-group><award-group><funding-source id="cn001"><institution-wrap><institution>Russian Science Foundation
</institution><institution-id institution-id-type="doi">10.13039/501100006769</institution-id></institution-wrap></funding-source><award-id award-type="contract" rid="cn001">This research was funded by Russian Science Foundation grant #19-74-30007.</award-id></award-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This research was funded by Russian Science Foundation grant #19-74-30007.</funding-statement></funding-group><counts><page-count count="10"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Pharmacology of Ion Channels and Channelopathies</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Beta-amyloid peptide (A&#946;), and mutations that lead to its accelerated oligomerization are the key to the onset of Alzheimer&#8217;s disease (AD), one of the most common neurodegenerative diseases (<xref rid="B32" ref-type="bibr">Prusiner, 2012</xref>; <xref rid="B13" ref-type="bibr">Jucker and Walker, 2013</xref>; <xref rid="B20" ref-type="bibr">Ma et al., 2022</xref>). This disease leads to synapse loss, neuronal dysfunction and death, causing progressive dementia accompanied by the formation of amyloid plaques in the brain (<xref rid="B18" ref-type="bibr">Lane et al., 2018</xref>). The risk of the emergence of AD increases with age (<xref rid="B4" ref-type="bibr">Burrinha and Guimas Almeida, 2022</xref>).</p><p>A&#946; is produced from beta-amyloid precursor protein (APP) by &#946;-site APP-cleaving enzyme 1 (BACE1) and gamma-secretase (<xref rid="B26" ref-type="bibr">Orobets and Karamyshev, 2023</xref>). Membrane trafficking of APP and BACE 1 determines the probability of their contact and consequently the rate of A&#946; production (<xref rid="B38" ref-type="bibr">Sun and Roy, 2018</xref>). In neuronal cells, the interaction between APP and BACE1 has been detected in the cytoplasmic membrane, endoplasmic reticulum (ER), trans-Golgi network, and endosomes (<xref rid="B38" ref-type="bibr">Sun and Roy, 2018</xref>). APP is represented in all parts of the neuronal cell including soma, axons, dendrites, and synaptic sites (<xref rid="B38" ref-type="bibr">Sun and Roy, 2018</xref>). From the trans-Golgi network, APP is transported to the cytoplasmic membrane (<xref rid="B22" ref-type="bibr">M&#252;ller et al., 2017</xref>), where it is processed through either a non-amyloidogenic pathway, which leads to the formation of the neuroprotective soluble APP (after cleavage by &#945;-secretase and &#947;-secretase) (<xref rid="B22" ref-type="bibr">M&#252;ller et al., 2017</xref>), or an amyloidogenic pathway, which results in A&#946; formation (after cleavage by BACE1 and gamma-secretase).</p><p>A&#946; is secreted pre- and postsynaptically (<xref rid="B24" ref-type="bibr">Niederst et al., 2015</xref>) and then binds to the post- or presynaptic membrane, being further captured to the cell by endocytosis. Accumulation and oligomerization of A&#946; affects synaptic plasticity (<xref rid="B27" ref-type="bibr">Perdig&#227;o et al., 2020</xref>). On the membrane surface of neuronal cells, A&#946; binds several proteins (<xref rid="B12" ref-type="bibr">Jarosz-Griffiths et al., 2016</xref>). One important target of A&#946; is Na,K-ATPase (<xref rid="B6" ref-type="bibr">Dickey et al., 2005</xref>), which creates the sodium-potassium gradient crucial for neuronal viability and functionality. In Alzheimer&#8217;s disease, a steady decrease in Na,K-ATPase activity is observed (<xref rid="B6" ref-type="bibr">Dickey et al., 2005</xref>; <xref rid="B43" ref-type="bibr">Zhang et al., 2013</xref>; <xref rid="B16" ref-type="bibr">Kreutz et al., 2013</xref>). This is caused by A&#946; binding (<xref rid="B28" ref-type="bibr">Petrushanko et al., 2016</xref>) and subsequent oligomerization on the Na,K-ATPase (<xref rid="B3" ref-type="bibr">Barykin et al., 2018</xref>). Particularly, we have previously shown that a monomer of A&#946; acts as a ligand of Na,K-ATPase that, being bound, induces the activation of Src kinase (<xref rid="B29" ref-type="bibr">Petrushanko et al., 2022</xref>). Since Src kinase, in its turn, regulates APP trafficking by phosphorylating Munc-18&#8211;1 interacting protein (Mint) (<xref rid="B8" ref-type="bibr">Dunning et al., 2016</xref>), we hypothesized (<xref rid="B29" ref-type="bibr">Petrushanko et al., 2022</xref>) that A&#946; may also influence the trafficking of its precursor protein by creating a positive feedback loop via Src kinase activation.</p><p>A&#946; accumulation has been shown in the aging brain (<xref rid="B21" ref-type="bibr">Marks et al., 2017</xref>; <xref rid="B15" ref-type="bibr">Koinuma et al., 2021</xref>; <xref rid="B41" ref-type="bibr">Welikovitch et al., 2018</xref>). Additionally, it is shown that APP processing also increases with age (<xref rid="B5" ref-type="bibr">Burrinha et al., 2021</xref>). Presumably, this happens due to altered APP trafficking in aging neurons (<xref rid="B4" ref-type="bibr">Burrinha and Guimas Almeida, 2022</xref>). In murine cortical senescent neurons, disturbed APP trafficking has been shown <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>. As a result, APP accumulates in neurites with age (<xref rid="B5" ref-type="bibr">Burrinha et al., 2021</xref>). However, until now, it has not been determined whether A&#946; can directly affect APP content and transport.</p><p>In the present study, we demonstrated on SY-SY5Y human neuroblastoma cells that A&#946;<sub>42</sub> leads to an increase in the total level of APP and its accumulation in the neurites of the cells. Since cardiotonic steroid ouabain is a specific ligand of Na,K-ATPase (<xref rid="B34" ref-type="bibr">Schatzmann, 1953</xref>) that is also able to induce the activation of Na,K-ATPase-associated Src kinase (for review see <xref rid="B25" ref-type="bibr">Orlov et al., 2021</xref>; <xref rid="B31" ref-type="bibr">Poluektov et al., 2025</xref>), ouabain was presumed to modulate the action of A&#946;<sub>42</sub> on Src kinase activation. Ouabain-like factor is present in cerebrospinal fluid (<xref rid="B11" ref-type="bibr">Halper&#237;n et al., 1983</xref>) and is produced directly in the brain (<xref rid="B2" ref-type="bibr">Bagrov et al., 2009</xref>). Acute binding of ouabain to Na,K-ATPase does not affect its binding to A&#946;<sub>42</sub> (<xref rid="B1" ref-type="bibr">Adzhubei et al., 2022</xref>), it is reasonable to suggest that this ligand may bind Na,K-ATPase simultaneously with A&#946;<sub>42</sub>, influencing the cellular response to A&#946;<sub>42</sub>. We characterized the effect of ouabain on A&#946;<sub>42</sub>-induced changes in APP level and proved its ability to attenuate APP accumulation induced by A&#946;<sub>42</sub>.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and methods</title><sec id="s2-1"><title>Cell line</title><p>Human neuroblastoma cell line SH-SY5Y obtained from the American Type Culture Collection was cultured in RPMI-1640 medium (Gibco, ThermoFisher Scientific, Waltham, MA, United States), containing 10% fetal bovine serum (FBS; Gibco, ThermoFisher Scientific, MA, United States), 100 units/mL penicillin, 100&#160;&#956;g/mL streptomycin, pyruvate and glutamax (Gibco, ThermoFisher Scientific, Waltham, MA, United States). Culture maintenance was performed in cultural flasks T-25 and T-75&#160;at 37&#160;&#176;C in humid atmosphere, containing 5% CO<sub>2</sub>. SH-SY5Y cells were dissociated via washing with Versene solution (Gibco, ThermoFisher Scientific, Waltham, MA, United States) and 0.05% trypsin-EDTA (Gibco, ThermoFisher Scientific, Waltham, MA, United States) digestion at 37&#160;&#176;C during 5&#160;min. Passages did not exceed 15. For confocal microscopy cells were seeded on 35&#160;mm glass-based Petri dishes (Nunc, Rochester, NY, United States, 150680) in a quantity 15000 per dish. For Western blotting, redox parameters and Ca<sup>2+</sup> level measurements SH-SY5Y cells were grown on 6- and 12-well plates until 80%&#8211;90% confluency was achieved.</p></sec><sec id="s2-2"><title>A&#946;<sub>42</sub> preparation</title><p>Synthetic peptide A&#946;<sub>42</sub>: [H2N]-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA-[COOH] was obtained from Biopeptide (San Diego, CA, United States). Preparation of the monomeric form of A&#946;<sub>42</sub> was performed as described elsewhere. Cold hexafluoroisopropanol (Fluka) was added to dry A&#946;<sub>42</sub> until peptide concentration 1&#160;mM was achieved. After 1&#160;h incubation peptide solution was transferred on ice for 10&#160;min and aliquoted into microcentrifuge tubes (0.56&#160;mg &#1040;&#946;<sub>42</sub> per tube). Aliquots were dried under vacuum using Eppendorf Concentrator 5301. Dried peptide films were stored at &#8722;80&#160;&#176;C. 2.5&#160;mM stock solution was prepared by dissolving 0.22&#160;mg of dry peptide in 20&#160;&#956;L of 100% anhydrous DMSO (Sigma-Aldrich, St. Louis, MO, United States) and 1-h incubation. The required concentration of A&#946;<sub>42</sub> was achieved by dilution of stock solution with RPMI-1640 medium or Tyrode solution. An equivalent volume of pure DMSO was added to control probes. Only fresh-dissolved A&#946;<sub>42</sub> was used in experiments.</p></sec><sec id="s2-3"><title>A&#946;<sub>42</sub> and ouabain treatment</title><p>Incubation of SH-SY5Y cells on plates or dishes with amyloid peptide required medium replacement with FBS-free RPMI-1640. For the flow cytometry studies SH-SY5Y &#1089;ells were dissociated and suspended in Tyrode solution with following staining before incubations with ouabain and A&#946;<sub>42</sub>. A&#946;<sub>42</sub> stock solution was diluted and added to samples in final concentration 100&#160;nM. Beta-amyloid effects was studied by SH-SY5Y incubation for 30&#160;min. Influence of ouabain or Src kinase inhibitor 1 (SRCI1) was estimated by pre-treatment with single compounds for 30&#160;min before adding of A&#946;<sub>42</sub> solution. Ouabain (Fluka) was used in 100&#160;nM concentration, SRCI1 &#8211; 10&#160;&#956;M. All incubations were performed at 37&#160;&#176;C in humid atmosphere, containing 5% CO<sub>2</sub>.</p></sec><sec id="s2-4"><title>Amyloid precursor protein distribution studies</title><p>SH-SY5Y cells were cultured on Petri dishes until 50% confluency was achieved. Medium was replaced with FBS-free RPMI-1640 and cells were incubated with 100&#160;nM&#160;A&#946;<sub>42</sub> during 15&#8211;240&#160;min. For each time point own control without addition of A&#946;<sub>42</sub> was performed. As incubations ended cells were washed with ice-cold Ca<sup>2+</sup>/Mg<sup>2+</sup> PBS and fixed in 4% para-formaldehyde solution for 10&#160;min. At the end of fixation cells were washed with Ca<sup>2+</sup>/Mg<sup>2+</sup> PBS and treated with monoclonal rabbit antibodies against N-terminal extracellular domain of amyloid precursor protein (dilution in PBS to the concentration 3.84&#160;&#956;g/mL, Abcam Limited, Discovery Drive, Cambridge Biomedical Campus, Cambridge, United Kingdom, ab126732) at 4&#160;&#176;C overnight. Next day, samples were washed with Ca<sup>2+</sup>/Mg<sup>2+</sup> PBS and incubated for 2&#160;h at room temperature with secondary antibodies, conjugated with AlexaFluor<sup>&#174;</sup> 488 (Ex/Em = 495/519&#160;nm, dilution in PBS to the concentration 4&#160;&#956;g/mL, Abcam Limited, Discovery Drive, Cambridge Biomedical Campus, Cambridge, United Kingdom, ab150077). Before the imaging nuclei were stained with NucBlue&#8482; (Hoechst 33342) (Ex/Em = 360/460, Invitrogen, ThermoFisher Scientific, MA, United States, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="R37605">R37605</ext-link>) in accordance with the manufacturer&#8217;s protocol.</p></sec><sec id="s2-5"><title>Laser scanning confocal microscopy</title><p>The attached and stained SH-SY5Y cells in the 35&#160;mm glass-based Petri dishes were covered with Ca<sup>2+</sup>/Mg<sup>2+</sup> PBS and imaged using a confocal microscope Leica TCS SP5 (Leica, Wetzlar, Germany). APP was labeled with AlexaFluor<sup>&#174;</sup> 488-conjugated antibodies and imaged using a 488&#160;nm argon laser. Nuclei were stained with NucBlue&#8482; (Hoechst 33342) and visualized with 405&#160;nm diode laser. The resulting images were analyzed using LAS X imaging software (Leica, Wetzlar, Germany). Received images were analyzed using ImageJ 1.54&#160;g (Wayne Rasband and contributors, National Institutes of health, United States). The fluorescence ratio between neurites and cell bodies was calculated, value of every single time measurement was normalized to control with the same time of incubation.</p></sec><sec id="s2-6"><title>Estimation of APP levels and Src kinase activation</title><p>Cells were grown on 6- and 12-well plates until 80%&#8211;90% confluency was achieved. Medium was replaced with FBS-free RPMI-1640 and cells were incubated with A&#946;<sub>42</sub>, cardiotonic steroids and Src kinase inhibitor 1. After the ending of incubation wells were washed with Ca<sup>2+</sup>/Mg<sup>2+</sup> PBS and cells were lysed with RIPA-buffer (ThermoFisher Scientific, Waltham, MA, United States, 89900), containing protease inhibitors cocktail (Roche, 11836145001), phosphatase inhibitors cocktail (Roche, 4906837001), 0.2&#160;mM PMSF and 5&#160;&#956;M thiorphan (Cayman Chemical, Ann Arbor, MI, United States, 15600), with stirring for an hour at 4&#160;&#176;C. Lysates were centrifuged at 4&#160;&#176;C and 16000&#160;g for 10&#160;min and supernatants were collected.</p><p>The cell lysates were separated via 10% SDS-PAGE electrophoresis and transferred to a PVDF-membrane (Bio-Rad, Hercules, CA, United States, 1620137). Membranes were blocked in 5% nonfat milk in TBST (50&#160;mM Tis-HCl, pH 7.4, 150&#160;mM NaCl, 0.1% Tween-20) for an hour and were incubated with monoclonal primary rabbit antibodies specific to APP (dilution in 5% milk-TBST to the concentration 76,8&#160;ng/mL, Abcam Limited, Discovery Drive, Cambridge Biomedical Campus, Cambridge, United Kingdom, ab32136), &#946;-actin (dilution in TBST to the concentration 60&#160;ng/mL, Abcam Limited, Discovery Drive, Cambridge Biomedical Campus, Cambridge, United Kingdom, ab8227), Src kinase (dilution in 5% milk-TBST to the concentration 67&#160;ng/mL, Cell Signaling Technology, Danvers, MA, United States, 2108S) and Phospho-Src Family (Tyr416) (dilution in 5% milk-TBST to the concentration 51&#160;ng/mL, Cell Signaling Technology, Danvers, MA, United States, 6943S) overnight at 4&#160;&#176;C. Then, the membranes were washed in TBST and incubated with goat anti-rabbit secondary antibodies, conjugated with HRP (dilution in TBST to the concentration 140&#160;ng/mL, HyTest, Moscow, Russia, GARC). Imaging of the membranes was performed using SuperSignal&#8482; West Femto Maximum Sensitivity Substrate kit (ThermoFisher Scientific, MA, United States, 34096) and Bio-Rad ChemiDoc MP instrument (Bio-Rad, Hercules, CA, United States). Densitometric analysis was performed with Image Lab 6.0.1 program (Bio-Rad, Hercules, CA, United States). Results were expressed as APP levels, normalized on that in control (APP, %), or phospho-Src/Src ratio (p-Src/Src, fold change).</p></sec><sec id="s2-7"><title>Assessment of Ca<sup>2+</sup> levels, mitochondrial potential and redox status of the cells</title><p>SH-SY5Y cells were grown on 12-well plates at 37&#160;&#176;C in humid atmosphere, containing 5% CO<sub>2</sub>, and suspended in Tyrode solution after achieving 80%&#8211;90% confluency. Then, suspensions from every well were divided into two parts, every sample was stained simultaneously with GSH- and Ca<sup>2+</sup>-specific or ROS- and mitochondrial membrane potential-specific dyes. The ROS level was assessed using the dihydrorodamine 123 (DHR) dye (Ex/Em = 488/525&#160;nm; Invitrogen, ThermoFisher Scientific, MA, United States, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="D23806">D23806</ext-link>, used in a concentration 5&#160;&#956;M). Assessment of the Ca<sup>2+</sup> level was performed by staining with fluo-4, AM (Ex/Em = 494/506&#160;nm; Invitrogen, ThermoFisher Scientific, MA, United States, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F14201">F14201</ext-link>). The monobromobimane dye (Ex/Em = 393/490&#160;nm, Sigma-Aldrich, St. Louis, MO, B4380, used in a concentration 20&#160;&#956;M) was used for the reduced glutathione (GSH) staining. The mitochondrial potential was assessed using the MitoProbe&#8482; DiIC1(5) Assay Kit (Ex/Em = 638/658&#160;nm; Invitrogen, ThermoFisher Scientific, MA, United States, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="M34151">M34151</ext-link>, used in a concentration 50&#160;nM). All parameters were recorded for the cells with intact membrane. The dyes were incubated at 37&#160;&#176;C for 30&#160;min. Detection of the cells with damaged membrane (dead cells) was performed by staining with propidium iodide (PI) (Ex/Em = 535/617&#160;nm, Sigma-Aldrich, St. Louis, MO, P4170, used in a concentration 10&#160;&#956;g/mL) 1&#160;minute before measurement. When assessing the levels of ROS, GSH and mitochondrial potential, dead cells were excluded from consideration. The cells were analyzed using a flow cytometer BD LSR Fortessa (Becton Dickinson, Franklin Lakes, NJ, United States).</p></sec><sec id="s2-8"><title>Statistical analysis</title><p>All experimental data are shown as mean values &#177; standard deviations of mean (SD), with the number of independent experiments (n) indicated in Figure legends. The statistical difference between experimental groups was analyzed by one-way ANOVA with Tukey correction for multiple comparisons. Probability values (p) less than 0.05 were considered significant. Statistical analysis was performed using GraphPad Prism 9.1.2 software (GraphPad Software Inc., San Diego, CA, United States).</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3-1"><title>&#1040;&#946;<sub>42</sub> increases APP level and alters its distribution in SH-SY5Y cells</title><p>Western blot analysis revealed that 30-min of incubation with 100&#160;nM &#1040;&#946;<sub>42</sub> causes significant increase in APP level in SH-SY-5Y cells by 75% (<xref rid="F1" ref-type="fig">Figures 1A,B</xref>). Using confocal microscopy, we evaluated the change of fluorescence level in neurites relative to the cell body after 15, 30&#160;min, 1, 2 and 4&#160;h of incubation with 100&#160;nM&#160;A&#946;<sub>42</sub> (<xref rid="F1" ref-type="fig">Figures 1C,D</xref>). In cells untreated with primary antibodies to APP signal was not detected (<xref rid="s11" ref-type="sec">Supplementary Figure S1</xref>). Relative fluorescence in neurites after 1&#160;hour of incubation is higher than after 15&#160;min of incubation with A&#946;<sub>42</sub>. After 2&#160;h of A&#946;<sub>42</sub> exposure, the relative fluorescence is significantly increased compared to the control cells. After 4&#160;h, the relative fluorescence in neurites already exceeds this value in the control cells by 1.5 times. All in all, &#1040;&#946;<sub>42</sub> induces the increase in APP level and its latter accumulation on the surface of neurites.</p><fig position="float" id="F1" orientation="portrait"><label>FIGURE 1</label><caption><p>Effect of A&#946;<sub>42</sub> on APP expression and distribution in SH-SY5Y cells. <bold>(A,B)</bold> APP level is increased in presence of 100&#160;nM&#160;A&#946;<sub>42</sub>. For each lane, the APP (&#8764;120&#160;kDa) signal was normalized to actin (&#8764;40&#160;kDa). APP levels were measured by Western blot analysis of lysates of human neuroblastoma SH-SY5Y cells treated with 100&#160;nM&#160;A&#946;<sub>42</sub> for 30&#160;min. Full-size Western blot membranes, from which the bar plots were calculated, are provided in the Supplementary. Mean values &#177; SD from at least three independent experiments are shown. <bold>(C,D)</bold> Localization of amyloid precursor protein in SH-SY5Y cells incubated with 100&#160;nM&#160;A&#946;<sub>42</sub>. APP was labeled with AlexaFluor<sup>&#174;</sup> 488-conjugated antibodies and is indicated by green color, nuclei are stained with NucBlue (Hoechst 33342) and indicated by blue color. For each incubation time, the ratio of fluorescence in neurites and cell bodies was calculated, and the values were normalized to the control. Mean values &#177;SD, n = 3 from at least three independent fields are shown. * &#8211; p &lt; 0.05, ** &#8211; p &lt; 0.01, *** &#8211; p &lt; 0.001 compared to the control.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-16-1665715-g001.jpg"><alt-text content-type="machine-generated">Western blot and graphs demonstrating APP expression changes. (A) Western blot showing APP and Actin levels in control and A&#946;42-treated samples. (B) Bar graph displaying APP percentage increase in A&#946;42 versus control, marked with three asterisks indicating significance. (C) Bar graph of relative intensity at different time points post-treatment, with significance denoted by asterisks. (D) Panels of immunofluorescence images showing APP (green) and DAPI (blue) staining over various time intervals post-treatment, demonstrating APP localization and intensity changes. Scale bars are visible in the images.</alt-text></graphic></fig></sec><sec id="s3-2"><title>Src kinase mediates A&#946;<sub>42</sub>-dependent APP accumulation in a redox-independent way</title><p>According to the data obtained in our previous studies (<xref rid="B29" ref-type="bibr">Petrushanko et al., 2022</xref>), A&#946;<sub>42</sub> induces Src kinase activation in SH-SY5Y cells. Treatment by100&#160;nM&#160;A&#946;<sub>42</sub> increased APP level in cells by 75%, whereas 10&#160;&#956;M Src inhibitor (SRCI1) pre-treatment completely prevented this effect (<xref rid="F2" ref-type="fig">Figures 2A,B</xref>). Notably, the inhibitor itself did not affect APP accumulation. Src kinase activation in these probes was evaluated as a ratio of phosphorylated at Y419 Src kinase (p-Src) to total Src kinase signals. SRCI1 decreases Src activation in cells and prevents its growth after A&#946;<sub>42</sub> treatment (<xref rid="F2" ref-type="fig">Figures 2C,D</xref>). The obtained data show that Src kinase activation has a crucial role in the A&#946;<sub>42</sub>-mediated gain of APP accumulation.</p><fig position="float" id="F2" orientation="portrait"><label>FIGURE 2</label><caption><p>Inhibition of Src by SRCI1 prevents amyloid-mediated increase of APP level but does not affect GSH level decrease induced by A&#946;<sub>42</sub>. <bold>(A,B)</bold> Impact of A&#946;<sub>42</sub>, SRCI1 and A&#946;<sub>42</sub> after SRCI1 pre-treatment on APP expression. The APP (&#8764;120&#160;kDa) to actin (&#8764;40&#160;kDa) ratio has been calculated for every single band. Mean values &#177; SD from at least three independent experiments are shown. <bold>(C,D)</bold> Dependence of Src kinase activation on the presence of A&#946;<sub>42</sub> and/or SRCI1. The ratio of phospho (Tyr)-416 Src to the total Src (&#8764;60&#160;kDa) has been calculated. The APP, phosphorylated and total Src levels were measured with Western blot in SH-SY5Y human neuroblastoma cells treated with 100&#160;nM&#160;A&#946;<sub>42</sub>, 10&#160;&#181;M SRCI1 or both for 30&#160;min and normalized for control. Mean values &#177; SD, n = 3-4 are shown. <bold>(E)</bold> Reduced glutathione alteration in a presence of A&#946;<sub>42</sub>, Src kinase inhibitor 1 and both. The SH-SY5Y human neuroblastoma cells were harvested and stained with monobromobimane for GSH measurements and incubated with 100&#160;nM&#160;A&#946;<sub>42</sub> and, if required, 10&#160;&#181;M SRCI1 for 30&#160;min. Full-size Western blot membranes, from which the bar plots were calculated, are provided in the Supplementary. Mean values &#177; SD, n = 3-4 are shown. * &#8211; p &lt; 0.05, ** &#8211; p &lt; 0.01, *** &#8211; p &lt; 0.001 compared to the control.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-16-1665715-g002.jpg"><alt-text content-type="machine-generated">Western blot and bar graphs showing protein and biochemical changes in four conditions: Control, A&#946;&#8324;&#8322;, SRCI1 (Src inhibitor), and SRCI1 + A&#946;&#8324;&#8322;. Panel A displays APP and Actin levels; B compares APP percentage, highlighting increases in A&#946;&#8324;&#8322; group compare with Control, SRCI1, and SRCI1 + A&#946;&#8324;&#8322; groups with significant differences. Panel C shows Src and p-Src levels; D compares p-Src/Src fold change, with increases in A&#946;&#8324;&#8322; group and significant reductions in SRCI1 and SRCI1+A&#946;&#8324;&#8322; groups. Panel E indicates GSH levels, showing a decrease in A&#946;&#8324;&#8322; with significant differences. All significant differences are marked by asterisks. Bars represent mean &#177; standard deviation.</alt-text></graphic></fig><p>Earlier, we demonstrated that incubation with A&#946;<sub>42</sub> during 30&#160;min declines GSH and ROS levels in SH-SY5Y cells (<xref rid="B29" ref-type="bibr">Petrushanko et al., 2022</xref>). This change in redox status is not associated with changes in calcium and mitochondrial potential (<xref rid="s11" ref-type="sec">Supplementary Figure S2</xref>). To find out whether the observed change in redox status of cells is associated with Src kinase activation and altered APP trafficking, we added Src kinase inhibitor to the cells that were further exposed to &#1040;&#946;<sub>42</sub>, and evaluated whether the inhibition of Src kinase affected the A&#946;<sub>42</sub> -induced changes in GSH (<xref rid="F2" ref-type="fig">Figure 2E</xref>). The 30-min pre-treatment with 10&#160;mM SRCI1 before exposing to 100&#160;nM&#160;A&#946;<sub>42</sub> does not prevent A&#946;<sub>42</sub>-induced changes in GSH levels, suggesting that the reduced glutathione decrease in the presence of &#1040;&#946;<sub>42</sub> is achieved by mechanisms that do not imply Src kinase activation. Also, it does not change the effect of A&#946;<sub>42</sub> on ROS level (<xref rid="s11" ref-type="sec">Supplementary Figure S3</xref>). Therefore, A&#946;<sub>42</sub>-induced increase in APP level does not depend on the redox status of cells.</p></sec><sec id="s3-3"><title>Ouabain diminishes A&#946;<sub>42</sub>-mediated amplification of APP level</title><p>Activation of Src kinase is induced by the interaction of A&#946;<sub>42</sub> with Na,K-ATPase (<xref rid="B29" ref-type="bibr">Petrushanko et al., 2022</xref>). Earlier, we demonstrated that CTS ouabain binding to Na,K-ATPase does not affect its binding to A&#946;<sub>42</sub> (<xref rid="B1" ref-type="bibr">Adzhubei et al., 2022</xref>). Therefore, we presumed that ouabain can modulate effects caused by &#1040;&#946;<sub>42</sub> via Na,K-ATPase. To study the potential ability of ouabain to modulate the effect of A&#946;<sub>42</sub> on neuronal cells, we performed a series of experiments with 100&#160;nM ouabain, which is equimolar to A&#946;<sub>42</sub>. At this concentration, ouabain does not exert a toxic effect on the cells (<xref rid="s11" ref-type="sec">Supplementary Figure S4</xref>).</p><p>Treatment of cells with 100&#160;nM ouabain for 30&#160;min does not alter APP accumulation (<xref rid="F3" ref-type="fig">Figures 3A,B</xref>). Adding of A&#946;<sub>42</sub> after ouabain pre-treatment prevents the A&#946;<sub>42-</sub> induced increase in APP level (<xref rid="F3" ref-type="fig">Figures 3A,B</xref>). Thereby, ouabain blocks the effect of A&#946;<sub>42</sub> on APP level and prevents the accumulation of APP in SH-SY5Y cells.</p><fig position="float" id="F3" orientation="portrait"><label>FIGURE 3</label><caption><p>Effect of ouabain and A&#946;<sub>42</sub> on the APP level and Src kinase activation. <bold>(A,B)</bold> Impact of A&#946;<sub>42</sub>, ouabain (OU) and A&#946;<sub>42</sub> after ouabain pre-treatment on APP level. The APP (&#8764;120&#160;kDa) to actin (&#8764;40&#160;kDa) ratio has been calculated for every single membrane. Full-size Western blot membranes, from which the bar plots were calculated, are provided in the Supplementary. Mean values &#177; SD from at least three independent experiments are shown. <bold>(C,D)</bold> Dependence of Src kinase activation on the presence of A&#946;<sub>42</sub> and/or ouabain. The ratio of phospho (Tyr)-416 Src to the total Src (&#8764;60&#160;kDa) has been calculated. The APP levels and the ratio of phospho (Tyr)-416 Src to the total Src were measured with Western blot in SH-SY5Y human neuroblastoma cells treated with 100&#160;nM&#160;A&#946;<sub>42</sub>, 100&#160;nM ouabain or both for 30&#160;min and normalized for control. Full-size Western blot membranes, from which the bar plots were calculated, are provided in the Supplementary. Mean values &#177; SD, n = 3-4 are shown. *&#8212;p &lt; 0.05, **&#8212;p &lt; 0.01, ***&#8212;p &lt; 0.001 compared to the control.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-16-1665715-g003.jpg"><alt-text content-type="machine-generated">Western blot and bar graph analysis of APP and Src protein levels across different conditions. Panel A shows Western blot bands for APP and Actin under Control, A&#946;&#8324;&#8322;, OU (ouabain), and OU+A&#946;&#8324;&#8322; conditions. Panel B displays a bar graph of APP percentage, showing significant increases in A&#946;&#8324;&#8322; compared to Control, OU and OU+A&#946;&#8324;&#8322; with statistical significance marked by asterisks. Panel C shows Western blot bands for Src and phosphorylated Src (pSrc) conditions. Panel D is a bar graph depicting fold change in p-Src/Src ratio, with a significant increase in A&#946;&#8324;&#8322; group compared to Control, OU and OU+A&#946;&#8324;&#8322;.</alt-text></graphic></fig></sec><sec id="s3-4"><title>Ouabain prevents A&#946;<sub>42</sub>-induced Src kinase activation</title><p>The signaling cascade via Src kinase seems to be a key mechanism of the APP level amplification caused by A&#946;<sub>42</sub> (<xref rid="F2" ref-type="fig">Figure 2</xref>). Ouabain affects Src kinase-dependent and Src-independent signaling pathways (<xref rid="B42" ref-type="bibr">Wu et al., 2013</xref>; <xref rid="B35" ref-type="bibr">Shin et al., 2015</xref>; <xref rid="B19" ref-type="bibr">Liu and Xie, 2010</xref>). That is why we found it important to define the impact of ouabain on Src kinase activation.</p><p>30-min incubation of SH-SY5Y cells with 100&#160;nM ouabain does not induce Src kinase activation. Moreover, ouabain prevents Src activation by A&#946;<sub>42</sub> (<xref rid="F3" ref-type="fig">Figures 3C,D</xref>). These data are in a good agreement with the results described above (<xref rid="F3" ref-type="fig">Figures 3A,B</xref>).</p></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>It has been previously suggested that altered trafficking of APP in aging neurons and its accumulation in neurites with age (<xref rid="B4" ref-type="bibr">Burrinha and Guimas Almeida, 2022</xref>), accompanied by its intensified processing (<xref rid="B5" ref-type="bibr">Burrinha et al., 2021</xref>), may be responsible for the observed age-dependent increase in brain A&#946; levels (<xref rid="B21" ref-type="bibr">Marks et al., 2017</xref>; <xref rid="B15" ref-type="bibr">Koinuma et al., 2021</xref>; <xref rid="B41" ref-type="bibr">Welikovitch et al., 2018</xref>). Moreover, APP accumulation in neurites has been described in animal models of AD (<xref rid="B39" ref-type="bibr">Walton and Wang, 2009</xref>). Still, it was unclear whether a feedback loop between A&#946; and its precursor protein exists and whether increasing levels of A&#946; can influence APP protein level and trafficking.</p><p>In this study, we found that A&#946;<sub>42</sub> stimulates the increase in APP level and its accumulation in neurites in human neuroblastoma SH-SY5Y cells. As local accumulation of APP sets off its amyloidogenic procession, our findings suggest the existence of a positive feedback loop via Src-kinase activation that enhances the A&#946; formation. This observation suggests a number of implications regarding both the A&#946; accumulation itself and the dysregulation of APP-mediated signaling cascades. First of all, pre- and postsynaptic secretion of A&#946; (<xref rid="B24" ref-type="bibr">Niederst et al., 2015</xref>) can lead to its accumulation, oligomerization and impaired synaptic plasticity (<xref rid="B27" ref-type="bibr">Perdig&#227;o et al., 2020</xref>). The positive feedback loop between A&#946; and APP may serve as a signal amplifier in active synapses and increase the risk of A&#946; aggregation in synapses that overproduced it. In turn, it is known that, being accumulated in neuronal terminals, APP affects vesicle coupling to kinesin-I, reducing axonal transport (<xref rid="B37" ref-type="bibr">Stokin et al., 2005</xref>). Thus, the A&#946;-induced accumulation of APP possibly reduces the efficiency of kinesin-I-mediated axonal transport.</p><p>It is important to denote the pattern of A&#946;<sub>42</sub>-induced APP accumulation. According to our data, the total APP content in cells is increased after 30&#160;min of A&#946;<sub>42</sub> exposure, followed by a steady relocation to neurites. The increase of APP level in neurites develops over time and indicates alterations in APP trafficking.</p><p>Earlier, we demonstrated that incubation of SH-SY5Y cells with 100&#160;nM&#160;A&#946;<sub>42</sub> results in rapid (within 30&#160;min) activation of Na,K-ATPase-associated Src kinase via A&#946;<sub>42</sub> binding to Na,K-ATPase (<xref rid="B29" ref-type="bibr">Petrushanko et al., 2022</xref>) and does not change Na,K-ATPase activity. We hypothesized that Src kinase may be involved in the regulation of APP trafficking (<xref rid="B29" ref-type="bibr">Petrushanko et al., 2022</xref>). This hypothesis was confirmed using a Src kinase inhibitor, which completely prevented &#1040;&#946;-mediated upregulation of APP (<xref rid="F2" ref-type="fig">Figure 2A</xref>). Thus, we assert the following sequence of events that form the positive feedback loop (<xref rid="F4" ref-type="fig">Figure 4</xref>). First, binding of &#1040;&#946; to Na,K-ATPase activates the Na,K-ATPase-associated Src kinase. In turn, Src kinase causes an increase in APP levels and its transport into neurites. It is likely that self-amplification of A&#946; synthesis by the proposed mechanism serves as one of the key events in the pathogenesis of Alzheimer&#8217;s disease and explains the exponential pattern of its development (<xref rid="B7" ref-type="bibr">Dickson, 1997</xref>).</p><fig position="float" id="F4" orientation="portrait"><label>FIGURE 4</label><caption><p>Schematic representation of A&#946; effect on APP level in cells and its trafficking. Binding of A&#946; (shown in red) to Na,K-ATPase (NKA, &#945;-subunit shown in blue, &#946;-subunit shown in green) leads to the activation of Na,K-ATPase-associated Src kinase (Src, shown in purple). This initiates a signaling cascade, which results in an increase in the total APP level in the cell. Consequently, the accumulation of APP is observed on the cytoplasmic membrane of neurites.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-16-1665715-g004.jpg"><alt-text content-type="machine-generated">Schematic representation showing membrane protein interactions with NKA (Na,K-ATPase), Src, and APP in two states. Left panel shows NKA, Src, and APP in absence of A&#946;42. Right panel shows NKA interaction with A&#946;42, leading to Src phosphorylation and accumulation of APP, with increased APP presence in the cell membrane.</alt-text></graphic></fig><p>It should also be noted that, apart from a positive one, a negative feedback loop is also possible. In particular, Src kinase can activate phospholipase C, enhancing &#945;-secretase activity involved in APP cleavage via the non-amyloidogenic pathway (<xref rid="B30" ref-type="bibr">Pimenova et al., 2014</xref>). Thus, it is possible that activation of Src kinase by A&#946; enhances APP level in cells, simultaneously increasing the contribution of the non-amyloid pathway to its proteolysis and preventing beta-amyloid from further excessive formation. On the other hand, the effect of Src kinase on APP may also turn out to be indirect. Namely, the phosphorylation of Src kinase by trafficking adapter Mint leads to APP accumulation in the trans-Golgi network, which impairs its transport through dendrites to synaptic terminals (<xref rid="B8" ref-type="bibr">Dunning et al., 2016</xref>). However, in our case, conversely, the level of APP in neurites is increased (<xref rid="F1" ref-type="fig">Figure 1</xref>), hence another regulatory pathway can be assumed.</p><p>One could also suppose that one of the possible indirect ways in which Src kinase affects APP is via alterations of the redox status of cells. In particular, this could be caused by &#1040;&#946;-mediated reduction in ROS and reduced glutathione (GSH) levels that occurs after 30&#160;min of incubation in SH-SY5Y cells, as we have shown in (<xref rid="B29" ref-type="bibr">Petrushanko et al., 2022</xref>). However, inhibition of Src kinase exerted no effect on the &#1040;&#946;-mediated reduction of GSH, which proves the independence of these effects (<xref rid="F2" ref-type="fig">Figure 2E</xref>).</p><p>Since Src kinase activation is mediated by the binding of A&#946;<sub>42</sub> to Na,K-ATPase, which also acts as the receptor for cardiotonic steroids, we hypothesized that ouabain may influence the positive feedback loop we found. This hypothesis was confirmed: at a concentration of 100&#160;nM, ouabain prevents A&#946;<sub>42</sub>-induced activation of Src kinase and increase in APP levels, which makes it a promising CTS for preventing A&#946;<sub>42</sub>-induced APP growth.</p><p>Earlier, the possibility of using CTS as part of the complex therapy of Alzheimer&#8217;s disease has been evaluated (<xref rid="B23" ref-type="bibr">Nguyen et al., 2023</xref>; <xref rid="B40" ref-type="bibr">Wang et al., 2024</xref>; <xref rid="B36" ref-type="bibr">Song et al., 2019</xref>; <xref rid="B9" ref-type="bibr">Erdogan et al., 2022</xref>). It was demonstrated that ouabain and digoxin, another cardiotonic steroid, can prevent cytotoxic effects in neurons due to inhibition of tau protein synthesis. This process is mediated by miR-132, one of the key neuroprotective miRNAs that is suppressed in Alzheimer&#8217;s disease (<xref rid="B23" ref-type="bibr">Nguyen et al., 2023</xref>). Moreover, ouabain is able to reduce microglial neuroinflammation in murine models of Alzheimer&#8217;s disease (<xref rid="B40" ref-type="bibr">Wang et al., 2024</xref>). Although the data obtained in mice are difficult to extrapolate to humans due to the presence of a ouabain-resistant Na,K-ATPase isoform in rodents (<xref rid="B31" ref-type="bibr">Poluektov et al., 2025</xref>), our data support the idea of considering ouabain as a possible addition to Alzheimer&#8217;s disease therapy. It is ouabain that can offset the effect of A&#946;, thereby preventing the development of a feedback loop between APP and A&#946; and, as a result, reducing the dramatic increase in beta-amyloid in Alzheimer&#8217;s disease. Our findings demonstrate the possibility of diminished beta-amyloid-induced effects not only by regulating the activity of microglia (<xref rid="B40" ref-type="bibr">Wang et al., 2024</xref>), but also by direct action of ouabain on neuronal cells. Remarkably, 100&#160;nM ouabain does not inhibit Na,K-ATPase and does not affect the levels of sodium and potassium in SH-SY5Y cells after 30&#160;min of incubation (<xref rid="B17" ref-type="bibr">Kulikov et al., 2007</xref>). Thus, observed effect of ouabain on Src kinase activation and beta-amyloid-induced changes in APP levels is not associated with Na,K-ATPase inhibition. Further, since ouabain binding to Na,K-ATPase does not prevent amyloid binding (<xref rid="B1" ref-type="bibr">Adzhubei et al., 2022</xref>), it can be concluded that ouabain and A&#946; are likely not to share the same binding site. One can suggest that ouabain prevents the signaling effects of beta-amyloid that are mediated by conformational changes of Na,K-ATPase (<xref rid="B14" ref-type="bibr">Klimanova et al., 2015</xref>).</p><p>Notably, ouabain is detectable in cerebrospinal fluid at higher concentrations than in plasma (<xref rid="B46" ref-type="bibr">Dvela et al., 2012</xref>). Endogenous ouabain is now recognized not only as a centrally acting hormone but also as a paracrine neurohormone locally produced in the CNS, likely by the hypothalamus (<xref rid="B44" ref-type="bibr">Weidemann et al., 2004</xref>; <xref rid="B45" ref-type="bibr">Leenen et al., 2017</xref>). The levels of endogenous CTSs may vary under pathological conditions (<xref rid="B25" ref-type="bibr">Orlov et al., 2021</xref>). In a murine model of AD, marinobufagenin levels are shown to be decreased. Administration of exogenous marinobufagenin has been demonstrated to reduce neuroinflammation and lower IL-6 levels (<xref rid="B10" ref-type="bibr">Fedorova et al., 2020</xref>). Despite the limited knowledge regarding CTS levels in AD patients, we hypothesize a decline in endogenous CTS levels in AD. This assumption is supported by previous observations indicating that the hypothalamus, a primary source of endogenous CTSs in the brain, is suppressed in AD. Particularly, levels of sex hormones were decreased in murine AD models (<xref rid="B33" ref-type="bibr">Qi et al., 2024</xref>). Our data on ouabain modulation of beta-amyloid-induced alterations in APP levels and trafficking suggest its key regulatory role in beta-amyloid signaling. In this context, restoring physiological levels of CTSs could potentially inhibit AD progression. The administration of exogenous ouabain could restore ouabain levels to physiologically normal without inhibiting Na,K-ATPase, but rather slowing the accelerated formation of APP.</p><p>To sum up, the data suggest that A&#946; activates Src kinase by binding to Na,K-ATPase, causing an increase in the APP level and its relocation to neurites in SH-SY5Y cells. This can lead to an even greater increase in beta-amyloid levels due to APP processing and a feedback loop. Specific Na,K-ATPase ligand, cardiotonic steroid ouabain, prevents impact of beta-amyloid on Src kinase and APP, which makes it a potential therapeutics against Alzheimer&#8217;s disease.</p></sec></body><back><sec sec-type="data-availability" id="s5"><title>Data availability statement</title><p>The original contributions presented in the study are included in the article/<xref rid="s11" ref-type="sec">Supplementary Material</xref>, further inquiries can be directed to the corresponding authors.</p></sec><sec sec-type="author-contributions" id="s6"><title>Author contributions</title><p>IP: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Project administration, Validation, Visualization, Writing &#8211; original draft, Writing &#8211; review and editing. DL: Data curation, Formal Analysis, Investigation, Methodology, Visualization, Writing &#8211; original draft, Writing &#8211; review and editing. FF: Investigation, Writing &#8211; review and editing. OL: Investigation, Methodology, Validation, Writing &#8211; review and editing. VM: Conceptualization, Project administration, Writing &#8211; original draft, Writing &#8211; review and editing. MS: Data curation, Formal Analysis, Investigation, Methodology, Visualization, Writing &#8211; original draft, Writing &#8211; review and editing. AM: Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing &#8211; original draft, Writing &#8211; review and editing.</p></sec><sec sec-type="COI-statement" id="s8"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s9"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p><p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec><sec sec-type="disclaimer" id="s10"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="s11"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2025.1665715/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fphar.2025.1665715/full#supplementary-material</ext-link>
</p><supplementary-material id="SM1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="DataSheet1.pdf" position="float" orientation="portrait"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adzhubei</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Tolstova</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Strelkova</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Mitkevich</surname><given-names>V. A.</given-names></name><name name-style="western"><surname>Petrushanko</surname><given-names>I. Y.</given-names></name><name name-style="western"><surname>Makarov</surname><given-names>A. A.</given-names></name></person-group> (<year>2022</year>). <article-title>Interaction interface of A&#946;42 with human Na,K-ATPase studied by MD and ITC and inhibitor screening by MD</article-title>. <source>Biomedicines</source><volume>10</volume> (<issue>7</issue>), <fpage>1663</fpage>. <pub-id pub-id-type="doi">10.3390/biomedicines10071663</pub-id><pub-id pub-id-type="pmid">35884966</pub-id><pub-id pub-id-type="pmcid">PMC9313104</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bagrov</surname><given-names>A. Y.</given-names></name><name name-style="western"><surname>Shapiro</surname><given-names>J. I.</given-names></name><name name-style="western"><surname>Fedorova</surname><given-names>O. V.</given-names></name></person-group> (<year>2009</year>). <article-title>Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets</article-title>. <source>Pharmacol. Rev.</source><volume>61</volume> (<issue>1</issue>), <fpage>9</fpage>&#8211;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1124/pr.108.000711</pub-id><pub-id pub-id-type="pmid">19325075</pub-id><pub-id pub-id-type="pmcid">PMC2763610</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barykin</surname><given-names>E. P.</given-names></name><name name-style="western"><surname>Petrushanko</surname><given-names>I. Y.</given-names></name><name name-style="western"><surname>Kozin</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Telegin</surname><given-names>G. B.</given-names></name><name name-style="western"><surname>Chernov</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Lopina</surname><given-names>O. D.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Phosphorylation of the amyloid-beta peptide inhibits zinc-dependent aggregation, prevents Na,K-ATPase inhibition, and reduces cerebral plaque deposition</article-title>. <source>Front. Mol. Neurosci.</source><volume>11</volume>, <fpage>302</fpage>. <pub-id pub-id-type="doi">10.3389/fnmol.2018.00302</pub-id><pub-id pub-id-type="pmid">30210292</pub-id><pub-id pub-id-type="pmcid">PMC6123382</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burrinha</surname><given-names>T.</given-names></name><name name-style="western"><surname>Guimas Almeida</surname><given-names>C.</given-names></name></person-group> (<year>2022</year>). <article-title>Aging impact on amyloid precursor protein neuronal trafficking</article-title>. <source>Curr. Opin. Neurobiol.</source><volume>73</volume>, <fpage>102524</fpage>. <pub-id pub-id-type="doi">10.1016/j.conb.2022.102524</pub-id><pub-id pub-id-type="pmid">35303572</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burrinha</surname><given-names>T.</given-names></name><name name-style="western"><surname>Martinsson</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Terrasso</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Gouras</surname><given-names>G. K.</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>C. G.</given-names></name></person-group> (<year>2021</year>). <article-title>Upregulation of APP endocytosis by neuronal aging drives amyloid-dependent synapse loss</article-title>. <source>J. Cell Sci.</source><volume>134</volume> (<issue>9</issue>), <fpage>jcs255752</fpage>. <pub-id pub-id-type="doi">10.1242/jcs.255752</pub-id><pub-id pub-id-type="pmid">33910234</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dickey</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>M. N.</given-names></name><name name-style="western"><surname>Wilcock</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Herber</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>D.</given-names></name></person-group> (<year>2005</year>). <article-title>Dysregulation of Na+/K+ ATPase by amyloid in APP+PS1 transgenic mice</article-title>. <source>BMC Neurosci.</source><volume>6</volume>, <fpage>7</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2202-6-7</pub-id><pub-id pub-id-type="pmid">15689237</pub-id><pub-id pub-id-type="pmcid">PMC549198</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dickson</surname><given-names>D. W.</given-names></name></person-group> (<year>1997</year>). <article-title>The pathogenesis of senile plaques</article-title>. <source>Exp. Neurol.</source><volume>56</volume> (<issue>4</issue>), <fpage>321</fpage>&#8211;<lpage>339</lpage>. <pub-id pub-id-type="doi">10.1097/00005072-199704000-00001</pub-id><pub-id pub-id-type="pmid">9100663</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunning</surname><given-names>C. J. R.</given-names></name><name name-style="western"><surname>Black</surname><given-names>H. L.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>K. L.</given-names></name><name name-style="western"><surname>Davenport</surname><given-names>E. C.</given-names></name><name name-style="western"><surname>Conboy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chawla</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Multisite tyrosine phosphorylation of the N-terminus of Mint1/X11&#945; by src kinase regulates the trafficking of amyloid precursor protein</article-title>. <source>J. Neurochem.</source><volume>137</volume> (<issue>4</issue>), <fpage>518</fpage>&#8211;<lpage>527</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.13571</pub-id><pub-id pub-id-type="pmid">26865271</pub-id><pub-id pub-id-type="pmcid">PMC4982022</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dvela</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ben-Ami</surname><given-names>H. C.</given-names></name><name name-style="western"><surname>Lichtstein</surname><given-names>D.</given-names></name></person-group> (<year>2012</year>). <article-title>Endogenous ouabain regulates cell viability</article-title>. <source>Am. J. Physiol. Cell. Physiol.</source><volume>302</volume> (<issue>2</issue>), <fpage>442</fpage>&#8211;<lpage>452</lpage>. <pub-id pub-id-type="doi">10.1152/ajpcell.00336.2011</pub-id><pub-id pub-id-type="pmid">22031604</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erdogan</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Kirazlar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yigitturk</surname><given-names>G.</given-names></name><name name-style="western"><surname>Erbas</surname><given-names>O.</given-names></name></person-group> (<year>2022</year>). <article-title>Digoxin exhibits neuroprotective properties in a rat model of dementia</article-title>. <source>Res.</source><volume>47</volume> (<issue>5</issue>), <fpage>1290</fpage>&#8211;<lpage>1298</lpage>. <pub-id pub-id-type="doi">10.1007/s11064-022-03528-w</pub-id><pub-id pub-id-type="pmid">35064518</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fedorova</surname><given-names>O. V.</given-names></name><name name-style="western"><surname>Zahariadis</surname><given-names>E.</given-names></name><name name-style="western"><surname>McDevitt</surname><given-names>R.</given-names></name><name name-style="western"><surname>Grigorova</surname><given-names>Y. N.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zernetkina</surname><given-names>V. I.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Steroidal inhibitor of Na/K&#8208;ATPase marinobufagenin in a mouse model of Alzheimer&#8217;s disease: biomarkers (non&#8208;neuroimaging)/novel biomarkers</article-title>. <source>Alzheimers Dement.</source><volume>16</volume>, <fpage>e046617</fpage>. <pub-id pub-id-type="doi">10.1002/alz.046617</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halper&#237;n</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schaeffer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Galvez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Malav&#233;</surname><given-names>S.</given-names></name></person-group> (<year>1983</year>). <article-title>Ouabain-like activity in human cerebrospinal fluid</article-title>. <source>Proc. Natl. Acad. Sci.</source><volume>80</volume> (<issue>19</issue>), <fpage>6101</fpage>&#8211;<lpage>6104</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.80.19.6101</pub-id><pub-id pub-id-type="pmid">6310614</pub-id><pub-id pub-id-type="pmcid">PMC534368</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jarosz-Griffiths</surname><given-names>H. H.</given-names></name><name name-style="western"><surname>Noble</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rushworth</surname><given-names>J. V.</given-names></name><name name-style="western"><surname>Hooper</surname><given-names>N. M.</given-names></name></person-group> (<year>2016</year>). <article-title>Amyloid-&#946; receptors: the good, the bad, and the prion protein</article-title>. <source>J. Biol. Chem.</source><volume>291</volume> (<issue>7</issue>), <fpage>3174</fpage>&#8211;<lpage>3183</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.R115.702704</pub-id><pub-id pub-id-type="pmid">26719327</pub-id><pub-id pub-id-type="pmcid">PMC4751366</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jucker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>L. C.</given-names></name></person-group> (<year>2013</year>). <article-title>Self-propagation of pathogenic protein aggregates in neurodegenerative diseases</article-title>. <source>Nature</source><volume>501</volume> (<issue>7465</issue>), <fpage>45</fpage>&#8211;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1038/nature12481</pub-id><pub-id pub-id-type="pmid">24005412</pub-id><pub-id pub-id-type="pmcid">PMC3963807</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klimanova</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Petrushanko</surname><given-names>I. Y.</given-names></name><name name-style="western"><surname>Mitkevich</surname><given-names>V. A.</given-names></name><name name-style="western"><surname>Anashkina</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Orlov</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Makarov</surname><given-names>A. A.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Binding of ouabain and marinobufagenin leads to different structural changes in Na,K-ATPase and depends on the enzyme conformation</article-title>. <source>FEBS Lett.</source><volume>589</volume>, <fpage>2668</fpage>&#8211;<lpage>2674</lpage>. <comment>19 Pt B. P</comment>. <pub-id pub-id-type="doi">10.1016/j.febslet.2015.08.011</pub-id><pub-id pub-id-type="pmid">26297827</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koinuma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shimozawa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yasutomi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>N.</given-names></name></person-group> (<year>2021</year>). <article-title>Aging induces abnormal accumulation of A&#946; in extracellular vesicle And/Or intraluminal membrane vesicle-rich fractions in nonhuman primate brain</article-title>. <source>Aging</source><volume>106</volume>, <fpage>268</fpage>&#8211;<lpage>281</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2021.06.022</pub-id><pub-id pub-id-type="pmid">34329965</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kreutz</surname><given-names>F.</given-names></name><name name-style="western"><surname>Scherer</surname><given-names>E. B.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>A. G. K.</given-names></name><name name-style="western"><surname>Petry</surname><given-names>F. D. S.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Santana</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Alterations on Na<sup>+</sup>,K<sup>+</sup>-ATPase and acetylcholinesterase activities induced by amyloid-&#946; peptide in rat brain and GM1 ganglioside neuroprotective action//neurochem</article-title>. <source>Res</source><volume>38</volume> (<issue>11</issue>), <fpage>2342</fpage>&#8211;<lpage>2350</lpage>. <pub-id pub-id-type="doi">10.1007/s11064-013-1145-6</pub-id><pub-id pub-id-type="pmid">24013887</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kulikov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eva</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kirch</surname><given-names>U.</given-names></name><name name-style="western"><surname>Boldyrev</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scheiner-Bobis</surname><given-names>G.</given-names></name></person-group> (<year>2007</year>). <article-title>Ouabain activates signaling pathways associated with cell death in human neuroblastoma</article-title>. <source>Biochim. Biophys. Acta BBA - Biomembr.</source><volume>1768</volume> (<issue>7</issue>), <fpage>1691</fpage>&#8211;<lpage>1702</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamem.2007.04.012</pub-id><pub-id pub-id-type="pmid">17524349</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lane</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Hardy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schott</surname><given-names>J. M.</given-names></name></person-group> (<year>2018</year>). <article-title>Alzheimer's disease</article-title>. <source>J. Neurol.</source><volume>25</volume> (<issue>1</issue>), <fpage>59</fpage>&#8211;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1111/ene.13439</pub-id><pub-id pub-id-type="pmid">28872215</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leenen</surname><given-names>F. H. H.</given-names></name><name name-style="western"><surname>Blaustein</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Hamlyn</surname><given-names>J. M.</given-names></name></person-group> (<year>2017</year>). <article-title>Update on angiotensin II: new endocrine connections between the brain, adrenal glands and the cardiovascular system</article-title>. <source>Endocr. Connect.</source><volume>6</volume> (<issue>7</issue>), <fpage>R131</fpage>&#8211;<lpage>R145</lpage>. <pub-id pub-id-type="doi">10.1530/EC-17-0161</pub-id><pub-id pub-id-type="pmid">28855243</pub-id><pub-id pub-id-type="pmcid">PMC5613704</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Z.</given-names></name></person-group> (<year>2010</year>). <article-title>The sodium pump and cardiotonic steroids-induced signal transduction protein kinases and calcium-signaling microdomain in regulation of transporter trafficking</article-title>. <source>Biochim. Biophys. Acta BBA - Mol. Basis Dis.</source>, <fpage>1802</fpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2010.01.013</pub-id><pub-id pub-id-type="pmid">20144708</pub-id><pub-id pub-id-type="pmcid">PMC5375027</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name></person-group> (<year>2022</year>). <article-title>Amyloidosis in alzheimer&#8217;s disease: Pathogeny, etiology, and related therapeutic directions</article-title>. <source>Molecules</source><volume>27</volume> (<issue>4</issue>), <fpage>1210</fpage>. <pub-id pub-id-type="doi">10.3390/molecules27041210</pub-id><pub-id pub-id-type="pmid">35209007</pub-id><pub-id pub-id-type="pmcid">PMC8876037</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marks</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Jagust</surname><given-names>W. J.</given-names></name></person-group> (<year>2017</year>). <article-title>Tau and &#946;-Amyloid are associated with medial temporal lobe structure, function, and memory encoding in normal aging</article-title>. <source>J. Neurosci.</source><volume>37</volume> (<issue>12</issue>), <fpage>3192</fpage>&#8211;<lpage>3201</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3769-16.2017</pub-id><pub-id pub-id-type="pmid">28213439</pub-id><pub-id pub-id-type="pmcid">PMC5373113</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;ller</surname><given-names>U. C.</given-names></name><name name-style="western"><surname>Deller</surname><given-names>T.</given-names></name><name name-style="western"><surname>Korte</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Not just amyloid: physiological functions of the amyloid precursor protein family</article-title>. <source>Nat. Rev. Neurosci.</source><volume>18</volume> (<issue>5</issue>), <fpage>281</fpage>&#8211;<lpage>298</lpage>. <pub-id pub-id-type="doi">10.1038/nrn.2017.29</pub-id><pub-id pub-id-type="pmid">28360418</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>L. D.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Barber&#225;n-Soler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rabinovsky</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Small molecule regulators of microRNAs identified by high-throughput screen coupled with high-throughput sequencing</article-title>. <source>Nat. Commun.</source><volume>14</volume>, <fpage>7575</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-023-43293-0</pub-id><pub-id pub-id-type="pmid">37989753</pub-id><pub-id pub-id-type="pmcid">PMC10663445</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niederst</surname><given-names>E. D.</given-names></name><name name-style="western"><surname>Reyna</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>L. S. B.</given-names></name></person-group> (<year>2015</year>). <article-title>Axonal amyloid precursor protein and its fragments undergo somatodendritic endocytosis and processing</article-title>. <source>Mol. Biol. Cell.</source><volume>26</volume> (<issue>2</issue>), <fpage>205</fpage>&#8211;<lpage>217</lpage>. <pub-id pub-id-type="doi">10.1091/mbc.E14-06-1049</pub-id><pub-id pub-id-type="pmid">25392299</pub-id><pub-id pub-id-type="pmcid">PMC4294669</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orlov</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Tverskoi</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Sidorenko</surname><given-names>S. V.</given-names></name><name name-style="western"><surname>Smolyaninova</surname><given-names>L. V.</given-names></name><name name-style="western"><surname>Lopina</surname><given-names>O. D.</given-names></name><name name-style="western"><surname>Dulin</surname><given-names>N. O.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>K-ATPase as a target for endogenous cardiotonic steroids: what&#8217;s the evidence?</article-title>. <source>Genes Dis.</source><volume>8</volume> (<issue>3</issue>), <fpage>259</fpage>&#8211;<lpage>271</lpage>. <pub-id pub-id-type="doi">10.1016/j.gendis.2020.01.008</pub-id><pub-id pub-id-type="pmid">33997173</pub-id><pub-id pub-id-type="pmcid">PMC8093582</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orobets</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Karamyshev</surname><given-names>A. L.</given-names></name></person-group> (<year>2023</year>). <article-title>Amyloid precursor protein and alzheimer&#8217;s disease</article-title>. <source>Int. J. Mol. Sci.</source><volume>24</volume> (<issue>19</issue>), <fpage>14794</fpage>. <pub-id pub-id-type="doi">10.3390/ijms241914794</pub-id><pub-id pub-id-type="pmid">37834241</pub-id><pub-id pub-id-type="pmcid">PMC10573485</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perdig&#227;o</surname><given-names>C.</given-names></name><name name-style="western"><surname>Barata</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Ara&#250;jo</surname><given-names>M. N.</given-names></name><name name-style="western"><surname>Mirfakhar</surname><given-names>F. S.</given-names></name><name name-style="western"><surname>Castanheira</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guimas Almeida</surname><given-names>C.</given-names></name></person-group> (<year>2020</year>). <article-title>Intracellular trafficking mechanisms of synaptic dysfunction in alzheimer&#8217;s disease</article-title>. <source>Front. Cell. Neurosci.</source><volume>14</volume>, <fpage>72</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2020.00072</pub-id><pub-id pub-id-type="pmid">32362813</pub-id><pub-id pub-id-type="pmcid">PMC7180223</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrushanko</surname><given-names>I. Y.</given-names></name><name name-style="western"><surname>Mitkevich</surname><given-names>V. A.</given-names></name><name name-style="western"><surname>Anashkina</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Adzhubei</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Burnysheva</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Lakunina</surname><given-names>V. A.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Direct interaction of beta-amyloid with Na,K-ATPase as a putative regulator of the enzyme function</article-title>. <source>Sci. Rep.</source><volume>6</volume>, <fpage>27738</fpage>. <pub-id pub-id-type="doi">10.1038/srep27738</pub-id><pub-id pub-id-type="pmid">27296892</pub-id><pub-id pub-id-type="pmcid">PMC4906314</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrushanko</surname><given-names>I. Y.</given-names></name><name name-style="western"><surname>Tverskoi</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Barykin</surname><given-names>E. P.</given-names></name><name name-style="western"><surname>Petrovskaya</surname><given-names>A. V.</given-names></name><name name-style="western"><surname>Strelkova</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Leonova</surname><given-names>O. G.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Na,K-ATPase acts as a beta-amyloid receptor triggering src kinase activation</article-title>. <source>Cells</source><volume>11</volume> (<issue>17</issue>), <fpage>2753</fpage>. <pub-id pub-id-type="doi">10.3390/cells11172753</pub-id><pub-id pub-id-type="pmid">36078160</pub-id><pub-id pub-id-type="pmcid">PMC9455167</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pimenova</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Thathiah</surname><given-names>A.</given-names></name><name name-style="western"><surname>De Strooper</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tesseur</surname><given-names>I.</given-names></name></person-group> (<year>2014</year>). <article-title>Regulation of amyloid precursor protein processing by serotonin signaling</article-title>. <source>PloS One</source><volume>9</volume> (<issue>1</issue>), <fpage>e87014</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0087014</pub-id><pub-id pub-id-type="pmid">24466315</pub-id><pub-id pub-id-type="pmcid">PMC3897773</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poluektov</surname><given-names>Y. M.</given-names></name><name name-style="western"><surname>Lopina</surname><given-names>O. D.</given-names></name><name name-style="western"><surname>Strelkova</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Kuleshova</surname><given-names>I. D.</given-names></name><name name-style="western"><surname>Makarov</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Petrushanko</surname><given-names>I. Y.</given-names></name></person-group> (<year>2025</year>). <article-title>Mechanisms mediating effects of cardiotonic steroids in Mammalian blood cells</article-title>. <source>Front. Pharmacol.</source><volume>16</volume>, <fpage>1520927</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2025.1520927</pub-id><pub-id pub-id-type="pmid">40196366</pub-id><pub-id pub-id-type="pmcid">PMC11973394</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prusiner</surname><given-names>S. B.</given-names></name></person-group> (<year>2012</year>). <article-title>Cell biology. A unifying role for prions in neurodegenerative diseases</article-title>. <source>Science</source><volume>336</volume>, <fpage>1511</fpage>&#8211;<lpage>1513</lpage>. <pub-id pub-id-type="doi">10.1126/science.1222951</pub-id><pub-id pub-id-type="pmid">22723400</pub-id><pub-id pub-id-type="pmcid">PMC3942086</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Sex-specific hypothalamic neuropathology and glucose metabolism in an amyloidosis transgenic mouse model of Alzheimer&#8217;s disease</article-title>. <source>Cell Biosci.</source><volume>14</volume> (<issue>1</issue>), <fpage>120</fpage>. <pub-id pub-id-type="doi">10.1186/s13578-024-01295-5</pub-id><pub-id pub-id-type="pmid">39272160</pub-id><pub-id pub-id-type="pmcid">PMC11395863</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schatzmann</surname><given-names>H. J.</given-names></name></person-group> (<year>1953</year>). <article-title>cardiac glycosides as inhibitors of active potassium and sodium transport by erythrocyte membrane</article-title>. <source>Physiol. Pharmacol. Acta.</source><volume>11</volume> (<issue>4</issue>), <fpage>346</fpage>&#8211;<lpage>354</lpage>.
<pub-id pub-id-type="pmid">13142506</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>H. K.</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S.-W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.</given-names></name></person-group> (<year>2015</year>). <article-title>Inactivation of src-to-ezrin pathway: a possible mechanism in the ouabain-mediated inhibition of A549 cell migration</article-title>. <source>Biomed. Res. Int.</source><volume>2015</volume>, <fpage>537136</fpage>. <pub-id pub-id-type="doi">10.1155/2015/537136</pub-id><pub-id pub-id-type="pmid">25866790</pub-id><pub-id pub-id-type="pmcid">PMC4383155</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>H.-L.</given-names></name><name name-style="western"><surname>Demirev</surname><given-names>A. V.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>N.-Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.-H.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>S.-Y.</given-names></name></person-group> (<year>2019</year>). <article-title>Ouabain activates transcription factor EB and exerts neuroprotection in models of Alzheimer&#8217;s disease</article-title>. <source>Mol. Cell. Neurosci.</source><volume>95</volume>, <fpage>13</fpage>&#8211;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/j.mcn.2018.12.007</pub-id><pub-id pub-id-type="pmid">30594669</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stokin</surname><given-names>G. B.</given-names></name><name name-style="western"><surname>Lillo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Falzone</surname><given-names>T. L.</given-names></name><name name-style="western"><surname>Brusch</surname><given-names>R. G.</given-names></name><name name-style="western"><surname>Rockenstein</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mount</surname><given-names>S. L.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Axonopathy and transport deficits early in the pathogenesis of alzheimer&#8217;s disease</article-title>. <source>Science</source><volume>307</volume> (<issue>5713</issue>), <fpage>1282</fpage>&#8211;<lpage>1288</lpage>. <pub-id pub-id-type="doi">10.1126/science.1105681</pub-id><pub-id pub-id-type="pmid">15731448</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>S.</given-names></name></person-group> (<year>2018</year>). <article-title>The physical approximation of APP and BACE-1: a key event in alzheimer&#8217;s disease pathogenesis</article-title>. <source>Dev. Neurobiol.</source><volume>78</volume> (<issue>3</issue>), <fpage>340</fpage>&#8211;<lpage>347</lpage>. <pub-id pub-id-type="doi">10.1002/dneu.22556</pub-id><pub-id pub-id-type="pmid">29106038</pub-id><pub-id pub-id-type="pmcid">PMC7336871</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walton</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.-X.</given-names></name></person-group> (<year>2009</year>). <article-title>APP expression, distribution and accumulation are altered by aluminum in a rodent model for Alzheimer&#8217;s disease</article-title>. <source>J. Inorg. Biochem.</source><volume>103</volume> (<issue>11</issue>), <fpage>1548</fpage>&#8211;<lpage>1554</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinorgbio.2009.07.027</pub-id><pub-id pub-id-type="pmid">19818510</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Ouabain ameliorates alzheimer&#8217;s disease-associated neuropathology and cognitive impairment in FAD4T mice</article-title>. <source>Nutrients</source><volume>16</volume> (<issue>20</issue>), <fpage>3558</fpage>. <pub-id pub-id-type="doi">10.3390/nu16203558</pub-id><pub-id pub-id-type="pmid">39458551</pub-id><pub-id pub-id-type="pmcid">PMC11510559</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weidemann</surname><given-names>H.</given-names></name><name name-style="western"><surname>Salomon</surname><given-names>N.</given-names></name><name name-style="western"><surname>Avnit-Sagi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Weidenfeld</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lichtstein</surname><given-names>D.</given-names></name></person-group> (<year>2004</year>). <article-title>Diverse effects of stress and additional adrenocorticotropic hormone on digitalis-like compounds in normal and nude mice</article-title>. <source>J. Neuroendocrinol.</source><volume>16</volume> (<issue>5</issue>), <fpage>458</fpage>&#8211;<lpage>463</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2826.2004.01181.x</pub-id><pub-id pub-id-type="pmid">15117339</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Welikovitch</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Do</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Magl&#243;czky</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Szocsics</surname><given-names>P.</given-names></name><name name-style="western"><surname>L&#337;ke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Freund</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Evidence of intraneuronal A&#946; accumulation preceding tau pathology in the entorhinal cortex</article-title>. <source>Acta Neuropathol. (Berl.).</source><volume>136</volume> (<issue>6</issue>), <fpage>901</fpage>&#8211;<lpage>917</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-018-1922-z</pub-id><pub-id pub-id-type="pmid">30362029</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Akkuratov</surname><given-names>E. E.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gaskill</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Askari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name></person-group> (<year>2013</year>). <article-title>Cell signaling associated with Na(+)/K(+)-ATPase: activation of phosphatidylinositide 3-kinase IA/Akt by ouabain is independent of src</article-title>. <source>Biochemistry</source><volume>52</volume> (<issue>50</issue>), <fpage>9059</fpage>&#8211;<lpage>9067</lpage>. <pub-id pub-id-type="doi">10.1021/bi4011804</pub-id><pub-id pub-id-type="pmid">24266852</pub-id><pub-id pub-id-type="pmcid">PMC3868411</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.-N.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.-J.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.-X.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>Y.-E.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Na<sup>+</sup>-K<sup>+</sup>-ATPase, a potent neuroprotective modulator against alzheimer disease//fundam</article-title>. <source>Clin. Pharmacol.</source><volume>27</volume> (<issue>1</issue>), <fpage>96</fpage>&#8211;<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1111/fcp.12000</pub-id><pub-id pub-id-type="pmid">23033963</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JMIR Res Protoc</journal-id><journal-id journal-id-type="iso-abbrev">JMIR Res Protoc</journal-id><journal-id journal-id-type="pmc-domain-id">2066</journal-id><journal-id journal-id-type="pmc-domain">resprot</journal-id><journal-id journal-id-type="publisher-id">ResProt</journal-id><journal-title-group><journal-title>JMIR Research Protocols</journal-title></journal-title-group><issn pub-type="epub">1929-0748</issn><publisher><publisher-name>JMIR Publications Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12504890</article-id><article-id pub-id-type="pmcid-ver">PMC12504890.1</article-id><article-id pub-id-type="pmcaid">12504890</article-id><article-id pub-id-type="pmcaiid">12504890</article-id><article-id pub-id-type="doi">10.2196/73039</article-id><article-id pub-id-type="publisher-id">v14i1e73039</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Protocol</subject></subj-group><subj-group subj-group-type="article-type"><subject>Protocol</subject></subj-group></article-categories><title-group><article-title>Effectiveness of Tocotrienol-Rich Fraction in Older Adults: Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial</article-title></title-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Sarvestan</surname><given-names initials="J">Javad</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name name-style="western"><surname>Chusri</surname><given-names initials="S">Sasitorn</given-names></name></contrib><contrib contrib-type="reviewer"><name name-style="western"><surname>Udensi</surname><given-names initials="C">Chukwuma</given-names></name></contrib><contrib contrib-type="reviewer"><name name-style="western"><surname>Agu</surname><given-names initials="CP">Chiamaka Pamela</given-names></name></contrib></contrib-group><contrib-group><contrib id="contrib1" contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Amir Razak</surname><given-names initials="NAN">Nor Amira Nabila</given-names></name><degrees>BSc</degrees><xref rid="aff1" ref-type="aff">1</xref><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0005-1566-8438</contrib-id></contrib><contrib id="contrib2" contrib-type="author" corresp="yes" equal-contrib="yes"><name name-style="western"><surname>Goon</surname><given-names initials="JA">Jo Aan</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1757-3780</contrib-id><xref rid="aff1" ref-type="aff">1</xref><address><institution>Department of Biochemistry</institution><institution>Faculty of Medicine</institution><institution>Universiti Kebangsaan Malaysia</institution><addr-line>Jalan Yaacob Latif</addr-line><addr-line>Kuala Lumpur, 56000</addr-line><country>Malaysia</country><phone>60 16 5329035</phone><email>joaan@ukm.edu.my</email></address></contrib><contrib id="contrib3" contrib-type="author"><name name-style="western"><surname>Wan Ngah</surname><given-names initials="WZ">Wan Zurinah</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">1</xref><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9363-1650</contrib-id></contrib><contrib id="contrib4" contrib-type="author"><name name-style="western"><surname>Makpol</surname><given-names initials="S">Suzana</given-names></name><degrees>BSc, PhD</degrees><xref rid="aff1" ref-type="aff">1</xref><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5239-6196</contrib-id></contrib><contrib id="contrib5" contrib-type="author"><name name-style="western"><surname>Ahmad Damanhuri</surname><given-names initials="MH">Mohd Hanafi</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">1</xref><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6948-8839</contrib-id></contrib><contrib id="contrib6" contrib-type="author"><name name-style="western"><surname>Ibrahim</surname><given-names initials="NF">Nor Faeizah</given-names></name><degrees>BSc, PhD</degrees><xref rid="aff1" ref-type="aff">1</xref><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7041-4688</contrib-id></contrib><contrib id="contrib7" contrib-type="author"><name name-style="western"><surname>Abdul Sani</surname><given-names initials="NF">Nur Fathiah</given-names></name><degrees>MMSc</degrees><xref rid="aff1" ref-type="aff">1</xref><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2638-3076</contrib-id></contrib><contrib id="contrib8" contrib-type="author"><name name-style="western"><surname>Mohd Murshid</surname><given-names initials="N">Nuraqila</given-names></name><degrees>Dr med</degrees><xref rid="aff1" ref-type="aff">1</xref><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6490-8550</contrib-id></contrib><contrib id="contrib9" contrib-type="author"><name name-style="western"><surname>Mohd Azizan</surname><given-names initials="AF">Anis Faqihah</given-names></name><degrees>BSc</degrees><xref rid="aff1" ref-type="aff">1</xref><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0007-8683-1348</contrib-id></contrib><contrib id="contrib10" contrib-type="author"><name name-style="western"><surname>Chin</surname><given-names initials="KY">Kok Yong</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">2</xref><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6628-1552</contrib-id></contrib><contrib id="contrib11" contrib-type="author"><name name-style="western"><surname>Aminuddin</surname><given-names initials="A">Amilia</given-names></name><degrees>PhD</degrees><xref rid="aff3" ref-type="aff">3</xref><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1329-0444</contrib-id></contrib><contrib id="contrib12" contrib-type="author"><name name-style="western"><surname>Mohd Yunus</surname><given-names initials="MH">Mohd Heikal</given-names></name><degrees>MD, MMSc, PhD</degrees><xref rid="aff3" ref-type="aff">3</xref><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6793-2043</contrib-id></contrib><contrib id="contrib13" contrib-type="author"><name name-style="western"><surname>Md Mansor</surname><given-names initials="M">Munirah</given-names></name><degrees>MBBS, DrPath</degrees><xref rid="aff4" ref-type="aff">4</xref><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6500-7823</contrib-id></contrib><contrib id="contrib14" contrib-type="author"><name name-style="western"><surname>Neo</surname><given-names initials="JRE">Juvenia Rui En</given-names></name><degrees>BSc</degrees><xref rid="aff5" ref-type="aff">5</xref><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0004-9695-485X</contrib-id></contrib><contrib id="contrib15" contrib-type="author"><name name-style="western"><surname>Yap</surname><given-names initials="WN">Wei Ney</given-names></name><degrees>PhD</degrees><xref rid="aff5" ref-type="aff">5</xref><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9108-8567</contrib-id></contrib><contrib id="contrib16" contrib-type="author"><name name-style="western"><surname>Loong</surname><given-names initials="HY">Hsieu Yen</given-names></name><degrees>MSc</degrees><xref rid="aff6" ref-type="aff">6</xref><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0007-7359-4590</contrib-id></contrib><contrib id="contrib17" contrib-type="author"><name name-style="western"><surname>Ung</surname><given-names initials="YW">Yee Wei</given-names></name><degrees>BSc</degrees><xref rid="aff6" ref-type="aff">6</xref><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3197-0435</contrib-id></contrib></contrib-group><aff id="aff1">
<label>1</label>
<institution>Department of Biochemistry</institution>
<institution>Faculty of Medicine</institution>
<institution>Universiti Kebangsaan Malaysia</institution>
<addr-line>Kuala Lumpur</addr-line>
<country>Malaysia</country>
</aff><aff id="aff2">
<label>2</label>
<institution>Department of Pharmacology</institution>
<institution>Faculty of Medicine</institution>
<institution>Universiti Kebangsaan Malaysia</institution>
<addr-line>Kuala Lumpur</addr-line>
<country>Malaysia</country>
</aff><aff id="aff3">
<label>3</label>
<institution>Department of Physiology</institution>
<institution>Faculty of Medicine</institution>
<institution>Universiti Kebangsaan Malaysia</institution>
<addr-line>Kuala Lumpur</addr-line>
<country>Malaysia</country>
</aff><aff id="aff4">
<label>4</label>
<institution>Department of Pathology</institution>
<institution>Faculty of Medicine</institution>
<institution>Universiti Kebangsaan Malaysia</institution>
<addr-line>Kuala Lumpur</addr-line>
<country>Malaysia</country>
</aff><aff id="aff5">
<label>5</label>
<institution>Research and Development Department</institution>
<institution>Davos Life Science</institution>
<addr-line>Singapore</addr-line>
<country>Singapore</country>
</aff><aff id="aff6">
<label>6</label>
<institution>Research and Development Department</institution>
<institution>KL-Kepong Oleomas</institution>
<addr-line>Selangor</addr-line>
<country>Malaysia</country>
</aff><author-notes><corresp>Corresponding Author: Jo Aan Goon <email>joaan@ukm.edu.my</email></corresp></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>23</day><month>9</month><year>2025</year></pub-date><volume>14</volume><issue-id pub-id-type="pmc-issue-id">479701</issue-id><elocation-id>e73039</elocation-id><history><date date-type="received"><day>24</day><month>2</month><year>2025</year></date><date date-type="rev-request"><day>19</day><month>3</month><year>2025</year></date><date date-type="rev-recd"><day>9</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>25</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>23</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169;Nor Amira Nabila Amir Razak, Jo Aan Goon, Wan Zurinah Wan Ngah, Suzana Makpol, Mohd Hanafi Ahmad Damanhuri, Nor Faeizah Ibrahim, Nur Fathiah Abdul Sani, Nuraqila Mohd Murshid, Anis Faqihah Mohd Azizan, Kok Yong Chin, Amilia Aminuddin, Mohd Heikal Mohd Yunus, Munirah Md Mansor, Juvenia Rui En Neo, Wei Ney Yap, Hsieu Yen Loong, Yee Wei Ung. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 23.09.2025.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by/4.0/" ext-link-type="uri">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.researchprotocols.org" ext-link-type="uri">https://www.researchprotocols.org</ext-link>, as well as this copyright and license information must be included.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="resprot_v14i1e73039.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.researchprotocols.org/2025/1/e73039"/><abstract><sec sec-type="background"><title>Background</title><p>Tocotrienol, a naturally occurring form of vitamin E, has been extensively studied for its potent antioxidant, anti-inflammatory, and immune-stimulating properties. However, the clinical impact of tocotrienol supplementation on older adults&#8217; overall health and well-being remains relatively unexplored. This research aims to investigate the efficacy of tocotrienol-rich fraction (TRF) on various health parameters associated with general well-being in individuals aged between 50 years and 75 years.</p></sec><sec sec-type="objective"><title>Objective</title><p>It is hypothesized that TRF supplementation may exhibit positive outcomes on blood biochemistry and several physiological aspects, including lowered levels of oxidative stress and inflammation biomarkers; improvement in vascular age; and enhancement of skin condition, bone mineral density, and cognitive function.</p></sec><sec sec-type="methods"><title>Methods</title><p>This randomized, double-blind, placebo-controlled trial was designed to investigate the effectiveness of TRF supplementation on overall health in healthy older adults. The study aims to assess the impact of a daily dosage of 200 mg of TRF over a period of 6 months. A total of 220 participants is enrolled in the study, with one-half receiving the placebo and the other one-half receiving TRF supplementation. The study comprises 3 time points: baseline, 3 months, and 6 months. At each time point, various measurements are taken to evaluate different aspects of health. The primary outcome measurements include blood biochemistry assessments, such as liver function tests, renal profile, lipid profile, and full blood count. Oxidative stress markers, including malondialdehyde, advanced glycation end products, protein carbonyl, and isoprostane, are also evaluated. Immune response markers such as interleukin-6 and tumor necrosis factor-&#945; are assessed. Satiety regulation is examined through measurements of leptin and ghrelin. Body composition and skin health parameters, including wrinkling, pigmentation, elasticity, hydration, and sebum secretion, are evaluated. Additionally, arterial stiffness is assessed using arteriography at baseline and 6 months. For secondary outcome measures, bone mineral density is measured using dual x-ray absorptiometry, and cognitive function is assessed using the Montreal Cognitive Assessment, Rey Auditory Verbal Learning Test, and digital span test. Both bone mineral density and cognitive function are also measured at baseline and 6 months.</p></sec><sec sec-type="results"><title>Results</title><p>The study is progressing as planned, with 209 participants recruited as of April 2025. The research was funded in 2019, and data collection started in December 2020. Preliminary data analysis has been completed for the first 120 participants, and final results are expected upon completion of data collection and unblinding in 2026.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>By comprehensively evaluating these health aspects, this study seeks to provide valuable insights into the potential benefits of tocotrienol supplementation for promoting the overall health and well-being of the aging population.</p></sec><sec sec-type="trial registration"><title>Trial Registration</title><p>National Medical Research Register (NMRR) NMRR-19-2972-51179; https://tinyurl.com/yy9yueer</p></sec><sec sec-type="registered-report"><title>International Registered Report Identifier (IRRID)</title><p>DERR1-10.2196/73039</p></sec></abstract><kwd-group><kwd>tocotrienol</kwd><kwd>skin</kwd><kwd>cognition</kwd><kwd>brain</kwd><kwd>weight</kwd><kwd>satiety</kwd><kwd>aging</kwd><kwd>oxidative stress</kwd><kwd>immune</kwd><kwd>inflammation</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="introduction"><title>Introduction</title><sec><title>Background</title><p>Aging is a progressive process characterized by the gradual loss of tissue and organ function over time [<xref rid="ref1" ref-type="bibr">1</xref>]. Two theories of aging include the free radical theory of aging, which later evolved into the oxidative stress theory of aging, and a theory based on low-grade inflammation, or inflammaging, in older adults. The oxidative stress theory of aging is based on the hypothesis that age-related functional declines occur as a result of the accumulation of oxidative damage to macromolecules such as lipids, DNA, and proteins caused by reactive oxygen and nitrogen species (RONS) buildup [<xref rid="ref2" ref-type="bibr">2</xref>]. With advancing age, the accumulation of RONS leads to post-transcriptional modifications and oxidative damage, often contributed to by elevated levels of oxidative stress biomarkers including advanced glycation end products (AGEs), malondialdehyde (MDA), protein carbonyl (PC), and F2-isoprostanes (F2-IsoPs) [<xref rid="ref3" ref-type="bibr">3</xref>]. In parallel, chronic low-grade inflammation has been linked to the onset of age-related chronic diseases such as cardiovascular disease, diabetes, and cancer [<xref rid="ref4" ref-type="bibr">4</xref>]. In older adults, there is often an imbalance between excessive free radicals and low antioxidant levels, along with increased risk of chronic inflammation due to elevated inflammatory cytokine production, which may lead to disruption in normal cellular physiology [<xref rid="ref5" ref-type="bibr">5</xref>,<xref rid="ref6" ref-type="bibr">6</xref>]. High levels of oxidative stress biomarkers and inflammatory cytokines are associated with low cognitive performance, osteoporosis, atherosclerotic characteristics, skin conditions, and renal problems in older adults [<xref rid="ref7" ref-type="bibr">7</xref>-<xref rid="ref9" ref-type="bibr">9</xref>].</p><p>According to the Department of Statistics, Malaysia is officially regarded as an aging nation, as individuals aged 65 years and older were predicted to make up 7.7% of the population as of 2024 [<xref rid="ref10" ref-type="bibr">10</xref>]. This indicates an urgent need to identify preventive, nonpharmacological strategies for maintaining the health and well-being of the older adult population. Introducing natural adjuncts like tocotrienol-rich fraction (TRF) supplementation may serve as a cost-effective and physiologically beneficial approach to reducing the health care burden associated with aging while potentially supporting healthy aging and improving overall quality of life for older adults.</p><p>Tocotrienol is a naturally occurring vitamin E that is predominantly found in palm oil [<xref rid="ref11" ref-type="bibr">11</xref>]. It can be further distinguished into 4 isomeric forms (&#945;, &#946;, &#947;, and &#948;), depending on the location and number of methyl groups on the chromanol ring. Tocotrienols, as opposed to tocopherols, have unsaturated isoprenoid side chains with 3 double bonds, allowing for greater cellular penetration and dispersion inside lipid membranes [<xref rid="ref6" ref-type="bibr">6</xref>,<xref rid="ref12" ref-type="bibr">12</xref>]. This structural difference improves their antioxidant and anti-inflammatory properties. Cumulative scientific evidence has convincingly shown that tocotrienol possesses pronounced antioxidative function by effectively neutralizing free radicals, including RONS, which ultimately reduces oxidative stress [<xref rid="ref11" ref-type="bibr">11</xref>,<xref rid="ref13" ref-type="bibr">13</xref>-<xref rid="ref22" ref-type="bibr">22</xref>]. Tocotrienol also possesses anti-inflammatory properties by ameliorating inflammatory markers that are consistently associated with age-related chronic diseases and disability [<xref rid="ref4" ref-type="bibr">4</xref>], including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-&#945;), and C-reactive protein (CRP) [<xref rid="ref23" ref-type="bibr">23</xref>-<xref rid="ref25" ref-type="bibr">25</xref>]. IL-6 is a pleiotropic cytokine produced by the immune cells, vascular endothelial cells, adipocytes, and skeletal muscle and possesses both anti-inflammatory and pro-inflammatory properties [<xref rid="ref26" ref-type="bibr">26</xref>]. TNF-&#945;, another cytokine, is mainly produced by macrophages and other cell types in response to cell damage [<xref rid="ref27" ref-type="bibr">27</xref>], while CRP is an acute-phase protein produced by the liver in response to elevated IL-6 and TNF-&#945; levels [<xref rid="ref28" ref-type="bibr">28</xref>-<xref rid="ref30" ref-type="bibr">30</xref>]. These properties render tocotrienol an attractive therapeutic candidate for slowing down the aging process and thus potentially extending the lifespan of older adults [<xref rid="ref11" ref-type="bibr">11</xref>,<xref rid="ref13" ref-type="bibr">13</xref>].</p><p>Moreover, tocotrienol also modulates inflammation by targeting crucial transcription factors such as nuclear factor kappa B (NF-&#954;B), the signal transducer and activator of the transcription-3 (STAT-3) pathway, and other cytokine regulators integral to the inflammatory signaling cascade [<xref rid="ref12" ref-type="bibr">12</xref>,<xref rid="ref13" ref-type="bibr">13</xref>,<xref rid="ref22" ref-type="bibr">22</xref>,<xref rid="ref31" ref-type="bibr">31</xref>-<xref rid="ref33" ref-type="bibr">33</xref>]. Tocotrienols have been shown to exhibit isoform-specific effects on anti-inflammatory potency. For instance, several studies have demonstrated that &#948;-tocotrienol exhibited the most potent inhibitory effect on IL-6 and TNF-&#945; production as compared with other isoforms [<xref rid="ref24" ref-type="bibr">24</xref>,<xref rid="ref34" ref-type="bibr">34</xref>]. Another study has shown that &#948;-tocotrienol inhibits TNF-&#945;&#8211;induced NF-&#954;B activation caused by upregulation of the anti-inflammatory protein A20 [<xref rid="ref35" ref-type="bibr">35</xref>]. In addition, Muid et al [<xref rid="ref32" ref-type="bibr">32</xref>] demonstrated that both &#948;- and &#947;-tocotrienols have higher potency in inhibiting IL-6 production and NF-&#954;B activation than &#945;- and &#946;-tocotrienols in lipopolysaccharide-stimulated human umbilical vein endothelial cells. The NF-&#954;B pathway inhibition induced by &#947;-tocotrienol also contributes to downregulation of oncogenic gene expression, thus promoting tumor cell apoptosis, which is crucial for suppressing tumor metastasis [<xref rid="ref36" ref-type="bibr">36</xref>]. Moreover, combined treatment with &#947;-tocotrienol and an epidermal growth factor receptor inhibitor showed suppression in epidermal growth factor&#8211;dependent STAT-3 signaling in mammary tumor cells [<xref rid="ref37" ref-type="bibr">37</xref>]. Collectively, these findings underscore the pivotal role of tocotrienols in modulating inflammation through multifaceted inhibition of key transcription factors, suppression of pro-inflammatory cytokines, and regulation of signaling pathways central to the inflammatory cascade. This positions tocotrienols as promising agents for the prevention and management of inflammation-driven diseases, including cancer and chronic inflammatory conditions.</p><p>Furthermore, these scientific investigations have illuminated tocotrienols&#8217; ability to enhance skin health through UV protection and skin-lightening effects, both in preclinical and clinical models [<xref rid="ref38" ref-type="bibr">38</xref>-<xref rid="ref42" ref-type="bibr">42</xref>]. Tocotrienols have also demonstrated their potential for improving lipid profiles among individuals with dyslipidemia and hypertension [<xref rid="ref12" ref-type="bibr">12</xref>,<xref rid="ref43" ref-type="bibr">43</xref>-<xref rid="ref48" ref-type="bibr">48</xref>] and have been shown to regulate leptin expression, thereby influencing appetite control and energy homeostasis [<xref rid="ref49" ref-type="bibr">49</xref>-<xref rid="ref54" ref-type="bibr">54</xref>]. To date, no study has specifically investigated the effect of tocotrienols on ghrelin expression. Therefore, our study aims to fill this knowledge gap and provide novel insights into this unexplored area.</p><p>In bone health, tocotrienols promote osteoblast survival and proliferation through free radical protection and inhibit osteoclasts by downregulating the mevalonate pathway. They also regulate gene expression to promote bone formation [<xref rid="ref55" ref-type="bibr">55</xref>-<xref rid="ref66" ref-type="bibr">66</xref>]. Similarly, tocotrienols positively influence neurological health by modulating gene expression in the brain, potentially enhancing memory and motor function while delaying Alzheimer disease progression. Notably, &#945;-tocotrienol at nanomolar concentrations has been shown to attenuate enzymatic and nonenzymatic mediators of arachidonic acid metabolism and neurodegeneration [<xref rid="ref11" ref-type="bibr">11</xref>,<xref rid="ref67" ref-type="bibr">67</xref>-<xref rid="ref71" ref-type="bibr">71</xref>].</p><p>TRF is a commercial mixture of vitamin E isomers, containing approximately equal proportions of &#945;-tocopherol (&#945;TP) and &#945;-, &#946;-, &#947;-, and &#948;-tocotrienol isomers. TRF supplement with a complete spectrum of tocotrienol isomers has been found to alleviate inflammatory symptoms of allergic rhinitis [<xref rid="ref72" ref-type="bibr">72</xref>], enhance mental health and cognition [<xref rid="ref73" ref-type="bibr">73</xref>], reduce inflammation and oxidative stress in ulcerative colitis [<xref rid="ref31" ref-type="bibr">31</xref>], and mitigate UV-induced skin inflammation [<xref rid="ref38" ref-type="bibr">38</xref>]. A previous study reported that TRF can improve antioxidant enzyme activities and glutathione levels in women aged between 50 years and 55 years [<xref rid="ref74" ref-type="bibr">74</xref>]. In the same study, TRF supplementation was found to reduce MDA levels as early as 3 months, while oxidative damage toward DNA was reduced in women after 6 months of supplementation [<xref rid="ref75" ref-type="bibr">75</xref>]. Furthermore, related isomers derived from the same source have demonstrated benefits in cardiovascular, liver, and metabolic functions [<xref rid="ref12" ref-type="bibr">12</xref>,<xref rid="ref76" ref-type="bibr">76</xref>] while exhibiting inhibitory effects on the growth of gastric cancer [<xref rid="ref77" ref-type="bibr">77</xref>], prostate cancer [<xref rid="ref78" ref-type="bibr">78</xref>], and breast cancer [<xref rid="ref79" ref-type="bibr">79</xref>]. The findings from these studies provide a compelling basis to initiate a clinical trial aimed at evaluating the impact of TRF on the well-being of healthy individuals.</p></sec><sec><title>Prior Work</title><p>To establish an appropriate dosage and duration for the clinical trial, systematic research of human studies involving vitamin E supplementation in healthy participants spanning the years 1997 to 2019 was conducted. A comprehensive search using keywords such as &#8220;human,&#8221; &#8220;vitamin E,&#8221; &#8220;tocopherol,&#8221; and &#8220;tocotrienol&#8221; in the PubMed database yielded 9 published papers. These studies shed light on the dosages and durations of tocotrienols that are suitable for this clinical trial. In a comparative study investigating the impact of supplementation with TRF and &#945;TP on gene expression in healthy older adults, the administration of &#945;TP (400 IU/day) and TRF (150 mg/day) over a period of 6 months was found to influence pathways related to immune response, drug response, cell adhesion, and signal transduction pathways. Notably, TRF supplementation exhibited a more pronounced effect than &#945;TP in modulating gene expression involved in signaling pathways [<xref rid="ref80" ref-type="bibr">80</xref>]. The same study also revealed that TRF and &#945;TP supplementation demonstrated similar antioxidative and anti-inflammatory effects in older adults, with TRF showing more significant impacts in female participants [<xref rid="ref74" ref-type="bibr">74</xref>]. This occurrence may be associated with the downregulation of the apoptotic pathway such as ERK1/2 cascades and NF-&#954;B pathway after 6 months of TRF supplementation [<xref rid="ref80" ref-type="bibr">80</xref>]. Moreover, another study revealed that TRF supplementation (150 mg/day) for 6 months led to alterations in plasma protein levels including upregulation of apolipoprotein A-I and E precursors and downregulation of CRP precursors in both young and older individuals, actions that are associated with a therapeutic effect against atherosclerosis [<xref rid="ref81" ref-type="bibr">81</xref>]. These findings provide a perspective that TRF also alters protein expression as shown by elevated plasma protein levels following 6 months of TRF supplementation.</p><p>Another investigation focused on the effects of TRF supplementation at a dosage of 400 mg/day for 2 months on the immune response to tetanus toxoid immunization in healthy volunteers. The findings indicated that TRF exhibited immunostimulatory effects [<xref rid="ref82" ref-type="bibr">82</xref>], thus reinforcing the notion that TRF is associated with handling cellular inflammation. In a randomized controlled trial spanning 6 months, daily supplementation of 150 mg/day TRF was associated with improvements in lipid profile and oxidative status in healthy older adults [<xref rid="ref83" ref-type="bibr">83</xref>]. Interestingly, a separate trial found that daily supplementation with TRF (150 mg/day) for 6 months did not induce immunomodulatory changes in healthy human volunteers [<xref rid="ref84" ref-type="bibr">84</xref>]. A much earlier clinical trial, comparing 50-mg with 100-mg vitamin E supplementation over 6 months, suggested that the higher dose (100 mg) had a more pronounced effect on cellular immune function in noninstitutionalized older adults aged 65 years to 80 years [<xref rid="ref85" ref-type="bibr">85</xref>]. Moreover, a 4-month supplementation regimen of 60 IU to 800 IU vitamin E daily had no adverse effects on various health parameters, including general health, nutrient status, liver enzyme function, thyroid hormone concentrations, creatinine concentrations, serum autoantibodies, killing of <italic toggle="yes">Candida albicans</italic> by neutrophils, and bleeding time in healthy participants older than 65 years [<xref rid="ref86" ref-type="bibr">86</xref>]. In another randomized controlled trial, older adults consuming 200 mg/d of vitamin E for 4 months exhibited an increase in delayed-type hypersensitivity skin response and an elevation in antibody titer to hepatitis B [<xref rid="ref87" ref-type="bibr">87</xref>].</p><p>Following the review of the literature, a supplementation regimen of 200 mg per day for 6 months was selected. Although no published human studies have reported any serious adverse effects attributed to tocotrienols, it is worth noting that, in animal studies, tocotrienol doses of 500 mg/kg body weight and 1000 mg/kg body weight (administered orally) were found to increase bleeding and clotting times in mice during subacute (14 days) and subchronic (42 days) investigations [<xref rid="ref88" ref-type="bibr">88</xref>]. When these doses are converted to a human equivalent dose, they equate to 2400 mg and 4800 mg, respectively in humans. This discovery implies that high doses of tocotrienols (&gt;2400 mg) should be used cautiously, particularly by individuals with a tendency to bleed or those taking anticoagulants. Consequently, individuals who are currently on anticoagulant or antithrombotic medication are ineligible for participation in this research.</p><p>Although several human studies have explored the potential benefits of tocotrienols, there is a noticeable lack of published, comprehensive data that substantiate their advantages specifically in older adults. To address this knowledge gap, we designed a randomized, double-blind, placebo-controlled study, also widely recognized as the &#8220;gold standard&#8221; in intervention research [<xref rid="ref89" ref-type="bibr">89</xref>]. This research design excels in establishing causal relationships, enabling us to demonstrate the efficacy of tocotrienols, compared with placebo, in older adults. The connection between oxidative stress, chronic low-grade inflammation, and the aging process, as well as age-related diseases, has been firmly established through extensive epidemiological studies involving older adults [<xref rid="ref90" ref-type="bibr">90</xref>]. Consequently, several key investigative areas, including antioxidant and inflammation levels, arterial stiffness, appetite regulation, skin parameters, cognitive functions, and bone mineral density, were chosen as focal points for this research. Tocotrienol supplementation is predicted to have a positive impact on all of these parameters, adding to the increasing amount of data that demonstrates its ability to improve general quality of life of older adults. In particular, tocotrienols have been demonstrated to attenuate arterial stiffness [<xref rid="ref91" ref-type="bibr">91</xref>], modulate hormones related to appetite [<xref rid="ref92" ref-type="bibr">92</xref>], improve skin health through improvements in hydration and elasticity [<xref rid="ref93" ref-type="bibr">93</xref>], promote cognitive performance through neuroprotective mechanisms [<xref rid="ref11" ref-type="bibr">11</xref>,<xref rid="ref94" ref-type="bibr">94</xref>], lower oxidative stress and pro-inflammatory markers [<xref rid="ref95" ref-type="bibr">95</xref>,<xref rid="ref96" ref-type="bibr">96</xref>], and positively influence bone metabolism [<xref rid="ref65" ref-type="bibr">65</xref>].</p><p>The objective of this randomized, double-blinded, placebo-controlled study is to evaluate the efficacy of TRF supplement on health indices for older adults who have been reported to be at risk of reduced antioxidant levels and low-grade chronic inflammation, factors that contribute to an increased susceptibility to chronic diseases [<xref rid="ref97" ref-type="bibr">97</xref>]. This study design offers the advantage of establishing causality by assessing the efficacy of TRF compared with placebo in older adults. The outcomes of this trial will provide crucial insights into the potential benefits of TRF supplements for enhancing the health and well-being of older adults.</p></sec><sec><title>Aim of This Study</title><p>The comprehensive objectives of this research involve the evaluation of the effectiveness of TRF at enhancing antioxidant levels and reducing inflammation among individuals aged 50 years to 75 years. Furthermore, changes in appetite hormones, arterial stiffness, and skin parameters over 3-month and 6-month supplementation periods are monitored relative to baseline measurements. In addition, alterations in bone mineral density following 6 months of tocotrienol supplementation are being determined, and potential enhancements in cognitive function between baseline and the 6-month point are being investigated. Finally, the influence of supplementation on vitamin E levels within the body is being assessed after 3 months and 6 months of TRF supplementation.</p></sec></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study Setting</title><p>Healthy men and women aged between 50 years and 75 years are recruited from the Klang Valley, which is centered in the federal territories of Kuala Lumpur and Putrajaya in Malaysia. Participants are divided into two cohorts, which are supplemented with either placebo or tocotrienols for 6 months.</p></sec><sec><title>Ethical Considerations</title><p>This research upholds the principles of Good Clinical Practice and adheres to the pertinent regulatory guidelines established by the Malaysia Ministry of Health. The research was approved by the Research Ethics Committee of Universiti Kebangsaan Malaysia (ethics approval number: UKM PPI/111/8/JEP-2019-798) and was registered with the Malaysia National Medical Research Register and National Pharmaceutical Regulatory Agency. Funding for the study was provided by KL-Kepong Oleomas Sdn Bhd, with the research itself being independently conducted by scholars and experts from a higher learning institution. Before the clinical trial commenced, the two parties signed a distinct legal agreement designed to safeguard the rights of the sponsor and researchers involved.</p><p>The investigators have no financial nor other competing interests in relation to the overall trial, ensuring impartiality and scientific integrity. Any alterations to the protocol are communicated by the investigators to both the Research Ethics Committee and the sponsor prior to implementation.</p><p>Upon completion of the trial, the principal investigator (PI) and sponsor will collaborate in publishing the results and deriving pertinent conclusions while ensuring strict confidentiality of participants&#8217; personal information.</p><p>The PI is responsible for retaining the data for a minimum duration of 7 years from the date of closure of the database. The sponsor possesses exclusive rights to use the data for commercial purposes, except for any personal information related to the participants. Concurrently, researchers are granted the privilege to use the data for noncommercial purposes, encompassing but not limited to patient care and treatment, academic pursuits, and publication.</p><p>Special ethical considerations have been addressed in accordance to the specific needs of the older adult participants in this study. Given the possibility of age-related cognitive decline, the informed consent process incorporates simplified language and comprehension testing to assure accurate understanding. Extra care is taken to reduce any psychological pain or stigmatization, and cognitive examinations are carried out using validated instruments suitable for older adults. All study procedures are intended to accommodate physical or emotional weaknesses, including flexible scheduling and participant comfort during data collection. Throughout the research process, these safeguards maintain each participant's autonomy, dignity, and safety. The eligible participants were compensated RM 40 (US $9.48) for each visit.</p></sec><sec><title>Eligibility Criteria</title><p>Participants in this research must meet specific health criteria, including being generally healthy as determined using physical examination and lab-based blood tests, with satisfactory liver and renal function tests. Eligible participants can be of either gender and aged between 50 years and 75 years. They should not be allergic to palm oil and vitamin E and should not have consumed vitamin E or any other antioxidant supplements in the past 3 months. Furthermore, they must be willing and able to adhere to the study&#8217;s visit schedule and procedures, reside within a geographically feasible proximity for adequate follow-up (as determined by the investigator), and have a clear understanding of the study protocol, as indicated by their signed informed consent forms.</p><p>Participants in this study are expected to reflect greater distribution among the Malay and Chinese population, as these two races are the majority in Malaysia. Meanwhile, participation from the Indian community is less expected as they avoid bovine-related products in their dietary consumption due to religious reasons, aside from being the minority in the country. Moreover, the gender distribution is expected to be balanced between both men and women as there were 2 million individuals of each gender in people aged 60 years and older as of the 4th quarter of 2024 [<xref rid="ref10" ref-type="bibr">10</xref>]. The socioeconomic background of the participants (ie, education background, occupation, and social status) is not entirely restricted as we intend to be inclusive of all population groups, aside from factoring in the limited availability of participants. However, we note that the participants&#8217; education background may influence cognitive performance before and after supplementation. Thus, we will record their academic background when performing the assessments for cognitive function.</p><p>Participation in this research is restricted based on several exclusion criteria, such as individuals with fat malabsorption. This is because tocotrienols, as fat-soluble compounds, require adequate lipid absorption to achieve maximum bioavailability. In addition, those with chronic conditions such as cardiac diseases, neurological diseases, diabetes, HIV infection, or psychiatric illness or social situations are not eligible because these conditions and their associated treatments may have an impact on the study end points by obscuring the specific effects of tocotrienol supplementation.</p><p>Individuals following a vegan diet are also excluded due to potential nutritional differences, particularly in fat intake and fat-soluble vitamin levels, which may alter tocotrienol absorption and metabolism. Moreover, those who have smoked within the past 3 months are also excluded since smoking can cause oxidative and systemic stress, which can alter overall inflammation, vascular function, and antioxidant status. Excluding people who have recently undergone or are planning for surgery may be helpful to eliminate confounding side effects from surgical stress and postoperative drugs. Furthermore, pregnant and lactating women are excluded for ethical and safety reasons, given the lack of data on tocotrienol use in these populations. Individuals with a history of bleeding disorders, liver dysfunction, or gastrointestinal ulcers (eg, thrombocytopenia, abnormal liver function, liver diseases such as chronic hepatitis, gastrointestinal ulcers) are also excluded due to the potential risk of bleeding complications as well as reduced tocotrienol metabolism and clearance. Participants who are taking antibiotics, anticoagulants, antithrombotics, or other supplements that may interact with tocotrienol activity are excluded to avoid pharmacological interactions that could compromise research safety or supplementation efficacy.</p></sec><sec><title>Interventions</title><p>This research encompasses the evaluation of two investigation products that are supplied by KL-Kepong Oleomas Sdn Bhd. The first product, known as DavosLifeE3 Complete (50 mg), contains 50 mg of tocotrienols that are sourced from palm oil and meets the specifications outlined in the US Food and Drug Administration &#8220;generally recognized as safe&#8221; exemption claim 21 CFR 170.36 (c) [<xref rid="ref98" ref-type="bibr">98</xref>]. The second product, Placebo Softgel, is a palm oil supplement that has the vitamin E compounds stripped off, serving as a vital control within the study. The blinding of the supplement is performed such that each group is labelled with their respective intervention product (IP) number without disclosing the content in the softgel. The softgels for both groups are odorless, of similar size and shape, and packaged in a fully opaque bottle. Contract research assistants generated the random allocation sequence, enroll participants, and assign participants to the interventions. Study participants, researchers, and data analysts will remain blinded throughout the clinical study to maintain blinding integrity throughout the 6-month intervention period.</p></sec><sec><title>Outcomes</title><p>The study outcomes are divided into primary and secondary end points. The primary end points include vascular health (arterial stiffness), blood biochemistry (liver function, lipid profile, renal function, full blood count, and fasting glucose), oxidative stress (F2-IsoPs, MDA, AGEs, and PC), inflammation markers (TNF-&#945; and IL-6), appetite regulation (ghrelin and leptin), and skin assessment (elasticity, hydration, transepidermal water loss, pigmentation, sebum secretion, wrinkles, and roughness). Meanwhile, cognitive function (Montreal Cognitive Assessment [MoCA], Rey Auditory Verbal Learning Test [RAVLT], and digit span test) and bone density fall under the secondary outcome measures.</p><p>The study encompasses a multifaceted array of assessments and procedures (<xref rid="figure1" ref-type="fig">Figure 1</xref>). For primary outcome measures, blood samples (15 mL) are collected as baseline samples for blood biochemistry analyses. Venous blood samples are drawn from the antecubital vein between 8 AM and 10 AM, following an 8- to 10-hour overnight fast. The standardized timing and fasting procedure are followed throughout all study visits (baseline, 3 months, and 6 months) to reduce biological variability caused by circadian rhythms and postprandial effects. After at least 5 minutes of rest to stabilize hemodynamic parameters before sampling, participants are seated, and blood is collected using sterile procedures.</p><fig position="float" id="figure1" orientation="portrait"><label>Figure 1</label><caption><p>Overview of assessments and procedures for the 6-month clinical trial. DEXA: dual-energy X-ray absorptiometry; MoCA: Montreal Cognitive Assessment; RAVLT: Rey Auditory Verbal Learning Test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="resprot_v14i1e73039_fig1.jpg"/></fig><p>Tubes containing samples are labeled with the participant&#8217;s code, trial ID, and date for accurate identification. From the collected blood samples, 4 mL is routed to the chemical pathology laboratory for blood biochemistry analysis. The remaining samples are stored appropriately on ice or in a 4 &#176;C refrigerator until they undergo centrifugation, facilitating the isolation of plasma samples. These collected plasma samples are apportioned into 1-mL storage tubes and immediately stored in a &#8211;80 &#176;C freezer. This storage method ensures that the samples are preserved for the analysis of oxidative stress markers (MDA, AGE, F2-IsoPs, and PC), inflammatory markers (TNF-&#945; and IL-6), vitamin E, and appetite regulation markers (leptin and ghrelin), all to be conducted within 12 months of storage (<xref rid="table1" ref-type="table">Table 1</xref>).</p><table-wrap position="float" id="table1" orientation="portrait"><label>Table 1</label><caption><p>Summary of tests performed at 0, 3, and 6 months.</p></caption><table frame="hsides" rules="groups" width="1000" cellpadding="5" cellspacing="0" border="1"><col width="30" span="1"/><col width="30" span="1"/><col width="490" span="1"/><col width="0" span="1"/><col width="150" span="1"/><col width="0" span="1"/><col width="300" span="1"/><thead><tr valign="top"><td colspan="3" rowspan="1">Number and time points, category, and parameters</td><td colspan="2" rowspan="1">Sample</td><td colspan="2" rowspan="1">Methodology</td></tr></thead><tbody><tr valign="top"><td colspan="7" rowspan="1">
<bold>(1) Screening</bold>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td colspan="6" rowspan="1">
<bold>Blood biochemistry tests</bold>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Liver function (ALT<sup>a</sup>, ALP<sup>b</sup>, albumin, protein, bilirubin)</td><td colspan="2" rowspan="1">Blood</td><td colspan="2" rowspan="1">Clinical chemistry analyzer</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Lipid profile (TG<sup>c</sup>, HDL<sup>d</sup>, LDL<sup>e</sup>, cholesterol)</td><td colspan="2" rowspan="1">Blood</td><td colspan="2" rowspan="1">Clinical chemistry analyzer</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Renal function (Na, K, Cl, urea, creatinine)</td><td colspan="2" rowspan="1">Blood</td><td colspan="2" rowspan="1">Clinical chemistry analyzer</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Full blood count (WBC<sup>f</sup>, RBC<sup>g</sup>, hematocrit, MCV<sup>h</sup>, platelets)</td><td colspan="2" rowspan="1">Blood</td><td colspan="2" rowspan="1">Clinical chemistry analyzer</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Fasting glucose</td><td colspan="2" rowspan="1">Blood</td><td colspan="2" rowspan="1">Clinical chemistry analyzer</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">C-reactive protein</td><td colspan="2" rowspan="1">Blood</td><td colspan="2" rowspan="1">Clinical chemistry analyzer</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td colspan="6" rowspan="1">
<bold>Physical examination</bold>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Blood pressure</td><td colspan="2" rowspan="1">&#8212;<sup>i</sup></td><td colspan="2" rowspan="1">Blood pressure monitor</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Heart rate</td><td colspan="2" rowspan="1">&#8212;</td><td colspan="2" rowspan="1">
<break/>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">BMI</td><td colspan="2" rowspan="1">&#8212;</td><td colspan="2" rowspan="1">Body weight scale and stadiometer</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td colspan="6" rowspan="1">
<bold>Past medical history</bold>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Medications</td><td colspan="2" rowspan="1">&#8212;</td><td colspan="2" rowspan="1">Screening form</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Supplements</td><td colspan="2" rowspan="1">&#8212;</td><td colspan="2" rowspan="1">Screening form</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">History of illness</td><td colspan="2" rowspan="1">&#8212;</td><td colspan="2" rowspan="1">Screening form</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td colspan="6" rowspan="1">
<bold>Social history</bold>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Smoking</td><td colspan="2" rowspan="1">&#8212;</td><td colspan="2" rowspan="1">Screening form</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Alcoholic consumption</td><td colspan="2" rowspan="1">&#8212;</td><td colspan="2" rowspan="1">Screening form</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Exercise</td><td colspan="2" rowspan="1">&#8212;</td><td colspan="2" rowspan="1">Screening form</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Dietary patterns</td><td colspan="2" rowspan="1">&#8212;</td><td colspan="2" rowspan="1">Screening form</td></tr><tr valign="top"><td colspan="7" rowspan="1">
<bold>(2) 0, 3, and 6 months</bold>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td colspan="6" rowspan="1">
<bold>Physical examination</bold>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Blood pressure</td><td colspan="2" rowspan="1">&#8212;</td><td colspan="2" rowspan="1">Blood pressure monitor</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Heart rate</td><td colspan="2" rowspan="1">&#8212;</td><td colspan="2" rowspan="1">
<break/>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">BMI</td><td colspan="2" rowspan="1">&#8212;</td><td colspan="2" rowspan="1">Body weight scale and stadiometer</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td colspan="6" rowspan="1">
<bold>Body composition measurements</bold>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">BMI</td><td colspan="2" rowspan="1">Whole body</td><td colspan="2" rowspan="1">Body composition analyzer</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Segmental and visceral fat</td><td colspan="2" rowspan="1">Whole body</td><td colspan="2" rowspan="1">Body composition analyzer</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Basal metabolic rate</td><td colspan="2" rowspan="1">Whole body</td><td colspan="2" rowspan="1">Body composition analyzer</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td colspan="3" rowspan="1">Blood biochemistry tests</td><td colspan="2" rowspan="1">Blood</td><td rowspan="1" colspan="1">Clinical chemistry analyzer</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td colspan="6" rowspan="1">
<bold>Oxidative stress markers</bold>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">AGEs<sup>j</sup></td><td colspan="2" rowspan="1">Blood</td><td colspan="2" rowspan="1">ELISA<sup>k</sup> kit</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">PC<sup>l</sup></td><td colspan="2" rowspan="1">Blood</td><td colspan="2" rowspan="1">ELISA kit</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">F2-IsoPs<sup>m</sup></td><td colspan="2" rowspan="1">Blood</td><td colspan="2" rowspan="1">ELISA kit</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">MDA<sup>n</sup></td><td colspan="2" rowspan="1">Blood</td><td colspan="2" rowspan="1">HPLC<sup>o</sup></td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td colspan="6" rowspan="1">
<bold>Inflammation markers</bold>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">TNF&#945;<sup>p</sup></td><td colspan="2" rowspan="1">Blood</td><td colspan="2" rowspan="1">ELISA kit</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">IL-6<sup>q</sup></td><td colspan="2" rowspan="1">Blood</td><td colspan="2" rowspan="1">ELISA kit</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td colspan="6" rowspan="1">
<bold>Weight management</bold>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Ghrelin</td><td colspan="2" rowspan="1">Blood</td><td colspan="2" rowspan="1">ELISA kit</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Leptin</td><td colspan="2" rowspan="1">Blood</td><td colspan="2" rowspan="1">ELISA kit</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td colspan="3" rowspan="1">Vitamin E level</td><td colspan="2" rowspan="1">Blood</td><td rowspan="1" colspan="1">HPLC</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td colspan="6" rowspan="1">
<bold>Skin assessment</bold>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Elasticity</td><td colspan="2" rowspan="1">Face and arm</td><td colspan="2" rowspan="1">Cutometer</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Hydration</td><td colspan="2" rowspan="1">Face and arm</td><td colspan="2" rowspan="1">Corneometer</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Transepidermal water loss</td><td colspan="2" rowspan="1">Face and arm</td><td colspan="2" rowspan="1">Tewameter</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Pigmentation</td><td colspan="2" rowspan="1">Face and arm</td><td colspan="2" rowspan="1">Mexameter</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Sebum secretion</td><td colspan="2" rowspan="1">Face and arm</td><td colspan="2" rowspan="1">Sebumeter</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Wrinkles and roughness</td><td colspan="2" rowspan="1">Face and arm</td><td colspan="2" rowspan="1">Visioscan</td></tr><tr valign="top"><td colspan="7" rowspan="1">
<bold>(3) 0 and 6 months</bold>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td colspan="3" rowspan="1">Arterial stiffness assessment</td><td colspan="2" rowspan="1">Whole body</td><td rowspan="1" colspan="1">Arteriograph device /photoplethysmography</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td colspan="3" rowspan="1">Bone density assessment</td><td colspan="2" rowspan="1">Whole Body</td><td rowspan="1" colspan="1">Dual-energy x-ray absorptiometry</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td colspan="6" rowspan="1">
<bold>Cognitive function assessment</bold>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">MoCA<sup>r</sup></td><td colspan="2" rowspan="1">&#8212;</td><td colspan="2" rowspan="1">Questionnaires</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">RAVLT<sup>s</sup></td><td colspan="2" rowspan="1">&#8212;</td><td colspan="2" rowspan="1">Questionnaires</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Digit span test</td><td colspan="2" rowspan="1">&#8212;</td><td colspan="2" rowspan="1">Questionnaires</td></tr></tbody></table><table-wrap-foot><fn id="table1fn1"><p><sup>a</sup>ALT: alanine transaminase.</p></fn><fn id="table1fn2"><p><sup>b</sup>ALP: alkaline phosphatase.</p></fn><fn id="table1fn3"><p><sup>c</sup>TG: triglycerides.</p></fn><fn id="table1fn4"><p><sup>d</sup>HDL: high-density lipoprotein.</p></fn><fn id="table1fn5"><p><sup>e</sup>LDL: low-density lipoprotein.</p></fn><fn id="table1fn6"><p><sup>f</sup>WBC: white blood cells.</p></fn><fn id="table1fn7"><p><sup>g</sup>RBC: red blood cells.</p></fn><fn id="table1fn8"><p><sup>h</sup>MCV: mean corpuscular volume.</p></fn><fn id="table1fn9"><p><sup>i</sup>Not applicable.</p></fn><fn id="table1fn10"><p><sup>j</sup>AGEs: advanced glycation end products.</p></fn><fn id="table1fn11"><p><sup>k</sup>ELISA: enzyme-linked immunosorbent assay.</p></fn><fn id="table1fn12"><p><sup>l</sup>PC: protein carbonyl.</p></fn><fn id="table1fn13"><p><sup>m</sup>F2-IsoPs: F2-isoprostanes.</p></fn><fn id="table1fn14"><p><sup>n</sup>MDA: malondialdehyde.</p></fn><fn id="table1fn15"><p><sup>o</sup>HPLC: high-performance liquid chromatography.</p></fn><fn id="table1fn16"><p><sup>p</sup>TNF&#945;: tumor necrosis factor-&#945;.</p></fn><fn id="table1fn17"><p><sup>q</sup>IL-6: interleukin-6.</p></fn><fn id="table1fn18"><p><sup>r</sup>MoCA: Montreal Cognitive Assessment.</p></fn><fn id="table1fn19"><p><sup>s</sup>RAVLT: Rey Auditory Verbal Learning Test.</p></fn></table-wrap-foot></table-wrap><p>Furthermore, the assessment of arterial stiffness is conducted by skilled laboratory assistants using arteriography during the participants&#8217; visits at both the 0- and 6-month time points. This assessment uses inflatable cuffs and is noninvasive. The arteriograph primarily measures pulse wave velocity, augmentation index, and central blood pressure, all of which reflect vascular health. Total body fat and lean mass measurements are accomplished using an InBody device during the participant visits at 0, 3, and 6 months.</p><p>In addition, skin health is analyzed using a Cutometer (Courage+Khazaka electronic GmbH) and Visioscan (Courage+Khazaka electronic GmbH) during participant visits at 0, 3, and 6 months. At 2 anatomical locations (volar side of the forearm and lateral periorbital region of the face), skin characteristics such as elasticity, hydration, transepidermal water loss, pigmentation, sebum secretion, wrinkles, and roughness will be studied. At both locations, 4 to 5 repeated measurements are made for each parameter, and the results are averaged. To ensure site uniformity and accommodate anatomical changes, slight positional deviations of a few centimeters are permitted. By measuring at the forearm and face, it is possible to conduct a thorough analysis of skin alterations in regions with low and high levels of sun exposure, respectively. This increases sensitivity to both the local and systemic effects of the intervention.</p><p>Subsequently, for secondary outcome measures, participants undergo cognitive function assessments, which include the MoCA, RAVLT, and digit span test. These assessments are performed with the assistance of a trained research assistant during the participants&#8217; visits at 0 and 6 months. Finally, the measurement of bone mineral density is conducted using a dual-energy X-ray absorptiometry device at 0 and 6 months. Full body, lumbar spine, and hip scans are conducted. The lumbar spine and hip are essential locations for measuring bone density in older adults, which is crucial for comprehending how tocotrienol supplementation affects bone health. These regions are significant to the study since they represent general bone health.</p><p>To monitor changes in dietary habits, participants complete a food frequency questionnaire during their visits at 0, 3, and 6 months. The food intake checklist was developed to monitor changes in dietary habits throughout the study. Nutritionist Pro software is used to analyze the diet history data for each participant to quantify their nutrient intake values. Statistical analysis is then conducted to determine whether the nutrient value is significantly different from the blood biochemistry composition. <xref rid="figure1" ref-type="fig">Figure 1</xref> presents a flowchart illustrating the study period and the tests conducted at each time point.</p></sec><sec><title>Participant Timeline</title><p>Over the study period, 3 assessments are carried out at 0, 3, and 6 months across various domains of inquiry, encompassing oxidative stress, inflammation, skin conditions, arterial stiffness, cognitive function, appetite regulation, bone mineral density, and vitamin E levels. To ensure comprehensive oversight of the assessments, delegation of an authority log was established and formally endorsed by the respective investigators, each of whom possesses expertise in their specific area of assessment.</p></sec><sec><title>Sample Size</title><p>Sample size estimation was based on a comparison of mean low-density lipoprotein levels, referencing a previous case-control study on biomarkers for premature coronary artery disease by Shukor et al [<xref rid="ref99" ref-type="bibr">99</xref>]. The sample size was calculated using a power and sample size program. The effect size was calculated based on a mean value of 3.11 (SD 0.81) for group one and a mean value of 2.66 (SD 1.25) for group two.</p><p>The total number of required participants calculated per group of the experimental design was 93 when dichotomous outcomes were presumed with a Type I error probability, &#945; of .05, and power of 0.8. To maintain the power, a 20% dropout rate was factored in. Consequently, 110 participants are required to be enrolled in each group (placebo and supplementation). Therefore, a total of 220 participants are required to perform this clinical study.</p></sec><sec><title>Recruitment</title><p>The selection of potential trial participants is conducted by the PI based on the inclusion and exclusion criteria. Participants who fail to meet the inclusion and exclusion criteria are defined as screening failures. The PI maintains a Screening Log, which includes screen failures to ensure a systematic selection of participants. Informed consent is obtained from each participant by the contract research assistants. During enrollment, general information (name, gender, age, address, and contact information) is obtained. To ensure security and confidentiality, each participant is assigned a participant-specific code. The code is used to label the participant&#8217;s laboratory results. Each participant is reimbursed for standard transportation fees.</p><p>Participants are free to withdraw from the study at any time for any reason. Participants may also be withdrawn at any time at the discretion of the PI. Possible reasons for withdrawal include abnormal laboratory values, protocol violation, the participant requiring the use of an unacceptable concomitant medication, participant not complying with protocol procedures, participant developing a condition during the study that violates the inclusion or exclusion criteria, loss to follow-up, death, or any other reason in the PI&#8217;s opinion that would impede participation in the study.</p></sec><sec><title>Assignment of Interventions</title><p>Tocotrienols and placebo supplements are prepared and labelled with the IP number by the sponsor. Assignment of supplements to participants is by chance through the drawing of lots by contract research assistants. The treatment is double-blinded throughout the study period until all data have been collected and analyzed, after which the supplementation IP numbers are revealed to the PI by the sponsor. However, in case of any serious adverse event reported during the study period, the unmasking of the code is immediate.</p><p>A set of numbers, from 1 to 60, is randomized using the randomization application for every block of 60 participants. The participants are assigned a randomized number according to the numerical sequence 1 to 60 in the list of randomized numbers. All even numbers are treated with the same IP, while odd numbers are treated with another IP. Thus, every block randomization has an equal number of participants for each IP. The randomization will be repeated until 220 participants are recruited.</p><p>The unblinding in emergency situations is only permitted in case of a suspected, unexpected serious adverse reaction or other important adverse event, when knowledge of the supplemented product in question is required for therapeutic decisions in the medical management of the participant.</p><p>In the event of an emergency, an emergency decoding option is accessible to both the PI and designated personnel at the sponsor. The responsibility for breaking the blind for individual participants in emergency situations lies with the PI. If the need to break the blind arises, the PI will communicate this to the sponsor. Before the treatment code is broken, the PI responsible for unblinding must document the reason and date for unblinding in the case report form (CRF) to ensure proper documentation of the unblinding event, including a clear explanation of the reason for unblinding.</p><p>In the event that the sponsor requires unblinding of the treatment, the reason and date of unblinding are recorded in the CRF. In situations where it is necessary to unblind an individual participant&#8217;s treatment for the purpose of expedited reporting to the authorities, only designated individuals at the sponsor who are responsible for reporting this information will have access to the identity of the product. Every effort is made to ensure that all other members of the clinical trial remain blinded throughout the entire duration of the trial.</p></sec><sec><title>Data Collection and Management</title><p>During the screening process, potential participants are assessed for eligibility to enter the study according to the inclusion and exclusion criteria. After an overnight fast, a 10-mL blood sample is taken from each volunteer. The screening tests consist of comprehensive evaluations, encompassing blood lipid profile, liver function tests, renal profile, full blood count, and fasting blood glucose measurements. Additionally, records of past supplementation and medical history are reviewed to obtain a holistic understanding of the individual&#8217;s health status. The results of blood tests are revealed to volunteers upon request. Volunteers who meet the inclusion criteria are selected for baseline sampling typically within a timeframe of 1 month to 2 months after the screening process.</p><p>Eligible participants are contacted to schedule appointments for data collection at baseline, 3 months, and 6 months. During each visit, a physician conducts a comprehensive medical evaluation, encompassing an assessment of medical history; documentation of any concurrent medications; measurements of participants&#8217; weight, height, resting blood pressure, pulse rate, and temperature; and evaluation of vital signs. Subsequently, blood samples are drawn from each participant for immediate analysis of blood biochemistry, and additional samples are preserved for future analysis of oxidative stress markers, inflammatory markers, vitamin E, and appetite regulation marker levels. Furthermore, on the same day as the visit, assessments are performed for arterial stiffness, body fat composition, skin health, bone mineral density, and cognitive function.</p><p>Participant records and data for analyses are kept in separate folders according to the protocol and transferred into the CRF of each participant by the contract research assistants. The result for each assessment is monitored by specific investigators with expertise in the field, to facilitate comprehensive monitoring of the data.</p><p>A contractual disclosure agreement signed by the sponsors and investigators outlines the sponsor&#8217;s access rights to the trial data set and source data. Both the investigators and sponsor should collaborate and jointly author publications reporting the trial&#8217;s results to ensure an accurate representation of the results and drawing of appropriate conclusions, thereby preserving the integrity of the findings. All data are reported in a collective manner with no reference to any participants in the trial to ensure that the identities of participants remain confidential.</p></sec><sec><title>Analyses</title><p>Statistical analysis is conducted using SPSS (IBM Corp). The Kolmogorov-Smirnov test will be performed to assess the normality of the data distribution. Type III sum of squares is set to evaluate the hypotheses.</p><p>A mixed-design ANOVA will be used to determine whether supplementation affects the blood biochemistry parameters (inflammation and oxidative stress) and physical health (body composition, skin, cognitive function, and vascular health) at baseline, 3 months, and 6 months among the groups. The Mauchly test of sphericity will be conducted to assess homogeneity of variance and compare the means of the supplemented group with those of the placebo group. To account for the risk of a Type I error as a result of many primary and secondary outcomes, multiplicity correction procedures will be used. In particular, the Benjamini-Hochberg approach for false discovery rate control will be used in each outcome domain (eg, oxidative stress markers, inflammatory markers, cognitive tests). Statistical power and Type I error control are balanced for exploratory research in this method with connected variables. The Tukey post hoc test will be used for comparisons between groups, while the Dunnett test will be used for comparisons within groups over time. In terms of missing data, linear mixed-effects models with the missing at random assumption will be used, which is acceptable given the repeated-measures design and inclusion of observed predictors. Nevertheless, dropout rates in older adult groups might differ from missing at random (for example, because of undetected health decline). To evaluate the possible impact of data missing not at random, sensitivity analyses will be conducted using pattern-mixture models and multiple imputation with delta-adjustment scenarios. These methods aid with determining the robustness of the findings under alternate missingness assumptions. All data will be presented as mean (SD), with statistical significance defined as <italic toggle="yes">P</italic>&lt;.05.</p><p>This study requires a total of 220 volunteers as calculated using the power and sample size program. In the case where any participant withdraws or is eliminated during the course of the project, their ID number is not reused. Instead, new volunteers are recruited to maintain the total sample size at 220. The distribution of the IP numbers is rerandomized and adjusted as needed to ensure that both groups remain equally balanced, with 110 participants receiving each IP.</p><p>All randomized participants are included in the primary analysis using the intention-to-treat approach, which analyzes participants based on their initial group allocation regardless of whether they adhere to the intervention. Only participants who complete the study without significant protocol deviations are included in a secondary per-protocol analysis.</p></sec><sec><title>Monitoring</title><p>Participants are instructed to maintain their regular lifestyle throughout the study duration. We recommend that they adhere to their usual routine regarding the number of meals and dietary plan. If there is a need to use any medication, they are required to inform the PI to ensure proper documentation in the CRF.</p><p>To ensure compliance, participants are requested to submit the provided supplement bottles during their visits at 3 and 6 months. The percentage of the leftover supplements in the returned bottles are used to track compliance. The purpose of these data is to evaluate intervention adherence. To account for adherence-related differences in the treatment effect, the compliance percentage is incorporated as a covariate in the statistical analyses. Additionally, subgroup analyses based on adherence levels (high, medium, and low compliance) will be carried out.</p><p>Additionally, plasma vitamin E levels are measured at 0, 3, and 6 months to assess the participants&#8217; response to supplementation. In the event of suspected side effects or adverse reactions, participants should promptly report to the PI and seek immediate medical assistance. The PI must assess whether the observed effects are related to the trial and determine if the participant should be excluded from the study accordingly.</p></sec></sec><sec sec-type="results"><title>Results</title><p>The study was approved by the Research Ethics Committee of Universiti Kebangsaan Malaysia for implementation from January 27, 2020, to July 26, 2026. The sponsor successfully disbursed funding in June 2020. Participant screening, recruitment, and data collection commenced in September 2020. As of April 2025, 339 participants were screened, with 211 recruited and 167 having completed the study. Data analysis was completed for the first 120 participants, evenly divided between the placebo and TRF supplementation groups. Final results are expected to be published in 2026, following the completion of data collection and unblinding of the IPs by the sponsor.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>This study was conducted to evaluate the effectiveness of TRF (DavosLife E3 Complete) on blood biochemical composition (liver function, lipid profile, renal function, full blood count, and fasting glucose), oxidative status biomarkers (MDA, AGE, F2-IsoPs, and PC), inflammation biomarkers (TNF-&#945; and IL6), appetite regulation biomarkers (leptin and ghrelin), arterial stiffness, skin health, bone density, and cognitive function in healthy older adults aged 50 years to 75 years over a 6-month intervention period. We hypothesized that the high antioxidant and anti-inflammatory properties of TRF would result in significant improvements across several different areas, particularly vascular function and cognitive performance. In order to provide more thorough knowledge on the role of TRF in promoting healthy aging, skin and bone parameters were also included to investigate the potential benefits of TRF on structural and aesthetic elements of aging. The goal of this study is to meet the increasing need for a safe, nonpharmacological intervention that can help the older population maintain their functional lifespan, quality of life, and physiological resilience.</p><p>The 5-year clinical trial was designed in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines and registered in the National Medical Research Register of Malaysia. Prior to the initiation of the trial, the investigators and sponsor signed a mutual confidentiality agreement. This agreement serves to safeguard against any unauthorized use, disclosure, publication, or dissemination of confidential information by both parties involved. Separately, a comprehensive research agreement was signed, addressing the roles of the investigators and sponsor, ownership of liabilities, indemnification and insurance, quality assurance, record-keeping, reporting, access, intellectual property, and publication and authorship.</p><p>The trial commenced in 2019 after ethical approval was obtained. Notably, although sponsored by a commercial company, the trial is conducted entirely by the institution independently of the sponsors. Participant recruitment, sampling, and analyses are performed by the investigators who are blinded to the participants&#8217; identification to prevent bias. Volunteers undergo random screening and are recruited based on their fulfillment of the inclusion criteria. Similarly, the administration of investigational products is also randomized.</p><p>The trial protocol was collaboratively designed by investigators from diverse backgrounds, each bringing their expertise in the relevant measured parameters. Through careful consideration and discussion, the team determined the optimal parameters to be measured and the appropriate time points at which these measures were most likely to effectively detect changes. As a result, blood tests, skin assessment, and body composition were assessed at 3 time points, while parameters such as bone density, arterial stiffness, and cognitive function were measured exclusively at the baseline (0 months) and end point (6 months) evaluations.</p><p>The MoCA was used under the licensing agreement with the MoCA Clinic and Institute, ensuring that only trained research assistants administered the test to the participants. The RAVLT is a widely recognized measure that assesses an individual&#8217;s capacity to encode, integrate, retain, and retrieve verbal information across various stages of immediate memory [<xref rid="ref100" ref-type="bibr">100</xref>]. As a result, this assessment tool is valuable for evaluating the impact of interference stimulus, delayed memory, and recognition. Additionally, the digit span test, which gauges the ability to maintain and manipulate a limited amount of information within a readily accessible state for short durations, typically less than 30 seconds, provides crucial insights when assessing working memory [<xref rid="ref101" ref-type="bibr">101</xref>].</p><p>The dosage of TRF was determined based on previous reports that demonstrated its efficacy while not reporting any adverse events. Careful consideration was given to selecting an appropriate dose to ensure safety and prevent potential toxicity, as TRF is a fat-soluble compound and excessive dosage can lead to adverse effects. Research with rats has shown that oral administration of a vitamin E supplement was not safe for the liver and kidney [<xref rid="ref102" ref-type="bibr">102</xref>]. Nevertheless, considering the ongoing changes in population lifestyles and dietary habits, it becomes imperative to conduct a comprehensive review of the TRF dosage for future clinical trials especially for therapeutic purposes.</p><p>On average, the screening process typically lasts around 2 hours. According to the latest data, approximately 60% of the volunteers successfully met the inclusion criteria and became eligible for recruitment into the study. The primary reasons for volunteer exclusions were elevated levels of total cholesterol, low-density lipoprotein cholesterol, fasting blood glucose, and blood pressure. On average, each participant requires approximately 3 hours to complete all assessments, excluding blood tests. To accommodate the fasting requirement for blood withdrawal and arterial stiffness assessment, these tests are conducted first. Subsequently, the remaining assessments are performed simultaneously at different stations, allowing participants to visit any available station. To minimize the waiting time, a maximum of 5 participants are scheduled per sampling day. This ensures that participants do not experience prolonged waiting periods.</p><p>Throughout the treatment period, the research assistants monitor the compliance of the participants through regular phone calls and short messages. However, the effectiveness of this monitoring method relies on the participants&#8217; availability to respond to or read the messages. Noncompliant cases were primarily attributed to participants&#8217; difficulty with remembering to take the supplement, which is evident when they return the bottles with a higher number of remaining softgels than expected during the 3- and 6-month visits. The data from noncompliant participants are still analyzed. However, it is specifically noted in the CRF so that any potential outliers in data analysis can be identified later.</p><p>The findings of this study will further extend our current knowledge in many ways. As the older adult population continues to increase globally [<xref rid="ref103" ref-type="bibr">103</xref>], understanding the efficacy of TRF supplementation for promoting healthy aging becomes increasingly imperative. The use of a randomized, double-blind, placebo-controlled study protocol to assess the effectiveness of TRF in older adults offers numerous advantages that significantly enhance the credibility and reliability of the research findings. First, the randomization process ensures an unbiased allocation of participants into the treatment and control groups, minimizing the influence of confounding variables and increasing the validity of the study results. Second, the double-blinded nature of the trial eliminates both participant and researcher bias, as neither knows who is receiving the active intervention or the placebo, thereby preventing any preconceived notions from influencing outcomes. This rigorous blinding protocol ensures the integrity of the data collected and provides a more accurate assessment of the true effects of TRF supplementation. Finally, the inclusion of a placebo group enables researchers to distinguish between the specific effects of TRF and any placebo effects, ensuring that observed improvements in health outcomes can be confidently attributed to the intervention. Overall, by adhering to such a meticulous study protocol, researchers can generate robust evidence regarding the efficacy of TRF for promoting health and well-being among older adults, ultimately informing clinical practice and guiding future research endeavors.</p><p>There are some possible limitations of this study. One significant limitation is the potential for dropout or noncompliance among older participants, which can compromise the integrity of the study results and introduce bias. Older adults may face unique challenges such as cognitive impairment, mobility issues, or comorbidities that affect their ability to consistently adhere to the study protocol. Moreover, the relatively long duration often required for such trials increases the likelihood of attrition over time. Additionally, the strict inclusion and exclusion criteria necessary to ensure the internal validity of the study may limit the generalizability of the findings to broader older adult populations with diverse characteristics and health profiles [<xref rid="ref104" ref-type="bibr">104</xref>]. Thus, researchers must remain cognizant of these limitations and use strategies to mitigate their impact on the study outcomes.</p><p>In conclusion, our study holds immense promise for advancing our understanding of the potential health benefits of TRF. While acknowledging the inherent challenges and limitations associated with conducting trials in older adult populations, the insights gleaned from this study have the potential to significantly impact clinical practice. Ultimately, by generating robust evidence regarding the efficacy of TRF supplementation for promoting healthy aging, this study protocol has the potential to contribute valuable insights to the field of geriatric medicine, paving the way for improved strategies to enhance the quality of life and well-being of older adults worldwide.</p></sec></body><back><ack><p>We would like to thank KL-Kepong Oleomas Sdn Bhd for providing funding for this trial and to Universiti Kebangsaan Malaysia for their invaluable support through a matching grant, Dana Padanan Kolaborasi (DPK-2020-008).</p></ack><fn-group><fn fn-type="con"><p>Authors' Contributions: Conceptualization: JAG, WZWN, SM, MHAD, NFI, KYC, AA, MHMY, MMM, HYL, WNY, YWU</p><p>Formal analysis: JAG, NANAR, AFMA</p><p>Funding acquisition: JAG, WNY, YWU</p><p>Investigation: NANAR, AFMA, NFAS, AA, MHMY, MMM</p><p>Methodology: JAG, WZWN, SM, MHAD, NFI, KYC, AA, MHMY, MMM</p><p>Project administration: JAG, NANAR, AFMA, NFI</p><p>Writing &#8211; original draft:&#160;JAG</p><p>Writing &#8211; review &amp; editing:&#8203;&#160;WZWN, SM, MHAD, NFI, KYC, AA, MHMY, MMM, HYL, JREN, HYL, YWU, WNY</p></fn><fn fn-type="COI-statement"><p>Conflicts of Interest: JAG, WZWN, SM, MHAD, NFI, KYC, AA, MHMY, and MMM declare they have no competing interests.
JREN, HYL, WNY, and YWU work for the commercial organization that sponsors the clinical trial.</p></fn></fn-group><app-group><supplementary-material id="app1" position="float" content-type="local-data" orientation="portrait"><label>Multimedia Appendix 1</label><p>SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) checklist.</p><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="resprot_v14i1e73039_app1.doc" xlink:title="DOC File , 123 KB" id="d100e1667" position="anchor" orientation="portrait"/></supplementary-material></app-group><glossary><title>Abbreviations</title><def-list><def-item><term id="abb1">&#945;TP</term><def><p>alpha tocopherol</p></def></def-item><def-item><term id="abb2">AGE</term><def><p>advanced glycation end product</p></def></def-item><def-item><term id="abb3">CRF</term><def><p>case report form</p></def></def-item><def-item><term id="abb4">CRP</term><def><p>C-reactive protein</p></def></def-item><def-item><term id="abb5">DEXA</term><def><p>dual-energy X-ray absorptiometry</p></def></def-item><def-item><term id="abb6">F2-IsoPs</term><def><p>F2-isoprostanes</p></def></def-item><def-item><term id="abb7">IL-6</term><def><p>interleukin-6</p></def></def-item><def-item><term id="abb8">IP</term><def><p>intervention product</p></def></def-item><def-item><term id="abb9">MDA</term><def><p>malondialdehyde</p></def></def-item><def-item><term id="abb10">MoCA</term><def><p>Montreal Cognitive Assessment</p></def></def-item><def-item><term id="abb11">NF-&#954;B</term><def><p>nuclear factor kappa B</p></def></def-item><def-item><term id="abb12">PC</term><def><p>protein carbonyl</p></def></def-item><def-item><term id="abb13">PI</term><def><p>principal investigator</p></def></def-item><def-item><term id="abb14">RAVLT</term><def><p>Rey Auditory Verbal Learning Test</p></def></def-item><def-item><term id="abb15">RONS</term><def><p>reactive oxygen and nitrogen species</p></def></def-item><def-item><term id="abb16">SPIRIT</term><def><p>Standard Protocol Items: Recommendations for Interventional Trials</p></def></def-item><def-item><term id="abb17">STAT-3</term><def><p>signal transducer and activator of the transcription-3</p></def></def-item><def-item><term id="abb18">TNF-&#945;</term><def><p>tumor necrosis factor &#945;</p></def></def-item><def-item><term id="abb19">TRF</term><def><p>tocotrienol-rich fraction</p></def></def-item></def-list></glossary><notes><sec sec-type="data-availability"><title>Data Availability</title><p>The data and materials are available upon request, subject to reasonable conditions.</p></sec></notes><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flatt</surname><given-names>T</given-names></name></person-group><article-title>A new definition of aging?</article-title><source>Front Genet</source><year>2012</year><volume>3</volume><fpage>148</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/22936945" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.3389/fgene.2012.00148</pub-id><pub-id pub-id-type="medline">22936945</pub-id><pub-id pub-id-type="pmid">22936945</pub-id><pub-id pub-id-type="pmcid">PMC3425790</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beckman</surname><given-names>KB</given-names></name><name name-style="western"><surname>Ames</surname><given-names>BN</given-names></name></person-group><article-title>The free radical theory of aging matures</article-title><source>Physiol Rev</source><year>1998</year><month>04</month><day>01</day><volume>78</volume><issue>2</issue><fpage>547</fpage><lpage>81</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.physiology.org/doi/10.1152/physrev.1998.78.2.547?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub0pubmed" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1152/physrev.1998.78.2.547</pub-id><pub-id pub-id-type="medline">9562038</pub-id><pub-id pub-id-type="pmid">9562038</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olinski</surname><given-names>R</given-names></name><name name-style="western"><surname>Siomek</surname><given-names>A</given-names></name><name name-style="western"><surname>Rozalski</surname><given-names>R</given-names></name><name name-style="western"><surname>Gackowski</surname><given-names>D</given-names></name><name name-style="western"><surname>Foksinski</surname><given-names>M</given-names></name><name name-style="western"><surname>Guz</surname><given-names>J</given-names></name><name name-style="western"><surname>Dziaman</surname><given-names>T</given-names></name><name name-style="western"><surname>Szpila</surname><given-names>A</given-names></name><name name-style="western"><surname>Tudek</surname><given-names>B</given-names></name></person-group><article-title>Oxidative damage to DNA and antioxidant status in aging and age-related diseases</article-title><source>Acta Biochim Pol</source><year>2007</year><month>01</month><day>09</day><volume>54</volume><issue>1</issue><fpage>11</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.18388/abp.2007_3265</pub-id><pub-id pub-id-type="pmid">17220955</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>T</given-names></name><name name-style="western"><surname>Newman</surname><given-names>AB</given-names></name></person-group><article-title>Inflammatory markers in population studies of aging</article-title><source>Ageing Res Rev</source><year>2011</year><month>07</month><volume>10</volume><issue>3</issue><fpage>319</fpage><lpage>29</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/21145432" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1016/j.arr.2010.11.002</pub-id><pub-id pub-id-type="medline">21145432</pub-id><pub-id pub-id-type="pii">S1568-1637(10)00111-X</pub-id><pub-id pub-id-type="pmid">21145432</pub-id><pub-id pub-id-type="pmcid">PMC3098911</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conti</surname><given-names>V</given-names></name><name name-style="western"><surname>Izzo</surname><given-names>V</given-names></name><name name-style="western"><surname>Corbi</surname><given-names>G</given-names></name><name name-style="western"><surname>Russomanno</surname><given-names>G</given-names></name><name name-style="western"><surname>Manzo</surname><given-names>V</given-names></name><name name-style="western"><surname>De Lise</surname><given-names>F</given-names></name><name name-style="western"><surname>Di Donato</surname><given-names>A</given-names></name><name name-style="western"><surname>Filippelli</surname><given-names>A</given-names></name></person-group><article-title>Antioxidant supplementation in the treatment of aging-associated diseases</article-title><source>Front Pharmacol</source><year>2016</year><month>02</month><day>12</day><volume>7</volume><fpage>24</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/26903869" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.3389/fphar.2016.00024</pub-id><pub-id pub-id-type="medline">26903869</pub-id><pub-id pub-id-type="pmid">26903869</pub-id><pub-id pub-id-type="pmcid">PMC4751263</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khor</surname><given-names>Ban-Hock</given-names></name><name name-style="western"><surname>Tiong</surname><given-names>Hui-Ci</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Shing Cheng</given-names></name><name name-style="western"><surname>Wong</surname><given-names>Sok Kuan</given-names></name><name name-style="western"><surname>Chin</surname><given-names>Kok-Yong</given-names></name><name name-style="western"><surname>Karupaiah</surname><given-names>Tilakavati</given-names></name><name name-style="western"><surname>Ima-Nirwana</surname><given-names>Soelaiman</given-names></name><name name-style="western"><surname>Abdul Gafor</surname><given-names>Abdul Halim</given-names></name></person-group><article-title>Effects of tocotrienols supplementation on markers of inflammation and oxidative stress: a systematic review and meta-analysis of randomized controlled trials</article-title><source>PLoS One</source><year>2021</year><volume>16</volume><issue>7</issue><fpage>e0255205</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://dx.plos.org/10.1371/journal.pone.0255205" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1371/journal.pone.0255205</pub-id><pub-id pub-id-type="medline">34297765</pub-id><pub-id pub-id-type="pii">PONE-D-20-38529</pub-id><pub-id pub-id-type="pmid">34297765</pub-id><pub-id pub-id-type="pmcid">PMC8301652</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baierle</surname><given-names>M</given-names></name><name name-style="western"><surname>Nascimento</surname><given-names>SN</given-names></name><name name-style="western"><surname>Moro</surname><given-names>AM</given-names></name><name name-style="western"><surname>Brucker</surname><given-names>N</given-names></name><name name-style="western"><surname>Freitas</surname><given-names>F</given-names></name><name name-style="western"><surname>Gauer</surname><given-names>B</given-names></name><name name-style="western"><surname>Durgante</surname><given-names>J</given-names></name><name name-style="western"><surname>Bordignon</surname><given-names>S</given-names></name><name name-style="western"><surname>Zibetti</surname><given-names>M</given-names></name><name name-style="western"><surname>Trentini</surname><given-names>CM</given-names></name><name name-style="western"><surname>Duarte</surname><given-names>MMMF</given-names></name><name name-style="western"><surname>Grune</surname><given-names>T</given-names></name><name name-style="western"><surname>Breusing</surname><given-names>N</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>SC</given-names></name></person-group><article-title>Relationship between inflammation and oxidative stress and cognitive decline in the institutionalized elderly</article-title><source>Oxid Med Cell Longev</source><year>2015</year><volume>2015</volume><fpage>804198</fpage><lpage>12</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/25874023" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1155/2015/804198</pub-id><pub-id pub-id-type="medline">25874023</pub-id><pub-id pub-id-type="pmid">25874023</pub-id><pub-id pub-id-type="pmcid">PMC4383403</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Semba</surname><given-names>RD</given-names></name><name name-style="western"><surname>Bandinelli</surname><given-names>S</given-names></name><name name-style="western"><surname>Sun</surname><given-names>K</given-names></name><name name-style="western"><surname>Guralnik</surname><given-names>JM</given-names></name><name name-style="western"><surname>Ferrucci</surname><given-names>L</given-names></name></person-group><article-title>Plasma carboxymethyl-lysine, an advanced glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling adults</article-title><source>J Am Geriatr Soc</source><year>2009</year><month>10</month><day>05</day><volume>57</volume><issue>10</issue><fpage>1874</fpage><lpage>80</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/19682127" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1111/j.1532-5415.2009.02438.x</pub-id><pub-id pub-id-type="medline">19682127</pub-id><pub-id pub-id-type="pii">JGS2438</pub-id><pub-id pub-id-type="pmid">19682127</pub-id><pub-id pub-id-type="pmcid">PMC2785105</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pilleron</surname><given-names>S</given-names></name><name name-style="western"><surname>Rajaobelina</surname><given-names>K</given-names></name><name name-style="western"><surname>Tabue Teguo</surname><given-names>M</given-names></name><name name-style="western"><surname>Dartigues</surname><given-names>J</given-names></name><name name-style="western"><surname>Helmer</surname><given-names>C</given-names></name><name name-style="western"><surname>Delcourt</surname><given-names>C</given-names></name><name name-style="western"><surname>Rigalleau</surname><given-names>V</given-names></name><name name-style="western"><surname>F&#233;art</surname><given-names>Catherine</given-names></name></person-group><article-title>Accumulation of advanced glycation end products evaluated by skin autofluorescence and incident frailty in older adults from the Bordeaux Three-City cohort</article-title><source>PLoS One</source><year>2017</year><month>10</month><day>17</day><volume>12</volume><issue>10</issue><fpage>e0186087</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://dx.plos.org/10.1371/journal.pone.0186087" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1371/journal.pone.0186087</pub-id><pub-id pub-id-type="medline">29040310</pub-id><pub-id pub-id-type="pii">PONE-D-17-26308</pub-id><pub-id pub-id-type="pmid">29040310</pub-id><pub-id pub-id-type="pmcid">PMC5645102</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Department of Statistics Malaysia</collab></person-group><article-title>[2024] Life Expectancy</article-title><source>OpenDOSM</source><year>2024</year><month>09</month><day>30</day><date-in-citation content-type="access-date">2025-08-27</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://open.dosm.gov.my/publications/life_expectancy_2024" ext-link-type="uri">https://open.dosm.gov.my/publications/life_expectancy_2024</ext-link></comment></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sen</surname><given-names>CK</given-names></name><name name-style="western"><surname>Khanna</surname><given-names>S</given-names></name><name name-style="western"><surname>Roy</surname><given-names>S</given-names></name></person-group><article-title>Tocotrienols: vitamin E beyond tocopherols</article-title><source>Life Sci</source><year>2006</year><month>03</month><day>27</day><volume>78</volume><issue>18</issue><fpage>2088</fpage><lpage>98</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/16458936" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1016/j.lfs.2005.12.001</pub-id><pub-id pub-id-type="medline">16458936</pub-id><pub-id pub-id-type="pii">S0024-3205(05)01236-1</pub-id><pub-id pub-id-type="pmid">16458936</pub-id><pub-id pub-id-type="pmcid">PMC1790869</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>W</given-names></name><name name-style="western"><surname>Ward</surname><given-names>LC</given-names></name><name name-style="western"><surname>Fong</surname><given-names>CW</given-names></name><name name-style="western"><surname>Yap</surname><given-names>WN</given-names></name><name name-style="western"><surname>Brown</surname><given-names>L</given-names></name></person-group><article-title>Anti-inflammatory &#947;- and &#948;-tocotrienols improve cardiovascular, liver and metabolic function in diet-induced obese rats</article-title><source>Eur J Nutr</source><year>2017</year><month>02</month><day>8</day><volume>56</volume><issue>1</issue><fpage>133</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1007/s00394-015-1064-1</pub-id><pub-id pub-id-type="medline">26446095</pub-id><pub-id pub-id-type="pii">10.1007/s00394-015-1064-1</pub-id><pub-id pub-id-type="pmid">26446095</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aggarwal</surname><given-names>BB</given-names></name><name name-style="western"><surname>Sundaram</surname><given-names>C</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>S</given-names></name><name name-style="western"><surname>Kannappan</surname><given-names>R</given-names></name></person-group><article-title>Tocotrienols, the vitamin E of the 21st century: its potential against cancer and other chronic diseases</article-title><source>Biochem Pharmacol</source><year>2010</year><month>12</month><day>01</day><volume>80</volume><issue>11</issue><fpage>1613</fpage><lpage>31</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/20696139" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1016/j.bcp.2010.07.043</pub-id><pub-id pub-id-type="medline">20696139</pub-id><pub-id pub-id-type="pii">S0006-2952(10)00581-2</pub-id><pub-id pub-id-type="pmid">20696139</pub-id><pub-id pub-id-type="pmcid">PMC2956867</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaileh</surname><given-names>M</given-names></name><name name-style="western"><surname>Sen</surname><given-names>R</given-names></name></person-group><article-title>Role of NF-kappaB in the anti-inflammatory effects of tocotrienols</article-title><source>J Am Coll Nutr</source><year>2010</year><month>06</month><volume>29</volume><issue>3 Suppl</issue><fpage>334S</fpage><lpage>339S</lpage><pub-id pub-id-type="doi">10.1080/07315724.2010.10719848</pub-id><pub-id pub-id-type="medline">20823493</pub-id><pub-id pub-id-type="pii">29/3_Supplement_1/334S</pub-id><pub-id pub-id-type="pmid">20823493</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serbinova</surname><given-names>E</given-names></name><name name-style="western"><surname>Kagan</surname><given-names>V</given-names></name><name name-style="western"><surname>Han</surname><given-names>D</given-names></name><name name-style="western"><surname>Packer</surname><given-names>L</given-names></name></person-group><article-title>Free radical recycling and intramembrane mobility in the antioxidant properties of alpha-tocopherol and alpha-tocotrienol</article-title><source>Free Radic Biol Med</source><year>1991</year><month>1</month><volume>10</volume><issue>5</issue><fpage>263</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/0891-5849(91)90033-y</pub-id><pub-id pub-id-type="medline">1649783</pub-id><pub-id pub-id-type="pii">0891-5849(91)90033-Y</pub-id><pub-id pub-id-type="pmid">1649783</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suzuki</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Tsuchiya</surname><given-names>M</given-names></name><name name-style="western"><surname>Wassall</surname><given-names>SR</given-names></name><name name-style="western"><surname>Choo</surname><given-names>YM</given-names></name><name name-style="western"><surname>Govil</surname><given-names>G</given-names></name><name name-style="western"><surname>Kagan</surname><given-names>VE</given-names></name><name name-style="western"><surname>Packer</surname><given-names>L</given-names></name></person-group><article-title>Structural and dynamic membrane properties of alpha-tocopherol and alpha-tocotrienol: implication to the molecular mechanism of their antioxidant potency</article-title><source>Biochemistry</source><year>1993</year><month>10</month><day>12</day><volume>32</volume><issue>40</issue><fpage>10692</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1021/bi00091a020</pub-id><pub-id pub-id-type="medline">8399214</pub-id><pub-id pub-id-type="pmid">8399214</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Packer</surname><given-names>L</given-names></name><name name-style="western"><surname>Weber</surname><given-names>SU</given-names></name><name name-style="western"><surname>Rimbach</surname><given-names>G</given-names></name></person-group><article-title>Molecular aspects of &#945;-tocotrienol antioxidant action and cell signalling</article-title><source>The Journal of Nutrition</source><year>2001</year><month>02</month><volume>131</volume><issue>2</issue><fpage>369S</fpage><lpage>373S</lpage><pub-id pub-id-type="doi">10.1093/jn/131.2.369s</pub-id><pub-id pub-id-type="pmid">11160563</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;ller</surname><given-names>Lars</given-names></name><name name-style="western"><surname>Theile</surname><given-names>K</given-names></name><name name-style="western"><surname>B&#246;hm</surname><given-names>Volker</given-names></name></person-group><article-title>In vitro antioxidant activity of tocopherols and tocotrienols and comparison of vitamin E concentration and lipophilic antioxidant capacity in human plasma</article-title><source>Mol Nutr Food Res</source><year>2010</year><month>05</month><day>10</day><volume>54</volume><issue>5</issue><fpage>731</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1002/mnfr.200900399</pub-id><pub-id pub-id-type="medline">20333724</pub-id><pub-id pub-id-type="pmid">20333724</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamal&#8208;Eldin</surname><given-names>A</given-names></name><name name-style="western"><surname>Appelqvist</surname><given-names>L</given-names></name></person-group><article-title>The chemistry and antioxidant properties of tocopherols and tocotrienols</article-title><source>Lipids</source><year>1996</year><month>07</month><volume>31</volume><issue>7</issue><fpage>671</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1007/bf02522884</pub-id><pub-id pub-id-type="pmid">8827691</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Q</given-names></name></person-group><article-title>Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy</article-title><source>Free Radic Biol Med</source><year>2014</year><month>07</month><volume>72</volume><fpage>76</fpage><lpage>90</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/24704972" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2014.03.035</pub-id><pub-id pub-id-type="medline">24704972</pub-id><pub-id pub-id-type="pii">S0891-5849(14)00152-X</pub-id><pub-id pub-id-type="pmid">24704972</pub-id><pub-id pub-id-type="pmcid">PMC4120831</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matringe</surname><given-names>M</given-names></name><name name-style="western"><surname>Ksas</surname><given-names>B</given-names></name><name name-style="western"><surname>Rey</surname><given-names>P</given-names></name><name name-style="western"><surname>Havaux</surname><given-names>M</given-names></name></person-group><article-title>Tocotrienols, the unsaturated forms of vitamin E, can function as antioxidants and lipid protectors in tobacco leaves</article-title><source>Plant Physiol</source><year>2008</year><month>06</month><volume>147</volume><issue>2</issue><fpage>764</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1104/pp.108.117614</pub-id><pub-id pub-id-type="medline">18441223</pub-id><pub-id pub-id-type="pii">pp.108.117614</pub-id><pub-id pub-id-type="pmid">18441223</pub-id><pub-id pub-id-type="pmcid">PMC2409017</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahsan</surname><given-names>H</given-names></name><name name-style="western"><surname>Ahad</surname><given-names>A</given-names></name><name name-style="western"><surname>Iqbal</surname><given-names>J</given-names></name><name name-style="western"><surname>Siddiqui</surname><given-names>WA</given-names></name></person-group><article-title>Pharmacological potential of tocotrienols: a review</article-title><source>Nutr Metab (Lond)</source><year>2014</year><month>11</month><day>12</day><volume>11</volume><issue>1</issue><fpage>52</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://nutritionandmetabolism.biomedcentral.com/articles/10.1186/1743-7075-11-52" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1186/1743-7075-11-52</pub-id><pub-id pub-id-type="medline">25435896</pub-id><pub-id pub-id-type="pii">623</pub-id><pub-id pub-id-type="pmid">25435896</pub-id><pub-id pub-id-type="pmcid">PMC4247006</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsunaga</surname><given-names>T</given-names></name><name name-style="western"><surname>Shoji</surname><given-names>A</given-names></name><name name-style="western"><surname>Gu</surname><given-names>N</given-names></name><name name-style="western"><surname>Joo</surname><given-names>E</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Adachi</surname><given-names>T</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>H</given-names></name><name name-style="western"><surname>Yasuda</surname><given-names>K</given-names></name><name name-style="western"><surname>Kondoh</surname><given-names>T</given-names></name><name name-style="western"><surname>Tsuda</surname><given-names>K</given-names></name></person-group><article-title>&#947;-Tocotrienol attenuates TNF-&#945;-induced changes in secretion and gene expression of MCP-1, IL-6 and adiponectin in 3T3-L1 adipocytes</article-title><source>Mol Med Rep</source><year>2012</year><month>04</month><volume>5</volume><issue>4</issue><fpage>905</fpage><lpage>9</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/22293775" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.3892/mmr.2012.770</pub-id><pub-id pub-id-type="medline">22293775</pub-id><pub-id pub-id-type="pmid">22293775</pub-id><pub-id pub-id-type="pmcid">PMC3493080</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qureshi</surname><given-names>AA</given-names></name><name name-style="western"><surname>Reis</surname><given-names>JC</given-names></name><name name-style="western"><surname>Papasian</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>DC</given-names></name><name name-style="western"><surname>Qureshi</surname><given-names>N</given-names></name></person-group><article-title>Tocotrienols inhibit lipopolysaccharide-induced pro-inflammatory cytokines in macrophages of female mice</article-title><source>Lipids Health Dis</source><year>2010</year><volume>9</volume><issue>1</issue><fpage>143</fpage><pub-id pub-id-type="doi">10.1186/1476-511x-9-143</pub-id><pub-id pub-id-type="pmid">21162750</pub-id><pub-id pub-id-type="pmcid">PMC3016328</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pervez</surname><given-names>MA</given-names></name><name name-style="western"><surname>Khan</surname><given-names>DA</given-names></name><name name-style="western"><surname>Ijaz</surname><given-names>A</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S</given-names></name></person-group><article-title>Effects of delta-tocotrienol supplementation on liver enzymes, inflammation, oxidative stress and hepatic steatosis in patients with nonalcoholic fatty liver disease</article-title><source>Turk J Gastroenterol</source><year>2018</year><month>03</month><day>05</day><volume>29</volume><issue>2</issue><fpage>170</fpage><lpage>176</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/29749323" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.5152/tjg.2018.17297</pub-id><pub-id pub-id-type="medline">29749323</pub-id><pub-id pub-id-type="pmid">29749323</pub-id><pub-id pub-id-type="pmcid">PMC6284694</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>Toshio</given-names></name><name name-style="western"><surname>Narazaki</surname><given-names>Masashi</given-names></name><name name-style="western"><surname>Kishimoto</surname><given-names>Tadamitsu</given-names></name></person-group><article-title>IL-6 in inflammation, immunity, and disease</article-title><source>Cold Spring Harb Perspect Biol</source><year>2014</year><month>09</month><day>04</day><volume>6</volume><issue>10</issue><fpage>a016295</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/25190079" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1101/cshperspect.a016295</pub-id><pub-id pub-id-type="medline">25190079</pub-id><pub-id pub-id-type="pii">cshperspect.a016295</pub-id><pub-id pub-id-type="pmid">25190079</pub-id><pub-id pub-id-type="pmcid">PMC4176007</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>Dan-In</given-names></name><name name-style="western"><surname>Lee</surname><given-names>A-Hyeon</given-names></name><name name-style="western"><surname>Shin</surname><given-names>Hye-Yoon</given-names></name><name name-style="western"><surname>Song</surname><given-names>Hyo-Ryeong</given-names></name><name name-style="western"><surname>Park</surname><given-names>Jong-Hwi</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Tae-Bong</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Sang-Ryong</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Seung-Hoon</given-names></name></person-group><article-title>The role of tumor necrosis factor alpha (TNF-&#945;) in autoimmune disease and current TNF-&#945; inhibitors in therapeutics</article-title><source>Int J Mol Sci</source><year>2021</year><month>03</month><day>08</day><volume>22</volume><issue>5</issue><fpage>1</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/resolver?pii=ijms22052719" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.3390/ijms22052719</pub-id><pub-id pub-id-type="medline">33800290</pub-id><pub-id pub-id-type="pii">ijms22052719</pub-id><pub-id pub-id-type="pmcid">PMC7962638</pub-id><pub-id pub-id-type="pmid">33800290</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeRijk</surname><given-names>R</given-names></name><name name-style="western"><surname>Michelson</surname><given-names>D</given-names></name><name name-style="western"><surname>Karp</surname><given-names>B</given-names></name><name name-style="western"><surname>Petrides</surname><given-names>J</given-names></name><name name-style="western"><surname>Galliven</surname><given-names>E</given-names></name><name name-style="western"><surname>Deuster</surname><given-names>P</given-names></name><name name-style="western"><surname>Paciotti</surname><given-names>G</given-names></name><name name-style="western"><surname>Gold</surname><given-names>PW</given-names></name><name name-style="western"><surname>Sternberg</surname><given-names>EM</given-names></name></person-group><article-title>Exercise and circadian rhythm-induced variations in plasma cortisol differentially regulate interleukin-1 beta (IL-1 beta), IL-6, and tumor necrosis factor-alpha (TNF alpha) production in humans: high sensitivity of TNF alpha and resistance of IL-6</article-title><source>J Clin Endocrinol Metab</source><year>1997</year><month>07</month><volume>82</volume><issue>7</issue><fpage>2182</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1210/jcem.82.7.4041</pub-id><pub-id pub-id-type="medline">9215292</pub-id><pub-id pub-id-type="pmid">9215292</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xing</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gauldie</surname><given-names>J</given-names></name><name name-style="western"><surname>Cox</surname><given-names>G</given-names></name><name name-style="western"><surname>Baumann</surname><given-names>H</given-names></name><name name-style="western"><surname>Jordana</surname><given-names>M</given-names></name><name name-style="western"><surname>Lei</surname><given-names>XF</given-names></name><name name-style="western"><surname>Achong</surname><given-names>MK</given-names></name></person-group><article-title>IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses</article-title><source>J. Clin. Invest</source><year>1998</year><month>1</month><day>15</day><volume>101</volume><issue>2</issue><fpage>311</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1172/jci1368</pub-id><pub-id pub-id-type="pmid">9435302</pub-id><pub-id pub-id-type="pmcid">PMC508569</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maggio</surname><given-names>M</given-names></name><name name-style="western"><surname>Guralnik</surname><given-names>J</given-names></name><name name-style="western"><surname>Longo</surname><given-names>D</given-names></name><name name-style="western"><surname>Ferrucci</surname><given-names>L</given-names></name></person-group><article-title>Interleukin-6 in aging and chronic disease: a magnificent pathway</article-title><source>J Gerontol A Biol Sci Med Sci</source><year>2006</year><month>06</month><volume>61</volume><issue>6</issue><fpage>575</fpage><lpage>84</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/16799139" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1093/gerona/61.6.575</pub-id><pub-id pub-id-type="medline">16799139</pub-id><pub-id pub-id-type="pii">61/6/575</pub-id><pub-id pub-id-type="pmid">16799139</pub-id><pub-id pub-id-type="pmcid">PMC2645627</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saw</surname><given-names>Tzuen Yih</given-names></name><name name-style="western"><surname>Malik</surname><given-names>Najib Abdul</given-names></name><name name-style="western"><surname>Lim</surname><given-names>Kee Pah</given-names></name><name name-style="western"><surname>Teo</surname><given-names>Cheryl Wei Ling</given-names></name><name name-style="western"><surname>Wong</surname><given-names>Esther Sook Miin</given-names></name><name name-style="western"><surname>Kong</surname><given-names>San Choon</given-names></name><name name-style="western"><surname>Fong</surname><given-names>Chee Wai</given-names></name><name name-style="western"><surname>Petkov</surname><given-names>Jordan</given-names></name><name name-style="western"><surname>Yap</surname><given-names>Wei Ney</given-names></name></person-group><article-title>Oral supplementation of tocotrienol-rich fraction alleviates severity of ulcerative colitis in mice</article-title><source>J Nutr Sci Vitaminol (Tokyo)</source><year>2019</year><volume>65</volume><issue>4</issue><fpage>318</fpage><lpage>327</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://dx.doi.org/10.3177/jnsv.65.318" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.3177/jnsv.65.318</pub-id><pub-id pub-id-type="medline">31474681</pub-id><pub-id pub-id-type="pmid">31474681</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muid</surname><given-names>S</given-names></name><name name-style="western"><surname>Froemming</surname><given-names>GRA</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>T</given-names></name><name name-style="western"><surname>Ali</surname><given-names>AM</given-names></name><name name-style="western"><surname>Nawawi</surname><given-names>HM</given-names></name></person-group><article-title>Delta- and gamma-tocotrienol isomers are potent in inhibiting inflammation and endothelial activation in stimulated human endothelial cells</article-title><source>Food Nutr Res</source><year>2016</year><month>07</month><day>06</day><volume>60</volume><issue>1</issue><fpage>31526</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.tandfonline.com/doi/10.3402/fnr.v60.31526?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub0pubmed" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.3402/fnr.v60.31526</pub-id><pub-id pub-id-type="medline">27396399</pub-id><pub-id pub-id-type="pii">31526</pub-id><pub-id pub-id-type="pmid">27396399</pub-id><pub-id pub-id-type="pmcid">PMC4938891</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P</given-names></name><name name-style="western"><surname>Ng</surname><given-names>L</given-names></name></person-group><article-title>Tocotrienol-rich fraction of palm oil exhibits anti-inflammatory property by suppressing the expression of inflammatory mediators in human monocytic cells</article-title><source>Mol Nutr Food Res</source><year>2008</year><month>08</month><day>18</day><volume>52</volume><issue>8</issue><fpage>921</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1002/mnfr.200700418</pub-id><pub-id pub-id-type="medline">18481320</pub-id><pub-id pub-id-type="pmid">18481320</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yam</surname><given-names>Mun-Li</given-names></name><name name-style="western"><surname>Abdul Hafid</surname><given-names>Sitti Rahma</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Hwee-Ming</given-names></name><name name-style="western"><surname>Nesaretnam</surname><given-names>Kalanithi</given-names></name></person-group><article-title>Tocotrienols suppress proinflammatory markers and cyclooxygenase-2 expression in RAW264.7 macrophages</article-title><source>Lipids</source><year>2009</year><month>09</month><volume>44</volume><issue>9</issue><fpage>787</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1007/s11745-009-3326-2</pub-id><pub-id pub-id-type="medline">19655189</pub-id><pub-id pub-id-type="pmid">19655189</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Chao</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Qing</given-names></name></person-group><article-title>Vitamin E &#948;-tocotrienol inhibits TNF-&#945;-stimulated NF-&#954;B activation by up-regulation of anti-inflammatory A20 via modulation of sphingolipid including elevation of intracellular dihydroceramides</article-title><source>J Nutr Biochem</source><year>2019</year><month>02</month><volume>64</volume><fpage>101</fpage><lpage>109</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/30471562" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1016/j.jnutbio.2018.10.013</pub-id><pub-id pub-id-type="medline">30471562</pub-id><pub-id pub-id-type="pii">S0955-2863(18)30722-8</pub-id><pub-id pub-id-type="pmid">30471562</pub-id><pub-id pub-id-type="pmcid">PMC6363855</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahn</surname><given-names>Kwang Seok</given-names></name><name name-style="western"><surname>Sethi</surname><given-names>Gautam</given-names></name><name name-style="western"><surname>Krishnan</surname><given-names>Koyamangalath</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>Bharat B</given-names></name></person-group><article-title>Gamma-tocotrienol inhibits nuclear factor-kappaB signaling pathway through inhibition of receptor-interacting protein and TAK1 leading to suppression of antiapoptotic gene products and potentiation of apoptosis</article-title><source>J Biol Chem</source><year>2007</year><month>01</month><day>05</day><volume>282</volume><issue>1</issue><fpage>809</fpage><lpage>20</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S0021-9258(20)79870-4" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1074/jbc.M610028200</pub-id><pub-id pub-id-type="medline">17114179</pub-id><pub-id pub-id-type="pii">S0021-9258(20)79870-4</pub-id><pub-id pub-id-type="pmid">17114179</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eitsuka</surname><given-names>Takahiro</given-names></name><name name-style="western"><surname>Tatewaki</surname><given-names>Naoto</given-names></name><name name-style="western"><surname>Nishida</surname><given-names>Hiroshi</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>Kiyotaka</given-names></name><name name-style="western"><surname>Miyazawa</surname><given-names>Teruo</given-names></name></person-group><article-title>Synergistic anticancer effect of tocotrienol combined with chemotherapeutic agents or dietary components: a review</article-title><source>Int J Mol Sci</source><year>2016</year><month>09</month><day>22</day><volume>17</volume><issue>10</issue><fpage>1</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/resolver?pii=ijms17101605" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.3390/ijms17101605</pub-id><pub-id pub-id-type="medline">27669218</pub-id><pub-id pub-id-type="pii">ijms17101605</pub-id><pub-id pub-id-type="pmcid">PMC5085638</pub-id><pub-id pub-id-type="pmid">27669218</pub-id></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yap</surname><given-names>WN</given-names></name></person-group><article-title>Tocotrienol-rich fraction attenuates UV-induced inflammaging: a bench to bedside study</article-title><source>J Cosmet Dermatol</source><year>2018</year><month>06</month><day>26</day><volume>17</volume><issue>3</issue><fpage>555</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1111/jocd.12421</pub-id><pub-id pub-id-type="medline">28952200</pub-id><pub-id pub-id-type="pmid">28952200</pub-id></element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yap</surname><given-names>WN</given-names></name><name name-style="western"><surname>Zaiden</surname><given-names>N</given-names></name><name name-style="western"><surname>Xu</surname><given-names>CH</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A</given-names></name><name name-style="western"><surname>Ong</surname><given-names>S</given-names></name><name name-style="western"><surname>Teo</surname><given-names>V</given-names></name><name name-style="western"><surname>Yap</surname><given-names>YL</given-names></name></person-group><article-title>Gamma&#8208; and delta&#8208;tocotrienols inhibit skin melanin synthesis by suppressing constitutive and UV&#8208;induced tyrosinase activation</article-title><source>Pigment Cell Melanoma Res</source><year>2010</year><month>09</month><volume>23</volume><issue>5</issue><fpage>688</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1111/j.1755-148x.2010.00740.x</pub-id><pub-id pub-id-type="pmid">20609176</pub-id></element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weber</surname><given-names>C</given-names></name><name name-style="western"><surname>Podda</surname><given-names>M</given-names></name><name name-style="western"><surname>Rallis</surname><given-names>M</given-names></name><name name-style="western"><surname>Thiele</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Traber</surname><given-names>MG</given-names></name><name name-style="western"><surname>Packer</surname><given-names>L</given-names></name></person-group><article-title>Efficacy of topically applied tocopherols and tocotrienols in protection of murine skin from oxidative damage induced by UV-irradiation</article-title><source>Free Radic Biol Med</source><year>1997</year><month>1</month><volume>22</volume><issue>5</issue><fpage>761</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/s0891-5849(96)00346-2</pub-id><pub-id pub-id-type="medline">9119243</pub-id><pub-id pub-id-type="pii">S0891-5849(96)00346-2</pub-id><pub-id pub-id-type="pmid">9119243</pub-id></element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weber</surname><given-names>C</given-names></name><name name-style="western"><surname>Podda</surname><given-names>M</given-names></name><name name-style="western"><surname>Rallis</surname><given-names>M</given-names></name><name name-style="western"><surname>Thiele</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Traber</surname><given-names>MG</given-names></name><name name-style="western"><surname>Packer</surname><given-names>L</given-names></name></person-group><article-title>Efficacy of topically applied tocopherols and tocotrienols in protection of murine skin from oxidative damage induced by UV-irradiation</article-title><source>Free Radical Biology and Medicine</source><year>1997</year><month>1</month><volume>22</volume><issue>5</issue><fpage>761</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1016/s0891-5849(96)00346-2</pub-id><pub-id pub-id-type="medline">24394657</pub-id><pub-id pub-id-type="pmid">9119243</pub-id></element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamada</surname><given-names>Yasushi</given-names></name><name name-style="western"><surname>Obayashi</surname><given-names>Mariko</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>Tomoko</given-names></name><name name-style="western"><surname>Kiso</surname><given-names>Yoshinobu</given-names></name><name name-style="western"><surname>Ono</surname><given-names>Yoshiko</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>Kanae</given-names></name></person-group><article-title>Dietary tocotrienol reduces UVB-induced skin damage and sesamin enhances tocotrienol effects in hairless mice</article-title><source>J Nutr Sci Vitaminol (Tokyo)</source><year>2008</year><month>04</month><volume>54</volume><issue>2</issue><fpage>117</fpage><lpage>23</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://japanlinkcenter.org/JST.JSTAGE/jnsv/54.117?from=PubMed" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.3177/jnsv.54.117</pub-id><pub-id pub-id-type="medline">18490840</pub-id><pub-id pub-id-type="pii">JST.JSTAGE/jnsv/54.117</pub-id><pub-id pub-id-type="pmid">18490840</pub-id></element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zaiden</surname><given-names>N</given-names></name><name name-style="western"><surname>Yap</surname><given-names>W</given-names></name><name name-style="western"><surname>Ong</surname><given-names>S</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><name name-style="western"><surname>Teo</surname><given-names>V</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Nesaretnam</surname><given-names>K</given-names></name><name name-style="western"><surname>Shiba</surname><given-names>S</given-names></name><name name-style="western"><surname>Yap</surname><given-names>Y</given-names></name></person-group><article-title>Gamma delta tocotrienols reduce hepatic triglyceride synthesis and VLDL secretion</article-title><source>J Atheroscler Thromb</source><year>2010</year><month>10</month><day>27</day><volume>17</volume><issue>10</issue><fpage>1019</fpage><lpage>32</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://joi.jlc.jst.go.jp/JST.JSTAGE/jat/4911?from=PubMed" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.5551/jat.4911</pub-id><pub-id pub-id-type="medline">20702976</pub-id><pub-id pub-id-type="pii">JST.JSTAGE/jat/4911</pub-id><pub-id pub-id-type="pmid">20702976</pub-id></element-citation></ref><ref id="ref44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramanathan</surname><given-names>N</given-names></name><name name-style="western"><surname>Tan</surname><given-names>E</given-names></name><name name-style="western"><surname>Loh</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Soh</surname><given-names>BS</given-names></name><name name-style="western"><surname>Yap</surname><given-names>WN</given-names></name></person-group><article-title>Tocotrienol is a cardioprotective agent against ageing-associated cardiovascular disease and its associated morbidities</article-title><source>Nutr Metab (Lond)</source><year>2018</year><month>1</month><day>19</day><volume>15</volume><issue>1</issue><fpage>6</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://nutritionandmetabolism.biomedcentral.com/articles/10.1186/s12986-018-0244-4" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1186/s12986-018-0244-4</pub-id><pub-id pub-id-type="medline">29387138</pub-id><pub-id pub-id-type="pii">244</pub-id><pub-id pub-id-type="pmid">29387138</pub-id><pub-id pub-id-type="pmcid">PMC5775572</pub-id></element-citation></ref><ref id="ref45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kooyenga</surname><given-names>DK</given-names></name><name name-style="western"><surname>Geller</surname><given-names>M</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>TR</given-names></name><name name-style="western"><surname>Gapor</surname><given-names>A</given-names></name><name name-style="western"><surname>Diakoumakis</surname><given-names>E</given-names></name><name name-style="western"><surname>Bierenbaum</surname><given-names>ML</given-names></name></person-group><article-title>Palm oil antioxidant effects in patients with hyperlipidaemia and carotid stenosis-2 year experience</article-title><source>Asia Pac J Clin Nutr</source><year>1997</year><month>03</month><volume>6</volume><issue>1</issue><fpage>72</fpage><lpage>5</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://apjcn.nhri.org.tw/server/APJCN/6/1/72.pdf" ext-link-type="uri"/></comment><pub-id pub-id-type="medline">24394659</pub-id><pub-id pub-id-type="pmid">24394659</pub-id></element-citation></ref><ref id="ref46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prasad</surname><given-names>K</given-names></name></person-group><article-title>Tocotrienols and cardiovascular health</article-title><source>Curr Pharm Des</source><year>2011</year><month>07</month><day>01</day><volume>17</volume><issue>21</issue><fpage>2147</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.2174/138161211796957418</pub-id><pub-id pub-id-type="medline">21774782</pub-id><pub-id pub-id-type="pii">BSP/CPD/E-Pub/000534</pub-id><pub-id pub-id-type="pmid">21774782</pub-id></element-citation></ref><ref id="ref47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qureshi</surname><given-names>AA</given-names></name><name name-style="western"><surname>Sami</surname><given-names>SA</given-names></name><name name-style="western"><surname>Salser</surname><given-names>WA</given-names></name><name name-style="western"><surname>Khan</surname><given-names>FA</given-names></name></person-group><article-title>Dose-dependent suppression of serum cholesterol by tocotrienol-rich fraction (TRF25) of rice bran in hypercholesterolemic humans</article-title><source>Atherosclerosis</source><year>2002</year><month>03</month><volume>161</volume><issue>1</issue><fpage>199</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/s0021-9150(01)00619-0</pub-id><pub-id pub-id-type="medline">11882333</pub-id><pub-id pub-id-type="pii">S0021-9150(01)00619-0</pub-id><pub-id pub-id-type="pmid">11882333</pub-id></element-citation></ref><ref id="ref48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rasool</surname><given-names>AHG</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>ARA</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>KH</given-names></name><name name-style="western"><surname>Wong</surname><given-names>AR</given-names></name></person-group><article-title>Arterial compliance and vitamin E blood levels with a self emulsifying preparation of tocotrienol rich vitamin E</article-title><source>Arch Pharm Res</source><year>2008</year><month>09</month><day>30</day><volume>31</volume><issue>9</issue><fpage>1212</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1007/s12272-001-1291-5</pub-id><pub-id pub-id-type="medline">18806966</pub-id><pub-id pub-id-type="pmid">18806966</pub-id></element-citation></ref><ref id="ref49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>Q</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Z</given-names></name><name name-style="western"><surname>Nuyt</surname><given-names>AM</given-names></name><name name-style="western"><surname>Audibert</surname><given-names>F</given-names></name><name name-style="western"><surname>Julien</surname><given-names>P</given-names></name><name name-style="western"><surname>Wei</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><name name-style="western"><surname>Fraser</surname><given-names>W</given-names></name><name name-style="western"><surname>Levy</surname><given-names>E</given-names></name></person-group><article-title>Vitamin A and E nutritional status in relation to leptin, adiponectin, IGF-I and IGF-II in early life - a birth cohort study</article-title><source>Sci Rep</source><year>2018</year><month>01</month><day>08</day><volume>8</volume><issue>1</issue><fpage>100</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1038/s41598-017-18531-3" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1038/s41598-017-18531-3</pub-id><pub-id pub-id-type="medline">29311590</pub-id><pub-id pub-id-type="pii">10.1038/s41598-017-18531-3</pub-id><pub-id pub-id-type="pmid">29311590</pub-id><pub-id pub-id-type="pmcid">PMC5758521</pub-id></element-citation></ref><ref id="ref50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>X</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name><name name-style="western"><surname>Cai</surname><given-names>W</given-names></name></person-group><article-title>Vitamin E regulates adipocytokine expression in a rat model of dietary-induced obesity</article-title><source>Exp Biol Med (Maywood)</source><year>2010</year><month>01</month><day>01</day><volume>235</volume><issue>1</issue><fpage>47</fpage><lpage>51</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1258/ebm.2009.009122" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1258/ebm.2009.009122</pub-id><pub-id pub-id-type="medline">20404018</pub-id><pub-id pub-id-type="pii">235/1/47</pub-id><pub-id pub-id-type="pmid">20404018</pub-id></element-citation></ref><ref id="ref51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krawczynska</surname><given-names>A</given-names></name><name name-style="western"><surname>Olczak</surname><given-names>E</given-names></name><name name-style="western"><surname>Rembiszewska</surname><given-names>A</given-names></name><name name-style="western"><surname>Herman</surname><given-names>AP</given-names></name><name name-style="western"><surname>Gromadzka-Ostrowska</surname><given-names>J</given-names></name></person-group><article-title>Time-dependent supplementation of vitamin E influences leptin expression in the aortic layers of rats fed atherogenic diet</article-title><source>J Physiol Pharmacol</source><year>2014</year><month>02</month><volume>65</volume><issue>1</issue><fpage>33</fpage><lpage>9</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.jpp.krakow.pl/journal/archive/02_14/pdf/33_02_14_article.pdf" ext-link-type="uri"/></comment><pub-id pub-id-type="medline">24622827</pub-id><pub-id pub-id-type="pmid">24622827</pub-id></element-citation></ref><ref id="ref52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiong</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wan</surname><given-names>W</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J</given-names></name><name name-style="western"><surname>Luo</surname><given-names>B</given-names></name><name name-style="western"><surname>Gan</surname><given-names>L</given-names></name></person-group><article-title>Effects and mechanisms of vitamin A and vitamin E on the levels of serum leptin and other related cytokines in rats with rheumatoid arthritis</article-title><source>Exp Ther Med</source><year>2014</year><month>08</month><volume>8</volume><issue>2</issue><fpage>499</fpage><lpage>504</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/25009608" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.3892/etm.2014.1777</pub-id><pub-id pub-id-type="medline">25009608</pub-id><pub-id pub-id-type="pii">etm-08-02-0499</pub-id><pub-id pub-id-type="pmid">25009608</pub-id><pub-id pub-id-type="pmcid">PMC4079452</pub-id></element-citation></ref><ref id="ref53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ikeda</surname><given-names>Saiko</given-names></name><name name-style="western"><surname>Tohyama</surname><given-names>Tomoko</given-names></name><name name-style="western"><surname>Yoshimura</surname><given-names>Hiroyuki</given-names></name><name name-style="western"><surname>Hamamura</surname><given-names>Kimio</given-names></name><name name-style="western"><surname>Abe</surname><given-names>Kouichi</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>Kanae</given-names></name></person-group><article-title>Dietary alpha-tocopherol decreases alpha-tocotrienol but not gamma-tocotrienol concentration in rats</article-title><source>J Nutr</source><year>2003</year><month>02</month><volume>133</volume><issue>2</issue><fpage>428</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1093/jn/133.2.428</pub-id><pub-id pub-id-type="medline">12566479</pub-id><pub-id pub-id-type="pmid">12566479</pub-id></element-citation></ref><ref id="ref54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fairus</surname><given-names>Syed</given-names></name><name name-style="western"><surname>Nor</surname><given-names>Rosnah M</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Hwee M</given-names></name><name name-style="western"><surname>Sundram</surname><given-names>Kalyana</given-names></name></person-group><article-title>Alpha-tocotrienol is the most abundant tocotrienol isomer circulated in plasma and lipoproteins after postprandial tocotrienol-rich vitamin E supplementation</article-title><source>Nutr J</source><year>2012</year><month>01</month><day>17</day><volume>11</volume><fpage>5</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://nutritionj.biomedcentral.com/articles/10.1186/1475-2891-11-5" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1186/1475-2891-11-5</pub-id><pub-id pub-id-type="medline">22252050</pub-id><pub-id pub-id-type="pii">1475-2891-11-5</pub-id><pub-id pub-id-type="pmid">22252050</pub-id><pub-id pub-id-type="pmcid">PMC3286415</pub-id></element-citation></ref><ref id="ref55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>C</given-names></name><name name-style="western"><surname>Klein</surname><given-names>A</given-names></name><name name-style="western"><surname>Chin</surname><given-names>K</given-names></name><name name-style="western"><surname>Mo</surname><given-names>H</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>P</given-names></name><name name-style="western"><surname>Yang</surname><given-names>R</given-names></name><name name-style="western"><surname>Chyu</surname><given-names>M</given-names></name><name name-style="western"><surname>Ima-Nirwana</surname><given-names>Soelaiman</given-names></name></person-group><article-title>Tocotrienols for bone health: a translational approach</article-title><source>Ann N Y Acad Sci</source><year>2017</year><month>08</month><volume>1401</volume><issue>1</issue><fpage>150</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1111/nyas.13449</pub-id><pub-id pub-id-type="medline">28891093</pub-id><pub-id pub-id-type="pmid">28891093</pub-id></element-citation></ref><ref id="ref56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>C</given-names></name><name name-style="western"><surname>Mo</surname><given-names>H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Felton</surname><given-names>CK</given-names></name><name name-style="western"><surname>Tomison</surname><given-names>MD</given-names></name><name name-style="western"><surname>Soelaiman</surname><given-names>IN</given-names></name></person-group><article-title>Safety and efficacy of tocotrienol supplementation for bone health in postmenopausal women: protocol for a dose-response double-blinded placebo-controlled randomised trial</article-title><source>BMJ Open</source><year>2016</year><month>12</month><day>23</day><volume>6</volume><issue>12</issue><fpage>e012572</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://bmjopen.bmj.com/lookup/pmidlookup?view=long&amp;pmid=28011809" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1136/bmjopen-2016-012572</pub-id><pub-id pub-id-type="medline">28011809</pub-id><pub-id pub-id-type="pii">bmjopen-2016-012572</pub-id><pub-id pub-id-type="pmcid">PMC5223723</pub-id><pub-id pub-id-type="pmid">28011809</pub-id></element-citation></ref><ref id="ref57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ima-Nirwana</surname><given-names>S</given-names></name><name name-style="western"><surname>Suhaniza</surname><given-names>S</given-names></name></person-group><article-title>Effects of tocopherols and tocotrienols on body composition and bone calcium content in adrenalectomized rats replaced with dexamethasone</article-title><source>J Med Food</source><year>2004</year><month>04</month><volume>7</volume><issue>1</issue><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1089/109662004322984699</pub-id><pub-id pub-id-type="medline">15117552</pub-id><pub-id pub-id-type="pmid">15117552</pub-id></element-citation></ref><ref id="ref58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muhammad</surname><given-names>N</given-names></name><name name-style="western"><surname>Luke</surname><given-names>DA</given-names></name><name name-style="western"><surname>Shuid</surname><given-names>AN</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>N</given-names></name><name name-style="western"><surname>Soelaiman</surname><given-names>I</given-names></name></person-group><article-title>Two different isomers of vitamin e prevent bone loss in postmenopausal osteoporosis rat model</article-title><source>Evid Based Complement Alternat Med</source><year>2012</year><volume>2012</volume><fpage>161527</fpage><lpage>7</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/23118785" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1155/2012/161527</pub-id><pub-id pub-id-type="medline">23118785</pub-id><pub-id pub-id-type="pmid">23118785</pub-id><pub-id pub-id-type="pmcid">PMC3484319</pub-id></element-citation></ref><ref id="ref59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chin</surname><given-names>K</given-names></name><name name-style="western"><surname>Ima-Nirwana</surname><given-names>S</given-names></name></person-group><article-title>The biological effects of tocotrienol on bone: a review on evidence from rodent models</article-title><source>DDDT</source><year>2015</year><month>04</month><fpage>2049</fpage><pub-id pub-id-type="doi">10.2147/dddt.s79660</pub-id><pub-id pub-id-type="pmid">25897211</pub-id><pub-id pub-id-type="pmcid">PMC4396581</pub-id></element-citation></ref><ref id="ref60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brooks</surname><given-names>R</given-names></name><name name-style="western"><surname>Kalia</surname><given-names>P</given-names></name><name name-style="western"><surname>Ireland</surname><given-names>DC</given-names></name><name name-style="western"><surname>Beeton</surname><given-names>C</given-names></name><name name-style="western"><surname>Rushton</surname><given-names>N</given-names></name></person-group><article-title>Direct inhibition of osteoclast formation and activity by the vitamin E isomer gamma-tocotrienol</article-title><source>Int J Vitam Nutr Res</source><year>2011</year><month>11</month><volume>81</volume><issue>6</issue><fpage>358</fpage><lpage>67</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.imrpress.com/journal/IJVNR/81/6/10.1024/0300-9831/a000087" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1024/0300-9831/a000087</pub-id><pub-id pub-id-type="medline">22673919</pub-id><pub-id pub-id-type="pmid">22673919</pub-id></element-citation></ref><ref id="ref61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ha</surname><given-names>H</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><name name-style="western"><surname>Lee</surname><given-names>ZH</given-names></name></person-group><article-title>&#945;-Tocotrienol inhibits osteoclastic bone resorption by suppressing RANKL expression and signaling and bone resorbing activity</article-title><source>Biochem Biophys Res Commun</source><year>2011</year><month>03</month><day>25</day><volume>406</volume><issue>4</issue><fpage>546</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2011.02.085</pub-id><pub-id pub-id-type="medline">21352805</pub-id><pub-id pub-id-type="pii">S0006-291X(11)00290-7</pub-id><pub-id pub-id-type="pmid">21352805</pub-id></element-citation></ref><ref id="ref62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nizar</surname><given-names>AM</given-names></name><name name-style="western"><surname>Nazrun</surname><given-names>AS</given-names></name><name name-style="western"><surname>Norazlina</surname><given-names>M</given-names></name><name name-style="western"><surname>Norliza</surname><given-names>M</given-names></name><name name-style="western"><surname>Ima Nirwana</surname><given-names>S</given-names></name></person-group><article-title>Low dose of tocotrienols protects osteoblasts against oxidative stress</article-title><source>Clin Ter</source><year>2011</year><volume>162</volume><issue>6</issue><fpage>533</fpage><lpage>8</lpage><pub-id pub-id-type="medline">22262323</pub-id><pub-id pub-id-type="pmid">22262323</pub-id></element-citation></ref><ref id="ref63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Norazlina</surname><given-names>M</given-names></name><name name-style="western"><surname>Ima-Nirwana</surname><given-names>S</given-names></name><name name-style="western"><surname>Gapor</surname><given-names>M</given-names></name><name name-style="western"><surname>Khalid</surname><given-names>B</given-names></name></person-group><article-title>Palm vitamin E is comparable to alpha-tocopherol in maintaining bone mineral density in ovariectomised female rats</article-title><source>Exp Clin Endocrinol Diabetes</source><year>2000</year><month>12</month><day>31</day><volume>108</volume><issue>4</issue><fpage>305</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1055/s-2000-7758</pub-id><pub-id pub-id-type="medline">10961363</pub-id><pub-id pub-id-type="pmid">10961363</pub-id></element-citation></ref><ref id="ref64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdul-Majeed</surname><given-names>S</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>N</given-names></name><name name-style="western"><surname>Soelaiman</surname><given-names>I</given-names></name></person-group><article-title>A review on the use of statins and tocotrienols, individually or in combination for the treatment of osteoporosis</article-title><source>Curr Drug Targets</source><year>2013</year><month>12</month><day>31</day><volume>14</volume><issue>13</issue><fpage>1579</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.2174/13894501113149990193</pub-id><pub-id pub-id-type="medline">23848479</pub-id><pub-id pub-id-type="pii">53835</pub-id><pub-id pub-id-type="pmid">23848479</pub-id></element-citation></ref><ref id="ref65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muhammad</surname><given-names>Norliza</given-names></name><name name-style="western"><surname>Luke</surname><given-names>Douglas Alwyn</given-names></name><name name-style="western"><surname>Shuid</surname><given-names>Ahmad Nazrun</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>Norazlina</given-names></name><name name-style="western"><surname>Soelaiman</surname><given-names>Ima Nirwana</given-names></name></person-group><article-title>Tocotrienol supplementation in postmenopausal osteoporosis: evidence from a laboratory study</article-title><source>Clinics (Sao Paulo)</source><year>2013</year><month>10</month><volume>68</volume><issue>10</issue><fpage>1338</fpage><lpage>43</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S1807-5932(22)02966-0" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.6061/clinics/2013(10)08</pub-id><pub-id pub-id-type="medline">24212841</pub-id><pub-id pub-id-type="pii">S1807-5932(22)02966-0</pub-id><pub-id pub-id-type="pmid">24212841</pub-id><pub-id pub-id-type="pmcid">PMC3798611</pub-id></element-citation></ref><ref id="ref66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Norazlina</surname><given-names>M</given-names></name><name name-style="western"><surname>Lee</surname><given-names>P L</given-names></name><name name-style="western"><surname>Lukman</surname><given-names>H I</given-names></name><name name-style="western"><surname>Nazrun</surname><given-names>A S</given-names></name><name name-style="western"><surname>Ima-Nirwana</surname><given-names>S</given-names></name></person-group><article-title>Effects of vitamin E supplementation on bone metabolism in nicotine-treated rats</article-title><source>Singapore Med J</source><year>2007</year><month>03</month><volume>48</volume><issue>3</issue><fpage>195</fpage><lpage>9</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://smj.sma.org.sg/4803/4803a2.pdf" ext-link-type="uri"/></comment><pub-id pub-id-type="medline">17342286</pub-id><pub-id pub-id-type="pmid">17342286</pub-id></element-citation></ref><ref id="ref67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wan Nasri</surname><given-names>WN</given-names></name><name name-style="western"><surname>Makpol</surname><given-names>S</given-names></name><name name-style="western"><surname>Mazlan</surname><given-names>M</given-names></name><name name-style="western"><surname>Tooyama</surname><given-names>I</given-names></name><name name-style="western"><surname>Wan Ngah</surname><given-names>WZ</given-names></name><name name-style="western"><surname>Damanhuri</surname><given-names>HA</given-names></name></person-group><article-title>Tocotrienol rich fraction supplementation modulate brain hippocampal gene expression in APPswe/PS1dE9 Alzheimer&#8217;s disease mouse model</article-title><source>Journal of Alzheimer&#8217;s Disease</source><year>2018</year><month>11</month><day>28</day><volume>70</volume><issue>s1</issue><fpage>S239</fpage><lpage>S254</lpage><pub-id pub-id-type="doi">10.3233/jad-180496</pub-id><pub-id pub-id-type="pmcid">PMC6700627</pub-id><pub-id pub-id-type="pmid">30507571</pub-id></element-citation></ref><ref id="ref68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazlan</surname><given-names>M</given-names></name><name name-style="western"><surname>Hamezah</surname><given-names>HS</given-names></name><name name-style="western"><surname>Taridi</surname><given-names>NM</given-names></name><name name-style="western"><surname>Jing</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wan Ngah</surname><given-names>WZ</given-names></name><name name-style="western"><surname>Damanhuri</surname><given-names>HA</given-names></name></person-group><article-title>Effects of aging and tocotrienol-rich fraction supplementation on brain arginine metabolism in rats</article-title><source>Oxid Med Cell Longev</source><year>2017</year><month>11</month><day>19</day><volume>2017</volume><issue>1</issue><fpage>6019796</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/29348790" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1155/2017/6019796</pub-id><pub-id pub-id-type="medline">29348790</pub-id><pub-id pub-id-type="pmid">29348790</pub-id><pub-id pub-id-type="pmcid">PMC5733770</pub-id></element-citation></ref><ref id="ref69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sen</surname><given-names>CK</given-names></name><name name-style="western"><surname>Rink</surname><given-names>C</given-names></name><name name-style="western"><surname>Khanna</surname><given-names>S</given-names></name></person-group><article-title>Palm oil-derived natural vitamin E alpha-tocotrienol in brain health and disease</article-title><source>J Am Coll Nutr</source><year>2010</year><month>06</month><volume>29</volume><issue>3 Suppl</issue><fpage>314S</fpage><lpage>323S</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/20823491" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1080/07315724.2010.10719846</pub-id><pub-id pub-id-type="medline">20823491</pub-id><pub-id pub-id-type="pii">29/3_Supplement_1/314S</pub-id><pub-id pub-id-type="pmid">20823491</pub-id><pub-id pub-id-type="pmcid">PMC3065441</pub-id></element-citation></ref><ref id="ref70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yatin</surname><given-names>S M</given-names></name><name name-style="western"><surname>Varadarajan</surname><given-names>S</given-names></name><name name-style="western"><surname>Link</surname><given-names>C D</given-names></name><name name-style="western"><surname>Butterfield</surname><given-names>D A</given-names></name></person-group><article-title>In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide (1-42)</article-title><source>Neurobiol Aging</source><year>1999</year><volume>20</volume><issue>3</issue><fpage>325</fpage><lpage>30; discussion 339</lpage><pub-id pub-id-type="doi">10.1016/s0197-4580(99)00056-1</pub-id><pub-id pub-id-type="medline">10588580</pub-id><pub-id pub-id-type="pii">S0197458099000561</pub-id><pub-id pub-id-type="pmid">10588580</pub-id></element-citation></ref><ref id="ref71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khanna</surname><given-names>Savita</given-names></name><name name-style="western"><surname>Roy</surname><given-names>Sashwati</given-names></name><name name-style="western"><surname>Parinandi</surname><given-names>Narasimham L</given-names></name><name name-style="western"><surname>Maurer</surname><given-names>Mariah</given-names></name><name name-style="western"><surname>Sen</surname><given-names>Chandan K</given-names></name></person-group><article-title>Characterization of the potent neuroprotective properties of the natural vitamin E alpha-tocotrienol</article-title><source>J Neurochem</source><year>2006</year><month>09</month><volume>98</volume><issue>5</issue><fpage>1474</fpage><lpage>86</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/16923160" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1111/j.1471-4159.2006.04000.x</pub-id><pub-id pub-id-type="medline">16923160</pub-id><pub-id pub-id-type="pii">JNC4000</pub-id><pub-id pub-id-type="pmid">16923160</pub-id><pub-id pub-id-type="pmcid">PMC1847628</pub-id></element-citation></ref><ref id="ref72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teo</surname><given-names>CWL</given-names></name><name name-style="western"><surname>Png</surname><given-names>SJY</given-names></name><name name-style="western"><surname>Ung</surname><given-names>YW</given-names></name><name name-style="western"><surname>Yap</surname><given-names>WN</given-names></name></person-group><article-title>Therapeutic effects of intranasal tocotrienol-rich fraction on rhinitis symptoms in platelet-activating factor induced allergic rhinitis</article-title><source>Allergy Asthma Clin Immunol</source><year>2022</year><month>06</month><day>13</day><volume>18</volume><issue>1</issue><fpage>52</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://aacijournal.biomedcentral.com/articles/10.1186/s13223-022-00695-x" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1186/s13223-022-00695-x</pub-id><pub-id pub-id-type="medline">35698169</pub-id><pub-id pub-id-type="pii">10.1186/s13223-022-00695-x</pub-id><pub-id pub-id-type="pmid">35698169</pub-id><pub-id pub-id-type="pmcid">PMC9195334</pub-id></element-citation></ref><ref id="ref73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Par</surname><given-names>Ryx</given-names></name><name name-style="western"><surname>Teo</surname><given-names>Cwl</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Jjk</given-names></name><name name-style="western"><surname>Ung</surname><given-names>Yw</given-names></name><name name-style="western"><surname>Heng</surname><given-names>Ks</given-names></name><name name-style="western"><surname>Hang</surname><given-names>Lt</given-names></name><name name-style="western"><surname>Yeo</surname><given-names>M</given-names></name><name name-style="western"><surname>Yap</surname><given-names>Wn</given-names></name></person-group><article-title>An open-label, single-arm pilot study of tocotrienols supplementation on improving memory and attention in healthy young adults</article-title><source>Journal of Functional Foods</source><year>2022</year><month>05</month><volume>92</volume><fpage>105055</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1016/j.jff.2022.105055" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1016/j.jff.2022.105055</pub-id></element-citation></ref><ref id="ref74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nor Azman</surname><given-names>NHE</given-names></name><name name-style="western"><surname>Goon</surname><given-names>JA</given-names></name><name name-style="western"><surname>Abdul Ghani</surname><given-names>SM</given-names></name><name name-style="western"><surname>Hamid</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wan Ngah</surname><given-names>WZ</given-names></name></person-group><article-title>Comparing palm oil, tocotrienol-rich fraction and &#945;-tocopherol supplementation on the antioxidant levels of older adults</article-title><source>Antioxidants (Basel)</source><year>2018</year><month>05</month><day>28</day><volume>7</volume><issue>6</issue><fpage>1</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/resolver?pii=antiox7060074" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.3390/antiox7060074</pub-id><pub-id pub-id-type="medline">29843393</pub-id><pub-id pub-id-type="pii">antiox7060074</pub-id><pub-id pub-id-type="pmcid">PMC6025588</pub-id><pub-id pub-id-type="pmid">29843393</pub-id></element-citation></ref><ref id="ref75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goon</surname><given-names>JA</given-names></name><name name-style="western"><surname>Nor Azman</surname><given-names>NHE</given-names></name><name name-style="western"><surname>Abdul Ghani</surname><given-names>SM</given-names></name><name name-style="western"><surname>Hamid</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wan Ngah</surname><given-names>WZ</given-names></name></person-group><article-title>Comparing palm oil tocotrienol rich fraction with &#945;-tocopherol supplementation on oxidative stress in healthy older adults</article-title><source>Clin Nutr ESPEN</source><year>2017</year><month>10</month><volume>21</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.clnesp.2017.07.004</pub-id><pub-id pub-id-type="medline">30014863</pub-id><pub-id pub-id-type="pii">S2405-4577(17)30273-5</pub-id><pub-id pub-id-type="pmid">30014863</pub-id></element-citation></ref><ref id="ref76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siveen</surname><given-names>KS</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>KS</given-names></name><name name-style="western"><surname>Ong</surname><given-names>TH</given-names></name><name name-style="western"><surname>Shanmugam</surname><given-names>MK</given-names></name><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><name name-style="western"><surname>Yap</surname><given-names>WN</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>AP</given-names></name><name name-style="western"><surname>Fong</surname><given-names>CW</given-names></name><name name-style="western"><surname>Tergaonkar</surname><given-names>V</given-names></name><name name-style="western"><surname>Hui</surname><given-names>KM</given-names></name><name name-style="western"><surname>Sethi</surname><given-names>G</given-names></name></person-group><article-title>Y-tocotrienol inhibits angiogenesis-dependent growth of human hepatocellular carcinoma through abrogation of AKT/mTOR pathway in an orthotopic mouse model</article-title><source>Oncotarget</source><year>2014</year><month>04</month><day>15</day><volume>5</volume><issue>7</issue><fpage>1897</fpage><lpage>911</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.1876" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.18632/oncotarget.1876</pub-id><pub-id pub-id-type="medline">24722367</pub-id><pub-id pub-id-type="pii">1876</pub-id><pub-id pub-id-type="pmid">24722367</pub-id><pub-id pub-id-type="pmcid">PMC4039111</pub-id></element-citation></ref><ref id="ref77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manu</surname><given-names>K</given-names></name><name name-style="western"><surname>Shanmugam</surname><given-names>M</given-names></name><name name-style="western"><surname>Ramachandran</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><name name-style="western"><surname>Fong</surname><given-names>C</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name><name name-style="western"><surname>Tan</surname><given-names>P</given-names></name><name name-style="western"><surname>Sethi</surname><given-names>G</given-names></name></person-group><article-title>First evidence that &#947;-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-&#954;B pathway</article-title><source>Clin Cancer Res</source><year>2012</year><month>04</month><day>15</day><volume>18</volume><issue>8</issue><fpage>2220</fpage><lpage>9</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://research-repository.uwa.edu.au/en/publications/first-evidence-that-y-tocotrienol-inhibits-the-growth-of-human-ga" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-2470</pub-id><pub-id pub-id-type="medline">22351692</pub-id><pub-id pub-id-type="pii">1078-0432.CCR-11-2470</pub-id><pub-id pub-id-type="pmid">22351692</pub-id></element-citation></ref><ref id="ref78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luk</surname><given-names>SU</given-names></name><name name-style="western"><surname>Yap</surname><given-names>WN</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lee</surname><given-names>DT</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S</given-names></name><name name-style="western"><surname>Lee</surname><given-names>TKW</given-names></name><name name-style="western"><surname>Vasireddy</surname><given-names>RS</given-names></name><name name-style="western"><surname>Wong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ching</surname><given-names>YP</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>C</given-names></name><name name-style="western"><surname>Yap</surname><given-names>YL</given-names></name><name name-style="western"><surname>Ling</surname><given-names>M</given-names></name></person-group><article-title>Gamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population</article-title><source>Int J Cancer</source><year>2011</year><month>05</month><day>01</day><volume>128</volume><issue>9</issue><fpage>2182</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1002/ijc.25546</pub-id><pub-id pub-id-type="medline">20617516</pub-id><pub-id pub-id-type="pmid">20617516</pub-id></element-citation></ref><ref id="ref79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yap</surname><given-names>WN</given-names></name><name name-style="western"><surname>Zaiden</surname><given-names>N</given-names></name><name name-style="western"><surname>Tan</surname><given-names>YL</given-names></name><name name-style="western"><surname>Ngoh</surname><given-names>CP</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>XW</given-names></name><name name-style="western"><surname>Wong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ling</surname><given-names>M</given-names></name><name name-style="western"><surname>Yap</surname><given-names>YL</given-names></name></person-group><article-title>Id1, inhibitor of differentiation, is a key protein mediating anti-tumor responses of gamma-tocotrienol in breast cancer cells</article-title><source>Cancer Lett</source><year>2010</year><month>05</month><day>28</day><volume>291</volume><issue>2</issue><fpage>187</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2009.10.012</pub-id><pub-id pub-id-type="medline">19926394</pub-id><pub-id pub-id-type="pii">S0304-3835(09)00634-X</pub-id><pub-id pub-id-type="pmid">19926394</pub-id></element-citation></ref><ref id="ref80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghani</surname><given-names>SMA</given-names></name><name name-style="western"><surname>Goon</surname><given-names>JA</given-names></name><name name-style="western"><surname>Azman</surname><given-names>NHEN</given-names></name><name name-style="western"><surname>Zakaria</surname><given-names>SNA</given-names></name><name name-style="western"><surname>Hamid</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ngah</surname><given-names>WZW</given-names></name></person-group><article-title>Comparing the effects of vitamin E tocotrienol-rich fraction supplementation and &#945;-tocopherol supplementation on gene expression in healthy older adults</article-title><source>Clinics (Sao Paulo)</source><year>2019</year><month>03</month><day>07</day><volume>74</volume><fpage>e688</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S1807-5932(22)00635-4" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.6061/clinics/2019/e688</pub-id><pub-id pub-id-type="medline">30864639</pub-id><pub-id pub-id-type="pii">S1807-5932(22)00635-4</pub-id><pub-id pub-id-type="pmid">30864639</pub-id><pub-id pub-id-type="pmcid">PMC6438703</pub-id></element-citation></ref><ref id="ref81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heng</surname><given-names>EC</given-names></name><name name-style="western"><surname>Karsani</surname><given-names>SA</given-names></name><name name-style="western"><surname>Abdul Rahman</surname><given-names>M</given-names></name><name name-style="western"><surname>Abdul Hamid</surname><given-names>NA</given-names></name><name name-style="western"><surname>Hamid</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wan Ngah</surname><given-names>WZ</given-names></name></person-group><article-title>Supplementation with tocotrienol-rich fraction alters the plasma levels of apolipoprotein A-I precursor, apolipoprotein E precursor, and C-reactive protein precursor from young and old individuals</article-title><source>Eur J Nutr</source><year>2013</year><month>10</month><day>4</day><volume>52</volume><issue>7</issue><fpage>1811</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1007/s00394-012-0485-3</pub-id><pub-id pub-id-type="medline">23287846</pub-id><pub-id pub-id-type="pmid">23287846</pub-id></element-citation></ref><ref id="ref82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahalingam</surname><given-names>D</given-names></name><name name-style="western"><surname>Radhakrishnan</surname><given-names>AK</given-names></name><name name-style="western"><surname>Amom</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>N</given-names></name><name name-style="western"><surname>Nesaretnam</surname><given-names>K</given-names></name></person-group><article-title>Effects of supplementation with tocotrienol-rich fraction on immune response to tetanus toxoid immunization in normal healthy volunteers</article-title><source>Eur J Clin Nutr</source><year>2011</year><month>01</month><day>22</day><volume>65</volume><issue>1</issue><fpage>63</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/ejcn.2010.184</pub-id><pub-id pub-id-type="medline">20859299</pub-id><pub-id pub-id-type="pii">ejcn2010184</pub-id><pub-id pub-id-type="pmid">20859299</pub-id></element-citation></ref><ref id="ref83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chin</surname><given-names>S</given-names></name><name name-style="western"><surname>Ibahim</surname><given-names>J</given-names></name><name name-style="western"><surname>Makpol</surname><given-names>S</given-names></name><name name-style="western"><surname>Abdul Hamid</surname><given-names>NA</given-names></name><name name-style="western"><surname>Abdul Latiff</surname><given-names>A</given-names></name><name name-style="western"><surname>Zakaria</surname><given-names>Z</given-names></name><name name-style="western"><surname>Mazlan</surname><given-names>M</given-names></name><name name-style="western"><surname>Mohd Yusof</surname><given-names>YA</given-names></name><name name-style="western"><surname>Abdul Karim</surname><given-names>A</given-names></name><name name-style="western"><surname>Wan Ngah</surname><given-names>WZ</given-names></name></person-group><article-title>Tocotrienol rich fraction supplementation improved lipid profile and oxidative status in healthy older adults: a randomized controlled study</article-title><source>Nutr Metab (Lond)</source><year>2011</year><month>06</month><day>24</day><volume>8</volume><issue>1</issue><fpage>42</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://nutritionandmetabolism.biomedcentral.com/articles/10.1186/1743-7075-8-42" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1186/1743-7075-8-42</pub-id><pub-id pub-id-type="medline">21702918</pub-id><pub-id pub-id-type="pii">1743-7075-8-42</pub-id><pub-id pub-id-type="pmid">21702918</pub-id><pub-id pub-id-type="pmcid">PMC3148956</pub-id></element-citation></ref><ref id="ref84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Radhakrishnan</surname><given-names>AK</given-names></name><name name-style="western"><surname>Lee</surname><given-names>A</given-names></name><name name-style="western"><surname>Wong</surname><given-names>P</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>J</given-names></name><name name-style="western"><surname>Aung</surname><given-names>H</given-names></name><name name-style="western"><surname>Nesaretnam</surname><given-names>K</given-names></name></person-group><article-title>Daily supplementation of tocotrienol-rich fraction or &#945;-tocopherol did not induce immunomodulatory changes in healthy human volunteers</article-title><source>Br J Nutr</source><year>2008</year><month>08</month><day>15</day><volume>101</volume><issue>6</issue><fpage>810</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1017/s0007114508039998</pub-id><pub-id pub-id-type="pmid">18702848</pub-id></element-citation></ref><ref id="ref85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pallast</surname><given-names>EG</given-names></name><name name-style="western"><surname>Schouten</surname><given-names>EG</given-names></name><name name-style="western"><surname>de Waart</surname><given-names>FG</given-names></name><name name-style="western"><surname>Fonk</surname><given-names>HC</given-names></name><name name-style="western"><surname>Doekes</surname><given-names>G</given-names></name><name name-style="western"><surname>von Blomberg</surname><given-names>BM</given-names></name><name name-style="western"><surname>Kok</surname><given-names>FJ</given-names></name></person-group><article-title>Effect of 50- and 100-mg vitamin E supplements on cellular immune function in noninstitutionalized elderly persons</article-title><source>Am J Clin Nutr</source><year>1999</year><month>06</month><volume>69</volume><issue>6</issue><fpage>1273</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1093/ajcn/69.6.1273</pub-id><pub-id pub-id-type="medline">10357750</pub-id><pub-id pub-id-type="pmid">10357750</pub-id></element-citation></ref><ref id="ref86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meydani</surname><given-names>SN</given-names></name><name name-style="western"><surname>Meydani</surname><given-names>M</given-names></name><name name-style="western"><surname>Blumberg</surname><given-names>JB</given-names></name><name name-style="western"><surname>Leka</surname><given-names>LS</given-names></name><name name-style="western"><surname>Pedrosa</surname><given-names>M</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>R</given-names></name><name name-style="western"><surname>Schaefer</surname><given-names>EJ</given-names></name></person-group><article-title>Assessment of the safety of supplementation with different amounts of vitamin E in healthy older adults</article-title><source>Am J Clin Nutr</source><year>1998</year><month>08</month><volume>68</volume><issue>2</issue><fpage>311</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/ajcn/68.2.311</pub-id><pub-id pub-id-type="medline">9701188</pub-id><pub-id pub-id-type="pmid">9701188</pub-id></element-citation></ref><ref id="ref87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meydani</surname><given-names>SN</given-names></name><name name-style="western"><surname>Meydani</surname><given-names>M</given-names></name><name name-style="western"><surname>Blumberg</surname><given-names>J B</given-names></name><name name-style="western"><surname>Leka</surname><given-names>L S</given-names></name><name name-style="western"><surname>Siber</surname><given-names>G</given-names></name><name name-style="western"><surname>Loszewski</surname><given-names>R</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>C</given-names></name><name name-style="western"><surname>Pedrosa</surname><given-names>M C</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>R D</given-names></name><name name-style="western"><surname>Stollar</surname><given-names>B D</given-names></name></person-group><article-title>Vitamin E supplementation and in vivo immune response in healthy elderly subjects. A randomized controlled trial</article-title><source>JAMA</source><year>1997</year><month>05</month><day>07</day><volume>277</volume><issue>17</issue><fpage>1380</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1001/jama.1997.03540410058031</pub-id><pub-id pub-id-type="medline">9134944</pub-id><pub-id pub-id-type="pmid">9134944</pub-id></element-citation></ref><ref id="ref88"><label>88</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>NutraSource</collab></person-group><article-title>Generally Recognized As Safe (GUS) Determination for the Use of Palm Tocotrienol Rich Fractions (TRF) as Ingredients in Food</article-title><source>KLK OLEO</source><year>2009</year><date-in-citation content-type="access-date">2025-08-12</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.klkoleo.com/davoslife/wp-content/uploads/2017/04/GRAS-determination-for-the-use-of-palm-tocotrienol-rich-fractions-as-ingredient-in-food.compressed.pdf" ext-link-type="uri">https://www.klkoleo.com/davoslife/wp-content/uploads/2017/04/GRAS-determination-for-the-use-of-palm-tocotrienol-rich-fractions-as-ingredient-in-food.compressed.pdf</ext-link></comment></element-citation></ref><ref id="ref89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Misra</surname><given-names>S</given-names></name></person-group><article-title>Randomized double blind placebo control studies, the "gold standard" in intervention based studies</article-title><source>Indian J Sex Transm Dis AIDS</source><year>2012</year><month>07</month><volume>33</volume><issue>2</issue><fpage>131</fpage><lpage>134</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/23188942" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.4103/0253-7184.102130</pub-id><pub-id pub-id-type="medline">23188942</pub-id><pub-id pub-id-type="pii">IJSTD-33-131</pub-id><pub-id pub-id-type="pmid">23188942</pub-id><pub-id pub-id-type="pmcid">PMC3505292</pub-id></element-citation></ref><ref id="ref90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liguori</surname><given-names>I</given-names></name><name name-style="western"><surname>Russo</surname><given-names>G</given-names></name><name name-style="western"><surname>Curcio</surname><given-names>F</given-names></name><name name-style="western"><surname>Bulli</surname><given-names>G</given-names></name><name name-style="western"><surname>Aran</surname><given-names>L</given-names></name><name name-style="western"><surname>Della-Morte</surname><given-names>D</given-names></name><name name-style="western"><surname>Gargiulo</surname><given-names>G</given-names></name><name name-style="western"><surname>Testa</surname><given-names>G</given-names></name><name name-style="western"><surname>Cacciatore</surname><given-names>F</given-names></name><name name-style="western"><surname>Bonaduce</surname><given-names>D</given-names></name><name name-style="western"><surname>Abete</surname><given-names>P</given-names></name></person-group><article-title>Oxidative stress, aging, and diseases</article-title><source>CIA</source><year>2018</year><month>04</month><volume>Volume 13</volume><fpage>757</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.2147/cia.s158513</pub-id><pub-id pub-id-type="pmcid">PMC5927356</pub-id><pub-id pub-id-type="pmid">29731617</pub-id></element-citation></ref><ref id="ref91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malavolta</surname><given-names>Marco</given-names></name><name name-style="western"><surname>Pierpaoli</surname><given-names>Elisa</given-names></name><name name-style="western"><surname>Giacconi</surname><given-names>Robertina</given-names></name><name name-style="western"><surname>Basso</surname><given-names>Andrea</given-names></name><name name-style="western"><surname>Cardelli</surname><given-names>Maurizio</given-names></name><name name-style="western"><surname>Piacenza</surname><given-names>Francesco</given-names></name><name name-style="western"><surname>Provinciali</surname><given-names>Mauro</given-names></name></person-group><article-title>Anti-inflammatory activity of tocotrienols in age-related pathologies: a SASPected involvement of cellular senescence</article-title><source>Biol Proced Online</source><year>2018</year><volume>20</volume><fpage>22</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://biologicalproceduresonline.biomedcentral.com/articles/10.1186/s12575-018-0087-4" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1186/s12575-018-0087-4</pub-id><pub-id pub-id-type="medline">30479579</pub-id><pub-id pub-id-type="pii">87</pub-id><pub-id pub-id-type="pmid">30479579</pub-id><pub-id pub-id-type="pmcid">PMC6247629</pub-id></element-citation></ref><ref id="ref92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>Eunhee</given-names></name><name name-style="western"><surname>Elmassry</surname><given-names>Moamen M</given-names></name><name name-style="western"><surname>Kottapalli</surname><given-names>Pratibha</given-names></name><name name-style="western"><surname>Kottapalli</surname><given-names>Kameswara Rao</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>Gurvinder</given-names></name><name name-style="western"><surname>Dufour</surname><given-names>Jannette M</given-names></name><name name-style="western"><surname>Wright</surname><given-names>Kandis</given-names></name><name name-style="western"><surname>Ramalingam</surname><given-names>Latha</given-names></name><name name-style="western"><surname>Moustaid-Moussa</surname><given-names>Naima</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Rui</given-names></name><name name-style="western"><surname>Hamood</surname><given-names>Abdul N</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Chwan-Li</given-names></name></person-group><article-title>Metabolic benefits of annatto-extracted tocotrienol on glucose homeostasis, inflammation, and gut microbiome</article-title><source>Nutr Res</source><year>2020</year><month>05</month><volume>77</volume><fpage>97</fpage><lpage>107</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S0271-5317(19)30777-8" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1016/j.nutres.2020.04.001</pub-id><pub-id pub-id-type="medline">32438021</pub-id><pub-id pub-id-type="pii">S0271-5317(19)30777-8</pub-id><pub-id pub-id-type="pmid">32438021</pub-id></element-citation></ref><ref id="ref93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morgan</surname><given-names>Nevvin Raaj</given-names></name><name name-style="western"><surname>Magalingam</surname><given-names>Kasthuri Bai</given-names></name><name name-style="western"><surname>Radhakrishnan</surname><given-names>Ammu Kutty</given-names></name><name name-style="western"><surname>Arumugam</surname><given-names>Mohan</given-names></name><name name-style="western"><surname>Jamil</surname><given-names>Adawiyah</given-names></name><name name-style="western"><surname>Bhuvanendran</surname><given-names>Saatheeyavaane</given-names></name></person-group><article-title>Explicating the multifunctional roles of tocotrienol and squalene in promoting skin health</article-title><source>Skin Health Dis</source><year>2024</year><month>10</month><volume>4</volume><issue>5</issue><fpage>e448</fpage><pub-id pub-id-type="doi">10.1002/ski2.448</pub-id><pub-id pub-id-type="medline">39355739</pub-id><pub-id pub-id-type="pii">SKI2448</pub-id><pub-id pub-id-type="pmid">39355739</pub-id><pub-id pub-id-type="pmcid">PMC11442061</pub-id></element-citation></ref><ref id="ref94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yatin</surname><given-names>Servet M.</given-names></name><name name-style="western"><surname>Varadarajan</surname><given-names>Sridhar</given-names></name><name name-style="western"><surname>Butterfield</surname><given-names>D. Allan</given-names></name></person-group><article-title>Vitamin E prevents Alzheimer's amyloid beta-peptide (1-42)-induced neuronal protein oxidation and reactive oxygen species production</article-title><source>J Alzheimers Dis</source><year>2000</year><month>06</month><volume>2</volume><issue>2</issue><fpage>123</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.3233/jad-2000-2212</pub-id><pub-id pub-id-type="medline">12214102</pub-id><pub-id pub-id-type="pmid">12214102</pub-id></element-citation></ref><ref id="ref95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qureshi</surname><given-names>A A</given-names></name><name name-style="western"><surname>Mo</surname><given-names>H</given-names></name><name name-style="western"><surname>Packer</surname><given-names>L</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>D M</given-names></name></person-group><article-title>Isolation and identification of novel tocotrienols from rice bran with hypocholesterolemic, antioxidant, and antitumor properties</article-title><source>J Agric Food Chem</source><year>2000</year><month>08</month><volume>48</volume><issue>8</issue><fpage>3130</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1021/jf000099t</pub-id><pub-id pub-id-type="medline">10956081</pub-id><pub-id pub-id-type="pii">jf000099t</pub-id><pub-id pub-id-type="pmid">10956081</pub-id></element-citation></ref><ref id="ref96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Budin</surname><given-names>Siti Balkis</given-names></name><name name-style="western"><surname>Othman</surname><given-names>Faizah</given-names></name><name name-style="western"><surname>Louis</surname><given-names>Santhana Raj</given-names></name><name name-style="western"><surname>Bakar</surname><given-names>Mokhtar Abu</given-names></name><name name-style="western"><surname>Das</surname><given-names>Srijit</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>Jamaludin</given-names></name></person-group><article-title>The effects of palm oil tocotrienol-rich fraction supplementation on biochemical parameters, oxidative stress and the vascular wall of streptozotocin-induced diabetic rats</article-title><source>Clinics (Sao Paulo)</source><year>2009</year><volume>64</volume><issue>3</issue><fpage>235</fpage><lpage>44</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S1807-5932(22)02676-X" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1590/s1807-59322009000300015</pub-id><pub-id pub-id-type="medline">19330251</pub-id><pub-id pub-id-type="pii">S1807-5932(22)02676-X</pub-id><pub-id pub-id-type="pmid">19330251</pub-id><pub-id pub-id-type="pmcid">PMC2666447</pub-id></element-citation></ref><ref id="ref97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>BL</given-names></name><name name-style="western"><surname>Norhaizan</surname><given-names>ME</given-names></name><name name-style="western"><surname>Liew</surname><given-names>W</given-names></name><name name-style="western"><surname>Sulaiman Rahman</surname><given-names>H</given-names></name></person-group><article-title>Antioxidant and oxidative stress: a mutual interplay in age-related diseases</article-title><source>Front Pharmacol</source><year>2018</year><month>10</month><day>16</day><volume>9</volume><fpage>1162</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/30405405" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.3389/fphar.2018.01162</pub-id><pub-id pub-id-type="medline">30405405</pub-id><pub-id pub-id-type="pmid">30405405</pub-id><pub-id pub-id-type="pmcid">PMC6204759</pub-id></element-citation></ref><ref id="ref98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Razali</surname><given-names>R</given-names></name><name name-style="western"><surname>Jean-Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Jaffar</surname><given-names>A</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>M</given-names></name><name name-style="western"><surname>Shah</surname><given-names>SA</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>N</given-names></name><name name-style="western"><surname>Din</surname><given-names>NC</given-names></name><name name-style="western"><surname>Nik Jaafar</surname><given-names>Nik Ruszyanei</given-names></name><name name-style="western"><surname>Midin</surname><given-names>M</given-names></name><name name-style="western"><surname>Sidi</surname><given-names>H</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>S</given-names></name></person-group><article-title>Is the Bahasa Malaysia version of the Montreal Cognitive Assessment (MoCA-BM) a better instrument than the Malay version of the Mini Mental State Examination (M-MMSE) in screening for mild cognitive impairment (MCI) in the elderly?</article-title><source>Compr Psychiatry</source><year>2014</year><month>01</month><volume>55 Suppl 1</volume><fpage>S70</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.comppsych.2013.04.010</pub-id><pub-id pub-id-type="medline">24314103</pub-id><pub-id pub-id-type="pii">S0010-440X(13)00102-8</pub-id><pub-id pub-id-type="pmid">24314103</pub-id></element-citation></ref><ref id="ref99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shukor</surname><given-names>Muhammad Faizan A</given-names></name><name name-style="western"><surname>Musthafa</surname><given-names>Qurratu Aini</given-names></name><name name-style="western"><surname>Mohd Yusof</surname><given-names>Yasmin Anum</given-names></name><name name-style="western"><surname>Wan Ngah</surname><given-names>Wan Zurinah</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>Noor Akmal Shareela</given-names></name></person-group><article-title>Biomarkers for premature coronary artery disease (PCAD): a case control study</article-title><source>Diagnostics (Basel)</source><year>2023</year><month>01</month><day>04</day><volume>13</volume><issue>2</issue><fpage>1</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/resolver?pii=diagnostics13020188" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.3390/diagnostics13020188</pub-id><pub-id pub-id-type="medline">36672997</pub-id><pub-id pub-id-type="pii">diagnostics13020188</pub-id><pub-id pub-id-type="pmcid">PMC9858259</pub-id><pub-id pub-id-type="pmid">36672997</pub-id></element-citation></ref><ref id="ref100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gottlieb</surname><given-names>A</given-names></name><name name-style="western"><surname>Doniger</surname><given-names>GM</given-names></name><name name-style="western"><surname>Kimel-Naor</surname><given-names>S</given-names></name><name name-style="western"><surname>Ben-Gal</surname><given-names>O</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>M</given-names></name><name name-style="western"><surname>Iny</surname><given-names>H</given-names></name><name name-style="western"><surname>Beeri</surname><given-names>MS</given-names></name><name name-style="western"><surname>Plotnik</surname><given-names>M</given-names></name></person-group><article-title>Development and validation of virtual reality-based Rey Auditory Verbal Learning Test</article-title><source>Front Aging Neurosci</source><year>2022</year><month>9</month><day>14</day><volume>14</volume><fpage>980093</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/36185470" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.3389/fnagi.2022.980093</pub-id><pub-id pub-id-type="medline">36185470</pub-id><pub-id pub-id-type="pmid">36185470</pub-id><pub-id pub-id-type="pmcid">PMC9519387</pub-id></element-citation></ref><ref id="ref101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bopp</surname><given-names>KL</given-names></name><name name-style="western"><surname>Verhaeghen</surname><given-names>P</given-names></name></person-group><article-title>Aging and verbal memory span: a meta-analysis</article-title><source>J Gerontol B Psychol Sci Soc Sci</source><year>2005</year><month>09</month><day>01</day><volume>60</volume><issue>5</issue><fpage>P223</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1093/geronb/60.5.p223</pub-id><pub-id pub-id-type="medline">16131616</pub-id><pub-id pub-id-type="pii">60/5/P223</pub-id><pub-id pub-id-type="pmid">16131616</pub-id></element-citation></ref><ref id="ref102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Hak</surname><given-names>Heba N Gad</given-names></name><name name-style="western"><surname>ELaraby</surname><given-names>EE</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>AK</given-names></name><name name-style="western"><surname>Abbas</surname><given-names>OA</given-names></name></person-group><article-title>Study of the toxic effect and safety of vitamin E supplement in male albino rats after 30 days of repeated treatment</article-title><source>Heliyon</source><year>2019</year><month>10</month><volume>5</volume><issue>10</issue><fpage>e02645</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S2405-8440(19)36305-4" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1016/j.heliyon.2019.e02645</pub-id><pub-id pub-id-type="medline">31667433</pub-id><pub-id pub-id-type="pii">S2405-8440(19)36305-4</pub-id><pub-id pub-id-type="pmid">31667433</pub-id><pub-id pub-id-type="pmcid">PMC6812462</pub-id></element-citation></ref><ref id="ref103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ismail</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>Wan Ibrahim Wan</given-names></name><name name-style="western"><surname>Hamjah</surname><given-names>SH</given-names></name><name name-style="western"><surname>Astina</surname><given-names>IK</given-names></name></person-group><article-title>The impact of population ageing: a review</article-title><source>Iran J Public Health</source><year>2021</year><month>12</month><day>06</day><volume>50</volume><issue>12</issue><fpage>2451</fpage><lpage>2460</lpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/36317043" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.18502/ijph.v50i12.7927</pub-id><pub-id pub-id-type="medline">36317043</pub-id><pub-id pub-id-type="pii">IJPH-50-2451</pub-id><pub-id pub-id-type="pmid">36317043</pub-id><pub-id pub-id-type="pmcid">PMC9577145</pub-id></element-citation></ref><ref id="ref104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodwin</surname><given-names>V</given-names></name><name name-style="western"><surname>Low</surname><given-names>M</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>T</given-names></name><name name-style="western"><surname>Cockcroft</surname><given-names>E</given-names></name><name name-style="western"><surname>Shepherd</surname><given-names>V</given-names></name><name name-style="western"><surname>Evans</surname><given-names>P</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>E</given-names></name><name name-style="western"><surname>Mahmood</surname><given-names>F</given-names></name><name name-style="western"><surname>Ni Lochlainn</surname><given-names>Mary</given-names></name><name name-style="western"><surname>Needham</surname><given-names>C</given-names></name><name name-style="western"><surname>Underwood</surname><given-names>B</given-names></name><name name-style="western"><surname>Arora</surname><given-names>A</given-names></name><name name-style="western"><surname>Witham</surname><given-names>M</given-names></name></person-group><article-title>Including older people in health and social care research: best practice recommendations based on the INCLUDE framework</article-title><source>Age Ageing</source><year>2023</year><month>06</month><day>01</day><volume>52</volume><issue>6</issue><fpage>a</fpage><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/abstract/MED/37261448" ext-link-type="uri"/></comment><pub-id pub-id-type="doi">10.1093/ageing/afad082</pub-id><pub-id pub-id-type="medline">37261448</pub-id><pub-id pub-id-type="pii">7187125</pub-id><pub-id pub-id-type="pmcid">PMC10234283</pub-id><pub-id pub-id-type="pmid">37261448</pub-id></element-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Nat Struct Mol Biol</journal-id><journal-id journal-id-type="iso-abbrev">Nat Struct Mol Biol</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Nature structural &amp; molecular biology</journal-title></journal-title-group><issn pub-type="ppub">1545-9993</issn><issn pub-type="epub">1545-9985</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12507181</article-id><article-id pub-id-type="pmcid-ver">PMC12507181.1</article-id><article-id pub-id-type="pmcaid">12507181</article-id><article-id pub-id-type="pmcaiid">12507181</article-id><article-id pub-id-type="manuscript-id">NIHMS2109735</article-id><article-id pub-id-type="pmid">40841486</article-id><article-id pub-id-type="doi">10.1038/s41594-025-01657-8</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2109735</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2109735</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Midkine Attenuates Amyloid-&#946; Fibril Assembly and Plaque Formation</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Zaman</surname><given-names initials="M">Masihuz</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="FN1" ref-type="author-notes">#</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="S">Shu</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A9" ref-type="aff">9</xref><xref rid="FN1" ref-type="author-notes">#</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="Y">Ya</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="FN1" ref-type="author-notes">#</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yarbro</surname><given-names initials="JM">Jay M.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hao</surname><given-names initials="Y">Yanhong</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Z">Zhen</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="D">Danting</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Harper</surname><given-names initials="KE">Kiara E.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Soliman</surname><given-names initials="H">Hadeer</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hemphill</surname><given-names initials="A">Alex</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Harvey</surname><given-names initials="S">Sarah</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pruett-Miller</surname><given-names initials="SM">Shondra M.</given-names></name><xref rid="A3" ref-type="aff">3</xref><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stewart</surname><given-names initials="V">Valerie</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tanwar</surname><given-names initials="AS">Ajay Singh</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kalathur</surname><given-names initials="R">Ravi</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Grace</surname><given-names initials="CR">Christy R.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Turk</surname><given-names initials="M">Martin</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chittori</surname><given-names initials="S">Sagar</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jiao</surname><given-names initials="Y">Yun</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="Z">Zhiping</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>High</surname><given-names initials="AA">Anthony A.</given-names></name><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="X">Xusheng</given-names></name><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Serrano</surname><given-names initials="GE">Geidy E.</given-names></name><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Beach</surname><given-names initials="TG">Thomas G.</given-names></name><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yu</surname><given-names initials="G">Gang</given-names></name><xref rid="A7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="Y">Yang</given-names></name><xref rid="A8" ref-type="aff">8</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="PC">Ping-Chung</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Peng</surname><given-names initials="J">Junmin</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Structural Biology, St. Jude Children&#8217;s Research Hospital, Memphis, TN 38105, USA</aff><aff id="A2"><label>2</label>Department of Developmental Neurobiology, St. Jude Children&#8217;s Research Hospital, Memphis, TN 38105, USA</aff><aff id="A3"><label>3</label>Center for Advanced Genome Engineering, St. Jude Children&#8217;s Research Hospital, Memphis, TN 38105, USA</aff><aff id="A4"><label>4</label>Department of Cell and Molecular Biology, St. Jude Children&#8217;s Research Hospital, Memphis, TN 38105, USA</aff><aff id="A5"><label>5</label>Center for Proteomics and Metabolomics, St. Jude Children&#8217;s Research Hospital, Memphis, TN 38105, USA</aff><aff id="A6"><label>6</label>Banner Sun Health Research Institute, Sun City, AZ 85351, USA</aff><aff id="A7"><label>7</label>Department of Neuroscience, Peter O&#8217;Donnell Jr. Brain Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA</aff><aff id="A8"><label>8</label>Department of Structural Biology, Van Andel Institute, Grand Rapids, MI 49503, USA</aff><aff id="A9"><label>9</label>Present address: Department of Medical Research Center, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100730, P. R. China.</aff><author-notes><fn fn-type="equal" id="FN1"><label>#</label><p id="P1">Equal contribution</p></fn><fn fn-type="con" id="FN2"><p id="P2">Contributions</p><p id="P3">J.P., P.-C.C., G.Y. M.Z. conceived this project. M.Z., Y.Y, J.M.Y., Y.H., A.S.T., R.K., C.R.G., M.T., and S.C. engaged in biophysical experiments. S.Y., Z.Wang, K.E.H., H.S., A.H., S.H., Y.J., and P.-C.C. performed biological experiments. P.-C.C., S.Y., Y.J., S.M.P.-M., and V.S. generated and bred the mouse models. S.Y., Z.Wang, D.L., Y, H., Z.Wu, A.A.H., X.W. contributed to the mass spectrometry-based proteomics analysis. G.E.S. and T.G.B. characterized and provided human brain samples. M.Z., Y.H., P.-C.C. and J.P. wrote the manuscript.</p></fn><corresp id="CR1"><label>*</label>Correspondence: <email>yyang@mrc-lmb.cam.ac.uk</email>; <email>ping-chung.chen@stjude.org</email>; or <email>junmin.peng@stjude.org</email></corresp><fn fn-type="COI-statement" id="FN3"><p id="P68">Competing interests</p><p id="P69">The authors declare no competing interests.</p></fn></author-notes><pub-date pub-type="epub"><day>21</day><month>8</month><year>2025</year></pub-date><issue-id pub-id-type="pmc-issue-id">498505</issue-id><elocation-id>10.1038/s41594-025-01657-8</elocation-id><pub-history><event event-type="nihms-submitted"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-release"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2109735.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="preprint" xml:lang="en" xlink:title="research-article" journal-id="bioRxiv" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC11957132"><article-title>Midkine Attenuates A&#946; Fibril Assembly and Amyloid Plaque Formation</article-title><date><day>20</day><month>3</month><year>2025</year></date><elocation-id>2025.03.20.644383</elocation-id><source>bioRxiv</source><pub-id pub-id-type="pmcid">PMC11957132</pub-id><pub-id pub-id-type="pmid">40166321</pub-id></related-article><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="preprint" xml:lang="en" xlink:title="research-article" journal-id="Res Sq" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC11177971"><article-title>Midkine Attenuates A&#946; Fibril Assembly and AmyloidPlaque Formation</article-title><date><day>7</day><month>6</month><year>2024</year></date><elocation-id>rs.3.rs-4361125</elocation-id><source>Research Square</source><pub-id pub-id-type="pmcid">PMC11177971</pub-id><pub-id pub-id-type="pmid">38883748</pub-id></related-article><abstract id="ABS1"><p id="P4">Proteomic profiling of Alzheimer&#8217;s disease (AD) brains has identified numerous understudied proteins, including midkine (MDK), that are highly upregulated and correlated with A&#946; since the early disease stage, but their roles in disease progression are not fully understood. Here we present that MDK attenuates A&#946; assembly and influences amyloid formation in the 5xFAD amyloidosis mouse model. MDK protein mitigates fibril formation of both A&#946;40 and A&#946;42 peptides in Thioflavin T fluorescence assay, circular dichroism, negative stain electron microscopy, and NMR analysis. Knockout of <italic toggle="yes">Mdk</italic> gene in 5xFAD increases amyloid formation and microglial activation in the brain. Further comprehensive mass spectrometry-based profiling of whole proteome and detergent-insoluble proteome in these mouse models indicates significant accumulation of A&#946; and A&#946;-correlated proteins, along with microglial components. Thus, our structural and mouse model studies reveal a protective role of MDK in counteracting amyloid pathology in Alzheimer&#8217;s disease.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>